doc_id,term,association
uuid-dd2748b5799a4ad2932ba666689eb770,therapy,0.311885
uuid-dd2748b5799a4ad2932ba666689eb770,treated,0.349064
uuid-dd2748b5799a4ad2932ba666689eb770,melanoma,0.31998
uuid-dd2748b5799a4ad2932ba666689eb770,commented,0.306236
uuid-dd2748b5799a4ad2932ba666689eb770,RCC,0.307431
uuid-dd2748b5799a4ad2932ba666689eb770,treatment,0.409306
uuid-dd2748b5799a4ad2932ba666689eb770,response,0.421849
uuid-dd2748b5799a4ad2932ba666689eb770,progression,0.421668
uuid-dd2748b5799a4ad2932ba666689eb770,respond,0.349638
uuid-dd2748b5799a4ad2932ba666689eb770,TL shared,0.360862
uuid-a574e72439964f0ea4007cdef26072da,patients,0.337911
uuid-a574e72439964f0ea4007cdef26072da,Opdivo,0.437141
uuid-a574e72439964f0ea4007cdef26072da,treated,0.342188
uuid-a574e72439964f0ea4007cdef26072da,shared,0.461784
uuid-a574e72439964f0ea4007cdef26072da,institution,0.349289
uuid-a574e72439964f0ea4007cdef26072da,stated,0.376187
uuid-a574e72439964f0ea4007cdef26072da,approval,0.356366
uuid-a574e72439964f0ea4007cdef26072da,physicians,0.480092
uuid-a574e72439964f0ea4007cdef26072da,clinical trials,0.373542
uuid-a574e72439964f0ea4007cdef26072da,HCP,0.318936
uuid-a574e72439964f0ea4007cdef26072da,tumor types,0.337923
uuid-a574e72439964f0ea4007cdef26072da,oncologist,0.334432
uuid-a574e72439964f0ea4007cdef26072da,Regional TL,0.315022
uuid-a8027c24223342b5aabc3066a61ab66b,BMS,0.361811
uuid-a8027c24223342b5aabc3066a61ab66b,PDL1,0.335065
uuid-a8027c24223342b5aabc3066a61ab66b,trial,0.446608
uuid-a8027c24223342b5aabc3066a61ab66b,efficacy,0.551193
uuid-a8027c24223342b5aabc3066a61ab66b,chemo,0.303088
uuid-a8027c24223342b5aabc3066a61ab66b,OS,0.798228
uuid-a8027c24223342b5aabc3066a61ab66b,data,0.694433
uuid-a8027c24223342b5aabc3066a61ab66b,PFS,0.748948
uuid-a8027c24223342b5aabc3066a61ab66b,ORR,0.730211
uuid-a8027c24223342b5aabc3066a61ab66b,nivo and pembro,0.356448
uuid-a8027c24223342b5aabc3066a61ab66b,believes,0.380718
uuid-a8027c24223342b5aabc3066a61ab66b,impressed,0.597345
uuid-a8027c24223342b5aabc3066a61ab66b,feels,0.527319
uuid-209d9787506e4f47936df7656dfffcb8,TL,0.428959
uuid-209d9787506e4f47936df7656dfffcb8,shared,0.43565
uuid-209d9787506e4f47936df7656dfffcb8,TL stated,0.385614
uuid-209d9787506e4f47936df7656dfffcb8,institution,0.37287
uuid-209d9787506e4f47936df7656dfffcb8,physicians,0.427999
uuid-209d9787506e4f47936df7656dfffcb8,PD-L1 testing,0.49697
uuid-209d9787506e4f47936df7656dfffcb8,testing,0.37099
uuid-209d9787506e4f47936df7656dfffcb8,PDL1 testing,0.43703
uuid-209d9787506e4f47936df7656dfffcb8,NSCLC patients,0.321781
uuid-209d9787506e4f47936df7656dfffcb8,oncology,0.302817
uuid-209d9787506e4f47936df7656dfffcb8,SCCHN,0.363227
uuid-209d9787506e4f47936df7656dfffcb8,oncologist,0.373647
uuid-209d9787506e4f47936df7656dfffcb8,LTL,0.304614
uuid-209d9787506e4f47936df7656dfffcb8,academic,0.372302
uuid-209d9787506e4f47936df7656dfffcb8,Regional TL,0.399598
uuid-209d9787506e4f47936df7656dfffcb8,RTL stated,0.300651
uuid-38b870589a0f4fda93afdfdf841a5b1f,therapy,0.318919
uuid-38b870589a0f4fda93afdfdf841a5b1f,regimen,0.442448
uuid-38b870589a0f4fda93afdfdf841a5b1f,combination,0.5419
uuid-38b870589a0f4fda93afdfdf841a5b1f,chemo,0.374137
uuid-38b870589a0f4fda93afdfdf841a5b1f,pts,0.420115
uuid-38b870589a0f4fda93afdfdf841a5b1f,IO,0.35343
uuid-38b870589a0f4fda93afdfdf841a5b1f,monotherapy,0.397107
uuid-38b870589a0f4fda93afdfdf841a5b1f,treatment,0.331349
uuid-38b870589a0f4fda93afdfdf841a5b1f,response,0.627743
uuid-38b870589a0f4fda93afdfdf841a5b1f,combo,0.493994
uuid-38b870589a0f4fda93afdfdf841a5b1f,PD1,0.545479
uuid-38b870589a0f4fda93afdfdf841a5b1f,progression,0.557256
uuid-38b870589a0f4fda93afdfdf841a5b1f,chemotherapy,0.413355
uuid-38b870589a0f4fda93afdfdf841a5b1f,impressed,0.320943
uuid-38b870589a0f4fda93afdfdf841a5b1f,respond,0.385016
uuid-58956b01eebd4d2786bedcfedf96af2a,Nivo,0.451618
uuid-58956b01eebd4d2786bedcfedf96af2a,patients,0.319239
uuid-58956b01eebd4d2786bedcfedf96af2a,pembro,0.603401
uuid-58956b01eebd4d2786bedcfedf96af2a,nivolumab,0.311386
uuid-58956b01eebd4d2786bedcfedf96af2a,1L,0.680632
uuid-58956b01eebd4d2786bedcfedf96af2a,shared,0.319761
uuid-58956b01eebd4d2786bedcfedf96af2a,RCC,0.495697
uuid-58956b01eebd4d2786bedcfedf96af2a,2L,0.680356
uuid-58956b01eebd4d2786bedcfedf96af2a,pts,0.34725
uuid-58956b01eebd4d2786bedcfedf96af2a,stated,0.353874
uuid-58956b01eebd4d2786bedcfedf96af2a,approval,0.490099
uuid-58956b01eebd4d2786bedcfedf96af2a,atezo,0.501316
uuid-58956b01eebd4d2786bedcfedf96af2a,preferred,0.556566
uuid-58956b01eebd4d2786bedcfedf96af2a,monotherapy,0.545381
uuid-58956b01eebd4d2786bedcfedf96af2a,using nivo,0.709682
uuid-58956b01eebd4d2786bedcfedf96af2a,combo,0.352909
uuid-58956b01eebd4d2786bedcfedf96af2a,clinical trials,0.377801
uuid-58956b01eebd4d2786bedcfedf96af2a,indication,0.304595
uuid-58956b01eebd4d2786bedcfedf96af2a,NSCLC patients,0.311675
uuid-58956b01eebd4d2786bedcfedf96af2a,approved,0.498105
uuid-58956b01eebd4d2786bedcfedf96af2a,SCCHN,0.502845
uuid-58956b01eebd4d2786bedcfedf96af2a,tumor types,0.375217
uuid-58956b01eebd4d2786bedcfedf96af2a,LTL,0.389343
uuid-58956b01eebd4d2786bedcfedf96af2a,SCLC,0.344217
uuid-58956b01eebd4d2786bedcfedf96af2a,feels,0.375195
uuid-58956b01eebd4d2786bedcfedf96af2a,Regional TL,0.312913
uuid-58956b01eebd4d2786bedcfedf96af2a,RTL stated,0.630569
uuid-58956b01eebd4d2786bedcfedf96af2a,TL shared,0.349459
uuid-58956b01eebd4d2786bedcfedf96af2a,option,0.522719
uuid-58956b01eebd4d2786bedcfedf96af2a,bladder,0.47076
uuid-0697d863a4bb440bab10b8a4a5da2a3c,patients,0.453799
uuid-0697d863a4bb440bab10b8a4a5da2a3c,Opdivo,0.62794
uuid-0697d863a4bb440bab10b8a4a5da2a3c,dose,0.532582
uuid-0697d863a4bb440bab10b8a4a5da2a3c,preferred,0.312761
uuid-0697d863a4bb440bab10b8a4a5da2a3c,drug,0.391552
uuid-0697d863a4bb440bab10b8a4a5da2a3c,Keytruda,0.470398
uuid-0697d863a4bb440bab10b8a4a5da2a3c,flat dosing,0.666491
uuid-50e922a8c9184edb95bfbb03c6a90a7f,TL,0.399092
uuid-50e922a8c9184edb95bfbb03c6a90a7f,RTL,0.363485
uuid-50e922a8c9184edb95bfbb03c6a90a7f,lung,0.429834
uuid-50e922a8c9184edb95bfbb03c6a90a7f,1L,0.35826
uuid-50e922a8c9184edb95bfbb03c6a90a7f,shared,0.395215
uuid-50e922a8c9184edb95bfbb03c6a90a7f,commented,0.336493
uuid-50e922a8c9184edb95bfbb03c6a90a7f,RCC,0.538187
uuid-50e922a8c9184edb95bfbb03c6a90a7f,TL stated,0.683662
uuid-50e922a8c9184edb95bfbb03c6a90a7f,2L,0.317754
uuid-50e922a8c9184edb95bfbb03c6a90a7f,institution,0.336636
uuid-50e922a8c9184edb95bfbb03c6a90a7f,stated,0.473154
uuid-50e922a8c9184edb95bfbb03c6a90a7f,PD-L1,0.477
uuid-50e922a8c9184edb95bfbb03c6a90a7f,approval,0.335017
uuid-50e922a8c9184edb95bfbb03c6a90a7f,PD-L1 testing,0.517595
uuid-50e922a8c9184edb95bfbb03c6a90a7f,testing,0.605866
uuid-50e922a8c9184edb95bfbb03c6a90a7f,expressed,0.349457
uuid-50e922a8c9184edb95bfbb03c6a90a7f,clinical trials,0.310086
uuid-50e922a8c9184edb95bfbb03c6a90a7f,PDL1 testing,0.718915
uuid-50e922a8c9184edb95bfbb03c6a90a7f,NSCLC patients,0.54471
uuid-50e922a8c9184edb95bfbb03c6a90a7f,SCCHN,0.540787
uuid-50e922a8c9184edb95bfbb03c6a90a7f,tumor types,0.510929
uuid-50e922a8c9184edb95bfbb03c6a90a7f,LTL,0.371508
uuid-50e922a8c9184edb95bfbb03c6a90a7f,TLs,0.457786
uuid-50e922a8c9184edb95bfbb03c6a90a7f,academic,0.324158
uuid-50e922a8c9184edb95bfbb03c6a90a7f,Regional TL,0.426914
uuid-50e922a8c9184edb95bfbb03c6a90a7f,RTL stated,0.478905
uuid-50e922a8c9184edb95bfbb03c6a90a7f,TL shared,0.411718
uuid-50e922a8c9184edb95bfbb03c6a90a7f,biomarker,0.320335
uuid-50e922a8c9184edb95bfbb03c6a90a7f,bladder,0.432808
uuid-b04d57870ca240edb4c7aba01b6ba51d,BMS,0.418691
uuid-b04d57870ca240edb4c7aba01b6ba51d,PDL1,0.391438
uuid-b04d57870ca240edb4c7aba01b6ba51d,discussed,0.329364
uuid-b04d57870ca240edb4c7aba01b6ba51d,commented,0.514768
uuid-b04d57870ca240edb4c7aba01b6ba51d,Merck,0.317845
uuid-b04d57870ca240edb4c7aba01b6ba51d,stated,0.511153
uuid-b04d57870ca240edb4c7aba01b6ba51d,OS,0.37841
uuid-b04d57870ca240edb4c7aba01b6ba51d,regards,0.436158
uuid-b04d57870ca240edb4c7aba01b6ba51d,data,0.724062
uuid-b04d57870ca240edb4c7aba01b6ba51d,expressed,0.354774
uuid-b04d57870ca240edb4c7aba01b6ba51d,indication,0.32366
uuid-b04d57870ca240edb4c7aba01b6ba51d,PFS,0.352307
uuid-b04d57870ca240edb4c7aba01b6ba51d,ORR,0.355689
uuid-b04d57870ca240edb4c7aba01b6ba51d,nivo and pembro,0.336932
uuid-b04d57870ca240edb4c7aba01b6ba51d,impressed,0.484118
uuid-b04d57870ca240edb4c7aba01b6ba51d,Regional TL,0.35756
uuid-b04d57870ca240edb4c7aba01b6ba51d,PDL1 expression,0.337783
uuid-b04d57870ca240edb4c7aba01b6ba51d,NCCN,0.509969
uuid-99fa36bc54344725be351a0061e1b615,1L,0.346915
uuid-99fa36bc54344725be351a0061e1b615,PDL1,0.514631
uuid-99fa36bc54344725be351a0061e1b615,efficacy,0.341787
uuid-99fa36bc54344725be351a0061e1b615,PD-L1,0.306931
uuid-99fa36bc54344725be351a0061e1b615,atezo,0.301032
uuid-99fa36bc54344725be351a0061e1b615,regards,0.391898
uuid-99fa36bc54344725be351a0061e1b615,indication,0.444588
uuid-99fa36bc54344725be351a0061e1b615,approved,0.338467
uuid-99fa36bc54344725be351a0061e1b615,nivo and pembro,0.450333
uuid-99fa36bc54344725be351a0061e1b615,believes,0.440199
uuid-99fa36bc54344725be351a0061e1b615,label,0.355937
uuid-99fa36bc54344725be351a0061e1b615,PDL1 expression,0.605817
uuid-99fa36bc54344725be351a0061e1b615,option,0.332987
uuid-99fa36bc54344725be351a0061e1b615,biomarker,0.465249
uuid-b5f0defa99d44ccea4c7714fc088e323,Opdivo,0.520346
uuid-b5f0defa99d44ccea4c7714fc088e323,dose,0.640795
uuid-b5f0defa99d44ccea4c7714fc088e323,toxicity,0.428314
uuid-b5f0defa99d44ccea4c7714fc088e323,regimen,0.39159
uuid-b5f0defa99d44ccea4c7714fc088e323,physicians,0.498482
uuid-b5f0defa99d44ccea4c7714fc088e323,treatment,0.338164
uuid-b5f0defa99d44ccea4c7714fc088e323,Keytruda,0.356374
uuid-b5f0defa99d44ccea4c7714fc088e323,flat dosing,0.486783
uuid-5c70926db46d4984abc3e13a497a1113,patients,0.573059
uuid-5c70926db46d4984abc3e13a497a1113,Opdivo,0.415858
uuid-5c70926db46d4984abc3e13a497a1113,therapy,0.489293
uuid-5c70926db46d4984abc3e13a497a1113,nivolumab,0.472227
uuid-5c70926db46d4984abc3e13a497a1113,treated,0.463163
uuid-5c70926db46d4984abc3e13a497a1113,approval,0.369751
uuid-5c70926db46d4984abc3e13a497a1113,physicians,0.316085
uuid-5c70926db46d4984abc3e13a497a1113,treatment,0.383186
uuid-5c70926db46d4984abc3e13a497a1113,using nivo,0.421793
uuid-5c70926db46d4984abc3e13a497a1113,mentioned,0.377373
uuid-5c70926db46d4984abc3e13a497a1113,cHL,0.565897
uuid-5c70926db46d4984abc3e13a497a1113,RTL stated,0.326038
uuid-576e178f98404572ab09f845d009aa86,Nivo,0.404858
uuid-576e178f98404572ab09f845d009aa86,pembro,0.446317
uuid-576e178f98404572ab09f845d009aa86,1L,0.319149
uuid-576e178f98404572ab09f845d009aa86,trial,0.561853
uuid-576e178f98404572ab09f845d009aa86,regimen,0.316346
uuid-576e178f98404572ab09f845d009aa86,combination,0.513952
uuid-576e178f98404572ab09f845d009aa86,chemo,0.400549
uuid-576e178f98404572ab09f845d009aa86,pts,0.364572
uuid-576e178f98404572ab09f845d009aa86,Ipi,0.499646
uuid-576e178f98404572ab09f845d009aa86,monotherapy,0.432858
uuid-576e178f98404572ab09f845d009aa86,combo,0.564991
uuid-576e178f98404572ab09f845d009aa86,clinical trials,0.416011
uuid-576e178f98404572ab09f845d009aa86,PD1,0.316737
uuid-576e178f98404572ab09f845d009aa86,chemotherapy,0.355899
uuid-576e178f98404572ab09f845d009aa86,impressed,0.318374
uuid-576e178f98404572ab09f845d009aa86,vs,0.421104
uuid-576e178f98404572ab09f845d009aa86,feels,0.410167
uuid-4b0305ca996c4437a4ec021c9f1bae4e,pembro,0.334004
uuid-4b0305ca996c4437a4ec021c9f1bae4e,trial,0.644004
uuid-4b0305ca996c4437a4ec021c9f1bae4e,clinical trials,0.36659
uuid-4f31ccc202474624ac07fb172795fd63,Nivo,0.619491
uuid-4f31ccc202474624ac07fb172795fd63,patients,0.609138
uuid-4f31ccc202474624ac07fb172795fd63,pembro,0.327205
uuid-4f31ccc202474624ac07fb172795fd63,therapy,0.438927
uuid-4f31ccc202474624ac07fb172795fd63,dose,0.368464
uuid-4f31ccc202474624ac07fb172795fd63,nivolumab,0.341595
uuid-4f31ccc202474624ac07fb172795fd63,1L,0.30951
uuid-4f31ccc202474624ac07fb172795fd63,toxicity,0.442256
uuid-4f31ccc202474624ac07fb172795fd63,efficacy,0.335878
uuid-4f31ccc202474624ac07fb172795fd63,regimen,0.65024
uuid-4f31ccc202474624ac07fb172795fd63,combination,0.450085
uuid-4f31ccc202474624ac07fb172795fd63,chemo,0.629482
uuid-4f31ccc202474624ac07fb172795fd63,2L,0.352781
uuid-4f31ccc202474624ac07fb172795fd63,pts,0.542951
uuid-4f31ccc202474624ac07fb172795fd63,Ipi,0.529003
uuid-4f31ccc202474624ac07fb172795fd63,monotherapy,0.62566
uuid-4f31ccc202474624ac07fb172795fd63,treatment,0.462664
uuid-4f31ccc202474624ac07fb172795fd63,using nivo,0.328419
uuid-4f31ccc202474624ac07fb172795fd63,response,0.392142
uuid-4f31ccc202474624ac07fb172795fd63,combo,0.492624
uuid-4f31ccc202474624ac07fb172795fd63,PD1,0.471529
uuid-4f31ccc202474624ac07fb172795fd63,progression,0.549747
uuid-4f31ccc202474624ac07fb172795fd63,believes,0.317462
uuid-4f31ccc202474624ac07fb172795fd63,chemotherapy,0.568509
uuid-4f31ccc202474624ac07fb172795fd63,vs,0.334214
uuid-4f31ccc202474624ac07fb172795fd63,respond,0.42019
uuid-4f31ccc202474624ac07fb172795fd63,feels,0.386136
uuid-4f31ccc202474624ac07fb172795fd63,option,0.478295
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,Nivo,0.312475
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,patients,0.850619
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,Opdivo,0.404304
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,therapy,0.762943
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,nivolumab,0.592856
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,regimen,0.518525
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,treated,0.60689
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,chemo,0.414174
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,pts,0.624303
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,monotherapy,0.433062
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,treatment,0.737823
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,using nivo,0.334877
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,response,0.53888
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,PD1,0.491106
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,cHL,0.49442
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,progression,0.765719
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,chemotherapy,0.510438
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,respond,0.527161
uuid-fad9cbcb9a5d45ec8506f0d0248beee1,option,0.37696
uuid-709d85ada66944bd9129b524fba83dcb,Nivo,0.518906
uuid-709d85ada66944bd9129b524fba83dcb,patients,0.603314
uuid-709d85ada66944bd9129b524fba83dcb,therapy,0.613093
uuid-709d85ada66944bd9129b524fba83dcb,nivolumab,0.524002
uuid-709d85ada66944bd9129b524fba83dcb,regimen,0.32462
uuid-709d85ada66944bd9129b524fba83dcb,treated,0.355537
uuid-709d85ada66944bd9129b524fba83dcb,combination,0.341742
uuid-709d85ada66944bd9129b524fba83dcb,chemo,0.419675
uuid-709d85ada66944bd9129b524fba83dcb,pts,0.306978
uuid-709d85ada66944bd9129b524fba83dcb,Ipi,0.34344
uuid-709d85ada66944bd9129b524fba83dcb,preferred,0.320369
uuid-709d85ada66944bd9129b524fba83dcb,monotherapy,0.451759
uuid-709d85ada66944bd9129b524fba83dcb,treatment,0.435678
uuid-709d85ada66944bd9129b524fba83dcb,using nivo,0.506816
uuid-709d85ada66944bd9129b524fba83dcb,PD1,0.429823
uuid-709d85ada66944bd9129b524fba83dcb,cHL,0.459035
uuid-709d85ada66944bd9129b524fba83dcb,progression,0.311345
uuid-709d85ada66944bd9129b524fba83dcb,chemotherapy,0.534837
uuid-709d85ada66944bd9129b524fba83dcb,option,0.412203
uuid-29f66aaa72a6428f8c71b1e96d4116f7,Ipi,0.407461
uuid-29f66aaa72a6428f8c71b1e96d4116f7,data,0.381166
uuid-29f66aaa72a6428f8c71b1e96d4116f7,ORR,0.328628
uuid-c5590c44dab345a08db5885dae953c57,Nivo,0.609217
uuid-c5590c44dab345a08db5885dae953c57,pembro,0.779728
uuid-c5590c44dab345a08db5885dae953c57,dose,0.616045
uuid-c5590c44dab345a08db5885dae953c57,1L,0.435211
uuid-c5590c44dab345a08db5885dae953c57,2L,0.596316
uuid-c5590c44dab345a08db5885dae953c57,agents,0.409146
uuid-c5590c44dab345a08db5885dae953c57,Ipi,0.482687
uuid-c5590c44dab345a08db5885dae953c57,approval,0.346593
uuid-c5590c44dab345a08db5885dae953c57,atezo,0.760509
uuid-c5590c44dab345a08db5885dae953c57,preferred,0.613528
uuid-c5590c44dab345a08db5885dae953c57,monotherapy,0.445281
uuid-c5590c44dab345a08db5885dae953c57,using nivo,0.550621
uuid-c5590c44dab345a08db5885dae953c57,combo,0.314182
uuid-c5590c44dab345a08db5885dae953c57,indication,0.320378
uuid-c5590c44dab345a08db5885dae953c57,approved,0.458841
uuid-c5590c44dab345a08db5885dae953c57,nivo and pembro,0.324054
uuid-c5590c44dab345a08db5885dae953c57,vs,0.65384
uuid-c5590c44dab345a08db5885dae953c57,option,0.430719
uuid-c5590c44dab345a08db5885dae953c57,flat dosing,0.467472
uuid-c55f10541c024e57b57ceba238089458,shared,0.534836
uuid-c55f10541c024e57b57ceba238089458,pts,0.40585
uuid-c55f10541c024e57b57ceba238089458,institution,0.360448
uuid-c55f10541c024e57b57ceba238089458,stated,0.352356
uuid-c55f10541c024e57b57ceba238089458,approval,0.372959
uuid-c0816fb1ed2845eabd27747589d08960,Nivo,0.303294
uuid-c0816fb1ed2845eabd27747589d08960,patients,0.432364
uuid-c0816fb1ed2845eabd27747589d08960,therapy,0.330684
uuid-c0816fb1ed2845eabd27747589d08960,nivolumab,0.449335
uuid-c0816fb1ed2845eabd27747589d08960,toxicity,0.498526
uuid-c0816fb1ed2845eabd27747589d08960,regimen,0.613022
uuid-c0816fb1ed2845eabd27747589d08960,treated,0.477899
uuid-c0816fb1ed2845eabd27747589d08960,combination,0.505234
uuid-c0816fb1ed2845eabd27747589d08960,chemo,0.337608
uuid-c0816fb1ed2845eabd27747589d08960,pts,0.323576
uuid-c0816fb1ed2845eabd27747589d08960,Ipi,0.333666
uuid-c0816fb1ed2845eabd27747589d08960,preferred,0.36558
uuid-c0816fb1ed2845eabd27747589d08960,monotherapy,0.621135
uuid-c0816fb1ed2845eabd27747589d08960,treatment,0.45364
uuid-c0816fb1ed2845eabd27747589d08960,using nivo,0.407542
uuid-c0816fb1ed2845eabd27747589d08960,combo,0.419023
uuid-c0816fb1ed2845eabd27747589d08960,PD1,0.39553
uuid-c0816fb1ed2845eabd27747589d08960,HCP,0.356479
uuid-c0816fb1ed2845eabd27747589d08960,progression,0.319725
uuid-c0816fb1ed2845eabd27747589d08960,chemotherapy,0.39648
uuid-c0816fb1ed2845eabd27747589d08960,SCLC,0.3542
uuid-c0816fb1ed2845eabd27747589d08960,feels,0.316793
uuid-c0816fb1ed2845eabd27747589d08960,RTL stated,0.409694
uuid-c0816fb1ed2845eabd27747589d08960,option,0.450978
uuid-48495fcee65749b194423550869a39f9,Nivo,0.47426
uuid-48495fcee65749b194423550869a39f9,pembro,0.329013
uuid-48495fcee65749b194423550869a39f9,RTL,0.470177
uuid-48495fcee65749b194423550869a39f9,trial,0.390982
uuid-48495fcee65749b194423550869a39f9,Ipi,0.334055
uuid-48495fcee65749b194423550869a39f9,OS,0.402004
uuid-48495fcee65749b194423550869a39f9,using nivo,0.372442
uuid-48495fcee65749b194423550869a39f9,data,0.329
uuid-48495fcee65749b194423550869a39f9,mentioned,0.382921
uuid-48495fcee65749b194423550869a39f9,PFS,0.404453
uuid-48495fcee65749b194423550869a39f9,ORR,0.373851
uuid-48495fcee65749b194423550869a39f9,HCP,0.515335
uuid-48495fcee65749b194423550869a39f9,impressed,0.376872
uuid-48495fcee65749b194423550869a39f9,LTL,0.339519
uuid-48495fcee65749b194423550869a39f9,feels,0.348561
uuid-92f68908654845d58ab886b1ee077996,patients,0.674458
uuid-92f68908654845d58ab886b1ee077996,Opdivo,0.511212
uuid-92f68908654845d58ab886b1ee077996,nivolumab,0.325901
uuid-92f68908654845d58ab886b1ee077996,treated,0.362054
uuid-92f68908654845d58ab886b1ee077996,pts,0.309193
uuid-92f68908654845d58ab886b1ee077996,approval,0.469851
uuid-92f68908654845d58ab886b1ee077996,treatment,0.348455
uuid-92f68908654845d58ab886b1ee077996,using nivo,0.351973
uuid-92f68908654845d58ab886b1ee077996,clinical trials,0.33746
uuid-92f68908654845d58ab886b1ee077996,approved,0.473588
uuid-92f68908654845d58ab886b1ee077996,tumor types,0.311636
uuid-92f68908654845d58ab886b1ee077996,label,0.360167
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,patients,0.385194
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,therapy,0.314007
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,1L,0.41751
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,regimen,0.403825
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,chemo,0.430233
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,2L,0.420095
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,agents,0.388861
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,preferred,0.668331
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,monotherapy,0.564577
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,treatment,0.346166
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,using nivo,0.352641
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,chemotherapy,0.436438
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,feels,0.327251
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,RTL stated,0.381962
uuid-9da5d60f2d064f0b9dcb1d72e1bba7c1,option,0.634472
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,Nivo,0.382299
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,patients,0.604789
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,therapy,0.538275
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,nivolumab,0.422825
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,1L,0.411929
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,regimen,0.533985
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,treated,0.377878
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,combination,0.354072
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,chemo,0.589582
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,2L,0.448637
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,pts,0.406228
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,agents,0.324689
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,preferred,0.583272
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,monotherapy,0.59506
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,treatment,0.503708
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,using nivo,0.432438
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,PD1,0.337076
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,progression,0.357463
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,chemotherapy,0.541003
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,respond,0.307007
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,RTL stated,0.3882
uuid-38908a22c8a24a7fa5f2ecbfb58f29bb,option,0.611909
uuid-41ab7a33245b41c2845df7cee163c675,Nivo,0.591116
uuid-41ab7a33245b41c2845df7cee163c675,pembro,0.369444
uuid-41ab7a33245b41c2845df7cee163c675,PFS,0.337075
uuid-41ab7a33245b41c2845df7cee163c675,cHL,0.507121
uuid-41ab7a33245b41c2845df7cee163c675,nivo and pembro,0.360264
uuid-41ab7a33245b41c2845df7cee163c675,vs,0.32763
uuid-1678b2ad80084b37a54b9bb64a4ef479,pembro,0.357022
uuid-1678b2ad80084b37a54b9bb64a4ef479,1L,0.331442
uuid-1678b2ad80084b37a54b9bb64a4ef479,PDL1,0.830805
uuid-1678b2ad80084b37a54b9bb64a4ef479,efficacy,0.320127
uuid-1678b2ad80084b37a54b9bb64a4ef479,Merck,0.336704
uuid-1678b2ad80084b37a54b9bb64a4ef479,PD-L1,0.697871
uuid-1678b2ad80084b37a54b9bb64a4ef479,OS,0.309062
uuid-1678b2ad80084b37a54b9bb64a4ef479,atezo,0.342868
uuid-1678b2ad80084b37a54b9bb64a4ef479,PD-L1 testing,0.372749
uuid-1678b2ad80084b37a54b9bb64a4ef479,testing,0.534086
uuid-1678b2ad80084b37a54b9bb64a4ef479,PDL1 testing,0.303285
uuid-1678b2ad80084b37a54b9bb64a4ef479,PFS,0.351935
uuid-1678b2ad80084b37a54b9bb64a4ef479,NSCLC patients,0.370621
uuid-1678b2ad80084b37a54b9bb64a4ef479,ORR,0.320191
uuid-1678b2ad80084b37a54b9bb64a4ef479,nivo and pembro,0.480528
uuid-1678b2ad80084b37a54b9bb64a4ef479,believes,0.364486
uuid-1678b2ad80084b37a54b9bb64a4ef479,assay,0.655047
uuid-1678b2ad80084b37a54b9bb64a4ef479,PDL1 expression,0.680619
uuid-1678b2ad80084b37a54b9bb64a4ef479,biomarker,0.554361
uuid-3a59a916c1724ce59d565324e6d29537,Nivo,0.466988
uuid-3a59a916c1724ce59d565324e6d29537,patients,0.608674
uuid-3a59a916c1724ce59d565324e6d29537,therapy,0.577373
uuid-3a59a916c1724ce59d565324e6d29537,dose,0.310105
uuid-3a59a916c1724ce59d565324e6d29537,nivolumab,0.479399
uuid-3a59a916c1724ce59d565324e6d29537,regimen,0.507252
uuid-3a59a916c1724ce59d565324e6d29537,treated,0.398626
uuid-3a59a916c1724ce59d565324e6d29537,combination,0.52077
uuid-3a59a916c1724ce59d565324e6d29537,chemo,0.509125
uuid-3a59a916c1724ce59d565324e6d29537,pts,0.538184
uuid-3a59a916c1724ce59d565324e6d29537,Ipi,0.497061
uuid-3a59a916c1724ce59d565324e6d29537,monotherapy,0.520423
uuid-3a59a916c1724ce59d565324e6d29537,treatment,0.511916
uuid-3a59a916c1724ce59d565324e6d29537,using nivo,0.377528
uuid-3a59a916c1724ce59d565324e6d29537,response,0.428271
uuid-3a59a916c1724ce59d565324e6d29537,combo,0.435067
uuid-3a59a916c1724ce59d565324e6d29537,PD1,0.518991
uuid-3a59a916c1724ce59d565324e6d29537,progression,0.571248
uuid-3a59a916c1724ce59d565324e6d29537,chemotherapy,0.539108
uuid-3a59a916c1724ce59d565324e6d29537,respond,0.386902
uuid-3a59a916c1724ce59d565324e6d29537,option,0.383788
uuid-76cd40bc214d455db8b821aa3a2bf600,patients,0.348435
uuid-76cd40bc214d455db8b821aa3a2bf600,toxicity,0.356576
uuid-76cd40bc214d455db8b821aa3a2bf600,regimen,0.350673
uuid-76cd40bc214d455db8b821aa3a2bf600,treated,0.373274
uuid-76cd40bc214d455db8b821aa3a2bf600,treatment,0.322346
uuid-76cd40bc214d455db8b821aa3a2bf600,respond,0.316505
uuid-76cd40bc214d455db8b821aa3a2bf600,feels,0.302813
uuid-76cd40bc214d455db8b821aa3a2bf600,TL shared,0.312253
uuid-9e3e1eb1ac354d98b505479b35047e78,Ipi,0.338611
uuid-b4ca25029d4940df8cecea0c45fe4153,RTL,0.450925
uuid-b4ca25029d4940df8cecea0c45fe4153,NTL,0.314964
uuid-b4ca25029d4940df8cecea0c45fe4153,using nivo,0.31598
uuid-b4ca25029d4940df8cecea0c45fe4153,expressed,0.361567
uuid-b4ca25029d4940df8cecea0c45fe4153,mentioned,0.50984
uuid-b4ca25029d4940df8cecea0c45fe4153,HCP,0.740614
uuid-b4ca25029d4940df8cecea0c45fe4153,LTL,0.35402
uuid-917bd50ef5a24184baaf7ac3551265c2,RTL,0.55564
uuid-917bd50ef5a24184baaf7ac3551265c2,NTL,0.442456
uuid-917bd50ef5a24184baaf7ac3551265c2,using nivo,0.358913
uuid-917bd50ef5a24184baaf7ac3551265c2,expressed,0.433768
uuid-917bd50ef5a24184baaf7ac3551265c2,mentioned,0.544277
uuid-917bd50ef5a24184baaf7ac3551265c2,SCCHN,0.361227
uuid-917bd50ef5a24184baaf7ac3551265c2,HCP,0.711537
uuid-917bd50ef5a24184baaf7ac3551265c2,LTL,0.429073
uuid-917bd50ef5a24184baaf7ac3551265c2,SCLC,0.375874
uuid-917bd50ef5a24184baaf7ac3551265c2,Regional TL,0.318276
uuid-c112cd3ea5654db69388b5a6dc6c5a57,mentioned,0.452099
uuid-c112cd3ea5654db69388b5a6dc6c5a57,HCP,0.698983
uuid-3884068d73fc42348553dcb720399c45,therapy,0.422692
uuid-3884068d73fc42348553dcb720399c45,nivolumab,0.353491
uuid-3884068d73fc42348553dcb720399c45,combination,0.332507
uuid-3884068d73fc42348553dcb720399c45,chemo,0.309464
uuid-3884068d73fc42348553dcb720399c45,agents,0.364821
uuid-3884068d73fc42348553dcb720399c45,treatment,0.35468
uuid-3884068d73fc42348553dcb720399c45,response,0.373281
uuid-3884068d73fc42348553dcb720399c45,PD1,0.74049
uuid-3884068d73fc42348553dcb720399c45,progression,0.413738
uuid-3884068d73fc42348553dcb720399c45,chemotherapy,0.325528
uuid-3884068d73fc42348553dcb720399c45,immunotherapy,0.486359
uuid-3884068d73fc42348553dcb720399c45,PD-1,0.549002
uuid-0500a55221c24cacb69af8e0e647a8fa,RTL,0.484615
uuid-0500a55221c24cacb69af8e0e647a8fa,BMS,0.412413
uuid-0500a55221c24cacb69af8e0e647a8fa,trial,0.701326
uuid-0500a55221c24cacb69af8e0e647a8fa,NTL,0.363936
uuid-0500a55221c24cacb69af8e0e647a8fa,shared,0.432936
uuid-0500a55221c24cacb69af8e0e647a8fa,commented,0.407417
uuid-0500a55221c24cacb69af8e0e647a8fa,Merck,0.316228
uuid-0500a55221c24cacb69af8e0e647a8fa,stated,0.359128
uuid-0500a55221c24cacb69af8e0e647a8fa,data,0.451868
uuid-0500a55221c24cacb69af8e0e647a8fa,expressed,0.338704
uuid-0500a55221c24cacb69af8e0e647a8fa,clinical trials,0.445585
uuid-0500a55221c24cacb69af8e0e647a8fa,ASCO,0.310131
uuid-0500a55221c24cacb69af8e0e647a8fa,impressed,0.522983
uuid-0500a55221c24cacb69af8e0e647a8fa,SCLC,0.328159
uuid-0500a55221c24cacb69af8e0e647a8fa,Regional TL,0.350694
uuid-95116212419e47eb91dae8c91ae95336,patients,0.608068
uuid-95116212419e47eb91dae8c91ae95336,Opdivo,0.316375
uuid-95116212419e47eb91dae8c91ae95336,therapy,0.352499
uuid-95116212419e47eb91dae8c91ae95336,nivolumab,0.436788
uuid-95116212419e47eb91dae8c91ae95336,regimen,0.513517
uuid-95116212419e47eb91dae8c91ae95336,treated,0.469287
uuid-95116212419e47eb91dae8c91ae95336,shared,0.4196
uuid-95116212419e47eb91dae8c91ae95336,RCC,0.344247
uuid-95116212419e47eb91dae8c91ae95336,combination,0.307826
uuid-95116212419e47eb91dae8c91ae95336,pts,0.454346
uuid-95116212419e47eb91dae8c91ae95336,IO,0.329169
uuid-95116212419e47eb91dae8c91ae95336,monotherapy,0.449224
uuid-95116212419e47eb91dae8c91ae95336,treatment,0.417255
uuid-95116212419e47eb91dae8c91ae95336,using nivo,0.409685
uuid-95116212419e47eb91dae8c91ae95336,response,0.302916
uuid-95116212419e47eb91dae8c91ae95336,combo,0.36422
uuid-95116212419e47eb91dae8c91ae95336,PD1,0.302685
uuid-95116212419e47eb91dae8c91ae95336,progression,0.520394
uuid-95116212419e47eb91dae8c91ae95336,respond,0.349263
uuid-95116212419e47eb91dae8c91ae95336,feels,0.318409
uuid-95116212419e47eb91dae8c91ae95336,RTL stated,0.401218
uuid-95116212419e47eb91dae8c91ae95336,TL shared,0.355285
uuid-95116212419e47eb91dae8c91ae95336,option,0.331943
uuid-e87f350f68d24be884f52d2404fa7663,patients,0.655349
uuid-e87f350f68d24be884f52d2404fa7663,Opdivo,0.36171
uuid-e87f350f68d24be884f52d2404fa7663,therapy,0.464737
uuid-e87f350f68d24be884f52d2404fa7663,nivolumab,0.391654
uuid-e87f350f68d24be884f52d2404fa7663,regimen,0.314779
uuid-e87f350f68d24be884f52d2404fa7663,treated,0.646788
uuid-e87f350f68d24be884f52d2404fa7663,pts,0.47898
uuid-e87f350f68d24be884f52d2404fa7663,treatment,0.553123
uuid-e87f350f68d24be884f52d2404fa7663,cHL,0.396428
uuid-e87f350f68d24be884f52d2404fa7663,progression,0.558474
uuid-e87f350f68d24be884f52d2404fa7663,respond,0.412587
uuid-2b1c95d8dbc44a279b7f42321bb007d1,patients,0.536213
uuid-2b1c95d8dbc44a279b7f42321bb007d1,Opdivo,0.304998
uuid-2b1c95d8dbc44a279b7f42321bb007d1,therapy,0.469692
uuid-2b1c95d8dbc44a279b7f42321bb007d1,nivolumab,0.500913
uuid-2b1c95d8dbc44a279b7f42321bb007d1,trial,0.303933
uuid-2b1c95d8dbc44a279b7f42321bb007d1,treated,0.387835
uuid-2b1c95d8dbc44a279b7f42321bb007d1,approval,0.362307
uuid-2b1c95d8dbc44a279b7f42321bb007d1,treatment,0.357225
uuid-2b1c95d8dbc44a279b7f42321bb007d1,clinical trials,0.318896
uuid-2b1c95d8dbc44a279b7f42321bb007d1,cHL,0.520946
uuid-2b1c95d8dbc44a279b7f42321bb007d1,chemotherapy,0.378899
uuid-4664696f348c409b8d8bce8026d75683,patients,0.497568
uuid-4664696f348c409b8d8bce8026d75683,RTL,0.378899
uuid-4664696f348c409b8d8bce8026d75683,nivolumab,0.451247
uuid-4664696f348c409b8d8bce8026d75683,trial,0.489325
uuid-4664696f348c409b8d8bce8026d75683,regimen,0.374777
uuid-4664696f348c409b8d8bce8026d75683,treated,0.44322
uuid-4664696f348c409b8d8bce8026d75683,combination,0.358285
uuid-4664696f348c409b8d8bce8026d75683,pts,0.374705
uuid-4664696f348c409b8d8bce8026d75683,Ipi,0.361196
uuid-4664696f348c409b8d8bce8026d75683,clinical trials,0.377121
uuid-b9dbf1f84afb42b49301381041d9c41b,RTL,0.725362
uuid-b9dbf1f84afb42b49301381041d9c41b,nivolumab,0.374209
uuid-b9dbf1f84afb42b49301381041d9c41b,NTL,0.59674
uuid-b9dbf1f84afb42b49301381041d9c41b,shared,0.378211
uuid-b9dbf1f84afb42b49301381041d9c41b,commented,0.422673
uuid-b9dbf1f84afb42b49301381041d9c41b,stated,0.531511
uuid-b9dbf1f84afb42b49301381041d9c41b,approval,0.310107
uuid-b9dbf1f84afb42b49301381041d9c41b,physicians,0.378513
uuid-b9dbf1f84afb42b49301381041d9c41b,using nivo,0.309422
uuid-b9dbf1f84afb42b49301381041d9c41b,mentioned,0.453326
uuid-b9dbf1f84afb42b49301381041d9c41b,SCCHN,0.51529
uuid-b9dbf1f84afb42b49301381041d9c41b,HCP,0.410581
uuid-b9dbf1f84afb42b49301381041d9c41b,impressed,0.338714
uuid-b9dbf1f84afb42b49301381041d9c41b,LTL,0.565249
uuid-b9dbf1f84afb42b49301381041d9c41b,TLs,0.365508
uuid-b9dbf1f84afb42b49301381041d9c41b,academic,0.39831
uuid-b9dbf1f84afb42b49301381041d9c41b,Regional TL,0.652811
uuid-b9dbf1f84afb42b49301381041d9c41b,RTL stated,0.403027
uuid-c78bff860e8f40de9f84ca43ed7e95e4,patients,0.653122
uuid-c78bff860e8f40de9f84ca43ed7e95e4,Opdivo,0.346819
uuid-c78bff860e8f40de9f84ca43ed7e95e4,therapy,0.410122
uuid-c78bff860e8f40de9f84ca43ed7e95e4,nivolumab,0.466625
uuid-c78bff860e8f40de9f84ca43ed7e95e4,regimen,0.391064
uuid-c78bff860e8f40de9f84ca43ed7e95e4,treated,0.660397
uuid-c78bff860e8f40de9f84ca43ed7e95e4,pts,0.455275
uuid-c78bff860e8f40de9f84ca43ed7e95e4,treatment,0.572897
uuid-c78bff860e8f40de9f84ca43ed7e95e4,response,0.364475
uuid-c78bff860e8f40de9f84ca43ed7e95e4,cHL,0.357024
uuid-c78bff860e8f40de9f84ca43ed7e95e4,progression,0.549717
uuid-c78bff860e8f40de9f84ca43ed7e95e4,respond,0.374449
uuid-56b8d250550744a99e3ecfdc981d1c58,RTL,0.422415
uuid-56b8d250550744a99e3ecfdc981d1c58,treated,0.340614
uuid-56b8d250550744a99e3ecfdc981d1c58,melanoma,0.422638
uuid-56b8d250550744a99e3ecfdc981d1c58,shared,0.436162
uuid-56b8d250550744a99e3ecfdc981d1c58,RCC,0.499568
uuid-56b8d250550744a99e3ecfdc981d1c58,TL stated,0.372381
uuid-56b8d250550744a99e3ecfdc981d1c58,2L,0.332284
uuid-56b8d250550744a99e3ecfdc981d1c58,preferred,0.406767
uuid-56b8d250550744a99e3ecfdc981d1c58,monotherapy,0.341593
uuid-56b8d250550744a99e3ecfdc981d1c58,using nivo,0.375093
uuid-56b8d250550744a99e3ecfdc981d1c58,clinical trials,0.3416
uuid-56b8d250550744a99e3ecfdc981d1c58,PDL1 testing,0.313994
uuid-56b8d250550744a99e3ecfdc981d1c58,NSCLC patients,0.336989
uuid-56b8d250550744a99e3ecfdc981d1c58,SCCHN,0.544575
uuid-56b8d250550744a99e3ecfdc981d1c58,LTL,0.431208
uuid-56b8d250550744a99e3ecfdc981d1c58,TLs,0.464679
uuid-56b8d250550744a99e3ecfdc981d1c58,academic,0.681926
uuid-56b8d250550744a99e3ecfdc981d1c58,Regional TL,0.42378
uuid-56b8d250550744a99e3ecfdc981d1c58,RTL stated,0.644551
uuid-56b8d250550744a99e3ecfdc981d1c58,TL shared,0.507405
uuid-33da533d7e71411ca3d1b2f33b76517b,RTL,0.479937
uuid-33da533d7e71411ca3d1b2f33b76517b,BMS,0.388576
uuid-33da533d7e71411ca3d1b2f33b76517b,PDL1,0.388298
uuid-33da533d7e71411ca3d1b2f33b76517b,trial,0.426316
uuid-33da533d7e71411ca3d1b2f33b76517b,efficacy,0.437898
uuid-33da533d7e71411ca3d1b2f33b76517b,commented,0.551154
uuid-33da533d7e71411ca3d1b2f33b76517b,stated,0.405071
uuid-33da533d7e71411ca3d1b2f33b76517b,OS,0.690598
uuid-33da533d7e71411ca3d1b2f33b76517b,regards,0.329428
uuid-33da533d7e71411ca3d1b2f33b76517b,data,0.853562
uuid-33da533d7e71411ca3d1b2f33b76517b,expressed,0.420437
uuid-33da533d7e71411ca3d1b2f33b76517b,PFS,0.606784
uuid-33da533d7e71411ca3d1b2f33b76517b,ORR,0.657414
uuid-33da533d7e71411ca3d1b2f33b76517b,SCCHN,0.302026
uuid-33da533d7e71411ca3d1b2f33b76517b,nivo and pembro,0.305054
uuid-33da533d7e71411ca3d1b2f33b76517b,ASCO,0.440862
uuid-33da533d7e71411ca3d1b2f33b76517b,impressed,0.779769
uuid-33da533d7e71411ca3d1b2f33b76517b,LTL,0.337428
uuid-33da533d7e71411ca3d1b2f33b76517b,TLs,0.430185
uuid-33da533d7e71411ca3d1b2f33b76517b,Regional TL,0.375725
uuid-33da533d7e71411ca3d1b2f33b76517b,PDL1 expression,0.353273
uuid-50ed903eb3cf4f83817fe38aec673a42,Nivo,0.366116
uuid-50ed903eb3cf4f83817fe38aec673a42,therapy,0.46478
uuid-50ed903eb3cf4f83817fe38aec673a42,nivolumab,0.439345
uuid-50ed903eb3cf4f83817fe38aec673a42,combination,0.316623
uuid-50ed903eb3cf4f83817fe38aec673a42,chemo,0.318225
uuid-50ed903eb3cf4f83817fe38aec673a42,pts,0.342768
uuid-50ed903eb3cf4f83817fe38aec673a42,response,0.382564
uuid-50ed903eb3cf4f83817fe38aec673a42,PD1,0.416005
uuid-50ed903eb3cf4f83817fe38aec673a42,cHL,0.348352
uuid-50ed903eb3cf4f83817fe38aec673a42,immunotherapy,0.319893
uuid-92c99359df9a488da702767ba6a0260b,Nivo,0.516522
uuid-92c99359df9a488da702767ba6a0260b,pembro,0.6341
uuid-92c99359df9a488da702767ba6a0260b,RTL,0.339445
uuid-92c99359df9a488da702767ba6a0260b,BMS,0.312225
uuid-92c99359df9a488da702767ba6a0260b,trial,0.480798
uuid-92c99359df9a488da702767ba6a0260b,efficacy,0.301685
uuid-92c99359df9a488da702767ba6a0260b,2L,0.397051
uuid-92c99359df9a488da702767ba6a0260b,stated,0.301626
uuid-92c99359df9a488da702767ba6a0260b,approval,0.33699
uuid-92c99359df9a488da702767ba6a0260b,atezo,0.533685
uuid-92c99359df9a488da702767ba6a0260b,using nivo,0.434499
uuid-92c99359df9a488da702767ba6a0260b,data,0.341797
uuid-92c99359df9a488da702767ba6a0260b,clinical trials,0.409535
uuid-92c99359df9a488da702767ba6a0260b,indication,0.374814
uuid-92c99359df9a488da702767ba6a0260b,approved,0.384592
uuid-92c99359df9a488da702767ba6a0260b,nivo and pembro,0.382416
uuid-92c99359df9a488da702767ba6a0260b,vs,0.389726
uuid-92c99359df9a488da702767ba6a0260b,label,0.39595
uuid-92c99359df9a488da702767ba6a0260b,LTL,0.310154
uuid-92c99359df9a488da702767ba6a0260b,feels,0.395825
uuid-92c99359df9a488da702767ba6a0260b,bladder,0.342058
uuid-c4fe2607308942a7b12bbe22c08e129e,patients,0.829653
uuid-c4fe2607308942a7b12bbe22c08e129e,Opdivo,0.667105
uuid-c4fe2607308942a7b12bbe22c08e129e,therapy,0.559591
uuid-c4fe2607308942a7b12bbe22c08e129e,nivolumab,0.537702
uuid-c4fe2607308942a7b12bbe22c08e129e,regimen,0.371175
uuid-c4fe2607308942a7b12bbe22c08e129e,treated,0.528474
uuid-c4fe2607308942a7b12bbe22c08e129e,pts,0.456942
uuid-c4fe2607308942a7b12bbe22c08e129e,approval,0.343379
uuid-c4fe2607308942a7b12bbe22c08e129e,treatment,0.661361
uuid-c4fe2607308942a7b12bbe22c08e129e,using nivo,0.373798
uuid-c4fe2607308942a7b12bbe22c08e129e,cHL,0.484423
uuid-c4fe2607308942a7b12bbe22c08e129e,progression,0.501573
uuid-c4fe2607308942a7b12bbe22c08e129e,label,0.302284
uuid-c4fe2607308942a7b12bbe22c08e129e,respond,0.338036
uuid-c4fe2607308942a7b12bbe22c08e129e,option,0.338985
uuid-68cb3b710ac1432d89eebd942aadc9a8,Nivo,0.44527
uuid-68cb3b710ac1432d89eebd942aadc9a8,patients,0.536455
uuid-68cb3b710ac1432d89eebd942aadc9a8,therapy,0.738782
uuid-68cb3b710ac1432d89eebd942aadc9a8,nivolumab,0.543123
uuid-68cb3b710ac1432d89eebd942aadc9a8,treated,0.346247
uuid-68cb3b710ac1432d89eebd942aadc9a8,chemo,0.309126
uuid-68cb3b710ac1432d89eebd942aadc9a8,monotherapy,0.33971
uuid-68cb3b710ac1432d89eebd942aadc9a8,treatment,0.399117
uuid-68cb3b710ac1432d89eebd942aadc9a8,using nivo,0.389911
uuid-68cb3b710ac1432d89eebd942aadc9a8,PD1,0.366488
uuid-68cb3b710ac1432d89eebd942aadc9a8,cHL,0.707984
uuid-68cb3b710ac1432d89eebd942aadc9a8,progression,0.35575
uuid-68cb3b710ac1432d89eebd942aadc9a8,chemotherapy,0.461326
uuid-68cb3b710ac1432d89eebd942aadc9a8,option,0.341623
uuid-d3ca1f99624a430fbfed580697b88427,patients,0.818331
uuid-d3ca1f99624a430fbfed580697b88427,therapy,0.606964
uuid-d3ca1f99624a430fbfed580697b88427,1L,0.304265
uuid-d3ca1f99624a430fbfed580697b88427,regimen,0.45254
uuid-d3ca1f99624a430fbfed580697b88427,treated,0.392742
uuid-d3ca1f99624a430fbfed580697b88427,chemo,0.563758
uuid-d3ca1f99624a430fbfed580697b88427,pts,0.645279
uuid-d3ca1f99624a430fbfed580697b88427,monotherapy,0.518024
uuid-d3ca1f99624a430fbfed580697b88427,treatment,0.64965
uuid-d3ca1f99624a430fbfed580697b88427,response,0.503167
uuid-d3ca1f99624a430fbfed580697b88427,PD1,0.435207
uuid-d3ca1f99624a430fbfed580697b88427,progression,0.654216
uuid-d3ca1f99624a430fbfed580697b88427,chemotherapy,0.545412
uuid-d3ca1f99624a430fbfed580697b88427,respond,0.598235
uuid-d3ca1f99624a430fbfed580697b88427,option,0.526083
uuid-fa307567b4934992b67289e66ec91d04,treated,0.423934
uuid-fa307567b4934992b67289e66ec91d04,melanoma,0.351783
uuid-fa307567b4934992b67289e66ec91d04,treatment,0.387428
uuid-fa307567b4934992b67289e66ec91d04,lung cancer,0.433217
uuid-fa307567b4934992b67289e66ec91d04,progression,0.467967
uuid-fa307567b4934992b67289e66ec91d04,TL shared,0.320973
uuid-f6585b20e6744d5ca30bc66762677eb1,toxicity,0.385733
uuid-f6585b20e6744d5ca30bc66762677eb1,melanoma,0.377822
uuid-0cbfa754fd1849b8b7e7402a0c57f47c,patients,0.467092
uuid-0cbfa754fd1849b8b7e7402a0c57f47c,TL,0.300348
uuid-0cbfa754fd1849b8b7e7402a0c57f47c,treated,0.363259
uuid-0cbfa754fd1849b8b7e7402a0c57f47c,TL stated,0.377887
uuid-0cbfa754fd1849b8b7e7402a0c57f47c,tumor,0.496061
uuid-0cbfa754fd1849b8b7e7402a0c57f47c,pts,0.397172
uuid-0cbfa754fd1849b8b7e7402a0c57f47c,PD-L1 testing,0.429055
uuid-0cbfa754fd1849b8b7e7402a0c57f47c,testing,0.444367
uuid-0cbfa754fd1849b8b7e7402a0c57f47c,PDL1 testing,0.394986
uuid-0cbfa754fd1849b8b7e7402a0c57f47c,NSCLC patients,0.42517
uuid-ad051cb531c34feeafa09d854eb5e6e5,trial,0.546193
uuid-ad051cb531c34feeafa09d854eb5e6e5,vs,0.316414
uuid-66f5311ebe8d410699a54c02295000b5,pembro,0.360251
uuid-66f5311ebe8d410699a54c02295000b5,PDL1,0.594944
uuid-66f5311ebe8d410699a54c02295000b5,trial,0.412853
uuid-66f5311ebe8d410699a54c02295000b5,efficacy,0.723721
uuid-66f5311ebe8d410699a54c02295000b5,chemo,0.317905
uuid-66f5311ebe8d410699a54c02295000b5,agents,0.509996
uuid-66f5311ebe8d410699a54c02295000b5,OS,0.622491
uuid-66f5311ebe8d410699a54c02295000b5,atezo,0.353336
uuid-66f5311ebe8d410699a54c02295000b5,data,0.630056
uuid-66f5311ebe8d410699a54c02295000b5,PFS,0.594331
uuid-66f5311ebe8d410699a54c02295000b5,PD1,0.323172
uuid-66f5311ebe8d410699a54c02295000b5,ORR,0.649761
uuid-66f5311ebe8d410699a54c02295000b5,nivo and pembro,0.653363
uuid-66f5311ebe8d410699a54c02295000b5,believes,0.4784
uuid-66f5311ebe8d410699a54c02295000b5,impressed,0.339484
uuid-66f5311ebe8d410699a54c02295000b5,vs,0.350792
uuid-66f5311ebe8d410699a54c02295000b5,feels,0.408046
uuid-66f5311ebe8d410699a54c02295000b5,PDL1 expression,0.504128
uuid-66f5311ebe8d410699a54c02295000b5,biomarker,0.399609
uuid-9fc296c17eb34b09b933a370ca267dc7,Nivo,0.324645
uuid-9fc296c17eb34b09b933a370ca267dc7,pembro,0.405004
uuid-9fc296c17eb34b09b933a370ca267dc7,RTL,0.372717
uuid-9fc296c17eb34b09b933a370ca267dc7,nivolumab,0.336617
uuid-9fc296c17eb34b09b933a370ca267dc7,1L,0.453077
uuid-9fc296c17eb34b09b933a370ca267dc7,trial,0.392165
uuid-9fc296c17eb34b09b933a370ca267dc7,NTL,0.3083
uuid-9fc296c17eb34b09b933a370ca267dc7,shared,0.341898
uuid-9fc296c17eb34b09b933a370ca267dc7,RCC,0.377824
uuid-9fc296c17eb34b09b933a370ca267dc7,combination,0.388044
uuid-9fc296c17eb34b09b933a370ca267dc7,2L,0.418593
uuid-9fc296c17eb34b09b933a370ca267dc7,approval,0.43451
uuid-9fc296c17eb34b09b933a370ca267dc7,preferred,0.368467
uuid-9fc296c17eb34b09b933a370ca267dc7,monotherapy,0.411991
uuid-9fc296c17eb34b09b933a370ca267dc7,using nivo,0.470167
uuid-9fc296c17eb34b09b933a370ca267dc7,combo,0.404349
uuid-9fc296c17eb34b09b933a370ca267dc7,clinical trials,0.431918
uuid-9fc296c17eb34b09b933a370ca267dc7,approved,0.391454
uuid-9fc296c17eb34b09b933a370ca267dc7,SCCHN,0.44175
uuid-9fc296c17eb34b09b933a370ca267dc7,impressed,0.397624
uuid-9fc296c17eb34b09b933a370ca267dc7,LTL,0.32348
uuid-9fc296c17eb34b09b933a370ca267dc7,SCLC,0.383158
uuid-9fc296c17eb34b09b933a370ca267dc7,feels,0.309978
uuid-9fc296c17eb34b09b933a370ca267dc7,Regional TL,0.346065
uuid-9fc296c17eb34b09b933a370ca267dc7,RTL stated,0.450211
uuid-9fc296c17eb34b09b933a370ca267dc7,TL shared,0.326508
uuid-9fc296c17eb34b09b933a370ca267dc7,option,0.376308
uuid-9fc296c17eb34b09b933a370ca267dc7,bladder,0.376844
uuid-6822a89fd589426ebdd5970e995c9f27,Nivo,0.56428
uuid-6822a89fd589426ebdd5970e995c9f27,pembro,0.412679
uuid-6822a89fd589426ebdd5970e995c9f27,trial,0.550391
uuid-6822a89fd589426ebdd5970e995c9f27,efficacy,0.591454
uuid-6822a89fd589426ebdd5970e995c9f27,combination,0.382929
uuid-6822a89fd589426ebdd5970e995c9f27,chemo,0.398634
uuid-6822a89fd589426ebdd5970e995c9f27,agents,0.320766
uuid-6822a89fd589426ebdd5970e995c9f27,Ipi,0.429364
uuid-6822a89fd589426ebdd5970e995c9f27,OS,0.445433
uuid-6822a89fd589426ebdd5970e995c9f27,atezo,0.309853
uuid-6822a89fd589426ebdd5970e995c9f27,data,0.504634
uuid-6822a89fd589426ebdd5970e995c9f27,combo,0.326544
uuid-6822a89fd589426ebdd5970e995c9f27,PFS,0.431742
uuid-6822a89fd589426ebdd5970e995c9f27,ORR,0.527402
uuid-6822a89fd589426ebdd5970e995c9f27,nivo and pembro,0.420146
uuid-6822a89fd589426ebdd5970e995c9f27,chemotherapy,0.357582
uuid-6822a89fd589426ebdd5970e995c9f27,impressed,0.322368
uuid-6822a89fd589426ebdd5970e995c9f27,vs,0.518493
uuid-6822a89fd589426ebdd5970e995c9f27,feels,0.426956
uuid-7edfc73a834345f4bf7bdf1c38894177,therapy,0.450415
uuid-7edfc73a834345f4bf7bdf1c38894177,regimen,0.319277
uuid-7edfc73a834345f4bf7bdf1c38894177,combination,0.548152
uuid-7edfc73a834345f4bf7bdf1c38894177,chemo,0.524353
uuid-7edfc73a834345f4bf7bdf1c38894177,IO,0.388921
uuid-7edfc73a834345f4bf7bdf1c38894177,agents,0.5563
uuid-7edfc73a834345f4bf7bdf1c38894177,preferred,0.305542
uuid-7edfc73a834345f4bf7bdf1c38894177,monotherapy,0.489134
uuid-7edfc73a834345f4bf7bdf1c38894177,treatment,0.415969
uuid-7edfc73a834345f4bf7bdf1c38894177,response,0.332488
uuid-7edfc73a834345f4bf7bdf1c38894177,combo,0.490061
uuid-7edfc73a834345f4bf7bdf1c38894177,PD1,0.501014
uuid-7edfc73a834345f4bf7bdf1c38894177,progression,0.357907
uuid-7edfc73a834345f4bf7bdf1c38894177,believes,0.379501
uuid-7edfc73a834345f4bf7bdf1c38894177,chemotherapy,0.503667
uuid-7edfc73a834345f4bf7bdf1c38894177,respond,0.324294
uuid-7edfc73a834345f4bf7bdf1c38894177,feels,0.32946
uuid-7edfc73a834345f4bf7bdf1c38894177,PD-1,0.423803
uuid-7edfc73a834345f4bf7bdf1c38894177,option,0.517109
uuid-0ecfd8b858014d8b8260842d490fe4f2,RTL,0.30342
uuid-0ecfd8b858014d8b8260842d490fe4f2,trial,0.44279
uuid-0ecfd8b858014d8b8260842d490fe4f2,NTL,0.325745
uuid-0ecfd8b858014d8b8260842d490fe4f2,combination,0.377871
uuid-0ecfd8b858014d8b8260842d490fe4f2,agents,0.381906
uuid-0ecfd8b858014d8b8260842d490fe4f2,stated,0.316382
uuid-0ecfd8b858014d8b8260842d490fe4f2,data,0.409088
uuid-0ecfd8b858014d8b8260842d490fe4f2,combo,0.308022
uuid-0ecfd8b858014d8b8260842d490fe4f2,clinical trials,0.308122
uuid-0ecfd8b858014d8b8260842d490fe4f2,PD1,0.312079
uuid-0ecfd8b858014d8b8260842d490fe4f2,ORR,0.332578
uuid-0ecfd8b858014d8b8260842d490fe4f2,impressed,0.407052
uuid-0ecfd8b858014d8b8260842d490fe4f2,feels,0.366058
uuid-0ecfd8b858014d8b8260842d490fe4f2,Regional TL,0.335629
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,BMS,0.357305
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,PDL1,0.441773
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,trial,0.529914
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,efficacy,0.571214
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,OS,0.622237
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,data,0.797695
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,PFS,0.625842
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,ORR,0.680012
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,nivo and pembro,0.443756
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,believes,0.328393
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,impressed,0.553096
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,feels,0.43285
uuid-23b357b2429f4e5f9fd4b6746b1df8c6,PDL1 expression,0.419127
uuid-b9eaa17dd0a34071bf6ac702faa8a39a,TL,0.528458
uuid-b9eaa17dd0a34071bf6ac702faa8a39a,lung,0.485869
uuid-b9eaa17dd0a34071bf6ac702faa8a39a,melanoma,0.337294
uuid-b9eaa17dd0a34071bf6ac702faa8a39a,RCC,0.334736
uuid-b9eaa17dd0a34071bf6ac702faa8a39a,TL stated,0.671659
uuid-b9eaa17dd0a34071bf6ac702faa8a39a,PD-L1,0.514835
uuid-b9eaa17dd0a34071bf6ac702faa8a39a,PD-L1 testing,0.641997
uuid-b9eaa17dd0a34071bf6ac702faa8a39a,testing,0.651001
uuid-b9eaa17dd0a34071bf6ac702faa8a39a,PDL1 testing,0.593027
uuid-b9eaa17dd0a34071bf6ac702faa8a39a,NSCLC patients,0.624278
uuid-b9eaa17dd0a34071bf6ac702faa8a39a,assay,0.426368
uuid-b9eaa17dd0a34071bf6ac702faa8a39a,TL shared,0.441799
uuid-1bd76461693b4c5d91971f136a921b14,TL,0.336615
uuid-1bd76461693b4c5d91971f136a921b14,PDL1,0.535882
uuid-1bd76461693b4c5d91971f136a921b14,PD-L1,0.674224
uuid-1bd76461693b4c5d91971f136a921b14,PD-L1 testing,0.612607
uuid-1bd76461693b4c5d91971f136a921b14,testing,0.656505
uuid-1bd76461693b4c5d91971f136a921b14,PDL1 testing,0.473308
uuid-1bd76461693b4c5d91971f136a921b14,NSCLC patients,0.470734
uuid-1bd76461693b4c5d91971f136a921b14,believes,0.31637
uuid-1bd76461693b4c5d91971f136a921b14,assay,0.472308
uuid-1bd76461693b4c5d91971f136a921b14,PDL1 expression,0.302234
uuid-1bd76461693b4c5d91971f136a921b14,biomarker,0.511274
uuid-2b3dc412639f4f7080e1a650914cbed2,PDL1,0.335275
uuid-2b3dc412639f4f7080e1a650914cbed2,regards,0.357185
uuid-2b3dc412639f4f7080e1a650914cbed2,data,0.34757
uuid-2b3dc412639f4f7080e1a650914cbed2,biomarker,0.332581
uuid-2b3dc412639f4f7080e1a650914cbed2,NCCN,0.324861
uuid-3fed2e6da17140098bb826b055820a5f,TL,0.372084
uuid-3fed2e6da17140098bb826b055820a5f,PDL1,0.319741
uuid-3fed2e6da17140098bb826b055820a5f,TL stated,0.414373
uuid-3fed2e6da17140098bb826b055820a5f,PD-L1,0.604568
uuid-3fed2e6da17140098bb826b055820a5f,PD-L1 testing,0.776062
uuid-3fed2e6da17140098bb826b055820a5f,testing,0.695479
uuid-3fed2e6da17140098bb826b055820a5f,PDL1 testing,0.583883
uuid-3fed2e6da17140098bb826b055820a5f,NSCLC patients,0.447679
uuid-3fed2e6da17140098bb826b055820a5f,assay,0.48737
uuid-3fed2e6da17140098bb826b055820a5f,biomarker,0.378589
uuid-9df470025630437c87bf8da55daa0069,pembro,0.490106
uuid-9df470025630437c87bf8da55daa0069,BMS,0.367544
uuid-9df470025630437c87bf8da55daa0069,1L,0.403867
uuid-9df470025630437c87bf8da55daa0069,PDL1,0.577883
uuid-9df470025630437c87bf8da55daa0069,commented,0.387902
uuid-9df470025630437c87bf8da55daa0069,TL stated,0.415425
uuid-9df470025630437c87bf8da55daa0069,2L,0.337946
uuid-9df470025630437c87bf8da55daa0069,Merck,0.436278
uuid-9df470025630437c87bf8da55daa0069,stated,0.449983
uuid-9df470025630437c87bf8da55daa0069,PD-L1,0.44122
uuid-9df470025630437c87bf8da55daa0069,atezo,0.489682
uuid-9df470025630437c87bf8da55daa0069,testing,0.39585
uuid-9df470025630437c87bf8da55daa0069,data,0.520937
uuid-9df470025630437c87bf8da55daa0069,expressed,0.374638
uuid-9df470025630437c87bf8da55daa0069,PDL1 testing,0.478022
uuid-9df470025630437c87bf8da55daa0069,NSCLC patients,0.356014
uuid-9df470025630437c87bf8da55daa0069,SCCHN,0.358337
uuid-9df470025630437c87bf8da55daa0069,nivo and pembro,0.426871
uuid-9df470025630437c87bf8da55daa0069,believes,0.306883
uuid-9df470025630437c87bf8da55daa0069,impressed,0.409982
uuid-9df470025630437c87bf8da55daa0069,tumor types,0.325423
uuid-9df470025630437c87bf8da55daa0069,LTL,0.318071
uuid-9df470025630437c87bf8da55daa0069,TLs,0.495542
uuid-9df470025630437c87bf8da55daa0069,feels,0.351109
uuid-9df470025630437c87bf8da55daa0069,assay,0.301136
uuid-9df470025630437c87bf8da55daa0069,PDL1 expression,0.457253
uuid-9df470025630437c87bf8da55daa0069,biomarker,0.341574
uuid-9df470025630437c87bf8da55daa0069,bladder,0.343824
uuid-39efcf62f5d249e6b0a166dfc5551535,Nivo,0.444615
uuid-39efcf62f5d249e6b0a166dfc5551535,patients,0.39156
uuid-39efcf62f5d249e6b0a166dfc5551535,pembro,0.433491
uuid-39efcf62f5d249e6b0a166dfc5551535,1L,0.305861
uuid-39efcf62f5d249e6b0a166dfc5551535,toxicity,0.366994
uuid-39efcf62f5d249e6b0a166dfc5551535,trial,0.401718
uuid-39efcf62f5d249e6b0a166dfc5551535,efficacy,0.325566
uuid-39efcf62f5d249e6b0a166dfc5551535,regimen,0.463562
uuid-39efcf62f5d249e6b0a166dfc5551535,combination,0.403338
uuid-39efcf62f5d249e6b0a166dfc5551535,chemo,0.416102
uuid-39efcf62f5d249e6b0a166dfc5551535,pts,0.349564
uuid-39efcf62f5d249e6b0a166dfc5551535,Ipi,0.417769
uuid-39efcf62f5d249e6b0a166dfc5551535,preferred,0.387927
uuid-39efcf62f5d249e6b0a166dfc5551535,monotherapy,0.489424
uuid-39efcf62f5d249e6b0a166dfc5551535,using nivo,0.346562
uuid-39efcf62f5d249e6b0a166dfc5551535,combo,0.378575
uuid-39efcf62f5d249e6b0a166dfc5551535,clinical trials,0.320411
uuid-39efcf62f5d249e6b0a166dfc5551535,chemotherapy,0.410805
uuid-39efcf62f5d249e6b0a166dfc5551535,impressed,0.303746
uuid-39efcf62f5d249e6b0a166dfc5551535,feels,0.47016
uuid-39efcf62f5d249e6b0a166dfc5551535,option,0.39327
uuid-8bb3e123daa74277b936c159dc40648e,TL,0.574448
uuid-8bb3e123daa74277b936c159dc40648e,PDL1,0.389254
uuid-8bb3e123daa74277b936c159dc40648e,TL stated,0.419388
uuid-8bb3e123daa74277b936c159dc40648e,Merck,0.319537
uuid-8bb3e123daa74277b936c159dc40648e,institution,0.358198
uuid-8bb3e123daa74277b936c159dc40648e,PD-L1,0.744924
uuid-8bb3e123daa74277b936c159dc40648e,PD-L1 testing,0.779123
uuid-8bb3e123daa74277b936c159dc40648e,testing,0.785185
uuid-8bb3e123daa74277b936c159dc40648e,PDL1 testing,0.588855
uuid-8bb3e123daa74277b936c159dc40648e,NSCLC patients,0.518169
uuid-8bb3e123daa74277b936c159dc40648e,assay,0.81386
uuid-8bb3e123daa74277b936c159dc40648e,biomarker,0.314645
uuid-c35539115dc544d4af6bb314f55f7fe6,therapy,0.303337
uuid-c35539115dc544d4af6bb314f55f7fe6,trial,0.329971
uuid-c35539115dc544d4af6bb314f55f7fe6,cHL,0.323753
uuid-c35539115dc544d4af6bb314f55f7fe6,chemotherapy,0.316587
uuid-63f80a5be80a45ce959efc94a07f59a4,pembro,0.30521
uuid-63f80a5be80a45ce959efc94a07f59a4,RTL,0.316384
uuid-63f80a5be80a45ce959efc94a07f59a4,BMS,0.394999
uuid-63f80a5be80a45ce959efc94a07f59a4,trial,0.615535
uuid-63f80a5be80a45ce959efc94a07f59a4,combination,0.301233
uuid-63f80a5be80a45ce959efc94a07f59a4,data,0.357639
uuid-63f80a5be80a45ce959efc94a07f59a4,clinical trials,0.413724
uuid-63f80a5be80a45ce959efc94a07f59a4,indication,0.363199
uuid-63f80a5be80a45ce959efc94a07f59a4,SCCHN,0.372449
uuid-63f80a5be80a45ce959efc94a07f59a4,impressed,0.374666
uuid-63f80a5be80a45ce959efc94a07f59a4,feels,0.394847
uuid-521986f80bdf48a3b4933d975261061d,therapy,0.451036
uuid-521986f80bdf48a3b4933d975261061d,regimen,0.320965
uuid-521986f80bdf48a3b4933d975261061d,combination,0.358127
uuid-521986f80bdf48a3b4933d975261061d,chemo,0.373306
uuid-521986f80bdf48a3b4933d975261061d,treatment,0.463684
uuid-521986f80bdf48a3b4933d975261061d,response,0.388198
uuid-521986f80bdf48a3b4933d975261061d,PD1,0.341435
uuid-521986f80bdf48a3b4933d975261061d,progression,0.483244
uuid-521986f80bdf48a3b4933d975261061d,chemotherapy,0.400651
uuid-521986f80bdf48a3b4933d975261061d,immunotherapy,0.383547
uuid-800e40cfbe2a48bea907e90eaa967c38,Nivo,0.413489
uuid-800e40cfbe2a48bea907e90eaa967c38,dose,0.314701
uuid-800e40cfbe2a48bea907e90eaa967c38,efficacy,0.646224
uuid-800e40cfbe2a48bea907e90eaa967c38,Ipi,0.306336
uuid-800e40cfbe2a48bea907e90eaa967c38,believes,0.392504
uuid-800e40cfbe2a48bea907e90eaa967c38,vs,0.341109
uuid-800e40cfbe2a48bea907e90eaa967c38,feels,0.36087
uuid-f67986b61e11484db8506ee3ce3bc951,NSCLC,0.508041
uuid-f67986b61e11484db8506ee3ce3bc951,treated,0.315508
uuid-f67986b61e11484db8506ee3ce3bc951,tumor,0.483738
uuid-f67986b61e11484db8506ee3ce3bc951,pts,0.359282
uuid-f67986b61e11484db8506ee3ce3bc951,IO,0.436343
uuid-f67986b61e11484db8506ee3ce3bc951,response,0.551114
uuid-f67986b61e11484db8506ee3ce3bc951,progression,0.430822
uuid-10c9db68a42149e2a89a9c8989c81c81,toxicity,0.500371
uuid-10c9db68a42149e2a89a9c8989c81c81,physicians,0.383079
uuid-10c9db68a42149e2a89a9c8989c81c81,treatment,0.368787
uuid-3f115589063b4e24acc43b796b7657ef,lung,0.349179
uuid-3f115589063b4e24acc43b796b7657ef,1L,0.303567
uuid-3f115589063b4e24acc43b796b7657ef,NTL,0.301295
uuid-3f115589063b4e24acc43b796b7657ef,melanoma,0.447188
uuid-3f115589063b4e24acc43b796b7657ef,RCC,0.391688
uuid-3f115589063b4e24acc43b796b7657ef,2L,0.302716
uuid-3f115589063b4e24acc43b796b7657ef,preferred,0.34365
uuid-3f115589063b4e24acc43b796b7657ef,using nivo,0.337293
uuid-3f115589063b4e24acc43b796b7657ef,SCCHN,0.642544
uuid-3f115589063b4e24acc43b796b7657ef,RTL stated,0.413293
uuid-3f115589063b4e24acc43b796b7657ef,TL shared,0.376874
uuid-3f115589063b4e24acc43b796b7657ef,NCCN,0.483148
uuid-3f115589063b4e24acc43b796b7657ef,bladder,0.419057
uuid-75b617b45ec0469b80f6de752af0e56b,lung,0.300191
uuid-75b617b45ec0469b80f6de752af0e56b,NTL,0.401806
uuid-75b617b45ec0469b80f6de752af0e56b,melanoma,0.422082
uuid-75b617b45ec0469b80f6de752af0e56b,commented,0.30668
uuid-75b617b45ec0469b80f6de752af0e56b,SCCHN,0.396401
uuid-75b617b45ec0469b80f6de752af0e56b,NCCN,0.638066
uuid-422bddf5260142c3bb76659152de04ce,Nivo,0.620222
uuid-422bddf5260142c3bb76659152de04ce,pembro,0.346451
uuid-422bddf5260142c3bb76659152de04ce,therapy,0.409493
uuid-422bddf5260142c3bb76659152de04ce,nivolumab,0.552287
uuid-422bddf5260142c3bb76659152de04ce,1L,0.418527
uuid-422bddf5260142c3bb76659152de04ce,RCC,0.585773
uuid-422bddf5260142c3bb76659152de04ce,2L,0.549854
uuid-422bddf5260142c3bb76659152de04ce,approval,0.419958
uuid-422bddf5260142c3bb76659152de04ce,preferred,0.422007
uuid-422bddf5260142c3bb76659152de04ce,monotherapy,0.444618
uuid-422bddf5260142c3bb76659152de04ce,using nivo,0.751979
uuid-422bddf5260142c3bb76659152de04ce,PD1,0.354567
uuid-422bddf5260142c3bb76659152de04ce,approved,0.380393
uuid-422bddf5260142c3bb76659152de04ce,SCCHN,0.35922
uuid-422bddf5260142c3bb76659152de04ce,cHL,0.48375
uuid-422bddf5260142c3bb76659152de04ce,RTL stated,0.60438
uuid-422bddf5260142c3bb76659152de04ce,TL shared,0.348379
uuid-422bddf5260142c3bb76659152de04ce,option,0.378402
uuid-422bddf5260142c3bb76659152de04ce,bladder,0.339118
uuid-c9747bd3d58d4db0a58836cf05cde291,Nivo,0.508009
uuid-c9747bd3d58d4db0a58836cf05cde291,patients,0.635481
uuid-c9747bd3d58d4db0a58836cf05cde291,therapy,0.740802
uuid-c9747bd3d58d4db0a58836cf05cde291,nivolumab,0.521454
uuid-c9747bd3d58d4db0a58836cf05cde291,1L,0.443282
uuid-c9747bd3d58d4db0a58836cf05cde291,regimen,0.419768
uuid-c9747bd3d58d4db0a58836cf05cde291,treated,0.372475
uuid-c9747bd3d58d4db0a58836cf05cde291,RCC,0.31357
uuid-c9747bd3d58d4db0a58836cf05cde291,combination,0.4463
uuid-c9747bd3d58d4db0a58836cf05cde291,chemo,0.557186
uuid-c9747bd3d58d4db0a58836cf05cde291,2L,0.456385
uuid-c9747bd3d58d4db0a58836cf05cde291,pts,0.50603
uuid-c9747bd3d58d4db0a58836cf05cde291,IO,0.300149
uuid-c9747bd3d58d4db0a58836cf05cde291,agents,0.351134
uuid-c9747bd3d58d4db0a58836cf05cde291,preferred,0.434219
uuid-c9747bd3d58d4db0a58836cf05cde291,monotherapy,0.657229
uuid-c9747bd3d58d4db0a58836cf05cde291,treatment,0.53474
uuid-c9747bd3d58d4db0a58836cf05cde291,using nivo,0.541693
uuid-c9747bd3d58d4db0a58836cf05cde291,response,0.423332
uuid-c9747bd3d58d4db0a58836cf05cde291,combo,0.389046
uuid-c9747bd3d58d4db0a58836cf05cde291,PD1,0.586963
uuid-c9747bd3d58d4db0a58836cf05cde291,cHL,0.375059
uuid-c9747bd3d58d4db0a58836cf05cde291,progression,0.564229
uuid-c9747bd3d58d4db0a58836cf05cde291,chemotherapy,0.587769
uuid-c9747bd3d58d4db0a58836cf05cde291,respond,0.391194
uuid-c9747bd3d58d4db0a58836cf05cde291,RTL stated,0.3564
uuid-c9747bd3d58d4db0a58836cf05cde291,option,0.666882
uuid-fabec3590af04e479f3f1ef3a130d9a5,pts,0.449965
uuid-fabec3590af04e479f3f1ef3a130d9a5,OS,0.350458
uuid-fabec3590af04e479f3f1ef3a130d9a5,response,0.386337
uuid-fabec3590af04e479f3f1ef3a130d9a5,data,0.310625
uuid-fabec3590af04e479f3f1ef3a130d9a5,progression,0.317244
uuid-fabec3590af04e479f3f1ef3a130d9a5,believes,0.409014
uuid-fabec3590af04e479f3f1ef3a130d9a5,impressed,0.33195
uuid-fabec3590af04e479f3f1ef3a130d9a5,respond,0.385646
uuid-fabec3590af04e479f3f1ef3a130d9a5,feels,0.408757
uuid-e1d26f0314eb4da0899e97f242fae304,RCC,0.363589
uuid-4aeb8212910042b2928bfc72451968e9,Nivo,0.612472
uuid-4aeb8212910042b2928bfc72451968e9,efficacy,0.446601
uuid-4aeb8212910042b2928bfc72451968e9,regimen,0.309071
uuid-4aeb8212910042b2928bfc72451968e9,combination,0.379677
uuid-4aeb8212910042b2928bfc72451968e9,chemo,0.478902
uuid-4aeb8212910042b2928bfc72451968e9,OS,0.453748
uuid-4aeb8212910042b2928bfc72451968e9,monotherapy,0.435145
uuid-4aeb8212910042b2928bfc72451968e9,response,0.362092
uuid-4aeb8212910042b2928bfc72451968e9,data,0.446508
uuid-4aeb8212910042b2928bfc72451968e9,combo,0.391638
uuid-4aeb8212910042b2928bfc72451968e9,PFS,0.422524
uuid-4aeb8212910042b2928bfc72451968e9,PD1,0.415266
uuid-4aeb8212910042b2928bfc72451968e9,ORR,0.484433
uuid-4aeb8212910042b2928bfc72451968e9,nivo and pembro,0.312462
uuid-4aeb8212910042b2928bfc72451968e9,progression,0.303178
uuid-4aeb8212910042b2928bfc72451968e9,believes,0.3228
uuid-4aeb8212910042b2928bfc72451968e9,chemotherapy,0.441063
uuid-4aeb8212910042b2928bfc72451968e9,impressed,0.433029
uuid-4aeb8212910042b2928bfc72451968e9,feels,0.38966
uuid-4aeb8212910042b2928bfc72451968e9,option,0.415044
uuid-30603350876146a299f10888a71754be,RTL,0.509168
uuid-30603350876146a299f10888a71754be,BMS,0.356121
uuid-30603350876146a299f10888a71754be,trial,0.471774
uuid-30603350876146a299f10888a71754be,NTL,0.499386
uuid-30603350876146a299f10888a71754be,discussed,0.308511
uuid-30603350876146a299f10888a71754be,commented,0.553659
uuid-30603350876146a299f10888a71754be,stated,0.336213
uuid-30603350876146a299f10888a71754be,regards,0.414766
uuid-30603350876146a299f10888a71754be,data,0.527076
uuid-30603350876146a299f10888a71754be,expressed,0.426576
uuid-30603350876146a299f10888a71754be,mentioned,0.41505
uuid-30603350876146a299f10888a71754be,ASCO,0.473472
uuid-30603350876146a299f10888a71754be,impressed,0.561365
uuid-30603350876146a299f10888a71754be,LTL,0.320043
uuid-30603350876146a299f10888a71754be,TLs,0.349192
uuid-30603350876146a299f10888a71754be,Regional TL,0.453335
uuid-b3ec6c31c01d416ba036d24241eba32d,TL,0.319925
uuid-b3ec6c31c01d416ba036d24241eba32d,RTL,0.420785
uuid-b3ec6c31c01d416ba036d24241eba32d,commented,0.301419
uuid-b3ec6c31c01d416ba036d24241eba32d,stated,0.313895
uuid-b3ec6c31c01d416ba036d24241eba32d,approval,0.31499
uuid-b3ec6c31c01d416ba036d24241eba32d,using nivo,0.434561
uuid-b3ec6c31c01d416ba036d24241eba32d,data,0.412114
uuid-b3ec6c31c01d416ba036d24241eba32d,SCCHN,0.445993
uuid-b3ec6c31c01d416ba036d24241eba32d,impressed,0.318145
uuid-b3ec6c31c01d416ba036d24241eba32d,indicated,0.438224
uuid-b3ec6c31c01d416ba036d24241eba32d,LTL,0.426792
uuid-b3ec6c31c01d416ba036d24241eba32d,TLs,0.366856
uuid-b3ec6c31c01d416ba036d24241eba32d,Regional TL,0.472271
uuid-b3ec6c31c01d416ba036d24241eba32d,RTL stated,0.317067
uuid-ed3a0d99e08149ec855c8d33a21f15cb,Nivo,0.453846
uuid-ed3a0d99e08149ec855c8d33a21f15cb,pembro,0.457123
uuid-ed3a0d99e08149ec855c8d33a21f15cb,BMS,0.306131
uuid-ed3a0d99e08149ec855c8d33a21f15cb,PDL1,0.52798
uuid-ed3a0d99e08149ec855c8d33a21f15cb,efficacy,0.7902
uuid-ed3a0d99e08149ec855c8d33a21f15cb,agents,0.350695
uuid-ed3a0d99e08149ec855c8d33a21f15cb,OS,0.549618
uuid-ed3a0d99e08149ec855c8d33a21f15cb,atezo,0.478653
uuid-ed3a0d99e08149ec855c8d33a21f15cb,data,0.667192
uuid-ed3a0d99e08149ec855c8d33a21f15cb,PFS,0.519255
uuid-ed3a0d99e08149ec855c8d33a21f15cb,ORR,0.583441
uuid-ed3a0d99e08149ec855c8d33a21f15cb,nivo and pembro,0.600206
uuid-ed3a0d99e08149ec855c8d33a21f15cb,believes,0.53335
uuid-ed3a0d99e08149ec855c8d33a21f15cb,impressed,0.434152
uuid-ed3a0d99e08149ec855c8d33a21f15cb,vs,0.385131
uuid-ed3a0d99e08149ec855c8d33a21f15cb,feels,0.440069
uuid-ed3a0d99e08149ec855c8d33a21f15cb,PDL1 expression,0.508763
uuid-e3b2511f71f845668d92b7a9d8d499e5,patients,0.733621
uuid-e3b2511f71f845668d92b7a9d8d499e5,Opdivo,0.674645
uuid-e3b2511f71f845668d92b7a9d8d499e5,therapy,0.46466
uuid-e3b2511f71f845668d92b7a9d8d499e5,nivolumab,0.528734
uuid-e3b2511f71f845668d92b7a9d8d499e5,regimen,0.346581
uuid-e3b2511f71f845668d92b7a9d8d499e5,treated,0.614791
uuid-e3b2511f71f845668d92b7a9d8d499e5,pts,0.380304
uuid-e3b2511f71f845668d92b7a9d8d499e5,treatment,0.576788
uuid-e3b2511f71f845668d92b7a9d8d499e5,cHL,0.539824
uuid-e3b2511f71f845668d92b7a9d8d499e5,progression,0.525129
uuid-e3b2511f71f845668d92b7a9d8d499e5,respond,0.30581
uuid-f6a0e191854e48a59533cac00ab01e9c,RTL,0.334193
uuid-f6a0e191854e48a59533cac00ab01e9c,nivolumab,0.384483
uuid-f6a0e191854e48a59533cac00ab01e9c,lung,0.342787
uuid-f6a0e191854e48a59533cac00ab01e9c,1L,0.405954
uuid-f6a0e191854e48a59533cac00ab01e9c,discussed,0.356877
uuid-f6a0e191854e48a59533cac00ab01e9c,melanoma,0.377764
uuid-f6a0e191854e48a59533cac00ab01e9c,shared,0.329147
uuid-f6a0e191854e48a59533cac00ab01e9c,RCC,0.636869
uuid-f6a0e191854e48a59533cac00ab01e9c,2L,0.489523
uuid-f6a0e191854e48a59533cac00ab01e9c,stated,0.342611
uuid-f6a0e191854e48a59533cac00ab01e9c,approval,0.626792
uuid-f6a0e191854e48a59533cac00ab01e9c,preferred,0.382417
uuid-f6a0e191854e48a59533cac00ab01e9c,monotherapy,0.308296
uuid-f6a0e191854e48a59533cac00ab01e9c,using nivo,0.545119
uuid-f6a0e191854e48a59533cac00ab01e9c,approved,0.538943
uuid-f6a0e191854e48a59533cac00ab01e9c,SCCHN,0.579355
uuid-f6a0e191854e48a59533cac00ab01e9c,LTL,0.314003
uuid-f6a0e191854e48a59533cac00ab01e9c,TLs,0.307757
uuid-f6a0e191854e48a59533cac00ab01e9c,academic,0.485556
uuid-f6a0e191854e48a59533cac00ab01e9c,Regional TL,0.406069
uuid-f6a0e191854e48a59533cac00ab01e9c,RTL stated,0.613918
uuid-f6a0e191854e48a59533cac00ab01e9c,TL shared,0.438497
uuid-f6a0e191854e48a59533cac00ab01e9c,option,0.336128
uuid-f6a0e191854e48a59533cac00ab01e9c,bladder,0.361443
uuid-5a1feb917dbc44e5ad0183dc3d5c7813,OS,0.375376
uuid-5a1feb917dbc44e5ad0183dc3d5c7813,PFS,0.346613
uuid-5a1feb917dbc44e5ad0183dc3d5c7813,ORR,0.356311
uuid-5a1feb917dbc44e5ad0183dc3d5c7813,ASCO,0.309895
uuid-64781cd8e6aa4b2f8c15d83fd56b8e7a,NSCLC,0.303214
uuid-64781cd8e6aa4b2f8c15d83fd56b8e7a,ASCO,0.408512
uuid-f78da841b8ec44f3a95ddbc8ddb3daf6,TL,0.316726
uuid-f78da841b8ec44f3a95ddbc8ddb3daf6,RTL,0.343942
uuid-f78da841b8ec44f3a95ddbc8ddb3daf6,commented,0.418373
uuid-f78da841b8ec44f3a95ddbc8ddb3daf6,stated,0.32754
uuid-f78da841b8ec44f3a95ddbc8ddb3daf6,data,0.396984
uuid-f78da841b8ec44f3a95ddbc8ddb3daf6,expressed,0.325671
uuid-f78da841b8ec44f3a95ddbc8ddb3daf6,SCCHN,0.328778
uuid-f78da841b8ec44f3a95ddbc8ddb3daf6,ASCO,0.344878
uuid-f78da841b8ec44f3a95ddbc8ddb3daf6,impressed,0.540327
uuid-f78da841b8ec44f3a95ddbc8ddb3daf6,Regional TL,0.545581
uuid-d00672d28f9f4e1b9498241af87d4877,Nivo,0.456
uuid-d00672d28f9f4e1b9498241af87d4877,patients,0.563322
uuid-d00672d28f9f4e1b9498241af87d4877,Opdivo,0.372344
uuid-d00672d28f9f4e1b9498241af87d4877,therapy,0.411298
uuid-d00672d28f9f4e1b9498241af87d4877,dose,0.369093
uuid-d00672d28f9f4e1b9498241af87d4877,nivolumab,0.352288
uuid-d00672d28f9f4e1b9498241af87d4877,regimen,0.396205
uuid-d00672d28f9f4e1b9498241af87d4877,chemo,0.31588
uuid-d00672d28f9f4e1b9498241af87d4877,pts,0.361276
uuid-d00672d28f9f4e1b9498241af87d4877,treatment,0.453397
uuid-d00672d28f9f4e1b9498241af87d4877,progression,0.493024
uuid-d00672d28f9f4e1b9498241af87d4877,respond,0.430861
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,Nivo,0.573855
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,patients,0.491695
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,Opdivo,0.379325
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,pembro,0.427522
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,dose,0.758362
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,nivolumab,0.415648
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,toxicity,0.300449
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,regimen,0.465364
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,chemo,0.340045
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,pts,0.346435
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,Ipi,0.576503
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,treatment,0.332389
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,progression,0.345021
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,vs,0.560905
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,respond,0.311722
uuid-5b3e7dee53ac421ea5ab78f99f6022b3,flat dosing,0.458951
uuid-0d81eef81fc04b2dafabaaee0a93d0ad,Nivo,0.319032
uuid-0d81eef81fc04b2dafabaaee0a93d0ad,patients,0.542516
uuid-0d81eef81fc04b2dafabaaee0a93d0ad,therapy,0.336072
uuid-0d81eef81fc04b2dafabaaee0a93d0ad,chemo,0.416235
uuid-0d81eef81fc04b2dafabaaee0a93d0ad,pts,0.342143
uuid-0d81eef81fc04b2dafabaaee0a93d0ad,response,0.325583
uuid-0d81eef81fc04b2dafabaaee0a93d0ad,NSCLC patients,0.400172
uuid-0d81eef81fc04b2dafabaaee0a93d0ad,progression,0.393182
uuid-0d81eef81fc04b2dafabaaee0a93d0ad,respond,0.484771
uuid-448441773ec64c1ead91e551c229bb88,patients,0.501459
uuid-448441773ec64c1ead91e551c229bb88,Opdivo,0.496773
uuid-448441773ec64c1ead91e551c229bb88,dose,0.538806
uuid-448441773ec64c1ead91e551c229bb88,treatment,0.342746
uuid-448441773ec64c1ead91e551c229bb88,Keytruda,0.308981
uuid-448441773ec64c1ead91e551c229bb88,flat dosing,0.366393
uuid-08090d06a31c47f3b62a4bb64117759f,lung,0.309882
uuid-08090d06a31c47f3b62a4bb64117759f,PDL1,0.310568
uuid-08090d06a31c47f3b62a4bb64117759f,discussed,0.463421
uuid-08090d06a31c47f3b62a4bb64117759f,melanoma,0.3657
uuid-08090d06a31c47f3b62a4bb64117759f,RCC,0.331655
uuid-08090d06a31c47f3b62a4bb64117759f,atezo,0.356452
uuid-08090d06a31c47f3b62a4bb64117759f,data,0.370029
uuid-08090d06a31c47f3b62a4bb64117759f,SCCHN,0.309814
uuid-08090d06a31c47f3b62a4bb64117759f,nivo and pembro,0.329282
uuid-08090d06a31c47f3b62a4bb64117759f,TLs,0.510423
uuid-08090d06a31c47f3b62a4bb64117759f,academic,0.510997
uuid-08090d06a31c47f3b62a4bb64117759f,RTL stated,0.330199
uuid-08090d06a31c47f3b62a4bb64117759f,TL shared,0.364271
uuid-08090d06a31c47f3b62a4bb64117759f,PDL1 expression,0.320201
uuid-10113251a49344b4893499102781b628,patients,0.793804
uuid-10113251a49344b4893499102781b628,Opdivo,0.40215
uuid-10113251a49344b4893499102781b628,therapy,0.512964
uuid-10113251a49344b4893499102781b628,nivolumab,0.505702
uuid-10113251a49344b4893499102781b628,regimen,0.436608
uuid-10113251a49344b4893499102781b628,treated,0.694086
uuid-10113251a49344b4893499102781b628,pts,0.489765
uuid-10113251a49344b4893499102781b628,treatment,0.609193
uuid-10113251a49344b4893499102781b628,using nivo,0.307341
uuid-10113251a49344b4893499102781b628,response,0.329103
uuid-10113251a49344b4893499102781b628,cHL,0.416363
uuid-10113251a49344b4893499102781b628,progression,0.605332
uuid-10113251a49344b4893499102781b628,chemotherapy,0.302761
uuid-10113251a49344b4893499102781b628,respond,0.359266
uuid-8bf176b93bea4c5dba780af21e5fb1db,RTL,0.48302
uuid-8bf176b93bea4c5dba780af21e5fb1db,nivolumab,0.392075
uuid-8bf176b93bea4c5dba780af21e5fb1db,trial,0.395391
uuid-8bf176b93bea4c5dba780af21e5fb1db,commented,0.454457
uuid-8bf176b93bea4c5dba780af21e5fb1db,RCC,0.306061
uuid-8bf176b93bea4c5dba780af21e5fb1db,stated,0.498331
uuid-8bf176b93bea4c5dba780af21e5fb1db,approval,0.385156
uuid-8bf176b93bea4c5dba780af21e5fb1db,using nivo,0.34479
uuid-8bf176b93bea4c5dba780af21e5fb1db,data,0.518078
uuid-8bf176b93bea4c5dba780af21e5fb1db,clinical trials,0.408239
uuid-8bf176b93bea4c5dba780af21e5fb1db,approved,0.315521
uuid-8bf176b93bea4c5dba780af21e5fb1db,SCCHN,0.44698
uuid-8bf176b93bea4c5dba780af21e5fb1db,ASCO,0.31273
uuid-8bf176b93bea4c5dba780af21e5fb1db,impressed,0.636588
uuid-8bf176b93bea4c5dba780af21e5fb1db,LTL,0.430498
uuid-8bf176b93bea4c5dba780af21e5fb1db,TLs,0.36863
uuid-8bf176b93bea4c5dba780af21e5fb1db,SCLC,0.405889
uuid-8bf176b93bea4c5dba780af21e5fb1db,feels,0.367965
uuid-8bf176b93bea4c5dba780af21e5fb1db,Regional TL,0.506535
uuid-8bf176b93bea4c5dba780af21e5fb1db,RTL stated,0.335058
uuid-8bf176b93bea4c5dba780af21e5fb1db,bladder,0.356198
uuid-06a74dc667a846d7a40b69a9dfd960fb,pembro,0.329735
uuid-06a74dc667a846d7a40b69a9dfd960fb,BMS,0.410689
uuid-06a74dc667a846d7a40b69a9dfd960fb,PDL1,0.336942
uuid-06a74dc667a846d7a40b69a9dfd960fb,trial,0.588244
uuid-06a74dc667a846d7a40b69a9dfd960fb,efficacy,0.43022
uuid-06a74dc667a846d7a40b69a9dfd960fb,discussed,0.342744
uuid-06a74dc667a846d7a40b69a9dfd960fb,commented,0.438319
uuid-06a74dc667a846d7a40b69a9dfd960fb,Merck,0.335528
uuid-06a74dc667a846d7a40b69a9dfd960fb,OS,0.584566
uuid-06a74dc667a846d7a40b69a9dfd960fb,regards,0.424996
uuid-06a74dc667a846d7a40b69a9dfd960fb,data,0.807333
uuid-06a74dc667a846d7a40b69a9dfd960fb,expressed,0.346878
uuid-06a74dc667a846d7a40b69a9dfd960fb,PFS,0.58408
uuid-06a74dc667a846d7a40b69a9dfd960fb,ORR,0.621614
uuid-06a74dc667a846d7a40b69a9dfd960fb,nivo and pembro,0.538252
uuid-06a74dc667a846d7a40b69a9dfd960fb,ASCO,0.419318
uuid-06a74dc667a846d7a40b69a9dfd960fb,impressed,0.59856
uuid-06a74dc667a846d7a40b69a9dfd960fb,TLs,0.388721
uuid-06a74dc667a846d7a40b69a9dfd960fb,SCLC,0.306972
uuid-06a74dc667a846d7a40b69a9dfd960fb,PDL1 expression,0.340716
uuid-dc595bf516da479199bd19f1cbbdf4a8,Nivo,0.708056
uuid-dc595bf516da479199bd19f1cbbdf4a8,pembro,0.537415
uuid-dc595bf516da479199bd19f1cbbdf4a8,1L,0.354641
uuid-dc595bf516da479199bd19f1cbbdf4a8,PDL1,0.427251
uuid-dc595bf516da479199bd19f1cbbdf4a8,trial,0.380858
uuid-dc595bf516da479199bd19f1cbbdf4a8,efficacy,0.640329
uuid-dc595bf516da479199bd19f1cbbdf4a8,chemo,0.477622
uuid-dc595bf516da479199bd19f1cbbdf4a8,2L,0.311035
uuid-dc595bf516da479199bd19f1cbbdf4a8,Ipi,0.319753
uuid-dc595bf516da479199bd19f1cbbdf4a8,OS,0.605822
uuid-dc595bf516da479199bd19f1cbbdf4a8,atezo,0.437102
uuid-dc595bf516da479199bd19f1cbbdf4a8,monotherapy,0.369262
uuid-dc595bf516da479199bd19f1cbbdf4a8,data,0.472897
uuid-dc595bf516da479199bd19f1cbbdf4a8,PFS,0.674677
uuid-dc595bf516da479199bd19f1cbbdf4a8,ORR,0.61119
uuid-dc595bf516da479199bd19f1cbbdf4a8,nivo and pembro,0.611078
uuid-dc595bf516da479199bd19f1cbbdf4a8,believes,0.428713
uuid-dc595bf516da479199bd19f1cbbdf4a8,chemotherapy,0.405108
uuid-dc595bf516da479199bd19f1cbbdf4a8,impressed,0.341593
uuid-dc595bf516da479199bd19f1cbbdf4a8,vs,0.399488
uuid-dc595bf516da479199bd19f1cbbdf4a8,feels,0.465715
uuid-dc595bf516da479199bd19f1cbbdf4a8,PDL1 expression,0.435347
uuid-dc595bf516da479199bd19f1cbbdf4a8,option,0.364956
uuid-4645dd4e5f364a6399563ba7712b9225,patients,0.316777
uuid-4645dd4e5f364a6399563ba7712b9225,TL,0.590553
uuid-4645dd4e5f364a6399563ba7712b9225,lung,0.367526
uuid-4645dd4e5f364a6399563ba7712b9225,TL stated,0.522223
uuid-4645dd4e5f364a6399563ba7712b9225,PD-L1,0.540362
uuid-4645dd4e5f364a6399563ba7712b9225,PD-L1 testing,0.66286
uuid-4645dd4e5f364a6399563ba7712b9225,testing,0.638613
uuid-4645dd4e5f364a6399563ba7712b9225,PDL1 testing,0.53393
uuid-4645dd4e5f364a6399563ba7712b9225,NSCLC patients,0.568256
uuid-4645dd4e5f364a6399563ba7712b9225,assay,0.463082
uuid-4645dd4e5f364a6399563ba7712b9225,TL shared,0.362591
uuid-b5a996a217f0479499911cc40dc9cbcf,Opdivo,0.382286
uuid-b5a996a217f0479499911cc40dc9cbcf,TL,0.307767
uuid-b5a996a217f0479499911cc40dc9cbcf,TL stated,0.454761
uuid-b5a996a217f0479499911cc40dc9cbcf,PD-L1,0.473939
uuid-b5a996a217f0479499911cc40dc9cbcf,approval,0.452476
uuid-b5a996a217f0479499911cc40dc9cbcf,PD-L1 testing,0.511417
uuid-b5a996a217f0479499911cc40dc9cbcf,testing,0.594294
uuid-b5a996a217f0479499911cc40dc9cbcf,PDL1 testing,0.569913
uuid-b5a996a217f0479499911cc40dc9cbcf,NSCLC patients,0.575017
uuid-b5a996a217f0479499911cc40dc9cbcf,approved,0.32965
uuid-b5a996a217f0479499911cc40dc9cbcf,SCCHN,0.309139
uuid-b5a996a217f0479499911cc40dc9cbcf,tumor types,0.33908
uuid-b5a996a217f0479499911cc40dc9cbcf,label,0.3012
uuid-b5a996a217f0479499911cc40dc9cbcf,Keytruda,0.302287
uuid-b5a996a217f0479499911cc40dc9cbcf,assay,0.303001
uuid-e5886d326ae5443e9648c07d2bb6eec8,patients,0.331629
uuid-e5886d326ae5443e9648c07d2bb6eec8,pembro,0.340435
uuid-e5886d326ae5443e9648c07d2bb6eec8,1L,0.437992
uuid-e5886d326ae5443e9648c07d2bb6eec8,PDL1,0.464599
uuid-e5886d326ae5443e9648c07d2bb6eec8,chemo,0.42656
uuid-e5886d326ae5443e9648c07d2bb6eec8,pts,0.333205
uuid-e5886d326ae5443e9648c07d2bb6eec8,nivo and pembro,0.425109
uuid-e5886d326ae5443e9648c07d2bb6eec8,believes,0.360859
uuid-e5886d326ae5443e9648c07d2bb6eec8,chemotherapy,0.352012
uuid-e5886d326ae5443e9648c07d2bb6eec8,respond,0.332675
uuid-e5886d326ae5443e9648c07d2bb6eec8,feels,0.326725
uuid-e5886d326ae5443e9648c07d2bb6eec8,PDL1 expression,0.423278
uuid-e5886d326ae5443e9648c07d2bb6eec8,option,0.416316
uuid-4ae1238cd618434fa4c3bf1cfd7e3a7b,TL,0.687366
uuid-4ae1238cd618434fa4c3bf1cfd7e3a7b,PDL1,0.319045
uuid-4ae1238cd618434fa4c3bf1cfd7e3a7b,TL stated,0.347742
uuid-4ae1238cd618434fa4c3bf1cfd7e3a7b,Merck,0.362658
uuid-4ae1238cd618434fa4c3bf1cfd7e3a7b,institution,0.395432
uuid-4ae1238cd618434fa4c3bf1cfd7e3a7b,PD-L1,0.761231
uuid-4ae1238cd618434fa4c3bf1cfd7e3a7b,PD-L1 testing,0.881896
uuid-4ae1238cd618434fa4c3bf1cfd7e3a7b,testing,0.851795
uuid-4ae1238cd618434fa4c3bf1cfd7e3a7b,PDL1 testing,0.59728
uuid-4ae1238cd618434fa4c3bf1cfd7e3a7b,NSCLC patients,0.520791
uuid-4ae1238cd618434fa4c3bf1cfd7e3a7b,assay,0.80477
uuid-4ae1238cd618434fa4c3bf1cfd7e3a7b,biomarker,0.387669
uuid-74be7dbefa164c8fba3026249a7b3fcd,toxicity,0.365011
uuid-74be7dbefa164c8fba3026249a7b3fcd,efficacy,0.318993
uuid-74be7dbefa164c8fba3026249a7b3fcd,indication,0.307545
uuid-74be7dbefa164c8fba3026249a7b3fcd,Keytruda,0.40139
uuid-74be7dbefa164c8fba3026249a7b3fcd,flat dosing,0.316294
uuid-6c9315e0878244169c6d984854e820ca,Nivo,0.401377
uuid-6c9315e0878244169c6d984854e820ca,patients,0.375397
uuid-6c9315e0878244169c6d984854e820ca,Opdivo,0.501317
uuid-6c9315e0878244169c6d984854e820ca,therapy,0.369632
uuid-6c9315e0878244169c6d984854e820ca,nivolumab,0.410921
uuid-6c9315e0878244169c6d984854e820ca,mentioned,0.325772
uuid-6c9315e0878244169c6d984854e820ca,cHL,0.636658
uuid-6c9315e0878244169c6d984854e820ca,impressed,0.303256
uuid-4e051fed7b994b0cb3581843e9fa03bb,Opdivo,0.62708
uuid-4e051fed7b994b0cb3581843e9fa03bb,stated,0.334838
uuid-4e051fed7b994b0cb3581843e9fa03bb,physicians,0.515688
uuid-4e051fed7b994b0cb3581843e9fa03bb,mentioned,0.394503
uuid-4e051fed7b994b0cb3581843e9fa03bb,HCP,0.414087
uuid-4e051fed7b994b0cb3581843e9fa03bb,cHL,0.417503
uuid-4e051fed7b994b0cb3581843e9fa03bb,impressed,0.311747
uuid-4e051fed7b994b0cb3581843e9fa03bb,LTL,0.304082
uuid-d22d8d0ece1c413793bdbc16f7a531cc,Nivo,0.418575
uuid-d22d8d0ece1c413793bdbc16f7a531cc,trial,0.416746
uuid-d22d8d0ece1c413793bdbc16f7a531cc,efficacy,0.32651
uuid-d22d8d0ece1c413793bdbc16f7a531cc,combination,0.587633
uuid-d22d8d0ece1c413793bdbc16f7a531cc,chemo,0.468619
uuid-d22d8d0ece1c413793bdbc16f7a531cc,tumor,0.390461
uuid-d22d8d0ece1c413793bdbc16f7a531cc,agents,0.354121
uuid-d22d8d0ece1c413793bdbc16f7a531cc,combo,0.405471
uuid-d22d8d0ece1c413793bdbc16f7a531cc,PD1,0.346546
uuid-d22d8d0ece1c413793bdbc16f7a531cc,chemotherapy,0.414283
uuid-d22d8d0ece1c413793bdbc16f7a531cc,feels,0.419597
uuid-8b1f2516c1aa48edb11173bfb372d863,trial,0.410845
uuid-ca427a8701ad4aa18a1ec01379a48c81,Nivo,0.619124
uuid-ca427a8701ad4aa18a1ec01379a48c81,patients,0.581723
uuid-ca427a8701ad4aa18a1ec01379a48c81,pembro,0.306051
uuid-ca427a8701ad4aa18a1ec01379a48c81,therapy,0.547068
uuid-ca427a8701ad4aa18a1ec01379a48c81,nivolumab,0.594092
uuid-ca427a8701ad4aa18a1ec01379a48c81,1L,0.335465
uuid-ca427a8701ad4aa18a1ec01379a48c81,regimen,0.499684
uuid-ca427a8701ad4aa18a1ec01379a48c81,treated,0.360063
uuid-ca427a8701ad4aa18a1ec01379a48c81,RCC,0.308369
uuid-ca427a8701ad4aa18a1ec01379a48c81,combination,0.546526
uuid-ca427a8701ad4aa18a1ec01379a48c81,chemo,0.485751
uuid-ca427a8701ad4aa18a1ec01379a48c81,2L,0.399081
uuid-ca427a8701ad4aa18a1ec01379a48c81,pts,0.558689
uuid-ca427a8701ad4aa18a1ec01379a48c81,Ipi,0.586691
uuid-ca427a8701ad4aa18a1ec01379a48c81,approval,0.36362
uuid-ca427a8701ad4aa18a1ec01379a48c81,preferred,0.321247
uuid-ca427a8701ad4aa18a1ec01379a48c81,monotherapy,0.570225
uuid-ca427a8701ad4aa18a1ec01379a48c81,treatment,0.454811
uuid-ca427a8701ad4aa18a1ec01379a48c81,using nivo,0.489775
uuid-ca427a8701ad4aa18a1ec01379a48c81,response,0.407865
uuid-ca427a8701ad4aa18a1ec01379a48c81,combo,0.472925
uuid-ca427a8701ad4aa18a1ec01379a48c81,PD1,0.480222
uuid-ca427a8701ad4aa18a1ec01379a48c81,approved,0.371338
uuid-ca427a8701ad4aa18a1ec01379a48c81,progression,0.496221
uuid-ca427a8701ad4aa18a1ec01379a48c81,chemotherapy,0.469617
uuid-ca427a8701ad4aa18a1ec01379a48c81,respond,0.339881
uuid-ca427a8701ad4aa18a1ec01379a48c81,SCLC,0.314594
uuid-ca427a8701ad4aa18a1ec01379a48c81,RTL stated,0.344027
uuid-ca427a8701ad4aa18a1ec01379a48c81,option,0.46282
uuid-54bf6924244a484783b7744c90dff5ee,tumor,0.483226
uuid-54bf6924244a484783b7744c90dff5ee,response,0.449425
uuid-54bf6924244a484783b7744c90dff5ee,progression,0.31419
uuid-54bf6924244a484783b7744c90dff5ee,clinical,0.358041
uuid-54bf6924244a484783b7744c90dff5ee,immunotherapy,0.373386
uuid-c460e9cb41174a779e8233ebb7d3c993,RTL,0.429162
uuid-c460e9cb41174a779e8233ebb7d3c993,nivolumab,0.335535
uuid-c460e9cb41174a779e8233ebb7d3c993,trial,0.442781
uuid-c460e9cb41174a779e8233ebb7d3c993,NTL,0.369303
uuid-c460e9cb41174a779e8233ebb7d3c993,shared,0.353583
uuid-c460e9cb41174a779e8233ebb7d3c993,commented,0.308219
uuid-c460e9cb41174a779e8233ebb7d3c993,RCC,0.422848
uuid-c460e9cb41174a779e8233ebb7d3c993,combination,0.45069
uuid-c460e9cb41174a779e8233ebb7d3c993,stated,0.398165
uuid-c460e9cb41174a779e8233ebb7d3c993,monotherapy,0.313887
uuid-c460e9cb41174a779e8233ebb7d3c993,data,0.500307
uuid-c460e9cb41174a779e8233ebb7d3c993,combo,0.409737
uuid-c460e9cb41174a779e8233ebb7d3c993,clinical trials,0.416183
uuid-c460e9cb41174a779e8233ebb7d3c993,PD1,0.398162
uuid-c460e9cb41174a779e8233ebb7d3c993,SCCHN,0.351208
uuid-c460e9cb41174a779e8233ebb7d3c993,ASCO,0.305228
uuid-c460e9cb41174a779e8233ebb7d3c993,impressed,0.4478
uuid-c460e9cb41174a779e8233ebb7d3c993,LTL,0.345365
uuid-c460e9cb41174a779e8233ebb7d3c993,SCLC,0.36051
uuid-c460e9cb41174a779e8233ebb7d3c993,Regional TL,0.41302
uuid-c460e9cb41174a779e8233ebb7d3c993,RTL stated,0.386494
uuid-c460e9cb41174a779e8233ebb7d3c993,bladder,0.371448
uuid-ca9d7e5981064550941260f310f7df3b,pembro,0.408184
uuid-ca9d7e5981064550941260f310f7df3b,BMS,0.617856
uuid-ca9d7e5981064550941260f310f7df3b,PDL1,0.340019
uuid-ca9d7e5981064550941260f310f7df3b,trial,0.72042
uuid-ca9d7e5981064550941260f310f7df3b,efficacy,0.385818
uuid-ca9d7e5981064550941260f310f7df3b,commented,0.369101
uuid-ca9d7e5981064550941260f310f7df3b,Merck,0.542477
uuid-ca9d7e5981064550941260f310f7df3b,stated,0.374295
uuid-ca9d7e5981064550941260f310f7df3b,approval,0.333953
uuid-ca9d7e5981064550941260f310f7df3b,OS,0.448531
uuid-ca9d7e5981064550941260f310f7df3b,regards,0.300155
uuid-ca9d7e5981064550941260f310f7df3b,data,0.80224
uuid-ca9d7e5981064550941260f310f7df3b,expressed,0.308343
uuid-ca9d7e5981064550941260f310f7df3b,clinical trials,0.412229
uuid-ca9d7e5981064550941260f310f7df3b,indication,0.38236
uuid-ca9d7e5981064550941260f310f7df3b,PFS,0.446078
uuid-ca9d7e5981064550941260f310f7df3b,ORR,0.516279
uuid-ca9d7e5981064550941260f310f7df3b,approved,0.308594
uuid-ca9d7e5981064550941260f310f7df3b,nivo and pembro,0.385772
uuid-ca9d7e5981064550941260f310f7df3b,impressed,0.550052
uuid-ca9d7e5981064550941260f310f7df3b,PDL1 expression,0.398878
uuid-516780c638d247ee9e2e235e6aee172e,patients,0.600861
uuid-516780c638d247ee9e2e235e6aee172e,Opdivo,0.334894
uuid-516780c638d247ee9e2e235e6aee172e,nivolumab,0.378559
uuid-516780c638d247ee9e2e235e6aee172e,toxicity,0.410238
uuid-516780c638d247ee9e2e235e6aee172e,regimen,0.581952
uuid-516780c638d247ee9e2e235e6aee172e,treated,0.548241
uuid-516780c638d247ee9e2e235e6aee172e,RCC,0.368857
uuid-516780c638d247ee9e2e235e6aee172e,pts,0.394622
uuid-516780c638d247ee9e2e235e6aee172e,treatment,0.567692
uuid-516780c638d247ee9e2e235e6aee172e,using nivo,0.371157
uuid-516780c638d247ee9e2e235e6aee172e,progression,0.374146
uuid-516780c638d247ee9e2e235e6aee172e,respond,0.469431
uuid-516780c638d247ee9e2e235e6aee172e,RTL stated,0.355698
uuid-516780c638d247ee9e2e235e6aee172e,TL shared,0.417728
uuid-b09066ca46674e2fb0aaa785984f34f4,Nivo,0.571366
uuid-b09066ca46674e2fb0aaa785984f34f4,patients,0.369232
uuid-b09066ca46674e2fb0aaa785984f34f4,pembro,0.579495
uuid-b09066ca46674e2fb0aaa785984f34f4,therapy,0.388504
uuid-b09066ca46674e2fb0aaa785984f34f4,dose,0.366716
uuid-b09066ca46674e2fb0aaa785984f34f4,nivolumab,0.369916
uuid-b09066ca46674e2fb0aaa785984f34f4,1L,0.522515
uuid-b09066ca46674e2fb0aaa785984f34f4,regimen,0.455426
uuid-b09066ca46674e2fb0aaa785984f34f4,combination,0.492528
uuid-b09066ca46674e2fb0aaa785984f34f4,chemo,0.483405
uuid-b09066ca46674e2fb0aaa785984f34f4,2L,0.614739
uuid-b09066ca46674e2fb0aaa785984f34f4,pts,0.336821
uuid-b09066ca46674e2fb0aaa785984f34f4,agents,0.526666
uuid-b09066ca46674e2fb0aaa785984f34f4,Ipi,0.402193
uuid-b09066ca46674e2fb0aaa785984f34f4,atezo,0.557108
uuid-b09066ca46674e2fb0aaa785984f34f4,preferred,0.645081
uuid-b09066ca46674e2fb0aaa785984f34f4,monotherapy,0.718574
uuid-b09066ca46674e2fb0aaa785984f34f4,treatment,0.318623
uuid-b09066ca46674e2fb0aaa785984f34f4,using nivo,0.502755
uuid-b09066ca46674e2fb0aaa785984f34f4,combo,0.468787
uuid-b09066ca46674e2fb0aaa785984f34f4,PD1,0.414156
uuid-b09066ca46674e2fb0aaa785984f34f4,approved,0.342733
uuid-b09066ca46674e2fb0aaa785984f34f4,believes,0.320904
uuid-b09066ca46674e2fb0aaa785984f34f4,chemotherapy,0.421394
uuid-b09066ca46674e2fb0aaa785984f34f4,vs,0.316883
uuid-b09066ca46674e2fb0aaa785984f34f4,feels,0.342454
uuid-b09066ca46674e2fb0aaa785984f34f4,RTL stated,0.397901
uuid-b09066ca46674e2fb0aaa785984f34f4,option,0.625311
uuid-7716bbe748734e3d9a5381cc325a78e1,Nivo,0.597649
uuid-7716bbe748734e3d9a5381cc325a78e1,pembro,0.615922
uuid-7716bbe748734e3d9a5381cc325a78e1,1L,0.342273
uuid-7716bbe748734e3d9a5381cc325a78e1,trial,0.400746
uuid-7716bbe748734e3d9a5381cc325a78e1,efficacy,0.516686
uuid-7716bbe748734e3d9a5381cc325a78e1,combination,0.42374
uuid-7716bbe748734e3d9a5381cc325a78e1,2L,0.404723
uuid-7716bbe748734e3d9a5381cc325a78e1,agents,0.399402
uuid-7716bbe748734e3d9a5381cc325a78e1,Ipi,0.524854
uuid-7716bbe748734e3d9a5381cc325a78e1,atezo,0.571338
uuid-7716bbe748734e3d9a5381cc325a78e1,preferred,0.37867
uuid-7716bbe748734e3d9a5381cc325a78e1,monotherapy,0.385425
uuid-7716bbe748734e3d9a5381cc325a78e1,using nivo,0.399139
uuid-7716bbe748734e3d9a5381cc325a78e1,data,0.494448
uuid-7716bbe748734e3d9a5381cc325a78e1,combo,0.451646
uuid-7716bbe748734e3d9a5381cc325a78e1,indication,0.414651
uuid-7716bbe748734e3d9a5381cc325a78e1,approved,0.408563
uuid-7716bbe748734e3d9a5381cc325a78e1,nivo and pembro,0.459006
uuid-7716bbe748734e3d9a5381cc325a78e1,believes,0.319661
uuid-7716bbe748734e3d9a5381cc325a78e1,impressed,0.408902
uuid-7716bbe748734e3d9a5381cc325a78e1,vs,0.453494
uuid-7716bbe748734e3d9a5381cc325a78e1,feels,0.429766
uuid-7716bbe748734e3d9a5381cc325a78e1,option,0.320379
uuid-cd53b5543f3a4fe9907dfc79b369f00b,Nivo,0.484623
uuid-cd53b5543f3a4fe9907dfc79b369f00b,patients,0.304453
uuid-cd53b5543f3a4fe9907dfc79b369f00b,therapy,0.366918
uuid-cd53b5543f3a4fe9907dfc79b369f00b,regimen,0.31388
uuid-cd53b5543f3a4fe9907dfc79b369f00b,chemo,0.4289
uuid-cd53b5543f3a4fe9907dfc79b369f00b,pts,0.436691
uuid-cd53b5543f3a4fe9907dfc79b369f00b,IO,0.336882
uuid-cd53b5543f3a4fe9907dfc79b369f00b,OS,0.325526
uuid-cd53b5543f3a4fe9907dfc79b369f00b,monotherapy,0.394183
uuid-cd53b5543f3a4fe9907dfc79b369f00b,response,0.616572
uuid-cd53b5543f3a4fe9907dfc79b369f00b,PD1,0.391864
uuid-cd53b5543f3a4fe9907dfc79b369f00b,progression,0.533366
uuid-cd53b5543f3a4fe9907dfc79b369f00b,chemotherapy,0.344079
uuid-cd53b5543f3a4fe9907dfc79b369f00b,respond,0.362554
uuid-a6f4a439db854f25a4787ba0264bef39,pembro,0.329715
uuid-a6f4a439db854f25a4787ba0264bef39,PDL1,0.400432
uuid-a6f4a439db854f25a4787ba0264bef39,Merck,0.347544
uuid-a6f4a439db854f25a4787ba0264bef39,stated,0.381553
uuid-a6f4a439db854f25a4787ba0264bef39,approval,0.361757
uuid-a6f4a439db854f25a4787ba0264bef39,clinical trials,0.411072
uuid-a6f4a439db854f25a4787ba0264bef39,approved,0.346712
uuid-a6f4a439db854f25a4787ba0264bef39,tumor types,0.384578
uuid-a6f4a439db854f25a4787ba0264bef39,feels,0.315467
uuid-a6f4a439db854f25a4787ba0264bef39,PDL1 expression,0.310362
uuid-b9bd7b7f885341199800a1c11d941b04,physicians,0.427922
uuid-b9bd7b7f885341199800a1c11d941b04,treatment,0.342461
uuid-b9bd7b7f885341199800a1c11d941b04,oncologist,0.422761
uuid-83f77a92303849f28978f745a550758e,tumor,0.844794
uuid-9cf5d4a84f5d46deb87d64642237dac4,NSCLC,0.383894
uuid-9cf5d4a84f5d46deb87d64642237dac4,NTL,0.40624
uuid-9cf5d4a84f5d46deb87d64642237dac4,stated,0.326321
uuid-9cf5d4a84f5d46deb87d64642237dac4,ASCO,0.392724
uuid-9cf5d4a84f5d46deb87d64642237dac4,Regional TL,0.316778
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,pembro,0.528257
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,dose,0.360224
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,BMS,0.372519
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,trial,0.38961
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,efficacy,0.567581
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,Merck,0.428414
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,OS,0.307003
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,atezo,0.43477
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,data,0.566715
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,ORR,0.317334
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,nivo and pembro,0.3762
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,impressed,0.331314
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,vs,0.665523
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,feels,0.329346
uuid-1e4bb58d11b9412c86ead46edb4b9d8b,flat dosing,0.361441
uuid-5ed4b1a69dd1466d99a99c6ab42e48ae,patients,0.403452
uuid-5ed4b1a69dd1466d99a99c6ab42e48ae,nivolumab,0.341734
uuid-5ed4b1a69dd1466d99a99c6ab42e48ae,regimen,0.368077
uuid-5ed4b1a69dd1466d99a99c6ab42e48ae,treated,0.420006
uuid-5ed4b1a69dd1466d99a99c6ab42e48ae,treatment,0.31621
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,TL,0.315055
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,RTL,0.373529
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,BMS,0.414566
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,trial,0.320373
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,discussed,0.386552
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,shared,0.300084
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,commented,0.508352
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,Merck,0.573447
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,stated,0.372665
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,approval,0.302949
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,data,0.512544
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,SCCHN,0.311294
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,ASCO,0.342105
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,impressed,0.428686
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,LTL,0.335532
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,TLs,0.365306
uuid-6cc8a4dd98e4417d8c4c3f2e8325e68a,Regional TL,0.424818
uuid-dae87cec3ad8482b946165694ebc11c6,Opdivo,0.337025
uuid-dae87cec3ad8482b946165694ebc11c6,dose,0.680994
uuid-dae87cec3ad8482b946165694ebc11c6,toxicity,0.610034
uuid-dae87cec3ad8482b946165694ebc11c6,regimen,0.376812
uuid-dae87cec3ad8482b946165694ebc11c6,physicians,0.393772
uuid-dae87cec3ad8482b946165694ebc11c6,treatment,0.322391
uuid-dae87cec3ad8482b946165694ebc11c6,respond,0.30972
uuid-dae87cec3ad8482b946165694ebc11c6,flat dosing,0.376345
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,patients,0.711725
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,Opdivo,0.449955
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,therapy,0.338879
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,nivolumab,0.365595
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,treated,0.483674
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,pts,0.467123
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,approval,0.420891
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,treatment,0.392684
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,using nivo,0.414343
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,NSCLC patients,0.406109
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,approved,0.302279
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,progression,0.323905
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,label,0.310365
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,RTL stated,0.340856
uuid-b6d36f9c2bae43ceb50d5554fb9c3e42,option,0.300848
uuid-6bdc00b95e674ecb91572f3c82549097,patients,0.481084
uuid-6bdc00b95e674ecb91572f3c82549097,Opdivo,0.514298
uuid-6bdc00b95e674ecb91572f3c82549097,pembro,0.323119
uuid-6bdc00b95e674ecb91572f3c82549097,dose,0.533303
uuid-6bdc00b95e674ecb91572f3c82549097,nivolumab,0.322657
uuid-6bdc00b95e674ecb91572f3c82549097,approval,0.3213
uuid-6bdc00b95e674ecb91572f3c82549097,preferred,0.310239
uuid-6bdc00b95e674ecb91572f3c82549097,using nivo,0.386736
uuid-6bdc00b95e674ecb91572f3c82549097,vs,0.329291
uuid-6bdc00b95e674ecb91572f3c82549097,Keytruda,0.349048
uuid-6bdc00b95e674ecb91572f3c82549097,flat dosing,0.553555
uuid-c1ac6c1af37649f5b5af87f48f5b605b,Nivo,0.321096
uuid-c1ac6c1af37649f5b5af87f48f5b605b,patients,0.677806
uuid-c1ac6c1af37649f5b5af87f48f5b605b,Opdivo,0.487275
uuid-c1ac6c1af37649f5b5af87f48f5b605b,therapy,0.362808
uuid-c1ac6c1af37649f5b5af87f48f5b605b,dose,0.596924
uuid-c1ac6c1af37649f5b5af87f48f5b605b,nivolumab,0.446112
uuid-c1ac6c1af37649f5b5af87f48f5b605b,toxicity,0.444607
uuid-c1ac6c1af37649f5b5af87f48f5b605b,regimen,0.510818
uuid-c1ac6c1af37649f5b5af87f48f5b605b,treated,0.382915
uuid-c1ac6c1af37649f5b5af87f48f5b605b,pts,0.435475
uuid-c1ac6c1af37649f5b5af87f48f5b605b,Ipi,0.392203
uuid-c1ac6c1af37649f5b5af87f48f5b605b,treatment,0.512624
uuid-c1ac6c1af37649f5b5af87f48f5b605b,response,0.303828
uuid-c1ac6c1af37649f5b5af87f48f5b605b,progression,0.488757
uuid-c1ac6c1af37649f5b5af87f48f5b605b,respond,0.432364
uuid-c1ac6c1af37649f5b5af87f48f5b605b,flat dosing,0.329001
uuid-1434b601545e4a2fb0d31ae5ecafc6ee,Nivo,0.405001
uuid-1434b601545e4a2fb0d31ae5ecafc6ee,patients,0.356767
uuid-1434b601545e4a2fb0d31ae5ecafc6ee,Opdivo,0.363703
uuid-1434b601545e4a2fb0d31ae5ecafc6ee,therapy,0.705251
uuid-1434b601545e4a2fb0d31ae5ecafc6ee,nivolumab,0.447855
uuid-1434b601545e4a2fb0d31ae5ecafc6ee,PD1,0.372319
uuid-1434b601545e4a2fb0d31ae5ecafc6ee,cHL,0.704024
uuid-1434b601545e4a2fb0d31ae5ecafc6ee,chemotherapy,0.410665
uuid-f98a7b4657e5499d9562520b5034e3d9,lung,0.328873
uuid-f98a7b4657e5499d9562520b5034e3d9,1L,0.370978
uuid-f98a7b4657e5499d9562520b5034e3d9,RCC,0.424618
uuid-f98a7b4657e5499d9562520b5034e3d9,TL stated,0.435845
uuid-f98a7b4657e5499d9562520b5034e3d9,2L,0.424694
uuid-f98a7b4657e5499d9562520b5034e3d9,PD-L1,0.366149
uuid-f98a7b4657e5499d9562520b5034e3d9,preferred,0.463019
uuid-f98a7b4657e5499d9562520b5034e3d9,PD-L1 testing,0.325609
uuid-f98a7b4657e5499d9562520b5034e3d9,testing,0.41469
uuid-f98a7b4657e5499d9562520b5034e3d9,PDL1 testing,0.470126
uuid-f98a7b4657e5499d9562520b5034e3d9,NSCLC patients,0.324889
uuid-f98a7b4657e5499d9562520b5034e3d9,assay,0.308681
uuid-f98a7b4657e5499d9562520b5034e3d9,RTL stated,0.338271
uuid-f98a7b4657e5499d9562520b5034e3d9,TL shared,0.361711
uuid-f98a7b4657e5499d9562520b5034e3d9,option,0.384171
uuid-99fc69e9d6944c90a11c250a166de454,patients,0.330298
uuid-99fc69e9d6944c90a11c250a166de454,therapy,0.319847
uuid-99fc69e9d6944c90a11c250a166de454,nivolumab,0.370774
uuid-99fc69e9d6944c90a11c250a166de454,toxicity,0.702399
uuid-99fc69e9d6944c90a11c250a166de454,regimen,0.343932
uuid-99fc69e9d6944c90a11c250a166de454,treated,0.318514
uuid-99fc69e9d6944c90a11c250a166de454,treatment,0.361911
uuid-99fc69e9d6944c90a11c250a166de454,cHL,0.419968
uuid-eff7081a079c41bca1e70a2a17571a8b,TL,0.498656
uuid-eff7081a079c41bca1e70a2a17571a8b,PD-L1,0.500594
uuid-eff7081a079c41bca1e70a2a17571a8b,PD-L1 testing,0.602477
uuid-eff7081a079c41bca1e70a2a17571a8b,testing,0.504439
uuid-eff7081a079c41bca1e70a2a17571a8b,PDL1 testing,0.33914
uuid-eff7081a079c41bca1e70a2a17571a8b,NSCLC patients,0.371555
uuid-eff7081a079c41bca1e70a2a17571a8b,indicated,0.363907
uuid-eff7081a079c41bca1e70a2a17571a8b,assay,0.433141
uuid-6aeeed80aad546e8a4eae03330771454,TL,0.34352
uuid-6aeeed80aad546e8a4eae03330771454,physicians,0.587734
uuid-6aeeed80aad546e8a4eae03330771454,oncologist,0.373512
uuid-6aeeed80aad546e8a4eae03330771454,indicated,0.498056
uuid-6aeeed80aad546e8a4eae03330771454,clinical,0.307128
uuid-6aeeed80aad546e8a4eae03330771454,Regional TL,0.372792
uuid-e5c67338f1644cf6bb87522665f4acda,RTL,0.375959
uuid-e5c67338f1644cf6bb87522665f4acda,BMS,0.42662
uuid-e5c67338f1644cf6bb87522665f4acda,lung,0.314427
uuid-e5c67338f1644cf6bb87522665f4acda,NTL,0.343336
uuid-e5c67338f1644cf6bb87522665f4acda,discussed,0.319633
uuid-e5c67338f1644cf6bb87522665f4acda,shared,0.478171
uuid-e5c67338f1644cf6bb87522665f4acda,commented,0.403619
uuid-e5c67338f1644cf6bb87522665f4acda,TL stated,0.32808
uuid-e5c67338f1644cf6bb87522665f4acda,Merck,0.491471
uuid-e5c67338f1644cf6bb87522665f4acda,stated,0.591709
uuid-e5c67338f1644cf6bb87522665f4acda,physicians,0.380457
uuid-e5c67338f1644cf6bb87522665f4acda,expressed,0.317229
uuid-e5c67338f1644cf6bb87522665f4acda,SCCHN,0.410298
uuid-e5c67338f1644cf6bb87522665f4acda,LTL,0.356549
uuid-e5c67338f1644cf6bb87522665f4acda,TLs,0.357467
uuid-e5c67338f1644cf6bb87522665f4acda,academic,0.410906
uuid-e5c67338f1644cf6bb87522665f4acda,Regional TL,0.499921
uuid-8f991c38630841f3aabafd3fd8f27a27,pembro,0.333429
uuid-8f991c38630841f3aabafd3fd8f27a27,RTL,0.304242
uuid-8f991c38630841f3aabafd3fd8f27a27,BMS,0.451318
uuid-8f991c38630841f3aabafd3fd8f27a27,trial,0.645769
uuid-8f991c38630841f3aabafd3fd8f27a27,commented,0.394187
uuid-8f991c38630841f3aabafd3fd8f27a27,Merck,0.655385
uuid-8f991c38630841f3aabafd3fd8f27a27,stated,0.305872
uuid-8f991c38630841f3aabafd3fd8f27a27,data,0.40872
uuid-8f991c38630841f3aabafd3fd8f27a27,expressed,0.35339
uuid-8f991c38630841f3aabafd3fd8f27a27,clinical trials,0.327434
uuid-8f991c38630841f3aabafd3fd8f27a27,ASCO,0.376932
uuid-8f991c38630841f3aabafd3fd8f27a27,impressed,0.354049
uuid-8f991c38630841f3aabafd3fd8f27a27,Regional TL,0.335055
uuid-8f991c38630841f3aabafd3fd8f27a27,bladder,0.411895
uuid-d9efa4bb7dfd429e8873441d89b4af35,Nivo,0.371678
uuid-d9efa4bb7dfd429e8873441d89b4af35,pembro,0.464802
uuid-d9efa4bb7dfd429e8873441d89b4af35,nivolumab,0.304584
uuid-d9efa4bb7dfd429e8873441d89b4af35,1L,0.444971
uuid-d9efa4bb7dfd429e8873441d89b4af35,2L,0.431287
uuid-d9efa4bb7dfd429e8873441d89b4af35,approval,0.520775
uuid-d9efa4bb7dfd429e8873441d89b4af35,atezo,0.39537
uuid-d9efa4bb7dfd429e8873441d89b4af35,preferred,0.438742
uuid-d9efa4bb7dfd429e8873441d89b4af35,monotherapy,0.356859
uuid-d9efa4bb7dfd429e8873441d89b4af35,using nivo,0.473943
uuid-d9efa4bb7dfd429e8873441d89b4af35,data,0.430778
uuid-d9efa4bb7dfd429e8873441d89b4af35,clinical trials,0.313257
uuid-d9efa4bb7dfd429e8873441d89b4af35,indication,0.561123
uuid-d9efa4bb7dfd429e8873441d89b4af35,approved,0.579804
uuid-d9efa4bb7dfd429e8873441d89b4af35,SCCHN,0.392959
uuid-d9efa4bb7dfd429e8873441d89b4af35,nivo and pembro,0.322509
uuid-d9efa4bb7dfd429e8873441d89b4af35,impressed,0.351908
uuid-d9efa4bb7dfd429e8873441d89b4af35,label,0.454936
uuid-d9efa4bb7dfd429e8873441d89b4af35,SCLC,0.563597
uuid-d9efa4bb7dfd429e8873441d89b4af35,RTL stated,0.32417
uuid-d9efa4bb7dfd429e8873441d89b4af35,option,0.522664
uuid-d9efa4bb7dfd429e8873441d89b4af35,bladder,0.346962
uuid-188b8d9ee80547df8d7a4fa8200741f4,dose,0.302592
uuid-188b8d9ee80547df8d7a4fa8200741f4,BMS,0.386018
uuid-188b8d9ee80547df8d7a4fa8200741f4,trial,0.438879
uuid-188b8d9ee80547df8d7a4fa8200741f4,commented,0.348345
uuid-188b8d9ee80547df8d7a4fa8200741f4,physicians,0.367678
uuid-188b8d9ee80547df8d7a4fa8200741f4,regards,0.311978
uuid-11ea454fa4d04c0fbfd702b7d0b35996,Nivo,0.445258
uuid-11ea454fa4d04c0fbfd702b7d0b35996,patients,0.652158
uuid-11ea454fa4d04c0fbfd702b7d0b35996,Opdivo,0.448962
uuid-11ea454fa4d04c0fbfd702b7d0b35996,therapy,0.597502
uuid-11ea454fa4d04c0fbfd702b7d0b35996,nivolumab,0.60599
uuid-11ea454fa4d04c0fbfd702b7d0b35996,regimen,0.302873
uuid-11ea454fa4d04c0fbfd702b7d0b35996,treated,0.522218
uuid-11ea454fa4d04c0fbfd702b7d0b35996,pts,0.322393
uuid-11ea454fa4d04c0fbfd702b7d0b35996,approval,0.306864
uuid-11ea454fa4d04c0fbfd702b7d0b35996,treatment,0.525452
uuid-11ea454fa4d04c0fbfd702b7d0b35996,using nivo,0.388
uuid-11ea454fa4d04c0fbfd702b7d0b35996,cHL,0.71202
uuid-11ea454fa4d04c0fbfd702b7d0b35996,progression,0.409984
uuid-c29b6c0945c94b55a2f5c2047ed00db0,patients,0.659201
uuid-c29b6c0945c94b55a2f5c2047ed00db0,Opdivo,0.588541
uuid-c29b6c0945c94b55a2f5c2047ed00db0,RTL,0.346326
uuid-c29b6c0945c94b55a2f5c2047ed00db0,therapy,0.328186
uuid-c29b6c0945c94b55a2f5c2047ed00db0,nivolumab,0.519497
uuid-c29b6c0945c94b55a2f5c2047ed00db0,toxicity,0.313244
uuid-c29b6c0945c94b55a2f5c2047ed00db0,regimen,0.446951
uuid-c29b6c0945c94b55a2f5c2047ed00db0,treated,0.530148
uuid-c29b6c0945c94b55a2f5c2047ed00db0,pts,0.350228
uuid-c29b6c0945c94b55a2f5c2047ed00db0,treatment,0.493748
uuid-c29b6c0945c94b55a2f5c2047ed00db0,using nivo,0.413248
uuid-c29b6c0945c94b55a2f5c2047ed00db0,SCCHN,0.314577
uuid-c29b6c0945c94b55a2f5c2047ed00db0,HCP,0.456852
uuid-c29b6c0945c94b55a2f5c2047ed00db0,cHL,0.426305
uuid-c29b6c0945c94b55a2f5c2047ed00db0,progression,0.354471
uuid-c29b6c0945c94b55a2f5c2047ed00db0,LTL,0.334613
uuid-c29b6c0945c94b55a2f5c2047ed00db0,RTL stated,0.355056
uuid-2aa3b607fc6a436db358140661e044f1,patients,0.76163
uuid-2aa3b607fc6a436db358140661e044f1,Opdivo,0.371861
uuid-2aa3b607fc6a436db358140661e044f1,therapy,0.572149
uuid-2aa3b607fc6a436db358140661e044f1,nivolumab,0.450882
uuid-2aa3b607fc6a436db358140661e044f1,regimen,0.370673
uuid-2aa3b607fc6a436db358140661e044f1,treated,0.525996
uuid-2aa3b607fc6a436db358140661e044f1,pts,0.464902
uuid-2aa3b607fc6a436db358140661e044f1,treatment,0.62674
uuid-2aa3b607fc6a436db358140661e044f1,response,0.33219
uuid-2aa3b607fc6a436db358140661e044f1,cHL,0.403181
uuid-2aa3b607fc6a436db358140661e044f1,progression,0.591404
uuid-2aa3b607fc6a436db358140661e044f1,chemotherapy,0.344005
uuid-2aa3b607fc6a436db358140661e044f1,respond,0.401627
uuid-d44de31e22064c84b881eacd8b308459,tumor,0.544306
uuid-d44de31e22064c84b881eacd8b308459,response,0.314454
uuid-d44de31e22064c84b881eacd8b308459,assay,0.351007
uuid-3ded94652bd0443fb95571cc5aabcf38,TL,0.610461
uuid-3ded94652bd0443fb95571cc5aabcf38,NSCLC,0.318038
uuid-3ded94652bd0443fb95571cc5aabcf38,NTL,0.355086
uuid-3ded94652bd0443fb95571cc5aabcf38,commented,0.386215
uuid-3ded94652bd0443fb95571cc5aabcf38,TL stated,0.484121
uuid-3ded94652bd0443fb95571cc5aabcf38,Merck,0.327779
uuid-3ded94652bd0443fb95571cc5aabcf38,institution,0.311217
uuid-3ded94652bd0443fb95571cc5aabcf38,PD-L1,0.458786
uuid-3ded94652bd0443fb95571cc5aabcf38,PD-L1 testing,0.659984
uuid-3ded94652bd0443fb95571cc5aabcf38,testing,0.592106
uuid-3ded94652bd0443fb95571cc5aabcf38,expressed,0.313893
uuid-3ded94652bd0443fb95571cc5aabcf38,mentioned,0.397949
uuid-3ded94652bd0443fb95571cc5aabcf38,PDL1 testing,0.61344
uuid-3ded94652bd0443fb95571cc5aabcf38,NSCLC patients,0.338039
uuid-3ded94652bd0443fb95571cc5aabcf38,oncologist,0.323144
uuid-3ded94652bd0443fb95571cc5aabcf38,assay,0.428975
uuid-3ded94652bd0443fb95571cc5aabcf38,Regional TL,0.389766
uuid-3eb056aef0274f7385d761900a99b8f2,mentioned,0.409136
uuid-3eb056aef0274f7385d761900a99b8f2,cHL,0.570378
uuid-abe9f19a6e1f49a888a953c6f3e12217,mentioned,0.344507
uuid-abe9f19a6e1f49a888a953c6f3e12217,AI,0.473683
uuid-abe9f19a6e1f49a888a953c6f3e12217,cHL,0.600423
uuid-91f085231d074e328f1721b03450c193,TL,0.566713
uuid-91f085231d074e328f1721b03450c193,TL stated,0.512895
uuid-91f085231d074e328f1721b03450c193,institution,0.33176
uuid-91f085231d074e328f1721b03450c193,stated,0.324145
uuid-91f085231d074e328f1721b03450c193,PD-L1,0.543098
uuid-91f085231d074e328f1721b03450c193,approval,0.340037
uuid-91f085231d074e328f1721b03450c193,PD-L1 testing,0.729524
uuid-91f085231d074e328f1721b03450c193,testing,0.719217
uuid-91f085231d074e328f1721b03450c193,PDL1 testing,0.716015
uuid-91f085231d074e328f1721b03450c193,NSCLC patients,0.608559
uuid-91f085231d074e328f1721b03450c193,assay,0.384999
uuid-91f085231d074e328f1721b03450c193,RTL stated,0.310144
uuid-d84a5fcee7514c9baf6b521298588006,patients,0.337189
uuid-d84a5fcee7514c9baf6b521298588006,RTL,0.415509
uuid-d84a5fcee7514c9baf6b521298588006,nivolumab,0.486537
uuid-d84a5fcee7514c9baf6b521298588006,treated,0.460817
uuid-d84a5fcee7514c9baf6b521298588006,melanoma,0.398891
uuid-d84a5fcee7514c9baf6b521298588006,shared,0.361643
uuid-d84a5fcee7514c9baf6b521298588006,RCC,0.570769
uuid-d84a5fcee7514c9baf6b521298588006,TL stated,0.306062
uuid-d84a5fcee7514c9baf6b521298588006,stated,0.410881
uuid-d84a5fcee7514c9baf6b521298588006,approval,0.434851
uuid-d84a5fcee7514c9baf6b521298588006,physicians,0.345413
uuid-d84a5fcee7514c9baf6b521298588006,preferred,0.318959
uuid-d84a5fcee7514c9baf6b521298588006,using nivo,0.482704
uuid-d84a5fcee7514c9baf6b521298588006,clinical trials,0.414182
uuid-d84a5fcee7514c9baf6b521298588006,approved,0.336417
uuid-d84a5fcee7514c9baf6b521298588006,SCCHN,0.566548
uuid-d84a5fcee7514c9baf6b521298588006,LTL,0.368529
uuid-d84a5fcee7514c9baf6b521298588006,TLs,0.334814
uuid-d84a5fcee7514c9baf6b521298588006,academic,0.35173
uuid-d84a5fcee7514c9baf6b521298588006,Regional TL,0.504752
uuid-d84a5fcee7514c9baf6b521298588006,RTL stated,0.593103
uuid-d84a5fcee7514c9baf6b521298588006,TL shared,0.479829
uuid-d84a5fcee7514c9baf6b521298588006,bladder,0.426462
uuid-09d95030cb0944d5a8cc3ae98961aae6,Nivo,0.602019
uuid-09d95030cb0944d5a8cc3ae98961aae6,pembro,0.733227
uuid-09d95030cb0944d5a8cc3ae98961aae6,1L,0.460898
uuid-09d95030cb0944d5a8cc3ae98961aae6,trial,0.339624
uuid-09d95030cb0944d5a8cc3ae98961aae6,efficacy,0.402954
uuid-09d95030cb0944d5a8cc3ae98961aae6,2L,0.54644
uuid-09d95030cb0944d5a8cc3ae98961aae6,agents,0.34127
uuid-09d95030cb0944d5a8cc3ae98961aae6,Ipi,0.432112
uuid-09d95030cb0944d5a8cc3ae98961aae6,approval,0.382371
uuid-09d95030cb0944d5a8cc3ae98961aae6,atezo,0.667496
uuid-09d95030cb0944d5a8cc3ae98961aae6,preferred,0.503253
uuid-09d95030cb0944d5a8cc3ae98961aae6,monotherapy,0.383505
uuid-09d95030cb0944d5a8cc3ae98961aae6,using nivo,0.514581
uuid-09d95030cb0944d5a8cc3ae98961aae6,data,0.311843
uuid-09d95030cb0944d5a8cc3ae98961aae6,combo,0.358628
uuid-09d95030cb0944d5a8cc3ae98961aae6,clinical trials,0.349594
uuid-09d95030cb0944d5a8cc3ae98961aae6,indication,0.414076
uuid-09d95030cb0944d5a8cc3ae98961aae6,approved,0.445512
uuid-09d95030cb0944d5a8cc3ae98961aae6,nivo and pembro,0.38735
uuid-09d95030cb0944d5a8cc3ae98961aae6,impressed,0.350764
uuid-09d95030cb0944d5a8cc3ae98961aae6,vs,0.496032
uuid-09d95030cb0944d5a8cc3ae98961aae6,feels,0.461613
uuid-09d95030cb0944d5a8cc3ae98961aae6,RTL stated,0.345177
uuid-09d95030cb0944d5a8cc3ae98961aae6,option,0.40866
uuid-09d95030cb0944d5a8cc3ae98961aae6,bladder,0.350513
uuid-7309720016de427fa4d13154d2a9281d,Nivo,0.324456
uuid-7309720016de427fa4d13154d2a9281d,patients,0.352315
uuid-7309720016de427fa4d13154d2a9281d,RTL,0.317048
uuid-7309720016de427fa4d13154d2a9281d,therapy,0.366833
uuid-7309720016de427fa4d13154d2a9281d,nivolumab,0.345551
uuid-7309720016de427fa4d13154d2a9281d,treated,0.334225
uuid-7309720016de427fa4d13154d2a9281d,stated,0.373568
uuid-7309720016de427fa4d13154d2a9281d,using nivo,0.384983
uuid-7309720016de427fa4d13154d2a9281d,data,0.405078
uuid-7309720016de427fa4d13154d2a9281d,SCCHN,0.36535
uuid-7309720016de427fa4d13154d2a9281d,cHL,0.374348
uuid-7309720016de427fa4d13154d2a9281d,chemotherapy,0.331065
uuid-7309720016de427fa4d13154d2a9281d,impressed,0.436307
uuid-7309720016de427fa4d13154d2a9281d,LTL,0.343149
uuid-7309720016de427fa4d13154d2a9281d,feels,0.383704
uuid-7309720016de427fa4d13154d2a9281d,Regional TL,0.357693
uuid-7309720016de427fa4d13154d2a9281d,RTL stated,0.389189
uuid-8f37d7eaa9b24eb2a036706920a06737,patients,0.344915
uuid-8f37d7eaa9b24eb2a036706920a06737,Opdivo,0.384718
uuid-8f37d7eaa9b24eb2a036706920a06737,therapy,0.487343
uuid-8f37d7eaa9b24eb2a036706920a06737,nivolumab,0.35704
uuid-8f37d7eaa9b24eb2a036706920a06737,mentioned,0.364936
uuid-8f37d7eaa9b24eb2a036706920a06737,cHL,0.833816
uuid-59c7f04dca3a475fa3206b848680e2c0,agents,0.350899
uuid-59c7f04dca3a475fa3206b848680e2c0,feels,0.315956
uuid-6f963d38291043b484203b142208fa91,TL,0.48096
uuid-6f963d38291043b484203b142208fa91,PDL1,0.580709
uuid-6f963d38291043b484203b142208fa91,TL stated,0.306651
uuid-6f963d38291043b484203b142208fa91,Merck,0.483757
uuid-6f963d38291043b484203b142208fa91,PD-L1,0.648991
uuid-6f963d38291043b484203b142208fa91,atezo,0.384713
uuid-6f963d38291043b484203b142208fa91,PD-L1 testing,0.533987
uuid-6f963d38291043b484203b142208fa91,testing,0.621175
uuid-6f963d38291043b484203b142208fa91,PDL1 testing,0.469195
uuid-6f963d38291043b484203b142208fa91,NSCLC patients,0.326414
uuid-6f963d38291043b484203b142208fa91,TLs,0.302166
uuid-6f963d38291043b484203b142208fa91,assay,0.706416
uuid-6f963d38291043b484203b142208fa91,PDL1 expression,0.494989
uuid-6f963d38291043b484203b142208fa91,biomarker,0.426625
uuid-e3d7ae241bac4b9d90da084c6ed950d8,patients,0.318106
uuid-7f88606c8da843dba945db2f56a61ccb,Nivo,0.33657
uuid-7f88606c8da843dba945db2f56a61ccb,pembro,0.383265
uuid-7f88606c8da843dba945db2f56a61ccb,RTL,0.346835
uuid-7f88606c8da843dba945db2f56a61ccb,trial,0.448582
uuid-7f88606c8da843dba945db2f56a61ccb,efficacy,0.407691
uuid-7f88606c8da843dba945db2f56a61ccb,shared,0.404466
uuid-7f88606c8da843dba945db2f56a61ccb,commented,0.449172
uuid-7f88606c8da843dba945db2f56a61ccb,Ipi,0.405803
uuid-7f88606c8da843dba945db2f56a61ccb,stated,0.339186
uuid-7f88606c8da843dba945db2f56a61ccb,OS,0.366744
uuid-7f88606c8da843dba945db2f56a61ccb,atezo,0.301261
uuid-7f88606c8da843dba945db2f56a61ccb,using nivo,0.313386
uuid-7f88606c8da843dba945db2f56a61ccb,data,0.595135
uuid-7f88606c8da843dba945db2f56a61ccb,expressed,0.367449
uuid-7f88606c8da843dba945db2f56a61ccb,clinical trials,0.331209
uuid-7f88606c8da843dba945db2f56a61ccb,indication,0.308552
uuid-7f88606c8da843dba945db2f56a61ccb,PFS,0.321082
uuid-7f88606c8da843dba945db2f56a61ccb,ORR,0.427613
uuid-7f88606c8da843dba945db2f56a61ccb,SCCHN,0.341732
uuid-7f88606c8da843dba945db2f56a61ccb,nivo and pembro,0.334875
uuid-7f88606c8da843dba945db2f56a61ccb,impressed,0.595757
uuid-7f88606c8da843dba945db2f56a61ccb,LTL,0.315082
uuid-7f88606c8da843dba945db2f56a61ccb,TLs,0.401871
uuid-7f88606c8da843dba945db2f56a61ccb,SCLC,0.545501
uuid-7f88606c8da843dba945db2f56a61ccb,feels,0.30416
uuid-7f88606c8da843dba945db2f56a61ccb,Regional TL,0.328056
uuid-7f88606c8da843dba945db2f56a61ccb,bladder,0.332449
uuid-b70e0deb738c4a57b4d6c93f9225ef90,NTL,0.421484
uuid-b70e0deb738c4a57b4d6c93f9225ef90,discussed,0.593769
uuid-b70e0deb738c4a57b4d6c93f9225ef90,commented,0.363027
uuid-b70e0deb738c4a57b4d6c93f9225ef90,regards,0.44033
uuid-b70e0deb738c4a57b4d6c93f9225ef90,data,0.333203
uuid-b70e0deb738c4a57b4d6c93f9225ef90,mentioned,0.323655
uuid-9789a3a33f1241eaaef73825c7683efb,BMS,0.55808
uuid-9789a3a33f1241eaaef73825c7683efb,lung,0.31633
uuid-9789a3a33f1241eaaef73825c7683efb,trial,0.457747
uuid-9789a3a33f1241eaaef73825c7683efb,shared,0.331596
uuid-9789a3a33f1241eaaef73825c7683efb,commented,0.344665
uuid-9789a3a33f1241eaaef73825c7683efb,Merck,0.480162
uuid-9789a3a33f1241eaaef73825c7683efb,clinical trials,0.379088
uuid-6b5bf812553b43e89cf01deafe99b7b6,RTL,0.671021
uuid-6b5bf812553b43e89cf01deafe99b7b6,trial,0.628959
uuid-6b5bf812553b43e89cf01deafe99b7b6,NTL,0.508253
uuid-6b5bf812553b43e89cf01deafe99b7b6,commented,0.310548
uuid-6b5bf812553b43e89cf01deafe99b7b6,stated,0.422392
uuid-6b5bf812553b43e89cf01deafe99b7b6,data,0.406821
uuid-6b5bf812553b43e89cf01deafe99b7b6,expressed,0.338714
uuid-6b5bf812553b43e89cf01deafe99b7b6,clinical trials,0.53717
uuid-6b5bf812553b43e89cf01deafe99b7b6,SCCHN,0.556949
uuid-6b5bf812553b43e89cf01deafe99b7b6,impressed,0.45273
uuid-6b5bf812553b43e89cf01deafe99b7b6,LTL,0.407344
uuid-6b5bf812553b43e89cf01deafe99b7b6,TLs,0.321347
uuid-6b5bf812553b43e89cf01deafe99b7b6,academic,0.401585
uuid-6b5bf812553b43e89cf01deafe99b7b6,Regional TL,0.482462
uuid-6b5bf812553b43e89cf01deafe99b7b6,RTL stated,0.441127
uuid-6b5bf812553b43e89cf01deafe99b7b6,bladder,0.52668
uuid-96e18564b59f4131b8c06dfded3dfeea,patients,0.633563
uuid-96e18564b59f4131b8c06dfded3dfeea,Opdivo,0.523667
uuid-96e18564b59f4131b8c06dfded3dfeea,dose,0.50134
uuid-96e18564b59f4131b8c06dfded3dfeea,nivolumab,0.370952
uuid-96e18564b59f4131b8c06dfded3dfeea,toxicity,0.425914
uuid-96e18564b59f4131b8c06dfded3dfeea,regimen,0.535081
uuid-96e18564b59f4131b8c06dfded3dfeea,treated,0.519318
uuid-96e18564b59f4131b8c06dfded3dfeea,pts,0.37941
uuid-96e18564b59f4131b8c06dfded3dfeea,treatment,0.466831
uuid-96e18564b59f4131b8c06dfded3dfeea,progression,0.426922
uuid-96e18564b59f4131b8c06dfded3dfeea,respond,0.340654
uuid-96e18564b59f4131b8c06dfded3dfeea,flat dosing,0.320036
uuid-849fa0c676eb48088f24bad6e530933a,Nivo,0.328283
uuid-849fa0c676eb48088f24bad6e530933a,pembro,0.321067
uuid-849fa0c676eb48088f24bad6e530933a,RTL,0.363226
uuid-849fa0c676eb48088f24bad6e530933a,trial,0.665509
uuid-849fa0c676eb48088f24bad6e530933a,efficacy,0.316537
uuid-849fa0c676eb48088f24bad6e530933a,approval,0.314601
uuid-849fa0c676eb48088f24bad6e530933a,data,0.424602
uuid-849fa0c676eb48088f24bad6e530933a,clinical trials,0.434877
uuid-849fa0c676eb48088f24bad6e530933a,ORR,0.378024
uuid-849fa0c676eb48088f24bad6e530933a,impressed,0.361468
uuid-2100859c186d4c7985ade33189ccdd20,RTL,0.439337
uuid-2100859c186d4c7985ade33189ccdd20,BMS,0.649895
uuid-2100859c186d4c7985ade33189ccdd20,trial,0.591588
uuid-2100859c186d4c7985ade33189ccdd20,NTL,0.334716
uuid-2100859c186d4c7985ade33189ccdd20,shared,0.38623
uuid-2100859c186d4c7985ade33189ccdd20,commented,0.497297
uuid-2100859c186d4c7985ade33189ccdd20,Merck,0.582964
uuid-2100859c186d4c7985ade33189ccdd20,stated,0.458402
uuid-2100859c186d4c7985ade33189ccdd20,physicians,0.316753
uuid-2100859c186d4c7985ade33189ccdd20,data,0.412913
uuid-2100859c186d4c7985ade33189ccdd20,expressed,0.406282
uuid-2100859c186d4c7985ade33189ccdd20,mentioned,0.324911
uuid-2100859c186d4c7985ade33189ccdd20,clinical trials,0.517319
uuid-2100859c186d4c7985ade33189ccdd20,oncology,0.331966
uuid-2100859c186d4c7985ade33189ccdd20,impressed,0.387294
uuid-2100859c186d4c7985ade33189ccdd20,LTL,0.389913
uuid-2100859c186d4c7985ade33189ccdd20,TLs,0.389881
uuid-2100859c186d4c7985ade33189ccdd20,Regional TL,0.480107
uuid-02a2e3a9aa53431b94f0b7773895b627,Nivo,0.339168
uuid-02a2e3a9aa53431b94f0b7773895b627,patients,0.437222
uuid-02a2e3a9aa53431b94f0b7773895b627,Opdivo,0.399537
uuid-02a2e3a9aa53431b94f0b7773895b627,dose,0.793585
uuid-02a2e3a9aa53431b94f0b7773895b627,toxicity,0.36477
uuid-02a2e3a9aa53431b94f0b7773895b627,regimen,0.424492
uuid-02a2e3a9aa53431b94f0b7773895b627,Ipi,0.460633
uuid-02a2e3a9aa53431b94f0b7773895b627,preferred,0.338173
uuid-02a2e3a9aa53431b94f0b7773895b627,treatment,0.349442
uuid-02a2e3a9aa53431b94f0b7773895b627,vs,0.564056
uuid-02a2e3a9aa53431b94f0b7773895b627,flat dosing,0.52199
uuid-fafd8689498d4f2b97ce5fc8bad4ceb8,patients,0.712589
uuid-fafd8689498d4f2b97ce5fc8bad4ceb8,Opdivo,0.389552
uuid-fafd8689498d4f2b97ce5fc8bad4ceb8,therapy,0.504949
uuid-fafd8689498d4f2b97ce5fc8bad4ceb8,nivolumab,0.511136
uuid-fafd8689498d4f2b97ce5fc8bad4ceb8,regimen,0.589436
uuid-fafd8689498d4f2b97ce5fc8bad4ceb8,treated,0.632491
uuid-fafd8689498d4f2b97ce5fc8bad4ceb8,pts,0.451286
uuid-fafd8689498d4f2b97ce5fc8bad4ceb8,monotherapy,0.364555
uuid-fafd8689498d4f2b97ce5fc8bad4ceb8,treatment,0.582667
uuid-fafd8689498d4f2b97ce5fc8bad4ceb8,progression,0.470441
uuid-9dfbfbdd47de4e7f8b545c9a9fd68a64,BMS,0.343995
uuid-9dfbfbdd47de4e7f8b545c9a9fd68a64,physicians,0.584055
uuid-9dfbfbdd47de4e7f8b545c9a9fd68a64,clinical trials,0.334646
uuid-9dfbfbdd47de4e7f8b545c9a9fd68a64,oncology,0.32917
uuid-9dfbfbdd47de4e7f8b545c9a9fd68a64,indicated,0.413525
uuid-9dfbfbdd47de4e7f8b545c9a9fd68a64,clinical,0.32626
uuid-9dfbfbdd47de4e7f8b545c9a9fd68a64,Regional TL,0.304768
uuid-951201cf50234cc9b1ad21b0b4132fa2,Nivo,0.352246
uuid-951201cf50234cc9b1ad21b0b4132fa2,patients,0.488773
uuid-951201cf50234cc9b1ad21b0b4132fa2,Opdivo,0.318592
uuid-951201cf50234cc9b1ad21b0b4132fa2,therapy,0.588844
uuid-951201cf50234cc9b1ad21b0b4132fa2,nivolumab,0.372759
uuid-951201cf50234cc9b1ad21b0b4132fa2,toxicity,0.315261
uuid-951201cf50234cc9b1ad21b0b4132fa2,treated,0.307864
uuid-951201cf50234cc9b1ad21b0b4132fa2,treatment,0.391058
uuid-951201cf50234cc9b1ad21b0b4132fa2,mentioned,0.325783
uuid-951201cf50234cc9b1ad21b0b4132fa2,cHL,0.63592
uuid-951201cf50234cc9b1ad21b0b4132fa2,chemotherapy,0.375129
uuid-68a5a1ebd96742378492ae673e0afc73,TL,0.465705
uuid-68a5a1ebd96742378492ae673e0afc73,commented,0.424556
uuid-68a5a1ebd96742378492ae673e0afc73,TL stated,0.448094
uuid-68a5a1ebd96742378492ae673e0afc73,stated,0.375086
uuid-68a5a1ebd96742378492ae673e0afc73,physicians,0.603842
uuid-68a5a1ebd96742378492ae673e0afc73,mentioned,0.368997
uuid-68a5a1ebd96742378492ae673e0afc73,PDL1 testing,0.304832
uuid-68a5a1ebd96742378492ae673e0afc73,oncologist,0.334465
uuid-68a5a1ebd96742378492ae673e0afc73,LTL,0.352321
uuid-68a5a1ebd96742378492ae673e0afc73,TLs,0.460674
uuid-68a5a1ebd96742378492ae673e0afc73,Regional TL,0.509518
uuid-d508ca8ed289453dbfd6d27b3b8653d5,BMS,0.630652
uuid-d508ca8ed289453dbfd6d27b3b8653d5,PDL1,0.450532
uuid-d508ca8ed289453dbfd6d27b3b8653d5,trial,0.409301
uuid-d508ca8ed289453dbfd6d27b3b8653d5,efficacy,0.336762
uuid-d508ca8ed289453dbfd6d27b3b8653d5,commented,0.462899
uuid-d508ca8ed289453dbfd6d27b3b8653d5,Merck,0.529366
uuid-d508ca8ed289453dbfd6d27b3b8653d5,stated,0.304783
uuid-d508ca8ed289453dbfd6d27b3b8653d5,OS,0.616863
uuid-d508ca8ed289453dbfd6d27b3b8653d5,regards,0.318393
uuid-d508ca8ed289453dbfd6d27b3b8653d5,data,0.77279
uuid-d508ca8ed289453dbfd6d27b3b8653d5,expressed,0.393912
uuid-d508ca8ed289453dbfd6d27b3b8653d5,PFS,0.546068
uuid-d508ca8ed289453dbfd6d27b3b8653d5,ORR,0.536952
uuid-d508ca8ed289453dbfd6d27b3b8653d5,ASCO,0.392194
uuid-d508ca8ed289453dbfd6d27b3b8653d5,impressed,0.639445
uuid-d508ca8ed289453dbfd6d27b3b8653d5,PDL1 expression,0.346476
uuid-cc714fab0576480290bd6da64ad0371c,Nivo,0.340746
uuid-cc714fab0576480290bd6da64ad0371c,patients,0.820412
uuid-cc714fab0576480290bd6da64ad0371c,Opdivo,0.408493
uuid-cc714fab0576480290bd6da64ad0371c,therapy,0.629564
uuid-cc714fab0576480290bd6da64ad0371c,nivolumab,0.517687
uuid-cc714fab0576480290bd6da64ad0371c,regimen,0.428661
uuid-cc714fab0576480290bd6da64ad0371c,treated,0.4506
uuid-cc714fab0576480290bd6da64ad0371c,chemo,0.402009
uuid-cc714fab0576480290bd6da64ad0371c,pts,0.435641
uuid-cc714fab0576480290bd6da64ad0371c,preferred,0.345456
uuid-cc714fab0576480290bd6da64ad0371c,monotherapy,0.457977
uuid-cc714fab0576480290bd6da64ad0371c,treatment,0.537273
uuid-cc714fab0576480290bd6da64ad0371c,using nivo,0.458471
uuid-cc714fab0576480290bd6da64ad0371c,PD1,0.30741
uuid-cc714fab0576480290bd6da64ad0371c,cHL,0.490577
uuid-cc714fab0576480290bd6da64ad0371c,progression,0.492201
uuid-cc714fab0576480290bd6da64ad0371c,chemotherapy,0.445822
uuid-cc714fab0576480290bd6da64ad0371c,option,0.487583
uuid-98a4403e82d647e9bf9527f29b5d2fcf,pembro,0.494139
uuid-98a4403e82d647e9bf9527f29b5d2fcf,dose,0.360683
uuid-98a4403e82d647e9bf9527f29b5d2fcf,TL stated,0.467839
uuid-98a4403e82d647e9bf9527f29b5d2fcf,2L,0.354044
uuid-98a4403e82d647e9bf9527f29b5d2fcf,Merck,0.374648
uuid-98a4403e82d647e9bf9527f29b5d2fcf,PD-L1,0.325792
uuid-98a4403e82d647e9bf9527f29b5d2fcf,atezo,0.518043
uuid-98a4403e82d647e9bf9527f29b5d2fcf,preferred,0.311389
uuid-98a4403e82d647e9bf9527f29b5d2fcf,testing,0.303808
uuid-98a4403e82d647e9bf9527f29b5d2fcf,PDL1 testing,0.359324
uuid-98a4403e82d647e9bf9527f29b5d2fcf,NSCLC patients,0.336056
uuid-98a4403e82d647e9bf9527f29b5d2fcf,vs,0.353764
uuid-98a4403e82d647e9bf9527f29b5d2fcf,Keytruda,0.317924
uuid-98a4403e82d647e9bf9527f29b5d2fcf,TLs,0.419436
uuid-98a4403e82d647e9bf9527f29b5d2fcf,bladder,0.317075
uuid-98a4403e82d647e9bf9527f29b5d2fcf,flat dosing,0.31277
uuid-074b1dd22f9344d08d6959a694499518,physicians,0.418146
uuid-531c909c364c43839c15175e5b0cacc1,patients,0.531624
uuid-531c909c364c43839c15175e5b0cacc1,dose,0.530389
uuid-531c909c364c43839c15175e5b0cacc1,toxicity,0.515682
uuid-531c909c364c43839c15175e5b0cacc1,regimen,0.420934
uuid-531c909c364c43839c15175e5b0cacc1,treated,0.313372
uuid-531c909c364c43839c15175e5b0cacc1,treatment,0.480235
uuid-531c909c364c43839c15175e5b0cacc1,respond,0.360369
uuid-75aca2714d1c4230aa4678c3ba076d53,chemo,0.317382
uuid-75aca2714d1c4230aa4678c3ba076d53,response,0.34064
uuid-75aca2714d1c4230aa4678c3ba076d53,AI,0.565811
uuid-75aca2714d1c4230aa4678c3ba076d53,immunotherapy,0.535541
uuid-e9378939a80447dfacca49a41680465a,efficacy,0.318937
uuid-e9378939a80447dfacca49a41680465a,combination,0.352744
uuid-e9378939a80447dfacca49a41680465a,agents,0.472657
uuid-e9378939a80447dfacca49a41680465a,preferred,0.317172
uuid-e9378939a80447dfacca49a41680465a,monotherapy,0.333265
uuid-e9378939a80447dfacca49a41680465a,combo,0.343733
uuid-e9378939a80447dfacca49a41680465a,believes,0.349988
uuid-e9378939a80447dfacca49a41680465a,drug,0.346472
uuid-e9378939a80447dfacca49a41680465a,feels,0.503065
uuid-e9378939a80447dfacca49a41680465a,option,0.362748
uuid-2356f4dc740b4b38b7fdc2b95da68ce2,RTL,0.513778
uuid-2356f4dc740b4b38b7fdc2b95da68ce2,BMS,0.342041
uuid-2356f4dc740b4b38b7fdc2b95da68ce2,trial,0.741251
uuid-2356f4dc740b4b38b7fdc2b95da68ce2,NTL,0.316635
uuid-2356f4dc740b4b38b7fdc2b95da68ce2,combination,0.381269
uuid-2356f4dc740b4b38b7fdc2b95da68ce2,data,0.499518
uuid-2356f4dc740b4b38b7fdc2b95da68ce2,expressed,0.302442
uuid-2356f4dc740b4b38b7fdc2b95da68ce2,clinical trials,0.402006
uuid-2356f4dc740b4b38b7fdc2b95da68ce2,ORR,0.364589
uuid-2356f4dc740b4b38b7fdc2b95da68ce2,impressed,0.516161
uuid-2356f4dc740b4b38b7fdc2b95da68ce2,SCLC,0.301397
uuid-2356f4dc740b4b38b7fdc2b95da68ce2,Regional TL,0.350411
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,efficacy,0.405244
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,regimen,0.350998
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,commented,0.436942
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,OS,0.519097
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,data,0.577233
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,expressed,0.320824
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,PFS,0.447272
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,ORR,0.524031
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,ASCO,0.469331
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,impressed,0.663202
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,TLs,0.324453
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,SCLC,0.414257
uuid-ace6cecf316d4a8796fc5f7cdc5ff25d,Regional TL,0.33781
uuid-ca7f15f3326543bba82f95f4efe59284,pembro,0.327453
uuid-ca7f15f3326543bba82f95f4efe59284,RTL,0.331241
uuid-ca7f15f3326543bba82f95f4efe59284,BMS,0.331505
uuid-ca7f15f3326543bba82f95f4efe59284,trial,0.761832
uuid-ca7f15f3326543bba82f95f4efe59284,combination,0.344927
uuid-ca7f15f3326543bba82f95f4efe59284,Ipi,0.440858
uuid-ca7f15f3326543bba82f95f4efe59284,combo,0.371367
uuid-ca7f15f3326543bba82f95f4efe59284,clinical trials,0.323755
uuid-ca7f15f3326543bba82f95f4efe59284,impressed,0.345876
uuid-ca7f15f3326543bba82f95f4efe59284,vs,0.334379
uuid-576434a5726d496cb7e0587298ecf95c,Opdivo,0.376773
uuid-576434a5726d496cb7e0587298ecf95c,dose,0.831854
uuid-576434a5726d496cb7e0587298ecf95c,toxicity,0.420487
uuid-576434a5726d496cb7e0587298ecf95c,regimen,0.347223
uuid-576434a5726d496cb7e0587298ecf95c,Ipi,0.62045
uuid-576434a5726d496cb7e0587298ecf95c,vs,0.409233
uuid-576434a5726d496cb7e0587298ecf95c,Keytruda,0.304123
uuid-576434a5726d496cb7e0587298ecf95c,flat dosing,0.687445
uuid-00deb5fcb7354ae4ae2f653f99b7606c,Nivo,0.308287
uuid-00deb5fcb7354ae4ae2f653f99b7606c,patients,0.486611
uuid-00deb5fcb7354ae4ae2f653f99b7606c,therapy,0.657784
uuid-00deb5fcb7354ae4ae2f653f99b7606c,nivolumab,0.376125
uuid-00deb5fcb7354ae4ae2f653f99b7606c,treatment,0.3955
uuid-00deb5fcb7354ae4ae2f653f99b7606c,cHL,0.656667
uuid-00deb5fcb7354ae4ae2f653f99b7606c,progression,0.385091
uuid-00deb5fcb7354ae4ae2f653f99b7606c,chemotherapy,0.4159
uuid-1ebae599cd75499e9dd766f412018936,Opdivo,0.408685
uuid-1ebae599cd75499e9dd766f412018936,RTL,0.365433
uuid-1ebae599cd75499e9dd766f412018936,nivolumab,0.327746
uuid-1ebae599cd75499e9dd766f412018936,NTL,0.321971
uuid-1ebae599cd75499e9dd766f412018936,shared,0.345689
uuid-1ebae599cd75499e9dd766f412018936,stated,0.306488
uuid-1ebae599cd75499e9dd766f412018936,physicians,0.576877
uuid-1ebae599cd75499e9dd766f412018936,HCP,0.371747
uuid-1ebae599cd75499e9dd766f412018936,oncologist,0.307386
uuid-1ebae599cd75499e9dd766f412018936,indicated,0.3522
uuid-1ebae599cd75499e9dd766f412018936,LTL,0.350253
uuid-1ebae599cd75499e9dd766f412018936,Regional TL,0.328786
uuid-8a22113c9cc74b12bef730d04c1b6890,RTL,0.340055
uuid-8a22113c9cc74b12bef730d04c1b6890,therapy,0.329149
uuid-8a22113c9cc74b12bef730d04c1b6890,trial,0.313344
uuid-8a22113c9cc74b12bef730d04c1b6890,mentioned,0.415792
uuid-8a22113c9cc74b12bef730d04c1b6890,cHL,0.588021
uuid-b2aca7c2620e4195b93f69c3dce1dfd9,Nivo,0.654696
uuid-b2aca7c2620e4195b93f69c3dce1dfd9,pembro,0.376333
uuid-b2aca7c2620e4195b93f69c3dce1dfd9,therapy,0.338219
uuid-b2aca7c2620e4195b93f69c3dce1dfd9,nivolumab,0.346396
uuid-b2aca7c2620e4195b93f69c3dce1dfd9,using nivo,0.407413
uuid-b2aca7c2620e4195b93f69c3dce1dfd9,mentioned,0.354977
uuid-b2aca7c2620e4195b93f69c3dce1dfd9,cHL,0.645585
uuid-b2aca7c2620e4195b93f69c3dce1dfd9,vs,0.455709
uuid-f70397337257479da865f34044231af1,BMS,0.439494
uuid-f70397337257479da865f34044231af1,PDL1,0.431857
uuid-f70397337257479da865f34044231af1,trial,0.668958
uuid-f70397337257479da865f34044231af1,efficacy,0.458575
uuid-f70397337257479da865f34044231af1,Merck,0.30259
uuid-f70397337257479da865f34044231af1,OS,0.714428
uuid-f70397337257479da865f34044231af1,data,0.626204
uuid-f70397337257479da865f34044231af1,PFS,0.765329
uuid-f70397337257479da865f34044231af1,ORR,0.704943
uuid-f70397337257479da865f34044231af1,nivo and pembro,0.377038
uuid-f70397337257479da865f34044231af1,believes,0.301114
uuid-f70397337257479da865f34044231af1,impressed,0.525668
uuid-f70397337257479da865f34044231af1,feels,0.461297
uuid-f70397337257479da865f34044231af1,PDL1 expression,0.402699
uuid-01b95321ea9e45a39eec597a5ba026cc,Nivo,0.526515
uuid-01b95321ea9e45a39eec597a5ba026cc,pembro,0.633199
uuid-01b95321ea9e45a39eec597a5ba026cc,dose,0.507978
uuid-01b95321ea9e45a39eec597a5ba026cc,1L,0.314955
uuid-01b95321ea9e45a39eec597a5ba026cc,efficacy,0.448931
uuid-01b95321ea9e45a39eec597a5ba026cc,2L,0.457769
uuid-01b95321ea9e45a39eec597a5ba026cc,agents,0.30143
uuid-01b95321ea9e45a39eec597a5ba026cc,Ipi,0.356756
uuid-01b95321ea9e45a39eec597a5ba026cc,atezo,0.660038
uuid-01b95321ea9e45a39eec597a5ba026cc,preferred,0.458017
uuid-01b95321ea9e45a39eec597a5ba026cc,using nivo,0.311824
uuid-01b95321ea9e45a39eec597a5ba026cc,indication,0.391786
uuid-01b95321ea9e45a39eec597a5ba026cc,approved,0.351924
uuid-01b95321ea9e45a39eec597a5ba026cc,nivo and pembro,0.355827
uuid-01b95321ea9e45a39eec597a5ba026cc,vs,0.607757
uuid-01b95321ea9e45a39eec597a5ba026cc,Keytruda,0.320994
uuid-01b95321ea9e45a39eec597a5ba026cc,feels,0.348913
uuid-01b95321ea9e45a39eec597a5ba026cc,option,0.379399
uuid-01b95321ea9e45a39eec597a5ba026cc,flat dosing,0.399057
uuid-9e749d4c16cb4cd3ba8863f9c611629d,pembro,0.308665
uuid-9e749d4c16cb4cd3ba8863f9c611629d,BMS,0.593716
uuid-9e749d4c16cb4cd3ba8863f9c611629d,PDL1,0.333438
uuid-9e749d4c16cb4cd3ba8863f9c611629d,trial,0.491556
uuid-9e749d4c16cb4cd3ba8863f9c611629d,efficacy,0.462335
uuid-9e749d4c16cb4cd3ba8863f9c611629d,discussed,0.343962
uuid-9e749d4c16cb4cd3ba8863f9c611629d,commented,0.437527
uuid-9e749d4c16cb4cd3ba8863f9c611629d,Merck,0.429408
uuid-9e749d4c16cb4cd3ba8863f9c611629d,stated,0.310382
uuid-9e749d4c16cb4cd3ba8863f9c611629d,OS,0.42368
uuid-9e749d4c16cb4cd3ba8863f9c611629d,regards,0.349534
uuid-9e749d4c16cb4cd3ba8863f9c611629d,data,0.758902
uuid-9e749d4c16cb4cd3ba8863f9c611629d,expressed,0.353427
uuid-9e749d4c16cb4cd3ba8863f9c611629d,clinical trials,0.318189
uuid-9e749d4c16cb4cd3ba8863f9c611629d,PFS,0.393587
uuid-9e749d4c16cb4cd3ba8863f9c611629d,ORR,0.462211
uuid-9e749d4c16cb4cd3ba8863f9c611629d,nivo and pembro,0.356653
uuid-9e749d4c16cb4cd3ba8863f9c611629d,impressed,0.589142
uuid-9e749d4c16cb4cd3ba8863f9c611629d,LTL,0.36826
uuid-9e749d4c16cb4cd3ba8863f9c611629d,feels,0.332127
uuid-9e749d4c16cb4cd3ba8863f9c611629d,PDL1 expression,0.319411
uuid-b266c872969341bfb3358058539b4cab,TL,0.323127
uuid-b266c872969341bfb3358058539b4cab,PDL1,0.464806
uuid-b266c872969341bfb3358058539b4cab,tumor,0.487114
uuid-b266c872969341bfb3358058539b4cab,PD-L1,0.735381
uuid-b266c872969341bfb3358058539b4cab,PD-L1 testing,0.559237
uuid-b266c872969341bfb3358058539b4cab,testing,0.669426
uuid-b266c872969341bfb3358058539b4cab,PDL1 testing,0.408631
uuid-b266c872969341bfb3358058539b4cab,NSCLC patients,0.494673
uuid-b266c872969341bfb3358058539b4cab,assay,0.623319
uuid-b266c872969341bfb3358058539b4cab,PDL1 expression,0.413204
uuid-b266c872969341bfb3358058539b4cab,biomarker,0.444714
uuid-aee73c0d1ed74f238b4073a262a61025,pembro,0.311639
uuid-aee73c0d1ed74f238b4073a262a61025,RTL,0.47273
uuid-aee73c0d1ed74f238b4073a262a61025,1L,0.390813
uuid-aee73c0d1ed74f238b4073a262a61025,trial,0.323919
uuid-aee73c0d1ed74f238b4073a262a61025,commented,0.335769
uuid-aee73c0d1ed74f238b4073a262a61025,RCC,0.339879
uuid-aee73c0d1ed74f238b4073a262a61025,2L,0.330311
uuid-aee73c0d1ed74f238b4073a262a61025,stated,0.428001
uuid-aee73c0d1ed74f238b4073a262a61025,monotherapy,0.335484
uuid-aee73c0d1ed74f238b4073a262a61025,using nivo,0.372347
uuid-aee73c0d1ed74f238b4073a262a61025,data,0.567407
uuid-aee73c0d1ed74f238b4073a262a61025,clinical trials,0.397706
uuid-aee73c0d1ed74f238b4073a262a61025,ORR,0.315525
uuid-aee73c0d1ed74f238b4073a262a61025,SCCHN,0.556267
uuid-aee73c0d1ed74f238b4073a262a61025,impressed,0.639119
uuid-aee73c0d1ed74f238b4073a262a61025,LTL,0.373281
uuid-aee73c0d1ed74f238b4073a262a61025,SCLC,0.357049
uuid-aee73c0d1ed74f238b4073a262a61025,feels,0.550662
uuid-aee73c0d1ed74f238b4073a262a61025,Regional TL,0.425259
uuid-aee73c0d1ed74f238b4073a262a61025,RTL stated,0.488908
uuid-aee73c0d1ed74f238b4073a262a61025,option,0.304299
uuid-aee73c0d1ed74f238b4073a262a61025,bladder,0.341586
uuid-1b2f60474eab473993b0db3815544c2f,TL,0.549905
uuid-1b2f60474eab473993b0db3815544c2f,PDL1,0.355153
uuid-1b2f60474eab473993b0db3815544c2f,TL stated,0.497891
uuid-1b2f60474eab473993b0db3815544c2f,institution,0.477048
uuid-1b2f60474eab473993b0db3815544c2f,PD-L1,0.763355
uuid-1b2f60474eab473993b0db3815544c2f,approval,0.337892
uuid-1b2f60474eab473993b0db3815544c2f,PD-L1 testing,0.84486
uuid-1b2f60474eab473993b0db3815544c2f,testing,0.887703
uuid-1b2f60474eab473993b0db3815544c2f,PDL1 testing,0.767394
uuid-1b2f60474eab473993b0db3815544c2f,NSCLC patients,0.746606
uuid-1b2f60474eab473993b0db3815544c2f,assay,0.595834
uuid-1b2f60474eab473993b0db3815544c2f,biomarker,0.360546
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,Nivo,0.437002
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,patients,0.570129
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,Opdivo,0.57528
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,pembro,0.349157
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,dose,0.60203
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,toxicity,0.39849
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,regimen,0.410883
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,Ipi,0.34655
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,preferred,0.346749
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,monotherapy,0.35668
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,indication,0.314235
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,vs,0.375463
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,Keytruda,0.42529
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,option,0.343206
uuid-7b9ced7b9cf242b3b2c3ac9aed5726d5,flat dosing,0.502605
uuid-75844be7f613407aab87479840e69b20,BMS,0.329696
uuid-75844be7f613407aab87479840e69b20,PDL1,0.471999
uuid-75844be7f613407aab87479840e69b20,trial,0.388734
uuid-75844be7f613407aab87479840e69b20,efficacy,0.816509
uuid-75844be7f613407aab87479840e69b20,OS,0.845256
uuid-75844be7f613407aab87479840e69b20,regards,0.398539
uuid-75844be7f613407aab87479840e69b20,data,0.745531
uuid-75844be7f613407aab87479840e69b20,PFS,0.817376
uuid-75844be7f613407aab87479840e69b20,ORR,0.820453
uuid-75844be7f613407aab87479840e69b20,nivo and pembro,0.548635
uuid-75844be7f613407aab87479840e69b20,believes,0.385141
uuid-75844be7f613407aab87479840e69b20,impressed,0.504253
uuid-75844be7f613407aab87479840e69b20,feels,0.341713
uuid-75844be7f613407aab87479840e69b20,PDL1 expression,0.470212
uuid-a04a04ca39984684a9643af890563314,patients,0.365362
uuid-a04a04ca39984684a9643af890563314,regimen,0.424172
uuid-a04a04ca39984684a9643af890563314,treated,0.508012
uuid-a04a04ca39984684a9643af890563314,melanoma,0.334962
uuid-a04a04ca39984684a9643af890563314,physicians,0.494573
uuid-a04a04ca39984684a9643af890563314,treatment,0.416658
uuid-a04a04ca39984684a9643af890563314,progression,0.439543
uuid-a04a04ca39984684a9643af890563314,oncologist,0.307095
uuid-a04a04ca39984684a9643af890563314,respond,0.347065
uuid-a04a04ca39984684a9643af890563314,TL shared,0.361651
uuid-05562ffe66f04567ae34adddbdb5fd27,Nivo,0.397263
uuid-05562ffe66f04567ae34adddbdb5fd27,pembro,0.345394
uuid-05562ffe66f04567ae34adddbdb5fd27,RTL,0.317162
uuid-05562ffe66f04567ae34adddbdb5fd27,1L,0.348798
uuid-05562ffe66f04567ae34adddbdb5fd27,trial,0.334621
uuid-05562ffe66f04567ae34adddbdb5fd27,2L,0.303326
uuid-05562ffe66f04567ae34adddbdb5fd27,pts,0.408902
uuid-05562ffe66f04567ae34adddbdb5fd27,stated,0.366501
uuid-05562ffe66f04567ae34adddbdb5fd27,OS,0.374023
uuid-05562ffe66f04567ae34adddbdb5fd27,monotherapy,0.386844
uuid-05562ffe66f04567ae34adddbdb5fd27,using nivo,0.340347
uuid-05562ffe66f04567ae34adddbdb5fd27,data,0.389804
uuid-05562ffe66f04567ae34adddbdb5fd27,combo,0.300783
uuid-05562ffe66f04567ae34adddbdb5fd27,PFS,0.314463
uuid-05562ffe66f04567ae34adddbdb5fd27,ORR,0.364288
uuid-05562ffe66f04567ae34adddbdb5fd27,SCCHN,0.319673
uuid-05562ffe66f04567ae34adddbdb5fd27,impressed,0.519322
uuid-05562ffe66f04567ae34adddbdb5fd27,SCLC,0.321776
uuid-05562ffe66f04567ae34adddbdb5fd27,feels,0.455767
uuid-05562ffe66f04567ae34adddbdb5fd27,RTL stated,0.34338
uuid-f2516aeffb61417cb8e01e9fd644a9ae,patients,0.321737
uuid-f2516aeffb61417cb8e01e9fd644a9ae,preferred,0.542183
uuid-f2516aeffb61417cb8e01e9fd644a9ae,monotherapy,0.322125
uuid-f2516aeffb61417cb8e01e9fd644a9ae,SCCHN,0.36022
uuid-f2516aeffb61417cb8e01e9fd644a9ae,RTL stated,0.380333
uuid-f2516aeffb61417cb8e01e9fd644a9ae,option,0.446811
uuid-0b016bbd7f674b93a8850a0a1c747151,BMS,0.318882
uuid-0b016bbd7f674b93a8850a0a1c747151,combination,0.364186
uuid-0b016bbd7f674b93a8850a0a1c747151,tumor,0.348136
uuid-0b016bbd7f674b93a8850a0a1c747151,clinical trials,0.300645
uuid-0b016bbd7f674b93a8850a0a1c747151,clinical,0.366485
uuid-87b3aa77aebd48359890dde3c9d439ee,RTL,0.320727
uuid-87b3aa77aebd48359890dde3c9d439ee,PDL1,0.406379
uuid-87b3aa77aebd48359890dde3c9d439ee,trial,0.309053
uuid-87b3aa77aebd48359890dde3c9d439ee,efficacy,0.380895
uuid-87b3aa77aebd48359890dde3c9d439ee,commented,0.454565
uuid-87b3aa77aebd48359890dde3c9d439ee,stated,0.375913
uuid-87b3aa77aebd48359890dde3c9d439ee,OS,0.514174
uuid-87b3aa77aebd48359890dde3c9d439ee,data,0.782835
uuid-87b3aa77aebd48359890dde3c9d439ee,expressed,0.341917
uuid-87b3aa77aebd48359890dde3c9d439ee,PFS,0.470114
uuid-87b3aa77aebd48359890dde3c9d439ee,ORR,0.549014
uuid-87b3aa77aebd48359890dde3c9d439ee,ASCO,0.378655
uuid-87b3aa77aebd48359890dde3c9d439ee,impressed,0.677638
uuid-87b3aa77aebd48359890dde3c9d439ee,TLs,0.310627
uuid-87b3aa77aebd48359890dde3c9d439ee,feels,0.362342
uuid-87b3aa77aebd48359890dde3c9d439ee,Regional TL,0.315323
uuid-87b3aa77aebd48359890dde3c9d439ee,PDL1 expression,0.310541
uuid-64494f790c2d4cdbb9f10d93e408c009,trial,0.363965
uuid-64494f790c2d4cdbb9f10d93e408c009,efficacy,0.603986
uuid-64494f790c2d4cdbb9f10d93e408c009,commented,0.322683
uuid-64494f790c2d4cdbb9f10d93e408c009,Ipi,0.372295
uuid-64494f790c2d4cdbb9f10d93e408c009,OS,0.690621
uuid-64494f790c2d4cdbb9f10d93e408c009,data,0.704517
uuid-64494f790c2d4cdbb9f10d93e408c009,combo,0.393096
uuid-64494f790c2d4cdbb9f10d93e408c009,PFS,0.602362
uuid-64494f790c2d4cdbb9f10d93e408c009,ORR,0.692505
uuid-64494f790c2d4cdbb9f10d93e408c009,nivo and pembro,0.322919
uuid-64494f790c2d4cdbb9f10d93e408c009,ASCO,0.330931
uuid-64494f790c2d4cdbb9f10d93e408c009,believes,0.350459
uuid-64494f790c2d4cdbb9f10d93e408c009,impressed,0.719936
uuid-64494f790c2d4cdbb9f10d93e408c009,feels,0.421079
uuid-295b6b301ba04b4e9abcc96e1257369f,pembro,0.316252
uuid-295b6b301ba04b4e9abcc96e1257369f,BMS,0.649366
uuid-295b6b301ba04b4e9abcc96e1257369f,PDL1,0.698821
uuid-295b6b301ba04b4e9abcc96e1257369f,trial,0.466955
uuid-295b6b301ba04b4e9abcc96e1257369f,efficacy,0.35654
uuid-295b6b301ba04b4e9abcc96e1257369f,Merck,0.722499
uuid-295b6b301ba04b4e9abcc96e1257369f,PD-L1,0.349463
uuid-295b6b301ba04b4e9abcc96e1257369f,OS,0.421354
uuid-295b6b301ba04b4e9abcc96e1257369f,regards,0.317592
uuid-295b6b301ba04b4e9abcc96e1257369f,data,0.624891
uuid-295b6b301ba04b4e9abcc96e1257369f,PFS,0.440351
uuid-295b6b301ba04b4e9abcc96e1257369f,ORR,0.429848
uuid-295b6b301ba04b4e9abcc96e1257369f,nivo and pembro,0.444204
uuid-295b6b301ba04b4e9abcc96e1257369f,impressed,0.344697
uuid-295b6b301ba04b4e9abcc96e1257369f,assay,0.422867
uuid-295b6b301ba04b4e9abcc96e1257369f,PDL1 expression,0.616609
uuid-295b6b301ba04b4e9abcc96e1257369f,biomarker,0.512916
uuid-1f778355d99a48518df4e701705df309,patients,0.501248
uuid-1f778355d99a48518df4e701705df309,Opdivo,0.475919
uuid-1f778355d99a48518df4e701705df309,nivolumab,0.355981
uuid-1f778355d99a48518df4e701705df309,regimen,0.390334
uuid-1f778355d99a48518df4e701705df309,treated,0.476501
uuid-1f778355d99a48518df4e701705df309,RCC,0.332334
uuid-1f778355d99a48518df4e701705df309,TL stated,0.353576
uuid-1f778355d99a48518df4e701705df309,pts,0.350087
uuid-1f778355d99a48518df4e701705df309,treatment,0.35476
uuid-1f778355d99a48518df4e701705df309,RTL stated,0.338402
uuid-1f778355d99a48518df4e701705df309,TL shared,0.346431
uuid-6b549c2769f443de845ebe7a42023c67,efficacy,0.320531
uuid-6b549c2769f443de845ebe7a42023c67,combination,0.409076
uuid-6b549c2769f443de845ebe7a42023c67,chemo,0.32312
uuid-6b549c2769f443de845ebe7a42023c67,Ipi,0.478203
uuid-6b549c2769f443de845ebe7a42023c67,data,0.301453
uuid-6b549c2769f443de845ebe7a42023c67,combo,0.49172
uuid-6b549c2769f443de845ebe7a42023c67,PD1,0.339085
uuid-6b549c2769f443de845ebe7a42023c67,ORR,0.327409
uuid-6b549c2769f443de845ebe7a42023c67,chemotherapy,0.304755
uuid-128aad47a8384e45b7b1429fc581875e,1L,0.471972
uuid-128aad47a8384e45b7b1429fc581875e,PDL1,0.393056
uuid-128aad47a8384e45b7b1429fc581875e,TL stated,0.433165
uuid-128aad47a8384e45b7b1429fc581875e,2L,0.399202
uuid-128aad47a8384e45b7b1429fc581875e,PD-L1,0.757583
uuid-128aad47a8384e45b7b1429fc581875e,approval,0.300351
uuid-128aad47a8384e45b7b1429fc581875e,preferred,0.391492
uuid-128aad47a8384e45b7b1429fc581875e,PD-L1 testing,0.622899
uuid-128aad47a8384e45b7b1429fc581875e,testing,0.828172
uuid-128aad47a8384e45b7b1429fc581875e,PDL1 testing,0.769228
uuid-128aad47a8384e45b7b1429fc581875e,NSCLC patients,0.838079
uuid-128aad47a8384e45b7b1429fc581875e,tumor types,0.469657
uuid-128aad47a8384e45b7b1429fc581875e,assay,0.394256
uuid-128aad47a8384e45b7b1429fc581875e,PD-1,0.345579
uuid-128aad47a8384e45b7b1429fc581875e,biomarker,0.406175
uuid-8424dc875ab94146b69bafb296164c16,patients,0.66929
uuid-8424dc875ab94146b69bafb296164c16,Opdivo,0.393976
uuid-8424dc875ab94146b69bafb296164c16,therapy,0.493158
uuid-8424dc875ab94146b69bafb296164c16,nivolumab,0.621885
uuid-8424dc875ab94146b69bafb296164c16,regimen,0.30781
uuid-8424dc875ab94146b69bafb296164c16,treated,0.591916
uuid-8424dc875ab94146b69bafb296164c16,pts,0.317514
uuid-8424dc875ab94146b69bafb296164c16,treatment,0.561448
uuid-8424dc875ab94146b69bafb296164c16,using nivo,0.38914
uuid-8424dc875ab94146b69bafb296164c16,cHL,0.402074
uuid-8424dc875ab94146b69bafb296164c16,progression,0.431747
uuid-8424dc875ab94146b69bafb296164c16,chemotherapy,0.362751
uuid-8424dc875ab94146b69bafb296164c16,RTL stated,0.379204
uuid-8424dc875ab94146b69bafb296164c16,TL shared,0.311935
uuid-be0a9e24265941b3b03160ef7548c6bc,patients,0.412919
uuid-be0a9e24265941b3b03160ef7548c6bc,regimen,0.348821
uuid-be0a9e24265941b3b03160ef7548c6bc,pts,0.347583
uuid-be0a9e24265941b3b03160ef7548c6bc,monotherapy,0.429148
uuid-be0a9e24265941b3b03160ef7548c6bc,combo,0.421431
uuid-be0a9e24265941b3b03160ef7548c6bc,clinical trials,0.308329
uuid-be0a9e24265941b3b03160ef7548c6bc,chemotherapy,0.307657
uuid-be0a9e24265941b3b03160ef7548c6bc,feels,0.360115
uuid-be0a9e24265941b3b03160ef7548c6bc,option,0.383178
uuid-955563ccbcc943598dc462636c653332,patients,0.401124
uuid-955563ccbcc943598dc462636c653332,shared,0.326996
uuid-955563ccbcc943598dc462636c653332,approval,0.333871
uuid-955563ccbcc943598dc462636c653332,approved,0.33189
uuid-955563ccbcc943598dc462636c653332,RTL stated,0.301451
uuid-2687703750524ccd8c63dd500ccb1e38,treated,0.458608
uuid-2687703750524ccd8c63dd500ccb1e38,treatment,0.326759
uuid-2687703750524ccd8c63dd500ccb1e38,ASCO,0.466543
uuid-61759c42a7364020b774fa623ab0ef7f,TL stated,0.308852
uuid-61759c42a7364020b774fa623ab0ef7f,Keytruda,0.36783
uuid-81ccb9e90db14e7186500f4b08e73e5b,patients,0.396877
uuid-81ccb9e90db14e7186500f4b08e73e5b,regimen,0.409239
uuid-81ccb9e90db14e7186500f4b08e73e5b,treated,0.402168
uuid-81ccb9e90db14e7186500f4b08e73e5b,pts,0.32197
uuid-81ccb9e90db14e7186500f4b08e73e5b,physicians,0.406094
uuid-81ccb9e90db14e7186500f4b08e73e5b,treatment,0.468669
uuid-81ccb9e90db14e7186500f4b08e73e5b,response,0.441736
uuid-81ccb9e90db14e7186500f4b08e73e5b,progression,0.564801
uuid-81ccb9e90db14e7186500f4b08e73e5b,respond,0.499201
uuid-81ccb9e90db14e7186500f4b08e73e5b,feels,0.369974
uuid-e10b0035201f4969a6219df2c2c932fd,lung,0.687848
uuid-e10b0035201f4969a6219df2c2c932fd,NSCLC,0.332115
uuid-e10b0035201f4969a6219df2c2c932fd,PDL1,0.314687
uuid-e10b0035201f4969a6219df2c2c932fd,melanoma,0.494302
uuid-e10b0035201f4969a6219df2c2c932fd,RCC,0.313156
uuid-e10b0035201f4969a6219df2c2c932fd,TL stated,0.350303
uuid-e10b0035201f4969a6219df2c2c932fd,tumor,0.307681
uuid-e10b0035201f4969a6219df2c2c932fd,PDL1 testing,0.36181
uuid-e10b0035201f4969a6219df2c2c932fd,AI,0.662357
uuid-e10b0035201f4969a6219df2c2c932fd,TL shared,0.382599
uuid-e10b0035201f4969a6219df2c2c932fd,biomarker,0.441746
uuid-e10b0035201f4969a6219df2c2c932fd,NCCN,0.384364
uuid-699c70e5d7b144538f065ba4281b5694,Nivo,0.625516
uuid-699c70e5d7b144538f065ba4281b5694,patients,0.587207
uuid-699c70e5d7b144538f065ba4281b5694,Opdivo,0.346503
uuid-699c70e5d7b144538f065ba4281b5694,therapy,0.432432
uuid-699c70e5d7b144538f065ba4281b5694,dose,0.412047
uuid-699c70e5d7b144538f065ba4281b5694,nivolumab,0.444847
uuid-699c70e5d7b144538f065ba4281b5694,toxicity,0.500532
uuid-699c70e5d7b144538f065ba4281b5694,regimen,0.596447
uuid-699c70e5d7b144538f065ba4281b5694,treated,0.317822
uuid-699c70e5d7b144538f065ba4281b5694,combination,0.487661
uuid-699c70e5d7b144538f065ba4281b5694,chemo,0.510573
uuid-699c70e5d7b144538f065ba4281b5694,2L,0.40912
uuid-699c70e5d7b144538f065ba4281b5694,pts,0.512431
uuid-699c70e5d7b144538f065ba4281b5694,Ipi,0.437484
uuid-699c70e5d7b144538f065ba4281b5694,preferred,0.424927
uuid-699c70e5d7b144538f065ba4281b5694,monotherapy,0.586316
uuid-699c70e5d7b144538f065ba4281b5694,treatment,0.477373
uuid-699c70e5d7b144538f065ba4281b5694,using nivo,0.403127
uuid-699c70e5d7b144538f065ba4281b5694,response,0.398155
uuid-699c70e5d7b144538f065ba4281b5694,combo,0.450555
uuid-699c70e5d7b144538f065ba4281b5694,PD1,0.397426
uuid-699c70e5d7b144538f065ba4281b5694,progression,0.486663
uuid-699c70e5d7b144538f065ba4281b5694,chemotherapy,0.407823
uuid-699c70e5d7b144538f065ba4281b5694,respond,0.449352
uuid-699c70e5d7b144538f065ba4281b5694,feels,0.33242
uuid-699c70e5d7b144538f065ba4281b5694,RTL stated,0.30238
uuid-699c70e5d7b144538f065ba4281b5694,option,0.541688
uuid-5338a7ec8e19478ebd01f15a5f740559,patients,0.406342
uuid-5338a7ec8e19478ebd01f15a5f740559,tumor,0.503142
uuid-5338a7ec8e19478ebd01f15a5f740559,pts,0.311766
uuid-5338a7ec8e19478ebd01f15a5f740559,PD-L1,0.309273
uuid-5338a7ec8e19478ebd01f15a5f740559,approval,0.418362
uuid-5338a7ec8e19478ebd01f15a5f740559,testing,0.396987
uuid-5338a7ec8e19478ebd01f15a5f740559,NSCLC patients,0.441636
uuid-5338a7ec8e19478ebd01f15a5f740559,approved,0.32318
uuid-5338a7ec8e19478ebd01f15a5f740559,tumor types,0.456023
uuid-5338a7ec8e19478ebd01f15a5f740559,bladder,0.422122
uuid-14ee67cdde774cf89f7944a319f01faa,therapy,0.347189
uuid-14ee67cdde774cf89f7944a319f01faa,PD1,0.302596
uuid-14ee67cdde774cf89f7944a319f01faa,cHL,0.307268
uuid-14ee67cdde774cf89f7944a319f01faa,immunotherapy,0.328762
uuid-749166e6e29d4d2281aa98ead8f41a6c,response,0.377195
uuid-09d5907fa2204afebbb38547f464bc42,patients,0.7001
uuid-09d5907fa2204afebbb38547f464bc42,Opdivo,0.567731
uuid-09d5907fa2204afebbb38547f464bc42,therapy,0.571014
uuid-09d5907fa2204afebbb38547f464bc42,nivolumab,0.439566
uuid-09d5907fa2204afebbb38547f464bc42,treated,0.410339
uuid-09d5907fa2204afebbb38547f464bc42,treatment,0.52226
uuid-09d5907fa2204afebbb38547f464bc42,cHL,0.587733
uuid-09d5907fa2204afebbb38547f464bc42,progression,0.474086
uuid-09d5907fa2204afebbb38547f464bc42,respond,0.38822
uuid-c05a76adfcfd4e9a8478973873c4c841,patients,0.476866
uuid-c05a76adfcfd4e9a8478973873c4c841,Opdivo,0.518776
uuid-c05a76adfcfd4e9a8478973873c4c841,therapy,0.39583
uuid-c05a76adfcfd4e9a8478973873c4c841,nivolumab,0.392306
uuid-c05a76adfcfd4e9a8478973873c4c841,treated,0.332067
uuid-c05a76adfcfd4e9a8478973873c4c841,treatment,0.417141
uuid-c05a76adfcfd4e9a8478973873c4c841,cHL,0.469014
uuid-c05a76adfcfd4e9a8478973873c4c841,progression,0.425097
uuid-0438e94ff1654990a8859bbbc6aee9e4,NTL,0.570553
uuid-31b35f0e8e664f58a36f0ef6936fc34e,pembro,0.493812
uuid-31b35f0e8e664f58a36f0ef6936fc34e,1L,0.550481
uuid-31b35f0e8e664f58a36f0ef6936fc34e,2L,0.64323
uuid-31b35f0e8e664f58a36f0ef6936fc34e,agents,0.534114
uuid-31b35f0e8e664f58a36f0ef6936fc34e,atezo,0.608709
uuid-31b35f0e8e664f58a36f0ef6936fc34e,preferred,0.545163
uuid-31b35f0e8e664f58a36f0ef6936fc34e,monotherapy,0.444256
uuid-31b35f0e8e664f58a36f0ef6936fc34e,using nivo,0.316101
uuid-31b35f0e8e664f58a36f0ef6936fc34e,combo,0.405767
uuid-31b35f0e8e664f58a36f0ef6936fc34e,approved,0.394097
uuid-31b35f0e8e664f58a36f0ef6936fc34e,nivo and pembro,0.365034
uuid-31b35f0e8e664f58a36f0ef6936fc34e,believes,0.418689
uuid-31b35f0e8e664f58a36f0ef6936fc34e,tumor types,0.303307
uuid-31b35f0e8e664f58a36f0ef6936fc34e,feels,0.434359
uuid-31b35f0e8e664f58a36f0ef6936fc34e,option,0.50787
uuid-31ea8ec00f9f438fbe6a81501fb4c415,Nivo,0.487556
uuid-31ea8ec00f9f438fbe6a81501fb4c415,pembro,0.511544
uuid-31ea8ec00f9f438fbe6a81501fb4c415,1L,0.673547
uuid-31ea8ec00f9f438fbe6a81501fb4c415,PDL1,0.306424
uuid-31ea8ec00f9f438fbe6a81501fb4c415,efficacy,0.352712
uuid-31ea8ec00f9f438fbe6a81501fb4c415,combination,0.440531
uuid-31ea8ec00f9f438fbe6a81501fb4c415,chemo,0.457212
uuid-31ea8ec00f9f438fbe6a81501fb4c415,2L,0.627243
uuid-31ea8ec00f9f438fbe6a81501fb4c415,IO,0.333805
uuid-31ea8ec00f9f438fbe6a81501fb4c415,agents,0.616879
uuid-31ea8ec00f9f438fbe6a81501fb4c415,atezo,0.505259
uuid-31ea8ec00f9f438fbe6a81501fb4c415,preferred,0.604679
uuid-31ea8ec00f9f438fbe6a81501fb4c415,monotherapy,0.651861
uuid-31ea8ec00f9f438fbe6a81501fb4c415,using nivo,0.438677
uuid-31ea8ec00f9f438fbe6a81501fb4c415,data,0.30312
uuid-31ea8ec00f9f438fbe6a81501fb4c415,combo,0.456633
uuid-31ea8ec00f9f438fbe6a81501fb4c415,indication,0.325151
uuid-31ea8ec00f9f438fbe6a81501fb4c415,PD1,0.39403
uuid-31ea8ec00f9f438fbe6a81501fb4c415,approved,0.473418
uuid-31ea8ec00f9f438fbe6a81501fb4c415,nivo and pembro,0.430017
uuid-31ea8ec00f9f438fbe6a81501fb4c415,believes,0.474982
uuid-31ea8ec00f9f438fbe6a81501fb4c415,chemotherapy,0.401155
uuid-31ea8ec00f9f438fbe6a81501fb4c415,feels,0.521489
uuid-31ea8ec00f9f438fbe6a81501fb4c415,RTL stated,0.321933
uuid-31ea8ec00f9f438fbe6a81501fb4c415,option,0.696977
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,patients,0.3913
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,RTL,0.321071
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,nivolumab,0.383337
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,trial,0.408326
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,treated,0.379626
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,stated,0.329121
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,approval,0.493421
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,clinical trials,0.417032
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,approved,0.364969
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,SCCHN,0.338162
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,impressed,0.373238
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,Regional TL,0.351277
uuid-16e43c6e455344e5a2f00a74c2cdbb1b,RTL stated,0.311053
uuid-89289a22ee404fccb09fdfc4e280af50,patients,0.374274
uuid-89289a22ee404fccb09fdfc4e280af50,treated,0.334278
uuid-89289a22ee404fccb09fdfc4e280af50,pts,0.310519
uuid-89289a22ee404fccb09fdfc4e280af50,treatment,0.386396
uuid-89289a22ee404fccb09fdfc4e280af50,response,0.386892
uuid-89289a22ee404fccb09fdfc4e280af50,lung cancer,0.321513
uuid-89289a22ee404fccb09fdfc4e280af50,progression,0.496671
uuid-89289a22ee404fccb09fdfc4e280af50,respond,0.339969
uuid-f485c33e784c42bca66879d96b018cb1,regimen,0.300948
uuid-f485c33e784c42bca66879d96b018cb1,chemo,0.336421
uuid-f485c33e784c42bca66879d96b018cb1,monotherapy,0.332009
uuid-f485c33e784c42bca66879d96b018cb1,chemotherapy,0.440971
uuid-f485c33e784c42bca66879d96b018cb1,feels,0.334195
uuid-f485c33e784c42bca66879d96b018cb1,option,0.378878
uuid-7bc40e07f6924ad4abcf862a12fb2eca,patients,0.300268
uuid-7bc40e07f6924ad4abcf862a12fb2eca,tumor,0.404089
uuid-c4929d00d0bb49aab0e83faea86f0e13,TL,0.315767
uuid-c4929d00d0bb49aab0e83faea86f0e13,pembro,0.334062
uuid-c4929d00d0bb49aab0e83faea86f0e13,1L,0.432326
uuid-c4929d00d0bb49aab0e83faea86f0e13,PDL1,0.415823
uuid-c4929d00d0bb49aab0e83faea86f0e13,TL stated,0.395711
uuid-c4929d00d0bb49aab0e83faea86f0e13,2L,0.388588
uuid-c4929d00d0bb49aab0e83faea86f0e13,PD-L1,0.74101
uuid-c4929d00d0bb49aab0e83faea86f0e13,approval,0.328143
uuid-c4929d00d0bb49aab0e83faea86f0e13,atezo,0.369666
uuid-c4929d00d0bb49aab0e83faea86f0e13,preferred,0.333763
uuid-c4929d00d0bb49aab0e83faea86f0e13,PD-L1 testing,0.658694
uuid-c4929d00d0bb49aab0e83faea86f0e13,testing,0.812887
uuid-c4929d00d0bb49aab0e83faea86f0e13,PDL1 testing,0.680295
uuid-c4929d00d0bb49aab0e83faea86f0e13,NSCLC patients,0.723604
uuid-c4929d00d0bb49aab0e83faea86f0e13,approved,0.323079
uuid-c4929d00d0bb49aab0e83faea86f0e13,tumor types,0.384479
uuid-c4929d00d0bb49aab0e83faea86f0e13,assay,0.514346
uuid-c4929d00d0bb49aab0e83faea86f0e13,PD-1,0.321515
uuid-c4929d00d0bb49aab0e83faea86f0e13,option,0.310905
uuid-c4929d00d0bb49aab0e83faea86f0e13,biomarker,0.396913
uuid-a7cbdf85f00945e697d055fc1029a8b4,patients,0.874979
uuid-a7cbdf85f00945e697d055fc1029a8b4,Opdivo,0.308545
uuid-a7cbdf85f00945e697d055fc1029a8b4,therapy,0.593886
uuid-a7cbdf85f00945e697d055fc1029a8b4,nivolumab,0.447285
uuid-a7cbdf85f00945e697d055fc1029a8b4,regimen,0.486297
uuid-a7cbdf85f00945e697d055fc1029a8b4,treated,0.538413
uuid-a7cbdf85f00945e697d055fc1029a8b4,chemo,0.442002
uuid-a7cbdf85f00945e697d055fc1029a8b4,pts,0.658083
uuid-a7cbdf85f00945e697d055fc1029a8b4,monotherapy,0.394392
uuid-a7cbdf85f00945e697d055fc1029a8b4,treatment,0.645664
uuid-a7cbdf85f00945e697d055fc1029a8b4,using nivo,0.32963
uuid-a7cbdf85f00945e697d055fc1029a8b4,response,0.458438
uuid-a7cbdf85f00945e697d055fc1029a8b4,PD1,0.360763
uuid-a7cbdf85f00945e697d055fc1029a8b4,progression,0.6549
uuid-a7cbdf85f00945e697d055fc1029a8b4,chemotherapy,0.470373
uuid-a7cbdf85f00945e697d055fc1029a8b4,respond,0.541993
uuid-a7cbdf85f00945e697d055fc1029a8b4,option,0.453563
uuid-7952239685104e1597636b3214114419,BMS,0.348742
uuid-7952239685104e1597636b3214114419,physicians,0.347882
uuid-7952239685104e1597636b3214114419,regards,0.338653
uuid-7952239685104e1597636b3214114419,oncology,0.499631
uuid-7952239685104e1597636b3214114419,drug,0.309948
uuid-7952239685104e1597636b3214114419,clinical,0.438308
uuid-09a1f822dfeb430088eb396b6b7a021d,TL,0.646605
uuid-09a1f822dfeb430088eb396b6b7a021d,RTL,0.319497
uuid-09a1f822dfeb430088eb396b6b7a021d,commented,0.337119
uuid-09a1f822dfeb430088eb396b6b7a021d,TL stated,0.379777
uuid-09a1f822dfeb430088eb396b6b7a021d,Merck,0.328952
uuid-09a1f822dfeb430088eb396b6b7a021d,institution,0.314973
uuid-09a1f822dfeb430088eb396b6b7a021d,stated,0.391217
uuid-09a1f822dfeb430088eb396b6b7a021d,PD-L1,0.523852
uuid-09a1f822dfeb430088eb396b6b7a021d,approval,0.328751
uuid-09a1f822dfeb430088eb396b6b7a021d,PD-L1 testing,0.685881
uuid-09a1f822dfeb430088eb396b6b7a021d,testing,0.54505
uuid-09a1f822dfeb430088eb396b6b7a021d,PDL1 testing,0.46859
uuid-09a1f822dfeb430088eb396b6b7a021d,NSCLC patients,0.341596
uuid-09a1f822dfeb430088eb396b6b7a021d,SCCHN,0.305886
uuid-09a1f822dfeb430088eb396b6b7a021d,TLs,0.388943
uuid-09a1f822dfeb430088eb396b6b7a021d,assay,0.49295
uuid-09a1f822dfeb430088eb396b6b7a021d,Regional TL,0.384833
uuid-142896ea1c0c44e8bdbf507e830dd179,TL,0.628532
uuid-142896ea1c0c44e8bdbf507e830dd179,TL stated,0.439781
uuid-142896ea1c0c44e8bdbf507e830dd179,institution,0.357425
uuid-142896ea1c0c44e8bdbf507e830dd179,PD-L1,0.709135
uuid-142896ea1c0c44e8bdbf507e830dd179,PD-L1 testing,0.91341
uuid-142896ea1c0c44e8bdbf507e830dd179,testing,0.833652
uuid-142896ea1c0c44e8bdbf507e830dd179,PDL1 testing,0.668626
uuid-142896ea1c0c44e8bdbf507e830dd179,NSCLC patients,0.589254
uuid-142896ea1c0c44e8bdbf507e830dd179,assay,0.628609
uuid-2667d3f79d8c4e8d819c7900db369b28,Nivo,0.464986
uuid-2667d3f79d8c4e8d819c7900db369b28,patients,0.554956
uuid-2667d3f79d8c4e8d819c7900db369b28,therapy,0.36449
uuid-2667d3f79d8c4e8d819c7900db369b28,efficacy,0.354993
uuid-2667d3f79d8c4e8d819c7900db369b28,regimen,0.458924
uuid-2667d3f79d8c4e8d819c7900db369b28,chemo,0.564244
uuid-2667d3f79d8c4e8d819c7900db369b28,pts,0.528897
uuid-2667d3f79d8c4e8d819c7900db369b28,OS,0.470139
uuid-2667d3f79d8c4e8d819c7900db369b28,monotherapy,0.422604
uuid-2667d3f79d8c4e8d819c7900db369b28,treatment,0.399053
uuid-2667d3f79d8c4e8d819c7900db369b28,response,0.557343
uuid-2667d3f79d8c4e8d819c7900db369b28,PFS,0.45553
uuid-2667d3f79d8c4e8d819c7900db369b28,PD1,0.350646
uuid-2667d3f79d8c4e8d819c7900db369b28,ORR,0.446183
uuid-2667d3f79d8c4e8d819c7900db369b28,progression,0.569831
uuid-2667d3f79d8c4e8d819c7900db369b28,chemotherapy,0.505067
uuid-2667d3f79d8c4e8d819c7900db369b28,respond,0.486867
uuid-2667d3f79d8c4e8d819c7900db369b28,feels,0.509593
uuid-2667d3f79d8c4e8d819c7900db369b28,option,0.36243
uuid-4bc4440e30dd464d9cca208e5e9925b9,patients,0.37323
uuid-4bc4440e30dd464d9cca208e5e9925b9,TL,0.331577
uuid-4bc4440e30dd464d9cca208e5e9925b9,1L,0.327849
uuid-4bc4440e30dd464d9cca208e5e9925b9,PDL1,0.319663
uuid-4bc4440e30dd464d9cca208e5e9925b9,TL stated,0.345906
uuid-4bc4440e30dd464d9cca208e5e9925b9,pts,0.309515
uuid-4bc4440e30dd464d9cca208e5e9925b9,PD-L1,0.647409
uuid-4bc4440e30dd464d9cca208e5e9925b9,approval,0.365188
uuid-4bc4440e30dd464d9cca208e5e9925b9,PD-L1 testing,0.672064
uuid-4bc4440e30dd464d9cca208e5e9925b9,testing,0.7921
uuid-4bc4440e30dd464d9cca208e5e9925b9,PDL1 testing,0.625715
uuid-4bc4440e30dd464d9cca208e5e9925b9,NSCLC patients,0.771979
uuid-4bc4440e30dd464d9cca208e5e9925b9,tumor types,0.333928
uuid-4bc4440e30dd464d9cca208e5e9925b9,assay,0.40151
uuid-4bc4440e30dd464d9cca208e5e9925b9,biomarker,0.34424
uuid-422953bd4dd443bdb13d8cad1bc7fff6,patients,0.513782
uuid-422953bd4dd443bdb13d8cad1bc7fff6,toxicity,0.460272
uuid-422953bd4dd443bdb13d8cad1bc7fff6,regimen,0.593258
uuid-422953bd4dd443bdb13d8cad1bc7fff6,treated,0.491002
uuid-422953bd4dd443bdb13d8cad1bc7fff6,physicians,0.389152
uuid-422953bd4dd443bdb13d8cad1bc7fff6,treatment,0.491578
uuid-422953bd4dd443bdb13d8cad1bc7fff6,combo,0.314387
uuid-422953bd4dd443bdb13d8cad1bc7fff6,progression,0.302719
uuid-5484838a644b403e8c8966d2e2c7d78c,patients,0.440335
uuid-5484838a644b403e8c8966d2e2c7d78c,Opdivo,0.478654
uuid-5484838a644b403e8c8966d2e2c7d78c,dose,0.804574
uuid-5484838a644b403e8c8966d2e2c7d78c,nivolumab,0.340035
uuid-5484838a644b403e8c8966d2e2c7d78c,toxicity,0.450069
uuid-5484838a644b403e8c8966d2e2c7d78c,regimen,0.524055
uuid-5484838a644b403e8c8966d2e2c7d78c,Ipi,0.45082
uuid-5484838a644b403e8c8966d2e2c7d78c,treatment,0.325244
uuid-5484838a644b403e8c8966d2e2c7d78c,vs,0.390337
uuid-5484838a644b403e8c8966d2e2c7d78c,flat dosing,0.578746
uuid-5cc034f4524649cf80afe82a4bdcc1d8,patients,0.508618
uuid-5cc034f4524649cf80afe82a4bdcc1d8,therapy,0.669926
uuid-5cc034f4524649cf80afe82a4bdcc1d8,1L,0.420439
uuid-5cc034f4524649cf80afe82a4bdcc1d8,regimen,0.393778
uuid-5cc034f4524649cf80afe82a4bdcc1d8,combination,0.354238
uuid-5cc034f4524649cf80afe82a4bdcc1d8,chemo,0.578611
uuid-5cc034f4524649cf80afe82a4bdcc1d8,2L,0.40929
uuid-5cc034f4524649cf80afe82a4bdcc1d8,pts,0.408355
uuid-5cc034f4524649cf80afe82a4bdcc1d8,agents,0.43841
uuid-5cc034f4524649cf80afe82a4bdcc1d8,preferred,0.426144
uuid-5cc034f4524649cf80afe82a4bdcc1d8,monotherapy,0.615763
uuid-5cc034f4524649cf80afe82a4bdcc1d8,treatment,0.531143
uuid-5cc034f4524649cf80afe82a4bdcc1d8,response,0.356205
uuid-5cc034f4524649cf80afe82a4bdcc1d8,combo,0.309828
uuid-5cc034f4524649cf80afe82a4bdcc1d8,PD1,0.489988
uuid-5cc034f4524649cf80afe82a4bdcc1d8,progression,0.509049
uuid-5cc034f4524649cf80afe82a4bdcc1d8,believes,0.362615
uuid-5cc034f4524649cf80afe82a4bdcc1d8,chemotherapy,0.614694
uuid-5cc034f4524649cf80afe82a4bdcc1d8,respond,0.339323
uuid-5cc034f4524649cf80afe82a4bdcc1d8,PD-1,0.404049
uuid-5cc034f4524649cf80afe82a4bdcc1d8,option,0.670326
uuid-5cc034f4524649cf80afe82a4bdcc1d8,biomarker,0.327349
uuid-e6fb188e6e5948328ef0ff7bbd4dbd90,TL,0.356235
uuid-e6fb188e6e5948328ef0ff7bbd4dbd90,BMS,0.408758
uuid-e6fb188e6e5948328ef0ff7bbd4dbd90,PDL1,0.419978
uuid-e6fb188e6e5948328ef0ff7bbd4dbd90,Merck,0.663513
uuid-e6fb188e6e5948328ef0ff7bbd4dbd90,PD-L1,0.494357
uuid-e6fb188e6e5948328ef0ff7bbd4dbd90,PD-L1 testing,0.41204
uuid-e6fb188e6e5948328ef0ff7bbd4dbd90,testing,0.469392
uuid-e6fb188e6e5948328ef0ff7bbd4dbd90,assay,0.70085
uuid-e6fb188e6e5948328ef0ff7bbd4dbd90,PDL1 expression,0.373085
uuid-e6fb188e6e5948328ef0ff7bbd4dbd90,biomarker,0.416514
uuid-2c15c1e4893f45ba9a90072fcb2bae65,Opdivo,0.555133
uuid-2c15c1e4893f45ba9a90072fcb2bae65,nivolumab,0.306825
uuid-2c15c1e4893f45ba9a90072fcb2bae65,treated,0.430544
uuid-2c15c1e4893f45ba9a90072fcb2bae65,shared,0.302917
uuid-2c15c1e4893f45ba9a90072fcb2bae65,commented,0.302005
uuid-2c15c1e4893f45ba9a90072fcb2bae65,RCC,0.30192
uuid-2c15c1e4893f45ba9a90072fcb2bae65,TL stated,0.347606
uuid-2c15c1e4893f45ba9a90072fcb2bae65,stated,0.351409
uuid-2c15c1e4893f45ba9a90072fcb2bae65,physicians,0.668108
uuid-2c15c1e4893f45ba9a90072fcb2bae65,treatment,0.331434
uuid-2c15c1e4893f45ba9a90072fcb2bae65,mentioned,0.305837
uuid-2c15c1e4893f45ba9a90072fcb2bae65,HCP,0.310877
uuid-2c15c1e4893f45ba9a90072fcb2bae65,Regional TL,0.423788
uuid-614de29b24a84b3f8c3bb0d0e5df3e8a,BMS,0.361549
uuid-614de29b24a84b3f8c3bb0d0e5df3e8a,Merck,0.498634
uuid-614de29b24a84b3f8c3bb0d0e5df3e8a,institution,0.305152
uuid-614de29b24a84b3f8c3bb0d0e5df3e8a,approval,0.310313
uuid-614de29b24a84b3f8c3bb0d0e5df3e8a,PDL1 testing,0.32352
uuid-614de29b24a84b3f8c3bb0d0e5df3e8a,indication,0.348214
uuid-614de29b24a84b3f8c3bb0d0e5df3e8a,AI,0.310569
uuid-614de29b24a84b3f8c3bb0d0e5df3e8a,approved,0.404782
uuid-614de29b24a84b3f8c3bb0d0e5df3e8a,label,0.367743
uuid-614de29b24a84b3f8c3bb0d0e5df3e8a,drug,0.356406
uuid-614de29b24a84b3f8c3bb0d0e5df3e8a,Keytruda,0.342505
uuid-10e5e39493e2442a8057b66a25ec33a7,patients,0.468776
uuid-10e5e39493e2442a8057b66a25ec33a7,Opdivo,0.381885
uuid-10e5e39493e2442a8057b66a25ec33a7,therapy,0.532537
uuid-10e5e39493e2442a8057b66a25ec33a7,nivolumab,0.532922
uuid-10e5e39493e2442a8057b66a25ec33a7,toxicity,0.384538
uuid-10e5e39493e2442a8057b66a25ec33a7,treated,0.459407
uuid-10e5e39493e2442a8057b66a25ec33a7,treatment,0.48688
uuid-10e5e39493e2442a8057b66a25ec33a7,cHL,0.612209
uuid-6c892bd452094de4ab34364363ebe7f8,Nivo,0.612296
uuid-6c892bd452094de4ab34364363ebe7f8,patients,0.360304
uuid-6c892bd452094de4ab34364363ebe7f8,pembro,0.423257
uuid-6c892bd452094de4ab34364363ebe7f8,dose,0.458577
uuid-6c892bd452094de4ab34364363ebe7f8,efficacy,0.339872
uuid-6c892bd452094de4ab34364363ebe7f8,regimen,0.365603
uuid-6c892bd452094de4ab34364363ebe7f8,Ipi,0.498125
uuid-6c892bd452094de4ab34364363ebe7f8,atezo,0.353137
uuid-6c892bd452094de4ab34364363ebe7f8,monotherapy,0.314994
uuid-6c892bd452094de4ab34364363ebe7f8,using nivo,0.376217
uuid-6c892bd452094de4ab34364363ebe7f8,vs,0.511517
uuid-6c892bd452094de4ab34364363ebe7f8,feels,0.479528
uuid-a882a4440f7747c690951a85f1f9573e,patients,0.467248
uuid-a882a4440f7747c690951a85f1f9573e,therapy,0.314675
uuid-a882a4440f7747c690951a85f1f9573e,toxicity,0.31245
uuid-a882a4440f7747c690951a85f1f9573e,efficacy,0.315148
uuid-a882a4440f7747c690951a85f1f9573e,regimen,0.361411
uuid-a882a4440f7747c690951a85f1f9573e,chemo,0.440478
uuid-a882a4440f7747c690951a85f1f9573e,pts,0.438921
uuid-a882a4440f7747c690951a85f1f9573e,OS,0.354917
uuid-a882a4440f7747c690951a85f1f9573e,treatment,0.38467
uuid-a882a4440f7747c690951a85f1f9573e,response,0.60218
uuid-a882a4440f7747c690951a85f1f9573e,PFS,0.360269
uuid-a882a4440f7747c690951a85f1f9573e,ORR,0.321803
uuid-a882a4440f7747c690951a85f1f9573e,progression,0.58585
uuid-a882a4440f7747c690951a85f1f9573e,believes,0.325882
uuid-a882a4440f7747c690951a85f1f9573e,chemotherapy,0.356377
uuid-a882a4440f7747c690951a85f1f9573e,respond,0.640691
uuid-a882a4440f7747c690951a85f1f9573e,feels,0.481359
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,TL,0.350701
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,1L,0.441709
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,TL stated,0.452756
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,2L,0.386641
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,PD-L1,0.570664
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,approval,0.396258
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,preferred,0.417315
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,PD-L1 testing,0.700052
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,testing,0.687713
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,using nivo,0.311125
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,PDL1 testing,0.681483
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,NSCLC patients,0.614411
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,approved,0.363133
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,SCCHN,0.326571
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,tumor types,0.313809
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,assay,0.390586
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,RTL stated,0.335847
uuid-b7fcf40719874b1b8c5d5f4b27ad81e7,option,0.307404
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,TL,0.550036
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,pembro,0.466518
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,1L,0.420223
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,2L,0.42241
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,Merck,0.311594
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,PD-L1,0.311638
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,approval,0.486684
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,atezo,0.427796
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,preferred,0.374068
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,using nivo,0.441042
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,approved,0.413815
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,SCCHN,0.300735
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,assay,0.339282
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,RTL stated,0.353241
uuid-1f7f7c9c0a9b41a598e4afbc3eeccad1,bladder,0.305873
uuid-45dc7b20d13a46d9a571627c32254c35,RTL,0.36208
uuid-45dc7b20d13a46d9a571627c32254c35,NSCLC,0.442007
uuid-45dc7b20d13a46d9a571627c32254c35,trial,0.357241
uuid-45dc7b20d13a46d9a571627c32254c35,NTL,0.373108
uuid-45dc7b20d13a46d9a571627c32254c35,discussed,0.548678
uuid-45dc7b20d13a46d9a571627c32254c35,commented,0.504158
uuid-45dc7b20d13a46d9a571627c32254c35,OS,0.39303
uuid-45dc7b20d13a46d9a571627c32254c35,regards,0.351093
uuid-45dc7b20d13a46d9a571627c32254c35,data,0.598647
uuid-45dc7b20d13a46d9a571627c32254c35,PFS,0.354205
uuid-45dc7b20d13a46d9a571627c32254c35,ORR,0.408861
uuid-45dc7b20d13a46d9a571627c32254c35,ASCO,0.541999
uuid-45dc7b20d13a46d9a571627c32254c35,impressed,0.52221
uuid-45dc7b20d13a46d9a571627c32254c35,TLs,0.422012
uuid-45dc7b20d13a46d9a571627c32254c35,academic,0.314526
uuid-45dc7b20d13a46d9a571627c32254c35,Regional TL,0.406804
uuid-1f036cab6bd34e25bc1d0fd97761f66f,Opdivo,0.374305
uuid-1f036cab6bd34e25bc1d0fd97761f66f,TL,0.383023
uuid-1f036cab6bd34e25bc1d0fd97761f66f,PDL1,0.316312
uuid-1f036cab6bd34e25bc1d0fd97761f66f,TL stated,0.330993
uuid-1f036cab6bd34e25bc1d0fd97761f66f,Merck,0.337338
uuid-1f036cab6bd34e25bc1d0fd97761f66f,PD-L1,0.623794
uuid-1f036cab6bd34e25bc1d0fd97761f66f,approval,0.332759
uuid-1f036cab6bd34e25bc1d0fd97761f66f,PD-L1 testing,0.547539
uuid-1f036cab6bd34e25bc1d0fd97761f66f,testing,0.633326
uuid-1f036cab6bd34e25bc1d0fd97761f66f,PDL1 testing,0.513929
uuid-1f036cab6bd34e25bc1d0fd97761f66f,NSCLC patients,0.491228
uuid-1f036cab6bd34e25bc1d0fd97761f66f,Keytruda,0.521271
uuid-1f036cab6bd34e25bc1d0fd97761f66f,assay,0.570769
uuid-68ad8993d65741d89e688544f2815017,RTL,0.377416
uuid-68ad8993d65741d89e688544f2815017,trial,0.317439
uuid-68ad8993d65741d89e688544f2815017,efficacy,0.399648
uuid-68ad8993d65741d89e688544f2815017,commented,0.490033
uuid-68ad8993d65741d89e688544f2815017,stated,0.311097
uuid-68ad8993d65741d89e688544f2815017,OS,0.653288
uuid-68ad8993d65741d89e688544f2815017,data,0.672578
uuid-68ad8993d65741d89e688544f2815017,expressed,0.30825
uuid-68ad8993d65741d89e688544f2815017,PFS,0.584743
uuid-68ad8993d65741d89e688544f2815017,ORR,0.625449
uuid-68ad8993d65741d89e688544f2815017,ASCO,0.446027
uuid-68ad8993d65741d89e688544f2815017,impressed,0.664941
uuid-47b0d0da2fae48ad862825c5abd630cf,patients,0.44682
uuid-47b0d0da2fae48ad862825c5abd630cf,toxicity,0.367233
uuid-47b0d0da2fae48ad862825c5abd630cf,regimen,0.338022
uuid-9c0595f72b894d4ea897c6c5cf1780bc,Nivo,0.320002
uuid-9c0595f72b894d4ea897c6c5cf1780bc,pembro,0.567248
uuid-9c0595f72b894d4ea897c6c5cf1780bc,RTL,0.327674
uuid-9c0595f72b894d4ea897c6c5cf1780bc,dose,0.496193
uuid-9c0595f72b894d4ea897c6c5cf1780bc,trial,0.400517
uuid-9c0595f72b894d4ea897c6c5cf1780bc,shared,0.324412
uuid-9c0595f72b894d4ea897c6c5cf1780bc,Ipi,0.377153
uuid-9c0595f72b894d4ea897c6c5cf1780bc,approval,0.339326
uuid-9c0595f72b894d4ea897c6c5cf1780bc,atezo,0.46681
uuid-9c0595f72b894d4ea897c6c5cf1780bc,preferred,0.314513
uuid-9c0595f72b894d4ea897c6c5cf1780bc,using nivo,0.393223
uuid-9c0595f72b894d4ea897c6c5cf1780bc,mentioned,0.34906
uuid-9c0595f72b894d4ea897c6c5cf1780bc,clinical trials,0.381911
uuid-9c0595f72b894d4ea897c6c5cf1780bc,indication,0.511465
uuid-9c0595f72b894d4ea897c6c5cf1780bc,approved,0.343531
uuid-9c0595f72b894d4ea897c6c5cf1780bc,SCCHN,0.356251
uuid-9c0595f72b894d4ea897c6c5cf1780bc,HCP,0.320607
uuid-9c0595f72b894d4ea897c6c5cf1780bc,vs,0.413959
uuid-9c0595f72b894d4ea897c6c5cf1780bc,label,0.343102
uuid-9c0595f72b894d4ea897c6c5cf1780bc,LTL,0.354091
uuid-9c0595f72b894d4ea897c6c5cf1780bc,Keytruda,0.332141
uuid-9c0595f72b894d4ea897c6c5cf1780bc,TLs,0.378775
uuid-9c0595f72b894d4ea897c6c5cf1780bc,bladder,0.350984
uuid-9c0595f72b894d4ea897c6c5cf1780bc,flat dosing,0.65349
uuid-bd6c25caf247444aa5fd13b28b88425f,RTL,0.554404
uuid-bd6c25caf247444aa5fd13b28b88425f,nivolumab,0.44212
uuid-bd6c25caf247444aa5fd13b28b88425f,1L,0.321454
uuid-bd6c25caf247444aa5fd13b28b88425f,treated,0.380846
uuid-bd6c25caf247444aa5fd13b28b88425f,commented,0.390979
uuid-bd6c25caf247444aa5fd13b28b88425f,RCC,0.472733
uuid-bd6c25caf247444aa5fd13b28b88425f,2L,0.333944
uuid-bd6c25caf247444aa5fd13b28b88425f,stated,0.568952
uuid-bd6c25caf247444aa5fd13b28b88425f,approval,0.556996
uuid-bd6c25caf247444aa5fd13b28b88425f,preferred,0.390995
uuid-bd6c25caf247444aa5fd13b28b88425f,using nivo,0.559349
uuid-bd6c25caf247444aa5fd13b28b88425f,clinical trials,0.375271
uuid-bd6c25caf247444aa5fd13b28b88425f,indication,0.417513
uuid-bd6c25caf247444aa5fd13b28b88425f,approved,0.464802
uuid-bd6c25caf247444aa5fd13b28b88425f,SCCHN,0.704831
uuid-bd6c25caf247444aa5fd13b28b88425f,HCP,0.366571
uuid-bd6c25caf247444aa5fd13b28b88425f,impressed,0.489481
uuid-bd6c25caf247444aa5fd13b28b88425f,label,0.342598
uuid-bd6c25caf247444aa5fd13b28b88425f,LTL,0.458238
uuid-bd6c25caf247444aa5fd13b28b88425f,SCLC,0.391412
uuid-bd6c25caf247444aa5fd13b28b88425f,Regional TL,0.578643
uuid-bd6c25caf247444aa5fd13b28b88425f,RTL stated,0.602063
uuid-bd6c25caf247444aa5fd13b28b88425f,TL shared,0.367795
uuid-bd6c25caf247444aa5fd13b28b88425f,option,0.328633
uuid-bd6c25caf247444aa5fd13b28b88425f,bladder,0.461707
uuid-d0347ff05aa44f21aef4860fa01ba90f,Nivo,0.421741
uuid-d0347ff05aa44f21aef4860fa01ba90f,patients,0.563401
uuid-d0347ff05aa44f21aef4860fa01ba90f,Opdivo,0.467157
uuid-d0347ff05aa44f21aef4860fa01ba90f,therapy,0.334972
uuid-d0347ff05aa44f21aef4860fa01ba90f,dose,0.577609
uuid-d0347ff05aa44f21aef4860fa01ba90f,nivolumab,0.462324
uuid-d0347ff05aa44f21aef4860fa01ba90f,regimen,0.35997
uuid-d0347ff05aa44f21aef4860fa01ba90f,pts,0.395858
uuid-d0347ff05aa44f21aef4860fa01ba90f,Ipi,0.33733
uuid-d0347ff05aa44f21aef4860fa01ba90f,treatment,0.379244
uuid-d0347ff05aa44f21aef4860fa01ba90f,cHL,0.342138
uuid-d0347ff05aa44f21aef4860fa01ba90f,vs,0.304596
uuid-d0347ff05aa44f21aef4860fa01ba90f,flat dosing,0.382092
uuid-ca2c38715f37456d8522634a5f5c9661,TL,0.350259
uuid-ca2c38715f37456d8522634a5f5c9661,PDL1,0.775665
uuid-ca2c38715f37456d8522634a5f5c9661,Merck,0.343021
uuid-ca2c38715f37456d8522634a5f5c9661,PD-L1,0.797478
uuid-ca2c38715f37456d8522634a5f5c9661,PD-L1 testing,0.549415
uuid-ca2c38715f37456d8522634a5f5c9661,testing,0.686925
uuid-ca2c38715f37456d8522634a5f5c9661,PDL1 testing,0.477574
uuid-ca2c38715f37456d8522634a5f5c9661,NSCLC patients,0.420063
uuid-ca2c38715f37456d8522634a5f5c9661,nivo and pembro,0.354414
uuid-ca2c38715f37456d8522634a5f5c9661,assay,0.676134
uuid-ca2c38715f37456d8522634a5f5c9661,PDL1 expression,0.579892
uuid-ca2c38715f37456d8522634a5f5c9661,biomarker,0.710072
uuid-01a1b1e107974bfea972411c48f55d87,Nivo,0.308861
uuid-01a1b1e107974bfea972411c48f55d87,patients,0.513698
uuid-01a1b1e107974bfea972411c48f55d87,therapy,0.315775
uuid-01a1b1e107974bfea972411c48f55d87,nivolumab,0.374867
uuid-01a1b1e107974bfea972411c48f55d87,lung,0.302299
uuid-01a1b1e107974bfea972411c48f55d87,1L,0.511919
uuid-01a1b1e107974bfea972411c48f55d87,regimen,0.384517
uuid-01a1b1e107974bfea972411c48f55d87,treated,0.44644
uuid-01a1b1e107974bfea972411c48f55d87,melanoma,0.372508
uuid-01a1b1e107974bfea972411c48f55d87,RCC,0.519893
uuid-01a1b1e107974bfea972411c48f55d87,2L,0.544078
uuid-01a1b1e107974bfea972411c48f55d87,pts,0.405959
uuid-01a1b1e107974bfea972411c48f55d87,approval,0.400171
uuid-01a1b1e107974bfea972411c48f55d87,preferred,0.483466
uuid-01a1b1e107974bfea972411c48f55d87,monotherapy,0.426373
uuid-01a1b1e107974bfea972411c48f55d87,treatment,0.374476
uuid-01a1b1e107974bfea972411c48f55d87,using nivo,0.549588
uuid-01a1b1e107974bfea972411c48f55d87,combo,0.373964
uuid-01a1b1e107974bfea972411c48f55d87,approved,0.379732
uuid-01a1b1e107974bfea972411c48f55d87,SCCHN,0.437251
uuid-01a1b1e107974bfea972411c48f55d87,chemotherapy,0.30718
uuid-01a1b1e107974bfea972411c48f55d87,tumor types,0.317654
uuid-01a1b1e107974bfea972411c48f55d87,SCLC,0.30908
uuid-01a1b1e107974bfea972411c48f55d87,RTL stated,0.577607
uuid-01a1b1e107974bfea972411c48f55d87,TL shared,0.495205
uuid-01a1b1e107974bfea972411c48f55d87,option,0.449257
uuid-01a1b1e107974bfea972411c48f55d87,bladder,0.534808
uuid-3fc85289e692433387cd42df2e3fdb7f,RTL,0.471717
uuid-3fc85289e692433387cd42df2e3fdb7f,BMS,0.302632
uuid-3fc85289e692433387cd42df2e3fdb7f,trial,0.360641
uuid-3fc85289e692433387cd42df2e3fdb7f,discussed,0.308032
uuid-3fc85289e692433387cd42df2e3fdb7f,shared,0.526452
uuid-3fc85289e692433387cd42df2e3fdb7f,commented,0.495192
uuid-3fc85289e692433387cd42df2e3fdb7f,stated,0.447265
uuid-3fc85289e692433387cd42df2e3fdb7f,OS,0.304668
uuid-3fc85289e692433387cd42df2e3fdb7f,data,0.657296
uuid-3fc85289e692433387cd42df2e3fdb7f,expressed,0.394085
uuid-3fc85289e692433387cd42df2e3fdb7f,clinical trials,0.317294
uuid-3fc85289e692433387cd42df2e3fdb7f,ORR,0.305527
uuid-3fc85289e692433387cd42df2e3fdb7f,SCCHN,0.388758
uuid-3fc85289e692433387cd42df2e3fdb7f,ASCO,0.357957
uuid-3fc85289e692433387cd42df2e3fdb7f,impressed,0.631681
uuid-3fc85289e692433387cd42df2e3fdb7f,LTL,0.450896
uuid-3fc85289e692433387cd42df2e3fdb7f,TLs,0.371049
uuid-3fc85289e692433387cd42df2e3fdb7f,SCLC,0.312193
uuid-3fc85289e692433387cd42df2e3fdb7f,Regional TL,0.493571
uuid-3fc85289e692433387cd42df2e3fdb7f,RTL stated,0.312431
uuid-8ca9e93f415d4ce7bd45908c47c384ba,patients,0.869231
uuid-8ca9e93f415d4ce7bd45908c47c384ba,Opdivo,0.480367
uuid-8ca9e93f415d4ce7bd45908c47c384ba,therapy,0.53919
uuid-8ca9e93f415d4ce7bd45908c47c384ba,nivolumab,0.44574
uuid-8ca9e93f415d4ce7bd45908c47c384ba,toxicity,0.520747
uuid-8ca9e93f415d4ce7bd45908c47c384ba,regimen,0.691704
uuid-8ca9e93f415d4ce7bd45908c47c384ba,treated,0.584693
uuid-8ca9e93f415d4ce7bd45908c47c384ba,chemo,0.307014
uuid-8ca9e93f415d4ce7bd45908c47c384ba,pts,0.539804
uuid-8ca9e93f415d4ce7bd45908c47c384ba,monotherapy,0.362739
uuid-8ca9e93f415d4ce7bd45908c47c384ba,treatment,0.759475
uuid-8ca9e93f415d4ce7bd45908c47c384ba,response,0.437443
uuid-8ca9e93f415d4ce7bd45908c47c384ba,progression,0.670433
uuid-8ca9e93f415d4ce7bd45908c47c384ba,chemotherapy,0.36779
uuid-8ca9e93f415d4ce7bd45908c47c384ba,respond,0.587701
uuid-52fc39ab659b4a95ac03a09b91fc39d5,TL,0.489471
uuid-52fc39ab659b4a95ac03a09b91fc39d5,TL stated,0.387098
uuid-52fc39ab659b4a95ac03a09b91fc39d5,tumor,0.394074
uuid-52fc39ab659b4a95ac03a09b91fc39d5,PD-L1,0.71487
uuid-52fc39ab659b4a95ac03a09b91fc39d5,PD-L1 testing,0.781153
uuid-52fc39ab659b4a95ac03a09b91fc39d5,testing,0.777501
uuid-52fc39ab659b4a95ac03a09b91fc39d5,PDL1 testing,0.59877
uuid-52fc39ab659b4a95ac03a09b91fc39d5,NSCLC patients,0.579635
uuid-52fc39ab659b4a95ac03a09b91fc39d5,assay,0.585384
uuid-52fc39ab659b4a95ac03a09b91fc39d5,biomarker,0.394181
uuid-209c41a047d249e8a66a99076cf84c71,toxicity,0.48969
uuid-209c41a047d249e8a66a99076cf84c71,regimen,0.418488
uuid-209c41a047d249e8a66a99076cf84c71,combination,0.548786
uuid-209c41a047d249e8a66a99076cf84c71,chemo,0.370706
uuid-209c41a047d249e8a66a99076cf84c71,tumor,0.491383
uuid-209c41a047d249e8a66a99076cf84c71,pts,0.346485
uuid-209c41a047d249e8a66a99076cf84c71,IO,0.309583
uuid-209c41a047d249e8a66a99076cf84c71,Ipi,0.327304
uuid-209c41a047d249e8a66a99076cf84c71,monotherapy,0.315126
uuid-209c41a047d249e8a66a99076cf84c71,treatment,0.310387
uuid-209c41a047d249e8a66a99076cf84c71,response,0.43778
uuid-209c41a047d249e8a66a99076cf84c71,combo,0.45581
uuid-209c41a047d249e8a66a99076cf84c71,PD1,0.342884
uuid-209c41a047d249e8a66a99076cf84c71,progression,0.398587
uuid-209c41a047d249e8a66a99076cf84c71,chemotherapy,0.338834
uuid-209c41a047d249e8a66a99076cf84c71,immunotherapy,0.34422
uuid-2529e29dc5b54cfdbe86a65b1b7b509f,PDL1,0.344997
uuid-2529e29dc5b54cfdbe86a65b1b7b509f,efficacy,0.435957
uuid-2529e29dc5b54cfdbe86a65b1b7b509f,OS,0.357277
uuid-2529e29dc5b54cfdbe86a65b1b7b509f,data,0.460862
uuid-2529e29dc5b54cfdbe86a65b1b7b509f,PFS,0.323101
uuid-2529e29dc5b54cfdbe86a65b1b7b509f,ORR,0.424264
uuid-2529e29dc5b54cfdbe86a65b1b7b509f,impressed,0.300198
uuid-2529e29dc5b54cfdbe86a65b1b7b509f,PDL1 expression,0.339417
uuid-bbf8268d75bc4768b48515a33200a0b4,RTL,0.378245
uuid-bbf8268d75bc4768b48515a33200a0b4,BMS,0.606578
uuid-bbf8268d75bc4768b48515a33200a0b4,trial,0.645285
uuid-bbf8268d75bc4768b48515a33200a0b4,efficacy,0.324964
uuid-bbf8268d75bc4768b48515a33200a0b4,shared,0.393331
uuid-bbf8268d75bc4768b48515a33200a0b4,commented,0.512702
uuid-bbf8268d75bc4768b48515a33200a0b4,Merck,0.55011
uuid-bbf8268d75bc4768b48515a33200a0b4,stated,0.415818
uuid-bbf8268d75bc4768b48515a33200a0b4,OS,0.340183
uuid-bbf8268d75bc4768b48515a33200a0b4,regards,0.305972
uuid-bbf8268d75bc4768b48515a33200a0b4,data,0.736092
uuid-bbf8268d75bc4768b48515a33200a0b4,expressed,0.499214
uuid-bbf8268d75bc4768b48515a33200a0b4,clinical trials,0.419647
uuid-bbf8268d75bc4768b48515a33200a0b4,PFS,0.329419
uuid-bbf8268d75bc4768b48515a33200a0b4,ORR,0.381199
uuid-bbf8268d75bc4768b48515a33200a0b4,ASCO,0.335251
uuid-bbf8268d75bc4768b48515a33200a0b4,impressed,0.569487
uuid-bbf8268d75bc4768b48515a33200a0b4,LTL,0.330614
uuid-bbf8268d75bc4768b48515a33200a0b4,TLs,0.324493
uuid-bbf8268d75bc4768b48515a33200a0b4,Regional TL,0.372403
uuid-bbf8268d75bc4768b48515a33200a0b4,bladder,0.406011
uuid-b95480aa8cf247fd9d707f3a3ce7a341,TL,0.590241
uuid-b95480aa8cf247fd9d707f3a3ce7a341,PDL1,0.318851
uuid-b95480aa8cf247fd9d707f3a3ce7a341,TL stated,0.490005
uuid-b95480aa8cf247fd9d707f3a3ce7a341,Merck,0.352527
uuid-b95480aa8cf247fd9d707f3a3ce7a341,institution,0.443524
uuid-b95480aa8cf247fd9d707f3a3ce7a341,PD-L1,0.744668
uuid-b95480aa8cf247fd9d707f3a3ce7a341,PD-L1 testing,0.774431
uuid-b95480aa8cf247fd9d707f3a3ce7a341,testing,0.831026
uuid-b95480aa8cf247fd9d707f3a3ce7a341,PDL1 testing,0.706056
uuid-b95480aa8cf247fd9d707f3a3ce7a341,NSCLC patients,0.571107
uuid-b95480aa8cf247fd9d707f3a3ce7a341,assay,0.770253
uuid-b95480aa8cf247fd9d707f3a3ce7a341,biomarker,0.362837
uuid-36c7da3e82eb458ea2a95aedf58509c9,patients,0.451328
uuid-36c7da3e82eb458ea2a95aedf58509c9,RTL,0.489958
uuid-36c7da3e82eb458ea2a95aedf58509c9,nivolumab,0.444245
uuid-36c7da3e82eb458ea2a95aedf58509c9,treated,0.613645
uuid-36c7da3e82eb458ea2a95aedf58509c9,NTL,0.410544
uuid-36c7da3e82eb458ea2a95aedf58509c9,melanoma,0.466308
uuid-36c7da3e82eb458ea2a95aedf58509c9,shared,0.433191
uuid-36c7da3e82eb458ea2a95aedf58509c9,RCC,0.387608
uuid-36c7da3e82eb458ea2a95aedf58509c9,pts,0.353927
uuid-36c7da3e82eb458ea2a95aedf58509c9,clinical trials,0.451889
uuid-36c7da3e82eb458ea2a95aedf58509c9,SCCHN,0.429867
uuid-36c7da3e82eb458ea2a95aedf58509c9,academic,0.338959
uuid-36c7da3e82eb458ea2a95aedf58509c9,Regional TL,0.405759
uuid-36c7da3e82eb458ea2a95aedf58509c9,RTL stated,0.442253
uuid-36c7da3e82eb458ea2a95aedf58509c9,TL shared,0.426589
uuid-36c7da3e82eb458ea2a95aedf58509c9,bladder,0.31718
uuid-4a44b26900b24ae7a2ef3972f30aaf5f,PDL1,0.344997
uuid-4a44b26900b24ae7a2ef3972f30aaf5f,efficacy,0.435957
uuid-4a44b26900b24ae7a2ef3972f30aaf5f,OS,0.357277
uuid-4a44b26900b24ae7a2ef3972f30aaf5f,data,0.460862
uuid-4a44b26900b24ae7a2ef3972f30aaf5f,PFS,0.323101
uuid-4a44b26900b24ae7a2ef3972f30aaf5f,ORR,0.424264
uuid-4a44b26900b24ae7a2ef3972f30aaf5f,impressed,0.300198
uuid-4a44b26900b24ae7a2ef3972f30aaf5f,PDL1 expression,0.339417
uuid-959e759b38e54eafb881079b95d3eaf3,TL,0.553434
uuid-959e759b38e54eafb881079b95d3eaf3,shared,0.348752
uuid-959e759b38e54eafb881079b95d3eaf3,TL stated,0.507866
uuid-959e759b38e54eafb881079b95d3eaf3,institution,0.470893
uuid-959e759b38e54eafb881079b95d3eaf3,PD-L1,0.484766
uuid-959e759b38e54eafb881079b95d3eaf3,physicians,0.398374
uuid-959e759b38e54eafb881079b95d3eaf3,PD-L1 testing,0.682713
uuid-959e759b38e54eafb881079b95d3eaf3,testing,0.619027
uuid-959e759b38e54eafb881079b95d3eaf3,PDL1 testing,0.617379
uuid-959e759b38e54eafb881079b95d3eaf3,NSCLC patients,0.460479
uuid-959e759b38e54eafb881079b95d3eaf3,assay,0.420172
uuid-853b6789ba9c47c19164a0dd2c6889f8,patients,0.687547
uuid-853b6789ba9c47c19164a0dd2c6889f8,Opdivo,0.342699
uuid-853b6789ba9c47c19164a0dd2c6889f8,therapy,0.357634
uuid-853b6789ba9c47c19164a0dd2c6889f8,nivolumab,0.329647
uuid-853b6789ba9c47c19164a0dd2c6889f8,toxicity,0.31134
uuid-853b6789ba9c47c19164a0dd2c6889f8,regimen,0.49995
uuid-853b6789ba9c47c19164a0dd2c6889f8,treated,0.583391
uuid-853b6789ba9c47c19164a0dd2c6889f8,pts,0.345628
uuid-853b6789ba9c47c19164a0dd2c6889f8,treatment,0.706461
uuid-853b6789ba9c47c19164a0dd2c6889f8,progression,0.416685
uuid-853b6789ba9c47c19164a0dd2c6889f8,respond,0.404597
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,Nivo,0.329759
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,nivolumab,0.417089
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,toxicity,0.404907
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,regimen,0.573327
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,treated,0.327548
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,shared,0.365184
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,combination,0.64173
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,chemo,0.368995
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,IO,0.30932
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,agents,0.305048
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,Ipi,0.436724
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,monotherapy,0.516933
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,treatment,0.318391
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,response,0.328009
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,combo,0.594605
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,PD1,0.436025
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,progression,0.356388
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,chemotherapy,0.393895
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,impressed,0.306069
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,feels,0.452512
uuid-ed4efcf9769d4da2b41a05bf3d74e8c3,option,0.332256
uuid-4db9d54512eb481da60852bb6ba070b7,patients,0.355253
uuid-4db9d54512eb481da60852bb6ba070b7,BMS,0.376594
uuid-4db9d54512eb481da60852bb6ba070b7,shared,0.349037
uuid-4db9d54512eb481da60852bb6ba070b7,stated,0.318027
uuid-4db9d54512eb481da60852bb6ba070b7,approval,0.371059
uuid-4db9d54512eb481da60852bb6ba070b7,physicians,0.32293
uuid-4db9d54512eb481da60852bb6ba070b7,clinical trials,0.429129
uuid-4db9d54512eb481da60852bb6ba070b7,approved,0.400454
uuid-4db9d54512eb481da60852bb6ba070b7,tumor types,0.332334
uuid-6ff254960f8a42b48753c588c4b34fea,patients,0.725383
uuid-6ff254960f8a42b48753c588c4b34fea,Opdivo,0.464559
uuid-6ff254960f8a42b48753c588c4b34fea,therapy,0.555435
uuid-6ff254960f8a42b48753c588c4b34fea,nivolumab,0.606569
uuid-6ff254960f8a42b48753c588c4b34fea,regimen,0.308682
uuid-6ff254960f8a42b48753c588c4b34fea,treated,0.524321
uuid-6ff254960f8a42b48753c588c4b34fea,pts,0.307436
uuid-6ff254960f8a42b48753c588c4b34fea,approval,0.340537
uuid-6ff254960f8a42b48753c588c4b34fea,monotherapy,0.304774
uuid-6ff254960f8a42b48753c588c4b34fea,treatment,0.544746
uuid-6ff254960f8a42b48753c588c4b34fea,using nivo,0.412996
uuid-6ff254960f8a42b48753c588c4b34fea,cHL,0.509828
uuid-6ff254960f8a42b48753c588c4b34fea,progression,0.39446
uuid-6ff254960f8a42b48753c588c4b34fea,chemotherapy,0.406325
uuid-6ff254960f8a42b48753c588c4b34fea,RTL stated,0.332278
uuid-6ff254960f8a42b48753c588c4b34fea,option,0.357232
uuid-99259d76e07b442d808c0e2a77e6e919,TL,0.318159
uuid-99259d76e07b442d808c0e2a77e6e919,PD-L1,0.350914
uuid-99259d76e07b442d808c0e2a77e6e919,PD-L1 testing,0.309689
uuid-99259d76e07b442d808c0e2a77e6e919,assay,0.403615
uuid-99259d76e07b442d808c0e2a77e6e919,biomarker,0.357966
uuid-ae80164adeab41288b8d074c0497323c,trial,0.386973
uuid-ae80164adeab41288b8d074c0497323c,efficacy,0.44585
uuid-ae80164adeab41288b8d074c0497323c,commented,0.304089
uuid-ae80164adeab41288b8d074c0497323c,OS,0.495189
uuid-ae80164adeab41288b8d074c0497323c,data,0.573667
uuid-ae80164adeab41288b8d074c0497323c,PFS,0.433639
uuid-ae80164adeab41288b8d074c0497323c,ORR,0.524603
uuid-ae80164adeab41288b8d074c0497323c,ASCO,0.393274
uuid-ae80164adeab41288b8d074c0497323c,impressed,0.585078
uuid-ae80164adeab41288b8d074c0497323c,indicated,0.35034
uuid-08a8acde8c93416684cc6ec90b174205,Nivo,0.419485
uuid-08a8acde8c93416684cc6ec90b174205,patients,0.395101
uuid-08a8acde8c93416684cc6ec90b174205,Opdivo,0.311985
uuid-08a8acde8c93416684cc6ec90b174205,pembro,0.405457
uuid-08a8acde8c93416684cc6ec90b174205,nivolumab,0.408319
uuid-08a8acde8c93416684cc6ec90b174205,1L,0.472031
uuid-08a8acde8c93416684cc6ec90b174205,regimen,0.423754
uuid-08a8acde8c93416684cc6ec90b174205,combination,0.51749
uuid-08a8acde8c93416684cc6ec90b174205,chemo,0.357009
uuid-08a8acde8c93416684cc6ec90b174205,2L,0.509741
uuid-08a8acde8c93416684cc6ec90b174205,agents,0.39323
uuid-08a8acde8c93416684cc6ec90b174205,Ipi,0.312597
uuid-08a8acde8c93416684cc6ec90b174205,approval,0.421869
uuid-08a8acde8c93416684cc6ec90b174205,atezo,0.305453
uuid-08a8acde8c93416684cc6ec90b174205,preferred,0.512552
uuid-08a8acde8c93416684cc6ec90b174205,monotherapy,0.562354
uuid-08a8acde8c93416684cc6ec90b174205,using nivo,0.483515
uuid-08a8acde8c93416684cc6ec90b174205,combo,0.55976
uuid-08a8acde8c93416684cc6ec90b174205,clinical trials,0.337065
uuid-08a8acde8c93416684cc6ec90b174205,indication,0.342913
uuid-08a8acde8c93416684cc6ec90b174205,approved,0.62122
uuid-08a8acde8c93416684cc6ec90b174205,chemotherapy,0.37083
uuid-08a8acde8c93416684cc6ec90b174205,feels,0.359262
uuid-08a8acde8c93416684cc6ec90b174205,RTL stated,0.376799
uuid-08a8acde8c93416684cc6ec90b174205,option,0.571343
uuid-5a31050d8b7b4d60ad33fe0e5f882c95,regards,0.300307
uuid-904ebbc53ce44a0484e833f947472cf6,Opdivo,0.316464
uuid-904ebbc53ce44a0484e833f947472cf6,RTL,0.386562
uuid-904ebbc53ce44a0484e833f947472cf6,therapy,0.376324
uuid-904ebbc53ce44a0484e833f947472cf6,nivolumab,0.554016
uuid-904ebbc53ce44a0484e833f947472cf6,regimen,0.320788
uuid-904ebbc53ce44a0484e833f947472cf6,NTL,0.367222
uuid-904ebbc53ce44a0484e833f947472cf6,combination,0.588284
uuid-904ebbc53ce44a0484e833f947472cf6,combo,0.342732
uuid-904ebbc53ce44a0484e833f947472cf6,PD1,0.357222
uuid-904ebbc53ce44a0484e833f947472cf6,cHL,0.42882
uuid-904ebbc53ce44a0484e833f947472cf6,chemotherapy,0.395957
uuid-0e141c49e8704024a8d00882e6e41f76,Nivo,0.421113
uuid-0e141c49e8704024a8d00882e6e41f76,trial,0.66674
uuid-0e141c49e8704024a8d00882e6e41f76,efficacy,0.515456
uuid-0e141c49e8704024a8d00882e6e41f76,chemo,0.418834
uuid-0e141c49e8704024a8d00882e6e41f76,Ipi,0.339075
uuid-0e141c49e8704024a8d00882e6e41f76,OS,0.692637
uuid-0e141c49e8704024a8d00882e6e41f76,data,0.435851
uuid-0e141c49e8704024a8d00882e6e41f76,PFS,0.704951
uuid-0e141c49e8704024a8d00882e6e41f76,ORR,0.668875
uuid-0e141c49e8704024a8d00882e6e41f76,nivo and pembro,0.33905
uuid-0e141c49e8704024a8d00882e6e41f76,chemotherapy,0.447277
uuid-0e141c49e8704024a8d00882e6e41f76,impressed,0.38095
uuid-0e141c49e8704024a8d00882e6e41f76,feels,0.330334
uuid-322740a3278449388f5ee0f20f644a9b,OS,0.493183
uuid-322740a3278449388f5ee0f20f644a9b,data,0.634873
uuid-322740a3278449388f5ee0f20f644a9b,PFS,0.446617
uuid-322740a3278449388f5ee0f20f644a9b,ORR,0.458856
uuid-322740a3278449388f5ee0f20f644a9b,impressed,0.526553
uuid-322740a3278449388f5ee0f20f644a9b,feels,0.393908
uuid-049b5e4b18d94928a6b1815c6b25d7f8,PDL1,0.335028
uuid-049b5e4b18d94928a6b1815c6b25d7f8,trial,0.462079
uuid-049b5e4b18d94928a6b1815c6b25d7f8,efficacy,0.479099
uuid-049b5e4b18d94928a6b1815c6b25d7f8,commented,0.380358
uuid-049b5e4b18d94928a6b1815c6b25d7f8,OS,0.656712
uuid-049b5e4b18d94928a6b1815c6b25d7f8,data,0.878612
uuid-049b5e4b18d94928a6b1815c6b25d7f8,PFS,0.652535
uuid-049b5e4b18d94928a6b1815c6b25d7f8,ORR,0.694468
uuid-049b5e4b18d94928a6b1815c6b25d7f8,nivo and pembro,0.365289
uuid-049b5e4b18d94928a6b1815c6b25d7f8,ASCO,0.446242
uuid-049b5e4b18d94928a6b1815c6b25d7f8,impressed,0.693035
uuid-049b5e4b18d94928a6b1815c6b25d7f8,feels,0.322386
uuid-049b5e4b18d94928a6b1815c6b25d7f8,PDL1 expression,0.350112
uuid-c4356ebf37dd4dbeb2eefa72e23f925d,Nivo,0.484863
uuid-c4356ebf37dd4dbeb2eefa72e23f925d,Opdivo,0.366681
uuid-c4356ebf37dd4dbeb2eefa72e23f925d,therapy,0.40191
uuid-c4356ebf37dd4dbeb2eefa72e23f925d,nivolumab,0.348046
uuid-c4356ebf37dd4dbeb2eefa72e23f925d,mentioned,0.315938
uuid-c4356ebf37dd4dbeb2eefa72e23f925d,cHL,0.622201
uuid-7b54bf28408749338a16216cd1be5ddf,TL,0.366614
uuid-7b54bf28408749338a16216cd1be5ddf,pembro,0.417977
uuid-7b54bf28408749338a16216cd1be5ddf,BMS,0.32291
uuid-7b54bf28408749338a16216cd1be5ddf,1L,0.350245
uuid-7b54bf28408749338a16216cd1be5ddf,PDL1,0.689697
uuid-7b54bf28408749338a16216cd1be5ddf,efficacy,0.340101
uuid-7b54bf28408749338a16216cd1be5ddf,commented,0.311031
uuid-7b54bf28408749338a16216cd1be5ddf,Merck,0.432692
uuid-7b54bf28408749338a16216cd1be5ddf,stated,0.331586
uuid-7b54bf28408749338a16216cd1be5ddf,PD-L1,0.564105
uuid-7b54bf28408749338a16216cd1be5ddf,OS,0.411971
uuid-7b54bf28408749338a16216cd1be5ddf,atezo,0.408744
uuid-7b54bf28408749338a16216cd1be5ddf,PD-L1 testing,0.344834
uuid-7b54bf28408749338a16216cd1be5ddf,testing,0.427537
uuid-7b54bf28408749338a16216cd1be5ddf,data,0.687098
uuid-7b54bf28408749338a16216cd1be5ddf,PDL1 testing,0.377462
uuid-7b54bf28408749338a16216cd1be5ddf,PFS,0.379604
uuid-7b54bf28408749338a16216cd1be5ddf,NSCLC patients,0.31317
uuid-7b54bf28408749338a16216cd1be5ddf,ORR,0.432268
uuid-7b54bf28408749338a16216cd1be5ddf,nivo and pembro,0.45256
uuid-7b54bf28408749338a16216cd1be5ddf,impressed,0.472518
uuid-7b54bf28408749338a16216cd1be5ddf,TLs,0.329866
uuid-7b54bf28408749338a16216cd1be5ddf,assay,0.455673
uuid-7b54bf28408749338a16216cd1be5ddf,PDL1 expression,0.50702
uuid-7b54bf28408749338a16216cd1be5ddf,biomarker,0.414894
uuid-796101d18f564e1994d29562884cafbc,Nivo,0.611843
uuid-796101d18f564e1994d29562884cafbc,patients,0.492318
uuid-796101d18f564e1994d29562884cafbc,therapy,0.663567
uuid-796101d18f564e1994d29562884cafbc,nivolumab,0.490881
uuid-796101d18f564e1994d29562884cafbc,combination,0.399926
uuid-796101d18f564e1994d29562884cafbc,chemo,0.408229
uuid-796101d18f564e1994d29562884cafbc,Ipi,0.308651
uuid-796101d18f564e1994d29562884cafbc,monotherapy,0.400351
uuid-796101d18f564e1994d29562884cafbc,treatment,0.351273
uuid-796101d18f564e1994d29562884cafbc,using nivo,0.388601
uuid-796101d18f564e1994d29562884cafbc,PD1,0.432697
uuid-796101d18f564e1994d29562884cafbc,cHL,0.485207
uuid-796101d18f564e1994d29562884cafbc,chemotherapy,0.570804
uuid-796101d18f564e1994d29562884cafbc,option,0.37134
uuid-d4bcea11462f400d8b48fe9df90070aa,patients,0.421433
uuid-d4bcea11462f400d8b48fe9df90070aa,Opdivo,0.398404
uuid-d4bcea11462f400d8b48fe9df90070aa,physicians,0.57764
uuid-d4bcea11462f400d8b48fe9df90070aa,treatment,0.483903
uuid-4d13fbb5e5464954b33d7ed32b6c9776,Nivo,0.390308
uuid-4d13fbb5e5464954b33d7ed32b6c9776,patients,0.410501
uuid-4d13fbb5e5464954b33d7ed32b6c9776,Opdivo,0.380013
uuid-4d13fbb5e5464954b33d7ed32b6c9776,therapy,0.461135
uuid-4d13fbb5e5464954b33d7ed32b6c9776,nivolumab,0.391981
uuid-4d13fbb5e5464954b33d7ed32b6c9776,approval,0.412964
uuid-4d13fbb5e5464954b33d7ed32b6c9776,mentioned,0.308681
uuid-4d13fbb5e5464954b33d7ed32b6c9776,cHL,0.708926
uuid-4d13fbb5e5464954b33d7ed32b6c9776,label,0.331238
uuid-eee5b03d39d648ec9798219b50ba7704,Nivo,0.300876
uuid-eee5b03d39d648ec9798219b50ba7704,patients,0.779765
uuid-eee5b03d39d648ec9798219b50ba7704,therapy,0.797469
uuid-eee5b03d39d648ec9798219b50ba7704,nivolumab,0.404198
uuid-eee5b03d39d648ec9798219b50ba7704,1L,0.301907
uuid-eee5b03d39d648ec9798219b50ba7704,regimen,0.561726
uuid-eee5b03d39d648ec9798219b50ba7704,treated,0.513348
uuid-eee5b03d39d648ec9798219b50ba7704,combination,0.322555
uuid-eee5b03d39d648ec9798219b50ba7704,chemo,0.61135
uuid-eee5b03d39d648ec9798219b50ba7704,pts,0.654268
uuid-eee5b03d39d648ec9798219b50ba7704,IO,0.327193
uuid-eee5b03d39d648ec9798219b50ba7704,monotherapy,0.569178
uuid-eee5b03d39d648ec9798219b50ba7704,treatment,0.743068
uuid-eee5b03d39d648ec9798219b50ba7704,response,0.663691
uuid-eee5b03d39d648ec9798219b50ba7704,PD1,0.581648
uuid-eee5b03d39d648ec9798219b50ba7704,progression,0.876765
uuid-eee5b03d39d648ec9798219b50ba7704,chemotherapy,0.57584
uuid-eee5b03d39d648ec9798219b50ba7704,respond,0.602519
uuid-eee5b03d39d648ec9798219b50ba7704,option,0.493341
uuid-bbe89923410d4c9f80b5c6db764d9a23,RTL,0.316337
uuid-bbe89923410d4c9f80b5c6db764d9a23,BMS,0.321668
uuid-bbe89923410d4c9f80b5c6db764d9a23,trial,0.307712
uuid-bbe89923410d4c9f80b5c6db764d9a23,shared,0.35848
uuid-bbe89923410d4c9f80b5c6db764d9a23,commented,0.455142
uuid-bbe89923410d4c9f80b5c6db764d9a23,stated,0.350784
uuid-bbe89923410d4c9f80b5c6db764d9a23,OS,0.339363
uuid-bbe89923410d4c9f80b5c6db764d9a23,data,0.624554
uuid-bbe89923410d4c9f80b5c6db764d9a23,expressed,0.401269
uuid-bbe89923410d4c9f80b5c6db764d9a23,mentioned,0.322536
uuid-bbe89923410d4c9f80b5c6db764d9a23,indication,0.424921
uuid-bbe89923410d4c9f80b5c6db764d9a23,SCCHN,0.346938
uuid-bbe89923410d4c9f80b5c6db764d9a23,impressed,0.546104
uuid-bbe89923410d4c9f80b5c6db764d9a23,LTL,0.35666
uuid-bbe89923410d4c9f80b5c6db764d9a23,Regional TL,0.334275
uuid-219e118c3fad4447967a097aea5dce8a,combination,0.55247
uuid-219e118c3fad4447967a097aea5dce8a,chemo,0.375267
uuid-219e118c3fad4447967a097aea5dce8a,tumor,0.348248
uuid-219e118c3fad4447967a097aea5dce8a,Ipi,0.304102
uuid-219e118c3fad4447967a097aea5dce8a,response,0.57972
uuid-219e118c3fad4447967a097aea5dce8a,combo,0.378208
uuid-219e118c3fad4447967a097aea5dce8a,PD1,0.332083
uuid-219e118c3fad4447967a097aea5dce8a,immunotherapy,0.410505
uuid-1e7500543d264caabad658bfc42dc7da,Nivo,0.612832
uuid-1e7500543d264caabad658bfc42dc7da,therapy,0.508176
uuid-1e7500543d264caabad658bfc42dc7da,nivolumab,0.313604
uuid-1e7500543d264caabad658bfc42dc7da,trial,0.422037
uuid-1e7500543d264caabad658bfc42dc7da,combination,0.576957
uuid-1e7500543d264caabad658bfc42dc7da,chemo,0.566017
uuid-1e7500543d264caabad658bfc42dc7da,agents,0.396207
uuid-1e7500543d264caabad658bfc42dc7da,Ipi,0.38036
uuid-1e7500543d264caabad658bfc42dc7da,monotherapy,0.502101
uuid-1e7500543d264caabad658bfc42dc7da,response,0.350332
uuid-1e7500543d264caabad658bfc42dc7da,combo,0.496008
uuid-1e7500543d264caabad658bfc42dc7da,PD1,0.537784
uuid-1e7500543d264caabad658bfc42dc7da,nivo and pembro,0.32889
uuid-1e7500543d264caabad658bfc42dc7da,believes,0.39255
uuid-1e7500543d264caabad658bfc42dc7da,chemotherapy,0.557732
uuid-1e7500543d264caabad658bfc42dc7da,feels,0.36916
uuid-1e7500543d264caabad658bfc42dc7da,option,0.418323
uuid-1de5851bcc454e7eab96c8a63d27f91a,Nivo,0.381764
uuid-1de5851bcc454e7eab96c8a63d27f91a,pembro,0.451
uuid-1de5851bcc454e7eab96c8a63d27f91a,BMS,0.308969
uuid-1de5851bcc454e7eab96c8a63d27f91a,1L,0.449152
uuid-1de5851bcc454e7eab96c8a63d27f91a,trial,0.508537
uuid-1de5851bcc454e7eab96c8a63d27f91a,efficacy,0.355331
uuid-1de5851bcc454e7eab96c8a63d27f91a,combination,0.388411
uuid-1de5851bcc454e7eab96c8a63d27f91a,chemo,0.387292
uuid-1de5851bcc454e7eab96c8a63d27f91a,2L,0.356098
uuid-1de5851bcc454e7eab96c8a63d27f91a,agents,0.339629
uuid-1de5851bcc454e7eab96c8a63d27f91a,Ipi,0.322881
uuid-1de5851bcc454e7eab96c8a63d27f91a,OS,0.373142
uuid-1de5851bcc454e7eab96c8a63d27f91a,atezo,0.350184
uuid-1de5851bcc454e7eab96c8a63d27f91a,monotherapy,0.399417
uuid-1de5851bcc454e7eab96c8a63d27f91a,data,0.377862
uuid-1de5851bcc454e7eab96c8a63d27f91a,combo,0.423061
uuid-1de5851bcc454e7eab96c8a63d27f91a,clinical trials,0.369987
uuid-1de5851bcc454e7eab96c8a63d27f91a,indication,0.356076
uuid-1de5851bcc454e7eab96c8a63d27f91a,PFS,0.34671
uuid-1de5851bcc454e7eab96c8a63d27f91a,ORR,0.345341
uuid-1de5851bcc454e7eab96c8a63d27f91a,approved,0.443989
uuid-1de5851bcc454e7eab96c8a63d27f91a,nivo and pembro,0.392815
uuid-1de5851bcc454e7eab96c8a63d27f91a,believes,0.424398
uuid-1de5851bcc454e7eab96c8a63d27f91a,chemotherapy,0.341087
uuid-1de5851bcc454e7eab96c8a63d27f91a,impressed,0.315045
uuid-1de5851bcc454e7eab96c8a63d27f91a,SCLC,0.3581
uuid-1de5851bcc454e7eab96c8a63d27f91a,feels,0.490143
uuid-1de5851bcc454e7eab96c8a63d27f91a,option,0.450738
uuid-8cba16b05cec4a9591bc545635a56d03,Nivo,0.369236
uuid-8cba16b05cec4a9591bc545635a56d03,pembro,0.339979
uuid-8cba16b05cec4a9591bc545635a56d03,lung,0.542481
uuid-8cba16b05cec4a9591bc545635a56d03,1L,0.387975
uuid-8cba16b05cec4a9591bc545635a56d03,efficacy,0.353923
uuid-8cba16b05cec4a9591bc545635a56d03,melanoma,0.425863
uuid-8cba16b05cec4a9591bc545635a56d03,RCC,0.356484
uuid-8cba16b05cec4a9591bc545635a56d03,2L,0.397363
uuid-8cba16b05cec4a9591bc545635a56d03,agents,0.320263
uuid-8cba16b05cec4a9591bc545635a56d03,OS,0.316478
uuid-8cba16b05cec4a9591bc545635a56d03,atezo,0.372356
uuid-8cba16b05cec4a9591bc545635a56d03,regards,0.347487
uuid-8cba16b05cec4a9591bc545635a56d03,PFS,0.314722
uuid-8cba16b05cec4a9591bc545635a56d03,AI,0.618323
uuid-8cba16b05cec4a9591bc545635a56d03,nivo and pembro,0.568821
uuid-8cba16b05cec4a9591bc545635a56d03,believes,0.406102
uuid-d1a76dc2e28541ac8be99e9b20a1c873,patients,0.314165
uuid-d1a76dc2e28541ac8be99e9b20a1c873,NSCLC,0.371927
uuid-d1a76dc2e28541ac8be99e9b20a1c873,treated,0.351734
uuid-d1a76dc2e28541ac8be99e9b20a1c873,melanoma,0.310985
uuid-d1a76dc2e28541ac8be99e9b20a1c873,tumor,0.541752
uuid-d1a76dc2e28541ac8be99e9b20a1c873,pts,0.416552
uuid-d1a76dc2e28541ac8be99e9b20a1c873,IO,0.358093
uuid-d1a76dc2e28541ac8be99e9b20a1c873,treatment,0.315257
uuid-d1a76dc2e28541ac8be99e9b20a1c873,response,0.591108
uuid-d1a76dc2e28541ac8be99e9b20a1c873,progression,0.544885
uuid-d1a76dc2e28541ac8be99e9b20a1c873,respond,0.34956
uuid-d1a76dc2e28541ac8be99e9b20a1c873,TL shared,0.334258
uuid-7b570962282142f78340f2a60f33ccc1,pembro,0.462931
uuid-7b570962282142f78340f2a60f33ccc1,dose,0.60755
uuid-7b570962282142f78340f2a60f33ccc1,trial,0.320678
uuid-7b570962282142f78340f2a60f33ccc1,efficacy,0.325404
uuid-7b570962282142f78340f2a60f33ccc1,Merck,0.359895
uuid-7b570962282142f78340f2a60f33ccc1,Ipi,0.335966
uuid-7b570962282142f78340f2a60f33ccc1,atezo,0.388425
uuid-7b570962282142f78340f2a60f33ccc1,vs,0.636054
uuid-7b570962282142f78340f2a60f33ccc1,flat dosing,0.555286
uuid-6f3891b6b5364ace93ccf0ed912aedca,patients,0.369407
uuid-6f3891b6b5364ace93ccf0ed912aedca,regimen,0.483595
uuid-6f3891b6b5364ace93ccf0ed912aedca,treated,0.373043
uuid-6f3891b6b5364ace93ccf0ed912aedca,OS,0.303305
uuid-6f3891b6b5364ace93ccf0ed912aedca,treatment,0.360256
uuid-6f3891b6b5364ace93ccf0ed912aedca,progression,0.377811
uuid-6f3891b6b5364ace93ccf0ed912aedca,impressed,0.515678
uuid-6f3891b6b5364ace93ccf0ed912aedca,respond,0.38766
uuid-6f3891b6b5364ace93ccf0ed912aedca,feels,0.373461
uuid-4668301fba0d40658441660f57fc3e52,PDL1,0.303443
uuid-4668301fba0d40658441660f57fc3e52,efficacy,0.443477
uuid-4668301fba0d40658441660f57fc3e52,regimen,0.306285
uuid-4668301fba0d40658441660f57fc3e52,chemo,0.377205
uuid-4668301fba0d40658441660f57fc3e52,OS,0.490676
uuid-4668301fba0d40658441660f57fc3e52,regards,0.316651
uuid-4668301fba0d40658441660f57fc3e52,response,0.432442
uuid-4668301fba0d40658441660f57fc3e52,PFS,0.478438
uuid-4668301fba0d40658441660f57fc3e52,ORR,0.53401
uuid-4668301fba0d40658441660f57fc3e52,nivo and pembro,0.303304
uuid-4668301fba0d40658441660f57fc3e52,believes,0.407517
uuid-4668301fba0d40658441660f57fc3e52,impressed,0.329038
uuid-4668301fba0d40658441660f57fc3e52,respond,0.383179
uuid-4668301fba0d40658441660f57fc3e52,PDL1 expression,0.303798
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,lung,0.609202
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,regimen,0.326149
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,treated,0.50868
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,melanoma,0.635217
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,commented,0.353739
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,RCC,0.576365
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,TL stated,0.465614
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,SCCHN,0.417787
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,progression,0.333225
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,TLs,0.391266
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,Regional TL,0.385796
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,RTL stated,0.421426
uuid-8a216d2bb3d1416d9b99c22f2aa9c9c2,TL shared,0.628447
uuid-59e9b7242cc14f27b201557ca8549068,PDL1,0.326325
uuid-59e9b7242cc14f27b201557ca8549068,trial,0.483452
uuid-59e9b7242cc14f27b201557ca8549068,efficacy,0.309737
uuid-59e9b7242cc14f27b201557ca8549068,OS,0.36033
uuid-59e9b7242cc14f27b201557ca8549068,data,0.498347
uuid-59e9b7242cc14f27b201557ca8549068,PFS,0.346299
uuid-59e9b7242cc14f27b201557ca8549068,ORR,0.403814
uuid-59e9b7242cc14f27b201557ca8549068,impressed,0.416192
uuid-59e9b7242cc14f27b201557ca8549068,feels,0.375401
uuid-304927cb060c4f41a54493632da51021,lung,0.303406
uuid-304927cb060c4f41a54493632da51021,efficacy,0.304463
uuid-304927cb060c4f41a54493632da51021,regimen,0.407483
uuid-304927cb060c4f41a54493632da51021,melanoma,0.367588
uuid-304927cb060c4f41a54493632da51021,RCC,0.303546
uuid-304927cb060c4f41a54493632da51021,combination,0.443518
uuid-304927cb060c4f41a54493632da51021,chemo,0.372542
uuid-304927cb060c4f41a54493632da51021,pts,0.327222
uuid-304927cb060c4f41a54493632da51021,monotherapy,0.379736
uuid-304927cb060c4f41a54493632da51021,response,0.405493
uuid-304927cb060c4f41a54493632da51021,combo,0.494858
uuid-304927cb060c4f41a54493632da51021,PD1,0.422813
uuid-304927cb060c4f41a54493632da51021,ORR,0.325476
uuid-304927cb060c4f41a54493632da51021,progression,0.357181
uuid-304927cb060c4f41a54493632da51021,believes,0.443456
uuid-304927cb060c4f41a54493632da51021,chemotherapy,0.310111
uuid-304927cb060c4f41a54493632da51021,SCLC,0.455395
uuid-8dfd945197c949eeb2a68a71e0d58fd4,patients,0.694129
uuid-8dfd945197c949eeb2a68a71e0d58fd4,therapy,0.456889
uuid-8dfd945197c949eeb2a68a71e0d58fd4,nivolumab,0.533147
uuid-8dfd945197c949eeb2a68a71e0d58fd4,1L,0.383508
uuid-8dfd945197c949eeb2a68a71e0d58fd4,toxicity,0.361276
uuid-8dfd945197c949eeb2a68a71e0d58fd4,regimen,0.598584
uuid-8dfd945197c949eeb2a68a71e0d58fd4,treated,0.488953
uuid-8dfd945197c949eeb2a68a71e0d58fd4,RCC,0.454226
uuid-8dfd945197c949eeb2a68a71e0d58fd4,combination,0.43676
uuid-8dfd945197c949eeb2a68a71e0d58fd4,chemo,0.477818
uuid-8dfd945197c949eeb2a68a71e0d58fd4,2L,0.384317
uuid-8dfd945197c949eeb2a68a71e0d58fd4,pts,0.6654
uuid-8dfd945197c949eeb2a68a71e0d58fd4,IO,0.319285
uuid-8dfd945197c949eeb2a68a71e0d58fd4,preferred,0.372774
uuid-8dfd945197c949eeb2a68a71e0d58fd4,monotherapy,0.610363
uuid-8dfd945197c949eeb2a68a71e0d58fd4,treatment,0.542729
uuid-8dfd945197c949eeb2a68a71e0d58fd4,using nivo,0.43307
uuid-8dfd945197c949eeb2a68a71e0d58fd4,response,0.470465
uuid-8dfd945197c949eeb2a68a71e0d58fd4,combo,0.441431
uuid-8dfd945197c949eeb2a68a71e0d58fd4,PD1,0.441497
uuid-8dfd945197c949eeb2a68a71e0d58fd4,progression,0.624277
uuid-8dfd945197c949eeb2a68a71e0d58fd4,chemotherapy,0.38881
uuid-8dfd945197c949eeb2a68a71e0d58fd4,respond,0.479409
uuid-8dfd945197c949eeb2a68a71e0d58fd4,RTL stated,0.478015
uuid-8dfd945197c949eeb2a68a71e0d58fd4,TL shared,0.395602
uuid-8dfd945197c949eeb2a68a71e0d58fd4,option,0.524346
uuid-970d0c6f0e594446b5ae1260ea0a4501,RTL,0.316601
uuid-970d0c6f0e594446b5ae1260ea0a4501,BMS,0.339277
uuid-970d0c6f0e594446b5ae1260ea0a4501,trial,0.649283
uuid-970d0c6f0e594446b5ae1260ea0a4501,NTL,0.327291
uuid-970d0c6f0e594446b5ae1260ea0a4501,commented,0.337318
uuid-970d0c6f0e594446b5ae1260ea0a4501,Merck,0.359314
uuid-970d0c6f0e594446b5ae1260ea0a4501,approval,0.377758
uuid-970d0c6f0e594446b5ae1260ea0a4501,data,0.377694
uuid-970d0c6f0e594446b5ae1260ea0a4501,clinical trials,0.506675
uuid-970d0c6f0e594446b5ae1260ea0a4501,impressed,0.414454
uuid-970d0c6f0e594446b5ae1260ea0a4501,Regional TL,0.35381
uuid-970d0c6f0e594446b5ae1260ea0a4501,bladder,0.436212
uuid-38690e8e696a4daf82c70d030be9f3c9,PDL1,0.304033
uuid-38690e8e696a4daf82c70d030be9f3c9,efficacy,0.37991
uuid-38690e8e696a4daf82c70d030be9f3c9,chemo,0.371713
uuid-38690e8e696a4daf82c70d030be9f3c9,OS,0.598214
uuid-38690e8e696a4daf82c70d030be9f3c9,response,0.380161
uuid-38690e8e696a4daf82c70d030be9f3c9,data,0.334277
uuid-38690e8e696a4daf82c70d030be9f3c9,PFS,0.585738
uuid-38690e8e696a4daf82c70d030be9f3c9,ORR,0.596097
uuid-38690e8e696a4daf82c70d030be9f3c9,believes,0.359325
uuid-38690e8e696a4daf82c70d030be9f3c9,chemotherapy,0.323824
uuid-38690e8e696a4daf82c70d030be9f3c9,impressed,0.346932
uuid-38690e8e696a4daf82c70d030be9f3c9,feels,0.337397
uuid-38690e8e696a4daf82c70d030be9f3c9,PDL1 expression,0.318206
uuid-3a76d841f3044a099a624f5fa9e04882,efficacy,0.410561
uuid-3a76d841f3044a099a624f5fa9e04882,regimen,0.325432
uuid-3a76d841f3044a099a624f5fa9e04882,chemo,0.339849
uuid-3a76d841f3044a099a624f5fa9e04882,pts,0.37693
uuid-3a76d841f3044a099a624f5fa9e04882,OS,0.632414
uuid-3a76d841f3044a099a624f5fa9e04882,response,0.57073
uuid-3a76d841f3044a099a624f5fa9e04882,data,0.40224
uuid-3a76d841f3044a099a624f5fa9e04882,PFS,0.528578
uuid-3a76d841f3044a099a624f5fa9e04882,PD1,0.300609
uuid-3a76d841f3044a099a624f5fa9e04882,ORR,0.577873
uuid-3a76d841f3044a099a624f5fa9e04882,progression,0.519998
uuid-3a76d841f3044a099a624f5fa9e04882,believes,0.302465
uuid-3a76d841f3044a099a624f5fa9e04882,impressed,0.400428
uuid-3a76d841f3044a099a624f5fa9e04882,respond,0.416899
uuid-a86cdb089f7e492aa2066a2f72eb01cf,1L,0.310547
uuid-a86cdb089f7e492aa2066a2f72eb01cf,efficacy,0.365111
uuid-a86cdb089f7e492aa2066a2f72eb01cf,regimen,0.315086
uuid-a86cdb089f7e492aa2066a2f72eb01cf,combination,0.549356
uuid-a86cdb089f7e492aa2066a2f72eb01cf,chemo,0.513506
uuid-a86cdb089f7e492aa2066a2f72eb01cf,IO,0.643228
uuid-a86cdb089f7e492aa2066a2f72eb01cf,agents,0.471037
uuid-a86cdb089f7e492aa2066a2f72eb01cf,monotherapy,0.470818
uuid-a86cdb089f7e492aa2066a2f72eb01cf,response,0.331502
uuid-a86cdb089f7e492aa2066a2f72eb01cf,combo,0.559724
uuid-a86cdb089f7e492aa2066a2f72eb01cf,PD1,0.355427
uuid-a86cdb089f7e492aa2066a2f72eb01cf,believes,0.4613
uuid-a86cdb089f7e492aa2066a2f72eb01cf,chemotherapy,0.463125
uuid-a86cdb089f7e492aa2066a2f72eb01cf,feels,0.425184
uuid-a86cdb089f7e492aa2066a2f72eb01cf,option,0.470236
uuid-e3b453db955e4a87aa32540b92a09e81,1L,0.510253
uuid-e3b453db955e4a87aa32540b92a09e81,RCC,0.388219
uuid-e3b453db955e4a87aa32540b92a09e81,chemo,0.326902
uuid-e3b453db955e4a87aa32540b92a09e81,2L,0.518877
uuid-e3b453db955e4a87aa32540b92a09e81,agents,0.412946
uuid-e3b453db955e4a87aa32540b92a09e81,preferred,0.71401
uuid-e3b453db955e4a87aa32540b92a09e81,monotherapy,0.466814
uuid-e3b453db955e4a87aa32540b92a09e81,using nivo,0.461809
uuid-e3b453db955e4a87aa32540b92a09e81,SCCHN,0.439253
uuid-e3b453db955e4a87aa32540b92a09e81,chemotherapy,0.323767
uuid-e3b453db955e4a87aa32540b92a09e81,feels,0.3304
uuid-e3b453db955e4a87aa32540b92a09e81,RTL stated,0.543939
uuid-e3b453db955e4a87aa32540b92a09e81,TL shared,0.311323
uuid-e3b453db955e4a87aa32540b92a09e81,option,0.600811
uuid-29a532fc97b141b88e0fc9994d8642cd,TL,0.355405
uuid-29a532fc97b141b88e0fc9994d8642cd,RTL,0.504294
uuid-29a532fc97b141b88e0fc9994d8642cd,NTL,0.31149
uuid-29a532fc97b141b88e0fc9994d8642cd,shared,0.303314
uuid-29a532fc97b141b88e0fc9994d8642cd,commented,0.429756
uuid-29a532fc97b141b88e0fc9994d8642cd,Merck,0.335602
uuid-29a532fc97b141b88e0fc9994d8642cd,stated,0.329037
uuid-29a532fc97b141b88e0fc9994d8642cd,approval,0.372343
uuid-29a532fc97b141b88e0fc9994d8642cd,expressed,0.305611
uuid-29a532fc97b141b88e0fc9994d8642cd,mentioned,0.592533
uuid-29a532fc97b141b88e0fc9994d8642cd,indication,0.341339
uuid-29a532fc97b141b88e0fc9994d8642cd,SCCHN,0.387895
uuid-29a532fc97b141b88e0fc9994d8642cd,HCP,0.510482
uuid-29a532fc97b141b88e0fc9994d8642cd,impressed,0.346003
uuid-29a532fc97b141b88e0fc9994d8642cd,label,0.3494
uuid-29a532fc97b141b88e0fc9994d8642cd,LTL,0.49721
uuid-29a532fc97b141b88e0fc9994d8642cd,Regional TL,0.489382
uuid-3c74e7d35e2a4354aef78fc5b4a572da,Nivo,0.548213
uuid-3c74e7d35e2a4354aef78fc5b4a572da,pembro,0.522985
uuid-3c74e7d35e2a4354aef78fc5b4a572da,1L,0.611118
uuid-3c74e7d35e2a4354aef78fc5b4a572da,efficacy,0.354969
uuid-3c74e7d35e2a4354aef78fc5b4a572da,combination,0.450154
uuid-3c74e7d35e2a4354aef78fc5b4a572da,chemo,0.572838
uuid-3c74e7d35e2a4354aef78fc5b4a572da,2L,0.551466
uuid-3c74e7d35e2a4354aef78fc5b4a572da,agents,0.466738
uuid-3c74e7d35e2a4354aef78fc5b4a572da,atezo,0.453375
uuid-3c74e7d35e2a4354aef78fc5b4a572da,preferred,0.552221
uuid-3c74e7d35e2a4354aef78fc5b4a572da,monotherapy,0.622472
uuid-3c74e7d35e2a4354aef78fc5b4a572da,using nivo,0.389346
uuid-3c74e7d35e2a4354aef78fc5b4a572da,combo,0.473302
uuid-3c74e7d35e2a4354aef78fc5b4a572da,PD1,0.35331
uuid-3c74e7d35e2a4354aef78fc5b4a572da,approved,0.376247
uuid-3c74e7d35e2a4354aef78fc5b4a572da,nivo and pembro,0.344537
uuid-3c74e7d35e2a4354aef78fc5b4a572da,believes,0.491921
uuid-3c74e7d35e2a4354aef78fc5b4a572da,chemotherapy,0.458799
uuid-3c74e7d35e2a4354aef78fc5b4a572da,feels,0.579299
uuid-3c74e7d35e2a4354aef78fc5b4a572da,option,0.668204
uuid-16ad4feaf7b84804a240c257389fccb3,Nivo,0.320812
uuid-16ad4feaf7b84804a240c257389fccb3,patients,0.710322
uuid-16ad4feaf7b84804a240c257389fccb3,Opdivo,0.341924
uuid-16ad4feaf7b84804a240c257389fccb3,therapy,0.521248
uuid-16ad4feaf7b84804a240c257389fccb3,nivolumab,0.615318
uuid-16ad4feaf7b84804a240c257389fccb3,regimen,0.565471
uuid-16ad4feaf7b84804a240c257389fccb3,treated,0.563262
uuid-16ad4feaf7b84804a240c257389fccb3,combination,0.311191
uuid-16ad4feaf7b84804a240c257389fccb3,chemo,0.401749
uuid-16ad4feaf7b84804a240c257389fccb3,pts,0.494723
uuid-16ad4feaf7b84804a240c257389fccb3,preferred,0.311163
uuid-16ad4feaf7b84804a240c257389fccb3,monotherapy,0.434849
uuid-16ad4feaf7b84804a240c257389fccb3,treatment,0.607673
uuid-16ad4feaf7b84804a240c257389fccb3,using nivo,0.375606
uuid-16ad4feaf7b84804a240c257389fccb3,PD1,0.335182
uuid-16ad4feaf7b84804a240c257389fccb3,cHL,0.323524
uuid-16ad4feaf7b84804a240c257389fccb3,progression,0.507164
uuid-16ad4feaf7b84804a240c257389fccb3,chemotherapy,0.518475
uuid-16ad4feaf7b84804a240c257389fccb3,respond,0.334091
uuid-16ad4feaf7b84804a240c257389fccb3,RTL stated,0.402771
uuid-16ad4feaf7b84804a240c257389fccb3,TL shared,0.315768
uuid-16ad4feaf7b84804a240c257389fccb3,option,0.437355
uuid-375860c3d78b46238ce80328d5e83d06,RTL,0.452438
uuid-375860c3d78b46238ce80328d5e83d06,BMS,0.384552
uuid-375860c3d78b46238ce80328d5e83d06,trial,0.486508
uuid-375860c3d78b46238ce80328d5e83d06,efficacy,0.429076
uuid-375860c3d78b46238ce80328d5e83d06,discussed,0.326299
uuid-375860c3d78b46238ce80328d5e83d06,commented,0.549503
uuid-375860c3d78b46238ce80328d5e83d06,stated,0.347251
uuid-375860c3d78b46238ce80328d5e83d06,OS,0.649261
uuid-375860c3d78b46238ce80328d5e83d06,regards,0.391805
uuid-375860c3d78b46238ce80328d5e83d06,data,0.776724
uuid-375860c3d78b46238ce80328d5e83d06,expressed,0.394221
uuid-375860c3d78b46238ce80328d5e83d06,PFS,0.60199
uuid-375860c3d78b46238ce80328d5e83d06,ORR,0.675568
uuid-375860c3d78b46238ce80328d5e83d06,ASCO,0.512239
uuid-375860c3d78b46238ce80328d5e83d06,impressed,0.8739
uuid-375860c3d78b46238ce80328d5e83d06,LTL,0.319398
uuid-375860c3d78b46238ce80328d5e83d06,TLs,0.414648
uuid-375860c3d78b46238ce80328d5e83d06,Regional TL,0.392924
uuid-025ac1b9e8bc45bcad1bc67f011e7162,pembro,0.62226
uuid-025ac1b9e8bc45bcad1bc67f011e7162,1L,0.562788
uuid-025ac1b9e8bc45bcad1bc67f011e7162,PDL1,0.619445
uuid-025ac1b9e8bc45bcad1bc67f011e7162,2L,0.485681
uuid-025ac1b9e8bc45bcad1bc67f011e7162,Merck,0.404726
uuid-025ac1b9e8bc45bcad1bc67f011e7162,PD-L1,0.619753
uuid-025ac1b9e8bc45bcad1bc67f011e7162,approval,0.436082
uuid-025ac1b9e8bc45bcad1bc67f011e7162,atezo,0.643172
uuid-025ac1b9e8bc45bcad1bc67f011e7162,preferred,0.349059
uuid-025ac1b9e8bc45bcad1bc67f011e7162,PD-L1 testing,0.463149
uuid-025ac1b9e8bc45bcad1bc67f011e7162,testing,0.552345
uuid-025ac1b9e8bc45bcad1bc67f011e7162,PDL1 testing,0.514576
uuid-025ac1b9e8bc45bcad1bc67f011e7162,indication,0.342801
uuid-025ac1b9e8bc45bcad1bc67f011e7162,NSCLC patients,0.432651
uuid-025ac1b9e8bc45bcad1bc67f011e7162,approved,0.387543
uuid-025ac1b9e8bc45bcad1bc67f011e7162,nivo and pembro,0.466876
uuid-025ac1b9e8bc45bcad1bc67f011e7162,assay,0.569386
uuid-025ac1b9e8bc45bcad1bc67f011e7162,PDL1 expression,0.541848
uuid-025ac1b9e8bc45bcad1bc67f011e7162,biomarker,0.384145
uuid-025ac1b9e8bc45bcad1bc67f011e7162,bladder,0.304365
uuid-6991d7aac884465891b2f22b0417512b,patients,0.527025
uuid-6991d7aac884465891b2f22b0417512b,TL stated,0.348529
uuid-6991d7aac884465891b2f22b0417512b,pts,0.380488
uuid-6991d7aac884465891b2f22b0417512b,PD-L1,0.474313
uuid-6991d7aac884465891b2f22b0417512b,PD-L1 testing,0.395809
uuid-6991d7aac884465891b2f22b0417512b,testing,0.605992
uuid-6991d7aac884465891b2f22b0417512b,PDL1 testing,0.552017
uuid-6991d7aac884465891b2f22b0417512b,NSCLC patients,0.782207
uuid-6991d7aac884465891b2f22b0417512b,progression,0.302931
uuid-6991d7aac884465891b2f22b0417512b,tumor types,0.476327
uuid-f8976d8d3ff742a0b74beace5a6ce597,therapy,0.305953
uuid-f8976d8d3ff742a0b74beace5a6ce597,trial,0.456572
uuid-f8976d8d3ff742a0b74beace5a6ce597,combination,0.389789
uuid-f8976d8d3ff742a0b74beace5a6ce597,chemo,0.395472
uuid-f8976d8d3ff742a0b74beace5a6ce597,pts,0.433549
uuid-f8976d8d3ff742a0b74beace5a6ce597,response,0.371457
uuid-f8976d8d3ff742a0b74beace5a6ce597,combo,0.382144
uuid-f8976d8d3ff742a0b74beace5a6ce597,PD1,0.375063
uuid-f8976d8d3ff742a0b74beace5a6ce597,progression,0.384214
uuid-f8976d8d3ff742a0b74beace5a6ce597,believes,0.403739
uuid-f8976d8d3ff742a0b74beace5a6ce597,chemotherapy,0.388811
uuid-f8976d8d3ff742a0b74beace5a6ce597,respond,0.315566
uuid-f8976d8d3ff742a0b74beace5a6ce597,feels,0.396469
uuid-b243503b3f7f4ca6989b63d003ec889b,treatment,0.341246
uuid-b243503b3f7f4ca6989b63d003ec889b,progression,0.309792
uuid-d5e8d7242955471bbf1e003352878225,BMS,0.422516
uuid-d5e8d7242955471bbf1e003352878225,trial,0.612576
uuid-d5e8d7242955471bbf1e003352878225,efficacy,0.446914
uuid-d5e8d7242955471bbf1e003352878225,OS,0.751413
uuid-d5e8d7242955471bbf1e003352878225,regards,0.335491
uuid-d5e8d7242955471bbf1e003352878225,data,0.634072
uuid-d5e8d7242955471bbf1e003352878225,PFS,0.742831
uuid-d5e8d7242955471bbf1e003352878225,ORR,0.720843
uuid-d5e8d7242955471bbf1e003352878225,ASCO,0.431638
uuid-d5e8d7242955471bbf1e003352878225,impressed,0.511193
uuid-d5e8d7242955471bbf1e003352878225,PDL1 expression,0.309212
uuid-a80e320e09d04f1e8bfe84575f9c0823,Nivo,0.3372
uuid-a80e320e09d04f1e8bfe84575f9c0823,patients,0.894761
uuid-a80e320e09d04f1e8bfe84575f9c0823,Opdivo,0.48311
uuid-a80e320e09d04f1e8bfe84575f9c0823,therapy,0.657
uuid-a80e320e09d04f1e8bfe84575f9c0823,nivolumab,0.584198
uuid-a80e320e09d04f1e8bfe84575f9c0823,regimen,0.442129
uuid-a80e320e09d04f1e8bfe84575f9c0823,treated,0.535361
uuid-a80e320e09d04f1e8bfe84575f9c0823,chemo,0.350713
uuid-a80e320e09d04f1e8bfe84575f9c0823,2L,0.306587
uuid-a80e320e09d04f1e8bfe84575f9c0823,pts,0.490727
uuid-a80e320e09d04f1e8bfe84575f9c0823,approval,0.328849
uuid-a80e320e09d04f1e8bfe84575f9c0823,preferred,0.383983
uuid-a80e320e09d04f1e8bfe84575f9c0823,monotherapy,0.435239
uuid-a80e320e09d04f1e8bfe84575f9c0823,treatment,0.673221
uuid-a80e320e09d04f1e8bfe84575f9c0823,using nivo,0.479568
uuid-a80e320e09d04f1e8bfe84575f9c0823,PD1,0.305016
uuid-a80e320e09d04f1e8bfe84575f9c0823,cHL,0.40762
uuid-a80e320e09d04f1e8bfe84575f9c0823,progression,0.519517
uuid-a80e320e09d04f1e8bfe84575f9c0823,chemotherapy,0.432146
uuid-a80e320e09d04f1e8bfe84575f9c0823,respond,0.383443
uuid-a80e320e09d04f1e8bfe84575f9c0823,RTL stated,0.342744
uuid-a80e320e09d04f1e8bfe84575f9c0823,option,0.501952
uuid-67d82ff51cd542019937fcb14794af7b,patients,0.517021
uuid-67d82ff51cd542019937fcb14794af7b,Opdivo,0.370799
uuid-67d82ff51cd542019937fcb14794af7b,therapy,0.574343
uuid-67d82ff51cd542019937fcb14794af7b,nivolumab,0.409109
uuid-67d82ff51cd542019937fcb14794af7b,treated,0.344953
uuid-67d82ff51cd542019937fcb14794af7b,treatment,0.379793
uuid-67d82ff51cd542019937fcb14794af7b,cHL,0.738722
uuid-04b531d1d2eb41af81048a90806e3b38,Nivo,0.317195
uuid-04b531d1d2eb41af81048a90806e3b38,patients,0.775783
uuid-04b531d1d2eb41af81048a90806e3b38,Opdivo,0.527211
uuid-04b531d1d2eb41af81048a90806e3b38,therapy,0.591879
uuid-04b531d1d2eb41af81048a90806e3b38,nivolumab,0.469359
uuid-04b531d1d2eb41af81048a90806e3b38,1L,0.309645
uuid-04b531d1d2eb41af81048a90806e3b38,regimen,0.342939
uuid-04b531d1d2eb41af81048a90806e3b38,treated,0.366386
uuid-04b531d1d2eb41af81048a90806e3b38,2L,0.35901
uuid-04b531d1d2eb41af81048a90806e3b38,pts,0.463444
uuid-04b531d1d2eb41af81048a90806e3b38,approval,0.446573
uuid-04b531d1d2eb41af81048a90806e3b38,preferred,0.402693
uuid-04b531d1d2eb41af81048a90806e3b38,monotherapy,0.417188
uuid-04b531d1d2eb41af81048a90806e3b38,treatment,0.533658
uuid-04b531d1d2eb41af81048a90806e3b38,using nivo,0.476258
uuid-04b531d1d2eb41af81048a90806e3b38,approved,0.42957
uuid-04b531d1d2eb41af81048a90806e3b38,cHL,0.355527
uuid-04b531d1d2eb41af81048a90806e3b38,progression,0.436218
uuid-04b531d1d2eb41af81048a90806e3b38,chemotherapy,0.363092
uuid-04b531d1d2eb41af81048a90806e3b38,option,0.546765
uuid-4a6f47f67be548749b7a9c0d3e7588bf,physicians,0.445897
uuid-4a6f47f67be548749b7a9c0d3e7588bf,ASCO,0.331773
uuid-4a6f47f67be548749b7a9c0d3e7588bf,oncologist,0.312213
uuid-4a6f47f67be548749b7a9c0d3e7588bf,indicated,0.329753
uuid-4a6f47f67be548749b7a9c0d3e7588bf,Regional TL,0.454905
uuid-cb7f600231a147cd933ad0e21cb95830,patients,0.499294
uuid-cb7f600231a147cd933ad0e21cb95830,Opdivo,0.46152
uuid-cb7f600231a147cd933ad0e21cb95830,therapy,0.324324
uuid-cb7f600231a147cd933ad0e21cb95830,physicians,0.388843
uuid-cb7f600231a147cd933ad0e21cb95830,treatment,0.456025
uuid-cb7f600231a147cd933ad0e21cb95830,progression,0.30516
uuid-cb7f600231a147cd933ad0e21cb95830,oncologist,0.329238
uuid-cb7f600231a147cd933ad0e21cb95830,drug,0.420378
uuid-19cd32058fea4cdfbb88f381159dfde1,patients,0.662164
uuid-19cd32058fea4cdfbb88f381159dfde1,therapy,0.30885
uuid-19cd32058fea4cdfbb88f381159dfde1,nivolumab,0.395353
uuid-19cd32058fea4cdfbb88f381159dfde1,toxicity,0.448728
uuid-19cd32058fea4cdfbb88f381159dfde1,regimen,0.621063
uuid-19cd32058fea4cdfbb88f381159dfde1,treated,0.600305
uuid-19cd32058fea4cdfbb88f381159dfde1,pts,0.551526
uuid-19cd32058fea4cdfbb88f381159dfde1,monotherapy,0.302845
uuid-19cd32058fea4cdfbb88f381159dfde1,treatment,0.525133
uuid-19cd32058fea4cdfbb88f381159dfde1,response,0.483884
uuid-19cd32058fea4cdfbb88f381159dfde1,progression,0.58076
uuid-19cd32058fea4cdfbb88f381159dfde1,impressed,0.332976
uuid-19cd32058fea4cdfbb88f381159dfde1,respond,0.542091
uuid-f4cc44cb5aed49faa339e8642645fa24,PDL1,0.35493
uuid-f4cc44cb5aed49faa339e8642645fa24,TL stated,0.363119
uuid-f4cc44cb5aed49faa339e8642645fa24,PD-L1,0.62728
uuid-f4cc44cb5aed49faa339e8642645fa24,PD-L1 testing,0.608119
uuid-f4cc44cb5aed49faa339e8642645fa24,testing,0.791252
uuid-f4cc44cb5aed49faa339e8642645fa24,PDL1 testing,0.720064
uuid-f4cc44cb5aed49faa339e8642645fa24,NSCLC patients,0.687796
uuid-f4cc44cb5aed49faa339e8642645fa24,tumor types,0.320371
uuid-f4cc44cb5aed49faa339e8642645fa24,assay,0.352176
uuid-f4cc44cb5aed49faa339e8642645fa24,biomarker,0.515715
uuid-0ff04d77dfa74d1b9054231eea29fb0f,cHL,0.33516
uuid-068ec76f3d534d91bf0b7e951706abfb,trial,0.349544
uuid-068ec76f3d534d91bf0b7e951706abfb,efficacy,0.545393
uuid-068ec76f3d534d91bf0b7e951706abfb,regimen,0.364696
uuid-068ec76f3d534d91bf0b7e951706abfb,commented,0.348999
uuid-068ec76f3d534d91bf0b7e951706abfb,Ipi,0.362453
uuid-068ec76f3d534d91bf0b7e951706abfb,OS,0.631485
uuid-068ec76f3d534d91bf0b7e951706abfb,data,0.666196
uuid-068ec76f3d534d91bf0b7e951706abfb,combo,0.355649
uuid-068ec76f3d534d91bf0b7e951706abfb,PFS,0.534148
uuid-068ec76f3d534d91bf0b7e951706abfb,ORR,0.618002
uuid-068ec76f3d534d91bf0b7e951706abfb,ASCO,0.383768
uuid-068ec76f3d534d91bf0b7e951706abfb,impressed,0.745388
uuid-068ec76f3d534d91bf0b7e951706abfb,SCLC,0.324057
uuid-068ec76f3d534d91bf0b7e951706abfb,feels,0.406778
uuid-2edabe8a067446209bcc4b57dfabd0b8,patients,0.897637
uuid-2edabe8a067446209bcc4b57dfabd0b8,Opdivo,0.456768
uuid-2edabe8a067446209bcc4b57dfabd0b8,therapy,0.611096
uuid-2edabe8a067446209bcc4b57dfabd0b8,nivolumab,0.531254
uuid-2edabe8a067446209bcc4b57dfabd0b8,regimen,0.614609
uuid-2edabe8a067446209bcc4b57dfabd0b8,treated,0.675835
uuid-2edabe8a067446209bcc4b57dfabd0b8,chemo,0.384055
uuid-2edabe8a067446209bcc4b57dfabd0b8,pts,0.655249
uuid-2edabe8a067446209bcc4b57dfabd0b8,monotherapy,0.444254
uuid-2edabe8a067446209bcc4b57dfabd0b8,treatment,0.73674
uuid-2edabe8a067446209bcc4b57dfabd0b8,response,0.431722
uuid-2edabe8a067446209bcc4b57dfabd0b8,PD1,0.387847
uuid-2edabe8a067446209bcc4b57dfabd0b8,cHL,0.308346
uuid-2edabe8a067446209bcc4b57dfabd0b8,progression,0.729308
uuid-2edabe8a067446209bcc4b57dfabd0b8,chemotherapy,0.412054
uuid-2edabe8a067446209bcc4b57dfabd0b8,respond,0.561443
uuid-2edabe8a067446209bcc4b57dfabd0b8,option,0.387224
uuid-a19c6933ca714f7d9ab5215f14b086d7,lung,0.40194
uuid-a19c6933ca714f7d9ab5215f14b086d7,melanoma,0.366666
uuid-a19c6933ca714f7d9ab5215f14b086d7,shared,0.348737
uuid-a19c6933ca714f7d9ab5215f14b086d7,RCC,0.377301
uuid-a19c6933ca714f7d9ab5215f14b086d7,institution,0.39976
uuid-a19c6933ca714f7d9ab5215f14b086d7,physicians,0.319205
uuid-a19c6933ca714f7d9ab5215f14b086d7,PDL1 testing,0.312052
uuid-a19c6933ca714f7d9ab5215f14b086d7,AI,0.449629
uuid-a19c6933ca714f7d9ab5215f14b086d7,oncology,0.448766
uuid-a19c6933ca714f7d9ab5215f14b086d7,oncologist,0.446686
uuid-a19c6933ca714f7d9ab5215f14b086d7,clinical,0.327617
uuid-a19c6933ca714f7d9ab5215f14b086d7,TL shared,0.309043
uuid-bc38ea20ce2e4edea2bfbe0364fb4c70,physicians,0.416761
uuid-bc38ea20ce2e4edea2bfbe0364fb4c70,oncology,0.37393
uuid-7a15c95828d34bf28a84868d1adb2c82,RTL,0.348886
uuid-7a15c95828d34bf28a84868d1adb2c82,BMS,0.456466
uuid-7a15c95828d34bf28a84868d1adb2c82,1L,0.319168
uuid-7a15c95828d34bf28a84868d1adb2c82,trial,0.356862
uuid-7a15c95828d34bf28a84868d1adb2c82,shared,0.305737
uuid-7a15c95828d34bf28a84868d1adb2c82,RCC,0.468774
uuid-7a15c95828d34bf28a84868d1adb2c82,combination,0.41622
uuid-7a15c95828d34bf28a84868d1adb2c82,2L,0.41379
uuid-7a15c95828d34bf28a84868d1adb2c82,agents,0.391618
uuid-7a15c95828d34bf28a84868d1adb2c82,Merck,0.351582
uuid-7a15c95828d34bf28a84868d1adb2c82,stated,0.474253
uuid-7a15c95828d34bf28a84868d1adb2c82,atezo,0.349254
uuid-7a15c95828d34bf28a84868d1adb2c82,preferred,0.327998
uuid-7a15c95828d34bf28a84868d1adb2c82,using nivo,0.373456
uuid-7a15c95828d34bf28a84868d1adb2c82,combo,0.43597
uuid-7a15c95828d34bf28a84868d1adb2c82,expressed,0.407062
uuid-7a15c95828d34bf28a84868d1adb2c82,clinical trials,0.422519
uuid-7a15c95828d34bf28a84868d1adb2c82,indication,0.313371
uuid-7a15c95828d34bf28a84868d1adb2c82,approved,0.438573
uuid-7a15c95828d34bf28a84868d1adb2c82,SCCHN,0.37401
uuid-7a15c95828d34bf28a84868d1adb2c82,impressed,0.339891
uuid-7a15c95828d34bf28a84868d1adb2c82,tumor types,0.305766
uuid-7a15c95828d34bf28a84868d1adb2c82,LTL,0.362109
uuid-7a15c95828d34bf28a84868d1adb2c82,TLs,0.389648
uuid-7a15c95828d34bf28a84868d1adb2c82,feels,0.330906
uuid-7a15c95828d34bf28a84868d1adb2c82,Regional TL,0.370144
uuid-7a15c95828d34bf28a84868d1adb2c82,RTL stated,0.408807
uuid-7a15c95828d34bf28a84868d1adb2c82,bladder,0.475082
uuid-33979ee5b4a24cc8bad0c976f603fdd5,Nivo,0.496713
uuid-33979ee5b4a24cc8bad0c976f603fdd5,Opdivo,0.449101
uuid-33979ee5b4a24cc8bad0c976f603fdd5,pembro,0.428561
uuid-33979ee5b4a24cc8bad0c976f603fdd5,dose,0.59158
uuid-33979ee5b4a24cc8bad0c976f603fdd5,Ipi,0.336087
uuid-33979ee5b4a24cc8bad0c976f603fdd5,atezo,0.356971
uuid-33979ee5b4a24cc8bad0c976f603fdd5,indication,0.37389
uuid-33979ee5b4a24cc8bad0c976f603fdd5,vs,0.443034
uuid-33979ee5b4a24cc8bad0c976f603fdd5,label,0.302327
uuid-33979ee5b4a24cc8bad0c976f603fdd5,drug,0.517087
uuid-33979ee5b4a24cc8bad0c976f603fdd5,Keytruda,0.514527
uuid-33979ee5b4a24cc8bad0c976f603fdd5,flat dosing,0.645936
uuid-31329aac9f314947995501bb7844e3a5,patients,0.535788
uuid-31329aac9f314947995501bb7844e3a5,therapy,0.56614
uuid-31329aac9f314947995501bb7844e3a5,1L,0.358832
uuid-31329aac9f314947995501bb7844e3a5,regimen,0.537468
uuid-31329aac9f314947995501bb7844e3a5,treated,0.362383
uuid-31329aac9f314947995501bb7844e3a5,combination,0.468813
uuid-31329aac9f314947995501bb7844e3a5,chemo,0.665922
uuid-31329aac9f314947995501bb7844e3a5,pts,0.58248
uuid-31329aac9f314947995501bb7844e3a5,IO,0.682847
uuid-31329aac9f314947995501bb7844e3a5,monotherapy,0.617606
uuid-31329aac9f314947995501bb7844e3a5,treatment,0.548668
uuid-31329aac9f314947995501bb7844e3a5,response,0.680577
uuid-31329aac9f314947995501bb7844e3a5,combo,0.46375
uuid-31329aac9f314947995501bb7844e3a5,PD1,0.52329
uuid-31329aac9f314947995501bb7844e3a5,progression,0.730545
uuid-31329aac9f314947995501bb7844e3a5,believes,0.339111
uuid-31329aac9f314947995501bb7844e3a5,chemotherapy,0.519709
uuid-31329aac9f314947995501bb7844e3a5,respond,0.544974
uuid-31329aac9f314947995501bb7844e3a5,option,0.520535
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,patients,0.487564
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,Opdivo,0.31058
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,nivolumab,0.36879
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,regimen,0.339339
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,treated,0.351747
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,RCC,0.386427
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,pts,0.308755
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,approval,0.386151
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,using nivo,0.437056
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,clinical trials,0.31471
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,SCCHN,0.370575
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,impressed,0.453268
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,Regional TL,0.323907
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,RTL stated,0.371849
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,TL shared,0.338774
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,option,0.305668
uuid-4896a5d5ddda4f1fa85541c2cc8fea04,bladder,0.38128
uuid-8cc652aa9c274430b36cb339af80aeee,TL,0.401758
uuid-8cc652aa9c274430b36cb339af80aeee,RTL,0.420655
uuid-8cc652aa9c274430b36cb339af80aeee,BMS,0.462305
uuid-8cc652aa9c274430b36cb339af80aeee,PDL1,0.344539
uuid-8cc652aa9c274430b36cb339af80aeee,discussed,0.324104
uuid-8cc652aa9c274430b36cb339af80aeee,commented,0.522895
uuid-8cc652aa9c274430b36cb339af80aeee,TL stated,0.34666
uuid-8cc652aa9c274430b36cb339af80aeee,Merck,0.518262
uuid-8cc652aa9c274430b36cb339af80aeee,stated,0.470759
uuid-8cc652aa9c274430b36cb339af80aeee,atezo,0.301965
uuid-8cc652aa9c274430b36cb339af80aeee,regards,0.347162
uuid-8cc652aa9c274430b36cb339af80aeee,data,0.557996
uuid-8cc652aa9c274430b36cb339af80aeee,expressed,0.463878
uuid-8cc652aa9c274430b36cb339af80aeee,PDL1 testing,0.307379
uuid-8cc652aa9c274430b36cb339af80aeee,SCCHN,0.40908
uuid-8cc652aa9c274430b36cb339af80aeee,ASCO,0.304491
uuid-8cc652aa9c274430b36cb339af80aeee,impressed,0.49793
uuid-8cc652aa9c274430b36cb339af80aeee,LTL,0.337026
uuid-8cc652aa9c274430b36cb339af80aeee,TLs,0.614763
uuid-8cc652aa9c274430b36cb339af80aeee,academic,0.31815
uuid-8cc652aa9c274430b36cb339af80aeee,assay,0.391232
uuid-8cc652aa9c274430b36cb339af80aeee,Regional TL,0.424172
uuid-8cc652aa9c274430b36cb339af80aeee,PDL1 expression,0.31179
uuid-8cc652aa9c274430b36cb339af80aeee,bladder,0.416138
uuid-749a64965e624878b48616bb7f48840b,toxicity,0.47864
uuid-91511f1f0b49473bb90de9e772678361,Nivo,0.366868
uuid-91511f1f0b49473bb90de9e772678361,patients,0.874271
uuid-91511f1f0b49473bb90de9e772678361,Opdivo,0.4608
uuid-91511f1f0b49473bb90de9e772678361,therapy,0.567782
uuid-91511f1f0b49473bb90de9e772678361,nivolumab,0.537059
uuid-91511f1f0b49473bb90de9e772678361,regimen,0.570507
uuid-91511f1f0b49473bb90de9e772678361,treated,0.58641
uuid-91511f1f0b49473bb90de9e772678361,chemo,0.433214
uuid-91511f1f0b49473bb90de9e772678361,pts,0.597267
uuid-91511f1f0b49473bb90de9e772678361,preferred,0.353865
uuid-91511f1f0b49473bb90de9e772678361,monotherapy,0.468351
uuid-91511f1f0b49473bb90de9e772678361,treatment,0.716577
uuid-91511f1f0b49473bb90de9e772678361,using nivo,0.428052
uuid-91511f1f0b49473bb90de9e772678361,response,0.35266
uuid-91511f1f0b49473bb90de9e772678361,PD1,0.328429
uuid-91511f1f0b49473bb90de9e772678361,progression,0.623173
uuid-91511f1f0b49473bb90de9e772678361,chemotherapy,0.439209
uuid-91511f1f0b49473bb90de9e772678361,respond,0.519455
uuid-91511f1f0b49473bb90de9e772678361,RTL stated,0.359312
uuid-91511f1f0b49473bb90de9e772678361,option,0.483259
uuid-e2d8e8154fc84e8685375700a8f4c457,Nivo,0.364272
uuid-e2d8e8154fc84e8685375700a8f4c457,trial,0.472868
uuid-e2d8e8154fc84e8685375700a8f4c457,combination,0.517765
uuid-e2d8e8154fc84e8685375700a8f4c457,chemo,0.493207
uuid-e2d8e8154fc84e8685375700a8f4c457,IO,0.345984
uuid-e2d8e8154fc84e8685375700a8f4c457,monotherapy,0.373064
uuid-e2d8e8154fc84e8685375700a8f4c457,combo,0.518025
uuid-e2d8e8154fc84e8685375700a8f4c457,clinical trials,0.336284
uuid-e2d8e8154fc84e8685375700a8f4c457,PD1,0.338426
uuid-e2d8e8154fc84e8685375700a8f4c457,believes,0.331808
uuid-e2d8e8154fc84e8685375700a8f4c457,chemotherapy,0.492133
uuid-e2d8e8154fc84e8685375700a8f4c457,feels,0.418347
uuid-e2d8e8154fc84e8685375700a8f4c457,RTL stated,0.303632
uuid-e2d8e8154fc84e8685375700a8f4c457,option,0.310206
uuid-e2d8e8154fc84e8685375700a8f4c457,bladder,0.365587
uuid-1c2f35b845574fde9678cf62a40ac4b2,RCC,0.327625
uuid-1c2f35b845574fde9678cf62a40ac4b2,preferred,0.484253
uuid-1c2f35b845574fde9678cf62a40ac4b2,SCCHN,0.566172
uuid-1c2f35b845574fde9678cf62a40ac4b2,RTL stated,0.422657
uuid-1c2f35b845574fde9678cf62a40ac4b2,TL shared,0.315227
uuid-1c2f35b845574fde9678cf62a40ac4b2,option,0.349954
uuid-5edeef3cd47844438cc2197ecf92cfda,Nivo,0.473064
uuid-5edeef3cd47844438cc2197ecf92cfda,pembro,0.498575
uuid-5edeef3cd47844438cc2197ecf92cfda,1L,0.607727
uuid-5edeef3cd47844438cc2197ecf92cfda,trial,0.43887
uuid-5edeef3cd47844438cc2197ecf92cfda,RCC,0.375611
uuid-5edeef3cd47844438cc2197ecf92cfda,combination,0.393178
uuid-5edeef3cd47844438cc2197ecf92cfda,chemo,0.363675
uuid-5edeef3cd47844438cc2197ecf92cfda,2L,0.536458
uuid-5edeef3cd47844438cc2197ecf92cfda,pts,0.346369
uuid-5edeef3cd47844438cc2197ecf92cfda,stated,0.348151
uuid-5edeef3cd47844438cc2197ecf92cfda,approval,0.445153
uuid-5edeef3cd47844438cc2197ecf92cfda,atezo,0.357037
uuid-5edeef3cd47844438cc2197ecf92cfda,preferred,0.4601
uuid-5edeef3cd47844438cc2197ecf92cfda,monotherapy,0.520334
uuid-5edeef3cd47844438cc2197ecf92cfda,using nivo,0.504625
uuid-5edeef3cd47844438cc2197ecf92cfda,data,0.326668
uuid-5edeef3cd47844438cc2197ecf92cfda,combo,0.468526
uuid-5edeef3cd47844438cc2197ecf92cfda,clinical trials,0.452911
uuid-5edeef3cd47844438cc2197ecf92cfda,indication,0.345643
uuid-5edeef3cd47844438cc2197ecf92cfda,PD1,0.333994
uuid-5edeef3cd47844438cc2197ecf92cfda,approved,0.509944
uuid-5edeef3cd47844438cc2197ecf92cfda,SCCHN,0.411739
uuid-5edeef3cd47844438cc2197ecf92cfda,chemotherapy,0.380267
uuid-5edeef3cd47844438cc2197ecf92cfda,impressed,0.368051
uuid-5edeef3cd47844438cc2197ecf92cfda,SCLC,0.355951
uuid-5edeef3cd47844438cc2197ecf92cfda,feels,0.42765
uuid-5edeef3cd47844438cc2197ecf92cfda,RTL stated,0.457898
uuid-5edeef3cd47844438cc2197ecf92cfda,option,0.550432
uuid-5edeef3cd47844438cc2197ecf92cfda,bladder,0.399029
uuid-03a929b3338a4f33941e487da840bbcc,Nivo,0.360194
uuid-03a929b3338a4f33941e487da840bbcc,patients,0.687643
uuid-03a929b3338a4f33941e487da840bbcc,Opdivo,0.302853
uuid-03a929b3338a4f33941e487da840bbcc,therapy,0.503254
uuid-03a929b3338a4f33941e487da840bbcc,nivolumab,0.529538
uuid-03a929b3338a4f33941e487da840bbcc,1L,0.32704
uuid-03a929b3338a4f33941e487da840bbcc,regimen,0.426936
uuid-03a929b3338a4f33941e487da840bbcc,treated,0.430539
uuid-03a929b3338a4f33941e487da840bbcc,RCC,0.307642
uuid-03a929b3338a4f33941e487da840bbcc,combination,0.367946
uuid-03a929b3338a4f33941e487da840bbcc,chemo,0.370872
uuid-03a929b3338a4f33941e487da840bbcc,2L,0.362582
uuid-03a929b3338a4f33941e487da840bbcc,pts,0.540267
uuid-03a929b3338a4f33941e487da840bbcc,approval,0.351974
uuid-03a929b3338a4f33941e487da840bbcc,preferred,0.408397
uuid-03a929b3338a4f33941e487da840bbcc,monotherapy,0.468858
uuid-03a929b3338a4f33941e487da840bbcc,treatment,0.479727
uuid-03a929b3338a4f33941e487da840bbcc,using nivo,0.48732
uuid-03a929b3338a4f33941e487da840bbcc,combo,0.362654
uuid-03a929b3338a4f33941e487da840bbcc,PD1,0.330059
uuid-03a929b3338a4f33941e487da840bbcc,approved,0.40201
uuid-03a929b3338a4f33941e487da840bbcc,progression,0.483978
uuid-03a929b3338a4f33941e487da840bbcc,chemotherapy,0.372302
uuid-03a929b3338a4f33941e487da840bbcc,respond,0.324225
uuid-03a929b3338a4f33941e487da840bbcc,RTL stated,0.406098
uuid-03a929b3338a4f33941e487da840bbcc,option,0.498897
uuid-5ab14114873a4818a59045ad2a59438e,patients,0.416258
uuid-5ab14114873a4818a59045ad2a59438e,therapy,0.397021
uuid-5ab14114873a4818a59045ad2a59438e,regimen,0.436072
uuid-5ab14114873a4818a59045ad2a59438e,treated,0.410784
uuid-5ab14114873a4818a59045ad2a59438e,combination,0.389446
uuid-5ab14114873a4818a59045ad2a59438e,chemo,0.358962
uuid-5ab14114873a4818a59045ad2a59438e,tumor,0.441881
uuid-5ab14114873a4818a59045ad2a59438e,pts,0.496966
uuid-5ab14114873a4818a59045ad2a59438e,IO,0.399305
uuid-5ab14114873a4818a59045ad2a59438e,monotherapy,0.363652
uuid-5ab14114873a4818a59045ad2a59438e,treatment,0.399681
uuid-5ab14114873a4818a59045ad2a59438e,response,0.4677
uuid-5ab14114873a4818a59045ad2a59438e,combo,0.417564
uuid-5ab14114873a4818a59045ad2a59438e,PD1,0.378957
uuid-5ab14114873a4818a59045ad2a59438e,progression,0.60506
uuid-5ab14114873a4818a59045ad2a59438e,chemotherapy,0.327312
uuid-5ab14114873a4818a59045ad2a59438e,respond,0.338471
uuid-c7eb7c32ea254a47851f16f48335010d,institution,0.322595
uuid-c7eb7c32ea254a47851f16f48335010d,physicians,0.39959
uuid-c7eb7c32ea254a47851f16f48335010d,oncology,0.564423
uuid-c7eb7c32ea254a47851f16f48335010d,drug,0.670817
uuid-c7eb7c32ea254a47851f16f48335010d,clinical,0.354316
uuid-75c1736a4670480eb7335584c17e050b,Nivo,0.312768
uuid-75c1736a4670480eb7335584c17e050b,patients,0.896319
uuid-75c1736a4670480eb7335584c17e050b,Opdivo,0.427792
uuid-75c1736a4670480eb7335584c17e050b,therapy,0.689859
uuid-75c1736a4670480eb7335584c17e050b,nivolumab,0.525926
uuid-75c1736a4670480eb7335584c17e050b,regimen,0.381752
uuid-75c1736a4670480eb7335584c17e050b,treated,0.531116
uuid-75c1736a4670480eb7335584c17e050b,chemo,0.325822
uuid-75c1736a4670480eb7335584c17e050b,pts,0.514817
uuid-75c1736a4670480eb7335584c17e050b,monotherapy,0.354284
uuid-75c1736a4670480eb7335584c17e050b,treatment,0.633433
uuid-75c1736a4670480eb7335584c17e050b,using nivo,0.381452
uuid-75c1736a4670480eb7335584c17e050b,response,0.336517
uuid-75c1736a4670480eb7335584c17e050b,cHL,0.467677
uuid-75c1736a4670480eb7335584c17e050b,progression,0.605285
uuid-75c1736a4670480eb7335584c17e050b,chemotherapy,0.411789
uuid-75c1736a4670480eb7335584c17e050b,respond,0.422981
uuid-75c1736a4670480eb7335584c17e050b,option,0.35061
uuid-f871bd1df76c4acda3379160e6ca02aa,patients,0.332753
uuid-f871bd1df76c4acda3379160e6ca02aa,lung,0.36854
uuid-f871bd1df76c4acda3379160e6ca02aa,treated,0.659526
uuid-f871bd1df76c4acda3379160e6ca02aa,melanoma,0.391902
uuid-f871bd1df76c4acda3379160e6ca02aa,RCC,0.451239
uuid-f871bd1df76c4acda3379160e6ca02aa,TL stated,0.602557
uuid-f871bd1df76c4acda3379160e6ca02aa,PDL1 testing,0.346052
uuid-f871bd1df76c4acda3379160e6ca02aa,NSCLC patients,0.457919
uuid-f871bd1df76c4acda3379160e6ca02aa,SCCHN,0.337845
uuid-f871bd1df76c4acda3379160e6ca02aa,RTL stated,0.428831
uuid-f871bd1df76c4acda3379160e6ca02aa,TL shared,0.601903
uuid-725df679a6c34ba29f2be155bf308167,dose,0.499934
uuid-725df679a6c34ba29f2be155bf308167,toxicity,0.463937
uuid-725df679a6c34ba29f2be155bf308167,Ipi,0.445063
uuid-68079045a7c94c97832957a32f38c8f8,Nivo,0.553082
uuid-68079045a7c94c97832957a32f38c8f8,pembro,0.562797
uuid-68079045a7c94c97832957a32f38c8f8,1L,0.626737
uuid-68079045a7c94c97832957a32f38c8f8,PDL1,0.367271
uuid-68079045a7c94c97832957a32f38c8f8,efficacy,0.451004
uuid-68079045a7c94c97832957a32f38c8f8,regimen,0.346895
uuid-68079045a7c94c97832957a32f38c8f8,combination,0.439698
uuid-68079045a7c94c97832957a32f38c8f8,chemo,0.555008
uuid-68079045a7c94c97832957a32f38c8f8,2L,0.551447
uuid-68079045a7c94c97832957a32f38c8f8,pts,0.36757
uuid-68079045a7c94c97832957a32f38c8f8,IO,0.30204
uuid-68079045a7c94c97832957a32f38c8f8,agents,0.422769
uuid-68079045a7c94c97832957a32f38c8f8,Ipi,0.397245
uuid-68079045a7c94c97832957a32f38c8f8,atezo,0.507147
uuid-68079045a7c94c97832957a32f38c8f8,preferred,0.494012
uuid-68079045a7c94c97832957a32f38c8f8,monotherapy,0.66287
uuid-68079045a7c94c97832957a32f38c8f8,using nivo,0.363972
uuid-68079045a7c94c97832957a32f38c8f8,combo,0.554207
uuid-68079045a7c94c97832957a32f38c8f8,PD1,0.40967
uuid-68079045a7c94c97832957a32f38c8f8,approved,0.309765
uuid-68079045a7c94c97832957a32f38c8f8,nivo and pembro,0.433974
uuid-68079045a7c94c97832957a32f38c8f8,believes,0.515778
uuid-68079045a7c94c97832957a32f38c8f8,chemotherapy,0.407476
uuid-68079045a7c94c97832957a32f38c8f8,vs,0.347009
uuid-68079045a7c94c97832957a32f38c8f8,feels,0.450106
uuid-68079045a7c94c97832957a32f38c8f8,option,0.583279
uuid-f9fe79df7b24403eb7c01a5f30f04255,Opdivo,0.375033
uuid-f9fe79df7b24403eb7c01a5f30f04255,dose,0.305531
uuid-f9fe79df7b24403eb7c01a5f30f04255,efficacy,0.43658
uuid-f9fe79df7b24403eb7c01a5f30f04255,data,0.345268
uuid-f9fe79df7b24403eb7c01a5f30f04255,vs,0.337078
uuid-f9fe79df7b24403eb7c01a5f30f04255,Keytruda,0.355397
uuid-f9fe79df7b24403eb7c01a5f30f04255,flat dosing,0.321255
uuid-d95d5ef14f3f4ccf96cf51c58daccd46,patients,0.312063
uuid-d95d5ef14f3f4ccf96cf51c58daccd46,Opdivo,0.305675
uuid-d95d5ef14f3f4ccf96cf51c58daccd46,toxicity,0.394821
uuid-d95d5ef14f3f4ccf96cf51c58daccd46,regimen,0.558682
uuid-d95d5ef14f3f4ccf96cf51c58daccd46,treated,0.375486
uuid-d95d5ef14f3f4ccf96cf51c58daccd46,melanoma,0.482456
uuid-d95d5ef14f3f4ccf96cf51c58daccd46,physicians,0.330863
uuid-d95d5ef14f3f4ccf96cf51c58daccd46,treatment,0.531622
uuid-d95d5ef14f3f4ccf96cf51c58daccd46,progression,0.371481
uuid-d95d5ef14f3f4ccf96cf51c58daccd46,TL shared,0.47772
uuid-be361c12eeb04a4a91ffc45c3a22f29a,TL,0.463447
uuid-be361c12eeb04a4a91ffc45c3a22f29a,1L,0.305772
uuid-be361c12eeb04a4a91ffc45c3a22f29a,shared,0.317345
uuid-be361c12eeb04a4a91ffc45c3a22f29a,RCC,0.334387
uuid-be361c12eeb04a4a91ffc45c3a22f29a,TL stated,0.585889
uuid-be361c12eeb04a4a91ffc45c3a22f29a,2L,0.318758
uuid-be361c12eeb04a4a91ffc45c3a22f29a,institution,0.558231
uuid-be361c12eeb04a4a91ffc45c3a22f29a,stated,0.396236
uuid-be361c12eeb04a4a91ffc45c3a22f29a,PD-L1,0.53908
uuid-be361c12eeb04a4a91ffc45c3a22f29a,approval,0.343839
uuid-be361c12eeb04a4a91ffc45c3a22f29a,PD-L1 testing,0.687439
uuid-be361c12eeb04a4a91ffc45c3a22f29a,testing,0.67661
uuid-be361c12eeb04a4a91ffc45c3a22f29a,PDL1 testing,0.741257
uuid-be361c12eeb04a4a91ffc45c3a22f29a,NSCLC patients,0.612192
uuid-be361c12eeb04a4a91ffc45c3a22f29a,SCCHN,0.419309
uuid-be361c12eeb04a4a91ffc45c3a22f29a,tumor types,0.345659
uuid-be361c12eeb04a4a91ffc45c3a22f29a,academic,0.307521
uuid-be361c12eeb04a4a91ffc45c3a22f29a,assay,0.337121
uuid-be361c12eeb04a4a91ffc45c3a22f29a,Regional TL,0.337866
uuid-be361c12eeb04a4a91ffc45c3a22f29a,RTL stated,0.404542
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,patients,0.365311
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,Opdivo,0.309955
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,therapy,0.376131
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,nivolumab,0.314502
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,toxicity,0.345882
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,regimen,0.731369
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,treated,0.350717
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,RCC,0.312951
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,combination,0.444269
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,chemo,0.366382
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,pts,0.425989
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,IO,0.421306
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,monotherapy,0.518982
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,treatment,0.50205
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,response,0.385456
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,combo,0.488385
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,PD1,0.329707
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,progression,0.524592
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,chemotherapy,0.336185
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,respond,0.383812
uuid-b4d498a543f34bc8a0b3dbfe1131b2ff,option,0.392883
uuid-904172a4a7d84b7a8696250e13a6bbf1,patients,0.357606
uuid-904172a4a7d84b7a8696250e13a6bbf1,therapy,0.366917
uuid-904172a4a7d84b7a8696250e13a6bbf1,lung,0.332373
uuid-904172a4a7d84b7a8696250e13a6bbf1,1L,0.579043
uuid-904172a4a7d84b7a8696250e13a6bbf1,regimen,0.549811
uuid-904172a4a7d84b7a8696250e13a6bbf1,treated,0.318665
uuid-904172a4a7d84b7a8696250e13a6bbf1,melanoma,0.452603
uuid-904172a4a7d84b7a8696250e13a6bbf1,RCC,0.559724
uuid-904172a4a7d84b7a8696250e13a6bbf1,combination,0.349424
uuid-904172a4a7d84b7a8696250e13a6bbf1,chemo,0.41399
uuid-904172a4a7d84b7a8696250e13a6bbf1,2L,0.534883
uuid-904172a4a7d84b7a8696250e13a6bbf1,pts,0.43735
uuid-904172a4a7d84b7a8696250e13a6bbf1,IO,0.329135
uuid-904172a4a7d84b7a8696250e13a6bbf1,agents,0.30625
uuid-904172a4a7d84b7a8696250e13a6bbf1,preferred,0.47542
uuid-904172a4a7d84b7a8696250e13a6bbf1,monotherapy,0.595772
uuid-904172a4a7d84b7a8696250e13a6bbf1,treatment,0.490774
uuid-904172a4a7d84b7a8696250e13a6bbf1,using nivo,0.368254
uuid-904172a4a7d84b7a8696250e13a6bbf1,combo,0.488967
uuid-904172a4a7d84b7a8696250e13a6bbf1,PD1,0.413062
uuid-904172a4a7d84b7a8696250e13a6bbf1,SCCHN,0.322866
uuid-904172a4a7d84b7a8696250e13a6bbf1,progression,0.460579
uuid-904172a4a7d84b7a8696250e13a6bbf1,believes,0.300276
uuid-904172a4a7d84b7a8696250e13a6bbf1,chemotherapy,0.37875
uuid-904172a4a7d84b7a8696250e13a6bbf1,RTL stated,0.439648
uuid-904172a4a7d84b7a8696250e13a6bbf1,TL shared,0.486029
uuid-904172a4a7d84b7a8696250e13a6bbf1,option,0.634841
uuid-739c89a7f1ce44aebcb7b960a86d43eb,Opdivo,0.335262
uuid-739c89a7f1ce44aebcb7b960a86d43eb,dose,0.471457
uuid-739c89a7f1ce44aebcb7b960a86d43eb,drug,0.525534
uuid-739c89a7f1ce44aebcb7b960a86d43eb,Keytruda,0.561538
uuid-739c89a7f1ce44aebcb7b960a86d43eb,flat dosing,0.540156
uuid-adad7a8c66c340d398f7927136c065a4,Nivo,0.451948
uuid-adad7a8c66c340d398f7927136c065a4,patients,0.763935
uuid-adad7a8c66c340d398f7927136c065a4,Opdivo,0.352311
uuid-adad7a8c66c340d398f7927136c065a4,therapy,0.784122
uuid-adad7a8c66c340d398f7927136c065a4,nivolumab,0.47341
uuid-adad7a8c66c340d398f7927136c065a4,treated,0.383616
uuid-adad7a8c66c340d398f7927136c065a4,chemo,0.472565
uuid-adad7a8c66c340d398f7927136c065a4,pts,0.408268
uuid-adad7a8c66c340d398f7927136c065a4,monotherapy,0.337343
uuid-adad7a8c66c340d398f7927136c065a4,treatment,0.586431
uuid-adad7a8c66c340d398f7927136c065a4,response,0.378075
uuid-adad7a8c66c340d398f7927136c065a4,PD1,0.454279
uuid-adad7a8c66c340d398f7927136c065a4,cHL,0.591223
uuid-adad7a8c66c340d398f7927136c065a4,progression,0.566436
uuid-adad7a8c66c340d398f7927136c065a4,chemotherapy,0.56041
uuid-adad7a8c66c340d398f7927136c065a4,respond,0.414886
uuid-adad7a8c66c340d398f7927136c065a4,option,0.35964
uuid-84c0d0549421497e89cc5557bc2d8706,Nivo,0.418373
uuid-84c0d0549421497e89cc5557bc2d8706,patients,0.495757
uuid-84c0d0549421497e89cc5557bc2d8706,therapy,0.555142
uuid-84c0d0549421497e89cc5557bc2d8706,nivolumab,0.39611
uuid-84c0d0549421497e89cc5557bc2d8706,chemo,0.370018
uuid-84c0d0549421497e89cc5557bc2d8706,treatment,0.320294
uuid-84c0d0549421497e89cc5557bc2d8706,response,0.326253
uuid-84c0d0549421497e89cc5557bc2d8706,PD1,0.328919
uuid-84c0d0549421497e89cc5557bc2d8706,cHL,0.490332
uuid-84c0d0549421497e89cc5557bc2d8706,progression,0.350285
uuid-84c0d0549421497e89cc5557bc2d8706,chemotherapy,0.480341
uuid-84c0d0549421497e89cc5557bc2d8706,respond,0.319991
uuid-b3dfbba4f145446598758374d204a3f5,BMS,0.447807
uuid-b3dfbba4f145446598758374d204a3f5,NTL,0.356787
uuid-b3dfbba4f145446598758374d204a3f5,discussed,0.396701
uuid-b3dfbba4f145446598758374d204a3f5,commented,0.587928
uuid-b3dfbba4f145446598758374d204a3f5,OS,0.331492
uuid-b3dfbba4f145446598758374d204a3f5,regards,0.469123
uuid-b3dfbba4f145446598758374d204a3f5,data,0.549716
uuid-b3dfbba4f145446598758374d204a3f5,expressed,0.362991
uuid-b3dfbba4f145446598758374d204a3f5,ORR,0.320913
uuid-b3dfbba4f145446598758374d204a3f5,lung cancer,0.480769
uuid-b3dfbba4f145446598758374d204a3f5,ASCO,0.60531
uuid-b3dfbba4f145446598758374d204a3f5,impressed,0.52398
uuid-b3dfbba4f145446598758374d204a3f5,Regional TL,0.328208
uuid-62ad988f502a4b8abcf239125eedb080,dose,0.592892
uuid-62ad988f502a4b8abcf239125eedb080,toxicity,0.411663
uuid-62ad988f502a4b8abcf239125eedb080,regimen,0.311606
uuid-62ad988f502a4b8abcf239125eedb080,combination,0.496769
uuid-62ad988f502a4b8abcf239125eedb080,chemo,0.307884
uuid-62ad988f502a4b8abcf239125eedb080,Ipi,0.613106
uuid-62ad988f502a4b8abcf239125eedb080,combo,0.494222
uuid-62ad988f502a4b8abcf239125eedb080,vs,0.468988
uuid-62ad988f502a4b8abcf239125eedb080,flat dosing,0.319639
uuid-82e1a591d5c5469899de29c756313c4b,patients,0.395541
uuid-82e1a591d5c5469899de29c756313c4b,nivolumab,0.453548
uuid-82e1a591d5c5469899de29c756313c4b,treated,0.593842
uuid-82e1a591d5c5469899de29c756313c4b,treatment,0.351061
uuid-82e1a591d5c5469899de29c756313c4b,SCCHN,0.303002
uuid-82e1a591d5c5469899de29c756313c4b,ASCO,0.367898
uuid-82e1a591d5c5469899de29c756313c4b,Regional TL,0.443103
uuid-82e1a591d5c5469899de29c756313c4b,TL shared,0.322473
uuid-82e1a591d5c5469899de29c756313c4b,bladder,0.34833
uuid-28106a8168de4aa08b9d8e0ead86cc3b,efficacy,0.314655
uuid-28106a8168de4aa08b9d8e0ead86cc3b,discussed,0.641661
uuid-28106a8168de4aa08b9d8e0ead86cc3b,commented,0.476571
uuid-28106a8168de4aa08b9d8e0ead86cc3b,OS,0.324689
uuid-28106a8168de4aa08b9d8e0ead86cc3b,data,0.60782
uuid-28106a8168de4aa08b9d8e0ead86cc3b,ORR,0.34234
uuid-28106a8168de4aa08b9d8e0ead86cc3b,ASCO,0.711231
uuid-28106a8168de4aa08b9d8e0ead86cc3b,impressed,0.539181
uuid-28106a8168de4aa08b9d8e0ead86cc3b,Regional TL,0.314943
uuid-9b443b331fb2492894b8048b8d99774a,1L,0.333446
uuid-9b443b331fb2492894b8048b8d99774a,2L,0.311245
uuid-9b443b331fb2492894b8048b8d99774a,PD-L1,0.304463
uuid-9b443b331fb2492894b8048b8d99774a,testing,0.363238
uuid-9b443b331fb2492894b8048b8d99774a,PDL1 testing,0.378239
uuid-9b443b331fb2492894b8048b8d99774a,NSCLC patients,0.359965
uuid-2bfc4f69558e4e4cbb74186ff378d133,patients,0.614717
uuid-2bfc4f69558e4e4cbb74186ff378d133,therapy,0.351464
uuid-2bfc4f69558e4e4cbb74186ff378d133,nivolumab,0.327748
uuid-2bfc4f69558e4e4cbb74186ff378d133,chemo,0.327886
uuid-2bfc4f69558e4e4cbb74186ff378d133,pts,0.353068
uuid-2bfc4f69558e4e4cbb74186ff378d133,preferred,0.310279
uuid-2bfc4f69558e4e4cbb74186ff378d133,monotherapy,0.361148
uuid-2bfc4f69558e4e4cbb74186ff378d133,using nivo,0.358502
uuid-2bfc4f69558e4e4cbb74186ff378d133,clinical trials,0.327951
uuid-2bfc4f69558e4e4cbb74186ff378d133,NSCLC patients,0.328579
uuid-2bfc4f69558e4e4cbb74186ff378d133,chemotherapy,0.363627
uuid-2bfc4f69558e4e4cbb74186ff378d133,tumor types,0.384839
uuid-2bfc4f69558e4e4cbb74186ff378d133,feels,0.334429
uuid-2bfc4f69558e4e4cbb74186ff378d133,RTL stated,0.346984
uuid-2bfc4f69558e4e4cbb74186ff378d133,option,0.482346
uuid-b68921ce87d74ea29932fa0567f00179,patients,0.343586
uuid-b68921ce87d74ea29932fa0567f00179,toxicity,0.389598
uuid-b68921ce87d74ea29932fa0567f00179,regimen,0.388263
uuid-b68921ce87d74ea29932fa0567f00179,treated,0.349388
uuid-b68921ce87d74ea29932fa0567f00179,physicians,0.420572
uuid-b68921ce87d74ea29932fa0567f00179,treatment,0.536433
uuid-b68921ce87d74ea29932fa0567f00179,progression,0.366299
uuid-b68921ce87d74ea29932fa0567f00179,respond,0.385771
uuid-b68921ce87d74ea29932fa0567f00179,option,0.320273
uuid-d93aa814750844c8ad1aad0a42344baf,AI,0.436007
uuid-d93aa814750844c8ad1aad0a42344baf,oncology,0.375462
uuid-d93aa814750844c8ad1aad0a42344baf,drug,0.537384
uuid-d93aa814750844c8ad1aad0a42344baf,clinical,0.461766
uuid-07f4b45cbf6c41bbad28ce8bd91fdbd7,2L,0.323739
uuid-07f4b45cbf6c41bbad28ce8bd91fdbd7,agents,0.57461
uuid-07f4b45cbf6c41bbad28ce8bd91fdbd7,preferred,0.446099
uuid-07f4b45cbf6c41bbad28ce8bd91fdbd7,indication,0.453915
uuid-07f4b45cbf6c41bbad28ce8bd91fdbd7,oncology,0.382727
uuid-07f4b45cbf6c41bbad28ce8bd91fdbd7,approved,0.328544
uuid-07f4b45cbf6c41bbad28ce8bd91fdbd7,drug,0.317926
uuid-07f4b45cbf6c41bbad28ce8bd91fdbd7,clinical,0.499003
uuid-07f4b45cbf6c41bbad28ce8bd91fdbd7,option,0.358876
uuid-5fc7f62eced34ef3a8aefebb44e854e6,patients,0.54581
uuid-5fc7f62eced34ef3a8aefebb44e854e6,therapy,0.473608
uuid-5fc7f62eced34ef3a8aefebb44e854e6,nivolumab,0.435003
uuid-5fc7f62eced34ef3a8aefebb44e854e6,treated,0.47563
uuid-5fc7f62eced34ef3a8aefebb44e854e6,stated,0.341267
uuid-5fc7f62eced34ef3a8aefebb44e854e6,approval,0.317521
uuid-5fc7f62eced34ef3a8aefebb44e854e6,treatment,0.438373
uuid-5fc7f62eced34ef3a8aefebb44e854e6,using nivo,0.430375
uuid-5fc7f62eced34ef3a8aefebb44e854e6,clinical trials,0.320753
uuid-5fc7f62eced34ef3a8aefebb44e854e6,SCCHN,0.393187
uuid-5fc7f62eced34ef3a8aefebb44e854e6,cHL,0.434892
uuid-5fc7f62eced34ef3a8aefebb44e854e6,RTL stated,0.443095
uuid-5fc7f62eced34ef3a8aefebb44e854e6,option,0.315165
uuid-4d45728d51734609bb94727c3b8144f3,Nivo,0.526337
uuid-4d45728d51734609bb94727c3b8144f3,patients,0.30845
uuid-4d45728d51734609bb94727c3b8144f3,pembro,0.338642
uuid-4d45728d51734609bb94727c3b8144f3,RTL,0.316027
uuid-4d45728d51734609bb94727c3b8144f3,nivolumab,0.373268
uuid-4d45728d51734609bb94727c3b8144f3,1L,0.345924
uuid-4d45728d51734609bb94727c3b8144f3,trial,0.367078
uuid-4d45728d51734609bb94727c3b8144f3,combination,0.385108
uuid-4d45728d51734609bb94727c3b8144f3,chemo,0.377114
uuid-4d45728d51734609bb94727c3b8144f3,OS,0.344566
uuid-4d45728d51734609bb94727c3b8144f3,monotherapy,0.478462
uuid-4d45728d51734609bb94727c3b8144f3,using nivo,0.445484
uuid-4d45728d51734609bb94727c3b8144f3,data,0.450551
uuid-4d45728d51734609bb94727c3b8144f3,combo,0.318434
uuid-4d45728d51734609bb94727c3b8144f3,clinical trials,0.353992
uuid-4d45728d51734609bb94727c3b8144f3,PFS,0.322525
uuid-4d45728d51734609bb94727c3b8144f3,PD1,0.343916
uuid-4d45728d51734609bb94727c3b8144f3,ORR,0.364547
uuid-4d45728d51734609bb94727c3b8144f3,SCCHN,0.334585
uuid-4d45728d51734609bb94727c3b8144f3,chemotherapy,0.429866
uuid-4d45728d51734609bb94727c3b8144f3,impressed,0.507794
uuid-4d45728d51734609bb94727c3b8144f3,SCLC,0.34919
uuid-4d45728d51734609bb94727c3b8144f3,feels,0.433416
uuid-4d45728d51734609bb94727c3b8144f3,RTL stated,0.350341
uuid-4d45728d51734609bb94727c3b8144f3,option,0.487459
uuid-4d45728d51734609bb94727c3b8144f3,bladder,0.316081
uuid-9d54c2c0f2ec4841a2b8de5989772203,Nivo,0.519591
uuid-9d54c2c0f2ec4841a2b8de5989772203,patients,0.467851
uuid-9d54c2c0f2ec4841a2b8de5989772203,pembro,0.389441
uuid-9d54c2c0f2ec4841a2b8de5989772203,therapy,0.489805
uuid-9d54c2c0f2ec4841a2b8de5989772203,nivolumab,0.383011
uuid-9d54c2c0f2ec4841a2b8de5989772203,1L,0.438926
uuid-9d54c2c0f2ec4841a2b8de5989772203,trial,0.34711
uuid-9d54c2c0f2ec4841a2b8de5989772203,regimen,0.31067
uuid-9d54c2c0f2ec4841a2b8de5989772203,combination,0.457291
uuid-9d54c2c0f2ec4841a2b8de5989772203,chemo,0.595476
uuid-9d54c2c0f2ec4841a2b8de5989772203,2L,0.325645
uuid-9d54c2c0f2ec4841a2b8de5989772203,pts,0.644624
uuid-9d54c2c0f2ec4841a2b8de5989772203,monotherapy,0.573681
uuid-9d54c2c0f2ec4841a2b8de5989772203,using nivo,0.351351
uuid-9d54c2c0f2ec4841a2b8de5989772203,response,0.379749
uuid-9d54c2c0f2ec4841a2b8de5989772203,combo,0.409816
uuid-9d54c2c0f2ec4841a2b8de5989772203,PD1,0.513299
uuid-9d54c2c0f2ec4841a2b8de5989772203,progression,0.430146
uuid-9d54c2c0f2ec4841a2b8de5989772203,believes,0.301039
uuid-9d54c2c0f2ec4841a2b8de5989772203,chemotherapy,0.533017
uuid-9d54c2c0f2ec4841a2b8de5989772203,respond,0.324351
uuid-9d54c2c0f2ec4841a2b8de5989772203,feels,0.385839
uuid-9d54c2c0f2ec4841a2b8de5989772203,option,0.487907
uuid-822fb52dfc574dfe973b635c91419389,TL,0.327645
uuid-822fb52dfc574dfe973b635c91419389,RTL,0.42307
uuid-822fb52dfc574dfe973b635c91419389,NTL,0.34036
uuid-822fb52dfc574dfe973b635c91419389,shared,0.398926
uuid-822fb52dfc574dfe973b635c91419389,institution,0.362423
uuid-822fb52dfc574dfe973b635c91419389,stated,0.356362
uuid-822fb52dfc574dfe973b635c91419389,physicians,0.406754
uuid-822fb52dfc574dfe973b635c91419389,clinical trials,0.311324
uuid-822fb52dfc574dfe973b635c91419389,oncology,0.61301
uuid-822fb52dfc574dfe973b635c91419389,SCCHN,0.332229
uuid-822fb52dfc574dfe973b635c91419389,oncologist,0.40097
uuid-822fb52dfc574dfe973b635c91419389,LTL,0.389849
uuid-822fb52dfc574dfe973b635c91419389,clinical,0.467462
uuid-822fb52dfc574dfe973b635c91419389,academic,0.408129
uuid-822fb52dfc574dfe973b635c91419389,Regional TL,0.516562
uuid-11abd32c936a44f1935d4786a6773ffe,patients,0.67903
uuid-11abd32c936a44f1935d4786a6773ffe,therapy,0.515071
uuid-11abd32c936a44f1935d4786a6773ffe,nivolumab,0.418732
uuid-11abd32c936a44f1935d4786a6773ffe,1L,0.593872
uuid-11abd32c936a44f1935d4786a6773ffe,regimen,0.37881
uuid-11abd32c936a44f1935d4786a6773ffe,treated,0.451507
uuid-11abd32c936a44f1935d4786a6773ffe,RCC,0.34032
uuid-11abd32c936a44f1935d4786a6773ffe,chemo,0.493555
uuid-11abd32c936a44f1935d4786a6773ffe,2L,0.522311
uuid-11abd32c936a44f1935d4786a6773ffe,pts,0.571883
uuid-11abd32c936a44f1935d4786a6773ffe,preferred,0.471375
uuid-11abd32c936a44f1935d4786a6773ffe,testing,0.302738
uuid-11abd32c936a44f1935d4786a6773ffe,monotherapy,0.630147
uuid-11abd32c936a44f1935d4786a6773ffe,treatment,0.471897
uuid-11abd32c936a44f1935d4786a6773ffe,using nivo,0.461319
uuid-11abd32c936a44f1935d4786a6773ffe,combo,0.314579
uuid-11abd32c936a44f1935d4786a6773ffe,PDL1 testing,0.331928
uuid-11abd32c936a44f1935d4786a6773ffe,NSCLC patients,0.52822
uuid-11abd32c936a44f1935d4786a6773ffe,PD1,0.461561
uuid-11abd32c936a44f1935d4786a6773ffe,progression,0.484088
uuid-11abd32c936a44f1935d4786a6773ffe,chemotherapy,0.469117
uuid-11abd32c936a44f1935d4786a6773ffe,respond,0.3116
uuid-11abd32c936a44f1935d4786a6773ffe,PD-1,0.322643
uuid-11abd32c936a44f1935d4786a6773ffe,RTL stated,0.442989
uuid-11abd32c936a44f1935d4786a6773ffe,option,0.612768
uuid-39b17c9b4bb54f44aff7ca5082a675a8,RTL,0.349008
uuid-39b17c9b4bb54f44aff7ca5082a675a8,BMS,0.320351
uuid-39b17c9b4bb54f44aff7ca5082a675a8,commented,0.324827
uuid-39b17c9b4bb54f44aff7ca5082a675a8,institution,0.323799
uuid-39b17c9b4bb54f44aff7ca5082a675a8,stated,0.560059
uuid-39b17c9b4bb54f44aff7ca5082a675a8,approval,0.358677
uuid-39b17c9b4bb54f44aff7ca5082a675a8,data,0.439641
uuid-39b17c9b4bb54f44aff7ca5082a675a8,indication,0.327758
uuid-39b17c9b4bb54f44aff7ca5082a675a8,approved,0.33931
uuid-39b17c9b4bb54f44aff7ca5082a675a8,SCCHN,0.477737
uuid-39b17c9b4bb54f44aff7ca5082a675a8,impressed,0.323605
uuid-39b17c9b4bb54f44aff7ca5082a675a8,label,0.381641
uuid-39b17c9b4bb54f44aff7ca5082a675a8,SCLC,0.314243
uuid-39b17c9b4bb54f44aff7ca5082a675a8,Regional TL,0.31087
uuid-39b17c9b4bb54f44aff7ca5082a675a8,NCCN,0.513131
uuid-796919e73c76436296214de608ed57fa,patients,0.421545
uuid-796919e73c76436296214de608ed57fa,regimen,0.354185
uuid-796919e73c76436296214de608ed57fa,chemo,0.422237
uuid-796919e73c76436296214de608ed57fa,pts,0.422911
uuid-796919e73c76436296214de608ed57fa,treatment,0.358213
uuid-796919e73c76436296214de608ed57fa,response,0.428873
uuid-796919e73c76436296214de608ed57fa,PD1,0.308145
uuid-796919e73c76436296214de608ed57fa,progression,0.555839
uuid-796919e73c76436296214de608ed57fa,believes,0.35596
uuid-796919e73c76436296214de608ed57fa,respond,0.59507
uuid-796919e73c76436296214de608ed57fa,feels,0.415686
uuid-bc4019a475be4c51848dd55d236ed39a,patients,0.660676
uuid-bc4019a475be4c51848dd55d236ed39a,therapy,0.390719
uuid-bc4019a475be4c51848dd55d236ed39a,regimen,0.364289
uuid-bc4019a475be4c51848dd55d236ed39a,treated,0.431563
uuid-bc4019a475be4c51848dd55d236ed39a,pts,0.447523
uuid-bc4019a475be4c51848dd55d236ed39a,treatment,0.552069
uuid-bc4019a475be4c51848dd55d236ed39a,response,0.358594
uuid-bc4019a475be4c51848dd55d236ed39a,progression,0.558783
uuid-bc4019a475be4c51848dd55d236ed39a,respond,0.484918
uuid-efed5d8e4ab24fb089a97df6ea21a870,Nivo,0.448491
uuid-efed5d8e4ab24fb089a97df6ea21a870,RTL,0.499963
uuid-efed5d8e4ab24fb089a97df6ea21a870,trial,0.36144
uuid-efed5d8e4ab24fb089a97df6ea21a870,RCC,0.310451
uuid-efed5d8e4ab24fb089a97df6ea21a870,stated,0.32409
uuid-efed5d8e4ab24fb089a97df6ea21a870,approval,0.312413
uuid-efed5d8e4ab24fb089a97df6ea21a870,OS,0.32107
uuid-efed5d8e4ab24fb089a97df6ea21a870,using nivo,0.385544
uuid-efed5d8e4ab24fb089a97df6ea21a870,data,0.460442
uuid-efed5d8e4ab24fb089a97df6ea21a870,ORR,0.336463
uuid-efed5d8e4ab24fb089a97df6ea21a870,SCCHN,0.360564
uuid-efed5d8e4ab24fb089a97df6ea21a870,impressed,0.597065
uuid-efed5d8e4ab24fb089a97df6ea21a870,LTL,0.365513
uuid-efed5d8e4ab24fb089a97df6ea21a870,SCLC,0.348459
uuid-efed5d8e4ab24fb089a97df6ea21a870,Regional TL,0.387352
uuid-efed5d8e4ab24fb089a97df6ea21a870,RTL stated,0.318655
uuid-2354a2d4b7214086b89421db18292ed8,pembro,0.393642
uuid-2354a2d4b7214086b89421db18292ed8,lung,0.507775
uuid-2354a2d4b7214086b89421db18292ed8,1L,0.658074
uuid-2354a2d4b7214086b89421db18292ed8,PDL1,0.321875
uuid-2354a2d4b7214086b89421db18292ed8,melanoma,0.315641
uuid-2354a2d4b7214086b89421db18292ed8,RCC,0.6369
uuid-2354a2d4b7214086b89421db18292ed8,TL stated,0.571485
uuid-2354a2d4b7214086b89421db18292ed8,2L,0.650992
uuid-2354a2d4b7214086b89421db18292ed8,agents,0.378531
uuid-2354a2d4b7214086b89421db18292ed8,PD-L1,0.312453
uuid-2354a2d4b7214086b89421db18292ed8,approval,0.305408
uuid-2354a2d4b7214086b89421db18292ed8,atezo,0.46072
uuid-2354a2d4b7214086b89421db18292ed8,preferred,0.604243
uuid-2354a2d4b7214086b89421db18292ed8,monotherapy,0.378202
uuid-2354a2d4b7214086b89421db18292ed8,using nivo,0.495303
uuid-2354a2d4b7214086b89421db18292ed8,expressed,0.321251
uuid-2354a2d4b7214086b89421db18292ed8,PDL1 testing,0.535949
uuid-2354a2d4b7214086b89421db18292ed8,indication,0.356851
uuid-2354a2d4b7214086b89421db18292ed8,NSCLC patients,0.370976
uuid-2354a2d4b7214086b89421db18292ed8,approved,0.358989
uuid-2354a2d4b7214086b89421db18292ed8,SCCHN,0.554815
uuid-2354a2d4b7214086b89421db18292ed8,nivo and pembro,0.324118
uuid-2354a2d4b7214086b89421db18292ed8,believes,0.32149
uuid-2354a2d4b7214086b89421db18292ed8,tumor types,0.421917
uuid-2354a2d4b7214086b89421db18292ed8,TLs,0.422891
uuid-2354a2d4b7214086b89421db18292ed8,Regional TL,0.346365
uuid-2354a2d4b7214086b89421db18292ed8,RTL stated,0.570059
uuid-2354a2d4b7214086b89421db18292ed8,TL shared,0.506048
uuid-2354a2d4b7214086b89421db18292ed8,option,0.449752
uuid-2354a2d4b7214086b89421db18292ed8,bladder,0.497256
uuid-00a0e30dacef4cf89caafabc6c519d70,Nivo,0.395825
uuid-00a0e30dacef4cf89caafabc6c519d70,patients,0.352166
uuid-00a0e30dacef4cf89caafabc6c519d70,therapy,0.379418
uuid-00a0e30dacef4cf89caafabc6c519d70,nivolumab,0.358954
uuid-00a0e30dacef4cf89caafabc6c519d70,1L,0.517793
uuid-00a0e30dacef4cf89caafabc6c519d70,toxicity,0.325003
uuid-00a0e30dacef4cf89caafabc6c519d70,regimen,0.487675
uuid-00a0e30dacef4cf89caafabc6c519d70,RCC,0.365964
uuid-00a0e30dacef4cf89caafabc6c519d70,combination,0.550466
uuid-00a0e30dacef4cf89caafabc6c519d70,chemo,0.503362
uuid-00a0e30dacef4cf89caafabc6c519d70,2L,0.546978
uuid-00a0e30dacef4cf89caafabc6c519d70,pts,0.372454
uuid-00a0e30dacef4cf89caafabc6c519d70,IO,0.503275
uuid-00a0e30dacef4cf89caafabc6c519d70,agents,0.496678
uuid-00a0e30dacef4cf89caafabc6c519d70,preferred,0.575629
uuid-00a0e30dacef4cf89caafabc6c519d70,monotherapy,0.686112
uuid-00a0e30dacef4cf89caafabc6c519d70,treatment,0.356705
uuid-00a0e30dacef4cf89caafabc6c519d70,using nivo,0.447562
uuid-00a0e30dacef4cf89caafabc6c519d70,response,0.311945
uuid-00a0e30dacef4cf89caafabc6c519d70,combo,0.553126
uuid-00a0e30dacef4cf89caafabc6c519d70,PD1,0.437118
uuid-00a0e30dacef4cf89caafabc6c519d70,approved,0.448198
uuid-00a0e30dacef4cf89caafabc6c519d70,progression,0.376051
uuid-00a0e30dacef4cf89caafabc6c519d70,believes,0.346467
uuid-00a0e30dacef4cf89caafabc6c519d70,chemotherapy,0.418744
uuid-00a0e30dacef4cf89caafabc6c519d70,feels,0.396386
uuid-00a0e30dacef4cf89caafabc6c519d70,RTL stated,0.381981
uuid-00a0e30dacef4cf89caafabc6c519d70,option,0.676663
uuid-e779069329c04dd785c61fdc1e1db4a9,lung,0.330351
uuid-e779069329c04dd785c61fdc1e1db4a9,shared,0.388228
uuid-e779069329c04dd785c61fdc1e1db4a9,institution,0.409495
uuid-e779069329c04dd785c61fdc1e1db4a9,physicians,0.347431
uuid-e779069329c04dd785c61fdc1e1db4a9,AI,0.442362
uuid-e779069329c04dd785c61fdc1e1db4a9,oncology,0.728122
uuid-e779069329c04dd785c61fdc1e1db4a9,drug,0.383083
uuid-e779069329c04dd785c61fdc1e1db4a9,clinical,0.432387
uuid-0b8afb673f5f404ca55f523524e27cd8,Nivo,0.42559
uuid-0b8afb673f5f404ca55f523524e27cd8,patients,0.453057
uuid-0b8afb673f5f404ca55f523524e27cd8,therapy,0.470072
uuid-0b8afb673f5f404ca55f523524e27cd8,1L,0.315998
uuid-0b8afb673f5f404ca55f523524e27cd8,regimen,0.449768
uuid-0b8afb673f5f404ca55f523524e27cd8,chemo,0.646777
uuid-0b8afb673f5f404ca55f523524e27cd8,pts,0.453376
uuid-0b8afb673f5f404ca55f523524e27cd8,IO,0.303694
uuid-0b8afb673f5f404ca55f523524e27cd8,OS,0.551595
uuid-0b8afb673f5f404ca55f523524e27cd8,monotherapy,0.475103
uuid-0b8afb673f5f404ca55f523524e27cd8,treatment,0.445192
uuid-0b8afb673f5f404ca55f523524e27cd8,response,0.515492
uuid-0b8afb673f5f404ca55f523524e27cd8,PFS,0.502812
uuid-0b8afb673f5f404ca55f523524e27cd8,PD1,0.397613
uuid-0b8afb673f5f404ca55f523524e27cd8,ORR,0.394274
uuid-0b8afb673f5f404ca55f523524e27cd8,progression,0.597504
uuid-0b8afb673f5f404ca55f523524e27cd8,believes,0.314353
uuid-0b8afb673f5f404ca55f523524e27cd8,chemotherapy,0.569716
uuid-0b8afb673f5f404ca55f523524e27cd8,respond,0.466576
uuid-0b8afb673f5f404ca55f523524e27cd8,feels,0.357871
uuid-0b8afb673f5f404ca55f523524e27cd8,option,0.402485
uuid-17e1c21d589e4319bf08acaa81269001,Nivo,0.506532
uuid-17e1c21d589e4319bf08acaa81269001,patients,0.318784
uuid-17e1c21d589e4319bf08acaa81269001,pembro,0.670782
uuid-17e1c21d589e4319bf08acaa81269001,1L,0.870263
uuid-17e1c21d589e4319bf08acaa81269001,RCC,0.40899
uuid-17e1c21d589e4319bf08acaa81269001,chemo,0.422514
uuid-17e1c21d589e4319bf08acaa81269001,2L,0.872507
uuid-17e1c21d589e4319bf08acaa81269001,pts,0.3367
uuid-17e1c21d589e4319bf08acaa81269001,agents,0.449008
uuid-17e1c21d589e4319bf08acaa81269001,approval,0.409699
uuid-17e1c21d589e4319bf08acaa81269001,atezo,0.663428
uuid-17e1c21d589e4319bf08acaa81269001,preferred,0.712464
uuid-17e1c21d589e4319bf08acaa81269001,testing,0.324843
uuid-17e1c21d589e4319bf08acaa81269001,monotherapy,0.611905
uuid-17e1c21d589e4319bf08acaa81269001,using nivo,0.635663
uuid-17e1c21d589e4319bf08acaa81269001,combo,0.352826
uuid-17e1c21d589e4319bf08acaa81269001,PDL1 testing,0.466675
uuid-17e1c21d589e4319bf08acaa81269001,NSCLC patients,0.469829
uuid-17e1c21d589e4319bf08acaa81269001,PD1,0.311818
uuid-17e1c21d589e4319bf08acaa81269001,approved,0.554058
uuid-17e1c21d589e4319bf08acaa81269001,nivo and pembro,0.354145
uuid-17e1c21d589e4319bf08acaa81269001,believes,0.316509
uuid-17e1c21d589e4319bf08acaa81269001,tumor types,0.335988
uuid-17e1c21d589e4319bf08acaa81269001,RTL stated,0.469748
uuid-17e1c21d589e4319bf08acaa81269001,option,0.661826
uuid-17e1c21d589e4319bf08acaa81269001,bladder,0.310715
uuid-24b8fdddbda34a499b3e2413356251da,patients,0.501966
uuid-24b8fdddbda34a499b3e2413356251da,Opdivo,0.682434
uuid-24b8fdddbda34a499b3e2413356251da,nivolumab,0.489793
uuid-24b8fdddbda34a499b3e2413356251da,treated,0.317526
uuid-24b8fdddbda34a499b3e2413356251da,treatment,0.412368
uuid-24b8fdddbda34a499b3e2413356251da,cHL,0.404475
uuid-24b8fdddbda34a499b3e2413356251da,progression,0.30595
uuid-53f82cacb5fd45e88e7421dcda54afbc,BMS,0.430079
uuid-53f82cacb5fd45e88e7421dcda54afbc,discussed,0.55633
uuid-53f82cacb5fd45e88e7421dcda54afbc,physicians,0.370081
uuid-53f82cacb5fd45e88e7421dcda54afbc,academic,0.471757
uuid-b4652b7519ed42c09e8e9afee950aa23,patients,0.690399
uuid-b4652b7519ed42c09e8e9afee950aa23,Opdivo,0.559223
uuid-b4652b7519ed42c09e8e9afee950aa23,therapy,0.359773
uuid-b4652b7519ed42c09e8e9afee950aa23,nivolumab,0.44997
uuid-b4652b7519ed42c09e8e9afee950aa23,toxicity,0.313936
uuid-b4652b7519ed42c09e8e9afee950aa23,regimen,0.440665
uuid-b4652b7519ed42c09e8e9afee950aa23,treated,0.440386
uuid-b4652b7519ed42c09e8e9afee950aa23,pts,0.433319
uuid-b4652b7519ed42c09e8e9afee950aa23,treatment,0.462599
uuid-b4652b7519ed42c09e8e9afee950aa23,progression,0.429722
uuid-64db4e038b1d42579a83bfaac6c36fc5,RTL,0.412669
uuid-64db4e038b1d42579a83bfaac6c36fc5,BMS,0.31565
uuid-64db4e038b1d42579a83bfaac6c36fc5,trial,0.413095
uuid-64db4e038b1d42579a83bfaac6c36fc5,commented,0.513589
uuid-64db4e038b1d42579a83bfaac6c36fc5,stated,0.340569
uuid-64db4e038b1d42579a83bfaac6c36fc5,OS,0.553316
uuid-64db4e038b1d42579a83bfaac6c36fc5,data,0.658152
uuid-64db4e038b1d42579a83bfaac6c36fc5,expressed,0.321213
uuid-64db4e038b1d42579a83bfaac6c36fc5,PFS,0.549181
uuid-64db4e038b1d42579a83bfaac6c36fc5,ORR,0.547934
uuid-64db4e038b1d42579a83bfaac6c36fc5,ASCO,0.450179
uuid-64db4e038b1d42579a83bfaac6c36fc5,impressed,0.660995
uuid-64db4e038b1d42579a83bfaac6c36fc5,LTL,0.307488
uuid-64db4e038b1d42579a83bfaac6c36fc5,TLs,0.34917
uuid-64db4e038b1d42579a83bfaac6c36fc5,Regional TL,0.372577
uuid-e8b2baec2d8046d2b99bb3155907ae12,patients,0.366145
uuid-e8b2baec2d8046d2b99bb3155907ae12,toxicity,0.603109
uuid-e8b2baec2d8046d2b99bb3155907ae12,efficacy,0.310985
uuid-e8b2baec2d8046d2b99bb3155907ae12,regimen,0.387806
uuid-e8b2baec2d8046d2b99bb3155907ae12,chemo,0.329952
uuid-e8b2baec2d8046d2b99bb3155907ae12,treatment,0.307293
uuid-e8b2baec2d8046d2b99bb3155907ae12,response,0.480379
uuid-e8b2baec2d8046d2b99bb3155907ae12,progression,0.376165
uuid-e8b2baec2d8046d2b99bb3155907ae12,chemotherapy,0.337379
uuid-e8b2baec2d8046d2b99bb3155907ae12,respond,0.394517
uuid-6f1fba28d2fa42149809e93b9c1948bf,patients,0.759355
uuid-6f1fba28d2fa42149809e93b9c1948bf,Opdivo,0.507624
uuid-6f1fba28d2fa42149809e93b9c1948bf,therapy,0.591323
uuid-6f1fba28d2fa42149809e93b9c1948bf,nivolumab,0.434401
uuid-6f1fba28d2fa42149809e93b9c1948bf,toxicity,0.325493
uuid-6f1fba28d2fa42149809e93b9c1948bf,regimen,0.561658
uuid-6f1fba28d2fa42149809e93b9c1948bf,treated,0.542496
uuid-6f1fba28d2fa42149809e93b9c1948bf,pts,0.499999
uuid-6f1fba28d2fa42149809e93b9c1948bf,treatment,0.797652
uuid-6f1fba28d2fa42149809e93b9c1948bf,response,0.313524
uuid-6f1fba28d2fa42149809e93b9c1948bf,cHL,0.34975
uuid-6f1fba28d2fa42149809e93b9c1948bf,progression,0.673826
uuid-6f1fba28d2fa42149809e93b9c1948bf,chemotherapy,0.376151
uuid-6f1fba28d2fa42149809e93b9c1948bf,respond,0.483914
uuid-6f1fba28d2fa42149809e93b9c1948bf,option,0.320344
uuid-a633773a83aa4d2691f11dfffacf006a,oncology,0.364202
uuid-a633773a83aa4d2691f11dfffacf006a,drug,0.611902
uuid-777693faa8b340ad9a8ac5e36b18e96a,Opdivo,0.334535
uuid-777693faa8b340ad9a8ac5e36b18e96a,dose,0.692441
uuid-777693faa8b340ad9a8ac5e36b18e96a,indication,0.421418
uuid-777693faa8b340ad9a8ac5e36b18e96a,vs,0.405215
uuid-777693faa8b340ad9a8ac5e36b18e96a,label,0.328761
uuid-777693faa8b340ad9a8ac5e36b18e96a,drug,0.37724
uuid-777693faa8b340ad9a8ac5e36b18e96a,Keytruda,0.444874
uuid-777693faa8b340ad9a8ac5e36b18e96a,flat dosing,0.874767
uuid-e36fb276ea4749f0975218aea17b4846,pembro,0.604809
uuid-e36fb276ea4749f0975218aea17b4846,1L,0.515078
uuid-e36fb276ea4749f0975218aea17b4846,PDL1,0.580848
uuid-e36fb276ea4749f0975218aea17b4846,2L,0.504811
uuid-e36fb276ea4749f0975218aea17b4846,agents,0.336949
uuid-e36fb276ea4749f0975218aea17b4846,Merck,0.357945
uuid-e36fb276ea4749f0975218aea17b4846,PD-L1,0.550964
uuid-e36fb276ea4749f0975218aea17b4846,atezo,0.643642
uuid-e36fb276ea4749f0975218aea17b4846,preferred,0.407557
uuid-e36fb276ea4749f0975218aea17b4846,PD-L1 testing,0.340077
uuid-e36fb276ea4749f0975218aea17b4846,testing,0.489052
uuid-e36fb276ea4749f0975218aea17b4846,PDL1 testing,0.436966
uuid-e36fb276ea4749f0975218aea17b4846,NSCLC patients,0.365819
uuid-e36fb276ea4749f0975218aea17b4846,approved,0.362853
uuid-e36fb276ea4749f0975218aea17b4846,nivo and pembro,0.466043
uuid-e36fb276ea4749f0975218aea17b4846,believes,0.360934
uuid-e36fb276ea4749f0975218aea17b4846,vs,0.301874
uuid-e36fb276ea4749f0975218aea17b4846,feels,0.360527
uuid-e36fb276ea4749f0975218aea17b4846,assay,0.495338
uuid-e36fb276ea4749f0975218aea17b4846,PDL1 expression,0.408244
uuid-e36fb276ea4749f0975218aea17b4846,biomarker,0.358799
uuid-94b8fe8796354cb59ace20c3748be161,1L,0.362013
uuid-94b8fe8796354cb59ace20c3748be161,RCC,0.406269
uuid-94b8fe8796354cb59ace20c3748be161,TL stated,0.575659
uuid-94b8fe8796354cb59ace20c3748be161,2L,0.338683
uuid-94b8fe8796354cb59ace20c3748be161,stated,0.432538
uuid-94b8fe8796354cb59ace20c3748be161,PD-L1,0.435822
uuid-94b8fe8796354cb59ace20c3748be161,PD-L1 testing,0.405614
uuid-94b8fe8796354cb59ace20c3748be161,testing,0.462436
uuid-94b8fe8796354cb59ace20c3748be161,PDL1 testing,0.638455
uuid-94b8fe8796354cb59ace20c3748be161,NSCLC patients,0.409762
uuid-94b8fe8796354cb59ace20c3748be161,SCCHN,0.364318
uuid-94b8fe8796354cb59ace20c3748be161,tumor types,0.40582
uuid-94b8fe8796354cb59ace20c3748be161,TLs,0.427936
uuid-94b8fe8796354cb59ace20c3748be161,Regional TL,0.351472
uuid-94b8fe8796354cb59ace20c3748be161,biomarker,0.403358
uuid-7653f03fbc214d75a2802bb07227afa2,patients,0.673011
uuid-7653f03fbc214d75a2802bb07227afa2,Opdivo,0.373088
uuid-7653f03fbc214d75a2802bb07227afa2,therapy,0.554435
uuid-7653f03fbc214d75a2802bb07227afa2,nivolumab,0.579437
uuid-7653f03fbc214d75a2802bb07227afa2,regimen,0.605726
uuid-7653f03fbc214d75a2802bb07227afa2,treated,0.688298
uuid-7653f03fbc214d75a2802bb07227afa2,pts,0.442405
uuid-7653f03fbc214d75a2802bb07227afa2,monotherapy,0.381844
uuid-7653f03fbc214d75a2802bb07227afa2,treatment,0.710418
uuid-7653f03fbc214d75a2802bb07227afa2,using nivo,0.35589
uuid-7653f03fbc214d75a2802bb07227afa2,response,0.360686
uuid-7653f03fbc214d75a2802bb07227afa2,PD1,0.33964
uuid-7653f03fbc214d75a2802bb07227afa2,cHL,0.368134
uuid-7653f03fbc214d75a2802bb07227afa2,progression,0.587664
uuid-7653f03fbc214d75a2802bb07227afa2,chemotherapy,0.372838
uuid-7653f03fbc214d75a2802bb07227afa2,respond,0.493211
uuid-7653f03fbc214d75a2802bb07227afa2,RTL stated,0.329139
uuid-7653f03fbc214d75a2802bb07227afa2,TL shared,0.365591
uuid-7653f03fbc214d75a2802bb07227afa2,option,0.331286
uuid-ec40c687865446d397107cfbcb7ce022,Nivo,0.354021
uuid-ec40c687865446d397107cfbcb7ce022,patients,0.625178
uuid-ec40c687865446d397107cfbcb7ce022,Opdivo,0.371333
uuid-ec40c687865446d397107cfbcb7ce022,therapy,0.315075
uuid-ec40c687865446d397107cfbcb7ce022,dose,0.496583
uuid-ec40c687865446d397107cfbcb7ce022,nivolumab,0.433163
uuid-ec40c687865446d397107cfbcb7ce022,toxicity,0.593853
uuid-ec40c687865446d397107cfbcb7ce022,regimen,0.736961
uuid-ec40c687865446d397107cfbcb7ce022,treated,0.492751
uuid-ec40c687865446d397107cfbcb7ce022,combination,0.422907
uuid-ec40c687865446d397107cfbcb7ce022,chemo,0.354678
uuid-ec40c687865446d397107cfbcb7ce022,pts,0.570616
uuid-ec40c687865446d397107cfbcb7ce022,Ipi,0.490755
uuid-ec40c687865446d397107cfbcb7ce022,monotherapy,0.427128
uuid-ec40c687865446d397107cfbcb7ce022,treatment,0.514438
uuid-ec40c687865446d397107cfbcb7ce022,response,0.430977
uuid-ec40c687865446d397107cfbcb7ce022,combo,0.390649
uuid-ec40c687865446d397107cfbcb7ce022,PD1,0.313861
uuid-ec40c687865446d397107cfbcb7ce022,progression,0.549358
uuid-ec40c687865446d397107cfbcb7ce022,chemotherapy,0.354592
uuid-ec40c687865446d397107cfbcb7ce022,respond,0.458752
uuid-6c3a272688854ddd8afe5a6857ce1b0f,patients,0.492334
uuid-6c3a272688854ddd8afe5a6857ce1b0f,toxicity,0.52946
uuid-6c3a272688854ddd8afe5a6857ce1b0f,regimen,0.455535
uuid-6c3a272688854ddd8afe5a6857ce1b0f,monotherapy,0.305301
uuid-6c3a272688854ddd8afe5a6857ce1b0f,treatment,0.338881
uuid-6c3a272688854ddd8afe5a6857ce1b0f,response,0.358564
uuid-6c3a272688854ddd8afe5a6857ce1b0f,progression,0.378468
uuid-6c3a272688854ddd8afe5a6857ce1b0f,chemotherapy,0.325006
uuid-6c3a272688854ddd8afe5a6857ce1b0f,respond,0.35927
uuid-b4f784a0b24549aca13a57fa12e96796,1L,0.384574
uuid-b4f784a0b24549aca13a57fa12e96796,toxicity,0.369385
uuid-b4f784a0b24549aca13a57fa12e96796,regimen,0.379622
uuid-b4f784a0b24549aca13a57fa12e96796,RCC,0.395968
uuid-b4f784a0b24549aca13a57fa12e96796,combination,0.709156
uuid-b4f784a0b24549aca13a57fa12e96796,chemo,0.411307
uuid-b4f784a0b24549aca13a57fa12e96796,2L,0.422451
uuid-b4f784a0b24549aca13a57fa12e96796,agents,0.533962
uuid-b4f784a0b24549aca13a57fa12e96796,Ipi,0.305419
uuid-b4f784a0b24549aca13a57fa12e96796,preferred,0.498382
uuid-b4f784a0b24549aca13a57fa12e96796,monotherapy,0.589543
uuid-b4f784a0b24549aca13a57fa12e96796,combo,0.608445
uuid-b4f784a0b24549aca13a57fa12e96796,PD1,0.400556
uuid-b4f784a0b24549aca13a57fa12e96796,chemotherapy,0.369353
uuid-b4f784a0b24549aca13a57fa12e96796,feels,0.362221
uuid-b4f784a0b24549aca13a57fa12e96796,RTL stated,0.43819
uuid-b4f784a0b24549aca13a57fa12e96796,option,0.450019
uuid-b4f784a0b24549aca13a57fa12e96796,bladder,0.354097
uuid-d8e0da7beeca48978dd39fbd6daccf3c,patients,0.925427
uuid-d8e0da7beeca48978dd39fbd6daccf3c,Opdivo,0.455381
uuid-d8e0da7beeca48978dd39fbd6daccf3c,therapy,0.553576
uuid-d8e0da7beeca48978dd39fbd6daccf3c,nivolumab,0.430013
uuid-d8e0da7beeca48978dd39fbd6daccf3c,regimen,0.372979
uuid-d8e0da7beeca48978dd39fbd6daccf3c,treated,0.55089
uuid-d8e0da7beeca48978dd39fbd6daccf3c,pts,0.517001
uuid-d8e0da7beeca48978dd39fbd6daccf3c,treatment,0.641425
uuid-d8e0da7beeca48978dd39fbd6daccf3c,using nivo,0.310205
uuid-d8e0da7beeca48978dd39fbd6daccf3c,cHL,0.444782
uuid-d8e0da7beeca48978dd39fbd6daccf3c,progression,0.60548
uuid-d8e0da7beeca48978dd39fbd6daccf3c,chemotherapy,0.322155
uuid-d8e0da7beeca48978dd39fbd6daccf3c,respond,0.439039
uuid-d8e0da7beeca48978dd39fbd6daccf3c,option,0.313593
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,RTL,0.316608
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,1L,0.322
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,NTL,0.338552
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,RCC,0.362686
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,pts,0.301248
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,PD-L1,0.450981
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,PD-L1 testing,0.331115
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,testing,0.36377
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,using nivo,0.329222
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,NSCLC patients,0.48382
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,SCCHN,0.358432
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,oncologist,0.385174
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,indicated,0.496585
uuid-fdf4bbbd9c624f5db41152fecb4d7efd,bladder,0.437876
uuid-7b5db495065d41c0940912d64c186df1,patients,0.562991
uuid-7b5db495065d41c0940912d64c186df1,RTL,0.301169
uuid-7b5db495065d41c0940912d64c186df1,nivolumab,0.346376
uuid-7b5db495065d41c0940912d64c186df1,1L,0.366807
uuid-7b5db495065d41c0940912d64c186df1,treated,0.380926
uuid-7b5db495065d41c0940912d64c186df1,RCC,0.433457
uuid-7b5db495065d41c0940912d64c186df1,2L,0.368886
uuid-7b5db495065d41c0940912d64c186df1,pts,0.368377
uuid-7b5db495065d41c0940912d64c186df1,stated,0.388379
uuid-7b5db495065d41c0940912d64c186df1,approval,0.432763
uuid-7b5db495065d41c0940912d64c186df1,preferred,0.339869
uuid-7b5db495065d41c0940912d64c186df1,monotherapy,0.301959
uuid-7b5db495065d41c0940912d64c186df1,using nivo,0.556426
uuid-7b5db495065d41c0940912d64c186df1,clinical trials,0.306107
uuid-7b5db495065d41c0940912d64c186df1,NSCLC patients,0.320244
uuid-7b5db495065d41c0940912d64c186df1,approved,0.35248
uuid-7b5db495065d41c0940912d64c186df1,SCCHN,0.553549
uuid-7b5db495065d41c0940912d64c186df1,HCP,0.347404
uuid-7b5db495065d41c0940912d64c186df1,impressed,0.31922
uuid-7b5db495065d41c0940912d64c186df1,tumor types,0.378419
uuid-7b5db495065d41c0940912d64c186df1,LTL,0.334883
uuid-7b5db495065d41c0940912d64c186df1,SCLC,0.32837
uuid-7b5db495065d41c0940912d64c186df1,Regional TL,0.417995
uuid-7b5db495065d41c0940912d64c186df1,RTL stated,0.525747
uuid-7b5db495065d41c0940912d64c186df1,TL shared,0.373971
uuid-7b5db495065d41c0940912d64c186df1,option,0.367841
uuid-7b5db495065d41c0940912d64c186df1,bladder,0.544034
uuid-02d59e26a71e4d4788becf54838bbf18,Opdivo,0.338506
uuid-02d59e26a71e4d4788becf54838bbf18,dose,0.407493
uuid-02d59e26a71e4d4788becf54838bbf18,efficacy,0.488864
uuid-02d59e26a71e4d4788becf54838bbf18,atezo,0.331288
uuid-02d59e26a71e4d4788becf54838bbf18,regards,0.349327
uuid-02d59e26a71e4d4788becf54838bbf18,data,0.306626
uuid-02d59e26a71e4d4788becf54838bbf18,indication,0.378098
uuid-02d59e26a71e4d4788becf54838bbf18,nivo and pembro,0.351794
uuid-02d59e26a71e4d4788becf54838bbf18,vs,0.414974
uuid-02d59e26a71e4d4788becf54838bbf18,Keytruda,0.591519
uuid-02d59e26a71e4d4788becf54838bbf18,flat dosing,0.479756
uuid-6f4c1b414947417aba692bdebcf58e6f,pembro,0.391873
uuid-6f4c1b414947417aba692bdebcf58e6f,1L,0.593872
uuid-6f4c1b414947417aba692bdebcf58e6f,PDL1,0.373938
uuid-6f4c1b414947417aba692bdebcf58e6f,RCC,0.317669
uuid-6f4c1b414947417aba692bdebcf58e6f,chemo,0.374786
uuid-6f4c1b414947417aba692bdebcf58e6f,2L,0.517558
uuid-6f4c1b414947417aba692bdebcf58e6f,agents,0.453983
uuid-6f4c1b414947417aba692bdebcf58e6f,atezo,0.380098
uuid-6f4c1b414947417aba692bdebcf58e6f,preferred,0.471533
uuid-6f4c1b414947417aba692bdebcf58e6f,monotherapy,0.470027
uuid-6f4c1b414947417aba692bdebcf58e6f,using nivo,0.35676
uuid-6f4c1b414947417aba692bdebcf58e6f,data,0.368587
uuid-6f4c1b414947417aba692bdebcf58e6f,clinical trials,0.345868
uuid-6f4c1b414947417aba692bdebcf58e6f,indication,0.318947
uuid-6f4c1b414947417aba692bdebcf58e6f,PD1,0.3057
uuid-6f4c1b414947417aba692bdebcf58e6f,approved,0.427701
uuid-6f4c1b414947417aba692bdebcf58e6f,nivo and pembro,0.370004
uuid-6f4c1b414947417aba692bdebcf58e6f,believes,0.415201
uuid-6f4c1b414947417aba692bdebcf58e6f,chemotherapy,0.317055
uuid-6f4c1b414947417aba692bdebcf58e6f,tumor types,0.310343
uuid-6f4c1b414947417aba692bdebcf58e6f,feels,0.560477
uuid-6f4c1b414947417aba692bdebcf58e6f,PDL1 expression,0.374206
uuid-6f4c1b414947417aba692bdebcf58e6f,option,0.566739
uuid-4164ea24ae4e47ada9416d8e77ddd534,patients,0.307568
uuid-4164ea24ae4e47ada9416d8e77ddd534,nivolumab,0.36833
uuid-4164ea24ae4e47ada9416d8e77ddd534,trial,0.403622
uuid-4164ea24ae4e47ada9416d8e77ddd534,NTL,0.369584
uuid-4164ea24ae4e47ada9416d8e77ddd534,chemotherapy,0.355634
uuid-a4e9d5cf378842f797e3e3b906e235c3,toxicity,0.361649
uuid-a4e9d5cf378842f797e3e3b906e235c3,drug,0.304062
uuid-a4e9d5cf378842f797e3e3b906e235c3,Keytruda,0.331435
uuid-a4e9d5cf378842f797e3e3b906e235c3,flat dosing,0.335686
uuid-235a641bfc58492db89853a11146c670,institution,0.558261
uuid-235a641bfc58492db89853a11146c670,NCCN,0.51816
uuid-0b6357ac7ff14e3a8913831cacee37ff,lung,0.303337
uuid-0b6357ac7ff14e3a8913831cacee37ff,toxicity,0.398448
uuid-0b6357ac7ff14e3a8913831cacee37ff,regimen,0.44148
uuid-0b6357ac7ff14e3a8913831cacee37ff,melanoma,0.439235
uuid-0b6357ac7ff14e3a8913831cacee37ff,Ipi,0.425108
uuid-0b6357ac7ff14e3a8913831cacee37ff,monotherapy,0.309789
uuid-0b6357ac7ff14e3a8913831cacee37ff,AI,0.468698
uuid-0b6357ac7ff14e3a8913831cacee37ff,SCLC,0.407115
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,TL,0.577344
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,pembro,0.335806
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,1L,0.315528
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,PDL1,0.475568
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,TL stated,0.31535
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,Merck,0.386691
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,PD-L1,0.715003
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,approval,0.360324
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,atezo,0.364999
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,PD-L1 testing,0.686152
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,testing,0.680354
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,PDL1 testing,0.564021
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,NSCLC patients,0.460977
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,indicated,0.334084
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,assay,0.602579
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,PDL1 expression,0.352047
uuid-8c3b27e3bd594c8185d03ff4f7b82d39,biomarker,0.381321
uuid-4bba9b00ccff4455a0c6b3f2cd5a97ec,TL,0.327972
uuid-4bba9b00ccff4455a0c6b3f2cd5a97ec,PDL1,0.681659
uuid-4bba9b00ccff4455a0c6b3f2cd5a97ec,Merck,0.319232
uuid-4bba9b00ccff4455a0c6b3f2cd5a97ec,institution,0.325615
uuid-4bba9b00ccff4455a0c6b3f2cd5a97ec,PD-L1,0.790986
uuid-4bba9b00ccff4455a0c6b3f2cd5a97ec,PD-L1 testing,0.686619
uuid-4bba9b00ccff4455a0c6b3f2cd5a97ec,testing,0.788309
uuid-4bba9b00ccff4455a0c6b3f2cd5a97ec,PDL1 testing,0.611042
uuid-4bba9b00ccff4455a0c6b3f2cd5a97ec,NSCLC patients,0.520486
uuid-4bba9b00ccff4455a0c6b3f2cd5a97ec,assay,0.760385
uuid-4bba9b00ccff4455a0c6b3f2cd5a97ec,PDL1 expression,0.557096
uuid-4bba9b00ccff4455a0c6b3f2cd5a97ec,biomarker,0.576292
uuid-5cfd9ac06f394d8caaf947c076782af2,toxicity,0.40703
uuid-989f566ac5cf4e38b899d4248e489dd3,pembro,0.369878
uuid-989f566ac5cf4e38b899d4248e489dd3,trial,0.726369
uuid-989f566ac5cf4e38b899d4248e489dd3,NTL,0.329009
uuid-989f566ac5cf4e38b899d4248e489dd3,data,0.422734
uuid-989f566ac5cf4e38b899d4248e489dd3,ORR,0.40887
uuid-989f566ac5cf4e38b899d4248e489dd3,impressed,0.326786
uuid-6f871049b5d943e0bbb6797838583091,TL,0.44821
uuid-6f871049b5d943e0bbb6797838583091,TL stated,0.395364
uuid-6f871049b5d943e0bbb6797838583091,institution,0.422944
uuid-6f871049b5d943e0bbb6797838583091,PD-L1,0.531507
uuid-6f871049b5d943e0bbb6797838583091,PD-L1 testing,0.655097
uuid-6f871049b5d943e0bbb6797838583091,testing,0.617492
uuid-6f871049b5d943e0bbb6797838583091,PDL1 testing,0.572347
uuid-6f871049b5d943e0bbb6797838583091,NSCLC patients,0.470928
uuid-6f871049b5d943e0bbb6797838583091,oncology,0.342681
uuid-6f871049b5d943e0bbb6797838583091,oncologist,0.351393
uuid-6f871049b5d943e0bbb6797838583091,clinical,0.393289
uuid-6f871049b5d943e0bbb6797838583091,academic,0.363072
uuid-6f871049b5d943e0bbb6797838583091,assay,0.353732
uuid-6f871049b5d943e0bbb6797838583091,biomarker,0.320433
uuid-9d20a7518ce14b109e1290ca9b50a60a,TL,0.307484
uuid-9d20a7518ce14b109e1290ca9b50a60a,pembro,0.381605
uuid-9d20a7518ce14b109e1290ca9b50a60a,PDL1,0.506285
uuid-9d20a7518ce14b109e1290ca9b50a60a,commented,0.364796
uuid-9d20a7518ce14b109e1290ca9b50a60a,Merck,0.440261
uuid-9d20a7518ce14b109e1290ca9b50a60a,stated,0.322225
uuid-9d20a7518ce14b109e1290ca9b50a60a,PD-L1,0.443398
uuid-9d20a7518ce14b109e1290ca9b50a60a,approval,0.303195
uuid-9d20a7518ce14b109e1290ca9b50a60a,atezo,0.387935
uuid-9d20a7518ce14b109e1290ca9b50a60a,PD-L1 testing,0.42429
uuid-9d20a7518ce14b109e1290ca9b50a60a,testing,0.441328
uuid-9d20a7518ce14b109e1290ca9b50a60a,data,0.404223
uuid-9d20a7518ce14b109e1290ca9b50a60a,PDL1 testing,0.482608
uuid-9d20a7518ce14b109e1290ca9b50a60a,indication,0.338087
uuid-9d20a7518ce14b109e1290ca9b50a60a,NSCLC patients,0.352753
uuid-9d20a7518ce14b109e1290ca9b50a60a,SCCHN,0.306312
uuid-9d20a7518ce14b109e1290ca9b50a60a,nivo and pembro,0.354384
uuid-9d20a7518ce14b109e1290ca9b50a60a,TLs,0.374567
uuid-9d20a7518ce14b109e1290ca9b50a60a,assay,0.364653
uuid-9d20a7518ce14b109e1290ca9b50a60a,PDL1 expression,0.40349
uuid-55e8c40a9adc45519df09d316ede200f,BMS,0.385539
uuid-55e8c40a9adc45519df09d316ede200f,PDL1,0.627812
uuid-55e8c40a9adc45519df09d316ede200f,trial,0.454176
uuid-55e8c40a9adc45519df09d316ede200f,efficacy,0.56031
uuid-55e8c40a9adc45519df09d316ede200f,discussed,0.315715
uuid-55e8c40a9adc45519df09d316ede200f,Merck,0.376255
uuid-55e8c40a9adc45519df09d316ede200f,OS,0.627931
uuid-55e8c40a9adc45519df09d316ede200f,regards,0.376427
uuid-55e8c40a9adc45519df09d316ede200f,data,0.659381
uuid-55e8c40a9adc45519df09d316ede200f,PFS,0.691919
uuid-55e8c40a9adc45519df09d316ede200f,ORR,0.619706
uuid-55e8c40a9adc45519df09d316ede200f,nivo and pembro,0.564291
uuid-55e8c40a9adc45519df09d316ede200f,believes,0.333662
uuid-55e8c40a9adc45519df09d316ede200f,impressed,0.340253
uuid-55e8c40a9adc45519df09d316ede200f,assay,0.389972
uuid-55e8c40a9adc45519df09d316ede200f,PDL1 expression,0.560752
uuid-55e8c40a9adc45519df09d316ede200f,biomarker,0.372405
uuid-ebb1a482d9d049e7aa1456e04a644820,pembro,0.31395
uuid-ebb1a482d9d049e7aa1456e04a644820,RTL,0.367252
uuid-ebb1a482d9d049e7aa1456e04a644820,BMS,0.3781
uuid-ebb1a482d9d049e7aa1456e04a644820,trial,0.381635
uuid-ebb1a482d9d049e7aa1456e04a644820,efficacy,0.321585
uuid-ebb1a482d9d049e7aa1456e04a644820,shared,0.341459
uuid-ebb1a482d9d049e7aa1456e04a644820,commented,0.403
uuid-ebb1a482d9d049e7aa1456e04a644820,Merck,0.350804
uuid-ebb1a482d9d049e7aa1456e04a644820,stated,0.399668
uuid-ebb1a482d9d049e7aa1456e04a644820,approval,0.304547
uuid-ebb1a482d9d049e7aa1456e04a644820,data,0.628101
uuid-ebb1a482d9d049e7aa1456e04a644820,expressed,0.477394
uuid-ebb1a482d9d049e7aa1456e04a644820,mentioned,0.332507
uuid-ebb1a482d9d049e7aa1456e04a644820,clinical trials,0.311333
uuid-ebb1a482d9d049e7aa1456e04a644820,indication,0.508375
uuid-ebb1a482d9d049e7aa1456e04a644820,HCP,0.341994
uuid-ebb1a482d9d049e7aa1456e04a644820,ASCO,0.319138
uuid-ebb1a482d9d049e7aa1456e04a644820,impressed,0.521506
uuid-ebb1a482d9d049e7aa1456e04a644820,label,0.323093
uuid-ebb1a482d9d049e7aa1456e04a644820,LTL,0.367438
uuid-ebb1a482d9d049e7aa1456e04a644820,Keytruda,0.32876
uuid-ebb1a482d9d049e7aa1456e04a644820,TLs,0.356388
uuid-ebb1a482d9d049e7aa1456e04a644820,Regional TL,0.31756
uuid-ebb1a482d9d049e7aa1456e04a644820,flat dosing,0.591815
uuid-4aaae98c0d964cefa035d431d36251bf,RTL,0.495403
uuid-4aaae98c0d964cefa035d431d36251bf,BMS,0.342432
uuid-4aaae98c0d964cefa035d431d36251bf,trial,0.493105
uuid-4aaae98c0d964cefa035d431d36251bf,efficacy,0.318894
uuid-4aaae98c0d964cefa035d431d36251bf,NTL,0.512284
uuid-4aaae98c0d964cefa035d431d36251bf,commented,0.471424
uuid-4aaae98c0d964cefa035d431d36251bf,stated,0.428502
uuid-4aaae98c0d964cefa035d431d36251bf,OS,0.698119
uuid-4aaae98c0d964cefa035d431d36251bf,regards,0.313091
uuid-4aaae98c0d964cefa035d431d36251bf,data,0.68086
uuid-4aaae98c0d964cefa035d431d36251bf,expressed,0.374165
uuid-4aaae98c0d964cefa035d431d36251bf,PFS,0.73773
uuid-4aaae98c0d964cefa035d431d36251bf,ORR,0.683739
uuid-4aaae98c0d964cefa035d431d36251bf,ASCO,0.391998
uuid-4aaae98c0d964cefa035d431d36251bf,impressed,0.624142
uuid-4aaae98c0d964cefa035d431d36251bf,LTL,0.351161
uuid-4aaae98c0d964cefa035d431d36251bf,TLs,0.304664
uuid-4aaae98c0d964cefa035d431d36251bf,Regional TL,0.353753
uuid-f3cfb44c7261401e9030ddfb55458c9e,Nivo,0.320942
uuid-f3cfb44c7261401e9030ddfb55458c9e,patients,0.535862
uuid-f3cfb44c7261401e9030ddfb55458c9e,Opdivo,0.414907
uuid-f3cfb44c7261401e9030ddfb55458c9e,pembro,0.312078
uuid-f3cfb44c7261401e9030ddfb55458c9e,therapy,0.323553
uuid-f3cfb44c7261401e9030ddfb55458c9e,dose,0.573122
uuid-f3cfb44c7261401e9030ddfb55458c9e,nivolumab,0.595762
uuid-f3cfb44c7261401e9030ddfb55458c9e,toxicity,0.33299
uuid-f3cfb44c7261401e9030ddfb55458c9e,regimen,0.512745
uuid-f3cfb44c7261401e9030ddfb55458c9e,treated,0.499496
uuid-f3cfb44c7261401e9030ddfb55458c9e,RCC,0.349947
uuid-f3cfb44c7261401e9030ddfb55458c9e,combination,0.39708
uuid-f3cfb44c7261401e9030ddfb55458c9e,2L,0.426912
uuid-f3cfb44c7261401e9030ddfb55458c9e,pts,0.348871
uuid-f3cfb44c7261401e9030ddfb55458c9e,Ipi,0.355394
uuid-f3cfb44c7261401e9030ddfb55458c9e,preferred,0.549947
uuid-f3cfb44c7261401e9030ddfb55458c9e,monotherapy,0.463618
uuid-f3cfb44c7261401e9030ddfb55458c9e,treatment,0.461357
uuid-f3cfb44c7261401e9030ddfb55458c9e,using nivo,0.468648
uuid-f3cfb44c7261401e9030ddfb55458c9e,combo,0.319702
uuid-f3cfb44c7261401e9030ddfb55458c9e,approved,0.358822
uuid-f3cfb44c7261401e9030ddfb55458c9e,RTL stated,0.554891
uuid-f3cfb44c7261401e9030ddfb55458c9e,TL shared,0.338215
uuid-f3cfb44c7261401e9030ddfb55458c9e,option,0.376032
uuid-f3cfb44c7261401e9030ddfb55458c9e,flat dosing,0.382835
uuid-2641a4573731452e87d6ccea2842bbb3,Nivo,0.437401
uuid-2641a4573731452e87d6ccea2842bbb3,pembro,0.604931
uuid-2641a4573731452e87d6ccea2842bbb3,1L,0.751271
uuid-2641a4573731452e87d6ccea2842bbb3,PDL1,0.338877
uuid-2641a4573731452e87d6ccea2842bbb3,efficacy,0.334256
uuid-2641a4573731452e87d6ccea2842bbb3,combination,0.428618
uuid-2641a4573731452e87d6ccea2842bbb3,chemo,0.463941
uuid-2641a4573731452e87d6ccea2842bbb3,2L,0.693386
uuid-2641a4573731452e87d6ccea2842bbb3,pts,0.339474
uuid-2641a4573731452e87d6ccea2842bbb3,agents,0.521262
uuid-2641a4573731452e87d6ccea2842bbb3,approval,0.353746
uuid-2641a4573731452e87d6ccea2842bbb3,atezo,0.573223
uuid-2641a4573731452e87d6ccea2842bbb3,preferred,0.607213
uuid-2641a4573731452e87d6ccea2842bbb3,monotherapy,0.692619
uuid-2641a4573731452e87d6ccea2842bbb3,using nivo,0.484163
uuid-2641a4573731452e87d6ccea2842bbb3,combo,0.506843
uuid-2641a4573731452e87d6ccea2842bbb3,clinical trials,0.316242
uuid-2641a4573731452e87d6ccea2842bbb3,indication,0.366551
uuid-2641a4573731452e87d6ccea2842bbb3,PD1,0.387638
uuid-2641a4573731452e87d6ccea2842bbb3,approved,0.507015
uuid-2641a4573731452e87d6ccea2842bbb3,nivo and pembro,0.41347
uuid-2641a4573731452e87d6ccea2842bbb3,believes,0.474139
uuid-2641a4573731452e87d6ccea2842bbb3,chemotherapy,0.382385
uuid-2641a4573731452e87d6ccea2842bbb3,feels,0.549703
uuid-2641a4573731452e87d6ccea2842bbb3,RTL stated,0.366649
uuid-2641a4573731452e87d6ccea2842bbb3,option,0.688542
uuid-0ec918e74d364bddb250419de9266e9c,Nivo,0.48744
uuid-0ec918e74d364bddb250419de9266e9c,patients,0.802351
uuid-0ec918e74d364bddb250419de9266e9c,Opdivo,0.403443
uuid-0ec918e74d364bddb250419de9266e9c,therapy,0.794487
uuid-0ec918e74d364bddb250419de9266e9c,nivolumab,0.57606
uuid-0ec918e74d364bddb250419de9266e9c,regimen,0.518569
uuid-0ec918e74d364bddb250419de9266e9c,treated,0.560917
uuid-0ec918e74d364bddb250419de9266e9c,chemo,0.434353
uuid-0ec918e74d364bddb250419de9266e9c,pts,0.574548
uuid-0ec918e74d364bddb250419de9266e9c,monotherapy,0.436233
uuid-0ec918e74d364bddb250419de9266e9c,treatment,0.751458
uuid-0ec918e74d364bddb250419de9266e9c,using nivo,0.359684
uuid-0ec918e74d364bddb250419de9266e9c,response,0.497104
uuid-0ec918e74d364bddb250419de9266e9c,PD1,0.474338
uuid-0ec918e74d364bddb250419de9266e9c,cHL,0.561137
uuid-0ec918e74d364bddb250419de9266e9c,progression,0.725003
uuid-0ec918e74d364bddb250419de9266e9c,chemotherapy,0.523837
uuid-0ec918e74d364bddb250419de9266e9c,respond,0.495538
uuid-0ec918e74d364bddb250419de9266e9c,option,0.354123
uuid-dd2fd889b7074788896dfaab90888155,Nivo,0.312616
uuid-dd2fd889b7074788896dfaab90888155,patients,0.838532
uuid-dd2fd889b7074788896dfaab90888155,Opdivo,0.403624
uuid-dd2fd889b7074788896dfaab90888155,therapy,0.57722
uuid-dd2fd889b7074788896dfaab90888155,nivolumab,0.431609
uuid-dd2fd889b7074788896dfaab90888155,regimen,0.545228
uuid-dd2fd889b7074788896dfaab90888155,treated,0.444859
uuid-dd2fd889b7074788896dfaab90888155,chemo,0.388814
uuid-dd2fd889b7074788896dfaab90888155,pts,0.486753
uuid-dd2fd889b7074788896dfaab90888155,monotherapy,0.395142
uuid-dd2fd889b7074788896dfaab90888155,treatment,0.568356
uuid-dd2fd889b7074788896dfaab90888155,using nivo,0.310154
uuid-dd2fd889b7074788896dfaab90888155,response,0.333607
uuid-dd2fd889b7074788896dfaab90888155,cHL,0.310893
uuid-dd2fd889b7074788896dfaab90888155,progression,0.545555
uuid-dd2fd889b7074788896dfaab90888155,chemotherapy,0.435484
uuid-dd2fd889b7074788896dfaab90888155,respond,0.418183
uuid-dd2fd889b7074788896dfaab90888155,option,0.366487
uuid-c6e757c360d04345afe6214875c5154c,patients,0.492334
uuid-c6e757c360d04345afe6214875c5154c,toxicity,0.52946
uuid-c6e757c360d04345afe6214875c5154c,regimen,0.455535
uuid-c6e757c360d04345afe6214875c5154c,monotherapy,0.305301
uuid-c6e757c360d04345afe6214875c5154c,treatment,0.338881
uuid-c6e757c360d04345afe6214875c5154c,response,0.358564
uuid-c6e757c360d04345afe6214875c5154c,progression,0.378468
uuid-c6e757c360d04345afe6214875c5154c,chemotherapy,0.325006
uuid-c6e757c360d04345afe6214875c5154c,respond,0.35927
uuid-32b488395f0447559e9c7ea3416b554e,Nivo,0.437565
uuid-32b488395f0447559e9c7ea3416b554e,patients,0.701083
uuid-32b488395f0447559e9c7ea3416b554e,Opdivo,0.393983
uuid-32b488395f0447559e9c7ea3416b554e,therapy,0.526131
uuid-32b488395f0447559e9c7ea3416b554e,dose,0.422719
uuid-32b488395f0447559e9c7ea3416b554e,nivolumab,0.57
uuid-32b488395f0447559e9c7ea3416b554e,toxicity,0.378259
uuid-32b488395f0447559e9c7ea3416b554e,regimen,0.649575
uuid-32b488395f0447559e9c7ea3416b554e,treated,0.461622
uuid-32b488395f0447559e9c7ea3416b554e,combination,0.38306
uuid-32b488395f0447559e9c7ea3416b554e,chemo,0.450989
uuid-32b488395f0447559e9c7ea3416b554e,2L,0.306404
uuid-32b488395f0447559e9c7ea3416b554e,pts,0.60024
uuid-32b488395f0447559e9c7ea3416b554e,Ipi,0.35906
uuid-32b488395f0447559e9c7ea3416b554e,preferred,0.388993
uuid-32b488395f0447559e9c7ea3416b554e,monotherapy,0.550017
uuid-32b488395f0447559e9c7ea3416b554e,treatment,0.623033
uuid-32b488395f0447559e9c7ea3416b554e,using nivo,0.368345
uuid-32b488395f0447559e9c7ea3416b554e,response,0.354421
uuid-32b488395f0447559e9c7ea3416b554e,combo,0.355378
uuid-32b488395f0447559e9c7ea3416b554e,PD1,0.445136
uuid-32b488395f0447559e9c7ea3416b554e,progression,0.556797
uuid-32b488395f0447559e9c7ea3416b554e,chemotherapy,0.432452
uuid-32b488395f0447559e9c7ea3416b554e,respond,0.445005
uuid-32b488395f0447559e9c7ea3416b554e,option,0.515361
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,Nivo,0.458327
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,patients,0.546611
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,therapy,0.413527
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,efficacy,0.37848
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,regimen,0.436948
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,chemo,0.564024
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,pts,0.458786
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,OS,0.523943
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,monotherapy,0.42386
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,treatment,0.421477
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,response,0.488936
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,PFS,0.559531
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,PD1,0.344623
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,ORR,0.464467
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,progression,0.547166
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,chemotherapy,0.566193
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,respond,0.476225
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,feels,0.368781
uuid-faa1fb6bc3fe4c1ab3f59482b842a55a,option,0.445243
uuid-6edb4e5e8f704afca0460e367305a94d,TL,0.522746
uuid-6edb4e5e8f704afca0460e367305a94d,lung,0.318251
uuid-6edb4e5e8f704afca0460e367305a94d,1L,0.369467
uuid-6edb4e5e8f704afca0460e367305a94d,RCC,0.365649
uuid-6edb4e5e8f704afca0460e367305a94d,TL stated,0.537544
uuid-6edb4e5e8f704afca0460e367305a94d,2L,0.336134
uuid-6edb4e5e8f704afca0460e367305a94d,institution,0.363813
uuid-6edb4e5e8f704afca0460e367305a94d,PD-L1,0.700761
uuid-6edb4e5e8f704afca0460e367305a94d,approval,0.396981
uuid-6edb4e5e8f704afca0460e367305a94d,atezo,0.323309
uuid-6edb4e5e8f704afca0460e367305a94d,PD-L1 testing,0.760979
uuid-6edb4e5e8f704afca0460e367305a94d,testing,0.821289
uuid-6edb4e5e8f704afca0460e367305a94d,PDL1 testing,0.742493
uuid-6edb4e5e8f704afca0460e367305a94d,NSCLC patients,0.75946
uuid-6edb4e5e8f704afca0460e367305a94d,SCCHN,0.309583
uuid-6edb4e5e8f704afca0460e367305a94d,assay,0.644435
uuid-6edb4e5e8f704afca0460e367305a94d,RTL stated,0.349455
uuid-6edb4e5e8f704afca0460e367305a94d,TL shared,0.343616
uuid-3217af1d195140f3bc802a0658fcb8e3,Nivo,0.515013
uuid-3217af1d195140f3bc802a0658fcb8e3,patients,0.302128
uuid-3217af1d195140f3bc802a0658fcb8e3,pembro,0.451486
uuid-3217af1d195140f3bc802a0658fcb8e3,therapy,0.327141
uuid-3217af1d195140f3bc802a0658fcb8e3,trial,0.437318
uuid-3217af1d195140f3bc802a0658fcb8e3,efficacy,0.303531
uuid-3217af1d195140f3bc802a0658fcb8e3,combination,0.317707
uuid-3217af1d195140f3bc802a0658fcb8e3,chemo,0.457397
uuid-3217af1d195140f3bc802a0658fcb8e3,Ipi,0.301574
uuid-3217af1d195140f3bc802a0658fcb8e3,preferred,0.323565
uuid-3217af1d195140f3bc802a0658fcb8e3,monotherapy,0.396034
uuid-3217af1d195140f3bc802a0658fcb8e3,indication,0.333836
uuid-3217af1d195140f3bc802a0658fcb8e3,approved,0.330527
uuid-3217af1d195140f3bc802a0658fcb8e3,chemotherapy,0.496618
uuid-3217af1d195140f3bc802a0658fcb8e3,option,0.431725
uuid-3c4fe48900b345308fe7bd62b92d2ab8,pembro,0.34417
uuid-3c4fe48900b345308fe7bd62b92d2ab8,BMS,0.308739
uuid-3c4fe48900b345308fe7bd62b92d2ab8,PDL1,0.469241
uuid-3c4fe48900b345308fe7bd62b92d2ab8,efficacy,0.518794
uuid-3c4fe48900b345308fe7bd62b92d2ab8,commented,0.419407
uuid-3c4fe48900b345308fe7bd62b92d2ab8,stated,0.381247
uuid-3c4fe48900b345308fe7bd62b92d2ab8,OS,0.477212
uuid-3c4fe48900b345308fe7bd62b92d2ab8,atezo,0.403188
uuid-3c4fe48900b345308fe7bd62b92d2ab8,regards,0.333182
uuid-3c4fe48900b345308fe7bd62b92d2ab8,data,0.666434
uuid-3c4fe48900b345308fe7bd62b92d2ab8,expressed,0.339509
uuid-3c4fe48900b345308fe7bd62b92d2ab8,clinical trials,0.306277
uuid-3c4fe48900b345308fe7bd62b92d2ab8,indication,0.302057
uuid-3c4fe48900b345308fe7bd62b92d2ab8,PFS,0.440865
uuid-3c4fe48900b345308fe7bd62b92d2ab8,ORR,0.51056
uuid-3c4fe48900b345308fe7bd62b92d2ab8,nivo and pembro,0.468984
uuid-3c4fe48900b345308fe7bd62b92d2ab8,believes,0.340639
uuid-3c4fe48900b345308fe7bd62b92d2ab8,impressed,0.550547
uuid-3c4fe48900b345308fe7bd62b92d2ab8,TLs,0.608562
uuid-3c4fe48900b345308fe7bd62b92d2ab8,feels,0.404864
uuid-3c4fe48900b345308fe7bd62b92d2ab8,PDL1 expression,0.491597
uuid-a9aa8c7d0878443d9f0ac8fce867972c,patients,0.325462
uuid-a9aa8c7d0878443d9f0ac8fce867972c,RTL,0.416842
uuid-a9aa8c7d0878443d9f0ac8fce867972c,dose,0.345186
uuid-a9aa8c7d0878443d9f0ac8fce867972c,nivolumab,0.623978
uuid-a9aa8c7d0878443d9f0ac8fce867972c,treated,0.37648
uuid-a9aa8c7d0878443d9f0ac8fce867972c,NTL,0.338924
uuid-a9aa8c7d0878443d9f0ac8fce867972c,SCCHN,0.317545
uuid-a9aa8c7d0878443d9f0ac8fce867972c,Regional TL,0.359181
uuid-a9aa8c7d0878443d9f0ac8fce867972c,RTL stated,0.328024
uuid-a9aa8c7d0878443d9f0ac8fce867972c,flat dosing,0.31482
uuid-43d18ad9971548caaf5dbf2aa3a8c57a,Nivo,0.370195
uuid-43d18ad9971548caaf5dbf2aa3a8c57a,patients,0.442937
uuid-43d18ad9971548caaf5dbf2aa3a8c57a,therapy,0.384735
uuid-43d18ad9971548caaf5dbf2aa3a8c57a,nivolumab,0.444237
uuid-43d18ad9971548caaf5dbf2aa3a8c57a,treated,0.33284
uuid-43d18ad9971548caaf5dbf2aa3a8c57a,approval,0.526593
uuid-43d18ad9971548caaf5dbf2aa3a8c57a,using nivo,0.338625
uuid-43d18ad9971548caaf5dbf2aa3a8c57a,cHL,0.575012
uuid-b237083e24814d229874acfae2f35d1c,Nivo,0.400329
uuid-b237083e24814d229874acfae2f35d1c,patients,0.791291
uuid-b237083e24814d229874acfae2f35d1c,Opdivo,0.402704
uuid-b237083e24814d229874acfae2f35d1c,therapy,0.825956
uuid-b237083e24814d229874acfae2f35d1c,nivolumab,0.645501
uuid-b237083e24814d229874acfae2f35d1c,regimen,0.399502
uuid-b237083e24814d229874acfae2f35d1c,treated,0.575768
uuid-b237083e24814d229874acfae2f35d1c,chemo,0.381879
uuid-b237083e24814d229874acfae2f35d1c,pts,0.472323
uuid-b237083e24814d229874acfae2f35d1c,monotherapy,0.363584
uuid-b237083e24814d229874acfae2f35d1c,treatment,0.702353
uuid-b237083e24814d229874acfae2f35d1c,using nivo,0.38464
uuid-b237083e24814d229874acfae2f35d1c,response,0.416798
uuid-b237083e24814d229874acfae2f35d1c,PD1,0.448369
uuid-b237083e24814d229874acfae2f35d1c,cHL,0.633071
uuid-b237083e24814d229874acfae2f35d1c,progression,0.642612
uuid-b237083e24814d229874acfae2f35d1c,chemotherapy,0.506513
uuid-b237083e24814d229874acfae2f35d1c,respond,0.427059
uuid-b237083e24814d229874acfae2f35d1c,option,0.335636
uuid-816cd3d038fb4cc6860ce448003898b3,RTL,0.39862
uuid-816cd3d038fb4cc6860ce448003898b3,therapy,0.341773
uuid-816cd3d038fb4cc6860ce448003898b3,nivolumab,0.753333
uuid-816cd3d038fb4cc6860ce448003898b3,regimen,0.462897
uuid-816cd3d038fb4cc6860ce448003898b3,treated,0.554472
uuid-816cd3d038fb4cc6860ce448003898b3,melanoma,0.536726
uuid-816cd3d038fb4cc6860ce448003898b3,shared,0.353357
uuid-816cd3d038fb4cc6860ce448003898b3,RCC,0.546281
uuid-816cd3d038fb4cc6860ce448003898b3,combination,0.537374
uuid-816cd3d038fb4cc6860ce448003898b3,pts,0.33816
uuid-816cd3d038fb4cc6860ce448003898b3,monotherapy,0.410211
uuid-816cd3d038fb4cc6860ce448003898b3,treatment,0.326246
uuid-816cd3d038fb4cc6860ce448003898b3,using nivo,0.409841
uuid-816cd3d038fb4cc6860ce448003898b3,combo,0.418774
uuid-816cd3d038fb4cc6860ce448003898b3,PD1,0.392034
uuid-816cd3d038fb4cc6860ce448003898b3,SCCHN,0.454794
uuid-816cd3d038fb4cc6860ce448003898b3,SCLC,0.473393
uuid-816cd3d038fb4cc6860ce448003898b3,Regional TL,0.453249
uuid-816cd3d038fb4cc6860ce448003898b3,RTL stated,0.585448
uuid-816cd3d038fb4cc6860ce448003898b3,TL shared,0.51133
uuid-816cd3d038fb4cc6860ce448003898b3,bladder,0.403908
uuid-d89baf891c874363891e3b8ccfa0539a,patients,0.76907
uuid-d89baf891c874363891e3b8ccfa0539a,Opdivo,0.414735
uuid-d89baf891c874363891e3b8ccfa0539a,therapy,0.443572
uuid-d89baf891c874363891e3b8ccfa0539a,nivolumab,0.369743
uuid-d89baf891c874363891e3b8ccfa0539a,treated,0.525901
uuid-d89baf891c874363891e3b8ccfa0539a,pts,0.529885
uuid-d89baf891c874363891e3b8ccfa0539a,testing,0.332394
uuid-d89baf891c874363891e3b8ccfa0539a,treatment,0.482333
uuid-d89baf891c874363891e3b8ccfa0539a,NSCLC patients,0.453592
uuid-d89baf891c874363891e3b8ccfa0539a,cHL,0.349361
uuid-d89baf891c874363891e3b8ccfa0539a,progression,0.469611
uuid-d89baf891c874363891e3b8ccfa0539a,respond,0.306942
uuid-97222ade92ca4d4e87840370ceb813a6,patients,0.321069
uuid-97222ade92ca4d4e87840370ceb813a6,therapy,0.329455
uuid-97222ade92ca4d4e87840370ceb813a6,treated,0.327503
uuid-97222ade92ca4d4e87840370ceb813a6,chemo,0.330958
uuid-97222ade92ca4d4e87840370ceb813a6,tumor,0.400901
uuid-97222ade92ca4d4e87840370ceb813a6,pts,0.430987
uuid-97222ade92ca4d4e87840370ceb813a6,response,0.393736
uuid-97222ade92ca4d4e87840370ceb813a6,progression,0.410766
uuid-97222ade92ca4d4e87840370ceb813a6,feels,0.486691
uuid-103f2a66a98c4693b4e9a8e29b5c814e,Nivo,0.636098
uuid-103f2a66a98c4693b4e9a8e29b5c814e,patients,0.396108
uuid-103f2a66a98c4693b4e9a8e29b5c814e,pembro,0.400305
uuid-103f2a66a98c4693b4e9a8e29b5c814e,nivolumab,0.381697
uuid-103f2a66a98c4693b4e9a8e29b5c814e,trial,0.481496
uuid-103f2a66a98c4693b4e9a8e29b5c814e,efficacy,0.313257
uuid-103f2a66a98c4693b4e9a8e29b5c814e,regimen,0.328134
uuid-103f2a66a98c4693b4e9a8e29b5c814e,combination,0.34996
uuid-103f2a66a98c4693b4e9a8e29b5c814e,chemo,0.435555
uuid-103f2a66a98c4693b4e9a8e29b5c814e,pts,0.32398
uuid-103f2a66a98c4693b4e9a8e29b5c814e,Ipi,0.380913
uuid-103f2a66a98c4693b4e9a8e29b5c814e,OS,0.33098
uuid-103f2a66a98c4693b4e9a8e29b5c814e,monotherapy,0.399985
uuid-103f2a66a98c4693b4e9a8e29b5c814e,using nivo,0.306149
uuid-103f2a66a98c4693b4e9a8e29b5c814e,data,0.344791
uuid-103f2a66a98c4693b4e9a8e29b5c814e,clinical trials,0.304399
uuid-103f2a66a98c4693b4e9a8e29b5c814e,PFS,0.303494
uuid-103f2a66a98c4693b4e9a8e29b5c814e,ORR,0.392356
uuid-103f2a66a98c4693b4e9a8e29b5c814e,chemotherapy,0.428219
uuid-103f2a66a98c4693b4e9a8e29b5c814e,impressed,0.475081
uuid-103f2a66a98c4693b4e9a8e29b5c814e,feels,0.48168
uuid-103f2a66a98c4693b4e9a8e29b5c814e,option,0.309574
uuid-6da754c57f4c406b980e952f2d96c921,patients,0.785213
uuid-6da754c57f4c406b980e952f2d96c921,Opdivo,0.431351
uuid-6da754c57f4c406b980e952f2d96c921,therapy,0.716078
uuid-6da754c57f4c406b980e952f2d96c921,nivolumab,0.583159
uuid-6da754c57f4c406b980e952f2d96c921,regimen,0.58192
uuid-6da754c57f4c406b980e952f2d96c921,treated,0.628834
uuid-6da754c57f4c406b980e952f2d96c921,chemo,0.391494
uuid-6da754c57f4c406b980e952f2d96c921,pts,0.499271
uuid-6da754c57f4c406b980e952f2d96c921,monotherapy,0.416211
uuid-6da754c57f4c406b980e952f2d96c921,treatment,0.814427
uuid-6da754c57f4c406b980e952f2d96c921,response,0.470318
uuid-6da754c57f4c406b980e952f2d96c921,PD1,0.42638
uuid-6da754c57f4c406b980e952f2d96c921,cHL,0.457605
uuid-6da754c57f4c406b980e952f2d96c921,progression,0.71681
uuid-6da754c57f4c406b980e952f2d96c921,chemotherapy,0.486958
uuid-6da754c57f4c406b980e952f2d96c921,respond,0.527793
uuid-6da754c57f4c406b980e952f2d96c921,option,0.38507
uuid-707c147aaf574826a1951f2ef71a5c1a,Nivo,0.437665
uuid-707c147aaf574826a1951f2ef71a5c1a,patients,0.51355
uuid-707c147aaf574826a1951f2ef71a5c1a,therapy,0.618743
uuid-707c147aaf574826a1951f2ef71a5c1a,nivolumab,0.360577
uuid-707c147aaf574826a1951f2ef71a5c1a,treatment,0.335154
uuid-707c147aaf574826a1951f2ef71a5c1a,cHL,0.737074
uuid-707c147aaf574826a1951f2ef71a5c1a,chemotherapy,0.369944
uuid-8367261952904a1780c2ad07b5cc6694,Nivo,0.461757
uuid-8367261952904a1780c2ad07b5cc6694,patients,0.340178
uuid-8367261952904a1780c2ad07b5cc6694,Opdivo,0.311758
uuid-8367261952904a1780c2ad07b5cc6694,therapy,0.43114
uuid-8367261952904a1780c2ad07b5cc6694,nivolumab,0.334794
uuid-8367261952904a1780c2ad07b5cc6694,using nivo,0.323634
uuid-8367261952904a1780c2ad07b5cc6694,mentioned,0.371996
uuid-8367261952904a1780c2ad07b5cc6694,cHL,0.667103
uuid-08747bf27b9e4bf4b18a698e8fa02013,Nivo,0.412133
uuid-08747bf27b9e4bf4b18a698e8fa02013,patients,0.413195
uuid-08747bf27b9e4bf4b18a698e8fa02013,therapy,0.707766
uuid-08747bf27b9e4bf4b18a698e8fa02013,nivolumab,0.503159
uuid-08747bf27b9e4bf4b18a698e8fa02013,treated,0.318413
uuid-08747bf27b9e4bf4b18a698e8fa02013,combination,0.352671
uuid-08747bf27b9e4bf4b18a698e8fa02013,chemo,0.37301
uuid-08747bf27b9e4bf4b18a698e8fa02013,agents,0.363441
uuid-08747bf27b9e4bf4b18a698e8fa02013,monotherapy,0.392728
uuid-08747bf27b9e4bf4b18a698e8fa02013,treatment,0.419566
uuid-08747bf27b9e4bf4b18a698e8fa02013,using nivo,0.340001
uuid-08747bf27b9e4bf4b18a698e8fa02013,PD1,0.425903
uuid-08747bf27b9e4bf4b18a698e8fa02013,cHL,0.505429
uuid-08747bf27b9e4bf4b18a698e8fa02013,chemotherapy,0.552194
uuid-08747bf27b9e4bf4b18a698e8fa02013,PD-1,0.32993
uuid-08747bf27b9e4bf4b18a698e8fa02013,option,0.455799
uuid-e93613c1a30946eca3bb557b25ffe260,Nivo,0.303283
uuid-e93613c1a30946eca3bb557b25ffe260,BMS,0.309081
uuid-e93613c1a30946eca3bb557b25ffe260,PDL1,0.308976
uuid-e93613c1a30946eca3bb557b25ffe260,trial,0.466011
uuid-e93613c1a30946eca3bb557b25ffe260,efficacy,0.635819
uuid-e93613c1a30946eca3bb557b25ffe260,commented,0.344955
uuid-e93613c1a30946eca3bb557b25ffe260,OS,0.714501
uuid-e93613c1a30946eca3bb557b25ffe260,data,0.804585
uuid-e93613c1a30946eca3bb557b25ffe260,combo,0.366618
uuid-e93613c1a30946eca3bb557b25ffe260,PFS,0.66476
uuid-e93613c1a30946eca3bb557b25ffe260,ORR,0.74699
uuid-e93613c1a30946eca3bb557b25ffe260,nivo and pembro,0.462185
uuid-e93613c1a30946eca3bb557b25ffe260,ASCO,0.409288
uuid-e93613c1a30946eca3bb557b25ffe260,believes,0.353756
uuid-e93613c1a30946eca3bb557b25ffe260,impressed,0.758164
uuid-e93613c1a30946eca3bb557b25ffe260,TLs,0.363397
uuid-e93613c1a30946eca3bb557b25ffe260,SCLC,0.316249
uuid-e93613c1a30946eca3bb557b25ffe260,feels,0.397725
uuid-1db74d2841814b4e8d8cd4416558c5e7,1L,0.437999
uuid-1db74d2841814b4e8d8cd4416558c5e7,PDL1,0.498896
uuid-1db74d2841814b4e8d8cd4416558c5e7,efficacy,0.47765
uuid-1db74d2841814b4e8d8cd4416558c5e7,chemo,0.400971
uuid-1db74d2841814b4e8d8cd4416558c5e7,2L,0.382096
uuid-1db74d2841814b4e8d8cd4416558c5e7,IO,0.323952
uuid-1db74d2841814b4e8d8cd4416558c5e7,agents,0.530254
uuid-1db74d2841814b4e8d8cd4416558c5e7,atezo,0.357345
uuid-1db74d2841814b4e8d8cd4416558c5e7,preferred,0.403474
uuid-1db74d2841814b4e8d8cd4416558c5e7,monotherapy,0.442965
uuid-1db74d2841814b4e8d8cd4416558c5e7,combo,0.330584
uuid-1db74d2841814b4e8d8cd4416558c5e7,nivo and pembro,0.381214
uuid-1db74d2841814b4e8d8cd4416558c5e7,believes,0.502786
uuid-1db74d2841814b4e8d8cd4416558c5e7,chemotherapy,0.320659
uuid-1db74d2841814b4e8d8cd4416558c5e7,feels,0.539378
uuid-1db74d2841814b4e8d8cd4416558c5e7,PDL1 expression,0.452088
uuid-1db74d2841814b4e8d8cd4416558c5e7,option,0.538462
uuid-1db74d2841814b4e8d8cd4416558c5e7,biomarker,0.460228
uuid-de0c3cc4ab464167ad50a2013ab30dae,PDL1,0.398039
uuid-de0c3cc4ab464167ad50a2013ab30dae,PD-L1,0.383903
uuid-de0c3cc4ab464167ad50a2013ab30dae,testing,0.336673
uuid-de0c3cc4ab464167ad50a2013ab30dae,regards,0.340568
uuid-de0c3cc4ab464167ad50a2013ab30dae,PDL1 testing,0.317425
uuid-de0c3cc4ab464167ad50a2013ab30dae,lung cancer,0.316003
uuid-de0c3cc4ab464167ad50a2013ab30dae,ASCO,0.319243
uuid-de0c3cc4ab464167ad50a2013ab30dae,PDL1 expression,0.380484
uuid-de0c3cc4ab464167ad50a2013ab30dae,biomarker,0.59432
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,patients,0.70197
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,therapy,0.582276
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,nivolumab,0.393619
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,regimen,0.58809
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,treated,0.500403
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,combination,0.455256
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,chemo,0.422583
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,pts,0.567258
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,IO,0.304622
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,monotherapy,0.513275
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,treatment,0.681203
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,response,0.48078
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,combo,0.425477
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,PD1,0.44222
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,progression,0.736036
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,chemotherapy,0.478873
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,respond,0.46775
uuid-d98e8e395c3d4f9488f3fb33b0f47f2d,option,0.467102
uuid-ce4ba05af1814be5b4d8fe00da91fb41,patients,0.435703
uuid-ce4ba05af1814be5b4d8fe00da91fb41,chemo,0.302548
uuid-ce4ba05af1814be5b4d8fe00da91fb41,pts,0.341382
uuid-ce4ba05af1814be5b4d8fe00da91fb41,NSCLC patients,0.314715
uuid-ce4ba05af1814be5b4d8fe00da91fb41,chemotherapy,0.33344
uuid-e93948dfef224f78bdbe852e236c3f87,RTL,0.546599
uuid-e93948dfef224f78bdbe852e236c3f87,NSCLC,0.332642
uuid-e93948dfef224f78bdbe852e236c3f87,1L,0.397949
uuid-e93948dfef224f78bdbe852e236c3f87,trial,0.358374
uuid-e93948dfef224f78bdbe852e236c3f87,combination,0.365681
uuid-e93948dfef224f78bdbe852e236c3f87,IO,0.327044
uuid-e93948dfef224f78bdbe852e236c3f87,preferred,0.313473
uuid-e93948dfef224f78bdbe852e236c3f87,monotherapy,0.385775
uuid-e93948dfef224f78bdbe852e236c3f87,using nivo,0.314256
uuid-e93948dfef224f78bdbe852e236c3f87,data,0.343578
uuid-e93948dfef224f78bdbe852e236c3f87,combo,0.396524
uuid-e93948dfef224f78bdbe852e236c3f87,SCCHN,0.382611
uuid-e93948dfef224f78bdbe852e236c3f87,impressed,0.38428
uuid-e93948dfef224f78bdbe852e236c3f87,LTL,0.357783
uuid-e93948dfef224f78bdbe852e236c3f87,TLs,0.33108
uuid-e93948dfef224f78bdbe852e236c3f87,Regional TL,0.394941
uuid-e93948dfef224f78bdbe852e236c3f87,RTL stated,0.372832
uuid-e93948dfef224f78bdbe852e236c3f87,option,0.309774
uuid-af37c980f5d1401b80d30a871a97b827,TL,0.378169
uuid-af37c980f5d1401b80d30a871a97b827,TL stated,0.306152
uuid-af37c980f5d1401b80d30a871a97b827,tumor,0.575443
uuid-af37c980f5d1401b80d30a871a97b827,PD-L1,0.335894
uuid-af37c980f5d1401b80d30a871a97b827,PD-L1 testing,0.391876
uuid-af37c980f5d1401b80d30a871a97b827,testing,0.394358
uuid-af37c980f5d1401b80d30a871a97b827,NSCLC patients,0.356744
uuid-f1831389ef164942ae274a7269e3760f,patients,0.755183
uuid-f1831389ef164942ae274a7269e3760f,therapy,0.328091
uuid-f1831389ef164942ae274a7269e3760f,1L,0.495971
uuid-f1831389ef164942ae274a7269e3760f,treated,0.353896
uuid-f1831389ef164942ae274a7269e3760f,2L,0.434972
uuid-f1831389ef164942ae274a7269e3760f,pts,0.503122
uuid-f1831389ef164942ae274a7269e3760f,PD-L1,0.358825
uuid-f1831389ef164942ae274a7269e3760f,approval,0.400863
uuid-f1831389ef164942ae274a7269e3760f,preferred,0.396176
uuid-f1831389ef164942ae274a7269e3760f,PD-L1 testing,0.388305
uuid-f1831389ef164942ae274a7269e3760f,testing,0.494496
uuid-f1831389ef164942ae274a7269e3760f,monotherapy,0.352894
uuid-f1831389ef164942ae274a7269e3760f,treatment,0.358013
uuid-f1831389ef164942ae274a7269e3760f,using nivo,0.488305
uuid-f1831389ef164942ae274a7269e3760f,PDL1 testing,0.484306
uuid-f1831389ef164942ae274a7269e3760f,NSCLC patients,0.681
uuid-f1831389ef164942ae274a7269e3760f,approved,0.317756
uuid-f1831389ef164942ae274a7269e3760f,progression,0.364801
uuid-f1831389ef164942ae274a7269e3760f,tumor types,0.342709
uuid-f1831389ef164942ae274a7269e3760f,RTL stated,0.403943
uuid-f1831389ef164942ae274a7269e3760f,option,0.442648
uuid-71c17379eeac4c448c806e852c30e960,pembro,0.378883
uuid-71c17379eeac4c448c806e852c30e960,dose,0.781174
uuid-71c17379eeac4c448c806e852c30e960,Ipi,0.460044
uuid-71c17379eeac4c448c806e852c30e960,atezo,0.448632
uuid-71c17379eeac4c448c806e852c30e960,preferred,0.342383
uuid-71c17379eeac4c448c806e852c30e960,indication,0.304615
uuid-71c17379eeac4c448c806e852c30e960,vs,0.516208
uuid-71c17379eeac4c448c806e852c30e960,Keytruda,0.300753
uuid-71c17379eeac4c448c806e852c30e960,flat dosing,0.626173
uuid-8dabd2052fe543d99d5d45f0bd203844,Nivo,0.454493
uuid-8dabd2052fe543d99d5d45f0bd203844,pembro,0.627242
uuid-8dabd2052fe543d99d5d45f0bd203844,PDL1,0.556414
uuid-8dabd2052fe543d99d5d45f0bd203844,trial,0.491832
uuid-8dabd2052fe543d99d5d45f0bd203844,efficacy,0.738388
uuid-8dabd2052fe543d99d5d45f0bd203844,Ipi,0.315015
uuid-8dabd2052fe543d99d5d45f0bd203844,OS,0.566982
uuid-8dabd2052fe543d99d5d45f0bd203844,atezo,0.575029
uuid-8dabd2052fe543d99d5d45f0bd203844,regards,0.34923
uuid-8dabd2052fe543d99d5d45f0bd203844,data,0.642355
uuid-8dabd2052fe543d99d5d45f0bd203844,PFS,0.579471
uuid-8dabd2052fe543d99d5d45f0bd203844,ORR,0.621749
uuid-8dabd2052fe543d99d5d45f0bd203844,nivo and pembro,0.723979
uuid-8dabd2052fe543d99d5d45f0bd203844,believes,0.378589
uuid-8dabd2052fe543d99d5d45f0bd203844,impressed,0.400086
uuid-8dabd2052fe543d99d5d45f0bd203844,vs,0.651945
uuid-8dabd2052fe543d99d5d45f0bd203844,TLs,0.305983
uuid-8dabd2052fe543d99d5d45f0bd203844,feels,0.400431
uuid-8dabd2052fe543d99d5d45f0bd203844,PDL1 expression,0.513742
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,Nivo,0.602461
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,patients,0.362555
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,pembro,0.58233
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,nivolumab,0.344785
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,1L,0.460993
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,2L,0.471541
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,Ipi,0.320857
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,approval,0.51014
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,atezo,0.445837
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,preferred,0.454031
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,monotherapy,0.416893
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,using nivo,0.600544
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,indication,0.324335
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,approved,0.473373
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,SCCHN,0.391037
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,impressed,0.393265
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,label,0.301382
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,SCLC,0.340004
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,feels,0.350147
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,RTL stated,0.417359
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,option,0.481766
uuid-19c95d9b12314f4fa9835c0b9eec8fe2,bladder,0.300388
uuid-e2962071b9b947339acd98704ec0695b,Nivo,0.325126
uuid-e2962071b9b947339acd98704ec0695b,trial,0.556736
uuid-e2962071b9b947339acd98704ec0695b,efficacy,0.326798
uuid-e2962071b9b947339acd98704ec0695b,OS,0.627967
uuid-e2962071b9b947339acd98704ec0695b,data,0.577696
uuid-e2962071b9b947339acd98704ec0695b,PFS,0.662315
uuid-e2962071b9b947339acd98704ec0695b,ORR,0.689418
uuid-e2962071b9b947339acd98704ec0695b,nivo and pembro,0.309238
uuid-e2962071b9b947339acd98704ec0695b,ASCO,0.322757
uuid-e2962071b9b947339acd98704ec0695b,impressed,0.459781
uuid-e2962071b9b947339acd98704ec0695b,PDL1 expression,0.32532
uuid-38891ddf4e464581ac0c78d47d02767a,Nivo,0.373222
uuid-38891ddf4e464581ac0c78d47d02767a,pembro,0.324143
uuid-38891ddf4e464581ac0c78d47d02767a,dose,0.497708
uuid-38891ddf4e464581ac0c78d47d02767a,Ipi,0.496245
uuid-38891ddf4e464581ac0c78d47d02767a,vs,0.472094
uuid-38891ddf4e464581ac0c78d47d02767a,flat dosing,0.396907
uuid-7c88fcc36d934508a9513a9b20c03882,patients,0.65749
uuid-7c88fcc36d934508a9513a9b20c03882,RTL,0.461713
uuid-7c88fcc36d934508a9513a9b20c03882,therapy,0.32273
uuid-7c88fcc36d934508a9513a9b20c03882,nivolumab,0.462251
uuid-7c88fcc36d934508a9513a9b20c03882,regimen,0.354002
uuid-7c88fcc36d934508a9513a9b20c03882,treated,0.535275
uuid-7c88fcc36d934508a9513a9b20c03882,RCC,0.38207
uuid-7c88fcc36d934508a9513a9b20c03882,pts,0.464119
uuid-7c88fcc36d934508a9513a9b20c03882,stated,0.321177
uuid-7c88fcc36d934508a9513a9b20c03882,approval,0.312673
uuid-7c88fcc36d934508a9513a9b20c03882,monotherapy,0.340855
uuid-7c88fcc36d934508a9513a9b20c03882,treatment,0.428883
uuid-7c88fcc36d934508a9513a9b20c03882,using nivo,0.532764
uuid-7c88fcc36d934508a9513a9b20c03882,SCCHN,0.528535
uuid-7c88fcc36d934508a9513a9b20c03882,HCP,0.310654
uuid-7c88fcc36d934508a9513a9b20c03882,progression,0.391764
uuid-7c88fcc36d934508a9513a9b20c03882,LTL,0.376326
uuid-7c88fcc36d934508a9513a9b20c03882,academic,0.436668
uuid-7c88fcc36d934508a9513a9b20c03882,Regional TL,0.412087
uuid-7c88fcc36d934508a9513a9b20c03882,RTL stated,0.555981
uuid-7c88fcc36d934508a9513a9b20c03882,TL shared,0.369877
uuid-7c88fcc36d934508a9513a9b20c03882,option,0.305594
uuid-2410b65c95034cb49623d19c670ea9f4,RTL,0.481372
uuid-2410b65c95034cb49623d19c670ea9f4,BMS,0.378099
uuid-2410b65c95034cb49623d19c670ea9f4,trial,0.793289
uuid-2410b65c95034cb49623d19c670ea9f4,NTL,0.392564
uuid-2410b65c95034cb49623d19c670ea9f4,commented,0.333277
uuid-2410b65c95034cb49623d19c670ea9f4,Merck,0.372913
uuid-2410b65c95034cb49623d19c670ea9f4,data,0.548561
uuid-2410b65c95034cb49623d19c670ea9f4,clinical trials,0.47287
uuid-2410b65c95034cb49623d19c670ea9f4,ORR,0.383125
uuid-2410b65c95034cb49623d19c670ea9f4,ASCO,0.325994
uuid-2410b65c95034cb49623d19c670ea9f4,impressed,0.489202
uuid-2410b65c95034cb49623d19c670ea9f4,Regional TL,0.337797
uuid-88867d8b7f4e49829fbd690d2ae4624f,patients,0.351547
uuid-88867d8b7f4e49829fbd690d2ae4624f,Opdivo,0.323451
uuid-88867d8b7f4e49829fbd690d2ae4624f,RTL,0.32978
uuid-88867d8b7f4e49829fbd690d2ae4624f,therapy,0.338512
uuid-88867d8b7f4e49829fbd690d2ae4624f,nivolumab,0.490614
uuid-88867d8b7f4e49829fbd690d2ae4624f,treated,0.478854
uuid-88867d8b7f4e49829fbd690d2ae4624f,mentioned,0.382554
uuid-88867d8b7f4e49829fbd690d2ae4624f,cHL,0.643692
uuid-70e88cc1354d4854becf62687c277452,Nivo,0.430202
uuid-70e88cc1354d4854becf62687c277452,patients,0.872514
uuid-70e88cc1354d4854becf62687c277452,Opdivo,0.393121
uuid-70e88cc1354d4854becf62687c277452,therapy,0.515752
uuid-70e88cc1354d4854becf62687c277452,nivolumab,0.471121
uuid-70e88cc1354d4854becf62687c277452,regimen,0.486132
uuid-70e88cc1354d4854becf62687c277452,treated,0.462399
uuid-70e88cc1354d4854becf62687c277452,chemo,0.451954
uuid-70e88cc1354d4854becf62687c277452,pts,0.628048
uuid-70e88cc1354d4854becf62687c277452,monotherapy,0.474967
uuid-70e88cc1354d4854becf62687c277452,treatment,0.559112
uuid-70e88cc1354d4854becf62687c277452,using nivo,0.401608
uuid-70e88cc1354d4854becf62687c277452,response,0.320998
uuid-70e88cc1354d4854becf62687c277452,PD1,0.315303
uuid-70e88cc1354d4854becf62687c277452,progression,0.590252
uuid-70e88cc1354d4854becf62687c277452,chemotherapy,0.441149
uuid-70e88cc1354d4854becf62687c277452,respond,0.441709
uuid-70e88cc1354d4854becf62687c277452,feels,0.32337
uuid-70e88cc1354d4854becf62687c277452,option,0.461625
uuid-a0908b99823e4a3cb819ebcb8f106987,HCP,0.30634
uuid-0df1318c58eb4a0d9445abf183fbfdee,commented,0.345665
uuid-0df1318c58eb4a0d9445abf183fbfdee,TL stated,0.308109
uuid-0df1318c58eb4a0d9445abf183fbfdee,physicians,0.442364
uuid-0df1318c58eb4a0d9445abf183fbfdee,ASCO,0.397857
uuid-0df1318c58eb4a0d9445abf183fbfdee,TLs,0.330676
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,Nivo,0.444712
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,patients,0.809625
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,Opdivo,0.423496
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,therapy,0.619837
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,nivolumab,0.684969
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,1L,0.332403
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,toxicity,0.351287
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,regimen,0.605397
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,treated,0.568411
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,RCC,0.385883
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,combination,0.339091
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,chemo,0.452158
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,2L,0.409698
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,pts,0.588692
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,preferred,0.434099
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,monotherapy,0.589259
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,treatment,0.681771
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,using nivo,0.53177
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,response,0.352201
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,PD1,0.452362
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,approved,0.301261
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,cHL,0.321897
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,progression,0.610056
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,chemotherapy,0.447777
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,respond,0.420784
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,RTL stated,0.484315
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,TL shared,0.341034
uuid-7c81953d91ae4f17bd9958dc79dd2ceb,option,0.530776
uuid-cec5b419d6154737b6e3fb46882bb40b,TL,0.483575
uuid-cec5b419d6154737b6e3fb46882bb40b,TL stated,0.337974
uuid-cec5b419d6154737b6e3fb46882bb40b,institution,0.443049
uuid-cec5b419d6154737b6e3fb46882bb40b,PD-L1,0.748306
uuid-cec5b419d6154737b6e3fb46882bb40b,PD-L1 testing,0.833587
uuid-cec5b419d6154737b6e3fb46882bb40b,testing,0.858824
uuid-cec5b419d6154737b6e3fb46882bb40b,PDL1 testing,0.679928
uuid-cec5b419d6154737b6e3fb46882bb40b,NSCLC patients,0.631091
uuid-cec5b419d6154737b6e3fb46882bb40b,assay,0.670447
uuid-cec5b419d6154737b6e3fb46882bb40b,biomarker,0.43094
uuid-386af9eabd8a45ffb2c0a7d0158a563f,patients,0.315727
uuid-386af9eabd8a45ffb2c0a7d0158a563f,PDL1,0.386072
uuid-386af9eabd8a45ffb2c0a7d0158a563f,PD-L1,0.389244
uuid-386af9eabd8a45ffb2c0a7d0158a563f,testing,0.415313
uuid-386af9eabd8a45ffb2c0a7d0158a563f,PDL1 testing,0.350582
uuid-386af9eabd8a45ffb2c0a7d0158a563f,NSCLC patients,0.55231
uuid-386af9eabd8a45ffb2c0a7d0158a563f,PDL1 expression,0.315818
uuid-386af9eabd8a45ffb2c0a7d0158a563f,biomarker,0.332086
uuid-f56ef93c38814152abac2d42713264a1,Nivo,0.379712
uuid-f56ef93c38814152abac2d42713264a1,patients,0.349332
uuid-f56ef93c38814152abac2d42713264a1,Opdivo,0.481084
uuid-f56ef93c38814152abac2d42713264a1,pembro,0.572177
uuid-f56ef93c38814152abac2d42713264a1,nivolumab,0.363239
uuid-f56ef93c38814152abac2d42713264a1,1L,0.646819
uuid-f56ef93c38814152abac2d42713264a1,RCC,0.527052
uuid-f56ef93c38814152abac2d42713264a1,TL stated,0.419846
uuid-f56ef93c38814152abac2d42713264a1,2L,0.773173
uuid-f56ef93c38814152abac2d42713264a1,agents,0.323865
uuid-f56ef93c38814152abac2d42713264a1,approval,0.490317
uuid-f56ef93c38814152abac2d42713264a1,atezo,0.563676
uuid-f56ef93c38814152abac2d42713264a1,preferred,0.696665
uuid-f56ef93c38814152abac2d42713264a1,monotherapy,0.490486
uuid-f56ef93c38814152abac2d42713264a1,using nivo,0.673833
uuid-f56ef93c38814152abac2d42713264a1,PDL1 testing,0.425436
uuid-f56ef93c38814152abac2d42713264a1,indication,0.424026
uuid-f56ef93c38814152abac2d42713264a1,NSCLC patients,0.361053
uuid-f56ef93c38814152abac2d42713264a1,approved,0.590492
uuid-f56ef93c38814152abac2d42713264a1,SCCHN,0.385584
uuid-f56ef93c38814152abac2d42713264a1,tumor types,0.326046
uuid-f56ef93c38814152abac2d42713264a1,label,0.362207
uuid-f56ef93c38814152abac2d42713264a1,Keytruda,0.441471
uuid-f56ef93c38814152abac2d42713264a1,RTL stated,0.523303
uuid-f56ef93c38814152abac2d42713264a1,TL shared,0.324962
uuid-f56ef93c38814152abac2d42713264a1,option,0.523089
uuid-f56ef93c38814152abac2d42713264a1,bladder,0.346118
uuid-f56ef93c38814152abac2d42713264a1,flat dosing,0.30358
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,Nivo,0.530995
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,pembro,0.548842
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,BMS,0.337156
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,PDL1,0.340397
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,trial,0.507259
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,efficacy,0.616229
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,chemo,0.318514
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,agents,0.362679
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,OS,0.443588
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,atezo,0.449506
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,data,0.582433
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,indication,0.390048
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,PFS,0.465063
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,ORR,0.463918
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,nivo and pembro,0.55192
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,believes,0.405556
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,chemotherapy,0.314463
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,impressed,0.335479
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,vs,0.394034
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,feels,0.514543
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,PDL1 expression,0.357026
uuid-bd55f8e66c4d4dd18a8fe72cff759c8c,option,0.348224
uuid-ebfc958b562a45ea9b5352b3702e2568,RTL,0.350528
uuid-ebfc958b562a45ea9b5352b3702e2568,discussed,0.615458
uuid-ebfc958b562a45ea9b5352b3702e2568,commented,0.330834
uuid-ebfc958b562a45ea9b5352b3702e2568,physicians,0.364875
uuid-ebfc958b562a45ea9b5352b3702e2568,ASCO,0.332872
uuid-ebfc958b562a45ea9b5352b3702e2568,academic,0.506866
uuid-ebfc958b562a45ea9b5352b3702e2568,Regional TL,0.327215
uuid-c996ecffb2564e36867d57b9b0ca3b64,patients,0.599298
uuid-c996ecffb2564e36867d57b9b0ca3b64,Opdivo,0.306786
uuid-c996ecffb2564e36867d57b9b0ca3b64,therapy,0.413973
uuid-c996ecffb2564e36867d57b9b0ca3b64,regimen,0.336727
uuid-c996ecffb2564e36867d57b9b0ca3b64,treated,0.400703
uuid-c996ecffb2564e36867d57b9b0ca3b64,pts,0.419133
uuid-c996ecffb2564e36867d57b9b0ca3b64,treatment,0.533468
uuid-c996ecffb2564e36867d57b9b0ca3b64,response,0.462057
uuid-c996ecffb2564e36867d57b9b0ca3b64,progression,0.612467
uuid-c996ecffb2564e36867d57b9b0ca3b64,respond,0.42441
uuid-c220f2eff85649e2882d6946fa5a88d6,patients,0.494665
uuid-c220f2eff85649e2882d6946fa5a88d6,Opdivo,0.301025
uuid-c220f2eff85649e2882d6946fa5a88d6,treatment,0.407416
uuid-c220f2eff85649e2882d6946fa5a88d6,progression,0.348783
uuid-c220f2eff85649e2882d6946fa5a88d6,respond,0.328142
uuid-e6fcc20c9d9844dbb710f1b2cc89056c,patients,0.622512
uuid-e6fcc20c9d9844dbb710f1b2cc89056c,therapy,0.384092
uuid-e6fcc20c9d9844dbb710f1b2cc89056c,lung,0.326008
uuid-e6fcc20c9d9844dbb710f1b2cc89056c,regimen,0.357663
uuid-e6fcc20c9d9844dbb710f1b2cc89056c,treated,0.476292
uuid-e6fcc20c9d9844dbb710f1b2cc89056c,melanoma,0.330635
uuid-e6fcc20c9d9844dbb710f1b2cc89056c,pts,0.42491
uuid-e6fcc20c9d9844dbb710f1b2cc89056c,treatment,0.554426
uuid-e6fcc20c9d9844dbb710f1b2cc89056c,response,0.334763
uuid-e6fcc20c9d9844dbb710f1b2cc89056c,progression,0.620982
uuid-e6fcc20c9d9844dbb710f1b2cc89056c,respond,0.428051
uuid-e6fcc20c9d9844dbb710f1b2cc89056c,TL shared,0.40536
uuid-42a139efa8154fc6a12d02d638427af0,TL,0.466941
uuid-42a139efa8154fc6a12d02d638427af0,1L,0.316273
uuid-42a139efa8154fc6a12d02d638427af0,PDL1,0.403735
uuid-42a139efa8154fc6a12d02d638427af0,TL stated,0.498866
uuid-42a139efa8154fc6a12d02d638427af0,institution,0.30991
uuid-42a139efa8154fc6a12d02d638427af0,PD-L1,0.810876
uuid-42a139efa8154fc6a12d02d638427af0,PD-L1 testing,0.846838
uuid-42a139efa8154fc6a12d02d638427af0,testing,0.891954
uuid-42a139efa8154fc6a12d02d638427af0,PDL1 testing,0.764056
uuid-42a139efa8154fc6a12d02d638427af0,NSCLC patients,0.747333
uuid-42a139efa8154fc6a12d02d638427af0,assay,0.559457
uuid-42a139efa8154fc6a12d02d638427af0,biomarker,0.397872
uuid-489ee6d38c1e4a7ab0269baf5d37a60f,therapy,0.320257
uuid-489ee6d38c1e4a7ab0269baf5d37a60f,nivolumab,0.387861
uuid-489ee6d38c1e4a7ab0269baf5d37a60f,trial,0.411097
uuid-489ee6d38c1e4a7ab0269baf5d37a60f,NTL,0.356069
uuid-489ee6d38c1e4a7ab0269baf5d37a60f,combination,0.346486
uuid-489ee6d38c1e4a7ab0269baf5d37a60f,cHL,0.372257
uuid-489ee6d38c1e4a7ab0269baf5d37a60f,chemotherapy,0.325747
uuid-383a0a62af2c452bb6aab6c8565f44d5,patients,0.663854
uuid-383a0a62af2c452bb6aab6c8565f44d5,therapy,0.440274
uuid-383a0a62af2c452bb6aab6c8565f44d5,nivolumab,0.527418
uuid-383a0a62af2c452bb6aab6c8565f44d5,toxicity,0.337962
uuid-383a0a62af2c452bb6aab6c8565f44d5,regimen,0.595129
uuid-383a0a62af2c452bb6aab6c8565f44d5,treated,0.666871
uuid-383a0a62af2c452bb6aab6c8565f44d5,melanoma,0.47453
uuid-383a0a62af2c452bb6aab6c8565f44d5,RCC,0.4034
uuid-383a0a62af2c452bb6aab6c8565f44d5,combination,0.397632
uuid-383a0a62af2c452bb6aab6c8565f44d5,chemo,0.304291
uuid-383a0a62af2c452bb6aab6c8565f44d5,pts,0.578923
uuid-383a0a62af2c452bb6aab6c8565f44d5,Ipi,0.341667
uuid-383a0a62af2c452bb6aab6c8565f44d5,monotherapy,0.434133
uuid-383a0a62af2c452bb6aab6c8565f44d5,treatment,0.573054
uuid-383a0a62af2c452bb6aab6c8565f44d5,using nivo,0.303867
uuid-383a0a62af2c452bb6aab6c8565f44d5,response,0.344024
uuid-383a0a62af2c452bb6aab6c8565f44d5,combo,0.398679
uuid-383a0a62af2c452bb6aab6c8565f44d5,PD1,0.366546
uuid-383a0a62af2c452bb6aab6c8565f44d5,progression,0.599773
uuid-383a0a62af2c452bb6aab6c8565f44d5,chemotherapy,0.321244
uuid-383a0a62af2c452bb6aab6c8565f44d5,respond,0.389997
uuid-383a0a62af2c452bb6aab6c8565f44d5,RTL stated,0.372114
uuid-383a0a62af2c452bb6aab6c8565f44d5,TL shared,0.475954
uuid-1d40155317a74b9b9d36e0ad25a73c3d,patients,0.719877
uuid-1d40155317a74b9b9d36e0ad25a73c3d,therapy,0.342586
uuid-1d40155317a74b9b9d36e0ad25a73c3d,nivolumab,0.430648
uuid-1d40155317a74b9b9d36e0ad25a73c3d,regimen,0.397708
uuid-1d40155317a74b9b9d36e0ad25a73c3d,treated,0.644569
uuid-1d40155317a74b9b9d36e0ad25a73c3d,pts,0.526323
uuid-1d40155317a74b9b9d36e0ad25a73c3d,approval,0.301714
uuid-1d40155317a74b9b9d36e0ad25a73c3d,monotherapy,0.331936
uuid-1d40155317a74b9b9d36e0ad25a73c3d,treatment,0.467594
uuid-1d40155317a74b9b9d36e0ad25a73c3d,using nivo,0.341994
uuid-1d40155317a74b9b9d36e0ad25a73c3d,progression,0.376389
uuid-1d40155317a74b9b9d36e0ad25a73c3d,RTL stated,0.403779
uuid-1d40155317a74b9b9d36e0ad25a73c3d,TL shared,0.364983
uuid-a6f2ac4d42f04fc0b0588067331c93fb,dose,0.464845
uuid-a6f2ac4d42f04fc0b0588067331c93fb,shared,0.406305
uuid-a6f2ac4d42f04fc0b0588067331c93fb,clinical trials,0.358447
uuid-a6f2ac4d42f04fc0b0588067331c93fb,LTL,0.317246
uuid-a6f2ac4d42f04fc0b0588067331c93fb,drug,0.317599
uuid-a6f2ac4d42f04fc0b0588067331c93fb,flat dosing,0.723889
uuid-470c41838989437e8094cb0b96a9b906,Opdivo,0.430252
uuid-470c41838989437e8094cb0b96a9b906,dose,0.360549
uuid-470c41838989437e8094cb0b96a9b906,melanoma,0.31606
uuid-470c41838989437e8094cb0b96a9b906,shared,0.689408
uuid-470c41838989437e8094cb0b96a9b906,RCC,0.320503
uuid-470c41838989437e8094cb0b96a9b906,institution,0.558287
uuid-470c41838989437e8094cb0b96a9b906,stated,0.329414
uuid-470c41838989437e8094cb0b96a9b906,approval,0.400704
uuid-470c41838989437e8094cb0b96a9b906,preferred,0.327645
uuid-470c41838989437e8094cb0b96a9b906,using nivo,0.321839
uuid-470c41838989437e8094cb0b96a9b906,indication,0.370281
uuid-470c41838989437e8094cb0b96a9b906,approved,0.410352
uuid-470c41838989437e8094cb0b96a9b906,SCCHN,0.395995
uuid-470c41838989437e8094cb0b96a9b906,HCP,0.302138
uuid-470c41838989437e8094cb0b96a9b906,label,0.346707
uuid-470c41838989437e8094cb0b96a9b906,LTL,0.358238
uuid-470c41838989437e8094cb0b96a9b906,Keytruda,0.417553
uuid-470c41838989437e8094cb0b96a9b906,RTL stated,0.318024
uuid-470c41838989437e8094cb0b96a9b906,flat dosing,0.669328
uuid-e09a4b514f484df392a4e538d342072c,Nivo,0.369199
uuid-e09a4b514f484df392a4e538d342072c,patients,0.797835
uuid-e09a4b514f484df392a4e538d342072c,Opdivo,0.414874
uuid-e09a4b514f484df392a4e538d342072c,therapy,0.481795
uuid-e09a4b514f484df392a4e538d342072c,dose,0.404272
uuid-e09a4b514f484df392a4e538d342072c,nivolumab,0.529573
uuid-e09a4b514f484df392a4e538d342072c,toxicity,0.354864
uuid-e09a4b514f484df392a4e538d342072c,regimen,0.572265
uuid-e09a4b514f484df392a4e538d342072c,treated,0.500834
uuid-e09a4b514f484df392a4e538d342072c,combination,0.403811
uuid-e09a4b514f484df392a4e538d342072c,chemo,0.399839
uuid-e09a4b514f484df392a4e538d342072c,pts,0.564711
uuid-e09a4b514f484df392a4e538d342072c,Ipi,0.309657
uuid-e09a4b514f484df392a4e538d342072c,preferred,0.322119
uuid-e09a4b514f484df392a4e538d342072c,monotherapy,0.501998
uuid-e09a4b514f484df392a4e538d342072c,treatment,0.54339
uuid-e09a4b514f484df392a4e538d342072c,using nivo,0.333274
uuid-e09a4b514f484df392a4e538d342072c,response,0.36638
uuid-e09a4b514f484df392a4e538d342072c,combo,0.331948
uuid-e09a4b514f484df392a4e538d342072c,PD1,0.332873
uuid-e09a4b514f484df392a4e538d342072c,progression,0.540301
uuid-e09a4b514f484df392a4e538d342072c,chemotherapy,0.488841
uuid-e09a4b514f484df392a4e538d342072c,respond,0.407313
uuid-e09a4b514f484df392a4e538d342072c,option,0.42695
uuid-88ea78f44e424dac8ec559b7a904d464,PDL1,0.32406
uuid-88ea78f44e424dac8ec559b7a904d464,PD1,0.416031
uuid-88ea78f44e424dac8ec559b7a904d464,PD-1,0.417589
uuid-b82c13267030444b9b8ce5232f4e4c14,label,0.402431
uuid-b82c13267030444b9b8ce5232f4e4c14,drug,0.300303
uuid-ecd23eb86e2e4a359db3a711497a1b1d,patients,0.600757
uuid-ecd23eb86e2e4a359db3a711497a1b1d,Opdivo,0.321032
uuid-ecd23eb86e2e4a359db3a711497a1b1d,nivolumab,0.367576
uuid-ecd23eb86e2e4a359db3a711497a1b1d,toxicity,0.420737
uuid-ecd23eb86e2e4a359db3a711497a1b1d,regimen,0.48138
uuid-ecd23eb86e2e4a359db3a711497a1b1d,treated,0.596977
uuid-ecd23eb86e2e4a359db3a711497a1b1d,pts,0.350937
uuid-ecd23eb86e2e4a359db3a711497a1b1d,treatment,0.585558
uuid-ecd23eb86e2e4a359db3a711497a1b1d,progression,0.423339
uuid-ecd23eb86e2e4a359db3a711497a1b1d,respond,0.513392
uuid-ecd23eb86e2e4a359db3a711497a1b1d,TL shared,0.379644
uuid-1f9280488aa547ce97b27f2265766029,patients,0.654559
uuid-1f9280488aa547ce97b27f2265766029,Opdivo,0.384536
uuid-1f9280488aa547ce97b27f2265766029,therapy,0.584898
uuid-1f9280488aa547ce97b27f2265766029,nivolumab,0.379017
uuid-1f9280488aa547ce97b27f2265766029,toxicity,0.320056
uuid-1f9280488aa547ce97b27f2265766029,regimen,0.323407
uuid-1f9280488aa547ce97b27f2265766029,treated,0.402364
uuid-1f9280488aa547ce97b27f2265766029,pts,0.323266
uuid-1f9280488aa547ce97b27f2265766029,treatment,0.506208
uuid-1f9280488aa547ce97b27f2265766029,cHL,0.61273
uuid-1f9280488aa547ce97b27f2265766029,progression,0.43446
uuid-1f9280488aa547ce97b27f2265766029,chemotherapy,0.335181
uuid-1f9280488aa547ce97b27f2265766029,respond,0.351682
uuid-8bd3ab286ec14e1888ad71a9206b997c,PD-L1,0.347494
uuid-8bd3ab286ec14e1888ad71a9206b997c,testing,0.304358
uuid-8bd3ab286ec14e1888ad71a9206b997c,oncologist,0.564283
uuid-8bd3ab286ec14e1888ad71a9206b997c,indicated,0.670116
uuid-a06e8c9d31454218aec06d0465410755,Nivo,0.54492
uuid-a06e8c9d31454218aec06d0465410755,patients,0.655097
uuid-a06e8c9d31454218aec06d0465410755,Opdivo,0.317901
uuid-a06e8c9d31454218aec06d0465410755,pembro,0.494191
uuid-a06e8c9d31454218aec06d0465410755,dose,0.400958
uuid-a06e8c9d31454218aec06d0465410755,nivolumab,0.333066
uuid-a06e8c9d31454218aec06d0465410755,1L,0.341055
uuid-a06e8c9d31454218aec06d0465410755,regimen,0.404825
uuid-a06e8c9d31454218aec06d0465410755,treated,0.312309
uuid-a06e8c9d31454218aec06d0465410755,chemo,0.373379
uuid-a06e8c9d31454218aec06d0465410755,2L,0.435028
uuid-a06e8c9d31454218aec06d0465410755,pts,0.547428
uuid-a06e8c9d31454218aec06d0465410755,Ipi,0.340891
uuid-a06e8c9d31454218aec06d0465410755,atezo,0.374883
uuid-a06e8c9d31454218aec06d0465410755,preferred,0.445618
uuid-a06e8c9d31454218aec06d0465410755,monotherapy,0.43672
uuid-a06e8c9d31454218aec06d0465410755,treatment,0.346925
uuid-a06e8c9d31454218aec06d0465410755,using nivo,0.489223
uuid-a06e8c9d31454218aec06d0465410755,progression,0.323091
uuid-a06e8c9d31454218aec06d0465410755,vs,0.315807
uuid-a06e8c9d31454218aec06d0465410755,respond,0.375538
uuid-a06e8c9d31454218aec06d0465410755,feels,0.31801
uuid-a06e8c9d31454218aec06d0465410755,RTL stated,0.319219
uuid-a06e8c9d31454218aec06d0465410755,option,0.440461
uuid-39a6dfaf09a44bcbb3937469847c1f3f,oncologist,0.561524
uuid-39a6dfaf09a44bcbb3937469847c1f3f,indicated,0.832699
uuid-0f897ffab5f54be2b8606aa2a8f8c701,PDL1,0.472608
uuid-0f897ffab5f54be2b8606aa2a8f8c701,trial,0.4242
uuid-0f897ffab5f54be2b8606aa2a8f8c701,efficacy,0.713336
uuid-0f897ffab5f54be2b8606aa2a8f8c701,chemo,0.331982
uuid-0f897ffab5f54be2b8606aa2a8f8c701,OS,0.840673
uuid-0f897ffab5f54be2b8606aa2a8f8c701,data,0.681605
uuid-0f897ffab5f54be2b8606aa2a8f8c701,combo,0.306813
uuid-0f897ffab5f54be2b8606aa2a8f8c701,PFS,0.840388
uuid-0f897ffab5f54be2b8606aa2a8f8c701,ORR,0.808038
uuid-0f897ffab5f54be2b8606aa2a8f8c701,nivo and pembro,0.53763
uuid-0f897ffab5f54be2b8606aa2a8f8c701,believes,0.518171
uuid-0f897ffab5f54be2b8606aa2a8f8c701,impressed,0.513031
uuid-0f897ffab5f54be2b8606aa2a8f8c701,feels,0.433328
uuid-0f897ffab5f54be2b8606aa2a8f8c701,PDL1 expression,0.430734
uuid-e087e8c3a62442cd9219f1e7c5921696,efficacy,0.416315
uuid-e087e8c3a62442cd9219f1e7c5921696,OS,0.568919
uuid-e087e8c3a62442cd9219f1e7c5921696,regards,0.320155
uuid-e087e8c3a62442cd9219f1e7c5921696,data,0.48002
uuid-e087e8c3a62442cd9219f1e7c5921696,PFS,0.612999
uuid-e087e8c3a62442cd9219f1e7c5921696,ORR,0.532505
uuid-e087e8c3a62442cd9219f1e7c5921696,nivo and pembro,0.314107
uuid-e087e8c3a62442cd9219f1e7c5921696,impressed,0.37203
uuid-e087e8c3a62442cd9219f1e7c5921696,indicated,0.574323
uuid-23f6491afbd24278a544650e57e7ce13,efficacy,0.466449
uuid-23f6491afbd24278a544650e57e7ce13,OS,0.438547
uuid-23f6491afbd24278a544650e57e7ce13,regards,0.302897
uuid-23f6491afbd24278a544650e57e7ce13,data,0.370297
uuid-23f6491afbd24278a544650e57e7ce13,PFS,0.480388
uuid-23f6491afbd24278a544650e57e7ce13,ORR,0.491289
uuid-23f6491afbd24278a544650e57e7ce13,impressed,0.309551
uuid-23f6491afbd24278a544650e57e7ce13,oncologist,0.360725
uuid-23f6491afbd24278a544650e57e7ce13,indicated,0.643975
uuid-cd256941af3a40bf9b4a549b1ddda298,using nivo,0.304923
uuid-cd256941af3a40bf9b4a549b1ddda298,oncologist,0.504301
uuid-cd256941af3a40bf9b4a549b1ddda298,indicated,0.782985
uuid-8af33785a1c849498af4832ae438aba2,oncologist,0.638871
uuid-8af33785a1c849498af4832ae438aba2,indicated,0.798994
uuid-2f3179718b83406f9d02b04fc7e1ef0f,using nivo,0.475299
uuid-2f3179718b83406f9d02b04fc7e1ef0f,oncologist,0.582626
uuid-2f3179718b83406f9d02b04fc7e1ef0f,indicated,0.685144
uuid-2f3179718b83406f9d02b04fc7e1ef0f,option,0.33684
uuid-d2867b3147324d09a1dd497557959be9,oncologist,0.581538
uuid-d2867b3147324d09a1dd497557959be9,indicated,0.834342
uuid-6ea14d03812b479ca38f240dc61b40a1,RTL,0.428457
uuid-6ea14d03812b479ca38f240dc61b40a1,BMS,0.355697
uuid-6ea14d03812b479ca38f240dc61b40a1,NTL,0.348674
uuid-6ea14d03812b479ca38f240dc61b40a1,discussed,0.347159
uuid-6ea14d03812b479ca38f240dc61b40a1,commented,0.577392
uuid-6ea14d03812b479ca38f240dc61b40a1,stated,0.378754
uuid-6ea14d03812b479ca38f240dc61b40a1,OS,0.392434
uuid-6ea14d03812b479ca38f240dc61b40a1,regards,0.385508
uuid-6ea14d03812b479ca38f240dc61b40a1,data,0.704288
uuid-6ea14d03812b479ca38f240dc61b40a1,expressed,0.362727
uuid-6ea14d03812b479ca38f240dc61b40a1,PFS,0.335679
uuid-6ea14d03812b479ca38f240dc61b40a1,ORR,0.383321
uuid-6ea14d03812b479ca38f240dc61b40a1,SCCHN,0.463842
uuid-6ea14d03812b479ca38f240dc61b40a1,ASCO,0.403807
uuid-6ea14d03812b479ca38f240dc61b40a1,impressed,0.629829
uuid-6ea14d03812b479ca38f240dc61b40a1,SCLC,0.317169
uuid-6ea14d03812b479ca38f240dc61b40a1,Regional TL,0.405126
uuid-6ea14d03812b479ca38f240dc61b40a1,NCCN,0.557754
uuid-9f70fa81120f43cea712519e0bc4e7a9,Nivo,0.393291
uuid-9f70fa81120f43cea712519e0bc4e7a9,patients,0.589755
uuid-9f70fa81120f43cea712519e0bc4e7a9,therapy,0.431275
uuid-9f70fa81120f43cea712519e0bc4e7a9,nivolumab,0.720068
uuid-9f70fa81120f43cea712519e0bc4e7a9,1L,0.311734
uuid-9f70fa81120f43cea712519e0bc4e7a9,trial,0.3549
uuid-9f70fa81120f43cea712519e0bc4e7a9,regimen,0.449369
uuid-9f70fa81120f43cea712519e0bc4e7a9,treated,0.481602
uuid-9f70fa81120f43cea712519e0bc4e7a9,RCC,0.357356
uuid-9f70fa81120f43cea712519e0bc4e7a9,combination,0.572403
uuid-9f70fa81120f43cea712519e0bc4e7a9,chemo,0.392337
uuid-9f70fa81120f43cea712519e0bc4e7a9,2L,0.340122
uuid-9f70fa81120f43cea712519e0bc4e7a9,pts,0.546355
uuid-9f70fa81120f43cea712519e0bc4e7a9,Ipi,0.329697
uuid-9f70fa81120f43cea712519e0bc4e7a9,approval,0.311429
uuid-9f70fa81120f43cea712519e0bc4e7a9,preferred,0.318971
uuid-9f70fa81120f43cea712519e0bc4e7a9,monotherapy,0.505755
uuid-9f70fa81120f43cea712519e0bc4e7a9,treatment,0.380848
uuid-9f70fa81120f43cea712519e0bc4e7a9,using nivo,0.45276
uuid-9f70fa81120f43cea712519e0bc4e7a9,combo,0.499548
uuid-9f70fa81120f43cea712519e0bc4e7a9,clinical trials,0.321282
uuid-9f70fa81120f43cea712519e0bc4e7a9,PD1,0.410891
uuid-9f70fa81120f43cea712519e0bc4e7a9,approved,0.334342
uuid-9f70fa81120f43cea712519e0bc4e7a9,progression,0.379775
uuid-9f70fa81120f43cea712519e0bc4e7a9,chemotherapy,0.436505
uuid-9f70fa81120f43cea712519e0bc4e7a9,SCLC,0.314606
uuid-9f70fa81120f43cea712519e0bc4e7a9,RTL stated,0.447141
uuid-9f70fa81120f43cea712519e0bc4e7a9,option,0.401695
uuid-9f70fa81120f43cea712519e0bc4e7a9,bladder,0.340086
uuid-e98568b6843241dc8d20184a623fda21,regimen,0.341767
uuid-e98568b6843241dc8d20184a623fda21,melanoma,0.300011
uuid-e98568b6843241dc8d20184a623fda21,combination,0.406443
uuid-e98568b6843241dc8d20184a623fda21,chemo,0.336531
uuid-e98568b6843241dc8d20184a623fda21,IO,0.364189
uuid-e98568b6843241dc8d20184a623fda21,monotherapy,0.33389
uuid-e98568b6843241dc8d20184a623fda21,treatment,0.32261
uuid-e98568b6843241dc8d20184a623fda21,combo,0.30345
uuid-e98568b6843241dc8d20184a623fda21,PD1,0.306655
uuid-e98568b6843241dc8d20184a623fda21,chemotherapy,0.449497
uuid-e98568b6843241dc8d20184a623fda21,immunotherapy,0.312914
uuid-e98568b6843241dc8d20184a623fda21,option,0.345353
uuid-29421f3a367f433b904de2e00aba459d,nivolumab,0.352649
uuid-29421f3a367f433b904de2e00aba459d,treated,0.334634
uuid-29421f3a367f433b904de2e00aba459d,NTL,0.34351
uuid-29421f3a367f433b904de2e00aba459d,cHL,0.456343
uuid-6500b6fb4b8641b1a3aa64931d56203c,patients,0.612245
uuid-6500b6fb4b8641b1a3aa64931d56203c,Opdivo,0.483989
uuid-6500b6fb4b8641b1a3aa64931d56203c,therapy,0.37314
uuid-6500b6fb4b8641b1a3aa64931d56203c,nivolumab,0.376057
uuid-6500b6fb4b8641b1a3aa64931d56203c,regimen,0.360485
uuid-6500b6fb4b8641b1a3aa64931d56203c,treated,0.500296
uuid-6500b6fb4b8641b1a3aa64931d56203c,physicians,0.506672
uuid-6500b6fb4b8641b1a3aa64931d56203c,treatment,0.553048
uuid-6500b6fb4b8641b1a3aa64931d56203c,oncology,0.378854
uuid-6500b6fb4b8641b1a3aa64931d56203c,cHL,0.302598
uuid-6500b6fb4b8641b1a3aa64931d56203c,progression,0.380029
uuid-6500b6fb4b8641b1a3aa64931d56203c,oncologist,0.392762
uuid-6500b6fb4b8641b1a3aa64931d56203c,clinical,0.303949
uuid-499e84f632224fcbbe357bd7aa38d80f,physicians,0.581058
uuid-499e84f632224fcbbe357bd7aa38d80f,treatment,0.444491
uuid-499e84f632224fcbbe357bd7aa38d80f,progression,0.311316
uuid-b26d2c12317d4bfda0792b4b394702e5,Opdivo,0.429608
uuid-b26d2c12317d4bfda0792b4b394702e5,dose,0.848722
uuid-b26d2c12317d4bfda0792b4b394702e5,toxicity,0.584842
uuid-b26d2c12317d4bfda0792b4b394702e5,regimen,0.352729
uuid-b26d2c12317d4bfda0792b4b394702e5,Ipi,0.520386
uuid-b26d2c12317d4bfda0792b4b394702e5,vs,0.444433
uuid-b26d2c12317d4bfda0792b4b394702e5,Keytruda,0.320184
uuid-b26d2c12317d4bfda0792b4b394702e5,flat dosing,0.751951
uuid-b3a659ce45a440c187f996fcefec9094,Nivo,0.303391
uuid-b3a659ce45a440c187f996fcefec9094,patients,0.302567
uuid-b3a659ce45a440c187f996fcefec9094,pembro,0.328317
uuid-b3a659ce45a440c187f996fcefec9094,trial,0.431413
uuid-b3a659ce45a440c187f996fcefec9094,chemo,0.339475
uuid-b3a659ce45a440c187f996fcefec9094,monotherapy,0.311504
uuid-b3a659ce45a440c187f996fcefec9094,combo,0.317069
uuid-b3a659ce45a440c187f996fcefec9094,clinical trials,0.407036
uuid-b3a659ce45a440c187f996fcefec9094,approved,0.357988
uuid-b3a659ce45a440c187f996fcefec9094,believes,0.302007
uuid-b3a659ce45a440c187f996fcefec9094,chemotherapy,0.360168
uuid-b3a659ce45a440c187f996fcefec9094,feels,0.470244
uuid-b3a659ce45a440c187f996fcefec9094,option,0.471867
uuid-90bce53db8d3495e8582b1221f585f99,pembro,0.443081
uuid-90bce53db8d3495e8582b1221f585f99,RTL,0.447135
uuid-90bce53db8d3495e8582b1221f585f99,trial,0.589083
uuid-90bce53db8d3495e8582b1221f585f99,shared,0.469544
uuid-90bce53db8d3495e8582b1221f585f99,commented,0.305468
uuid-90bce53db8d3495e8582b1221f585f99,Ipi,0.353256
uuid-90bce53db8d3495e8582b1221f585f99,stated,0.384057
uuid-90bce53db8d3495e8582b1221f585f99,approval,0.405177
uuid-90bce53db8d3495e8582b1221f585f99,atezo,0.325117
uuid-90bce53db8d3495e8582b1221f585f99,combo,0.301022
uuid-90bce53db8d3495e8582b1221f585f99,clinical trials,0.543622
uuid-90bce53db8d3495e8582b1221f585f99,approved,0.321765
uuid-90bce53db8d3495e8582b1221f585f99,SCCHN,0.415618
uuid-90bce53db8d3495e8582b1221f585f99,LTL,0.333269
uuid-90bce53db8d3495e8582b1221f585f99,TLs,0.373297
uuid-90bce53db8d3495e8582b1221f585f99,SCLC,0.307279
uuid-90bce53db8d3495e8582b1221f585f99,Regional TL,0.392424
uuid-90bce53db8d3495e8582b1221f585f99,RTL stated,0.351995
uuid-90bce53db8d3495e8582b1221f585f99,bladder,0.411078
uuid-aa7fbc86230e41dba4967fed85bb8c39,pembro,0.404692
uuid-aa7fbc86230e41dba4967fed85bb8c39,BMS,0.361121
uuid-aa7fbc86230e41dba4967fed85bb8c39,PDL1,0.498275
uuid-aa7fbc86230e41dba4967fed85bb8c39,trial,0.460921
uuid-aa7fbc86230e41dba4967fed85bb8c39,efficacy,0.703327
uuid-aa7fbc86230e41dba4967fed85bb8c39,commented,0.307228
uuid-aa7fbc86230e41dba4967fed85bb8c39,OS,0.650686
uuid-aa7fbc86230e41dba4967fed85bb8c39,atezo,0.360077
uuid-aa7fbc86230e41dba4967fed85bb8c39,regards,0.327039
uuid-aa7fbc86230e41dba4967fed85bb8c39,data,0.799998
uuid-aa7fbc86230e41dba4967fed85bb8c39,PFS,0.618818
uuid-aa7fbc86230e41dba4967fed85bb8c39,ORR,0.688766
uuid-aa7fbc86230e41dba4967fed85bb8c39,nivo and pembro,0.545849
uuid-aa7fbc86230e41dba4967fed85bb8c39,believes,0.386725
uuid-aa7fbc86230e41dba4967fed85bb8c39,impressed,0.595893
uuid-aa7fbc86230e41dba4967fed85bb8c39,vs,0.353387
uuid-aa7fbc86230e41dba4967fed85bb8c39,TLs,0.374012
uuid-aa7fbc86230e41dba4967fed85bb8c39,feels,0.479056
uuid-aa7fbc86230e41dba4967fed85bb8c39,PDL1 expression,0.466387
uuid-12c7136e19d743e290249de2546c5e27,patients,0.482819
uuid-12c7136e19d743e290249de2546c5e27,nivolumab,0.383177
uuid-12c7136e19d743e290249de2546c5e27,1L,0.412215
uuid-12c7136e19d743e290249de2546c5e27,treated,0.447456
uuid-12c7136e19d743e290249de2546c5e27,RCC,0.535573
uuid-12c7136e19d743e290249de2546c5e27,TL stated,0.348519
uuid-12c7136e19d743e290249de2546c5e27,tumor,0.30039
uuid-12c7136e19d743e290249de2546c5e27,2L,0.440626
uuid-12c7136e19d743e290249de2546c5e27,pts,0.472923
uuid-12c7136e19d743e290249de2546c5e27,approval,0.457115
uuid-12c7136e19d743e290249de2546c5e27,preferred,0.362707
uuid-12c7136e19d743e290249de2546c5e27,using nivo,0.544602
uuid-12c7136e19d743e290249de2546c5e27,NSCLC patients,0.410191
uuid-12c7136e19d743e290249de2546c5e27,approved,0.305464
uuid-12c7136e19d743e290249de2546c5e27,SCCHN,0.43117
uuid-12c7136e19d743e290249de2546c5e27,Regional TL,0.30959
uuid-12c7136e19d743e290249de2546c5e27,RTL stated,0.534245
uuid-12c7136e19d743e290249de2546c5e27,TL shared,0.358211
uuid-12c7136e19d743e290249de2546c5e27,option,0.346996
uuid-12c7136e19d743e290249de2546c5e27,bladder,0.458932
uuid-7eb990a74f514d4c9d474fb5bb1736bf,Nivo,0.31006
uuid-7eb990a74f514d4c9d474fb5bb1736bf,PDL1,0.377294
uuid-7eb990a74f514d4c9d474fb5bb1736bf,trial,0.382077
uuid-7eb990a74f514d4c9d474fb5bb1736bf,efficacy,0.495048
uuid-7eb990a74f514d4c9d474fb5bb1736bf,combination,0.401216
uuid-7eb990a74f514d4c9d474fb5bb1736bf,chemo,0.528327
uuid-7eb990a74f514d4c9d474fb5bb1736bf,tumor,0.453753
uuid-7eb990a74f514d4c9d474fb5bb1736bf,agents,0.313326
uuid-7eb990a74f514d4c9d474fb5bb1736bf,OS,0.35996
uuid-7eb990a74f514d4c9d474fb5bb1736bf,response,0.364054
uuid-7eb990a74f514d4c9d474fb5bb1736bf,combo,0.387049
uuid-7eb990a74f514d4c9d474fb5bb1736bf,PFS,0.353984
uuid-7eb990a74f514d4c9d474fb5bb1736bf,PD1,0.332364
uuid-7eb990a74f514d4c9d474fb5bb1736bf,ORR,0.398084
uuid-7eb990a74f514d4c9d474fb5bb1736bf,nivo and pembro,0.318861
uuid-7eb990a74f514d4c9d474fb5bb1736bf,believes,0.480985
uuid-7eb990a74f514d4c9d474fb5bb1736bf,chemotherapy,0.354465
uuid-7eb990a74f514d4c9d474fb5bb1736bf,feels,0.317987
uuid-7eb990a74f514d4c9d474fb5bb1736bf,PDL1 expression,0.376602
uuid-7eb990a74f514d4c9d474fb5bb1736bf,biomarker,0.302964
uuid-38dd3e60d7b2456db440b73384a3146b,patients,0.359332
uuid-38dd3e60d7b2456db440b73384a3146b,Opdivo,0.336132
uuid-38dd3e60d7b2456db440b73384a3146b,RTL,0.319653
uuid-38dd3e60d7b2456db440b73384a3146b,therapy,0.338149
uuid-38dd3e60d7b2456db440b73384a3146b,nivolumab,0.306221
uuid-38dd3e60d7b2456db440b73384a3146b,mentioned,0.59075
uuid-38dd3e60d7b2456db440b73384a3146b,cHL,0.609443
uuid-c36a981645ce44028fbdb1c344041aac,dose,0.744032
uuid-c36a981645ce44028fbdb1c344041aac,toxicity,0.335796
uuid-c36a981645ce44028fbdb1c344041aac,Ipi,0.373908
uuid-c36a981645ce44028fbdb1c344041aac,AI,0.310496
uuid-c36a981645ce44028fbdb1c344041aac,vs,0.382554
uuid-c36a981645ce44028fbdb1c344041aac,drug,0.514886
uuid-c36a981645ce44028fbdb1c344041aac,Keytruda,0.300574
uuid-c36a981645ce44028fbdb1c344041aac,flat dosing,0.606922
uuid-7172f64309624f3a95234281dc1556f6,pembro,0.30637
uuid-7172f64309624f3a95234281dc1556f6,lung,0.389445
uuid-7172f64309624f3a95234281dc1556f6,1L,0.663754
uuid-7172f64309624f3a95234281dc1556f6,melanoma,0.334944
uuid-7172f64309624f3a95234281dc1556f6,RCC,0.736305
uuid-7172f64309624f3a95234281dc1556f6,TL stated,0.627702
uuid-7172f64309624f3a95234281dc1556f6,2L,0.645474
uuid-7172f64309624f3a95234281dc1556f6,pts,0.468833
uuid-7172f64309624f3a95234281dc1556f6,PD-L1,0.556699
uuid-7172f64309624f3a95234281dc1556f6,approval,0.338848
uuid-7172f64309624f3a95234281dc1556f6,atezo,0.362935
uuid-7172f64309624f3a95234281dc1556f6,preferred,0.481086
uuid-7172f64309624f3a95234281dc1556f6,PD-L1 testing,0.456236
uuid-7172f64309624f3a95234281dc1556f6,testing,0.549076
uuid-7172f64309624f3a95234281dc1556f6,monotherapy,0.424079
uuid-7172f64309624f3a95234281dc1556f6,using nivo,0.520516
uuid-7172f64309624f3a95234281dc1556f6,PDL1 testing,0.644455
uuid-7172f64309624f3a95234281dc1556f6,NSCLC patients,0.687311
uuid-7172f64309624f3a95234281dc1556f6,approved,0.373252
uuid-7172f64309624f3a95234281dc1556f6,SCCHN,0.472557
uuid-7172f64309624f3a95234281dc1556f6,tumor types,0.485385
uuid-7172f64309624f3a95234281dc1556f6,PD-1,0.362267
uuid-7172f64309624f3a95234281dc1556f6,RTL stated,0.622797
uuid-7172f64309624f3a95234281dc1556f6,TL shared,0.503482
uuid-7172f64309624f3a95234281dc1556f6,option,0.400023
uuid-7172f64309624f3a95234281dc1556f6,bladder,0.455419
uuid-a05b106940374f52ba634361277b6cfe,shared,0.539883
uuid-a05b106940374f52ba634361277b6cfe,institution,0.75561
uuid-84947ffbf84e4cc1a6a560a0db5819e5,Nivo,0.551379
uuid-84947ffbf84e4cc1a6a560a0db5819e5,pembro,0.59065
uuid-84947ffbf84e4cc1a6a560a0db5819e5,RTL,0.39402
uuid-84947ffbf84e4cc1a6a560a0db5819e5,nivolumab,0.325963
uuid-84947ffbf84e4cc1a6a560a0db5819e5,1L,0.471896
uuid-84947ffbf84e4cc1a6a560a0db5819e5,trial,0.301149
uuid-84947ffbf84e4cc1a6a560a0db5819e5,RCC,0.33678
uuid-84947ffbf84e4cc1a6a560a0db5819e5,combination,0.330973
uuid-84947ffbf84e4cc1a6a560a0db5819e5,2L,0.517859
uuid-84947ffbf84e4cc1a6a560a0db5819e5,Ipi,0.318895
uuid-84947ffbf84e4cc1a6a560a0db5819e5,approval,0.376971
uuid-84947ffbf84e4cc1a6a560a0db5819e5,atezo,0.491518
uuid-84947ffbf84e4cc1a6a560a0db5819e5,preferred,0.582931
uuid-84947ffbf84e4cc1a6a560a0db5819e5,monotherapy,0.457362
uuid-84947ffbf84e4cc1a6a560a0db5819e5,using nivo,0.600764
uuid-84947ffbf84e4cc1a6a560a0db5819e5,combo,0.308097
uuid-84947ffbf84e4cc1a6a560a0db5819e5,clinical trials,0.31146
uuid-84947ffbf84e4cc1a6a560a0db5819e5,indication,0.343838
uuid-84947ffbf84e4cc1a6a560a0db5819e5,approved,0.424438
uuid-84947ffbf84e4cc1a6a560a0db5819e5,SCCHN,0.482256
uuid-84947ffbf84e4cc1a6a560a0db5819e5,impressed,0.345747
uuid-84947ffbf84e4cc1a6a560a0db5819e5,LTL,0.388251
uuid-84947ffbf84e4cc1a6a560a0db5819e5,feels,0.456699
uuid-84947ffbf84e4cc1a6a560a0db5819e5,Regional TL,0.333974
uuid-84947ffbf84e4cc1a6a560a0db5819e5,RTL stated,0.594689
uuid-84947ffbf84e4cc1a6a560a0db5819e5,option,0.452739
uuid-84947ffbf84e4cc1a6a560a0db5819e5,bladder,0.343761
uuid-b2bf2648b9894af7a183750b5ff8b5ad,Nivo,0.568496
uuid-b2bf2648b9894af7a183750b5ff8b5ad,patients,0.633169
uuid-b2bf2648b9894af7a183750b5ff8b5ad,pembro,0.478707
uuid-b2bf2648b9894af7a183750b5ff8b5ad,therapy,0.514463
uuid-b2bf2648b9894af7a183750b5ff8b5ad,nivolumab,0.550907
uuid-b2bf2648b9894af7a183750b5ff8b5ad,1L,0.556181
uuid-b2bf2648b9894af7a183750b5ff8b5ad,regimen,0.348975
uuid-b2bf2648b9894af7a183750b5ff8b5ad,treated,0.358357
uuid-b2bf2648b9894af7a183750b5ff8b5ad,RCC,0.344643
uuid-b2bf2648b9894af7a183750b5ff8b5ad,combination,0.34249
uuid-b2bf2648b9894af7a183750b5ff8b5ad,chemo,0.436865
uuid-b2bf2648b9894af7a183750b5ff8b5ad,2L,0.601459
uuid-b2bf2648b9894af7a183750b5ff8b5ad,pts,0.41331
uuid-b2bf2648b9894af7a183750b5ff8b5ad,approval,0.458559
uuid-b2bf2648b9894af7a183750b5ff8b5ad,atezo,0.33653
uuid-b2bf2648b9894af7a183750b5ff8b5ad,preferred,0.652637
uuid-b2bf2648b9894af7a183750b5ff8b5ad,monotherapy,0.628326
uuid-b2bf2648b9894af7a183750b5ff8b5ad,treatment,0.382762
uuid-b2bf2648b9894af7a183750b5ff8b5ad,using nivo,0.741009
uuid-b2bf2648b9894af7a183750b5ff8b5ad,combo,0.302419
uuid-b2bf2648b9894af7a183750b5ff8b5ad,PD1,0.357948
uuid-b2bf2648b9894af7a183750b5ff8b5ad,approved,0.476882
uuid-b2bf2648b9894af7a183750b5ff8b5ad,SCCHN,0.399453
uuid-b2bf2648b9894af7a183750b5ff8b5ad,cHL,0.300445
uuid-b2bf2648b9894af7a183750b5ff8b5ad,progression,0.310173
uuid-b2bf2648b9894af7a183750b5ff8b5ad,chemotherapy,0.475349
uuid-b2bf2648b9894af7a183750b5ff8b5ad,feels,0.354062
uuid-b2bf2648b9894af7a183750b5ff8b5ad,RTL stated,0.600286
uuid-b2bf2648b9894af7a183750b5ff8b5ad,option,0.708128
uuid-b2bf2648b9894af7a183750b5ff8b5ad,bladder,0.332643
uuid-4efab6879c8642b1be53b50970fb362b,Nivo,0.388217
uuid-4efab6879c8642b1be53b50970fb362b,dose,0.748826
uuid-4efab6879c8642b1be53b50970fb362b,toxicity,0.512982
uuid-4efab6879c8642b1be53b50970fb362b,efficacy,0.48696
uuid-4efab6879c8642b1be53b50970fb362b,regimen,0.454803
uuid-4efab6879c8642b1be53b50970fb362b,combination,0.38643
uuid-4efab6879c8642b1be53b50970fb362b,Ipi,0.736545
uuid-4efab6879c8642b1be53b50970fb362b,combo,0.405031
uuid-4efab6879c8642b1be53b50970fb362b,vs,0.546604
uuid-4efab6879c8642b1be53b50970fb362b,flat dosing,0.534253
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,Nivo,0.403596
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,patients,0.40458
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,pembro,0.437574
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,1L,0.379363
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,trial,0.410351
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,efficacy,0.327447
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,regimen,0.363963
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,combination,0.43987
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,chemo,0.462843
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,pts,0.488279
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,Ipi,0.450342
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,monotherapy,0.504611
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,combo,0.54762
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,clinical trials,0.328723
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,PD1,0.370335
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,ORR,0.326977
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,progression,0.328297
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,believes,0.321729
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,chemotherapy,0.3918
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,impressed,0.355965
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,vs,0.303733
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,feels,0.412044
uuid-e027d6a5adb54d11a58a7b4ca053c1d0,option,0.355041
uuid-6071c3ff93ff4847a2934549cb834a74,PDL1,0.367727
uuid-6071c3ff93ff4847a2934549cb834a74,trial,0.466505
uuid-6071c3ff93ff4847a2934549cb834a74,efficacy,0.639028
uuid-6071c3ff93ff4847a2934549cb834a74,chemo,0.307148
uuid-6071c3ff93ff4847a2934549cb834a74,OS,0.83774
uuid-6071c3ff93ff4847a2934549cb834a74,response,0.392314
uuid-6071c3ff93ff4847a2934549cb834a74,data,0.555615
uuid-6071c3ff93ff4847a2934549cb834a74,PFS,0.866233
uuid-6071c3ff93ff4847a2934549cb834a74,ORR,0.86294
uuid-6071c3ff93ff4847a2934549cb834a74,nivo and pembro,0.356547
uuid-6071c3ff93ff4847a2934549cb834a74,believes,0.35916
uuid-6071c3ff93ff4847a2934549cb834a74,impressed,0.497131
uuid-6071c3ff93ff4847a2934549cb834a74,feels,0.364287
uuid-6071c3ff93ff4847a2934549cb834a74,PDL1 expression,0.393911
uuid-cc627897a01148a3a9a358da741eff27,Nivo,0.361144
uuid-cc627897a01148a3a9a358da741eff27,patients,0.716407
uuid-cc627897a01148a3a9a358da741eff27,pembro,0.374639
uuid-cc627897a01148a3a9a358da741eff27,therapy,0.315179
uuid-cc627897a01148a3a9a358da741eff27,1L,0.434542
uuid-cc627897a01148a3a9a358da741eff27,PDL1,0.301534
uuid-cc627897a01148a3a9a358da741eff27,chemo,0.347084
uuid-cc627897a01148a3a9a358da741eff27,2L,0.372766
uuid-cc627897a01148a3a9a358da741eff27,pts,0.538777
uuid-cc627897a01148a3a9a358da741eff27,preferred,0.319713
uuid-cc627897a01148a3a9a358da741eff27,monotherapy,0.414597
uuid-cc627897a01148a3a9a358da741eff27,treatment,0.324576
uuid-cc627897a01148a3a9a358da741eff27,using nivo,0.417857
uuid-cc627897a01148a3a9a358da741eff27,NSCLC patients,0.485304
uuid-cc627897a01148a3a9a358da741eff27,progression,0.393129
uuid-cc627897a01148a3a9a358da741eff27,respond,0.419829
uuid-cc627897a01148a3a9a358da741eff27,option,0.460167
uuid-84d2e4deb52a42da8c1689e5f467e7c9,Nivo,0.374547
uuid-84d2e4deb52a42da8c1689e5f467e7c9,pembro,0.409607
uuid-84d2e4deb52a42da8c1689e5f467e7c9,PDL1,0.479107
uuid-84d2e4deb52a42da8c1689e5f467e7c9,trial,0.560372
uuid-84d2e4deb52a42da8c1689e5f467e7c9,efficacy,0.658635
uuid-84d2e4deb52a42da8c1689e5f467e7c9,OS,0.448671
uuid-84d2e4deb52a42da8c1689e5f467e7c9,atezo,0.315175
uuid-84d2e4deb52a42da8c1689e5f467e7c9,regards,0.350629
uuid-84d2e4deb52a42da8c1689e5f467e7c9,data,0.41686
uuid-84d2e4deb52a42da8c1689e5f467e7c9,PFS,0.514372
uuid-84d2e4deb52a42da8c1689e5f467e7c9,ORR,0.507487
uuid-84d2e4deb52a42da8c1689e5f467e7c9,nivo and pembro,0.47798
uuid-84d2e4deb52a42da8c1689e5f467e7c9,believes,0.323639
uuid-84d2e4deb52a42da8c1689e5f467e7c9,vs,0.449309
uuid-84d2e4deb52a42da8c1689e5f467e7c9,feels,0.398362
uuid-84d2e4deb52a42da8c1689e5f467e7c9,PDL1 expression,0.503031
uuid-91d432c79ccc4194acbae875b62c8eac,patients,0.464427
uuid-91d432c79ccc4194acbae875b62c8eac,pts,0.3547
uuid-91d432c79ccc4194acbae875b62c8eac,response,0.312975
uuid-91d432c79ccc4194acbae875b62c8eac,NSCLC patients,0.416146
uuid-91d432c79ccc4194acbae875b62c8eac,progression,0.406699
uuid-91d432c79ccc4194acbae875b62c8eac,respond,0.479877
uuid-0850775be1604766a45b2e445031cc72,BMS,0.539878
uuid-0850775be1604766a45b2e445031cc72,shared,0.305714
uuid-0850775be1604766a45b2e445031cc72,Merck,0.414105
uuid-0850775be1604766a45b2e445031cc72,physicians,0.547246
uuid-0850775be1604766a45b2e445031cc72,regards,0.312462
uuid-0850775be1604766a45b2e445031cc72,expressed,0.341734
uuid-0850775be1604766a45b2e445031cc72,clinical,0.357689
uuid-7ca4251dd99147f5bb03cd9c2e13ed24,dose,0.333522
uuid-7ca4251dd99147f5bb03cd9c2e13ed24,toxicity,0.563581
uuid-7ca4251dd99147f5bb03cd9c2e13ed24,regimen,0.43229
uuid-7ca4251dd99147f5bb03cd9c2e13ed24,treated,0.321458
uuid-7ca4251dd99147f5bb03cd9c2e13ed24,physicians,0.360714
uuid-7ca4251dd99147f5bb03cd9c2e13ed24,treatment,0.463617
uuid-7ca4251dd99147f5bb03cd9c2e13ed24,respond,0.397079
uuid-7174e0aface84429bde47b1401bc2f78,dose,0.744032
uuid-7174e0aface84429bde47b1401bc2f78,toxicity,0.335796
uuid-7174e0aface84429bde47b1401bc2f78,Ipi,0.373908
uuid-7174e0aface84429bde47b1401bc2f78,AI,0.310496
uuid-7174e0aface84429bde47b1401bc2f78,vs,0.382554
uuid-7174e0aface84429bde47b1401bc2f78,drug,0.514886
uuid-7174e0aface84429bde47b1401bc2f78,Keytruda,0.300574
uuid-7174e0aface84429bde47b1401bc2f78,flat dosing,0.606922
uuid-8eb43c9e0ab545dc83b2fd37cca12cf4,patients,0.304602
uuid-8eb43c9e0ab545dc83b2fd37cca12cf4,Opdivo,0.4811
uuid-8eb43c9e0ab545dc83b2fd37cca12cf4,treated,0.384543
uuid-8eb43c9e0ab545dc83b2fd37cca12cf4,physicians,0.452085
uuid-8eb43c9e0ab545dc83b2fd37cca12cf4,treatment,0.432311
uuid-8eb43c9e0ab545dc83b2fd37cca12cf4,progression,0.310993
uuid-8eb43c9e0ab545dc83b2fd37cca12cf4,academic,0.372331
uuid-5104d9412d534ec6b6bc2ae1df318e8f,NSCLC,0.583769
uuid-5104d9412d534ec6b6bc2ae1df318e8f,trial,0.3271
uuid-5104d9412d534ec6b6bc2ae1df318e8f,combination,0.302419
uuid-5104d9412d534ec6b6bc2ae1df318e8f,IO,0.651067
uuid-5104d9412d534ec6b6bc2ae1df318e8f,OS,0.351678
uuid-5104d9412d534ec6b6bc2ae1df318e8f,response,0.323382
uuid-5104d9412d534ec6b6bc2ae1df318e8f,PFS,0.340713
uuid-5104d9412d534ec6b6bc2ae1df318e8f,ORR,0.390534
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,Nivo,0.356831
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,patients,0.794514
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,Opdivo,0.381733
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,therapy,0.586064
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,nivolumab,0.55121
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,1L,0.332158
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,regimen,0.59591
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,treated,0.520912
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,combination,0.34837
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,chemo,0.422675
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,2L,0.33332
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,pts,0.662786
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,preferred,0.306271
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,monotherapy,0.566114
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,treatment,0.598719
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,using nivo,0.429149
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,response,0.448604
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,combo,0.367788
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,PD1,0.409817
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,progression,0.671138
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,chemotherapy,0.462061
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,respond,0.494231
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,SCLC,0.367918
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,RTL stated,0.308464
uuid-795fde7e9cf143d3b1f4e6d0dee7f2d7,option,0.53304
uuid-9fcff4d839ec4d16bf86338ddc36ad59,oncologist,0.593849
uuid-9fcff4d839ec4d16bf86338ddc36ad59,indicated,0.850489
uuid-50f88eacb1204c88b87f2f4b9a50bf40,PD-L1,0.590663
uuid-50f88eacb1204c88b87f2f4b9a50bf40,PD-L1 testing,0.583263
uuid-50f88eacb1204c88b87f2f4b9a50bf40,testing,0.583418
uuid-50f88eacb1204c88b87f2f4b9a50bf40,PDL1 testing,0.458395
uuid-50f88eacb1204c88b87f2f4b9a50bf40,NSCLC patients,0.471886
uuid-50f88eacb1204c88b87f2f4b9a50bf40,oncologist,0.573878
uuid-50f88eacb1204c88b87f2f4b9a50bf40,indicated,0.66101
uuid-50f88eacb1204c88b87f2f4b9a50bf40,assay,0.315335
uuid-50f88eacb1204c88b87f2f4b9a50bf40,biomarker,0.310354
uuid-9661cd4fa88247edacefd2a4daad6844,therapy,0.310776
uuid-9661cd4fa88247edacefd2a4daad6844,using nivo,0.347328
uuid-9661cd4fa88247edacefd2a4daad6844,cHL,0.490304
uuid-9661cd4fa88247edacefd2a4daad6844,oncologist,0.443193
uuid-9661cd4fa88247edacefd2a4daad6844,indicated,0.66253
uuid-b95170a3f1cc461bb2fb74f22144519f,dose,0.32498
uuid-b95170a3f1cc461bb2fb74f22144519f,toxicity,0.53656
uuid-b95170a3f1cc461bb2fb74f22144519f,physicians,0.372749
uuid-b95170a3f1cc461bb2fb74f22144519f,treatment,0.327643
uuid-0019b28675254bbf960cea2b7c79cbf8,patients,0.528365
uuid-0019b28675254bbf960cea2b7c79cbf8,therapy,0.328137
uuid-0019b28675254bbf960cea2b7c79cbf8,treated,0.363775
uuid-0019b28675254bbf960cea2b7c79cbf8,treatment,0.409583
uuid-0019b28675254bbf960cea2b7c79cbf8,response,0.350742
uuid-0019b28675254bbf960cea2b7c79cbf8,progression,0.442019
uuid-0019b28675254bbf960cea2b7c79cbf8,respond,0.351924
uuid-cd408908232b4397b8b4e83b00b884ca,patients,0.414768
uuid-cd408908232b4397b8b4e83b00b884ca,therapy,0.413402
uuid-cd408908232b4397b8b4e83b00b884ca,treatment,0.448586
uuid-cd408908232b4397b8b4e83b00b884ca,response,0.478291
uuid-cd408908232b4397b8b4e83b00b884ca,progression,0.520284
uuid-cd408908232b4397b8b4e83b00b884ca,chemotherapy,0.306837
uuid-cd408908232b4397b8b4e83b00b884ca,respond,0.48541
uuid-603748267a804805bae31af599f52740,lung,0.609553
uuid-603748267a804805bae31af599f52740,melanoma,0.44021
uuid-603748267a804805bae31af599f52740,regards,0.38465
uuid-603748267a804805bae31af599f52740,AI,0.758111
uuid-603748267a804805bae31af599f52740,nivo and pembro,0.331203
uuid-603748267a804805bae31af599f52740,TL shared,0.328599
uuid-603748267a804805bae31af599f52740,NCCN,0.328614
uuid-0447bd7da08d4df1ac3720528159820e,patients,0.439154
uuid-0447bd7da08d4df1ac3720528159820e,Opdivo,0.493551
uuid-0447bd7da08d4df1ac3720528159820e,regimen,0.425826
uuid-0447bd7da08d4df1ac3720528159820e,treated,0.447876
uuid-0447bd7da08d4df1ac3720528159820e,shared,0.334008
uuid-0447bd7da08d4df1ac3720528159820e,physicians,0.720201
uuid-0447bd7da08d4df1ac3720528159820e,treatment,0.478576
uuid-b67bc1e6e92847bbb00f53407e95bd9c,NTL,0.324717
uuid-b67bc1e6e92847bbb00f53407e95bd9c,mentioned,0.412725
uuid-b67bc1e6e92847bbb00f53407e95bd9c,cHL,0.563809
uuid-e777d1f87a0042189cda5780f748882b,patients,0.722322
uuid-e777d1f87a0042189cda5780f748882b,Opdivo,0.462191
uuid-e777d1f87a0042189cda5780f748882b,therapy,0.590207
uuid-e777d1f87a0042189cda5780f748882b,nivolumab,0.474827
uuid-e777d1f87a0042189cda5780f748882b,regimen,0.544032
uuid-e777d1f87a0042189cda5780f748882b,treated,0.576524
uuid-e777d1f87a0042189cda5780f748882b,melanoma,0.398286
uuid-e777d1f87a0042189cda5780f748882b,pts,0.562749
uuid-e777d1f87a0042189cda5780f748882b,monotherapy,0.317051
uuid-e777d1f87a0042189cda5780f748882b,treatment,0.744227
uuid-e777d1f87a0042189cda5780f748882b,response,0.529555
uuid-e777d1f87a0042189cda5780f748882b,PD1,0.36692
uuid-e777d1f87a0042189cda5780f748882b,cHL,0.421282
uuid-e777d1f87a0042189cda5780f748882b,progression,0.756446
uuid-e777d1f87a0042189cda5780f748882b,chemotherapy,0.325263
uuid-e777d1f87a0042189cda5780f748882b,respond,0.514294
uuid-e777d1f87a0042189cda5780f748882b,TL shared,0.374149
uuid-235b693942e740ea91cf461796f4f68a,Nivo,0.393302
uuid-235b693942e740ea91cf461796f4f68a,pembro,0.472446
uuid-235b693942e740ea91cf461796f4f68a,BMS,0.325213
uuid-235b693942e740ea91cf461796f4f68a,PDL1,0.489546
uuid-235b693942e740ea91cf461796f4f68a,trial,0.43085
uuid-235b693942e740ea91cf461796f4f68a,efficacy,0.625441
uuid-235b693942e740ea91cf461796f4f68a,OS,0.612699
uuid-235b693942e740ea91cf461796f4f68a,atezo,0.364246
uuid-235b693942e740ea91cf461796f4f68a,regards,0.318784
uuid-235b693942e740ea91cf461796f4f68a,data,0.727144
uuid-235b693942e740ea91cf461796f4f68a,PFS,0.635312
uuid-235b693942e740ea91cf461796f4f68a,ORR,0.643425
uuid-235b693942e740ea91cf461796f4f68a,nivo and pembro,0.614728
uuid-235b693942e740ea91cf461796f4f68a,believes,0.335304
uuid-235b693942e740ea91cf461796f4f68a,impressed,0.513908
uuid-235b693942e740ea91cf461796f4f68a,vs,0.438499
uuid-235b693942e740ea91cf461796f4f68a,feels,0.494662
uuid-235b693942e740ea91cf461796f4f68a,PDL1 expression,0.445687
uuid-94876563f1594b90857eff6d4c87b5f8,Opdivo,0.425769
uuid-94876563f1594b90857eff6d4c87b5f8,dose,0.448936
uuid-94876563f1594b90857eff6d4c87b5f8,physicians,0.380644
uuid-94876563f1594b90857eff6d4c87b5f8,oncology,0.460872
uuid-94876563f1594b90857eff6d4c87b5f8,Keytruda,0.324834
uuid-94876563f1594b90857eff6d4c87b5f8,flat dosing,0.655221
uuid-337111c4ea1c4ad196f923227b7af28e,TL,0.404294
uuid-337111c4ea1c4ad196f923227b7af28e,RTL,0.445475
uuid-337111c4ea1c4ad196f923227b7af28e,BMS,0.376436
uuid-337111c4ea1c4ad196f923227b7af28e,NTL,0.365395
uuid-337111c4ea1c4ad196f923227b7af28e,shared,0.456056
uuid-337111c4ea1c4ad196f923227b7af28e,commented,0.42284
uuid-337111c4ea1c4ad196f923227b7af28e,Merck,0.367553
uuid-337111c4ea1c4ad196f923227b7af28e,institution,0.35408
uuid-337111c4ea1c4ad196f923227b7af28e,stated,0.51865
uuid-337111c4ea1c4ad196f923227b7af28e,physicians,0.379859
uuid-337111c4ea1c4ad196f923227b7af28e,data,0.327583
uuid-337111c4ea1c4ad196f923227b7af28e,mentioned,0.346141
uuid-337111c4ea1c4ad196f923227b7af28e,ASCO,0.30837
uuid-337111c4ea1c4ad196f923227b7af28e,impressed,0.367588
uuid-337111c4ea1c4ad196f923227b7af28e,LTL,0.413316
uuid-337111c4ea1c4ad196f923227b7af28e,Regional TL,0.535156
uuid-eafb24cbd3894dec83d5c25846714110,pembro,0.409933
uuid-eafb24cbd3894dec83d5c25846714110,BMS,0.570528
uuid-eafb24cbd3894dec83d5c25846714110,trial,0.631971
uuid-eafb24cbd3894dec83d5c25846714110,efficacy,0.507647
uuid-eafb24cbd3894dec83d5c25846714110,Merck,0.390356
uuid-eafb24cbd3894dec83d5c25846714110,OS,0.404459
uuid-eafb24cbd3894dec83d5c25846714110,atezo,0.323291
uuid-eafb24cbd3894dec83d5c25846714110,data,0.585753
uuid-eafb24cbd3894dec83d5c25846714110,clinical trials,0.334497
uuid-eafb24cbd3894dec83d5c25846714110,indication,0.308142
uuid-eafb24cbd3894dec83d5c25846714110,PFS,0.401579
uuid-eafb24cbd3894dec83d5c25846714110,ORR,0.448743
uuid-eafb24cbd3894dec83d5c25846714110,nivo and pembro,0.370714
uuid-eafb24cbd3894dec83d5c25846714110,believes,0.30757
uuid-eafb24cbd3894dec83d5c25846714110,impressed,0.41785
uuid-eafb24cbd3894dec83d5c25846714110,feels,0.542547
uuid-eafb24cbd3894dec83d5c25846714110,PDL1 expression,0.322687
uuid-5b6fe1f3467046ab80bf06c616476812,patients,0.591141
uuid-5b6fe1f3467046ab80bf06c616476812,Opdivo,0.326612
uuid-5b6fe1f3467046ab80bf06c616476812,therapy,0.644611
uuid-5b6fe1f3467046ab80bf06c616476812,nivolumab,0.405464
uuid-5b6fe1f3467046ab80bf06c616476812,regimen,0.523293
uuid-5b6fe1f3467046ab80bf06c616476812,treated,0.661173
uuid-5b6fe1f3467046ab80bf06c616476812,chemo,0.309615
uuid-5b6fe1f3467046ab80bf06c616476812,pts,0.426373
uuid-5b6fe1f3467046ab80bf06c616476812,monotherapy,0.379693
uuid-5b6fe1f3467046ab80bf06c616476812,treatment,0.871797
uuid-5b6fe1f3467046ab80bf06c616476812,response,0.41215
uuid-5b6fe1f3467046ab80bf06c616476812,PD1,0.392083
uuid-5b6fe1f3467046ab80bf06c616476812,progression,0.658194
uuid-5b6fe1f3467046ab80bf06c616476812,chemotherapy,0.393349
uuid-5b6fe1f3467046ab80bf06c616476812,respond,0.508251
uuid-5b6fe1f3467046ab80bf06c616476812,option,0.365117
uuid-faac0541acdf403492445541c405e921,patients,0.388454
uuid-faac0541acdf403492445541c405e921,Opdivo,0.401103
uuid-faac0541acdf403492445541c405e921,pembro,0.366556
uuid-faac0541acdf403492445541c405e921,dose,0.505176
uuid-faac0541acdf403492445541c405e921,regimen,0.440471
uuid-faac0541acdf403492445541c405e921,2L,0.407883
uuid-faac0541acdf403492445541c405e921,Ipi,0.332878
uuid-faac0541acdf403492445541c405e921,approval,0.300118
uuid-faac0541acdf403492445541c405e921,atezo,0.372621
uuid-faac0541acdf403492445541c405e921,physicians,0.309877
uuid-faac0541acdf403492445541c405e921,preferred,0.518309
uuid-faac0541acdf403492445541c405e921,monotherapy,0.331317
uuid-faac0541acdf403492445541c405e921,treatment,0.316814
uuid-faac0541acdf403492445541c405e921,using nivo,0.423464
uuid-faac0541acdf403492445541c405e921,approved,0.352155
uuid-faac0541acdf403492445541c405e921,vs,0.310512
uuid-faac0541acdf403492445541c405e921,option,0.351062
uuid-faac0541acdf403492445541c405e921,flat dosing,0.337249
uuid-caa0919ee52a4dae8573c495da00bf43,patients,0.437382
uuid-caa0919ee52a4dae8573c495da00bf43,Opdivo,0.327481
uuid-caa0919ee52a4dae8573c495da00bf43,regimen,0.304382
uuid-caa0919ee52a4dae8573c495da00bf43,treated,0.308856
uuid-caa0919ee52a4dae8573c495da00bf43,physicians,0.532042
uuid-caa0919ee52a4dae8573c495da00bf43,treatment,0.533969
uuid-caa0919ee52a4dae8573c495da00bf43,progression,0.397654
uuid-caa0919ee52a4dae8573c495da00bf43,respond,0.346319
uuid-3039b45c2ff246ba8a1d0f15eafe9199,lung,0.530696
uuid-3039b45c2ff246ba8a1d0f15eafe9199,toxicity,0.451723
uuid-3039b45c2ff246ba8a1d0f15eafe9199,regimen,0.340629
uuid-3039b45c2ff246ba8a1d0f15eafe9199,treated,0.341714
uuid-3039b45c2ff246ba8a1d0f15eafe9199,melanoma,0.657666
uuid-3039b45c2ff246ba8a1d0f15eafe9199,RCC,0.437873
uuid-3039b45c2ff246ba8a1d0f15eafe9199,RTL stated,0.315976
uuid-3039b45c2ff246ba8a1d0f15eafe9199,TL shared,0.618121
uuid-375f04e8453b4714b0150069b3f703a8,Nivo,0.416996
uuid-375f04e8453b4714b0150069b3f703a8,patients,0.716175
uuid-375f04e8453b4714b0150069b3f703a8,Opdivo,0.456325
uuid-375f04e8453b4714b0150069b3f703a8,pembro,0.335052
uuid-375f04e8453b4714b0150069b3f703a8,therapy,0.475547
uuid-375f04e8453b4714b0150069b3f703a8,nivolumab,0.64189
uuid-375f04e8453b4714b0150069b3f703a8,1L,0.416398
uuid-375f04e8453b4714b0150069b3f703a8,regimen,0.447181
uuid-375f04e8453b4714b0150069b3f703a8,treated,0.546307
uuid-375f04e8453b4714b0150069b3f703a8,RCC,0.385845
uuid-375f04e8453b4714b0150069b3f703a8,chemo,0.331932
uuid-375f04e8453b4714b0150069b3f703a8,2L,0.525657
uuid-375f04e8453b4714b0150069b3f703a8,pts,0.486869
uuid-375f04e8453b4714b0150069b3f703a8,approval,0.502898
uuid-375f04e8453b4714b0150069b3f703a8,preferred,0.575074
uuid-375f04e8453b4714b0150069b3f703a8,monotherapy,0.544678
uuid-375f04e8453b4714b0150069b3f703a8,treatment,0.517302
uuid-375f04e8453b4714b0150069b3f703a8,using nivo,0.682165
uuid-375f04e8453b4714b0150069b3f703a8,PD1,0.344198
uuid-375f04e8453b4714b0150069b3f703a8,approved,0.524718
uuid-375f04e8453b4714b0150069b3f703a8,SCCHN,0.365768
uuid-375f04e8453b4714b0150069b3f703a8,progression,0.416816
uuid-375f04e8453b4714b0150069b3f703a8,chemotherapy,0.331704
uuid-375f04e8453b4714b0150069b3f703a8,RTL stated,0.522093
uuid-375f04e8453b4714b0150069b3f703a8,option,0.567969
uuid-07bc1e4442ff4df0a981265ff7525afc,RTL,0.404502
uuid-07bc1e4442ff4df0a981265ff7525afc,BMS,0.574092
uuid-07bc1e4442ff4df0a981265ff7525afc,trial,0.612645
uuid-07bc1e4442ff4df0a981265ff7525afc,NTL,0.358295
uuid-07bc1e4442ff4df0a981265ff7525afc,commented,0.304251
uuid-07bc1e4442ff4df0a981265ff7525afc,Merck,0.42697
uuid-07bc1e4442ff4df0a981265ff7525afc,stated,0.305339
uuid-07bc1e4442ff4df0a981265ff7525afc,data,0.383771
uuid-07bc1e4442ff4df0a981265ff7525afc,clinical trials,0.388326
uuid-07bc1e4442ff4df0a981265ff7525afc,impressed,0.340489
uuid-69fcfe9c0dcb45ca85ba74f74225bfd7,patients,0.38449
uuid-69fcfe9c0dcb45ca85ba74f74225bfd7,regimen,0.380168
uuid-69fcfe9c0dcb45ca85ba74f74225bfd7,treated,0.390718
uuid-69fcfe9c0dcb45ca85ba74f74225bfd7,IO,0.381278
uuid-69fcfe9c0dcb45ca85ba74f74225bfd7,physicians,0.4208
uuid-69fcfe9c0dcb45ca85ba74f74225bfd7,treatment,0.46727
uuid-69fcfe9c0dcb45ca85ba74f74225bfd7,progression,0.376049
uuid-69fcfe9c0dcb45ca85ba74f74225bfd7,oncologist,0.357332
uuid-69fcfe9c0dcb45ca85ba74f74225bfd7,indicated,0.356205
uuid-d4bfba472c8e421f912f6c7a36502692,TL,0.379238
uuid-d4bfba472c8e421f912f6c7a36502692,NSCLC,0.373829
uuid-d4bfba472c8e421f912f6c7a36502692,trial,0.416448
uuid-d4bfba472c8e421f912f6c7a36502692,efficacy,0.348029
uuid-d4bfba472c8e421f912f6c7a36502692,commented,0.338542
uuid-d4bfba472c8e421f912f6c7a36502692,combination,0.340138
uuid-d4bfba472c8e421f912f6c7a36502692,IO,0.399063
uuid-d4bfba472c8e421f912f6c7a36502692,regards,0.309835
uuid-d4bfba472c8e421f912f6c7a36502692,data,0.429784
uuid-d4bfba472c8e421f912f6c7a36502692,combo,0.360626
uuid-d4bfba472c8e421f912f6c7a36502692,expressed,0.318474
uuid-d4bfba472c8e421f912f6c7a36502692,believes,0.309387
uuid-d4bfba472c8e421f912f6c7a36502692,impressed,0.452038
uuid-d4bfba472c8e421f912f6c7a36502692,TLs,0.434408
uuid-64ae9585e5fb4a9e9c77c8259341a690,Nivo,0.302751
uuid-64ae9585e5fb4a9e9c77c8259341a690,patients,0.811156
uuid-64ae9585e5fb4a9e9c77c8259341a690,Opdivo,0.357386
uuid-64ae9585e5fb4a9e9c77c8259341a690,pembro,0.319279
uuid-64ae9585e5fb4a9e9c77c8259341a690,therapy,0.411633
uuid-64ae9585e5fb4a9e9c77c8259341a690,nivolumab,0.350785
uuid-64ae9585e5fb4a9e9c77c8259341a690,1L,0.47903
uuid-64ae9585e5fb4a9e9c77c8259341a690,regimen,0.345303
uuid-64ae9585e5fb4a9e9c77c8259341a690,treated,0.416432
uuid-64ae9585e5fb4a9e9c77c8259341a690,2L,0.508911
uuid-64ae9585e5fb4a9e9c77c8259341a690,pts,0.549344
uuid-64ae9585e5fb4a9e9c77c8259341a690,approval,0.351824
uuid-64ae9585e5fb4a9e9c77c8259341a690,preferred,0.498073
uuid-64ae9585e5fb4a9e9c77c8259341a690,monotherapy,0.456318
uuid-64ae9585e5fb4a9e9c77c8259341a690,treatment,0.525577
uuid-64ae9585e5fb4a9e9c77c8259341a690,using nivo,0.523048
uuid-64ae9585e5fb4a9e9c77c8259341a690,PDL1 testing,0.317073
uuid-64ae9585e5fb4a9e9c77c8259341a690,NSCLC patients,0.498471
uuid-64ae9585e5fb4a9e9c77c8259341a690,approved,0.351752
uuid-64ae9585e5fb4a9e9c77c8259341a690,progression,0.47622
uuid-64ae9585e5fb4a9e9c77c8259341a690,respond,0.37464
uuid-64ae9585e5fb4a9e9c77c8259341a690,RTL stated,0.38025
uuid-64ae9585e5fb4a9e9c77c8259341a690,option,0.524528
uuid-6e167bd5cb0848d69763b0849b44ee23,trial,0.394546
uuid-6e167bd5cb0848d69763b0849b44ee23,efficacy,0.653307
uuid-6e167bd5cb0848d69763b0849b44ee23,combination,0.419817
uuid-6e167bd5cb0848d69763b0849b44ee23,chemo,0.404947
uuid-6e167bd5cb0848d69763b0849b44ee23,IO,0.325482
uuid-6e167bd5cb0848d69763b0849b44ee23,OS,0.567434
uuid-6e167bd5cb0848d69763b0849b44ee23,response,0.382019
uuid-6e167bd5cb0848d69763b0849b44ee23,data,0.478375
uuid-6e167bd5cb0848d69763b0849b44ee23,combo,0.382325
uuid-6e167bd5cb0848d69763b0849b44ee23,PFS,0.533518
uuid-6e167bd5cb0848d69763b0849b44ee23,ORR,0.589398
uuid-6e167bd5cb0848d69763b0849b44ee23,believes,0.434345
uuid-6e167bd5cb0848d69763b0849b44ee23,chemotherapy,0.374819
uuid-6e167bd5cb0848d69763b0849b44ee23,impressed,0.413886
uuid-6e167bd5cb0848d69763b0849b44ee23,feels,0.450838
uuid-5f62ba052c734bd181a362b828355d97,patients,0.692232
uuid-5f62ba052c734bd181a362b828355d97,Opdivo,0.530787
uuid-5f62ba052c734bd181a362b828355d97,therapy,0.443348
uuid-5f62ba052c734bd181a362b828355d97,nivolumab,0.514483
uuid-5f62ba052c734bd181a362b828355d97,regimen,0.415636
uuid-5f62ba052c734bd181a362b828355d97,treated,0.502681
uuid-5f62ba052c734bd181a362b828355d97,RCC,0.393777
uuid-5f62ba052c734bd181a362b828355d97,pts,0.506476
uuid-5f62ba052c734bd181a362b828355d97,approval,0.348509
uuid-5f62ba052c734bd181a362b828355d97,monotherapy,0.328013
uuid-5f62ba052c734bd181a362b828355d97,treatment,0.605453
uuid-5f62ba052c734bd181a362b828355d97,using nivo,0.388454
uuid-5f62ba052c734bd181a362b828355d97,progression,0.512203
uuid-5f62ba052c734bd181a362b828355d97,respond,0.306041
uuid-5f62ba052c734bd181a362b828355d97,RTL stated,0.374812
uuid-5f62ba052c734bd181a362b828355d97,option,0.333448
uuid-d9bc3ca8a7b04826b43edf1a271ebfe9,NSCLC,0.718289
uuid-d9bc3ca8a7b04826b43edf1a271ebfe9,combination,0.316189
uuid-d9bc3ca8a7b04826b43edf1a271ebfe9,chemo,0.378237
uuid-d9bc3ca8a7b04826b43edf1a271ebfe9,IO,0.80193
uuid-d9bc3ca8a7b04826b43edf1a271ebfe9,monotherapy,0.351138
uuid-d9bc3ca8a7b04826b43edf1a271ebfe9,response,0.381522
uuid-d9bc3ca8a7b04826b43edf1a271ebfe9,combo,0.328382
uuid-d9bc3ca8a7b04826b43edf1a271ebfe9,chemotherapy,0.309148
uuid-d8d4f387efeb44e7bf23165f15a63358,BMS,0.602346
uuid-d8d4f387efeb44e7bf23165f15a63358,PDL1,0.331176
uuid-d8d4f387efeb44e7bf23165f15a63358,trial,0.729589
uuid-d8d4f387efeb44e7bf23165f15a63358,efficacy,0.448158
uuid-d8d4f387efeb44e7bf23165f15a63358,commented,0.459068
uuid-d8d4f387efeb44e7bf23165f15a63358,Merck,0.43648
uuid-d8d4f387efeb44e7bf23165f15a63358,OS,0.585751
uuid-d8d4f387efeb44e7bf23165f15a63358,regards,0.424781
uuid-d8d4f387efeb44e7bf23165f15a63358,data,0.755307
uuid-d8d4f387efeb44e7bf23165f15a63358,expressed,0.342261
uuid-d8d4f387efeb44e7bf23165f15a63358,PFS,0.582797
uuid-d8d4f387efeb44e7bf23165f15a63358,ORR,0.609965
uuid-d8d4f387efeb44e7bf23165f15a63358,nivo and pembro,0.3333
uuid-d8d4f387efeb44e7bf23165f15a63358,ASCO,0.31286
uuid-d8d4f387efeb44e7bf23165f15a63358,impressed,0.611351
uuid-d8d4f387efeb44e7bf23165f15a63358,feels,0.407384
uuid-d8d4f387efeb44e7bf23165f15a63358,PDL1 expression,0.324915
uuid-82018073d0e14f4db23ecf43fe88e8cb,Nivo,0.309006
uuid-82018073d0e14f4db23ecf43fe88e8cb,therapy,0.488841
uuid-82018073d0e14f4db23ecf43fe88e8cb,nivolumab,0.335386
uuid-82018073d0e14f4db23ecf43fe88e8cb,OS,0.347728
uuid-82018073d0e14f4db23ecf43fe88e8cb,PFS,0.456265
uuid-82018073d0e14f4db23ecf43fe88e8cb,ORR,0.329393
uuid-82018073d0e14f4db23ecf43fe88e8cb,cHL,0.644287
uuid-82018073d0e14f4db23ecf43fe88e8cb,progression,0.301799
uuid-82018073d0e14f4db23ecf43fe88e8cb,chemotherapy,0.37121
uuid-d60d7ef224094448b64d5ce7468aff77,Nivo,0.447129
uuid-d60d7ef224094448b64d5ce7468aff77,Opdivo,0.326362
uuid-d60d7ef224094448b64d5ce7468aff77,pembro,0.497165
uuid-d60d7ef224094448b64d5ce7468aff77,dose,0.91085
uuid-d60d7ef224094448b64d5ce7468aff77,Ipi,0.624778
uuid-d60d7ef224094448b64d5ce7468aff77,atezo,0.464925
uuid-d60d7ef224094448b64d5ce7468aff77,vs,0.682526
uuid-d60d7ef224094448b64d5ce7468aff77,Keytruda,0.401862
uuid-d60d7ef224094448b64d5ce7468aff77,flat dosing,0.772192
uuid-0dd530c5c118436698c58802483e4dbd,Nivo,0.48911
uuid-0dd530c5c118436698c58802483e4dbd,pembro,0.477173
uuid-0dd530c5c118436698c58802483e4dbd,dose,0.335563
uuid-0dd530c5c118436698c58802483e4dbd,trial,0.664924
uuid-0dd530c5c118436698c58802483e4dbd,combination,0.335729
uuid-0dd530c5c118436698c58802483e4dbd,chemo,0.317035
uuid-0dd530c5c118436698c58802483e4dbd,Ipi,0.614398
uuid-0dd530c5c118436698c58802483e4dbd,atezo,0.319113
uuid-0dd530c5c118436698c58802483e4dbd,combo,0.31971
uuid-0dd530c5c118436698c58802483e4dbd,chemotherapy,0.345142
uuid-0dd530c5c118436698c58802483e4dbd,vs,0.491269
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,PDL1,0.309762
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,efficacy,0.523311
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,combination,0.326012
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,chemo,0.371584
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,tumor,0.455949
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,OS,0.358382
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,response,0.432133
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,PFS,0.415132
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,PD1,0.325523
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,ORR,0.408522
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,believes,0.430377
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,chemotherapy,0.315593
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,immunotherapy,0.308037
uuid-d1fc67876d5a4e04b6f0d5f4bb1de7fa,PDL1 expression,0.329351
uuid-5252499c2a1248ec9088fabb42ba0fa0,Nivo,0.519448
uuid-5252499c2a1248ec9088fabb42ba0fa0,patients,0.63579
uuid-5252499c2a1248ec9088fabb42ba0fa0,therapy,0.431822
uuid-5252499c2a1248ec9088fabb42ba0fa0,nivolumab,0.479003
uuid-5252499c2a1248ec9088fabb42ba0fa0,regimen,0.367198
uuid-5252499c2a1248ec9088fabb42ba0fa0,treated,0.411165
uuid-5252499c2a1248ec9088fabb42ba0fa0,chemo,0.348394
uuid-5252499c2a1248ec9088fabb42ba0fa0,pts,0.469129
uuid-5252499c2a1248ec9088fabb42ba0fa0,monotherapy,0.356937
uuid-5252499c2a1248ec9088fabb42ba0fa0,treatment,0.372887
uuid-5252499c2a1248ec9088fabb42ba0fa0,using nivo,0.383409
uuid-5252499c2a1248ec9088fabb42ba0fa0,response,0.335736
uuid-5252499c2a1248ec9088fabb42ba0fa0,PD1,0.318283
uuid-5252499c2a1248ec9088fabb42ba0fa0,cHL,0.409277
uuid-5252499c2a1248ec9088fabb42ba0fa0,progression,0.429127
uuid-5252499c2a1248ec9088fabb42ba0fa0,chemotherapy,0.350697
uuid-5252499c2a1248ec9088fabb42ba0fa0,respond,0.383212
uuid-4023a0f8006d44dba86ed6c60266e326,Nivo,0.604907
uuid-4023a0f8006d44dba86ed6c60266e326,patients,0.448654
uuid-4023a0f8006d44dba86ed6c60266e326,therapy,0.595177
uuid-4023a0f8006d44dba86ed6c60266e326,nivolumab,0.329161
uuid-4023a0f8006d44dba86ed6c60266e326,chemo,0.321907
uuid-4023a0f8006d44dba86ed6c60266e326,treatment,0.308985
uuid-4023a0f8006d44dba86ed6c60266e326,cHL,0.618477
uuid-4023a0f8006d44dba86ed6c60266e326,chemotherapy,0.398132
uuid-a5d069f38d134db29635f1d2d692364f,Nivo,0.329318
uuid-a5d069f38d134db29635f1d2d692364f,trial,0.479872
uuid-a5d069f38d134db29635f1d2d692364f,efficacy,0.368905
uuid-a5d069f38d134db29635f1d2d692364f,OS,0.626986
uuid-a5d069f38d134db29635f1d2d692364f,data,0.454709
uuid-a5d069f38d134db29635f1d2d692364f,PFS,0.721187
uuid-a5d069f38d134db29635f1d2d692364f,ORR,0.628948
uuid-a5d069f38d134db29635f1d2d692364f,nivo and pembro,0.322845
uuid-a5d069f38d134db29635f1d2d692364f,impressed,0.439208
uuid-63fa256778904e79a9a55248b67a861b,Nivo,0.476979
uuid-63fa256778904e79a9a55248b67a861b,pembro,0.371272
uuid-63fa256778904e79a9a55248b67a861b,dose,0.51495
uuid-63fa256778904e79a9a55248b67a861b,toxicity,0.424905
uuid-63fa256778904e79a9a55248b67a861b,efficacy,0.557061
uuid-63fa256778904e79a9a55248b67a861b,combination,0.362552
uuid-63fa256778904e79a9a55248b67a861b,Ipi,0.730889
uuid-63fa256778904e79a9a55248b67a861b,atezo,0.364582
uuid-63fa256778904e79a9a55248b67a861b,combo,0.427612
uuid-63fa256778904e79a9a55248b67a861b,ORR,0.318694
uuid-63fa256778904e79a9a55248b67a861b,nivo and pembro,0.313902
uuid-63fa256778904e79a9a55248b67a861b,impressed,0.351294
uuid-63fa256778904e79a9a55248b67a861b,vs,0.493524
uuid-63fa256778904e79a9a55248b67a861b,TLs,0.309874
uuid-63fa256778904e79a9a55248b67a861b,flat dosing,0.348593
uuid-06eb1061445a452cad144c9f885495b0,pembro,0.399275
uuid-06eb1061445a452cad144c9f885495b0,BMS,0.379627
uuid-06eb1061445a452cad144c9f885495b0,NSCLC,0.319785
uuid-06eb1061445a452cad144c9f885495b0,PDL1,0.663094
uuid-06eb1061445a452cad144c9f885495b0,trial,0.417076
uuid-06eb1061445a452cad144c9f885495b0,efficacy,0.575442
uuid-06eb1061445a452cad144c9f885495b0,Merck,0.415316
uuid-06eb1061445a452cad144c9f885495b0,PD-L1,0.36582
uuid-06eb1061445a452cad144c9f885495b0,OS,0.393745
uuid-06eb1061445a452cad144c9f885495b0,atezo,0.44993
uuid-06eb1061445a452cad144c9f885495b0,regards,0.312513
uuid-06eb1061445a452cad144c9f885495b0,data,0.451664
uuid-06eb1061445a452cad144c9f885495b0,PFS,0.426378
uuid-06eb1061445a452cad144c9f885495b0,ORR,0.435423
uuid-06eb1061445a452cad144c9f885495b0,nivo and pembro,0.592898
uuid-06eb1061445a452cad144c9f885495b0,believes,0.461428
uuid-06eb1061445a452cad144c9f885495b0,vs,0.421387
uuid-06eb1061445a452cad144c9f885495b0,assay,0.465042
uuid-06eb1061445a452cad144c9f885495b0,PDL1 expression,0.504117
uuid-06eb1061445a452cad144c9f885495b0,biomarker,0.418483
uuid-b85c4f4a28be48e68f0756272ca0b964,TL,0.447386
uuid-b85c4f4a28be48e68f0756272ca0b964,PDL1,0.345654
uuid-b85c4f4a28be48e68f0756272ca0b964,TL stated,0.323285
uuid-b85c4f4a28be48e68f0756272ca0b964,institution,0.434478
uuid-b85c4f4a28be48e68f0756272ca0b964,PD-L1,0.619526
uuid-b85c4f4a28be48e68f0756272ca0b964,PD-L1 testing,0.74244
uuid-b85c4f4a28be48e68f0756272ca0b964,testing,0.73615
uuid-b85c4f4a28be48e68f0756272ca0b964,PDL1 testing,0.634657
uuid-b85c4f4a28be48e68f0756272ca0b964,NSCLC patients,0.479113
uuid-b85c4f4a28be48e68f0756272ca0b964,assay,0.585848
uuid-6bdc1387408f49ed968eefeb10a9416c,Nivo,0.413055
uuid-6bdc1387408f49ed968eefeb10a9416c,pembro,0.460601
uuid-6bdc1387408f49ed968eefeb10a9416c,1L,0.350626
uuid-6bdc1387408f49ed968eefeb10a9416c,PDL1,0.420048
uuid-6bdc1387408f49ed968eefeb10a9416c,efficacy,0.337648
uuid-6bdc1387408f49ed968eefeb10a9416c,2L,0.386376
uuid-6bdc1387408f49ed968eefeb10a9416c,agents,0.324717
uuid-6bdc1387408f49ed968eefeb10a9416c,atezo,0.488726
uuid-6bdc1387408f49ed968eefeb10a9416c,data,0.414825
uuid-6bdc1387408f49ed968eefeb10a9416c,PFS,0.304484
uuid-6bdc1387408f49ed968eefeb10a9416c,nivo and pembro,0.567016
uuid-6bdc1387408f49ed968eefeb10a9416c,believes,0.334838
uuid-6bdc1387408f49ed968eefeb10a9416c,feels,0.329783
uuid-6bdc1387408f49ed968eefeb10a9416c,PDL1 expression,0.300271
uuid-0c0ce87ed5954958b7a023af222a883f,Nivo,0.486889
uuid-0c0ce87ed5954958b7a023af222a883f,pembro,0.505529
uuid-0c0ce87ed5954958b7a023af222a883f,1L,0.647156
uuid-0c0ce87ed5954958b7a023af222a883f,PDL1,0.404662
uuid-0c0ce87ed5954958b7a023af222a883f,efficacy,0.304137
uuid-0c0ce87ed5954958b7a023af222a883f,RCC,0.395155
uuid-0c0ce87ed5954958b7a023af222a883f,combination,0.399815
uuid-0c0ce87ed5954958b7a023af222a883f,chemo,0.504877
uuid-0c0ce87ed5954958b7a023af222a883f,2L,0.613711
uuid-0c0ce87ed5954958b7a023af222a883f,agents,0.575014
uuid-0c0ce87ed5954958b7a023af222a883f,atezo,0.456621
uuid-0c0ce87ed5954958b7a023af222a883f,preferred,0.499664
uuid-0c0ce87ed5954958b7a023af222a883f,monotherapy,0.647688
uuid-0c0ce87ed5954958b7a023af222a883f,using nivo,0.465992
uuid-0c0ce87ed5954958b7a023af222a883f,data,0.327683
uuid-0c0ce87ed5954958b7a023af222a883f,combo,0.448158
uuid-0c0ce87ed5954958b7a023af222a883f,PD1,0.510661
uuid-0c0ce87ed5954958b7a023af222a883f,approved,0.319722
uuid-0c0ce87ed5954958b7a023af222a883f,nivo and pembro,0.544092
uuid-0c0ce87ed5954958b7a023af222a883f,believes,0.451707
uuid-0c0ce87ed5954958b7a023af222a883f,chemotherapy,0.41405
uuid-0c0ce87ed5954958b7a023af222a883f,feels,0.431651
uuid-0c0ce87ed5954958b7a023af222a883f,PD-1,0.304172
uuid-0c0ce87ed5954958b7a023af222a883f,RTL stated,0.405509
uuid-0c0ce87ed5954958b7a023af222a883f,PDL1 expression,0.306574
uuid-0c0ce87ed5954958b7a023af222a883f,option,0.603358
uuid-2a7a4fea981947c59bba2ac87724035f,BMS,0.322525
uuid-2a7a4fea981947c59bba2ac87724035f,trial,0.313424
uuid-2a7a4fea981947c59bba2ac87724035f,commented,0.475689
uuid-2a7a4fea981947c59bba2ac87724035f,tumor,0.333448
uuid-2a7a4fea981947c59bba2ac87724035f,Merck,0.328846
uuid-2a7a4fea981947c59bba2ac87724035f,stated,0.319294
uuid-2a7a4fea981947c59bba2ac87724035f,OS,0.322977
uuid-2a7a4fea981947c59bba2ac87724035f,regards,0.3695
uuid-2a7a4fea981947c59bba2ac87724035f,data,0.620069
uuid-2a7a4fea981947c59bba2ac87724035f,expressed,0.338917
uuid-2a7a4fea981947c59bba2ac87724035f,PFS,0.305232
uuid-2a7a4fea981947c59bba2ac87724035f,ASCO,0.371242
uuid-2a7a4fea981947c59bba2ac87724035f,impressed,0.514822
uuid-2a7a4fea981947c59bba2ac87724035f,feels,0.345789
uuid-2a7a4fea981947c59bba2ac87724035f,Regional TL,0.322306
uuid-298eb9126f264a769f26394f51f77157,commented,0.332384
uuid-298eb9126f264a769f26394f51f77157,OS,0.332796
uuid-298eb9126f264a769f26394f51f77157,PFS,0.329153
uuid-298eb9126f264a769f26394f51f77157,Regional TL,0.361475
uuid-ca4e63521cca4e9ead8f57aded62ad52,PDL1,0.310788
uuid-ca4e63521cca4e9ead8f57aded62ad52,efficacy,0.53512
uuid-ca4e63521cca4e9ead8f57aded62ad52,OS,0.515244
uuid-ca4e63521cca4e9ead8f57aded62ad52,data,0.395959
uuid-ca4e63521cca4e9ead8f57aded62ad52,PFS,0.426468
uuid-ca4e63521cca4e9ead8f57aded62ad52,ORR,0.514955
uuid-ca4e63521cca4e9ead8f57aded62ad52,nivo and pembro,0.367166
uuid-ca4e63521cca4e9ead8f57aded62ad52,believes,0.508766
uuid-ca4e63521cca4e9ead8f57aded62ad52,impressed,0.345755
uuid-9a7855b9650a46699174241feef93891,BMS,0.332662
uuid-9a7855b9650a46699174241feef93891,PDL1,0.516023
uuid-9a7855b9650a46699174241feef93891,trial,0.42098
uuid-9a7855b9650a46699174241feef93891,efficacy,0.587661
uuid-9a7855b9650a46699174241feef93891,OS,0.504969
uuid-9a7855b9650a46699174241feef93891,regards,0.468774
uuid-9a7855b9650a46699174241feef93891,data,0.604305
uuid-9a7855b9650a46699174241feef93891,PFS,0.543143
uuid-9a7855b9650a46699174241feef93891,ORR,0.549588
uuid-9a7855b9650a46699174241feef93891,nivo and pembro,0.528962
uuid-9a7855b9650a46699174241feef93891,believes,0.518696
uuid-9a7855b9650a46699174241feef93891,impressed,0.383469
uuid-9a7855b9650a46699174241feef93891,feels,0.322808
uuid-9a7855b9650a46699174241feef93891,PDL1 expression,0.45225
uuid-9a7855b9650a46699174241feef93891,biomarker,0.37357
uuid-18a02aa560c44da7b7a1c4786800de1e,BMS,0.381038
uuid-18a02aa560c44da7b7a1c4786800de1e,lung,0.37245
uuid-18a02aa560c44da7b7a1c4786800de1e,shared,0.341677
uuid-18a02aa560c44da7b7a1c4786800de1e,commented,0.384007
uuid-18a02aa560c44da7b7a1c4786800de1e,RCC,0.392355
uuid-18a02aa560c44da7b7a1c4786800de1e,TL stated,0.305462
uuid-18a02aa560c44da7b7a1c4786800de1e,2L,0.317868
uuid-18a02aa560c44da7b7a1c4786800de1e,Merck,0.32794
uuid-18a02aa560c44da7b7a1c4786800de1e,stated,0.504377
uuid-18a02aa560c44da7b7a1c4786800de1e,approval,0.499546
uuid-18a02aa560c44da7b7a1c4786800de1e,using nivo,0.396367
uuid-18a02aa560c44da7b7a1c4786800de1e,mentioned,0.315113
uuid-18a02aa560c44da7b7a1c4786800de1e,indication,0.405552
uuid-18a02aa560c44da7b7a1c4786800de1e,approved,0.433982
uuid-18a02aa560c44da7b7a1c4786800de1e,SCCHN,0.503697
uuid-18a02aa560c44da7b7a1c4786800de1e,impressed,0.31362
uuid-18a02aa560c44da7b7a1c4786800de1e,label,0.316718
uuid-18a02aa560c44da7b7a1c4786800de1e,LTL,0.30712
uuid-18a02aa560c44da7b7a1c4786800de1e,TLs,0.34139
uuid-18a02aa560c44da7b7a1c4786800de1e,Regional TL,0.41674
uuid-18a02aa560c44da7b7a1c4786800de1e,RTL stated,0.3836
uuid-18a02aa560c44da7b7a1c4786800de1e,NCCN,0.325218
uuid-18a02aa560c44da7b7a1c4786800de1e,bladder,0.354369
uuid-6c85a999472d40b5b240f902a1a5efc8,pembro,0.528884
uuid-6c85a999472d40b5b240f902a1a5efc8,RTL,0.377192
uuid-6c85a999472d40b5b240f902a1a5efc8,dose,0.418474
uuid-6c85a999472d40b5b240f902a1a5efc8,shared,0.301252
uuid-6c85a999472d40b5b240f902a1a5efc8,RCC,0.348157
uuid-6c85a999472d40b5b240f902a1a5efc8,TL stated,0.40525
uuid-6c85a999472d40b5b240f902a1a5efc8,2L,0.3446
uuid-6c85a999472d40b5b240f902a1a5efc8,stated,0.39458
uuid-6c85a999472d40b5b240f902a1a5efc8,approval,0.396996
uuid-6c85a999472d40b5b240f902a1a5efc8,atezo,0.51956
uuid-6c85a999472d40b5b240f902a1a5efc8,preferred,0.386562
uuid-6c85a999472d40b5b240f902a1a5efc8,using nivo,0.427862
uuid-6c85a999472d40b5b240f902a1a5efc8,mentioned,0.303066
uuid-6c85a999472d40b5b240f902a1a5efc8,indication,0.487485
uuid-6c85a999472d40b5b240f902a1a5efc8,approved,0.356646
uuid-6c85a999472d40b5b240f902a1a5efc8,SCCHN,0.522688
uuid-6c85a999472d40b5b240f902a1a5efc8,HCP,0.330012
uuid-6c85a999472d40b5b240f902a1a5efc8,vs,0.446948
uuid-6c85a999472d40b5b240f902a1a5efc8,LTL,0.417678
uuid-6c85a999472d40b5b240f902a1a5efc8,TLs,0.549203
uuid-6c85a999472d40b5b240f902a1a5efc8,Regional TL,0.367474
uuid-6c85a999472d40b5b240f902a1a5efc8,RTL stated,0.367019
uuid-6c85a999472d40b5b240f902a1a5efc8,bladder,0.316523
uuid-6c85a999472d40b5b240f902a1a5efc8,flat dosing,0.589704
uuid-63b62c894e584b649181b6fbfe5ebe0f,Nivo,0.396051
uuid-63b62c894e584b649181b6fbfe5ebe0f,patients,0.659404
uuid-63b62c894e584b649181b6fbfe5ebe0f,Opdivo,0.481985
uuid-63b62c894e584b649181b6fbfe5ebe0f,pembro,0.449645
uuid-63b62c894e584b649181b6fbfe5ebe0f,therapy,0.351994
uuid-63b62c894e584b649181b6fbfe5ebe0f,nivolumab,0.504363
uuid-63b62c894e584b649181b6fbfe5ebe0f,1L,0.326694
uuid-63b62c894e584b649181b6fbfe5ebe0f,treated,0.351713
uuid-63b62c894e584b649181b6fbfe5ebe0f,2L,0.385713
uuid-63b62c894e584b649181b6fbfe5ebe0f,pts,0.370436
uuid-63b62c894e584b649181b6fbfe5ebe0f,approval,0.676263
uuid-63b62c894e584b649181b6fbfe5ebe0f,preferred,0.402289
uuid-63b62c894e584b649181b6fbfe5ebe0f,treatment,0.377463
uuid-63b62c894e584b649181b6fbfe5ebe0f,using nivo,0.532214
uuid-63b62c894e584b649181b6fbfe5ebe0f,indication,0.387762
uuid-63b62c894e584b649181b6fbfe5ebe0f,approved,0.571317
uuid-63b62c894e584b649181b6fbfe5ebe0f,SCCHN,0.30297
uuid-63b62c894e584b649181b6fbfe5ebe0f,label,0.450888
uuid-63b62c894e584b649181b6fbfe5ebe0f,RTL stated,0.375502
uuid-63b62c894e584b649181b6fbfe5ebe0f,option,0.37102
uuid-dd249c17ecd94ea2ac933d557565671f,TL,0.631091
uuid-dd249c17ecd94ea2ac933d557565671f,TL stated,0.314814
uuid-dd249c17ecd94ea2ac933d557565671f,institution,0.396468
uuid-dd249c17ecd94ea2ac933d557565671f,PD-L1,0.743456
uuid-dd249c17ecd94ea2ac933d557565671f,PD-L1 testing,0.923082
uuid-dd249c17ecd94ea2ac933d557565671f,testing,0.82178
uuid-dd249c17ecd94ea2ac933d557565671f,PDL1 testing,0.604547
uuid-dd249c17ecd94ea2ac933d557565671f,NSCLC patients,0.533161
uuid-dd249c17ecd94ea2ac933d557565671f,assay,0.659499
uuid-dd249c17ecd94ea2ac933d557565671f,biomarker,0.326055
uuid-be4d472600af4765855ea2afc469d10a,patients,0.636327
uuid-be4d472600af4765855ea2afc469d10a,Opdivo,0.447813
uuid-be4d472600af4765855ea2afc469d10a,therapy,0.463909
uuid-be4d472600af4765855ea2afc469d10a,nivolumab,0.585222
uuid-be4d472600af4765855ea2afc469d10a,regimen,0.366415
uuid-be4d472600af4765855ea2afc469d10a,treated,0.505608
uuid-be4d472600af4765855ea2afc469d10a,pts,0.323186
uuid-be4d472600af4765855ea2afc469d10a,approval,0.490112
uuid-be4d472600af4765855ea2afc469d10a,preferred,0.355068
uuid-be4d472600af4765855ea2afc469d10a,treatment,0.524965
uuid-be4d472600af4765855ea2afc469d10a,using nivo,0.425674
uuid-be4d472600af4765855ea2afc469d10a,approved,0.404164
uuid-be4d472600af4765855ea2afc469d10a,HCP,0.330644
uuid-be4d472600af4765855ea2afc469d10a,cHL,0.338022
uuid-be4d472600af4765855ea2afc469d10a,label,0.421749
uuid-be4d472600af4765855ea2afc469d10a,SCLC,0.32505
uuid-be4d472600af4765855ea2afc469d10a,RTL stated,0.334579
uuid-be4d472600af4765855ea2afc469d10a,option,0.334202
uuid-9f5307945b8e467881950486f8d72dd7,PDL1,0.598378
uuid-9f5307945b8e467881950486f8d72dd7,trial,0.31781
uuid-9f5307945b8e467881950486f8d72dd7,efficacy,0.713835
uuid-9f5307945b8e467881950486f8d72dd7,commented,0.303803
uuid-9f5307945b8e467881950486f8d72dd7,PD-L1,0.305275
uuid-9f5307945b8e467881950486f8d72dd7,OS,0.544249
uuid-9f5307945b8e467881950486f8d72dd7,atezo,0.303532
uuid-9f5307945b8e467881950486f8d72dd7,regards,0.468674
uuid-9f5307945b8e467881950486f8d72dd7,data,0.700677
uuid-9f5307945b8e467881950486f8d72dd7,expressed,0.318927
uuid-9f5307945b8e467881950486f8d72dd7,PFS,0.539889
uuid-9f5307945b8e467881950486f8d72dd7,ORR,0.61226
uuid-9f5307945b8e467881950486f8d72dd7,nivo and pembro,0.53965
uuid-9f5307945b8e467881950486f8d72dd7,believes,0.34954
uuid-9f5307945b8e467881950486f8d72dd7,impressed,0.453355
uuid-9f5307945b8e467881950486f8d72dd7,TLs,0.304445
uuid-9f5307945b8e467881950486f8d72dd7,feels,0.301364
uuid-9f5307945b8e467881950486f8d72dd7,PDL1 expression,0.557642
uuid-9f5307945b8e467881950486f8d72dd7,biomarker,0.474906
uuid-9d0f27f72e5242fd8652a3d9168baf5c,patients,0.75082
uuid-9d0f27f72e5242fd8652a3d9168baf5c,Opdivo,0.452912
uuid-9d0f27f72e5242fd8652a3d9168baf5c,therapy,0.404083
uuid-9d0f27f72e5242fd8652a3d9168baf5c,nivolumab,0.329197
uuid-9d0f27f72e5242fd8652a3d9168baf5c,1L,0.394455
uuid-9d0f27f72e5242fd8652a3d9168baf5c,regimen,0.413162
uuid-9d0f27f72e5242fd8652a3d9168baf5c,treated,0.5221
uuid-9d0f27f72e5242fd8652a3d9168baf5c,2L,0.393461
uuid-9d0f27f72e5242fd8652a3d9168baf5c,pts,0.57045
uuid-9d0f27f72e5242fd8652a3d9168baf5c,preferred,0.347401
uuid-9d0f27f72e5242fd8652a3d9168baf5c,testing,0.372949
uuid-9d0f27f72e5242fd8652a3d9168baf5c,monotherapy,0.438914
uuid-9d0f27f72e5242fd8652a3d9168baf5c,treatment,0.535205
uuid-9d0f27f72e5242fd8652a3d9168baf5c,using nivo,0.399275
uuid-9d0f27f72e5242fd8652a3d9168baf5c,PDL1 testing,0.356322
uuid-9d0f27f72e5242fd8652a3d9168baf5c,NSCLC patients,0.559055
uuid-9d0f27f72e5242fd8652a3d9168baf5c,progression,0.565152
uuid-9d0f27f72e5242fd8652a3d9168baf5c,respond,0.411478
uuid-9d0f27f72e5242fd8652a3d9168baf5c,RTL stated,0.318631
uuid-9d0f27f72e5242fd8652a3d9168baf5c,option,0.39589
uuid-a7f28df080bc4000a5a5fb5fd0eca80e,testing,0.455391
uuid-a7f28df080bc4000a5a5fb5fd0eca80e,PDL1 testing,0.461478
uuid-a7f28df080bc4000a5a5fb5fd0eca80e,NSCLC patients,0.597339
uuid-a7f28df080bc4000a5a5fb5fd0eca80e,tumor types,0.355586
uuid-2bfb92c503e941109e4319ca7df6179a,patients,0.675978
uuid-2bfb92c503e941109e4319ca7df6179a,Opdivo,0.640657
uuid-2bfb92c503e941109e4319ca7df6179a,therapy,0.521838
uuid-2bfb92c503e941109e4319ca7df6179a,nivolumab,0.451397
uuid-2bfb92c503e941109e4319ca7df6179a,regimen,0.3978
uuid-2bfb92c503e941109e4319ca7df6179a,treated,0.579843
uuid-2bfb92c503e941109e4319ca7df6179a,pts,0.446322
uuid-2bfb92c503e941109e4319ca7df6179a,treatment,0.658842
uuid-2bfb92c503e941109e4319ca7df6179a,cHL,0.464314
uuid-2bfb92c503e941109e4319ca7df6179a,lung cancer,0.32535
uuid-2bfb92c503e941109e4319ca7df6179a,progression,0.594228
uuid-2bfb92c503e941109e4319ca7df6179a,respond,0.417021
uuid-24769678d13c4f21b5590d9504c31dc6,patients,0.463774
uuid-24769678d13c4f21b5590d9504c31dc6,treated,0.400651
uuid-24769678d13c4f21b5590d9504c31dc6,approval,0.324292
uuid-24769678d13c4f21b5590d9504c31dc6,preferred,0.300141
uuid-24769678d13c4f21b5590d9504c31dc6,PD-L1 testing,0.333829
uuid-24769678d13c4f21b5590d9504c31dc6,testing,0.333601
uuid-24769678d13c4f21b5590d9504c31dc6,treatment,0.35745
uuid-24769678d13c4f21b5590d9504c31dc6,NSCLC patients,0.354742
uuid-24769678d13c4f21b5590d9504c31dc6,RTL stated,0.30724
uuid-af746aa02efc43aaa152997b15f081b4,Nivo,0.391994
uuid-af746aa02efc43aaa152997b15f081b4,patients,0.37267
uuid-af746aa02efc43aaa152997b15f081b4,therapy,0.34099
uuid-af746aa02efc43aaa152997b15f081b4,nivolumab,0.530237
uuid-af746aa02efc43aaa152997b15f081b4,1L,0.313266
uuid-af746aa02efc43aaa152997b15f081b4,2L,0.420956
uuid-af746aa02efc43aaa152997b15f081b4,stated,0.314002
uuid-af746aa02efc43aaa152997b15f081b4,approval,0.476517
uuid-af746aa02efc43aaa152997b15f081b4,preferred,0.578941
uuid-af746aa02efc43aaa152997b15f081b4,monotherapy,0.37168
uuid-af746aa02efc43aaa152997b15f081b4,using nivo,0.580807
uuid-af746aa02efc43aaa152997b15f081b4,indication,0.406419
uuid-af746aa02efc43aaa152997b15f081b4,approved,0.518478
uuid-af746aa02efc43aaa152997b15f081b4,SCCHN,0.45454
uuid-af746aa02efc43aaa152997b15f081b4,cHL,0.301565
uuid-af746aa02efc43aaa152997b15f081b4,label,0.313145
uuid-af746aa02efc43aaa152997b15f081b4,Regional TL,0.323329
uuid-af746aa02efc43aaa152997b15f081b4,RTL stated,0.471393
uuid-af746aa02efc43aaa152997b15f081b4,option,0.531856
uuid-688b68385eab439898be0dc440cae245,physicians,0.375619
uuid-688b68385eab439898be0dc440cae245,mentioned,0.410105
uuid-688b68385eab439898be0dc440cae245,oncology,0.402896
uuid-688b68385eab439898be0dc440cae245,HCP,0.383601
uuid-13724bd958a745f2b775edb9638846b3,toxicity,0.34167
uuid-13724bd958a745f2b775edb9638846b3,combination,0.572303
uuid-13724bd958a745f2b775edb9638846b3,chemo,0.314108
uuid-13724bd958a745f2b775edb9638846b3,IO,0.336211
uuid-13724bd958a745f2b775edb9638846b3,agents,0.351361
uuid-13724bd958a745f2b775edb9638846b3,combo,0.39323
uuid-13724bd958a745f2b775edb9638846b3,believes,0.340527
uuid-13724bd958a745f2b775edb9638846b3,chemotherapy,0.350688
uuid-13724bd958a745f2b775edb9638846b3,immunotherapy,0.363624
uuid-9a37127c882f477e9a9fbc43b67cdc1d,physicians,0.30031
uuid-9a37127c882f477e9a9fbc43b67cdc1d,oncology,0.495396
uuid-9a37127c882f477e9a9fbc43b67cdc1d,drug,0.533708
uuid-9a37127c882f477e9a9fbc43b67cdc1d,clinical,0.467897
uuid-9a37127c882f477e9a9fbc43b67cdc1d,flat dosing,0.355488
uuid-b3207a73a5c74822ac3f4f677af47c66,TL,0.518217
uuid-b3207a73a5c74822ac3f4f677af47c66,TL stated,0.455528
uuid-b3207a73a5c74822ac3f4f677af47c66,institution,0.502784
uuid-b3207a73a5c74822ac3f4f677af47c66,PD-L1,0.777074
uuid-b3207a73a5c74822ac3f4f677af47c66,PD-L1 testing,0.913058
uuid-b3207a73a5c74822ac3f4f677af47c66,testing,0.894783
uuid-b3207a73a5c74822ac3f4f677af47c66,PDL1 testing,0.747474
uuid-b3207a73a5c74822ac3f4f677af47c66,NSCLC patients,0.698558
uuid-b3207a73a5c74822ac3f4f677af47c66,assay,0.647023
uuid-b3207a73a5c74822ac3f4f677af47c66,biomarker,0.323454
uuid-316c38e73e90489c9e1f8a92e96e2452,RTL,0.563417
uuid-316c38e73e90489c9e1f8a92e96e2452,nivolumab,0.322244
uuid-316c38e73e90489c9e1f8a92e96e2452,lung,0.433831
uuid-316c38e73e90489c9e1f8a92e96e2452,1L,0.397283
uuid-316c38e73e90489c9e1f8a92e96e2452,NTL,0.348091
uuid-316c38e73e90489c9e1f8a92e96e2452,melanoma,0.448089
uuid-316c38e73e90489c9e1f8a92e96e2452,shared,0.435942
uuid-316c38e73e90489c9e1f8a92e96e2452,commented,0.351848
uuid-316c38e73e90489c9e1f8a92e96e2452,RCC,0.786009
uuid-316c38e73e90489c9e1f8a92e96e2452,TL stated,0.570373
uuid-316c38e73e90489c9e1f8a92e96e2452,2L,0.453115
uuid-316c38e73e90489c9e1f8a92e96e2452,pts,0.348894
uuid-316c38e73e90489c9e1f8a92e96e2452,stated,0.711433
uuid-316c38e73e90489c9e1f8a92e96e2452,approval,0.416393
uuid-316c38e73e90489c9e1f8a92e96e2452,preferred,0.331721
uuid-316c38e73e90489c9e1f8a92e96e2452,using nivo,0.584433
uuid-316c38e73e90489c9e1f8a92e96e2452,clinical trials,0.349298
uuid-316c38e73e90489c9e1f8a92e96e2452,PDL1 testing,0.348308
uuid-316c38e73e90489c9e1f8a92e96e2452,NSCLC patients,0.310882
uuid-316c38e73e90489c9e1f8a92e96e2452,approved,0.399909
uuid-316c38e73e90489c9e1f8a92e96e2452,SCCHN,0.739261
uuid-316c38e73e90489c9e1f8a92e96e2452,HCP,0.358069
uuid-316c38e73e90489c9e1f8a92e96e2452,impressed,0.31702
uuid-316c38e73e90489c9e1f8a92e96e2452,tumor types,0.44421
uuid-316c38e73e90489c9e1f8a92e96e2452,LTL,0.60374
uuid-316c38e73e90489c9e1f8a92e96e2452,TLs,0.492658
uuid-316c38e73e90489c9e1f8a92e96e2452,academic,0.32665
uuid-316c38e73e90489c9e1f8a92e96e2452,SCLC,0.358483
uuid-316c38e73e90489c9e1f8a92e96e2452,Regional TL,0.66097
uuid-316c38e73e90489c9e1f8a92e96e2452,RTL stated,0.697669
uuid-316c38e73e90489c9e1f8a92e96e2452,TL shared,0.562665
uuid-316c38e73e90489c9e1f8a92e96e2452,bladder,0.541182
uuid-422929cb55974f06ac5aeb22c3715902,TL,0.489221
uuid-422929cb55974f06ac5aeb22c3715902,TL stated,0.505946
uuid-422929cb55974f06ac5aeb22c3715902,institution,0.486837
uuid-422929cb55974f06ac5aeb22c3715902,PD-L1,0.694519
uuid-422929cb55974f06ac5aeb22c3715902,approval,0.335999
uuid-422929cb55974f06ac5aeb22c3715902,PD-L1 testing,0.857712
uuid-422929cb55974f06ac5aeb22c3715902,testing,0.857847
uuid-422929cb55974f06ac5aeb22c3715902,PDL1 testing,0.754435
uuid-422929cb55974f06ac5aeb22c3715902,NSCLC patients,0.67391
uuid-422929cb55974f06ac5aeb22c3715902,assay,0.553927
uuid-f12512bc863741459e15fa8b2cd5bdf9,lung,0.802354
uuid-f12512bc863741459e15fa8b2cd5bdf9,1L,0.480747
uuid-f12512bc863741459e15fa8b2cd5bdf9,melanoma,0.566412
uuid-f12512bc863741459e15fa8b2cd5bdf9,RCC,0.69889
uuid-f12512bc863741459e15fa8b2cd5bdf9,TL stated,0.679329
uuid-f12512bc863741459e15fa8b2cd5bdf9,2L,0.481193
uuid-f12512bc863741459e15fa8b2cd5bdf9,PD-L1,0.318559
uuid-f12512bc863741459e15fa8b2cd5bdf9,preferred,0.310839
uuid-f12512bc863741459e15fa8b2cd5bdf9,PD-L1 testing,0.347259
uuid-f12512bc863741459e15fa8b2cd5bdf9,testing,0.445186
uuid-f12512bc863741459e15fa8b2cd5bdf9,using nivo,0.389438
uuid-f12512bc863741459e15fa8b2cd5bdf9,PDL1 testing,0.683927
uuid-f12512bc863741459e15fa8b2cd5bdf9,AI,0.40278
uuid-f12512bc863741459e15fa8b2cd5bdf9,NSCLC patients,0.522132
uuid-f12512bc863741459e15fa8b2cd5bdf9,SCCHN,0.547116
uuid-f12512bc863741459e15fa8b2cd5bdf9,tumor types,0.646344
uuid-f12512bc863741459e15fa8b2cd5bdf9,TLs,0.35493
uuid-f12512bc863741459e15fa8b2cd5bdf9,Regional TL,0.353948
uuid-f12512bc863741459e15fa8b2cd5bdf9,RTL stated,0.515108
uuid-f12512bc863741459e15fa8b2cd5bdf9,TL shared,0.635763
uuid-f12512bc863741459e15fa8b2cd5bdf9,NCCN,0.306095
uuid-f12512bc863741459e15fa8b2cd5bdf9,bladder,0.500981
uuid-fa702d989e534d989e4581c04c42f692,lung,0.523806
uuid-fa702d989e534d989e4581c04c42f692,melanoma,0.575706
uuid-fa702d989e534d989e4581c04c42f692,shared,0.302294
uuid-fa702d989e534d989e4581c04c42f692,commented,0.430967
uuid-fa702d989e534d989e4581c04c42f692,RCC,0.375237
uuid-fa702d989e534d989e4581c04c42f692,TL stated,0.312281
uuid-fa702d989e534d989e4581c04c42f692,regards,0.336824
uuid-fa702d989e534d989e4581c04c42f692,AI,0.493467
uuid-fa702d989e534d989e4581c04c42f692,SCCHN,0.443269
uuid-fa702d989e534d989e4581c04c42f692,SCLC,0.337783
uuid-fa702d989e534d989e4581c04c42f692,TL shared,0.407246
uuid-fa702d989e534d989e4581c04c42f692,NCCN,0.687612
uuid-a3abbaec648646fbbc9256c0b18e9547,commented,0.325341
uuid-a3abbaec648646fbbc9256c0b18e9547,physicians,0.326274
uuid-a3abbaec648646fbbc9256c0b18e9547,oncology,0.553656
uuid-a3abbaec648646fbbc9256c0b18e9547,clinical,0.509499
uuid-a3abbaec648646fbbc9256c0b18e9547,Regional TL,0.348498
uuid-8c6d48fe31074d148a889adbf504a2cc,RTL,0.346565
uuid-8c6d48fe31074d148a889adbf504a2cc,BMS,0.403428
uuid-8c6d48fe31074d148a889adbf504a2cc,discussed,0.301971
uuid-8c6d48fe31074d148a889adbf504a2cc,commented,0.428974
uuid-8c6d48fe31074d148a889adbf504a2cc,Merck,0.406403
uuid-8c6d48fe31074d148a889adbf504a2cc,stated,0.345702
uuid-8c6d48fe31074d148a889adbf504a2cc,data,0.481104
uuid-8c6d48fe31074d148a889adbf504a2cc,expressed,0.365438
uuid-8c6d48fe31074d148a889adbf504a2cc,impressed,0.398602
uuid-e08b062c863d47f7be83f501febefaa1,TL,0.405111
uuid-e08b062c863d47f7be83f501febefaa1,RTL,0.462339
uuid-e08b062c863d47f7be83f501febefaa1,trial,0.331834
uuid-e08b062c863d47f7be83f501febefaa1,NTL,0.492746
uuid-e08b062c863d47f7be83f501febefaa1,commented,0.310167
uuid-e08b062c863d47f7be83f501febefaa1,SCCHN,0.303335
uuid-e08b062c863d47f7be83f501febefaa1,oncologist,0.337895
uuid-e08b062c863d47f7be83f501febefaa1,indicated,0.312858
uuid-e08b062c863d47f7be83f501febefaa1,academic,0.301056
uuid-e08b062c863d47f7be83f501febefaa1,Regional TL,0.500726
uuid-a08d5ad6cde94d3181ffd3e8e5c5ec3b,trial,0.341119
uuid-6d5eae685439465ca1ccd01a9d868c97,Nivo,0.425044
uuid-6d5eae685439465ca1ccd01a9d868c97,patients,0.839577
uuid-6d5eae685439465ca1ccd01a9d868c97,Opdivo,0.352196
uuid-6d5eae685439465ca1ccd01a9d868c97,therapy,0.599486
uuid-6d5eae685439465ca1ccd01a9d868c97,dose,0.344471
uuid-6d5eae685439465ca1ccd01a9d868c97,nivolumab,0.412871
uuid-6d5eae685439465ca1ccd01a9d868c97,toxicity,0.518352
uuid-6d5eae685439465ca1ccd01a9d868c97,regimen,0.703029
uuid-6d5eae685439465ca1ccd01a9d868c97,treated,0.416455
uuid-6d5eae685439465ca1ccd01a9d868c97,combination,0.380674
uuid-6d5eae685439465ca1ccd01a9d868c97,chemo,0.597278
uuid-6d5eae685439465ca1ccd01a9d868c97,pts,0.61239
uuid-6d5eae685439465ca1ccd01a9d868c97,Ipi,0.321583
uuid-6d5eae685439465ca1ccd01a9d868c97,monotherapy,0.571245
uuid-6d5eae685439465ca1ccd01a9d868c97,treatment,0.685419
uuid-6d5eae685439465ca1ccd01a9d868c97,response,0.529657
uuid-6d5eae685439465ca1ccd01a9d868c97,combo,0.365452
uuid-6d5eae685439465ca1ccd01a9d868c97,PD1,0.444105
uuid-6d5eae685439465ca1ccd01a9d868c97,progression,0.707727
uuid-6d5eae685439465ca1ccd01a9d868c97,chemotherapy,0.571369
uuid-6d5eae685439465ca1ccd01a9d868c97,respond,0.587873
uuid-6d5eae685439465ca1ccd01a9d868c97,option,0.487632
uuid-43650bb8a2d444dab8a29fff55c06258,patients,0.739787
uuid-43650bb8a2d444dab8a29fff55c06258,Opdivo,0.406343
uuid-43650bb8a2d444dab8a29fff55c06258,therapy,0.396942
uuid-43650bb8a2d444dab8a29fff55c06258,nivolumab,0.324237
uuid-43650bb8a2d444dab8a29fff55c06258,regimen,0.537548
uuid-43650bb8a2d444dab8a29fff55c06258,treated,0.514672
uuid-43650bb8a2d444dab8a29fff55c06258,pts,0.404915
uuid-43650bb8a2d444dab8a29fff55c06258,treatment,0.562496
uuid-43650bb8a2d444dab8a29fff55c06258,progression,0.49843
uuid-43650bb8a2d444dab8a29fff55c06258,respond,0.342154
uuid-657511f51669436e9b622f46dce6c27c,Nivo,0.393591
uuid-657511f51669436e9b622f46dce6c27c,pembro,0.30053
uuid-657511f51669436e9b622f46dce6c27c,trial,0.395553
uuid-657511f51669436e9b622f46dce6c27c,efficacy,0.488689
uuid-657511f51669436e9b622f46dce6c27c,discussed,0.433499
uuid-657511f51669436e9b622f46dce6c27c,OS,0.519105
uuid-657511f51669436e9b622f46dce6c27c,data,0.679104
uuid-657511f51669436e9b622f46dce6c27c,PFS,0.506222
uuid-657511f51669436e9b622f46dce6c27c,ORR,0.552526
uuid-657511f51669436e9b622f46dce6c27c,nivo and pembro,0.441147
uuid-657511f51669436e9b622f46dce6c27c,believes,0.362243
uuid-657511f51669436e9b622f46dce6c27c,impressed,0.521281
uuid-657511f51669436e9b622f46dce6c27c,feels,0.555259
uuid-cec7e291dae745f2ba29e59ac31c4a2d,RTL,0.446914
uuid-cec7e291dae745f2ba29e59ac31c4a2d,trial,0.315202
uuid-cec7e291dae745f2ba29e59ac31c4a2d,treated,0.309306
uuid-cec7e291dae745f2ba29e59ac31c4a2d,shared,0.375039
uuid-cec7e291dae745f2ba29e59ac31c4a2d,combination,0.394932
uuid-cec7e291dae745f2ba29e59ac31c4a2d,stated,0.333087
uuid-cec7e291dae745f2ba29e59ac31c4a2d,combo,0.363781
uuid-cec7e291dae745f2ba29e59ac31c4a2d,clinical trials,0.573819
uuid-cec7e291dae745f2ba29e59ac31c4a2d,academic,0.368655
uuid-cec7e291dae745f2ba29e59ac31c4a2d,feels,0.352549
uuid-cec7e291dae745f2ba29e59ac31c4a2d,Regional TL,0.415489
uuid-cec7e291dae745f2ba29e59ac31c4a2d,RTL stated,0.362977
uuid-e262cad3e6f44f9099f0eb5c05de148d,RTL,0.31049
uuid-e262cad3e6f44f9099f0eb5c05de148d,BMS,0.468603
uuid-e262cad3e6f44f9099f0eb5c05de148d,lung,0.375828
uuid-e262cad3e6f44f9099f0eb5c05de148d,trial,0.312475
uuid-e262cad3e6f44f9099f0eb5c05de148d,NTL,0.346453
uuid-e262cad3e6f44f9099f0eb5c05de148d,discussed,0.501234
uuid-e262cad3e6f44f9099f0eb5c05de148d,commented,0.631103
uuid-e262cad3e6f44f9099f0eb5c05de148d,Merck,0.37854
uuid-e262cad3e6f44f9099f0eb5c05de148d,stated,0.339035
uuid-e262cad3e6f44f9099f0eb5c05de148d,OS,0.383635
uuid-e262cad3e6f44f9099f0eb5c05de148d,regards,0.484848
uuid-e262cad3e6f44f9099f0eb5c05de148d,data,0.678505
uuid-e262cad3e6f44f9099f0eb5c05de148d,expressed,0.439439
uuid-e262cad3e6f44f9099f0eb5c05de148d,PFS,0.381686
uuid-e262cad3e6f44f9099f0eb5c05de148d,ORR,0.383594
uuid-e262cad3e6f44f9099f0eb5c05de148d,ASCO,0.443905
uuid-e262cad3e6f44f9099f0eb5c05de148d,impressed,0.504695
uuid-e262cad3e6f44f9099f0eb5c05de148d,TLs,0.372038
uuid-e262cad3e6f44f9099f0eb5c05de148d,Regional TL,0.34537
uuid-211b28653aa042efb5e50f42692af0df,pembro,0.496414
uuid-211b28653aa042efb5e50f42692af0df,BMS,0.468578
uuid-211b28653aa042efb5e50f42692af0df,shared,0.48861
uuid-211b28653aa042efb5e50f42692af0df,2L,0.442104
uuid-211b28653aa042efb5e50f42692af0df,Merck,0.337598
uuid-211b28653aa042efb5e50f42692af0df,atezo,0.578169
uuid-211b28653aa042efb5e50f42692af0df,preferred,0.388056
uuid-211b28653aa042efb5e50f42692af0df,using nivo,0.355668
uuid-211b28653aa042efb5e50f42692af0df,combo,0.30968
uuid-211b28653aa042efb5e50f42692af0df,clinical trials,0.318645
uuid-211b28653aa042efb5e50f42692af0df,approved,0.36419
uuid-211b28653aa042efb5e50f42692af0df,vs,0.334258
uuid-211b28653aa042efb5e50f42692af0df,LTL,0.315328
uuid-211b28653aa042efb5e50f42692af0df,TLs,0.375264
uuid-211b28653aa042efb5e50f42692af0df,feels,0.375821
uuid-211b28653aa042efb5e50f42692af0df,flat dosing,0.301983
uuid-9ed08bab17584d968d60d664cd2b7122,TL,0.351702
uuid-9ed08bab17584d968d60d664cd2b7122,RTL,0.401199
uuid-9ed08bab17584d968d60d664cd2b7122,lung,0.343836
uuid-9ed08bab17584d968d60d664cd2b7122,NTL,0.461091
uuid-9ed08bab17584d968d60d664cd2b7122,shared,0.478578
uuid-9ed08bab17584d968d60d664cd2b7122,commented,0.445773
uuid-9ed08bab17584d968d60d664cd2b7122,TL stated,0.397133
uuid-9ed08bab17584d968d60d664cd2b7122,Merck,0.37966
uuid-9ed08bab17584d968d60d664cd2b7122,institution,0.401651
uuid-9ed08bab17584d968d60d664cd2b7122,stated,0.363687
uuid-9ed08bab17584d968d60d664cd2b7122,PD-L1,0.340708
uuid-9ed08bab17584d968d60d664cd2b7122,approval,0.303337
uuid-9ed08bab17584d968d60d664cd2b7122,PD-L1 testing,0.39236
uuid-9ed08bab17584d968d60d664cd2b7122,testing,0.423378
uuid-9ed08bab17584d968d60d664cd2b7122,regards,0.367603
uuid-9ed08bab17584d968d60d664cd2b7122,expressed,0.425476
uuid-9ed08bab17584d968d60d664cd2b7122,mentioned,0.306948
uuid-9ed08bab17584d968d60d664cd2b7122,PDL1 testing,0.507696
uuid-9ed08bab17584d968d60d664cd2b7122,indication,0.335101
uuid-9ed08bab17584d968d60d664cd2b7122,SCCHN,0.452265
uuid-9ed08bab17584d968d60d664cd2b7122,tumor types,0.304334
uuid-9ed08bab17584d968d60d664cd2b7122,LTL,0.377807
uuid-9ed08bab17584d968d60d664cd2b7122,TLs,0.38497
uuid-9ed08bab17584d968d60d664cd2b7122,academic,0.341655
uuid-9ed08bab17584d968d60d664cd2b7122,assay,0.308636
uuid-9ed08bab17584d968d60d664cd2b7122,Regional TL,0.399726
uuid-9ed08bab17584d968d60d664cd2b7122,bladder,0.321171
uuid-642c02285e1c43e7bc037ee6d98c3b3b,RTL,0.38918
uuid-642c02285e1c43e7bc037ee6d98c3b3b,BMS,0.516568
uuid-642c02285e1c43e7bc037ee6d98c3b3b,trial,0.355288
uuid-642c02285e1c43e7bc037ee6d98c3b3b,NTL,0.428617
uuid-642c02285e1c43e7bc037ee6d98c3b3b,discussed,0.306278
uuid-642c02285e1c43e7bc037ee6d98c3b3b,shared,0.375314
uuid-642c02285e1c43e7bc037ee6d98c3b3b,commented,0.468319
uuid-642c02285e1c43e7bc037ee6d98c3b3b,Merck,0.474805
uuid-642c02285e1c43e7bc037ee6d98c3b3b,stated,0.379191
uuid-642c02285e1c43e7bc037ee6d98c3b3b,regards,0.301017
uuid-642c02285e1c43e7bc037ee6d98c3b3b,data,0.60649
uuid-642c02285e1c43e7bc037ee6d98c3b3b,expressed,0.438918
uuid-642c02285e1c43e7bc037ee6d98c3b3b,ASCO,0.350488
uuid-642c02285e1c43e7bc037ee6d98c3b3b,impressed,0.433323
uuid-642c02285e1c43e7bc037ee6d98c3b3b,LTL,0.314624
uuid-642c02285e1c43e7bc037ee6d98c3b3b,TLs,0.32015
uuid-642c02285e1c43e7bc037ee6d98c3b3b,clinical,0.323326
uuid-642c02285e1c43e7bc037ee6d98c3b3b,Regional TL,0.361069
uuid-3ff05587fa984e8680f17c289b15e5e9,Nivo,0.373143
uuid-3ff05587fa984e8680f17c289b15e5e9,pembro,0.323014
uuid-3ff05587fa984e8680f17c289b15e5e9,PDL1,0.348658
uuid-3ff05587fa984e8680f17c289b15e5e9,trial,0.494636
uuid-3ff05587fa984e8680f17c289b15e5e9,efficacy,0.424106
uuid-3ff05587fa984e8680f17c289b15e5e9,OS,0.707781
uuid-3ff05587fa984e8680f17c289b15e5e9,data,0.669522
uuid-3ff05587fa984e8680f17c289b15e5e9,PFS,0.722799
uuid-3ff05587fa984e8680f17c289b15e5e9,ORR,0.678204
uuid-3ff05587fa984e8680f17c289b15e5e9,nivo and pembro,0.428924
uuid-3ff05587fa984e8680f17c289b15e5e9,impressed,0.570952
uuid-3ff05587fa984e8680f17c289b15e5e9,feels,0.38574
uuid-3ff05587fa984e8680f17c289b15e5e9,PDL1 expression,0.328488
uuid-f37a44049d164c8b88f9991f0f2a4c9e,physicians,0.325303
uuid-f37a44049d164c8b88f9991f0f2a4c9e,oncology,0.362255
uuid-f37a44049d164c8b88f9991f0f2a4c9e,label,0.349249
uuid-2b36e52760494fb4a3766ce7bedda9e0,pembro,0.455181
uuid-2b36e52760494fb4a3766ce7bedda9e0,BMS,0.429585
uuid-2b36e52760494fb4a3766ce7bedda9e0,PDL1,0.440424
uuid-2b36e52760494fb4a3766ce7bedda9e0,trial,0.3656
uuid-2b36e52760494fb4a3766ce7bedda9e0,efficacy,0.524041
uuid-2b36e52760494fb4a3766ce7bedda9e0,commented,0.424749
uuid-2b36e52760494fb4a3766ce7bedda9e0,agents,0.323848
uuid-2b36e52760494fb4a3766ce7bedda9e0,Merck,0.410827
uuid-2b36e52760494fb4a3766ce7bedda9e0,OS,0.3378
uuid-2b36e52760494fb4a3766ce7bedda9e0,atezo,0.49795
uuid-2b36e52760494fb4a3766ce7bedda9e0,regards,0.422311
uuid-2b36e52760494fb4a3766ce7bedda9e0,data,0.715946
uuid-2b36e52760494fb4a3766ce7bedda9e0,expressed,0.38396
uuid-2b36e52760494fb4a3766ce7bedda9e0,indication,0.443812
uuid-2b36e52760494fb4a3766ce7bedda9e0,PFS,0.313884
uuid-2b36e52760494fb4a3766ce7bedda9e0,ORR,0.378578
uuid-2b36e52760494fb4a3766ce7bedda9e0,nivo and pembro,0.572105
uuid-2b36e52760494fb4a3766ce7bedda9e0,believes,0.316843
uuid-2b36e52760494fb4a3766ce7bedda9e0,impressed,0.450411
uuid-2b36e52760494fb4a3766ce7bedda9e0,TLs,0.446653
uuid-2b36e52760494fb4a3766ce7bedda9e0,feels,0.437537
uuid-2b36e52760494fb4a3766ce7bedda9e0,PDL1 expression,0.448092
uuid-06cee65292e7482e9f0f497f002ee685,chemo,0.413516
uuid-06cee65292e7482e9f0f497f002ee685,OS,0.480391
uuid-06cee65292e7482e9f0f497f002ee685,PFS,0.484441
uuid-06cee65292e7482e9f0f497f002ee685,ORR,0.473829
uuid-06cee65292e7482e9f0f497f002ee685,chemotherapy,0.416279
uuid-06cee65292e7482e9f0f497f002ee685,impressed,0.315432
uuid-256525a8da04491c8af84fd58185bd80,patients,0.48547
uuid-256525a8da04491c8af84fd58185bd80,Opdivo,0.518491
uuid-256525a8da04491c8af84fd58185bd80,dose,0.554873
uuid-256525a8da04491c8af84fd58185bd80,nivolumab,0.389814
uuid-256525a8da04491c8af84fd58185bd80,treated,0.369343
uuid-256525a8da04491c8af84fd58185bd80,pts,0.303222
uuid-256525a8da04491c8af84fd58185bd80,approval,0.357614
uuid-256525a8da04491c8af84fd58185bd80,treatment,0.343165
uuid-256525a8da04491c8af84fd58185bd80,flat dosing,0.448637
uuid-e9ba98cf61b84ecd888d362837af0e6e,TL,0.612649
uuid-e9ba98cf61b84ecd888d362837af0e6e,PDL1,0.499068
uuid-e9ba98cf61b84ecd888d362837af0e6e,Merck,0.386772
uuid-e9ba98cf61b84ecd888d362837af0e6e,institution,0.346577
uuid-e9ba98cf61b84ecd888d362837af0e6e,PD-L1,0.812085
uuid-e9ba98cf61b84ecd888d362837af0e6e,PD-L1 testing,0.807768
uuid-e9ba98cf61b84ecd888d362837af0e6e,testing,0.78666
uuid-e9ba98cf61b84ecd888d362837af0e6e,PDL1 testing,0.491444
uuid-e9ba98cf61b84ecd888d362837af0e6e,NSCLC patients,0.42724
uuid-e9ba98cf61b84ecd888d362837af0e6e,assay,0.866844
uuid-e9ba98cf61b84ecd888d362837af0e6e,PDL1 expression,0.315229
uuid-e9ba98cf61b84ecd888d362837af0e6e,biomarker,0.476065
uuid-bdf4ff5f1f264d688a4d2351d5215196,TL,0.458373
uuid-bdf4ff5f1f264d688a4d2351d5215196,1L,0.316771
uuid-bdf4ff5f1f264d688a4d2351d5215196,PDL1,0.466265
uuid-bdf4ff5f1f264d688a4d2351d5215196,PD-L1,0.813187
uuid-bdf4ff5f1f264d688a4d2351d5215196,approval,0.320927
uuid-bdf4ff5f1f264d688a4d2351d5215196,PD-L1 testing,0.774962
uuid-bdf4ff5f1f264d688a4d2351d5215196,testing,0.84849
uuid-bdf4ff5f1f264d688a4d2351d5215196,PDL1 testing,0.627326
uuid-bdf4ff5f1f264d688a4d2351d5215196,NSCLC patients,0.624838
uuid-bdf4ff5f1f264d688a4d2351d5215196,assay,0.767586
uuid-bdf4ff5f1f264d688a4d2351d5215196,biomarker,0.35068
uuid-eb00d477ebd04f93b41ed02216a1f2bd,RTL,0.579521
uuid-eb00d477ebd04f93b41ed02216a1f2bd,nivolumab,0.304715
uuid-eb00d477ebd04f93b41ed02216a1f2bd,NTL,0.445762
uuid-eb00d477ebd04f93b41ed02216a1f2bd,shared,0.317015
uuid-eb00d477ebd04f93b41ed02216a1f2bd,commented,0.336711
uuid-eb00d477ebd04f93b41ed02216a1f2bd,stated,0.417514
uuid-eb00d477ebd04f93b41ed02216a1f2bd,physicians,0.30565
uuid-eb00d477ebd04f93b41ed02216a1f2bd,mentioned,0.425554
uuid-eb00d477ebd04f93b41ed02216a1f2bd,SCCHN,0.315793
uuid-eb00d477ebd04f93b41ed02216a1f2bd,HCP,0.364049
uuid-eb00d477ebd04f93b41ed02216a1f2bd,cHL,0.400639
uuid-eb00d477ebd04f93b41ed02216a1f2bd,impressed,0.359266
uuid-eb00d477ebd04f93b41ed02216a1f2bd,LTL,0.436083
uuid-eb00d477ebd04f93b41ed02216a1f2bd,Regional TL,0.542036
uuid-668e76ad306b4746a411896bdb11df79,TL,0.703909
uuid-668e76ad306b4746a411896bdb11df79,TL stated,0.391184
uuid-668e76ad306b4746a411896bdb11df79,institution,0.404885
uuid-668e76ad306b4746a411896bdb11df79,PD-L1,0.689936
uuid-668e76ad306b4746a411896bdb11df79,PD-L1 testing,0.917446
uuid-668e76ad306b4746a411896bdb11df79,testing,0.811698
uuid-668e76ad306b4746a411896bdb11df79,PDL1 testing,0.643692
uuid-668e76ad306b4746a411896bdb11df79,NSCLC patients,0.557183
uuid-668e76ad306b4746a411896bdb11df79,assay,0.611383
uuid-668e76ad306b4746a411896bdb11df79,biomarker,0.302134
uuid-2d704d1e67474fd2b4fb73e691b9837a,BMS,0.336219
uuid-2d704d1e67474fd2b4fb73e691b9837a,lung,0.39259
uuid-2d704d1e67474fd2b4fb73e691b9837a,institution,0.340235
uuid-2d704d1e67474fd2b4fb73e691b9837a,regards,0.365043
uuid-2d704d1e67474fd2b4fb73e691b9837a,data,0.424822
uuid-2d704d1e67474fd2b4fb73e691b9837a,indication,0.337035
uuid-2d704d1e67474fd2b4fb73e691b9837a,AI,0.64361
uuid-2d704d1e67474fd2b4fb73e691b9837a,nivo and pembro,0.339142
uuid-2d704d1e67474fd2b4fb73e691b9837a,label,0.3104
uuid-2d704d1e67474fd2b4fb73e691b9837a,SCLC,0.330252
uuid-2d704d1e67474fd2b4fb73e691b9837a,NCCN,0.600115
uuid-37b726b10e3f4aa8ab3c4e98225e1438,patients,0.37079
uuid-37b726b10e3f4aa8ab3c4e98225e1438,Opdivo,0.304605
uuid-37b726b10e3f4aa8ab3c4e98225e1438,therapy,0.311025
uuid-37b726b10e3f4aa8ab3c4e98225e1438,nivolumab,0.443519
uuid-37b726b10e3f4aa8ab3c4e98225e1438,treated,0.553207
uuid-37b726b10e3f4aa8ab3c4e98225e1438,shared,0.323235
uuid-37b726b10e3f4aa8ab3c4e98225e1438,RCC,0.320245
uuid-37b726b10e3f4aa8ab3c4e98225e1438,stated,0.312799
uuid-37b726b10e3f4aa8ab3c4e98225e1438,approval,0.30924
uuid-37b726b10e3f4aa8ab3c4e98225e1438,treatment,0.344449
uuid-37b726b10e3f4aa8ab3c4e98225e1438,using nivo,0.369062
uuid-37b726b10e3f4aa8ab3c4e98225e1438,Regional TL,0.468055
uuid-37b726b10e3f4aa8ab3c4e98225e1438,RTL stated,0.410432
uuid-559ea0066794421b9e771be6810190ae,NSCLC,0.618048
uuid-559ea0066794421b9e771be6810190ae,IO,0.62623
uuid-559ea0066794421b9e771be6810190ae,response,0.39245
uuid-ecc9dc68b03943289c57c428e42d107f,NSCLC,0.757653
uuid-ecc9dc68b03943289c57c428e42d107f,IO,0.746856
uuid-ecc9dc68b03943289c57c428e42d107f,response,0.320588
uuid-ecc9dc68b03943289c57c428e42d107f,combo,0.304196
uuid-2b592645b1a241098bda97933eec69a7,NSCLC,0.734263
uuid-2b592645b1a241098bda97933eec69a7,IO,0.704934
uuid-4643264e1ec6415182c87d7951173dfe,NSCLC,0.76686
uuid-4643264e1ec6415182c87d7951173dfe,IO,0.718334
uuid-bd8dca9232f749a49767e2dc40905209,dose,0.314982
uuid-bd8dca9232f749a49767e2dc40905209,NSCLC,0.69452
uuid-bd8dca9232f749a49767e2dc40905209,regimen,0.300881
uuid-bd8dca9232f749a49767e2dc40905209,IO,0.671106
uuid-bd8dca9232f749a49767e2dc40905209,monotherapy,0.311773
uuid-ca5857dc72244e4484d484a06830890e,RTL,0.361702
uuid-ca5857dc72244e4484d484a06830890e,BMS,0.36429
uuid-ca5857dc72244e4484d484a06830890e,trial,0.427738
uuid-ca5857dc72244e4484d484a06830890e,discussed,0.432592
uuid-ca5857dc72244e4484d484a06830890e,commented,0.433537
uuid-ca5857dc72244e4484d484a06830890e,OS,0.494389
uuid-ca5857dc72244e4484d484a06830890e,regards,0.308916
uuid-ca5857dc72244e4484d484a06830890e,data,0.798937
uuid-ca5857dc72244e4484d484a06830890e,mentioned,0.341972
uuid-ca5857dc72244e4484d484a06830890e,PFS,0.515305
uuid-ca5857dc72244e4484d484a06830890e,ORR,0.518886
uuid-ca5857dc72244e4484d484a06830890e,nivo and pembro,0.358872
uuid-ca5857dc72244e4484d484a06830890e,ASCO,0.419281
uuid-ca5857dc72244e4484d484a06830890e,impressed,0.576817
uuid-ca5857dc72244e4484d484a06830890e,LTL,0.31455
uuid-9dd94d66e1274f36b449734dcdf33432,Nivo,0.306353
uuid-9dd94d66e1274f36b449734dcdf33432,patients,0.401374
uuid-9dd94d66e1274f36b449734dcdf33432,therapy,0.355514
uuid-9dd94d66e1274f36b449734dcdf33432,dose,0.316337
uuid-9dd94d66e1274f36b449734dcdf33432,nivolumab,0.303124
uuid-9dd94d66e1274f36b449734dcdf33432,toxicity,0.569544
uuid-9dd94d66e1274f36b449734dcdf33432,regimen,0.475474
uuid-9dd94d66e1274f36b449734dcdf33432,treated,0.38996
uuid-9dd94d66e1274f36b449734dcdf33432,combination,0.396066
uuid-9dd94d66e1274f36b449734dcdf33432,chemo,0.35616
uuid-9dd94d66e1274f36b449734dcdf33432,pts,0.356678
uuid-9dd94d66e1274f36b449734dcdf33432,Ipi,0.564721
uuid-9dd94d66e1274f36b449734dcdf33432,monotherapy,0.327861
uuid-9dd94d66e1274f36b449734dcdf33432,treatment,0.323734
uuid-9dd94d66e1274f36b449734dcdf33432,combo,0.387989
uuid-9dd94d66e1274f36b449734dcdf33432,PD1,0.304564
uuid-9dd94d66e1274f36b449734dcdf33432,progression,0.334795
uuid-9dd94d66e1274f36b449734dcdf33432,chemotherapy,0.321132
uuid-9dd94d66e1274f36b449734dcdf33432,respond,0.308667
uuid-bbbf127c15ba48b8920b9b9629c5cc42,lung,0.360993
uuid-bbbf127c15ba48b8920b9b9629c5cc42,melanoma,0.470116
uuid-bbbf127c15ba48b8920b9b9629c5cc42,shared,0.504639
uuid-bbbf127c15ba48b8920b9b9629c5cc42,institution,0.404179
uuid-bbbf127c15ba48b8920b9b9629c5cc42,physicians,0.397809
uuid-bbbf127c15ba48b8920b9b9629c5cc42,TL shared,0.318177
uuid-bb6de6c9d11242d1a1760cf821b1b460,pembro,0.48682
uuid-bb6de6c9d11242d1a1760cf821b1b460,RTL,0.411644
uuid-bb6de6c9d11242d1a1760cf821b1b460,shared,0.521117
uuid-bb6de6c9d11242d1a1760cf821b1b460,RCC,0.378358
uuid-bb6de6c9d11242d1a1760cf821b1b460,2L,0.436699
uuid-bb6de6c9d11242d1a1760cf821b1b460,stated,0.385944
uuid-bb6de6c9d11242d1a1760cf821b1b460,approval,0.558518
uuid-bb6de6c9d11242d1a1760cf821b1b460,atezo,0.529061
uuid-bb6de6c9d11242d1a1760cf821b1b460,preferred,0.483731
uuid-bb6de6c9d11242d1a1760cf821b1b460,using nivo,0.486613
uuid-bb6de6c9d11242d1a1760cf821b1b460,clinical trials,0.365371
uuid-bb6de6c9d11242d1a1760cf821b1b460,indication,0.459099
uuid-bb6de6c9d11242d1a1760cf821b1b460,approved,0.505234
uuid-bb6de6c9d11242d1a1760cf821b1b460,SCCHN,0.628315
uuid-bb6de6c9d11242d1a1760cf821b1b460,label,0.363336
uuid-bb6de6c9d11242d1a1760cf821b1b460,LTL,0.42723
uuid-bb6de6c9d11242d1a1760cf821b1b460,TLs,0.344547
uuid-bb6de6c9d11242d1a1760cf821b1b460,academic,0.414764
uuid-bb6de6c9d11242d1a1760cf821b1b460,Regional TL,0.451339
uuid-bb6de6c9d11242d1a1760cf821b1b460,RTL stated,0.545406
uuid-bb6de6c9d11242d1a1760cf821b1b460,bladder,0.38712
uuid-bb6de6c9d11242d1a1760cf821b1b460,flat dosing,0.316324
uuid-6c7739fed94d409e9fc49737ac857ab7,TL,0.728565
uuid-6c7739fed94d409e9fc49737ac857ab7,TL stated,0.325336
uuid-6c7739fed94d409e9fc49737ac857ab7,institution,0.411119
uuid-6c7739fed94d409e9fc49737ac857ab7,PD-L1,0.672161
uuid-6c7739fed94d409e9fc49737ac857ab7,approval,0.329174
uuid-6c7739fed94d409e9fc49737ac857ab7,PD-L1 testing,0.806731
uuid-6c7739fed94d409e9fc49737ac857ab7,testing,0.74368
uuid-6c7739fed94d409e9fc49737ac857ab7,PDL1 testing,0.581538
uuid-6c7739fed94d409e9fc49737ac857ab7,NSCLC patients,0.521304
uuid-6c7739fed94d409e9fc49737ac857ab7,assay,0.718471
uuid-63731a843e7f49fcb7816e8083c61810,pembro,0.378779
uuid-63731a843e7f49fcb7816e8083c61810,2L,0.332392
uuid-63731a843e7f49fcb7816e8083c61810,stated,0.306984
uuid-63731a843e7f49fcb7816e8083c61810,approval,0.333957
uuid-63731a843e7f49fcb7816e8083c61810,atezo,0.312558
uuid-63731a843e7f49fcb7816e8083c61810,preferred,0.518572
uuid-63731a843e7f49fcb7816e8083c61810,using nivo,0.435752
uuid-63731a843e7f49fcb7816e8083c61810,indication,0.349032
uuid-63731a843e7f49fcb7816e8083c61810,SCCHN,0.459375
uuid-63731a843e7f49fcb7816e8083c61810,impressed,0.307596
uuid-63731a843e7f49fcb7816e8083c61810,feels,0.461174
uuid-63731a843e7f49fcb7816e8083c61810,Regional TL,0.306906
uuid-63731a843e7f49fcb7816e8083c61810,RTL stated,0.44427
uuid-63731a843e7f49fcb7816e8083c61810,option,0.395223
uuid-76e3a046b32d4c3da1a81d13f3fc68a4,PDL1,0.582694
uuid-76e3a046b32d4c3da1a81d13f3fc68a4,efficacy,0.441375
uuid-76e3a046b32d4c3da1a81d13f3fc68a4,chemo,0.35007
uuid-76e3a046b32d4c3da1a81d13f3fc68a4,OS,0.405392
uuid-76e3a046b32d4c3da1a81d13f3fc68a4,PFS,0.433042
uuid-76e3a046b32d4c3da1a81d13f3fc68a4,ORR,0.381413
uuid-76e3a046b32d4c3da1a81d13f3fc68a4,nivo and pembro,0.449514
uuid-76e3a046b32d4c3da1a81d13f3fc68a4,believes,0.499834
uuid-76e3a046b32d4c3da1a81d13f3fc68a4,vs,0.378268
uuid-76e3a046b32d4c3da1a81d13f3fc68a4,PDL1 expression,0.498611
uuid-76e3a046b32d4c3da1a81d13f3fc68a4,biomarker,0.352979
uuid-95fbffb2ceac46a8abbe0080c6fbbbd7,BMS,0.524829
uuid-95fbffb2ceac46a8abbe0080c6fbbbd7,trial,0.379184
uuid-95fbffb2ceac46a8abbe0080c6fbbbd7,commented,0.435249
uuid-95fbffb2ceac46a8abbe0080c6fbbbd7,Merck,0.417913
uuid-95fbffb2ceac46a8abbe0080c6fbbbd7,regards,0.354239
uuid-95fbffb2ceac46a8abbe0080c6fbbbd7,data,0.586293
uuid-95fbffb2ceac46a8abbe0080c6fbbbd7,expressed,0.320158
uuid-95fbffb2ceac46a8abbe0080c6fbbbd7,PFS,0.302906
uuid-95fbffb2ceac46a8abbe0080c6fbbbd7,ORR,0.302688
uuid-95fbffb2ceac46a8abbe0080c6fbbbd7,nivo and pembro,0.329642
uuid-95fbffb2ceac46a8abbe0080c6fbbbd7,impressed,0.334251
uuid-95fbffb2ceac46a8abbe0080c6fbbbd7,feels,0.304401
uuid-7eb4ae81a77b4114ada267f2dbbd9f33,drug,0.404405
uuid-98b2c29370cb4cd0afe6721a6ba821de,tumor,0.374806
uuid-98b2c29370cb4cd0afe6721a6ba821de,PD-L1,0.343193
uuid-98b2c29370cb4cd0afe6721a6ba821de,testing,0.486595
uuid-98b2c29370cb4cd0afe6721a6ba821de,PDL1 testing,0.427813
uuid-98b2c29370cb4cd0afe6721a6ba821de,NSCLC patients,0.53288
uuid-98b2c29370cb4cd0afe6721a6ba821de,lung cancer,0.321151
uuid-98b2c29370cb4cd0afe6721a6ba821de,tumor types,0.436432
uuid-98b2c29370cb4cd0afe6721a6ba821de,biomarker,0.330456
uuid-c9df0201267d4ea5af38d983cd4c8200,RTL,0.382848
uuid-c9df0201267d4ea5af38d983cd4c8200,lung,0.364027
uuid-c9df0201267d4ea5af38d983cd4c8200,melanoma,0.542045
uuid-c9df0201267d4ea5af38d983cd4c8200,RCC,0.467947
uuid-c9df0201267d4ea5af38d983cd4c8200,TL stated,0.489463
uuid-c9df0201267d4ea5af38d983cd4c8200,pts,0.418128
uuid-c9df0201267d4ea5af38d983cd4c8200,institution,0.303575
uuid-c9df0201267d4ea5af38d983cd4c8200,stated,0.365178
uuid-c9df0201267d4ea5af38d983cd4c8200,PD-L1,0.31279
uuid-c9df0201267d4ea5af38d983cd4c8200,PD-L1 testing,0.451664
uuid-c9df0201267d4ea5af38d983cd4c8200,testing,0.355774
uuid-c9df0201267d4ea5af38d983cd4c8200,PDL1 testing,0.428358
uuid-c9df0201267d4ea5af38d983cd4c8200,NSCLC patients,0.395882
uuid-c9df0201267d4ea5af38d983cd4c8200,SCCHN,0.433036
uuid-c9df0201267d4ea5af38d983cd4c8200,TLs,0.393815
uuid-c9df0201267d4ea5af38d983cd4c8200,academic,0.362663
uuid-c9df0201267d4ea5af38d983cd4c8200,Regional TL,0.354238
uuid-c9df0201267d4ea5af38d983cd4c8200,RTL stated,0.465094
uuid-c9df0201267d4ea5af38d983cd4c8200,TL shared,0.42726
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,Nivo,0.504162
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,patients,0.362298
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,pembro,0.480347
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,therapy,0.38906
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,nivolumab,0.502706
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,1L,0.702328
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,RCC,0.609358
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,combination,0.360705
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,chemo,0.311806
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,2L,0.78518
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,pts,0.308321
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,agents,0.376416
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,approval,0.482889
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,atezo,0.440211
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,preferred,0.734083
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,monotherapy,0.634446
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,treatment,0.304768
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,using nivo,0.831565
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,combo,0.364104
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,indication,0.335984
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,PD1,0.369561
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,approved,0.556793
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,SCCHN,0.530671
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,chemotherapy,0.304057
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,tumor types,0.315288
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,label,0.305808
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,SCLC,0.313191
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,RTL stated,0.690963
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,TL shared,0.346382
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,option,0.685007
uuid-a4b07d0bdbb841b5a48d3e18ff38345f,bladder,0.410213
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,TL,0.434668
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,pembro,0.405079
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,1L,0.430969
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,PDL1,0.480058
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,TL stated,0.433256
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,2L,0.380452
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,PD-L1,0.773638
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,atezo,0.480924
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,preferred,0.333071
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,PD-L1 testing,0.738725
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,testing,0.814413
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,PDL1 testing,0.728637
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,NSCLC patients,0.711281
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,tumor types,0.300239
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,assay,0.514003
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,PDL1 expression,0.377982
uuid-04c263e8ffbc48b0a151c8b6afaa43ed,biomarker,0.409082
uuid-c855ae869df24ec8b61cf618b6bf6859,Nivo,0.398311
uuid-c855ae869df24ec8b61cf618b6bf6859,patients,0.664259
uuid-c855ae869df24ec8b61cf618b6bf6859,Opdivo,0.371959
uuid-c855ae869df24ec8b61cf618b6bf6859,therapy,0.630613
uuid-c855ae869df24ec8b61cf618b6bf6859,nivolumab,0.443519
uuid-c855ae869df24ec8b61cf618b6bf6859,treated,0.40674
uuid-c855ae869df24ec8b61cf618b6bf6859,pts,0.448772
uuid-c855ae869df24ec8b61cf618b6bf6859,treatment,0.534667
uuid-c855ae869df24ec8b61cf618b6bf6859,response,0.331778
uuid-c855ae869df24ec8b61cf618b6bf6859,mentioned,0.307629
uuid-c855ae869df24ec8b61cf618b6bf6859,cHL,0.607984
uuid-c855ae869df24ec8b61cf618b6bf6859,progression,0.49215
uuid-c855ae869df24ec8b61cf618b6bf6859,chemotherapy,0.350481
uuid-c855ae869df24ec8b61cf618b6bf6859,respond,0.423846
uuid-8da3818445eb41f0bebbecc41cd5d080,RTL,0.301335
uuid-8da3818445eb41f0bebbecc41cd5d080,therapy,0.325106
uuid-8da3818445eb41f0bebbecc41cd5d080,nivolumab,0.310012
uuid-8da3818445eb41f0bebbecc41cd5d080,NTL,0.365719
uuid-8da3818445eb41f0bebbecc41cd5d080,mentioned,0.585593
uuid-8da3818445eb41f0bebbecc41cd5d080,HCP,0.473019
uuid-8da3818445eb41f0bebbecc41cd5d080,cHL,0.487292
uuid-3487e2a265b34d819ade813d90aa713e,Nivo,0.522459
uuid-3487e2a265b34d819ade813d90aa713e,patients,0.666483
uuid-3487e2a265b34d819ade813d90aa713e,Opdivo,0.390886
uuid-3487e2a265b34d819ade813d90aa713e,therapy,0.482552
uuid-3487e2a265b34d819ade813d90aa713e,nivolumab,0.594968
uuid-3487e2a265b34d819ade813d90aa713e,toxicity,0.342328
uuid-3487e2a265b34d819ade813d90aa713e,regimen,0.578038
uuid-3487e2a265b34d819ade813d90aa713e,treated,0.516021
uuid-3487e2a265b34d819ade813d90aa713e,combination,0.492273
uuid-3487e2a265b34d819ade813d90aa713e,chemo,0.449333
uuid-3487e2a265b34d819ade813d90aa713e,2L,0.320449
uuid-3487e2a265b34d819ade813d90aa713e,pts,0.49266
uuid-3487e2a265b34d819ade813d90aa713e,Ipi,0.338082
uuid-3487e2a265b34d819ade813d90aa713e,preferred,0.3642
uuid-3487e2a265b34d819ade813d90aa713e,monotherapy,0.52608
uuid-3487e2a265b34d819ade813d90aa713e,treatment,0.562624
uuid-3487e2a265b34d819ade813d90aa713e,using nivo,0.460555
uuid-3487e2a265b34d819ade813d90aa713e,combo,0.404682
uuid-3487e2a265b34d819ade813d90aa713e,PD1,0.382462
uuid-3487e2a265b34d819ade813d90aa713e,approved,0.307787
uuid-3487e2a265b34d819ade813d90aa713e,progression,0.493222
uuid-3487e2a265b34d819ade813d90aa713e,chemotherapy,0.472447
uuid-3487e2a265b34d819ade813d90aa713e,respond,0.369248
uuid-3487e2a265b34d819ade813d90aa713e,RTL stated,0.435042
uuid-3487e2a265b34d819ade813d90aa713e,option,0.462289
uuid-4336031eb16347aab8bdecf5cb5742e3,patients,0.38513
uuid-4336031eb16347aab8bdecf5cb5742e3,regimen,0.36435
uuid-4336031eb16347aab8bdecf5cb5742e3,treated,0.341319
uuid-4336031eb16347aab8bdecf5cb5742e3,pts,0.390586
uuid-4336031eb16347aab8bdecf5cb5742e3,IO,0.300366
uuid-4336031eb16347aab8bdecf5cb5742e3,treatment,0.475444
uuid-4336031eb16347aab8bdecf5cb5742e3,response,0.543412
uuid-4336031eb16347aab8bdecf5cb5742e3,PD1,0.314977
uuid-4336031eb16347aab8bdecf5cb5742e3,progression,0.499464
uuid-4336031eb16347aab8bdecf5cb5742e3,respond,0.452514
uuid-309ba5760e6948f5af411be8b6b16b0c,Nivo,0.482541
uuid-309ba5760e6948f5af411be8b6b16b0c,pembro,0.602895
uuid-309ba5760e6948f5af411be8b6b16b0c,BMS,0.33599
uuid-309ba5760e6948f5af411be8b6b16b0c,PDL1,0.34322
uuid-309ba5760e6948f5af411be8b6b16b0c,trial,0.47488
uuid-309ba5760e6948f5af411be8b6b16b0c,efficacy,0.612278
uuid-309ba5760e6948f5af411be8b6b16b0c,discussed,0.336658
uuid-309ba5760e6948f5af411be8b6b16b0c,OS,0.469286
uuid-309ba5760e6948f5af411be8b6b16b0c,atezo,0.523126
uuid-309ba5760e6948f5af411be8b6b16b0c,data,0.701766
uuid-309ba5760e6948f5af411be8b6b16b0c,PFS,0.469918
uuid-309ba5760e6948f5af411be8b6b16b0c,ORR,0.513224
uuid-309ba5760e6948f5af411be8b6b16b0c,nivo and pembro,0.623463
uuid-309ba5760e6948f5af411be8b6b16b0c,impressed,0.395443
uuid-309ba5760e6948f5af411be8b6b16b0c,vs,0.611149
uuid-309ba5760e6948f5af411be8b6b16b0c,feels,0.389768
uuid-309ba5760e6948f5af411be8b6b16b0c,PDL1 expression,0.389908
uuid-808a793d37124ea3ad163af7ebd0455c,TL,0.506649
uuid-808a793d37124ea3ad163af7ebd0455c,1L,0.33264
uuid-808a793d37124ea3ad163af7ebd0455c,PDL1,0.48076
uuid-808a793d37124ea3ad163af7ebd0455c,TL stated,0.571013
uuid-808a793d37124ea3ad163af7ebd0455c,PD-L1,0.786142
uuid-808a793d37124ea3ad163af7ebd0455c,PD-L1 testing,0.777921
uuid-808a793d37124ea3ad163af7ebd0455c,testing,0.903856
uuid-808a793d37124ea3ad163af7ebd0455c,PDL1 testing,0.815766
uuid-808a793d37124ea3ad163af7ebd0455c,NSCLC patients,0.783132
uuid-808a793d37124ea3ad163af7ebd0455c,tumor types,0.36618
uuid-808a793d37124ea3ad163af7ebd0455c,assay,0.555731
uuid-808a793d37124ea3ad163af7ebd0455c,PDL1 expression,0.309221
uuid-808a793d37124ea3ad163af7ebd0455c,biomarker,0.486879
uuid-3b0dea7740624e9583b691c71240f6a0,RTL,0.330064
uuid-3b0dea7740624e9583b691c71240f6a0,nivolumab,0.317001
uuid-3b0dea7740624e9583b691c71240f6a0,NTL,0.442743
uuid-3b0dea7740624e9583b691c71240f6a0,mentioned,0.499453
uuid-3b0dea7740624e9583b691c71240f6a0,cHL,0.542469
uuid-2d8268b6b0e34331b360746f32496bcd,physicians,0.46934
uuid-2d8268b6b0e34331b360746f32496bcd,oncology,0.48335
uuid-2d8268b6b0e34331b360746f32496bcd,oncologist,0.496984
uuid-2d8268b6b0e34331b360746f32496bcd,indicated,0.550173
uuid-2d8268b6b0e34331b360746f32496bcd,clinical,0.442365
uuid-19bdc45acd2946b0921ecb0635c3af6b,Opdivo,0.390023
uuid-19bdc45acd2946b0921ecb0635c3af6b,lung,0.348799
uuid-19bdc45acd2946b0921ecb0635c3af6b,1L,0.391746
uuid-19bdc45acd2946b0921ecb0635c3af6b,RCC,0.383849
uuid-19bdc45acd2946b0921ecb0635c3af6b,TL stated,0.332615
uuid-19bdc45acd2946b0921ecb0635c3af6b,2L,0.447182
uuid-19bdc45acd2946b0921ecb0635c3af6b,stated,0.31533
uuid-19bdc45acd2946b0921ecb0635c3af6b,approval,0.309083
uuid-19bdc45acd2946b0921ecb0635c3af6b,preferred,0.380676
uuid-19bdc45acd2946b0921ecb0635c3af6b,using nivo,0.336567
uuid-19bdc45acd2946b0921ecb0635c3af6b,indication,0.378226
uuid-19bdc45acd2946b0921ecb0635c3af6b,approved,0.38336
uuid-19bdc45acd2946b0921ecb0635c3af6b,SCCHN,0.397525
uuid-19bdc45acd2946b0921ecb0635c3af6b,tumor types,0.335336
uuid-19bdc45acd2946b0921ecb0635c3af6b,Keytruda,0.366938
uuid-19bdc45acd2946b0921ecb0635c3af6b,RTL stated,0.33548
uuid-19bdc45acd2946b0921ecb0635c3af6b,option,0.330326
uuid-19bdc45acd2946b0921ecb0635c3af6b,bladder,0.302524
uuid-1c4a278bee034eee92e1b4e34bff2386,efficacy,0.350104
uuid-1c4a278bee034eee92e1b4e34bff2386,agents,0.361955
uuid-1c4a278bee034eee92e1b4e34bff2386,preferred,0.313389
uuid-1c4a278bee034eee92e1b4e34bff2386,indication,0.377496
uuid-1c4a278bee034eee92e1b4e34bff2386,drug,0.461198
uuid-1c4a278bee034eee92e1b4e34bff2386,Keytruda,0.327001
uuid-57909bd799b14e8b9af1cb58af3b7a30,pembro,0.350873
uuid-57909bd799b14e8b9af1cb58af3b7a30,1L,0.325154
uuid-57909bd799b14e8b9af1cb58af3b7a30,shared,0.360372
uuid-57909bd799b14e8b9af1cb58af3b7a30,2L,0.451215
uuid-57909bd799b14e8b9af1cb58af3b7a30,institution,0.568506
uuid-57909bd799b14e8b9af1cb58af3b7a30,approval,0.440499
uuid-57909bd799b14e8b9af1cb58af3b7a30,atezo,0.474297
uuid-57909bd799b14e8b9af1cb58af3b7a30,preferred,0.576057
uuid-57909bd799b14e8b9af1cb58af3b7a30,using nivo,0.375118
uuid-57909bd799b14e8b9af1cb58af3b7a30,PDL1 testing,0.410608
uuid-57909bd799b14e8b9af1cb58af3b7a30,indication,0.522544
uuid-57909bd799b14e8b9af1cb58af3b7a30,approved,0.478715
uuid-57909bd799b14e8b9af1cb58af3b7a30,SCCHN,0.378903
uuid-57909bd799b14e8b9af1cb58af3b7a30,label,0.393886
uuid-57909bd799b14e8b9af1cb58af3b7a30,Keytruda,0.424343
uuid-21b6c8c2297043d79e5a20ba18c5e5c0,combination,0.438922
uuid-21b6c8c2297043d79e5a20ba18c5e5c0,chemo,0.397604
uuid-21b6c8c2297043d79e5a20ba18c5e5c0,tumor,0.346636
uuid-21b6c8c2297043d79e5a20ba18c5e5c0,IO,0.352517
uuid-21b6c8c2297043d79e5a20ba18c5e5c0,agents,0.326075
uuid-21b6c8c2297043d79e5a20ba18c5e5c0,response,0.420483
uuid-21b6c8c2297043d79e5a20ba18c5e5c0,PD1,0.322567
uuid-21b6c8c2297043d79e5a20ba18c5e5c0,chemotherapy,0.383624
uuid-21b6c8c2297043d79e5a20ba18c5e5c0,feels,0.302655
uuid-21b6c8c2297043d79e5a20ba18c5e5c0,immunotherapy,0.383747
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,BMS,0.30487
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,PDL1,0.63157
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,trial,0.373788
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,efficacy,0.655621
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,OS,0.580414
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,regards,0.406381
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,data,0.542963
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,PFS,0.612555
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,AI,0.36506
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,ORR,0.626436
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,nivo and pembro,0.68514
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,believes,0.515542
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,PDL1 expression,0.610099
uuid-a7b6196d1493462e88aec2f0d2cbdbf7,biomarker,0.412697
uuid-bb30e79f7a384a31b21435c87cb99c3e,pembro,0.318808
uuid-bb30e79f7a384a31b21435c87cb99c3e,BMS,0.543719
uuid-bb30e79f7a384a31b21435c87cb99c3e,PDL1,0.543943
uuid-bb30e79f7a384a31b21435c87cb99c3e,trial,0.408296
uuid-bb30e79f7a384a31b21435c87cb99c3e,efficacy,0.508101
uuid-bb30e79f7a384a31b21435c87cb99c3e,Merck,0.488672
uuid-bb30e79f7a384a31b21435c87cb99c3e,OS,0.494281
uuid-bb30e79f7a384a31b21435c87cb99c3e,data,0.698471
uuid-bb30e79f7a384a31b21435c87cb99c3e,PFS,0.532066
uuid-bb30e79f7a384a31b21435c87cb99c3e,ORR,0.532527
uuid-bb30e79f7a384a31b21435c87cb99c3e,nivo and pembro,0.448522
uuid-bb30e79f7a384a31b21435c87cb99c3e,impressed,0.374444
uuid-bb30e79f7a384a31b21435c87cb99c3e,feels,0.332129
uuid-bb30e79f7a384a31b21435c87cb99c3e,PDL1 expression,0.585002
uuid-349b101895304c559f50f97c83bcc2e3,lung,0.374491
uuid-349b101895304c559f50f97c83bcc2e3,melanoma,0.358995
uuid-349b101895304c559f50f97c83bcc2e3,combination,0.315299
uuid-349b101895304c559f50f97c83bcc2e3,chemo,0.312087
uuid-349b101895304c559f50f97c83bcc2e3,combo,0.39096
uuid-349b101895304c559f50f97c83bcc2e3,AI,0.680612
uuid-349b101895304c559f50f97c83bcc2e3,PD1,0.312224
uuid-349b101895304c559f50f97c83bcc2e3,nivo and pembro,0.308437
uuid-349b101895304c559f50f97c83bcc2e3,believes,0.323316
uuid-b28a298868964bd9ba0783d23af61407,pembro,0.442165
uuid-b28a298868964bd9ba0783d23af61407,1L,0.312867
uuid-b28a298868964bd9ba0783d23af61407,PDL1,0.519408
uuid-b28a298868964bd9ba0783d23af61407,trial,0.436928
uuid-b28a298868964bd9ba0783d23af61407,efficacy,0.497551
uuid-b28a298868964bd9ba0783d23af61407,OS,0.534397
uuid-b28a298868964bd9ba0783d23af61407,atezo,0.35612
uuid-b28a298868964bd9ba0783d23af61407,data,0.714618
uuid-b28a298868964bd9ba0783d23af61407,PFS,0.530563
uuid-b28a298868964bd9ba0783d23af61407,ORR,0.563949
uuid-b28a298868964bd9ba0783d23af61407,nivo and pembro,0.498463
uuid-b28a298868964bd9ba0783d23af61407,believes,0.373008
uuid-b28a298868964bd9ba0783d23af61407,impressed,0.472903
uuid-b28a298868964bd9ba0783d23af61407,feels,0.406679
uuid-b28a298868964bd9ba0783d23af61407,PDL1 expression,0.532992
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,BMS,0.381403
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,trial,0.606104
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,efficacy,0.30225
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,NTL,0.335229
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,Merck,0.350792
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,OS,0.310985
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,regards,0.35798
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,data,0.484431
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,PFS,0.32234
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,ORR,0.389323
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,nivo and pembro,0.331465
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,believes,0.339886
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,PDL1 expression,0.311292
uuid-4cd5dcf60c84426284fc01b6ffa6b6f3,biomarker,0.30348
uuid-b67e27b25fc04d53b8790b7b4692fb7c,Nivo,0.341986
uuid-b67e27b25fc04d53b8790b7b4692fb7c,patients,0.496208
uuid-b67e27b25fc04d53b8790b7b4692fb7c,pembro,0.512181
uuid-b67e27b25fc04d53b8790b7b4692fb7c,nivolumab,0.407549
uuid-b67e27b25fc04d53b8790b7b4692fb7c,1L,0.353092
uuid-b67e27b25fc04d53b8790b7b4692fb7c,trial,0.355023
uuid-b67e27b25fc04d53b8790b7b4692fb7c,treated,0.345271
uuid-b67e27b25fc04d53b8790b7b4692fb7c,2L,0.402245
uuid-b67e27b25fc04d53b8790b7b4692fb7c,pts,0.356149
uuid-b67e27b25fc04d53b8790b7b4692fb7c,approval,0.500241
uuid-b67e27b25fc04d53b8790b7b4692fb7c,atezo,0.380831
uuid-b67e27b25fc04d53b8790b7b4692fb7c,preferred,0.346119
uuid-b67e27b25fc04d53b8790b7b4692fb7c,monotherapy,0.327617
uuid-b67e27b25fc04d53b8790b7b4692fb7c,using nivo,0.54694
uuid-b67e27b25fc04d53b8790b7b4692fb7c,clinical trials,0.477699
uuid-b67e27b25fc04d53b8790b7b4692fb7c,approved,0.402826
uuid-b67e27b25fc04d53b8790b7b4692fb7c,SCCHN,0.400625
uuid-b67e27b25fc04d53b8790b7b4692fb7c,tumor types,0.330958
uuid-b67e27b25fc04d53b8790b7b4692fb7c,SCLC,0.311508
uuid-b67e27b25fc04d53b8790b7b4692fb7c,RTL stated,0.383044
uuid-b67e27b25fc04d53b8790b7b4692fb7c,bladder,0.512072
uuid-233dac3dc94e440eb4569adddd99d301,PDL1,0.500498
uuid-233dac3dc94e440eb4569adddd99d301,efficacy,0.395777
uuid-233dac3dc94e440eb4569adddd99d301,PD-L1,0.481265
uuid-233dac3dc94e440eb4569adddd99d301,atezo,0.333241
uuid-233dac3dc94e440eb4569adddd99d301,testing,0.302987
uuid-233dac3dc94e440eb4569adddd99d301,regards,0.316853
uuid-233dac3dc94e440eb4569adddd99d301,data,0.347277
uuid-233dac3dc94e440eb4569adddd99d301,indication,0.312246
uuid-233dac3dc94e440eb4569adddd99d301,PFS,0.341117
uuid-233dac3dc94e440eb4569adddd99d301,ORR,0.317729
uuid-233dac3dc94e440eb4569adddd99d301,nivo and pembro,0.438694
uuid-233dac3dc94e440eb4569adddd99d301,assay,0.365291
uuid-233dac3dc94e440eb4569adddd99d301,PDL1 expression,0.499372
uuid-233dac3dc94e440eb4569adddd99d301,biomarker,0.46483
uuid-64437bf91c74414bb28b7d64b6c07f3c,patients,0.891722
uuid-64437bf91c74414bb28b7d64b6c07f3c,Opdivo,0.538087
uuid-64437bf91c74414bb28b7d64b6c07f3c,therapy,0.559496
uuid-64437bf91c74414bb28b7d64b6c07f3c,nivolumab,0.510656
uuid-64437bf91c74414bb28b7d64b6c07f3c,regimen,0.493317
uuid-64437bf91c74414bb28b7d64b6c07f3c,treated,0.56099
uuid-64437bf91c74414bb28b7d64b6c07f3c,pts,0.520464
uuid-64437bf91c74414bb28b7d64b6c07f3c,monotherapy,0.324143
uuid-64437bf91c74414bb28b7d64b6c07f3c,treatment,0.711288
uuid-64437bf91c74414bb28b7d64b6c07f3c,using nivo,0.383418
uuid-64437bf91c74414bb28b7d64b6c07f3c,cHL,0.351974
uuid-64437bf91c74414bb28b7d64b6c07f3c,progression,0.554818
uuid-64437bf91c74414bb28b7d64b6c07f3c,chemotherapy,0.328081
uuid-64437bf91c74414bb28b7d64b6c07f3c,respond,0.452549
uuid-64437bf91c74414bb28b7d64b6c07f3c,option,0.408756
uuid-fd99d541a5cc422b882c568845d3a20d,toxicity,0.341183
uuid-fd99d541a5cc422b882c568845d3a20d,physicians,0.558244
uuid-fd99d541a5cc422b882c568845d3a20d,treatment,0.315179
uuid-fd5aebcc53d74ce89c15c1631c502aaa,RTL,0.393972
uuid-fd5aebcc53d74ce89c15c1631c502aaa,dose,0.457827
uuid-fd5aebcc53d74ce89c15c1631c502aaa,commented,0.36912
uuid-fd5aebcc53d74ce89c15c1631c502aaa,mentioned,0.555408
uuid-fd5aebcc53d74ce89c15c1631c502aaa,HCP,0.436024
uuid-fd5aebcc53d74ce89c15c1631c502aaa,vs,0.355047
uuid-fd5aebcc53d74ce89c15c1631c502aaa,LTL,0.410811
uuid-fd5aebcc53d74ce89c15c1631c502aaa,TLs,0.315478
uuid-fd5aebcc53d74ce89c15c1631c502aaa,Regional TL,0.335577
uuid-fd5aebcc53d74ce89c15c1631c502aaa,flat dosing,0.429331
uuid-56d6f8a8b1164073b25b033ff12d7d12,lung,0.324914
uuid-56d6f8a8b1164073b25b033ff12d7d12,regimen,0.325842
uuid-56d6f8a8b1164073b25b033ff12d7d12,treated,0.41178
uuid-56d6f8a8b1164073b25b033ff12d7d12,discussed,0.429272
uuid-56d6f8a8b1164073b25b033ff12d7d12,melanoma,0.498295
uuid-56d6f8a8b1164073b25b033ff12d7d12,commented,0.36291
uuid-56d6f8a8b1164073b25b033ff12d7d12,physicians,0.316168
uuid-56d6f8a8b1164073b25b033ff12d7d12,treatment,0.423946
uuid-56d6f8a8b1164073b25b033ff12d7d12,progression,0.316909
uuid-56d6f8a8b1164073b25b033ff12d7d12,ASCO,0.436253
uuid-56d6f8a8b1164073b25b033ff12d7d12,academic,0.318368
uuid-56d6f8a8b1164073b25b033ff12d7d12,TL shared,0.460105
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,Nivo,0.608458
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,patients,0.575169
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,Opdivo,0.332557
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,therapy,0.607717
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,nivolumab,0.368872
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,toxicity,0.460856
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,regimen,0.393083
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,chemo,0.392567
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,pts,0.329436
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,monotherapy,0.314596
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,treatment,0.472794
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,response,0.455643
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,PD1,0.351806
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,cHL,0.518316
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,progression,0.472755
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,chemotherapy,0.425679
uuid-5ebb175c89ed4e8dacdd42be6ea19f08,respond,0.47647
uuid-e840998526bc4c58a70d1257ddae66ba,Nivo,0.435848
uuid-e840998526bc4c58a70d1257ddae66ba,patients,0.745263
uuid-e840998526bc4c58a70d1257ddae66ba,Opdivo,0.39728
uuid-e840998526bc4c58a70d1257ddae66ba,therapy,0.606253
uuid-e840998526bc4c58a70d1257ddae66ba,nivolumab,0.636358
uuid-e840998526bc4c58a70d1257ddae66ba,toxicity,0.507178
uuid-e840998526bc4c58a70d1257ddae66ba,regimen,0.55493
uuid-e840998526bc4c58a70d1257ddae66ba,treated,0.466849
uuid-e840998526bc4c58a70d1257ddae66ba,combination,0.371062
uuid-e840998526bc4c58a70d1257ddae66ba,chemo,0.461771
uuid-e840998526bc4c58a70d1257ddae66ba,pts,0.43618
uuid-e840998526bc4c58a70d1257ddae66ba,preferred,0.321423
uuid-e840998526bc4c58a70d1257ddae66ba,monotherapy,0.499329
uuid-e840998526bc4c58a70d1257ddae66ba,treatment,0.603432
uuid-e840998526bc4c58a70d1257ddae66ba,using nivo,0.331951
uuid-e840998526bc4c58a70d1257ddae66ba,response,0.347975
uuid-e840998526bc4c58a70d1257ddae66ba,PD1,0.379804
uuid-e840998526bc4c58a70d1257ddae66ba,cHL,0.378748
uuid-e840998526bc4c58a70d1257ddae66ba,progression,0.498225
uuid-e840998526bc4c58a70d1257ddae66ba,chemotherapy,0.516413
uuid-e840998526bc4c58a70d1257ddae66ba,respond,0.408625
uuid-e840998526bc4c58a70d1257ddae66ba,option,0.442791
uuid-5b524d462afa4eda9592295043fe94fb,Nivo,0.321372
uuid-5b524d462afa4eda9592295043fe94fb,Opdivo,0.472935
uuid-5b524d462afa4eda9592295043fe94fb,dose,0.869516
uuid-5b524d462afa4eda9592295043fe94fb,toxicity,0.428623
uuid-5b524d462afa4eda9592295043fe94fb,efficacy,0.371796
uuid-5b524d462afa4eda9592295043fe94fb,regimen,0.318201
uuid-5b524d462afa4eda9592295043fe94fb,Ipi,0.444745
uuid-5b524d462afa4eda9592295043fe94fb,vs,0.58711
uuid-5b524d462afa4eda9592295043fe94fb,drug,0.342844
uuid-5b524d462afa4eda9592295043fe94fb,Keytruda,0.395406
uuid-5b524d462afa4eda9592295043fe94fb,flat dosing,0.760373
uuid-31980303a87a4035a39cb9abfd933c58,tumor,0.350675
uuid-31980303a87a4035a39cb9abfd933c58,PDL1 expression,0.415453
uuid-31980303a87a4035a39cb9abfd933c58,biomarker,0.407401
uuid-16355fc9fe56426285396413444de254,patients,0.356045
uuid-16355fc9fe56426285396413444de254,Opdivo,0.375692
uuid-16355fc9fe56426285396413444de254,dose,0.710019
uuid-16355fc9fe56426285396413444de254,toxicity,0.352881
uuid-16355fc9fe56426285396413444de254,regimen,0.336017
uuid-16355fc9fe56426285396413444de254,treated,0.318125
uuid-16355fc9fe56426285396413444de254,physicians,0.315026
uuid-16355fc9fe56426285396413444de254,treatment,0.334687
uuid-16355fc9fe56426285396413444de254,vs,0.300548
uuid-16355fc9fe56426285396413444de254,flat dosing,0.468511
uuid-0ca3cb527a4a416795e36914284920d2,Nivo,0.372658
uuid-0ca3cb527a4a416795e36914284920d2,RTL,0.374588
uuid-0ca3cb527a4a416795e36914284920d2,trial,0.395416
uuid-0ca3cb527a4a416795e36914284920d2,efficacy,0.346111
uuid-0ca3cb527a4a416795e36914284920d2,combination,0.327434
uuid-0ca3cb527a4a416795e36914284920d2,Ipi,0.436718
uuid-0ca3cb527a4a416795e36914284920d2,OS,0.384873
uuid-0ca3cb527a4a416795e36914284920d2,data,0.421077
uuid-0ca3cb527a4a416795e36914284920d2,combo,0.301938
uuid-0ca3cb527a4a416795e36914284920d2,PFS,0.361615
uuid-0ca3cb527a4a416795e36914284920d2,ORR,0.474965
uuid-0ca3cb527a4a416795e36914284920d2,HCP,0.516934
uuid-0ca3cb527a4a416795e36914284920d2,impressed,0.527197
uuid-0ca3cb527a4a416795e36914284920d2,SCLC,0.494196
uuid-0fdb2bddfd9a40a49cced79d5a836cf0,dose,0.362413
uuid-0fdb2bddfd9a40a49cced79d5a836cf0,toxicity,0.352195
uuid-0fdb2bddfd9a40a49cced79d5a836cf0,regimen,0.381853
uuid-0fdb2bddfd9a40a49cced79d5a836cf0,physicians,0.473884
uuid-0fdb2bddfd9a40a49cced79d5a836cf0,treatment,0.378061
uuid-88721f68b3fe45fda1a6eebf51c37fa2,RTL,0.492514
uuid-88721f68b3fe45fda1a6eebf51c37fa2,commented,0.327023
uuid-88721f68b3fe45fda1a6eebf51c37fa2,using nivo,0.31397
uuid-88721f68b3fe45fda1a6eebf51c37fa2,expressed,0.353921
uuid-88721f68b3fe45fda1a6eebf51c37fa2,mentioned,0.555058
uuid-88721f68b3fe45fda1a6eebf51c37fa2,SCCHN,0.364149
uuid-88721f68b3fe45fda1a6eebf51c37fa2,HCP,0.699628
uuid-88721f68b3fe45fda1a6eebf51c37fa2,impressed,0.355319
uuid-88721f68b3fe45fda1a6eebf51c37fa2,LTL,0.421292
uuid-88721f68b3fe45fda1a6eebf51c37fa2,SCLC,0.34493
uuid-88721f68b3fe45fda1a6eebf51c37fa2,Regional TL,0.319864
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,TL,0.312427
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,TL stated,0.325161
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,PD-L1,0.567797
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,approval,0.334838
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,PD-L1 testing,0.600672
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,testing,0.646801
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,using nivo,0.308519
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,expressed,0.332304
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,mentioned,0.40736
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,PDL1 testing,0.566411
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,NSCLC patients,0.572948
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,HCP,0.591168
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,LTL,0.31807
uuid-1d3bcaf605e14b37a1a681a4ace1e9c4,assay,0.356106
uuid-d6491ffc471b426c95a46d8250894d24,PD-L1,0.408675
uuid-d6491ffc471b426c95a46d8250894d24,PD-L1 testing,0.483567
uuid-d6491ffc471b426c95a46d8250894d24,testing,0.621377
uuid-d6491ffc471b426c95a46d8250894d24,PDL1 testing,0.52559
uuid-d6491ffc471b426c95a46d8250894d24,NSCLC patients,0.463916
uuid-d6491ffc471b426c95a46d8250894d24,lung cancer,0.311589
uuid-d6491ffc471b426c95a46d8250894d24,assay,0.303976
uuid-e3f38a0a17704ba38f4b306e25cae916,RTL,0.366019
uuid-e3f38a0a17704ba38f4b306e25cae916,nivolumab,0.414729
uuid-e3f38a0a17704ba38f4b306e25cae916,lung,0.421553
uuid-e3f38a0a17704ba38f4b306e25cae916,treated,0.374654
uuid-e3f38a0a17704ba38f4b306e25cae916,melanoma,0.388722
uuid-e3f38a0a17704ba38f4b306e25cae916,shared,0.354936
uuid-e3f38a0a17704ba38f4b306e25cae916,commented,0.312656
uuid-e3f38a0a17704ba38f4b306e25cae916,RCC,0.556492
uuid-e3f38a0a17704ba38f4b306e25cae916,TL stated,0.389674
uuid-e3f38a0a17704ba38f4b306e25cae916,2L,0.352673
uuid-e3f38a0a17704ba38f4b306e25cae916,stated,0.402748
uuid-e3f38a0a17704ba38f4b306e25cae916,approval,0.416222
uuid-e3f38a0a17704ba38f4b306e25cae916,preferred,0.415218
uuid-e3f38a0a17704ba38f4b306e25cae916,using nivo,0.528136
uuid-e3f38a0a17704ba38f4b306e25cae916,mentioned,0.410802
uuid-e3f38a0a17704ba38f4b306e25cae916,clinical trials,0.30295
uuid-e3f38a0a17704ba38f4b306e25cae916,approved,0.356696
uuid-e3f38a0a17704ba38f4b306e25cae916,SCCHN,0.675208
uuid-e3f38a0a17704ba38f4b306e25cae916,HCP,0.33908
uuid-e3f38a0a17704ba38f4b306e25cae916,tumor types,0.361078
uuid-e3f38a0a17704ba38f4b306e25cae916,LTL,0.399543
uuid-e3f38a0a17704ba38f4b306e25cae916,SCLC,0.324166
uuid-e3f38a0a17704ba38f4b306e25cae916,Regional TL,0.480939
uuid-e3f38a0a17704ba38f4b306e25cae916,RTL stated,0.605841
uuid-e3f38a0a17704ba38f4b306e25cae916,TL shared,0.527948
uuid-e3f38a0a17704ba38f4b306e25cae916,bladder,0.461052
uuid-9d046b1c1c564e0e8927e007c996c249,Nivo,0.520537
uuid-9d046b1c1c564e0e8927e007c996c249,patients,0.548887
uuid-9d046b1c1c564e0e8927e007c996c249,Opdivo,0.325928
uuid-9d046b1c1c564e0e8927e007c996c249,therapy,0.681259
uuid-9d046b1c1c564e0e8927e007c996c249,nivolumab,0.438012
uuid-9d046b1c1c564e0e8927e007c996c249,toxicity,0.388131
uuid-9d046b1c1c564e0e8927e007c996c249,regimen,0.622843
uuid-9d046b1c1c564e0e8927e007c996c249,treated,0.40308
uuid-9d046b1c1c564e0e8927e007c996c249,combination,0.406623
uuid-9d046b1c1c564e0e8927e007c996c249,chemo,0.493492
uuid-9d046b1c1c564e0e8927e007c996c249,pts,0.323427
uuid-9d046b1c1c564e0e8927e007c996c249,preferred,0.301982
uuid-9d046b1c1c564e0e8927e007c996c249,monotherapy,0.549258
uuid-9d046b1c1c564e0e8927e007c996c249,treatment,0.728123
uuid-9d046b1c1c564e0e8927e007c996c249,response,0.344392
uuid-9d046b1c1c564e0e8927e007c996c249,PD1,0.422648
uuid-9d046b1c1c564e0e8927e007c996c249,cHL,0.378482
uuid-9d046b1c1c564e0e8927e007c996c249,progression,0.49237
uuid-9d046b1c1c564e0e8927e007c996c249,chemotherapy,0.557224
uuid-9d046b1c1c564e0e8927e007c996c249,respond,0.423182
uuid-9d046b1c1c564e0e8927e007c996c249,option,0.502792
uuid-67a33f3067f844ed843b352ecae2d478,Nivo,0.597257
uuid-67a33f3067f844ed843b352ecae2d478,therapy,0.449271
uuid-67a33f3067f844ed843b352ecae2d478,nivolumab,0.487303
uuid-67a33f3067f844ed843b352ecae2d478,trial,0.331682
uuid-67a33f3067f844ed843b352ecae2d478,combination,0.376705
uuid-67a33f3067f844ed843b352ecae2d478,chemo,0.306349
uuid-67a33f3067f844ed843b352ecae2d478,using nivo,0.391198
uuid-67a33f3067f844ed843b352ecae2d478,PD1,0.322514
uuid-67a33f3067f844ed843b352ecae2d478,cHL,0.519102
uuid-67a33f3067f844ed843b352ecae2d478,chemotherapy,0.410579
uuid-d8e091f5bc93400d866ee4e7ef92aa62,patients,0.719888
uuid-d8e091f5bc93400d866ee4e7ef92aa62,Opdivo,0.353494
uuid-d8e091f5bc93400d866ee4e7ef92aa62,therapy,0.504948
uuid-d8e091f5bc93400d866ee4e7ef92aa62,toxicity,0.331879
uuid-d8e091f5bc93400d866ee4e7ef92aa62,regimen,0.521307
uuid-d8e091f5bc93400d866ee4e7ef92aa62,treated,0.581894
uuid-d8e091f5bc93400d866ee4e7ef92aa62,pts,0.448371
uuid-d8e091f5bc93400d866ee4e7ef92aa62,physicians,0.355335
uuid-d8e091f5bc93400d866ee4e7ef92aa62,treatment,0.868718
uuid-d8e091f5bc93400d866ee4e7ef92aa62,response,0.384668
uuid-d8e091f5bc93400d866ee4e7ef92aa62,progression,0.65782
uuid-d8e091f5bc93400d866ee4e7ef92aa62,chemotherapy,0.316998
uuid-d8e091f5bc93400d866ee4e7ef92aa62,respond,0.590388
uuid-bb143ae974334c4d907919a843471ac3,Nivo,0.37794
uuid-bb143ae974334c4d907919a843471ac3,therapy,0.334727
uuid-bb143ae974334c4d907919a843471ac3,toxicity,0.473802
uuid-bb143ae974334c4d907919a843471ac3,treatment,0.337818
uuid-bb143ae974334c4d907919a843471ac3,cHL,0.397718
uuid-bb143ae974334c4d907919a843471ac3,respond,0.328626
uuid-3578b8cab5b049448c0a7195e7198bc5,Nivo,0.529085
uuid-3578b8cab5b049448c0a7195e7198bc5,patients,0.369462
uuid-3578b8cab5b049448c0a7195e7198bc5,therapy,0.500914
uuid-3578b8cab5b049448c0a7195e7198bc5,1L,0.357731
uuid-3578b8cab5b049448c0a7195e7198bc5,regimen,0.411834
uuid-3578b8cab5b049448c0a7195e7198bc5,combination,0.492164
uuid-3578b8cab5b049448c0a7195e7198bc5,chemo,0.607181
uuid-3578b8cab5b049448c0a7195e7198bc5,2L,0.398171
uuid-3578b8cab5b049448c0a7195e7198bc5,pts,0.408157
uuid-3578b8cab5b049448c0a7195e7198bc5,IO,0.434971
uuid-3578b8cab5b049448c0a7195e7198bc5,agents,0.464171
uuid-3578b8cab5b049448c0a7195e7198bc5,Ipi,0.30939
uuid-3578b8cab5b049448c0a7195e7198bc5,monotherapy,0.56065
uuid-3578b8cab5b049448c0a7195e7198bc5,treatment,0.398572
uuid-3578b8cab5b049448c0a7195e7198bc5,response,0.66475
uuid-3578b8cab5b049448c0a7195e7198bc5,combo,0.451569
uuid-3578b8cab5b049448c0a7195e7198bc5,PD1,0.542443
uuid-3578b8cab5b049448c0a7195e7198bc5,progression,0.573317
uuid-3578b8cab5b049448c0a7195e7198bc5,believes,0.387027
uuid-3578b8cab5b049448c0a7195e7198bc5,chemotherapy,0.443725
uuid-3578b8cab5b049448c0a7195e7198bc5,respond,0.510015
uuid-3578b8cab5b049448c0a7195e7198bc5,option,0.45108
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,1L,0.334359
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,2L,0.436749
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,agents,0.375886
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,atezo,0.356811
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,preferred,0.605683
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,monotherapy,0.327124
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,using nivo,0.364021
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,PDL1 testing,0.317591
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,indication,0.322991
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,approved,0.365978
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,HCP,0.304804
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,RTL stated,0.333339
uuid-32f0bbf0cf3a450aa0e1804e0efaa797,option,0.420987
uuid-82da25bfdb274db09b01f156fc12c992,Opdivo,0.308042
uuid-82da25bfdb274db09b01f156fc12c992,therapy,0.56204
uuid-82da25bfdb274db09b01f156fc12c992,treatment,0.379109
uuid-82da25bfdb274db09b01f156fc12c992,cHL,0.524764
uuid-564dee623e7b41cf8a120271af3aeecd,Nivo,0.620043
uuid-564dee623e7b41cf8a120271af3aeecd,pembro,0.589102
uuid-564dee623e7b41cf8a120271af3aeecd,1L,0.393631
uuid-564dee623e7b41cf8a120271af3aeecd,efficacy,0.497643
uuid-564dee623e7b41cf8a120271af3aeecd,combination,0.309972
uuid-564dee623e7b41cf8a120271af3aeecd,chemo,0.382538
uuid-564dee623e7b41cf8a120271af3aeecd,2L,0.445026
uuid-564dee623e7b41cf8a120271af3aeecd,agents,0.408276
uuid-564dee623e7b41cf8a120271af3aeecd,Ipi,0.49396
uuid-564dee623e7b41cf8a120271af3aeecd,atezo,0.580133
uuid-564dee623e7b41cf8a120271af3aeecd,preferred,0.414031
uuid-564dee623e7b41cf8a120271af3aeecd,monotherapy,0.420893
uuid-564dee623e7b41cf8a120271af3aeecd,using nivo,0.332191
uuid-564dee623e7b41cf8a120271af3aeecd,combo,0.359371
uuid-564dee623e7b41cf8a120271af3aeecd,indication,0.310237
uuid-564dee623e7b41cf8a120271af3aeecd,nivo and pembro,0.512062
uuid-564dee623e7b41cf8a120271af3aeecd,believes,0.475341
uuid-564dee623e7b41cf8a120271af3aeecd,vs,0.371932
uuid-564dee623e7b41cf8a120271af3aeecd,feels,0.443589
uuid-564dee623e7b41cf8a120271af3aeecd,option,0.413976
uuid-41e1518f90784254811d627b99dec3c8,TL,0.331736
uuid-41e1518f90784254811d627b99dec3c8,PDL1,0.411953
uuid-41e1518f90784254811d627b99dec3c8,TL stated,0.319493
uuid-41e1518f90784254811d627b99dec3c8,PD-L1,0.740937
uuid-41e1518f90784254811d627b99dec3c8,PD-L1 testing,0.733472
uuid-41e1518f90784254811d627b99dec3c8,testing,0.833462
uuid-41e1518f90784254811d627b99dec3c8,PDL1 testing,0.659418
uuid-41e1518f90784254811d627b99dec3c8,NSCLC patients,0.670218
uuid-41e1518f90784254811d627b99dec3c8,assay,0.580792
uuid-41e1518f90784254811d627b99dec3c8,biomarker,0.484144
uuid-2a5e2d78295243b39b7bb9535d83708d,Nivo,0.359442
uuid-2a5e2d78295243b39b7bb9535d83708d,therapy,0.435727
uuid-2a5e2d78295243b39b7bb9535d83708d,approval,0.356836
uuid-2a5e2d78295243b39b7bb9535d83708d,using nivo,0.346157
uuid-2a5e2d78295243b39b7bb9535d83708d,cHL,0.591128
uuid-be5c5ba699c54a6aab94f70b07ca0208,agents,0.480928
uuid-be5c5ba699c54a6aab94f70b07ca0208,Merck,0.302675
uuid-be5c5ba699c54a6aab94f70b07ca0208,preferred,0.415548
uuid-be5c5ba699c54a6aab94f70b07ca0208,clinical trials,0.410892
uuid-be5c5ba699c54a6aab94f70b07ca0208,indication,0.306952
uuid-be5c5ba699c54a6aab94f70b07ca0208,tumor types,0.311962
uuid-be5c5ba699c54a6aab94f70b07ca0208,RTL stated,0.315544
uuid-be5c5ba699c54a6aab94f70b07ca0208,bladder,0.348597
uuid-e1c50b4f1c0644969c60166ea5680517,Nivo,0.542227
uuid-e1c50b4f1c0644969c60166ea5680517,patients,0.429429
uuid-e1c50b4f1c0644969c60166ea5680517,therapy,0.605148
uuid-e1c50b4f1c0644969c60166ea5680517,nivolumab,0.488217
uuid-e1c50b4f1c0644969c60166ea5680517,1L,0.381843
uuid-e1c50b4f1c0644969c60166ea5680517,toxicity,0.422171
uuid-e1c50b4f1c0644969c60166ea5680517,regimen,0.667023
uuid-e1c50b4f1c0644969c60166ea5680517,treated,0.355892
uuid-e1c50b4f1c0644969c60166ea5680517,combination,0.686459
uuid-e1c50b4f1c0644969c60166ea5680517,chemo,0.604294
uuid-e1c50b4f1c0644969c60166ea5680517,2L,0.455135
uuid-e1c50b4f1c0644969c60166ea5680517,pts,0.322129
uuid-e1c50b4f1c0644969c60166ea5680517,IO,0.360225
uuid-e1c50b4f1c0644969c60166ea5680517,agents,0.584336
uuid-e1c50b4f1c0644969c60166ea5680517,Ipi,0.330374
uuid-e1c50b4f1c0644969c60166ea5680517,preferred,0.52327
uuid-e1c50b4f1c0644969c60166ea5680517,monotherapy,0.755395
uuid-e1c50b4f1c0644969c60166ea5680517,treatment,0.611782
uuid-e1c50b4f1c0644969c60166ea5680517,using nivo,0.402455
uuid-e1c50b4f1c0644969c60166ea5680517,combo,0.537393
uuid-e1c50b4f1c0644969c60166ea5680517,PD1,0.559216
uuid-e1c50b4f1c0644969c60166ea5680517,progression,0.431373
uuid-e1c50b4f1c0644969c60166ea5680517,chemotherapy,0.641771
uuid-e1c50b4f1c0644969c60166ea5680517,respond,0.313533
uuid-e1c50b4f1c0644969c60166ea5680517,feels,0.313768
uuid-e1c50b4f1c0644969c60166ea5680517,RTL stated,0.340285
uuid-e1c50b4f1c0644969c60166ea5680517,option,0.628678
uuid-9375879af2784a4593322456a8d3dc61,Nivo,0.687043
uuid-9375879af2784a4593322456a8d3dc61,pembro,0.62939
uuid-9375879af2784a4593322456a8d3dc61,1L,0.384092
uuid-9375879af2784a4593322456a8d3dc61,trial,0.331685
uuid-9375879af2784a4593322456a8d3dc61,efficacy,0.396832
uuid-9375879af2784a4593322456a8d3dc61,chemo,0.395663
uuid-9375879af2784a4593322456a8d3dc61,2L,0.407228
uuid-9375879af2784a4593322456a8d3dc61,Ipi,0.586179
uuid-9375879af2784a4593322456a8d3dc61,atezo,0.567574
uuid-9375879af2784a4593322456a8d3dc61,monotherapy,0.345084
uuid-9375879af2784a4593322456a8d3dc61,using nivo,0.353172
uuid-9375879af2784a4593322456a8d3dc61,combo,0.331858
uuid-9375879af2784a4593322456a8d3dc61,nivo and pembro,0.487883
uuid-9375879af2784a4593322456a8d3dc61,believes,0.452793
uuid-9375879af2784a4593322456a8d3dc61,vs,0.466406
uuid-9375879af2784a4593322456a8d3dc61,feels,0.357028
uuid-91832c20a3984cf68a36c8d8074a0555,Nivo,0.53105
uuid-91832c20a3984cf68a36c8d8074a0555,patients,0.488226
uuid-91832c20a3984cf68a36c8d8074a0555,therapy,0.570803
uuid-91832c20a3984cf68a36c8d8074a0555,nivolumab,0.37595
uuid-91832c20a3984cf68a36c8d8074a0555,1L,0.452687
uuid-91832c20a3984cf68a36c8d8074a0555,regimen,0.536554
uuid-91832c20a3984cf68a36c8d8074a0555,combination,0.582682
uuid-91832c20a3984cf68a36c8d8074a0555,chemo,0.64679
uuid-91832c20a3984cf68a36c8d8074a0555,2L,0.463318
uuid-91832c20a3984cf68a36c8d8074a0555,pts,0.534755
uuid-91832c20a3984cf68a36c8d8074a0555,IO,0.392923
uuid-91832c20a3984cf68a36c8d8074a0555,agents,0.44421
uuid-91832c20a3984cf68a36c8d8074a0555,Ipi,0.452072
uuid-91832c20a3984cf68a36c8d8074a0555,preferred,0.352221
uuid-91832c20a3984cf68a36c8d8074a0555,monotherapy,0.679727
uuid-91832c20a3984cf68a36c8d8074a0555,treatment,0.436911
uuid-91832c20a3984cf68a36c8d8074a0555,using nivo,0.326942
uuid-91832c20a3984cf68a36c8d8074a0555,response,0.509878
uuid-91832c20a3984cf68a36c8d8074a0555,combo,0.596915
uuid-91832c20a3984cf68a36c8d8074a0555,PD1,0.592832
uuid-91832c20a3984cf68a36c8d8074a0555,progression,0.566993
uuid-91832c20a3984cf68a36c8d8074a0555,believes,0.395143
uuid-91832c20a3984cf68a36c8d8074a0555,chemotherapy,0.523773
uuid-91832c20a3984cf68a36c8d8074a0555,respond,0.490276
uuid-91832c20a3984cf68a36c8d8074a0555,PD-1,0.313265
uuid-91832c20a3984cf68a36c8d8074a0555,option,0.575956
uuid-d436cbe22c704529b8b9f4b42bc384b5,patients,0.611031
uuid-d436cbe22c704529b8b9f4b42bc384b5,therapy,0.469152
uuid-d436cbe22c704529b8b9f4b42bc384b5,toxicity,0.305698
uuid-d436cbe22c704529b8b9f4b42bc384b5,regimen,0.381309
uuid-d436cbe22c704529b8b9f4b42bc384b5,treated,0.396646
uuid-d436cbe22c704529b8b9f4b42bc384b5,chemo,0.370307
uuid-d436cbe22c704529b8b9f4b42bc384b5,tumor,0.515333
uuid-d436cbe22c704529b8b9f4b42bc384b5,pts,0.560784
uuid-d436cbe22c704529b8b9f4b42bc384b5,treatment,0.606333
uuid-d436cbe22c704529b8b9f4b42bc384b5,response,0.649746
uuid-d436cbe22c704529b8b9f4b42bc384b5,PD1,0.311827
uuid-d436cbe22c704529b8b9f4b42bc384b5,progression,0.678217
uuid-d436cbe22c704529b8b9f4b42bc384b5,chemotherapy,0.325973
uuid-d436cbe22c704529b8b9f4b42bc384b5,respond,0.562356
uuid-d436cbe22c704529b8b9f4b42bc384b5,immunotherapy,0.327312
uuid-44ea24c70c6b4063b1ba6c5691484d08,Nivo,0.327839
uuid-44ea24c70c6b4063b1ba6c5691484d08,pembro,0.365803
uuid-44ea24c70c6b4063b1ba6c5691484d08,1L,0.373451
uuid-44ea24c70c6b4063b1ba6c5691484d08,trial,0.300471
uuid-44ea24c70c6b4063b1ba6c5691484d08,2L,0.3411
uuid-44ea24c70c6b4063b1ba6c5691484d08,atezo,0.311737
uuid-44ea24c70c6b4063b1ba6c5691484d08,preferred,0.441677
uuid-44ea24c70c6b4063b1ba6c5691484d08,feels,0.375364
uuid-44ea24c70c6b4063b1ba6c5691484d08,option,0.373095
uuid-ecfa34cf2638445da8389c0ba401952a,Nivo,0.347759
uuid-ecfa34cf2638445da8389c0ba401952a,pembro,0.611684
uuid-ecfa34cf2638445da8389c0ba401952a,NSCLC,0.460015
uuid-ecfa34cf2638445da8389c0ba401952a,1L,0.431059
uuid-ecfa34cf2638445da8389c0ba401952a,2L,0.516537
uuid-ecfa34cf2638445da8389c0ba401952a,agents,0.403803
uuid-ecfa34cf2638445da8389c0ba401952a,approval,0.324117
uuid-ecfa34cf2638445da8389c0ba401952a,atezo,0.647066
uuid-ecfa34cf2638445da8389c0ba401952a,preferred,0.564853
uuid-ecfa34cf2638445da8389c0ba401952a,using nivo,0.439148
uuid-ecfa34cf2638445da8389c0ba401952a,indication,0.420413
uuid-ecfa34cf2638445da8389c0ba401952a,approved,0.342407
uuid-ecfa34cf2638445da8389c0ba401952a,nivo and pembro,0.360812
uuid-ecfa34cf2638445da8389c0ba401952a,vs,0.378485
uuid-ecfa34cf2638445da8389c0ba401952a,RTL stated,0.328649
uuid-e21cf1523d73463dac5617a8c8503c89,Nivo,0.358839
uuid-e21cf1523d73463dac5617a8c8503c89,pembro,0.497108
uuid-e21cf1523d73463dac5617a8c8503c89,NSCLC,0.428146
uuid-e21cf1523d73463dac5617a8c8503c89,1L,0.649671
uuid-e21cf1523d73463dac5617a8c8503c89,combination,0.329173
uuid-e21cf1523d73463dac5617a8c8503c89,chemo,0.304428
uuid-e21cf1523d73463dac5617a8c8503c89,2L,0.645033
uuid-e21cf1523d73463dac5617a8c8503c89,IO,0.370253
uuid-e21cf1523d73463dac5617a8c8503c89,agents,0.404202
uuid-e21cf1523d73463dac5617a8c8503c89,Ipi,0.311923
uuid-e21cf1523d73463dac5617a8c8503c89,approval,0.401837
uuid-e21cf1523d73463dac5617a8c8503c89,atezo,0.581276
uuid-e21cf1523d73463dac5617a8c8503c89,preferred,0.553848
uuid-e21cf1523d73463dac5617a8c8503c89,monotherapy,0.524883
uuid-e21cf1523d73463dac5617a8c8503c89,using nivo,0.398186
uuid-e21cf1523d73463dac5617a8c8503c89,combo,0.464802
uuid-e21cf1523d73463dac5617a8c8503c89,indication,0.319291
uuid-e21cf1523d73463dac5617a8c8503c89,approved,0.54371
uuid-e21cf1523d73463dac5617a8c8503c89,RTL stated,0.325524
uuid-e21cf1523d73463dac5617a8c8503c89,option,0.472372
uuid-ab56d81f514c436fb874efbe1115f239,RTL,0.379053
uuid-ab56d81f514c436fb874efbe1115f239,NSCLC,0.300324
uuid-ab56d81f514c436fb874efbe1115f239,efficacy,0.326561
uuid-ab56d81f514c436fb874efbe1115f239,discussed,0.310162
uuid-ab56d81f514c436fb874efbe1115f239,commented,0.547287
uuid-ab56d81f514c436fb874efbe1115f239,OS,0.545137
uuid-ab56d81f514c436fb874efbe1115f239,data,0.660735
uuid-ab56d81f514c436fb874efbe1115f239,PFS,0.450275
uuid-ab56d81f514c436fb874efbe1115f239,ORR,0.546243
uuid-ab56d81f514c436fb874efbe1115f239,ASCO,0.560948
uuid-ab56d81f514c436fb874efbe1115f239,impressed,0.745347
uuid-ab56d81f514c436fb874efbe1115f239,LTL,0.306219
uuid-ab56d81f514c436fb874efbe1115f239,TLs,0.420969
uuid-ab56d81f514c436fb874efbe1115f239,Regional TL,0.40801
uuid-fcde7f6925dc4638868df1c9030e6f91,TL,0.303105
uuid-fcde7f6925dc4638868df1c9030e6f91,shared,0.308884
uuid-fcde7f6925dc4638868df1c9030e6f91,oncology,0.353373
uuid-fcde7f6925dc4638868df1c9030e6f91,indicated,0.363841
uuid-fcde7f6925dc4638868df1c9030e6f91,flat dosing,0.390257
uuid-8b89ab71dac74bad80cbf3d97ffed80b,Opdivo,0.558268
uuid-8b89ab71dac74bad80cbf3d97ffed80b,dose,0.551811
uuid-8b89ab71dac74bad80cbf3d97ffed80b,shared,0.342046
uuid-8b89ab71dac74bad80cbf3d97ffed80b,physicians,0.435629
uuid-8b89ab71dac74bad80cbf3d97ffed80b,oncology,0.309948
uuid-8b89ab71dac74bad80cbf3d97ffed80b,drug,0.558358
uuid-8b89ab71dac74bad80cbf3d97ffed80b,Keytruda,0.428087
uuid-8b89ab71dac74bad80cbf3d97ffed80b,flat dosing,0.685593
uuid-f0bc59c4211e432b93e6b56392c077e4,1L,0.317941
uuid-f0bc59c4211e432b93e6b56392c077e4,RCC,0.414653
uuid-f0bc59c4211e432b93e6b56392c077e4,TL stated,0.355788
uuid-f0bc59c4211e432b93e6b56392c077e4,PD-L1,0.363182
uuid-f0bc59c4211e432b93e6b56392c077e4,preferred,0.307109
uuid-f0bc59c4211e432b93e6b56392c077e4,PD-L1 testing,0.427807
uuid-f0bc59c4211e432b93e6b56392c077e4,testing,0.420232
uuid-f0bc59c4211e432b93e6b56392c077e4,PDL1 testing,0.458871
uuid-f0bc59c4211e432b93e6b56392c077e4,NSCLC patients,0.40203
uuid-f0bc59c4211e432b93e6b56392c077e4,SCCHN,0.331638
uuid-f0bc59c4211e432b93e6b56392c077e4,RTL stated,0.343663
uuid-e9089b3fd55d4be4ae753b4cdc720420,pembro,0.327987
uuid-e9089b3fd55d4be4ae753b4cdc720420,lung,0.379531
uuid-e9089b3fd55d4be4ae753b4cdc720420,1L,0.556148
uuid-e9089b3fd55d4be4ae753b4cdc720420,RCC,0.77318
uuid-e9089b3fd55d4be4ae753b4cdc720420,TL stated,0.439855
uuid-e9089b3fd55d4be4ae753b4cdc720420,2L,0.621822
uuid-e9089b3fd55d4be4ae753b4cdc720420,stated,0.439028
uuid-e9089b3fd55d4be4ae753b4cdc720420,approval,0.467641
uuid-e9089b3fd55d4be4ae753b4cdc720420,atezo,0.357031
uuid-e9089b3fd55d4be4ae753b4cdc720420,preferred,0.526679
uuid-e9089b3fd55d4be4ae753b4cdc720420,monotherapy,0.306646
uuid-e9089b3fd55d4be4ae753b4cdc720420,using nivo,0.630162
uuid-e9089b3fd55d4be4ae753b4cdc720420,clinical trials,0.336943
uuid-e9089b3fd55d4be4ae753b4cdc720420,PDL1 testing,0.418128
uuid-e9089b3fd55d4be4ae753b4cdc720420,indication,0.340509
uuid-e9089b3fd55d4be4ae753b4cdc720420,NSCLC patients,0.309228
uuid-e9089b3fd55d4be4ae753b4cdc720420,approved,0.507772
uuid-e9089b3fd55d4be4ae753b4cdc720420,SCCHN,0.631902
uuid-e9089b3fd55d4be4ae753b4cdc720420,tumor types,0.473975
uuid-e9089b3fd55d4be4ae753b4cdc720420,LTL,0.312526
uuid-e9089b3fd55d4be4ae753b4cdc720420,TLs,0.359467
uuid-e9089b3fd55d4be4ae753b4cdc720420,Regional TL,0.511613
uuid-e9089b3fd55d4be4ae753b4cdc720420,RTL stated,0.625895
uuid-e9089b3fd55d4be4ae753b4cdc720420,TL shared,0.474362
uuid-e9089b3fd55d4be4ae753b4cdc720420,option,0.390985
uuid-e9089b3fd55d4be4ae753b4cdc720420,bladder,0.513471
uuid-ac3884721b5348a6823f84fcad9bca1b,patients,0.324096
uuid-ac3884721b5348a6823f84fcad9bca1b,RTL,0.324538
uuid-ac3884721b5348a6823f84fcad9bca1b,trial,0.42083
uuid-ac3884721b5348a6823f84fcad9bca1b,commented,0.315757
uuid-ac3884721b5348a6823f84fcad9bca1b,chemo,0.328683
uuid-ac3884721b5348a6823f84fcad9bca1b,pts,0.389144
uuid-ac3884721b5348a6823f84fcad9bca1b,OS,0.322615
uuid-ac3884721b5348a6823f84fcad9bca1b,monotherapy,0.340913
uuid-ac3884721b5348a6823f84fcad9bca1b,response,0.309784
uuid-ac3884721b5348a6823f84fcad9bca1b,data,0.361116
uuid-ac3884721b5348a6823f84fcad9bca1b,clinical trials,0.394334
uuid-ac3884721b5348a6823f84fcad9bca1b,ORR,0.35535
uuid-ac3884721b5348a6823f84fcad9bca1b,chemotherapy,0.324655
uuid-ac3884721b5348a6823f84fcad9bca1b,impressed,0.473613
uuid-ac3884721b5348a6823f84fcad9bca1b,feels,0.451349
uuid-a4b489d7516c47db88da4fb6d8ee3a87,patients,0.574955
uuid-a4b489d7516c47db88da4fb6d8ee3a87,therapy,0.302374
uuid-a4b489d7516c47db88da4fb6d8ee3a87,1L,0.478828
uuid-a4b489d7516c47db88da4fb6d8ee3a87,treated,0.46481
uuid-a4b489d7516c47db88da4fb6d8ee3a87,RCC,0.464451
uuid-a4b489d7516c47db88da4fb6d8ee3a87,TL stated,0.333111
uuid-a4b489d7516c47db88da4fb6d8ee3a87,2L,0.449473
uuid-a4b489d7516c47db88da4fb6d8ee3a87,pts,0.519186
uuid-a4b489d7516c47db88da4fb6d8ee3a87,preferred,0.394334
uuid-a4b489d7516c47db88da4fb6d8ee3a87,monotherapy,0.439631
uuid-a4b489d7516c47db88da4fb6d8ee3a87,treatment,0.391087
uuid-a4b489d7516c47db88da4fb6d8ee3a87,using nivo,0.447823
uuid-a4b489d7516c47db88da4fb6d8ee3a87,PDL1 testing,0.37418
uuid-a4b489d7516c47db88da4fb6d8ee3a87,NSCLC patients,0.490387
uuid-a4b489d7516c47db88da4fb6d8ee3a87,progression,0.388464
uuid-a4b489d7516c47db88da4fb6d8ee3a87,tumor types,0.301761
uuid-a4b489d7516c47db88da4fb6d8ee3a87,respond,0.309818
uuid-a4b489d7516c47db88da4fb6d8ee3a87,RTL stated,0.470942
uuid-a4b489d7516c47db88da4fb6d8ee3a87,TL shared,0.46335
uuid-a4b489d7516c47db88da4fb6d8ee3a87,option,0.445744
uuid-f8fb8798edc64009b87b0ed17e017e58,patients,0.333143
uuid-f8fb8798edc64009b87b0ed17e017e58,Opdivo,0.406922
uuid-f8fb8798edc64009b87b0ed17e017e58,TL,0.31417
uuid-f8fb8798edc64009b87b0ed17e017e58,pembro,0.3689
uuid-f8fb8798edc64009b87b0ed17e017e58,dose,0.738719
uuid-f8fb8798edc64009b87b0ed17e017e58,Ipi,0.38058
uuid-f8fb8798edc64009b87b0ed17e017e58,atezo,0.395919
uuid-f8fb8798edc64009b87b0ed17e017e58,vs,0.42912
uuid-f8fb8798edc64009b87b0ed17e017e58,Keytruda,0.37128
uuid-f8fb8798edc64009b87b0ed17e017e58,flat dosing,0.564446
uuid-d3917b3f5b01457c8a93876b219a8d61,RTL,0.81974
uuid-d3917b3f5b01457c8a93876b219a8d61,trial,0.380538
uuid-d3917b3f5b01457c8a93876b219a8d61,NTL,0.5369
uuid-d3917b3f5b01457c8a93876b219a8d61,melanoma,0.301042
uuid-d3917b3f5b01457c8a93876b219a8d61,shared,0.498874
uuid-d3917b3f5b01457c8a93876b219a8d61,commented,0.403451
uuid-d3917b3f5b01457c8a93876b219a8d61,institution,0.373852
uuid-d3917b3f5b01457c8a93876b219a8d61,stated,0.499005
uuid-d3917b3f5b01457c8a93876b219a8d61,expressed,0.337497
uuid-d3917b3f5b01457c8a93876b219a8d61,mentioned,0.387279
uuid-d3917b3f5b01457c8a93876b219a8d61,clinical trials,0.458073
uuid-d3917b3f5b01457c8a93876b219a8d61,SCCHN,0.571369
uuid-d3917b3f5b01457c8a93876b219a8d61,HCP,0.4599
uuid-d3917b3f5b01457c8a93876b219a8d61,impressed,0.37155
uuid-d3917b3f5b01457c8a93876b219a8d61,LTL,0.580486
uuid-d3917b3f5b01457c8a93876b219a8d61,TLs,0.410492
uuid-d3917b3f5b01457c8a93876b219a8d61,academic,0.480718
uuid-d3917b3f5b01457c8a93876b219a8d61,Regional TL,0.561876
uuid-d3917b3f5b01457c8a93876b219a8d61,RTL stated,0.389119
uuid-d3917b3f5b01457c8a93876b219a8d61,bladder,0.309683
uuid-c4188d68cc1240fabcadd0f52e62515b,BMS,0.596166
uuid-c4188d68cc1240fabcadd0f52e62515b,lung,0.367744
uuid-c4188d68cc1240fabcadd0f52e62515b,trial,0.342221
uuid-c4188d68cc1240fabcadd0f52e62515b,melanoma,0.333572
uuid-c4188d68cc1240fabcadd0f52e62515b,shared,0.314342
uuid-c4188d68cc1240fabcadd0f52e62515b,commented,0.382628
uuid-c4188d68cc1240fabcadd0f52e62515b,Merck,0.362274
uuid-c4188d68cc1240fabcadd0f52e62515b,regards,0.388337
uuid-c4188d68cc1240fabcadd0f52e62515b,data,0.309662
uuid-c4188d68cc1240fabcadd0f52e62515b,expressed,0.442526
uuid-c4188d68cc1240fabcadd0f52e62515b,AI,0.49175
uuid-c4188d68cc1240fabcadd0f52e62515b,NCCN,0.388068
uuid-100b55f4a92246bf9f83c6adc9d79942,toxicity,0.419226
uuid-100b55f4a92246bf9f83c6adc9d79942,efficacy,0.308826
uuid-100b55f4a92246bf9f83c6adc9d79942,combination,0.444191
uuid-100b55f4a92246bf9f83c6adc9d79942,agents,0.339248
uuid-100b55f4a92246bf9f83c6adc9d79942,combo,0.387667
uuid-100b55f4a92246bf9f83c6adc9d79942,believes,0.444468
uuid-100b55f4a92246bf9f83c6adc9d79942,feels,0.374291
uuid-ea6a6e6776aa4b85ab411faef170dd37,pembro,0.538597
uuid-ea6a6e6776aa4b85ab411faef170dd37,lung,0.489998
uuid-ea6a6e6776aa4b85ab411faef170dd37,1L,0.595852
uuid-ea6a6e6776aa4b85ab411faef170dd37,trial,0.38504
uuid-ea6a6e6776aa4b85ab411faef170dd37,melanoma,0.390462
uuid-ea6a6e6776aa4b85ab411faef170dd37,RCC,0.552996
uuid-ea6a6e6776aa4b85ab411faef170dd37,TL stated,0.507589
uuid-ea6a6e6776aa4b85ab411faef170dd37,2L,0.538199
uuid-ea6a6e6776aa4b85ab411faef170dd37,pts,0.387089
uuid-ea6a6e6776aa4b85ab411faef170dd37,approval,0.381609
uuid-ea6a6e6776aa4b85ab411faef170dd37,atezo,0.432224
uuid-ea6a6e6776aa4b85ab411faef170dd37,preferred,0.358012
uuid-ea6a6e6776aa4b85ab411faef170dd37,monotherapy,0.333983
uuid-ea6a6e6776aa4b85ab411faef170dd37,using nivo,0.456244
uuid-ea6a6e6776aa4b85ab411faef170dd37,combo,0.413444
uuid-ea6a6e6776aa4b85ab411faef170dd37,PDL1 testing,0.350395
uuid-ea6a6e6776aa4b85ab411faef170dd37,NSCLC patients,0.342325
uuid-ea6a6e6776aa4b85ab411faef170dd37,approved,0.355977
uuid-ea6a6e6776aa4b85ab411faef170dd37,SCCHN,0.415657
uuid-ea6a6e6776aa4b85ab411faef170dd37,SCLC,0.334656
uuid-ea6a6e6776aa4b85ab411faef170dd37,RTL stated,0.489721
uuid-ea6a6e6776aa4b85ab411faef170dd37,TL shared,0.466905
uuid-ea6a6e6776aa4b85ab411faef170dd37,option,0.303008
uuid-ea6a6e6776aa4b85ab411faef170dd37,bladder,0.455567
uuid-bb117262cd494163b36718ede491e7e6,Nivo,0.432639
uuid-bb117262cd494163b36718ede491e7e6,trial,0.347894
uuid-bb117262cd494163b36718ede491e7e6,efficacy,0.534696
uuid-bb117262cd494163b36718ede491e7e6,regimen,0.300515
uuid-bb117262cd494163b36718ede491e7e6,chemo,0.357625
uuid-bb117262cd494163b36718ede491e7e6,Ipi,0.40304
uuid-bb117262cd494163b36718ede491e7e6,OS,0.608383
uuid-bb117262cd494163b36718ede491e7e6,monotherapy,0.308463
uuid-bb117262cd494163b36718ede491e7e6,response,0.384868
uuid-bb117262cd494163b36718ede491e7e6,data,0.508953
uuid-bb117262cd494163b36718ede491e7e6,combo,0.353529
uuid-bb117262cd494163b36718ede491e7e6,PFS,0.548076
uuid-bb117262cd494163b36718ede491e7e6,PD1,0.379649
uuid-bb117262cd494163b36718ede491e7e6,ORR,0.70795
uuid-bb117262cd494163b36718ede491e7e6,nivo and pembro,0.318107
uuid-bb117262cd494163b36718ede491e7e6,ASCO,0.330063
uuid-bb117262cd494163b36718ede491e7e6,chemotherapy,0.343864
uuid-bb117262cd494163b36718ede491e7e6,impressed,0.578348
uuid-bb117262cd494163b36718ede491e7e6,SCLC,0.304693
uuid-bb117262cd494163b36718ede491e7e6,feels,0.32417
uuid-3ff0d6579bee4bbbacb0bcacb9634674,patients,0.57801
uuid-3ff0d6579bee4bbbacb0bcacb9634674,Opdivo,0.768503
uuid-3ff0d6579bee4bbbacb0bcacb9634674,therapy,0.477142
uuid-3ff0d6579bee4bbbacb0bcacb9634674,nivolumab,0.475097
uuid-3ff0d6579bee4bbbacb0bcacb9634674,regimen,0.343018
uuid-3ff0d6579bee4bbbacb0bcacb9634674,treated,0.475101
uuid-3ff0d6579bee4bbbacb0bcacb9634674,treatment,0.548611
uuid-3ff0d6579bee4bbbacb0bcacb9634674,using nivo,0.312361
uuid-3ff0d6579bee4bbbacb0bcacb9634674,cHL,0.501953
uuid-3ff0d6579bee4bbbacb0bcacb9634674,progression,0.367716
uuid-3ff0d6579bee4bbbacb0bcacb9634674,Keytruda,0.319009
uuid-1f7181cf61204bd6962333ec326dc649,patients,0.472286
uuid-1f7181cf61204bd6962333ec326dc649,Opdivo,0.701268
uuid-1f7181cf61204bd6962333ec326dc649,dose,0.388629
uuid-1f7181cf61204bd6962333ec326dc649,nivolumab,0.312165
uuid-1f7181cf61204bd6962333ec326dc649,approval,0.401809
uuid-1f7181cf61204bd6962333ec326dc649,physicians,0.331721
uuid-1f7181cf61204bd6962333ec326dc649,treatment,0.319858
uuid-1f7181cf61204bd6962333ec326dc649,indication,0.300398
uuid-1f7181cf61204bd6962333ec326dc649,approved,0.448434
uuid-1f7181cf61204bd6962333ec326dc649,label,0.439837
uuid-1f7181cf61204bd6962333ec326dc649,Keytruda,0.388235
uuid-1f7181cf61204bd6962333ec326dc649,flat dosing,0.611396
uuid-b0d0adb022734aa2b1b956e1ccd8f9dc,therapy,0.363494
uuid-b0d0adb022734aa2b1b956e1ccd8f9dc,vs,0.365968
uuid-8a0411d1167d402aac51e397ff39fcf6,TL,0.327575
uuid-8a0411d1167d402aac51e397ff39fcf6,1L,0.32393
uuid-8a0411d1167d402aac51e397ff39fcf6,PDL1,0.531343
uuid-8a0411d1167d402aac51e397ff39fcf6,TL stated,0.374463
uuid-8a0411d1167d402aac51e397ff39fcf6,PD-L1,0.835684
uuid-8a0411d1167d402aac51e397ff39fcf6,PD-L1 testing,0.70416
uuid-8a0411d1167d402aac51e397ff39fcf6,testing,0.889224
uuid-8a0411d1167d402aac51e397ff39fcf6,PDL1 testing,0.670904
uuid-8a0411d1167d402aac51e397ff39fcf6,NSCLC patients,0.713548
uuid-8a0411d1167d402aac51e397ff39fcf6,assay,0.6142
uuid-8a0411d1167d402aac51e397ff39fcf6,PD-1,0.478281
uuid-8a0411d1167d402aac51e397ff39fcf6,PDL1 expression,0.33698
uuid-8a0411d1167d402aac51e397ff39fcf6,biomarker,0.608857
uuid-4ab29e50c0b7409bbe4d45eb11c7ee13,TL,0.380483
uuid-4ab29e50c0b7409bbe4d45eb11c7ee13,PDL1,0.582471
uuid-4ab29e50c0b7409bbe4d45eb11c7ee13,TL stated,0.345654
uuid-4ab29e50c0b7409bbe4d45eb11c7ee13,PD-L1,0.854551
uuid-4ab29e50c0b7409bbe4d45eb11c7ee13,PD-L1 testing,0.718364
uuid-4ab29e50c0b7409bbe4d45eb11c7ee13,testing,0.903456
uuid-4ab29e50c0b7409bbe4d45eb11c7ee13,PDL1 testing,0.686895
uuid-4ab29e50c0b7409bbe4d45eb11c7ee13,NSCLC patients,0.665774
uuid-4ab29e50c0b7409bbe4d45eb11c7ee13,assay,0.689044
uuid-4ab29e50c0b7409bbe4d45eb11c7ee13,PD-1,0.457327
uuid-4ab29e50c0b7409bbe4d45eb11c7ee13,PDL1 expression,0.418451
uuid-4ab29e50c0b7409bbe4d45eb11c7ee13,biomarker,0.676428
uuid-1cfb06af6d4848fca86ea58c1bc7d3a5,Opdivo,0.316577
uuid-1cfb06af6d4848fca86ea58c1bc7d3a5,therapy,0.350791
uuid-1cfb06af6d4848fca86ea58c1bc7d3a5,toxicity,0.455045
uuid-1cfb06af6d4848fca86ea58c1bc7d3a5,treated,0.303199
uuid-1cfb06af6d4848fca86ea58c1bc7d3a5,treatment,0.338845
uuid-1cfb06af6d4848fca86ea58c1bc7d3a5,cHL,0.483241
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,BMS,0.58308
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,PDL1,0.357192
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,trial,0.350513
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,efficacy,0.334864
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,commented,0.499176
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,Merck,0.483417
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,stated,0.401755
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,OS,0.394497
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,regards,0.400427
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,data,0.76126
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,expressed,0.400349
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,PFS,0.361328
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,ORR,0.407212
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,nivo and pembro,0.339732
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,ASCO,0.367398
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,impressed,0.538599
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,Regional TL,0.32396
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,PDL1 expression,0.315613
uuid-7c3632f41f8c4e10ae5b1bce50e6bac5,NCCN,0.492235
uuid-2387a91e2fe64e709f99bdd7347d35ac,pembro,0.344826
uuid-2387a91e2fe64e709f99bdd7347d35ac,dose,0.500216
uuid-2387a91e2fe64e709f99bdd7347d35ac,NSCLC,0.318995
uuid-2387a91e2fe64e709f99bdd7347d35ac,trial,0.390148
uuid-2387a91e2fe64e709f99bdd7347d35ac,efficacy,0.304559
uuid-2387a91e2fe64e709f99bdd7347d35ac,Ipi,0.451346
uuid-2387a91e2fe64e709f99bdd7347d35ac,atezo,0.339622
uuid-2387a91e2fe64e709f99bdd7347d35ac,data,0.304147
uuid-2387a91e2fe64e709f99bdd7347d35ac,vs,0.48149
uuid-2387a91e2fe64e709f99bdd7347d35ac,flat dosing,0.446645
uuid-338f68af93ec48d7958473024e28e523,RTL,0.334911
uuid-338f68af93ec48d7958473024e28e523,lung,0.407643
uuid-338f68af93ec48d7958473024e28e523,trial,0.314506
uuid-338f68af93ec48d7958473024e28e523,NTL,0.423052
uuid-338f68af93ec48d7958473024e28e523,melanoma,0.478173
uuid-338f68af93ec48d7958473024e28e523,RCC,0.380099
uuid-338f68af93ec48d7958473024e28e523,ASCO,0.409947
uuid-338f68af93ec48d7958473024e28e523,SCLC,0.343491
uuid-338f68af93ec48d7958473024e28e523,TL shared,0.397837
uuid-c20255dbbbc14ab18f53594124db57d6,RTL,0.366398
uuid-c20255dbbbc14ab18f53594124db57d6,BMS,0.636974
uuid-c20255dbbbc14ab18f53594124db57d6,lung,0.305254
uuid-c20255dbbbc14ab18f53594124db57d6,trial,0.442473
uuid-c20255dbbbc14ab18f53594124db57d6,efficacy,0.311228
uuid-c20255dbbbc14ab18f53594124db57d6,NTL,0.313013
uuid-c20255dbbbc14ab18f53594124db57d6,discussed,0.355001
uuid-c20255dbbbc14ab18f53594124db57d6,commented,0.538171
uuid-c20255dbbbc14ab18f53594124db57d6,Merck,0.400602
uuid-c20255dbbbc14ab18f53594124db57d6,stated,0.360126
uuid-c20255dbbbc14ab18f53594124db57d6,OS,0.38233
uuid-c20255dbbbc14ab18f53594124db57d6,regards,0.542208
uuid-c20255dbbbc14ab18f53594124db57d6,data,0.568411
uuid-c20255dbbbc14ab18f53594124db57d6,expressed,0.428295
uuid-c20255dbbbc14ab18f53594124db57d6,PFS,0.339633
uuid-c20255dbbbc14ab18f53594124db57d6,ORR,0.379438
uuid-c20255dbbbc14ab18f53594124db57d6,ASCO,0.349302
uuid-c20255dbbbc14ab18f53594124db57d6,impressed,0.580464
uuid-c20255dbbbc14ab18f53594124db57d6,TLs,0.459602
uuid-8044279e22654aeb97b22242812c475f,RTL,0.376687
uuid-8044279e22654aeb97b22242812c475f,therapy,0.327593
uuid-8044279e22654aeb97b22242812c475f,nivolumab,0.57098
uuid-8044279e22654aeb97b22242812c475f,treated,0.422768
uuid-8044279e22654aeb97b22242812c475f,NTL,0.557413
uuid-8044279e22654aeb97b22242812c475f,treatment,0.323173
uuid-8044279e22654aeb97b22242812c475f,PD1,0.358739
uuid-8044279e22654aeb97b22242812c475f,cHL,0.40597
uuid-8044279e22654aeb97b22242812c475f,chemotherapy,0.308876
uuid-a3323668271a4ee3b449a8399049316b,patients,0.675626
uuid-a3323668271a4ee3b449a8399049316b,Opdivo,0.399395
uuid-a3323668271a4ee3b449a8399049316b,therapy,0.486925
uuid-a3323668271a4ee3b449a8399049316b,nivolumab,0.499291
uuid-a3323668271a4ee3b449a8399049316b,treated,0.526722
uuid-a3323668271a4ee3b449a8399049316b,pts,0.308585
uuid-a3323668271a4ee3b449a8399049316b,treatment,0.553789
uuid-a3323668271a4ee3b449a8399049316b,cHL,0.505963
uuid-a3323668271a4ee3b449a8399049316b,progression,0.443394
uuid-a3323668271a4ee3b449a8399049316b,respond,0.398868
uuid-82b12ba606034c10b7b8fb8ff503e778,RTL,0.509533
uuid-82b12ba606034c10b7b8fb8ff503e778,nivolumab,0.461516
uuid-82b12ba606034c10b7b8fb8ff503e778,trial,0.393837
uuid-82b12ba606034c10b7b8fb8ff503e778,NTL,0.610762
uuid-82b12ba606034c10b7b8fb8ff503e778,mentioned,0.431118
uuid-82b12ba606034c10b7b8fb8ff503e778,cHL,0.420694
uuid-82b12ba606034c10b7b8fb8ff503e778,indicated,0.312831
uuid-82b12ba606034c10b7b8fb8ff503e778,LTL,0.330596
uuid-82b12ba606034c10b7b8fb8ff503e778,Regional TL,0.448824
uuid-aa8009e8b0704e7ab2708ffc14ab11df,RTL,0.313842
uuid-aa8009e8b0704e7ab2708ffc14ab11df,NTL,0.528405
uuid-aa8009e8b0704e7ab2708ffc14ab11df,discussed,0.330906
uuid-aa8009e8b0704e7ab2708ffc14ab11df,cHL,0.315162
uuid-aa8009e8b0704e7ab2708ffc14ab11df,indicated,0.403599
uuid-26dd66382809471194555cafbc6762a6,Opdivo,0.39212
uuid-26dd66382809471194555cafbc6762a6,1L,0.330724
uuid-26dd66382809471194555cafbc6762a6,shared,0.384471
uuid-26dd66382809471194555cafbc6762a6,2L,0.393557
uuid-26dd66382809471194555cafbc6762a6,institution,0.336998
uuid-26dd66382809471194555cafbc6762a6,preferred,0.510319
uuid-26dd66382809471194555cafbc6762a6,testing,0.313665
uuid-26dd66382809471194555cafbc6762a6,PDL1 testing,0.397154
uuid-26dd66382809471194555cafbc6762a6,approved,0.394028
uuid-26dd66382809471194555cafbc6762a6,Keytruda,0.391942
uuid-26dd66382809471194555cafbc6762a6,option,0.380585
uuid-89691766689f43c88930ca473c94641d,BMS,0.35255
uuid-89691766689f43c88930ca473c94641d,commented,0.368259
uuid-89691766689f43c88930ca473c94641d,regards,0.31994
uuid-89691766689f43c88930ca473c94641d,data,0.457566
uuid-89691766689f43c88930ca473c94641d,nivo and pembro,0.344314
uuid-89691766689f43c88930ca473c94641d,believes,0.355906
uuid-89691766689f43c88930ca473c94641d,feels,0.488735
uuid-3e087b06b27049e189a9d25f59bbcb87,patients,0.813426
uuid-3e087b06b27049e189a9d25f59bbcb87,Opdivo,0.458103
uuid-3e087b06b27049e189a9d25f59bbcb87,therapy,0.605279
uuid-3e087b06b27049e189a9d25f59bbcb87,nivolumab,0.387473
uuid-3e087b06b27049e189a9d25f59bbcb87,regimen,0.454977
uuid-3e087b06b27049e189a9d25f59bbcb87,treated,0.499325
uuid-3e087b06b27049e189a9d25f59bbcb87,chemo,0.437766
uuid-3e087b06b27049e189a9d25f59bbcb87,pts,0.584197
uuid-3e087b06b27049e189a9d25f59bbcb87,monotherapy,0.338476
uuid-3e087b06b27049e189a9d25f59bbcb87,treatment,0.700811
uuid-3e087b06b27049e189a9d25f59bbcb87,response,0.381802
uuid-3e087b06b27049e189a9d25f59bbcb87,PD1,0.317923
uuid-3e087b06b27049e189a9d25f59bbcb87,progression,0.622572
uuid-3e087b06b27049e189a9d25f59bbcb87,chemotherapy,0.529736
uuid-3e087b06b27049e189a9d25f59bbcb87,respond,0.513574
uuid-3e087b06b27049e189a9d25f59bbcb87,immunotherapy,0.397329
uuid-3e087b06b27049e189a9d25f59bbcb87,option,0.439183
uuid-eab255b912204ee99a1ba7eb3c81dd63,Nivo,0.360103
uuid-eab255b912204ee99a1ba7eb3c81dd63,patients,0.874996
uuid-eab255b912204ee99a1ba7eb3c81dd63,Opdivo,0.415968
uuid-eab255b912204ee99a1ba7eb3c81dd63,therapy,0.712795
uuid-eab255b912204ee99a1ba7eb3c81dd63,nivolumab,0.64182
uuid-eab255b912204ee99a1ba7eb3c81dd63,regimen,0.487675
uuid-eab255b912204ee99a1ba7eb3c81dd63,treated,0.548992
uuid-eab255b912204ee99a1ba7eb3c81dd63,combination,0.304525
uuid-eab255b912204ee99a1ba7eb3c81dd63,chemo,0.463985
uuid-eab255b912204ee99a1ba7eb3c81dd63,pts,0.58571
uuid-eab255b912204ee99a1ba7eb3c81dd63,preferred,0.3622
uuid-eab255b912204ee99a1ba7eb3c81dd63,monotherapy,0.513639
uuid-eab255b912204ee99a1ba7eb3c81dd63,treatment,0.683642
uuid-eab255b912204ee99a1ba7eb3c81dd63,using nivo,0.423623
uuid-eab255b912204ee99a1ba7eb3c81dd63,response,0.328276
uuid-eab255b912204ee99a1ba7eb3c81dd63,PD1,0.430227
uuid-eab255b912204ee99a1ba7eb3c81dd63,cHL,0.387669
uuid-eab255b912204ee99a1ba7eb3c81dd63,progression,0.594687
uuid-eab255b912204ee99a1ba7eb3c81dd63,chemotherapy,0.519808
uuid-eab255b912204ee99a1ba7eb3c81dd63,respond,0.442797
uuid-eab255b912204ee99a1ba7eb3c81dd63,RTL stated,0.30901
uuid-eab255b912204ee99a1ba7eb3c81dd63,option,0.556915
uuid-7e5834de8e4a4e75b2df0fc214f8b163,patients,0.367838
uuid-7e5834de8e4a4e75b2df0fc214f8b163,Opdivo,0.306832
uuid-7e5834de8e4a4e75b2df0fc214f8b163,toxicity,0.38612
uuid-f9ed32cfab054636a5f2355a74a76498,Opdivo,0.431278
uuid-f9ed32cfab054636a5f2355a74a76498,shared,0.461103
uuid-f9ed32cfab054636a5f2355a74a76498,physicians,0.595852
uuid-f9ed32cfab054636a5f2355a74a76498,oncology,0.302212
uuid-f9ed32cfab054636a5f2355a74a76498,HCP,0.302941
uuid-f9ed32cfab054636a5f2355a74a76498,Keytruda,0.325734
uuid-f62bb836d2774458a7316a03829d8410,tumor,0.729872
uuid-f62bb836d2774458a7316a03829d8410,response,0.32988
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,Nivo,0.361208
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,patients,0.378875
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,therapy,0.838113
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,nivolumab,0.545015
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,treated,0.323243
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,combination,0.448195
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,chemo,0.4939
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,monotherapy,0.385827
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,treatment,0.467244
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,response,0.390209
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,PD1,0.505841
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,cHL,0.492136
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,progression,0.451721
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,chemotherapy,0.600703
uuid-d436a5840c4c4cb8a8d8cfda73a318eb,PD-1,0.366356
uuid-ecf911bbd385408dba15fb157a12f511,patients,0.427487
uuid-ecf911bbd385408dba15fb157a12f511,nivolumab,0.355726
uuid-ecf911bbd385408dba15fb157a12f511,regimen,0.354126
uuid-ecf911bbd385408dba15fb157a12f511,treated,0.412812
uuid-ecf911bbd385408dba15fb157a12f511,shared,0.347136
uuid-ecf911bbd385408dba15fb157a12f511,RCC,0.32661
uuid-ecf911bbd385408dba15fb157a12f511,pts,0.321934
uuid-ecf911bbd385408dba15fb157a12f511,preferred,0.432401
uuid-ecf911bbd385408dba15fb157a12f511,monotherapy,0.335529
uuid-ecf911bbd385408dba15fb157a12f511,treatment,0.301437
uuid-ecf911bbd385408dba15fb157a12f511,using nivo,0.320215
uuid-ecf911bbd385408dba15fb157a12f511,RTL stated,0.448906
uuid-ecf911bbd385408dba15fb157a12f511,option,0.377909
uuid-ef2c23ca3896449f9e9af812e8527b37,discussed,0.549601
uuid-ef2c23ca3896449f9e9af812e8527b37,academic,0.525844
uuid-ef2c23ca3896449f9e9af812e8527b37,feels,0.343686
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,BMS,0.475909
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,PDL1,0.422729
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,trial,0.653118
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,efficacy,0.549916
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,chemo,0.319248
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,OS,0.394994
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,data,0.441791
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,PFS,0.438406
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,ORR,0.493898
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,nivo and pembro,0.371861
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,believes,0.387164
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,feels,0.457595
uuid-5dd927f963dc49f7b83d97cbf5a3ca6e,PDL1 expression,0.462996
uuid-561d210188dd4a318dee0f63164c9b6b,patients,0.904962
uuid-561d210188dd4a318dee0f63164c9b6b,Opdivo,0.546798
uuid-561d210188dd4a318dee0f63164c9b6b,therapy,0.549813
uuid-561d210188dd4a318dee0f63164c9b6b,nivolumab,0.422335
uuid-561d210188dd4a318dee0f63164c9b6b,regimen,0.585249
uuid-561d210188dd4a318dee0f63164c9b6b,treated,0.584589
uuid-561d210188dd4a318dee0f63164c9b6b,chemo,0.320021
uuid-561d210188dd4a318dee0f63164c9b6b,pts,0.606159
uuid-561d210188dd4a318dee0f63164c9b6b,monotherapy,0.384284
uuid-561d210188dd4a318dee0f63164c9b6b,treatment,0.752498
uuid-561d210188dd4a318dee0f63164c9b6b,using nivo,0.302538
uuid-561d210188dd4a318dee0f63164c9b6b,response,0.385645
uuid-561d210188dd4a318dee0f63164c9b6b,progression,0.747954
uuid-561d210188dd4a318dee0f63164c9b6b,chemotherapy,0.343628
uuid-561d210188dd4a318dee0f63164c9b6b,respond,0.55721
uuid-561d210188dd4a318dee0f63164c9b6b,option,0.37221
uuid-14151902039244f7ab768d94f4192cea,patients,0.743645
uuid-14151902039244f7ab768d94f4192cea,Opdivo,0.625561
uuid-14151902039244f7ab768d94f4192cea,therapy,0.33932
uuid-14151902039244f7ab768d94f4192cea,nivolumab,0.517997
uuid-14151902039244f7ab768d94f4192cea,treated,0.500056
uuid-14151902039244f7ab768d94f4192cea,RCC,0.390225
uuid-14151902039244f7ab768d94f4192cea,2L,0.302626
uuid-14151902039244f7ab768d94f4192cea,pts,0.462409
uuid-14151902039244f7ab768d94f4192cea,approval,0.582105
uuid-14151902039244f7ab768d94f4192cea,preferred,0.308623
uuid-14151902039244f7ab768d94f4192cea,treatment,0.478305
uuid-14151902039244f7ab768d94f4192cea,using nivo,0.54492
uuid-14151902039244f7ab768d94f4192cea,approved,0.435071
uuid-14151902039244f7ab768d94f4192cea,SCCHN,0.480956
uuid-14151902039244f7ab768d94f4192cea,cHL,0.337434
uuid-14151902039244f7ab768d94f4192cea,progression,0.364367
uuid-14151902039244f7ab768d94f4192cea,label,0.322599
uuid-14151902039244f7ab768d94f4192cea,RTL stated,0.434253
uuid-14151902039244f7ab768d94f4192cea,TL shared,0.342084
uuid-14151902039244f7ab768d94f4192cea,option,0.332202
uuid-14151902039244f7ab768d94f4192cea,bladder,0.322776
uuid-fb483f98c7cf44b29325f5da86678fb8,TL,0.315267
uuid-fb483f98c7cf44b29325f5da86678fb8,PDL1,0.567408
uuid-fb483f98c7cf44b29325f5da86678fb8,TL stated,0.43279
uuid-fb483f98c7cf44b29325f5da86678fb8,Merck,0.371785
uuid-fb483f98c7cf44b29325f5da86678fb8,PD-L1,0.547633
uuid-fb483f98c7cf44b29325f5da86678fb8,PD-L1 testing,0.377908
uuid-fb483f98c7cf44b29325f5da86678fb8,testing,0.583001
uuid-fb483f98c7cf44b29325f5da86678fb8,PDL1 testing,0.545838
uuid-fb483f98c7cf44b29325f5da86678fb8,NSCLC patients,0.367306
uuid-fb483f98c7cf44b29325f5da86678fb8,believes,0.311759
uuid-fb483f98c7cf44b29325f5da86678fb8,tumor types,0.328725
uuid-fb483f98c7cf44b29325f5da86678fb8,assay,0.485872
uuid-fb483f98c7cf44b29325f5da86678fb8,PDL1 expression,0.341752
uuid-fb483f98c7cf44b29325f5da86678fb8,biomarker,0.483858
uuid-39630347e3b34ba29b60ffb57a16db7a,Nivo,0.615789
uuid-39630347e3b34ba29b60ffb57a16db7a,pembro,0.726679
uuid-39630347e3b34ba29b60ffb57a16db7a,BMS,0.36282
uuid-39630347e3b34ba29b60ffb57a16db7a,1L,0.353742
uuid-39630347e3b34ba29b60ffb57a16db7a,trial,0.537433
uuid-39630347e3b34ba29b60ffb57a16db7a,efficacy,0.501977
uuid-39630347e3b34ba29b60ffb57a16db7a,2L,0.380404
uuid-39630347e3b34ba29b60ffb57a16db7a,agents,0.310116
uuid-39630347e3b34ba29b60ffb57a16db7a,Merck,0.332116
uuid-39630347e3b34ba29b60ffb57a16db7a,Ipi,0.305459
uuid-39630347e3b34ba29b60ffb57a16db7a,approval,0.416076
uuid-39630347e3b34ba29b60ffb57a16db7a,OS,0.339869
uuid-39630347e3b34ba29b60ffb57a16db7a,atezo,0.606117
uuid-39630347e3b34ba29b60ffb57a16db7a,preferred,0.340754
uuid-39630347e3b34ba29b60ffb57a16db7a,using nivo,0.427031
uuid-39630347e3b34ba29b60ffb57a16db7a,data,0.640056
uuid-39630347e3b34ba29b60ffb57a16db7a,clinical trials,0.341711
uuid-39630347e3b34ba29b60ffb57a16db7a,indication,0.473372
uuid-39630347e3b34ba29b60ffb57a16db7a,PFS,0.331291
uuid-39630347e3b34ba29b60ffb57a16db7a,ORR,0.386308
uuid-39630347e3b34ba29b60ffb57a16db7a,approved,0.446945
uuid-39630347e3b34ba29b60ffb57a16db7a,nivo and pembro,0.526264
uuid-39630347e3b34ba29b60ffb57a16db7a,impressed,0.47227
uuid-39630347e3b34ba29b60ffb57a16db7a,vs,0.429029
uuid-39630347e3b34ba29b60ffb57a16db7a,label,0.320521
uuid-39630347e3b34ba29b60ffb57a16db7a,feels,0.477152
uuid-39630347e3b34ba29b60ffb57a16db7a,option,0.302351
uuid-894a666467de4dc88dbbcec194517fe9,patients,0.463301
uuid-894a666467de4dc88dbbcec194517fe9,Opdivo,0.457075
uuid-894a666467de4dc88dbbcec194517fe9,dose,0.465815
uuid-894a666467de4dc88dbbcec194517fe9,toxicity,0.437636
uuid-894a666467de4dc88dbbcec194517fe9,regimen,0.524816
uuid-894a666467de4dc88dbbcec194517fe9,treated,0.304206
uuid-894a666467de4dc88dbbcec194517fe9,physicians,0.449316
uuid-894a666467de4dc88dbbcec194517fe9,treatment,0.520572
uuid-894a666467de4dc88dbbcec194517fe9,progression,0.312137
uuid-894a666467de4dc88dbbcec194517fe9,respond,0.335836
uuid-894a666467de4dc88dbbcec194517fe9,drug,0.337925
uuid-5f402bb14b1e4b23a1a515084f80217d,Nivo,0.522569
uuid-5f402bb14b1e4b23a1a515084f80217d,patients,0.597796
uuid-5f402bb14b1e4b23a1a515084f80217d,Opdivo,0.324034
uuid-5f402bb14b1e4b23a1a515084f80217d,pembro,0.432156
uuid-5f402bb14b1e4b23a1a515084f80217d,therapy,0.480417
uuid-5f402bb14b1e4b23a1a515084f80217d,nivolumab,0.49138
uuid-5f402bb14b1e4b23a1a515084f80217d,1L,0.687358
uuid-5f402bb14b1e4b23a1a515084f80217d,regimen,0.451259
uuid-5f402bb14b1e4b23a1a515084f80217d,treated,0.356494
uuid-5f402bb14b1e4b23a1a515084f80217d,RCC,0.476913
uuid-5f402bb14b1e4b23a1a515084f80217d,combination,0.33443
uuid-5f402bb14b1e4b23a1a515084f80217d,chemo,0.42438
uuid-5f402bb14b1e4b23a1a515084f80217d,2L,0.789854
uuid-5f402bb14b1e4b23a1a515084f80217d,pts,0.491332
uuid-5f402bb14b1e4b23a1a515084f80217d,agents,0.38588
uuid-5f402bb14b1e4b23a1a515084f80217d,approval,0.403115
uuid-5f402bb14b1e4b23a1a515084f80217d,atezo,0.410127
uuid-5f402bb14b1e4b23a1a515084f80217d,preferred,0.728992
uuid-5f402bb14b1e4b23a1a515084f80217d,monotherapy,0.695775
uuid-5f402bb14b1e4b23a1a515084f80217d,treatment,0.462334
uuid-5f402bb14b1e4b23a1a515084f80217d,using nivo,0.728096
uuid-5f402bb14b1e4b23a1a515084f80217d,combo,0.369751
uuid-5f402bb14b1e4b23a1a515084f80217d,NSCLC patients,0.328933
uuid-5f402bb14b1e4b23a1a515084f80217d,PD1,0.402466
uuid-5f402bb14b1e4b23a1a515084f80217d,approved,0.526526
uuid-5f402bb14b1e4b23a1a515084f80217d,progression,0.361476
uuid-5f402bb14b1e4b23a1a515084f80217d,chemotherapy,0.346853
uuid-5f402bb14b1e4b23a1a515084f80217d,RTL stated,0.591481
uuid-5f402bb14b1e4b23a1a515084f80217d,option,0.702972
uuid-7bc304ce79134454981075ccb872de32,Nivo,0.357372
uuid-7bc304ce79134454981075ccb872de32,efficacy,0.642784
uuid-7bc304ce79134454981075ccb872de32,regimen,0.503112
uuid-7bc304ce79134454981075ccb872de32,combination,0.393255
uuid-7bc304ce79134454981075ccb872de32,chemo,0.327517
uuid-7bc304ce79134454981075ccb872de32,Ipi,0.368919
uuid-7bc304ce79134454981075ccb872de32,OS,0.446271
uuid-7bc304ce79134454981075ccb872de32,monotherapy,0.445077
uuid-7bc304ce79134454981075ccb872de32,data,0.545517
uuid-7bc304ce79134454981075ccb872de32,combo,0.405577
uuid-7bc304ce79134454981075ccb872de32,PFS,0.403151
uuid-7bc304ce79134454981075ccb872de32,ORR,0.525237
uuid-7bc304ce79134454981075ccb872de32,nivo and pembro,0.353679
uuid-7bc304ce79134454981075ccb872de32,believes,0.354833
uuid-7bc304ce79134454981075ccb872de32,chemotherapy,0.339051
uuid-7bc304ce79134454981075ccb872de32,impressed,0.449897
uuid-7bc304ce79134454981075ccb872de32,SCLC,0.342636
uuid-7bc304ce79134454981075ccb872de32,feels,0.398234
uuid-7bc304ce79134454981075ccb872de32,option,0.327967
uuid-7b1d4f1414374c83a3102c3f3889dce1,Opdivo,0.502695
uuid-7b1d4f1414374c83a3102c3f3889dce1,shared,0.469549
uuid-7b1d4f1414374c83a3102c3f3889dce1,commented,0.330434
uuid-7b1d4f1414374c83a3102c3f3889dce1,physicians,0.584859
uuid-7b1d4f1414374c83a3102c3f3889dce1,mentioned,0.300116
uuid-7b1d4f1414374c83a3102c3f3889dce1,oncology,0.381781
uuid-7b1d4f1414374c83a3102c3f3889dce1,HCP,0.314142
uuid-7b1d4f1414374c83a3102c3f3889dce1,LTL,0.370049
uuid-7b1d4f1414374c83a3102c3f3889dce1,drug,0.425848
uuid-7b1d4f1414374c83a3102c3f3889dce1,Regional TL,0.311184
uuid-7b1d4f1414374c83a3102c3f3889dce1,flat dosing,0.393817
uuid-c9a8c591b29845d1a7f57e5782fd30ea,BMS,0.365633
uuid-c9a8c591b29845d1a7f57e5782fd30ea,PDL1,0.621635
uuid-c9a8c591b29845d1a7f57e5782fd30ea,trial,0.574219
uuid-c9a8c591b29845d1a7f57e5782fd30ea,efficacy,0.387049
uuid-c9a8c591b29845d1a7f57e5782fd30ea,Merck,0.446019
uuid-c9a8c591b29845d1a7f57e5782fd30ea,PD-L1,0.443597
uuid-c9a8c591b29845d1a7f57e5782fd30ea,OS,0.499725
uuid-c9a8c591b29845d1a7f57e5782fd30ea,testing,0.307466
uuid-c9a8c591b29845d1a7f57e5782fd30ea,data,0.636084
uuid-c9a8c591b29845d1a7f57e5782fd30ea,PFS,0.494761
uuid-c9a8c591b29845d1a7f57e5782fd30ea,ORR,0.540753
uuid-c9a8c591b29845d1a7f57e5782fd30ea,nivo and pembro,0.345533
uuid-c9a8c591b29845d1a7f57e5782fd30ea,impressed,0.421955
uuid-c9a8c591b29845d1a7f57e5782fd30ea,assay,0.398927
uuid-c9a8c591b29845d1a7f57e5782fd30ea,PDL1 expression,0.515852
uuid-c9a8c591b29845d1a7f57e5782fd30ea,biomarker,0.418939
uuid-ca04bd7630504a4089e13e3def19c977,Nivo,0.438106
uuid-ca04bd7630504a4089e13e3def19c977,patients,0.600439
uuid-ca04bd7630504a4089e13e3def19c977,Opdivo,0.409219
uuid-ca04bd7630504a4089e13e3def19c977,therapy,0.505151
uuid-ca04bd7630504a4089e13e3def19c977,nivolumab,0.503896
uuid-ca04bd7630504a4089e13e3def19c977,1L,0.455987
uuid-ca04bd7630504a4089e13e3def19c977,regimen,0.593286
uuid-ca04bd7630504a4089e13e3def19c977,treated,0.412123
uuid-ca04bd7630504a4089e13e3def19c977,RCC,0.473068
uuid-ca04bd7630504a4089e13e3def19c977,combination,0.322924
uuid-ca04bd7630504a4089e13e3def19c977,chemo,0.412239
uuid-ca04bd7630504a4089e13e3def19c977,2L,0.542731
uuid-ca04bd7630504a4089e13e3def19c977,pts,0.454837
uuid-ca04bd7630504a4089e13e3def19c977,approval,0.323053
uuid-ca04bd7630504a4089e13e3def19c977,preferred,0.502678
uuid-ca04bd7630504a4089e13e3def19c977,monotherapy,0.617219
uuid-ca04bd7630504a4089e13e3def19c977,treatment,0.574591
uuid-ca04bd7630504a4089e13e3def19c977,using nivo,0.542516
uuid-ca04bd7630504a4089e13e3def19c977,combo,0.343815
uuid-ca04bd7630504a4089e13e3def19c977,PD1,0.38481
uuid-ca04bd7630504a4089e13e3def19c977,approved,0.385687
uuid-ca04bd7630504a4089e13e3def19c977,progression,0.507777
uuid-ca04bd7630504a4089e13e3def19c977,chemotherapy,0.427888
uuid-ca04bd7630504a4089e13e3def19c977,respond,0.320643
uuid-ca04bd7630504a4089e13e3def19c977,RTL stated,0.475166
uuid-ca04bd7630504a4089e13e3def19c977,TL shared,0.37835
uuid-ca04bd7630504a4089e13e3def19c977,option,0.537096
uuid-5ce667fef0c84491b6751c8ef12a6d7f,lung,0.490075
uuid-5ce667fef0c84491b6751c8ef12a6d7f,melanoma,0.381237
uuid-5ce667fef0c84491b6751c8ef12a6d7f,RCC,0.353098
uuid-5ce667fef0c84491b6751c8ef12a6d7f,TL stated,0.32879
uuid-5ce667fef0c84491b6751c8ef12a6d7f,SCCHN,0.376287
uuid-5ce667fef0c84491b6751c8ef12a6d7f,TLs,0.398323
uuid-5ce667fef0c84491b6751c8ef12a6d7f,academic,0.40143
uuid-5ce667fef0c84491b6751c8ef12a6d7f,feels,0.414623
uuid-5ce667fef0c84491b6751c8ef12a6d7f,RTL stated,0.34818
uuid-5ce667fef0c84491b6751c8ef12a6d7f,TL shared,0.37741
uuid-1cb9e089e5fa4683b785a5c5515b1f6c,lung,0.541636
uuid-1cb9e089e5fa4683b785a5c5515b1f6c,melanoma,0.325736
uuid-1cb9e089e5fa4683b785a5c5515b1f6c,TL stated,0.522892
uuid-1cb9e089e5fa4683b785a5c5515b1f6c,PDL1 testing,0.402722
uuid-1cb9e089e5fa4683b785a5c5515b1f6c,AI,0.377193
uuid-1cb9e089e5fa4683b785a5c5515b1f6c,TLs,0.305038
uuid-1cb9e089e5fa4683b785a5c5515b1f6c,PD-1,0.392627
uuid-1cb9e089e5fa4683b785a5c5515b1f6c,biomarker,0.307287
uuid-519920cefd3d4c27801800e171cdc28c,TL,0.390213
uuid-519920cefd3d4c27801800e171cdc28c,RTL,0.397565
uuid-519920cefd3d4c27801800e171cdc28c,lung,0.465532
uuid-519920cefd3d4c27801800e171cdc28c,NTL,0.500001
uuid-519920cefd3d4c27801800e171cdc28c,melanoma,0.39132
uuid-519920cefd3d4c27801800e171cdc28c,shared,0.368898
uuid-519920cefd3d4c27801800e171cdc28c,commented,0.367568
uuid-519920cefd3d4c27801800e171cdc28c,RCC,0.463511
uuid-519920cefd3d4c27801800e171cdc28c,TL stated,0.315003
uuid-519920cefd3d4c27801800e171cdc28c,oncology,0.301882
uuid-519920cefd3d4c27801800e171cdc28c,SCCHN,0.490606
uuid-519920cefd3d4c27801800e171cdc28c,ASCO,0.40974
uuid-519920cefd3d4c27801800e171cdc28c,oncologist,0.395473
uuid-519920cefd3d4c27801800e171cdc28c,TLs,0.363981
uuid-519920cefd3d4c27801800e171cdc28c,academic,0.362416
uuid-519920cefd3d4c27801800e171cdc28c,Regional TL,0.617964
uuid-519920cefd3d4c27801800e171cdc28c,RTL stated,0.359487
uuid-519920cefd3d4c27801800e171cdc28c,TL shared,0.437916
uuid-519920cefd3d4c27801800e171cdc28c,bladder,0.396946
uuid-478b68f7073f499f975a62eab7c93331,pembro,0.354428
uuid-478b68f7073f499f975a62eab7c93331,RTL,0.419144
uuid-478b68f7073f499f975a62eab7c93331,BMS,0.369242
uuid-478b68f7073f499f975a62eab7c93331,lung,0.357171
uuid-478b68f7073f499f975a62eab7c93331,trial,0.690306
uuid-478b68f7073f499f975a62eab7c93331,efficacy,0.305383
uuid-478b68f7073f499f975a62eab7c93331,discussed,0.324829
uuid-478b68f7073f499f975a62eab7c93331,melanoma,0.323052
uuid-478b68f7073f499f975a62eab7c93331,commented,0.406041
uuid-478b68f7073f499f975a62eab7c93331,Merck,0.377091
uuid-478b68f7073f499f975a62eab7c93331,OS,0.366659
uuid-478b68f7073f499f975a62eab7c93331,regards,0.378578
uuid-478b68f7073f499f975a62eab7c93331,data,0.493775
uuid-478b68f7073f499f975a62eab7c93331,expressed,0.350224
uuid-478b68f7073f499f975a62eab7c93331,clinical trials,0.34484
uuid-478b68f7073f499f975a62eab7c93331,PFS,0.354137
uuid-478b68f7073f499f975a62eab7c93331,ORR,0.38258
uuid-478b68f7073f499f975a62eab7c93331,SCCHN,0.365164
uuid-478b68f7073f499f975a62eab7c93331,nivo and pembro,0.325664
uuid-478b68f7073f499f975a62eab7c93331,impressed,0.476379
uuid-478b68f7073f499f975a62eab7c93331,TLs,0.452258
uuid-478b68f7073f499f975a62eab7c93331,academic,0.324174
uuid-478b68f7073f499f975a62eab7c93331,Regional TL,0.314649
uuid-478b68f7073f499f975a62eab7c93331,bladder,0.319397
uuid-009956d761a94c928634d279f7513842,patients,0.833475
uuid-009956d761a94c928634d279f7513842,Opdivo,0.394548
uuid-009956d761a94c928634d279f7513842,therapy,0.563562
uuid-009956d761a94c928634d279f7513842,nivolumab,0.494522
uuid-009956d761a94c928634d279f7513842,regimen,0.474826
uuid-009956d761a94c928634d279f7513842,treated,0.624891
uuid-009956d761a94c928634d279f7513842,pts,0.487825
uuid-009956d761a94c928634d279f7513842,treatment,0.621476
uuid-009956d761a94c928634d279f7513842,cHL,0.365208
uuid-009956d761a94c928634d279f7513842,progression,0.550977
uuid-009956d761a94c928634d279f7513842,chemotherapy,0.33403
uuid-009956d761a94c928634d279f7513842,respond,0.35262
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,Nivo,0.583751
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,pembro,0.476487
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,therapy,0.320576
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,nivolumab,0.332273
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,1L,0.69166
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,regimen,0.404426
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,RCC,0.376947
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,combination,0.504742
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,chemo,0.565717
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,2L,0.780375
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,pts,0.352128
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,agents,0.579038
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,Ipi,0.393594
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,atezo,0.540555
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,preferred,0.63523
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,monotherapy,0.769761
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,using nivo,0.555942
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,combo,0.61368
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,PD1,0.54048
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,approved,0.409847
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,nivo and pembro,0.354764
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,believes,0.484836
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,chemotherapy,0.408559
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,feels,0.359838
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,RTL stated,0.353415
uuid-51379fcc0dae4bd1a6cccddb3295dcc3,option,0.658848
uuid-37a5606f053945fda65b694e3f615333,pembro,0.387667
uuid-37a5606f053945fda65b694e3f615333,RTL,0.380132
uuid-37a5606f053945fda65b694e3f615333,lung,0.389718
uuid-37a5606f053945fda65b694e3f615333,1L,0.436998
uuid-37a5606f053945fda65b694e3f615333,commented,0.411464
uuid-37a5606f053945fda65b694e3f615333,RCC,0.584318
uuid-37a5606f053945fda65b694e3f615333,TL stated,0.404206
uuid-37a5606f053945fda65b694e3f615333,2L,0.457286
uuid-37a5606f053945fda65b694e3f615333,stated,0.493493
uuid-37a5606f053945fda65b694e3f615333,approval,0.405231
uuid-37a5606f053945fda65b694e3f615333,atezo,0.383577
uuid-37a5606f053945fda65b694e3f615333,preferred,0.315996
uuid-37a5606f053945fda65b694e3f615333,using nivo,0.457082
uuid-37a5606f053945fda65b694e3f615333,data,0.517038
uuid-37a5606f053945fda65b694e3f615333,expressed,0.321747
uuid-37a5606f053945fda65b694e3f615333,clinical trials,0.303409
uuid-37a5606f053945fda65b694e3f615333,indication,0.354057
uuid-37a5606f053945fda65b694e3f615333,approved,0.428205
uuid-37a5606f053945fda65b694e3f615333,SCCHN,0.546564
uuid-37a5606f053945fda65b694e3f615333,nivo and pembro,0.324931
uuid-37a5606f053945fda65b694e3f615333,impressed,0.500197
uuid-37a5606f053945fda65b694e3f615333,LTL,0.37165
uuid-37a5606f053945fda65b694e3f615333,TLs,0.47509
uuid-37a5606f053945fda65b694e3f615333,SCLC,0.381689
uuid-37a5606f053945fda65b694e3f615333,Regional TL,0.492662
uuid-37a5606f053945fda65b694e3f615333,RTL stated,0.483891
uuid-37a5606f053945fda65b694e3f615333,TL shared,0.348268
uuid-37a5606f053945fda65b694e3f615333,bladder,0.439099
uuid-4fd70c6b1e3f449893f5d96ee829830d,Nivo,0.45942
uuid-4fd70c6b1e3f449893f5d96ee829830d,PDL1,0.366106
uuid-4fd70c6b1e3f449893f5d96ee829830d,efficacy,0.441057
uuid-4fd70c6b1e3f449893f5d96ee829830d,chemo,0.302385
uuid-4fd70c6b1e3f449893f5d96ee829830d,OS,0.734497
uuid-4fd70c6b1e3f449893f5d96ee829830d,data,0.480358
uuid-4fd70c6b1e3f449893f5d96ee829830d,PFS,0.646213
uuid-4fd70c6b1e3f449893f5d96ee829830d,ORR,0.629592
uuid-4fd70c6b1e3f449893f5d96ee829830d,nivo and pembro,0.431381
uuid-4fd70c6b1e3f449893f5d96ee829830d,impressed,0.473833
uuid-4fd70c6b1e3f449893f5d96ee829830d,PDL1 expression,0.302549
uuid-ef6d14edfb0e4d4db131994d2feef21e,patients,0.561908
uuid-ef6d14edfb0e4d4db131994d2feef21e,lung,0.33128
uuid-ef6d14edfb0e4d4db131994d2feef21e,regimen,0.42016
uuid-ef6d14edfb0e4d4db131994d2feef21e,treated,0.548332
uuid-ef6d14edfb0e4d4db131994d2feef21e,melanoma,0.425681
uuid-ef6d14edfb0e4d4db131994d2feef21e,RCC,0.418661
uuid-ef6d14edfb0e4d4db131994d2feef21e,tumor,0.443878
uuid-ef6d14edfb0e4d4db131994d2feef21e,pts,0.48428
uuid-ef6d14edfb0e4d4db131994d2feef21e,treatment,0.505067
uuid-ef6d14edfb0e4d4db131994d2feef21e,response,0.309156
uuid-ef6d14edfb0e4d4db131994d2feef21e,progression,0.456512
uuid-ef6d14edfb0e4d4db131994d2feef21e,respond,0.31463
uuid-ef6d14edfb0e4d4db131994d2feef21e,TL shared,0.476581
uuid-e960524311a644dc8ccf3de1487c8d78,Nivo,0.483896
uuid-e960524311a644dc8ccf3de1487c8d78,pembro,0.544016
uuid-e960524311a644dc8ccf3de1487c8d78,1L,0.823006
uuid-e960524311a644dc8ccf3de1487c8d78,RCC,0.53046
uuid-e960524311a644dc8ccf3de1487c8d78,TL stated,0.300905
uuid-e960524311a644dc8ccf3de1487c8d78,combination,0.365167
uuid-e960524311a644dc8ccf3de1487c8d78,chemo,0.435157
uuid-e960524311a644dc8ccf3de1487c8d78,2L,0.792621
uuid-e960524311a644dc8ccf3de1487c8d78,pts,0.324649
uuid-e960524311a644dc8ccf3de1487c8d78,agents,0.472357
uuid-e960524311a644dc8ccf3de1487c8d78,approval,0.411823
uuid-e960524311a644dc8ccf3de1487c8d78,atezo,0.524792
uuid-e960524311a644dc8ccf3de1487c8d78,preferred,0.639343
uuid-e960524311a644dc8ccf3de1487c8d78,monotherapy,0.689537
uuid-e960524311a644dc8ccf3de1487c8d78,using nivo,0.631345
uuid-e960524311a644dc8ccf3de1487c8d78,combo,0.498625
uuid-e960524311a644dc8ccf3de1487c8d78,PD1,0.395367
uuid-e960524311a644dc8ccf3de1487c8d78,approved,0.566743
uuid-e960524311a644dc8ccf3de1487c8d78,SCCHN,0.349473
uuid-e960524311a644dc8ccf3de1487c8d78,nivo and pembro,0.35657
uuid-e960524311a644dc8ccf3de1487c8d78,believes,0.414432
uuid-e960524311a644dc8ccf3de1487c8d78,tumor types,0.309634
uuid-e960524311a644dc8ccf3de1487c8d78,feels,0.401784
uuid-e960524311a644dc8ccf3de1487c8d78,RTL stated,0.504191
uuid-e960524311a644dc8ccf3de1487c8d78,option,0.673514
uuid-e960524311a644dc8ccf3de1487c8d78,bladder,0.361331
uuid-3ecc0c3b574c44aeaf0dbd5b329da415,BMS,0.542028
uuid-3ecc0c3b574c44aeaf0dbd5b329da415,trial,0.36457
uuid-3ecc0c3b574c44aeaf0dbd5b329da415,NTL,0.426525
uuid-3ecc0c3b574c44aeaf0dbd5b329da415,shared,0.314631
uuid-3ecc0c3b574c44aeaf0dbd5b329da415,commented,0.344943
uuid-3ecc0c3b574c44aeaf0dbd5b329da415,Merck,0.45539
uuid-3ecc0c3b574c44aeaf0dbd5b329da415,regards,0.339648
uuid-3ecc0c3b574c44aeaf0dbd5b329da415,data,0.323992
uuid-3ecc0c3b574c44aeaf0dbd5b329da415,expressed,0.358047
uuid-3ecc0c3b574c44aeaf0dbd5b329da415,clinical trials,0.316655
uuid-3ecc0c3b574c44aeaf0dbd5b329da415,TLs,0.382649
uuid-7687168c0f0d472b906ea1ed87cbba58,TL,0.420944
uuid-7687168c0f0d472b906ea1ed87cbba58,pembro,0.413803
uuid-7687168c0f0d472b906ea1ed87cbba58,1L,0.454103
uuid-7687168c0f0d472b906ea1ed87cbba58,PDL1,0.338219
uuid-7687168c0f0d472b906ea1ed87cbba58,RCC,0.330127
uuid-7687168c0f0d472b906ea1ed87cbba58,TL stated,0.431241
uuid-7687168c0f0d472b906ea1ed87cbba58,2L,0.437269
uuid-7687168c0f0d472b906ea1ed87cbba58,Merck,0.379131
uuid-7687168c0f0d472b906ea1ed87cbba58,institution,0.398871
uuid-7687168c0f0d472b906ea1ed87cbba58,PD-L1,0.69448
uuid-7687168c0f0d472b906ea1ed87cbba58,approval,0.415238
uuid-7687168c0f0d472b906ea1ed87cbba58,atezo,0.499497
uuid-7687168c0f0d472b906ea1ed87cbba58,preferred,0.406835
uuid-7687168c0f0d472b906ea1ed87cbba58,PD-L1 testing,0.652396
uuid-7687168c0f0d472b906ea1ed87cbba58,testing,0.725013
uuid-7687168c0f0d472b906ea1ed87cbba58,PDL1 testing,0.677447
uuid-7687168c0f0d472b906ea1ed87cbba58,NSCLC patients,0.623011
uuid-7687168c0f0d472b906ea1ed87cbba58,approved,0.346197
uuid-7687168c0f0d472b906ea1ed87cbba58,assay,0.622379
uuid-7687168c0f0d472b906ea1ed87cbba58,PD-1,0.306849
uuid-7687168c0f0d472b906ea1ed87cbba58,RTL stated,0.323855
uuid-c82cafabb4354dd4bea11427e69656ff,TL,0.498949
uuid-c82cafabb4354dd4bea11427e69656ff,lung,0.309779
uuid-c82cafabb4354dd4bea11427e69656ff,NSCLC,0.413086
uuid-c82cafabb4354dd4bea11427e69656ff,shared,0.384051
uuid-c82cafabb4354dd4bea11427e69656ff,RCC,0.302626
uuid-c82cafabb4354dd4bea11427e69656ff,TL stated,0.481482
uuid-c82cafabb4354dd4bea11427e69656ff,Merck,0.319099
uuid-c82cafabb4354dd4bea11427e69656ff,institution,0.561374
uuid-c82cafabb4354dd4bea11427e69656ff,PD-L1,0.563504
uuid-c82cafabb4354dd4bea11427e69656ff,approval,0.371284
uuid-c82cafabb4354dd4bea11427e69656ff,PD-L1 testing,0.696726
uuid-c82cafabb4354dd4bea11427e69656ff,testing,0.68365
uuid-c82cafabb4354dd4bea11427e69656ff,PDL1 testing,0.660802
uuid-c82cafabb4354dd4bea11427e69656ff,NSCLC patients,0.567217
uuid-c82cafabb4354dd4bea11427e69656ff,SCCHN,0.382437
uuid-c82cafabb4354dd4bea11427e69656ff,academic,0.356681
uuid-c82cafabb4354dd4bea11427e69656ff,assay,0.531671
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,RTL,0.508526
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,BMS,0.56959
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,lung,0.360269
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,trial,0.422586
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,NTL,0.38175
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,shared,0.365829
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,commented,0.593279
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,TL stated,0.34318
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,Merck,0.440812
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,stated,0.596192
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,OS,0.335087
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,regards,0.397726
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,data,0.585811
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,expressed,0.511441
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,mentioned,0.302806
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,ORR,0.30813
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,SCCHN,0.351783
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,ASCO,0.345561
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,impressed,0.60405
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,LTL,0.44547
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,TLs,0.487963
uuid-9ba8b2e6eaf74d89909f20bcd4d95ef4,Regional TL,0.494381
uuid-05f377a04f67488cbf8a2761d421d2d0,Nivo,0.497749
uuid-05f377a04f67488cbf8a2761d421d2d0,pembro,0.383285
uuid-05f377a04f67488cbf8a2761d421d2d0,BMS,0.318025
uuid-05f377a04f67488cbf8a2761d421d2d0,trial,0.453191
uuid-05f377a04f67488cbf8a2761d421d2d0,efficacy,0.50281
uuid-05f377a04f67488cbf8a2761d421d2d0,combination,0.377144
uuid-05f377a04f67488cbf8a2761d421d2d0,chemo,0.322419
uuid-05f377a04f67488cbf8a2761d421d2d0,agents,0.33825
uuid-05f377a04f67488cbf8a2761d421d2d0,Ipi,0.326752
uuid-05f377a04f67488cbf8a2761d421d2d0,OS,0.484898
uuid-05f377a04f67488cbf8a2761d421d2d0,atezo,0.331998
uuid-05f377a04f67488cbf8a2761d421d2d0,monotherapy,0.323342
uuid-05f377a04f67488cbf8a2761d421d2d0,data,0.641528
uuid-05f377a04f67488cbf8a2761d421d2d0,combo,0.409478
uuid-05f377a04f67488cbf8a2761d421d2d0,PFS,0.42842
uuid-05f377a04f67488cbf8a2761d421d2d0,ORR,0.503406
uuid-05f377a04f67488cbf8a2761d421d2d0,nivo and pembro,0.472167
uuid-05f377a04f67488cbf8a2761d421d2d0,believes,0.43797
uuid-05f377a04f67488cbf8a2761d421d2d0,impressed,0.539315
uuid-05f377a04f67488cbf8a2761d421d2d0,vs,0.303883
uuid-05f377a04f67488cbf8a2761d421d2d0,feels,0.579572
uuid-a50ff534902d44e285e44df2ed1ffb5a,PDL1,0.387957
uuid-a50ff534902d44e285e44df2ed1ffb5a,data,0.333914
uuid-a50ff534902d44e285e44df2ed1ffb5a,biomarker,0.468251
uuid-8c421272a6c44c1d8e904e134b03fc4c,patients,0.332161
uuid-8c421272a6c44c1d8e904e134b03fc4c,Opdivo,0.565675
uuid-8c421272a6c44c1d8e904e134b03fc4c,nivolumab,0.314109
uuid-8c421272a6c44c1d8e904e134b03fc4c,1L,0.320772
uuid-8c421272a6c44c1d8e904e134b03fc4c,regimen,0.377498
uuid-8c421272a6c44c1d8e904e134b03fc4c,treated,0.338155
uuid-8c421272a6c44c1d8e904e134b03fc4c,RCC,0.347298
uuid-8c421272a6c44c1d8e904e134b03fc4c,2L,0.505389
uuid-8c421272a6c44c1d8e904e134b03fc4c,agents,0.31102
uuid-8c421272a6c44c1d8e904e134b03fc4c,approval,0.302225
uuid-8c421272a6c44c1d8e904e134b03fc4c,physicians,0.39069
uuid-8c421272a6c44c1d8e904e134b03fc4c,preferred,0.597479
uuid-8c421272a6c44c1d8e904e134b03fc4c,monotherapy,0.407092
uuid-8c421272a6c44c1d8e904e134b03fc4c,treatment,0.348925
uuid-8c421272a6c44c1d8e904e134b03fc4c,using nivo,0.446152
uuid-8c421272a6c44c1d8e904e134b03fc4c,approved,0.460525
uuid-8c421272a6c44c1d8e904e134b03fc4c,Keytruda,0.30499
uuid-8c421272a6c44c1d8e904e134b03fc4c,RTL stated,0.383898
uuid-8c421272a6c44c1d8e904e134b03fc4c,option,0.435614
uuid-a0b2bfd35b8e4f769bf7a5f1b2dba30a,OS,0.66286
uuid-a0b2bfd35b8e4f769bf7a5f1b2dba30a,response,0.359913
uuid-a0b2bfd35b8e4f769bf7a5f1b2dba30a,PFS,0.641457
uuid-a0b2bfd35b8e4f769bf7a5f1b2dba30a,ORR,0.517431
uuid-a0b2bfd35b8e4f769bf7a5f1b2dba30a,progression,0.30894
uuid-a0b2bfd35b8e4f769bf7a5f1b2dba30a,impressed,0.356587
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,RTL,0.31855
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,BMS,0.519036
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,PDL1,0.428787
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,trial,0.439913
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,commented,0.525877
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,Merck,0.526027
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,stated,0.534425
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,OS,0.362192
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,regards,0.371038
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,data,0.752621
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,expressed,0.430688
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,indication,0.316606
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,PFS,0.324355
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,ORR,0.363303
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,SCCHN,0.352541
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,nivo and pembro,0.331361
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,ASCO,0.335734
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,impressed,0.536756
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,TLs,0.352056
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,Regional TL,0.391219
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,PDL1 expression,0.405313
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,NCCN,0.39041
uuid-eeb85314d78b48c2bfd9f9f222a6c6fb,bladder,0.327088
uuid-7cd2f99d8d11486ca81f779c40b6041c,BMS,0.429266
uuid-7cd2f99d8d11486ca81f779c40b6041c,commented,0.511033
uuid-7cd2f99d8d11486ca81f779c40b6041c,tumor,0.334985
uuid-7cd2f99d8d11486ca81f779c40b6041c,Merck,0.371034
uuid-7cd2f99d8d11486ca81f779c40b6041c,stated,0.331258
uuid-7cd2f99d8d11486ca81f779c40b6041c,regards,0.365343
uuid-7cd2f99d8d11486ca81f779c40b6041c,data,0.344159
uuid-7cd2f99d8d11486ca81f779c40b6041c,expressed,0.431634
uuid-7cd2f99d8d11486ca81f779c40b6041c,impressed,0.339964
uuid-7cd2f99d8d11486ca81f779c40b6041c,Regional TL,0.327773
uuid-7cd2f99d8d11486ca81f779c40b6041c,biomarker,0.337585
uuid-aeac9fe5fc454c84b65358fdb57904c2,treated,0.320063
uuid-aeac9fe5fc454c84b65358fdb57904c2,clinical trials,0.385529
uuid-aeac9fe5fc454c84b65358fdb57904c2,tumor types,0.393138
uuid-aeac9fe5fc454c84b65358fdb57904c2,feels,0.396661
uuid-142ef1b698e842a2bfe845bda42f272a,pembro,0.581318
uuid-142ef1b698e842a2bfe845bda42f272a,trial,0.536589
uuid-142ef1b698e842a2bfe845bda42f272a,Merck,0.364216
uuid-142ef1b698e842a2bfe845bda42f272a,approval,0.38418
uuid-142ef1b698e842a2bfe845bda42f272a,atezo,0.550235
uuid-142ef1b698e842a2bfe845bda42f272a,PD-L1 testing,0.322953
uuid-142ef1b698e842a2bfe845bda42f272a,testing,0.320807
uuid-142ef1b698e842a2bfe845bda42f272a,vs,0.376474
uuid-142ef1b698e842a2bfe845bda42f272a,assay,0.382277
uuid-142ef1b698e842a2bfe845bda42f272a,bladder,0.357161
uuid-82ab01068cf0467b8f8f53f2dae77cf0,BMS,0.323794
uuid-82ab01068cf0467b8f8f53f2dae77cf0,PDL1,0.399313
uuid-82ab01068cf0467b8f8f53f2dae77cf0,trial,0.477691
uuid-82ab01068cf0467b8f8f53f2dae77cf0,efficacy,0.631878
uuid-82ab01068cf0467b8f8f53f2dae77cf0,commented,0.305355
uuid-82ab01068cf0467b8f8f53f2dae77cf0,OS,0.854133
uuid-82ab01068cf0467b8f8f53f2dae77cf0,regards,0.301049
uuid-82ab01068cf0467b8f8f53f2dae77cf0,data,0.810512
uuid-82ab01068cf0467b8f8f53f2dae77cf0,PFS,0.854843
uuid-82ab01068cf0467b8f8f53f2dae77cf0,ORR,0.815562
uuid-82ab01068cf0467b8f8f53f2dae77cf0,nivo and pembro,0.433839
uuid-82ab01068cf0467b8f8f53f2dae77cf0,ASCO,0.376872
uuid-82ab01068cf0467b8f8f53f2dae77cf0,believes,0.32864
uuid-82ab01068cf0467b8f8f53f2dae77cf0,impressed,0.647215
uuid-82ab01068cf0467b8f8f53f2dae77cf0,feels,0.35426
uuid-82ab01068cf0467b8f8f53f2dae77cf0,PDL1 expression,0.360375
uuid-769236fd539a438cbb30b95ecfd9cd6d,Nivo,0.30305
uuid-769236fd539a438cbb30b95ecfd9cd6d,patients,0.371062
uuid-769236fd539a438cbb30b95ecfd9cd6d,therapy,0.548118
uuid-769236fd539a438cbb30b95ecfd9cd6d,nivolumab,0.400503
uuid-769236fd539a438cbb30b95ecfd9cd6d,1L,0.324415
uuid-769236fd539a438cbb30b95ecfd9cd6d,regimen,0.428319
uuid-769236fd539a438cbb30b95ecfd9cd6d,treated,0.331679
uuid-769236fd539a438cbb30b95ecfd9cd6d,combination,0.700525
uuid-769236fd539a438cbb30b95ecfd9cd6d,chemo,0.524788
uuid-769236fd539a438cbb30b95ecfd9cd6d,pts,0.428688
uuid-769236fd539a438cbb30b95ecfd9cd6d,IO,0.456808
uuid-769236fd539a438cbb30b95ecfd9cd6d,agents,0.387104
uuid-769236fd539a438cbb30b95ecfd9cd6d,monotherapy,0.585126
uuid-769236fd539a438cbb30b95ecfd9cd6d,treatment,0.390326
uuid-769236fd539a438cbb30b95ecfd9cd6d,response,0.370407
uuid-769236fd539a438cbb30b95ecfd9cd6d,combo,0.600957
uuid-769236fd539a438cbb30b95ecfd9cd6d,PD1,0.569427
uuid-769236fd539a438cbb30b95ecfd9cd6d,progression,0.440896
uuid-769236fd539a438cbb30b95ecfd9cd6d,believes,0.328833
uuid-769236fd539a438cbb30b95ecfd9cd6d,chemotherapy,0.620119
uuid-769236fd539a438cbb30b95ecfd9cd6d,feels,0.379602
uuid-769236fd539a438cbb30b95ecfd9cd6d,option,0.564762
uuid-ef424b1c7f6547958c958502433ed30d,Nivo,0.311722
uuid-ef424b1c7f6547958c958502433ed30d,pembro,0.308689
uuid-ef424b1c7f6547958c958502433ed30d,1L,0.401688
uuid-ef424b1c7f6547958c958502433ed30d,PDL1,0.531287
uuid-ef424b1c7f6547958c958502433ed30d,trial,0.388126
uuid-ef424b1c7f6547958c958502433ed30d,efficacy,0.48569
uuid-ef424b1c7f6547958c958502433ed30d,chemo,0.347772
uuid-ef424b1c7f6547958c958502433ed30d,OS,0.747082
uuid-ef424b1c7f6547958c958502433ed30d,data,0.550307
uuid-ef424b1c7f6547958c958502433ed30d,PFS,0.713102
uuid-ef424b1c7f6547958c958502433ed30d,ORR,0.664701
uuid-ef424b1c7f6547958c958502433ed30d,nivo and pembro,0.469417
uuid-ef424b1c7f6547958c958502433ed30d,believes,0.445812
uuid-ef424b1c7f6547958c958502433ed30d,impressed,0.507735
uuid-ef424b1c7f6547958c958502433ed30d,feels,0.449934
uuid-ef424b1c7f6547958c958502433ed30d,PDL1 expression,0.45418
uuid-5b5756b3858a4a09bbdb74d03032ba3b,Nivo,0.499297
uuid-5b5756b3858a4a09bbdb74d03032ba3b,patients,0.420755
uuid-5b5756b3858a4a09bbdb74d03032ba3b,pembro,0.531561
uuid-5b5756b3858a4a09bbdb74d03032ba3b,therapy,0.388651
uuid-5b5756b3858a4a09bbdb74d03032ba3b,1L,0.414557
uuid-5b5756b3858a4a09bbdb74d03032ba3b,chemo,0.383488
uuid-5b5756b3858a4a09bbdb74d03032ba3b,2L,0.333828
uuid-5b5756b3858a4a09bbdb74d03032ba3b,pts,0.382899
uuid-5b5756b3858a4a09bbdb74d03032ba3b,approval,0.488715
uuid-5b5756b3858a4a09bbdb74d03032ba3b,atezo,0.322466
uuid-5b5756b3858a4a09bbdb74d03032ba3b,monotherapy,0.352217
uuid-5b5756b3858a4a09bbdb74d03032ba3b,using nivo,0.359288
uuid-5b5756b3858a4a09bbdb74d03032ba3b,PD1,0.324146
uuid-5b5756b3858a4a09bbdb74d03032ba3b,approved,0.364767
uuid-5b5756b3858a4a09bbdb74d03032ba3b,chemotherapy,0.340478
uuid-5b5756b3858a4a09bbdb74d03032ba3b,option,0.368531
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,Nivo,0.487941
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,patients,0.723918
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,therapy,0.523589
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,nivolumab,0.317833
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,1L,0.336154
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,regimen,0.480709
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,treated,0.399266
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,chemo,0.658158
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,2L,0.306267
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,pts,0.526504
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,preferred,0.3308
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,monotherapy,0.521077
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,treatment,0.493814
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,using nivo,0.316185
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,response,0.334104
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,PD1,0.349404
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,progression,0.487439
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,chemotherapy,0.645722
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,respond,0.352442
uuid-7eaaddc41ff0410c9e3873cbd226ee6e,option,0.494123
uuid-629d453f35ee45b0a6f45625ec3df234,Nivo,0.504589
uuid-629d453f35ee45b0a6f45625ec3df234,pembro,0.705327
uuid-629d453f35ee45b0a6f45625ec3df234,1L,0.313946
uuid-629d453f35ee45b0a6f45625ec3df234,trial,0.42784
uuid-629d453f35ee45b0a6f45625ec3df234,2L,0.316851
uuid-629d453f35ee45b0a6f45625ec3df234,Ipi,0.30098
uuid-629d453f35ee45b0a6f45625ec3df234,PD-L1,0.305159
uuid-629d453f35ee45b0a6f45625ec3df234,approval,0.433712
uuid-629d453f35ee45b0a6f45625ec3df234,atezo,0.596232
uuid-629d453f35ee45b0a6f45625ec3df234,using nivo,0.374813
uuid-629d453f35ee45b0a6f45625ec3df234,nivo and pembro,0.371115
uuid-629d453f35ee45b0a6f45625ec3df234,vs,0.380187
uuid-629d453f35ee45b0a6f45625ec3df234,assay,0.414765
uuid-00b80ad03d4f4fe7877d146d016e125d,patients,0.708167
uuid-00b80ad03d4f4fe7877d146d016e125d,Opdivo,0.413091
uuid-00b80ad03d4f4fe7877d146d016e125d,therapy,0.306333
uuid-00b80ad03d4f4fe7877d146d016e125d,dose,0.428657
uuid-00b80ad03d4f4fe7877d146d016e125d,nivolumab,0.310003
uuid-00b80ad03d4f4fe7877d146d016e125d,toxicity,0.50574
uuid-00b80ad03d4f4fe7877d146d016e125d,regimen,0.528109
uuid-00b80ad03d4f4fe7877d146d016e125d,treated,0.523861
uuid-00b80ad03d4f4fe7877d146d016e125d,pts,0.342457
uuid-00b80ad03d4f4fe7877d146d016e125d,treatment,0.629971
uuid-00b80ad03d4f4fe7877d146d016e125d,progression,0.48513
uuid-00b80ad03d4f4fe7877d146d016e125d,respond,0.49146
uuid-3c6cf1d40d18452ca27dec519c8224c9,patients,0.713819
uuid-3c6cf1d40d18452ca27dec519c8224c9,Opdivo,0.418339
uuid-3c6cf1d40d18452ca27dec519c8224c9,therapy,0.583259
uuid-3c6cf1d40d18452ca27dec519c8224c9,nivolumab,0.380323
uuid-3c6cf1d40d18452ca27dec519c8224c9,regimen,0.608473
uuid-3c6cf1d40d18452ca27dec519c8224c9,treated,0.492872
uuid-3c6cf1d40d18452ca27dec519c8224c9,chemo,0.385018
uuid-3c6cf1d40d18452ca27dec519c8224c9,pts,0.469848
uuid-3c6cf1d40d18452ca27dec519c8224c9,IO,0.333351
uuid-3c6cf1d40d18452ca27dec519c8224c9,monotherapy,0.344083
uuid-3c6cf1d40d18452ca27dec519c8224c9,treatment,0.816936
uuid-3c6cf1d40d18452ca27dec519c8224c9,response,0.574745
uuid-3c6cf1d40d18452ca27dec519c8224c9,PD1,0.335716
uuid-3c6cf1d40d18452ca27dec519c8224c9,progression,0.756605
uuid-3c6cf1d40d18452ca27dec519c8224c9,chemotherapy,0.441919
uuid-3c6cf1d40d18452ca27dec519c8224c9,respond,0.561144
uuid-3c6cf1d40d18452ca27dec519c8224c9,option,0.321131
uuid-6a8945d42f55407da3323155bd95600e,TL,0.55297
uuid-6a8945d42f55407da3323155bd95600e,lung,0.402914
uuid-6a8945d42f55407da3323155bd95600e,PDL1,0.379642
uuid-6a8945d42f55407da3323155bd95600e,TL stated,0.533843
uuid-6a8945d42f55407da3323155bd95600e,Merck,0.307415
uuid-6a8945d42f55407da3323155bd95600e,institution,0.376644
uuid-6a8945d42f55407da3323155bd95600e,PD-L1,0.664001
uuid-6a8945d42f55407da3323155bd95600e,PD-L1 testing,0.714881
uuid-6a8945d42f55407da3323155bd95600e,testing,0.744671
uuid-6a8945d42f55407da3323155bd95600e,PDL1 testing,0.705613
uuid-6a8945d42f55407da3323155bd95600e,NSCLC patients,0.439327
uuid-6a8945d42f55407da3323155bd95600e,assay,0.685129
uuid-6a8945d42f55407da3323155bd95600e,biomarker,0.489094
uuid-78ca4d09ed704419ac81d4912d7b0161,1L,0.579243
uuid-78ca4d09ed704419ac81d4912d7b0161,PDL1,0.564112
uuid-78ca4d09ed704419ac81d4912d7b0161,TL stated,0.367127
uuid-78ca4d09ed704419ac81d4912d7b0161,2L,0.416707
uuid-78ca4d09ed704419ac81d4912d7b0161,PD-L1,0.669701
uuid-78ca4d09ed704419ac81d4912d7b0161,preferred,0.304798
uuid-78ca4d09ed704419ac81d4912d7b0161,PD-L1 testing,0.555616
uuid-78ca4d09ed704419ac81d4912d7b0161,testing,0.71066
uuid-78ca4d09ed704419ac81d4912d7b0161,PDL1 testing,0.678721
uuid-78ca4d09ed704419ac81d4912d7b0161,NSCLC patients,0.652335
uuid-78ca4d09ed704419ac81d4912d7b0161,tumor types,0.350061
uuid-78ca4d09ed704419ac81d4912d7b0161,assay,0.3098
uuid-78ca4d09ed704419ac81d4912d7b0161,PD-1,0.304677
uuid-78ca4d09ed704419ac81d4912d7b0161,PDL1 expression,0.36098
uuid-78ca4d09ed704419ac81d4912d7b0161,option,0.419158
uuid-78ca4d09ed704419ac81d4912d7b0161,biomarker,0.52056
uuid-6c7cece902ed4669bc457a8ae80a2931,patients,0.369144
uuid-6c7cece902ed4669bc457a8ae80a2931,PDL1,0.31089
uuid-6c7cece902ed4669bc457a8ae80a2931,PD-L1,0.5978
uuid-6c7cece902ed4669bc457a8ae80a2931,PD-L1 testing,0.676524
uuid-6c7cece902ed4669bc457a8ae80a2931,testing,0.72999
uuid-6c7cece902ed4669bc457a8ae80a2931,PDL1 testing,0.631971
uuid-6c7cece902ed4669bc457a8ae80a2931,NSCLC patients,0.575859
uuid-6c7cece902ed4669bc457a8ae80a2931,assay,0.335004
uuid-6c7cece902ed4669bc457a8ae80a2931,biomarker,0.411125
uuid-604b45a46abd4aeeaab8ddabdb6286e3,Nivo,0.35138
uuid-604b45a46abd4aeeaab8ddabdb6286e3,patients,0.525874
uuid-604b45a46abd4aeeaab8ddabdb6286e3,pembro,0.483733
uuid-604b45a46abd4aeeaab8ddabdb6286e3,therapy,0.329149
uuid-604b45a46abd4aeeaab8ddabdb6286e3,1L,0.603063
uuid-604b45a46abd4aeeaab8ddabdb6286e3,PDL1,0.397715
uuid-604b45a46abd4aeeaab8ddabdb6286e3,chemo,0.50994
uuid-604b45a46abd4aeeaab8ddabdb6286e3,2L,0.473955
uuid-604b45a46abd4aeeaab8ddabdb6286e3,pts,0.475102
uuid-604b45a46abd4aeeaab8ddabdb6286e3,atezo,0.352885
uuid-604b45a46abd4aeeaab8ddabdb6286e3,preferred,0.377983
uuid-604b45a46abd4aeeaab8ddabdb6286e3,monotherapy,0.524907
uuid-604b45a46abd4aeeaab8ddabdb6286e3,combo,0.353382
uuid-604b45a46abd4aeeaab8ddabdb6286e3,clinical trials,0.336042
uuid-604b45a46abd4aeeaab8ddabdb6286e3,NSCLC patients,0.383676
uuid-604b45a46abd4aeeaab8ddabdb6286e3,PD1,0.313313
uuid-604b45a46abd4aeeaab8ddabdb6286e3,approved,0.373773
uuid-604b45a46abd4aeeaab8ddabdb6286e3,chemotherapy,0.494402
uuid-604b45a46abd4aeeaab8ddabdb6286e3,feels,0.316739
uuid-604b45a46abd4aeeaab8ddabdb6286e3,PDL1 expression,0.361345
uuid-604b45a46abd4aeeaab8ddabdb6286e3,option,0.586841
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,pembro,0.46488
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,1L,0.43924
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,2L,0.410245
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,agents,0.344137
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,Merck,0.306808
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,approval,0.348325
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,atezo,0.464532
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,preferred,0.457743
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,using nivo,0.338187
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,clinical trials,0.48253
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,indication,0.402005
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,approved,0.529468
uuid-a84864c38ff14d97b2d3c27a2b3dbda8,option,0.328205
uuid-f8973311ff75425fac08b06e5c9e5118,Nivo,0.350572
uuid-f8973311ff75425fac08b06e5c9e5118,patients,0.695499
uuid-f8973311ff75425fac08b06e5c9e5118,therapy,0.612024
uuid-f8973311ff75425fac08b06e5c9e5118,toxicity,0.304908
uuid-f8973311ff75425fac08b06e5c9e5118,regimen,0.392417
uuid-f8973311ff75425fac08b06e5c9e5118,treated,0.304721
uuid-f8973311ff75425fac08b06e5c9e5118,chemo,0.603787
uuid-f8973311ff75425fac08b06e5c9e5118,pts,0.524122
uuid-f8973311ff75425fac08b06e5c9e5118,monotherapy,0.419808
uuid-f8973311ff75425fac08b06e5c9e5118,treatment,0.566953
uuid-f8973311ff75425fac08b06e5c9e5118,response,0.437238
uuid-f8973311ff75425fac08b06e5c9e5118,PD1,0.367831
uuid-f8973311ff75425fac08b06e5c9e5118,progression,0.566905
uuid-f8973311ff75425fac08b06e5c9e5118,chemotherapy,0.625055
uuid-f8973311ff75425fac08b06e5c9e5118,respond,0.477929
uuid-f8973311ff75425fac08b06e5c9e5118,option,0.436784
uuid-2d61d01b2d614c32becf5b48c074513e,Nivo,0.404816
uuid-2d61d01b2d614c32becf5b48c074513e,pembro,0.490187
uuid-2d61d01b2d614c32becf5b48c074513e,1L,0.345449
uuid-2d61d01b2d614c32becf5b48c074513e,PDL1,0.484366
uuid-2d61d01b2d614c32becf5b48c074513e,trial,0.577792
uuid-2d61d01b2d614c32becf5b48c074513e,efficacy,0.627026
uuid-2d61d01b2d614c32becf5b48c074513e,chemo,0.342984
uuid-2d61d01b2d614c32becf5b48c074513e,OS,0.508345
uuid-2d61d01b2d614c32becf5b48c074513e,atezo,0.401856
uuid-2d61d01b2d614c32becf5b48c074513e,data,0.545855
uuid-2d61d01b2d614c32becf5b48c074513e,indication,0.352855
uuid-2d61d01b2d614c32becf5b48c074513e,PFS,0.507297
uuid-2d61d01b2d614c32becf5b48c074513e,ORR,0.531791
uuid-2d61d01b2d614c32becf5b48c074513e,nivo and pembro,0.486955
uuid-2d61d01b2d614c32becf5b48c074513e,believes,0.421019
uuid-2d61d01b2d614c32becf5b48c074513e,chemotherapy,0.380269
uuid-2d61d01b2d614c32becf5b48c074513e,impressed,0.349186
uuid-2d61d01b2d614c32becf5b48c074513e,vs,0.314325
uuid-2d61d01b2d614c32becf5b48c074513e,feels,0.409509
uuid-2d61d01b2d614c32becf5b48c074513e,PDL1 expression,0.466253
uuid-2d61d01b2d614c32becf5b48c074513e,option,0.324965
uuid-2ce9a61dcfc14527b6be811b8afbdbac,pembro,0.431654
uuid-2ce9a61dcfc14527b6be811b8afbdbac,1L,0.467587
uuid-2ce9a61dcfc14527b6be811b8afbdbac,PDL1,0.665428
uuid-2ce9a61dcfc14527b6be811b8afbdbac,efficacy,0.473076
uuid-2ce9a61dcfc14527b6be811b8afbdbac,2L,0.325056
uuid-2ce9a61dcfc14527b6be811b8afbdbac,PD-L1,0.444138
uuid-2ce9a61dcfc14527b6be811b8afbdbac,OS,0.476424
uuid-2ce9a61dcfc14527b6be811b8afbdbac,atezo,0.427277
uuid-2ce9a61dcfc14527b6be811b8afbdbac,data,0.596135
uuid-2ce9a61dcfc14527b6be811b8afbdbac,indication,0.327637
uuid-2ce9a61dcfc14527b6be811b8afbdbac,PFS,0.464829
uuid-2ce9a61dcfc14527b6be811b8afbdbac,ORR,0.466034
uuid-2ce9a61dcfc14527b6be811b8afbdbac,nivo and pembro,0.555669
uuid-2ce9a61dcfc14527b6be811b8afbdbac,believes,0.486216
uuid-2ce9a61dcfc14527b6be811b8afbdbac,impressed,0.370081
uuid-2ce9a61dcfc14527b6be811b8afbdbac,feels,0.374065
uuid-2ce9a61dcfc14527b6be811b8afbdbac,PDL1 expression,0.602553
uuid-2ce9a61dcfc14527b6be811b8afbdbac,option,0.32284
uuid-2ce9a61dcfc14527b6be811b8afbdbac,biomarker,0.41104
uuid-114310fa540e4b19ba580b5dcf11b3ac,Nivo,0.377454
uuid-114310fa540e4b19ba580b5dcf11b3ac,pembro,0.508279
uuid-114310fa540e4b19ba580b5dcf11b3ac,therapy,0.302139
uuid-114310fa540e4b19ba580b5dcf11b3ac,1L,0.610618
uuid-114310fa540e4b19ba580b5dcf11b3ac,trial,0.414296
uuid-114310fa540e4b19ba580b5dcf11b3ac,combination,0.501913
uuid-114310fa540e4b19ba580b5dcf11b3ac,chemo,0.475793
uuid-114310fa540e4b19ba580b5dcf11b3ac,2L,0.528717
uuid-114310fa540e4b19ba580b5dcf11b3ac,agents,0.584685
uuid-114310fa540e4b19ba580b5dcf11b3ac,atezo,0.431356
uuid-114310fa540e4b19ba580b5dcf11b3ac,preferred,0.480917
uuid-114310fa540e4b19ba580b5dcf11b3ac,monotherapy,0.569564
uuid-114310fa540e4b19ba580b5dcf11b3ac,using nivo,0.310721
uuid-114310fa540e4b19ba580b5dcf11b3ac,combo,0.489679
uuid-114310fa540e4b19ba580b5dcf11b3ac,clinical trials,0.359414
uuid-114310fa540e4b19ba580b5dcf11b3ac,indication,0.334535
uuid-114310fa540e4b19ba580b5dcf11b3ac,PD1,0.414107
uuid-114310fa540e4b19ba580b5dcf11b3ac,approved,0.451023
uuid-114310fa540e4b19ba580b5dcf11b3ac,nivo and pembro,0.358199
uuid-114310fa540e4b19ba580b5dcf11b3ac,believes,0.388209
uuid-114310fa540e4b19ba580b5dcf11b3ac,chemotherapy,0.45035
uuid-114310fa540e4b19ba580b5dcf11b3ac,tumor types,0.302055
uuid-114310fa540e4b19ba580b5dcf11b3ac,feels,0.332479
uuid-114310fa540e4b19ba580b5dcf11b3ac,PD-1,0.40473
uuid-114310fa540e4b19ba580b5dcf11b3ac,option,0.545108
uuid-fa34108ede4a4c878b84320bc4d698f5,TL,0.362502
uuid-fa34108ede4a4c878b84320bc4d698f5,pembro,0.458771
uuid-fa34108ede4a4c878b84320bc4d698f5,NSCLC,0.334267
uuid-fa34108ede4a4c878b84320bc4d698f5,1L,0.478767
uuid-fa34108ede4a4c878b84320bc4d698f5,RCC,0.320646
uuid-fa34108ede4a4c878b84320bc4d698f5,TL stated,0.431582
uuid-fa34108ede4a4c878b84320bc4d698f5,2L,0.580696
uuid-fa34108ede4a4c878b84320bc4d698f5,agents,0.351898
uuid-fa34108ede4a4c878b84320bc4d698f5,PD-L1,0.392628
uuid-fa34108ede4a4c878b84320bc4d698f5,atezo,0.639721
uuid-fa34108ede4a4c878b84320bc4d698f5,preferred,0.560531
uuid-fa34108ede4a4c878b84320bc4d698f5,PD-L1 testing,0.424794
uuid-fa34108ede4a4c878b84320bc4d698f5,testing,0.428401
uuid-fa34108ede4a4c878b84320bc4d698f5,using nivo,0.374737
uuid-fa34108ede4a4c878b84320bc4d698f5,PDL1 testing,0.500774
uuid-fa34108ede4a4c878b84320bc4d698f5,NSCLC patients,0.376501
uuid-fa34108ede4a4c878b84320bc4d698f5,approved,0.369064
uuid-fa34108ede4a4c878b84320bc4d698f5,TLs,0.343908
uuid-fa34108ede4a4c878b84320bc4d698f5,RTL stated,0.31736
uuid-fa34108ede4a4c878b84320bc4d698f5,bladder,0.329498
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,Nivo,0.340498
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,patients,0.693289
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,therapy,0.736737
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,nivolumab,0.433904
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,toxicity,0.304938
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,regimen,0.455613
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,treated,0.364517
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,combination,0.423567
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,chemo,0.594583
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,pts,0.565267
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,IO,0.356755
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,monotherapy,0.520719
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,treatment,0.608795
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,response,0.784146
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,PD1,0.589974
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,progression,0.729728
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,chemotherapy,0.571782
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,respond,0.592458
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,immunotherapy,0.317853
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,PD-1,0.307568
uuid-7f79c4ccd2de4d709b2d47f881fbbbfe,option,0.430382
uuid-baf77e03d21640f2bff9a962d7a16f22,BMS,0.379685
uuid-baf77e03d21640f2bff9a962d7a16f22,PDL1,0.4303
uuid-baf77e03d21640f2bff9a962d7a16f22,trial,0.36851
uuid-baf77e03d21640f2bff9a962d7a16f22,efficacy,0.562262
uuid-baf77e03d21640f2bff9a962d7a16f22,commented,0.33409
uuid-baf77e03d21640f2bff9a962d7a16f22,OS,0.826823
uuid-baf77e03d21640f2bff9a962d7a16f22,regards,0.356314
uuid-baf77e03d21640f2bff9a962d7a16f22,data,0.779879
uuid-baf77e03d21640f2bff9a962d7a16f22,PFS,0.791224
uuid-baf77e03d21640f2bff9a962d7a16f22,ORR,0.755949
uuid-baf77e03d21640f2bff9a962d7a16f22,nivo and pembro,0.359172
uuid-baf77e03d21640f2bff9a962d7a16f22,ASCO,0.35095
uuid-baf77e03d21640f2bff9a962d7a16f22,impressed,0.608155
uuid-baf77e03d21640f2bff9a962d7a16f22,feels,0.348546
uuid-baf77e03d21640f2bff9a962d7a16f22,PDL1 expression,0.376134
uuid-495b84e51cde4025852ad9597d976076,Nivo,0.392029
uuid-495b84e51cde4025852ad9597d976076,pembro,0.401091
uuid-495b84e51cde4025852ad9597d976076,PDL1,0.531152
uuid-495b84e51cde4025852ad9597d976076,trial,0.470021
uuid-495b84e51cde4025852ad9597d976076,efficacy,0.691334
uuid-495b84e51cde4025852ad9597d976076,chemo,0.304683
uuid-495b84e51cde4025852ad9597d976076,OS,0.600524
uuid-495b84e51cde4025852ad9597d976076,atezo,0.34129
uuid-495b84e51cde4025852ad9597d976076,data,0.591498
uuid-495b84e51cde4025852ad9597d976076,PFS,0.618935
uuid-495b84e51cde4025852ad9597d976076,ORR,0.688792
uuid-495b84e51cde4025852ad9597d976076,nivo and pembro,0.576525
uuid-495b84e51cde4025852ad9597d976076,believes,0.370005
uuid-495b84e51cde4025852ad9597d976076,impressed,0.348284
uuid-495b84e51cde4025852ad9597d976076,vs,0.429045
uuid-495b84e51cde4025852ad9597d976076,feels,0.36025
uuid-495b84e51cde4025852ad9597d976076,PDL1 expression,0.587038
uuid-cb70f6703a5149459327d910313ca3d4,lung,0.315676
uuid-cb70f6703a5149459327d910313ca3d4,NTL,0.383745
uuid-cb70f6703a5149459327d910313ca3d4,shared,0.339811
uuid-cb70f6703a5149459327d910313ca3d4,commented,0.339717
uuid-cb70f6703a5149459327d910313ca3d4,mentioned,0.300332
uuid-cb70f6703a5149459327d910313ca3d4,Regional TL,0.334702
uuid-cb70f6703a5149459327d910313ca3d4,NCCN,0.421284
uuid-8b70c4bb3fb042f48c20cd869951eb4a,patients,0.775259
uuid-8b70c4bb3fb042f48c20cd869951eb4a,Opdivo,0.545728
uuid-8b70c4bb3fb042f48c20cd869951eb4a,therapy,0.470129
uuid-8b70c4bb3fb042f48c20cd869951eb4a,nivolumab,0.481861
uuid-8b70c4bb3fb042f48c20cd869951eb4a,regimen,0.41551
uuid-8b70c4bb3fb042f48c20cd869951eb4a,treated,0.546724
uuid-8b70c4bb3fb042f48c20cd869951eb4a,pts,0.538466
uuid-8b70c4bb3fb042f48c20cd869951eb4a,treatment,0.558509
uuid-8b70c4bb3fb042f48c20cd869951eb4a,response,0.446572
uuid-8b70c4bb3fb042f48c20cd869951eb4a,cHL,0.324834
uuid-8b70c4bb3fb042f48c20cd869951eb4a,progression,0.619233
uuid-8b70c4bb3fb042f48c20cd869951eb4a,respond,0.448761
uuid-d7c949b081a74b9a8ec16a665b73c4be,NTL,0.382005
uuid-d7c949b081a74b9a8ec16a665b73c4be,lung cancer,0.436077
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,Nivo,0.349154
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,patients,0.347319
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,pembro,0.543229
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,1L,0.612105
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,PDL1,0.4048
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,chemo,0.398752
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,2L,0.560765
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,agents,0.331416
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,PD-L1,0.308774
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,approval,0.316654
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,atezo,0.474713
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,preferred,0.479814
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,monotherapy,0.449985
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,using nivo,0.408422
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,NSCLC patients,0.366895
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,PD1,0.33491
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,approved,0.384859
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,nivo and pembro,0.407117
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,believes,0.435183
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,vs,0.340081
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,feels,0.317
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,PDL1 expression,0.345234
uuid-f6b8de46e68641b7aa3b4c1b982e0a9c,option,0.508169
uuid-e8f7202e49414a54bc1bf141e2125c27,lung,0.462639
uuid-e8f7202e49414a54bc1bf141e2125c27,melanoma,0.350988
uuid-e8f7202e49414a54bc1bf141e2125c27,OS,0.362071
uuid-e8f7202e49414a54bc1bf141e2125c27,regards,0.444378
uuid-e8f7202e49414a54bc1bf141e2125c27,PFS,0.422073
uuid-e8f7202e49414a54bc1bf141e2125c27,AI,0.817301
uuid-e8f7202e49414a54bc1bf141e2125c27,ORR,0.337475
uuid-e8f7202e49414a54bc1bf141e2125c27,nivo and pembro,0.361696
uuid-e8f7202e49414a54bc1bf141e2125c27,believes,0.300926
uuid-e8f7202e49414a54bc1bf141e2125c27,NCCN,0.348866
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,Nivo,0.392599
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,pembro,0.392875
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,RTL,0.3738
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,BMS,0.402257
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,trial,0.758539
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,Merck,0.302706
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,OS,0.32244
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,data,0.573193
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,clinical trials,0.456784
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,PFS,0.35683
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,ORR,0.430053
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,impressed,0.540619
uuid-b2b50670fc1c4c10a532c75c37fbd5a9,feels,0.375362
uuid-db6d2c9b48044588b81a165e197aef9d,patients,0.546562
uuid-db6d2c9b48044588b81a165e197aef9d,therapy,0.328005
uuid-db6d2c9b48044588b81a165e197aef9d,nivolumab,0.50368
uuid-db6d2c9b48044588b81a165e197aef9d,regimen,0.323738
uuid-db6d2c9b48044588b81a165e197aef9d,treated,0.523837
uuid-db6d2c9b48044588b81a165e197aef9d,shared,0.387064
uuid-db6d2c9b48044588b81a165e197aef9d,RCC,0.383785
uuid-db6d2c9b48044588b81a165e197aef9d,combination,0.310884
uuid-db6d2c9b48044588b81a165e197aef9d,2L,0.362294
uuid-db6d2c9b48044588b81a165e197aef9d,pts,0.437637
uuid-db6d2c9b48044588b81a165e197aef9d,stated,0.300595
uuid-db6d2c9b48044588b81a165e197aef9d,approval,0.388657
uuid-db6d2c9b48044588b81a165e197aef9d,preferred,0.303134
uuid-db6d2c9b48044588b81a165e197aef9d,monotherapy,0.396298
uuid-db6d2c9b48044588b81a165e197aef9d,treatment,0.331673
uuid-db6d2c9b48044588b81a165e197aef9d,using nivo,0.487543
uuid-db6d2c9b48044588b81a165e197aef9d,clinical trials,0.391886
uuid-db6d2c9b48044588b81a165e197aef9d,approved,0.365792
uuid-db6d2c9b48044588b81a165e197aef9d,SCCHN,0.386149
uuid-db6d2c9b48044588b81a165e197aef9d,progression,0.30073
uuid-db6d2c9b48044588b81a165e197aef9d,chemotherapy,0.345046
uuid-db6d2c9b48044588b81a165e197aef9d,tumor types,0.397658
uuid-db6d2c9b48044588b81a165e197aef9d,SCLC,0.308013
uuid-db6d2c9b48044588b81a165e197aef9d,Regional TL,0.308769
uuid-db6d2c9b48044588b81a165e197aef9d,RTL stated,0.428224
uuid-db6d2c9b48044588b81a165e197aef9d,option,0.369485
uuid-db6d2c9b48044588b81a165e197aef9d,bladder,0.443579
uuid-de472559ba674d6c806593c3b4296f31,BMS,0.642003
uuid-de472559ba674d6c806593c3b4296f31,PDL1,0.680859
uuid-de472559ba674d6c806593c3b4296f31,trial,0.364753
uuid-de472559ba674d6c806593c3b4296f31,efficacy,0.412307
uuid-de472559ba674d6c806593c3b4296f31,commented,0.353771
uuid-de472559ba674d6c806593c3b4296f31,Merck,0.669557
uuid-de472559ba674d6c806593c3b4296f31,PD-L1,0.428134
uuid-de472559ba674d6c806593c3b4296f31,OS,0.456132
uuid-de472559ba674d6c806593c3b4296f31,testing,0.34928
uuid-de472559ba674d6c806593c3b4296f31,regards,0.466812
uuid-de472559ba674d6c806593c3b4296f31,data,0.657399
uuid-de472559ba674d6c806593c3b4296f31,expressed,0.357235
uuid-de472559ba674d6c806593c3b4296f31,PFS,0.458682
uuid-de472559ba674d6c806593c3b4296f31,ORR,0.431762
uuid-de472559ba674d6c806593c3b4296f31,nivo and pembro,0.455631
uuid-de472559ba674d6c806593c3b4296f31,impressed,0.374393
uuid-de472559ba674d6c806593c3b4296f31,assay,0.48188
uuid-de472559ba674d6c806593c3b4296f31,PDL1 expression,0.590015
uuid-de472559ba674d6c806593c3b4296f31,biomarker,0.53253
uuid-7eb914ce1fda43f492dfb1942da1ae84,BMS,0.399386
uuid-7eb914ce1fda43f492dfb1942da1ae84,PDL1,0.427609
uuid-7eb914ce1fda43f492dfb1942da1ae84,trial,0.402404
uuid-7eb914ce1fda43f492dfb1942da1ae84,efficacy,0.528459
uuid-7eb914ce1fda43f492dfb1942da1ae84,discussed,0.306432
uuid-7eb914ce1fda43f492dfb1942da1ae84,commented,0.309942
uuid-7eb914ce1fda43f492dfb1942da1ae84,OS,0.713196
uuid-7eb914ce1fda43f492dfb1942da1ae84,regards,0.391427
uuid-7eb914ce1fda43f492dfb1942da1ae84,data,0.773669
uuid-7eb914ce1fda43f492dfb1942da1ae84,PFS,0.683201
uuid-7eb914ce1fda43f492dfb1942da1ae84,ORR,0.674131
uuid-7eb914ce1fda43f492dfb1942da1ae84,nivo and pembro,0.401135
uuid-7eb914ce1fda43f492dfb1942da1ae84,ASCO,0.350998
uuid-7eb914ce1fda43f492dfb1942da1ae84,impressed,0.505837
uuid-7eb914ce1fda43f492dfb1942da1ae84,PDL1 expression,0.560927
uuid-fc2f737c4a5e421499a9c12bdd2de481,RTL,0.429739
uuid-fc2f737c4a5e421499a9c12bdd2de481,lung,0.418014
uuid-fc2f737c4a5e421499a9c12bdd2de481,NTL,0.351616
uuid-fc2f737c4a5e421499a9c12bdd2de481,melanoma,0.498871
uuid-fc2f737c4a5e421499a9c12bdd2de481,shared,0.4093
uuid-fc2f737c4a5e421499a9c12bdd2de481,commented,0.501118
uuid-fc2f737c4a5e421499a9c12bdd2de481,RCC,0.370769
uuid-fc2f737c4a5e421499a9c12bdd2de481,Ipi,0.319019
uuid-fc2f737c4a5e421499a9c12bdd2de481,stated,0.454417
uuid-fc2f737c4a5e421499a9c12bdd2de481,atezo,0.320143
uuid-fc2f737c4a5e421499a9c12bdd2de481,regards,0.366815
uuid-fc2f737c4a5e421499a9c12bdd2de481,data,0.507275
uuid-fc2f737c4a5e421499a9c12bdd2de481,expressed,0.409311
uuid-fc2f737c4a5e421499a9c12bdd2de481,indication,0.362132
uuid-fc2f737c4a5e421499a9c12bdd2de481,SCCHN,0.512781
uuid-fc2f737c4a5e421499a9c12bdd2de481,ASCO,0.304217
uuid-fc2f737c4a5e421499a9c12bdd2de481,impressed,0.476598
uuid-fc2f737c4a5e421499a9c12bdd2de481,TLs,0.471709
uuid-fc2f737c4a5e421499a9c12bdd2de481,SCLC,0.541764
uuid-fc2f737c4a5e421499a9c12bdd2de481,Regional TL,0.374421
uuid-fc2f737c4a5e421499a9c12bdd2de481,NCCN,0.466275
uuid-fc2f737c4a5e421499a9c12bdd2de481,bladder,0.370232
uuid-065b9e0b9a7b4e29874985640f2ce2b1,patients,0.660323
uuid-065b9e0b9a7b4e29874985640f2ce2b1,Opdivo,0.311148
uuid-065b9e0b9a7b4e29874985640f2ce2b1,toxicity,0.606315
uuid-065b9e0b9a7b4e29874985640f2ce2b1,regimen,0.526493
uuid-065b9e0b9a7b4e29874985640f2ce2b1,treated,0.363234
uuid-065b9e0b9a7b4e29874985640f2ce2b1,chemo,0.320848
uuid-065b9e0b9a7b4e29874985640f2ce2b1,pts,0.444643
uuid-065b9e0b9a7b4e29874985640f2ce2b1,treatment,0.555987
uuid-065b9e0b9a7b4e29874985640f2ce2b1,response,0.35517
uuid-065b9e0b9a7b4e29874985640f2ce2b1,progression,0.488298
uuid-065b9e0b9a7b4e29874985640f2ce2b1,respond,0.579434
uuid-7cd18ffcab3843ad99d94c996900c73a,RTL,0.382458
uuid-7cd18ffcab3843ad99d94c996900c73a,1L,0.424773
uuid-7cd18ffcab3843ad99d94c996900c73a,melanoma,0.371034
uuid-7cd18ffcab3843ad99d94c996900c73a,shared,0.519298
uuid-7cd18ffcab3843ad99d94c996900c73a,RCC,0.469864
uuid-7cd18ffcab3843ad99d94c996900c73a,combination,0.44267
uuid-7cd18ffcab3843ad99d94c996900c73a,2L,0.459924
uuid-7cd18ffcab3843ad99d94c996900c73a,agents,0.323374
uuid-7cd18ffcab3843ad99d94c996900c73a,stated,0.399338
uuid-7cd18ffcab3843ad99d94c996900c73a,preferred,0.489255
uuid-7cd18ffcab3843ad99d94c996900c73a,monotherapy,0.45684
uuid-7cd18ffcab3843ad99d94c996900c73a,using nivo,0.403513
uuid-7cd18ffcab3843ad99d94c996900c73a,combo,0.520059
uuid-7cd18ffcab3843ad99d94c996900c73a,expressed,0.303156
uuid-7cd18ffcab3843ad99d94c996900c73a,clinical trials,0.413878
uuid-7cd18ffcab3843ad99d94c996900c73a,SCCHN,0.471155
uuid-7cd18ffcab3843ad99d94c996900c73a,tumor types,0.318654
uuid-7cd18ffcab3843ad99d94c996900c73a,LTL,0.427893
uuid-7cd18ffcab3843ad99d94c996900c73a,TLs,0.407579
uuid-7cd18ffcab3843ad99d94c996900c73a,academic,0.326461
uuid-7cd18ffcab3843ad99d94c996900c73a,feels,0.348774
uuid-7cd18ffcab3843ad99d94c996900c73a,Regional TL,0.357732
uuid-7cd18ffcab3843ad99d94c996900c73a,RTL stated,0.526489
uuid-7cd18ffcab3843ad99d94c996900c73a,TL shared,0.358251
uuid-7cd18ffcab3843ad99d94c996900c73a,option,0.49039
uuid-7cd18ffcab3843ad99d94c996900c73a,bladder,0.391476
uuid-a4c31d938a6548be92627f38f2cc2241,pembro,0.538206
uuid-a4c31d938a6548be92627f38f2cc2241,dose,0.342323
uuid-a4c31d938a6548be92627f38f2cc2241,BMS,0.51391
uuid-a4c31d938a6548be92627f38f2cc2241,trial,0.388125
uuid-a4c31d938a6548be92627f38f2cc2241,shared,0.379043
uuid-a4c31d938a6548be92627f38f2cc2241,commented,0.331232
uuid-a4c31d938a6548be92627f38f2cc2241,Merck,0.46249
uuid-a4c31d938a6548be92627f38f2cc2241,stated,0.391561
uuid-a4c31d938a6548be92627f38f2cc2241,approval,0.528714
uuid-a4c31d938a6548be92627f38f2cc2241,atezo,0.496722
uuid-a4c31d938a6548be92627f38f2cc2241,data,0.473442
uuid-a4c31d938a6548be92627f38f2cc2241,expressed,0.30314
uuid-a4c31d938a6548be92627f38f2cc2241,clinical trials,0.441488
uuid-a4c31d938a6548be92627f38f2cc2241,indication,0.603868
uuid-a4c31d938a6548be92627f38f2cc2241,approved,0.560624
uuid-a4c31d938a6548be92627f38f2cc2241,SCCHN,0.36871
uuid-a4c31d938a6548be92627f38f2cc2241,impressed,0.383186
uuid-a4c31d938a6548be92627f38f2cc2241,vs,0.343097
uuid-a4c31d938a6548be92627f38f2cc2241,label,0.447927
uuid-a4c31d938a6548be92627f38f2cc2241,LTL,0.348264
uuid-a4c31d938a6548be92627f38f2cc2241,Keytruda,0.331854
uuid-a4c31d938a6548be92627f38f2cc2241,TLs,0.362943
uuid-a4c31d938a6548be92627f38f2cc2241,bladder,0.339861
uuid-a4c31d938a6548be92627f38f2cc2241,flat dosing,0.615099
uuid-e53c650ae0284adda8e00147435461f8,Nivo,0.378394
uuid-e53c650ae0284adda8e00147435461f8,pembro,0.500424
uuid-e53c650ae0284adda8e00147435461f8,1L,0.518273
uuid-e53c650ae0284adda8e00147435461f8,PDL1,0.456203
uuid-e53c650ae0284adda8e00147435461f8,trial,0.40007
uuid-e53c650ae0284adda8e00147435461f8,efficacy,0.396519
uuid-e53c650ae0284adda8e00147435461f8,chemo,0.406284
uuid-e53c650ae0284adda8e00147435461f8,2L,0.404596
uuid-e53c650ae0284adda8e00147435461f8,OS,0.405651
uuid-e53c650ae0284adda8e00147435461f8,atezo,0.403332
uuid-e53c650ae0284adda8e00147435461f8,monotherapy,0.414728
uuid-e53c650ae0284adda8e00147435461f8,data,0.462568
uuid-e53c650ae0284adda8e00147435461f8,combo,0.36829
uuid-e53c650ae0284adda8e00147435461f8,PFS,0.391952
uuid-e53c650ae0284adda8e00147435461f8,ORR,0.418368
uuid-e53c650ae0284adda8e00147435461f8,nivo and pembro,0.512164
uuid-e53c650ae0284adda8e00147435461f8,believes,0.487354
uuid-e53c650ae0284adda8e00147435461f8,impressed,0.364415
uuid-e53c650ae0284adda8e00147435461f8,feels,0.589309
uuid-e53c650ae0284adda8e00147435461f8,PDL1 expression,0.38346
uuid-e53c650ae0284adda8e00147435461f8,option,0.410155
uuid-7e00958822f342658dfa4e8b51475e0e,1L,0.440517
uuid-7e00958822f342658dfa4e8b51475e0e,PDL1,0.705641
uuid-7e00958822f342658dfa4e8b51475e0e,efficacy,0.390974
uuid-7e00958822f342658dfa4e8b51475e0e,2L,0.370518
uuid-7e00958822f342658dfa4e8b51475e0e,agents,0.494136
uuid-7e00958822f342658dfa4e8b51475e0e,PD-L1,0.508044
uuid-7e00958822f342658dfa4e8b51475e0e,atezo,0.378895
uuid-7e00958822f342658dfa4e8b51475e0e,testing,0.370168
uuid-7e00958822f342658dfa4e8b51475e0e,data,0.302387
uuid-7e00958822f342658dfa4e8b51475e0e,PDL1 testing,0.358139
uuid-7e00958822f342658dfa4e8b51475e0e,nivo and pembro,0.512755
uuid-7e00958822f342658dfa4e8b51475e0e,believes,0.456055
uuid-7e00958822f342658dfa4e8b51475e0e,tumor types,0.307939
uuid-7e00958822f342658dfa4e8b51475e0e,assay,0.36688
uuid-7e00958822f342658dfa4e8b51475e0e,PD-1,0.427532
uuid-7e00958822f342658dfa4e8b51475e0e,PDL1 expression,0.609049
uuid-7e00958822f342658dfa4e8b51475e0e,biomarker,0.614712
uuid-0df62354680f4221ac3cfb446e1d8c49,Nivo,0.334355
uuid-0df62354680f4221ac3cfb446e1d8c49,patients,0.66842
uuid-0df62354680f4221ac3cfb446e1d8c49,Opdivo,0.484442
uuid-0df62354680f4221ac3cfb446e1d8c49,therapy,0.361903
uuid-0df62354680f4221ac3cfb446e1d8c49,dose,0.540519
uuid-0df62354680f4221ac3cfb446e1d8c49,nivolumab,0.416132
uuid-0df62354680f4221ac3cfb446e1d8c49,toxicity,0.501611
uuid-0df62354680f4221ac3cfb446e1d8c49,regimen,0.598606
uuid-0df62354680f4221ac3cfb446e1d8c49,treated,0.364831
uuid-0df62354680f4221ac3cfb446e1d8c49,combination,0.350956
uuid-0df62354680f4221ac3cfb446e1d8c49,chemo,0.370016
uuid-0df62354680f4221ac3cfb446e1d8c49,2L,0.316762
uuid-0df62354680f4221ac3cfb446e1d8c49,pts,0.492315
uuid-0df62354680f4221ac3cfb446e1d8c49,Ipi,0.391592
uuid-0df62354680f4221ac3cfb446e1d8c49,preferred,0.394878
uuid-0df62354680f4221ac3cfb446e1d8c49,monotherapy,0.463591
uuid-0df62354680f4221ac3cfb446e1d8c49,treatment,0.497499
uuid-0df62354680f4221ac3cfb446e1d8c49,using nivo,0.335598
uuid-0df62354680f4221ac3cfb446e1d8c49,response,0.312155
uuid-0df62354680f4221ac3cfb446e1d8c49,combo,0.387704
uuid-0df62354680f4221ac3cfb446e1d8c49,progression,0.537391
uuid-0df62354680f4221ac3cfb446e1d8c49,chemotherapy,0.306523
uuid-0df62354680f4221ac3cfb446e1d8c49,respond,0.406415
uuid-0df62354680f4221ac3cfb446e1d8c49,option,0.415916
uuid-0df62354680f4221ac3cfb446e1d8c49,flat dosing,0.302897
uuid-fa48aff2434f4ff893c8a6779d5f33c4,Nivo,0.324798
uuid-fa48aff2434f4ff893c8a6779d5f33c4,therapy,0.322761
uuid-fa48aff2434f4ff893c8a6779d5f33c4,nivolumab,0.374882
uuid-fa48aff2434f4ff893c8a6779d5f33c4,combination,0.318981
uuid-fa48aff2434f4ff893c8a6779d5f33c4,chemo,0.307143
uuid-fa48aff2434f4ff893c8a6779d5f33c4,treatment,0.329011
uuid-fa48aff2434f4ff893c8a6779d5f33c4,chemotherapy,0.314954
uuid-a6a11f58f71b402f96f834e973665628,patients,0.63739
uuid-a6a11f58f71b402f96f834e973665628,Opdivo,0.371488
uuid-a6a11f58f71b402f96f834e973665628,therapy,0.431987
uuid-a6a11f58f71b402f96f834e973665628,nivolumab,0.373238
uuid-a6a11f58f71b402f96f834e973665628,toxicity,0.334724
uuid-a6a11f58f71b402f96f834e973665628,regimen,0.557255
uuid-a6a11f58f71b402f96f834e973665628,treated,0.553475
uuid-a6a11f58f71b402f96f834e973665628,pts,0.337687
uuid-a6a11f58f71b402f96f834e973665628,physicians,0.49611
uuid-a6a11f58f71b402f96f834e973665628,treatment,0.640578
uuid-a6a11f58f71b402f96f834e973665628,response,0.47341
uuid-a6a11f58f71b402f96f834e973665628,progression,0.550112
uuid-a6a11f58f71b402f96f834e973665628,chemotherapy,0.301171
uuid-a6a11f58f71b402f96f834e973665628,respond,0.478421
uuid-72fc8defc7184dec84b7d9a0c3231b1f,1L,0.502667
uuid-72fc8defc7184dec84b7d9a0c3231b1f,PDL1,0.551814
uuid-72fc8defc7184dec84b7d9a0c3231b1f,chemo,0.435555
uuid-72fc8defc7184dec84b7d9a0c3231b1f,PD-L1,0.411285
uuid-72fc8defc7184dec84b7d9a0c3231b1f,testing,0.415261
uuid-72fc8defc7184dec84b7d9a0c3231b1f,monotherapy,0.345918
uuid-72fc8defc7184dec84b7d9a0c3231b1f,combo,0.328518
uuid-72fc8defc7184dec84b7d9a0c3231b1f,NSCLC patients,0.39754
uuid-72fc8defc7184dec84b7d9a0c3231b1f,believes,0.451537
uuid-72fc8defc7184dec84b7d9a0c3231b1f,chemotherapy,0.33402
uuid-72fc8defc7184dec84b7d9a0c3231b1f,PD-1,0.306496
uuid-72fc8defc7184dec84b7d9a0c3231b1f,PDL1 expression,0.479991
uuid-72fc8defc7184dec84b7d9a0c3231b1f,option,0.441026
uuid-72fc8defc7184dec84b7d9a0c3231b1f,biomarker,0.502436
uuid-618a44b4ec2d4a8fb573cfec4cf49d13,patients,0.350735
uuid-618a44b4ec2d4a8fb573cfec4cf49d13,Opdivo,0.573462
uuid-618a44b4ec2d4a8fb573cfec4cf49d13,dose,0.824259
uuid-618a44b4ec2d4a8fb573cfec4cf49d13,toxicity,0.35163
uuid-618a44b4ec2d4a8fb573cfec4cf49d13,regimen,0.31584
uuid-618a44b4ec2d4a8fb573cfec4cf49d13,Ipi,0.421366
uuid-618a44b4ec2d4a8fb573cfec4cf49d13,vs,0.369567
uuid-618a44b4ec2d4a8fb573cfec4cf49d13,drug,0.306784
uuid-618a44b4ec2d4a8fb573cfec4cf49d13,Keytruda,0.350699
uuid-618a44b4ec2d4a8fb573cfec4cf49d13,flat dosing,0.756369
uuid-1535b4e6855d4e66b2b72be28c02b62c,tumor,0.553307
uuid-1535b4e6855d4e66b2b72be28c02b62c,pts,0.333589
uuid-1535b4e6855d4e66b2b72be28c02b62c,OS,0.36353
uuid-1535b4e6855d4e66b2b72be28c02b62c,response,0.563648
uuid-1535b4e6855d4e66b2b72be28c02b62c,PFS,0.340843
uuid-1535b4e6855d4e66b2b72be28c02b62c,ORR,0.363528
uuid-1535b4e6855d4e66b2b72be28c02b62c,progression,0.345428
uuid-1535b4e6855d4e66b2b72be28c02b62c,impressed,0.346327
uuid-ab63e121b1e64087bbf903e4735307d4,Nivo,0.345284
uuid-ab63e121b1e64087bbf903e4735307d4,Opdivo,0.382736
uuid-ab63e121b1e64087bbf903e4735307d4,therapy,0.486958
uuid-ab63e121b1e64087bbf903e4735307d4,nivolumab,0.594526
uuid-ab63e121b1e64087bbf903e4735307d4,combination,0.312829
uuid-ab63e121b1e64087bbf903e4735307d4,treatment,0.357273
uuid-ab63e121b1e64087bbf903e4735307d4,cHL,0.62752
uuid-ab63e121b1e64087bbf903e4735307d4,chemotherapy,0.35135
uuid-6e182d7b7ddd43c9b0e216692c29293e,Nivo,0.491226
uuid-6e182d7b7ddd43c9b0e216692c29293e,patients,0.385462
uuid-6e182d7b7ddd43c9b0e216692c29293e,therapy,0.538009
uuid-6e182d7b7ddd43c9b0e216692c29293e,cHL,0.56636
uuid-6e182d7b7ddd43c9b0e216692c29293e,chemotherapy,0.341872
uuid-29d4abb3a59944aeabd421e744eb680a,patients,0.322261
uuid-29d4abb3a59944aeabd421e744eb680a,RTL,0.368851
uuid-29d4abb3a59944aeabd421e744eb680a,nivolumab,0.35219
uuid-29d4abb3a59944aeabd421e744eb680a,treated,0.342822
uuid-29d4abb3a59944aeabd421e744eb680a,NTL,0.364121
uuid-29d4abb3a59944aeabd421e744eb680a,RCC,0.318787
uuid-29d4abb3a59944aeabd421e744eb680a,approval,0.384015
uuid-29d4abb3a59944aeabd421e744eb680a,preferred,0.360332
uuid-29d4abb3a59944aeabd421e744eb680a,using nivo,0.595322
uuid-29d4abb3a59944aeabd421e744eb680a,mentioned,0.342019
uuid-29d4abb3a59944aeabd421e744eb680a,SCCHN,0.51593
uuid-29d4abb3a59944aeabd421e744eb680a,HCP,0.348187
uuid-29d4abb3a59944aeabd421e744eb680a,cHL,0.300877
uuid-29d4abb3a59944aeabd421e744eb680a,oncologist,0.48746
uuid-29d4abb3a59944aeabd421e744eb680a,indicated,0.509291
uuid-29d4abb3a59944aeabd421e744eb680a,Regional TL,0.397192
uuid-29d4abb3a59944aeabd421e744eb680a,RTL stated,0.38655
uuid-29d4abb3a59944aeabd421e744eb680a,bladder,0.374037
uuid-b9918ea5287847ca870798b5d4ea2375,patients,0.482874
uuid-b9918ea5287847ca870798b5d4ea2375,Opdivo,0.466298
uuid-b9918ea5287847ca870798b5d4ea2375,dose,0.766319
uuid-b9918ea5287847ca870798b5d4ea2375,toxicity,0.636966
uuid-b9918ea5287847ca870798b5d4ea2375,regimen,0.49859
uuid-b9918ea5287847ca870798b5d4ea2375,treated,0.3382
uuid-b9918ea5287847ca870798b5d4ea2375,Ipi,0.344964
uuid-b9918ea5287847ca870798b5d4ea2375,treatment,0.417799
uuid-b9918ea5287847ca870798b5d4ea2375,vs,0.321034
uuid-b9918ea5287847ca870798b5d4ea2375,respond,0.339089
uuid-b9918ea5287847ca870798b5d4ea2375,flat dosing,0.45173
uuid-63dae064326c46aba77b4d0151dd5b10,RTL,0.404735
uuid-63dae064326c46aba77b4d0151dd5b10,NSCLC patients,0.39485
uuid-0005ece265474a1dbb4d3c405e97db35,Nivo,0.377175
uuid-0005ece265474a1dbb4d3c405e97db35,patients,0.370045
uuid-0005ece265474a1dbb4d3c405e97db35,pembro,0.431055
uuid-0005ece265474a1dbb4d3c405e97db35,RTL,0.658176
uuid-0005ece265474a1dbb4d3c405e97db35,nivolumab,0.502548
uuid-0005ece265474a1dbb4d3c405e97db35,1L,0.378777
uuid-0005ece265474a1dbb4d3c405e97db35,treated,0.338639
uuid-0005ece265474a1dbb4d3c405e97db35,NTL,0.329428
uuid-0005ece265474a1dbb4d3c405e97db35,RCC,0.45286
uuid-0005ece265474a1dbb4d3c405e97db35,2L,0.432712
uuid-0005ece265474a1dbb4d3c405e97db35,pts,0.343075
uuid-0005ece265474a1dbb4d3c405e97db35,stated,0.424204
uuid-0005ece265474a1dbb4d3c405e97db35,approval,0.482008
uuid-0005ece265474a1dbb4d3c405e97db35,preferred,0.3866
uuid-0005ece265474a1dbb4d3c405e97db35,monotherapy,0.358514
uuid-0005ece265474a1dbb4d3c405e97db35,using nivo,0.694713
uuid-0005ece265474a1dbb4d3c405e97db35,clinical trials,0.391382
uuid-0005ece265474a1dbb4d3c405e97db35,approved,0.362034
uuid-0005ece265474a1dbb4d3c405e97db35,SCCHN,0.676431
uuid-0005ece265474a1dbb4d3c405e97db35,HCP,0.425422
uuid-0005ece265474a1dbb4d3c405e97db35,impressed,0.303448
uuid-0005ece265474a1dbb4d3c405e97db35,LTL,0.492925
uuid-0005ece265474a1dbb4d3c405e97db35,academic,0.322579
uuid-0005ece265474a1dbb4d3c405e97db35,SCLC,0.452329
uuid-0005ece265474a1dbb4d3c405e97db35,Regional TL,0.525371
uuid-0005ece265474a1dbb4d3c405e97db35,RTL stated,0.677911
uuid-0005ece265474a1dbb4d3c405e97db35,TL shared,0.354644
uuid-0005ece265474a1dbb4d3c405e97db35,bladder,0.459585
uuid-aa4486837eee4ca5b3757800b2ddd164,Nivo,0.623945
uuid-aa4486837eee4ca5b3757800b2ddd164,pembro,0.683698
uuid-aa4486837eee4ca5b3757800b2ddd164,1L,0.673384
uuid-aa4486837eee4ca5b3757800b2ddd164,PDL1,0.369334
uuid-aa4486837eee4ca5b3757800b2ddd164,trial,0.329338
uuid-aa4486837eee4ca5b3757800b2ddd164,efficacy,0.392053
uuid-aa4486837eee4ca5b3757800b2ddd164,chemo,0.363358
uuid-aa4486837eee4ca5b3757800b2ddd164,2L,0.65224
uuid-aa4486837eee4ca5b3757800b2ddd164,agents,0.449323
uuid-aa4486837eee4ca5b3757800b2ddd164,approval,0.444392
uuid-aa4486837eee4ca5b3757800b2ddd164,OS,0.305802
uuid-aa4486837eee4ca5b3757800b2ddd164,atezo,0.630813
uuid-aa4486837eee4ca5b3757800b2ddd164,preferred,0.439952
uuid-aa4486837eee4ca5b3757800b2ddd164,monotherapy,0.484907
uuid-aa4486837eee4ca5b3757800b2ddd164,using nivo,0.49201
uuid-aa4486837eee4ca5b3757800b2ddd164,data,0.503762
uuid-aa4486837eee4ca5b3757800b2ddd164,combo,0.354108
uuid-aa4486837eee4ca5b3757800b2ddd164,indication,0.397143
uuid-aa4486837eee4ca5b3757800b2ddd164,PD1,0.350983
uuid-aa4486837eee4ca5b3757800b2ddd164,ORR,0.327346
uuid-aa4486837eee4ca5b3757800b2ddd164,approved,0.577004
uuid-aa4486837eee4ca5b3757800b2ddd164,nivo and pembro,0.573353
uuid-aa4486837eee4ca5b3757800b2ddd164,believes,0.426042
uuid-aa4486837eee4ca5b3757800b2ddd164,impressed,0.341966
uuid-aa4486837eee4ca5b3757800b2ddd164,SCLC,0.33881
uuid-aa4486837eee4ca5b3757800b2ddd164,feels,0.434974
uuid-aa4486837eee4ca5b3757800b2ddd164,RTL stated,0.32799
uuid-aa4486837eee4ca5b3757800b2ddd164,PDL1 expression,0.342763
uuid-aa4486837eee4ca5b3757800b2ddd164,option,0.484998
uuid-aa4486837eee4ca5b3757800b2ddd164,bladder,0.313105
uuid-d114c85d622742e9820864a2a8b3d726,Nivo,0.657223
uuid-d114c85d622742e9820864a2a8b3d726,pembro,0.793274
uuid-d114c85d622742e9820864a2a8b3d726,dose,0.543304
uuid-d114c85d622742e9820864a2a8b3d726,1L,0.474378
uuid-d114c85d622742e9820864a2a8b3d726,efficacy,0.446461
uuid-d114c85d622742e9820864a2a8b3d726,2L,0.649598
uuid-d114c85d622742e9820864a2a8b3d726,agents,0.448011
uuid-d114c85d622742e9820864a2a8b3d726,Ipi,0.50219
uuid-d114c85d622742e9820864a2a8b3d726,atezo,0.857157
uuid-d114c85d622742e9820864a2a8b3d726,preferred,0.547113
uuid-d114c85d622742e9820864a2a8b3d726,monotherapy,0.396296
uuid-d114c85d622742e9820864a2a8b3d726,using nivo,0.512834
uuid-d114c85d622742e9820864a2a8b3d726,combo,0.339961
uuid-d114c85d622742e9820864a2a8b3d726,indication,0.360099
uuid-d114c85d622742e9820864a2a8b3d726,approved,0.470821
uuid-d114c85d622742e9820864a2a8b3d726,nivo and pembro,0.507243
uuid-d114c85d622742e9820864a2a8b3d726,believes,0.315775
uuid-d114c85d622742e9820864a2a8b3d726,vs,0.681115
uuid-d114c85d622742e9820864a2a8b3d726,TLs,0.321296
uuid-d114c85d622742e9820864a2a8b3d726,feels,0.319258
uuid-d114c85d622742e9820864a2a8b3d726,option,0.348112
uuid-d114c85d622742e9820864a2a8b3d726,flat dosing,0.4152
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,Nivo,0.727173
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,patients,0.309141
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,pembro,0.467511
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,1L,0.48567
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,efficacy,0.458254
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,regimen,0.374626
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,combination,0.377404
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,chemo,0.549959
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,2L,0.480666
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,pts,0.366265
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,agents,0.365619
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,Ipi,0.380512
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,OS,0.386612
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,atezo,0.383394
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,preferred,0.346517
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,monotherapy,0.609228
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,using nivo,0.415491
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,response,0.314725
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,data,0.328669
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,combo,0.452682
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,PFS,0.331996
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,PD1,0.458085
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,ORR,0.412541
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,nivo and pembro,0.412453
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,progression,0.304341
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,believes,0.391758
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,chemotherapy,0.44932
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,impressed,0.378566
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,vs,0.321114
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,feels,0.455595
uuid-43ab0cb9783e4c18bab5e65ecdd6fa4c,option,0.541479
uuid-da0050764d9c4312a346874a84220702,Nivo,0.596526
uuid-da0050764d9c4312a346874a84220702,patients,0.509077
uuid-da0050764d9c4312a346874a84220702,therapy,0.414829
uuid-da0050764d9c4312a346874a84220702,efficacy,0.32894
uuid-da0050764d9c4312a346874a84220702,regimen,0.475316
uuid-da0050764d9c4312a346874a84220702,combination,0.362863
uuid-da0050764d9c4312a346874a84220702,chemo,0.655526
uuid-da0050764d9c4312a346874a84220702,pts,0.53129
uuid-da0050764d9c4312a346874a84220702,Ipi,0.351547
uuid-da0050764d9c4312a346874a84220702,monotherapy,0.526017
uuid-da0050764d9c4312a346874a84220702,treatment,0.369101
uuid-da0050764d9c4312a346874a84220702,response,0.51104
uuid-da0050764d9c4312a346874a84220702,combo,0.388654
uuid-da0050764d9c4312a346874a84220702,PD1,0.463117
uuid-da0050764d9c4312a346874a84220702,progression,0.552082
uuid-da0050764d9c4312a346874a84220702,believes,0.407058
uuid-da0050764d9c4312a346874a84220702,chemotherapy,0.515872
uuid-da0050764d9c4312a346874a84220702,respond,0.526965
uuid-da0050764d9c4312a346874a84220702,feels,0.473461
uuid-da0050764d9c4312a346874a84220702,option,0.428637
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,pembro,0.471992
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,lung,0.307387
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,1L,0.36422
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,shared,0.449444
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,RCC,0.349167
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,TL stated,0.331608
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,2L,0.501167
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,institution,0.699342
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,approval,0.456573
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,atezo,0.616429
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,preferred,0.390093
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,PD-L1 testing,0.329696
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,using nivo,0.438921
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,PDL1 testing,0.416732
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,indication,0.328345
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,approved,0.397169
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,SCCHN,0.361177
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,RTL stated,0.350579
uuid-41a39ff4e1ae4d65b1baff87d5bef6f9,bladder,0.461956
uuid-17351c4c81d1437e997b96e1a4c62890,patients,0.457845
uuid-17351c4c81d1437e997b96e1a4c62890,therapy,0.637238
uuid-17351c4c81d1437e997b96e1a4c62890,regimen,0.442996
uuid-17351c4c81d1437e997b96e1a4c62890,treated,0.359676
uuid-17351c4c81d1437e997b96e1a4c62890,combination,0.422965
uuid-17351c4c81d1437e997b96e1a4c62890,chemo,0.553306
uuid-17351c4c81d1437e997b96e1a4c62890,pts,0.390552
uuid-17351c4c81d1437e997b96e1a4c62890,IO,0.340648
uuid-17351c4c81d1437e997b96e1a4c62890,monotherapy,0.430364
uuid-17351c4c81d1437e997b96e1a4c62890,treatment,0.564258
uuid-17351c4c81d1437e997b96e1a4c62890,response,0.417793
uuid-17351c4c81d1437e997b96e1a4c62890,combo,0.393751
uuid-17351c4c81d1437e997b96e1a4c62890,PD1,0.462212
uuid-17351c4c81d1437e997b96e1a4c62890,progression,0.571912
uuid-17351c4c81d1437e997b96e1a4c62890,chemotherapy,0.680085
uuid-17351c4c81d1437e997b96e1a4c62890,respond,0.313314
uuid-17351c4c81d1437e997b96e1a4c62890,immunotherapy,0.365451
uuid-17351c4c81d1437e997b96e1a4c62890,option,0.449126
uuid-4c60c5f02c2e4d00b8ef10b6a1f9c52b,BMS,0.480597
uuid-4c60c5f02c2e4d00b8ef10b6a1f9c52b,physicians,0.458559
uuid-da461296894e405f938cde820c9f66e6,Nivo,0.505231
uuid-da461296894e405f938cde820c9f66e6,pembro,0.47339
uuid-da461296894e405f938cde820c9f66e6,1L,0.610629
uuid-da461296894e405f938cde820c9f66e6,regimen,0.400006
uuid-da461296894e405f938cde820c9f66e6,melanoma,0.357642
uuid-da461296894e405f938cde820c9f66e6,RCC,0.548699
uuid-da461296894e405f938cde820c9f66e6,combination,0.448708
uuid-da461296894e405f938cde820c9f66e6,chemo,0.401307
uuid-da461296894e405f938cde820c9f66e6,2L,0.693143
uuid-da461296894e405f938cde820c9f66e6,agents,0.375961
uuid-da461296894e405f938cde820c9f66e6,Ipi,0.500736
uuid-da461296894e405f938cde820c9f66e6,atezo,0.524225
uuid-da461296894e405f938cde820c9f66e6,preferred,0.572544
uuid-da461296894e405f938cde820c9f66e6,monotherapy,0.591347
uuid-da461296894e405f938cde820c9f66e6,using nivo,0.595323
uuid-da461296894e405f938cde820c9f66e6,combo,0.563495
uuid-da461296894e405f938cde820c9f66e6,PD1,0.330844
uuid-da461296894e405f938cde820c9f66e6,approved,0.379154
uuid-da461296894e405f938cde820c9f66e6,SCCHN,0.420322
uuid-da461296894e405f938cde820c9f66e6,believes,0.34676
uuid-da461296894e405f938cde820c9f66e6,chemotherapy,0.322968
uuid-da461296894e405f938cde820c9f66e6,TLs,0.35134
uuid-da461296894e405f938cde820c9f66e6,SCLC,0.362806
uuid-da461296894e405f938cde820c9f66e6,RTL stated,0.492901
uuid-da461296894e405f938cde820c9f66e6,TL shared,0.319512
uuid-da461296894e405f938cde820c9f66e6,option,0.499047
uuid-da461296894e405f938cde820c9f66e6,bladder,0.44776
uuid-584f0533619b47fcabe5ea9aeba00db4,commented,0.340125
uuid-584f0533619b47fcabe5ea9aeba00db4,stated,0.348762
uuid-584f0533619b47fcabe5ea9aeba00db4,regards,0.446585
uuid-584f0533619b47fcabe5ea9aeba00db4,data,0.340277
uuid-584f0533619b47fcabe5ea9aeba00db4,indication,0.385612
uuid-584f0533619b47fcabe5ea9aeba00db4,SCCHN,0.351862
uuid-584f0533619b47fcabe5ea9aeba00db4,label,0.403002
uuid-584f0533619b47fcabe5ea9aeba00db4,NCCN,0.677931
uuid-694aa1a49a4c48f2b7acbec6b1086383,pembro,0.339855
uuid-694aa1a49a4c48f2b7acbec6b1086383,BMS,0.354596
uuid-694aa1a49a4c48f2b7acbec6b1086383,PDL1,0.60508
uuid-694aa1a49a4c48f2b7acbec6b1086383,trial,0.446883
uuid-694aa1a49a4c48f2b7acbec6b1086383,efficacy,0.51274
uuid-694aa1a49a4c48f2b7acbec6b1086383,OS,0.556662
uuid-694aa1a49a4c48f2b7acbec6b1086383,atezo,0.315529
uuid-694aa1a49a4c48f2b7acbec6b1086383,regards,0.433283
uuid-694aa1a49a4c48f2b7acbec6b1086383,data,0.530846
uuid-694aa1a49a4c48f2b7acbec6b1086383,expressed,0.323916
uuid-694aa1a49a4c48f2b7acbec6b1086383,PFS,0.626443
uuid-694aa1a49a4c48f2b7acbec6b1086383,AI,0.537526
uuid-694aa1a49a4c48f2b7acbec6b1086383,ORR,0.589372
uuid-694aa1a49a4c48f2b7acbec6b1086383,nivo and pembro,0.728419
uuid-694aa1a49a4c48f2b7acbec6b1086383,believes,0.427881
uuid-694aa1a49a4c48f2b7acbec6b1086383,PDL1 expression,0.60524
uuid-694aa1a49a4c48f2b7acbec6b1086383,biomarker,0.371212
uuid-83f66f80afa24567930317627aa9a10f,Nivo,0.31137
uuid-83f66f80afa24567930317627aa9a10f,patients,0.864042
uuid-83f66f80afa24567930317627aa9a10f,Opdivo,0.515457
uuid-83f66f80afa24567930317627aa9a10f,therapy,0.73562
uuid-83f66f80afa24567930317627aa9a10f,nivolumab,0.676318
uuid-83f66f80afa24567930317627aa9a10f,regimen,0.474724
uuid-83f66f80afa24567930317627aa9a10f,treated,0.646567
uuid-83f66f80afa24567930317627aa9a10f,chemo,0.310618
uuid-83f66f80afa24567930317627aa9a10f,pts,0.499367
uuid-83f66f80afa24567930317627aa9a10f,monotherapy,0.351374
uuid-83f66f80afa24567930317627aa9a10f,treatment,0.763965
uuid-83f66f80afa24567930317627aa9a10f,using nivo,0.355483
uuid-83f66f80afa24567930317627aa9a10f,response,0.363223
uuid-83f66f80afa24567930317627aa9a10f,PD1,0.377125
uuid-83f66f80afa24567930317627aa9a10f,cHL,0.622284
uuid-83f66f80afa24567930317627aa9a10f,progression,0.629572
uuid-83f66f80afa24567930317627aa9a10f,chemotherapy,0.445135
uuid-83f66f80afa24567930317627aa9a10f,respond,0.441455
uuid-83f66f80afa24567930317627aa9a10f,option,0.300628
uuid-67dfb6a0deda4f7188966000141a7fbb,trial,0.406155
uuid-67dfb6a0deda4f7188966000141a7fbb,tumor,0.467689
uuid-21345733ee7944918f4b0ce4076a8c7c,PDL1,0.777495
uuid-21345733ee7944918f4b0ce4076a8c7c,efficacy,0.424962
uuid-21345733ee7944918f4b0ce4076a8c7c,PD-L1,0.435622
uuid-21345733ee7944918f4b0ce4076a8c7c,OS,0.477849
uuid-21345733ee7944918f4b0ce4076a8c7c,data,0.329088
uuid-21345733ee7944918f4b0ce4076a8c7c,PFS,0.489381
uuid-21345733ee7944918f4b0ce4076a8c7c,ORR,0.458486
uuid-21345733ee7944918f4b0ce4076a8c7c,nivo and pembro,0.513441
uuid-21345733ee7944918f4b0ce4076a8c7c,believes,0.524762
uuid-21345733ee7944918f4b0ce4076a8c7c,assay,0.392784
uuid-21345733ee7944918f4b0ce4076a8c7c,PDL1 expression,0.666228
uuid-21345733ee7944918f4b0ce4076a8c7c,biomarker,0.637245
uuid-3ce8f2b6658147a5859e976e988c24b7,lung,0.326236
uuid-3ce8f2b6658147a5859e976e988c24b7,PDL1,0.570569
uuid-3ce8f2b6658147a5859e976e988c24b7,efficacy,0.425115
uuid-3ce8f2b6658147a5859e976e988c24b7,OS,0.499309
uuid-3ce8f2b6658147a5859e976e988c24b7,regards,0.517339
uuid-3ce8f2b6658147a5859e976e988c24b7,data,0.47461
uuid-3ce8f2b6658147a5859e976e988c24b7,expressed,0.33134
uuid-3ce8f2b6658147a5859e976e988c24b7,PFS,0.582671
uuid-3ce8f2b6658147a5859e976e988c24b7,AI,0.672215
uuid-3ce8f2b6658147a5859e976e988c24b7,ORR,0.51305
uuid-3ce8f2b6658147a5859e976e988c24b7,nivo and pembro,0.640852
uuid-3ce8f2b6658147a5859e976e988c24b7,believes,0.303585
uuid-3ce8f2b6658147a5859e976e988c24b7,PDL1 expression,0.557307
uuid-3ce8f2b6658147a5859e976e988c24b7,biomarker,0.382959
uuid-3ce8f2b6658147a5859e976e988c24b7,NCCN,0.487196
uuid-cc1ea45d4c574f8a97f20cadfd3ccb58,TL,0.389003
uuid-cc1ea45d4c574f8a97f20cadfd3ccb58,PDL1,0.39681
uuid-cc1ea45d4c574f8a97f20cadfd3ccb58,tumor,0.37036
uuid-cc1ea45d4c574f8a97f20cadfd3ccb58,PD-L1,0.593585
uuid-cc1ea45d4c574f8a97f20cadfd3ccb58,PD-L1 testing,0.547791
uuid-cc1ea45d4c574f8a97f20cadfd3ccb58,testing,0.600114
uuid-cc1ea45d4c574f8a97f20cadfd3ccb58,PDL1 testing,0.349191
uuid-cc1ea45d4c574f8a97f20cadfd3ccb58,NSCLC patients,0.426286
uuid-cc1ea45d4c574f8a97f20cadfd3ccb58,assay,0.527148
uuid-cc1ea45d4c574f8a97f20cadfd3ccb58,biomarker,0.341008
uuid-db74e83b3b4547918c8f74b846ee3d47,lung,0.37785
uuid-db74e83b3b4547918c8f74b846ee3d47,OS,0.574836
uuid-db74e83b3b4547918c8f74b846ee3d47,regards,0.336028
uuid-db74e83b3b4547918c8f74b846ee3d47,response,0.424467
uuid-db74e83b3b4547918c8f74b846ee3d47,PFS,0.587051
uuid-db74e83b3b4547918c8f74b846ee3d47,AI,0.491564
uuid-db74e83b3b4547918c8f74b846ee3d47,ORR,0.499758
uuid-db74e83b3b4547918c8f74b846ee3d47,nivo and pembro,0.354839
uuid-db74e83b3b4547918c8f74b846ee3d47,believes,0.411693
uuid-915b181df79342a99e019755032d4bfd,pembro,0.398153
uuid-915b181df79342a99e019755032d4bfd,nivolumab,0.377972
uuid-915b181df79342a99e019755032d4bfd,1L,0.480938
uuid-915b181df79342a99e019755032d4bfd,RCC,0.571871
uuid-915b181df79342a99e019755032d4bfd,TL stated,0.314737
uuid-915b181df79342a99e019755032d4bfd,combination,0.518351
uuid-915b181df79342a99e019755032d4bfd,2L,0.586459
uuid-915b181df79342a99e019755032d4bfd,agents,0.448437
uuid-915b181df79342a99e019755032d4bfd,Ipi,0.308453
uuid-915b181df79342a99e019755032d4bfd,approval,0.330645
uuid-915b181df79342a99e019755032d4bfd,atezo,0.454846
uuid-915b181df79342a99e019755032d4bfd,preferred,0.600547
uuid-915b181df79342a99e019755032d4bfd,monotherapy,0.496365
uuid-915b181df79342a99e019755032d4bfd,using nivo,0.491199
uuid-915b181df79342a99e019755032d4bfd,combo,0.54643
uuid-915b181df79342a99e019755032d4bfd,clinical trials,0.352407
uuid-915b181df79342a99e019755032d4bfd,approved,0.468458
uuid-915b181df79342a99e019755032d4bfd,SCCHN,0.389297
uuid-915b181df79342a99e019755032d4bfd,RTL stated,0.560538
uuid-915b181df79342a99e019755032d4bfd,TL shared,0.370406
uuid-915b181df79342a99e019755032d4bfd,option,0.4436
uuid-915b181df79342a99e019755032d4bfd,bladder,0.517306
uuid-3d80480b454f49b3a83516dd760d526c,patients,0.350206
uuid-82bdfbfae32e4ebe8631bebc875bf063,patients,0.488776
uuid-82bdfbfae32e4ebe8631bebc875bf063,RTL,0.606499
uuid-82bdfbfae32e4ebe8631bebc875bf063,nivolumab,0.566092
uuid-82bdfbfae32e4ebe8631bebc875bf063,treated,0.477303
uuid-82bdfbfae32e4ebe8631bebc875bf063,NTL,0.352003
uuid-82bdfbfae32e4ebe8631bebc875bf063,RCC,0.403544
uuid-82bdfbfae32e4ebe8631bebc875bf063,pts,0.406114
uuid-82bdfbfae32e4ebe8631bebc875bf063,stated,0.318742
uuid-82bdfbfae32e4ebe8631bebc875bf063,approval,0.358985
uuid-82bdfbfae32e4ebe8631bebc875bf063,using nivo,0.546133
uuid-82bdfbfae32e4ebe8631bebc875bf063,mentioned,0.359579
uuid-82bdfbfae32e4ebe8631bebc875bf063,clinical trials,0.330909
uuid-82bdfbfae32e4ebe8631bebc875bf063,SCCHN,0.537176
uuid-82bdfbfae32e4ebe8631bebc875bf063,HCP,0.418133
uuid-82bdfbfae32e4ebe8631bebc875bf063,cHL,0.400469
uuid-82bdfbfae32e4ebe8631bebc875bf063,LTL,0.426243
uuid-82bdfbfae32e4ebe8631bebc875bf063,SCLC,0.508814
uuid-82bdfbfae32e4ebe8631bebc875bf063,Regional TL,0.458073
uuid-82bdfbfae32e4ebe8631bebc875bf063,RTL stated,0.538265
uuid-82bdfbfae32e4ebe8631bebc875bf063,TL shared,0.346603
uuid-82bdfbfae32e4ebe8631bebc875bf063,bladder,0.39141
uuid-65a91fb30e924ddd849eb813fa46f7c6,Nivo,0.328563
uuid-65a91fb30e924ddd849eb813fa46f7c6,patients,0.741873
uuid-65a91fb30e924ddd849eb813fa46f7c6,therapy,0.432827
uuid-65a91fb30e924ddd849eb813fa46f7c6,nivolumab,0.419357
uuid-65a91fb30e924ddd849eb813fa46f7c6,toxicity,0.508187
uuid-65a91fb30e924ddd849eb813fa46f7c6,regimen,0.653186
uuid-65a91fb30e924ddd849eb813fa46f7c6,treated,0.526249
uuid-65a91fb30e924ddd849eb813fa46f7c6,combination,0.35346
uuid-65a91fb30e924ddd849eb813fa46f7c6,chemo,0.429569
uuid-65a91fb30e924ddd849eb813fa46f7c6,pts,0.605763
uuid-65a91fb30e924ddd849eb813fa46f7c6,Ipi,0.344741
uuid-65a91fb30e924ddd849eb813fa46f7c6,monotherapy,0.474188
uuid-65a91fb30e924ddd849eb813fa46f7c6,treatment,0.562383
uuid-65a91fb30e924ddd849eb813fa46f7c6,response,0.473386
uuid-65a91fb30e924ddd849eb813fa46f7c6,PD1,0.332343
uuid-65a91fb30e924ddd849eb813fa46f7c6,progression,0.581459
uuid-65a91fb30e924ddd849eb813fa46f7c6,chemotherapy,0.40451
uuid-65a91fb30e924ddd849eb813fa46f7c6,respond,0.505446
uuid-65a91fb30e924ddd849eb813fa46f7c6,option,0.319591
uuid-9203c3b6a76a496b8027f9e25772f41d,patients,0.709281
uuid-9203c3b6a76a496b8027f9e25772f41d,RTL,0.454359
uuid-9203c3b6a76a496b8027f9e25772f41d,therapy,0.350555
uuid-9203c3b6a76a496b8027f9e25772f41d,nivolumab,0.5751
uuid-9203c3b6a76a496b8027f9e25772f41d,regimen,0.417349
uuid-9203c3b6a76a496b8027f9e25772f41d,treated,0.567962
uuid-9203c3b6a76a496b8027f9e25772f41d,pts,0.513731
uuid-9203c3b6a76a496b8027f9e25772f41d,monotherapy,0.322107
uuid-9203c3b6a76a496b8027f9e25772f41d,treatment,0.450452
uuid-9203c3b6a76a496b8027f9e25772f41d,using nivo,0.468296
uuid-9203c3b6a76a496b8027f9e25772f41d,SCCHN,0.385783
uuid-9203c3b6a76a496b8027f9e25772f41d,HCP,0.380872
uuid-9203c3b6a76a496b8027f9e25772f41d,cHL,0.356961
uuid-9203c3b6a76a496b8027f9e25772f41d,progression,0.429431
uuid-9203c3b6a76a496b8027f9e25772f41d,chemotherapy,0.320275
uuid-9203c3b6a76a496b8027f9e25772f41d,LTL,0.312702
uuid-9203c3b6a76a496b8027f9e25772f41d,SCLC,0.300982
uuid-9203c3b6a76a496b8027f9e25772f41d,Regional TL,0.300979
uuid-9203c3b6a76a496b8027f9e25772f41d,RTL stated,0.419706
uuid-9203c3b6a76a496b8027f9e25772f41d,bladder,0.354774
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,patients,0.71485
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,Opdivo,0.396366
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,therapy,0.50525
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,nivolumab,0.452313
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,toxicity,0.38853
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,regimen,0.481387
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,treated,0.505476
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,pts,0.379748
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,treatment,0.567305
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,using nivo,0.310864
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,progression,0.449616
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,chemotherapy,0.384073
uuid-9b805d1fb3a24d2db7797e4d2fce3af3,respond,0.351242
uuid-52ea6db5df8548ddbcd883d902bd9dac,patients,0.464877
uuid-52ea6db5df8548ddbcd883d902bd9dac,Opdivo,0.517809
uuid-52ea6db5df8548ddbcd883d902bd9dac,dose,0.469875
uuid-52ea6db5df8548ddbcd883d902bd9dac,flat dosing,0.535433
uuid-cf469b79c87245c5908fbaa7f6d84763,commented,0.48357
uuid-cf469b79c87245c5908fbaa7f6d84763,OS,0.628295
uuid-cf469b79c87245c5908fbaa7f6d84763,regards,0.338364
uuid-cf469b79c87245c5908fbaa7f6d84763,data,0.537027
uuid-cf469b79c87245c5908fbaa7f6d84763,PFS,0.559418
uuid-cf469b79c87245c5908fbaa7f6d84763,ORR,0.522271
uuid-cf469b79c87245c5908fbaa7f6d84763,ASCO,0.429934
uuid-cf469b79c87245c5908fbaa7f6d84763,impressed,0.523175
uuid-cf469b79c87245c5908fbaa7f6d84763,NCCN,0.377261
uuid-19d3fc27a0e34ce08a81db112e1a33ef,regimen,0.324504
uuid-19d3fc27a0e34ce08a81db112e1a33ef,chemo,0.318957
uuid-19d3fc27a0e34ce08a81db112e1a33ef,OS,0.31448
uuid-19d3fc27a0e34ce08a81db112e1a33ef,response,0.513801
uuid-19d3fc27a0e34ce08a81db112e1a33ef,progression,0.474682
uuid-19d3fc27a0e34ce08a81db112e1a33ef,respond,0.413039
uuid-41ec3d76a6444869999392c975b3db17,RTL,0.478043
uuid-41ec3d76a6444869999392c975b3db17,lung,0.510394
uuid-41ec3d76a6444869999392c975b3db17,melanoma,0.399264
uuid-41ec3d76a6444869999392c975b3db17,shared,0.340823
uuid-41ec3d76a6444869999392c975b3db17,commented,0.419321
uuid-41ec3d76a6444869999392c975b3db17,RCC,0.544259
uuid-41ec3d76a6444869999392c975b3db17,TL stated,0.636643
uuid-41ec3d76a6444869999392c975b3db17,stated,0.518829
uuid-41ec3d76a6444869999392c975b3db17,testing,0.354564
uuid-41ec3d76a6444869999392c975b3db17,PDL1 testing,0.573833
uuid-41ec3d76a6444869999392c975b3db17,NSCLC patients,0.533251
uuid-41ec3d76a6444869999392c975b3db17,SCCHN,0.566853
uuid-41ec3d76a6444869999392c975b3db17,impressed,0.309411
uuid-41ec3d76a6444869999392c975b3db17,tumor types,0.491666
uuid-41ec3d76a6444869999392c975b3db17,LTL,0.367361
uuid-41ec3d76a6444869999392c975b3db17,TLs,0.453592
uuid-41ec3d76a6444869999392c975b3db17,academic,0.399511
uuid-41ec3d76a6444869999392c975b3db17,Regional TL,0.509253
uuid-41ec3d76a6444869999392c975b3db17,RTL stated,0.498886
uuid-41ec3d76a6444869999392c975b3db17,TL shared,0.494597
uuid-41ec3d76a6444869999392c975b3db17,bladder,0.367465
uuid-33a46e5d7f0d42258a4c493259d9dca9,patients,0.361351
uuid-33a46e5d7f0d42258a4c493259d9dca9,therapy,0.371806
uuid-33a46e5d7f0d42258a4c493259d9dca9,toxicity,0.309542
uuid-33a46e5d7f0d42258a4c493259d9dca9,regimen,0.347275
uuid-33a46e5d7f0d42258a4c493259d9dca9,combination,0.343307
uuid-33a46e5d7f0d42258a4c493259d9dca9,chemo,0.380872
uuid-33a46e5d7f0d42258a4c493259d9dca9,2L,0.319516
uuid-33a46e5d7f0d42258a4c493259d9dca9,pts,0.312443
uuid-33a46e5d7f0d42258a4c493259d9dca9,monotherapy,0.413833
uuid-33a46e5d7f0d42258a4c493259d9dca9,response,0.301456
uuid-33a46e5d7f0d42258a4c493259d9dca9,combo,0.39043
uuid-33a46e5d7f0d42258a4c493259d9dca9,PD1,0.431783
uuid-33a46e5d7f0d42258a4c493259d9dca9,progression,0.352139
uuid-33a46e5d7f0d42258a4c493259d9dca9,option,0.390215
uuid-150a5f06764345cdbd645b3254e9ae76,patients,0.321572
uuid-150a5f06764345cdbd645b3254e9ae76,therapy,0.57129
uuid-150a5f06764345cdbd645b3254e9ae76,nivolumab,0.503358
uuid-150a5f06764345cdbd645b3254e9ae76,treated,0.468752
uuid-150a5f06764345cdbd645b3254e9ae76,tumor,0.436514
uuid-150a5f06764345cdbd645b3254e9ae76,pts,0.314231
uuid-150a5f06764345cdbd645b3254e9ae76,treatment,0.384226
uuid-150a5f06764345cdbd645b3254e9ae76,response,0.524631
uuid-150a5f06764345cdbd645b3254e9ae76,PD1,0.430544
uuid-150a5f06764345cdbd645b3254e9ae76,cHL,0.555659
uuid-150a5f06764345cdbd645b3254e9ae76,progression,0.449449
uuid-150a5f06764345cdbd645b3254e9ae76,immunotherapy,0.394559
uuid-60f6e41974b345de8f6350647b4f6141,Nivo,0.562412
uuid-60f6e41974b345de8f6350647b4f6141,pembro,0.468487
uuid-60f6e41974b345de8f6350647b4f6141,trial,0.550957
uuid-60f6e41974b345de8f6350647b4f6141,efficacy,0.347127
uuid-60f6e41974b345de8f6350647b4f6141,combination,0.386937
uuid-60f6e41974b345de8f6350647b4f6141,chemo,0.459575
uuid-60f6e41974b345de8f6350647b4f6141,Ipi,0.489965
uuid-60f6e41974b345de8f6350647b4f6141,atezo,0.307462
uuid-60f6e41974b345de8f6350647b4f6141,monotherapy,0.314502
uuid-60f6e41974b345de8f6350647b4f6141,combo,0.386166
uuid-60f6e41974b345de8f6350647b4f6141,clinical trials,0.357077
uuid-60f6e41974b345de8f6350647b4f6141,chemotherapy,0.383116
uuid-60f6e41974b345de8f6350647b4f6141,vs,0.513351
uuid-60f6e41974b345de8f6350647b4f6141,feels,0.579344
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,RTL,0.370635
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,lung,0.301555
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,NTL,0.315697
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,shared,0.313621
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,commented,0.517417
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,RCC,0.319869
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,TL stated,0.305601
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,stated,0.334607
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,physicians,0.313065
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,SCCHN,0.426589
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,ASCO,0.586094
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,impressed,0.4996
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,TLs,0.307346
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,Regional TL,0.536414
uuid-b5d8d43c9a7f4a5cbd791f7566ee20d5,TL shared,0.343527
uuid-a02569c3f1f04f5ab07f2f14f5cf4386,pembro,0.468858
uuid-a02569c3f1f04f5ab07f2f14f5cf4386,dose,0.784684
uuid-a02569c3f1f04f5ab07f2f14f5cf4386,toxicity,0.427162
uuid-a02569c3f1f04f5ab07f2f14f5cf4386,Ipi,0.397859
uuid-a02569c3f1f04f5ab07f2f14f5cf4386,atezo,0.372915
uuid-a02569c3f1f04f5ab07f2f14f5cf4386,vs,0.650818
uuid-a02569c3f1f04f5ab07f2f14f5cf4386,flat dosing,0.51851
uuid-890c0e7e4482484bbf5270d8dc7e2225,RTL,0.38107
uuid-890c0e7e4482484bbf5270d8dc7e2225,trial,0.315034
uuid-890c0e7e4482484bbf5270d8dc7e2225,treated,0.30638
uuid-890c0e7e4482484bbf5270d8dc7e2225,RCC,0.411073
uuid-890c0e7e4482484bbf5270d8dc7e2225,stated,0.329878
uuid-890c0e7e4482484bbf5270d8dc7e2225,preferred,0.41299
uuid-890c0e7e4482484bbf5270d8dc7e2225,using nivo,0.394329
uuid-890c0e7e4482484bbf5270d8dc7e2225,clinical trials,0.32728
uuid-890c0e7e4482484bbf5270d8dc7e2225,SCCHN,0.570229
uuid-890c0e7e4482484bbf5270d8dc7e2225,Regional TL,0.411852
uuid-890c0e7e4482484bbf5270d8dc7e2225,RTL stated,0.529506
uuid-890c0e7e4482484bbf5270d8dc7e2225,TL shared,0.452641
uuid-890c0e7e4482484bbf5270d8dc7e2225,bladder,0.379477
uuid-be9a6d88d2f6434b89c6040dbd12ed54,patients,0.68364
uuid-be9a6d88d2f6434b89c6040dbd12ed54,Opdivo,0.347419
uuid-be9a6d88d2f6434b89c6040dbd12ed54,therapy,0.486541
uuid-be9a6d88d2f6434b89c6040dbd12ed54,nivolumab,0.566837
uuid-be9a6d88d2f6434b89c6040dbd12ed54,regimen,0.407625
uuid-be9a6d88d2f6434b89c6040dbd12ed54,treated,0.772135
uuid-be9a6d88d2f6434b89c6040dbd12ed54,pts,0.355922
uuid-be9a6d88d2f6434b89c6040dbd12ed54,treatment,0.582146
uuid-be9a6d88d2f6434b89c6040dbd12ed54,response,0.304876
uuid-be9a6d88d2f6434b89c6040dbd12ed54,cHL,0.401611
uuid-be9a6d88d2f6434b89c6040dbd12ed54,progression,0.471721
uuid-be9a6d88d2f6434b89c6040dbd12ed54,respond,0.335628
uuid-be9a6d88d2f6434b89c6040dbd12ed54,RTL stated,0.338174
uuid-be9a6d88d2f6434b89c6040dbd12ed54,TL shared,0.333169
uuid-60b1f0a4e5874cb286501b082bc75ad3,RTL,0.375982
uuid-60b1f0a4e5874cb286501b082bc75ad3,BMS,0.549705
uuid-60b1f0a4e5874cb286501b082bc75ad3,trial,0.399664
uuid-60b1f0a4e5874cb286501b082bc75ad3,commented,0.637614
uuid-60b1f0a4e5874cb286501b082bc75ad3,Merck,0.425376
uuid-60b1f0a4e5874cb286501b082bc75ad3,stated,0.491975
uuid-60b1f0a4e5874cb286501b082bc75ad3,OS,0.476347
uuid-60b1f0a4e5874cb286501b082bc75ad3,regards,0.42943
uuid-60b1f0a4e5874cb286501b082bc75ad3,data,0.788854
uuid-60b1f0a4e5874cb286501b082bc75ad3,expressed,0.452713
uuid-60b1f0a4e5874cb286501b082bc75ad3,PFS,0.417648
uuid-60b1f0a4e5874cb286501b082bc75ad3,ORR,0.454753
uuid-60b1f0a4e5874cb286501b082bc75ad3,SCCHN,0.362276
uuid-60b1f0a4e5874cb286501b082bc75ad3,nivo and pembro,0.354962
uuid-60b1f0a4e5874cb286501b082bc75ad3,ASCO,0.439254
uuid-60b1f0a4e5874cb286501b082bc75ad3,impressed,0.635618
uuid-60b1f0a4e5874cb286501b082bc75ad3,LTL,0.312384
uuid-60b1f0a4e5874cb286501b082bc75ad3,TLs,0.462183
uuid-60b1f0a4e5874cb286501b082bc75ad3,Regional TL,0.428605
uuid-60b1f0a4e5874cb286501b082bc75ad3,NCCN,0.352055
uuid-03686f02985f40e0a0fb83190fc6a1f1,patients,0.542125
uuid-03686f02985f40e0a0fb83190fc6a1f1,chemo,0.409498
uuid-03686f02985f40e0a0fb83190fc6a1f1,pts,0.499703
uuid-03686f02985f40e0a0fb83190fc6a1f1,response,0.459538
uuid-03686f02985f40e0a0fb83190fc6a1f1,NSCLC patients,0.520593
uuid-03686f02985f40e0a0fb83190fc6a1f1,progression,0.439858
uuid-03686f02985f40e0a0fb83190fc6a1f1,respond,0.515268
uuid-f83f19b864474949adcd54fa5148251b,toxicity,0.393909
uuid-f83f19b864474949adcd54fa5148251b,efficacy,0.304813
uuid-f83f19b864474949adcd54fa5148251b,chemo,0.330763
uuid-f83f19b864474949adcd54fa5148251b,chemotherapy,0.359211
uuid-f83f19b864474949adcd54fa5148251b,feels,0.353546
uuid-55dd42d82586431c89c7e7de9a2d5d54,RTL,0.483185
uuid-55dd42d82586431c89c7e7de9a2d5d54,nivolumab,0.453247
uuid-55dd42d82586431c89c7e7de9a2d5d54,lung,0.339635
uuid-55dd42d82586431c89c7e7de9a2d5d54,trial,0.376406
uuid-55dd42d82586431c89c7e7de9a2d5d54,NTL,0.60303
uuid-55dd42d82586431c89c7e7de9a2d5d54,melanoma,0.309394
uuid-55dd42d82586431c89c7e7de9a2d5d54,stated,0.311144
uuid-55dd42d82586431c89c7e7de9a2d5d54,mentioned,0.365169
uuid-55dd42d82586431c89c7e7de9a2d5d54,cHL,0.321792
uuid-55dd42d82586431c89c7e7de9a2d5d54,Regional TL,0.461572
uuid-55dd42d82586431c89c7e7de9a2d5d54,bladder,0.303086
uuid-bc9124aa8224407e99b0742a5cd9d90c,lung,0.535269
uuid-bc9124aa8224407e99b0742a5cd9d90c,melanoma,0.322277
uuid-bc9124aa8224407e99b0742a5cd9d90c,institution,0.321128
uuid-bc9124aa8224407e99b0742a5cd9d90c,regards,0.408519
uuid-bc9124aa8224407e99b0742a5cd9d90c,AI,0.941087
uuid-bc9124aa8224407e99b0742a5cd9d90c,oncology,0.391327
uuid-bc9124aa8224407e99b0742a5cd9d90c,nivo and pembro,0.342464
uuid-bc9124aa8224407e99b0742a5cd9d90c,NCCN,0.549678
uuid-c095cde760c34906b2a02ad88a92187a,Nivo,0.429808
uuid-c095cde760c34906b2a02ad88a92187a,patients,0.641622
uuid-c095cde760c34906b2a02ad88a92187a,therapy,0.415277
uuid-c095cde760c34906b2a02ad88a92187a,toxicity,0.491391
uuid-c095cde760c34906b2a02ad88a92187a,regimen,0.471648
uuid-c095cde760c34906b2a02ad88a92187a,treated,0.322259
uuid-c095cde760c34906b2a02ad88a92187a,chemo,0.49021
uuid-c095cde760c34906b2a02ad88a92187a,pts,0.483064
uuid-c095cde760c34906b2a02ad88a92187a,monotherapy,0.326737
uuid-c095cde760c34906b2a02ad88a92187a,treatment,0.483997
uuid-c095cde760c34906b2a02ad88a92187a,response,0.500184
uuid-c095cde760c34906b2a02ad88a92187a,progression,0.520173
uuid-c095cde760c34906b2a02ad88a92187a,chemotherapy,0.445104
uuid-c095cde760c34906b2a02ad88a92187a,respond,0.511157
uuid-3eaeaedde14449e99a77d85a127bb4c1,lung,0.421209
uuid-3eaeaedde14449e99a77d85a127bb4c1,toxicity,0.368436
uuid-3eaeaedde14449e99a77d85a127bb4c1,regimen,0.447456
uuid-3eaeaedde14449e99a77d85a127bb4c1,melanoma,0.490269
uuid-3eaeaedde14449e99a77d85a127bb4c1,AI,0.69466
uuid-dde05d823edc4582a3ec9d1f554211ae,Opdivo,0.313067
uuid-dde05d823edc4582a3ec9d1f554211ae,shared,0.367285
uuid-dde05d823edc4582a3ec9d1f554211ae,commented,0.357084
uuid-dde05d823edc4582a3ec9d1f554211ae,stated,0.314352
uuid-dde05d823edc4582a3ec9d1f554211ae,approval,0.35529
uuid-dde05d823edc4582a3ec9d1f554211ae,indication,0.379714
uuid-dde05d823edc4582a3ec9d1f554211ae,oncology,0.390818
uuid-dde05d823edc4582a3ec9d1f554211ae,approved,0.335124
uuid-dde05d823edc4582a3ec9d1f554211ae,SCCHN,0.348874
uuid-dde05d823edc4582a3ec9d1f554211ae,label,0.391518
uuid-dde05d823edc4582a3ec9d1f554211ae,oncologist,0.306416
uuid-dde05d823edc4582a3ec9d1f554211ae,indicated,0.375453
uuid-dde05d823edc4582a3ec9d1f554211ae,clinical,0.306785
uuid-dde05d823edc4582a3ec9d1f554211ae,Regional TL,0.351981
uuid-dde05d823edc4582a3ec9d1f554211ae,NCCN,0.360529
uuid-dde05d823edc4582a3ec9d1f554211ae,flat dosing,0.441036
uuid-85a51313342044f8875eea3620415dfe,patients,0.660672
uuid-85a51313342044f8875eea3620415dfe,therapy,0.596819
uuid-85a51313342044f8875eea3620415dfe,nivolumab,0.359768
uuid-85a51313342044f8875eea3620415dfe,toxicity,0.348539
uuid-85a51313342044f8875eea3620415dfe,regimen,0.571339
uuid-85a51313342044f8875eea3620415dfe,treated,0.425886
uuid-85a51313342044f8875eea3620415dfe,combination,0.452655
uuid-85a51313342044f8875eea3620415dfe,chemo,0.617394
uuid-85a51313342044f8875eea3620415dfe,pts,0.528014
uuid-85a51313342044f8875eea3620415dfe,IO,0.388347
uuid-85a51313342044f8875eea3620415dfe,monotherapy,0.518906
uuid-85a51313342044f8875eea3620415dfe,treatment,0.668446
uuid-85a51313342044f8875eea3620415dfe,response,0.615217
uuid-85a51313342044f8875eea3620415dfe,combo,0.37553
uuid-85a51313342044f8875eea3620415dfe,PD1,0.547593
uuid-85a51313342044f8875eea3620415dfe,progression,0.752785
uuid-85a51313342044f8875eea3620415dfe,chemotherapy,0.608226
uuid-85a51313342044f8875eea3620415dfe,respond,0.554711
uuid-85a51313342044f8875eea3620415dfe,feels,0.367322
uuid-85a51313342044f8875eea3620415dfe,option,0.457842
uuid-5329f48e3efc41adb60c3b617e966222,patients,0.457658
uuid-2b0a1c5496b8484e879666a93be68bda,RTL,0.443287
uuid-2b0a1c5496b8484e879666a93be68bda,lung,0.315964
uuid-2b0a1c5496b8484e879666a93be68bda,toxicity,0.358608
uuid-2b0a1c5496b8484e879666a93be68bda,regimen,0.417613
uuid-2b0a1c5496b8484e879666a93be68bda,treated,0.396793
uuid-2b0a1c5496b8484e879666a93be68bda,melanoma,0.528087
uuid-2b0a1c5496b8484e879666a93be68bda,shared,0.364815
uuid-2b0a1c5496b8484e879666a93be68bda,commented,0.300166
uuid-2b0a1c5496b8484e879666a93be68bda,RCC,0.372155
uuid-2b0a1c5496b8484e879666a93be68bda,stated,0.427792
uuid-2b0a1c5496b8484e879666a93be68bda,SCCHN,0.451835
uuid-2b0a1c5496b8484e879666a93be68bda,LTL,0.379883
uuid-2b0a1c5496b8484e879666a93be68bda,academic,0.340129
uuid-2b0a1c5496b8484e879666a93be68bda,SCLC,0.379631
uuid-2b0a1c5496b8484e879666a93be68bda,Regional TL,0.407865
uuid-2b0a1c5496b8484e879666a93be68bda,RTL stated,0.362982
uuid-2b0a1c5496b8484e879666a93be68bda,TL shared,0.423561
uuid-b60185e2d5e1465099a21502ca231586,TL,0.464336
uuid-b60185e2d5e1465099a21502ca231586,1L,0.315652
uuid-b60185e2d5e1465099a21502ca231586,PDL1,0.405188
uuid-b60185e2d5e1465099a21502ca231586,TL stated,0.502702
uuid-b60185e2d5e1465099a21502ca231586,PD-L1,0.810368
uuid-b60185e2d5e1465099a21502ca231586,PD-L1 testing,0.801233
uuid-b60185e2d5e1465099a21502ca231586,testing,0.85929
uuid-b60185e2d5e1465099a21502ca231586,PDL1 testing,0.738596
uuid-b60185e2d5e1465099a21502ca231586,NSCLC patients,0.715206
uuid-b60185e2d5e1465099a21502ca231586,tumor types,0.328978
uuid-b60185e2d5e1465099a21502ca231586,assay,0.594051
uuid-b60185e2d5e1465099a21502ca231586,biomarker,0.449718
uuid-121c9a4522c245e28b7470a60962a6af,patients,0.436288
uuid-121c9a4522c245e28b7470a60962a6af,regimen,0.314726
uuid-121c9a4522c245e28b7470a60962a6af,pts,0.487619
uuid-121c9a4522c245e28b7470a60962a6af,IO,0.324854
uuid-121c9a4522c245e28b7470a60962a6af,monotherapy,0.329011
uuid-121c9a4522c245e28b7470a60962a6af,response,0.370329
uuid-121c9a4522c245e28b7470a60962a6af,combo,0.303284
uuid-121c9a4522c245e28b7470a60962a6af,NSCLC patients,0.338319
uuid-121c9a4522c245e28b7470a60962a6af,progression,0.446304
uuid-121c9a4522c245e28b7470a60962a6af,respond,0.341679
uuid-121c9a4522c245e28b7470a60962a6af,TL shared,0.31315
uuid-b461379935284dfbac198d5f19894cd3,Nivo,0.311838
uuid-b461379935284dfbac198d5f19894cd3,pembro,0.359971
uuid-b461379935284dfbac198d5f19894cd3,efficacy,0.501077
uuid-b461379935284dfbac198d5f19894cd3,agents,0.327636
uuid-b461379935284dfbac198d5f19894cd3,atezo,0.340774
uuid-b461379935284dfbac198d5f19894cd3,ORR,0.352058
uuid-b461379935284dfbac198d5f19894cd3,nivo and pembro,0.557374
uuid-b461379935284dfbac198d5f19894cd3,believes,0.316307
uuid-b461379935284dfbac198d5f19894cd3,vs,0.4859
uuid-b461379935284dfbac198d5f19894cd3,feels,0.453233
uuid-968f31cd03474c9ab4c7e7ef91dd4420,pembro,0.344233
uuid-968f31cd03474c9ab4c7e7ef91dd4420,BMS,0.36278
uuid-968f31cd03474c9ab4c7e7ef91dd4420,PDL1,0.659307
uuid-968f31cd03474c9ab4c7e7ef91dd4420,trial,0.568518
uuid-968f31cd03474c9ab4c7e7ef91dd4420,efficacy,0.570019
uuid-968f31cd03474c9ab4c7e7ef91dd4420,OS,0.61352
uuid-968f31cd03474c9ab4c7e7ef91dd4420,data,0.637146
uuid-968f31cd03474c9ab4c7e7ef91dd4420,PFS,0.678782
uuid-968f31cd03474c9ab4c7e7ef91dd4420,ORR,0.688956
uuid-968f31cd03474c9ab4c7e7ef91dd4420,nivo and pembro,0.60552
uuid-968f31cd03474c9ab4c7e7ef91dd4420,believes,0.422462
uuid-968f31cd03474c9ab4c7e7ef91dd4420,impressed,0.436641
uuid-968f31cd03474c9ab4c7e7ef91dd4420,feels,0.571573
uuid-968f31cd03474c9ab4c7e7ef91dd4420,PDL1 expression,0.627962
uuid-968f31cd03474c9ab4c7e7ef91dd4420,biomarker,0.329754
uuid-5225ee0cf6c74476b6e00a780d1f6e44,pembro,0.453745
uuid-5225ee0cf6c74476b6e00a780d1f6e44,dose,0.330358
uuid-5225ee0cf6c74476b6e00a780d1f6e44,Merck,0.44875
uuid-5225ee0cf6c74476b6e00a780d1f6e44,atezo,0.397026
uuid-5225ee0cf6c74476b6e00a780d1f6e44,data,0.358036
uuid-5225ee0cf6c74476b6e00a780d1f6e44,vs,0.450352
uuid-5225ee0cf6c74476b6e00a780d1f6e44,flat dosing,0.368371
uuid-5875104abfeb4675bc67b71193b8caec,1L,0.327543
uuid-5875104abfeb4675bc67b71193b8caec,toxicity,0.397585
uuid-5875104abfeb4675bc67b71193b8caec,regimen,0.323444
uuid-5875104abfeb4675bc67b71193b8caec,combination,0.635081
uuid-5875104abfeb4675bc67b71193b8caec,chemo,0.44719
uuid-5875104abfeb4675bc67b71193b8caec,2L,0.367304
uuid-5875104abfeb4675bc67b71193b8caec,IO,0.447897
uuid-5875104abfeb4675bc67b71193b8caec,agents,0.707019
uuid-5875104abfeb4675bc67b71193b8caec,preferred,0.31903
uuid-5875104abfeb4675bc67b71193b8caec,monotherapy,0.50868
uuid-5875104abfeb4675bc67b71193b8caec,combo,0.666113
uuid-5875104abfeb4675bc67b71193b8caec,PD1,0.459302
uuid-5875104abfeb4675bc67b71193b8caec,believes,0.394534
uuid-5875104abfeb4675bc67b71193b8caec,chemotherapy,0.382312
uuid-5875104abfeb4675bc67b71193b8caec,PD-1,0.385202
uuid-5875104abfeb4675bc67b71193b8caec,option,0.368471
uuid-3d03240219694d7bb785c374132490ac,TL,0.329105
uuid-3d03240219694d7bb785c374132490ac,pembro,0.422726
uuid-3d03240219694d7bb785c374132490ac,BMS,0.358122
uuid-3d03240219694d7bb785c374132490ac,PDL1,0.604906
uuid-3d03240219694d7bb785c374132490ac,Merck,0.584301
uuid-3d03240219694d7bb785c374132490ac,PD-L1,0.695107
uuid-3d03240219694d7bb785c374132490ac,atezo,0.529162
uuid-3d03240219694d7bb785c374132490ac,PD-L1 testing,0.516766
uuid-3d03240219694d7bb785c374132490ac,testing,0.695257
uuid-3d03240219694d7bb785c374132490ac,PDL1 testing,0.53707
uuid-3d03240219694d7bb785c374132490ac,NSCLC patients,0.417915
uuid-3d03240219694d7bb785c374132490ac,nivo and pembro,0.357221
uuid-3d03240219694d7bb785c374132490ac,assay,0.747507
uuid-3d03240219694d7bb785c374132490ac,PDL1 expression,0.482089
uuid-3d03240219694d7bb785c374132490ac,biomarker,0.504142
uuid-8c86e6110fb64d6981fdd6d31db1ae46,Nivo,0.316682
uuid-8c86e6110fb64d6981fdd6d31db1ae46,pembro,0.514601
uuid-8c86e6110fb64d6981fdd6d31db1ae46,dose,0.804098
uuid-8c86e6110fb64d6981fdd6d31db1ae46,efficacy,0.460852
uuid-8c86e6110fb64d6981fdd6d31db1ae46,Ipi,0.501278
uuid-8c86e6110fb64d6981fdd6d31db1ae46,atezo,0.599032
uuid-8c86e6110fb64d6981fdd6d31db1ae46,preferred,0.346828
uuid-8c86e6110fb64d6981fdd6d31db1ae46,vs,0.748909
uuid-8c86e6110fb64d6981fdd6d31db1ae46,TLs,0.409262
uuid-8c86e6110fb64d6981fdd6d31db1ae46,flat dosing,0.62251
uuid-3a0d4f5ae78049eab18e16b09c1202a2,patients,0.781477
uuid-3a0d4f5ae78049eab18e16b09c1202a2,Opdivo,0.436624
uuid-3a0d4f5ae78049eab18e16b09c1202a2,therapy,0.385529
uuid-3a0d4f5ae78049eab18e16b09c1202a2,dose,0.343882
uuid-3a0d4f5ae78049eab18e16b09c1202a2,nivolumab,0.436971
uuid-3a0d4f5ae78049eab18e16b09c1202a2,toxicity,0.35153
uuid-3a0d4f5ae78049eab18e16b09c1202a2,regimen,0.495041
uuid-3a0d4f5ae78049eab18e16b09c1202a2,treated,0.620623
uuid-3a0d4f5ae78049eab18e16b09c1202a2,pts,0.403039
uuid-3a0d4f5ae78049eab18e16b09c1202a2,treatment,0.602718
uuid-3a0d4f5ae78049eab18e16b09c1202a2,using nivo,0.319749
uuid-3a0d4f5ae78049eab18e16b09c1202a2,cHL,0.313115
uuid-3a0d4f5ae78049eab18e16b09c1202a2,progression,0.49528
uuid-3a0d4f5ae78049eab18e16b09c1202a2,respond,0.403198
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,patients,0.451919
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,RTL,0.401998
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,treated,0.467963
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,melanoma,0.306307
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,shared,0.346773
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,commented,0.366028
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,RCC,0.40699
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,stated,0.363514
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,approval,0.302866
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,using nivo,0.315137
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,clinical trials,0.410015
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,SCCHN,0.524899
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,Regional TL,0.473842
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,RTL stated,0.484073
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,TL shared,0.44655
uuid-2cdd20e41b174713bdf3bbcc2e43c97a,bladder,0.348154
uuid-6b1bf68a91e1415ba7616f5869797a7d,lung,0.432445
uuid-6b1bf68a91e1415ba7616f5869797a7d,1L,0.414741
uuid-6b1bf68a91e1415ba7616f5869797a7d,melanoma,0.36263
uuid-6b1bf68a91e1415ba7616f5869797a7d,RCC,0.450958
uuid-6b1bf68a91e1415ba7616f5869797a7d,TL stated,0.34676
uuid-6b1bf68a91e1415ba7616f5869797a7d,2L,0.450815
uuid-6b1bf68a91e1415ba7616f5869797a7d,agents,0.487693
uuid-6b1bf68a91e1415ba7616f5869797a7d,preferred,0.365417
uuid-6b1bf68a91e1415ba7616f5869797a7d,monotherapy,0.38128
uuid-6b1bf68a91e1415ba7616f5869797a7d,using nivo,0.322823
uuid-6b1bf68a91e1415ba7616f5869797a7d,PD1,0.415323
uuid-6b1bf68a91e1415ba7616f5869797a7d,PD-1,0.477355
uuid-6b1bf68a91e1415ba7616f5869797a7d,RTL stated,0.364928
uuid-6b1bf68a91e1415ba7616f5869797a7d,TL shared,0.335378
uuid-6b1bf68a91e1415ba7616f5869797a7d,option,0.361004
uuid-a0dd4753776745309a6996dd9f0ba10f,lung,0.432445
uuid-a0dd4753776745309a6996dd9f0ba10f,1L,0.414741
uuid-a0dd4753776745309a6996dd9f0ba10f,melanoma,0.36263
uuid-a0dd4753776745309a6996dd9f0ba10f,RCC,0.450958
uuid-a0dd4753776745309a6996dd9f0ba10f,TL stated,0.34676
uuid-a0dd4753776745309a6996dd9f0ba10f,2L,0.450815
uuid-a0dd4753776745309a6996dd9f0ba10f,agents,0.487693
uuid-a0dd4753776745309a6996dd9f0ba10f,preferred,0.365417
uuid-a0dd4753776745309a6996dd9f0ba10f,monotherapy,0.38128
uuid-a0dd4753776745309a6996dd9f0ba10f,using nivo,0.322823
uuid-a0dd4753776745309a6996dd9f0ba10f,PD1,0.415323
uuid-a0dd4753776745309a6996dd9f0ba10f,PD-1,0.477355
uuid-a0dd4753776745309a6996dd9f0ba10f,RTL stated,0.364928
uuid-a0dd4753776745309a6996dd9f0ba10f,TL shared,0.335378
uuid-a0dd4753776745309a6996dd9f0ba10f,option,0.361004
uuid-27fb073bbe3a4132b659d204c95a1fab,Nivo,0.402565
uuid-27fb073bbe3a4132b659d204c95a1fab,pembro,0.429759
uuid-27fb073bbe3a4132b659d204c95a1fab,dose,0.333789
uuid-27fb073bbe3a4132b659d204c95a1fab,trial,0.419865
uuid-27fb073bbe3a4132b659d204c95a1fab,efficacy,0.586732
uuid-27fb073bbe3a4132b659d204c95a1fab,combination,0.307183
uuid-27fb073bbe3a4132b659d204c95a1fab,chemo,0.311392
uuid-27fb073bbe3a4132b659d204c95a1fab,agents,0.35953
uuid-27fb073bbe3a4132b659d204c95a1fab,Ipi,0.334602
uuid-27fb073bbe3a4132b659d204c95a1fab,atezo,0.395585
uuid-27fb073bbe3a4132b659d204c95a1fab,combo,0.334896
uuid-27fb073bbe3a4132b659d204c95a1fab,nivo and pembro,0.400457
uuid-27fb073bbe3a4132b659d204c95a1fab,believes,0.403088
uuid-27fb073bbe3a4132b659d204c95a1fab,vs,0.647296
uuid-27fb073bbe3a4132b659d204c95a1fab,feels,0.544736
uuid-d817a5cb4da94f768d5ec428266c6e14,patients,0.436288
uuid-d817a5cb4da94f768d5ec428266c6e14,regimen,0.314726
uuid-d817a5cb4da94f768d5ec428266c6e14,pts,0.487619
uuid-d817a5cb4da94f768d5ec428266c6e14,IO,0.324854
uuid-d817a5cb4da94f768d5ec428266c6e14,monotherapy,0.329011
uuid-d817a5cb4da94f768d5ec428266c6e14,response,0.370329
uuid-d817a5cb4da94f768d5ec428266c6e14,combo,0.303284
uuid-d817a5cb4da94f768d5ec428266c6e14,NSCLC patients,0.338319
uuid-d817a5cb4da94f768d5ec428266c6e14,progression,0.446304
uuid-d817a5cb4da94f768d5ec428266c6e14,respond,0.341679
uuid-d817a5cb4da94f768d5ec428266c6e14,TL shared,0.31315
uuid-257034734cd04037b3323b8d678a1c8a,Opdivo,0.430018
uuid-257034734cd04037b3323b8d678a1c8a,dose,0.885298
uuid-257034734cd04037b3323b8d678a1c8a,toxicity,0.40225
uuid-257034734cd04037b3323b8d678a1c8a,efficacy,0.325901
uuid-257034734cd04037b3323b8d678a1c8a,Ipi,0.452246
uuid-257034734cd04037b3323b8d678a1c8a,vs,0.545441
uuid-257034734cd04037b3323b8d678a1c8a,drug,0.36785
uuid-257034734cd04037b3323b8d678a1c8a,Keytruda,0.487659
uuid-257034734cd04037b3323b8d678a1c8a,flat dosing,0.832086
uuid-bc025448824f4301ba786880901b94a1,Opdivo,0.567015
uuid-bc025448824f4301ba786880901b94a1,dose,0.754348
uuid-bc025448824f4301ba786880901b94a1,toxicity,0.511359
uuid-bc025448824f4301ba786880901b94a1,regimen,0.311253
uuid-bc025448824f4301ba786880901b94a1,Ipi,0.352549
uuid-bc025448824f4301ba786880901b94a1,vs,0.331206
uuid-bc025448824f4301ba786880901b94a1,Keytruda,0.412525
uuid-bc025448824f4301ba786880901b94a1,flat dosing,0.668827
uuid-ee772b123b31454bb9f6af94cde5a92f,treatment,0.335856
uuid-ee772b123b31454bb9f6af94cde5a92f,ASCO,0.513907
uuid-ee772b123b31454bb9f6af94cde5a92f,oncologist,0.344854
uuid-ee772b123b31454bb9f6af94cde5a92f,immunotherapy,0.42251
uuid-464043816f35432d8efb81d86b08d177,patients,0.771906
uuid-464043816f35432d8efb81d86b08d177,Opdivo,0.594371
uuid-464043816f35432d8efb81d86b08d177,therapy,0.366916
uuid-464043816f35432d8efb81d86b08d177,nivolumab,0.301383
uuid-464043816f35432d8efb81d86b08d177,treated,0.386133
uuid-464043816f35432d8efb81d86b08d177,pts,0.497391
uuid-464043816f35432d8efb81d86b08d177,approval,0.405027
uuid-464043816f35432d8efb81d86b08d177,PD-L1 testing,0.412467
uuid-464043816f35432d8efb81d86b08d177,testing,0.373549
uuid-464043816f35432d8efb81d86b08d177,treatment,0.461656
uuid-464043816f35432d8efb81d86b08d177,using nivo,0.324038
uuid-464043816f35432d8efb81d86b08d177,PDL1 testing,0.302245
uuid-464043816f35432d8efb81d86b08d177,NSCLC patients,0.472217
uuid-464043816f35432d8efb81d86b08d177,progression,0.412618
uuid-464043816f35432d8efb81d86b08d177,respond,0.335086
uuid-464043816f35432d8efb81d86b08d177,option,0.305503
uuid-c1d24c1856de42ca87d7b85360e35106,TL,0.415986
uuid-c1d24c1856de42ca87d7b85360e35106,TL stated,0.372153
uuid-c1d24c1856de42ca87d7b85360e35106,PD-L1,0.616913
uuid-c1d24c1856de42ca87d7b85360e35106,PD-L1 testing,0.755908
uuid-c1d24c1856de42ca87d7b85360e35106,testing,0.770254
uuid-c1d24c1856de42ca87d7b85360e35106,PDL1 testing,0.692271
uuid-c1d24c1856de42ca87d7b85360e35106,NSCLC patients,0.603492
uuid-c1d24c1856de42ca87d7b85360e35106,assay,0.410351
uuid-c1d24c1856de42ca87d7b85360e35106,biomarker,0.37432
uuid-d19d52db38d94412833482caad25e636,Nivo,0.646327
uuid-d19d52db38d94412833482caad25e636,patients,0.822145
uuid-d19d52db38d94412833482caad25e636,Opdivo,0.397046
uuid-d19d52db38d94412833482caad25e636,therapy,0.733126
uuid-d19d52db38d94412833482caad25e636,nivolumab,0.596106
uuid-d19d52db38d94412833482caad25e636,1L,0.347714
uuid-d19d52db38d94412833482caad25e636,regimen,0.416492
uuid-d19d52db38d94412833482caad25e636,treated,0.449575
uuid-d19d52db38d94412833482caad25e636,chemo,0.497246
uuid-d19d52db38d94412833482caad25e636,2L,0.36899
uuid-d19d52db38d94412833482caad25e636,pts,0.558965
uuid-d19d52db38d94412833482caad25e636,approval,0.388233
uuid-d19d52db38d94412833482caad25e636,preferred,0.321455
uuid-d19d52db38d94412833482caad25e636,monotherapy,0.52558
uuid-d19d52db38d94412833482caad25e636,treatment,0.590307
uuid-d19d52db38d94412833482caad25e636,using nivo,0.545457
uuid-d19d52db38d94412833482caad25e636,response,0.352276
uuid-d19d52db38d94412833482caad25e636,PD1,0.42683
uuid-d19d52db38d94412833482caad25e636,approved,0.346119
uuid-d19d52db38d94412833482caad25e636,cHL,0.503677
uuid-d19d52db38d94412833482caad25e636,progression,0.564954
uuid-d19d52db38d94412833482caad25e636,chemotherapy,0.530476
uuid-d19d52db38d94412833482caad25e636,respond,0.395457
uuid-d19d52db38d94412833482caad25e636,RTL stated,0.342752
uuid-d19d52db38d94412833482caad25e636,option,0.515679
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,Nivo,0.310142
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,pembro,0.55615
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,RTL,0.343147
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,1L,0.407885
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,trial,0.748991
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,shared,0.326691
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,RCC,0.302702
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,combination,0.48899
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,2L,0.383824
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,agents,0.323837
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,Merck,0.305142
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,Ipi,0.382717
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,approval,0.331734
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,atezo,0.442531
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,preferred,0.336065
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,monotherapy,0.324126
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,using nivo,0.334532
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,data,0.332933
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,combo,0.494169
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,clinical trials,0.498187
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,approved,0.364451
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,SCCHN,0.321402
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,impressed,0.304168
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,vs,0.308264
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,Regional TL,0.318347
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,RTL stated,0.363961
uuid-fe6e2c17c3544d0cb2c94f3e62a8cf02,bladder,0.416544
uuid-ad778e401a8548b8ba0d658c090d83bf,TL,0.407182
uuid-ad778e401a8548b8ba0d658c090d83bf,PDL1,0.352887
uuid-ad778e401a8548b8ba0d658c090d83bf,institution,0.321714
uuid-ad778e401a8548b8ba0d658c090d83bf,PD-L1,0.660311
uuid-ad778e401a8548b8ba0d658c090d83bf,PD-L1 testing,0.687408
uuid-ad778e401a8548b8ba0d658c090d83bf,testing,0.675084
uuid-ad778e401a8548b8ba0d658c090d83bf,PDL1 testing,0.532225
uuid-ad778e401a8548b8ba0d658c090d83bf,NSCLC patients,0.428931
uuid-ad778e401a8548b8ba0d658c090d83bf,assay,0.609457
uuid-ad778e401a8548b8ba0d658c090d83bf,biomarker,0.41713
uuid-2d9f1eb5b49448c489bbde36f124e4da,Nivo,0.574026
uuid-2d9f1eb5b49448c489bbde36f124e4da,patients,0.484693
uuid-2d9f1eb5b49448c489bbde36f124e4da,pembro,0.444806
uuid-2d9f1eb5b49448c489bbde36f124e4da,therapy,0.387166
uuid-2d9f1eb5b49448c489bbde36f124e4da,nivolumab,0.582872
uuid-2d9f1eb5b49448c489bbde36f124e4da,1L,0.600204
uuid-2d9f1eb5b49448c489bbde36f124e4da,regimen,0.431961
uuid-2d9f1eb5b49448c489bbde36f124e4da,RCC,0.445645
uuid-2d9f1eb5b49448c489bbde36f124e4da,combination,0.399214
uuid-2d9f1eb5b49448c489bbde36f124e4da,chemo,0.423394
uuid-2d9f1eb5b49448c489bbde36f124e4da,2L,0.712743
uuid-2d9f1eb5b49448c489bbde36f124e4da,pts,0.376898
uuid-2d9f1eb5b49448c489bbde36f124e4da,agents,0.39441
uuid-2d9f1eb5b49448c489bbde36f124e4da,approval,0.374623
uuid-2d9f1eb5b49448c489bbde36f124e4da,atezo,0.400001
uuid-2d9f1eb5b49448c489bbde36f124e4da,preferred,0.640354
uuid-2d9f1eb5b49448c489bbde36f124e4da,monotherapy,0.668104
uuid-2d9f1eb5b49448c489bbde36f124e4da,treatment,0.339723
uuid-2d9f1eb5b49448c489bbde36f124e4da,using nivo,0.739147
uuid-2d9f1eb5b49448c489bbde36f124e4da,combo,0.410729
uuid-2d9f1eb5b49448c489bbde36f124e4da,PD1,0.404195
uuid-2d9f1eb5b49448c489bbde36f124e4da,approved,0.501266
uuid-2d9f1eb5b49448c489bbde36f124e4da,SCCHN,0.391212
uuid-2d9f1eb5b49448c489bbde36f124e4da,chemotherapy,0.396153
uuid-2d9f1eb5b49448c489bbde36f124e4da,SCLC,0.314434
uuid-2d9f1eb5b49448c489bbde36f124e4da,feels,0.462932
uuid-2d9f1eb5b49448c489bbde36f124e4da,RTL stated,0.557902
uuid-2d9f1eb5b49448c489bbde36f124e4da,option,0.631021
uuid-2d9f1eb5b49448c489bbde36f124e4da,bladder,0.360811
uuid-324a8b2f3a0949b4b3b527942c8a3ec2,trial,0.749541
uuid-324a8b2f3a0949b4b3b527942c8a3ec2,OS,0.468998
uuid-324a8b2f3a0949b4b3b527942c8a3ec2,data,0.480492
uuid-324a8b2f3a0949b4b3b527942c8a3ec2,clinical trials,0.319818
uuid-324a8b2f3a0949b4b3b527942c8a3ec2,PFS,0.48099
uuid-324a8b2f3a0949b4b3b527942c8a3ec2,ORR,0.565609
uuid-324a8b2f3a0949b4b3b527942c8a3ec2,impressed,0.427468
uuid-572465ef999d4a47bfedc97cd4b4df2e,Nivo,0.362896
uuid-572465ef999d4a47bfedc97cd4b4df2e,patients,0.822844
uuid-572465ef999d4a47bfedc97cd4b4df2e,Opdivo,0.458553
uuid-572465ef999d4a47bfedc97cd4b4df2e,therapy,0.674945
uuid-572465ef999d4a47bfedc97cd4b4df2e,nivolumab,0.526786
uuid-572465ef999d4a47bfedc97cd4b4df2e,regimen,0.565797
uuid-572465ef999d4a47bfedc97cd4b4df2e,treated,0.589123
uuid-572465ef999d4a47bfedc97cd4b4df2e,chemo,0.408423
uuid-572465ef999d4a47bfedc97cd4b4df2e,pts,0.592645
uuid-572465ef999d4a47bfedc97cd4b4df2e,monotherapy,0.402748
uuid-572465ef999d4a47bfedc97cd4b4df2e,treatment,0.713138
uuid-572465ef999d4a47bfedc97cd4b4df2e,using nivo,0.321514
uuid-572465ef999d4a47bfedc97cd4b4df2e,response,0.471194
uuid-572465ef999d4a47bfedc97cd4b4df2e,PD1,0.402342
uuid-572465ef999d4a47bfedc97cd4b4df2e,cHL,0.389046
uuid-572465ef999d4a47bfedc97cd4b4df2e,progression,0.758567
uuid-572465ef999d4a47bfedc97cd4b4df2e,chemotherapy,0.422815
uuid-572465ef999d4a47bfedc97cd4b4df2e,respond,0.552104
uuid-572465ef999d4a47bfedc97cd4b4df2e,option,0.330351
uuid-b965b81677c64c888444befb38fecc6e,pembro,0.313577
uuid-b965b81677c64c888444befb38fecc6e,BMS,0.372569
uuid-b965b81677c64c888444befb38fecc6e,PDL1,0.64215
uuid-b965b81677c64c888444befb38fecc6e,efficacy,0.443022
uuid-b965b81677c64c888444befb38fecc6e,Merck,0.413235
uuid-b965b81677c64c888444befb38fecc6e,OS,0.541631
uuid-b965b81677c64c888444befb38fecc6e,atezo,0.324648
uuid-b965b81677c64c888444befb38fecc6e,regards,0.317919
uuid-b965b81677c64c888444befb38fecc6e,data,0.467299
uuid-b965b81677c64c888444befb38fecc6e,PFS,0.517099
uuid-b965b81677c64c888444befb38fecc6e,ORR,0.430486
uuid-b965b81677c64c888444befb38fecc6e,nivo and pembro,0.537276
uuid-b965b81677c64c888444befb38fecc6e,believes,0.401915
uuid-b965b81677c64c888444befb38fecc6e,Keytruda,0.318501
uuid-b965b81677c64c888444befb38fecc6e,feels,0.327967
uuid-b965b81677c64c888444befb38fecc6e,PDL1 expression,0.486305
uuid-b965b81677c64c888444befb38fecc6e,biomarker,0.322537
uuid-ff2d4a6102c8496d9b75768447a249cb,toxicity,0.301219
uuid-ff2d4a6102c8496d9b75768447a249cb,treated,0.378632
uuid-ff2d4a6102c8496d9b75768447a249cb,physicians,0.555308
uuid-ff2d4a6102c8496d9b75768447a249cb,treatment,0.308075
uuid-ff2d4a6102c8496d9b75768447a249cb,oncology,0.393745
uuid-ff2d4a6102c8496d9b75768447a249cb,academic,0.316039
uuid-e52eb95c099146929aca416f5d40aa74,BMS,0.398822
uuid-e52eb95c099146929aca416f5d40aa74,Merck,0.430671
uuid-e52eb95c099146929aca416f5d40aa74,approval,0.315718
uuid-e52eb95c099146929aca416f5d40aa74,clinical trials,0.327752
uuid-8a62d3be28424af681e65e6e8c26e5d6,PDL1,0.63503
uuid-8a62d3be28424af681e65e6e8c26e5d6,agents,0.338679
uuid-8a62d3be28424af681e65e6e8c26e5d6,PD-L1,0.586901
uuid-8a62d3be28424af681e65e6e8c26e5d6,PD-L1 testing,0.34163
uuid-8a62d3be28424af681e65e6e8c26e5d6,testing,0.543245
uuid-8a62d3be28424af681e65e6e8c26e5d6,PDL1 testing,0.483657
uuid-8a62d3be28424af681e65e6e8c26e5d6,believes,0.413571
uuid-8a62d3be28424af681e65e6e8c26e5d6,assay,0.477764
uuid-8a62d3be28424af681e65e6e8c26e5d6,PDL1 expression,0.510111
uuid-8a62d3be28424af681e65e6e8c26e5d6,biomarker,0.70718
uuid-6617c007d77f4b80abba8de79e060806,TL,0.369489
uuid-6617c007d77f4b80abba8de79e060806,1L,0.497381
uuid-6617c007d77f4b80abba8de79e060806,PDL1,0.417059
uuid-6617c007d77f4b80abba8de79e060806,TL stated,0.502605
uuid-6617c007d77f4b80abba8de79e060806,2L,0.437634
uuid-6617c007d77f4b80abba8de79e060806,PD-L1,0.733486
uuid-6617c007d77f4b80abba8de79e060806,approval,0.39473
uuid-6617c007d77f4b80abba8de79e060806,atezo,0.327083
uuid-6617c007d77f4b80abba8de79e060806,preferred,0.3802
uuid-6617c007d77f4b80abba8de79e060806,PD-L1 testing,0.725586
uuid-6617c007d77f4b80abba8de79e060806,testing,0.864263
uuid-6617c007d77f4b80abba8de79e060806,using nivo,0.302779
uuid-6617c007d77f4b80abba8de79e060806,PDL1 testing,0.801852
uuid-6617c007d77f4b80abba8de79e060806,NSCLC patients,0.781015
uuid-6617c007d77f4b80abba8de79e060806,approved,0.347346
uuid-6617c007d77f4b80abba8de79e060806,tumor types,0.451822
uuid-6617c007d77f4b80abba8de79e060806,assay,0.523904
uuid-6617c007d77f4b80abba8de79e060806,RTL stated,0.344339
uuid-6617c007d77f4b80abba8de79e060806,biomarker,0.381351
uuid-e7427d8690044a9f8cfe1e0c021fc3ab,patients,0.423449
uuid-e7427d8690044a9f8cfe1e0c021fc3ab,Opdivo,0.427891
uuid-e7427d8690044a9f8cfe1e0c021fc3ab,dose,0.587541
uuid-e7427d8690044a9f8cfe1e0c021fc3ab,toxicity,0.597686
uuid-e7427d8690044a9f8cfe1e0c021fc3ab,regimen,0.446672
uuid-e7427d8690044a9f8cfe1e0c021fc3ab,treated,0.42586
uuid-e7427d8690044a9f8cfe1e0c021fc3ab,Ipi,0.317997
uuid-e7427d8690044a9f8cfe1e0c021fc3ab,treatment,0.514686
uuid-e7427d8690044a9f8cfe1e0c021fc3ab,respond,0.336926
uuid-e7427d8690044a9f8cfe1e0c021fc3ab,flat dosing,0.317946
uuid-e01aee326df547349872e67bcffe2599,patients,0.560401
uuid-e01aee326df547349872e67bcffe2599,Opdivo,0.354741
uuid-e01aee326df547349872e67bcffe2599,therapy,0.374355
uuid-e01aee326df547349872e67bcffe2599,nivolumab,0.56889
uuid-e01aee326df547349872e67bcffe2599,regimen,0.375128
uuid-e01aee326df547349872e67bcffe2599,treated,0.471177
uuid-e01aee326df547349872e67bcffe2599,physicians,0.424294
uuid-e01aee326df547349872e67bcffe2599,treatment,0.422598
uuid-e01aee326df547349872e67bcffe2599,using nivo,0.36155
uuid-e01aee326df547349872e67bcffe2599,cHL,0.330207
uuid-e01aee326df547349872e67bcffe2599,progression,0.302472
uuid-e01aee326df547349872e67bcffe2599,oncologist,0.336793
uuid-e01aee326df547349872e67bcffe2599,Regional TL,0.362638
uuid-10f1809c182e4291bb67206505f807df,RTL,0.391078
uuid-10f1809c182e4291bb67206505f807df,nivolumab,0.392005
uuid-10f1809c182e4291bb67206505f807df,trial,0.385564
uuid-10f1809c182e4291bb67206505f807df,physicians,0.337617
uuid-10f1809c182e4291bb67206505f807df,clinical trials,0.424464
uuid-10f1809c182e4291bb67206505f807df,Regional TL,0.389176
uuid-08fc02d18a3c4bcdb8fa21bbb6ddbbf4,lung,0.410175
uuid-08fc02d18a3c4bcdb8fa21bbb6ddbbf4,commented,0.317196
uuid-08fc02d18a3c4bcdb8fa21bbb6ddbbf4,institution,0.402987
uuid-08fc02d18a3c4bcdb8fa21bbb6ddbbf4,stated,0.313624
uuid-08fc02d18a3c4bcdb8fa21bbb6ddbbf4,regards,0.322588
uuid-08fc02d18a3c4bcdb8fa21bbb6ddbbf4,expressed,0.309664
uuid-08fc02d18a3c4bcdb8fa21bbb6ddbbf4,AI,0.605746
uuid-08fc02d18a3c4bcdb8fa21bbb6ddbbf4,oncology,0.416786
uuid-08fc02d18a3c4bcdb8fa21bbb6ddbbf4,NCCN,0.719096
uuid-fc56d8696d7c4d908ba056a260507880,Nivo,0.319162
uuid-fc56d8696d7c4d908ba056a260507880,pembro,0.572626
uuid-fc56d8696d7c4d908ba056a260507880,dose,0.602781
uuid-fc56d8696d7c4d908ba056a260507880,trial,0.324359
uuid-fc56d8696d7c4d908ba056a260507880,efficacy,0.449391
uuid-fc56d8696d7c4d908ba056a260507880,Ipi,0.370791
uuid-fc56d8696d7c4d908ba056a260507880,atezo,0.524224
uuid-fc56d8696d7c4d908ba056a260507880,data,0.335988
uuid-fc56d8696d7c4d908ba056a260507880,nivo and pembro,0.341584
uuid-fc56d8696d7c4d908ba056a260507880,vs,0.75361
uuid-fc56d8696d7c4d908ba056a260507880,TLs,0.313217
uuid-fc56d8696d7c4d908ba056a260507880,flat dosing,0.517014
uuid-97e2d4c7b31a45e3853515e62e12c457,Nivo,0.654756
uuid-97e2d4c7b31a45e3853515e62e12c457,patients,0.707539
uuid-97e2d4c7b31a45e3853515e62e12c457,Opdivo,0.327881
uuid-97e2d4c7b31a45e3853515e62e12c457,therapy,0.696973
uuid-97e2d4c7b31a45e3853515e62e12c457,nivolumab,0.536961
uuid-97e2d4c7b31a45e3853515e62e12c457,toxicity,0.371318
uuid-97e2d4c7b31a45e3853515e62e12c457,regimen,0.506619
uuid-97e2d4c7b31a45e3853515e62e12c457,treated,0.360752
uuid-97e2d4c7b31a45e3853515e62e12c457,combination,0.404765
uuid-97e2d4c7b31a45e3853515e62e12c457,chemo,0.575118
uuid-97e2d4c7b31a45e3853515e62e12c457,pts,0.464092
uuid-97e2d4c7b31a45e3853515e62e12c457,Ipi,0.35211
uuid-97e2d4c7b31a45e3853515e62e12c457,monotherapy,0.533955
uuid-97e2d4c7b31a45e3853515e62e12c457,treatment,0.535491
uuid-97e2d4c7b31a45e3853515e62e12c457,using nivo,0.363102
uuid-97e2d4c7b31a45e3853515e62e12c457,response,0.475434
uuid-97e2d4c7b31a45e3853515e62e12c457,PD1,0.512902
uuid-97e2d4c7b31a45e3853515e62e12c457,cHL,0.494928
uuid-97e2d4c7b31a45e3853515e62e12c457,progression,0.561073
uuid-97e2d4c7b31a45e3853515e62e12c457,chemotherapy,0.590214
uuid-97e2d4c7b31a45e3853515e62e12c457,respond,0.461559
uuid-97e2d4c7b31a45e3853515e62e12c457,feels,0.344762
uuid-97e2d4c7b31a45e3853515e62e12c457,option,0.424156
uuid-7a094b2b755d4ae8a40970a848a9c663,patients,0.557362
uuid-7a094b2b755d4ae8a40970a848a9c663,Opdivo,0.464138
uuid-7a094b2b755d4ae8a40970a848a9c663,therapy,0.393286
uuid-7a094b2b755d4ae8a40970a848a9c663,dose,0.348748
uuid-7a094b2b755d4ae8a40970a848a9c663,nivolumab,0.427549
uuid-7a094b2b755d4ae8a40970a848a9c663,regimen,0.469305
uuid-7a094b2b755d4ae8a40970a848a9c663,treated,0.61143
uuid-7a094b2b755d4ae8a40970a848a9c663,physicians,0.446
uuid-7a094b2b755d4ae8a40970a848a9c663,treatment,0.639699
uuid-7a094b2b755d4ae8a40970a848a9c663,progression,0.334929
uuid-c050db523c334b3b871ab510f0906e43,Opdivo,0.442135
uuid-c050db523c334b3b871ab510f0906e43,RTL,0.335782
uuid-c050db523c334b3b871ab510f0906e43,BMS,0.36771
uuid-c050db523c334b3b871ab510f0906e43,shared,0.438993
uuid-c050db523c334b3b871ab510f0906e43,commented,0.359169
uuid-c050db523c334b3b871ab510f0906e43,stated,0.433479
uuid-c050db523c334b3b871ab510f0906e43,physicians,0.607829
uuid-c050db523c334b3b871ab510f0906e43,mentioned,0.416166
uuid-c050db523c334b3b871ab510f0906e43,oncology,0.360485
uuid-c050db523c334b3b871ab510f0906e43,HCP,0.321398
uuid-c050db523c334b3b871ab510f0906e43,LTL,0.395114
uuid-c050db523c334b3b871ab510f0906e43,clinical,0.307264
uuid-c050db523c334b3b871ab510f0906e43,Regional TL,0.391281
uuid-99e1331c1a364ee7a6086f7b6290435b,Nivo,0.560076
uuid-99e1331c1a364ee7a6086f7b6290435b,patients,0.559815
uuid-99e1331c1a364ee7a6086f7b6290435b,Opdivo,0.395685
uuid-99e1331c1a364ee7a6086f7b6290435b,therapy,0.682162
uuid-99e1331c1a364ee7a6086f7b6290435b,nivolumab,0.53172
uuid-99e1331c1a364ee7a6086f7b6290435b,treatment,0.351362
uuid-99e1331c1a364ee7a6086f7b6290435b,using nivo,0.459277
uuid-99e1331c1a364ee7a6086f7b6290435b,cHL,0.768069
uuid-99e1331c1a364ee7a6086f7b6290435b,chemotherapy,0.348062
uuid-7830ddbc46444750a2124551ad960107,Nivo,0.563262
uuid-7830ddbc46444750a2124551ad960107,patients,0.591093
uuid-7830ddbc46444750a2124551ad960107,therapy,0.569319
uuid-7830ddbc46444750a2124551ad960107,nivolumab,0.548923
uuid-7830ddbc46444750a2124551ad960107,toxicity,0.309478
uuid-7830ddbc46444750a2124551ad960107,regimen,0.470038
uuid-7830ddbc46444750a2124551ad960107,treated,0.384039
uuid-7830ddbc46444750a2124551ad960107,combination,0.579529
uuid-7830ddbc46444750a2124551ad960107,chemo,0.662508
uuid-7830ddbc46444750a2124551ad960107,pts,0.477048
uuid-7830ddbc46444750a2124551ad960107,monotherapy,0.572505
uuid-7830ddbc46444750a2124551ad960107,treatment,0.512417
uuid-7830ddbc46444750a2124551ad960107,response,0.455564
uuid-7830ddbc46444750a2124551ad960107,combo,0.449842
uuid-7830ddbc46444750a2124551ad960107,PD1,0.564889
uuid-7830ddbc46444750a2124551ad960107,progression,0.537777
uuid-7830ddbc46444750a2124551ad960107,chemotherapy,0.649024
uuid-7830ddbc46444750a2124551ad960107,respond,0.368485
uuid-7830ddbc46444750a2124551ad960107,feels,0.471162
uuid-7830ddbc46444750a2124551ad960107,option,0.516513
uuid-135162691c1249aa986739140260885b,patients,0.457156
uuid-135162691c1249aa986739140260885b,Opdivo,0.411906
uuid-135162691c1249aa986739140260885b,treated,0.338219
uuid-135162691c1249aa986739140260885b,physicians,0.653144
uuid-135162691c1249aa986739140260885b,treatment,0.371332
uuid-135162691c1249aa986739140260885b,oncology,0.311117
uuid-d8fbc1a84226480ca983378bed05b22f,patients,0.678897
uuid-d8fbc1a84226480ca983378bed05b22f,Opdivo,0.568731
uuid-d8fbc1a84226480ca983378bed05b22f,therapy,0.319366
uuid-d8fbc1a84226480ca983378bed05b22f,dose,0.45741
uuid-d8fbc1a84226480ca983378bed05b22f,toxicity,0.502166
uuid-d8fbc1a84226480ca983378bed05b22f,regimen,0.511557
uuid-d8fbc1a84226480ca983378bed05b22f,treated,0.513842
uuid-d8fbc1a84226480ca983378bed05b22f,pts,0.369206
uuid-d8fbc1a84226480ca983378bed05b22f,treatment,0.655952
uuid-d8fbc1a84226480ca983378bed05b22f,response,0.307891
uuid-d8fbc1a84226480ca983378bed05b22f,progression,0.551278
uuid-d8fbc1a84226480ca983378bed05b22f,respond,0.518237
uuid-af1cafb4f99a42819ad74d183a6aa3c3,Nivo,0.468903
uuid-af1cafb4f99a42819ad74d183a6aa3c3,trial,0.313285
uuid-af1cafb4f99a42819ad74d183a6aa3c3,efficacy,0.399941
uuid-af1cafb4f99a42819ad74d183a6aa3c3,OS,0.644187
uuid-af1cafb4f99a42819ad74d183a6aa3c3,data,0.503578
uuid-af1cafb4f99a42819ad74d183a6aa3c3,PFS,0.71245
uuid-af1cafb4f99a42819ad74d183a6aa3c3,ORR,0.671354
uuid-af1cafb4f99a42819ad74d183a6aa3c3,cHL,0.377606
uuid-af1cafb4f99a42819ad74d183a6aa3c3,impressed,0.460761
uuid-66b4329cbfdc46d395dd71eddf675c40,Nivo,0.39479
uuid-66b4329cbfdc46d395dd71eddf675c40,patients,0.437831
uuid-66b4329cbfdc46d395dd71eddf675c40,therapy,0.567373
uuid-66b4329cbfdc46d395dd71eddf675c40,nivolumab,0.311847
uuid-66b4329cbfdc46d395dd71eddf675c40,regimen,0.30622
uuid-66b4329cbfdc46d395dd71eddf675c40,treated,0.329132
uuid-66b4329cbfdc46d395dd71eddf675c40,chemo,0.3208
uuid-66b4329cbfdc46d395dd71eddf675c40,pts,0.324656
uuid-66b4329cbfdc46d395dd71eddf675c40,treatment,0.552998
uuid-66b4329cbfdc46d395dd71eddf675c40,response,0.534776
uuid-66b4329cbfdc46d395dd71eddf675c40,PD1,0.381505
uuid-66b4329cbfdc46d395dd71eddf675c40,cHL,0.526654
uuid-66b4329cbfdc46d395dd71eddf675c40,progression,0.563154
uuid-66b4329cbfdc46d395dd71eddf675c40,chemotherapy,0.382167
uuid-66b4329cbfdc46d395dd71eddf675c40,respond,0.48995
uuid-07e8b3fa049449f1814dc3fbb143c510,BMS,0.328011
uuid-07e8b3fa049449f1814dc3fbb143c510,PDL1,0.307802
uuid-07e8b3fa049449f1814dc3fbb143c510,trial,0.331068
uuid-07e8b3fa049449f1814dc3fbb143c510,discussed,0.405237
uuid-07e8b3fa049449f1814dc3fbb143c510,commented,0.323255
uuid-07e8b3fa049449f1814dc3fbb143c510,OS,0.39265
uuid-07e8b3fa049449f1814dc3fbb143c510,regards,0.498748
uuid-07e8b3fa049449f1814dc3fbb143c510,data,0.577742
uuid-07e8b3fa049449f1814dc3fbb143c510,PFS,0.427512
uuid-07e8b3fa049449f1814dc3fbb143c510,AI,0.435993
uuid-07e8b3fa049449f1814dc3fbb143c510,ORR,0.388512
uuid-07e8b3fa049449f1814dc3fbb143c510,nivo and pembro,0.402698
uuid-07e8b3fa049449f1814dc3fbb143c510,NCCN,0.521965
uuid-ecba89504e72437b8ebed123ab97ce7b,patients,0.304656
uuid-ecba89504e72437b8ebed123ab97ce7b,treated,0.46237
uuid-ecba89504e72437b8ebed123ab97ce7b,RCC,0.304232
uuid-ecba89504e72437b8ebed123ab97ce7b,approval,0.345089
uuid-ecba89504e72437b8ebed123ab97ce7b,SCCHN,0.305595
uuid-ecba89504e72437b8ebed123ab97ce7b,RTL stated,0.338183
uuid-ecba89504e72437b8ebed123ab97ce7b,TL shared,0.3063
uuid-ecba89504e72437b8ebed123ab97ce7b,bladder,0.516099
uuid-316649ab939f48a9bd8af69e165d2f71,physicians,0.330757
uuid-316649ab939f48a9bd8af69e165d2f71,oncology,0.615921
uuid-316649ab939f48a9bd8af69e165d2f71,drug,0.319939
uuid-316649ab939f48a9bd8af69e165d2f71,clinical,0.694407
uuid-de82a740fd324b87921255485ff308e8,therapy,0.356717
uuid-de82a740fd324b87921255485ff308e8,nivolumab,0.385133
uuid-de82a740fd324b87921255485ff308e8,NTL,0.314515
uuid-de82a740fd324b87921255485ff308e8,mentioned,0.433765
uuid-de82a740fd324b87921255485ff308e8,cHL,0.605139
uuid-e52b8858fa984d7086600ba11ef42d0a,1L,0.330221
uuid-e52b8858fa984d7086600ba11ef42d0a,trial,0.397797
uuid-e52b8858fa984d7086600ba11ef42d0a,combination,0.356337
uuid-e52b8858fa984d7086600ba11ef42d0a,chemo,0.342421
uuid-e52b8858fa984d7086600ba11ef42d0a,IO,0.338402
uuid-e52b8858fa984d7086600ba11ef42d0a,agents,0.333686
uuid-e52b8858fa984d7086600ba11ef42d0a,monotherapy,0.303074
uuid-e52b8858fa984d7086600ba11ef42d0a,combo,0.500982
uuid-e52b8858fa984d7086600ba11ef42d0a,believes,0.412716
uuid-e52b8858fa984d7086600ba11ef42d0a,feels,0.321405
uuid-e52b8858fa984d7086600ba11ef42d0a,option,0.326166
uuid-f8f7828b025743d8b27e8aedc622bcdb,pembro,0.380011
uuid-f8f7828b025743d8b27e8aedc622bcdb,BMS,0.325418
uuid-f8f7828b025743d8b27e8aedc622bcdb,trial,0.56913
uuid-f8f7828b025743d8b27e8aedc622bcdb,combination,0.333685
uuid-f8f7828b025743d8b27e8aedc622bcdb,agents,0.304536
uuid-f8f7828b025743d8b27e8aedc622bcdb,Merck,0.471292
uuid-f8f7828b025743d8b27e8aedc622bcdb,PD-L1,0.306698
uuid-f8f7828b025743d8b27e8aedc622bcdb,atezo,0.306587
uuid-f8f7828b025743d8b27e8aedc622bcdb,combo,0.316147
uuid-f8f7828b025743d8b27e8aedc622bcdb,clinical trials,0.431216
uuid-f8f7828b025743d8b27e8aedc622bcdb,assay,0.305107
uuid-362bb300f24f4f5fb7d86c4f6cfe2cff,BMS,0.707447
uuid-362bb300f24f4f5fb7d86c4f6cfe2cff,trial,0.332119
uuid-362bb300f24f4f5fb7d86c4f6cfe2cff,shared,0.34266
uuid-362bb300f24f4f5fb7d86c4f6cfe2cff,commented,0.409699
uuid-362bb300f24f4f5fb7d86c4f6cfe2cff,Merck,0.485398
uuid-362bb300f24f4f5fb7d86c4f6cfe2cff,stated,0.366201
uuid-362bb300f24f4f5fb7d86c4f6cfe2cff,expressed,0.429417
uuid-362bb300f24f4f5fb7d86c4f6cfe2cff,clinical trials,0.416828
uuid-362bb300f24f4f5fb7d86c4f6cfe2cff,impressed,0.323553
uuid-8d133852518c43f0b15024e7042eeffa,Nivo,0.440225
uuid-8d133852518c43f0b15024e7042eeffa,1L,0.474616
uuid-8d133852518c43f0b15024e7042eeffa,regimen,0.387775
uuid-8d133852518c43f0b15024e7042eeffa,RCC,0.419296
uuid-8d133852518c43f0b15024e7042eeffa,combination,0.424392
uuid-8d133852518c43f0b15024e7042eeffa,chemo,0.467719
uuid-8d133852518c43f0b15024e7042eeffa,2L,0.519168
uuid-8d133852518c43f0b15024e7042eeffa,IO,0.422702
uuid-8d133852518c43f0b15024e7042eeffa,agents,0.475268
uuid-8d133852518c43f0b15024e7042eeffa,preferred,0.440349
uuid-8d133852518c43f0b15024e7042eeffa,monotherapy,0.566305
uuid-8d133852518c43f0b15024e7042eeffa,using nivo,0.36638
uuid-8d133852518c43f0b15024e7042eeffa,combo,0.519334
uuid-8d133852518c43f0b15024e7042eeffa,PD1,0.4562
uuid-8d133852518c43f0b15024e7042eeffa,believes,0.527384
uuid-8d133852518c43f0b15024e7042eeffa,chemotherapy,0.356125
uuid-8d133852518c43f0b15024e7042eeffa,feels,0.304692
uuid-8d133852518c43f0b15024e7042eeffa,RTL stated,0.310711
uuid-8d133852518c43f0b15024e7042eeffa,option,0.498734
uuid-aea41f3d2bad4beea82561570ab5abf5,patients,0.82377
uuid-aea41f3d2bad4beea82561570ab5abf5,Opdivo,0.379835
uuid-aea41f3d2bad4beea82561570ab5abf5,therapy,0.563559
uuid-aea41f3d2bad4beea82561570ab5abf5,nivolumab,0.416102
uuid-aea41f3d2bad4beea82561570ab5abf5,regimen,0.414555
uuid-aea41f3d2bad4beea82561570ab5abf5,treated,0.477951
uuid-aea41f3d2bad4beea82561570ab5abf5,chemo,0.363064
uuid-aea41f3d2bad4beea82561570ab5abf5,pts,0.61758
uuid-aea41f3d2bad4beea82561570ab5abf5,treatment,0.619573
uuid-aea41f3d2bad4beea82561570ab5abf5,response,0.567388
uuid-aea41f3d2bad4beea82561570ab5abf5,PD1,0.34663
uuid-aea41f3d2bad4beea82561570ab5abf5,progression,0.750072
uuid-aea41f3d2bad4beea82561570ab5abf5,chemotherapy,0.373238
uuid-aea41f3d2bad4beea82561570ab5abf5,respond,0.574981
uuid-f97f56a226d3421593034e36f88f1582,combination,0.617768
uuid-f97f56a226d3421593034e36f88f1582,chemo,0.403357
uuid-f97f56a226d3421593034e36f88f1582,2L,0.340545
uuid-f97f56a226d3421593034e36f88f1582,IO,0.466645
uuid-f97f56a226d3421593034e36f88f1582,agents,0.568511
uuid-f97f56a226d3421593034e36f88f1582,preferred,0.401795
uuid-f97f56a226d3421593034e36f88f1582,monotherapy,0.523593
uuid-f97f56a226d3421593034e36f88f1582,combo,0.539728
uuid-f97f56a226d3421593034e36f88f1582,PD1,0.41674
uuid-f97f56a226d3421593034e36f88f1582,believes,0.449345
uuid-f97f56a226d3421593034e36f88f1582,chemotherapy,0.345723
uuid-f97f56a226d3421593034e36f88f1582,feels,0.39778
uuid-f97f56a226d3421593034e36f88f1582,PD-1,0.302723
uuid-f97f56a226d3421593034e36f88f1582,option,0.439329
uuid-38501c75b0c74b51b8f2cd7644f06f66,Nivo,0.578618
uuid-38501c75b0c74b51b8f2cd7644f06f66,patients,0.657421
uuid-38501c75b0c74b51b8f2cd7644f06f66,Opdivo,0.62795
uuid-38501c75b0c74b51b8f2cd7644f06f66,therapy,0.534756
uuid-38501c75b0c74b51b8f2cd7644f06f66,dose,0.303949
uuid-38501c75b0c74b51b8f2cd7644f06f66,nivolumab,0.548051
uuid-38501c75b0c74b51b8f2cd7644f06f66,regimen,0.328395
uuid-38501c75b0c74b51b8f2cd7644f06f66,pts,0.348369
uuid-38501c75b0c74b51b8f2cd7644f06f66,approval,0.393478
uuid-38501c75b0c74b51b8f2cd7644f06f66,monotherapy,0.310663
uuid-38501c75b0c74b51b8f2cd7644f06f66,treatment,0.45085
uuid-38501c75b0c74b51b8f2cd7644f06f66,using nivo,0.444839
uuid-38501c75b0c74b51b8f2cd7644f06f66,approved,0.357659
uuid-38501c75b0c74b51b8f2cd7644f06f66,cHL,0.525238
uuid-38501c75b0c74b51b8f2cd7644f06f66,progression,0.399557
uuid-38501c75b0c74b51b8f2cd7644f06f66,chemotherapy,0.324394
uuid-38501c75b0c74b51b8f2cd7644f06f66,respond,0.326932
uuid-38501c75b0c74b51b8f2cd7644f06f66,option,0.338052
uuid-2347923d4a574bb18e1606d0b4aae689,Opdivo,0.381947
uuid-2347923d4a574bb18e1606d0b4aae689,BMS,0.403298
uuid-2347923d4a574bb18e1606d0b4aae689,physicians,0.612709
uuid-2347923d4a574bb18e1606d0b4aae689,drug,0.371288
uuid-9fd13e6282694cb8babeb1a1de69d733,patients,0.596719
uuid-9fd13e6282694cb8babeb1a1de69d733,Opdivo,0.537349
uuid-9fd13e6282694cb8babeb1a1de69d733,therapy,0.346443
uuid-9fd13e6282694cb8babeb1a1de69d733,dose,0.364403
uuid-9fd13e6282694cb8babeb1a1de69d733,nivolumab,0.371637
uuid-9fd13e6282694cb8babeb1a1de69d733,regimen,0.363356
uuid-9fd13e6282694cb8babeb1a1de69d733,treated,0.390753
uuid-9fd13e6282694cb8babeb1a1de69d733,physicians,0.462522
uuid-9fd13e6282694cb8babeb1a1de69d733,treatment,0.489892
uuid-9fd13e6282694cb8babeb1a1de69d733,progression,0.401879
uuid-9fd13e6282694cb8babeb1a1de69d733,oncologist,0.304345
uuid-9fd13e6282694cb8babeb1a1de69d733,respond,0.334266
uuid-9fd13e6282694cb8babeb1a1de69d733,flat dosing,0.320553
uuid-bb27e13cbbce453b8ce1397812106d72,Nivo,0.321266
uuid-bb27e13cbbce453b8ce1397812106d72,patients,0.513186
uuid-bb27e13cbbce453b8ce1397812106d72,therapy,0.3285
uuid-bb27e13cbbce453b8ce1397812106d72,1L,0.399177
uuid-bb27e13cbbce453b8ce1397812106d72,PDL1,0.384952
uuid-bb27e13cbbce453b8ce1397812106d72,regimen,0.328395
uuid-bb27e13cbbce453b8ce1397812106d72,chemo,0.507648
uuid-bb27e13cbbce453b8ce1397812106d72,pts,0.587793
uuid-bb27e13cbbce453b8ce1397812106d72,monotherapy,0.492956
uuid-bb27e13cbbce453b8ce1397812106d72,treatment,0.300431
uuid-bb27e13cbbce453b8ce1397812106d72,response,0.552714
uuid-bb27e13cbbce453b8ce1397812106d72,PD1,0.437386
uuid-bb27e13cbbce453b8ce1397812106d72,progression,0.52253
uuid-bb27e13cbbce453b8ce1397812106d72,believes,0.364812
uuid-bb27e13cbbce453b8ce1397812106d72,chemotherapy,0.368705
uuid-bb27e13cbbce453b8ce1397812106d72,respond,0.522841
uuid-bb27e13cbbce453b8ce1397812106d72,feels,0.38306
uuid-bb27e13cbbce453b8ce1397812106d72,option,0.399183
uuid-a8cf4d4a15754effbd4b680aa1c97b86,RTL,0.568375
uuid-a8cf4d4a15754effbd4b680aa1c97b86,NTL,0.416185
uuid-a8cf4d4a15754effbd4b680aa1c97b86,shared,0.514172
uuid-a8cf4d4a15754effbd4b680aa1c97b86,commented,0.456497
uuid-a8cf4d4a15754effbd4b680aa1c97b86,stated,0.593703
uuid-a8cf4d4a15754effbd4b680aa1c97b86,clinical trials,0.363826
uuid-a8cf4d4a15754effbd4b680aa1c97b86,SCCHN,0.405873
uuid-a8cf4d4a15754effbd4b680aa1c97b86,impressed,0.345227
uuid-a8cf4d4a15754effbd4b680aa1c97b86,LTL,0.399857
uuid-a8cf4d4a15754effbd4b680aa1c97b86,academic,0.331666
uuid-a8cf4d4a15754effbd4b680aa1c97b86,Regional TL,0.628137
uuid-5217acbd3ec4438796e20f335bd99e85,therapy,0.30224
uuid-5217acbd3ec4438796e20f335bd99e85,treatment,0.386522
uuid-5217acbd3ec4438796e20f335bd99e85,NSCLC patients,0.317251
uuid-5217acbd3ec4438796e20f335bd99e85,SCCHN,0.353163
uuid-5217acbd3ec4438796e20f335bd99e85,oncologist,0.473002
uuid-5217acbd3ec4438796e20f335bd99e85,indicated,0.472861
uuid-5217acbd3ec4438796e20f335bd99e85,option,0.339301
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,RTL,0.34458
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,PDL1,0.308166
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,trial,0.308602
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,efficacy,0.345916
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,commented,0.360924
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,OS,0.536378
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,data,0.584969
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,expressed,0.354419
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,PFS,0.493689
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,ORR,0.631515
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,ASCO,0.362087
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,impressed,0.697597
uuid-3b64cf62adcf40d6be8eb1001e4a4e94,PDL1 expression,0.367661
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,patients,0.757288
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,Opdivo,0.302669
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,therapy,0.529414
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,nivolumab,0.533073
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,1L,0.334517
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,toxicity,0.305291
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,regimen,0.655246
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,treated,0.599647
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,combination,0.38211
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,chemo,0.428033
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,2L,0.347753
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,pts,0.507673
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,preferred,0.376639
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,monotherapy,0.574898
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,treatment,0.69205
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,using nivo,0.443141
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,response,0.333686
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,combo,0.349226
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,PD1,0.42033
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,progression,0.572771
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,chemotherapy,0.453345
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,respond,0.48622
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,RTL stated,0.382325
uuid-ab7d25c84d0d4fbca85ac09ab8c56df2,option,0.489146
uuid-427926c7b2c2419a937f086bb48a0b01,pembro,0.385921
uuid-427926c7b2c2419a937f086bb48a0b01,RTL,0.412467
uuid-427926c7b2c2419a937f086bb48a0b01,BMS,0.30453
uuid-427926c7b2c2419a937f086bb48a0b01,trial,0.576462
uuid-427926c7b2c2419a937f086bb48a0b01,efficacy,0.426097
uuid-427926c7b2c2419a937f086bb48a0b01,commented,0.4072
uuid-427926c7b2c2419a937f086bb48a0b01,stated,0.352349
uuid-427926c7b2c2419a937f086bb48a0b01,OS,0.48972
uuid-427926c7b2c2419a937f086bb48a0b01,data,0.62291
uuid-427926c7b2c2419a937f086bb48a0b01,PFS,0.45891
uuid-427926c7b2c2419a937f086bb48a0b01,ORR,0.497984
uuid-427926c7b2c2419a937f086bb48a0b01,impressed,0.638243
uuid-427926c7b2c2419a937f086bb48a0b01,vs,0.342681
uuid-427926c7b2c2419a937f086bb48a0b01,LTL,0.362568
uuid-427926c7b2c2419a937f086bb48a0b01,TLs,0.349615
uuid-427926c7b2c2419a937f086bb48a0b01,feels,0.476496
uuid-427926c7b2c2419a937f086bb48a0b01,Regional TL,0.307226
uuid-a720531199b740d583c5e6b07dc00e60,pembro,0.392205
uuid-a720531199b740d583c5e6b07dc00e60,RTL,0.594432
uuid-a720531199b740d583c5e6b07dc00e60,trial,0.625999
uuid-a720531199b740d583c5e6b07dc00e60,NTL,0.337626
uuid-a720531199b740d583c5e6b07dc00e60,commented,0.470063
uuid-a720531199b740d583c5e6b07dc00e60,Merck,0.311222
uuid-a720531199b740d583c5e6b07dc00e60,stated,0.468541
uuid-a720531199b740d583c5e6b07dc00e60,approval,0.300937
uuid-a720531199b740d583c5e6b07dc00e60,OS,0.441462
uuid-a720531199b740d583c5e6b07dc00e60,data,0.68182
uuid-a720531199b740d583c5e6b07dc00e60,expressed,0.345671
uuid-a720531199b740d583c5e6b07dc00e60,clinical trials,0.320811
uuid-a720531199b740d583c5e6b07dc00e60,PFS,0.364045
uuid-a720531199b740d583c5e6b07dc00e60,ORR,0.421563
uuid-a720531199b740d583c5e6b07dc00e60,SCCHN,0.468128
uuid-a720531199b740d583c5e6b07dc00e60,HCP,0.306953
uuid-a720531199b740d583c5e6b07dc00e60,ASCO,0.338441
uuid-a720531199b740d583c5e6b07dc00e60,impressed,0.660113
uuid-a720531199b740d583c5e6b07dc00e60,LTL,0.399325
uuid-a720531199b740d583c5e6b07dc00e60,TLs,0.326897
uuid-a720531199b740d583c5e6b07dc00e60,SCLC,0.370426
uuid-a720531199b740d583c5e6b07dc00e60,Regional TL,0.457867
uuid-a720531199b740d583c5e6b07dc00e60,bladder,0.347721
uuid-5d0f7f4d6e764e87a3e4e6ac99dcedfa,Opdivo,0.383359
uuid-5d0f7f4d6e764e87a3e4e6ac99dcedfa,pembro,0.386239
uuid-5d0f7f4d6e764e87a3e4e6ac99dcedfa,dose,0.862068
uuid-5d0f7f4d6e764e87a3e4e6ac99dcedfa,toxicity,0.333931
uuid-5d0f7f4d6e764e87a3e4e6ac99dcedfa,efficacy,0.334233
uuid-5d0f7f4d6e764e87a3e4e6ac99dcedfa,Ipi,0.470486
uuid-5d0f7f4d6e764e87a3e4e6ac99dcedfa,atezo,0.329613
uuid-5d0f7f4d6e764e87a3e4e6ac99dcedfa,indication,0.342905
uuid-5d0f7f4d6e764e87a3e4e6ac99dcedfa,vs,0.591724
uuid-5d0f7f4d6e764e87a3e4e6ac99dcedfa,Keytruda,0.381412
uuid-5d0f7f4d6e764e87a3e4e6ac99dcedfa,flat dosing,0.791528
uuid-004f247b2c28417d8590d7c6abcba035,Nivo,0.404964
uuid-004f247b2c28417d8590d7c6abcba035,patients,0.406389
uuid-004f247b2c28417d8590d7c6abcba035,pembro,0.336691
uuid-004f247b2c28417d8590d7c6abcba035,therapy,0.369267
uuid-004f247b2c28417d8590d7c6abcba035,nivolumab,0.565268
uuid-004f247b2c28417d8590d7c6abcba035,1L,0.615442
uuid-004f247b2c28417d8590d7c6abcba035,regimen,0.442297
uuid-004f247b2c28417d8590d7c6abcba035,treated,0.357277
uuid-004f247b2c28417d8590d7c6abcba035,RCC,0.665298
uuid-004f247b2c28417d8590d7c6abcba035,combination,0.381692
uuid-004f247b2c28417d8590d7c6abcba035,chemo,0.3493
uuid-004f247b2c28417d8590d7c6abcba035,2L,0.733464
uuid-004f247b2c28417d8590d7c6abcba035,pts,0.361392
uuid-004f247b2c28417d8590d7c6abcba035,agents,0.444021
uuid-004f247b2c28417d8590d7c6abcba035,approval,0.472713
uuid-004f247b2c28417d8590d7c6abcba035,atezo,0.342749
uuid-004f247b2c28417d8590d7c6abcba035,preferred,0.724474
uuid-004f247b2c28417d8590d7c6abcba035,monotherapy,0.65715
uuid-004f247b2c28417d8590d7c6abcba035,treatment,0.397815
uuid-004f247b2c28417d8590d7c6abcba035,using nivo,0.700151
uuid-004f247b2c28417d8590d7c6abcba035,combo,0.418996
uuid-004f247b2c28417d8590d7c6abcba035,PD1,0.425277
uuid-004f247b2c28417d8590d7c6abcba035,approved,0.595346
uuid-004f247b2c28417d8590d7c6abcba035,SCCHN,0.402865
uuid-004f247b2c28417d8590d7c6abcba035,RTL stated,0.620053
uuid-004f247b2c28417d8590d7c6abcba035,TL shared,0.42407
uuid-004f247b2c28417d8590d7c6abcba035,option,0.644597
uuid-004f247b2c28417d8590d7c6abcba035,bladder,0.34852
uuid-fc3b524a00624f24b223e885d408732e,Nivo,0.418625
uuid-fc3b524a00624f24b223e885d408732e,pembro,0.375995
uuid-fc3b524a00624f24b223e885d408732e,PDL1,0.618394
uuid-fc3b524a00624f24b223e885d408732e,efficacy,0.687719
uuid-fc3b524a00624f24b223e885d408732e,chemo,0.451708
uuid-fc3b524a00624f24b223e885d408732e,agents,0.484983
uuid-fc3b524a00624f24b223e885d408732e,OS,0.439944
uuid-fc3b524a00624f24b223e885d408732e,atezo,0.352178
uuid-fc3b524a00624f24b223e885d408732e,monotherapy,0.312688
uuid-fc3b524a00624f24b223e885d408732e,response,0.354308
uuid-fc3b524a00624f24b223e885d408732e,data,0.386835
uuid-fc3b524a00624f24b223e885d408732e,PFS,0.485042
uuid-fc3b524a00624f24b223e885d408732e,PD1,0.386942
uuid-fc3b524a00624f24b223e885d408732e,ORR,0.522894
uuid-fc3b524a00624f24b223e885d408732e,nivo and pembro,0.704861
uuid-fc3b524a00624f24b223e885d408732e,believes,0.52602
uuid-fc3b524a00624f24b223e885d408732e,vs,0.417268
uuid-fc3b524a00624f24b223e885d408732e,feels,0.373045
uuid-fc3b524a00624f24b223e885d408732e,PD-1,0.3043
uuid-fc3b524a00624f24b223e885d408732e,PDL1 expression,0.637561
uuid-fc3b524a00624f24b223e885d408732e,biomarker,0.377866
uuid-27bdd7e854f94f61a7a785ead2453f57,patients,0.552889
uuid-27bdd7e854f94f61a7a785ead2453f57,RTL,0.362636
uuid-27bdd7e854f94f61a7a785ead2453f57,nivolumab,0.510204
uuid-27bdd7e854f94f61a7a785ead2453f57,regimen,0.360965
uuid-27bdd7e854f94f61a7a785ead2453f57,treated,0.503801
uuid-27bdd7e854f94f61a7a785ead2453f57,RCC,0.509555
uuid-27bdd7e854f94f61a7a785ead2453f57,combination,0.347095
uuid-27bdd7e854f94f61a7a785ead2453f57,2L,0.343753
uuid-27bdd7e854f94f61a7a785ead2453f57,pts,0.389073
uuid-27bdd7e854f94f61a7a785ead2453f57,stated,0.390877
uuid-27bdd7e854f94f61a7a785ead2453f57,approval,0.349465
uuid-27bdd7e854f94f61a7a785ead2453f57,preferred,0.386106
uuid-27bdd7e854f94f61a7a785ead2453f57,monotherapy,0.362405
uuid-27bdd7e854f94f61a7a785ead2453f57,treatment,0.403738
uuid-27bdd7e854f94f61a7a785ead2453f57,using nivo,0.490729
uuid-27bdd7e854f94f61a7a785ead2453f57,combo,0.337455
uuid-27bdd7e854f94f61a7a785ead2453f57,clinical trials,0.472187
uuid-27bdd7e854f94f61a7a785ead2453f57,approved,0.367582
uuid-27bdd7e854f94f61a7a785ead2453f57,SCCHN,0.504594
uuid-27bdd7e854f94f61a7a785ead2453f57,chemotherapy,0.305525
uuid-27bdd7e854f94f61a7a785ead2453f57,tumor types,0.35144
uuid-27bdd7e854f94f61a7a785ead2453f57,Regional TL,0.404804
uuid-27bdd7e854f94f61a7a785ead2453f57,RTL stated,0.540807
uuid-27bdd7e854f94f61a7a785ead2453f57,TL shared,0.391919
uuid-27bdd7e854f94f61a7a785ead2453f57,option,0.398782
uuid-27bdd7e854f94f61a7a785ead2453f57,bladder,0.5632
uuid-87b1936ba59542c8a6ffb535a18da6ac,patients,0.759909
uuid-87b1936ba59542c8a6ffb535a18da6ac,therapy,0.362493
uuid-87b1936ba59542c8a6ffb535a18da6ac,nivolumab,0.349313
uuid-87b1936ba59542c8a6ffb535a18da6ac,1L,0.420869
uuid-87b1936ba59542c8a6ffb535a18da6ac,regimen,0.495985
uuid-87b1936ba59542c8a6ffb535a18da6ac,treated,0.431234
uuid-87b1936ba59542c8a6ffb535a18da6ac,chemo,0.381831
uuid-87b1936ba59542c8a6ffb535a18da6ac,2L,0.418312
uuid-87b1936ba59542c8a6ffb535a18da6ac,pts,0.631317
uuid-87b1936ba59542c8a6ffb535a18da6ac,preferred,0.427668
uuid-87b1936ba59542c8a6ffb535a18da6ac,monotherapy,0.531639
uuid-87b1936ba59542c8a6ffb535a18da6ac,treatment,0.46551
uuid-87b1936ba59542c8a6ffb535a18da6ac,using nivo,0.450974
uuid-87b1936ba59542c8a6ffb535a18da6ac,NSCLC patients,0.420737
uuid-87b1936ba59542c8a6ffb535a18da6ac,PD1,0.317998
uuid-87b1936ba59542c8a6ffb535a18da6ac,progression,0.514477
uuid-87b1936ba59542c8a6ffb535a18da6ac,chemotherapy,0.30283
uuid-87b1936ba59542c8a6ffb535a18da6ac,respond,0.435071
uuid-87b1936ba59542c8a6ffb535a18da6ac,RTL stated,0.375379
uuid-87b1936ba59542c8a6ffb535a18da6ac,option,0.491117
uuid-2919d71ae03c4dd8aef2337c817d0e13,lung,0.438717
uuid-2919d71ae03c4dd8aef2337c817d0e13,melanoma,0.449976
uuid-2919d71ae03c4dd8aef2337c817d0e13,RCC,0.491499
uuid-2919d71ae03c4dd8aef2337c817d0e13,TL stated,0.363684
uuid-2919d71ae03c4dd8aef2337c817d0e13,tumor,0.542765
uuid-2919d71ae03c4dd8aef2337c817d0e13,tumor types,0.465191
uuid-2919d71ae03c4dd8aef2337c817d0e13,RTL stated,0.347428
uuid-2919d71ae03c4dd8aef2337c817d0e13,TL shared,0.472771
uuid-2919d71ae03c4dd8aef2337c817d0e13,bladder,0.419626
uuid-32d2ee1d0b7745ccb0fabe4024a36f35,patients,0.427939
uuid-32d2ee1d0b7745ccb0fabe4024a36f35,Opdivo,0.355043
uuid-32d2ee1d0b7745ccb0fabe4024a36f35,therapy,0.53414
uuid-32d2ee1d0b7745ccb0fabe4024a36f35,nivolumab,0.412556
uuid-32d2ee1d0b7745ccb0fabe4024a36f35,mentioned,0.307024
uuid-32d2ee1d0b7745ccb0fabe4024a36f35,cHL,0.768113
uuid-40cb4f22a6bf485c8364e3c9bebbb938,RTL,0.522853
uuid-40cb4f22a6bf485c8364e3c9bebbb938,trial,0.541928
uuid-40cb4f22a6bf485c8364e3c9bebbb938,NTL,0.460945
uuid-40cb4f22a6bf485c8364e3c9bebbb938,commented,0.372472
uuid-40cb4f22a6bf485c8364e3c9bebbb938,OS,0.329299
uuid-40cb4f22a6bf485c8364e3c9bebbb938,data,0.529315
uuid-40cb4f22a6bf485c8364e3c9bebbb938,expressed,0.41166
uuid-40cb4f22a6bf485c8364e3c9bebbb938,mentioned,0.526171
uuid-40cb4f22a6bf485c8364e3c9bebbb938,PFS,0.327283
uuid-40cb4f22a6bf485c8364e3c9bebbb938,ORR,0.432153
uuid-40cb4f22a6bf485c8364e3c9bebbb938,HCP,0.481257
uuid-40cb4f22a6bf485c8364e3c9bebbb938,ASCO,0.351523
uuid-40cb4f22a6bf485c8364e3c9bebbb938,impressed,0.500842
uuid-40cb4f22a6bf485c8364e3c9bebbb938,LTL,0.374409
uuid-40cb4f22a6bf485c8364e3c9bebbb938,SCLC,0.394404
uuid-40cb4f22a6bf485c8364e3c9bebbb938,Regional TL,0.332851
uuid-109f9a1835c143f4aded69d6c3dd89ff,Nivo,0.548531
uuid-109f9a1835c143f4aded69d6c3dd89ff,patients,0.429828
uuid-109f9a1835c143f4aded69d6c3dd89ff,Opdivo,0.450272
uuid-109f9a1835c143f4aded69d6c3dd89ff,therapy,0.472921
uuid-109f9a1835c143f4aded69d6c3dd89ff,nivolumab,0.522611
uuid-109f9a1835c143f4aded69d6c3dd89ff,approval,0.424516
uuid-109f9a1835c143f4aded69d6c3dd89ff,monotherapy,0.323383
uuid-109f9a1835c143f4aded69d6c3dd89ff,using nivo,0.558325
uuid-109f9a1835c143f4aded69d6c3dd89ff,mentioned,0.418248
uuid-109f9a1835c143f4aded69d6c3dd89ff,approved,0.335467
uuid-109f9a1835c143f4aded69d6c3dd89ff,cHL,0.650913
uuid-109f9a1835c143f4aded69d6c3dd89ff,label,0.327197
uuid-109f9a1835c143f4aded69d6c3dd89ff,LTL,0.356156
uuid-109f9a1835c143f4aded69d6c3dd89ff,RTL stated,0.307774
uuid-109f9a1835c143f4aded69d6c3dd89ff,option,0.371652
uuid-0e46fa90265b49d6b60fee4d618821c8,pembro,0.344454
uuid-0e46fa90265b49d6b60fee4d618821c8,RTL,0.419051
uuid-0e46fa90265b49d6b60fee4d618821c8,dose,0.366577
uuid-0e46fa90265b49d6b60fee4d618821c8,Ipi,0.396059
uuid-0e46fa90265b49d6b60fee4d618821c8,stated,0.317903
uuid-0e46fa90265b49d6b60fee4d618821c8,atezo,0.341348
uuid-0e46fa90265b49d6b60fee4d618821c8,clinical trials,0.356157
uuid-0e46fa90265b49d6b60fee4d618821c8,indication,0.342358
uuid-0e46fa90265b49d6b60fee4d618821c8,impressed,0.343171
uuid-0e46fa90265b49d6b60fee4d618821c8,vs,0.305229
uuid-0e46fa90265b49d6b60fee4d618821c8,LTL,0.368296
uuid-0e46fa90265b49d6b60fee4d618821c8,TLs,0.452997
uuid-0e46fa90265b49d6b60fee4d618821c8,Regional TL,0.324698
uuid-0e46fa90265b49d6b60fee4d618821c8,flat dosing,0.442221
uuid-f8c38268163d48b99b5ec345868c77d1,patients,0.364321
uuid-f8c38268163d48b99b5ec345868c77d1,Opdivo,0.354219
uuid-f8c38268163d48b99b5ec345868c77d1,therapy,0.391266
uuid-f8c38268163d48b99b5ec345868c77d1,nivolumab,0.354345
uuid-f8c38268163d48b99b5ec345868c77d1,treated,0.31776
uuid-f8c38268163d48b99b5ec345868c77d1,treatment,0.33949
uuid-f8c38268163d48b99b5ec345868c77d1,cHL,0.541969
uuid-330beed324a24a43985fa0e86cb2dc5e,pembro,0.531987
uuid-330beed324a24a43985fa0e86cb2dc5e,1L,0.436562
uuid-330beed324a24a43985fa0e86cb2dc5e,2L,0.477176
uuid-330beed324a24a43985fa0e86cb2dc5e,approval,0.393819
uuid-330beed324a24a43985fa0e86cb2dc5e,atezo,0.571653
uuid-330beed324a24a43985fa0e86cb2dc5e,preferred,0.400126
uuid-330beed324a24a43985fa0e86cb2dc5e,using nivo,0.467672
uuid-330beed324a24a43985fa0e86cb2dc5e,indication,0.434226
uuid-330beed324a24a43985fa0e86cb2dc5e,approved,0.420953
uuid-330beed324a24a43985fa0e86cb2dc5e,SCCHN,0.473557
uuid-330beed324a24a43985fa0e86cb2dc5e,label,0.426835
uuid-330beed324a24a43985fa0e86cb2dc5e,NCCN,0.450627
uuid-330beed324a24a43985fa0e86cb2dc5e,bladder,0.321003
uuid-a24e10907fff445688191c48a55627e8,patients,0.423956
uuid-a24e10907fff445688191c48a55627e8,RTL,0.427258
uuid-a24e10907fff445688191c48a55627e8,nivolumab,0.382841
uuid-a24e10907fff445688191c48a55627e8,treated,0.403819
uuid-a24e10907fff445688191c48a55627e8,shared,0.486172
uuid-a24e10907fff445688191c48a55627e8,RCC,0.460887
uuid-a24e10907fff445688191c48a55627e8,stated,0.35542
uuid-a24e10907fff445688191c48a55627e8,approval,0.449131
uuid-a24e10907fff445688191c48a55627e8,using nivo,0.436743
uuid-a24e10907fff445688191c48a55627e8,clinical trials,0.457471
uuid-a24e10907fff445688191c48a55627e8,SCCHN,0.483644
uuid-a24e10907fff445688191c48a55627e8,LTL,0.326633
uuid-a24e10907fff445688191c48a55627e8,Regional TL,0.489926
uuid-a24e10907fff445688191c48a55627e8,RTL stated,0.494447
uuid-a24e10907fff445688191c48a55627e8,TL shared,0.380518
uuid-a24e10907fff445688191c48a55627e8,bladder,0.431344
uuid-50f6347d4f2b4f8d897362c9cf082237,patients,0.361146
uuid-50f6347d4f2b4f8d897362c9cf082237,treated,0.673266
uuid-50f6347d4f2b4f8d897362c9cf082237,tumor,0.405991
uuid-50f6347d4f2b4f8d897362c9cf082237,pts,0.301305
uuid-50f6347d4f2b4f8d897362c9cf082237,treatment,0.414408
uuid-50f6347d4f2b4f8d897362c9cf082237,progression,0.380643
uuid-37db84eef2f44b1abddb0a230f5c42ba,therapy,0.362093
uuid-37db84eef2f44b1abddb0a230f5c42ba,chemotherapy,0.325348
uuid-37db84eef2f44b1abddb0a230f5c42ba,oncologist,0.375998
uuid-5e3fbee05b554276a43b175cc9f47d15,Nivo,0.465697
uuid-5e3fbee05b554276a43b175cc9f47d15,patients,0.89568
uuid-5e3fbee05b554276a43b175cc9f47d15,Opdivo,0.532591
uuid-5e3fbee05b554276a43b175cc9f47d15,therapy,0.656293
uuid-5e3fbee05b554276a43b175cc9f47d15,nivolumab,0.503494
uuid-5e3fbee05b554276a43b175cc9f47d15,toxicity,0.381174
uuid-5e3fbee05b554276a43b175cc9f47d15,regimen,0.571847
uuid-5e3fbee05b554276a43b175cc9f47d15,treated,0.473365
uuid-5e3fbee05b554276a43b175cc9f47d15,chemo,0.446018
uuid-5e3fbee05b554276a43b175cc9f47d15,pts,0.616211
uuid-5e3fbee05b554276a43b175cc9f47d15,monotherapy,0.479032
uuid-5e3fbee05b554276a43b175cc9f47d15,treatment,0.698698
uuid-5e3fbee05b554276a43b175cc9f47d15,using nivo,0.329251
uuid-5e3fbee05b554276a43b175cc9f47d15,response,0.469078
uuid-5e3fbee05b554276a43b175cc9f47d15,PD1,0.413015
uuid-5e3fbee05b554276a43b175cc9f47d15,cHL,0.398466
uuid-5e3fbee05b554276a43b175cc9f47d15,progression,0.737511
uuid-5e3fbee05b554276a43b175cc9f47d15,chemotherapy,0.464098
uuid-5e3fbee05b554276a43b175cc9f47d15,respond,0.570085
uuid-5e3fbee05b554276a43b175cc9f47d15,option,0.427908
uuid-10522425842c48cfba4b8d5c88055be3,pembro,0.413163
uuid-10522425842c48cfba4b8d5c88055be3,BMS,0.497525
uuid-10522425842c48cfba4b8d5c88055be3,PDL1,0.443645
uuid-10522425842c48cfba4b8d5c88055be3,efficacy,0.499455
uuid-10522425842c48cfba4b8d5c88055be3,agents,0.524447
uuid-10522425842c48cfba4b8d5c88055be3,Merck,0.479199
uuid-10522425842c48cfba4b8d5c88055be3,atezo,0.492959
uuid-10522425842c48cfba4b8d5c88055be3,data,0.368613
uuid-10522425842c48cfba4b8d5c88055be3,indication,0.345883
uuid-10522425842c48cfba4b8d5c88055be3,nivo and pembro,0.464723
uuid-10522425842c48cfba4b8d5c88055be3,believes,0.431802
uuid-10522425842c48cfba4b8d5c88055be3,feels,0.450442
uuid-10522425842c48cfba4b8d5c88055be3,PDL1 expression,0.39979
uuid-10522425842c48cfba4b8d5c88055be3,biomarker,0.352356
uuid-bb8be711a8c043028db886f9838c7389,1L,0.322734
uuid-bb8be711a8c043028db886f9838c7389,combination,0.318652
uuid-bb8be711a8c043028db886f9838c7389,chemo,0.301763
uuid-bb8be711a8c043028db886f9838c7389,2L,0.313169
uuid-bb8be711a8c043028db886f9838c7389,agents,0.408418
uuid-bb8be711a8c043028db886f9838c7389,preferred,0.396526
uuid-bb8be711a8c043028db886f9838c7389,monotherapy,0.318909
uuid-bb8be711a8c043028db886f9838c7389,believes,0.335542
uuid-bb8be711a8c043028db886f9838c7389,chemotherapy,0.318515
uuid-bb8be711a8c043028db886f9838c7389,tumor types,0.306425
uuid-bb8be711a8c043028db886f9838c7389,feels,0.357891
uuid-bb8be711a8c043028db886f9838c7389,option,0.508677
uuid-bb8be711a8c043028db886f9838c7389,biomarker,0.337574
uuid-61c2bf6f69cb424ab5b1c29e11f15ba3,patients,0.489453
uuid-61c2bf6f69cb424ab5b1c29e11f15ba3,pts,0.318917
uuid-61c2bf6f69cb424ab5b1c29e11f15ba3,PD-L1,0.405886
uuid-61c2bf6f69cb424ab5b1c29e11f15ba3,PD-L1 testing,0.343934
uuid-61c2bf6f69cb424ab5b1c29e11f15ba3,testing,0.463345
uuid-61c2bf6f69cb424ab5b1c29e11f15ba3,PDL1 testing,0.358889
uuid-61c2bf6f69cb424ab5b1c29e11f15ba3,NSCLC patients,0.439755
uuid-61c2bf6f69cb424ab5b1c29e11f15ba3,tumor types,0.324044
uuid-61c2bf6f69cb424ab5b1c29e11f15ba3,option,0.399602
uuid-61c2bf6f69cb424ab5b1c29e11f15ba3,biomarker,0.420026
uuid-bbe0a4f066614cd29b89c11484745aa1,Nivo,0.357155
uuid-bbe0a4f066614cd29b89c11484745aa1,pembro,0.397464
uuid-bbe0a4f066614cd29b89c11484745aa1,dose,0.507839
uuid-bbe0a4f066614cd29b89c11484745aa1,BMS,0.468945
uuid-bbe0a4f066614cd29b89c11484745aa1,trial,0.567827
uuid-bbe0a4f066614cd29b89c11484745aa1,efficacy,0.534901
uuid-bbe0a4f066614cd29b89c11484745aa1,Ipi,0.711889
uuid-bbe0a4f066614cd29b89c11484745aa1,atezo,0.337035
uuid-bbe0a4f066614cd29b89c11484745aa1,data,0.469975
uuid-bbe0a4f066614cd29b89c11484745aa1,ORR,0.376124
uuid-bbe0a4f066614cd29b89c11484745aa1,impressed,0.432013
uuid-bbe0a4f066614cd29b89c11484745aa1,vs,0.529193
uuid-bbe0a4f066614cd29b89c11484745aa1,flat dosing,0.468388
uuid-6295f03dafe44b4fb6a9eca753fc272e,RTL,0.468057
uuid-6295f03dafe44b4fb6a9eca753fc272e,trial,0.391367
uuid-6295f03dafe44b4fb6a9eca753fc272e,NTL,0.396466
uuid-6295f03dafe44b4fb6a9eca753fc272e,commented,0.435325
uuid-6295f03dafe44b4fb6a9eca753fc272e,OS,0.320465
uuid-6295f03dafe44b4fb6a9eca753fc272e,data,0.541774
uuid-6295f03dafe44b4fb6a9eca753fc272e,expressed,0.337654
uuid-6295f03dafe44b4fb6a9eca753fc272e,mentioned,0.615941
uuid-6295f03dafe44b4fb6a9eca753fc272e,PFS,0.347066
uuid-6295f03dafe44b4fb6a9eca753fc272e,ORR,0.351812
uuid-6295f03dafe44b4fb6a9eca753fc272e,HCP,0.450522
uuid-6295f03dafe44b4fb6a9eca753fc272e,cHL,0.42491
uuid-6295f03dafe44b4fb6a9eca753fc272e,ASCO,0.461923
uuid-6295f03dafe44b4fb6a9eca753fc272e,impressed,0.516398
uuid-6295f03dafe44b4fb6a9eca753fc272e,LTL,0.386041
uuid-6295f03dafe44b4fb6a9eca753fc272e,Regional TL,0.334367
uuid-79f10d025e4a42ef9677296aa502bc89,therapy,0.304679
uuid-79f10d025e4a42ef9677296aa502bc89,regimen,0.367159
uuid-79f10d025e4a42ef9677296aa502bc89,treated,0.557249
uuid-79f10d025e4a42ef9677296aa502bc89,treatment,0.309981
uuid-f313a56b1cd54cec987855d92a4077db,Opdivo,0.333331
uuid-f313a56b1cd54cec987855d92a4077db,treated,0.335973
uuid-f313a56b1cd54cec987855d92a4077db,shared,0.356715
uuid-f313a56b1cd54cec987855d92a4077db,physicians,0.81159
uuid-f313a56b1cd54cec987855d92a4077db,oncologist,0.309091
uuid-d9d49e8954be4f7cace6baeb21fbfd94,Opdivo,0.306131
uuid-d9d49e8954be4f7cace6baeb21fbfd94,shared,0.318032
uuid-d9d49e8954be4f7cace6baeb21fbfd94,physicians,0.5991
uuid-d9d49e8954be4f7cace6baeb21fbfd94,clinical,0.307286
uuid-c2a4eb30c00d4aac8e69022adedd41f3,patients,0.498462
uuid-c2a4eb30c00d4aac8e69022adedd41f3,Opdivo,0.419685
uuid-c2a4eb30c00d4aac8e69022adedd41f3,therapy,0.301162
uuid-c2a4eb30c00d4aac8e69022adedd41f3,regimen,0.426626
uuid-c2a4eb30c00d4aac8e69022adedd41f3,treated,0.516898
uuid-c2a4eb30c00d4aac8e69022adedd41f3,physicians,0.588575
uuid-c2a4eb30c00d4aac8e69022adedd41f3,treatment,0.583516
uuid-c2a4eb30c00d4aac8e69022adedd41f3,response,0.329467
uuid-c2a4eb30c00d4aac8e69022adedd41f3,progression,0.529502
uuid-c2a4eb30c00d4aac8e69022adedd41f3,respond,0.38105
uuid-91c4bd53eba54cd0ba3b6bdeb163ba1b,commented,0.312046
uuid-91c4bd53eba54cd0ba3b6bdeb163ba1b,Merck,0.317042
uuid-91c4bd53eba54cd0ba3b6bdeb163ba1b,data,0.418152
uuid-91c4bd53eba54cd0ba3b6bdeb163ba1b,expressed,0.312131
uuid-91c4bd53eba54cd0ba3b6bdeb163ba1b,ASCO,0.412933
uuid-91c4bd53eba54cd0ba3b6bdeb163ba1b,impressed,0.350248
uuid-9e7d85e829cc45dab62fe319f4d1554a,option,0.367237
uuid-27eef8c9cfe3473cbbff1217107ed559,Nivo,0.33242
uuid-27eef8c9cfe3473cbbff1217107ed559,pembro,0.505584
uuid-27eef8c9cfe3473cbbff1217107ed559,dose,0.480349
uuid-27eef8c9cfe3473cbbff1217107ed559,trial,0.309236
uuid-27eef8c9cfe3473cbbff1217107ed559,efficacy,0.679148
uuid-27eef8c9cfe3473cbbff1217107ed559,Ipi,0.422036
uuid-27eef8c9cfe3473cbbff1217107ed559,OS,0.348476
uuid-27eef8c9cfe3473cbbff1217107ed559,atezo,0.558351
uuid-27eef8c9cfe3473cbbff1217107ed559,regards,0.326847
uuid-27eef8c9cfe3473cbbff1217107ed559,data,0.447558
uuid-27eef8c9cfe3473cbbff1217107ed559,ORR,0.378414
uuid-27eef8c9cfe3473cbbff1217107ed559,nivo and pembro,0.477876
uuid-27eef8c9cfe3473cbbff1217107ed559,vs,0.709989
uuid-27eef8c9cfe3473cbbff1217107ed559,flat dosing,0.38906
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,RTL,0.317958
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,trial,0.39575
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,commented,0.4495
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,OS,0.303497
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,data,0.559673
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,expressed,0.301511
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,clinical trials,0.410535
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,ORR,0.333452
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,ASCO,0.461298
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,impressed,0.525112
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,SCLC,0.449557
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,Regional TL,0.441798
uuid-2064283b4eb64f8c8dc2c9d1d4c5bf96,bladder,0.430348
uuid-6d29cf54d9eb467697b2c0490b9a20ab,patients,0.496531
uuid-6d29cf54d9eb467697b2c0490b9a20ab,Opdivo,0.506892
uuid-6d29cf54d9eb467697b2c0490b9a20ab,therapy,0.359633
uuid-6d29cf54d9eb467697b2c0490b9a20ab,pts,0.402279
uuid-6d29cf54d9eb467697b2c0490b9a20ab,monotherapy,0.373616
uuid-6d29cf54d9eb467697b2c0490b9a20ab,treatment,0.361003
uuid-6d29cf54d9eb467697b2c0490b9a20ab,approved,0.393574
uuid-6d29cf54d9eb467697b2c0490b9a20ab,progression,0.413069
uuid-6d29cf54d9eb467697b2c0490b9a20ab,respond,0.332272
uuid-6d29cf54d9eb467697b2c0490b9a20ab,feels,0.433114
uuid-6d29cf54d9eb467697b2c0490b9a20ab,option,0.44535
uuid-7e85cea7f6eb4e1d84bb24b5e5553e69,RTL,0.392979
uuid-7e85cea7f6eb4e1d84bb24b5e5553e69,BMS,0.398977
uuid-7e85cea7f6eb4e1d84bb24b5e5553e69,trial,0.698942
uuid-7e85cea7f6eb4e1d84bb24b5e5553e69,NTL,0.412779
uuid-7e85cea7f6eb4e1d84bb24b5e5553e69,commented,0.458063
uuid-7e85cea7f6eb4e1d84bb24b5e5553e69,Merck,0.420317
uuid-7e85cea7f6eb4e1d84bb24b5e5553e69,data,0.337401
uuid-7e85cea7f6eb4e1d84bb24b5e5553e69,expressed,0.311611
uuid-7e85cea7f6eb4e1d84bb24b5e5553e69,clinical trials,0.405271
uuid-7e85cea7f6eb4e1d84bb24b5e5553e69,lung cancer,0.306949
uuid-7e85cea7f6eb4e1d84bb24b5e5553e69,impressed,0.408521
uuid-7e85cea7f6eb4e1d84bb24b5e5553e69,Regional TL,0.366325
uuid-b7f9eab3bbf64bcf8ab406e1499323a1,Nivo,0.384741
uuid-b7f9eab3bbf64bcf8ab406e1499323a1,RTL,0.357834
uuid-b7f9eab3bbf64bcf8ab406e1499323a1,nivolumab,0.326585
uuid-b7f9eab3bbf64bcf8ab406e1499323a1,trial,0.451365
uuid-b7f9eab3bbf64bcf8ab406e1499323a1,approval,0.339496
uuid-b7f9eab3bbf64bcf8ab406e1499323a1,data,0.342771
uuid-b7f9eab3bbf64bcf8ab406e1499323a1,clinical trials,0.344247
uuid-b7f9eab3bbf64bcf8ab406e1499323a1,ASCO,0.308144
uuid-b7f9eab3bbf64bcf8ab406e1499323a1,impressed,0.454754
uuid-b7f9eab3bbf64bcf8ab406e1499323a1,Regional TL,0.315414
uuid-b7f9eab3bbf64bcf8ab406e1499323a1,bladder,0.518006
uuid-1c2dc9dcb9f6429492344e6afc3b4a8d,patients,0.888386
uuid-1c2dc9dcb9f6429492344e6afc3b4a8d,Opdivo,0.629662
uuid-1c2dc9dcb9f6429492344e6afc3b4a8d,therapy,0.512193
uuid-1c2dc9dcb9f6429492344e6afc3b4a8d,nivolumab,0.473172
uuid-1c2dc9dcb9f6429492344e6afc3b4a8d,regimen,0.507639
uuid-1c2dc9dcb9f6429492344e6afc3b4a8d,treated,0.615092
uuid-1c2dc9dcb9f6429492344e6afc3b4a8d,pts,0.480993
uuid-1c2dc9dcb9f6429492344e6afc3b4a8d,treatment,0.766656
uuid-1c2dc9dcb9f6429492344e6afc3b4a8d,progression,0.596606
uuid-1c2dc9dcb9f6429492344e6afc3b4a8d,chemotherapy,0.303641
uuid-1c2dc9dcb9f6429492344e6afc3b4a8d,respond,0.429332
uuid-25028643448a41858b048d0f6366808e,Nivo,0.541926
uuid-25028643448a41858b048d0f6366808e,patients,0.740035
uuid-25028643448a41858b048d0f6366808e,Opdivo,0.535942
uuid-25028643448a41858b048d0f6366808e,therapy,0.667568
uuid-25028643448a41858b048d0f6366808e,nivolumab,0.477513
uuid-25028643448a41858b048d0f6366808e,regimen,0.382248
uuid-25028643448a41858b048d0f6366808e,treated,0.348331
uuid-25028643448a41858b048d0f6366808e,chemo,0.343715
uuid-25028643448a41858b048d0f6366808e,pts,0.363703
uuid-25028643448a41858b048d0f6366808e,monotherapy,0.314427
uuid-25028643448a41858b048d0f6366808e,treatment,0.543334
uuid-25028643448a41858b048d0f6366808e,using nivo,0.313237
uuid-25028643448a41858b048d0f6366808e,response,0.331954
uuid-25028643448a41858b048d0f6366808e,cHL,0.538192
uuid-25028643448a41858b048d0f6366808e,progression,0.524127
uuid-25028643448a41858b048d0f6366808e,chemotherapy,0.424797
uuid-25028643448a41858b048d0f6366808e,respond,0.420596
uuid-3254f83757684a48913807895743b249,TL,0.635878
uuid-3254f83757684a48913807895743b249,PDL1,0.478308
uuid-3254f83757684a48913807895743b249,Merck,0.332603
uuid-3254f83757684a48913807895743b249,PD-L1,0.774436
uuid-3254f83757684a48913807895743b249,PD-L1 testing,0.725184
uuid-3254f83757684a48913807895743b249,testing,0.719512
uuid-3254f83757684a48913807895743b249,PDL1 testing,0.424546
uuid-3254f83757684a48913807895743b249,NSCLC patients,0.401716
uuid-3254f83757684a48913807895743b249,assay,0.907903
uuid-3254f83757684a48913807895743b249,biomarker,0.368087
uuid-124ec8d643614e7dad180395a01bcced,Nivo,0.425609
uuid-124ec8d643614e7dad180395a01bcced,patients,0.541283
uuid-124ec8d643614e7dad180395a01bcced,Opdivo,0.30113
uuid-124ec8d643614e7dad180395a01bcced,RTL,0.317449
uuid-124ec8d643614e7dad180395a01bcced,therapy,0.578407
uuid-124ec8d643614e7dad180395a01bcced,nivolumab,0.608131
uuid-124ec8d643614e7dad180395a01bcced,treated,0.543749
uuid-124ec8d643614e7dad180395a01bcced,pts,0.312662
uuid-124ec8d643614e7dad180395a01bcced,treatment,0.365441
uuid-124ec8d643614e7dad180395a01bcced,using nivo,0.46834
uuid-124ec8d643614e7dad180395a01bcced,mentioned,0.449284
uuid-124ec8d643614e7dad180395a01bcced,PD1,0.359593
uuid-124ec8d643614e7dad180395a01bcced,cHL,0.716111
uuid-124ec8d643614e7dad180395a01bcced,progression,0.344525
uuid-124ec8d643614e7dad180395a01bcced,chemotherapy,0.331059
uuid-124ec8d643614e7dad180395a01bcced,RTL stated,0.345679
uuid-afb269025c184a34a5c75a8cf142c72f,Nivo,0.504302
uuid-afb269025c184a34a5c75a8cf142c72f,patients,0.600807
uuid-afb269025c184a34a5c75a8cf142c72f,Opdivo,0.353433
uuid-afb269025c184a34a5c75a8cf142c72f,therapy,0.499894
uuid-afb269025c184a34a5c75a8cf142c72f,nivolumab,0.441614
uuid-afb269025c184a34a5c75a8cf142c72f,pts,0.379735
uuid-afb269025c184a34a5c75a8cf142c72f,treatment,0.344847
uuid-afb269025c184a34a5c75a8cf142c72f,response,0.3456
uuid-afb269025c184a34a5c75a8cf142c72f,cHL,0.58629
uuid-afb269025c184a34a5c75a8cf142c72f,progression,0.416241
uuid-afb269025c184a34a5c75a8cf142c72f,chemotherapy,0.312886
uuid-afb269025c184a34a5c75a8cf142c72f,respond,0.313296
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,Nivo,0.402047
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,pembro,0.361657
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,combination,0.300564
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,2L,0.309696
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,Ipi,0.308242
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,atezo,0.345964
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,preferred,0.398836
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,monotherapy,0.326267
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,using nivo,0.39534
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,mentioned,0.324983
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,indication,0.308215
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,approved,0.305925
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,HCP,0.519352
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,feels,0.381383
uuid-bff3149ec7b24ab8b8adb49e6ab6800d,option,0.355246
uuid-d40c43c56f414627addabf8af6c095ed,commented,0.336804
uuid-d40c43c56f414627addabf8af6c095ed,OS,0.57085
uuid-d40c43c56f414627addabf8af6c095ed,regards,0.377518
uuid-d40c43c56f414627addabf8af6c095ed,data,0.414452
uuid-d40c43c56f414627addabf8af6c095ed,PFS,0.633904
uuid-d40c43c56f414627addabf8af6c095ed,ORR,0.493647
uuid-d40c43c56f414627addabf8af6c095ed,ASCO,0.385261
uuid-d40c43c56f414627addabf8af6c095ed,impressed,0.395443
uuid-d40c43c56f414627addabf8af6c095ed,TLs,0.323038
uuid-10a0cd6fdf2c4a6fa365172152df3f65,toxicity,0.5048
uuid-10a0cd6fdf2c4a6fa365172152df3f65,regimen,0.511026
uuid-10a0cd6fdf2c4a6fa365172152df3f65,treated,0.472156
uuid-10a0cd6fdf2c4a6fa365172152df3f65,physicians,0.466123
uuid-10a0cd6fdf2c4a6fa365172152df3f65,treatment,0.442504
uuid-10a0cd6fdf2c4a6fa365172152df3f65,response,0.406972
uuid-10a0cd6fdf2c4a6fa365172152df3f65,progression,0.302582
uuid-10a0cd6fdf2c4a6fa365172152df3f65,respond,0.439096
uuid-7fc3440fb61d47828748afdbd3915828,Opdivo,0.596015
uuid-7fc3440fb61d47828748afdbd3915828,shared,0.387212
uuid-7fc3440fb61d47828748afdbd3915828,stated,0.368046
uuid-7fc3440fb61d47828748afdbd3915828,physicians,0.341674
uuid-7fc3440fb61d47828748afdbd3915828,drug,0.381889
uuid-7fc3440fb61d47828748afdbd3915828,Keytruda,0.329732
uuid-665d3550a4cf468f90496fe1a2c5515b,Nivo,0.45544
uuid-665d3550a4cf468f90496fe1a2c5515b,pembro,0.349349
uuid-665d3550a4cf468f90496fe1a2c5515b,1L,0.523076
uuid-665d3550a4cf468f90496fe1a2c5515b,efficacy,0.422581
uuid-665d3550a4cf468f90496fe1a2c5515b,regimen,0.46784
uuid-665d3550a4cf468f90496fe1a2c5515b,combination,0.414248
uuid-665d3550a4cf468f90496fe1a2c5515b,chemo,0.589141
uuid-665d3550a4cf468f90496fe1a2c5515b,2L,0.482235
uuid-665d3550a4cf468f90496fe1a2c5515b,agents,0.433196
uuid-665d3550a4cf468f90496fe1a2c5515b,OS,0.358978
uuid-665d3550a4cf468f90496fe1a2c5515b,atezo,0.31781
uuid-665d3550a4cf468f90496fe1a2c5515b,preferred,0.396775
uuid-665d3550a4cf468f90496fe1a2c5515b,monotherapy,0.591253
uuid-665d3550a4cf468f90496fe1a2c5515b,combo,0.549531
uuid-665d3550a4cf468f90496fe1a2c5515b,PFS,0.350575
uuid-665d3550a4cf468f90496fe1a2c5515b,PD1,0.434934
uuid-665d3550a4cf468f90496fe1a2c5515b,ORR,0.320236
uuid-665d3550a4cf468f90496fe1a2c5515b,nivo and pembro,0.396862
uuid-665d3550a4cf468f90496fe1a2c5515b,progression,0.316894
uuid-665d3550a4cf468f90496fe1a2c5515b,believes,0.443802
uuid-665d3550a4cf468f90496fe1a2c5515b,chemotherapy,0.504927
uuid-665d3550a4cf468f90496fe1a2c5515b,feels,0.545812
uuid-665d3550a4cf468f90496fe1a2c5515b,option,0.562197
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,TL,0.313282
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,RTL,0.358538
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,shared,0.382528
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,commented,0.306448
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,RCC,0.300887
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,TL stated,0.41332
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,stated,0.41344
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,physicians,0.565109
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,preferred,0.359215
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,PD-L1 testing,0.303646
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,testing,0.300981
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,using nivo,0.359392
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,mentioned,0.391029
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,PDL1 testing,0.463538
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,indication,0.325705
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,SCCHN,0.496621
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,HCP,0.420635
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,tumor types,0.371316
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,oncologist,0.342558
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,LTL,0.477866
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,TLs,0.351145
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,academic,0.33913
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,Regional TL,0.503314
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,RTL stated,0.379754
uuid-b51e8a4026084ee4b1d6bb4b257b41d2,bladder,0.328418
uuid-b16d36171936412196b222c65ce2d734,TL,0.624221
uuid-b16d36171936412196b222c65ce2d734,TL stated,0.556151
uuid-b16d36171936412196b222c65ce2d734,institution,0.333351
uuid-b16d36171936412196b222c65ce2d734,PD-L1,0.694968
uuid-b16d36171936412196b222c65ce2d734,PD-L1 testing,0.85628
uuid-b16d36171936412196b222c65ce2d734,testing,0.858748
uuid-b16d36171936412196b222c65ce2d734,PDL1 testing,0.729793
uuid-b16d36171936412196b222c65ce2d734,NSCLC patients,0.693355
uuid-b16d36171936412196b222c65ce2d734,assay,0.581469
uuid-44f93921723e4753bc1655a578236019,therapy,0.40905
uuid-44f93921723e4753bc1655a578236019,mentioned,0.384473
uuid-44f93921723e4753bc1655a578236019,cHL,0.640755
uuid-0fba2c3212a0424db18c243d6f0e6080,Nivo,0.302098
uuid-0fba2c3212a0424db18c243d6f0e6080,Opdivo,0.386075
uuid-0fba2c3212a0424db18c243d6f0e6080,therapy,0.457489
uuid-0fba2c3212a0424db18c243d6f0e6080,nivolumab,0.612139
uuid-0fba2c3212a0424db18c243d6f0e6080,treated,0.311461
uuid-0fba2c3212a0424db18c243d6f0e6080,approval,0.477976
uuid-0fba2c3212a0424db18c243d6f0e6080,using nivo,0.412236
uuid-0fba2c3212a0424db18c243d6f0e6080,mentioned,0.388375
uuid-0fba2c3212a0424db18c243d6f0e6080,cHL,0.710435
uuid-0fba2c3212a0424db18c243d6f0e6080,label,0.400485
uuid-17960b415cab4827803a34aafe0b0f07,toxicity,0.511221
uuid-17960b415cab4827803a34aafe0b0f07,regimen,0.474379
uuid-17960b415cab4827803a34aafe0b0f07,treated,0.398066
uuid-17960b415cab4827803a34aafe0b0f07,treatment,0.354785
uuid-2287359cb1134e04ae950bd14ccb6639,RTL,0.395841
uuid-2287359cb1134e04ae950bd14ccb6639,BMS,0.377961
uuid-2287359cb1134e04ae950bd14ccb6639,NTL,0.36736
uuid-2287359cb1134e04ae950bd14ccb6639,commented,0.636588
uuid-2287359cb1134e04ae950bd14ccb6639,stated,0.466638
uuid-2287359cb1134e04ae950bd14ccb6639,OS,0.373171
uuid-2287359cb1134e04ae950bd14ccb6639,regards,0.438754
uuid-2287359cb1134e04ae950bd14ccb6639,data,0.676395
uuid-2287359cb1134e04ae950bd14ccb6639,expressed,0.563232
uuid-2287359cb1134e04ae950bd14ccb6639,mentioned,0.373292
uuid-2287359cb1134e04ae950bd14ccb6639,indication,0.33354
uuid-2287359cb1134e04ae950bd14ccb6639,PFS,0.33095
uuid-2287359cb1134e04ae950bd14ccb6639,ORR,0.367798
uuid-2287359cb1134e04ae950bd14ccb6639,SCCHN,0.357451
uuid-2287359cb1134e04ae950bd14ccb6639,ASCO,0.466824
uuid-2287359cb1134e04ae950bd14ccb6639,impressed,0.669892
uuid-2287359cb1134e04ae950bd14ccb6639,LTL,0.329927
uuid-2287359cb1134e04ae950bd14ccb6639,SCLC,0.459213
uuid-2287359cb1134e04ae950bd14ccb6639,Regional TL,0.433032
uuid-2287359cb1134e04ae950bd14ccb6639,NCCN,0.526521
uuid-d87e646594574a2096ba55abc098b36f,TL,0.680442
uuid-d87e646594574a2096ba55abc098b36f,TL stated,0.499697
uuid-d87e646594574a2096ba55abc098b36f,institution,0.376856
uuid-d87e646594574a2096ba55abc098b36f,PD-L1,0.680641
uuid-d87e646594574a2096ba55abc098b36f,approval,0.326398
uuid-d87e646594574a2096ba55abc098b36f,PD-L1 testing,0.861808
uuid-d87e646594574a2096ba55abc098b36f,testing,0.854404
uuid-d87e646594574a2096ba55abc098b36f,PDL1 testing,0.685584
uuid-d87e646594574a2096ba55abc098b36f,NSCLC patients,0.675051
uuid-d87e646594574a2096ba55abc098b36f,assay,0.586504
uuid-979f278e8ac5485eb4b2fd6d074f992f,TL,0.724328
uuid-979f278e8ac5485eb4b2fd6d074f992f,PDL1,0.303319
uuid-979f278e8ac5485eb4b2fd6d074f992f,Merck,0.367265
uuid-979f278e8ac5485eb4b2fd6d074f992f,PD-L1,0.595319
uuid-979f278e8ac5485eb4b2fd6d074f992f,PD-L1 testing,0.680221
uuid-979f278e8ac5485eb4b2fd6d074f992f,testing,0.57244
uuid-979f278e8ac5485eb4b2fd6d074f992f,PDL1 testing,0.308377
uuid-979f278e8ac5485eb4b2fd6d074f992f,assay,0.764679
uuid-13061a25b0b54b0eba9845eb0510aad3,TL,0.522734
uuid-13061a25b0b54b0eba9845eb0510aad3,PDL1,0.367979
uuid-13061a25b0b54b0eba9845eb0510aad3,tumor,0.518816
uuid-13061a25b0b54b0eba9845eb0510aad3,PD-L1,0.640654
uuid-13061a25b0b54b0eba9845eb0510aad3,PD-L1 testing,0.601694
uuid-13061a25b0b54b0eba9845eb0510aad3,testing,0.597217
uuid-13061a25b0b54b0eba9845eb0510aad3,PDL1 testing,0.341921
uuid-13061a25b0b54b0eba9845eb0510aad3,assay,0.71201
uuid-13061a25b0b54b0eba9845eb0510aad3,PDL1 expression,0.321966
uuid-13061a25b0b54b0eba9845eb0510aad3,biomarker,0.42047
uuid-a5141d43b27341d3a6d9ae40da36cd61,nivolumab,0.377792
uuid-a5141d43b27341d3a6d9ae40da36cd61,1L,0.321785
uuid-a5141d43b27341d3a6d9ae40da36cd61,regimen,0.398344
uuid-a5141d43b27341d3a6d9ae40da36cd61,RCC,0.358255
uuid-a5141d43b27341d3a6d9ae40da36cd61,combination,0.495135
uuid-a5141d43b27341d3a6d9ae40da36cd61,2L,0.394469
uuid-a5141d43b27341d3a6d9ae40da36cd61,IO,0.302295
uuid-a5141d43b27341d3a6d9ae40da36cd61,agents,0.419516
uuid-a5141d43b27341d3a6d9ae40da36cd61,preferred,0.489958
uuid-a5141d43b27341d3a6d9ae40da36cd61,monotherapy,0.551395
uuid-a5141d43b27341d3a6d9ae40da36cd61,using nivo,0.387036
uuid-a5141d43b27341d3a6d9ae40da36cd61,combo,0.421455
uuid-a5141d43b27341d3a6d9ae40da36cd61,clinical trials,0.40933
uuid-a5141d43b27341d3a6d9ae40da36cd61,PD1,0.365752
uuid-a5141d43b27341d3a6d9ae40da36cd61,SCCHN,0.371961
uuid-a5141d43b27341d3a6d9ae40da36cd61,chemotherapy,0.362093
uuid-a5141d43b27341d3a6d9ae40da36cd61,academic,0.526252
uuid-a5141d43b27341d3a6d9ae40da36cd61,feels,0.410322
uuid-a5141d43b27341d3a6d9ae40da36cd61,RTL stated,0.517291
uuid-a5141d43b27341d3a6d9ae40da36cd61,option,0.459946
uuid-ea1c7455e4804c939b8d2b110618b4fd,RTL,0.300843
uuid-ea1c7455e4804c939b8d2b110618b4fd,shared,0.317552
uuid-ea1c7455e4804c939b8d2b110618b4fd,stated,0.480955
uuid-ea1c7455e4804c939b8d2b110618b4fd,approval,0.330832
uuid-ea1c7455e4804c939b8d2b110618b4fd,physicians,0.301069
uuid-ea1c7455e4804c939b8d2b110618b4fd,oncology,0.345964
uuid-ea1c7455e4804c939b8d2b110618b4fd,approved,0.341344
uuid-ea1c7455e4804c939b8d2b110618b4fd,SCCHN,0.407797
uuid-ea1c7455e4804c939b8d2b110618b4fd,LTL,0.365641
uuid-ea1c7455e4804c939b8d2b110618b4fd,Regional TL,0.391338
uuid-ea1c7455e4804c939b8d2b110618b4fd,RTL stated,0.306157
uuid-19a81426240449f5a0c4e5a38e2abcb5,patients,0.329751
uuid-19a81426240449f5a0c4e5a38e2abcb5,RTL,0.54481
uuid-19a81426240449f5a0c4e5a38e2abcb5,nivolumab,0.436653
uuid-19a81426240449f5a0c4e5a38e2abcb5,treated,0.511106
uuid-19a81426240449f5a0c4e5a38e2abcb5,NTL,0.380922
uuid-19a81426240449f5a0c4e5a38e2abcb5,melanoma,0.336853
uuid-19a81426240449f5a0c4e5a38e2abcb5,shared,0.393967
uuid-19a81426240449f5a0c4e5a38e2abcb5,commented,0.335234
uuid-19a81426240449f5a0c4e5a38e2abcb5,RCC,0.47618
uuid-19a81426240449f5a0c4e5a38e2abcb5,stated,0.38378
uuid-19a81426240449f5a0c4e5a38e2abcb5,approval,0.391556
uuid-19a81426240449f5a0c4e5a38e2abcb5,using nivo,0.447496
uuid-19a81426240449f5a0c4e5a38e2abcb5,clinical trials,0.47925
uuid-19a81426240449f5a0c4e5a38e2abcb5,SCCHN,0.616429
uuid-19a81426240449f5a0c4e5a38e2abcb5,HCP,0.36399
uuid-19a81426240449f5a0c4e5a38e2abcb5,LTL,0.400298
uuid-19a81426240449f5a0c4e5a38e2abcb5,SCLC,0.31493
uuid-19a81426240449f5a0c4e5a38e2abcb5,Regional TL,0.554125
uuid-19a81426240449f5a0c4e5a38e2abcb5,RTL stated,0.551503
uuid-19a81426240449f5a0c4e5a38e2abcb5,TL shared,0.425376
uuid-19a81426240449f5a0c4e5a38e2abcb5,bladder,0.660851
uuid-03f4983ac2ee4f69925661fa21281e75,Nivo,0.390251
uuid-03f4983ac2ee4f69925661fa21281e75,pembro,0.532746
uuid-03f4983ac2ee4f69925661fa21281e75,1L,0.331137
uuid-03f4983ac2ee4f69925661fa21281e75,PDL1,0.518775
uuid-03f4983ac2ee4f69925661fa21281e75,trial,0.352163
uuid-03f4983ac2ee4f69925661fa21281e75,efficacy,0.653634
uuid-03f4983ac2ee4f69925661fa21281e75,chemo,0.309259
uuid-03f4983ac2ee4f69925661fa21281e75,agents,0.308982
uuid-03f4983ac2ee4f69925661fa21281e75,OS,0.502801
uuid-03f4983ac2ee4f69925661fa21281e75,atezo,0.516062
uuid-03f4983ac2ee4f69925661fa21281e75,data,0.593723
uuid-03f4983ac2ee4f69925661fa21281e75,indication,0.319801
uuid-03f4983ac2ee4f69925661fa21281e75,PFS,0.47738
uuid-03f4983ac2ee4f69925661fa21281e75,ORR,0.547557
uuid-03f4983ac2ee4f69925661fa21281e75,nivo and pembro,0.6059
uuid-03f4983ac2ee4f69925661fa21281e75,believes,0.442598
uuid-03f4983ac2ee4f69925661fa21281e75,impressed,0.451316
uuid-03f4983ac2ee4f69925661fa21281e75,vs,0.421249
uuid-03f4983ac2ee4f69925661fa21281e75,feels,0.446658
uuid-03f4983ac2ee4f69925661fa21281e75,PDL1 expression,0.530691
uuid-d00a4662f6a042a7857276fda7d96e19,patients,0.793497
uuid-d00a4662f6a042a7857276fda7d96e19,Opdivo,0.665737
uuid-d00a4662f6a042a7857276fda7d96e19,therapy,0.553613
uuid-d00a4662f6a042a7857276fda7d96e19,nivolumab,0.531992
uuid-d00a4662f6a042a7857276fda7d96e19,treated,0.45121
uuid-d00a4662f6a042a7857276fda7d96e19,pts,0.320074
uuid-d00a4662f6a042a7857276fda7d96e19,approval,0.335531
uuid-d00a4662f6a042a7857276fda7d96e19,treatment,0.542081
uuid-d00a4662f6a042a7857276fda7d96e19,using nivo,0.355542
uuid-d00a4662f6a042a7857276fda7d96e19,cHL,0.568245
uuid-d00a4662f6a042a7857276fda7d96e19,progression,0.388288
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,Nivo,0.392454
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,patients,0.301998
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,therapy,0.666939
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,1L,0.408295
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,regimen,0.327568
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,combination,0.470826
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,chemo,0.739829
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,pts,0.330072
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,IO,0.384518
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,agents,0.463604
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,monotherapy,0.589528
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,treatment,0.393446
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,response,0.476702
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,combo,0.414125
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,PD1,0.641232
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,progression,0.523511
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,believes,0.535554
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,chemotherapy,0.700627
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,respond,0.349875
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,feels,0.471096
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,immunotherapy,0.31785
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,PD-1,0.330434
uuid-a90d8b881b4d4f2da4ae4b9021e51bf3,option,0.592769
uuid-f1680cb033f14f309d481a9ceda4ea74,commented,0.436498
uuid-f1680cb033f14f309d481a9ceda4ea74,stated,0.301024
uuid-f1680cb033f14f309d481a9ceda4ea74,physicians,0.574846
uuid-f1680cb033f14f309d481a9ceda4ea74,Regional TL,0.30604
uuid-2dff76de6ed84aa7afa31a18793f605b,patients,0.472861
uuid-2dff76de6ed84aa7afa31a18793f605b,nivolumab,0.451164
uuid-2dff76de6ed84aa7afa31a18793f605b,1L,0.56987
uuid-2dff76de6ed84aa7afa31a18793f605b,regimen,0.472546
uuid-2dff76de6ed84aa7afa31a18793f605b,treated,0.353325
uuid-2dff76de6ed84aa7afa31a18793f605b,RCC,0.50644
uuid-2dff76de6ed84aa7afa31a18793f605b,combination,0.393813
uuid-2dff76de6ed84aa7afa31a18793f605b,chemo,0.428115
uuid-2dff76de6ed84aa7afa31a18793f605b,2L,0.626404
uuid-2dff76de6ed84aa7afa31a18793f605b,pts,0.439809
uuid-2dff76de6ed84aa7afa31a18793f605b,agents,0.339621
uuid-2dff76de6ed84aa7afa31a18793f605b,atezo,0.301825
uuid-2dff76de6ed84aa7afa31a18793f605b,preferred,0.633505
uuid-2dff76de6ed84aa7afa31a18793f605b,monotherapy,0.656034
uuid-2dff76de6ed84aa7afa31a18793f605b,treatment,0.327134
uuid-2dff76de6ed84aa7afa31a18793f605b,using nivo,0.525455
uuid-2dff76de6ed84aa7afa31a18793f605b,combo,0.444686
uuid-2dff76de6ed84aa7afa31a18793f605b,NSCLC patients,0.346012
uuid-2dff76de6ed84aa7afa31a18793f605b,PD1,0.398247
uuid-2dff76de6ed84aa7afa31a18793f605b,approved,0.358649
uuid-2dff76de6ed84aa7afa31a18793f605b,SCCHN,0.375096
uuid-2dff76de6ed84aa7afa31a18793f605b,progression,0.303954
uuid-2dff76de6ed84aa7afa31a18793f605b,chemotherapy,0.382787
uuid-2dff76de6ed84aa7afa31a18793f605b,tumor types,0.373783
uuid-2dff76de6ed84aa7afa31a18793f605b,RTL stated,0.509834
uuid-2dff76de6ed84aa7afa31a18793f605b,TL shared,0.373813
uuid-2dff76de6ed84aa7afa31a18793f605b,option,0.606336
uuid-2dff76de6ed84aa7afa31a18793f605b,bladder,0.379098
uuid-6546c34af7d842c6bdf5490a62b4091b,patients,0.606004
uuid-6546c34af7d842c6bdf5490a62b4091b,therapy,0.382073
uuid-6546c34af7d842c6bdf5490a62b4091b,nivolumab,0.556477
uuid-6546c34af7d842c6bdf5490a62b4091b,1L,0.568787
uuid-6546c34af7d842c6bdf5490a62b4091b,regimen,0.381985
uuid-6546c34af7d842c6bdf5490a62b4091b,treated,0.461349
uuid-6546c34af7d842c6bdf5490a62b4091b,RCC,0.552033
uuid-6546c34af7d842c6bdf5490a62b4091b,TL stated,0.371698
uuid-6546c34af7d842c6bdf5490a62b4091b,2L,0.650244
uuid-6546c34af7d842c6bdf5490a62b4091b,pts,0.402769
uuid-6546c34af7d842c6bdf5490a62b4091b,approval,0.414855
uuid-6546c34af7d842c6bdf5490a62b4091b,preferred,0.732567
uuid-6546c34af7d842c6bdf5490a62b4091b,monotherapy,0.554225
uuid-6546c34af7d842c6bdf5490a62b4091b,treatment,0.414755
uuid-6546c34af7d842c6bdf5490a62b4091b,using nivo,0.6603
uuid-6546c34af7d842c6bdf5490a62b4091b,PDL1 testing,0.315726
uuid-6546c34af7d842c6bdf5490a62b4091b,NSCLC patients,0.393771
uuid-6546c34af7d842c6bdf5490a62b4091b,approved,0.438063
uuid-6546c34af7d842c6bdf5490a62b4091b,SCCHN,0.450301
uuid-6546c34af7d842c6bdf5490a62b4091b,progression,0.33088
uuid-6546c34af7d842c6bdf5490a62b4091b,chemotherapy,0.305286
uuid-6546c34af7d842c6bdf5490a62b4091b,tumor types,0.33646
uuid-6546c34af7d842c6bdf5490a62b4091b,RTL stated,0.633772
uuid-6546c34af7d842c6bdf5490a62b4091b,TL shared,0.41971
uuid-6546c34af7d842c6bdf5490a62b4091b,option,0.599961
uuid-6546c34af7d842c6bdf5490a62b4091b,bladder,0.383367
uuid-dbb0781e4fe84f1097566ff30efec979,tumor,0.503664
uuid-dbb0781e4fe84f1097566ff30efec979,response,0.320506
uuid-dbb0781e4fe84f1097566ff30efec979,immunotherapy,0.553929
uuid-df8fd4e881c84115b4bb15fb10b40df1,RTL,0.340015
uuid-df8fd4e881c84115b4bb15fb10b40df1,BMS,0.351351
uuid-df8fd4e881c84115b4bb15fb10b40df1,trial,0.430368
uuid-df8fd4e881c84115b4bb15fb10b40df1,efficacy,0.31083
uuid-df8fd4e881c84115b4bb15fb10b40df1,commented,0.545445
uuid-df8fd4e881c84115b4bb15fb10b40df1,OS,0.426605
uuid-df8fd4e881c84115b4bb15fb10b40df1,data,0.742615
uuid-df8fd4e881c84115b4bb15fb10b40df1,expressed,0.364586
uuid-df8fd4e881c84115b4bb15fb10b40df1,mentioned,0.315959
uuid-df8fd4e881c84115b4bb15fb10b40df1,PFS,0.390749
uuid-df8fd4e881c84115b4bb15fb10b40df1,ORR,0.458623
uuid-df8fd4e881c84115b4bb15fb10b40df1,ASCO,0.631942
uuid-df8fd4e881c84115b4bb15fb10b40df1,impressed,0.668521
uuid-df8fd4e881c84115b4bb15fb10b40df1,LTL,0.313527
uuid-df8fd4e881c84115b4bb15fb10b40df1,Regional TL,0.311156
uuid-7c1fcddde5b04e98ae44085eb3cd4434,TL,0.375205
uuid-7c1fcddde5b04e98ae44085eb3cd4434,pembro,0.363918
uuid-7c1fcddde5b04e98ae44085eb3cd4434,NSCLC,0.368694
uuid-7c1fcddde5b04e98ae44085eb3cd4434,1L,0.328948
uuid-7c1fcddde5b04e98ae44085eb3cd4434,PDL1,0.503185
uuid-7c1fcddde5b04e98ae44085eb3cd4434,PD-L1,0.647206
uuid-7c1fcddde5b04e98ae44085eb3cd4434,atezo,0.368799
uuid-7c1fcddde5b04e98ae44085eb3cd4434,PD-L1 testing,0.471773
uuid-7c1fcddde5b04e98ae44085eb3cd4434,testing,0.5267
uuid-7c1fcddde5b04e98ae44085eb3cd4434,NSCLC patients,0.416618
uuid-7c1fcddde5b04e98ae44085eb3cd4434,nivo and pembro,0.336415
uuid-7c1fcddde5b04e98ae44085eb3cd4434,assay,0.612461
uuid-7c1fcddde5b04e98ae44085eb3cd4434,PDL1 expression,0.33062
uuid-7c1fcddde5b04e98ae44085eb3cd4434,biomarker,0.418635
uuid-23fae953a65f4d14881870246dcb520e,patients,0.668009
uuid-23fae953a65f4d14881870246dcb520e,RTL,0.326998
uuid-23fae953a65f4d14881870246dcb520e,therapy,0.426495
uuid-23fae953a65f4d14881870246dcb520e,nivolumab,0.534202
uuid-23fae953a65f4d14881870246dcb520e,regimen,0.39219
uuid-23fae953a65f4d14881870246dcb520e,treated,0.643204
uuid-23fae953a65f4d14881870246dcb520e,chemo,0.304909
uuid-23fae953a65f4d14881870246dcb520e,pts,0.489631
uuid-23fae953a65f4d14881870246dcb520e,treatment,0.576749
uuid-23fae953a65f4d14881870246dcb520e,response,0.305797
uuid-23fae953a65f4d14881870246dcb520e,progression,0.517747
uuid-23fae953a65f4d14881870246dcb520e,chemotherapy,0.362439
uuid-23fae953a65f4d14881870246dcb520e,respond,0.341846
uuid-648d94a7df8647fd943d0a83be8acb5d,response,0.38557
uuid-648d94a7df8647fd943d0a83be8acb5d,PD1,0.637268
uuid-648d94a7df8647fd943d0a83be8acb5d,immunotherapy,0.458256
uuid-648d94a7df8647fd943d0a83be8acb5d,PD-1,0.525293
uuid-04c497ea86db43bf8d28db5bfa7d2473,patients,0.536559
uuid-04c497ea86db43bf8d28db5bfa7d2473,Opdivo,0.479569
uuid-04c497ea86db43bf8d28db5bfa7d2473,1L,0.325441
uuid-04c497ea86db43bf8d28db5bfa7d2473,treated,0.383127
uuid-04c497ea86db43bf8d28db5bfa7d2473,RCC,0.34789
uuid-04c497ea86db43bf8d28db5bfa7d2473,2L,0.373292
uuid-04c497ea86db43bf8d28db5bfa7d2473,pts,0.311694
uuid-04c497ea86db43bf8d28db5bfa7d2473,stated,0.328188
uuid-04c497ea86db43bf8d28db5bfa7d2473,approval,0.41288
uuid-04c497ea86db43bf8d28db5bfa7d2473,physicians,0.435527
uuid-04c497ea86db43bf8d28db5bfa7d2473,preferred,0.462989
uuid-04c497ea86db43bf8d28db5bfa7d2473,treatment,0.501795
uuid-04c497ea86db43bf8d28db5bfa7d2473,using nivo,0.436429
uuid-04c497ea86db43bf8d28db5bfa7d2473,approved,0.464375
uuid-04c497ea86db43bf8d28db5bfa7d2473,SCCHN,0.375097
uuid-04c497ea86db43bf8d28db5bfa7d2473,tumor types,0.301893
uuid-04c497ea86db43bf8d28db5bfa7d2473,oncologist,0.406422
uuid-04c497ea86db43bf8d28db5bfa7d2473,RTL stated,0.369556
uuid-04c497ea86db43bf8d28db5bfa7d2473,option,0.483858
uuid-5887d85fb79348f4a29036cacb8a334a,1L,0.355339
uuid-5887d85fb79348f4a29036cacb8a334a,2L,0.347192
uuid-5887d85fb79348f4a29036cacb8a334a,agents,0.35045
uuid-5887d85fb79348f4a29036cacb8a334a,preferred,0.621789
uuid-5887d85fb79348f4a29036cacb8a334a,monotherapy,0.414924
uuid-5887d85fb79348f4a29036cacb8a334a,using nivo,0.305698
uuid-5887d85fb79348f4a29036cacb8a334a,indication,0.31293
uuid-5887d85fb79348f4a29036cacb8a334a,SCCHN,0.33513
uuid-5887d85fb79348f4a29036cacb8a334a,chemotherapy,0.360265
uuid-5887d85fb79348f4a29036cacb8a334a,RTL stated,0.379394
uuid-5887d85fb79348f4a29036cacb8a334a,option,0.506157
uuid-9afcc112b02b483886b32ffb975e0a93,pembro,0.351563
uuid-9afcc112b02b483886b32ffb975e0a93,PDL1,0.614006
uuid-9afcc112b02b483886b32ffb975e0a93,trial,0.351899
uuid-9afcc112b02b483886b32ffb975e0a93,efficacy,0.548468
uuid-9afcc112b02b483886b32ffb975e0a93,OS,0.573313
uuid-9afcc112b02b483886b32ffb975e0a93,atezo,0.324686
uuid-9afcc112b02b483886b32ffb975e0a93,data,0.707342
uuid-9afcc112b02b483886b32ffb975e0a93,PFS,0.527935
uuid-9afcc112b02b483886b32ffb975e0a93,ORR,0.569609
uuid-9afcc112b02b483886b32ffb975e0a93,nivo and pembro,0.471259
uuid-9afcc112b02b483886b32ffb975e0a93,believes,0.311496
uuid-9afcc112b02b483886b32ffb975e0a93,impressed,0.477457
uuid-9afcc112b02b483886b32ffb975e0a93,vs,0.33643
uuid-9afcc112b02b483886b32ffb975e0a93,feels,0.4068
uuid-9afcc112b02b483886b32ffb975e0a93,PDL1 expression,0.513885
uuid-9afcc112b02b483886b32ffb975e0a93,biomarker,0.392834
uuid-9d60b0d58d4f4179b84c158723b9e0a0,PDL1,0.358073
uuid-9d60b0d58d4f4179b84c158723b9e0a0,efficacy,0.386033
uuid-9d60b0d58d4f4179b84c158723b9e0a0,chemo,0.341369
uuid-9d60b0d58d4f4179b84c158723b9e0a0,response,0.327091
uuid-9d60b0d58d4f4179b84c158723b9e0a0,believes,0.484642
uuid-9d60b0d58d4f4179b84c158723b9e0a0,feels,0.42705
uuid-9d60b0d58d4f4179b84c158723b9e0a0,PDL1 expression,0.336504
uuid-9d60b0d58d4f4179b84c158723b9e0a0,option,0.345676
uuid-9d60b0d58d4f4179b84c158723b9e0a0,biomarker,0.375166
uuid-296e55f2bc204da9a4bc2f1da9287d21,PD-L1,0.419258
uuid-296e55f2bc204da9a4bc2f1da9287d21,PD-L1 testing,0.328872
uuid-296e55f2bc204da9a4bc2f1da9287d21,testing,0.615984
uuid-296e55f2bc204da9a4bc2f1da9287d21,PDL1 testing,0.590054
uuid-296e55f2bc204da9a4bc2f1da9287d21,NSCLC patients,0.626493
uuid-296e55f2bc204da9a4bc2f1da9287d21,tumor types,0.358358
uuid-296e55f2bc204da9a4bc2f1da9287d21,biomarker,0.421425
uuid-b5aff642d5fd4cad8558d65b34ab8548,TL,0.517479
uuid-b5aff642d5fd4cad8558d65b34ab8548,PDL1,0.333437
uuid-b5aff642d5fd4cad8558d65b34ab8548,TL stated,0.516191
uuid-b5aff642d5fd4cad8558d65b34ab8548,Merck,0.310089
uuid-b5aff642d5fd4cad8558d65b34ab8548,institution,0.415104
uuid-b5aff642d5fd4cad8558d65b34ab8548,PD-L1,0.760714
uuid-b5aff642d5fd4cad8558d65b34ab8548,PD-L1 testing,0.856445
uuid-b5aff642d5fd4cad8558d65b34ab8548,testing,0.91855
uuid-b5aff642d5fd4cad8558d65b34ab8548,PDL1 testing,0.827914
uuid-b5aff642d5fd4cad8558d65b34ab8548,NSCLC patients,0.710586
uuid-b5aff642d5fd4cad8558d65b34ab8548,assay,0.608884
uuid-b5aff642d5fd4cad8558d65b34ab8548,biomarker,0.377827
uuid-127482fc65844db9baa46c53bec23bab,patients,0.532537
uuid-127482fc65844db9baa46c53bec23bab,Opdivo,0.485725
uuid-127482fc65844db9baa46c53bec23bab,therapy,0.518311
uuid-127482fc65844db9baa46c53bec23bab,nivolumab,0.455137
uuid-127482fc65844db9baa46c53bec23bab,treated,0.323258
uuid-127482fc65844db9baa46c53bec23bab,treatment,0.323363
uuid-127482fc65844db9baa46c53bec23bab,cHL,0.770689
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,patients,0.463114
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,therapy,0.541531
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,nivolumab,0.327796
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,toxicity,0.606717
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,regimen,0.399285
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,combination,0.376692
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,chemo,0.328093
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,treatment,0.440329
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,response,0.365331
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,PD1,0.300735
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,cHL,0.3714
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,progression,0.383347
uuid-c5b0ac10b7cf46c3a13448b52f2b7848,chemotherapy,0.459641
uuid-dd5744a4168d4c50ac22902273ebecef,stated,0.358055
uuid-dd5744a4168d4c50ac22902273ebecef,physicians,0.327406
uuid-dd5744a4168d4c50ac22902273ebecef,ASCO,0.326269
uuid-2d623e8724a146d68a011e061298dc13,Nivo,0.315015
uuid-2d623e8724a146d68a011e061298dc13,therapy,0.540104
uuid-2d623e8724a146d68a011e061298dc13,nivolumab,0.343703
uuid-2d623e8724a146d68a011e061298dc13,combination,0.373649
uuid-2d623e8724a146d68a011e061298dc13,PD1,0.391477
uuid-2d623e8724a146d68a011e061298dc13,cHL,0.445209
uuid-2d623e8724a146d68a011e061298dc13,chemotherapy,0.512209
uuid-d81bfa3499c34374a6520cc05889a0b2,Nivo,0.44192
uuid-d81bfa3499c34374a6520cc05889a0b2,patients,0.667575
uuid-d81bfa3499c34374a6520cc05889a0b2,Opdivo,0.448916
uuid-d81bfa3499c34374a6520cc05889a0b2,therapy,0.755798
uuid-d81bfa3499c34374a6520cc05889a0b2,nivolumab,0.523019
uuid-d81bfa3499c34374a6520cc05889a0b2,treated,0.35791
uuid-d81bfa3499c34374a6520cc05889a0b2,treatment,0.477337
uuid-d81bfa3499c34374a6520cc05889a0b2,using nivo,0.356323
uuid-d81bfa3499c34374a6520cc05889a0b2,PD1,0.326133
uuid-d81bfa3499c34374a6520cc05889a0b2,cHL,0.772033
uuid-d81bfa3499c34374a6520cc05889a0b2,progression,0.450962
uuid-d81bfa3499c34374a6520cc05889a0b2,chemotherapy,0.398188
uuid-d81bfa3499c34374a6520cc05889a0b2,respond,0.307435
uuid-88fc1882c58546b8a66f0afae4539261,Nivo,0.574199
uuid-88fc1882c58546b8a66f0afae4539261,patients,0.328036
uuid-88fc1882c58546b8a66f0afae4539261,therapy,0.561691
uuid-88fc1882c58546b8a66f0afae4539261,nivolumab,0.498255
uuid-88fc1882c58546b8a66f0afae4539261,1L,0.358925
uuid-88fc1882c58546b8a66f0afae4539261,regimen,0.38923
uuid-88fc1882c58546b8a66f0afae4539261,combination,0.611893
uuid-88fc1882c58546b8a66f0afae4539261,chemo,0.691985
uuid-88fc1882c58546b8a66f0afae4539261,2L,0.355585
uuid-88fc1882c58546b8a66f0afae4539261,pts,0.37658
uuid-88fc1882c58546b8a66f0afae4539261,IO,0.362877
uuid-88fc1882c58546b8a66f0afae4539261,agents,0.432576
uuid-88fc1882c58546b8a66f0afae4539261,preferred,0.305481
uuid-88fc1882c58546b8a66f0afae4539261,monotherapy,0.613102
uuid-88fc1882c58546b8a66f0afae4539261,treatment,0.322986
uuid-88fc1882c58546b8a66f0afae4539261,using nivo,0.352677
uuid-88fc1882c58546b8a66f0afae4539261,response,0.393228
uuid-88fc1882c58546b8a66f0afae4539261,combo,0.505831
uuid-88fc1882c58546b8a66f0afae4539261,PD1,0.580866
uuid-88fc1882c58546b8a66f0afae4539261,progression,0.41879
uuid-88fc1882c58546b8a66f0afae4539261,believes,0.344948
uuid-88fc1882c58546b8a66f0afae4539261,chemotherapy,0.631579
uuid-88fc1882c58546b8a66f0afae4539261,feels,0.457647
uuid-88fc1882c58546b8a66f0afae4539261,RTL stated,0.362701
uuid-88fc1882c58546b8a66f0afae4539261,option,0.514897
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,patients,0.838349
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,Opdivo,0.385794
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,therapy,0.565777
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,regimen,0.457335
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,treated,0.445619
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,chemo,0.427591
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,pts,0.645902
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,monotherapy,0.462263
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,treatment,0.605552
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,response,0.449853
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,NSCLC patients,0.356771
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,progression,0.674528
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,chemotherapy,0.440547
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,respond,0.520755
uuid-0bc2293f2f6645a2a2d8c386e7c9a68f,option,0.491782
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,patients,0.778776
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,Opdivo,0.410784
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,therapy,0.470267
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,dose,0.350474
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,nivolumab,0.317418
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,toxicity,0.529423
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,regimen,0.60808
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,treated,0.395592
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,chemo,0.468297
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,pts,0.436637
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,monotherapy,0.350147
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,treatment,0.652206
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,response,0.390557
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,progression,0.533013
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,chemotherapy,0.419212
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,respond,0.54516
uuid-4e9479db0ffa47b3a9a7fe6fe7add4eb,option,0.340236
uuid-ec62726a01e14770b724238327c0aa57,lung,0.415778
uuid-ec62726a01e14770b724238327c0aa57,TL stated,0.464038
uuid-ec62726a01e14770b724238327c0aa57,PD-L1 testing,0.428448
uuid-ec62726a01e14770b724238327c0aa57,testing,0.400383
uuid-ec62726a01e14770b724238327c0aa57,PDL1 testing,0.497978
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,patients,0.762632
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,Opdivo,0.431234
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,therapy,0.614671
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,nivolumab,0.371436
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,regimen,0.43781
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,treated,0.526513
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,pts,0.459172
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,physicians,0.38207
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,treatment,0.689838
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,response,0.385057
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,PD1,0.314221
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,cHL,0.305511
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,progression,0.669231
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,chemotherapy,0.418479
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,respond,0.443714
uuid-4e436555de5a4d5db8e5d1a6f5d853f6,option,0.339181
uuid-fb54b2a20ec44ae0affb8a43a4431baa,1L,0.400504
uuid-fb54b2a20ec44ae0affb8a43a4431baa,PDL1,0.336994
uuid-fb54b2a20ec44ae0affb8a43a4431baa,TL stated,0.387411
uuid-fb54b2a20ec44ae0affb8a43a4431baa,PD-L1,0.541278
uuid-fb54b2a20ec44ae0affb8a43a4431baa,PD-L1 testing,0.380281
uuid-fb54b2a20ec44ae0affb8a43a4431baa,testing,0.698372
uuid-fb54b2a20ec44ae0affb8a43a4431baa,PDL1 testing,0.715721
uuid-fb54b2a20ec44ae0affb8a43a4431baa,NSCLC patients,0.769634
uuid-fb54b2a20ec44ae0affb8a43a4431baa,tumor types,0.451825
uuid-fb54b2a20ec44ae0affb8a43a4431baa,PD-1,0.422015
uuid-fb54b2a20ec44ae0affb8a43a4431baa,biomarker,0.4256
uuid-246e63486b334524a034170ecadd91be,Nivo,0.399139
uuid-246e63486b334524a034170ecadd91be,patients,0.867874
uuid-246e63486b334524a034170ecadd91be,Opdivo,0.390358
uuid-246e63486b334524a034170ecadd91be,therapy,0.655129
uuid-246e63486b334524a034170ecadd91be,nivolumab,0.426984
uuid-246e63486b334524a034170ecadd91be,regimen,0.498643
uuid-246e63486b334524a034170ecadd91be,treated,0.458279
uuid-246e63486b334524a034170ecadd91be,chemo,0.471346
uuid-246e63486b334524a034170ecadd91be,pts,0.55036
uuid-246e63486b334524a034170ecadd91be,monotherapy,0.411138
uuid-246e63486b334524a034170ecadd91be,treatment,0.714022
uuid-246e63486b334524a034170ecadd91be,response,0.372904
uuid-246e63486b334524a034170ecadd91be,PD1,0.327915
uuid-246e63486b334524a034170ecadd91be,progression,0.661484
uuid-246e63486b334524a034170ecadd91be,chemotherapy,0.504536
uuid-246e63486b334524a034170ecadd91be,respond,0.52655
uuid-246e63486b334524a034170ecadd91be,option,0.447422
uuid-189ac193aa034abbacb6ffad52ea8dc2,Nivo,0.421769
uuid-189ac193aa034abbacb6ffad52ea8dc2,PDL1,0.31097
uuid-189ac193aa034abbacb6ffad52ea8dc2,trial,0.488071
uuid-189ac193aa034abbacb6ffad52ea8dc2,efficacy,0.56975
uuid-189ac193aa034abbacb6ffad52ea8dc2,OS,0.720247
uuid-189ac193aa034abbacb6ffad52ea8dc2,data,0.820008
uuid-189ac193aa034abbacb6ffad52ea8dc2,PFS,0.714635
uuid-189ac193aa034abbacb6ffad52ea8dc2,ORR,0.807303
uuid-189ac193aa034abbacb6ffad52ea8dc2,nivo and pembro,0.403349
uuid-189ac193aa034abbacb6ffad52ea8dc2,ASCO,0.391122
uuid-189ac193aa034abbacb6ffad52ea8dc2,impressed,0.692215
uuid-189ac193aa034abbacb6ffad52ea8dc2,feels,0.336789
uuid-189ac193aa034abbacb6ffad52ea8dc2,PDL1 expression,0.318517
uuid-ab0ff91cf6874584a4726f7642a1acf8,Ipi,0.436448
uuid-ab152ddef1d94a159cbb35136dc06710,Nivo,0.404597
uuid-ab152ddef1d94a159cbb35136dc06710,patients,0.438026
uuid-ab152ddef1d94a159cbb35136dc06710,Opdivo,0.309016
uuid-ab152ddef1d94a159cbb35136dc06710,therapy,0.532813
uuid-ab152ddef1d94a159cbb35136dc06710,treatment,0.386945
uuid-ab152ddef1d94a159cbb35136dc06710,cHL,0.661912
uuid-ab152ddef1d94a159cbb35136dc06710,progression,0.329115
uuid-ab152ddef1d94a159cbb35136dc06710,respond,0.345094
uuid-52a611216fac4c8da3e1d21c93fc498d,Nivo,0.508157
uuid-52a611216fac4c8da3e1d21c93fc498d,patients,0.677055
uuid-52a611216fac4c8da3e1d21c93fc498d,Opdivo,0.364968
uuid-52a611216fac4c8da3e1d21c93fc498d,therapy,0.765483
uuid-52a611216fac4c8da3e1d21c93fc498d,nivolumab,0.547778
uuid-52a611216fac4c8da3e1d21c93fc498d,treated,0.410982
uuid-52a611216fac4c8da3e1d21c93fc498d,chemo,0.305866
uuid-52a611216fac4c8da3e1d21c93fc498d,pts,0.321569
uuid-52a611216fac4c8da3e1d21c93fc498d,treatment,0.466509
uuid-52a611216fac4c8da3e1d21c93fc498d,using nivo,0.409565
uuid-52a611216fac4c8da3e1d21c93fc498d,PD1,0.371586
uuid-52a611216fac4c8da3e1d21c93fc498d,cHL,0.772927
uuid-52a611216fac4c8da3e1d21c93fc498d,progression,0.425898
uuid-52a611216fac4c8da3e1d21c93fc498d,chemotherapy,0.444954
uuid-021007e165564a6aa54f057a8abb551c,pembro,0.310847
uuid-021007e165564a6aa54f057a8abb551c,BMS,0.432764
uuid-021007e165564a6aa54f057a8abb551c,PDL1,0.355465
uuid-021007e165564a6aa54f057a8abb551c,trial,0.536611
uuid-021007e165564a6aa54f057a8abb551c,efficacy,0.523733
uuid-021007e165564a6aa54f057a8abb551c,commented,0.396726
uuid-021007e165564a6aa54f057a8abb551c,stated,0.304738
uuid-021007e165564a6aa54f057a8abb551c,OS,0.628347
uuid-021007e165564a6aa54f057a8abb551c,data,0.877766
uuid-021007e165564a6aa54f057a8abb551c,PFS,0.576522
uuid-021007e165564a6aa54f057a8abb551c,ORR,0.651568
uuid-021007e165564a6aa54f057a8abb551c,nivo and pembro,0.462245
uuid-021007e165564a6aa54f057a8abb551c,ASCO,0.369932
uuid-021007e165564a6aa54f057a8abb551c,believes,0.300686
uuid-021007e165564a6aa54f057a8abb551c,impressed,0.711929
uuid-021007e165564a6aa54f057a8abb551c,SCLC,0.301742
uuid-021007e165564a6aa54f057a8abb551c,feels,0.48484
uuid-021007e165564a6aa54f057a8abb551c,PDL1 expression,0.325113
uuid-37d56180dd2143c79a546657ab7a2bbf,patients,0.374929
uuid-37d56180dd2143c79a546657ab7a2bbf,PDL1,0.605773
uuid-37d56180dd2143c79a546657ab7a2bbf,efficacy,0.398976
uuid-37d56180dd2143c79a546657ab7a2bbf,chemo,0.32533
uuid-37d56180dd2143c79a546657ab7a2bbf,pts,0.335802
uuid-37d56180dd2143c79a546657ab7a2bbf,OS,0.385249
uuid-37d56180dd2143c79a546657ab7a2bbf,response,0.328346
uuid-37d56180dd2143c79a546657ab7a2bbf,PFS,0.417295
uuid-37d56180dd2143c79a546657ab7a2bbf,ORR,0.384085
uuid-37d56180dd2143c79a546657ab7a2bbf,progression,0.325854
uuid-37d56180dd2143c79a546657ab7a2bbf,believes,0.34933
uuid-37d56180dd2143c79a546657ab7a2bbf,respond,0.35546
uuid-37d56180dd2143c79a546657ab7a2bbf,feels,0.365216
uuid-37d56180dd2143c79a546657ab7a2bbf,PDL1 expression,0.475437
uuid-37d56180dd2143c79a546657ab7a2bbf,biomarker,0.356976
uuid-7bd0555f1ee348968fd4b350607d3e40,Nivo,0.380537
uuid-7bd0555f1ee348968fd4b350607d3e40,pembro,0.375117
uuid-7bd0555f1ee348968fd4b350607d3e40,1L,0.556187
uuid-7bd0555f1ee348968fd4b350607d3e40,RCC,0.46917
uuid-7bd0555f1ee348968fd4b350607d3e40,combination,0.337698
uuid-7bd0555f1ee348968fd4b350607d3e40,chemo,0.304052
uuid-7bd0555f1ee348968fd4b350607d3e40,2L,0.693736
uuid-7bd0555f1ee348968fd4b350607d3e40,agents,0.496211
uuid-7bd0555f1ee348968fd4b350607d3e40,atezo,0.529908
uuid-7bd0555f1ee348968fd4b350607d3e40,preferred,0.634329
uuid-7bd0555f1ee348968fd4b350607d3e40,monotherapy,0.539923
uuid-7bd0555f1ee348968fd4b350607d3e40,using nivo,0.491539
uuid-7bd0555f1ee348968fd4b350607d3e40,combo,0.384781
uuid-7bd0555f1ee348968fd4b350607d3e40,approved,0.36259
uuid-7bd0555f1ee348968fd4b350607d3e40,believes,0.360348
uuid-7bd0555f1ee348968fd4b350607d3e40,RTL stated,0.413993
uuid-7bd0555f1ee348968fd4b350607d3e40,option,0.512322
uuid-c5e0d333426d4e24888079b509d90d89,pembro,0.324663
uuid-c5e0d333426d4e24888079b509d90d89,RTL,0.530245
uuid-c5e0d333426d4e24888079b509d90d89,BMS,0.338963
uuid-c5e0d333426d4e24888079b509d90d89,trial,0.425073
uuid-c5e0d333426d4e24888079b509d90d89,NTL,0.385867
uuid-c5e0d333426d4e24888079b509d90d89,shared,0.424021
uuid-c5e0d333426d4e24888079b509d90d89,commented,0.51415
uuid-c5e0d333426d4e24888079b509d90d89,RCC,0.45235
uuid-c5e0d333426d4e24888079b509d90d89,TL stated,0.346494
uuid-c5e0d333426d4e24888079b509d90d89,Merck,0.373424
uuid-c5e0d333426d4e24888079b509d90d89,stated,0.617442
uuid-c5e0d333426d4e24888079b509d90d89,approval,0.505619
uuid-c5e0d333426d4e24888079b509d90d89,atezo,0.310812
uuid-c5e0d333426d4e24888079b509d90d89,using nivo,0.370469
uuid-c5e0d333426d4e24888079b509d90d89,data,0.478089
uuid-c5e0d333426d4e24888079b509d90d89,expressed,0.44042
uuid-c5e0d333426d4e24888079b509d90d89,mentioned,0.356209
uuid-c5e0d333426d4e24888079b509d90d89,clinical trials,0.410549
uuid-c5e0d333426d4e24888079b509d90d89,indication,0.369162
uuid-c5e0d333426d4e24888079b509d90d89,approved,0.474358
uuid-c5e0d333426d4e24888079b509d90d89,SCCHN,0.55381
uuid-c5e0d333426d4e24888079b509d90d89,ASCO,0.434223
uuid-c5e0d333426d4e24888079b509d90d89,impressed,0.567068
uuid-c5e0d333426d4e24888079b509d90d89,LTL,0.47502
uuid-c5e0d333426d4e24888079b509d90d89,TLs,0.456523
uuid-c5e0d333426d4e24888079b509d90d89,SCLC,0.396006
uuid-c5e0d333426d4e24888079b509d90d89,Regional TL,0.625481
uuid-c5e0d333426d4e24888079b509d90d89,RTL stated,0.435208
uuid-c5e0d333426d4e24888079b509d90d89,bladder,0.599935
uuid-a2b368ab72a046538fd1dfef17302792,lung,0.329154
uuid-a2b368ab72a046538fd1dfef17302792,discussed,0.486789
uuid-a2b368ab72a046538fd1dfef17302792,testing,0.30753
uuid-a2b368ab72a046538fd1dfef17302792,academic,0.397413
uuid-a2b368ab72a046538fd1dfef17302792,biomarker,0.457345
uuid-11aa0cb02a9c4b7d9cb6801d66129957,lung,0.344509
uuid-11aa0cb02a9c4b7d9cb6801d66129957,NSCLC,0.439168
uuid-11aa0cb02a9c4b7d9cb6801d66129957,discussed,0.461905
uuid-11aa0cb02a9c4b7d9cb6801d66129957,melanoma,0.367052
uuid-11aa0cb02a9c4b7d9cb6801d66129957,SCCHN,0.342622
uuid-11aa0cb02a9c4b7d9cb6801d66129957,academic,0.44819
uuid-fefdf6e8a7754c4f8b0c9b4299020198,patients,0.403475
uuid-fefdf6e8a7754c4f8b0c9b4299020198,Opdivo,0.307746
uuid-fefdf6e8a7754c4f8b0c9b4299020198,therapy,0.303875
uuid-fefdf6e8a7754c4f8b0c9b4299020198,nivolumab,0.327863
uuid-fefdf6e8a7754c4f8b0c9b4299020198,regimen,0.316302
uuid-fefdf6e8a7754c4f8b0c9b4299020198,treated,0.495929
uuid-fefdf6e8a7754c4f8b0c9b4299020198,treatment,0.379876
uuid-fefdf6e8a7754c4f8b0c9b4299020198,cHL,0.48867
uuid-fefdf6e8a7754c4f8b0c9b4299020198,respond,0.319182
uuid-32e434d37a26457c9ef27ad91806e3ac,RTL,0.331069
uuid-32e434d37a26457c9ef27ad91806e3ac,commented,0.37745
uuid-32e434d37a26457c9ef27ad91806e3ac,stated,0.311967
uuid-32e434d37a26457c9ef27ad91806e3ac,physicians,0.313166
uuid-32e434d37a26457c9ef27ad91806e3ac,impressed,0.311984
uuid-32e434d37a26457c9ef27ad91806e3ac,LTL,0.324524
uuid-32e434d37a26457c9ef27ad91806e3ac,TLs,0.347748
uuid-32e434d37a26457c9ef27ad91806e3ac,Regional TL,0.343149
uuid-32e434d37a26457c9ef27ad91806e3ac,flat dosing,0.430423
uuid-218f4e68a6d9497a8a11a57458f5b218,Nivo,0.685788
uuid-218f4e68a6d9497a8a11a57458f5b218,patients,0.368554
uuid-218f4e68a6d9497a8a11a57458f5b218,pembro,0.467774
uuid-218f4e68a6d9497a8a11a57458f5b218,therapy,0.461959
uuid-218f4e68a6d9497a8a11a57458f5b218,nivolumab,0.364249
uuid-218f4e68a6d9497a8a11a57458f5b218,1L,0.672365
uuid-218f4e68a6d9497a8a11a57458f5b218,regimen,0.448704
uuid-218f4e68a6d9497a8a11a57458f5b218,combination,0.525296
uuid-218f4e68a6d9497a8a11a57458f5b218,chemo,0.600841
uuid-218f4e68a6d9497a8a11a57458f5b218,2L,0.723394
uuid-218f4e68a6d9497a8a11a57458f5b218,pts,0.389027
uuid-218f4e68a6d9497a8a11a57458f5b218,IO,0.366569
uuid-218f4e68a6d9497a8a11a57458f5b218,agents,0.597923
uuid-218f4e68a6d9497a8a11a57458f5b218,Ipi,0.326842
uuid-218f4e68a6d9497a8a11a57458f5b218,atezo,0.485695
uuid-218f4e68a6d9497a8a11a57458f5b218,preferred,0.661931
uuid-218f4e68a6d9497a8a11a57458f5b218,monotherapy,0.818609
uuid-218f4e68a6d9497a8a11a57458f5b218,treatment,0.306391
uuid-218f4e68a6d9497a8a11a57458f5b218,using nivo,0.519508
uuid-218f4e68a6d9497a8a11a57458f5b218,combo,0.535398
uuid-218f4e68a6d9497a8a11a57458f5b218,PD1,0.523281
uuid-218f4e68a6d9497a8a11a57458f5b218,approved,0.440232
uuid-218f4e68a6d9497a8a11a57458f5b218,believes,0.38371
uuid-218f4e68a6d9497a8a11a57458f5b218,chemotherapy,0.522532
uuid-218f4e68a6d9497a8a11a57458f5b218,feels,0.379643
uuid-218f4e68a6d9497a8a11a57458f5b218,RTL stated,0.362927
uuid-218f4e68a6d9497a8a11a57458f5b218,option,0.763747
uuid-1ce631e5315a410eb0d61b9714733cf3,pembro,0.306926
uuid-1ce631e5315a410eb0d61b9714733cf3,1L,0.360588
uuid-1ce631e5315a410eb0d61b9714733cf3,PDL1,0.566936
uuid-1ce631e5315a410eb0d61b9714733cf3,efficacy,0.469719
uuid-1ce631e5315a410eb0d61b9714733cf3,PD-L1,0.331718
uuid-1ce631e5315a410eb0d61b9714733cf3,OS,0.342122
uuid-1ce631e5315a410eb0d61b9714733cf3,data,0.456462
uuid-1ce631e5315a410eb0d61b9714733cf3,ORR,0.345869
uuid-1ce631e5315a410eb0d61b9714733cf3,nivo and pembro,0.396155
uuid-1ce631e5315a410eb0d61b9714733cf3,believes,0.389602
uuid-1ce631e5315a410eb0d61b9714733cf3,feels,0.313532
uuid-1ce631e5315a410eb0d61b9714733cf3,PDL1 expression,0.456396
uuid-1ce631e5315a410eb0d61b9714733cf3,biomarker,0.458431
uuid-4e882ddb74c844c89fea954c1f48ee0c,patients,0.783803
uuid-4e882ddb74c844c89fea954c1f48ee0c,Opdivo,0.444826
uuid-4e882ddb74c844c89fea954c1f48ee0c,therapy,0.760098
uuid-4e882ddb74c844c89fea954c1f48ee0c,nivolumab,0.62078
uuid-4e882ddb74c844c89fea954c1f48ee0c,regimen,0.372475
uuid-4e882ddb74c844c89fea954c1f48ee0c,treated,0.56576
uuid-4e882ddb74c844c89fea954c1f48ee0c,pts,0.441803
uuid-4e882ddb74c844c89fea954c1f48ee0c,monotherapy,0.303271
uuid-4e882ddb74c844c89fea954c1f48ee0c,treatment,0.67071
uuid-4e882ddb74c844c89fea954c1f48ee0c,using nivo,0.339245
uuid-4e882ddb74c844c89fea954c1f48ee0c,response,0.367221
uuid-4e882ddb74c844c89fea954c1f48ee0c,PD1,0.394736
uuid-4e882ddb74c844c89fea954c1f48ee0c,cHL,0.653884
uuid-4e882ddb74c844c89fea954c1f48ee0c,progression,0.609789
uuid-4e882ddb74c844c89fea954c1f48ee0c,chemotherapy,0.470583
uuid-4e882ddb74c844c89fea954c1f48ee0c,respond,0.364114
uuid-47eb3f5e29d34d3493ee4b2e4060c56a,Nivo,0.30719
uuid-47eb3f5e29d34d3493ee4b2e4060c56a,therapy,0.482947
uuid-47eb3f5e29d34d3493ee4b2e4060c56a,nivolumab,0.423622
uuid-47eb3f5e29d34d3493ee4b2e4060c56a,trial,0.301355
uuid-47eb3f5e29d34d3493ee4b2e4060c56a,PD1,0.34072
uuid-47eb3f5e29d34d3493ee4b2e4060c56a,cHL,0.563971
uuid-47eb3f5e29d34d3493ee4b2e4060c56a,chemotherapy,0.426676
uuid-6741dcc69de1410a9473ca04e2337e79,Nivo,0.646935
uuid-6741dcc69de1410a9473ca04e2337e79,patients,0.593891
uuid-6741dcc69de1410a9473ca04e2337e79,Opdivo,0.360566
uuid-6741dcc69de1410a9473ca04e2337e79,therapy,0.714782
uuid-6741dcc69de1410a9473ca04e2337e79,nivolumab,0.577301
uuid-6741dcc69de1410a9473ca04e2337e79,regimen,0.340206
uuid-6741dcc69de1410a9473ca04e2337e79,treated,0.347415
uuid-6741dcc69de1410a9473ca04e2337e79,chemo,0.354893
uuid-6741dcc69de1410a9473ca04e2337e79,pts,0.39017
uuid-6741dcc69de1410a9473ca04e2337e79,monotherapy,0.336835
uuid-6741dcc69de1410a9473ca04e2337e79,treatment,0.515877
uuid-6741dcc69de1410a9473ca04e2337e79,using nivo,0.398307
uuid-6741dcc69de1410a9473ca04e2337e79,response,0.410647
uuid-6741dcc69de1410a9473ca04e2337e79,PD1,0.419145
uuid-6741dcc69de1410a9473ca04e2337e79,cHL,0.652674
uuid-6741dcc69de1410a9473ca04e2337e79,progression,0.528672
uuid-6741dcc69de1410a9473ca04e2337e79,chemotherapy,0.444845
uuid-6741dcc69de1410a9473ca04e2337e79,respond,0.371087
uuid-8395cbc059f24e50840d7b57d99d81fb,RTL,0.352906
uuid-8395cbc059f24e50840d7b57d99d81fb,BMS,0.587036
uuid-8395cbc059f24e50840d7b57d99d81fb,trial,0.572572
uuid-8395cbc059f24e50840d7b57d99d81fb,NTL,0.328875
uuid-8395cbc059f24e50840d7b57d99d81fb,shared,0.334943
uuid-8395cbc059f24e50840d7b57d99d81fb,commented,0.325966
uuid-8395cbc059f24e50840d7b57d99d81fb,Merck,0.641245
uuid-8395cbc059f24e50840d7b57d99d81fb,stated,0.375137
uuid-8395cbc059f24e50840d7b57d99d81fb,approval,0.356985
uuid-8395cbc059f24e50840d7b57d99d81fb,expressed,0.35854
uuid-8395cbc059f24e50840d7b57d99d81fb,mentioned,0.48704
uuid-8395cbc059f24e50840d7b57d99d81fb,clinical trials,0.499789
uuid-8395cbc059f24e50840d7b57d99d81fb,indication,0.416585
uuid-8395cbc059f24e50840d7b57d99d81fb,approved,0.378207
uuid-8395cbc059f24e50840d7b57d99d81fb,label,0.363248
uuid-8395cbc059f24e50840d7b57d99d81fb,LTL,0.380822
uuid-8395cbc059f24e50840d7b57d99d81fb,Regional TL,0.343581
uuid-baabea7377e94588b88ebc8f44c080e4,Nivo,0.551713
uuid-baabea7377e94588b88ebc8f44c080e4,pembro,0.374693
uuid-baabea7377e94588b88ebc8f44c080e4,nivolumab,0.356224
uuid-baabea7377e94588b88ebc8f44c080e4,2L,0.306985
uuid-baabea7377e94588b88ebc8f44c080e4,atezo,0.316144
uuid-baabea7377e94588b88ebc8f44c080e4,preferred,0.328118
uuid-baabea7377e94588b88ebc8f44c080e4,using nivo,0.535483
uuid-baabea7377e94588b88ebc8f44c080e4,mentioned,0.569383
uuid-baabea7377e94588b88ebc8f44c080e4,indication,0.334043
uuid-baabea7377e94588b88ebc8f44c080e4,HCP,0.341112
uuid-baabea7377e94588b88ebc8f44c080e4,cHL,0.527566
uuid-baabea7377e94588b88ebc8f44c080e4,LTL,0.437975
uuid-baabea7377e94588b88ebc8f44c080e4,feels,0.339611
uuid-baabea7377e94588b88ebc8f44c080e4,RTL stated,0.357079
uuid-f00eb12a43d24e49af438f80493ee81d,Nivo,0.881086
uuid-f00eb12a43d24e49af438f80493ee81d,patients,0.366295
uuid-f00eb12a43d24e49af438f80493ee81d,pembro,0.52577
uuid-f00eb12a43d24e49af438f80493ee81d,therapy,0.494992
uuid-f00eb12a43d24e49af438f80493ee81d,nivolumab,0.483519
uuid-f00eb12a43d24e49af438f80493ee81d,1L,0.411499
uuid-f00eb12a43d24e49af438f80493ee81d,regimen,0.339501
uuid-f00eb12a43d24e49af438f80493ee81d,combination,0.479124
uuid-f00eb12a43d24e49af438f80493ee81d,chemo,0.505718
uuid-f00eb12a43d24e49af438f80493ee81d,2L,0.474122
uuid-f00eb12a43d24e49af438f80493ee81d,pts,0.32143
uuid-f00eb12a43d24e49af438f80493ee81d,agents,0.307779
uuid-f00eb12a43d24e49af438f80493ee81d,Ipi,0.497891
uuid-f00eb12a43d24e49af438f80493ee81d,atezo,0.400559
uuid-f00eb12a43d24e49af438f80493ee81d,preferred,0.405076
uuid-f00eb12a43d24e49af438f80493ee81d,monotherapy,0.59906
uuid-f00eb12a43d24e49af438f80493ee81d,using nivo,0.582245
uuid-f00eb12a43d24e49af438f80493ee81d,combo,0.413104
uuid-f00eb12a43d24e49af438f80493ee81d,PD1,0.434219
uuid-f00eb12a43d24e49af438f80493ee81d,approved,0.348517
uuid-f00eb12a43d24e49af438f80493ee81d,cHL,0.370388
uuid-f00eb12a43d24e49af438f80493ee81d,chemotherapy,0.490962
uuid-f00eb12a43d24e49af438f80493ee81d,vs,0.34197
uuid-f00eb12a43d24e49af438f80493ee81d,RTL stated,0.351537
uuid-f00eb12a43d24e49af438f80493ee81d,option,0.525464
uuid-cc57f46e2c2649859f65e6667655b3a6,RTL,0.404107
uuid-cc57f46e2c2649859f65e6667655b3a6,PDL1,0.482876
uuid-cc57f46e2c2649859f65e6667655b3a6,trial,0.401353
uuid-cc57f46e2c2649859f65e6667655b3a6,commented,0.326396
uuid-cc57f46e2c2649859f65e6667655b3a6,Merck,0.305492
uuid-cc57f46e2c2649859f65e6667655b3a6,PD-L1,0.397362
uuid-cc57f46e2c2649859f65e6667655b3a6,OS,0.602574
uuid-cc57f46e2c2649859f65e6667655b3a6,PD-L1 testing,0.341216
uuid-cc57f46e2c2649859f65e6667655b3a6,data,0.598336
uuid-cc57f46e2c2649859f65e6667655b3a6,PFS,0.616055
uuid-cc57f46e2c2649859f65e6667655b3a6,ORR,0.551478
uuid-cc57f46e2c2649859f65e6667655b3a6,nivo and pembro,0.300378
uuid-cc57f46e2c2649859f65e6667655b3a6,impressed,0.474151
uuid-cc57f46e2c2649859f65e6667655b3a6,assay,0.33318
uuid-cc57f46e2c2649859f65e6667655b3a6,PDL1 expression,0.453388
uuid-cc57f46e2c2649859f65e6667655b3a6,biomarker,0.361054
uuid-c98bc28854a4435a8c13f4f6e2757cbb,RTL,0.511987
uuid-c98bc28854a4435a8c13f4f6e2757cbb,BMS,0.38183
uuid-c98bc28854a4435a8c13f4f6e2757cbb,PDL1,0.322999
uuid-c98bc28854a4435a8c13f4f6e2757cbb,trial,0.468022
uuid-c98bc28854a4435a8c13f4f6e2757cbb,efficacy,0.456314
uuid-c98bc28854a4435a8c13f4f6e2757cbb,NTL,0.33102
uuid-c98bc28854a4435a8c13f4f6e2757cbb,commented,0.489697
uuid-c98bc28854a4435a8c13f4f6e2757cbb,Merck,0.329461
uuid-c98bc28854a4435a8c13f4f6e2757cbb,OS,0.599938
uuid-c98bc28854a4435a8c13f4f6e2757cbb,regards,0.36774
uuid-c98bc28854a4435a8c13f4f6e2757cbb,data,0.77226
uuid-c98bc28854a4435a8c13f4f6e2757cbb,expressed,0.481007
uuid-c98bc28854a4435a8c13f4f6e2757cbb,PFS,0.548026
uuid-c98bc28854a4435a8c13f4f6e2757cbb,ORR,0.598864
uuid-c98bc28854a4435a8c13f4f6e2757cbb,nivo and pembro,0.309947
uuid-c98bc28854a4435a8c13f4f6e2757cbb,ASCO,0.433391
uuid-c98bc28854a4435a8c13f4f6e2757cbb,impressed,0.68404
uuid-c98bc28854a4435a8c13f4f6e2757cbb,LTL,0.335088
uuid-c98bc28854a4435a8c13f4f6e2757cbb,TLs,0.427924
uuid-c98bc28854a4435a8c13f4f6e2757cbb,Regional TL,0.302546
uuid-c98bc28854a4435a8c13f4f6e2757cbb,PDL1 expression,0.346088
uuid-5e53334897af4c15bcc6685383c4965d,tumor,0.466145
uuid-30aa8abd367e40ad915f9a9725a18573,oncology,0.300812
uuid-7f8124102b024a7da5118688046d8462,Nivo,0.57536
uuid-7f8124102b024a7da5118688046d8462,patients,0.736234
uuid-7f8124102b024a7da5118688046d8462,Opdivo,0.458912
uuid-7f8124102b024a7da5118688046d8462,pembro,0.39841
uuid-7f8124102b024a7da5118688046d8462,therapy,0.358812
uuid-7f8124102b024a7da5118688046d8462,dose,0.675304
uuid-7f8124102b024a7da5118688046d8462,nivolumab,0.417594
uuid-7f8124102b024a7da5118688046d8462,toxicity,0.36328
uuid-7f8124102b024a7da5118688046d8462,regimen,0.495999
uuid-7f8124102b024a7da5118688046d8462,treated,0.309415
uuid-7f8124102b024a7da5118688046d8462,chemo,0.349779
uuid-7f8124102b024a7da5118688046d8462,2L,0.339092
uuid-7f8124102b024a7da5118688046d8462,pts,0.481186
uuid-7f8124102b024a7da5118688046d8462,Ipi,0.464443
uuid-7f8124102b024a7da5118688046d8462,atezo,0.302766
uuid-7f8124102b024a7da5118688046d8462,preferred,0.370047
uuid-7f8124102b024a7da5118688046d8462,monotherapy,0.4121
uuid-7f8124102b024a7da5118688046d8462,treatment,0.460574
uuid-7f8124102b024a7da5118688046d8462,using nivo,0.408591
uuid-7f8124102b024a7da5118688046d8462,progression,0.424822
uuid-7f8124102b024a7da5118688046d8462,chemotherapy,0.312063
uuid-7f8124102b024a7da5118688046d8462,vs,0.477331
uuid-7f8124102b024a7da5118688046d8462,respond,0.352086
uuid-7f8124102b024a7da5118688046d8462,option,0.376331
uuid-7f8124102b024a7da5118688046d8462,flat dosing,0.396481
uuid-140724f020c945cf839914f97f794597,Nivo,0.547241
uuid-140724f020c945cf839914f97f794597,pembro,0.373233
uuid-140724f020c945cf839914f97f794597,nivolumab,0.349078
uuid-140724f020c945cf839914f97f794597,1L,0.420097
uuid-140724f020c945cf839914f97f794597,regimen,0.32169
uuid-140724f020c945cf839914f97f794597,RCC,0.433473
uuid-140724f020c945cf839914f97f794597,combination,0.362584
uuid-140724f020c945cf839914f97f794597,chemo,0.391413
uuid-140724f020c945cf839914f97f794597,2L,0.407592
uuid-140724f020c945cf839914f97f794597,pts,0.448849
uuid-140724f020c945cf839914f97f794597,monotherapy,0.53204
uuid-140724f020c945cf839914f97f794597,using nivo,0.418096
uuid-140724f020c945cf839914f97f794597,response,0.311978
uuid-140724f020c945cf839914f97f794597,combo,0.34952
uuid-140724f020c945cf839914f97f794597,PD1,0.402406
uuid-140724f020c945cf839914f97f794597,ORR,0.325605
uuid-140724f020c945cf839914f97f794597,nivo and pembro,0.37975
uuid-140724f020c945cf839914f97f794597,impressed,0.413208
uuid-140724f020c945cf839914f97f794597,SCLC,0.41582
uuid-140724f020c945cf839914f97f794597,feels,0.368484
uuid-140724f020c945cf839914f97f794597,RTL stated,0.484886
uuid-140724f020c945cf839914f97f794597,option,0.323224
uuid-140724f020c945cf839914f97f794597,bladder,0.335852
uuid-19ccbb8dd78b42f9b057ba195f58ba52,Nivo,0.63979
uuid-19ccbb8dd78b42f9b057ba195f58ba52,patients,0.381919
uuid-19ccbb8dd78b42f9b057ba195f58ba52,pembro,0.439498
uuid-19ccbb8dd78b42f9b057ba195f58ba52,dose,0.641507
uuid-19ccbb8dd78b42f9b057ba195f58ba52,nivolumab,0.362009
uuid-19ccbb8dd78b42f9b057ba195f58ba52,toxicity,0.461831
uuid-19ccbb8dd78b42f9b057ba195f58ba52,efficacy,0.364709
uuid-19ccbb8dd78b42f9b057ba195f58ba52,regimen,0.622515
uuid-19ccbb8dd78b42f9b057ba195f58ba52,combination,0.494003
uuid-19ccbb8dd78b42f9b057ba195f58ba52,chemo,0.502253
uuid-19ccbb8dd78b42f9b057ba195f58ba52,2L,0.377744
uuid-19ccbb8dd78b42f9b057ba195f58ba52,pts,0.436891
uuid-19ccbb8dd78b42f9b057ba195f58ba52,Ipi,0.743994
uuid-19ccbb8dd78b42f9b057ba195f58ba52,atezo,0.383666
uuid-19ccbb8dd78b42f9b057ba195f58ba52,preferred,0.352141
uuid-19ccbb8dd78b42f9b057ba195f58ba52,monotherapy,0.559397
uuid-19ccbb8dd78b42f9b057ba195f58ba52,using nivo,0.34391
uuid-19ccbb8dd78b42f9b057ba195f58ba52,response,0.369204
uuid-19ccbb8dd78b42f9b057ba195f58ba52,combo,0.509338
uuid-19ccbb8dd78b42f9b057ba195f58ba52,PD1,0.370205
uuid-19ccbb8dd78b42f9b057ba195f58ba52,progression,0.350159
uuid-19ccbb8dd78b42f9b057ba195f58ba52,chemotherapy,0.362892
uuid-19ccbb8dd78b42f9b057ba195f58ba52,vs,0.490433
uuid-19ccbb8dd78b42f9b057ba195f58ba52,respond,0.348365
uuid-19ccbb8dd78b42f9b057ba195f58ba52,option,0.336139
uuid-86cd137571c243e4bab080af0b66221d,lung,0.375716
uuid-86cd137571c243e4bab080af0b66221d,NTL,0.400309
uuid-86cd137571c243e4bab080af0b66221d,discussed,0.484768
uuid-86cd137571c243e4bab080af0b66221d,melanoma,0.448596
uuid-86cd137571c243e4bab080af0b66221d,regards,0.405593
uuid-86cd137571c243e4bab080af0b66221d,SCCHN,0.394115
uuid-86cd137571c243e4bab080af0b66221d,lung cancer,0.309101
uuid-86cd137571c243e4bab080af0b66221d,academic,0.427798
uuid-86cd137571c243e4bab080af0b66221d,NCCN,0.480317
uuid-871b38d31040478a85447c37998106e6,therapy,0.363594
uuid-871b38d31040478a85447c37998106e6,nivolumab,0.411236
uuid-871b38d31040478a85447c37998106e6,1L,0.352675
uuid-871b38d31040478a85447c37998106e6,toxicity,0.313644
uuid-871b38d31040478a85447c37998106e6,regimen,0.353882
uuid-871b38d31040478a85447c37998106e6,melanoma,0.386326
uuid-871b38d31040478a85447c37998106e6,RCC,0.380524
uuid-871b38d31040478a85447c37998106e6,combination,0.482348
uuid-871b38d31040478a85447c37998106e6,2L,0.44772
uuid-871b38d31040478a85447c37998106e6,agents,0.374902
uuid-871b38d31040478a85447c37998106e6,preferred,0.445155
uuid-871b38d31040478a85447c37998106e6,monotherapy,0.54689
uuid-871b38d31040478a85447c37998106e6,treatment,0.359731
uuid-871b38d31040478a85447c37998106e6,using nivo,0.380835
uuid-871b38d31040478a85447c37998106e6,combo,0.442832
uuid-871b38d31040478a85447c37998106e6,PD1,0.379022
uuid-871b38d31040478a85447c37998106e6,approved,0.379366
uuid-871b38d31040478a85447c37998106e6,chemotherapy,0.30061
uuid-871b38d31040478a85447c37998106e6,RTL stated,0.406289
uuid-871b38d31040478a85447c37998106e6,option,0.494412
uuid-85bf1bdf492e421d833d82d34656e6f0,therapy,0.368914
uuid-85bf1bdf492e421d833d82d34656e6f0,combination,0.416299
uuid-85bf1bdf492e421d833d82d34656e6f0,chemo,0.333833
uuid-85bf1bdf492e421d833d82d34656e6f0,treatment,0.333874
uuid-85bf1bdf492e421d833d82d34656e6f0,response,0.407069
uuid-85bf1bdf492e421d833d82d34656e6f0,PD1,0.332566
uuid-85bf1bdf492e421d833d82d34656e6f0,chemotherapy,0.361381
uuid-85bf1bdf492e421d833d82d34656e6f0,immunotherapy,0.538813
uuid-5fd3e325e7524a258be3ff473c934255,physicians,0.314417
uuid-729b96b29ca84cd882ce301683ef6135,RTL,0.482417
uuid-729b96b29ca84cd882ce301683ef6135,BMS,0.497669
uuid-729b96b29ca84cd882ce301683ef6135,trial,0.893739
uuid-729b96b29ca84cd882ce301683ef6135,NTL,0.314229
uuid-729b96b29ca84cd882ce301683ef6135,commented,0.375974
uuid-729b96b29ca84cd882ce301683ef6135,Merck,0.468025
uuid-729b96b29ca84cd882ce301683ef6135,data,0.441011
uuid-729b96b29ca84cd882ce301683ef6135,expressed,0.320101
uuid-729b96b29ca84cd882ce301683ef6135,clinical trials,0.489164
uuid-729b96b29ca84cd882ce301683ef6135,ORR,0.319131
uuid-729b96b29ca84cd882ce301683ef6135,impressed,0.42904
uuid-16a27453bad249dba75ee64afad9dd71,patients,0.474935
uuid-16a27453bad249dba75ee64afad9dd71,toxicity,0.407183
uuid-16a27453bad249dba75ee64afad9dd71,regimen,0.339936
uuid-16a27453bad249dba75ee64afad9dd71,progression,0.430011
uuid-16a27453bad249dba75ee64afad9dd71,respond,0.322536
uuid-78dfae8b1cf54f10ac2b5c971c5c95f6,TL,0.523681
uuid-78dfae8b1cf54f10ac2b5c971c5c95f6,TL stated,0.31757
uuid-78dfae8b1cf54f10ac2b5c971c5c95f6,institution,0.419182
uuid-78dfae8b1cf54f10ac2b5c971c5c95f6,PD-L1,0.590959
uuid-78dfae8b1cf54f10ac2b5c971c5c95f6,approval,0.439537
uuid-78dfae8b1cf54f10ac2b5c971c5c95f6,PD-L1 testing,0.774904
uuid-78dfae8b1cf54f10ac2b5c971c5c95f6,testing,0.723715
uuid-78dfae8b1cf54f10ac2b5c971c5c95f6,PDL1 testing,0.588996
uuid-78dfae8b1cf54f10ac2b5c971c5c95f6,NSCLC patients,0.553722
uuid-78dfae8b1cf54f10ac2b5c971c5c95f6,assay,0.501305
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,patients,0.561748
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,therapy,0.477664
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,nivolumab,0.445902
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,1L,0.499687
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,toxicity,0.355898
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,regimen,0.628524
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,treated,0.512842
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,RCC,0.527229
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,combination,0.470039
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,chemo,0.478644
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,2L,0.553795
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,pts,0.489256
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,IO,0.308663
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,agents,0.392695
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,preferred,0.627269
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,monotherapy,0.686338
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,treatment,0.614233
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,using nivo,0.481715
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,combo,0.482479
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,PD1,0.471603
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,approved,0.31151
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,progression,0.488838
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,chemotherapy,0.429016
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,respond,0.383807
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,RTL stated,0.556443
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,TL shared,0.436016
uuid-b33c4756c92d40d0ac5a0f12f5b5c0dc,option,0.662159
uuid-67ea404c0e6f4831bbaa34dd007d1227,patients,0.828744
uuid-67ea404c0e6f4831bbaa34dd007d1227,Opdivo,0.393024
uuid-67ea404c0e6f4831bbaa34dd007d1227,therapy,0.657003
uuid-67ea404c0e6f4831bbaa34dd007d1227,nivolumab,0.604042
uuid-67ea404c0e6f4831bbaa34dd007d1227,regimen,0.493822
uuid-67ea404c0e6f4831bbaa34dd007d1227,treated,0.689406
uuid-67ea404c0e6f4831bbaa34dd007d1227,RCC,0.380644
uuid-67ea404c0e6f4831bbaa34dd007d1227,chemo,0.344365
uuid-67ea404c0e6f4831bbaa34dd007d1227,2L,0.301796
uuid-67ea404c0e6f4831bbaa34dd007d1227,pts,0.543759
uuid-67ea404c0e6f4831bbaa34dd007d1227,preferred,0.364324
uuid-67ea404c0e6f4831bbaa34dd007d1227,monotherapy,0.445833
uuid-67ea404c0e6f4831bbaa34dd007d1227,treatment,0.690306
uuid-67ea404c0e6f4831bbaa34dd007d1227,using nivo,0.503339
uuid-67ea404c0e6f4831bbaa34dd007d1227,PD1,0.347106
uuid-67ea404c0e6f4831bbaa34dd007d1227,cHL,0.409931
uuid-67ea404c0e6f4831bbaa34dd007d1227,progression,0.600848
uuid-67ea404c0e6f4831bbaa34dd007d1227,chemotherapy,0.435139
uuid-67ea404c0e6f4831bbaa34dd007d1227,respond,0.368346
uuid-67ea404c0e6f4831bbaa34dd007d1227,RTL stated,0.473995
uuid-67ea404c0e6f4831bbaa34dd007d1227,TL shared,0.400652
uuid-67ea404c0e6f4831bbaa34dd007d1227,option,0.439979
uuid-c236b01ae78f4e358553303c6ae20b3e,patients,0.661481
uuid-c236b01ae78f4e358553303c6ae20b3e,therapy,0.389475
uuid-c236b01ae78f4e358553303c6ae20b3e,regimen,0.403732
uuid-c236b01ae78f4e358553303c6ae20b3e,treated,0.326014
uuid-c236b01ae78f4e358553303c6ae20b3e,chemo,0.480649
uuid-c236b01ae78f4e358553303c6ae20b3e,pts,0.52018
uuid-c236b01ae78f4e358553303c6ae20b3e,IO,0.329402
uuid-c236b01ae78f4e358553303c6ae20b3e,monotherapy,0.403064
uuid-c236b01ae78f4e358553303c6ae20b3e,treatment,0.52689
uuid-c236b01ae78f4e358553303c6ae20b3e,response,0.426681
uuid-c236b01ae78f4e358553303c6ae20b3e,PD1,0.302815
uuid-c236b01ae78f4e358553303c6ae20b3e,progression,0.505809
uuid-c236b01ae78f4e358553303c6ae20b3e,chemotherapy,0.449065
uuid-c236b01ae78f4e358553303c6ae20b3e,respond,0.44822
uuid-c236b01ae78f4e358553303c6ae20b3e,feels,0.451425
uuid-c236b01ae78f4e358553303c6ae20b3e,option,0.459154
uuid-66b53ebfe9e940e193a7e4286c571ba2,toxicity,0.334291
uuid-66b53ebfe9e940e193a7e4286c571ba2,regimen,0.360107
uuid-66b53ebfe9e940e193a7e4286c571ba2,IO,0.390043
uuid-66b53ebfe9e940e193a7e4286c571ba2,lung cancer,0.526615
uuid-66b53ebfe9e940e193a7e4286c571ba2,chemotherapy,0.312857
uuid-9cc6782c93ee4c71bab89d20db5462c0,toxicity,0.390367
uuid-9cc6782c93ee4c71bab89d20db5462c0,tumor,0.673975
uuid-9cc6782c93ee4c71bab89d20db5462c0,response,0.37511
uuid-9cc6782c93ee4c71bab89d20db5462c0,respond,0.328621
uuid-ee54fa8036334612b8eba577b08d5b4a,TL,0.324198
uuid-ee54fa8036334612b8eba577b08d5b4a,RTL,0.300897
uuid-ee54fa8036334612b8eba577b08d5b4a,NSCLC,0.319611
uuid-ee54fa8036334612b8eba577b08d5b4a,NTL,0.478806
uuid-ee54fa8036334612b8eba577b08d5b4a,shared,0.3126
uuid-ee54fa8036334612b8eba577b08d5b4a,commented,0.301695
uuid-ee54fa8036334612b8eba577b08d5b4a,physicians,0.513472
uuid-ee54fa8036334612b8eba577b08d5b4a,oncology,0.4013
uuid-ee54fa8036334612b8eba577b08d5b4a,SCCHN,0.316296
uuid-ee54fa8036334612b8eba577b08d5b4a,lung cancer,0.491409
uuid-ee54fa8036334612b8eba577b08d5b4a,indicated,0.357101
uuid-ee54fa8036334612b8eba577b08d5b4a,LTL,0.360377
uuid-ee54fa8036334612b8eba577b08d5b4a,TLs,0.403963
uuid-ee54fa8036334612b8eba577b08d5b4a,clinical,0.302429
uuid-ee54fa8036334612b8eba577b08d5b4a,academic,0.38498
uuid-ee54fa8036334612b8eba577b08d5b4a,Regional TL,0.471059
uuid-7e6970a9e2f243d4a678436b14e4b68b,patients,0.866227
uuid-7e6970a9e2f243d4a678436b14e4b68b,Opdivo,0.506381
uuid-7e6970a9e2f243d4a678436b14e4b68b,therapy,0.630205
uuid-7e6970a9e2f243d4a678436b14e4b68b,nivolumab,0.52482
uuid-7e6970a9e2f243d4a678436b14e4b68b,regimen,0.402406
uuid-7e6970a9e2f243d4a678436b14e4b68b,treated,0.619113
uuid-7e6970a9e2f243d4a678436b14e4b68b,pts,0.512741
uuid-7e6970a9e2f243d4a678436b14e4b68b,treatment,0.676468
uuid-7e6970a9e2f243d4a678436b14e4b68b,response,0.314782
uuid-7e6970a9e2f243d4a678436b14e4b68b,cHL,0.519091
uuid-7e6970a9e2f243d4a678436b14e4b68b,progression,0.626469
uuid-7e6970a9e2f243d4a678436b14e4b68b,chemotherapy,0.39103
uuid-7e6970a9e2f243d4a678436b14e4b68b,respond,0.433525
uuid-4c3d60356bee46a8b1c10384d6d0737e,Nivo,0.438009
uuid-4c3d60356bee46a8b1c10384d6d0737e,patients,0.793528
uuid-4c3d60356bee46a8b1c10384d6d0737e,Opdivo,0.491356
uuid-4c3d60356bee46a8b1c10384d6d0737e,therapy,0.665945
uuid-4c3d60356bee46a8b1c10384d6d0737e,nivolumab,0.505301
uuid-4c3d60356bee46a8b1c10384d6d0737e,regimen,0.492852
uuid-4c3d60356bee46a8b1c10384d6d0737e,treated,0.457834
uuid-4c3d60356bee46a8b1c10384d6d0737e,chemo,0.508986
uuid-4c3d60356bee46a8b1c10384d6d0737e,pts,0.662701
uuid-4c3d60356bee46a8b1c10384d6d0737e,monotherapy,0.475274
uuid-4c3d60356bee46a8b1c10384d6d0737e,treatment,0.625566
uuid-4c3d60356bee46a8b1c10384d6d0737e,using nivo,0.337072
uuid-4c3d60356bee46a8b1c10384d6d0737e,response,0.438343
uuid-4c3d60356bee46a8b1c10384d6d0737e,PD1,0.395374
uuid-4c3d60356bee46a8b1c10384d6d0737e,cHL,0.349559
uuid-4c3d60356bee46a8b1c10384d6d0737e,progression,0.642486
uuid-4c3d60356bee46a8b1c10384d6d0737e,chemotherapy,0.507134
uuid-4c3d60356bee46a8b1c10384d6d0737e,respond,0.500103
uuid-4c3d60356bee46a8b1c10384d6d0737e,option,0.470511
uuid-724519cba01c4d1fbfb6e5e122bd61b4,Nivo,0.366623
uuid-724519cba01c4d1fbfb6e5e122bd61b4,patients,0.798565
uuid-724519cba01c4d1fbfb6e5e122bd61b4,Opdivo,0.492077
uuid-724519cba01c4d1fbfb6e5e122bd61b4,therapy,0.616969
uuid-724519cba01c4d1fbfb6e5e122bd61b4,nivolumab,0.686949
uuid-724519cba01c4d1fbfb6e5e122bd61b4,regimen,0.350853
uuid-724519cba01c4d1fbfb6e5e122bd61b4,treated,0.589056
uuid-724519cba01c4d1fbfb6e5e122bd61b4,pts,0.446294
uuid-724519cba01c4d1fbfb6e5e122bd61b4,approval,0.401272
uuid-724519cba01c4d1fbfb6e5e122bd61b4,monotherapy,0.344959
uuid-724519cba01c4d1fbfb6e5e122bd61b4,treatment,0.57163
uuid-724519cba01c4d1fbfb6e5e122bd61b4,using nivo,0.504383
uuid-724519cba01c4d1fbfb6e5e122bd61b4,PD1,0.331789
uuid-724519cba01c4d1fbfb6e5e122bd61b4,cHL,0.560375
uuid-724519cba01c4d1fbfb6e5e122bd61b4,progression,0.47479
uuid-724519cba01c4d1fbfb6e5e122bd61b4,chemotherapy,0.393724
uuid-724519cba01c4d1fbfb6e5e122bd61b4,RTL stated,0.383279
uuid-724519cba01c4d1fbfb6e5e122bd61b4,option,0.372812
uuid-bab58517ade1462881e2c9fe47531c80,Nivo,0.356695
uuid-bab58517ade1462881e2c9fe47531c80,patients,0.765785
uuid-bab58517ade1462881e2c9fe47531c80,Opdivo,0.481459
uuid-bab58517ade1462881e2c9fe47531c80,therapy,0.706757
uuid-bab58517ade1462881e2c9fe47531c80,nivolumab,0.66542
uuid-bab58517ade1462881e2c9fe47531c80,regimen,0.326095
uuid-bab58517ade1462881e2c9fe47531c80,treated,0.5308
uuid-bab58517ade1462881e2c9fe47531c80,pts,0.395505
uuid-bab58517ade1462881e2c9fe47531c80,treatment,0.575317
uuid-bab58517ade1462881e2c9fe47531c80,using nivo,0.35856
uuid-bab58517ade1462881e2c9fe47531c80,response,0.325391
uuid-bab58517ade1462881e2c9fe47531c80,PD1,0.313321
uuid-bab58517ade1462881e2c9fe47531c80,cHL,0.703639
uuid-bab58517ade1462881e2c9fe47531c80,progression,0.525165
uuid-bab58517ade1462881e2c9fe47531c80,chemotherapy,0.353646
uuid-bab58517ade1462881e2c9fe47531c80,respond,0.380657
uuid-434241bc04184785b9c1cf375c7d1297,commented,0.374181
uuid-434241bc04184785b9c1cf375c7d1297,lung cancer,0.585825
uuid-434241bc04184785b9c1cf375c7d1297,ASCO,0.426399
uuid-434241bc04184785b9c1cf375c7d1297,Regional TL,0.309368
uuid-0387b45c5f1f4d25b807985a42ac15eb,patients,0.642251
uuid-0387b45c5f1f4d25b807985a42ac15eb,therapy,0.405605
uuid-0387b45c5f1f4d25b807985a42ac15eb,1L,0.457385
uuid-0387b45c5f1f4d25b807985a42ac15eb,regimen,0.428783
uuid-0387b45c5f1f4d25b807985a42ac15eb,treated,0.425112
uuid-0387b45c5f1f4d25b807985a42ac15eb,RCC,0.438749
uuid-0387b45c5f1f4d25b807985a42ac15eb,chemo,0.48167
uuid-0387b45c5f1f4d25b807985a42ac15eb,tumor,0.30364
uuid-0387b45c5f1f4d25b807985a42ac15eb,2L,0.441311
uuid-0387b45c5f1f4d25b807985a42ac15eb,pts,0.593789
uuid-0387b45c5f1f4d25b807985a42ac15eb,IO,0.321893
uuid-0387b45c5f1f4d25b807985a42ac15eb,preferred,0.348163
uuid-0387b45c5f1f4d25b807985a42ac15eb,monotherapy,0.495486
uuid-0387b45c5f1f4d25b807985a42ac15eb,treatment,0.516722
uuid-0387b45c5f1f4d25b807985a42ac15eb,using nivo,0.360237
uuid-0387b45c5f1f4d25b807985a42ac15eb,response,0.388708
uuid-0387b45c5f1f4d25b807985a42ac15eb,combo,0.378628
uuid-0387b45c5f1f4d25b807985a42ac15eb,PD1,0.385583
uuid-0387b45c5f1f4d25b807985a42ac15eb,progression,0.598409
uuid-0387b45c5f1f4d25b807985a42ac15eb,chemotherapy,0.350111
uuid-0387b45c5f1f4d25b807985a42ac15eb,tumor types,0.394398
uuid-0387b45c5f1f4d25b807985a42ac15eb,respond,0.427835
uuid-0387b45c5f1f4d25b807985a42ac15eb,RTL stated,0.356107
uuid-0387b45c5f1f4d25b807985a42ac15eb,TL shared,0.338042
uuid-0387b45c5f1f4d25b807985a42ac15eb,option,0.533467
uuid-3c621518097a4432911143ea8ca5bc8e,BMS,0.367669
uuid-3c621518097a4432911143ea8ca5bc8e,PDL1,0.492924
uuid-3c621518097a4432911143ea8ca5bc8e,trial,0.588423
uuid-3c621518097a4432911143ea8ca5bc8e,efficacy,0.534416
uuid-3c621518097a4432911143ea8ca5bc8e,OS,0.680239
uuid-3c621518097a4432911143ea8ca5bc8e,regards,0.328989
uuid-3c621518097a4432911143ea8ca5bc8e,data,0.699177
uuid-3c621518097a4432911143ea8ca5bc8e,PFS,0.719412
uuid-3c621518097a4432911143ea8ca5bc8e,ORR,0.749415
uuid-3c621518097a4432911143ea8ca5bc8e,nivo and pembro,0.434511
uuid-3c621518097a4432911143ea8ca5bc8e,believes,0.303561
uuid-3c621518097a4432911143ea8ca5bc8e,impressed,0.543656
uuid-3c621518097a4432911143ea8ca5bc8e,feels,0.464228
uuid-3c621518097a4432911143ea8ca5bc8e,PDL1 expression,0.527391
uuid-958188b15638409aa6e711ceb029187a,RTL,0.315683
uuid-958188b15638409aa6e711ceb029187a,efficacy,0.324203
uuid-958188b15638409aa6e711ceb029187a,NTL,0.327707
uuid-958188b15638409aa6e711ceb029187a,discussed,0.415207
uuid-958188b15638409aa6e711ceb029187a,commented,0.573718
uuid-958188b15638409aa6e711ceb029187a,OS,0.470453
uuid-958188b15638409aa6e711ceb029187a,regards,0.372078
uuid-958188b15638409aa6e711ceb029187a,data,0.669839
uuid-958188b15638409aa6e711ceb029187a,PFS,0.437139
uuid-958188b15638409aa6e711ceb029187a,ORR,0.448481
uuid-958188b15638409aa6e711ceb029187a,lung cancer,0.46168
uuid-958188b15638409aa6e711ceb029187a,ASCO,0.546642
uuid-958188b15638409aa6e711ceb029187a,impressed,0.577051
uuid-958188b15638409aa6e711ceb029187a,Regional TL,0.367222
uuid-9cf4dce6a0b44c0193e9770b1fdd93e5,Nivo,0.311241
uuid-9cf4dce6a0b44c0193e9770b1fdd93e5,patients,0.509541
uuid-9cf4dce6a0b44c0193e9770b1fdd93e5,RTL,0.354335
uuid-9cf4dce6a0b44c0193e9770b1fdd93e5,nivolumab,0.316768
uuid-9cf4dce6a0b44c0193e9770b1fdd93e5,trial,0.436761
uuid-9cf4dce6a0b44c0193e9770b1fdd93e5,treated,0.300975
uuid-9cf4dce6a0b44c0193e9770b1fdd93e5,pts,0.427497
uuid-9cf4dce6a0b44c0193e9770b1fdd93e5,using nivo,0.303768
uuid-9cf4dce6a0b44c0193e9770b1fdd93e5,clinical trials,0.459318
uuid-9cf4dce6a0b44c0193e9770b1fdd93e5,chemotherapy,0.303897
uuid-9cf4dce6a0b44c0193e9770b1fdd93e5,feels,0.300105
uuid-d3b8ad0755dc4fe4b81a500401755016,Nivo,0.349395
uuid-d3b8ad0755dc4fe4b81a500401755016,pembro,0.462059
uuid-d3b8ad0755dc4fe4b81a500401755016,BMS,0.586103
uuid-d3b8ad0755dc4fe4b81a500401755016,trial,0.464232
uuid-d3b8ad0755dc4fe4b81a500401755016,efficacy,0.360578
uuid-d3b8ad0755dc4fe4b81a500401755016,commented,0.344574
uuid-d3b8ad0755dc4fe4b81a500401755016,2L,0.332214
uuid-d3b8ad0755dc4fe4b81a500401755016,agents,0.315231
uuid-d3b8ad0755dc4fe4b81a500401755016,Merck,0.451898
uuid-d3b8ad0755dc4fe4b81a500401755016,stated,0.368798
uuid-d3b8ad0755dc4fe4b81a500401755016,OS,0.377536
uuid-d3b8ad0755dc4fe4b81a500401755016,atezo,0.459515
uuid-d3b8ad0755dc4fe4b81a500401755016,regards,0.301122
uuid-d3b8ad0755dc4fe4b81a500401755016,data,0.612986
uuid-d3b8ad0755dc4fe4b81a500401755016,indication,0.358804
uuid-d3b8ad0755dc4fe4b81a500401755016,PFS,0.319493
uuid-d3b8ad0755dc4fe4b81a500401755016,ORR,0.32218
uuid-d3b8ad0755dc4fe4b81a500401755016,approved,0.381879
uuid-d3b8ad0755dc4fe4b81a500401755016,nivo and pembro,0.450194
uuid-d3b8ad0755dc4fe4b81a500401755016,impressed,0.478392
uuid-d3b8ad0755dc4fe4b81a500401755016,feels,0.450493
uuid-f24de0640b5943e69d897998b67e891c,physicians,0.355158
uuid-f24de0640b5943e69d897998b67e891c,treatment,0.345723
uuid-7bc76a0eb0a24cf191e1fc40d662884e,Nivo,0.362382
uuid-7bc76a0eb0a24cf191e1fc40d662884e,patients,0.847929
uuid-7bc76a0eb0a24cf191e1fc40d662884e,Opdivo,0.43554
uuid-7bc76a0eb0a24cf191e1fc40d662884e,therapy,0.783011
uuid-7bc76a0eb0a24cf191e1fc40d662884e,nivolumab,0.559126
uuid-7bc76a0eb0a24cf191e1fc40d662884e,regimen,0.422857
uuid-7bc76a0eb0a24cf191e1fc40d662884e,treated,0.517638
uuid-7bc76a0eb0a24cf191e1fc40d662884e,chemo,0.367651
uuid-7bc76a0eb0a24cf191e1fc40d662884e,pts,0.51547
uuid-7bc76a0eb0a24cf191e1fc40d662884e,monotherapy,0.349846
uuid-7bc76a0eb0a24cf191e1fc40d662884e,treatment,0.670557
uuid-7bc76a0eb0a24cf191e1fc40d662884e,response,0.464765
uuid-7bc76a0eb0a24cf191e1fc40d662884e,PD1,0.424442
uuid-7bc76a0eb0a24cf191e1fc40d662884e,cHL,0.587103
uuid-7bc76a0eb0a24cf191e1fc40d662884e,progression,0.650389
uuid-7bc76a0eb0a24cf191e1fc40d662884e,chemotherapy,0.460433
uuid-7bc76a0eb0a24cf191e1fc40d662884e,respond,0.462132
uuid-7bc76a0eb0a24cf191e1fc40d662884e,option,0.331147
uuid-770d7f933fab4eb499e9ed5a3bd415ae,Nivo,0.339797
uuid-770d7f933fab4eb499e9ed5a3bd415ae,pembro,0.31085
uuid-770d7f933fab4eb499e9ed5a3bd415ae,PDL1,0.485956
uuid-770d7f933fab4eb499e9ed5a3bd415ae,trial,0.398152
uuid-770d7f933fab4eb499e9ed5a3bd415ae,efficacy,0.767041
uuid-770d7f933fab4eb499e9ed5a3bd415ae,OS,0.688017
uuid-770d7f933fab4eb499e9ed5a3bd415ae,regards,0.349293
uuid-770d7f933fab4eb499e9ed5a3bd415ae,data,0.600166
uuid-770d7f933fab4eb499e9ed5a3bd415ae,PFS,0.707985
uuid-770d7f933fab4eb499e9ed5a3bd415ae,ORR,0.706329
uuid-770d7f933fab4eb499e9ed5a3bd415ae,nivo and pembro,0.571845
uuid-770d7f933fab4eb499e9ed5a3bd415ae,believes,0.412931
uuid-770d7f933fab4eb499e9ed5a3bd415ae,impressed,0.377562
uuid-770d7f933fab4eb499e9ed5a3bd415ae,vs,0.406307
uuid-770d7f933fab4eb499e9ed5a3bd415ae,feels,0.345891
uuid-770d7f933fab4eb499e9ed5a3bd415ae,PDL1 expression,0.498294
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,1L,0.382067
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,PDL1,0.444334
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,2L,0.365716
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,agents,0.426226
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,PD-L1,0.496199
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,atezo,0.367161
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,preferred,0.398373
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,PD-L1 testing,0.322132
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,testing,0.473769
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,PDL1 testing,0.436383
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,NSCLC patients,0.301011
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,believes,0.459331
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,assay,0.461524
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,option,0.337272
uuid-a297eecefe3b4b3fa5a9eb6d2173b1bc,biomarker,0.366884
uuid-e40bee9575474a3bbbe33e641c282318,TL,0.522692
uuid-e40bee9575474a3bbbe33e641c282318,TL stated,0.402833
uuid-e40bee9575474a3bbbe33e641c282318,institution,0.452034
uuid-e40bee9575474a3bbbe33e641c282318,PD-L1,0.329149
uuid-e40bee9575474a3bbbe33e641c282318,physicians,0.305261
uuid-e40bee9575474a3bbbe33e641c282318,PD-L1 testing,0.660395
uuid-e40bee9575474a3bbbe33e641c282318,testing,0.487572
uuid-e40bee9575474a3bbbe33e641c282318,PDL1 testing,0.512116
uuid-e40bee9575474a3bbbe33e641c282318,NSCLC patients,0.362874
uuid-e40bee9575474a3bbbe33e641c282318,oncology,0.656064
uuid-e40bee9575474a3bbbe33e641c282318,oncologist,0.328827
uuid-e40bee9575474a3bbbe33e641c282318,clinical,0.433998
uuid-e40bee9575474a3bbbe33e641c282318,academic,0.393404
uuid-e40bee9575474a3bbbe33e641c282318,Regional TL,0.373592
uuid-fcbb9a12927b49088458c9d6b585aa2c,toxicity,0.430489
uuid-fcbb9a12927b49088458c9d6b585aa2c,regimen,0.301341
uuid-fcbb9a12927b49088458c9d6b585aa2c,treated,0.435423
uuid-fcbb9a12927b49088458c9d6b585aa2c,physicians,0.525787
uuid-fcbb9a12927b49088458c9d6b585aa2c,treatment,0.390893
uuid-830c5abd72fb44699a6cbd3b55ed25d9,patients,0.557588
uuid-830c5abd72fb44699a6cbd3b55ed25d9,therapy,0.504849
uuid-830c5abd72fb44699a6cbd3b55ed25d9,toxicity,0.300867
uuid-830c5abd72fb44699a6cbd3b55ed25d9,regimen,0.322199
uuid-830c5abd72fb44699a6cbd3b55ed25d9,treatment,0.481198
uuid-830c5abd72fb44699a6cbd3b55ed25d9,cHL,0.442645
uuid-830c5abd72fb44699a6cbd3b55ed25d9,progression,0.406145
uuid-830c5abd72fb44699a6cbd3b55ed25d9,chemotherapy,0.323529
uuid-830c5abd72fb44699a6cbd3b55ed25d9,respond,0.420953
uuid-02e3d447eabd43a0a8a81b8dfcf0d931,patients,0.739661
uuid-02e3d447eabd43a0a8a81b8dfcf0d931,therapy,0.411471
uuid-02e3d447eabd43a0a8a81b8dfcf0d931,regimen,0.393499
uuid-02e3d447eabd43a0a8a81b8dfcf0d931,treated,0.530708
uuid-02e3d447eabd43a0a8a81b8dfcf0d931,chemo,0.445041
uuid-02e3d447eabd43a0a8a81b8dfcf0d931,tumor,0.560712
uuid-02e3d447eabd43a0a8a81b8dfcf0d931,pts,0.649786
uuid-02e3d447eabd43a0a8a81b8dfcf0d931,treatment,0.531782
uuid-02e3d447eabd43a0a8a81b8dfcf0d931,response,0.530431
uuid-02e3d447eabd43a0a8a81b8dfcf0d931,progression,0.610484
uuid-02e3d447eabd43a0a8a81b8dfcf0d931,chemotherapy,0.387773
uuid-02e3d447eabd43a0a8a81b8dfcf0d931,respond,0.494952
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,patients,0.411424
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,Opdivo,0.322583
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,nivolumab,0.324787
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,regimen,0.303473
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,treated,0.624424
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,RCC,0.330048
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,TL stated,0.327436
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,stated,0.315805
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,physicians,0.462711
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,treatment,0.374443
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,Regional TL,0.412399
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,RTL stated,0.331941
uuid-0b6e5a41c4c14bff82e1b95d34f1e9c5,TL shared,0.392444
uuid-8d34249e33644161869ce57e75b7dd2e,Nivo,0.702649
uuid-8d34249e33644161869ce57e75b7dd2e,efficacy,0.328129
uuid-8d34249e33644161869ce57e75b7dd2e,data,0.313728
uuid-8d34249e33644161869ce57e75b7dd2e,cHL,0.325905
uuid-8d34249e33644161869ce57e75b7dd2e,feels,0.319819
uuid-f045be7b19174532a2838dc321870802,Nivo,0.395066
uuid-f045be7b19174532a2838dc321870802,BMS,0.329943
uuid-f045be7b19174532a2838dc321870802,trial,0.536796
uuid-f045be7b19174532a2838dc321870802,data,0.481729
uuid-f045be7b19174532a2838dc321870802,mentioned,0.340818
uuid-f045be7b19174532a2838dc321870802,PFS,0.316804
uuid-f045be7b19174532a2838dc321870802,ORR,0.302176
uuid-f045be7b19174532a2838dc321870802,cHL,0.36497
uuid-f045be7b19174532a2838dc321870802,impressed,0.365093
uuid-f045be7b19174532a2838dc321870802,feels,0.442151
uuid-27c817d3861e442f9e10872c936d5ec1,patients,0.706066
uuid-27c817d3861e442f9e10872c936d5ec1,Opdivo,0.402342
uuid-27c817d3861e442f9e10872c936d5ec1,therapy,0.592952
uuid-27c817d3861e442f9e10872c936d5ec1,nivolumab,0.341612
uuid-27c817d3861e442f9e10872c936d5ec1,regimen,0.34631
uuid-27c817d3861e442f9e10872c936d5ec1,treated,0.434897
uuid-27c817d3861e442f9e10872c936d5ec1,pts,0.360593
uuid-27c817d3861e442f9e10872c936d5ec1,treatment,0.581086
uuid-27c817d3861e442f9e10872c936d5ec1,cHL,0.469579
uuid-27c817d3861e442f9e10872c936d5ec1,progression,0.44373
uuid-27c817d3861e442f9e10872c936d5ec1,chemotherapy,0.310066
uuid-27c817d3861e442f9e10872c936d5ec1,respond,0.337097
uuid-85f1d60312484a7d88d1699b772ad2ca,patients,0.409422
uuid-85f1d60312484a7d88d1699b772ad2ca,RTL,0.346189
uuid-85f1d60312484a7d88d1699b772ad2ca,mentioned,0.53942
uuid-85f1d60312484a7d88d1699b772ad2ca,HCP,0.326687
uuid-85f1d60312484a7d88d1699b772ad2ca,cHL,0.385518
uuid-85f1d60312484a7d88d1699b772ad2ca,LTL,0.394183
uuid-3cbdc927e2504f928bf98e2c3569eae9,patients,0.485849
uuid-3cbdc927e2504f928bf98e2c3569eae9,therapy,0.604828
uuid-3cbdc927e2504f928bf98e2c3569eae9,nivolumab,0.337338
uuid-3cbdc927e2504f928bf98e2c3569eae9,treated,0.427929
uuid-3cbdc927e2504f928bf98e2c3569eae9,chemo,0.431523
uuid-3cbdc927e2504f928bf98e2c3569eae9,pts,0.34927
uuid-3cbdc927e2504f928bf98e2c3569eae9,treatment,0.482954
uuid-3cbdc927e2504f928bf98e2c3569eae9,response,0.301069
uuid-3cbdc927e2504f928bf98e2c3569eae9,cHL,0.312821
uuid-3cbdc927e2504f928bf98e2c3569eae9,progression,0.468548
uuid-3cbdc927e2504f928bf98e2c3569eae9,chemotherapy,0.392246
uuid-3cbdc927e2504f928bf98e2c3569eae9,respond,0.354504
uuid-3cbdc927e2504f928bf98e2c3569eae9,option,0.325548
uuid-e199d30ec79c41c4859aef3527becc0d,trial,0.303919
uuid-e199d30ec79c41c4859aef3527becc0d,OS,0.773935
uuid-e199d30ec79c41c4859aef3527becc0d,response,0.329772
uuid-e199d30ec79c41c4859aef3527becc0d,data,0.364347
uuid-e199d30ec79c41c4859aef3527becc0d,PFS,0.712893
uuid-e199d30ec79c41c4859aef3527becc0d,ORR,0.642778
uuid-e199d30ec79c41c4859aef3527becc0d,impressed,0.482012
uuid-a6ef7ddded00499f80dc8656f620a035,Nivo,0.520632
uuid-a6ef7ddded00499f80dc8656f620a035,patients,0.387693
uuid-a6ef7ddded00499f80dc8656f620a035,Opdivo,0.38864
uuid-a6ef7ddded00499f80dc8656f620a035,therapy,0.552113
uuid-a6ef7ddded00499f80dc8656f620a035,nivolumab,0.443221
uuid-a6ef7ddded00499f80dc8656f620a035,using nivo,0.390521
uuid-a6ef7ddded00499f80dc8656f620a035,mentioned,0.34458
uuid-a6ef7ddded00499f80dc8656f620a035,cHL,0.774456
uuid-44b09d1140074c128488ac162c8b65cb,BMS,0.430028
uuid-44b09d1140074c128488ac162c8b65cb,trial,0.407972
uuid-44b09d1140074c128488ac162c8b65cb,commented,0.429998
uuid-44b09d1140074c128488ac162c8b65cb,Merck,0.390586
uuid-44b09d1140074c128488ac162c8b65cb,regards,0.462726
uuid-44b09d1140074c128488ac162c8b65cb,data,0.485652
uuid-44b09d1140074c128488ac162c8b65cb,expressed,0.362181
uuid-44b09d1140074c128488ac162c8b65cb,indication,0.49934
uuid-44b09d1140074c128488ac162c8b65cb,AI,0.446169
uuid-44b09d1140074c128488ac162c8b65cb,impressed,0.323635
uuid-44b09d1140074c128488ac162c8b65cb,label,0.410438
uuid-44b09d1140074c128488ac162c8b65cb,SCLC,0.323432
uuid-44b09d1140074c128488ac162c8b65cb,NCCN,0.685267
uuid-3e618907c5b3476193875dd1ec5985ef,pembro,0.342837
uuid-3e618907c5b3476193875dd1ec5985ef,RTL,0.396362
uuid-3e618907c5b3476193875dd1ec5985ef,lung,0.343097
uuid-3e618907c5b3476193875dd1ec5985ef,1L,0.414871
uuid-3e618907c5b3476193875dd1ec5985ef,trial,0.513667
uuid-3e618907c5b3476193875dd1ec5985ef,NTL,0.315132
uuid-3e618907c5b3476193875dd1ec5985ef,melanoma,0.313882
uuid-3e618907c5b3476193875dd1ec5985ef,commented,0.311772
uuid-3e618907c5b3476193875dd1ec5985ef,RCC,0.580683
uuid-3e618907c5b3476193875dd1ec5985ef,2L,0.36741
uuid-3e618907c5b3476193875dd1ec5985ef,stated,0.379125
uuid-3e618907c5b3476193875dd1ec5985ef,approval,0.327027
uuid-3e618907c5b3476193875dd1ec5985ef,OS,0.325742
uuid-3e618907c5b3476193875dd1ec5985ef,using nivo,0.385548
uuid-3e618907c5b3476193875dd1ec5985ef,data,0.472251
uuid-3e618907c5b3476193875dd1ec5985ef,combo,0.317682
uuid-3e618907c5b3476193875dd1ec5985ef,clinical trials,0.312283
uuid-3e618907c5b3476193875dd1ec5985ef,ORR,0.351853
uuid-3e618907c5b3476193875dd1ec5985ef,approved,0.333622
uuid-3e618907c5b3476193875dd1ec5985ef,SCCHN,0.501971
uuid-3e618907c5b3476193875dd1ec5985ef,ASCO,0.300521
uuid-3e618907c5b3476193875dd1ec5985ef,impressed,0.542871
uuid-3e618907c5b3476193875dd1ec5985ef,TLs,0.325096
uuid-3e618907c5b3476193875dd1ec5985ef,SCLC,0.415342
uuid-3e618907c5b3476193875dd1ec5985ef,Regional TL,0.438648
uuid-3e618907c5b3476193875dd1ec5985ef,RTL stated,0.434315
uuid-3e618907c5b3476193875dd1ec5985ef,TL shared,0.379932
uuid-3e618907c5b3476193875dd1ec5985ef,bladder,0.448131
uuid-168f2361712e4b1697fa0547abd25a2c,RTL,0.370182
uuid-168f2361712e4b1697fa0547abd25a2c,shared,0.311833
uuid-168f2361712e4b1697fa0547abd25a2c,stated,0.492376
uuid-168f2361712e4b1697fa0547abd25a2c,physicians,0.476908
uuid-168f2361712e4b1697fa0547abd25a2c,preferred,0.356598
uuid-168f2361712e4b1697fa0547abd25a2c,using nivo,0.462133
uuid-168f2361712e4b1697fa0547abd25a2c,mentioned,0.369893
uuid-168f2361712e4b1697fa0547abd25a2c,SCCHN,0.380236
uuid-168f2361712e4b1697fa0547abd25a2c,HCP,0.387181
uuid-168f2361712e4b1697fa0547abd25a2c,LTL,0.533559
uuid-168f2361712e4b1697fa0547abd25a2c,Regional TL,0.433083
uuid-168f2361712e4b1697fa0547abd25a2c,RTL stated,0.475439
uuid-485dc0251df64755b34f35178406dd57,patients,0.380415
uuid-485dc0251df64755b34f35178406dd57,therapy,0.3173
uuid-485dc0251df64755b34f35178406dd57,1L,0.472026
uuid-485dc0251df64755b34f35178406dd57,regimen,0.353602
uuid-485dc0251df64755b34f35178406dd57,combination,0.422442
uuid-485dc0251df64755b34f35178406dd57,chemo,0.508042
uuid-485dc0251df64755b34f35178406dd57,2L,0.404483
uuid-485dc0251df64755b34f35178406dd57,pts,0.348411
uuid-485dc0251df64755b34f35178406dd57,agents,0.358018
uuid-485dc0251df64755b34f35178406dd57,preferred,0.569352
uuid-485dc0251df64755b34f35178406dd57,monotherapy,0.560255
uuid-485dc0251df64755b34f35178406dd57,using nivo,0.383967
uuid-485dc0251df64755b34f35178406dd57,combo,0.387991
uuid-485dc0251df64755b34f35178406dd57,clinical trials,0.306107
uuid-485dc0251df64755b34f35178406dd57,PD1,0.329752
uuid-485dc0251df64755b34f35178406dd57,believes,0.365856
uuid-485dc0251df64755b34f35178406dd57,chemotherapy,0.506095
uuid-485dc0251df64755b34f35178406dd57,feels,0.514982
uuid-485dc0251df64755b34f35178406dd57,RTL stated,0.377928
uuid-485dc0251df64755b34f35178406dd57,option,0.637177
uuid-7542fbab030b4d21a64d9462d52e6502,trial,0.48299
uuid-7542fbab030b4d21a64d9462d52e6502,efficacy,0.311583
uuid-7542fbab030b4d21a64d9462d52e6502,combination,0.486217
uuid-7542fbab030b4d21a64d9462d52e6502,chemo,0.368557
uuid-7542fbab030b4d21a64d9462d52e6502,response,0.361642
uuid-7542fbab030b4d21a64d9462d52e6502,combo,0.414572
uuid-7542fbab030b4d21a64d9462d52e6502,ORR,0.328186
uuid-7542fbab030b4d21a64d9462d52e6502,believes,0.316607
uuid-7542fbab030b4d21a64d9462d52e6502,chemotherapy,0.316131
uuid-7542fbab030b4d21a64d9462d52e6502,impressed,0.326159
uuid-7542fbab030b4d21a64d9462d52e6502,feels,0.349441
uuid-d8e1d51340be4f66aa381f7761c2e66d,RTL,0.416986
uuid-d8e1d51340be4f66aa381f7761c2e66d,BMS,0.488588
uuid-d8e1d51340be4f66aa381f7761c2e66d,trial,0.634917
uuid-d8e1d51340be4f66aa381f7761c2e66d,efficacy,0.338329
uuid-d8e1d51340be4f66aa381f7761c2e66d,NTL,0.360957
uuid-d8e1d51340be4f66aa381f7761c2e66d,commented,0.547031
uuid-d8e1d51340be4f66aa381f7761c2e66d,Merck,0.355038
uuid-d8e1d51340be4f66aa381f7761c2e66d,stated,0.434986
uuid-d8e1d51340be4f66aa381f7761c2e66d,OS,0.582936
uuid-d8e1d51340be4f66aa381f7761c2e66d,regards,0.380198
uuid-d8e1d51340be4f66aa381f7761c2e66d,data,0.796747
uuid-d8e1d51340be4f66aa381f7761c2e66d,expressed,0.444134
uuid-d8e1d51340be4f66aa381f7761c2e66d,mentioned,0.316669
uuid-d8e1d51340be4f66aa381f7761c2e66d,PFS,0.585379
uuid-d8e1d51340be4f66aa381f7761c2e66d,ORR,0.590112
uuid-d8e1d51340be4f66aa381f7761c2e66d,nivo and pembro,0.362302
uuid-d8e1d51340be4f66aa381f7761c2e66d,ASCO,0.419402
uuid-d8e1d51340be4f66aa381f7761c2e66d,impressed,0.683374
uuid-d8e1d51340be4f66aa381f7761c2e66d,TLs,0.321025
uuid-d8e1d51340be4f66aa381f7761c2e66d,Regional TL,0.332118
uuid-beb6d74908854bd393b3f1bec096721d,patients,0.317313
uuid-beb6d74908854bd393b3f1bec096721d,1L,0.430005
uuid-beb6d74908854bd393b3f1bec096721d,PDL1,0.470207
uuid-beb6d74908854bd393b3f1bec096721d,TL stated,0.394002
uuid-beb6d74908854bd393b3f1bec096721d,pts,0.343472
uuid-beb6d74908854bd393b3f1bec096721d,PD-L1,0.436636
uuid-beb6d74908854bd393b3f1bec096721d,PD-L1 testing,0.325764
uuid-beb6d74908854bd393b3f1bec096721d,testing,0.463898
uuid-beb6d74908854bd393b3f1bec096721d,PDL1 testing,0.451523
uuid-beb6d74908854bd393b3f1bec096721d,NSCLC patients,0.560221
uuid-beb6d74908854bd393b3f1bec096721d,impressed,0.34748
uuid-beb6d74908854bd393b3f1bec096721d,tumor types,0.32937
uuid-beb6d74908854bd393b3f1bec096721d,feels,0.313423
uuid-beb6d74908854bd393b3f1bec096721d,PDL1 expression,0.333735
uuid-e3ae8acbe4184f26a5f4599f32e262a1,commented,0.335716
uuid-e3ae8acbe4184f26a5f4599f32e262a1,TL stated,0.342008
uuid-e3ae8acbe4184f26a5f4599f32e262a1,lung cancer,0.480554
uuid-e3ae8acbe4184f26a5f4599f32e262a1,ASCO,0.411752
uuid-e3ae8acbe4184f26a5f4599f32e262a1,Regional TL,0.316653
uuid-42ae4d50376743d8bbeec2d79b11a8c4,RTL,0.419808
uuid-42ae4d50376743d8bbeec2d79b11a8c4,BMS,0.600824
uuid-42ae4d50376743d8bbeec2d79b11a8c4,trial,0.564908
uuid-42ae4d50376743d8bbeec2d79b11a8c4,discussed,0.344142
uuid-42ae4d50376743d8bbeec2d79b11a8c4,commented,0.578155
uuid-42ae4d50376743d8bbeec2d79b11a8c4,Merck,0.559229
uuid-42ae4d50376743d8bbeec2d79b11a8c4,stated,0.473367
uuid-42ae4d50376743d8bbeec2d79b11a8c4,approval,0.302385
uuid-42ae4d50376743d8bbeec2d79b11a8c4,OS,0.465284
uuid-42ae4d50376743d8bbeec2d79b11a8c4,regards,0.344516
uuid-42ae4d50376743d8bbeec2d79b11a8c4,data,0.876821
uuid-42ae4d50376743d8bbeec2d79b11a8c4,expressed,0.397887
uuid-42ae4d50376743d8bbeec2d79b11a8c4,clinical trials,0.327046
uuid-42ae4d50376743d8bbeec2d79b11a8c4,PFS,0.409817
uuid-42ae4d50376743d8bbeec2d79b11a8c4,ORR,0.482836
uuid-42ae4d50376743d8bbeec2d79b11a8c4,SCCHN,0.313626
uuid-42ae4d50376743d8bbeec2d79b11a8c4,ASCO,0.494376
uuid-42ae4d50376743d8bbeec2d79b11a8c4,impressed,0.727487
uuid-42ae4d50376743d8bbeec2d79b11a8c4,LTL,0.339557
uuid-42ae4d50376743d8bbeec2d79b11a8c4,Regional TL,0.394714
uuid-00e94ca74c9149c4aba611c954e9d662,BMS,0.310827
uuid-00e94ca74c9149c4aba611c954e9d662,PDL1,0.35037
uuid-00e94ca74c9149c4aba611c954e9d662,trial,0.338036
uuid-00e94ca74c9149c4aba611c954e9d662,efficacy,0.435009
uuid-00e94ca74c9149c4aba611c954e9d662,discussed,0.317107
uuid-00e94ca74c9149c4aba611c954e9d662,commented,0.322092
uuid-00e94ca74c9149c4aba611c954e9d662,OS,0.660292
uuid-00e94ca74c9149c4aba611c954e9d662,data,0.707937
uuid-00e94ca74c9149c4aba611c954e9d662,PFS,0.59721
uuid-00e94ca74c9149c4aba611c954e9d662,ORR,0.637868
uuid-00e94ca74c9149c4aba611c954e9d662,ASCO,0.351156
uuid-00e94ca74c9149c4aba611c954e9d662,impressed,0.60155
uuid-00e94ca74c9149c4aba611c954e9d662,feels,0.389889
uuid-00e94ca74c9149c4aba611c954e9d662,PDL1 expression,0.333003
uuid-2594d8afe59e4e8e99e72b29e438eed6,discussed,0.338397
uuid-2594d8afe59e4e8e99e72b29e438eed6,commented,0.526651
uuid-2594d8afe59e4e8e99e72b29e438eed6,regards,0.331596
uuid-2594d8afe59e4e8e99e72b29e438eed6,data,0.378152
uuid-2594d8afe59e4e8e99e72b29e438eed6,expressed,0.306347
uuid-2594d8afe59e4e8e99e72b29e438eed6,lung cancer,0.615006
uuid-2594d8afe59e4e8e99e72b29e438eed6,ASCO,0.496131
uuid-2594d8afe59e4e8e99e72b29e438eed6,Regional TL,0.337256
uuid-2594d8afe59e4e8e99e72b29e438eed6,biomarker,0.377033
uuid-7b671b3ec25742e9ad5181357cb1d2ea,Nivo,0.470665
uuid-7b671b3ec25742e9ad5181357cb1d2ea,pembro,0.548642
uuid-7b671b3ec25742e9ad5181357cb1d2ea,BMS,0.356861
uuid-7b671b3ec25742e9ad5181357cb1d2ea,1L,0.345868
uuid-7b671b3ec25742e9ad5181357cb1d2ea,PDL1,0.479568
uuid-7b671b3ec25742e9ad5181357cb1d2ea,trial,0.61701
uuid-7b671b3ec25742e9ad5181357cb1d2ea,efficacy,0.558581
uuid-7b671b3ec25742e9ad5181357cb1d2ea,chemo,0.311348
uuid-7b671b3ec25742e9ad5181357cb1d2ea,OS,0.589467
uuid-7b671b3ec25742e9ad5181357cb1d2ea,atezo,0.424331
uuid-7b671b3ec25742e9ad5181357cb1d2ea,data,0.762673
uuid-7b671b3ec25742e9ad5181357cb1d2ea,PFS,0.589526
uuid-7b671b3ec25742e9ad5181357cb1d2ea,ORR,0.62899
uuid-7b671b3ec25742e9ad5181357cb1d2ea,nivo and pembro,0.581095
uuid-7b671b3ec25742e9ad5181357cb1d2ea,believes,0.39525
uuid-7b671b3ec25742e9ad5181357cb1d2ea,impressed,0.505608
uuid-7b671b3ec25742e9ad5181357cb1d2ea,vs,0.327835
uuid-7b671b3ec25742e9ad5181357cb1d2ea,feels,0.457487
uuid-7b671b3ec25742e9ad5181357cb1d2ea,PDL1 expression,0.456975
uuid-bb463a7195ca4027a43af5f244d5cd1a,NSCLC patients,0.358565
uuid-bb463a7195ca4027a43af5f244d5cd1a,lung cancer,0.492928
uuid-bb463a7195ca4027a43af5f244d5cd1a,tumor types,0.366489
uuid-2338972918834597af0ff0e8c2fe51f5,Nivo,0.526497
uuid-2338972918834597af0ff0e8c2fe51f5,pembro,0.719438
uuid-2338972918834597af0ff0e8c2fe51f5,dose,0.635034
uuid-2338972918834597af0ff0e8c2fe51f5,1L,0.487012
uuid-2338972918834597af0ff0e8c2fe51f5,2L,0.644764
uuid-2338972918834597af0ff0e8c2fe51f5,agents,0.409297
uuid-2338972918834597af0ff0e8c2fe51f5,Ipi,0.470118
uuid-2338972918834597af0ff0e8c2fe51f5,approval,0.300632
uuid-2338972918834597af0ff0e8c2fe51f5,atezo,0.75256
uuid-2338972918834597af0ff0e8c2fe51f5,preferred,0.64452
uuid-2338972918834597af0ff0e8c2fe51f5,monotherapy,0.448955
uuid-2338972918834597af0ff0e8c2fe51f5,using nivo,0.482018
uuid-2338972918834597af0ff0e8c2fe51f5,combo,0.366256
uuid-2338972918834597af0ff0e8c2fe51f5,indication,0.363433
uuid-2338972918834597af0ff0e8c2fe51f5,approved,0.47662
uuid-2338972918834597af0ff0e8c2fe51f5,vs,0.605009
uuid-2338972918834597af0ff0e8c2fe51f5,Keytruda,0.325585
uuid-2338972918834597af0ff0e8c2fe51f5,option,0.483043
uuid-2338972918834597af0ff0e8c2fe51f5,flat dosing,0.453354
uuid-0f39a8aa179a45b6897130634e36045b,Nivo,0.469058
uuid-0f39a8aa179a45b6897130634e36045b,pembro,0.579689
uuid-0f39a8aa179a45b6897130634e36045b,trial,0.686977
uuid-0f39a8aa179a45b6897130634e36045b,efficacy,0.487465
uuid-0f39a8aa179a45b6897130634e36045b,Ipi,0.405628
uuid-0f39a8aa179a45b6897130634e36045b,OS,0.383645
uuid-0f39a8aa179a45b6897130634e36045b,atezo,0.423325
uuid-0f39a8aa179a45b6897130634e36045b,data,0.467133
uuid-0f39a8aa179a45b6897130634e36045b,clinical trials,0.377574
uuid-0f39a8aa179a45b6897130634e36045b,PFS,0.394568
uuid-0f39a8aa179a45b6897130634e36045b,ORR,0.467208
uuid-0f39a8aa179a45b6897130634e36045b,nivo and pembro,0.404806
uuid-0f39a8aa179a45b6897130634e36045b,impressed,0.37099
uuid-0f39a8aa179a45b6897130634e36045b,vs,0.531857
uuid-0f39a8aa179a45b6897130634e36045b,feels,0.489202
uuid-0f39a8aa179a45b6897130634e36045b,PDL1 expression,0.307264
uuid-03b200a44cac4ab285ec62ec53fb4ea0,Nivo,0.390972
uuid-03b200a44cac4ab285ec62ec53fb4ea0,pembro,0.431274
uuid-03b200a44cac4ab285ec62ec53fb4ea0,PDL1,0.402353
uuid-03b200a44cac4ab285ec62ec53fb4ea0,trial,0.565115
uuid-03b200a44cac4ab285ec62ec53fb4ea0,efficacy,0.443626
uuid-03b200a44cac4ab285ec62ec53fb4ea0,OS,0.445625
uuid-03b200a44cac4ab285ec62ec53fb4ea0,data,0.430123
uuid-03b200a44cac4ab285ec62ec53fb4ea0,clinical trials,0.30445
uuid-03b200a44cac4ab285ec62ec53fb4ea0,PFS,0.534842
uuid-03b200a44cac4ab285ec62ec53fb4ea0,ORR,0.532858
uuid-03b200a44cac4ab285ec62ec53fb4ea0,nivo and pembro,0.552986
uuid-03b200a44cac4ab285ec62ec53fb4ea0,vs,0.433631
uuid-03b200a44cac4ab285ec62ec53fb4ea0,feels,0.369788
uuid-03b200a44cac4ab285ec62ec53fb4ea0,PDL1 expression,0.476946
uuid-bbaa62b7802e41278817a8355d7bf2bf,nivolumab,0.369986
uuid-bbaa62b7802e41278817a8355d7bf2bf,RCC,0.37872
uuid-bbaa62b7802e41278817a8355d7bf2bf,approval,0.374093
uuid-bbaa62b7802e41278817a8355d7bf2bf,approved,0.377169
uuid-bbaa62b7802e41278817a8355d7bf2bf,RTL stated,0.32489
uuid-bbaa62b7802e41278817a8355d7bf2bf,TL shared,0.319121
uuid-253d09366c334dd692c149ca311b0e15,therapy,0.457375
uuid-253d09366c334dd692c149ca311b0e15,tumor,0.515072
uuid-253d09366c334dd692c149ca311b0e15,pts,0.342055
uuid-253d09366c334dd692c149ca311b0e15,response,0.556903
uuid-253d09366c334dd692c149ca311b0e15,immunotherapy,0.334732
uuid-efe11dc3b10a42a084f965ebcc599916,Nivo,0.543238
uuid-efe11dc3b10a42a084f965ebcc599916,patients,0.497308
uuid-efe11dc3b10a42a084f965ebcc599916,therapy,0.593559
uuid-efe11dc3b10a42a084f965ebcc599916,nivolumab,0.385469
uuid-efe11dc3b10a42a084f965ebcc599916,regimen,0.496369
uuid-efe11dc3b10a42a084f965ebcc599916,treated,0.398952
uuid-efe11dc3b10a42a084f965ebcc599916,combination,0.478609
uuid-efe11dc3b10a42a084f965ebcc599916,chemo,0.673968
uuid-efe11dc3b10a42a084f965ebcc599916,2L,0.304397
uuid-efe11dc3b10a42a084f965ebcc599916,pts,0.587144
uuid-efe11dc3b10a42a084f965ebcc599916,IO,0.353179
uuid-efe11dc3b10a42a084f965ebcc599916,agents,0.319963
uuid-efe11dc3b10a42a084f965ebcc599916,monotherapy,0.588329
uuid-efe11dc3b10a42a084f965ebcc599916,treatment,0.513654
uuid-efe11dc3b10a42a084f965ebcc599916,using nivo,0.319769
uuid-efe11dc3b10a42a084f965ebcc599916,response,0.707043
uuid-efe11dc3b10a42a084f965ebcc599916,combo,0.365838
uuid-efe11dc3b10a42a084f965ebcc599916,PD1,0.589358
uuid-efe11dc3b10a42a084f965ebcc599916,progression,0.636924
uuid-efe11dc3b10a42a084f965ebcc599916,believes,0.344612
uuid-efe11dc3b10a42a084f965ebcc599916,chemotherapy,0.540769
uuid-efe11dc3b10a42a084f965ebcc599916,respond,0.570236
uuid-efe11dc3b10a42a084f965ebcc599916,feels,0.370778
uuid-efe11dc3b10a42a084f965ebcc599916,option,0.492029
uuid-bdafa08d245f48a6af1f5a8811a49187,commented,0.323908
uuid-bdafa08d245f48a6af1f5a8811a49187,tumor,0.525834
uuid-bdafa08d245f48a6af1f5a8811a49187,data,0.337485
uuid-bdafa08d245f48a6af1f5a8811a49187,clinical trials,0.321263
uuid-bdafa08d245f48a6af1f5a8811a49187,impressed,0.314532
uuid-bdafa08d245f48a6af1f5a8811a49187,tumor types,0.455436
uuid-bdafa08d245f48a6af1f5a8811a49187,bladder,0.341778
uuid-29d4f602226c4143ac76975034afda7c,regimen,0.345137
uuid-29d4f602226c4143ac76975034afda7c,melanoma,0.410693
uuid-29d4f602226c4143ac76975034afda7c,treatment,0.31503
uuid-29d4f602226c4143ac76975034afda7c,TL shared,0.313168
uuid-29d4f602226c4143ac76975034afda7c,NCCN,0.304569
uuid-777056c122074b64a28554875dc47191,RTL,0.424095
uuid-777056c122074b64a28554875dc47191,BMS,0.413247
uuid-777056c122074b64a28554875dc47191,trial,0.445348
uuid-777056c122074b64a28554875dc47191,efficacy,0.327974
uuid-777056c122074b64a28554875dc47191,commented,0.513268
uuid-777056c122074b64a28554875dc47191,Merck,0.30384
uuid-777056c122074b64a28554875dc47191,stated,0.365147
uuid-777056c122074b64a28554875dc47191,OS,0.529209
uuid-777056c122074b64a28554875dc47191,regards,0.323801
uuid-777056c122074b64a28554875dc47191,data,0.840185
uuid-777056c122074b64a28554875dc47191,expressed,0.335686
uuid-777056c122074b64a28554875dc47191,PFS,0.519126
uuid-777056c122074b64a28554875dc47191,ORR,0.546312
uuid-777056c122074b64a28554875dc47191,ASCO,0.560308
uuid-777056c122074b64a28554875dc47191,impressed,0.718313
uuid-777056c122074b64a28554875dc47191,LTL,0.312311
uuid-777056c122074b64a28554875dc47191,Regional TL,0.317008
uuid-f39a0e5d0fb94ef1adafcffd3d2f6d4c,discussed,0.499517
uuid-f39a0e5d0fb94ef1adafcffd3d2f6d4c,academic,0.477548
uuid-22db26299749436da687a15794e1992c,BMS,0.404942
uuid-22db26299749436da687a15794e1992c,trial,0.545004
uuid-22db26299749436da687a15794e1992c,combination,0.312924
uuid-22db26299749436da687a15794e1992c,IO,0.310046
uuid-22db26299749436da687a15794e1992c,OS,0.409849
uuid-22db26299749436da687a15794e1992c,data,0.426112
uuid-22db26299749436da687a15794e1992c,PFS,0.369853
uuid-22db26299749436da687a15794e1992c,ORR,0.370684
uuid-22db26299749436da687a15794e1992c,impressed,0.362718
uuid-22db26299749436da687a15794e1992c,feels,0.402406
uuid-541d6087fb1942899fd40562415c06ff,Nivo,0.312433
uuid-541d6087fb1942899fd40562415c06ff,1L,0.427423
uuid-541d6087fb1942899fd40562415c06ff,chemo,0.430381
uuid-541d6087fb1942899fd40562415c06ff,2L,0.456854
uuid-541d6087fb1942899fd40562415c06ff,agents,0.540608
uuid-541d6087fb1942899fd40562415c06ff,atezo,0.337207
uuid-541d6087fb1942899fd40562415c06ff,preferred,0.428204
uuid-541d6087fb1942899fd40562415c06ff,monotherapy,0.369662
uuid-541d6087fb1942899fd40562415c06ff,combo,0.335506
uuid-541d6087fb1942899fd40562415c06ff,PD1,0.393796
uuid-541d6087fb1942899fd40562415c06ff,believes,0.428086
uuid-541d6087fb1942899fd40562415c06ff,vs,0.309751
uuid-541d6087fb1942899fd40562415c06ff,option,0.462786
uuid-dd441b73342841f89d287da8fd5dc980,therapy,0.362032
uuid-dd441b73342841f89d287da8fd5dc980,discussed,0.614735
uuid-dd441b73342841f89d287da8fd5dc980,cHL,0.395277
uuid-dd441b73342841f89d287da8fd5dc980,academic,0.58486
uuid-94be30823bf54584902beb1e8bcb33e5,efficacy,0.352294
uuid-94be30823bf54584902beb1e8bcb33e5,physicians,0.335126
uuid-94be30823bf54584902beb1e8bcb33e5,impressed,0.342283
uuid-81eef8cd2a284fcaa8c1d8eb1650bf19,lung,0.319211
uuid-81eef8cd2a284fcaa8c1d8eb1650bf19,regimen,0.40149
uuid-81eef8cd2a284fcaa8c1d8eb1650bf19,melanoma,0.357393
uuid-81eef8cd2a284fcaa8c1d8eb1650bf19,treatment,0.342792
uuid-81eef8cd2a284fcaa8c1d8eb1650bf19,AI,0.667091
uuid-81eef8cd2a284fcaa8c1d8eb1650bf19,progression,0.303174
uuid-81eef8cd2a284fcaa8c1d8eb1650bf19,drug,0.304376
uuid-72935aa7d1364e469fe52bfe5a01377d,pembro,0.363344
uuid-72935aa7d1364e469fe52bfe5a01377d,BMS,0.402558
uuid-72935aa7d1364e469fe52bfe5a01377d,PDL1,0.563802
uuid-72935aa7d1364e469fe52bfe5a01377d,trial,0.514935
uuid-72935aa7d1364e469fe52bfe5a01377d,efficacy,0.335137
uuid-72935aa7d1364e469fe52bfe5a01377d,Merck,0.413276
uuid-72935aa7d1364e469fe52bfe5a01377d,OS,0.408289
uuid-72935aa7d1364e469fe52bfe5a01377d,atezo,0.316927
uuid-72935aa7d1364e469fe52bfe5a01377d,data,0.647857
uuid-72935aa7d1364e469fe52bfe5a01377d,PFS,0.4223
uuid-72935aa7d1364e469fe52bfe5a01377d,ORR,0.46061
uuid-72935aa7d1364e469fe52bfe5a01377d,nivo and pembro,0.464611
uuid-72935aa7d1364e469fe52bfe5a01377d,believes,0.306858
uuid-72935aa7d1364e469fe52bfe5a01377d,impressed,0.431871
uuid-72935aa7d1364e469fe52bfe5a01377d,feels,0.313948
uuid-72935aa7d1364e469fe52bfe5a01377d,PDL1 expression,0.523434
uuid-72935aa7d1364e469fe52bfe5a01377d,biomarker,0.405827
uuid-72935aa7d1364e469fe52bfe5a01377d,bladder,0.306348
uuid-56470c40b9d34c6da8e197e7cf880f9d,Opdivo,0.52459
uuid-56470c40b9d34c6da8e197e7cf880f9d,RTL,0.321413
uuid-56470c40b9d34c6da8e197e7cf880f9d,nivolumab,0.392082
uuid-56470c40b9d34c6da8e197e7cf880f9d,shared,0.368066
uuid-56470c40b9d34c6da8e197e7cf880f9d,commented,0.334973
uuid-56470c40b9d34c6da8e197e7cf880f9d,stated,0.504849
uuid-56470c40b9d34c6da8e197e7cf880f9d,approval,0.391564
uuid-56470c40b9d34c6da8e197e7cf880f9d,physicians,0.440268
uuid-56470c40b9d34c6da8e197e7cf880f9d,using nivo,0.332305
uuid-56470c40b9d34c6da8e197e7cf880f9d,clinical trials,0.402158
uuid-56470c40b9d34c6da8e197e7cf880f9d,indication,0.364683
uuid-56470c40b9d34c6da8e197e7cf880f9d,approved,0.346652
uuid-56470c40b9d34c6da8e197e7cf880f9d,SCCHN,0.42108
uuid-56470c40b9d34c6da8e197e7cf880f9d,HCP,0.383834
uuid-56470c40b9d34c6da8e197e7cf880f9d,impressed,0.375103
uuid-56470c40b9d34c6da8e197e7cf880f9d,tumor types,0.332482
uuid-56470c40b9d34c6da8e197e7cf880f9d,LTL,0.445861
uuid-56470c40b9d34c6da8e197e7cf880f9d,Regional TL,0.486519
uuid-56470c40b9d34c6da8e197e7cf880f9d,RTL stated,0.307546
uuid-56470c40b9d34c6da8e197e7cf880f9d,bladder,0.303884
uuid-df3afc01a2fc420088a463b56ab07ad3,patients,0.443341
uuid-df3afc01a2fc420088a463b56ab07ad3,Opdivo,0.336259
uuid-df3afc01a2fc420088a463b56ab07ad3,therapy,0.544608
uuid-df3afc01a2fc420088a463b56ab07ad3,nivolumab,0.484767
uuid-df3afc01a2fc420088a463b56ab07ad3,treated,0.340557
uuid-df3afc01a2fc420088a463b56ab07ad3,approval,0.365084
uuid-df3afc01a2fc420088a463b56ab07ad3,using nivo,0.379474
uuid-df3afc01a2fc420088a463b56ab07ad3,mentioned,0.339486
uuid-df3afc01a2fc420088a463b56ab07ad3,cHL,0.793148
uuid-b8a46902c61545678fd53213e98a6aba,patients,0.559267
uuid-b8a46902c61545678fd53213e98a6aba,Opdivo,0.404597
uuid-b8a46902c61545678fd53213e98a6aba,therapy,0.548723
uuid-b8a46902c61545678fd53213e98a6aba,nivolumab,0.45086
uuid-b8a46902c61545678fd53213e98a6aba,treated,0.410421
uuid-b8a46902c61545678fd53213e98a6aba,approval,0.377828
uuid-b8a46902c61545678fd53213e98a6aba,treatment,0.422124
uuid-b8a46902c61545678fd53213e98a6aba,cHL,0.616141
uuid-16ca980bfd9b4467876a15cc68ad0e1c,patients,0.381647
uuid-16ca980bfd9b4467876a15cc68ad0e1c,nivolumab,0.549638
uuid-16ca980bfd9b4467876a15cc68ad0e1c,treated,0.465565
uuid-16ca980bfd9b4467876a15cc68ad0e1c,pts,0.353056
uuid-16ca980bfd9b4467876a15cc68ad0e1c,physicians,0.31507
uuid-16ca980bfd9b4467876a15cc68ad0e1c,treatment,0.365094
uuid-16ca980bfd9b4467876a15cc68ad0e1c,PD1,0.374486
uuid-16ca980bfd9b4467876a15cc68ad0e1c,progression,0.355511
uuid-df58a3f20f7c406f9402c50566ea6186,patients,0.365084
uuid-df58a3f20f7c406f9402c50566ea6186,treatment,0.306819
uuid-06764f829dd644179fd8dea7555a338e,Nivo,0.49333
uuid-06764f829dd644179fd8dea7555a338e,efficacy,0.344271
uuid-06764f829dd644179fd8dea7555a338e,chemo,0.411103
uuid-06764f829dd644179fd8dea7555a338e,pts,0.31048
uuid-06764f829dd644179fd8dea7555a338e,OS,0.553384
uuid-06764f829dd644179fd8dea7555a338e,response,0.423876
uuid-06764f829dd644179fd8dea7555a338e,data,0.405949
uuid-06764f829dd644179fd8dea7555a338e,PFS,0.543536
uuid-06764f829dd644179fd8dea7555a338e,ORR,0.499151
uuid-06764f829dd644179fd8dea7555a338e,progression,0.335022
uuid-06764f829dd644179fd8dea7555a338e,chemotherapy,0.375442
uuid-06764f829dd644179fd8dea7555a338e,impressed,0.42189
uuid-06764f829dd644179fd8dea7555a338e,feels,0.30752
uuid-9604709477444e03960763794f0e54bd,TL,0.308838
uuid-9604709477444e03960763794f0e54bd,PDL1,0.666239
uuid-9604709477444e03960763794f0e54bd,trial,0.341684
uuid-9604709477444e03960763794f0e54bd,efficacy,0.426216
uuid-9604709477444e03960763794f0e54bd,Merck,0.441673
uuid-9604709477444e03960763794f0e54bd,PD-L1,0.538069
uuid-9604709477444e03960763794f0e54bd,OS,0.371255
uuid-9604709477444e03960763794f0e54bd,atezo,0.30156
uuid-9604709477444e03960763794f0e54bd,PD-L1 testing,0.323563
uuid-9604709477444e03960763794f0e54bd,testing,0.374806
uuid-9604709477444e03960763794f0e54bd,data,0.413311
uuid-9604709477444e03960763794f0e54bd,PFS,0.450413
uuid-9604709477444e03960763794f0e54bd,ORR,0.396119
uuid-9604709477444e03960763794f0e54bd,nivo and pembro,0.54815
uuid-9604709477444e03960763794f0e54bd,assay,0.764202
uuid-9604709477444e03960763794f0e54bd,PDL1 expression,0.542409
uuid-9604709477444e03960763794f0e54bd,biomarker,0.457243
uuid-77eaf2064dc8483ab167094f0a44486f,patients,0.507322
uuid-77eaf2064dc8483ab167094f0a44486f,toxicity,0.572747
uuid-77eaf2064dc8483ab167094f0a44486f,regimen,0.516371
uuid-77eaf2064dc8483ab167094f0a44486f,treated,0.451583
uuid-77eaf2064dc8483ab167094f0a44486f,treatment,0.478156
uuid-77eaf2064dc8483ab167094f0a44486f,progression,0.35048
uuid-77eaf2064dc8483ab167094f0a44486f,respond,0.359529
uuid-143ac4f57bf04753b2f592d5c934527d,pembro,0.582225
uuid-143ac4f57bf04753b2f592d5c934527d,1L,0.492358
uuid-143ac4f57bf04753b2f592d5c934527d,PDL1,0.604696
uuid-143ac4f57bf04753b2f592d5c934527d,efficacy,0.370219
uuid-143ac4f57bf04753b2f592d5c934527d,2L,0.49858
uuid-143ac4f57bf04753b2f592d5c934527d,agents,0.449817
uuid-143ac4f57bf04753b2f592d5c934527d,Merck,0.366866
uuid-143ac4f57bf04753b2f592d5c934527d,PD-L1,0.54475
uuid-143ac4f57bf04753b2f592d5c934527d,atezo,0.670717
uuid-143ac4f57bf04753b2f592d5c934527d,preferred,0.524837
uuid-143ac4f57bf04753b2f592d5c934527d,PD-L1 testing,0.300495
uuid-143ac4f57bf04753b2f592d5c934527d,testing,0.457905
uuid-143ac4f57bf04753b2f592d5c934527d,PDL1 testing,0.454139
uuid-143ac4f57bf04753b2f592d5c934527d,indication,0.480428
uuid-143ac4f57bf04753b2f592d5c934527d,NSCLC patients,0.346637
uuid-143ac4f57bf04753b2f592d5c934527d,approved,0.400775
uuid-143ac4f57bf04753b2f592d5c934527d,nivo and pembro,0.493757
uuid-143ac4f57bf04753b2f592d5c934527d,believes,0.326765
uuid-143ac4f57bf04753b2f592d5c934527d,assay,0.405562
uuid-143ac4f57bf04753b2f592d5c934527d,PDL1 expression,0.516273
uuid-143ac4f57bf04753b2f592d5c934527d,option,0.320977
uuid-143ac4f57bf04753b2f592d5c934527d,biomarker,0.437409
uuid-143ac4f57bf04753b2f592d5c934527d,bladder,0.345432
uuid-5e394e458ecf4331a06396a394571b31,Nivo,0.322546
uuid-5e394e458ecf4331a06396a394571b31,pembro,0.415737
uuid-5e394e458ecf4331a06396a394571b31,nivolumab,0.408711
uuid-5e394e458ecf4331a06396a394571b31,1L,0.67326
uuid-5e394e458ecf4331a06396a394571b31,regimen,0.333585
uuid-5e394e458ecf4331a06396a394571b31,RCC,0.703886
uuid-5e394e458ecf4331a06396a394571b31,TL stated,0.327225
uuid-5e394e458ecf4331a06396a394571b31,combination,0.439175
uuid-5e394e458ecf4331a06396a394571b31,chemo,0.302679
uuid-5e394e458ecf4331a06396a394571b31,2L,0.807694
uuid-5e394e458ecf4331a06396a394571b31,agents,0.63942
uuid-5e394e458ecf4331a06396a394571b31,approval,0.337829
uuid-5e394e458ecf4331a06396a394571b31,atezo,0.485182
uuid-5e394e458ecf4331a06396a394571b31,preferred,0.817794
uuid-5e394e458ecf4331a06396a394571b31,monotherapy,0.684648
uuid-5e394e458ecf4331a06396a394571b31,using nivo,0.681766
uuid-5e394e458ecf4331a06396a394571b31,combo,0.486938
uuid-5e394e458ecf4331a06396a394571b31,indication,0.345434
uuid-5e394e458ecf4331a06396a394571b31,PD1,0.374794
uuid-5e394e458ecf4331a06396a394571b31,approved,0.554667
uuid-5e394e458ecf4331a06396a394571b31,SCCHN,0.462606
uuid-5e394e458ecf4331a06396a394571b31,tumor types,0.378328
uuid-5e394e458ecf4331a06396a394571b31,RTL stated,0.653271
uuid-5e394e458ecf4331a06396a394571b31,TL shared,0.42345
uuid-5e394e458ecf4331a06396a394571b31,option,0.652216
uuid-5e394e458ecf4331a06396a394571b31,bladder,0.402986
uuid-b9540a4136424370be111472bd7bef55,trial,0.303472
uuid-b9540a4136424370be111472bd7bef55,combination,0.425702
uuid-b9540a4136424370be111472bd7bef55,chemo,0.312184
uuid-b9540a4136424370be111472bd7bef55,tumor,0.517031
uuid-b9540a4136424370be111472bd7bef55,response,0.345814
uuid-b9540a4136424370be111472bd7bef55,PD1,0.317885
uuid-b9540a4136424370be111472bd7bef55,immunotherapy,0.302008
uuid-947d7b2a298b4448900be8e2bcdd51b7,patients,0.493047
uuid-947d7b2a298b4448900be8e2bcdd51b7,Opdivo,0.373926
uuid-947d7b2a298b4448900be8e2bcdd51b7,1L,0.391282
uuid-947d7b2a298b4448900be8e2bcdd51b7,treated,0.415005
uuid-947d7b2a298b4448900be8e2bcdd51b7,RCC,0.383766
uuid-947d7b2a298b4448900be8e2bcdd51b7,TL stated,0.443952
uuid-947d7b2a298b4448900be8e2bcdd51b7,2L,0.415888
uuid-947d7b2a298b4448900be8e2bcdd51b7,pts,0.422247
uuid-947d7b2a298b4448900be8e2bcdd51b7,preferred,0.41963
uuid-947d7b2a298b4448900be8e2bcdd51b7,PD-L1 testing,0.324062
uuid-947d7b2a298b4448900be8e2bcdd51b7,testing,0.394976
uuid-947d7b2a298b4448900be8e2bcdd51b7,monotherapy,0.333289
uuid-947d7b2a298b4448900be8e2bcdd51b7,treatment,0.344549
uuid-947d7b2a298b4448900be8e2bcdd51b7,using nivo,0.42848
uuid-947d7b2a298b4448900be8e2bcdd51b7,PDL1 testing,0.515905
uuid-947d7b2a298b4448900be8e2bcdd51b7,NSCLC patients,0.518149
uuid-947d7b2a298b4448900be8e2bcdd51b7,SCCHN,0.363999
uuid-947d7b2a298b4448900be8e2bcdd51b7,tumor types,0.380915
uuid-947d7b2a298b4448900be8e2bcdd51b7,RTL stated,0.453514
uuid-947d7b2a298b4448900be8e2bcdd51b7,TL shared,0.354883
uuid-947d7b2a298b4448900be8e2bcdd51b7,option,0.37263
uuid-01620a4d48904f35856e3e533e5736fa,patients,0.346007
uuid-01620a4d48904f35856e3e533e5736fa,RTL,0.461842
uuid-01620a4d48904f35856e3e533e5736fa,therapy,0.3796
uuid-01620a4d48904f35856e3e533e5736fa,nivolumab,0.428503
uuid-01620a4d48904f35856e3e533e5736fa,treated,0.330717
uuid-01620a4d48904f35856e3e533e5736fa,NTL,0.397526
uuid-01620a4d48904f35856e3e533e5736fa,mentioned,0.421339
uuid-01620a4d48904f35856e3e533e5736fa,cHL,0.552899
uuid-a689dbe2763c466690238f66ca5d1325,TL,0.624478
uuid-a689dbe2763c466690238f66ca5d1325,PDL1,0.348384
uuid-a689dbe2763c466690238f66ca5d1325,TL stated,0.373098
uuid-a689dbe2763c466690238f66ca5d1325,Merck,0.307304
uuid-a689dbe2763c466690238f66ca5d1325,institution,0.360893
uuid-a689dbe2763c466690238f66ca5d1325,PD-L1,0.783026
uuid-a689dbe2763c466690238f66ca5d1325,PD-L1 testing,0.882403
uuid-a689dbe2763c466690238f66ca5d1325,testing,0.883602
uuid-a689dbe2763c466690238f66ca5d1325,PDL1 testing,0.656711
uuid-a689dbe2763c466690238f66ca5d1325,NSCLC patients,0.577254
uuid-a689dbe2763c466690238f66ca5d1325,assay,0.813228
uuid-a689dbe2763c466690238f66ca5d1325,biomarker,0.406344
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,patients,0.510053
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,therapy,0.392593
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,dose,0.391382
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,toxicity,0.58892
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,regimen,0.625737
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,combination,0.458587
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,chemo,0.515036
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,pts,0.328962
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,IO,0.596783
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,agents,0.326615
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,Ipi,0.301734
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,preferred,0.308822
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,monotherapy,0.578107
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,treatment,0.434261
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,response,0.343394
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,combo,0.452153
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,PD1,0.378517
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,progression,0.469213
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,believes,0.309558
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,chemotherapy,0.459234
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,vs,0.321874
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,respond,0.364205
uuid-b9ea1d4f1e734b1c9e657b43aa8ec95e,option,0.431401
uuid-e25535359180475d8c30baf48270e1e7,patients,0.475099
uuid-e25535359180475d8c30baf48270e1e7,Opdivo,0.470048
uuid-e25535359180475d8c30baf48270e1e7,nivolumab,0.315907
uuid-e25535359180475d8c30baf48270e1e7,treated,0.338898
uuid-e25535359180475d8c30baf48270e1e7,approval,0.458673
uuid-e25535359180475d8c30baf48270e1e7,physicians,0.361749
uuid-e25535359180475d8c30baf48270e1e7,treatment,0.301163
uuid-e25535359180475d8c30baf48270e1e7,clinical trials,0.345111
uuid-e25535359180475d8c30baf48270e1e7,approved,0.349317
uuid-e25535359180475d8c30baf48270e1e7,cHL,0.317825
uuid-e25535359180475d8c30baf48270e1e7,label,0.305392
uuid-0ee54f4fbdd54add974feb56aa635dcc,patients,0.556435
uuid-0ee54f4fbdd54add974feb56aa635dcc,Opdivo,0.662555
uuid-0ee54f4fbdd54add974feb56aa635dcc,physicians,0.420317
uuid-0ee54f4fbdd54add974feb56aa635dcc,treatment,0.445259
uuid-0ee54f4fbdd54add974feb56aa635dcc,progression,0.366748
uuid-0ee54f4fbdd54add974feb56aa635dcc,respond,0.330314
uuid-0ee54f4fbdd54add974feb56aa635dcc,drug,0.510931
uuid-927649ee4c264c5c8cace5ed02e58714,Nivo,0.333972
uuid-927649ee4c264c5c8cace5ed02e58714,patients,0.623447
uuid-927649ee4c264c5c8cace5ed02e58714,Opdivo,0.449669
uuid-927649ee4c264c5c8cace5ed02e58714,therapy,0.407453
uuid-927649ee4c264c5c8cace5ed02e58714,dose,0.695659
uuid-927649ee4c264c5c8cace5ed02e58714,nivolumab,0.36814
uuid-927649ee4c264c5c8cace5ed02e58714,toxicity,0.63302
uuid-927649ee4c264c5c8cace5ed02e58714,regimen,0.754259
uuid-927649ee4c264c5c8cace5ed02e58714,treated,0.346452
uuid-927649ee4c264c5c8cace5ed02e58714,combination,0.378782
uuid-927649ee4c264c5c8cace5ed02e58714,chemo,0.418644
uuid-927649ee4c264c5c8cace5ed02e58714,pts,0.438972
uuid-927649ee4c264c5c8cace5ed02e58714,Ipi,0.474391
uuid-927649ee4c264c5c8cace5ed02e58714,monotherapy,0.419985
uuid-927649ee4c264c5c8cace5ed02e58714,treatment,0.609703
uuid-927649ee4c264c5c8cace5ed02e58714,response,0.426786
uuid-927649ee4c264c5c8cace5ed02e58714,combo,0.352216
uuid-927649ee4c264c5c8cace5ed02e58714,progression,0.59376
uuid-927649ee4c264c5c8cace5ed02e58714,chemotherapy,0.391351
uuid-927649ee4c264c5c8cace5ed02e58714,respond,0.483709
uuid-927649ee4c264c5c8cace5ed02e58714,flat dosing,0.333338
uuid-1096ab7bac4b42d6a739c8adf403fc58,Nivo,0.305883
uuid-1096ab7bac4b42d6a739c8adf403fc58,trial,0.301592
uuid-1096ab7bac4b42d6a739c8adf403fc58,AI,0.382472
uuid-1096ab7bac4b42d6a739c8adf403fc58,SCCHN,0.344365
uuid-1096ab7bac4b42d6a739c8adf403fc58,SCLC,0.381347
uuid-1096ab7bac4b42d6a739c8adf403fc58,NCCN,0.580924
uuid-9b300107b4e441f9a976b6f1ec421b6f,patients,0.372289
uuid-9b300107b4e441f9a976b6f1ec421b6f,Opdivo,0.619984
uuid-9b300107b4e441f9a976b6f1ec421b6f,approval,0.321266
uuid-9b300107b4e441f9a976b6f1ec421b6f,physicians,0.50609
uuid-9b300107b4e441f9a976b6f1ec421b6f,treatment,0.378044
uuid-9b300107b4e441f9a976b6f1ec421b6f,oncology,0.429373
uuid-9b300107b4e441f9a976b6f1ec421b6f,flat dosing,0.340916
uuid-af224caeb87941c69d0881fcc4261614,patients,0.428916
uuid-af224caeb87941c69d0881fcc4261614,trial,0.38949
uuid-af224caeb87941c69d0881fcc4261614,chemo,0.331542
uuid-af224caeb87941c69d0881fcc4261614,pts,0.361854
uuid-af224caeb87941c69d0881fcc4261614,clinical trials,0.359821
uuid-af224caeb87941c69d0881fcc4261614,ORR,0.315973
uuid-af224caeb87941c69d0881fcc4261614,chemotherapy,0.399775
uuid-af224caeb87941c69d0881fcc4261614,impressed,0.312199
uuid-af224caeb87941c69d0881fcc4261614,feels,0.333643
uuid-43c42499c06641d1b17f9e8375fe1626,trial,0.328284
uuid-43c42499c06641d1b17f9e8375fe1626,efficacy,0.325274
uuid-43c42499c06641d1b17f9e8375fe1626,commented,0.490217
uuid-43c42499c06641d1b17f9e8375fe1626,OS,0.471569
uuid-43c42499c06641d1b17f9e8375fe1626,regards,0.437642
uuid-43c42499c06641d1b17f9e8375fe1626,data,0.746536
uuid-43c42499c06641d1b17f9e8375fe1626,mentioned,0.328451
uuid-43c42499c06641d1b17f9e8375fe1626,PFS,0.464504
uuid-43c42499c06641d1b17f9e8375fe1626,AI,0.304241
uuid-43c42499c06641d1b17f9e8375fe1626,ORR,0.47141
uuid-43c42499c06641d1b17f9e8375fe1626,nivo and pembro,0.459432
uuid-43c42499c06641d1b17f9e8375fe1626,ASCO,0.430631
uuid-43c42499c06641d1b17f9e8375fe1626,impressed,0.520921
uuid-43c42499c06641d1b17f9e8375fe1626,SCLC,0.36661
uuid-43c42499c06641d1b17f9e8375fe1626,NCCN,0.5455
uuid-69103f0677c84c9a95dec0fb786d8a2f,patients,0.392557
uuid-69103f0677c84c9a95dec0fb786d8a2f,Opdivo,0.411236
uuid-69103f0677c84c9a95dec0fb786d8a2f,treated,0.326595
uuid-69103f0677c84c9a95dec0fb786d8a2f,physicians,0.571929
uuid-69103f0677c84c9a95dec0fb786d8a2f,treatment,0.36056
uuid-8f35dd4f8bf44639bb83a16d87670cdb,discussed,0.794588
uuid-8f35dd4f8bf44639bb83a16d87670cdb,academic,0.701154
uuid-6488d0fc3f624bb09f9cebeec3e8e056,discussed,0.698136
uuid-6488d0fc3f624bb09f9cebeec3e8e056,cHL,0.301511
uuid-6488d0fc3f624bb09f9cebeec3e8e056,academic,0.665381
uuid-3796443278ef471a83c85874d00ccc4e,discussed,0.729005
uuid-3796443278ef471a83c85874d00ccc4e,academic,0.699898
uuid-b3161ea138794c79b874d52f68458be3,patients,0.690506
uuid-b3161ea138794c79b874d52f68458be3,Opdivo,0.404522
uuid-b3161ea138794c79b874d52f68458be3,therapy,0.461058
uuid-b3161ea138794c79b874d52f68458be3,nivolumab,0.4321
uuid-b3161ea138794c79b874d52f68458be3,toxicity,0.48821
uuid-b3161ea138794c79b874d52f68458be3,regimen,0.589216
uuid-b3161ea138794c79b874d52f68458be3,treated,0.559467
uuid-b3161ea138794c79b874d52f68458be3,pts,0.415223
uuid-b3161ea138794c79b874d52f68458be3,treatment,0.651326
uuid-b3161ea138794c79b874d52f68458be3,progression,0.584783
uuid-b3161ea138794c79b874d52f68458be3,respond,0.445665
uuid-b3161ea138794c79b874d52f68458be3,TL shared,0.352736
uuid-4a1201cba0114341a8fd6bc296ff42d7,patients,0.376586
uuid-4a1201cba0114341a8fd6bc296ff42d7,toxicity,0.529406
uuid-4a1201cba0114341a8fd6bc296ff42d7,regimen,0.576582
uuid-4a1201cba0114341a8fd6bc296ff42d7,treated,0.318076
uuid-4a1201cba0114341a8fd6bc296ff42d7,combination,0.458443
uuid-4a1201cba0114341a8fd6bc296ff42d7,chemo,0.380657
uuid-4a1201cba0114341a8fd6bc296ff42d7,pts,0.31195
uuid-4a1201cba0114341a8fd6bc296ff42d7,Ipi,0.451911
uuid-4a1201cba0114341a8fd6bc296ff42d7,monotherapy,0.458542
uuid-4a1201cba0114341a8fd6bc296ff42d7,treatment,0.363987
uuid-4a1201cba0114341a8fd6bc296ff42d7,combo,0.562668
uuid-4a1201cba0114341a8fd6bc296ff42d7,PD1,0.305205
uuid-4a1201cba0114341a8fd6bc296ff42d7,chemotherapy,0.421612
uuid-4a1201cba0114341a8fd6bc296ff42d7,option,0.307042
uuid-953777bedf374c7db3081a9da83a94f2,Nivo,0.465281
uuid-953777bedf374c7db3081a9da83a94f2,pembro,0.551017
uuid-953777bedf374c7db3081a9da83a94f2,1L,0.677055
uuid-953777bedf374c7db3081a9da83a94f2,RCC,0.609482
uuid-953777bedf374c7db3081a9da83a94f2,TL stated,0.331758
uuid-953777bedf374c7db3081a9da83a94f2,combination,0.421035
uuid-953777bedf374c7db3081a9da83a94f2,chemo,0.331028
uuid-953777bedf374c7db3081a9da83a94f2,2L,0.709346
uuid-953777bedf374c7db3081a9da83a94f2,agents,0.416488
uuid-953777bedf374c7db3081a9da83a94f2,Ipi,0.434627
uuid-953777bedf374c7db3081a9da83a94f2,stated,0.331449
uuid-953777bedf374c7db3081a9da83a94f2,approval,0.349955
uuid-953777bedf374c7db3081a9da83a94f2,atezo,0.545748
uuid-953777bedf374c7db3081a9da83a94f2,preferred,0.610812
uuid-953777bedf374c7db3081a9da83a94f2,monotherapy,0.569573
uuid-953777bedf374c7db3081a9da83a94f2,using nivo,0.589696
uuid-953777bedf374c7db3081a9da83a94f2,combo,0.557911
uuid-953777bedf374c7db3081a9da83a94f2,clinical trials,0.31587
uuid-953777bedf374c7db3081a9da83a94f2,indication,0.322169
uuid-953777bedf374c7db3081a9da83a94f2,PD1,0.308584
uuid-953777bedf374c7db3081a9da83a94f2,approved,0.503739
uuid-953777bedf374c7db3081a9da83a94f2,SCCHN,0.469888
uuid-953777bedf374c7db3081a9da83a94f2,nivo and pembro,0.30981
uuid-953777bedf374c7db3081a9da83a94f2,believes,0.369718
uuid-953777bedf374c7db3081a9da83a94f2,impressed,0.327684
uuid-953777bedf374c7db3081a9da83a94f2,TLs,0.387872
uuid-953777bedf374c7db3081a9da83a94f2,SCLC,0.39273
uuid-953777bedf374c7db3081a9da83a94f2,feels,0.383291
uuid-953777bedf374c7db3081a9da83a94f2,RTL stated,0.552376
uuid-953777bedf374c7db3081a9da83a94f2,TL shared,0.327971
uuid-953777bedf374c7db3081a9da83a94f2,option,0.487336
uuid-953777bedf374c7db3081a9da83a94f2,bladder,0.421555
uuid-51c96e8ab9fe49e084e26f2753fa985a,TL,0.349291
uuid-51c96e8ab9fe49e084e26f2753fa985a,pembro,0.389358
uuid-51c96e8ab9fe49e084e26f2753fa985a,1L,0.364256
uuid-51c96e8ab9fe49e084e26f2753fa985a,PDL1,0.594208
uuid-51c96e8ab9fe49e084e26f2753fa985a,TL stated,0.321721
uuid-51c96e8ab9fe49e084e26f2753fa985a,2L,0.304145
uuid-51c96e8ab9fe49e084e26f2753fa985a,Merck,0.46878
uuid-51c96e8ab9fe49e084e26f2753fa985a,PD-L1,0.698767
uuid-51c96e8ab9fe49e084e26f2753fa985a,atezo,0.458426
uuid-51c96e8ab9fe49e084e26f2753fa985a,preferred,0.327306
uuid-51c96e8ab9fe49e084e26f2753fa985a,PD-L1 testing,0.528092
uuid-51c96e8ab9fe49e084e26f2753fa985a,testing,0.676042
uuid-51c96e8ab9fe49e084e26f2753fa985a,PDL1 testing,0.569084
uuid-51c96e8ab9fe49e084e26f2753fa985a,NSCLC patients,0.497441
uuid-51c96e8ab9fe49e084e26f2753fa985a,nivo and pembro,0.357056
uuid-51c96e8ab9fe49e084e26f2753fa985a,assay,0.640506
uuid-51c96e8ab9fe49e084e26f2753fa985a,PDL1 expression,0.429619
uuid-51c96e8ab9fe49e084e26f2753fa985a,biomarker,0.461204
uuid-0f04838c4558458a91fa640df1e68f72,RTL,0.337791
uuid-0f04838c4558458a91fa640df1e68f72,BMS,0.30658
uuid-0f04838c4558458a91fa640df1e68f72,shared,0.402602
uuid-0f04838c4558458a91fa640df1e68f72,commented,0.400037
uuid-0f04838c4558458a91fa640df1e68f72,Merck,0.412915
uuid-0f04838c4558458a91fa640df1e68f72,stated,0.426087
uuid-0f04838c4558458a91fa640df1e68f72,approval,0.501126
uuid-0f04838c4558458a91fa640df1e68f72,PD-L1 testing,0.319693
uuid-0f04838c4558458a91fa640df1e68f72,data,0.344865
uuid-0f04838c4558458a91fa640df1e68f72,expressed,0.493274
uuid-0f04838c4558458a91fa640df1e68f72,clinical trials,0.321523
uuid-0f04838c4558458a91fa640df1e68f72,PDL1 testing,0.328666
uuid-0f04838c4558458a91fa640df1e68f72,indication,0.46242
uuid-0f04838c4558458a91fa640df1e68f72,approved,0.45589
uuid-0f04838c4558458a91fa640df1e68f72,SCCHN,0.458086
uuid-0f04838c4558458a91fa640df1e68f72,HCP,0.34752
uuid-0f04838c4558458a91fa640df1e68f72,impressed,0.355314
uuid-0f04838c4558458a91fa640df1e68f72,label,0.380341
uuid-0f04838c4558458a91fa640df1e68f72,LTL,0.382282
uuid-0f04838c4558458a91fa640df1e68f72,Regional TL,0.377682
uuid-0f04838c4558458a91fa640df1e68f72,bladder,0.365641
uuid-d55668cb9d0d40829872b7293023789d,physicians,0.379925
uuid-d55668cb9d0d40829872b7293023789d,oncology,0.324353
uuid-d55668cb9d0d40829872b7293023789d,drug,0.569755
uuid-d55668cb9d0d40829872b7293023789d,clinical,0.34193
uuid-ec696884a9a54ddd8bb1031417271fae,Opdivo,0.493721
uuid-ec696884a9a54ddd8bb1031417271fae,BMS,0.307077
uuid-ec696884a9a54ddd8bb1031417271fae,stated,0.512436
uuid-ec696884a9a54ddd8bb1031417271fae,physicians,0.419605
uuid-ec696884a9a54ddd8bb1031417271fae,HCP,0.300493
uuid-ec696884a9a54ddd8bb1031417271fae,LTL,0.322756
uuid-ec696884a9a54ddd8bb1031417271fae,feels,0.359131
uuid-354e45a173334ff896b8d40d4faa0522,RTL,0.422655
uuid-354e45a173334ff896b8d40d4faa0522,BMS,0.509555
uuid-354e45a173334ff896b8d40d4faa0522,trial,0.571107
uuid-354e45a173334ff896b8d40d4faa0522,NTL,0.522152
uuid-354e45a173334ff896b8d40d4faa0522,commented,0.503229
uuid-354e45a173334ff896b8d40d4faa0522,Merck,0.659153
uuid-354e45a173334ff896b8d40d4faa0522,stated,0.32092
uuid-354e45a173334ff896b8d40d4faa0522,OS,0.31286
uuid-354e45a173334ff896b8d40d4faa0522,regards,0.362012
uuid-354e45a173334ff896b8d40d4faa0522,data,0.557486
uuid-354e45a173334ff896b8d40d4faa0522,expressed,0.395762
uuid-354e45a173334ff896b8d40d4faa0522,mentioned,0.35216
uuid-354e45a173334ff896b8d40d4faa0522,PFS,0.315346
uuid-354e45a173334ff896b8d40d4faa0522,ASCO,0.41656
uuid-354e45a173334ff896b8d40d4faa0522,impressed,0.406454
uuid-354e45a173334ff896b8d40d4faa0522,Regional TL,0.361236
uuid-dd831e91598c4511929445143cbb6074,RTL,0.380837
uuid-dd831e91598c4511929445143cbb6074,BMS,0.321785
uuid-dd831e91598c4511929445143cbb6074,trial,0.608741
uuid-dd831e91598c4511929445143cbb6074,efficacy,0.355026
uuid-dd831e91598c4511929445143cbb6074,NTL,0.310378
uuid-dd831e91598c4511929445143cbb6074,commented,0.508571
uuid-dd831e91598c4511929445143cbb6074,OS,0.556639
uuid-dd831e91598c4511929445143cbb6074,regards,0.392277
uuid-dd831e91598c4511929445143cbb6074,data,0.703244
uuid-dd831e91598c4511929445143cbb6074,expressed,0.318343
uuid-dd831e91598c4511929445143cbb6074,PFS,0.518679
uuid-dd831e91598c4511929445143cbb6074,ORR,0.600617
uuid-dd831e91598c4511929445143cbb6074,ASCO,0.479209
uuid-dd831e91598c4511929445143cbb6074,impressed,0.657168
uuid-dd831e91598c4511929445143cbb6074,SCLC,0.354531
uuid-dd831e91598c4511929445143cbb6074,Regional TL,0.301883
uuid-dd831e91598c4511929445143cbb6074,NCCN,0.312623
uuid-aaad17106eb544c78a4431bde91af93d,Nivo,0.347189
uuid-aaad17106eb544c78a4431bde91af93d,patients,0.705002
uuid-aaad17106eb544c78a4431bde91af93d,Opdivo,0.393563
uuid-aaad17106eb544c78a4431bde91af93d,therapy,0.793693
uuid-aaad17106eb544c78a4431bde91af93d,nivolumab,0.500781
uuid-aaad17106eb544c78a4431bde91af93d,regimen,0.323844
uuid-aaad17106eb544c78a4431bde91af93d,treated,0.439936
uuid-aaad17106eb544c78a4431bde91af93d,pts,0.437825
uuid-aaad17106eb544c78a4431bde91af93d,treatment,0.650578
uuid-aaad17106eb544c78a4431bde91af93d,response,0.475313
uuid-aaad17106eb544c78a4431bde91af93d,PD1,0.384159
uuid-aaad17106eb544c78a4431bde91af93d,cHL,0.628292
uuid-aaad17106eb544c78a4431bde91af93d,progression,0.659321
uuid-aaad17106eb544c78a4431bde91af93d,chemotherapy,0.426944
uuid-aaad17106eb544c78a4431bde91af93d,respond,0.469506
uuid-b2b05e547aae41269f1ca27c9fd809fd,patients,0.502266
uuid-b2b05e547aae41269f1ca27c9fd809fd,therapy,0.690237
uuid-b2b05e547aae41269f1ca27c9fd809fd,nivolumab,0.397165
uuid-b2b05e547aae41269f1ca27c9fd809fd,toxicity,0.327895
uuid-b2b05e547aae41269f1ca27c9fd809fd,regimen,0.440328
uuid-b2b05e547aae41269f1ca27c9fd809fd,treated,0.339575
uuid-b2b05e547aae41269f1ca27c9fd809fd,combination,0.503378
uuid-b2b05e547aae41269f1ca27c9fd809fd,chemo,0.59219
uuid-b2b05e547aae41269f1ca27c9fd809fd,pts,0.438017
uuid-b2b05e547aae41269f1ca27c9fd809fd,IO,0.303026
uuid-b2b05e547aae41269f1ca27c9fd809fd,agents,0.405307
uuid-b2b05e547aae41269f1ca27c9fd809fd,monotherapy,0.502009
uuid-b2b05e547aae41269f1ca27c9fd809fd,treatment,0.564227
uuid-b2b05e547aae41269f1ca27c9fd809fd,response,0.561901
uuid-b2b05e547aae41269f1ca27c9fd809fd,combo,0.397562
uuid-b2b05e547aae41269f1ca27c9fd809fd,PD1,0.701938
uuid-b2b05e547aae41269f1ca27c9fd809fd,progression,0.630586
uuid-b2b05e547aae41269f1ca27c9fd809fd,chemotherapy,0.580815
uuid-b2b05e547aae41269f1ca27c9fd809fd,respond,0.501946
uuid-b2b05e547aae41269f1ca27c9fd809fd,immunotherapy,0.420028
uuid-b2b05e547aae41269f1ca27c9fd809fd,PD-1,0.418692
uuid-b2b05e547aae41269f1ca27c9fd809fd,option,0.43978
uuid-435a021ad5294c3cb017f6e56e4e13ca,patients,0.773876
uuid-435a021ad5294c3cb017f6e56e4e13ca,therapy,0.478258
uuid-435a021ad5294c3cb017f6e56e4e13ca,nivolumab,0.425651
uuid-435a021ad5294c3cb017f6e56e4e13ca,regimen,0.36495
uuid-435a021ad5294c3cb017f6e56e4e13ca,treated,0.545572
uuid-435a021ad5294c3cb017f6e56e4e13ca,pts,0.508844
uuid-435a021ad5294c3cb017f6e56e4e13ca,treatment,0.535866
uuid-435a021ad5294c3cb017f6e56e4e13ca,response,0.358299
uuid-435a021ad5294c3cb017f6e56e4e13ca,cHL,0.361358
uuid-435a021ad5294c3cb017f6e56e4e13ca,progression,0.615262
uuid-435a021ad5294c3cb017f6e56e4e13ca,chemotherapy,0.322974
uuid-435a021ad5294c3cb017f6e56e4e13ca,respond,0.39133
uuid-e61e645b98eb487f9b457adc6666a045,Nivo,0.468244
uuid-e61e645b98eb487f9b457adc6666a045,patients,0.481157
uuid-e61e645b98eb487f9b457adc6666a045,therapy,0.379885
uuid-e61e645b98eb487f9b457adc6666a045,trial,0.424503
uuid-e61e645b98eb487f9b457adc6666a045,regimen,0.363322
uuid-e61e645b98eb487f9b457adc6666a045,chemo,0.385346
uuid-e61e645b98eb487f9b457adc6666a045,pts,0.470321
uuid-e61e645b98eb487f9b457adc6666a045,Ipi,0.41229
uuid-e61e645b98eb487f9b457adc6666a045,OS,0.322045
uuid-e61e645b98eb487f9b457adc6666a045,response,0.439933
uuid-e61e645b98eb487f9b457adc6666a045,PFS,0.330694
uuid-e61e645b98eb487f9b457adc6666a045,ORR,0.347964
uuid-e61e645b98eb487f9b457adc6666a045,progression,0.45319
uuid-e61e645b98eb487f9b457adc6666a045,chemotherapy,0.437493
uuid-e61e645b98eb487f9b457adc6666a045,respond,0.424786
uuid-71eb7a49cf1c4d1ba7635bcda1cca299,physicians,0.452381
uuid-71eb7a49cf1c4d1ba7635bcda1cca299,oncology,0.78318
uuid-71eb7a49cf1c4d1ba7635bcda1cca299,oncologist,0.323314
uuid-71eb7a49cf1c4d1ba7635bcda1cca299,clinical,0.609214
uuid-8ba166686aa142fb8199b08b7134d9f5,Nivo,0.335503
uuid-8ba166686aa142fb8199b08b7134d9f5,pembro,0.430556
uuid-8ba166686aa142fb8199b08b7134d9f5,dose,0.446317
uuid-8ba166686aa142fb8199b08b7134d9f5,trial,0.327025
uuid-8ba166686aa142fb8199b08b7134d9f5,efficacy,0.569817
uuid-8ba166686aa142fb8199b08b7134d9f5,Ipi,0.560537
uuid-8ba166686aa142fb8199b08b7134d9f5,atezo,0.43948
uuid-8ba166686aa142fb8199b08b7134d9f5,data,0.312964
uuid-8ba166686aa142fb8199b08b7134d9f5,nivo and pembro,0.508197
uuid-8ba166686aa142fb8199b08b7134d9f5,believes,0.393496
uuid-8ba166686aa142fb8199b08b7134d9f5,vs,0.539834
uuid-8ba166686aa142fb8199b08b7134d9f5,SCLC,0.344626
uuid-8ba166686aa142fb8199b08b7134d9f5,feels,0.311555
uuid-2200ae233615478caae4de0e7f0ea75c,Nivo,0.470367
uuid-2200ae233615478caae4de0e7f0ea75c,pembro,0.650709
uuid-2200ae233615478caae4de0e7f0ea75c,BMS,0.322247
uuid-2200ae233615478caae4de0e7f0ea75c,1L,0.538585
uuid-2200ae233615478caae4de0e7f0ea75c,PDL1,0.597681
uuid-2200ae233615478caae4de0e7f0ea75c,trial,0.483355
uuid-2200ae233615478caae4de0e7f0ea75c,efficacy,0.563057
uuid-2200ae233615478caae4de0e7f0ea75c,chemo,0.303656
uuid-2200ae233615478caae4de0e7f0ea75c,2L,0.451243
uuid-2200ae233615478caae4de0e7f0ea75c,agents,0.394944
uuid-2200ae233615478caae4de0e7f0ea75c,OS,0.524493
uuid-2200ae233615478caae4de0e7f0ea75c,atezo,0.585744
uuid-2200ae233615478caae4de0e7f0ea75c,monotherapy,0.347244
uuid-2200ae233615478caae4de0e7f0ea75c,data,0.643943
uuid-2200ae233615478caae4de0e7f0ea75c,combo,0.340657
uuid-2200ae233615478caae4de0e7f0ea75c,indication,0.316911
uuid-2200ae233615478caae4de0e7f0ea75c,PFS,0.506111
uuid-2200ae233615478caae4de0e7f0ea75c,ORR,0.535475
uuid-2200ae233615478caae4de0e7f0ea75c,approved,0.326756
uuid-2200ae233615478caae4de0e7f0ea75c,nivo and pembro,0.728191
uuid-2200ae233615478caae4de0e7f0ea75c,believes,0.504233
uuid-2200ae233615478caae4de0e7f0ea75c,impressed,0.388179
uuid-2200ae233615478caae4de0e7f0ea75c,vs,0.358671
uuid-2200ae233615478caae4de0e7f0ea75c,feels,0.462729
uuid-2200ae233615478caae4de0e7f0ea75c,PDL1 expression,0.537416
uuid-2200ae233615478caae4de0e7f0ea75c,option,0.352395
uuid-4747402c7825431986c1fb5838ddf368,Nivo,0.390576
uuid-4747402c7825431986c1fb5838ddf368,patients,0.570667
uuid-4747402c7825431986c1fb5838ddf368,Opdivo,0.515218
uuid-4747402c7825431986c1fb5838ddf368,dose,0.732498
uuid-4747402c7825431986c1fb5838ddf368,nivolumab,0.380693
uuid-4747402c7825431986c1fb5838ddf368,toxicity,0.463649
uuid-4747402c7825431986c1fb5838ddf368,regimen,0.546616
uuid-4747402c7825431986c1fb5838ddf368,treated,0.343098
uuid-4747402c7825431986c1fb5838ddf368,2L,0.359804
uuid-4747402c7825431986c1fb5838ddf368,pts,0.33263
uuid-4747402c7825431986c1fb5838ddf368,Ipi,0.435337
uuid-4747402c7825431986c1fb5838ddf368,preferred,0.436229
uuid-4747402c7825431986c1fb5838ddf368,monotherapy,0.370674
uuid-4747402c7825431986c1fb5838ddf368,treatment,0.414022
uuid-4747402c7825431986c1fb5838ddf368,using nivo,0.406652
uuid-4747402c7825431986c1fb5838ddf368,progression,0.305187
uuid-4747402c7825431986c1fb5838ddf368,vs,0.396534
uuid-4747402c7825431986c1fb5838ddf368,RTL stated,0.325331
uuid-4747402c7825431986c1fb5838ddf368,option,0.306182
uuid-4747402c7825431986c1fb5838ddf368,flat dosing,0.514863
uuid-f55d409aeac5473b93d2579c49e5a012,1L,0.340096
uuid-f55d409aeac5473b93d2579c49e5a012,PDL1,0.432315
uuid-f55d409aeac5473b93d2579c49e5a012,2L,0.314644
uuid-f55d409aeac5473b93d2579c49e5a012,PD-L1,0.390969
uuid-f55d409aeac5473b93d2579c49e5a012,preferred,0.306108
uuid-f55d409aeac5473b93d2579c49e5a012,testing,0.384725
uuid-f55d409aeac5473b93d2579c49e5a012,PDL1 testing,0.354507
uuid-f55d409aeac5473b93d2579c49e5a012,NSCLC patients,0.330486
uuid-f55d409aeac5473b93d2579c49e5a012,tumor types,0.316108
uuid-f55d409aeac5473b93d2579c49e5a012,PDL1 expression,0.450925
uuid-f55d409aeac5473b93d2579c49e5a012,option,0.354518
uuid-f55d409aeac5473b93d2579c49e5a012,biomarker,0.438157
uuid-49e195b3d0f74d5d87144c46094b1abc,BMS,0.500128
uuid-49e195b3d0f74d5d87144c46094b1abc,PDL1,0.614014
uuid-49e195b3d0f74d5d87144c46094b1abc,trial,0.527552
uuid-49e195b3d0f74d5d87144c46094b1abc,efficacy,0.608214
uuid-49e195b3d0f74d5d87144c46094b1abc,Merck,0.343012
uuid-49e195b3d0f74d5d87144c46094b1abc,OS,0.6574
uuid-49e195b3d0f74d5d87144c46094b1abc,regards,0.386147
uuid-49e195b3d0f74d5d87144c46094b1abc,data,0.652443
uuid-49e195b3d0f74d5d87144c46094b1abc,PFS,0.671
uuid-49e195b3d0f74d5d87144c46094b1abc,ORR,0.683032
uuid-49e195b3d0f74d5d87144c46094b1abc,nivo and pembro,0.568095
uuid-49e195b3d0f74d5d87144c46094b1abc,believes,0.492914
uuid-49e195b3d0f74d5d87144c46094b1abc,impressed,0.463614
uuid-49e195b3d0f74d5d87144c46094b1abc,feels,0.372779
uuid-49e195b3d0f74d5d87144c46094b1abc,PDL1 expression,0.537914
uuid-49e195b3d0f74d5d87144c46094b1abc,biomarker,0.377223
uuid-55f761e0551340d0848a0c82a6182e9d,RTL,0.343235
uuid-55f761e0551340d0848a0c82a6182e9d,BMS,0.434488
uuid-55f761e0551340d0848a0c82a6182e9d,trial,0.691464
uuid-55f761e0551340d0848a0c82a6182e9d,commented,0.398469
uuid-55f761e0551340d0848a0c82a6182e9d,combination,0.306752
uuid-55f761e0551340d0848a0c82a6182e9d,Ipi,0.400314
uuid-55f761e0551340d0848a0c82a6182e9d,OS,0.316294
uuid-55f761e0551340d0848a0c82a6182e9d,data,0.489376
uuid-55f761e0551340d0848a0c82a6182e9d,combo,0.326412
uuid-55f761e0551340d0848a0c82a6182e9d,expressed,0.355824
uuid-55f761e0551340d0848a0c82a6182e9d,clinical trials,0.368156
uuid-55f761e0551340d0848a0c82a6182e9d,PFS,0.30537
uuid-55f761e0551340d0848a0c82a6182e9d,ORR,0.390162
uuid-55f761e0551340d0848a0c82a6182e9d,impressed,0.54686
uuid-55f761e0551340d0848a0c82a6182e9d,SCLC,0.467913
uuid-682910cfa6734d75868ab7d311a8ef0b,Nivo,0.614107
uuid-682910cfa6734d75868ab7d311a8ef0b,patients,0.651812
uuid-682910cfa6734d75868ab7d311a8ef0b,therapy,0.552106
uuid-682910cfa6734d75868ab7d311a8ef0b,nivolumab,0.53577
uuid-682910cfa6734d75868ab7d311a8ef0b,regimen,0.505831
uuid-682910cfa6734d75868ab7d311a8ef0b,treated,0.615708
uuid-682910cfa6734d75868ab7d311a8ef0b,combination,0.382374
uuid-682910cfa6734d75868ab7d311a8ef0b,chemo,0.533234
uuid-682910cfa6734d75868ab7d311a8ef0b,pts,0.666817
uuid-682910cfa6734d75868ab7d311a8ef0b,Ipi,0.305521
uuid-682910cfa6734d75868ab7d311a8ef0b,monotherapy,0.512956
uuid-682910cfa6734d75868ab7d311a8ef0b,treatment,0.480238
uuid-682910cfa6734d75868ab7d311a8ef0b,using nivo,0.417161
uuid-682910cfa6734d75868ab7d311a8ef0b,response,0.450737
uuid-682910cfa6734d75868ab7d311a8ef0b,combo,0.319653
uuid-682910cfa6734d75868ab7d311a8ef0b,PD1,0.459546
uuid-682910cfa6734d75868ab7d311a8ef0b,cHL,0.351878
uuid-682910cfa6734d75868ab7d311a8ef0b,progression,0.544831
uuid-682910cfa6734d75868ab7d311a8ef0b,chemotherapy,0.489135
uuid-682910cfa6734d75868ab7d311a8ef0b,respond,0.422109
uuid-682910cfa6734d75868ab7d311a8ef0b,RTL stated,0.357141
uuid-682910cfa6734d75868ab7d311a8ef0b,option,0.369671
uuid-4c0aecba721d447a8842445a6c995727,Nivo,0.35483
uuid-4c0aecba721d447a8842445a6c995727,patients,0.522045
uuid-4c0aecba721d447a8842445a6c995727,Opdivo,0.389248
uuid-4c0aecba721d447a8842445a6c995727,therapy,0.68555
uuid-4c0aecba721d447a8842445a6c995727,nivolumab,0.551911
uuid-4c0aecba721d447a8842445a6c995727,treated,0.403354
uuid-4c0aecba721d447a8842445a6c995727,treatment,0.419155
uuid-4c0aecba721d447a8842445a6c995727,PD1,0.302395
uuid-4c0aecba721d447a8842445a6c995727,cHL,0.833331
uuid-4c0aecba721d447a8842445a6c995727,progression,0.31623
uuid-4c0aecba721d447a8842445a6c995727,chemotherapy,0.317161
uuid-4b740685c1a64b599cc7d5fa38387eca,tumor,0.344405
uuid-4b740685c1a64b599cc7d5fa38387eca,progression,0.310318
uuid-4b740685c1a64b599cc7d5fa38387eca,TL shared,0.31618
uuid-8f3a746b7c3246149b24fae8a00a7dda,Opdivo,0.620199
uuid-8f3a746b7c3246149b24fae8a00a7dda,dose,0.43599
uuid-8f3a746b7c3246149b24fae8a00a7dda,nivolumab,0.557504
uuid-8f3a746b7c3246149b24fae8a00a7dda,regimen,0.308122
uuid-8f3a746b7c3246149b24fae8a00a7dda,shared,0.324798
uuid-8f3a746b7c3246149b24fae8a00a7dda,stated,0.332738
uuid-8f3a746b7c3246149b24fae8a00a7dda,approval,0.437674
uuid-8f3a746b7c3246149b24fae8a00a7dda,physicians,0.341821
uuid-8f3a746b7c3246149b24fae8a00a7dda,preferred,0.411227
uuid-8f3a746b7c3246149b24fae8a00a7dda,using nivo,0.411932
uuid-8f3a746b7c3246149b24fae8a00a7dda,indication,0.383708
uuid-8f3a746b7c3246149b24fae8a00a7dda,approved,0.534587
uuid-8f3a746b7c3246149b24fae8a00a7dda,label,0.411441
uuid-8f3a746b7c3246149b24fae8a00a7dda,LTL,0.308357
uuid-8f3a746b7c3246149b24fae8a00a7dda,Keytruda,0.35406
uuid-8f3a746b7c3246149b24fae8a00a7dda,RTL stated,0.347063
uuid-8f3a746b7c3246149b24fae8a00a7dda,flat dosing,0.617191
uuid-342fc7491db845a7ada3664ea1998269,patients,0.79391
uuid-342fc7491db845a7ada3664ea1998269,Opdivo,0.762011
uuid-342fc7491db845a7ada3664ea1998269,therapy,0.460449
uuid-342fc7491db845a7ada3664ea1998269,nivolumab,0.380778
uuid-342fc7491db845a7ada3664ea1998269,toxicity,0.326762
uuid-342fc7491db845a7ada3664ea1998269,regimen,0.522357
uuid-342fc7491db845a7ada3664ea1998269,treated,0.450664
uuid-342fc7491db845a7ada3664ea1998269,pts,0.513076
uuid-342fc7491db845a7ada3664ea1998269,monotherapy,0.344811
uuid-342fc7491db845a7ada3664ea1998269,treatment,0.681979
uuid-342fc7491db845a7ada3664ea1998269,progression,0.608645
uuid-342fc7491db845a7ada3664ea1998269,respond,0.499169
uuid-342fc7491db845a7ada3664ea1998269,Keytruda,0.32193
uuid-342fc7491db845a7ada3664ea1998269,option,0.331232
uuid-2082af83a5fd41578d4ca8049e123994,toxicity,0.41758
uuid-2082af83a5fd41578d4ca8049e123994,physicians,0.44755
uuid-2082af83a5fd41578d4ca8049e123994,treatment,0.330942
uuid-c54f689387f24b9a91cd0a92adf7d9eb,RTL,0.384837
uuid-c54f689387f24b9a91cd0a92adf7d9eb,commented,0.35665
uuid-c54f689387f24b9a91cd0a92adf7d9eb,stated,0.455183
uuid-c54f689387f24b9a91cd0a92adf7d9eb,preferred,0.305548
uuid-c54f689387f24b9a91cd0a92adf7d9eb,using nivo,0.402916
uuid-c54f689387f24b9a91cd0a92adf7d9eb,data,0.422783
uuid-c54f689387f24b9a91cd0a92adf7d9eb,expressed,0.330961
uuid-c54f689387f24b9a91cd0a92adf7d9eb,SCCHN,0.47365
uuid-c54f689387f24b9a91cd0a92adf7d9eb,impressed,0.390039
uuid-c54f689387f24b9a91cd0a92adf7d9eb,LTL,0.408259
uuid-c54f689387f24b9a91cd0a92adf7d9eb,TLs,0.394239
uuid-c54f689387f24b9a91cd0a92adf7d9eb,feels,0.303576
uuid-c54f689387f24b9a91cd0a92adf7d9eb,Regional TL,0.563102
uuid-c54f689387f24b9a91cd0a92adf7d9eb,RTL stated,0.443597
uuid-c54f689387f24b9a91cd0a92adf7d9eb,bladder,0.4083
uuid-a80824f8852b483e881c46b14741ab3f,Nivo,0.432934
uuid-a80824f8852b483e881c46b14741ab3f,pembro,0.311347
uuid-a80824f8852b483e881c46b14741ab3f,1L,0.434256
uuid-a80824f8852b483e881c46b14741ab3f,efficacy,0.327361
uuid-a80824f8852b483e881c46b14741ab3f,combination,0.353042
uuid-a80824f8852b483e881c46b14741ab3f,chemo,0.562316
uuid-a80824f8852b483e881c46b14741ab3f,2L,0.408253
uuid-a80824f8852b483e881c46b14741ab3f,agents,0.39525
uuid-a80824f8852b483e881c46b14741ab3f,preferred,0.445522
uuid-a80824f8852b483e881c46b14741ab3f,monotherapy,0.482426
uuid-a80824f8852b483e881c46b14741ab3f,using nivo,0.401141
uuid-a80824f8852b483e881c46b14741ab3f,combo,0.330887
uuid-a80824f8852b483e881c46b14741ab3f,PD1,0.318527
uuid-a80824f8852b483e881c46b14741ab3f,nivo and pembro,0.330297
uuid-a80824f8852b483e881c46b14741ab3f,believes,0.434408
uuid-a80824f8852b483e881c46b14741ab3f,chemotherapy,0.438094
uuid-a80824f8852b483e881c46b14741ab3f,feels,0.520028
uuid-a80824f8852b483e881c46b14741ab3f,RTL stated,0.301722
uuid-a80824f8852b483e881c46b14741ab3f,option,0.504976
uuid-8f8e62e2152449c199c6524d89d7f595,Nivo,0.386758
uuid-8f8e62e2152449c199c6524d89d7f595,patients,0.368631
uuid-8f8e62e2152449c199c6524d89d7f595,pembro,0.444005
uuid-8f8e62e2152449c199c6524d89d7f595,nivolumab,0.355926
uuid-8f8e62e2152449c199c6524d89d7f595,1L,0.741091
uuid-8f8e62e2152449c199c6524d89d7f595,RCC,0.607432
uuid-8f8e62e2152449c199c6524d89d7f595,TL stated,0.303351
uuid-8f8e62e2152449c199c6524d89d7f595,chemo,0.316857
uuid-8f8e62e2152449c199c6524d89d7f595,2L,0.745398
uuid-8f8e62e2152449c199c6524d89d7f595,pts,0.42242
uuid-8f8e62e2152449c199c6524d89d7f595,agents,0.332529
uuid-8f8e62e2152449c199c6524d89d7f595,approval,0.548075
uuid-8f8e62e2152449c199c6524d89d7f595,atezo,0.387849
uuid-8f8e62e2152449c199c6524d89d7f595,preferred,0.602432
uuid-8f8e62e2152449c199c6524d89d7f595,monotherapy,0.577125
uuid-8f8e62e2152449c199c6524d89d7f595,using nivo,0.642636
uuid-8f8e62e2152449c199c6524d89d7f595,combo,0.350503
uuid-8f8e62e2152449c199c6524d89d7f595,indication,0.307589
uuid-8f8e62e2152449c199c6524d89d7f595,NSCLC patients,0.347506
uuid-8f8e62e2152449c199c6524d89d7f595,PD1,0.31097
uuid-8f8e62e2152449c199c6524d89d7f595,approved,0.721554
uuid-8f8e62e2152449c199c6524d89d7f595,SCCHN,0.404511
uuid-8f8e62e2152449c199c6524d89d7f595,tumor types,0.43245
uuid-8f8e62e2152449c199c6524d89d7f595,label,0.328859
uuid-8f8e62e2152449c199c6524d89d7f595,SCLC,0.332529
uuid-8f8e62e2152449c199c6524d89d7f595,RTL stated,0.533429
uuid-8f8e62e2152449c199c6524d89d7f595,TL shared,0.348156
uuid-8f8e62e2152449c199c6524d89d7f595,option,0.62433
uuid-8f8e62e2152449c199c6524d89d7f595,bladder,0.374075
uuid-4ba20270d23c4d8ca832d894fa9f52de,toxicity,0.31599
uuid-4ba20270d23c4d8ca832d894fa9f52de,efficacy,0.513128
uuid-4ba20270d23c4d8ca832d894fa9f52de,regards,0.34586
uuid-4ba20270d23c4d8ca832d894fa9f52de,data,0.438317
uuid-4ba20270d23c4d8ca832d894fa9f52de,ORR,0.310802
uuid-4ba20270d23c4d8ca832d894fa9f52de,nivo and pembro,0.318063
uuid-4ba20270d23c4d8ca832d894fa9f52de,believes,0.332979
uuid-4ba20270d23c4d8ca832d894fa9f52de,impressed,0.385268
uuid-4ba20270d23c4d8ca832d894fa9f52de,TLs,0.382738
uuid-4ba20270d23c4d8ca832d894fa9f52de,feels,0.399939
uuid-9d325df766634a2e93defbc46a0f534e,Nivo,0.303374
uuid-9d325df766634a2e93defbc46a0f534e,patients,0.334787
uuid-9d325df766634a2e93defbc46a0f534e,therapy,0.327732
uuid-9d325df766634a2e93defbc46a0f534e,dose,0.542811
uuid-9d325df766634a2e93defbc46a0f534e,nivolumab,0.415727
uuid-9d325df766634a2e93defbc46a0f534e,toxicity,0.357155
uuid-9d325df766634a2e93defbc46a0f534e,regimen,0.406181
uuid-9d325df766634a2e93defbc46a0f534e,combination,0.377438
uuid-9d325df766634a2e93defbc46a0f534e,chemo,0.368054
uuid-9d325df766634a2e93defbc46a0f534e,agents,0.424623
uuid-9d325df766634a2e93defbc46a0f534e,Ipi,0.300565
uuid-9d325df766634a2e93defbc46a0f534e,preferred,0.408184
uuid-9d325df766634a2e93defbc46a0f534e,monotherapy,0.418267
uuid-9d325df766634a2e93defbc46a0f534e,treatment,0.329129
uuid-9d325df766634a2e93defbc46a0f534e,PD1,0.495246
uuid-9d325df766634a2e93defbc46a0f534e,vs,0.337054
uuid-9d325df766634a2e93defbc46a0f534e,PD-1,0.413045
uuid-9d325df766634a2e93defbc46a0f534e,option,0.349048
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,RTL,0.329121
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,BMS,0.405945
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,trial,0.591856
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,efficacy,0.458205
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,discussed,0.352521
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,commented,0.466585
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,OS,0.640071
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,regards,0.338969
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,data,0.817359
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,expressed,0.352827
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,PFS,0.603882
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,ORR,0.653897
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,nivo and pembro,0.356856
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,ASCO,0.513926
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,believes,0.312537
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,impressed,0.674728
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,TLs,0.303498
uuid-7b0767f37f5d4bb9b7bcc3a8343b77fd,feels,0.332835
uuid-a13697bda1104e01b9ef9ffdc5f77453,IO,0.349802
uuid-a13697bda1104e01b9ef9ffdc5f77453,monotherapy,0.305533
uuid-a13697bda1104e01b9ef9ffdc5f77453,combo,0.331222
uuid-a13697bda1104e01b9ef9ffdc5f77453,believes,0.456766
uuid-a13697bda1104e01b9ef9ffdc5f77453,SCLC,0.58673
uuid-a13697bda1104e01b9ef9ffdc5f77453,option,0.301157
uuid-149744de29394930a9d63219066587cd,NTL,0.307212
uuid-149744de29394930a9d63219066587cd,Merck,0.319437
uuid-2eb8e6ff65fb4c8eb57ab2b0e1d86c14,nivolumab,0.380769
uuid-2eb8e6ff65fb4c8eb57ab2b0e1d86c14,combination,0.570499
uuid-2eb8e6ff65fb4c8eb57ab2b0e1d86c14,monotherapy,0.33587
uuid-2eb8e6ff65fb4c8eb57ab2b0e1d86c14,combo,0.385799
uuid-2eb8e6ff65fb4c8eb57ab2b0e1d86c14,PD1,0.390767
uuid-2eb8e6ff65fb4c8eb57ab2b0e1d86c14,PD-1,0.371147
uuid-840a6e6715f44cc689f2ebaa086b62ce,PDL1,0.357887
uuid-840a6e6715f44cc689f2ebaa086b62ce,agents,0.308306
uuid-840a6e6715f44cc689f2ebaa086b62ce,PD-L1,0.317642
uuid-840a6e6715f44cc689f2ebaa086b62ce,PDL1 expression,0.337282
uuid-840a6e6715f44cc689f2ebaa086b62ce,biomarker,0.472024
uuid-0df81b716ff14e04ad8c86302bdcb716,patients,0.766482
uuid-0df81b716ff14e04ad8c86302bdcb716,Opdivo,0.537222
uuid-0df81b716ff14e04ad8c86302bdcb716,dose,0.391059
uuid-0df81b716ff14e04ad8c86302bdcb716,nivolumab,0.316858
uuid-0df81b716ff14e04ad8c86302bdcb716,regimen,0.431576
uuid-0df81b716ff14e04ad8c86302bdcb716,treated,0.447881
uuid-0df81b716ff14e04ad8c86302bdcb716,pts,0.488083
uuid-0df81b716ff14e04ad8c86302bdcb716,treatment,0.510165
uuid-0df81b716ff14e04ad8c86302bdcb716,progression,0.485838
uuid-0df81b716ff14e04ad8c86302bdcb716,respond,0.42537
uuid-4e8e28c6647a4a158b8db487ef688449,Nivo,0.384746
uuid-4e8e28c6647a4a158b8db487ef688449,patients,0.404269
uuid-4e8e28c6647a4a158b8db487ef688449,pembro,0.415013
uuid-4e8e28c6647a4a158b8db487ef688449,dose,0.353331
uuid-4e8e28c6647a4a158b8db487ef688449,nivolumab,0.368399
uuid-4e8e28c6647a4a158b8db487ef688449,trial,0.364385
uuid-4e8e28c6647a4a158b8db487ef688449,regimen,0.345526
uuid-4e8e28c6647a4a158b8db487ef688449,combination,0.340982
uuid-4e8e28c6647a4a158b8db487ef688449,pts,0.304985
uuid-4e8e28c6647a4a158b8db487ef688449,Ipi,0.423294
uuid-4e8e28c6647a4a158b8db487ef688449,monotherapy,0.320884
uuid-4e8e28c6647a4a158b8db487ef688449,combo,0.349371
uuid-4e8e28c6647a4a158b8db487ef688449,clinical trials,0.321211
uuid-4e8e28c6647a4a158b8db487ef688449,impressed,0.360733
uuid-4e8e28c6647a4a158b8db487ef688449,vs,0.340973
uuid-4e8e28c6647a4a158b8db487ef688449,feels,0.359779
uuid-29963725e9a942708253cab29a5bd09c,patients,0.902294
uuid-29963725e9a942708253cab29a5bd09c,Opdivo,0.520678
uuid-29963725e9a942708253cab29a5bd09c,therapy,0.568274
uuid-29963725e9a942708253cab29a5bd09c,nivolumab,0.523665
uuid-29963725e9a942708253cab29a5bd09c,regimen,0.560424
uuid-29963725e9a942708253cab29a5bd09c,treated,0.66574
uuid-29963725e9a942708253cab29a5bd09c,pts,0.603745
uuid-29963725e9a942708253cab29a5bd09c,monotherapy,0.326422
uuid-29963725e9a942708253cab29a5bd09c,treatment,0.798477
uuid-29963725e9a942708253cab29a5bd09c,response,0.3898
uuid-29963725e9a942708253cab29a5bd09c,cHL,0.315382
uuid-29963725e9a942708253cab29a5bd09c,progression,0.704726
uuid-29963725e9a942708253cab29a5bd09c,chemotherapy,0.347481
uuid-29963725e9a942708253cab29a5bd09c,respond,0.526296
uuid-29963725e9a942708253cab29a5bd09c,option,0.301144
uuid-d6d08462067b4ed1800713bdb1f1f4ee,Nivo,0.472678
uuid-d6d08462067b4ed1800713bdb1f1f4ee,pembro,0.592762
uuid-d6d08462067b4ed1800713bdb1f1f4ee,dose,0.570651
uuid-d6d08462067b4ed1800713bdb1f1f4ee,efficacy,0.594444
uuid-d6d08462067b4ed1800713bdb1f1f4ee,2L,0.379337
uuid-d6d08462067b4ed1800713bdb1f1f4ee,agents,0.422762
uuid-d6d08462067b4ed1800713bdb1f1f4ee,Ipi,0.395912
uuid-d6d08462067b4ed1800713bdb1f1f4ee,atezo,0.712708
uuid-d6d08462067b4ed1800713bdb1f1f4ee,preferred,0.414075
uuid-d6d08462067b4ed1800713bdb1f1f4ee,indication,0.375226
uuid-d6d08462067b4ed1800713bdb1f1f4ee,nivo and pembro,0.403628
uuid-d6d08462067b4ed1800713bdb1f1f4ee,vs,0.647386
uuid-d6d08462067b4ed1800713bdb1f1f4ee,Keytruda,0.393654
uuid-d6d08462067b4ed1800713bdb1f1f4ee,flat dosing,0.526936
uuid-fe94f34cfd09480db678d73c3908fe33,RTL,0.310065
uuid-fe94f34cfd09480db678d73c3908fe33,nivolumab,0.333944
uuid-fe94f34cfd09480db678d73c3908fe33,BMS,0.365592
uuid-fe94f34cfd09480db678d73c3908fe33,shared,0.502041
uuid-fe94f34cfd09480db678d73c3908fe33,commented,0.370713
uuid-fe94f34cfd09480db678d73c3908fe33,RCC,0.31696
uuid-fe94f34cfd09480db678d73c3908fe33,stated,0.374174
uuid-fe94f34cfd09480db678d73c3908fe33,approval,0.4561
uuid-fe94f34cfd09480db678d73c3908fe33,expressed,0.334333
uuid-fe94f34cfd09480db678d73c3908fe33,clinical trials,0.491458
uuid-fe94f34cfd09480db678d73c3908fe33,approved,0.405312
uuid-fe94f34cfd09480db678d73c3908fe33,SCCHN,0.333301
uuid-fe94f34cfd09480db678d73c3908fe33,impressed,0.435032
uuid-fe94f34cfd09480db678d73c3908fe33,LTL,0.301496
uuid-fe94f34cfd09480db678d73c3908fe33,Regional TL,0.390759
uuid-fe94f34cfd09480db678d73c3908fe33,bladder,0.325421
uuid-606520fb12fe48669fb7921e8ae4bfe2,patients,0.513429
uuid-606520fb12fe48669fb7921e8ae4bfe2,Opdivo,0.503911
uuid-606520fb12fe48669fb7921e8ae4bfe2,therapy,0.52098
uuid-606520fb12fe48669fb7921e8ae4bfe2,nivolumab,0.440718
uuid-606520fb12fe48669fb7921e8ae4bfe2,treated,0.428378
uuid-606520fb12fe48669fb7921e8ae4bfe2,treatment,0.447705
uuid-606520fb12fe48669fb7921e8ae4bfe2,cHL,0.614776
uuid-9b7b8439a5cc42bb80c513e1637c91cb,Nivo,0.421276
uuid-9b7b8439a5cc42bb80c513e1637c91cb,patients,0.503839
uuid-9b7b8439a5cc42bb80c513e1637c91cb,therapy,0.352389
uuid-9b7b8439a5cc42bb80c513e1637c91cb,toxicity,0.389558
uuid-9b7b8439a5cc42bb80c513e1637c91cb,monotherapy,0.310716
uuid-9b7b8439a5cc42bb80c513e1637c91cb,progression,0.33717
uuid-9b7b8439a5cc42bb80c513e1637c91cb,chemotherapy,0.392456
uuid-5a7edd52ac994ce2843e19ba6b359b09,TL,0.673403
uuid-5a7edd52ac994ce2843e19ba6b359b09,TL stated,0.434338
uuid-5a7edd52ac994ce2843e19ba6b359b09,institution,0.560794
uuid-5a7edd52ac994ce2843e19ba6b359b09,PD-L1,0.718024
uuid-5a7edd52ac994ce2843e19ba6b359b09,PD-L1 testing,0.934962
uuid-5a7edd52ac994ce2843e19ba6b359b09,testing,0.812766
uuid-5a7edd52ac994ce2843e19ba6b359b09,PDL1 testing,0.666803
uuid-5a7edd52ac994ce2843e19ba6b359b09,NSCLC patients,0.527462
uuid-5a7edd52ac994ce2843e19ba6b359b09,assay,0.703371
uuid-d6e8acc51e214e229a3d2ffec6417740,Nivo,0.451615
uuid-d6e8acc51e214e229a3d2ffec6417740,pembro,0.603283
uuid-d6e8acc51e214e229a3d2ffec6417740,dose,0.512246
uuid-d6e8acc51e214e229a3d2ffec6417740,1L,0.440792
uuid-d6e8acc51e214e229a3d2ffec6417740,efficacy,0.518799
uuid-d6e8acc51e214e229a3d2ffec6417740,combination,0.466156
uuid-d6e8acc51e214e229a3d2ffec6417740,chemo,0.371414
uuid-d6e8acc51e214e229a3d2ffec6417740,2L,0.530587
uuid-d6e8acc51e214e229a3d2ffec6417740,IO,0.32578
uuid-d6e8acc51e214e229a3d2ffec6417740,agents,0.549442
uuid-d6e8acc51e214e229a3d2ffec6417740,Ipi,0.544574
uuid-d6e8acc51e214e229a3d2ffec6417740,atezo,0.675025
uuid-d6e8acc51e214e229a3d2ffec6417740,preferred,0.454076
uuid-d6e8acc51e214e229a3d2ffec6417740,monotherapy,0.470368
uuid-d6e8acc51e214e229a3d2ffec6417740,combo,0.592325
uuid-d6e8acc51e214e229a3d2ffec6417740,approved,0.312967
uuid-d6e8acc51e214e229a3d2ffec6417740,nivo and pembro,0.449963
uuid-d6e8acc51e214e229a3d2ffec6417740,believes,0.468034
uuid-d6e8acc51e214e229a3d2ffec6417740,vs,0.603069
uuid-d6e8acc51e214e229a3d2ffec6417740,feels,0.382017
uuid-d6e8acc51e214e229a3d2ffec6417740,option,0.398717
uuid-3acbe4dcc2e145af9d5d2011c5c9e8c2,dose,0.602225
uuid-3acbe4dcc2e145af9d5d2011c5c9e8c2,trial,0.427244
uuid-3acbe4dcc2e145af9d5d2011c5c9e8c2,Ipi,0.620352
uuid-3acbe4dcc2e145af9d5d2011c5c9e8c2,vs,0.425433
uuid-3acbe4dcc2e145af9d5d2011c5c9e8c2,flat dosing,0.351031
uuid-b7ea34af86504633bb8cdf889f2de130,TL,0.340804
uuid-b7ea34af86504633bb8cdf889f2de130,RCC,0.345432
uuid-b7ea34af86504633bb8cdf889f2de130,approval,0.601705
uuid-b7ea34af86504633bb8cdf889f2de130,approved,0.355913
uuid-b7ea34af86504633bb8cdf889f2de130,bladder,0.323615
uuid-8e20fb51e0094c3aa18737ecad49da59,lung,0.350847
uuid-8e20fb51e0094c3aa18737ecad49da59,institution,0.327864
uuid-8e20fb51e0094c3aa18737ecad49da59,regards,0.32633
uuid-8e20fb51e0094c3aa18737ecad49da59,AI,0.706031
uuid-8e20fb51e0094c3aa18737ecad49da59,oncology,0.423092
uuid-8e20fb51e0094c3aa18737ecad49da59,clinical,0.343072
uuid-8e20fb51e0094c3aa18737ecad49da59,NCCN,0.333331
uuid-d95732ef66014b81b5d3542fa1888d66,TL,0.352046
uuid-d95732ef66014b81b5d3542fa1888d66,lung,0.649031
uuid-d95732ef66014b81b5d3542fa1888d66,1L,0.342144
uuid-d95732ef66014b81b5d3542fa1888d66,melanoma,0.418702
uuid-d95732ef66014b81b5d3542fa1888d66,RCC,0.568163
uuid-d95732ef66014b81b5d3542fa1888d66,TL stated,0.777755
uuid-d95732ef66014b81b5d3542fa1888d66,2L,0.332956
uuid-d95732ef66014b81b5d3542fa1888d66,institution,0.390631
uuid-d95732ef66014b81b5d3542fa1888d66,PD-L1,0.385491
uuid-d95732ef66014b81b5d3542fa1888d66,PD-L1 testing,0.552368
uuid-d95732ef66014b81b5d3542fa1888d66,testing,0.601726
uuid-d95732ef66014b81b5d3542fa1888d66,PDL1 testing,0.844282
uuid-d95732ef66014b81b5d3542fa1888d66,NSCLC patients,0.614985
uuid-d95732ef66014b81b5d3542fa1888d66,SCCHN,0.491531
uuid-d95732ef66014b81b5d3542fa1888d66,tumor types,0.428877
uuid-d95732ef66014b81b5d3542fa1888d66,TLs,0.389195
uuid-d95732ef66014b81b5d3542fa1888d66,academic,0.382352
uuid-d95732ef66014b81b5d3542fa1888d66,Regional TL,0.326578
uuid-d95732ef66014b81b5d3542fa1888d66,RTL stated,0.495853
uuid-d95732ef66014b81b5d3542fa1888d66,TL shared,0.571971
uuid-d95732ef66014b81b5d3542fa1888d66,bladder,0.318035
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,Nivo,0.52614
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,patients,0.530943
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,pembro,0.536828
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,therapy,0.346069
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,1L,0.602448
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,PDL1,0.374228
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,chemo,0.542014
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,2L,0.53221
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,pts,0.483638
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,atezo,0.420668
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,preferred,0.439574
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,monotherapy,0.586932
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,using nivo,0.446151
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,NSCLC patients,0.358046
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,PD1,0.372951
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,nivo and pembro,0.366467
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,progression,0.325866
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,believes,0.348141
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,chemotherapy,0.419736
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,feels,0.441123
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,RTL stated,0.314501
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,PDL1 expression,0.306994
uuid-6eb3a4bafd7f4fafaa831fa66c4bebcf,option,0.579512
uuid-1b94a9b9e922495aaf2f2bf452b199a7,PDL1,0.41484
uuid-1b94a9b9e922495aaf2f2bf452b199a7,trial,0.426645
uuid-1b94a9b9e922495aaf2f2bf452b199a7,efficacy,0.537819
uuid-1b94a9b9e922495aaf2f2bf452b199a7,commented,0.460325
uuid-1b94a9b9e922495aaf2f2bf452b199a7,Merck,0.313312
uuid-1b94a9b9e922495aaf2f2bf452b199a7,OS,0.607398
uuid-1b94a9b9e922495aaf2f2bf452b199a7,regards,0.406
uuid-1b94a9b9e922495aaf2f2bf452b199a7,data,0.764003
uuid-1b94a9b9e922495aaf2f2bf452b199a7,expressed,0.357153
uuid-1b94a9b9e922495aaf2f2bf452b199a7,PFS,0.573137
uuid-1b94a9b9e922495aaf2f2bf452b199a7,ORR,0.64619
uuid-1b94a9b9e922495aaf2f2bf452b199a7,nivo and pembro,0.398963
uuid-1b94a9b9e922495aaf2f2bf452b199a7,ASCO,0.473563
uuid-1b94a9b9e922495aaf2f2bf452b199a7,impressed,0.644913
uuid-1b94a9b9e922495aaf2f2bf452b199a7,PDL1 expression,0.368587
uuid-b223d53b5bc343dc9a469c99620daa49,TL,0.41921
uuid-b223d53b5bc343dc9a469c99620daa49,RTL,0.397329
uuid-b223d53b5bc343dc9a469c99620daa49,shared,0.324552
uuid-b223d53b5bc343dc9a469c99620daa49,commented,0.341586
uuid-b223d53b5bc343dc9a469c99620daa49,TL stated,0.391913
uuid-b223d53b5bc343dc9a469c99620daa49,institution,0.308311
uuid-b223d53b5bc343dc9a469c99620daa49,stated,0.350004
uuid-b223d53b5bc343dc9a469c99620daa49,physicians,0.370163
uuid-b223d53b5bc343dc9a469c99620daa49,PD-L1 testing,0.458443
uuid-b223d53b5bc343dc9a469c99620daa49,PDL1 testing,0.400797
uuid-b223d53b5bc343dc9a469c99620daa49,oncology,0.31943
uuid-b223d53b5bc343dc9a469c99620daa49,SCCHN,0.39883
uuid-b223d53b5bc343dc9a469c99620daa49,LTL,0.3716
uuid-b223d53b5bc343dc9a469c99620daa49,TLs,0.43022
uuid-b223d53b5bc343dc9a469c99620daa49,clinical,0.309492
uuid-b223d53b5bc343dc9a469c99620daa49,academic,0.485784
uuid-b223d53b5bc343dc9a469c99620daa49,Regional TL,0.462693
uuid-844afe222d2042348f33e345077490d6,Nivo,0.50363
uuid-844afe222d2042348f33e345077490d6,pembro,0.418159
uuid-844afe222d2042348f33e345077490d6,trial,0.483326
uuid-844afe222d2042348f33e345077490d6,efficacy,0.605955
uuid-844afe222d2042348f33e345077490d6,chemo,0.501772
uuid-844afe222d2042348f33e345077490d6,Ipi,0.425041
uuid-844afe222d2042348f33e345077490d6,OS,0.504504
uuid-844afe222d2042348f33e345077490d6,data,0.41027
uuid-844afe222d2042348f33e345077490d6,combo,0.317202
uuid-844afe222d2042348f33e345077490d6,PFS,0.494424
uuid-844afe222d2042348f33e345077490d6,ORR,0.530433
uuid-844afe222d2042348f33e345077490d6,nivo and pembro,0.392718
uuid-844afe222d2042348f33e345077490d6,believes,0.391109
uuid-844afe222d2042348f33e345077490d6,chemotherapy,0.472534
uuid-844afe222d2042348f33e345077490d6,impressed,0.30813
uuid-844afe222d2042348f33e345077490d6,vs,0.511467
uuid-844afe222d2042348f33e345077490d6,feels,0.527854
uuid-844afe222d2042348f33e345077490d6,option,0.349096
uuid-a63001811f3e44368cf3917c2c79e1b9,patients,0.476228
uuid-a63001811f3e44368cf3917c2c79e1b9,therapy,0.305694
uuid-a63001811f3e44368cf3917c2c79e1b9,toxicity,0.414682
uuid-a63001811f3e44368cf3917c2c79e1b9,regimen,0.468972
uuid-a63001811f3e44368cf3917c2c79e1b9,treated,0.300731
uuid-a63001811f3e44368cf3917c2c79e1b9,IO,0.548897
uuid-a63001811f3e44368cf3917c2c79e1b9,physicians,0.365644
uuid-a63001811f3e44368cf3917c2c79e1b9,treatment,0.452279
uuid-a63001811f3e44368cf3917c2c79e1b9,response,0.338719
uuid-a63001811f3e44368cf3917c2c79e1b9,progression,0.408383
uuid-a63001811f3e44368cf3917c2c79e1b9,respond,0.300411
uuid-f5470ddeab6d43098325287ca67fb805,dose,0.431577
uuid-f5470ddeab6d43098325287ca67fb805,toxicity,0.612477
uuid-f5470ddeab6d43098325287ca67fb805,regimen,0.359323
uuid-f5470ddeab6d43098325287ca67fb805,treatment,0.311545
uuid-9e92773ab6514361abfb13baa962439a,BMS,0.527148
uuid-9e92773ab6514361abfb13baa962439a,trial,0.388858
uuid-9e92773ab6514361abfb13baa962439a,commented,0.316088
uuid-9e92773ab6514361abfb13baa962439a,Merck,0.6821
uuid-37bfa707b1a045bc8da0c9acfb908c3b,NTL,0.387177
uuid-37bfa707b1a045bc8da0c9acfb908c3b,melanoma,0.446322
uuid-37bfa707b1a045bc8da0c9acfb908c3b,RCC,0.318371
uuid-37bfa707b1a045bc8da0c9acfb908c3b,oncologist,0.410099
uuid-64ade756241e4f83b23bef4158b3bee4,RTL,0.420504
uuid-64ade756241e4f83b23bef4158b3bee4,nivolumab,0.40975
uuid-64ade756241e4f83b23bef4158b3bee4,regimen,0.33967
uuid-64ade756241e4f83b23bef4158b3bee4,treated,0.45736
uuid-64ade756241e4f83b23bef4158b3bee4,melanoma,0.630662
uuid-64ade756241e4f83b23bef4158b3bee4,RCC,0.402045
uuid-64ade756241e4f83b23bef4158b3bee4,combination,0.370922
uuid-64ade756241e4f83b23bef4158b3bee4,pts,0.392386
uuid-64ade756241e4f83b23bef4158b3bee4,monotherapy,0.314721
uuid-64ade756241e4f83b23bef4158b3bee4,response,0.304068
uuid-64ade756241e4f83b23bef4158b3bee4,combo,0.314106
uuid-64ade756241e4f83b23bef4158b3bee4,PD1,0.485126
uuid-64ade756241e4f83b23bef4158b3bee4,progression,0.339244
uuid-64ade756241e4f83b23bef4158b3bee4,academic,0.322873
uuid-64ade756241e4f83b23bef4158b3bee4,PD-1,0.309048
uuid-64ade756241e4f83b23bef4158b3bee4,RTL stated,0.450567
uuid-64ade756241e4f83b23bef4158b3bee4,TL shared,0.426627
uuid-2dfb34a1c90641f2bf78c80575dc043f,trial,0.41075
uuid-2dfb34a1c90641f2bf78c80575dc043f,commented,0.373539
uuid-2dfb34a1c90641f2bf78c80575dc043f,RCC,0.33845
uuid-2dfb34a1c90641f2bf78c80575dc043f,data,0.401432
uuid-2dfb34a1c90641f2bf78c80575dc043f,combo,0.326807
uuid-2dfb34a1c90641f2bf78c80575dc043f,clinical trials,0.32994
uuid-2dfb34a1c90641f2bf78c80575dc043f,SCCHN,0.370826
uuid-2dfb34a1c90641f2bf78c80575dc043f,impressed,0.373997
uuid-2dfb34a1c90641f2bf78c80575dc043f,TLs,0.364907
uuid-2dfb34a1c90641f2bf78c80575dc043f,SCLC,0.310576
uuid-2dfb34a1c90641f2bf78c80575dc043f,bladder,0.480169
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,patients,0.309408
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,therapy,0.358419
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,1L,0.390282
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,treated,0.369098
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,combination,0.364426
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,chemo,0.533781
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,tumor,0.551641
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,2L,0.377034
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,pts,0.479226
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,agents,0.340834
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,preferred,0.300466
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,monotherapy,0.400622
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,response,0.477795
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,PD1,0.435342
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,progression,0.369377
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,believes,0.335496
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,chemotherapy,0.330104
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,respond,0.309697
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,PD-1,0.319626
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,RTL stated,0.310139
uuid-7a99633ca34b49cdbfa367e4d7dd01a6,option,0.405901
uuid-26327a60ad5c458d9ecc5e2710a92cb0,Nivo,0.341321
uuid-26327a60ad5c458d9ecc5e2710a92cb0,pembro,0.518869
uuid-26327a60ad5c458d9ecc5e2710a92cb0,1L,0.777272
uuid-26327a60ad5c458d9ecc5e2710a92cb0,RCC,0.610289
uuid-26327a60ad5c458d9ecc5e2710a92cb0,TL stated,0.410382
uuid-26327a60ad5c458d9ecc5e2710a92cb0,2L,0.777937
uuid-26327a60ad5c458d9ecc5e2710a92cb0,agents,0.459953
uuid-26327a60ad5c458d9ecc5e2710a92cb0,stated,0.369367
uuid-26327a60ad5c458d9ecc5e2710a92cb0,approval,0.438746
uuid-26327a60ad5c458d9ecc5e2710a92cb0,atezo,0.550882
uuid-26327a60ad5c458d9ecc5e2710a92cb0,preferred,0.649788
uuid-26327a60ad5c458d9ecc5e2710a92cb0,monotherapy,0.509932
uuid-26327a60ad5c458d9ecc5e2710a92cb0,using nivo,0.615866
uuid-26327a60ad5c458d9ecc5e2710a92cb0,data,0.315057
uuid-26327a60ad5c458d9ecc5e2710a92cb0,combo,0.406553
uuid-26327a60ad5c458d9ecc5e2710a92cb0,PDL1 testing,0.321004
uuid-26327a60ad5c458d9ecc5e2710a92cb0,indication,0.37587
uuid-26327a60ad5c458d9ecc5e2710a92cb0,approved,0.626512
uuid-26327a60ad5c458d9ecc5e2710a92cb0,SCCHN,0.51277
uuid-26327a60ad5c458d9ecc5e2710a92cb0,nivo and pembro,0.335696
uuid-26327a60ad5c458d9ecc5e2710a92cb0,believes,0.332372
uuid-26327a60ad5c458d9ecc5e2710a92cb0,impressed,0.356321
uuid-26327a60ad5c458d9ecc5e2710a92cb0,tumor types,0.401911
uuid-26327a60ad5c458d9ecc5e2710a92cb0,SCLC,0.405596
uuid-26327a60ad5c458d9ecc5e2710a92cb0,feels,0.34631
uuid-26327a60ad5c458d9ecc5e2710a92cb0,Regional TL,0.320065
uuid-26327a60ad5c458d9ecc5e2710a92cb0,RTL stated,0.55137
uuid-26327a60ad5c458d9ecc5e2710a92cb0,TL shared,0.30509
uuid-26327a60ad5c458d9ecc5e2710a92cb0,option,0.558784
uuid-26327a60ad5c458d9ecc5e2710a92cb0,bladder,0.434822
uuid-b0542b31350240be891ec3736d2b64a7,BMS,0.373054
uuid-b0542b31350240be891ec3736d2b64a7,efficacy,0.335822
uuid-b0542b31350240be891ec3736d2b64a7,discussed,0.333373
uuid-b0542b31350240be891ec3736d2b64a7,commented,0.386753
uuid-b0542b31350240be891ec3736d2b64a7,OS,0.664962
uuid-b0542b31350240be891ec3736d2b64a7,regards,0.48046
uuid-b0542b31350240be891ec3736d2b64a7,data,0.512272
uuid-b0542b31350240be891ec3736d2b64a7,expressed,0.388877
uuid-b0542b31350240be891ec3736d2b64a7,PFS,0.684287
uuid-b0542b31350240be891ec3736d2b64a7,AI,0.491298
uuid-b0542b31350240be891ec3736d2b64a7,ORR,0.552995
uuid-b0542b31350240be891ec3736d2b64a7,ASCO,0.379786
uuid-b0542b31350240be891ec3736d2b64a7,impressed,0.42731
uuid-b0542b31350240be891ec3736d2b64a7,TLs,0.308693
uuid-b0542b31350240be891ec3736d2b64a7,NCCN,0.322974
uuid-7a9575f392ce4d5c9af21769b563e45c,Nivo,0.382198
uuid-7a9575f392ce4d5c9af21769b563e45c,patients,0.584943
uuid-7a9575f392ce4d5c9af21769b563e45c,therapy,0.51186
uuid-7a9575f392ce4d5c9af21769b563e45c,nivolumab,0.482839
uuid-7a9575f392ce4d5c9af21769b563e45c,1L,0.563669
uuid-7a9575f392ce4d5c9af21769b563e45c,regimen,0.316
uuid-7a9575f392ce4d5c9af21769b563e45c,treated,0.330057
uuid-7a9575f392ce4d5c9af21769b563e45c,RCC,0.438314
uuid-7a9575f392ce4d5c9af21769b563e45c,2L,0.585767
uuid-7a9575f392ce4d5c9af21769b563e45c,pts,0.365079
uuid-7a9575f392ce4d5c9af21769b563e45c,approval,0.532092
uuid-7a9575f392ce4d5c9af21769b563e45c,preferred,0.522504
uuid-7a9575f392ce4d5c9af21769b563e45c,monotherapy,0.513118
uuid-7a9575f392ce4d5c9af21769b563e45c,treatment,0.476008
uuid-7a9575f392ce4d5c9af21769b563e45c,using nivo,0.612061
uuid-7a9575f392ce4d5c9af21769b563e45c,PD1,0.320187
uuid-7a9575f392ce4d5c9af21769b563e45c,approved,0.617356
uuid-7a9575f392ce4d5c9af21769b563e45c,progression,0.358005
uuid-7a9575f392ce4d5c9af21769b563e45c,chemotherapy,0.301423
uuid-7a9575f392ce4d5c9af21769b563e45c,label,0.394547
uuid-7a9575f392ce4d5c9af21769b563e45c,RTL stated,0.433212
uuid-7a9575f392ce4d5c9af21769b563e45c,option,0.580609
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,TL,0.386976
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,1L,0.34453
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,TL stated,0.561588
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,institution,0.352587
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,PD-L1,0.644513
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,approval,0.32182
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,PD-L1 testing,0.713541
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,testing,0.860346
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,PDL1 testing,0.834393
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,NSCLC patients,0.836126
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,tumor types,0.322958
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,assay,0.420945
uuid-b0b8b0d584e64f76a945b672ff5dd9ca,biomarker,0.303538
uuid-79437094fe48471684764ce583992054,pembro,0.631732
uuid-79437094fe48471684764ce583992054,1L,0.59861
uuid-79437094fe48471684764ce583992054,PDL1,0.54883
uuid-79437094fe48471684764ce583992054,TL stated,0.332611
uuid-79437094fe48471684764ce583992054,2L,0.588101
uuid-79437094fe48471684764ce583992054,agents,0.485212
uuid-79437094fe48471684764ce583992054,Merck,0.378602
uuid-79437094fe48471684764ce583992054,PD-L1,0.526442
uuid-79437094fe48471684764ce583992054,approval,0.307162
uuid-79437094fe48471684764ce583992054,atezo,0.697674
uuid-79437094fe48471684764ce583992054,preferred,0.53563
uuid-79437094fe48471684764ce583992054,PD-L1 testing,0.330022
uuid-79437094fe48471684764ce583992054,testing,0.483376
uuid-79437094fe48471684764ce583992054,using nivo,0.315666
uuid-79437094fe48471684764ce583992054,PDL1 testing,0.482482
uuid-79437094fe48471684764ce583992054,indication,0.34304
uuid-79437094fe48471684764ce583992054,NSCLC patients,0.373808
uuid-79437094fe48471684764ce583992054,approved,0.444312
uuid-79437094fe48471684764ce583992054,nivo and pembro,0.46818
uuid-79437094fe48471684764ce583992054,believes,0.425928
uuid-79437094fe48471684764ce583992054,feels,0.31536
uuid-79437094fe48471684764ce583992054,assay,0.469783
uuid-79437094fe48471684764ce583992054,PDL1 expression,0.380139
uuid-79437094fe48471684764ce583992054,option,0.390225
uuid-79437094fe48471684764ce583992054,biomarker,0.323262
uuid-afaca5347340422d82906601e650334a,RTL,0.529171
uuid-afaca5347340422d82906601e650334a,nivolumab,0.30571
uuid-afaca5347340422d82906601e650334a,trial,0.352019
uuid-afaca5347340422d82906601e650334a,NTL,0.435418
uuid-afaca5347340422d82906601e650334a,commented,0.372798
uuid-afaca5347340422d82906601e650334a,stated,0.316591
uuid-afaca5347340422d82906601e650334a,approval,0.304648
uuid-afaca5347340422d82906601e650334a,data,0.48945
uuid-afaca5347340422d82906601e650334a,mentioned,0.436741
uuid-afaca5347340422d82906601e650334a,SCCHN,0.36719
uuid-afaca5347340422d82906601e650334a,HCP,0.345387
uuid-afaca5347340422d82906601e650334a,ASCO,0.432344
uuid-afaca5347340422d82906601e650334a,impressed,0.454314
uuid-afaca5347340422d82906601e650334a,LTL,0.418338
uuid-afaca5347340422d82906601e650334a,SCLC,0.419042
uuid-afaca5347340422d82906601e650334a,Regional TL,0.434891
uuid-afaca5347340422d82906601e650334a,RTL stated,0.336685
uuid-42cfa413246244eb8bbb87e63cda2a37,Nivo,0.439959
uuid-42cfa413246244eb8bbb87e63cda2a37,pembro,0.67578
uuid-42cfa413246244eb8bbb87e63cda2a37,1L,0.719522
uuid-42cfa413246244eb8bbb87e63cda2a37,RCC,0.449791
uuid-42cfa413246244eb8bbb87e63cda2a37,chemo,0.361008
uuid-42cfa413246244eb8bbb87e63cda2a37,2L,0.788094
uuid-42cfa413246244eb8bbb87e63cda2a37,pts,0.369706
uuid-42cfa413246244eb8bbb87e63cda2a37,agents,0.450385
uuid-42cfa413246244eb8bbb87e63cda2a37,approval,0.440418
uuid-42cfa413246244eb8bbb87e63cda2a37,atezo,0.673438
uuid-42cfa413246244eb8bbb87e63cda2a37,preferred,0.679074
uuid-42cfa413246244eb8bbb87e63cda2a37,monotherapy,0.589984
uuid-42cfa413246244eb8bbb87e63cda2a37,using nivo,0.599155
uuid-42cfa413246244eb8bbb87e63cda2a37,combo,0.418801
uuid-42cfa413246244eb8bbb87e63cda2a37,clinical trials,0.322977
uuid-42cfa413246244eb8bbb87e63cda2a37,indication,0.36462
uuid-42cfa413246244eb8bbb87e63cda2a37,NSCLC patients,0.311651
uuid-42cfa413246244eb8bbb87e63cda2a37,approved,0.572449
uuid-42cfa413246244eb8bbb87e63cda2a37,SCCHN,0.35435
uuid-42cfa413246244eb8bbb87e63cda2a37,nivo and pembro,0.360481
uuid-42cfa413246244eb8bbb87e63cda2a37,believes,0.340069
uuid-42cfa413246244eb8bbb87e63cda2a37,tumor types,0.346329
uuid-42cfa413246244eb8bbb87e63cda2a37,TLs,0.354606
uuid-42cfa413246244eb8bbb87e63cda2a37,feels,0.392842
uuid-42cfa413246244eb8bbb87e63cda2a37,RTL stated,0.492143
uuid-42cfa413246244eb8bbb87e63cda2a37,option,0.567188
uuid-42cfa413246244eb8bbb87e63cda2a37,bladder,0.403892
uuid-8f3dc7aadca042eab1c648202fe4e959,TL,0.350606
uuid-8f3dc7aadca042eab1c648202fe4e959,1L,0.383221
uuid-8f3dc7aadca042eab1c648202fe4e959,PDL1,0.474028
uuid-8f3dc7aadca042eab1c648202fe4e959,TL stated,0.422625
uuid-8f3dc7aadca042eab1c648202fe4e959,PD-L1,0.801756
uuid-8f3dc7aadca042eab1c648202fe4e959,PD-L1 testing,0.720943
uuid-8f3dc7aadca042eab1c648202fe4e959,testing,0.869208
uuid-8f3dc7aadca042eab1c648202fe4e959,PDL1 testing,0.747326
uuid-8f3dc7aadca042eab1c648202fe4e959,NSCLC patients,0.732988
uuid-8f3dc7aadca042eab1c648202fe4e959,tumor types,0.37233
uuid-8f3dc7aadca042eab1c648202fe4e959,assay,0.527074
uuid-8f3dc7aadca042eab1c648202fe4e959,PDL1 expression,0.375676
uuid-8f3dc7aadca042eab1c648202fe4e959,biomarker,0.549684
uuid-360e4d392d9f4c06be84113e725c24e9,Nivo,0.46544
uuid-360e4d392d9f4c06be84113e725c24e9,pembro,0.459502
uuid-360e4d392d9f4c06be84113e725c24e9,1L,0.604039
uuid-360e4d392d9f4c06be84113e725c24e9,regimen,0.349583
uuid-360e4d392d9f4c06be84113e725c24e9,RCC,0.339284
uuid-360e4d392d9f4c06be84113e725c24e9,combination,0.54741
uuid-360e4d392d9f4c06be84113e725c24e9,chemo,0.460943
uuid-360e4d392d9f4c06be84113e725c24e9,2L,0.602271
uuid-360e4d392d9f4c06be84113e725c24e9,pts,0.379792
uuid-360e4d392d9f4c06be84113e725c24e9,agents,0.462336
uuid-360e4d392d9f4c06be84113e725c24e9,Ipi,0.31501
uuid-360e4d392d9f4c06be84113e725c24e9,atezo,0.401247
uuid-360e4d392d9f4c06be84113e725c24e9,preferred,0.437831
uuid-360e4d392d9f4c06be84113e725c24e9,monotherapy,0.631675
uuid-360e4d392d9f4c06be84113e725c24e9,using nivo,0.427824
uuid-360e4d392d9f4c06be84113e725c24e9,combo,0.666014
uuid-360e4d392d9f4c06be84113e725c24e9,PD1,0.435461
uuid-360e4d392d9f4c06be84113e725c24e9,approved,0.431107
uuid-360e4d392d9f4c06be84113e725c24e9,nivo and pembro,0.302308
uuid-360e4d392d9f4c06be84113e725c24e9,believes,0.433279
uuid-360e4d392d9f4c06be84113e725c24e9,chemotherapy,0.366418
uuid-360e4d392d9f4c06be84113e725c24e9,feels,0.583201
uuid-360e4d392d9f4c06be84113e725c24e9,RTL stated,0.353072
uuid-360e4d392d9f4c06be84113e725c24e9,option,0.577781
uuid-3a957a83cd1c4e279988a125c64c5d71,TL,0.541015
uuid-3a957a83cd1c4e279988a125c64c5d71,PDL1,0.572261
uuid-3a957a83cd1c4e279988a125c64c5d71,TL stated,0.340224
uuid-3a957a83cd1c4e279988a125c64c5d71,Merck,0.461659
uuid-3a957a83cd1c4e279988a125c64c5d71,institution,0.338249
uuid-3a957a83cd1c4e279988a125c64c5d71,PD-L1,0.837011
uuid-3a957a83cd1c4e279988a125c64c5d71,PD-L1 testing,0.815582
uuid-3a957a83cd1c4e279988a125c64c5d71,testing,0.890783
uuid-3a957a83cd1c4e279988a125c64c5d71,PDL1 testing,0.671097
uuid-3a957a83cd1c4e279988a125c64c5d71,NSCLC patients,0.57096
uuid-3a957a83cd1c4e279988a125c64c5d71,assay,0.807166
uuid-3a957a83cd1c4e279988a125c64c5d71,PDL1 expression,0.365143
uuid-3a957a83cd1c4e279988a125c64c5d71,biomarker,0.499659
uuid-ffeb9abc575343899d9baffad194fe03,TL,0.60695
uuid-ffeb9abc575343899d9baffad194fe03,TL stated,0.378727
uuid-ffeb9abc575343899d9baffad194fe03,PD-L1,0.566209
uuid-ffeb9abc575343899d9baffad194fe03,PD-L1 testing,0.797823
uuid-ffeb9abc575343899d9baffad194fe03,testing,0.746846
uuid-ffeb9abc575343899d9baffad194fe03,PDL1 testing,0.579408
uuid-ffeb9abc575343899d9baffad194fe03,NSCLC patients,0.539863
uuid-ffeb9abc575343899d9baffad194fe03,assay,0.529183
uuid-502e33c5721b49b2b597855bd9c0bcbd,data,0.303009
uuid-502e33c5721b49b2b597855bd9c0bcbd,Keytruda,0.39057
uuid-5fc29c2d6dfb4529abf9e00667c45088,pembro,0.412177
uuid-5fc29c2d6dfb4529abf9e00667c45088,1L,0.305643
uuid-5fc29c2d6dfb4529abf9e00667c45088,2L,0.330284
uuid-5fc29c2d6dfb4529abf9e00667c45088,atezo,0.343735
uuid-5fc29c2d6dfb4529abf9e00667c45088,preferred,0.487438
uuid-5fc29c2d6dfb4529abf9e00667c45088,using nivo,0.463723
uuid-5fc29c2d6dfb4529abf9e00667c45088,mentioned,0.394366
uuid-5fc29c2d6dfb4529abf9e00667c45088,indication,0.301818
uuid-5fc29c2d6dfb4529abf9e00667c45088,NSCLC patients,0.371752
uuid-5fc29c2d6dfb4529abf9e00667c45088,SCCHN,0.312432
uuid-5fc29c2d6dfb4529abf9e00667c45088,HCP,0.486323
uuid-5fc29c2d6dfb4529abf9e00667c45088,LTL,0.320564
uuid-5fc29c2d6dfb4529abf9e00667c45088,RTL stated,0.374325
uuid-5fc29c2d6dfb4529abf9e00667c45088,option,0.351981
uuid-13c760481e894081ab4d768ef024f436,Nivo,0.536806
uuid-13c760481e894081ab4d768ef024f436,nivolumab,0.323266
uuid-13c760481e894081ab4d768ef024f436,toxicity,0.357431
uuid-13c760481e894081ab4d768ef024f436,efficacy,0.366775
uuid-13c760481e894081ab4d768ef024f436,regimen,0.497293
uuid-13c760481e894081ab4d768ef024f436,combination,0.661727
uuid-13c760481e894081ab4d768ef024f436,chemo,0.461231
uuid-13c760481e894081ab4d768ef024f436,pts,0.34383
uuid-13c760481e894081ab4d768ef024f436,Ipi,0.575131
uuid-13c760481e894081ab4d768ef024f436,monotherapy,0.577486
uuid-13c760481e894081ab4d768ef024f436,using nivo,0.306442
uuid-13c760481e894081ab4d768ef024f436,response,0.325168
uuid-13c760481e894081ab4d768ef024f436,combo,0.567575
uuid-13c760481e894081ab4d768ef024f436,PD1,0.399755
uuid-13c760481e894081ab4d768ef024f436,chemotherapy,0.440569
uuid-13c760481e894081ab4d768ef024f436,SCLC,0.342746
uuid-13c760481e894081ab4d768ef024f436,feels,0.42277
uuid-13c760481e894081ab4d768ef024f436,option,0.403035
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,Opdivo,0.384056
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,shared,0.430401
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,institution,0.574721
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,approval,0.535341
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,preferred,0.322384
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,using nivo,0.471269
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,expressed,0.312479
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,mentioned,0.542066
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,PDL1 testing,0.300413
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,indication,0.409261
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,approved,0.397601
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,SCCHN,0.417389
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,HCP,0.545785
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,label,0.414666
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,LTL,0.406612
uuid-fd3d7d588bb24ac8a0b69eb4e60f3f4d,RTL stated,0.336181
uuid-4883cf986872485fbbfaed4dd4d3812f,Nivo,0.309608
uuid-4883cf986872485fbbfaed4dd4d3812f,pembro,0.378687
uuid-4883cf986872485fbbfaed4dd4d3812f,1L,0.604772
uuid-4883cf986872485fbbfaed4dd4d3812f,combination,0.389312
uuid-4883cf986872485fbbfaed4dd4d3812f,chemo,0.317616
uuid-4883cf986872485fbbfaed4dd4d3812f,2L,0.630637
uuid-4883cf986872485fbbfaed4dd4d3812f,agents,0.60058
uuid-4883cf986872485fbbfaed4dd4d3812f,atezo,0.401564
uuid-4883cf986872485fbbfaed4dd4d3812f,preferred,0.663409
uuid-4883cf986872485fbbfaed4dd4d3812f,monotherapy,0.593472
uuid-4883cf986872485fbbfaed4dd4d3812f,using nivo,0.445408
uuid-4883cf986872485fbbfaed4dd4d3812f,combo,0.398196
uuid-4883cf986872485fbbfaed4dd4d3812f,indication,0.348372
uuid-4883cf986872485fbbfaed4dd4d3812f,PD1,0.341438
uuid-4883cf986872485fbbfaed4dd4d3812f,approved,0.456282
uuid-4883cf986872485fbbfaed4dd4d3812f,believes,0.360819
uuid-4883cf986872485fbbfaed4dd4d3812f,chemotherapy,0.306191
uuid-4883cf986872485fbbfaed4dd4d3812f,feels,0.487087
uuid-4883cf986872485fbbfaed4dd4d3812f,RTL stated,0.397815
uuid-4883cf986872485fbbfaed4dd4d3812f,option,0.70991
uuid-636ef3845fb44f09a1a3fd64f402b736,therapy,0.33939
uuid-636ef3845fb44f09a1a3fd64f402b736,PDL1,0.337453
uuid-636ef3845fb44f09a1a3fd64f402b736,chemo,0.339451
uuid-636ef3845fb44f09a1a3fd64f402b736,PD-L1,0.449909
uuid-636ef3845fb44f09a1a3fd64f402b736,testing,0.305087
uuid-636ef3845fb44f09a1a3fd64f402b736,monotherapy,0.393068
uuid-636ef3845fb44f09a1a3fd64f402b736,chemotherapy,0.397067
uuid-636ef3845fb44f09a1a3fd64f402b736,Keytruda,0.31506
uuid-636ef3845fb44f09a1a3fd64f402b736,option,0.388016
uuid-baf20a1d27564c24bc9df07418098e8e,pembro,0.320925
uuid-baf20a1d27564c24bc9df07418098e8e,dose,0.469915
uuid-baf20a1d27564c24bc9df07418098e8e,toxicity,0.365969
uuid-baf20a1d27564c24bc9df07418098e8e,efficacy,0.426828
uuid-baf20a1d27564c24bc9df07418098e8e,agents,0.34869
uuid-baf20a1d27564c24bc9df07418098e8e,atezo,0.414932
uuid-baf20a1d27564c24bc9df07418098e8e,preferred,0.406948
uuid-baf20a1d27564c24bc9df07418098e8e,monotherapy,0.307216
uuid-baf20a1d27564c24bc9df07418098e8e,indication,0.306166
uuid-baf20a1d27564c24bc9df07418098e8e,vs,0.379774
uuid-baf20a1d27564c24bc9df07418098e8e,drug,0.379265
uuid-baf20a1d27564c24bc9df07418098e8e,Keytruda,0.475373
uuid-baf20a1d27564c24bc9df07418098e8e,flat dosing,0.399491
uuid-94af07f6a2d14888bfe46969016c9aaa,Nivo,0.338616
uuid-94af07f6a2d14888bfe46969016c9aaa,pembro,0.584825
uuid-94af07f6a2d14888bfe46969016c9aaa,BMS,0.435121
uuid-94af07f6a2d14888bfe46969016c9aaa,1L,0.513532
uuid-94af07f6a2d14888bfe46969016c9aaa,2L,0.603278
uuid-94af07f6a2d14888bfe46969016c9aaa,agents,0.39432
uuid-94af07f6a2d14888bfe46969016c9aaa,Merck,0.338104
uuid-94af07f6a2d14888bfe46969016c9aaa,approval,0.300909
uuid-94af07f6a2d14888bfe46969016c9aaa,atezo,0.631704
uuid-94af07f6a2d14888bfe46969016c9aaa,preferred,0.474599
uuid-94af07f6a2d14888bfe46969016c9aaa,monotherapy,0.315201
uuid-94af07f6a2d14888bfe46969016c9aaa,using nivo,0.371357
uuid-94af07f6a2d14888bfe46969016c9aaa,combo,0.443777
uuid-94af07f6a2d14888bfe46969016c9aaa,clinical trials,0.301591
uuid-94af07f6a2d14888bfe46969016c9aaa,indication,0.366015
uuid-94af07f6a2d14888bfe46969016c9aaa,approved,0.50597
uuid-94af07f6a2d14888bfe46969016c9aaa,nivo and pembro,0.345639
uuid-94af07f6a2d14888bfe46969016c9aaa,vs,0.314636
uuid-94af07f6a2d14888bfe46969016c9aaa,feels,0.438561
uuid-94af07f6a2d14888bfe46969016c9aaa,option,0.37252
uuid-eee091354ada4d1f9feb602280266771,RTL,0.52603
uuid-eee091354ada4d1f9feb602280266771,trial,0.552948
uuid-eee091354ada4d1f9feb602280266771,NTL,0.393961
uuid-eee091354ada4d1f9feb602280266771,shared,0.325729
uuid-eee091354ada4d1f9feb602280266771,commented,0.414662
uuid-eee091354ada4d1f9feb602280266771,tumor,0.319248
uuid-eee091354ada4d1f9feb602280266771,stated,0.396561
uuid-eee091354ada4d1f9feb602280266771,approval,0.397015
uuid-eee091354ada4d1f9feb602280266771,expressed,0.329873
uuid-eee091354ada4d1f9feb602280266771,clinical trials,0.418895
uuid-eee091354ada4d1f9feb602280266771,SCCHN,0.403104
uuid-eee091354ada4d1f9feb602280266771,ASCO,0.303115
uuid-eee091354ada4d1f9feb602280266771,impressed,0.369022
uuid-eee091354ada4d1f9feb602280266771,Regional TL,0.42148
uuid-eee091354ada4d1f9feb602280266771,bladder,0.397737
uuid-b18cee1895f04006b529c52d9ada8a4c,patients,0.78286
uuid-b18cee1895f04006b529c52d9ada8a4c,Opdivo,0.302808
uuid-b18cee1895f04006b529c52d9ada8a4c,therapy,0.503589
uuid-b18cee1895f04006b529c52d9ada8a4c,1L,0.340175
uuid-b18cee1895f04006b529c52d9ada8a4c,regimen,0.313046
uuid-b18cee1895f04006b529c52d9ada8a4c,treated,0.410838
uuid-b18cee1895f04006b529c52d9ada8a4c,chemo,0.366187
uuid-b18cee1895f04006b529c52d9ada8a4c,tumor,0.324453
uuid-b18cee1895f04006b529c52d9ada8a4c,pts,0.573541
uuid-b18cee1895f04006b529c52d9ada8a4c,testing,0.325885
uuid-b18cee1895f04006b529c52d9ada8a4c,monotherapy,0.36028
uuid-b18cee1895f04006b529c52d9ada8a4c,treatment,0.586587
uuid-b18cee1895f04006b529c52d9ada8a4c,response,0.302806
uuid-b18cee1895f04006b529c52d9ada8a4c,NSCLC patients,0.463083
uuid-b18cee1895f04006b529c52d9ada8a4c,progression,0.567711
uuid-b18cee1895f04006b529c52d9ada8a4c,chemotherapy,0.346302
uuid-b18cee1895f04006b529c52d9ada8a4c,respond,0.396537
uuid-b18cee1895f04006b529c52d9ada8a4c,option,0.471335
uuid-53c94d69f9be4609b06c82074eb3c906,TL,0.475702
uuid-53c94d69f9be4609b06c82074eb3c906,BMS,0.34606
uuid-53c94d69f9be4609b06c82074eb3c906,NSCLC,0.43309
uuid-53c94d69f9be4609b06c82074eb3c906,trial,0.382871
uuid-53c94d69f9be4609b06c82074eb3c906,IO,0.317139
uuid-53c94d69f9be4609b06c82074eb3c906,Merck,0.401864
uuid-53c94d69f9be4609b06c82074eb3c906,TLs,0.314599
uuid-fd5c3d98b043484d99e02e308a97cd4e,pembro,0.361827
uuid-fd5c3d98b043484d99e02e308a97cd4e,1L,0.428544
uuid-fd5c3d98b043484d99e02e308a97cd4e,2L,0.46597
uuid-fd5c3d98b043484d99e02e308a97cd4e,agents,0.316072
uuid-fd5c3d98b043484d99e02e308a97cd4e,PD-L1,0.338144
uuid-fd5c3d98b043484d99e02e308a97cd4e,approval,0.37468
uuid-fd5c3d98b043484d99e02e308a97cd4e,atezo,0.419201
uuid-fd5c3d98b043484d99e02e308a97cd4e,preferred,0.620631
uuid-fd5c3d98b043484d99e02e308a97cd4e,PD-L1 testing,0.411783
uuid-fd5c3d98b043484d99e02e308a97cd4e,testing,0.378769
uuid-fd5c3d98b043484d99e02e308a97cd4e,monotherapy,0.316512
uuid-fd5c3d98b043484d99e02e308a97cd4e,using nivo,0.382333
uuid-fd5c3d98b043484d99e02e308a97cd4e,clinical trials,0.321711
uuid-fd5c3d98b043484d99e02e308a97cd4e,PDL1 testing,0.425637
uuid-fd5c3d98b043484d99e02e308a97cd4e,indication,0.388781
uuid-fd5c3d98b043484d99e02e308a97cd4e,NSCLC patients,0.33609
uuid-fd5c3d98b043484d99e02e308a97cd4e,approved,0.432927
uuid-fd5c3d98b043484d99e02e308a97cd4e,SCCHN,0.42107
uuid-fd5c3d98b043484d99e02e308a97cd4e,RTL stated,0.464184
uuid-fd5c3d98b043484d99e02e308a97cd4e,option,0.438858
uuid-fd5c3d98b043484d99e02e308a97cd4e,bladder,0.35226
uuid-002a4eb7d2be4d9b807eb86d600e5e01,dose,0.346526
uuid-002a4eb7d2be4d9b807eb86d600e5e01,nivolumab,0.388729
uuid-002a4eb7d2be4d9b807eb86d600e5e01,toxicity,0.579737
uuid-002a4eb7d2be4d9b807eb86d600e5e01,regimen,0.492258
uuid-002a4eb7d2be4d9b807eb86d600e5e01,combination,0.78292
uuid-002a4eb7d2be4d9b807eb86d600e5e01,chemo,0.393954
uuid-002a4eb7d2be4d9b807eb86d600e5e01,2L,0.319033
uuid-002a4eb7d2be4d9b807eb86d600e5e01,IO,0.385575
uuid-002a4eb7d2be4d9b807eb86d600e5e01,agents,0.433925
uuid-002a4eb7d2be4d9b807eb86d600e5e01,Ipi,0.538872
uuid-002a4eb7d2be4d9b807eb86d600e5e01,preferred,0.419665
uuid-002a4eb7d2be4d9b807eb86d600e5e01,monotherapy,0.596153
uuid-002a4eb7d2be4d9b807eb86d600e5e01,combo,0.653047
uuid-002a4eb7d2be4d9b807eb86d600e5e01,PD1,0.433759
uuid-002a4eb7d2be4d9b807eb86d600e5e01,believes,0.309385
uuid-002a4eb7d2be4d9b807eb86d600e5e01,chemotherapy,0.390693
uuid-002a4eb7d2be4d9b807eb86d600e5e01,SCLC,0.326915
uuid-002a4eb7d2be4d9b807eb86d600e5e01,option,0.447283
uuid-991a9ca1e764438291b1a90e23d907e5,patients,0.738069
uuid-991a9ca1e764438291b1a90e23d907e5,Opdivo,0.316322
uuid-991a9ca1e764438291b1a90e23d907e5,therapy,0.416359
uuid-991a9ca1e764438291b1a90e23d907e5,nivolumab,0.323574
uuid-991a9ca1e764438291b1a90e23d907e5,regimen,0.381916
uuid-991a9ca1e764438291b1a90e23d907e5,treated,0.49931
uuid-991a9ca1e764438291b1a90e23d907e5,pts,0.420634
uuid-991a9ca1e764438291b1a90e23d907e5,treatment,0.559513
uuid-991a9ca1e764438291b1a90e23d907e5,progression,0.43221
uuid-991a9ca1e764438291b1a90e23d907e5,respond,0.41242
uuid-795bfc4434094f30a14046573fa20e1c,pembro,0.423228
uuid-795bfc4434094f30a14046573fa20e1c,1L,0.327926
uuid-795bfc4434094f30a14046573fa20e1c,PDL1,0.655234
uuid-795bfc4434094f30a14046573fa20e1c,trial,0.356768
uuid-795bfc4434094f30a14046573fa20e1c,efficacy,0.443731
uuid-795bfc4434094f30a14046573fa20e1c,Merck,0.36392
uuid-795bfc4434094f30a14046573fa20e1c,PD-L1,0.504991
uuid-795bfc4434094f30a14046573fa20e1c,OS,0.516746
uuid-795bfc4434094f30a14046573fa20e1c,atezo,0.384792
uuid-795bfc4434094f30a14046573fa20e1c,testing,0.384252
uuid-795bfc4434094f30a14046573fa20e1c,data,0.686855
uuid-795bfc4434094f30a14046573fa20e1c,PFS,0.457382
uuid-795bfc4434094f30a14046573fa20e1c,NSCLC patients,0.325657
uuid-795bfc4434094f30a14046573fa20e1c,ORR,0.520745
uuid-795bfc4434094f30a14046573fa20e1c,nivo and pembro,0.482056
uuid-795bfc4434094f30a14046573fa20e1c,impressed,0.45106
uuid-795bfc4434094f30a14046573fa20e1c,assay,0.387115
uuid-795bfc4434094f30a14046573fa20e1c,PDL1 expression,0.520146
uuid-795bfc4434094f30a14046573fa20e1c,biomarker,0.431241
uuid-a299fd88bafb448ab1441091853e3fe5,oncologist,0.375955
uuid-a299fd88bafb448ab1441091853e3fe5,indicated,0.393563
uuid-a299fd88bafb448ab1441091853e3fe5,SCLC,0.328769
uuid-a299fd88bafb448ab1441091853e3fe5,Regional TL,0.301854
uuid-a299fd88bafb448ab1441091853e3fe5,TL shared,0.329568
uuid-a299fd88bafb448ab1441091853e3fe5,NCCN,0.502269
uuid-2c7bbb5ef54d4292a58176dc6a1ee438,Nivo,0.390166
uuid-2c7bbb5ef54d4292a58176dc6a1ee438,pembro,0.493323
uuid-2c7bbb5ef54d4292a58176dc6a1ee438,trial,0.688912
uuid-2c7bbb5ef54d4292a58176dc6a1ee438,approval,0.350066
uuid-2c7bbb5ef54d4292a58176dc6a1ee438,atezo,0.316037
uuid-2c7bbb5ef54d4292a58176dc6a1ee438,data,0.449791
uuid-2c7bbb5ef54d4292a58176dc6a1ee438,clinical trials,0.404131
uuid-2c7bbb5ef54d4292a58176dc6a1ee438,indication,0.383102
uuid-2c7bbb5ef54d4292a58176dc6a1ee438,chemotherapy,0.334503
uuid-2c7bbb5ef54d4292a58176dc6a1ee438,impressed,0.386578
uuid-2c7bbb5ef54d4292a58176dc6a1ee438,feels,0.349634
uuid-2c7bbb5ef54d4292a58176dc6a1ee438,bladder,0.336691
uuid-93d81987964a4f07b496869e1bb2c5d1,tumor,0.345868
uuid-93d81987964a4f07b496869e1bb2c5d1,physicians,0.338873
uuid-fcc38a5c937849108d2e1908c3424b41,patients,0.658255
uuid-fcc38a5c937849108d2e1908c3424b41,Opdivo,0.38348
uuid-fcc38a5c937849108d2e1908c3424b41,therapy,0.534873
uuid-fcc38a5c937849108d2e1908c3424b41,nivolumab,0.573242
uuid-fcc38a5c937849108d2e1908c3424b41,regimen,0.474027
uuid-fcc38a5c937849108d2e1908c3424b41,treated,0.764861
uuid-fcc38a5c937849108d2e1908c3424b41,pts,0.459047
uuid-fcc38a5c937849108d2e1908c3424b41,treatment,0.581647
uuid-fcc38a5c937849108d2e1908c3424b41,cHL,0.449625
uuid-fcc38a5c937849108d2e1908c3424b41,progression,0.476014
uuid-fcc38a5c937849108d2e1908c3424b41,respond,0.32357
uuid-fcc38a5c937849108d2e1908c3424b41,RTL stated,0.31559
uuid-77f2682c40a04d2d9ae27779e63cc456,Nivo,0.392436
uuid-77f2682c40a04d2d9ae27779e63cc456,patients,0.65424
uuid-77f2682c40a04d2d9ae27779e63cc456,Opdivo,0.391945
uuid-77f2682c40a04d2d9ae27779e63cc456,therapy,0.569987
uuid-77f2682c40a04d2d9ae27779e63cc456,nivolumab,0.445113
uuid-77f2682c40a04d2d9ae27779e63cc456,regimen,0.498633
uuid-77f2682c40a04d2d9ae27779e63cc456,treated,0.5289
uuid-77f2682c40a04d2d9ae27779e63cc456,chemo,0.328174
uuid-77f2682c40a04d2d9ae27779e63cc456,pts,0.60689
uuid-77f2682c40a04d2d9ae27779e63cc456,monotherapy,0.302832
uuid-77f2682c40a04d2d9ae27779e63cc456,treatment,0.659247
uuid-77f2682c40a04d2d9ae27779e63cc456,response,0.54751
uuid-77f2682c40a04d2d9ae27779e63cc456,PD1,0.376564
uuid-77f2682c40a04d2d9ae27779e63cc456,cHL,0.432422
uuid-77f2682c40a04d2d9ae27779e63cc456,progression,0.71953
uuid-77f2682c40a04d2d9ae27779e63cc456,chemotherapy,0.353769
uuid-77f2682c40a04d2d9ae27779e63cc456,respond,0.580128
uuid-da838d366be74b85aeb4adec7d376e17,patients,0.638864
uuid-da838d366be74b85aeb4adec7d376e17,therapy,0.576372
uuid-da838d366be74b85aeb4adec7d376e17,nivolumab,0.378752
uuid-da838d366be74b85aeb4adec7d376e17,regimen,0.564197
uuid-da838d366be74b85aeb4adec7d376e17,treated,0.510359
uuid-da838d366be74b85aeb4adec7d376e17,chemo,0.412601
uuid-da838d366be74b85aeb4adec7d376e17,pts,0.676931
uuid-da838d366be74b85aeb4adec7d376e17,monotherapy,0.348043
uuid-da838d366be74b85aeb4adec7d376e17,treatment,0.678445
uuid-da838d366be74b85aeb4adec7d376e17,response,0.673639
uuid-da838d366be74b85aeb4adec7d376e17,PD1,0.422287
uuid-da838d366be74b85aeb4adec7d376e17,progression,0.799416
uuid-da838d366be74b85aeb4adec7d376e17,chemotherapy,0.44141
uuid-da838d366be74b85aeb4adec7d376e17,respond,0.666209
uuid-7e1800dad71045ad86713de2b994b00e,Nivo,0.30939
uuid-7e1800dad71045ad86713de2b994b00e,patients,0.701186
uuid-7e1800dad71045ad86713de2b994b00e,Opdivo,0.447151
uuid-7e1800dad71045ad86713de2b994b00e,therapy,0.464971
uuid-7e1800dad71045ad86713de2b994b00e,dose,0.572467
uuid-7e1800dad71045ad86713de2b994b00e,nivolumab,0.334449
uuid-7e1800dad71045ad86713de2b994b00e,toxicity,0.539579
uuid-7e1800dad71045ad86713de2b994b00e,regimen,0.663146
uuid-7e1800dad71045ad86713de2b994b00e,treated,0.462971
uuid-7e1800dad71045ad86713de2b994b00e,chemo,0.397102
uuid-7e1800dad71045ad86713de2b994b00e,pts,0.515722
uuid-7e1800dad71045ad86713de2b994b00e,Ipi,0.3389
uuid-7e1800dad71045ad86713de2b994b00e,monotherapy,0.316475
uuid-7e1800dad71045ad86713de2b994b00e,treatment,0.693466
uuid-7e1800dad71045ad86713de2b994b00e,response,0.453685
uuid-7e1800dad71045ad86713de2b994b00e,progression,0.615996
uuid-7e1800dad71045ad86713de2b994b00e,chemotherapy,0.387719
uuid-7e1800dad71045ad86713de2b994b00e,respond,0.594095
uuid-c3e3633f5d1c450ba3d577151cf778b7,patients,0.380307
uuid-c3e3633f5d1c450ba3d577151cf778b7,therapy,0.301965
uuid-c3e3633f5d1c450ba3d577151cf778b7,treated,0.389521
uuid-c3e3633f5d1c450ba3d577151cf778b7,treatment,0.425862
uuid-c3e3633f5d1c450ba3d577151cf778b7,chemotherapy,0.393278
uuid-c3e3633f5d1c450ba3d577151cf778b7,oncologist,0.370836
uuid-4e90ae5962a04824aafa2ec685cd7c3d,TL,0.433876
uuid-4e90ae5962a04824aafa2ec685cd7c3d,PDL1,0.326665
uuid-4e90ae5962a04824aafa2ec685cd7c3d,TL stated,0.476391
uuid-4e90ae5962a04824aafa2ec685cd7c3d,institution,0.417564
uuid-4e90ae5962a04824aafa2ec685cd7c3d,PD-L1,0.675979
uuid-4e90ae5962a04824aafa2ec685cd7c3d,PD-L1 testing,0.721547
uuid-4e90ae5962a04824aafa2ec685cd7c3d,testing,0.767053
uuid-4e90ae5962a04824aafa2ec685cd7c3d,PDL1 testing,0.731855
uuid-4e90ae5962a04824aafa2ec685cd7c3d,NSCLC patients,0.661709
uuid-4e90ae5962a04824aafa2ec685cd7c3d,SCCHN,0.406122
uuid-4e90ae5962a04824aafa2ec685cd7c3d,HCP,0.319502
uuid-4e90ae5962a04824aafa2ec685cd7c3d,tumor types,0.343785
uuid-4e90ae5962a04824aafa2ec685cd7c3d,assay,0.442333
uuid-4e90ae5962a04824aafa2ec685cd7c3d,biomarker,0.402461
uuid-810ec72ba61c46d28a9835744fd538f9,Nivo,0.411359
uuid-810ec72ba61c46d28a9835744fd538f9,pembro,0.333955
uuid-810ec72ba61c46d28a9835744fd538f9,1L,0.336723
uuid-810ec72ba61c46d28a9835744fd538f9,PDL1,0.435574
uuid-810ec72ba61c46d28a9835744fd538f9,trial,0.328098
uuid-810ec72ba61c46d28a9835744fd538f9,chemo,0.487808
uuid-810ec72ba61c46d28a9835744fd538f9,agents,0.334839
uuid-810ec72ba61c46d28a9835744fd538f9,OS,0.304765
uuid-810ec72ba61c46d28a9835744fd538f9,monotherapy,0.330668
uuid-810ec72ba61c46d28a9835744fd538f9,PFS,0.361011
uuid-810ec72ba61c46d28a9835744fd538f9,PD1,0.342238
uuid-810ec72ba61c46d28a9835744fd538f9,ORR,0.308322
uuid-810ec72ba61c46d28a9835744fd538f9,nivo and pembro,0.550505
uuid-810ec72ba61c46d28a9835744fd538f9,believes,0.520871
uuid-810ec72ba61c46d28a9835744fd538f9,chemotherapy,0.415974
uuid-810ec72ba61c46d28a9835744fd538f9,respond,0.309092
uuid-810ec72ba61c46d28a9835744fd538f9,feels,0.448002
uuid-810ec72ba61c46d28a9835744fd538f9,PDL1 expression,0.354507
uuid-810ec72ba61c46d28a9835744fd538f9,option,0.375604
uuid-3749f1fe002644a9bc9a8056c5e2e2df,RTL,0.37863
uuid-3749f1fe002644a9bc9a8056c5e2e2df,lung,0.647295
uuid-3749f1fe002644a9bc9a8056c5e2e2df,NTL,0.386233
uuid-3749f1fe002644a9bc9a8056c5e2e2df,discussed,0.389672
uuid-3749f1fe002644a9bc9a8056c5e2e2df,melanoma,0.496199
uuid-3749f1fe002644a9bc9a8056c5e2e2df,commented,0.542772
uuid-3749f1fe002644a9bc9a8056c5e2e2df,RCC,0.446017
uuid-3749f1fe002644a9bc9a8056c5e2e2df,TL stated,0.426289
uuid-3749f1fe002644a9bc9a8056c5e2e2df,stated,0.445635
uuid-3749f1fe002644a9bc9a8056c5e2e2df,regards,0.310565
uuid-3749f1fe002644a9bc9a8056c5e2e2df,data,0.483761
uuid-3749f1fe002644a9bc9a8056c5e2e2df,expressed,0.370225
uuid-3749f1fe002644a9bc9a8056c5e2e2df,AI,0.375894
uuid-3749f1fe002644a9bc9a8056c5e2e2df,SCCHN,0.438554
uuid-3749f1fe002644a9bc9a8056c5e2e2df,ASCO,0.478448
uuid-3749f1fe002644a9bc9a8056c5e2e2df,impressed,0.458007
uuid-3749f1fe002644a9bc9a8056c5e2e2df,TLs,0.455578
uuid-3749f1fe002644a9bc9a8056c5e2e2df,SCLC,0.313219
uuid-3749f1fe002644a9bc9a8056c5e2e2df,Regional TL,0.441175
uuid-3749f1fe002644a9bc9a8056c5e2e2df,TL shared,0.449214
uuid-3749f1fe002644a9bc9a8056c5e2e2df,NCCN,0.408608
uuid-cc39b96ac8ea486cb73b76bc3d537980,lung,0.383148
uuid-cc39b96ac8ea486cb73b76bc3d537980,NSCLC,0.315611
uuid-cc39b96ac8ea486cb73b76bc3d537980,NTL,0.379881
uuid-cc39b96ac8ea486cb73b76bc3d537980,discussed,0.434901
uuid-cc39b96ac8ea486cb73b76bc3d537980,melanoma,0.323438
uuid-cc39b96ac8ea486cb73b76bc3d537980,commented,0.411936
uuid-cc39b96ac8ea486cb73b76bc3d537980,regards,0.439557
uuid-cc39b96ac8ea486cb73b76bc3d537980,AI,0.382601
uuid-cc39b96ac8ea486cb73b76bc3d537980,lung cancer,0.365994
uuid-cc39b96ac8ea486cb73b76bc3d537980,NCCN,0.687876
uuid-9810dd8c34424761ba6f29b30fbed349,response,0.430403
uuid-9810dd8c34424761ba6f29b30fbed349,lung cancer,0.448173
uuid-1f373444285943e8b19f539222613170,PDL1,0.636384
uuid-1f373444285943e8b19f539222613170,tumor,0.348816
uuid-1f373444285943e8b19f539222613170,PD-L1,0.399552
uuid-1f373444285943e8b19f539222613170,nivo and pembro,0.335637
uuid-1f373444285943e8b19f539222613170,believes,0.394825
uuid-1f373444285943e8b19f539222613170,assay,0.333283
uuid-1f373444285943e8b19f539222613170,PDL1 expression,0.587838
uuid-1f373444285943e8b19f539222613170,biomarker,0.604686
uuid-3c0f15183f8a419ba940cccc6a4e794e,NSCLC,0.574958
uuid-3c0f15183f8a419ba940cccc6a4e794e,melanoma,0.396638
uuid-3c0f15183f8a419ba940cccc6a4e794e,RCC,0.33116
uuid-3c0f15183f8a419ba940cccc6a4e794e,TL stated,0.315023
uuid-3c0f15183f8a419ba940cccc6a4e794e,combination,0.308155
uuid-3c0f15183f8a419ba940cccc6a4e794e,IO,0.618394
uuid-3c0f15183f8a419ba940cccc6a4e794e,response,0.509872
uuid-3c0f15183f8a419ba940cccc6a4e794e,combo,0.31457
uuid-3c0f15183f8a419ba940cccc6a4e794e,progression,0.315023
uuid-3c0f15183f8a419ba940cccc6a4e794e,TLs,0.314886
uuid-3c0f15183f8a419ba940cccc6a4e794e,TL shared,0.382126
uuid-dd815b5ee01145299120f48e7c581aac,Nivo,0.340998
uuid-dd815b5ee01145299120f48e7c581aac,patients,0.495874
uuid-dd815b5ee01145299120f48e7c581aac,Opdivo,0.316519
uuid-dd815b5ee01145299120f48e7c581aac,therapy,0.503817
uuid-dd815b5ee01145299120f48e7c581aac,dose,0.33678
uuid-dd815b5ee01145299120f48e7c581aac,nivolumab,0.396661
uuid-dd815b5ee01145299120f48e7c581aac,toxicity,0.424539
uuid-dd815b5ee01145299120f48e7c581aac,regimen,0.444866
uuid-dd815b5ee01145299120f48e7c581aac,treated,0.338642
uuid-dd815b5ee01145299120f48e7c581aac,treatment,0.591733
uuid-dd815b5ee01145299120f48e7c581aac,cHL,0.300066
uuid-dd815b5ee01145299120f48e7c581aac,progression,0.360224
uuid-dd815b5ee01145299120f48e7c581aac,chemotherapy,0.403491
uuid-dd815b5ee01145299120f48e7c581aac,respond,0.358604
uuid-e5da6b70968241db8650781c0e0bfb0a,patients,0.448404
uuid-e5da6b70968241db8650781c0e0bfb0a,toxicity,0.417564
uuid-e5da6b70968241db8650781c0e0bfb0a,regimen,0.356893
uuid-e5da6b70968241db8650781c0e0bfb0a,treated,0.392734
uuid-e5da6b70968241db8650781c0e0bfb0a,tumor,0.436534
uuid-e5da6b70968241db8650781c0e0bfb0a,pts,0.408306
uuid-e5da6b70968241db8650781c0e0bfb0a,treatment,0.467477
uuid-e5da6b70968241db8650781c0e0bfb0a,response,0.475996
uuid-e5da6b70968241db8650781c0e0bfb0a,progression,0.562378
uuid-e5da6b70968241db8650781c0e0bfb0a,respond,0.476864
uuid-8cbad2ab1d22439ab95a4ef7ef996ce5,TL stated,0.300572
uuid-8cbad2ab1d22439ab95a4ef7ef996ce5,PD-L1,0.351279
uuid-8cbad2ab1d22439ab95a4ef7ef996ce5,testing,0.522699
uuid-8cbad2ab1d22439ab95a4ef7ef996ce5,PDL1 testing,0.530431
uuid-8cbad2ab1d22439ab95a4ef7ef996ce5,NSCLC patients,0.611864
uuid-8cbad2ab1d22439ab95a4ef7ef996ce5,tumor types,0.357788
uuid-8cbad2ab1d22439ab95a4ef7ef996ce5,biomarker,0.336387
uuid-12429c5552724338ba758631cec59f3a,patients,0.631399
uuid-12429c5552724338ba758631cec59f3a,Opdivo,0.710649
uuid-12429c5552724338ba758631cec59f3a,nivolumab,0.37877
uuid-12429c5552724338ba758631cec59f3a,treated,0.405053
uuid-12429c5552724338ba758631cec59f3a,shared,0.304539
uuid-12429c5552724338ba758631cec59f3a,approval,0.432898
uuid-12429c5552724338ba758631cec59f3a,physicians,0.382901
uuid-12429c5552724338ba758631cec59f3a,preferred,0.36938
uuid-12429c5552724338ba758631cec59f3a,treatment,0.446874
uuid-12429c5552724338ba758631cec59f3a,using nivo,0.394651
uuid-12429c5552724338ba758631cec59f3a,approved,0.423257
uuid-12429c5552724338ba758631cec59f3a,HCP,0.319511
uuid-12429c5552724338ba758631cec59f3a,label,0.344344
uuid-12429c5552724338ba758631cec59f3a,option,0.306542
uuid-12429c5552724338ba758631cec59f3a,flat dosing,0.317963
uuid-b6d355bce85e483ab28a81cc71fd573c,TL,0.420818
uuid-b6d355bce85e483ab28a81cc71fd573c,treated,0.326947
uuid-b6d355bce85e483ab28a81cc71fd573c,TL stated,0.513404
uuid-b6d355bce85e483ab28a81cc71fd573c,PD-L1,0.437705
uuid-b6d355bce85e483ab28a81cc71fd573c,PD-L1 testing,0.682949
uuid-b6d355bce85e483ab28a81cc71fd573c,testing,0.602607
uuid-b6d355bce85e483ab28a81cc71fd573c,PDL1 testing,0.582669
uuid-b6d355bce85e483ab28a81cc71fd573c,NSCLC patients,0.58332
uuid-b6d355bce85e483ab28a81cc71fd573c,lung cancer,0.578248
uuid-b6d355bce85e483ab28a81cc71fd573c,TL shared,0.368665
uuid-2437f6e0f1ed43f8b2c034a96b6c6def,commented,0.356885
uuid-2437f6e0f1ed43f8b2c034a96b6c6def,physicians,0.672338
uuid-2437f6e0f1ed43f8b2c034a96b6c6def,regards,0.353778
uuid-2437f6e0f1ed43f8b2c034a96b6c6def,oncology,0.604359
uuid-2437f6e0f1ed43f8b2c034a96b6c6def,ASCO,0.300631
uuid-2437f6e0f1ed43f8b2c034a96b6c6def,clinical,0.409101
uuid-e432f743b69f41898d94f8c950989094,pembro,0.371199
uuid-e432f743b69f41898d94f8c950989094,1L,0.646766
uuid-e432f743b69f41898d94f8c950989094,PDL1,0.52759
uuid-e432f743b69f41898d94f8c950989094,efficacy,0.356723
uuid-e432f743b69f41898d94f8c950989094,regimen,0.326442
uuid-e432f743b69f41898d94f8c950989094,combination,0.367003
uuid-e432f743b69f41898d94f8c950989094,chemo,0.593879
uuid-e432f743b69f41898d94f8c950989094,2L,0.569596
uuid-e432f743b69f41898d94f8c950989094,pts,0.372641
uuid-e432f743b69f41898d94f8c950989094,IO,0.334098
uuid-e432f743b69f41898d94f8c950989094,agents,0.609272
uuid-e432f743b69f41898d94f8c950989094,PD-L1,0.318083
uuid-e432f743b69f41898d94f8c950989094,atezo,0.398187
uuid-e432f743b69f41898d94f8c950989094,preferred,0.500363
uuid-e432f743b69f41898d94f8c950989094,monotherapy,0.675753
uuid-e432f743b69f41898d94f8c950989094,combo,0.448781
uuid-e432f743b69f41898d94f8c950989094,PD1,0.562375
uuid-e432f743b69f41898d94f8c950989094,nivo and pembro,0.460983
uuid-e432f743b69f41898d94f8c950989094,believes,0.549579
uuid-e432f743b69f41898d94f8c950989094,chemotherapy,0.421776
uuid-e432f743b69f41898d94f8c950989094,feels,0.46248
uuid-e432f743b69f41898d94f8c950989094,PD-1,0.399728
uuid-e432f743b69f41898d94f8c950989094,PDL1 expression,0.449762
uuid-e432f743b69f41898d94f8c950989094,option,0.621966
uuid-e432f743b69f41898d94f8c950989094,biomarker,0.337443
uuid-81b1521121f845049b1fd91150f92676,pembro,0.425125
uuid-81b1521121f845049b1fd91150f92676,1L,0.478748
uuid-81b1521121f845049b1fd91150f92676,2L,0.507291
uuid-81b1521121f845049b1fd91150f92676,agents,0.348767
uuid-81b1521121f845049b1fd91150f92676,approval,0.338504
uuid-81b1521121f845049b1fd91150f92676,atezo,0.402043
uuid-81b1521121f845049b1fd91150f92676,preferred,0.5181
uuid-81b1521121f845049b1fd91150f92676,monotherapy,0.375539
uuid-81b1521121f845049b1fd91150f92676,using nivo,0.365376
uuid-81b1521121f845049b1fd91150f92676,NSCLC patients,0.333985
uuid-81b1521121f845049b1fd91150f92676,approved,0.433378
uuid-81b1521121f845049b1fd91150f92676,feels,0.475374
uuid-81b1521121f845049b1fd91150f92676,option,0.489899
uuid-ef68e6fcac1b401087d31882b8effc91,therapy,0.320774
uuid-ef68e6fcac1b401087d31882b8effc91,regimen,0.31403
uuid-ef68e6fcac1b401087d31882b8effc91,chemo,0.351177
uuid-ef68e6fcac1b401087d31882b8effc91,pts,0.326544
uuid-ef68e6fcac1b401087d31882b8effc91,OS,0.373591
uuid-ef68e6fcac1b401087d31882b8effc91,response,0.500939
uuid-ef68e6fcac1b401087d31882b8effc91,data,0.363097
uuid-ef68e6fcac1b401087d31882b8effc91,PFS,0.31436
uuid-ef68e6fcac1b401087d31882b8effc91,PD1,0.361751
uuid-ef68e6fcac1b401087d31882b8effc91,ORR,0.368701
uuid-ef68e6fcac1b401087d31882b8effc91,progression,0.493521
uuid-ef68e6fcac1b401087d31882b8effc91,chemotherapy,0.324165
uuid-ef68e6fcac1b401087d31882b8effc91,impressed,0.400374
uuid-ef68e6fcac1b401087d31882b8effc91,respond,0.385248
uuid-ef68e6fcac1b401087d31882b8effc91,SCLC,0.397345
uuid-b18f22ed64db4526971f8f9bf9965bda,Nivo,0.332133
uuid-b18f22ed64db4526971f8f9bf9965bda,therapy,0.375566
uuid-b18f22ed64db4526971f8f9bf9965bda,nivolumab,0.495231
uuid-b18f22ed64db4526971f8f9bf9965bda,trial,0.454777
uuid-b18f22ed64db4526971f8f9bf9965bda,regimen,0.301782
uuid-b18f22ed64db4526971f8f9bf9965bda,combination,0.684097
uuid-b18f22ed64db4526971f8f9bf9965bda,chemo,0.457248
uuid-b18f22ed64db4526971f8f9bf9965bda,pts,0.331076
uuid-b18f22ed64db4526971f8f9bf9965bda,agents,0.360075
uuid-b18f22ed64db4526971f8f9bf9965bda,monotherapy,0.52912
uuid-b18f22ed64db4526971f8f9bf9965bda,combo,0.568086
uuid-b18f22ed64db4526971f8f9bf9965bda,clinical trials,0.372949
uuid-b18f22ed64db4526971f8f9bf9965bda,PD1,0.63472
uuid-b18f22ed64db4526971f8f9bf9965bda,chemotherapy,0.520471
uuid-b18f22ed64db4526971f8f9bf9965bda,impressed,0.308205
uuid-b18f22ed64db4526971f8f9bf9965bda,feels,0.467152
uuid-b18f22ed64db4526971f8f9bf9965bda,option,0.425965
uuid-f706a1b0436c4343930ead154112d3fb,pembro,0.65665
uuid-f706a1b0436c4343930ead154112d3fb,BMS,0.333325
uuid-f706a1b0436c4343930ead154112d3fb,1L,0.612466
uuid-f706a1b0436c4343930ead154112d3fb,PDL1,0.632256
uuid-f706a1b0436c4343930ead154112d3fb,efficacy,0.321655
uuid-f706a1b0436c4343930ead154112d3fb,2L,0.558192
uuid-f706a1b0436c4343930ead154112d3fb,agents,0.320402
uuid-f706a1b0436c4343930ead154112d3fb,Merck,0.406574
uuid-f706a1b0436c4343930ead154112d3fb,PD-L1,0.492055
uuid-f706a1b0436c4343930ead154112d3fb,approval,0.39676
uuid-f706a1b0436c4343930ead154112d3fb,atezo,0.700016
uuid-f706a1b0436c4343930ead154112d3fb,preferred,0.366166
uuid-f706a1b0436c4343930ead154112d3fb,testing,0.464379
uuid-f706a1b0436c4343930ead154112d3fb,data,0.400476
uuid-f706a1b0436c4343930ead154112d3fb,PDL1 testing,0.495421
uuid-f706a1b0436c4343930ead154112d3fb,indication,0.374838
uuid-f706a1b0436c4343930ead154112d3fb,NSCLC patients,0.382055
uuid-f706a1b0436c4343930ead154112d3fb,approved,0.463948
uuid-f706a1b0436c4343930ead154112d3fb,nivo and pembro,0.574176
uuid-f706a1b0436c4343930ead154112d3fb,believes,0.353391
uuid-f706a1b0436c4343930ead154112d3fb,tumor types,0.309762
uuid-f706a1b0436c4343930ead154112d3fb,TLs,0.301073
uuid-f706a1b0436c4343930ead154112d3fb,feels,0.308621
uuid-f706a1b0436c4343930ead154112d3fb,assay,0.381598
uuid-f706a1b0436c4343930ead154112d3fb,PDL1 expression,0.530957
uuid-f706a1b0436c4343930ead154112d3fb,option,0.300273
uuid-f706a1b0436c4343930ead154112d3fb,biomarker,0.390917
uuid-35dfa82e206a41f4bd3ae269f297531b,BMS,0.31823
uuid-35dfa82e206a41f4bd3ae269f297531b,toxicity,0.341271
uuid-35dfa82e206a41f4bd3ae269f297531b,regimen,0.303883
uuid-35dfa82e206a41f4bd3ae269f297531b,physicians,0.586514
uuid-0897123d2f8044b08846c0cc465a2014,Nivo,0.34422
uuid-f969711561934f15bb69bea66ffe25f2,Nivo,0.405695
uuid-f969711561934f15bb69bea66ffe25f2,pembro,0.608799
uuid-f969711561934f15bb69bea66ffe25f2,dose,0.601488
uuid-f969711561934f15bb69bea66ffe25f2,efficacy,0.47042
uuid-f969711561934f15bb69bea66ffe25f2,Ipi,0.498332
uuid-f969711561934f15bb69bea66ffe25f2,atezo,0.670275
uuid-f969711561934f15bb69bea66ffe25f2,nivo and pembro,0.36701
uuid-f969711561934f15bb69bea66ffe25f2,vs,0.752611
uuid-f969711561934f15bb69bea66ffe25f2,TLs,0.339351
uuid-f969711561934f15bb69bea66ffe25f2,flat dosing,0.496046
uuid-3c29955a831d476abe0eb7770f828295,Nivo,0.34422
uuid-24d13e4d1cda48f28c21d740688e3865,chemo,0.433031
uuid-24d13e4d1cda48f28c21d740688e3865,tumor,0.551241
uuid-24d13e4d1cda48f28c21d740688e3865,pts,0.316399
uuid-24d13e4d1cda48f28c21d740688e3865,response,0.345168
uuid-24d13e4d1cda48f28c21d740688e3865,progression,0.301433
uuid-24d13e4d1cda48f28c21d740688e3865,chemotherapy,0.311848
uuid-24d13e4d1cda48f28c21d740688e3865,immunotherapy,0.367662
uuid-24d13e4d1cda48f28c21d740688e3865,biomarker,0.315971
uuid-d01a4bfb8fd94d6aa27bc8779a2d1fe8,trial,0.320009
uuid-d01a4bfb8fd94d6aa27bc8779a2d1fe8,regards,0.375451
uuid-b827c2f671b044c2a8685e7c293de3cd,patients,0.320199
uuid-b827c2f671b044c2a8685e7c293de3cd,progression,0.342391
uuid-56c18241bd024140aff8c74f4f4d68b1,RTL,0.549726
uuid-56c18241bd024140aff8c74f4f4d68b1,nivolumab,0.305427
uuid-56c18241bd024140aff8c74f4f4d68b1,trial,0.412251
uuid-56c18241bd024140aff8c74f4f4d68b1,NTL,0.384967
uuid-56c18241bd024140aff8c74f4f4d68b1,commented,0.509812
uuid-56c18241bd024140aff8c74f4f4d68b1,stated,0.344293
uuid-56c18241bd024140aff8c74f4f4d68b1,data,0.429492
uuid-56c18241bd024140aff8c74f4f4d68b1,clinical trials,0.303296
uuid-56c18241bd024140aff8c74f4f4d68b1,SCCHN,0.338227
uuid-56c18241bd024140aff8c74f4f4d68b1,HCP,0.321778
uuid-56c18241bd024140aff8c74f4f4d68b1,ASCO,0.591969
uuid-56c18241bd024140aff8c74f4f4d68b1,impressed,0.63668
uuid-56c18241bd024140aff8c74f4f4d68b1,LTL,0.383908
uuid-56c18241bd024140aff8c74f4f4d68b1,SCLC,0.390137
uuid-56c18241bd024140aff8c74f4f4d68b1,Regional TL,0.457136
uuid-56c18241bd024140aff8c74f4f4d68b1,RTL stated,0.30097
uuid-56c18241bd024140aff8c74f4f4d68b1,bladder,0.304733
uuid-0bc8e4492d3643c3a24a7fad5c089dae,RTL,0.555915
uuid-0bc8e4492d3643c3a24a7fad5c089dae,NTL,0.493923
uuid-0bc8e4492d3643c3a24a7fad5c089dae,discussed,0.316253
uuid-0bc8e4492d3643c3a24a7fad5c089dae,commented,0.649757
uuid-0bc8e4492d3643c3a24a7fad5c089dae,stated,0.427275
uuid-0bc8e4492d3643c3a24a7fad5c089dae,regards,0.354327
uuid-0bc8e4492d3643c3a24a7fad5c089dae,data,0.404342
uuid-0bc8e4492d3643c3a24a7fad5c089dae,expressed,0.323462
uuid-0bc8e4492d3643c3a24a7fad5c089dae,mentioned,0.455173
uuid-0bc8e4492d3643c3a24a7fad5c089dae,SCCHN,0.431831
uuid-0bc8e4492d3643c3a24a7fad5c089dae,HCP,0.315627
uuid-0bc8e4492d3643c3a24a7fad5c089dae,ASCO,0.661049
uuid-0bc8e4492d3643c3a24a7fad5c089dae,impressed,0.540785
uuid-0bc8e4492d3643c3a24a7fad5c089dae,LTL,0.405076
uuid-0bc8e4492d3643c3a24a7fad5c089dae,TLs,0.331489
uuid-0bc8e4492d3643c3a24a7fad5c089dae,SCLC,0.307088
uuid-0bc8e4492d3643c3a24a7fad5c089dae,Regional TL,0.570531
uuid-bd8f0101ece949a087dc899f112a2c0e,RTL,0.537651
uuid-bd8f0101ece949a087dc899f112a2c0e,BMS,0.371987
uuid-bd8f0101ece949a087dc899f112a2c0e,trial,0.450156
uuid-bd8f0101ece949a087dc899f112a2c0e,NTL,0.377595
uuid-bd8f0101ece949a087dc899f112a2c0e,discussed,0.314259
uuid-bd8f0101ece949a087dc899f112a2c0e,commented,0.6058
uuid-bd8f0101ece949a087dc899f112a2c0e,Merck,0.361158
uuid-bd8f0101ece949a087dc899f112a2c0e,stated,0.390418
uuid-bd8f0101ece949a087dc899f112a2c0e,OS,0.455275
uuid-bd8f0101ece949a087dc899f112a2c0e,regards,0.373204
uuid-bd8f0101ece949a087dc899f112a2c0e,data,0.811231
uuid-bd8f0101ece949a087dc899f112a2c0e,expressed,0.500955
uuid-bd8f0101ece949a087dc899f112a2c0e,mentioned,0.344041
uuid-bd8f0101ece949a087dc899f112a2c0e,PFS,0.392109
uuid-bd8f0101ece949a087dc899f112a2c0e,ORR,0.501645
uuid-bd8f0101ece949a087dc899f112a2c0e,SCCHN,0.363279
uuid-bd8f0101ece949a087dc899f112a2c0e,ASCO,0.648502
uuid-bd8f0101ece949a087dc899f112a2c0e,impressed,0.771634
uuid-bd8f0101ece949a087dc899f112a2c0e,LTL,0.40679
uuid-bd8f0101ece949a087dc899f112a2c0e,TLs,0.381493
uuid-bd8f0101ece949a087dc899f112a2c0e,SCLC,0.395331
uuid-bd8f0101ece949a087dc899f112a2c0e,Regional TL,0.446917
uuid-b8e7c648751849ca8a5d062feea20c8c,patients,0.307157
uuid-b8e7c648751849ca8a5d062feea20c8c,toxicity,0.466302
uuid-b8e7c648751849ca8a5d062feea20c8c,combination,0.399533
uuid-b8e7c648751849ca8a5d062feea20c8c,chemo,0.365308
uuid-b8e7c648751849ca8a5d062feea20c8c,tumor,0.374342
uuid-b8e7c648751849ca8a5d062feea20c8c,pts,0.31953
uuid-b8e7c648751849ca8a5d062feea20c8c,treatment,0.302379
uuid-b8e7c648751849ca8a5d062feea20c8c,response,0.597759
uuid-b8e7c648751849ca8a5d062feea20c8c,PD1,0.32752
uuid-b8e7c648751849ca8a5d062feea20c8c,progression,0.408405
uuid-b8e7c648751849ca8a5d062feea20c8c,chemotherapy,0.378117
uuid-b8e7c648751849ca8a5d062feea20c8c,respond,0.41211
uuid-f9da0bdc97db457b989e57140a980563,Nivo,0.359975
uuid-f9da0bdc97db457b989e57140a980563,pembro,0.33967
uuid-f9da0bdc97db457b989e57140a980563,trial,0.545678
uuid-f9da0bdc97db457b989e57140a980563,efficacy,0.392013
uuid-f9da0bdc97db457b989e57140a980563,combination,0.664266
uuid-f9da0bdc97db457b989e57140a980563,chemo,0.444303
uuid-f9da0bdc97db457b989e57140a980563,agents,0.430063
uuid-f9da0bdc97db457b989e57140a980563,Ipi,0.456801
uuid-f9da0bdc97db457b989e57140a980563,monotherapy,0.402031
uuid-f9da0bdc97db457b989e57140a980563,combo,0.650411
uuid-f9da0bdc97db457b989e57140a980563,PD1,0.507548
uuid-f9da0bdc97db457b989e57140a980563,nivo and pembro,0.328627
uuid-f9da0bdc97db457b989e57140a980563,believes,0.344219
uuid-f9da0bdc97db457b989e57140a980563,chemotherapy,0.399292
uuid-f9da0bdc97db457b989e57140a980563,vs,0.32089
uuid-f9da0bdc97db457b989e57140a980563,feels,0.3296
uuid-b1947ef5600047c48cb3c51f353b9e22,BMS,0.494167
uuid-b1947ef5600047c48cb3c51f353b9e22,Merck,0.462666
uuid-719255e3d6d64bea8f20c423d5e961be,patients,0.318006
uuid-719255e3d6d64bea8f20c423d5e961be,pembro,0.310116
uuid-719255e3d6d64bea8f20c423d5e961be,RTL,0.300918
uuid-719255e3d6d64bea8f20c423d5e961be,nivolumab,0.404701
uuid-719255e3d6d64bea8f20c423d5e961be,1L,0.370166
uuid-719255e3d6d64bea8f20c423d5e961be,RCC,0.333285
uuid-719255e3d6d64bea8f20c423d5e961be,2L,0.364171
uuid-719255e3d6d64bea8f20c423d5e961be,approval,0.401817
uuid-719255e3d6d64bea8f20c423d5e961be,preferred,0.60648
uuid-719255e3d6d64bea8f20c423d5e961be,monotherapy,0.381684
uuid-719255e3d6d64bea8f20c423d5e961be,using nivo,0.532431
uuid-719255e3d6d64bea8f20c423d5e961be,indication,0.416343
uuid-719255e3d6d64bea8f20c423d5e961be,approved,0.331352
uuid-719255e3d6d64bea8f20c423d5e961be,SCCHN,0.571554
uuid-719255e3d6d64bea8f20c423d5e961be,chemotherapy,0.33837
uuid-719255e3d6d64bea8f20c423d5e961be,Regional TL,0.313306
uuid-719255e3d6d64bea8f20c423d5e961be,RTL stated,0.537003
uuid-719255e3d6d64bea8f20c423d5e961be,option,0.480868
uuid-719255e3d6d64bea8f20c423d5e961be,bladder,0.358195
uuid-f2e99b36672544f9a6e4ce3cc59987ab,patients,0.415079
uuid-f2e99b36672544f9a6e4ce3cc59987ab,PDL1,0.461089
uuid-f2e99b36672544f9a6e4ce3cc59987ab,pts,0.340336
uuid-f2e99b36672544f9a6e4ce3cc59987ab,OS,0.306321
uuid-f2e99b36672544f9a6e4ce3cc59987ab,PFS,0.344622
uuid-f2e99b36672544f9a6e4ce3cc59987ab,respond,0.381155
uuid-f2e99b36672544f9a6e4ce3cc59987ab,feels,0.327514
uuid-f2e99b36672544f9a6e4ce3cc59987ab,PDL1 expression,0.30071
uuid-6f1bbfb4f0be4442b8cee516a59ccf3d,pembro,0.401691
uuid-6f1bbfb4f0be4442b8cee516a59ccf3d,lung,0.333932
uuid-6f1bbfb4f0be4442b8cee516a59ccf3d,2L,0.328464
uuid-6f1bbfb4f0be4442b8cee516a59ccf3d,atezo,0.445336
uuid-6f1bbfb4f0be4442b8cee516a59ccf3d,nivo and pembro,0.631133
uuid-6f1bbfb4f0be4442b8cee516a59ccf3d,vs,0.31157
uuid-c741cdb65330443ba1b533bcb685fb50,Nivo,0.375552
uuid-c741cdb65330443ba1b533bcb685fb50,patients,0.750543
uuid-c741cdb65330443ba1b533bcb685fb50,Opdivo,0.348077
uuid-c741cdb65330443ba1b533bcb685fb50,therapy,0.553159
uuid-c741cdb65330443ba1b533bcb685fb50,dose,0.308421
uuid-c741cdb65330443ba1b533bcb685fb50,nivolumab,0.660704
uuid-c741cdb65330443ba1b533bcb685fb50,toxicity,0.313781
uuid-c741cdb65330443ba1b533bcb685fb50,regimen,0.567092
uuid-c741cdb65330443ba1b533bcb685fb50,treated,0.552927
uuid-c741cdb65330443ba1b533bcb685fb50,combination,0.509055
uuid-c741cdb65330443ba1b533bcb685fb50,chemo,0.470375
uuid-c741cdb65330443ba1b533bcb685fb50,pts,0.540753
uuid-c741cdb65330443ba1b533bcb685fb50,Ipi,0.317552
uuid-c741cdb65330443ba1b533bcb685fb50,preferred,0.344716
uuid-c741cdb65330443ba1b533bcb685fb50,monotherapy,0.489468
uuid-c741cdb65330443ba1b533bcb685fb50,treatment,0.610675
uuid-c741cdb65330443ba1b533bcb685fb50,using nivo,0.426345
uuid-c741cdb65330443ba1b533bcb685fb50,combo,0.415328
uuid-c741cdb65330443ba1b533bcb685fb50,PD1,0.375159
uuid-c741cdb65330443ba1b533bcb685fb50,progression,0.51512
uuid-c741cdb65330443ba1b533bcb685fb50,chemotherapy,0.554315
uuid-c741cdb65330443ba1b533bcb685fb50,respond,0.334432
uuid-c741cdb65330443ba1b533bcb685fb50,RTL stated,0.371922
uuid-c741cdb65330443ba1b533bcb685fb50,option,0.446773
uuid-ee21d5282fa24fb095cf6b414a86645d,patients,0.564248
uuid-ee21d5282fa24fb095cf6b414a86645d,Opdivo,0.315377
uuid-ee21d5282fa24fb095cf6b414a86645d,therapy,0.366655
uuid-ee21d5282fa24fb095cf6b414a86645d,toxicity,0.35164
uuid-ee21d5282fa24fb095cf6b414a86645d,regimen,0.327917
uuid-ee21d5282fa24fb095cf6b414a86645d,treated,0.477623
uuid-ee21d5282fa24fb095cf6b414a86645d,treatment,0.536018
uuid-ee21d5282fa24fb095cf6b414a86645d,cHL,0.321605
uuid-ee21d5282fa24fb095cf6b414a86645d,progression,0.395335
uuid-ee21d5282fa24fb095cf6b414a86645d,respond,0.403063
uuid-5516309feea14cb3b24cd0c9a851e430,Nivo,0.371048
uuid-5516309feea14cb3b24cd0c9a851e430,Opdivo,0.447425
uuid-5516309feea14cb3b24cd0c9a851e430,pembro,0.32583
uuid-5516309feea14cb3b24cd0c9a851e430,stated,0.397601
uuid-5516309feea14cb3b24cd0c9a851e430,approval,0.305811
uuid-5516309feea14cb3b24cd0c9a851e430,using nivo,0.377368
uuid-5516309feea14cb3b24cd0c9a851e430,data,0.341202
uuid-5516309feea14cb3b24cd0c9a851e430,clinical trials,0.375711
uuid-5516309feea14cb3b24cd0c9a851e430,indication,0.327474
uuid-5516309feea14cb3b24cd0c9a851e430,approved,0.348555
uuid-5516309feea14cb3b24cd0c9a851e430,SCCHN,0.338056
uuid-5516309feea14cb3b24cd0c9a851e430,HCP,0.360552
uuid-5516309feea14cb3b24cd0c9a851e430,impressed,0.435288
uuid-5516309feea14cb3b24cd0c9a851e430,LTL,0.384106
uuid-5516309feea14cb3b24cd0c9a851e430,feels,0.45832
uuid-5516309feea14cb3b24cd0c9a851e430,bladder,0.427015
uuid-f5d2363463cb4103b6ae22b8e2152858,efficacy,0.512527
uuid-f5d2363463cb4103b6ae22b8e2152858,discussed,0.332196
uuid-f5d2363463cb4103b6ae22b8e2152858,IO,0.304374
uuid-f5d2363463cb4103b6ae22b8e2152858,regards,0.321298
uuid-f5d2363463cb4103b6ae22b8e2152858,data,0.375164
uuid-f5d2363463cb4103b6ae22b8e2152858,oncology,0.427823
uuid-f5d2363463cb4103b6ae22b8e2152858,ORR,0.318134
uuid-f5d2363463cb4103b6ae22b8e2152858,TLs,0.39032
uuid-f5d2363463cb4103b6ae22b8e2152858,clinical,0.47693
uuid-d63b29f8a9ba445f99e3b011abc80952,patients,0.354558
uuid-d63b29f8a9ba445f99e3b011abc80952,Opdivo,0.388985
uuid-d63b29f8a9ba445f99e3b011abc80952,RTL,0.428668
uuid-d63b29f8a9ba445f99e3b011abc80952,nivolumab,0.441749
uuid-d63b29f8a9ba445f99e3b011abc80952,treated,0.360368
uuid-d63b29f8a9ba445f99e3b011abc80952,shared,0.302964
uuid-d63b29f8a9ba445f99e3b011abc80952,stated,0.633889
uuid-d63b29f8a9ba445f99e3b011abc80952,physicians,0.438196
uuid-d63b29f8a9ba445f99e3b011abc80952,using nivo,0.310061
uuid-d63b29f8a9ba445f99e3b011abc80952,mentioned,0.311516
uuid-d63b29f8a9ba445f99e3b011abc80952,SCCHN,0.311797
uuid-d63b29f8a9ba445f99e3b011abc80952,HCP,0.321386
uuid-d63b29f8a9ba445f99e3b011abc80952,LTL,0.471112
uuid-d63b29f8a9ba445f99e3b011abc80952,Regional TL,0.463464
uuid-d63b29f8a9ba445f99e3b011abc80952,RTL stated,0.359623
uuid-53b6b4cdd4474d8e95ac72370ac1939b,Nivo,0.42336
uuid-53b6b4cdd4474d8e95ac72370ac1939b,pembro,0.332784
uuid-53b6b4cdd4474d8e95ac72370ac1939b,1L,0.406095
uuid-53b6b4cdd4474d8e95ac72370ac1939b,melanoma,0.319883
uuid-53b6b4cdd4474d8e95ac72370ac1939b,RCC,0.51908
uuid-53b6b4cdd4474d8e95ac72370ac1939b,2L,0.489693
uuid-53b6b4cdd4474d8e95ac72370ac1939b,stated,0.302875
uuid-53b6b4cdd4474d8e95ac72370ac1939b,approval,0.367541
uuid-53b6b4cdd4474d8e95ac72370ac1939b,atezo,0.377505
uuid-53b6b4cdd4474d8e95ac72370ac1939b,preferred,0.398764
uuid-53b6b4cdd4474d8e95ac72370ac1939b,monotherapy,0.332526
uuid-53b6b4cdd4474d8e95ac72370ac1939b,using nivo,0.469198
uuid-53b6b4cdd4474d8e95ac72370ac1939b,data,0.335196
uuid-53b6b4cdd4474d8e95ac72370ac1939b,approved,0.380475
uuid-53b6b4cdd4474d8e95ac72370ac1939b,SCCHN,0.510614
uuid-53b6b4cdd4474d8e95ac72370ac1939b,impressed,0.352332
uuid-53b6b4cdd4474d8e95ac72370ac1939b,TLs,0.373786
uuid-53b6b4cdd4474d8e95ac72370ac1939b,SCLC,0.308334
uuid-53b6b4cdd4474d8e95ac72370ac1939b,Regional TL,0.369095
uuid-53b6b4cdd4474d8e95ac72370ac1939b,RTL stated,0.524321
uuid-53b6b4cdd4474d8e95ac72370ac1939b,TL shared,0.340752
uuid-53b6b4cdd4474d8e95ac72370ac1939b,option,0.388275
uuid-53b6b4cdd4474d8e95ac72370ac1939b,bladder,0.367608
uuid-7e112082037e44ac9b2fa26806053183,patients,0.726562
uuid-7e112082037e44ac9b2fa26806053183,Opdivo,0.330277
uuid-7e112082037e44ac9b2fa26806053183,therapy,0.633761
uuid-7e112082037e44ac9b2fa26806053183,nivolumab,0.487683
uuid-7e112082037e44ac9b2fa26806053183,treated,0.400339
uuid-7e112082037e44ac9b2fa26806053183,chemo,0.329447
uuid-7e112082037e44ac9b2fa26806053183,pts,0.435851
uuid-7e112082037e44ac9b2fa26806053183,treatment,0.535078
uuid-7e112082037e44ac9b2fa26806053183,using nivo,0.31209
uuid-7e112082037e44ac9b2fa26806053183,cHL,0.410247
uuid-7e112082037e44ac9b2fa26806053183,progression,0.506205
uuid-7e112082037e44ac9b2fa26806053183,chemotherapy,0.411416
uuid-7e112082037e44ac9b2fa26806053183,respond,0.378813
uuid-7e112082037e44ac9b2fa26806053183,option,0.337396
uuid-627e348b66c14d16bffbff7abf93ffec,patients,0.571826
uuid-627e348b66c14d16bffbff7abf93ffec,Opdivo,0.456146
uuid-627e348b66c14d16bffbff7abf93ffec,therapy,0.547549
uuid-627e348b66c14d16bffbff7abf93ffec,nivolumab,0.500369
uuid-627e348b66c14d16bffbff7abf93ffec,regimen,0.318223
uuid-627e348b66c14d16bffbff7abf93ffec,treated,0.425418
uuid-627e348b66c14d16bffbff7abf93ffec,treatment,0.52858
uuid-627e348b66c14d16bffbff7abf93ffec,cHL,0.62697
uuid-627e348b66c14d16bffbff7abf93ffec,progression,0.362852
uuid-1fc2813528f04610a63d215db29a01f6,toxicity,0.353159
uuid-1fc2813528f04610a63d215db29a01f6,efficacy,0.348908
uuid-1fc2813528f04610a63d215db29a01f6,combination,0.324185
uuid-1fc2813528f04610a63d215db29a01f6,chemo,0.357198
uuid-1fc2813528f04610a63d215db29a01f6,pts,0.338089
uuid-1fc2813528f04610a63d215db29a01f6,OS,0.339316
uuid-1fc2813528f04610a63d215db29a01f6,response,0.696644
uuid-1fc2813528f04610a63d215db29a01f6,PFS,0.323606
uuid-1fc2813528f04610a63d215db29a01f6,PD1,0.340859
uuid-1fc2813528f04610a63d215db29a01f6,ORR,0.371959
uuid-1fc2813528f04610a63d215db29a01f6,progression,0.390804
uuid-1fc2813528f04610a63d215db29a01f6,chemotherapy,0.313738
uuid-1fc2813528f04610a63d215db29a01f6,impressed,0.31526
uuid-1fc2813528f04610a63d215db29a01f6,respond,0.464959
uuid-1fc2813528f04610a63d215db29a01f6,feels,0.335413
uuid-1fc2813528f04610a63d215db29a01f6,immunotherapy,0.301836
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,pembro,0.30945
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,dose,0.358543
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,lung,0.355958
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,regimen,0.392461
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,melanoma,0.567647
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,shared,0.306056
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,RCC,0.551423
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,combination,0.39528
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,2L,0.426445
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,Ipi,0.521341
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,atezo,0.38605
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,preferred,0.366357
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,monotherapy,0.344118
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,using nivo,0.372977
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,combo,0.502598
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,clinical trials,0.311658
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,SCCHN,0.428574
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,TLs,0.529079
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,academic,0.31365
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,SCLC,0.381539
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,RTL stated,0.436007
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,TL shared,0.40731
uuid-5a7fa7bd08e74d87b5f31c6178ed7275,bladder,0.429441
uuid-b57ca39a090746608fbc868155b6d1bb,patients,0.570596
uuid-b57ca39a090746608fbc868155b6d1bb,Opdivo,0.427271
uuid-b57ca39a090746608fbc868155b6d1bb,therapy,0.474642
uuid-b57ca39a090746608fbc868155b6d1bb,nivolumab,0.572557
uuid-b57ca39a090746608fbc868155b6d1bb,treated,0.43913
uuid-b57ca39a090746608fbc868155b6d1bb,physicians,0.342438
uuid-b57ca39a090746608fbc868155b6d1bb,treatment,0.405455
uuid-b57ca39a090746608fbc868155b6d1bb,cHL,0.557823
uuid-b57ca39a090746608fbc868155b6d1bb,progression,0.310839
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,Nivo,0.654729
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,patients,0.459209
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,pembro,0.440742
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,therapy,0.310456
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,1L,0.436101
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,chemo,0.414689
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,2L,0.471269
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,pts,0.399203
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,approval,0.373377
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,atezo,0.314678
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,preferred,0.414524
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,monotherapy,0.453138
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,using nivo,0.482277
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,approved,0.51927
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,respond,0.343148
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,feels,0.451438
uuid-d2be2444ba4d4c03b9ac0a9fb0640e6c,option,0.576964
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,patients,0.507494
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,therapy,0.507017
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,toxicity,0.316683
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,regimen,0.515297
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,treated,0.317414
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,combination,0.316321
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,chemo,0.466934
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,pts,0.524325
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,IO,0.509733
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,monotherapy,0.410978
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,treatment,0.620208
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,response,0.728071
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,PD1,0.458901
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,progression,0.855586
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,believes,0.301999
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,chemotherapy,0.38793
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,respond,0.626503
uuid-cfb9b372ff374bafa3e59a6c6d5b8888,option,0.342083
uuid-3ec7005451ab4d79bec88decc65caf55,Nivo,0.340556
uuid-3ec7005451ab4d79bec88decc65caf55,patients,0.521493
uuid-3ec7005451ab4d79bec88decc65caf55,therapy,0.456426
uuid-3ec7005451ab4d79bec88decc65caf55,1L,0.423463
uuid-3ec7005451ab4d79bec88decc65caf55,regimen,0.388189
uuid-3ec7005451ab4d79bec88decc65caf55,chemo,0.498563
uuid-3ec7005451ab4d79bec88decc65caf55,2L,0.383958
uuid-3ec7005451ab4d79bec88decc65caf55,pts,0.472321
uuid-3ec7005451ab4d79bec88decc65caf55,preferred,0.372124
uuid-3ec7005451ab4d79bec88decc65caf55,monotherapy,0.540831
uuid-3ec7005451ab4d79bec88decc65caf55,treatment,0.46396
uuid-3ec7005451ab4d79bec88decc65caf55,using nivo,0.352899
uuid-3ec7005451ab4d79bec88decc65caf55,response,0.376646
uuid-3ec7005451ab4d79bec88decc65caf55,PD1,0.412832
uuid-3ec7005451ab4d79bec88decc65caf55,progression,0.523505
uuid-3ec7005451ab4d79bec88decc65caf55,believes,0.336814
uuid-3ec7005451ab4d79bec88decc65caf55,chemotherapy,0.410438
uuid-3ec7005451ab4d79bec88decc65caf55,respond,0.48108
uuid-3ec7005451ab4d79bec88decc65caf55,feels,0.460853
uuid-3ec7005451ab4d79bec88decc65caf55,option,0.61451
uuid-6d5f8c59e4f74257978ba03acf53265b,pembro,0.48489
uuid-6d5f8c59e4f74257978ba03acf53265b,RTL,0.343019
uuid-6d5f8c59e4f74257978ba03acf53265b,trial,0.362685
uuid-6d5f8c59e4f74257978ba03acf53265b,efficacy,0.308081
uuid-6d5f8c59e4f74257978ba03acf53265b,commented,0.33372
uuid-6d5f8c59e4f74257978ba03acf53265b,stated,0.361581
uuid-6d5f8c59e4f74257978ba03acf53265b,approval,0.483134
uuid-6d5f8c59e4f74257978ba03acf53265b,atezo,0.413492
uuid-6d5f8c59e4f74257978ba03acf53265b,data,0.610931
uuid-6d5f8c59e4f74257978ba03acf53265b,clinical trials,0.365315
uuid-6d5f8c59e4f74257978ba03acf53265b,indication,0.49717
uuid-6d5f8c59e4f74257978ba03acf53265b,approved,0.439382
uuid-6d5f8c59e4f74257978ba03acf53265b,SCCHN,0.350316
uuid-6d5f8c59e4f74257978ba03acf53265b,impressed,0.496935
uuid-6d5f8c59e4f74257978ba03acf53265b,vs,0.31879
uuid-6d5f8c59e4f74257978ba03acf53265b,label,0.415934
uuid-6d5f8c59e4f74257978ba03acf53265b,LTL,0.393015
uuid-6d5f8c59e4f74257978ba03acf53265b,TLs,0.339555
uuid-6d5f8c59e4f74257978ba03acf53265b,Regional TL,0.346753
uuid-6d5f8c59e4f74257978ba03acf53265b,flat dosing,0.53401
uuid-bdf33487bf504b058d41abdffa777436,pembro,0.435583
uuid-bdf33487bf504b058d41abdffa777436,BMS,0.41014
uuid-bdf33487bf504b058d41abdffa777436,PDL1,0.468252
uuid-bdf33487bf504b058d41abdffa777436,trial,0.463973
uuid-bdf33487bf504b058d41abdffa777436,efficacy,0.687411
uuid-bdf33487bf504b058d41abdffa777436,Merck,0.309318
uuid-bdf33487bf504b058d41abdffa777436,Ipi,0.317298
uuid-bdf33487bf504b058d41abdffa777436,OS,0.563976
uuid-bdf33487bf504b058d41abdffa777436,atezo,0.426531
uuid-bdf33487bf504b058d41abdffa777436,regards,0.337886
uuid-bdf33487bf504b058d41abdffa777436,data,0.740082
uuid-bdf33487bf504b058d41abdffa777436,PFS,0.541308
uuid-bdf33487bf504b058d41abdffa777436,ORR,0.600513
uuid-bdf33487bf504b058d41abdffa777436,nivo and pembro,0.543041
uuid-bdf33487bf504b058d41abdffa777436,believes,0.324079
uuid-bdf33487bf504b058d41abdffa777436,impressed,0.40935
uuid-bdf33487bf504b058d41abdffa777436,vs,0.511348
uuid-bdf33487bf504b058d41abdffa777436,PDL1 expression,0.434926
uuid-8572677ce9d84196addfeda7542f2868,BMS,0.530214
uuid-8572677ce9d84196addfeda7542f2868,PDL1,0.620879
uuid-8572677ce9d84196addfeda7542f2868,trial,0.420702
uuid-8572677ce9d84196addfeda7542f2868,efficacy,0.656781
uuid-8572677ce9d84196addfeda7542f2868,Merck,0.399471
uuid-8572677ce9d84196addfeda7542f2868,OS,0.710438
uuid-8572677ce9d84196addfeda7542f2868,regards,0.349148
uuid-8572677ce9d84196addfeda7542f2868,data,0.796815
uuid-8572677ce9d84196addfeda7542f2868,PFS,0.667298
uuid-8572677ce9d84196addfeda7542f2868,ORR,0.710271
uuid-8572677ce9d84196addfeda7542f2868,nivo and pembro,0.561909
uuid-8572677ce9d84196addfeda7542f2868,believes,0.376879
uuid-8572677ce9d84196addfeda7542f2868,impressed,0.509195
uuid-8572677ce9d84196addfeda7542f2868,feels,0.437109
uuid-8572677ce9d84196addfeda7542f2868,PDL1 expression,0.574715
uuid-8572677ce9d84196addfeda7542f2868,biomarker,0.339467
uuid-7fa088fd6992481babebc616b0a04b37,Nivo,0.304851
uuid-7fa088fd6992481babebc616b0a04b37,patients,0.591856
uuid-7fa088fd6992481babebc616b0a04b37,Opdivo,0.300796
uuid-7fa088fd6992481babebc616b0a04b37,therapy,0.396614
uuid-7fa088fd6992481babebc616b0a04b37,nivolumab,0.423231
uuid-7fa088fd6992481babebc616b0a04b37,regimen,0.529356
uuid-7fa088fd6992481babebc616b0a04b37,treated,0.395611
uuid-7fa088fd6992481babebc616b0a04b37,combination,0.303412
uuid-7fa088fd6992481babebc616b0a04b37,chemo,0.308669
uuid-7fa088fd6992481babebc616b0a04b37,pts,0.376185
uuid-7fa088fd6992481babebc616b0a04b37,preferred,0.430083
uuid-7fa088fd6992481babebc616b0a04b37,monotherapy,0.523948
uuid-7fa088fd6992481babebc616b0a04b37,treatment,0.446418
uuid-7fa088fd6992481babebc616b0a04b37,using nivo,0.388852
uuid-7fa088fd6992481babebc616b0a04b37,progression,0.347831
uuid-7fa088fd6992481babebc616b0a04b37,chemotherapy,0.330962
uuid-7fa088fd6992481babebc616b0a04b37,feels,0.338791
uuid-7fa088fd6992481babebc616b0a04b37,RTL stated,0.34375
uuid-7fa088fd6992481babebc616b0a04b37,option,0.495294
uuid-e5c9355e1e154fd28dbe929b9e5697ea,Nivo,0.351522
uuid-e5c9355e1e154fd28dbe929b9e5697ea,patients,0.531159
uuid-e5c9355e1e154fd28dbe929b9e5697ea,therapy,0.357899
uuid-e5c9355e1e154fd28dbe929b9e5697ea,nivolumab,0.303417
uuid-e5c9355e1e154fd28dbe929b9e5697ea,trial,0.420208
uuid-e5c9355e1e154fd28dbe929b9e5697ea,treated,0.324415
uuid-e5c9355e1e154fd28dbe929b9e5697ea,combination,0.30739
uuid-e5c9355e1e154fd28dbe929b9e5697ea,chemo,0.420553
uuid-e5c9355e1e154fd28dbe929b9e5697ea,pts,0.60481
uuid-e5c9355e1e154fd28dbe929b9e5697ea,monotherapy,0.319913
uuid-e5c9355e1e154fd28dbe929b9e5697ea,treatment,0.314777
uuid-e5c9355e1e154fd28dbe929b9e5697ea,combo,0.328117
uuid-e5c9355e1e154fd28dbe929b9e5697ea,clinical trials,0.359566
uuid-e5c9355e1e154fd28dbe929b9e5697ea,progression,0.325008
uuid-e5c9355e1e154fd28dbe929b9e5697ea,chemotherapy,0.480707
uuid-e5c9355e1e154fd28dbe929b9e5697ea,option,0.365012
uuid-e5c9355e1e154fd28dbe929b9e5697ea,bladder,0.433996
uuid-83c4870ba2e04a34bf8321813f917b77,expressed,0.332664
uuid-83c4870ba2e04a34bf8321813f917b77,clinical,0.322547
uuid-a5a146d12dad49ac8a71190c8d26d710,patients,0.438904
uuid-a5a146d12dad49ac8a71190c8d26d710,treated,0.384355
uuid-a5a146d12dad49ac8a71190c8d26d710,mentioned,0.398006
uuid-a5a146d12dad49ac8a71190c8d26d710,cHL,0.440668
uuid-62ed159174ac447d86a0843f8477dc6d,RTL,0.45175
uuid-62ed159174ac447d86a0843f8477dc6d,physicians,0.340431
uuid-62ed159174ac447d86a0843f8477dc6d,mentioned,0.452577
uuid-62ed159174ac447d86a0843f8477dc6d,cHL,0.352337
uuid-62ed159174ac447d86a0843f8477dc6d,LTL,0.381213
uuid-62ed159174ac447d86a0843f8477dc6d,Regional TL,0.364609
uuid-e20abebf84b04b47b8acd358cdffd80c,Opdivo,0.491394
uuid-e20abebf84b04b47b8acd358cdffd80c,RTL,0.321655
uuid-e20abebf84b04b47b8acd358cdffd80c,stated,0.316973
uuid-e20abebf84b04b47b8acd358cdffd80c,approval,0.439192
uuid-e20abebf84b04b47b8acd358cdffd80c,using nivo,0.350136
uuid-e20abebf84b04b47b8acd358cdffd80c,mentioned,0.422958
uuid-e20abebf84b04b47b8acd358cdffd80c,indication,0.482253
uuid-e20abebf84b04b47b8acd358cdffd80c,approved,0.415125
uuid-e20abebf84b04b47b8acd358cdffd80c,SCCHN,0.379246
uuid-e20abebf84b04b47b8acd358cdffd80c,HCP,0.320951
uuid-e20abebf84b04b47b8acd358cdffd80c,cHL,0.357095
uuid-e20abebf84b04b47b8acd358cdffd80c,label,0.528732
uuid-e20abebf84b04b47b8acd358cdffd80c,Keytruda,0.518163
uuid-e20abebf84b04b47b8acd358cdffd80c,flat dosing,0.364938
uuid-16a9ebbb456949dd8a8df0568c553ea2,Nivo,0.5137
uuid-16a9ebbb456949dd8a8df0568c553ea2,patients,0.656081
uuid-16a9ebbb456949dd8a8df0568c553ea2,Opdivo,0.471332
uuid-16a9ebbb456949dd8a8df0568c553ea2,therapy,0.744841
uuid-16a9ebbb456949dd8a8df0568c553ea2,nivolumab,0.541517
uuid-16a9ebbb456949dd8a8df0568c553ea2,regimen,0.325141
uuid-16a9ebbb456949dd8a8df0568c553ea2,treated,0.410367
uuid-16a9ebbb456949dd8a8df0568c553ea2,chemo,0.367031
uuid-16a9ebbb456949dd8a8df0568c553ea2,monotherapy,0.355336
uuid-16a9ebbb456949dd8a8df0568c553ea2,treatment,0.548176
uuid-16a9ebbb456949dd8a8df0568c553ea2,using nivo,0.399841
uuid-16a9ebbb456949dd8a8df0568c553ea2,PD1,0.398292
uuid-16a9ebbb456949dd8a8df0568c553ea2,cHL,0.659275
uuid-16a9ebbb456949dd8a8df0568c553ea2,progression,0.426381
uuid-16a9ebbb456949dd8a8df0568c553ea2,chemotherapy,0.500532
uuid-16a9ebbb456949dd8a8df0568c553ea2,respond,0.300387
uuid-16a9ebbb456949dd8a8df0568c553ea2,option,0.379786
uuid-3c3f16ac667e47dca4f80add85b382f2,Nivo,0.342515
uuid-3c3f16ac667e47dca4f80add85b382f2,patients,0.350752
uuid-3c3f16ac667e47dca4f80add85b382f2,Opdivo,0.556863
uuid-3c3f16ac667e47dca4f80add85b382f2,2L,0.398431
uuid-3c3f16ac667e47dca4f80add85b382f2,approval,0.393781
uuid-3c3f16ac667e47dca4f80add85b382f2,preferred,0.424235
uuid-3c3f16ac667e47dca4f80add85b382f2,using nivo,0.422954
uuid-3c3f16ac667e47dca4f80add85b382f2,indication,0.450775
uuid-3c3f16ac667e47dca4f80add85b382f2,approved,0.607285
uuid-3c3f16ac667e47dca4f80add85b382f2,label,0.505745
uuid-3c3f16ac667e47dca4f80add85b382f2,drug,0.46981
uuid-3c3f16ac667e47dca4f80add85b382f2,Keytruda,0.427874
uuid-3c3f16ac667e47dca4f80add85b382f2,option,0.45904
uuid-d2cc4b4925c84e859c936dd98d1ccb9e,Nivo,0.380919
uuid-d2cc4b4925c84e859c936dd98d1ccb9e,therapy,0.453482
uuid-d2cc4b4925c84e859c936dd98d1ccb9e,cHL,0.682789
uuid-a96487b6a3f3439abbc521c6b08cb3bb,patients,0.572451
uuid-a96487b6a3f3439abbc521c6b08cb3bb,Opdivo,0.393643
uuid-a96487b6a3f3439abbc521c6b08cb3bb,therapy,0.550863
uuid-a96487b6a3f3439abbc521c6b08cb3bb,nivolumab,0.561516
uuid-a96487b6a3f3439abbc521c6b08cb3bb,treated,0.420792
uuid-a96487b6a3f3439abbc521c6b08cb3bb,approval,0.377328
uuid-a96487b6a3f3439abbc521c6b08cb3bb,treatment,0.3846
uuid-a96487b6a3f3439abbc521c6b08cb3bb,using nivo,0.442967
uuid-a96487b6a3f3439abbc521c6b08cb3bb,mentioned,0.3132
uuid-a96487b6a3f3439abbc521c6b08cb3bb,cHL,0.659024
uuid-09cedda9fa614ccdb8fcc1da5670fbad,Nivo,0.309918
uuid-09cedda9fa614ccdb8fcc1da5670fbad,therapy,0.330671
uuid-09cedda9fa614ccdb8fcc1da5670fbad,mentioned,0.369234
uuid-09cedda9fa614ccdb8fcc1da5670fbad,cHL,0.549337
uuid-bc9a754cffbb4636b0118e18230f321e,Opdivo,0.485584
uuid-bc9a754cffbb4636b0118e18230f321e,physicians,0.36848
uuid-1e0618b1e9e54493bd4a12b0db70c44c,BMS,0.33041
uuid-1e0618b1e9e54493bd4a12b0db70c44c,PDL1,0.301462
uuid-1e0618b1e9e54493bd4a12b0db70c44c,trial,0.406278
uuid-1e0618b1e9e54493bd4a12b0db70c44c,commented,0.477828
uuid-1e0618b1e9e54493bd4a12b0db70c44c,Merck,0.351849
uuid-1e0618b1e9e54493bd4a12b0db70c44c,stated,0.547773
uuid-1e0618b1e9e54493bd4a12b0db70c44c,approval,0.368714
uuid-1e0618b1e9e54493bd4a12b0db70c44c,regards,0.330511
uuid-1e0618b1e9e54493bd4a12b0db70c44c,data,0.539093
uuid-1e0618b1e9e54493bd4a12b0db70c44c,expressed,0.348638
uuid-1e0618b1e9e54493bd4a12b0db70c44c,clinical trials,0.306618
uuid-1e0618b1e9e54493bd4a12b0db70c44c,indication,0.356633
uuid-1e0618b1e9e54493bd4a12b0db70c44c,approved,0.336842
uuid-1e0618b1e9e54493bd4a12b0db70c44c,SCCHN,0.342964
uuid-1e0618b1e9e54493bd4a12b0db70c44c,impressed,0.441924
uuid-1e0618b1e9e54493bd4a12b0db70c44c,feels,0.318563
uuid-1e0618b1e9e54493bd4a12b0db70c44c,Regional TL,0.326027
uuid-cdfdf6239b214cb5ae261d18275278b4,dose,0.335263
uuid-cdfdf6239b214cb5ae261d18275278b4,lung,0.440672
uuid-cdfdf6239b214cb5ae261d18275278b4,melanoma,0.48791
uuid-cdfdf6239b214cb5ae261d18275278b4,shared,0.421712
uuid-cdfdf6239b214cb5ae261d18275278b4,RCC,0.383851
uuid-cdfdf6239b214cb5ae261d18275278b4,preferred,0.411977
uuid-cdfdf6239b214cb5ae261d18275278b4,indication,0.412876
uuid-cdfdf6239b214cb5ae261d18275278b4,AI,0.368831
uuid-cdfdf6239b214cb5ae261d18275278b4,SCCHN,0.377371
uuid-cdfdf6239b214cb5ae261d18275278b4,label,0.313478
uuid-cdfdf6239b214cb5ae261d18275278b4,RTL stated,0.341178
uuid-cdfdf6239b214cb5ae261d18275278b4,TL shared,0.379292
uuid-cdfdf6239b214cb5ae261d18275278b4,flat dosing,0.390673
uuid-3a1209ec343b47fd8d1cb7239549b4a2,Nivo,0.588045
uuid-3a1209ec343b47fd8d1cb7239549b4a2,pembro,0.335335
uuid-3a1209ec343b47fd8d1cb7239549b4a2,therapy,0.51768
uuid-3a1209ec343b47fd8d1cb7239549b4a2,nivolumab,0.360835
uuid-3a1209ec343b47fd8d1cb7239549b4a2,1L,0.330382
uuid-3a1209ec343b47fd8d1cb7239549b4a2,combination,0.559951
uuid-3a1209ec343b47fd8d1cb7239549b4a2,chemo,0.463188
uuid-3a1209ec343b47fd8d1cb7239549b4a2,2L,0.38233
uuid-3a1209ec343b47fd8d1cb7239549b4a2,agents,0.511259
uuid-3a1209ec343b47fd8d1cb7239549b4a2,preferred,0.350743
uuid-3a1209ec343b47fd8d1cb7239549b4a2,monotherapy,0.577149
uuid-3a1209ec343b47fd8d1cb7239549b4a2,response,0.368433
uuid-3a1209ec343b47fd8d1cb7239549b4a2,combo,0.387633
uuid-3a1209ec343b47fd8d1cb7239549b4a2,PD1,0.543276
uuid-3a1209ec343b47fd8d1cb7239549b4a2,chemotherapy,0.404102
uuid-3a1209ec343b47fd8d1cb7239549b4a2,PD-1,0.475579
uuid-3a1209ec343b47fd8d1cb7239549b4a2,option,0.476809
uuid-f934c58dae1f48e5bd75e41d898c5e59,mentioned,0.630664
uuid-f934c58dae1f48e5bd75e41d898c5e59,cHL,0.614067
uuid-c7239a3997ee4b2aa2bdbf9b5d37067a,patients,0.607189
uuid-c7239a3997ee4b2aa2bdbf9b5d37067a,Opdivo,0.588188
uuid-c7239a3997ee4b2aa2bdbf9b5d37067a,therapy,0.355261
uuid-c7239a3997ee4b2aa2bdbf9b5d37067a,nivolumab,0.317111
uuid-c7239a3997ee4b2aa2bdbf9b5d37067a,treated,0.41658
uuid-c7239a3997ee4b2aa2bdbf9b5d37067a,pts,0.333209
uuid-c7239a3997ee4b2aa2bdbf9b5d37067a,physicians,0.358253
uuid-c7239a3997ee4b2aa2bdbf9b5d37067a,treatment,0.538194
uuid-c7239a3997ee4b2aa2bdbf9b5d37067a,progression,0.450548
uuid-c7239a3997ee4b2aa2bdbf9b5d37067a,respond,0.386714
uuid-25d68800f1f2423f939e2e84f7697678,pembro,0.416897
uuid-25d68800f1f2423f939e2e84f7697678,PDL1,0.376216
uuid-25d68800f1f2423f939e2e84f7697678,trial,0.422554
uuid-25d68800f1f2423f939e2e84f7697678,efficacy,0.446819
uuid-25d68800f1f2423f939e2e84f7697678,commented,0.358746
uuid-25d68800f1f2423f939e2e84f7697678,stated,0.324546
uuid-25d68800f1f2423f939e2e84f7697678,OS,0.446474
uuid-25d68800f1f2423f939e2e84f7697678,data,0.739074
uuid-25d68800f1f2423f939e2e84f7697678,PFS,0.413157
uuid-25d68800f1f2423f939e2e84f7697678,ORR,0.472154
uuid-25d68800f1f2423f939e2e84f7697678,nivo and pembro,0.340287
uuid-25d68800f1f2423f939e2e84f7697678,impressed,0.59307
uuid-25d68800f1f2423f939e2e84f7697678,feels,0.448629
uuid-25d68800f1f2423f939e2e84f7697678,PDL1 expression,0.301999
uuid-961874f3d535429c9909d8f1afa7883c,BMS,0.318121
uuid-961874f3d535429c9909d8f1afa7883c,discussed,0.377092
uuid-961874f3d535429c9909d8f1afa7883c,shared,0.324075
uuid-961874f3d535429c9909d8f1afa7883c,commented,0.33958
uuid-961874f3d535429c9909d8f1afa7883c,regards,0.309644
uuid-961874f3d535429c9909d8f1afa7883c,data,0.362745
uuid-961874f3d535429c9909d8f1afa7883c,indicated,0.4807
uuid-447a6f15975e4826ba27d3fc3dfdecdc,pembro,0.474975
uuid-447a6f15975e4826ba27d3fc3dfdecdc,BMS,0.316161
uuid-447a6f15975e4826ba27d3fc3dfdecdc,PDL1,0.566367
uuid-447a6f15975e4826ba27d3fc3dfdecdc,trial,0.45431
uuid-447a6f15975e4826ba27d3fc3dfdecdc,efficacy,0.643521
uuid-447a6f15975e4826ba27d3fc3dfdecdc,Merck,0.397638
uuid-447a6f15975e4826ba27d3fc3dfdecdc,OS,0.378163
uuid-447a6f15975e4826ba27d3fc3dfdecdc,atezo,0.461405
uuid-447a6f15975e4826ba27d3fc3dfdecdc,regards,0.313495
uuid-447a6f15975e4826ba27d3fc3dfdecdc,data,0.482729
uuid-447a6f15975e4826ba27d3fc3dfdecdc,PFS,0.419751
uuid-447a6f15975e4826ba27d3fc3dfdecdc,ORR,0.432005
uuid-447a6f15975e4826ba27d3fc3dfdecdc,nivo and pembro,0.708195
uuid-447a6f15975e4826ba27d3fc3dfdecdc,believes,0.435177
uuid-447a6f15975e4826ba27d3fc3dfdecdc,vs,0.414745
uuid-447a6f15975e4826ba27d3fc3dfdecdc,feels,0.316295
uuid-447a6f15975e4826ba27d3fc3dfdecdc,assay,0.336832
uuid-447a6f15975e4826ba27d3fc3dfdecdc,PDL1 expression,0.493386
uuid-0a3ac6f811734e499e5772f3f1bf64f7,1L,0.406722
uuid-0a3ac6f811734e499e5772f3f1bf64f7,PDL1,0.389797
uuid-0a3ac6f811734e499e5772f3f1bf64f7,2L,0.329733
uuid-0a3ac6f811734e499e5772f3f1bf64f7,PD-L1,0.459482
uuid-0a3ac6f811734e499e5772f3f1bf64f7,preferred,0.315241
uuid-0a3ac6f811734e499e5772f3f1bf64f7,testing,0.562494
uuid-0a3ac6f811734e499e5772f3f1bf64f7,PDL1 testing,0.608228
uuid-0a3ac6f811734e499e5772f3f1bf64f7,NSCLC patients,0.685679
uuid-0a3ac6f811734e499e5772f3f1bf64f7,tumor types,0.450108
uuid-0a3ac6f811734e499e5772f3f1bf64f7,PD-1,0.312611
uuid-0a3ac6f811734e499e5772f3f1bf64f7,biomarker,0.382674
uuid-d502a52590fc412586c18f51975119ff,pembro,0.330003
uuid-d502a52590fc412586c18f51975119ff,NSCLC,0.313631
uuid-d502a52590fc412586c18f51975119ff,trial,0.670406
uuid-d502a52590fc412586c18f51975119ff,efficacy,0.359334
uuid-d502a52590fc412586c18f51975119ff,combination,0.50496
uuid-d502a52590fc412586c18f51975119ff,IO,0.363158
uuid-d502a52590fc412586c18f51975119ff,Ipi,0.322143
uuid-d502a52590fc412586c18f51975119ff,OS,0.359764
uuid-d502a52590fc412586c18f51975119ff,monotherapy,0.301617
uuid-d502a52590fc412586c18f51975119ff,data,0.539339
uuid-d502a52590fc412586c18f51975119ff,combo,0.476939
uuid-d502a52590fc412586c18f51975119ff,clinical trials,0.346097
uuid-d502a52590fc412586c18f51975119ff,PFS,0.317262
uuid-d502a52590fc412586c18f51975119ff,ORR,0.459091
uuid-d502a52590fc412586c18f51975119ff,nivo and pembro,0.333113
uuid-d502a52590fc412586c18f51975119ff,believes,0.335703
uuid-d502a52590fc412586c18f51975119ff,impressed,0.523857
uuid-d502a52590fc412586c18f51975119ff,feels,0.415686
uuid-43741d24e4bf40559feab50570b2f898,pembro,0.60126
uuid-43741d24e4bf40559feab50570b2f898,BMS,0.631219
uuid-43741d24e4bf40559feab50570b2f898,PDL1,0.536311
uuid-43741d24e4bf40559feab50570b2f898,trial,0.518871
uuid-43741d24e4bf40559feab50570b2f898,efficacy,0.582172
uuid-43741d24e4bf40559feab50570b2f898,agents,0.309651
uuid-43741d24e4bf40559feab50570b2f898,Merck,0.61633
uuid-43741d24e4bf40559feab50570b2f898,OS,0.401838
uuid-43741d24e4bf40559feab50570b2f898,atezo,0.565562
uuid-43741d24e4bf40559feab50570b2f898,data,0.751247
uuid-43741d24e4bf40559feab50570b2f898,indication,0.356237
uuid-43741d24e4bf40559feab50570b2f898,PFS,0.374629
uuid-43741d24e4bf40559feab50570b2f898,ORR,0.432106
uuid-43741d24e4bf40559feab50570b2f898,nivo and pembro,0.593023
uuid-43741d24e4bf40559feab50570b2f898,believes,0.316188
uuid-43741d24e4bf40559feab50570b2f898,impressed,0.413078
uuid-43741d24e4bf40559feab50570b2f898,vs,0.364558
uuid-43741d24e4bf40559feab50570b2f898,feels,0.412356
uuid-43741d24e4bf40559feab50570b2f898,PDL1 expression,0.455516
uuid-23206fd9a70d494d9101ad14bcea237d,TL,0.358849
uuid-23206fd9a70d494d9101ad14bcea237d,TL stated,0.505302
uuid-23206fd9a70d494d9101ad14bcea237d,PD-L1,0.498952
uuid-23206fd9a70d494d9101ad14bcea237d,PD-L1 testing,0.424672
uuid-23206fd9a70d494d9101ad14bcea237d,testing,0.643951
uuid-23206fd9a70d494d9101ad14bcea237d,PDL1 testing,0.608893
uuid-23206fd9a70d494d9101ad14bcea237d,NSCLC patients,0.696096
uuid-23206fd9a70d494d9101ad14bcea237d,tumor types,0.502412
uuid-23206fd9a70d494d9101ad14bcea237d,biomarker,0.341607
uuid-3a6d808756e34410949e0be68f8410ce,pembro,0.344485
uuid-3a6d808756e34410949e0be68f8410ce,1L,0.304366
uuid-3a6d808756e34410949e0be68f8410ce,PDL1,0.694145
uuid-3a6d808756e34410949e0be68f8410ce,trial,0.358847
uuid-3a6d808756e34410949e0be68f8410ce,Merck,0.401079
uuid-3a6d808756e34410949e0be68f8410ce,PD-L1,0.648953
uuid-3a6d808756e34410949e0be68f8410ce,OS,0.302042
uuid-3a6d808756e34410949e0be68f8410ce,PD-L1 testing,0.45987
uuid-3a6d808756e34410949e0be68f8410ce,testing,0.599101
uuid-3a6d808756e34410949e0be68f8410ce,data,0.375904
uuid-3a6d808756e34410949e0be68f8410ce,PDL1 testing,0.381437
uuid-3a6d808756e34410949e0be68f8410ce,PFS,0.347108
uuid-3a6d808756e34410949e0be68f8410ce,NSCLC patients,0.41448
uuid-3a6d808756e34410949e0be68f8410ce,ORR,0.320844
uuid-3a6d808756e34410949e0be68f8410ce,nivo and pembro,0.40451
uuid-3a6d808756e34410949e0be68f8410ce,assay,0.595056
uuid-3a6d808756e34410949e0be68f8410ce,PDL1 expression,0.605783
uuid-3a6d808756e34410949e0be68f8410ce,biomarker,0.56707
uuid-982b66f2118142459cf9b4208bd6f8e8,PDL1,0.624244
uuid-982b66f2118142459cf9b4208bd6f8e8,trial,0.342214
uuid-982b66f2118142459cf9b4208bd6f8e8,efficacy,0.632165
uuid-982b66f2118142459cf9b4208bd6f8e8,chemo,0.313582
uuid-982b66f2118142459cf9b4208bd6f8e8,OS,0.583408
uuid-982b66f2118142459cf9b4208bd6f8e8,regards,0.346647
uuid-982b66f2118142459cf9b4208bd6f8e8,data,0.463999
uuid-982b66f2118142459cf9b4208bd6f8e8,PFS,0.656568
uuid-982b66f2118142459cf9b4208bd6f8e8,ORR,0.623855
uuid-982b66f2118142459cf9b4208bd6f8e8,nivo and pembro,0.629975
uuid-982b66f2118142459cf9b4208bd6f8e8,believes,0.530352
uuid-982b66f2118142459cf9b4208bd6f8e8,vs,0.308579
uuid-982b66f2118142459cf9b4208bd6f8e8,feels,0.418137
uuid-982b66f2118142459cf9b4208bd6f8e8,PDL1 expression,0.619805
uuid-982b66f2118142459cf9b4208bd6f8e8,biomarker,0.404618
uuid-0cb258e2ea424410ae4035862c293608,pembro,0.470966
uuid-0cb258e2ea424410ae4035862c293608,BMS,0.510908
uuid-0cb258e2ea424410ae4035862c293608,PDL1,0.530304
uuid-0cb258e2ea424410ae4035862c293608,trial,0.781168
uuid-0cb258e2ea424410ae4035862c293608,efficacy,0.49241
uuid-0cb258e2ea424410ae4035862c293608,commented,0.317777
uuid-0cb258e2ea424410ae4035862c293608,Merck,0.523245
uuid-0cb258e2ea424410ae4035862c293608,OS,0.527251
uuid-0cb258e2ea424410ae4035862c293608,atezo,0.356406
uuid-0cb258e2ea424410ae4035862c293608,regards,0.357751
uuid-0cb258e2ea424410ae4035862c293608,data,0.723053
uuid-0cb258e2ea424410ae4035862c293608,expressed,0.303485
uuid-0cb258e2ea424410ae4035862c293608,clinical trials,0.302404
uuid-0cb258e2ea424410ae4035862c293608,PFS,0.561617
uuid-0cb258e2ea424410ae4035862c293608,ORR,0.601425
uuid-0cb258e2ea424410ae4035862c293608,nivo and pembro,0.57408
uuid-0cb258e2ea424410ae4035862c293608,impressed,0.433771
uuid-0cb258e2ea424410ae4035862c293608,vs,0.319533
uuid-0cb258e2ea424410ae4035862c293608,PDL1 expression,0.543335
uuid-0cb258e2ea424410ae4035862c293608,biomarker,0.321112
uuid-d77869844e694074883f6f3318527d2b,pembro,0.311714
uuid-d77869844e694074883f6f3318527d2b,BMS,0.34019
uuid-d77869844e694074883f6f3318527d2b,PDL1,0.634966
uuid-d77869844e694074883f6f3318527d2b,trial,0.330271
uuid-d77869844e694074883f6f3318527d2b,efficacy,0.538172
uuid-d77869844e694074883f6f3318527d2b,Merck,0.365192
uuid-d77869844e694074883f6f3318527d2b,OS,0.388052
uuid-d77869844e694074883f6f3318527d2b,atezo,0.371686
uuid-d77869844e694074883f6f3318527d2b,regards,0.483966
uuid-d77869844e694074883f6f3318527d2b,data,0.506359
uuid-d77869844e694074883f6f3318527d2b,PFS,0.430669
uuid-d77869844e694074883f6f3318527d2b,ORR,0.399611
uuid-d77869844e694074883f6f3318527d2b,nivo and pembro,0.662829
uuid-d77869844e694074883f6f3318527d2b,believes,0.480079
uuid-d77869844e694074883f6f3318527d2b,assay,0.394106
uuid-d77869844e694074883f6f3318527d2b,PDL1 expression,0.537015
uuid-d77869844e694074883f6f3318527d2b,biomarker,0.404993
uuid-a7cd1605cbaf4007b5fee8c32d725b87,PDL1,0.355161
uuid-a7cd1605cbaf4007b5fee8c32d725b87,TL stated,0.324953
uuid-a7cd1605cbaf4007b5fee8c32d725b87,tumor,0.458325
uuid-a7cd1605cbaf4007b5fee8c32d725b87,PD-L1,0.616083
uuid-a7cd1605cbaf4007b5fee8c32d725b87,PD-L1 testing,0.419416
uuid-a7cd1605cbaf4007b5fee8c32d725b87,testing,0.517327
uuid-a7cd1605cbaf4007b5fee8c32d725b87,PDL1 testing,0.453437
uuid-a7cd1605cbaf4007b5fee8c32d725b87,NSCLC patients,0.401088
uuid-a7cd1605cbaf4007b5fee8c32d725b87,assay,0.383661
uuid-a7cd1605cbaf4007b5fee8c32d725b87,biomarker,0.473115
uuid-5aea69cb226743f1b210251bac668cc7,RTL,0.485991
uuid-5aea69cb226743f1b210251bac668cc7,NSCLC,0.340924
uuid-5aea69cb226743f1b210251bac668cc7,NTL,0.392191
uuid-5aea69cb226743f1b210251bac668cc7,melanoma,0.347304
uuid-5aea69cb226743f1b210251bac668cc7,shared,0.424659
uuid-5aea69cb226743f1b210251bac668cc7,IO,0.3265
uuid-5aea69cb226743f1b210251bac668cc7,stated,0.32113
uuid-5aea69cb226743f1b210251bac668cc7,impressed,0.322099
uuid-5aea69cb226743f1b210251bac668cc7,LTL,0.353834
uuid-5aea69cb226743f1b210251bac668cc7,TLs,0.386788
uuid-5aea69cb226743f1b210251bac668cc7,academic,0.358486
uuid-5aea69cb226743f1b210251bac668cc7,Regional TL,0.353227
uuid-2fada1466ff043f883e919100d28f98d,toxicity,0.309241
uuid-2fada1466ff043f883e919100d28f98d,regimen,0.390878
uuid-2fada1466ff043f883e919100d28f98d,combination,0.41208
uuid-2fada1466ff043f883e919100d28f98d,IO,0.446626
uuid-2fada1466ff043f883e919100d28f98d,monotherapy,0.316498
uuid-2fada1466ff043f883e919100d28f98d,response,0.363301
uuid-2fada1466ff043f883e919100d28f98d,combo,0.497191
uuid-2fada1466ff043f883e919100d28f98d,progression,0.372358
uuid-2fada1466ff043f883e919100d28f98d,feels,0.348245
uuid-a06fa20da18a4771ae3a08e6b08e7531,toxicity,0.329139
uuid-a06fa20da18a4771ae3a08e6b08e7531,treatment,0.378289
uuid-a06fa20da18a4771ae3a08e6b08e7531,progression,0.331057
uuid-a06fa20da18a4771ae3a08e6b08e7531,respond,0.435718
uuid-f1d1ef5affe240c7bbca44d046fe9aec,RTL,0.781543
uuid-f1d1ef5affe240c7bbca44d046fe9aec,NTL,0.5543
uuid-f1d1ef5affe240c7bbca44d046fe9aec,shared,0.493553
uuid-f1d1ef5affe240c7bbca44d046fe9aec,commented,0.544074
uuid-f1d1ef5affe240c7bbca44d046fe9aec,stated,0.745065
uuid-f1d1ef5affe240c7bbca44d046fe9aec,physicians,0.404911
uuid-f1d1ef5affe240c7bbca44d046fe9aec,expressed,0.342492
uuid-f1d1ef5affe240c7bbca44d046fe9aec,mentioned,0.49515
uuid-f1d1ef5affe240c7bbca44d046fe9aec,clinical trials,0.322921
uuid-f1d1ef5affe240c7bbca44d046fe9aec,SCCHN,0.539704
uuid-f1d1ef5affe240c7bbca44d046fe9aec,HCP,0.468154
uuid-f1d1ef5affe240c7bbca44d046fe9aec,impressed,0.357196
uuid-f1d1ef5affe240c7bbca44d046fe9aec,LTL,0.667781
uuid-f1d1ef5affe240c7bbca44d046fe9aec,TLs,0.469823
uuid-f1d1ef5affe240c7bbca44d046fe9aec,academic,0.482645
uuid-f1d1ef5affe240c7bbca44d046fe9aec,Regional TL,0.725942
uuid-f1d1ef5affe240c7bbca44d046fe9aec,RTL stated,0.337383
uuid-b54ef180295c4479bb2574bfdb1f33b3,Opdivo,0.303965
uuid-b54ef180295c4479bb2574bfdb1f33b3,dose,0.372117
uuid-b54ef180295c4479bb2574bfdb1f33b3,drug,0.684453
uuid-b54ef180295c4479bb2574bfdb1f33b3,Keytruda,0.41724
uuid-b54ef180295c4479bb2574bfdb1f33b3,flat dosing,0.486364
uuid-ecc9771918dc4a3ba50a9fc8a0882264,patients,0.647166
uuid-ecc9771918dc4a3ba50a9fc8a0882264,Opdivo,0.324009
uuid-ecc9771918dc4a3ba50a9fc8a0882264,therapy,0.583045
uuid-ecc9771918dc4a3ba50a9fc8a0882264,nivolumab,0.522295
uuid-ecc9771918dc4a3ba50a9fc8a0882264,regimen,0.433433
uuid-ecc9771918dc4a3ba50a9fc8a0882264,treated,0.406839
uuid-ecc9771918dc4a3ba50a9fc8a0882264,combination,0.379986
uuid-ecc9771918dc4a3ba50a9fc8a0882264,chemo,0.388736
uuid-ecc9771918dc4a3ba50a9fc8a0882264,pts,0.539942
uuid-ecc9771918dc4a3ba50a9fc8a0882264,IO,0.374196
uuid-ecc9771918dc4a3ba50a9fc8a0882264,monotherapy,0.376435
uuid-ecc9771918dc4a3ba50a9fc8a0882264,treatment,0.592159
uuid-ecc9771918dc4a3ba50a9fc8a0882264,response,0.597232
uuid-ecc9771918dc4a3ba50a9fc8a0882264,PD1,0.416521
uuid-ecc9771918dc4a3ba50a9fc8a0882264,progression,0.653084
uuid-ecc9771918dc4a3ba50a9fc8a0882264,chemotherapy,0.413665
uuid-ecc9771918dc4a3ba50a9fc8a0882264,respond,0.503214
uuid-ecc9771918dc4a3ba50a9fc8a0882264,option,0.322185
uuid-fcd2c4899df54b88b99f187a045ea3ef,Merck,0.369847
uuid-f4be3174f40645ce9d388b41eb814dc8,BMS,0.384013
uuid-f4be3174f40645ce9d388b41eb814dc8,PDL1,0.464399
uuid-f4be3174f40645ce9d388b41eb814dc8,trial,0.395606
uuid-f4be3174f40645ce9d388b41eb814dc8,efficacy,0.38806
uuid-f4be3174f40645ce9d388b41eb814dc8,OS,0.575652
uuid-f4be3174f40645ce9d388b41eb814dc8,data,0.726215
uuid-f4be3174f40645ce9d388b41eb814dc8,PFS,0.546947
uuid-f4be3174f40645ce9d388b41eb814dc8,ORR,0.547225
uuid-f4be3174f40645ce9d388b41eb814dc8,nivo and pembro,0.551549
uuid-f4be3174f40645ce9d388b41eb814dc8,believes,0.42513
uuid-f4be3174f40645ce9d388b41eb814dc8,impressed,0.492124
uuid-f4be3174f40645ce9d388b41eb814dc8,feels,0.477887
uuid-f4be3174f40645ce9d388b41eb814dc8,PDL1 expression,0.361692
uuid-5b42c3f73fea4eca80e3618e0709d496,dose,0.432493
uuid-5b42c3f73fea4eca80e3618e0709d496,indication,0.303262
uuid-5b42c3f73fea4eca80e3618e0709d496,vs,0.386491
uuid-5b42c3f73fea4eca80e3618e0709d496,Keytruda,0.348123
uuid-5b42c3f73fea4eca80e3618e0709d496,flat dosing,0.521194
uuid-3425796e3d6846179e362f92d286d371,patients,0.704579
uuid-3425796e3d6846179e362f92d286d371,Opdivo,0.322455
uuid-3425796e3d6846179e362f92d286d371,therapy,0.505891
uuid-3425796e3d6846179e362f92d286d371,nivolumab,0.406437
uuid-3425796e3d6846179e362f92d286d371,regimen,0.364481
uuid-3425796e3d6846179e362f92d286d371,treated,0.517456
uuid-3425796e3d6846179e362f92d286d371,pts,0.504723
uuid-3425796e3d6846179e362f92d286d371,treatment,0.550331
uuid-3425796e3d6846179e362f92d286d371,response,0.336262
uuid-3425796e3d6846179e362f92d286d371,cHL,0.326296
uuid-3425796e3d6846179e362f92d286d371,progression,0.653271
uuid-3425796e3d6846179e362f92d286d371,respond,0.426454
uuid-3425796e3d6846179e362f92d286d371,TL shared,0.450092
uuid-ba86bffa163149ea9001c9ed71d36171,patients,0.502895
uuid-ba86bffa163149ea9001c9ed71d36171,therapy,0.352682
uuid-ba86bffa163149ea9001c9ed71d36171,nivolumab,0.305413
uuid-ba86bffa163149ea9001c9ed71d36171,toxicity,0.302093
uuid-ba86bffa163149ea9001c9ed71d36171,regimen,0.445455
uuid-ba86bffa163149ea9001c9ed71d36171,treated,0.402998
uuid-ba86bffa163149ea9001c9ed71d36171,chemo,0.331768
uuid-ba86bffa163149ea9001c9ed71d36171,pts,0.5312
uuid-ba86bffa163149ea9001c9ed71d36171,monotherapy,0.357896
uuid-ba86bffa163149ea9001c9ed71d36171,treatment,0.394112
uuid-ba86bffa163149ea9001c9ed71d36171,response,0.522968
uuid-ba86bffa163149ea9001c9ed71d36171,PD1,0.414109
uuid-ba86bffa163149ea9001c9ed71d36171,progression,0.629084
uuid-ba86bffa163149ea9001c9ed71d36171,respond,0.463068
uuid-ba86bffa163149ea9001c9ed71d36171,TL shared,0.440567
uuid-b4a948d58ec14c9dac95068097b0b634,TL,0.45844
uuid-b4a948d58ec14c9dac95068097b0b634,RTL,0.521315
uuid-b4a948d58ec14c9dac95068097b0b634,NTL,0.421874
uuid-b4a948d58ec14c9dac95068097b0b634,shared,0.459243
uuid-b4a948d58ec14c9dac95068097b0b634,commented,0.387136
uuid-b4a948d58ec14c9dac95068097b0b634,TL stated,0.38277
uuid-b4a948d58ec14c9dac95068097b0b634,stated,0.516776
uuid-b4a948d58ec14c9dac95068097b0b634,physicians,0.55314
uuid-b4a948d58ec14c9dac95068097b0b634,PD-L1 testing,0.333202
uuid-b4a948d58ec14c9dac95068097b0b634,oncology,0.451302
uuid-b4a948d58ec14c9dac95068097b0b634,SCCHN,0.437557
uuid-b4a948d58ec14c9dac95068097b0b634,HCP,0.321828
uuid-b4a948d58ec14c9dac95068097b0b634,oncologist,0.415559
uuid-b4a948d58ec14c9dac95068097b0b634,indicated,0.376564
uuid-b4a948d58ec14c9dac95068097b0b634,LTL,0.497518
uuid-b4a948d58ec14c9dac95068097b0b634,TLs,0.521968
uuid-b4a948d58ec14c9dac95068097b0b634,clinical,0.345411
uuid-b4a948d58ec14c9dac95068097b0b634,academic,0.526042
uuid-b4a948d58ec14c9dac95068097b0b634,Regional TL,0.655829
uuid-23c54945a1f9480cacf843850fb005e4,Nivo,0.319862
uuid-23c54945a1f9480cacf843850fb005e4,pembro,0.532985
uuid-23c54945a1f9480cacf843850fb005e4,BMS,0.335623
uuid-23c54945a1f9480cacf843850fb005e4,1L,0.351163
uuid-23c54945a1f9480cacf843850fb005e4,PDL1,0.545994
uuid-23c54945a1f9480cacf843850fb005e4,trial,0.347167
uuid-23c54945a1f9480cacf843850fb005e4,efficacy,0.347348
uuid-23c54945a1f9480cacf843850fb005e4,agents,0.303537
uuid-23c54945a1f9480cacf843850fb005e4,Merck,0.376001
uuid-23c54945a1f9480cacf843850fb005e4,OS,0.338251
uuid-23c54945a1f9480cacf843850fb005e4,atezo,0.401902
uuid-23c54945a1f9480cacf843850fb005e4,data,0.526029
uuid-23c54945a1f9480cacf843850fb005e4,PFS,0.313132
uuid-23c54945a1f9480cacf843850fb005e4,ORR,0.335512
uuid-23c54945a1f9480cacf843850fb005e4,nivo and pembro,0.494323
uuid-23c54945a1f9480cacf843850fb005e4,believes,0.325812
uuid-23c54945a1f9480cacf843850fb005e4,feels,0.453581
uuid-23c54945a1f9480cacf843850fb005e4,PDL1 expression,0.467219
uuid-b4ac14621d934174afd5c105085db905,pembro,0.39675
uuid-b4ac14621d934174afd5c105085db905,BMS,0.309285
uuid-b4ac14621d934174afd5c105085db905,PDL1,0.362763
uuid-b4ac14621d934174afd5c105085db905,trial,0.610997
uuid-b4ac14621d934174afd5c105085db905,efficacy,0.321413
uuid-b4ac14621d934174afd5c105085db905,commented,0.422965
uuid-b4ac14621d934174afd5c105085db905,Merck,0.313085
uuid-b4ac14621d934174afd5c105085db905,OS,0.5199
uuid-b4ac14621d934174afd5c105085db905,data,0.652636
uuid-b4ac14621d934174afd5c105085db905,clinical trials,0.316557
uuid-b4ac14621d934174afd5c105085db905,PFS,0.513936
uuid-b4ac14621d934174afd5c105085db905,ORR,0.600269
uuid-b4ac14621d934174afd5c105085db905,nivo and pembro,0.374702
uuid-b4ac14621d934174afd5c105085db905,impressed,0.580723
uuid-b4ac14621d934174afd5c105085db905,feels,0.336393
uuid-b4ac14621d934174afd5c105085db905,PDL1 expression,0.376377
uuid-8e7a463b36e84d7586d2635ee3a50560,discussed,0.349516
uuid-8e7a463b36e84d7586d2635ee3a50560,data,0.393678
uuid-8e7a463b36e84d7586d2635ee3a50560,cHL,0.443108
uuid-04c6c028741b495c8362fdee7cdbb7fc,lung,0.388226
uuid-04c6c028741b495c8362fdee7cdbb7fc,AI,0.470583
uuid-04c6c028741b495c8362fdee7cdbb7fc,oncologist,0.533965
uuid-04c6c028741b495c8362fdee7cdbb7fc,indicated,0.683599
uuid-e89e49be254d451f8af45daab8c1126f,patients,0.556405
uuid-e89e49be254d451f8af45daab8c1126f,therapy,0.307274
uuid-e89e49be254d451f8af45daab8c1126f,nivolumab,0.320784
uuid-e89e49be254d451f8af45daab8c1126f,1L,0.425161
uuid-e89e49be254d451f8af45daab8c1126f,regimen,0.44876
uuid-e89e49be254d451f8af45daab8c1126f,treated,0.333898
uuid-e89e49be254d451f8af45daab8c1126f,2L,0.453461
uuid-e89e49be254d451f8af45daab8c1126f,pts,0.318711
uuid-e89e49be254d451f8af45daab8c1126f,preferred,0.690705
uuid-e89e49be254d451f8af45daab8c1126f,monotherapy,0.530433
uuid-e89e49be254d451f8af45daab8c1126f,treatment,0.406301
uuid-e89e49be254d451f8af45daab8c1126f,using nivo,0.448846
uuid-e89e49be254d451f8af45daab8c1126f,indication,0.319929
uuid-e89e49be254d451f8af45daab8c1126f,NSCLC patients,0.30375
uuid-e89e49be254d451f8af45daab8c1126f,approved,0.307903
uuid-e89e49be254d451f8af45daab8c1126f,SCCHN,0.323975
uuid-e89e49be254d451f8af45daab8c1126f,chemotherapy,0.343968
uuid-e89e49be254d451f8af45daab8c1126f,RTL stated,0.443919
uuid-e89e49be254d451f8af45daab8c1126f,option,0.636334
uuid-61b26b84842c43d1b911dca2b188f500,lung,0.633209
uuid-61b26b84842c43d1b911dca2b188f500,melanoma,0.509467
uuid-61b26b84842c43d1b911dca2b188f500,RCC,0.488119
uuid-61b26b84842c43d1b911dca2b188f500,using nivo,0.328667
uuid-61b26b84842c43d1b911dca2b188f500,AI,0.614587
uuid-61b26b84842c43d1b911dca2b188f500,SCCHN,0.306843
uuid-61b26b84842c43d1b911dca2b188f500,oncologist,0.583091
uuid-61b26b84842c43d1b911dca2b188f500,indicated,0.577336
uuid-61b26b84842c43d1b911dca2b188f500,TL shared,0.402551
uuid-61b26b84842c43d1b911dca2b188f500,NCCN,0.37977
uuid-bd7976fda3d2452f8d11c855f21ca4d9,melanoma,0.311757
uuid-bd7976fda3d2452f8d11c855f21ca4d9,shared,0.376532
uuid-bd7976fda3d2452f8d11c855f21ca4d9,tumor,0.321093
uuid-bd7976fda3d2452f8d11c855f21ca4d9,institution,0.322904
uuid-bd7976fda3d2452f8d11c855f21ca4d9,physicians,0.507255
uuid-bd7976fda3d2452f8d11c855f21ca4d9,oncologist,0.34238
uuid-bd7976fda3d2452f8d11c855f21ca4d9,clinical,0.307976
uuid-bd7976fda3d2452f8d11c855f21ca4d9,academic,0.457636
uuid-bd7976fda3d2452f8d11c855f21ca4d9,Regional TL,0.301863
uuid-613efc9f2a7640d79b7e5a79a821c59e,TL,0.425518
uuid-613efc9f2a7640d79b7e5a79a821c59e,PDL1,0.477447
uuid-613efc9f2a7640d79b7e5a79a821c59e,TL stated,0.375658
uuid-613efc9f2a7640d79b7e5a79a821c59e,PD-L1,0.793348
uuid-613efc9f2a7640d79b7e5a79a821c59e,PD-L1 testing,0.834214
uuid-613efc9f2a7640d79b7e5a79a821c59e,testing,0.911915
uuid-613efc9f2a7640d79b7e5a79a821c59e,PDL1 testing,0.740276
uuid-613efc9f2a7640d79b7e5a79a821c59e,NSCLC patients,0.672651
uuid-613efc9f2a7640d79b7e5a79a821c59e,assay,0.694814
uuid-613efc9f2a7640d79b7e5a79a821c59e,PDL1 expression,0.310335
uuid-613efc9f2a7640d79b7e5a79a821c59e,biomarker,0.493441
uuid-80b912168d6b4ee89693385ddc39d5dc,regimen,0.411493
uuid-80b912168d6b4ee89693385ddc39d5dc,combination,0.582361
uuid-80b912168d6b4ee89693385ddc39d5dc,chemo,0.453727
uuid-80b912168d6b4ee89693385ddc39d5dc,pts,0.463833
uuid-80b912168d6b4ee89693385ddc39d5dc,IO,0.489713
uuid-80b912168d6b4ee89693385ddc39d5dc,Ipi,0.334726
uuid-80b912168d6b4ee89693385ddc39d5dc,monotherapy,0.411436
uuid-80b912168d6b4ee89693385ddc39d5dc,response,0.567291
uuid-80b912168d6b4ee89693385ddc39d5dc,combo,0.505968
uuid-80b912168d6b4ee89693385ddc39d5dc,PD1,0.407407
uuid-80b912168d6b4ee89693385ddc39d5dc,progression,0.492899
uuid-80b912168d6b4ee89693385ddc39d5dc,chemotherapy,0.399582
uuid-80b912168d6b4ee89693385ddc39d5dc,respond,0.353079
uuid-80b912168d6b4ee89693385ddc39d5dc,feels,0.322711
uuid-27067fe6adea4803bb40fa6889f933a6,Nivo,0.310242
uuid-27067fe6adea4803bb40fa6889f933a6,pembro,0.36232
uuid-27067fe6adea4803bb40fa6889f933a6,lung,0.378001
uuid-27067fe6adea4803bb40fa6889f933a6,PDL1,0.322171
uuid-27067fe6adea4803bb40fa6889f933a6,efficacy,0.447341
uuid-27067fe6adea4803bb40fa6889f933a6,discussed,0.330393
uuid-27067fe6adea4803bb40fa6889f933a6,OS,0.43661
uuid-27067fe6adea4803bb40fa6889f933a6,atezo,0.35615
uuid-27067fe6adea4803bb40fa6889f933a6,regards,0.430771
uuid-27067fe6adea4803bb40fa6889f933a6,data,0.385969
uuid-27067fe6adea4803bb40fa6889f933a6,PFS,0.496843
uuid-27067fe6adea4803bb40fa6889f933a6,AI,0.545168
uuid-27067fe6adea4803bb40fa6889f933a6,ORR,0.426164
uuid-27067fe6adea4803bb40fa6889f933a6,nivo and pembro,0.644807
uuid-27067fe6adea4803bb40fa6889f933a6,believes,0.363493
uuid-27067fe6adea4803bb40fa6889f933a6,vs,0.35635
uuid-27067fe6adea4803bb40fa6889f933a6,TLs,0.313015
uuid-27067fe6adea4803bb40fa6889f933a6,PDL1 expression,0.352906
uuid-fb8e8717697a485da21a258a1c6f0061,pembro,0.321078
uuid-fb8e8717697a485da21a258a1c6f0061,BMS,0.394743
uuid-fb8e8717697a485da21a258a1c6f0061,PDL1,0.406625
uuid-fb8e8717697a485da21a258a1c6f0061,trial,0.442886
uuid-fb8e8717697a485da21a258a1c6f0061,efficacy,0.417039
uuid-fb8e8717697a485da21a258a1c6f0061,discussed,0.31001
uuid-fb8e8717697a485da21a258a1c6f0061,commented,0.449691
uuid-fb8e8717697a485da21a258a1c6f0061,Merck,0.330813
uuid-fb8e8717697a485da21a258a1c6f0061,stated,0.317885
uuid-fb8e8717697a485da21a258a1c6f0061,OS,0.604122
uuid-fb8e8717697a485da21a258a1c6f0061,regards,0.307403
uuid-fb8e8717697a485da21a258a1c6f0061,data,0.893153
uuid-fb8e8717697a485da21a258a1c6f0061,PFS,0.56499
uuid-fb8e8717697a485da21a258a1c6f0061,ORR,0.611838
uuid-fb8e8717697a485da21a258a1c6f0061,nivo and pembro,0.510324
uuid-fb8e8717697a485da21a258a1c6f0061,ASCO,0.376732
uuid-fb8e8717697a485da21a258a1c6f0061,impressed,0.620144
uuid-fb8e8717697a485da21a258a1c6f0061,feels,0.400849
uuid-fb8e8717697a485da21a258a1c6f0061,PDL1 expression,0.38037
uuid-d3edc377386044f3befce8ab7b94ca72,lung,0.411586
uuid-d3edc377386044f3befce8ab7b94ca72,regimen,0.356556
uuid-d3edc377386044f3befce8ab7b94ca72,melanoma,0.406428
uuid-d3edc377386044f3befce8ab7b94ca72,chemo,0.308375
uuid-d3edc377386044f3befce8ab7b94ca72,Ipi,0.343264
uuid-d3edc377386044f3befce8ab7b94ca72,monotherapy,0.334937
uuid-d3edc377386044f3befce8ab7b94ca72,combo,0.373481
uuid-d3edc377386044f3befce8ab7b94ca72,AI,0.37405
uuid-d3edc377386044f3befce8ab7b94ca72,believes,0.305924
uuid-d3edc377386044f3befce8ab7b94ca72,TL shared,0.309828
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,1L,0.333546
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,RCC,0.351022
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,2L,0.330844
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,agents,0.321566
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,preferred,0.479606
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,using nivo,0.308307
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,data,0.322798
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,indication,0.383377
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,SCCHN,0.471696
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,feels,0.390637
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,Regional TL,0.322678
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,RTL stated,0.379951
uuid-cdd6a8f69d1548d597e2da7f4e3edf22,option,0.33626
uuid-37d9a5a63c1f4add83da2bdb627c17bc,TL,0.410999
uuid-37d9a5a63c1f4add83da2bdb627c17bc,RTL,0.48458
uuid-37d9a5a63c1f4add83da2bdb627c17bc,NTL,0.317025
uuid-37d9a5a63c1f4add83da2bdb627c17bc,melanoma,0.411225
uuid-37d9a5a63c1f4add83da2bdb627c17bc,shared,0.414548
uuid-37d9a5a63c1f4add83da2bdb627c17bc,RCC,0.519281
uuid-37d9a5a63c1f4add83da2bdb627c17bc,TL stated,0.385049
uuid-37d9a5a63c1f4add83da2bdb627c17bc,2L,0.308332
uuid-37d9a5a63c1f4add83da2bdb627c17bc,institution,0.336376
uuid-37d9a5a63c1f4add83da2bdb627c17bc,approval,0.379258
uuid-37d9a5a63c1f4add83da2bdb627c17bc,preferred,0.377934
uuid-37d9a5a63c1f4add83da2bdb627c17bc,PD-L1 testing,0.312212
uuid-37d9a5a63c1f4add83da2bdb627c17bc,using nivo,0.374202
uuid-37d9a5a63c1f4add83da2bdb627c17bc,clinical trials,0.429239
uuid-37d9a5a63c1f4add83da2bdb627c17bc,PDL1 testing,0.343261
uuid-37d9a5a63c1f4add83da2bdb627c17bc,SCCHN,0.570189
uuid-37d9a5a63c1f4add83da2bdb627c17bc,LTL,0.321218
uuid-37d9a5a63c1f4add83da2bdb627c17bc,academic,0.348982
uuid-37d9a5a63c1f4add83da2bdb627c17bc,Regional TL,0.448132
uuid-37d9a5a63c1f4add83da2bdb627c17bc,RTL stated,0.588032
uuid-37d9a5a63c1f4add83da2bdb627c17bc,TL shared,0.436233
uuid-37d9a5a63c1f4add83da2bdb627c17bc,bladder,0.423306
uuid-f1c194c185d84d05be18e34544c1b108,patients,0.365802
uuid-f1c194c185d84d05be18e34544c1b108,pembro,0.361664
uuid-f1c194c185d84d05be18e34544c1b108,1L,0.413815
uuid-f1c194c185d84d05be18e34544c1b108,RCC,0.312372
uuid-f1c194c185d84d05be18e34544c1b108,TL stated,0.361237
uuid-f1c194c185d84d05be18e34544c1b108,2L,0.404524
uuid-f1c194c185d84d05be18e34544c1b108,Merck,0.361111
uuid-f1c194c185d84d05be18e34544c1b108,approval,0.41003
uuid-f1c194c185d84d05be18e34544c1b108,preferred,0.381584
uuid-f1c194c185d84d05be18e34544c1b108,testing,0.304249
uuid-f1c194c185d84d05be18e34544c1b108,using nivo,0.415195
uuid-f1c194c185d84d05be18e34544c1b108,PDL1 testing,0.426721
uuid-f1c194c185d84d05be18e34544c1b108,NSCLC patients,0.407532
uuid-f1c194c185d84d05be18e34544c1b108,approved,0.400026
uuid-f1c194c185d84d05be18e34544c1b108,feels,0.302319
uuid-f1c194c185d84d05be18e34544c1b108,RTL stated,0.358792
uuid-f1c194c185d84d05be18e34544c1b108,option,0.300987
uuid-1bf8f844fce84bc4a963717f70755d4a,tumor,0.567998
uuid-1bf8f844fce84bc4a963717f70755d4a,lung cancer,0.361027
uuid-1bf8f844fce84bc4a963717f70755d4a,immunotherapy,0.501526
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,Nivo,0.437829
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,pembro,0.680194
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,dose,0.575138
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,1L,0.326597
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,efficacy,0.480838
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,2L,0.460231
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,agents,0.446392
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,Ipi,0.426481
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,atezo,0.725678
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,preferred,0.51708
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,combo,0.30819
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,indication,0.408707
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,approved,0.424325
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,nivo and pembro,0.346071
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,vs,0.727009
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,feels,0.354006
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,option,0.328168
uuid-1c7a6f450957444f8986c1c6f8a2d1f5,flat dosing,0.476374
uuid-3c79b6ad3b6f4d408bf8cb884265e06d,PDL1,0.485166
uuid-3c79b6ad3b6f4d408bf8cb884265e06d,trial,0.414731
uuid-3c79b6ad3b6f4d408bf8cb884265e06d,efficacy,0.343072
uuid-3c79b6ad3b6f4d408bf8cb884265e06d,discussed,0.524327
uuid-3c79b6ad3b6f4d408bf8cb884265e06d,OS,0.477294
uuid-3c79b6ad3b6f4d408bf8cb884265e06d,regards,0.362738
uuid-3c79b6ad3b6f4d408bf8cb884265e06d,data,0.485713
uuid-3c79b6ad3b6f4d408bf8cb884265e06d,PFS,0.537374
uuid-3c79b6ad3b6f4d408bf8cb884265e06d,ORR,0.50165
uuid-3c79b6ad3b6f4d408bf8cb884265e06d,nivo and pembro,0.366679
uuid-3c79b6ad3b6f4d408bf8cb884265e06d,PDL1 expression,0.473521
uuid-3c79b6ad3b6f4d408bf8cb884265e06d,biomarker,0.319654
uuid-1febdd27b5e54e2784040c7c7cb17c8c,NSCLC,0.370063
uuid-1febdd27b5e54e2784040c7c7cb17c8c,efficacy,0.351937
uuid-1febdd27b5e54e2784040c7c7cb17c8c,discussed,0.694042
uuid-1febdd27b5e54e2784040c7c7cb17c8c,OS,0.384968
uuid-1febdd27b5e54e2784040c7c7cb17c8c,regards,0.423724
uuid-1febdd27b5e54e2784040c7c7cb17c8c,data,0.393534
uuid-1febdd27b5e54e2784040c7c7cb17c8c,PFS,0.396419
uuid-1febdd27b5e54e2784040c7c7cb17c8c,AI,0.323607
uuid-1febdd27b5e54e2784040c7c7cb17c8c,ORR,0.399994
uuid-1febdd27b5e54e2784040c7c7cb17c8c,academic,0.380629
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,NSCLC,0.390495
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,PDL1,0.335281
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,efficacy,0.445364
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,discussed,0.547237
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,IO,0.338744
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,OS,0.364843
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,regards,0.302733
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,data,0.303389
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,PFS,0.400549
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,ORR,0.370634
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,nivo and pembro,0.371914
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,believes,0.308922
uuid-82f4b40fa4544fd5ab5d09e7a532f8fc,PDL1 expression,0.304363
uuid-9295acc883a248358c1f3b0aa31b2c9d,Nivo,0.326213
uuid-9295acc883a248358c1f3b0aa31b2c9d,pembro,0.34111
uuid-9295acc883a248358c1f3b0aa31b2c9d,lung,0.309893
uuid-9295acc883a248358c1f3b0aa31b2c9d,NSCLC,0.468199
uuid-9295acc883a248358c1f3b0aa31b2c9d,1L,0.494322
uuid-9295acc883a248358c1f3b0aa31b2c9d,discussed,0.337708
uuid-9295acc883a248358c1f3b0aa31b2c9d,chemo,0.302818
uuid-9295acc883a248358c1f3b0aa31b2c9d,2L,0.429239
uuid-9295acc883a248358c1f3b0aa31b2c9d,IO,0.332242
uuid-9295acc883a248358c1f3b0aa31b2c9d,atezo,0.340254
uuid-9295acc883a248358c1f3b0aa31b2c9d,preferred,0.333949
uuid-9295acc883a248358c1f3b0aa31b2c9d,monotherapy,0.389847
uuid-9295acc883a248358c1f3b0aa31b2c9d,nivo and pembro,0.301403
uuid-9295acc883a248358c1f3b0aa31b2c9d,option,0.393636
uuid-00fe6214f69e4867abb1b91d689a6489,patients,0.499443
uuid-00fe6214f69e4867abb1b91d689a6489,Opdivo,0.585301
uuid-00fe6214f69e4867abb1b91d689a6489,dose,0.514324
uuid-00fe6214f69e4867abb1b91d689a6489,nivolumab,0.343227
uuid-00fe6214f69e4867abb1b91d689a6489,treated,0.330827
uuid-00fe6214f69e4867abb1b91d689a6489,approval,0.314834
uuid-00fe6214f69e4867abb1b91d689a6489,physicians,0.508167
uuid-00fe6214f69e4867abb1b91d689a6489,HCP,0.327248
uuid-00fe6214f69e4867abb1b91d689a6489,flat dosing,0.563034
uuid-50d6a35c9fdc4a04adca8f32828ac494,Opdivo,0.364788
uuid-50d6a35c9fdc4a04adca8f32828ac494,TL,0.374857
uuid-50d6a35c9fdc4a04adca8f32828ac494,dose,0.403971
uuid-50d6a35c9fdc4a04adca8f32828ac494,shared,0.4612
uuid-50d6a35c9fdc4a04adca8f32828ac494,physicians,0.475102
uuid-50d6a35c9fdc4a04adca8f32828ac494,HCP,0.322421
uuid-50d6a35c9fdc4a04adca8f32828ac494,indicated,0.362837
uuid-50d6a35c9fdc4a04adca8f32828ac494,LTL,0.369028
uuid-50d6a35c9fdc4a04adca8f32828ac494,TLs,0.352606
uuid-50d6a35c9fdc4a04adca8f32828ac494,academic,0.319588
uuid-50d6a35c9fdc4a04adca8f32828ac494,Regional TL,0.349784
uuid-50d6a35c9fdc4a04adca8f32828ac494,flat dosing,0.605917
uuid-28fab3de52d645a8a3113d873aedd460,Opdivo,0.396174
uuid-28fab3de52d645a8a3113d873aedd460,dose,0.477185
uuid-28fab3de52d645a8a3113d873aedd460,toxicity,0.313145
uuid-28fab3de52d645a8a3113d873aedd460,preferred,0.333239
uuid-28fab3de52d645a8a3113d873aedd460,indication,0.404709
uuid-28fab3de52d645a8a3113d873aedd460,drug,0.338604
uuid-28fab3de52d645a8a3113d873aedd460,Keytruda,0.453727
uuid-28fab3de52d645a8a3113d873aedd460,flat dosing,0.606921
uuid-a5a027a5eb2b492f9fe0606ba212fc44,BMS,0.520473
uuid-a5a027a5eb2b492f9fe0606ba212fc44,PDL1,0.401887
uuid-a5a027a5eb2b492f9fe0606ba212fc44,efficacy,0.698999
uuid-a5a027a5eb2b492f9fe0606ba212fc44,agents,0.3248
uuid-a5a027a5eb2b492f9fe0606ba212fc44,OS,0.412144
uuid-a5a027a5eb2b492f9fe0606ba212fc44,regards,0.398591
uuid-a5a027a5eb2b492f9fe0606ba212fc44,data,0.469619
uuid-a5a027a5eb2b492f9fe0606ba212fc44,PFS,0.415364
uuid-a5a027a5eb2b492f9fe0606ba212fc44,ORR,0.478874
uuid-a5a027a5eb2b492f9fe0606ba212fc44,nivo and pembro,0.427852
uuid-a5a027a5eb2b492f9fe0606ba212fc44,believes,0.465156
uuid-a5a027a5eb2b492f9fe0606ba212fc44,impressed,0.353499
uuid-a5a027a5eb2b492f9fe0606ba212fc44,feels,0.49319
uuid-a5a027a5eb2b492f9fe0606ba212fc44,PDL1 expression,0.373996
uuid-a5a027a5eb2b492f9fe0606ba212fc44,biomarker,0.341835
uuid-dbd5e3be34994ad49d507e99f239ae8e,pembro,0.504871
uuid-dbd5e3be34994ad49d507e99f239ae8e,BMS,0.405779
uuid-dbd5e3be34994ad49d507e99f239ae8e,1L,0.374247
uuid-dbd5e3be34994ad49d507e99f239ae8e,PDL1,0.670316
uuid-dbd5e3be34994ad49d507e99f239ae8e,trial,0.365025
uuid-dbd5e3be34994ad49d507e99f239ae8e,efficacy,0.374826
uuid-dbd5e3be34994ad49d507e99f239ae8e,2L,0.306715
uuid-dbd5e3be34994ad49d507e99f239ae8e,Merck,0.491413
uuid-dbd5e3be34994ad49d507e99f239ae8e,PD-L1,0.39131
uuid-dbd5e3be34994ad49d507e99f239ae8e,OS,0.314834
uuid-dbd5e3be34994ad49d507e99f239ae8e,atezo,0.562475
uuid-dbd5e3be34994ad49d507e99f239ae8e,data,0.506565
uuid-dbd5e3be34994ad49d507e99f239ae8e,indication,0.441878
uuid-dbd5e3be34994ad49d507e99f239ae8e,PFS,0.320915
uuid-dbd5e3be34994ad49d507e99f239ae8e,ORR,0.320232
uuid-dbd5e3be34994ad49d507e99f239ae8e,nivo and pembro,0.506464
uuid-dbd5e3be34994ad49d507e99f239ae8e,TLs,0.358125
uuid-dbd5e3be34994ad49d507e99f239ae8e,assay,0.354603
uuid-dbd5e3be34994ad49d507e99f239ae8e,PDL1 expression,0.666279
uuid-dbd5e3be34994ad49d507e99f239ae8e,biomarker,0.491204
uuid-dbd5e3be34994ad49d507e99f239ae8e,bladder,0.334434
uuid-91968cce721742148374c18b1fa2d090,TL,0.452369
uuid-91968cce721742148374c18b1fa2d090,1L,0.340048
uuid-91968cce721742148374c18b1fa2d090,PDL1,0.303428
uuid-91968cce721742148374c18b1fa2d090,TL stated,0.402995
uuid-91968cce721742148374c18b1fa2d090,2L,0.301225
uuid-91968cce721742148374c18b1fa2d090,Merck,0.314344
uuid-91968cce721742148374c18b1fa2d090,institution,0.409026
uuid-91968cce721742148374c18b1fa2d090,PD-L1,0.733061
uuid-91968cce721742148374c18b1fa2d090,approval,0.388832
uuid-91968cce721742148374c18b1fa2d090,atezo,0.322846
uuid-91968cce721742148374c18b1fa2d090,preferred,0.319112
uuid-91968cce721742148374c18b1fa2d090,PD-L1 testing,0.798154
uuid-91968cce721742148374c18b1fa2d090,testing,0.880216
uuid-91968cce721742148374c18b1fa2d090,PDL1 testing,0.744787
uuid-91968cce721742148374c18b1fa2d090,NSCLC patients,0.656679
uuid-91968cce721742148374c18b1fa2d090,approved,0.351359
uuid-91968cce721742148374c18b1fa2d090,assay,0.661218
uuid-91968cce721742148374c18b1fa2d090,biomarker,0.324463
uuid-b95a7cbfd8944ff1a957f587c45d3e08,RTL,0.500502
uuid-b95a7cbfd8944ff1a957f587c45d3e08,lung,0.447122
uuid-b95a7cbfd8944ff1a957f587c45d3e08,NTL,0.455321
uuid-b95a7cbfd8944ff1a957f587c45d3e08,melanoma,0.406224
uuid-b95a7cbfd8944ff1a957f587c45d3e08,shared,0.694186
uuid-b95a7cbfd8944ff1a957f587c45d3e08,commented,0.569585
uuid-b95a7cbfd8944ff1a957f587c45d3e08,RCC,0.570908
uuid-b95a7cbfd8944ff1a957f587c45d3e08,TL stated,0.553481
uuid-b95a7cbfd8944ff1a957f587c45d3e08,institution,0.309739
uuid-b95a7cbfd8944ff1a957f587c45d3e08,stated,0.552773
uuid-b95a7cbfd8944ff1a957f587c45d3e08,approval,0.30569
uuid-b95a7cbfd8944ff1a957f587c45d3e08,expressed,0.440987
uuid-b95a7cbfd8944ff1a957f587c45d3e08,PDL1 testing,0.335769
uuid-b95a7cbfd8944ff1a957f587c45d3e08,SCCHN,0.588628
uuid-b95a7cbfd8944ff1a957f587c45d3e08,HCP,0.378419
uuid-b95a7cbfd8944ff1a957f587c45d3e08,impressed,0.385406
uuid-b95a7cbfd8944ff1a957f587c45d3e08,tumor types,0.328118
uuid-b95a7cbfd8944ff1a957f587c45d3e08,LTL,0.491458
uuid-b95a7cbfd8944ff1a957f587c45d3e08,TLs,0.498133
uuid-b95a7cbfd8944ff1a957f587c45d3e08,academic,0.374287
uuid-b95a7cbfd8944ff1a957f587c45d3e08,Regional TL,0.599253
uuid-b95a7cbfd8944ff1a957f587c45d3e08,RTL stated,0.477705
uuid-b95a7cbfd8944ff1a957f587c45d3e08,TL shared,0.482941
uuid-b95a7cbfd8944ff1a957f587c45d3e08,bladder,0.381369
uuid-e163d795bdf244a594e22516d2a79e8a,patients,0.6647
uuid-e163d795bdf244a594e22516d2a79e8a,regimen,0.300245
uuid-e163d795bdf244a594e22516d2a79e8a,treated,0.411135
uuid-e163d795bdf244a594e22516d2a79e8a,pts,0.505577
uuid-e163d795bdf244a594e22516d2a79e8a,monotherapy,0.32572
uuid-e163d795bdf244a594e22516d2a79e8a,treatment,0.366222
uuid-e163d795bdf244a594e22516d2a79e8a,clinical trials,0.301697
uuid-e163d795bdf244a594e22516d2a79e8a,NSCLC patients,0.385296
uuid-e163d795bdf244a594e22516d2a79e8a,progression,0.371907
uuid-e163d795bdf244a594e22516d2a79e8a,tumor types,0.346953
uuid-e163d795bdf244a594e22516d2a79e8a,respond,0.325239
uuid-e163d795bdf244a594e22516d2a79e8a,option,0.336534
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,TL,0.445644
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,RTL,0.547624
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,BMS,0.377507
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,NTL,0.416378
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,shared,0.554762
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,commented,0.574836
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,TL stated,0.488374
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,Merck,0.496855
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,institution,0.335443
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,stated,0.547885
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,PD-L1,0.303881
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,approval,0.310876
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,PD-L1 testing,0.408111
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,testing,0.405013
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,data,0.335529
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,expressed,0.488679
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,mentioned,0.302187
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,clinical trials,0.348015
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,PDL1 testing,0.470868
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,SCCHN,0.461105
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,HCP,0.352116
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,ASCO,0.323541
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,impressed,0.382082
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,LTL,0.451475
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,TLs,0.420929
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,academic,0.330888
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,Regional TL,0.564831
uuid-fa97597f9b9b4c13a24dbe95b4e8a259,bladder,0.347087
uuid-91176e7ea57b44a799e87a019660398d,patients,0.719827
uuid-91176e7ea57b44a799e87a019660398d,therapy,0.352561
uuid-91176e7ea57b44a799e87a019660398d,nivolumab,0.343239
uuid-91176e7ea57b44a799e87a019660398d,regimen,0.389711
uuid-91176e7ea57b44a799e87a019660398d,treated,0.601811
uuid-91176e7ea57b44a799e87a019660398d,pts,0.544587
uuid-91176e7ea57b44a799e87a019660398d,monotherapy,0.347147
uuid-91176e7ea57b44a799e87a019660398d,treatment,0.476436
uuid-91176e7ea57b44a799e87a019660398d,NSCLC patients,0.373011
uuid-91176e7ea57b44a799e87a019660398d,progression,0.442727
uuid-91176e7ea57b44a799e87a019660398d,tumor types,0.32916
uuid-91176e7ea57b44a799e87a019660398d,respond,0.36855
uuid-91176e7ea57b44a799e87a019660398d,RTL stated,0.328441
uuid-91176e7ea57b44a799e87a019660398d,TL shared,0.31443
uuid-91176e7ea57b44a799e87a019660398d,option,0.322291
uuid-1c129b1645c44035abaf5e23d744e918,Nivo,0.378802
uuid-1c129b1645c44035abaf5e23d744e918,pembro,0.468993
uuid-1c129b1645c44035abaf5e23d744e918,dose,0.652366
uuid-1c129b1645c44035abaf5e23d744e918,trial,0.482244
uuid-1c129b1645c44035abaf5e23d744e918,efficacy,0.424147
uuid-1c129b1645c44035abaf5e23d744e918,combination,0.417475
uuid-1c129b1645c44035abaf5e23d744e918,Ipi,0.752742
uuid-1c129b1645c44035abaf5e23d744e918,atezo,0.413434
uuid-1c129b1645c44035abaf5e23d744e918,combo,0.452589
uuid-1c129b1645c44035abaf5e23d744e918,vs,0.560953
uuid-1c129b1645c44035abaf5e23d744e918,flat dosing,0.469764
uuid-a3c51dd187844955acf21eb31ed358d2,patients,0.486397
uuid-a3c51dd187844955acf21eb31ed358d2,Opdivo,0.599566
uuid-a3c51dd187844955acf21eb31ed358d2,dose,0.792129
uuid-a3c51dd187844955acf21eb31ed358d2,nivolumab,0.355319
uuid-a3c51dd187844955acf21eb31ed358d2,toxicity,0.345722
uuid-a3c51dd187844955acf21eb31ed358d2,regimen,0.359435
uuid-a3c51dd187844955acf21eb31ed358d2,Ipi,0.361209
uuid-a3c51dd187844955acf21eb31ed358d2,physicians,0.316963
uuid-a3c51dd187844955acf21eb31ed358d2,treatment,0.354792
uuid-a3c51dd187844955acf21eb31ed358d2,vs,0.357368
uuid-a3c51dd187844955acf21eb31ed358d2,Keytruda,0.330714
uuid-a3c51dd187844955acf21eb31ed358d2,flat dosing,0.678715
uuid-9a62ae8fb92f453b8ed635fa4e736fad,BMS,0.324431
uuid-9a62ae8fb92f453b8ed635fa4e736fad,trial,0.476802
uuid-9a62ae8fb92f453b8ed635fa4e736fad,efficacy,0.304855
uuid-9a62ae8fb92f453b8ed635fa4e736fad,combination,0.323888
uuid-9a62ae8fb92f453b8ed635fa4e736fad,OS,0.314882
uuid-9a62ae8fb92f453b8ed635fa4e736fad,data,0.505514
uuid-9a62ae8fb92f453b8ed635fa4e736fad,expressed,0.320068
uuid-9a62ae8fb92f453b8ed635fa4e736fad,ORR,0.377987
uuid-9a62ae8fb92f453b8ed635fa4e736fad,nivo and pembro,0.392077
uuid-9a62ae8fb92f453b8ed635fa4e736fad,believes,0.312973
uuid-9a62ae8fb92f453b8ed635fa4e736fad,impressed,0.406704
uuid-9a62ae8fb92f453b8ed635fa4e736fad,SCLC,0.56973
uuid-81f892022a7d426a9e17a41e3fa27658,patients,0.345848
uuid-81f892022a7d426a9e17a41e3fa27658,trial,0.600112
uuid-81f892022a7d426a9e17a41e3fa27658,pts,0.321627
uuid-81f892022a7d426a9e17a41e3fa27658,approval,0.319573
uuid-81f892022a7d426a9e17a41e3fa27658,clinical trials,0.520927
uuid-81f892022a7d426a9e17a41e3fa27658,approved,0.315163
uuid-e40c3f991eb7402fb73c5b043f9325fa,Opdivo,0.43863
uuid-e40c3f991eb7402fb73c5b043f9325fa,dose,0.777371
uuid-e40c3f991eb7402fb73c5b043f9325fa,shared,0.358318
uuid-e40c3f991eb7402fb73c5b043f9325fa,Ipi,0.36534
uuid-e40c3f991eb7402fb73c5b043f9325fa,vs,0.474309
uuid-e40c3f991eb7402fb73c5b043f9325fa,Keytruda,0.328781
uuid-e40c3f991eb7402fb73c5b043f9325fa,flat dosing,0.804141
uuid-d06b2672ca15437ca01a48cf023aa97e,BMS,0.409897
uuid-81d0463f67b0414e8f3dd6455dcf36d3,patients,0.352878
uuid-81d0463f67b0414e8f3dd6455dcf36d3,institution,0.300204
uuid-81d0463f67b0414e8f3dd6455dcf36d3,PD-L1,0.460345
uuid-81d0463f67b0414e8f3dd6455dcf36d3,PD-L1 testing,0.70474
uuid-81d0463f67b0414e8f3dd6455dcf36d3,testing,0.687621
uuid-81d0463f67b0414e8f3dd6455dcf36d3,PDL1 testing,0.569583
uuid-81d0463f67b0414e8f3dd6455dcf36d3,NSCLC patients,0.541828
uuid-047f997a355e4f5ea516fd50267079a8,Nivo,0.453458
uuid-047f997a355e4f5ea516fd50267079a8,patients,0.340921
uuid-047f997a355e4f5ea516fd50267079a8,therapy,0.581922
uuid-047f997a355e4f5ea516fd50267079a8,1L,0.550883
uuid-047f997a355e4f5ea516fd50267079a8,regimen,0.455883
uuid-047f997a355e4f5ea516fd50267079a8,combination,0.574682
uuid-047f997a355e4f5ea516fd50267079a8,chemo,0.738331
uuid-047f997a355e4f5ea516fd50267079a8,2L,0.469074
uuid-047f997a355e4f5ea516fd50267079a8,pts,0.395222
uuid-047f997a355e4f5ea516fd50267079a8,IO,0.65588
uuid-047f997a355e4f5ea516fd50267079a8,agents,0.52663
uuid-047f997a355e4f5ea516fd50267079a8,preferred,0.441847
uuid-047f997a355e4f5ea516fd50267079a8,monotherapy,0.732012
uuid-047f997a355e4f5ea516fd50267079a8,treatment,0.392541
uuid-047f997a355e4f5ea516fd50267079a8,response,0.447343
uuid-047f997a355e4f5ea516fd50267079a8,combo,0.590819
uuid-047f997a355e4f5ea516fd50267079a8,PD1,0.578153
uuid-047f997a355e4f5ea516fd50267079a8,progression,0.455716
uuid-047f997a355e4f5ea516fd50267079a8,believes,0.528665
uuid-047f997a355e4f5ea516fd50267079a8,chemotherapy,0.648935
uuid-047f997a355e4f5ea516fd50267079a8,respond,0.317177
uuid-047f997a355e4f5ea516fd50267079a8,feels,0.366104
uuid-047f997a355e4f5ea516fd50267079a8,PD-1,0.300604
uuid-047f997a355e4f5ea516fd50267079a8,option,0.688533
uuid-e35e62926fad4bbaa0b2ea550f1d815c,patients,0.68734
uuid-e35e62926fad4bbaa0b2ea550f1d815c,therapy,0.510881
uuid-e35e62926fad4bbaa0b2ea550f1d815c,regimen,0.35956
uuid-e35e62926fad4bbaa0b2ea550f1d815c,treated,0.507986
uuid-e35e62926fad4bbaa0b2ea550f1d815c,chemo,0.399702
uuid-e35e62926fad4bbaa0b2ea550f1d815c,tumor,0.390446
uuid-e35e62926fad4bbaa0b2ea550f1d815c,pts,0.560767
uuid-e35e62926fad4bbaa0b2ea550f1d815c,treatment,0.638249
uuid-e35e62926fad4bbaa0b2ea550f1d815c,response,0.612241
uuid-e35e62926fad4bbaa0b2ea550f1d815c,progression,0.719589
uuid-e35e62926fad4bbaa0b2ea550f1d815c,chemotherapy,0.43452
uuid-e35e62926fad4bbaa0b2ea550f1d815c,respond,0.546641
uuid-e35e62926fad4bbaa0b2ea550f1d815c,immunotherapy,0.310243
uuid-3387a3747d424b8a9d67ed409487aa9b,pembro,0.460518
uuid-3387a3747d424b8a9d67ed409487aa9b,1L,0.474306
uuid-3387a3747d424b8a9d67ed409487aa9b,PDL1,0.693161
uuid-3387a3747d424b8a9d67ed409487aa9b,TL stated,0.314085
uuid-3387a3747d424b8a9d67ed409487aa9b,2L,0.33631
uuid-3387a3747d424b8a9d67ed409487aa9b,Merck,0.385338
uuid-3387a3747d424b8a9d67ed409487aa9b,PD-L1,0.652495
uuid-3387a3747d424b8a9d67ed409487aa9b,approval,0.333584
uuid-3387a3747d424b8a9d67ed409487aa9b,atezo,0.473648
uuid-3387a3747d424b8a9d67ed409487aa9b,PD-L1 testing,0.424042
uuid-3387a3747d424b8a9d67ed409487aa9b,testing,0.583224
uuid-3387a3747d424b8a9d67ed409487aa9b,data,0.508711
uuid-3387a3747d424b8a9d67ed409487aa9b,PDL1 testing,0.531311
uuid-3387a3747d424b8a9d67ed409487aa9b,indication,0.353086
uuid-3387a3747d424b8a9d67ed409487aa9b,NSCLC patients,0.512183
uuid-3387a3747d424b8a9d67ed409487aa9b,approved,0.336332
uuid-3387a3747d424b8a9d67ed409487aa9b,nivo and pembro,0.426939
uuid-3387a3747d424b8a9d67ed409487aa9b,tumor types,0.393753
uuid-3387a3747d424b8a9d67ed409487aa9b,assay,0.462025
uuid-3387a3747d424b8a9d67ed409487aa9b,PDL1 expression,0.659632
uuid-3387a3747d424b8a9d67ed409487aa9b,biomarker,0.51125
uuid-6a570a684b484f2495952c54c8f96184,Nivo,0.397537
uuid-6a570a684b484f2495952c54c8f96184,pembro,0.683445
uuid-6a570a684b484f2495952c54c8f96184,BMS,0.382298
uuid-6a570a684b484f2495952c54c8f96184,1L,0.458266
uuid-6a570a684b484f2495952c54c8f96184,PDL1,0.398355
uuid-6a570a684b484f2495952c54c8f96184,trial,0.440704
uuid-6a570a684b484f2495952c54c8f96184,efficacy,0.345376
uuid-6a570a684b484f2495952c54c8f96184,commented,0.314563
uuid-6a570a684b484f2495952c54c8f96184,2L,0.433294
uuid-6a570a684b484f2495952c54c8f96184,Merck,0.428775
uuid-6a570a684b484f2495952c54c8f96184,stated,0.330243
uuid-6a570a684b484f2495952c54c8f96184,approval,0.478179
uuid-6a570a684b484f2495952c54c8f96184,OS,0.391499
uuid-6a570a684b484f2495952c54c8f96184,atezo,0.606655
uuid-6a570a684b484f2495952c54c8f96184,preferred,0.330817
uuid-6a570a684b484f2495952c54c8f96184,using nivo,0.347444
uuid-6a570a684b484f2495952c54c8f96184,data,0.679922
uuid-6a570a684b484f2495952c54c8f96184,indication,0.534646
uuid-6a570a684b484f2495952c54c8f96184,PFS,0.361046
uuid-6a570a684b484f2495952c54c8f96184,ORR,0.376905
uuid-6a570a684b484f2495952c54c8f96184,approved,0.483346
uuid-6a570a684b484f2495952c54c8f96184,SCCHN,0.346216
uuid-6a570a684b484f2495952c54c8f96184,nivo and pembro,0.608363
uuid-6a570a684b484f2495952c54c8f96184,impressed,0.462394
uuid-6a570a684b484f2495952c54c8f96184,label,0.363757
uuid-6a570a684b484f2495952c54c8f96184,feels,0.340723
uuid-6a570a684b484f2495952c54c8f96184,PDL1 expression,0.385412
uuid-6a570a684b484f2495952c54c8f96184,bladder,0.303597
uuid-7b57682076414c6e9dc25cf3d35c53f9,Nivo,0.302903
uuid-7b57682076414c6e9dc25cf3d35c53f9,patients,0.337273
uuid-7b57682076414c6e9dc25cf3d35c53f9,pembro,0.545624
uuid-7b57682076414c6e9dc25cf3d35c53f9,1L,0.620387
uuid-7b57682076414c6e9dc25cf3d35c53f9,RCC,0.512669
uuid-7b57682076414c6e9dc25cf3d35c53f9,TL stated,0.375678
uuid-7b57682076414c6e9dc25cf3d35c53f9,2L,0.633367
uuid-7b57682076414c6e9dc25cf3d35c53f9,pts,0.336228
uuid-7b57682076414c6e9dc25cf3d35c53f9,stated,0.33788
uuid-7b57682076414c6e9dc25cf3d35c53f9,approval,0.629765
uuid-7b57682076414c6e9dc25cf3d35c53f9,atezo,0.517882
uuid-7b57682076414c6e9dc25cf3d35c53f9,preferred,0.53463
uuid-7b57682076414c6e9dc25cf3d35c53f9,monotherapy,0.354713
uuid-7b57682076414c6e9dc25cf3d35c53f9,using nivo,0.664895
uuid-7b57682076414c6e9dc25cf3d35c53f9,clinical trials,0.315206
uuid-7b57682076414c6e9dc25cf3d35c53f9,PDL1 testing,0.395158
uuid-7b57682076414c6e9dc25cf3d35c53f9,indication,0.323615
uuid-7b57682076414c6e9dc25cf3d35c53f9,NSCLC patients,0.439408
uuid-7b57682076414c6e9dc25cf3d35c53f9,approved,0.590561
uuid-7b57682076414c6e9dc25cf3d35c53f9,SCCHN,0.546878
uuid-7b57682076414c6e9dc25cf3d35c53f9,tumor types,0.361057
uuid-7b57682076414c6e9dc25cf3d35c53f9,label,0.304416
uuid-7b57682076414c6e9dc25cf3d35c53f9,Regional TL,0.382466
uuid-7b57682076414c6e9dc25cf3d35c53f9,RTL stated,0.549202
uuid-7b57682076414c6e9dc25cf3d35c53f9,TL shared,0.320139
uuid-7b57682076414c6e9dc25cf3d35c53f9,option,0.428968
uuid-7b57682076414c6e9dc25cf3d35c53f9,bladder,0.541439
uuid-9efc7ff1af234151afe1eb89d043fb9f,patients,0.458814
uuid-9efc7ff1af234151afe1eb89d043fb9f,dose,0.651803
uuid-9efc7ff1af234151afe1eb89d043fb9f,toxicity,0.444265
uuid-9efc7ff1af234151afe1eb89d043fb9f,regimen,0.307793
uuid-9efc7ff1af234151afe1eb89d043fb9f,Ipi,0.381313
uuid-9efc7ff1af234151afe1eb89d043fb9f,vs,0.388441
uuid-9efc7ff1af234151afe1eb89d043fb9f,flat dosing,0.338978
uuid-67e238c37f1247a1a349aa1f94d85e57,TL,0.346104
uuid-67e238c37f1247a1a349aa1f94d85e57,TL stated,0.325574
uuid-67e238c37f1247a1a349aa1f94d85e57,tumor,0.580804
uuid-67e238c37f1247a1a349aa1f94d85e57,PD-L1,0.451212
uuid-67e238c37f1247a1a349aa1f94d85e57,PD-L1 testing,0.485519
uuid-67e238c37f1247a1a349aa1f94d85e57,testing,0.585933
uuid-67e238c37f1247a1a349aa1f94d85e57,PDL1 testing,0.463993
uuid-67e238c37f1247a1a349aa1f94d85e57,NSCLC patients,0.421332
uuid-67e238c37f1247a1a349aa1f94d85e57,assay,0.365204
uuid-67e238c37f1247a1a349aa1f94d85e57,biomarker,0.330097
uuid-6f98eabacaa64b75946a14025f21368f,pembro,0.484955
uuid-6f98eabacaa64b75946a14025f21368f,lung,0.461613
uuid-6f98eabacaa64b75946a14025f21368f,1L,0.596521
uuid-6f98eabacaa64b75946a14025f21368f,RCC,0.458186
uuid-6f98eabacaa64b75946a14025f21368f,TL stated,0.3549
uuid-6f98eabacaa64b75946a14025f21368f,2L,0.618835
uuid-6f98eabacaa64b75946a14025f21368f,PD-L1,0.405629
uuid-6f98eabacaa64b75946a14025f21368f,atezo,0.530818
uuid-6f98eabacaa64b75946a14025f21368f,preferred,0.515171
uuid-6f98eabacaa64b75946a14025f21368f,PD-L1 testing,0.377633
uuid-6f98eabacaa64b75946a14025f21368f,testing,0.418986
uuid-6f98eabacaa64b75946a14025f21368f,monotherapy,0.322544
uuid-6f98eabacaa64b75946a14025f21368f,using nivo,0.563513
uuid-6f98eabacaa64b75946a14025f21368f,PDL1 testing,0.490366
uuid-6f98eabacaa64b75946a14025f21368f,NSCLC patients,0.52625
uuid-6f98eabacaa64b75946a14025f21368f,approved,0.306047
uuid-6f98eabacaa64b75946a14025f21368f,SCCHN,0.336176
uuid-6f98eabacaa64b75946a14025f21368f,RTL stated,0.399537
uuid-6f98eabacaa64b75946a14025f21368f,TL shared,0.318745
uuid-6f98eabacaa64b75946a14025f21368f,option,0.386451
uuid-6f98eabacaa64b75946a14025f21368f,bladder,0.312028
uuid-9e33c7e3dfc14c6b9fc8514393ebaee2,patients,0.606267
uuid-9e33c7e3dfc14c6b9fc8514393ebaee2,treated,0.32568
uuid-9e33c7e3dfc14c6b9fc8514393ebaee2,pts,0.34908
uuid-9e33c7e3dfc14c6b9fc8514393ebaee2,PD-L1,0.398546
uuid-9e33c7e3dfc14c6b9fc8514393ebaee2,PD-L1 testing,0.505071
uuid-9e33c7e3dfc14c6b9fc8514393ebaee2,testing,0.553633
uuid-9e33c7e3dfc14c6b9fc8514393ebaee2,treatment,0.326509
uuid-9e33c7e3dfc14c6b9fc8514393ebaee2,PDL1 testing,0.51926
uuid-9e33c7e3dfc14c6b9fc8514393ebaee2,NSCLC patients,0.571113
uuid-1049c3d9dbd042d4938822de63f9b322,Nivo,0.5533
uuid-1049c3d9dbd042d4938822de63f9b322,pembro,0.38229
uuid-1049c3d9dbd042d4938822de63f9b322,lung,0.505722
uuid-1049c3d9dbd042d4938822de63f9b322,1L,0.336599
uuid-1049c3d9dbd042d4938822de63f9b322,melanoma,0.385464
uuid-1049c3d9dbd042d4938822de63f9b322,RCC,0.381641
uuid-1049c3d9dbd042d4938822de63f9b322,2L,0.426225
uuid-1049c3d9dbd042d4938822de63f9b322,atezo,0.346323
uuid-1049c3d9dbd042d4938822de63f9b322,using nivo,0.532936
uuid-1049c3d9dbd042d4938822de63f9b322,AI,0.480334
uuid-1049c3d9dbd042d4938822de63f9b322,nivo and pembro,0.303335
uuid-1049c3d9dbd042d4938822de63f9b322,vs,0.327779
uuid-1049c3d9dbd042d4938822de63f9b322,RTL stated,0.313607
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,Nivo,0.410776
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,patients,0.599835
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,Opdivo,0.717493
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,pembro,0.372707
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,therapy,0.309933
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,nivolumab,0.419558
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,2L,0.378815
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,pts,0.320435
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,approval,0.522141
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,preferred,0.416504
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,monotherapy,0.342721
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,treatment,0.313771
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,using nivo,0.520966
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,indication,0.398929
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,approved,0.588485
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,label,0.502602
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,Keytruda,0.466358
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,option,0.432977
uuid-7f31ae01bd83492e9bc68e2f1bb7915e,flat dosing,0.320823
uuid-cc62985c85154289baa171158d08c18a,RTL,0.32474
uuid-cc62985c85154289baa171158d08c18a,lung,0.629678
uuid-cc62985c85154289baa171158d08c18a,NTL,0.350544
uuid-cc62985c85154289baa171158d08c18a,melanoma,0.632334
uuid-cc62985c85154289baa171158d08c18a,shared,0.340941
uuid-cc62985c85154289baa171158d08c18a,RCC,0.415384
uuid-cc62985c85154289baa171158d08c18a,institution,0.438245
uuid-cc62985c85154289baa171158d08c18a,AI,0.509144
uuid-cc62985c85154289baa171158d08c18a,SCCHN,0.526317
uuid-cc62985c85154289baa171158d08c18a,oncologist,0.307859
uuid-cc62985c85154289baa171158d08c18a,academic,0.443747
uuid-cc62985c85154289baa171158d08c18a,RTL stated,0.393694
uuid-cc62985c85154289baa171158d08c18a,TL shared,0.451086
uuid-cc62985c85154289baa171158d08c18a,NCCN,0.417321
uuid-b317ff2a4aa04754bd281581cf6d9d6d,RTL,0.33332
uuid-b317ff2a4aa04754bd281581cf6d9d6d,BMS,0.337557
uuid-b317ff2a4aa04754bd281581cf6d9d6d,trial,0.680942
uuid-b317ff2a4aa04754bd281581cf6d9d6d,Merck,0.371689
uuid-b317ff2a4aa04754bd281581cf6d9d6d,data,0.349521
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,patients,0.794087
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,Opdivo,0.33417
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,therapy,0.418272
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,nivolumab,0.418779
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,toxicity,0.539264
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,regimen,0.639011
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,treated,0.675153
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,chemo,0.375938
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,pts,0.574192
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,monotherapy,0.432222
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,treatment,0.627599
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,response,0.36024
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,PD1,0.31095
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,progression,0.572924
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,chemotherapy,0.42547
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,respond,0.461116
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,TL shared,0.31167
uuid-c3ce847a1a4a4288b6e76df85a7d5d74,option,0.327466
uuid-883bcd2f774f4b17833bb06c82de726e,RTL,0.355094
uuid-883bcd2f774f4b17833bb06c82de726e,lung,0.35855
uuid-883bcd2f774f4b17833bb06c82de726e,NTL,0.431604
uuid-883bcd2f774f4b17833bb06c82de726e,melanoma,0.375987
uuid-883bcd2f774f4b17833bb06c82de726e,commented,0.402121
uuid-883bcd2f774f4b17833bb06c82de726e,RCC,0.332857
uuid-883bcd2f774f4b17833bb06c82de726e,stated,0.321558
uuid-883bcd2f774f4b17833bb06c82de726e,clinical trials,0.371897
uuid-883bcd2f774f4b17833bb06c82de726e,SCCHN,0.366016
uuid-883bcd2f774f4b17833bb06c82de726e,lung cancer,0.342142
uuid-883bcd2f774f4b17833bb06c82de726e,ASCO,0.394669
uuid-883bcd2f774f4b17833bb06c82de726e,impressed,0.4027
uuid-883bcd2f774f4b17833bb06c82de726e,tumor types,0.317776
uuid-883bcd2f774f4b17833bb06c82de726e,SCLC,0.404901
uuid-883bcd2f774f4b17833bb06c82de726e,Regional TL,0.388119
uuid-883bcd2f774f4b17833bb06c82de726e,TL shared,0.371831
uuid-883bcd2f774f4b17833bb06c82de726e,bladder,0.32733
uuid-84ac31d20dd149d7b0cfd642ae9fda72,PD-L1,0.392697
uuid-84ac31d20dd149d7b0cfd642ae9fda72,approval,0.330191
uuid-84ac31d20dd149d7b0cfd642ae9fda72,preferred,0.302189
uuid-84ac31d20dd149d7b0cfd642ae9fda72,PD-L1 testing,0.53794
uuid-84ac31d20dd149d7b0cfd642ae9fda72,testing,0.593255
uuid-84ac31d20dd149d7b0cfd642ae9fda72,PDL1 testing,0.553896
uuid-84ac31d20dd149d7b0cfd642ae9fda72,indication,0.309642
uuid-84ac31d20dd149d7b0cfd642ae9fda72,NSCLC patients,0.427288
uuid-84ac31d20dd149d7b0cfd642ae9fda72,approved,0.337057
uuid-581b3ffe63934547aa55cf896ebbadc3,patients,0.480809
uuid-581b3ffe63934547aa55cf896ebbadc3,therapy,0.409381
uuid-581b3ffe63934547aa55cf896ebbadc3,nivolumab,0.413889
uuid-581b3ffe63934547aa55cf896ebbadc3,lung,0.311755
uuid-581b3ffe63934547aa55cf896ebbadc3,regimen,0.479538
uuid-581b3ffe63934547aa55cf896ebbadc3,treated,0.573475
uuid-581b3ffe63934547aa55cf896ebbadc3,melanoma,0.649427
uuid-581b3ffe63934547aa55cf896ebbadc3,RCC,0.443892
uuid-581b3ffe63934547aa55cf896ebbadc3,pts,0.360125
uuid-581b3ffe63934547aa55cf896ebbadc3,monotherapy,0.318107
uuid-581b3ffe63934547aa55cf896ebbadc3,treatment,0.589841
uuid-581b3ffe63934547aa55cf896ebbadc3,SCCHN,0.344994
uuid-581b3ffe63934547aa55cf896ebbadc3,progression,0.50345
uuid-581b3ffe63934547aa55cf896ebbadc3,chemotherapy,0.359883
uuid-581b3ffe63934547aa55cf896ebbadc3,oncologist,0.330045
uuid-581b3ffe63934547aa55cf896ebbadc3,academic,0.342758
uuid-581b3ffe63934547aa55cf896ebbadc3,RTL stated,0.42886
uuid-581b3ffe63934547aa55cf896ebbadc3,TL shared,0.51199
uuid-5df76f4cdb22446d9529beffaee17b5d,toxicity,0.419417
uuid-5df76f4cdb22446d9529beffaee17b5d,treated,0.366838
uuid-5df76f4cdb22446d9529beffaee17b5d,physicians,0.326087
uuid-5df76f4cdb22446d9529beffaee17b5d,treatment,0.414178
uuid-3318a033c0e344be9aa46f3648b488fa,patients,0.613149
uuid-3318a033c0e344be9aa46f3648b488fa,therapy,0.582125
uuid-3318a033c0e344be9aa46f3648b488fa,nivolumab,0.593706
uuid-3318a033c0e344be9aa46f3648b488fa,1L,0.38475
uuid-3318a033c0e344be9aa46f3648b488fa,regimen,0.398485
uuid-3318a033c0e344be9aa46f3648b488fa,treated,0.490411
uuid-3318a033c0e344be9aa46f3648b488fa,RCC,0.46803
uuid-3318a033c0e344be9aa46f3648b488fa,chemo,0.356372
uuid-3318a033c0e344be9aa46f3648b488fa,2L,0.404682
uuid-3318a033c0e344be9aa46f3648b488fa,pts,0.527063
uuid-3318a033c0e344be9aa46f3648b488fa,approval,0.376357
uuid-3318a033c0e344be9aa46f3648b488fa,preferred,0.416826
uuid-3318a033c0e344be9aa46f3648b488fa,monotherapy,0.498637
uuid-3318a033c0e344be9aa46f3648b488fa,treatment,0.554697
uuid-3318a033c0e344be9aa46f3648b488fa,using nivo,0.548785
uuid-3318a033c0e344be9aa46f3648b488fa,response,0.335573
uuid-3318a033c0e344be9aa46f3648b488fa,PD1,0.444571
uuid-3318a033c0e344be9aa46f3648b488fa,approved,0.338036
uuid-3318a033c0e344be9aa46f3648b488fa,SCCHN,0.383755
uuid-3318a033c0e344be9aa46f3648b488fa,cHL,0.309321
uuid-3318a033c0e344be9aa46f3648b488fa,progression,0.547514
uuid-3318a033c0e344be9aa46f3648b488fa,chemotherapy,0.376589
uuid-3318a033c0e344be9aa46f3648b488fa,respond,0.349553
uuid-3318a033c0e344be9aa46f3648b488fa,RTL stated,0.540926
uuid-3318a033c0e344be9aa46f3648b488fa,TL shared,0.306565
uuid-3318a033c0e344be9aa46f3648b488fa,option,0.501897
uuid-f96f36b9b9a24654b89e62a2266a2ea1,patients,0.464309
uuid-f96f36b9b9a24654b89e62a2266a2ea1,Opdivo,0.375705
uuid-f96f36b9b9a24654b89e62a2266a2ea1,nivolumab,0.314874
uuid-f96f36b9b9a24654b89e62a2266a2ea1,treated,0.30436
uuid-f96f36b9b9a24654b89e62a2266a2ea1,RCC,0.31143
uuid-f96f36b9b9a24654b89e62a2266a2ea1,stated,0.34383
uuid-f96f36b9b9a24654b89e62a2266a2ea1,approval,0.372745
uuid-f96f36b9b9a24654b89e62a2266a2ea1,using nivo,0.365479
uuid-f96f36b9b9a24654b89e62a2266a2ea1,approved,0.399443
uuid-f96f36b9b9a24654b89e62a2266a2ea1,SCCHN,0.325808
uuid-f96f36b9b9a24654b89e62a2266a2ea1,tumor types,0.34376
uuid-f96f36b9b9a24654b89e62a2266a2ea1,label,0.308988
uuid-f96f36b9b9a24654b89e62a2266a2ea1,RTL stated,0.308614
uuid-c14d9267155f412f9c1682e61977ea0d,TL,0.32359
uuid-c14d9267155f412f9c1682e61977ea0d,pembro,0.309831
uuid-c14d9267155f412f9c1682e61977ea0d,1L,0.370154
uuid-c14d9267155f412f9c1682e61977ea0d,PDL1,0.571687
uuid-c14d9267155f412f9c1682e61977ea0d,TL stated,0.397802
uuid-c14d9267155f412f9c1682e61977ea0d,Merck,0.31569
uuid-c14d9267155f412f9c1682e61977ea0d,PD-L1,0.613567
uuid-c14d9267155f412f9c1682e61977ea0d,atezo,0.347879
uuid-c14d9267155f412f9c1682e61977ea0d,PD-L1 testing,0.438054
uuid-c14d9267155f412f9c1682e61977ea0d,testing,0.495653
uuid-c14d9267155f412f9c1682e61977ea0d,data,0.437322
uuid-c14d9267155f412f9c1682e61977ea0d,PDL1 testing,0.458458
uuid-c14d9267155f412f9c1682e61977ea0d,NSCLC patients,0.418045
uuid-c14d9267155f412f9c1682e61977ea0d,nivo and pembro,0.385834
uuid-c14d9267155f412f9c1682e61977ea0d,believes,0.342234
uuid-c14d9267155f412f9c1682e61977ea0d,impressed,0.319459
uuid-c14d9267155f412f9c1682e61977ea0d,TLs,0.413424
uuid-c14d9267155f412f9c1682e61977ea0d,assay,0.426159
uuid-c14d9267155f412f9c1682e61977ea0d,PDL1 expression,0.493932
uuid-c14d9267155f412f9c1682e61977ea0d,biomarker,0.441953
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,Nivo,0.46913
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,patients,0.411771
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,pembro,0.384634
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,therapy,0.349852
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,nivolumab,0.342484
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,1L,0.390453
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,trial,0.461155
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,regimen,0.319538
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,combination,0.488991
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,chemo,0.587726
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,2L,0.302559
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,pts,0.399756
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,Ipi,0.346589
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,preferred,0.366325
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,monotherapy,0.535564
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,combo,0.448833
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,clinical trials,0.33271
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,PD1,0.375513
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,chemotherapy,0.627506
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,feels,0.440488
uuid-c6b0a36dc0c24a1fb33951f66bd2a38f,option,0.561495
uuid-0019f43ab44f4a9aaca3ec3c5e2f134e,Nivo,0.447495
uuid-0019f43ab44f4a9aaca3ec3c5e2f134e,pembro,0.46787
uuid-0019f43ab44f4a9aaca3ec3c5e2f134e,dose,0.626069
uuid-0019f43ab44f4a9aaca3ec3c5e2f134e,Ipi,0.528941
uuid-0019f43ab44f4a9aaca3ec3c5e2f134e,atezo,0.459436
uuid-0019f43ab44f4a9aaca3ec3c5e2f134e,preferred,0.396299
uuid-0019f43ab44f4a9aaca3ec3c5e2f134e,using nivo,0.444391
uuid-0019f43ab44f4a9aaca3ec3c5e2f134e,HCP,0.491746
uuid-0019f43ab44f4a9aaca3ec3c5e2f134e,vs,0.541956
uuid-0019f43ab44f4a9aaca3ec3c5e2f134e,LTL,0.321521
uuid-0019f43ab44f4a9aaca3ec3c5e2f134e,feels,0.302229
uuid-0019f43ab44f4a9aaca3ec3c5e2f134e,flat dosing,0.48472
uuid-25772b649f564fbb81df4dbae702068e,RTL,0.644557
uuid-25772b649f564fbb81df4dbae702068e,trial,0.481974
uuid-25772b649f564fbb81df4dbae702068e,NTL,0.389704
uuid-25772b649f564fbb81df4dbae702068e,data,0.342328
uuid-25772b649f564fbb81df4dbae702068e,expressed,0.414748
uuid-25772b649f564fbb81df4dbae702068e,mentioned,0.458923
uuid-25772b649f564fbb81df4dbae702068e,ORR,0.322812
uuid-25772b649f564fbb81df4dbae702068e,HCP,0.607855
uuid-25772b649f564fbb81df4dbae702068e,impressed,0.428323
uuid-25772b649f564fbb81df4dbae702068e,LTL,0.432033
uuid-25772b649f564fbb81df4dbae702068e,SCLC,0.330401
uuid-270f5dac181c43dc96efc7bb26126f30,RTL,0.678638
uuid-270f5dac181c43dc96efc7bb26126f30,BMS,0.33102
uuid-270f5dac181c43dc96efc7bb26126f30,trial,0.543185
uuid-270f5dac181c43dc96efc7bb26126f30,NTL,0.487012
uuid-270f5dac181c43dc96efc7bb26126f30,commented,0.504108
uuid-270f5dac181c43dc96efc7bb26126f30,stated,0.405514
uuid-270f5dac181c43dc96efc7bb26126f30,OS,0.350274
uuid-270f5dac181c43dc96efc7bb26126f30,data,0.536875
uuid-270f5dac181c43dc96efc7bb26126f30,expressed,0.532864
uuid-270f5dac181c43dc96efc7bb26126f30,mentioned,0.504509
uuid-270f5dac181c43dc96efc7bb26126f30,PFS,0.328692
uuid-270f5dac181c43dc96efc7bb26126f30,ORR,0.342805
uuid-270f5dac181c43dc96efc7bb26126f30,SCCHN,0.334975
uuid-270f5dac181c43dc96efc7bb26126f30,HCP,0.531618
uuid-270f5dac181c43dc96efc7bb26126f30,ASCO,0.310999
uuid-270f5dac181c43dc96efc7bb26126f30,impressed,0.581673
uuid-270f5dac181c43dc96efc7bb26126f30,LTL,0.474952
uuid-270f5dac181c43dc96efc7bb26126f30,TLs,0.323609
uuid-270f5dac181c43dc96efc7bb26126f30,SCLC,0.321058
uuid-270f5dac181c43dc96efc7bb26126f30,Regional TL,0.437511
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,Nivo,0.681945
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,pembro,0.33159
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,RTL,0.407408
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,therapy,0.466249
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,nivolumab,0.527973
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,1L,0.325965
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,trial,0.335588
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,combination,0.512814
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,chemo,0.381404
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,2L,0.378781
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,Ipi,0.320291
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,approval,0.312903
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,preferred,0.327455
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,monotherapy,0.459831
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,using nivo,0.587104
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,combo,0.350987
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,mentioned,0.315843
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,PD1,0.453518
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,approved,0.305026
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,SCCHN,0.346013
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,cHL,0.400098
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,chemotherapy,0.420711
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,SCLC,0.394776
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,RTL stated,0.534237
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,option,0.385505
uuid-2359eed5f5b146de97c31a1a6e3e5d9d,bladder,0.330941
uuid-f3b7799fe5d641e390e4da94cc8167ab,patients,0.391041
uuid-f3b7799fe5d641e390e4da94cc8167ab,nivolumab,0.307423
uuid-f3b7799fe5d641e390e4da94cc8167ab,treated,0.518577
uuid-f3b7799fe5d641e390e4da94cc8167ab,treatment,0.473972
uuid-f3b7799fe5d641e390e4da94cc8167ab,TL shared,0.337804
uuid-ceacbbdd02db4dabbebf30b831101191,patients,0.321531
uuid-ceacbbdd02db4dabbebf30b831101191,Opdivo,0.463046
uuid-ceacbbdd02db4dabbebf30b831101191,toxicity,0.300146
uuid-ceacbbdd02db4dabbebf30b831101191,treated,0.340618
uuid-ceacbbdd02db4dabbebf30b831101191,physicians,0.547176
uuid-ceacbbdd02db4dabbebf30b831101191,treatment,0.417936
uuid-ceacbbdd02db4dabbebf30b831101191,feels,0.366515
uuid-4abc9af747b3415ea22c804228054a8a,Nivo,0.472228
uuid-4abc9af747b3415ea22c804228054a8a,patients,0.533614
uuid-4abc9af747b3415ea22c804228054a8a,therapy,0.610899
uuid-4abc9af747b3415ea22c804228054a8a,1L,0.325043
uuid-4abc9af747b3415ea22c804228054a8a,toxicity,0.42947
uuid-4abc9af747b3415ea22c804228054a8a,efficacy,0.305735
uuid-4abc9af747b3415ea22c804228054a8a,regimen,0.507776
uuid-4abc9af747b3415ea22c804228054a8a,combination,0.495201
uuid-4abc9af747b3415ea22c804228054a8a,chemo,0.782765
uuid-4abc9af747b3415ea22c804228054a8a,pts,0.491888
uuid-4abc9af747b3415ea22c804228054a8a,IO,0.351112
uuid-4abc9af747b3415ea22c804228054a8a,agents,0.442142
uuid-4abc9af747b3415ea22c804228054a8a,preferred,0.30151
uuid-4abc9af747b3415ea22c804228054a8a,monotherapy,0.619769
uuid-4abc9af747b3415ea22c804228054a8a,treatment,0.537255
uuid-4abc9af747b3415ea22c804228054a8a,response,0.607144
uuid-4abc9af747b3415ea22c804228054a8a,combo,0.427388
uuid-4abc9af747b3415ea22c804228054a8a,PD1,0.589813
uuid-4abc9af747b3415ea22c804228054a8a,progression,0.583079
uuid-4abc9af747b3415ea22c804228054a8a,believes,0.38764
uuid-4abc9af747b3415ea22c804228054a8a,chemotherapy,0.711215
uuid-4abc9af747b3415ea22c804228054a8a,respond,0.510067
uuid-4abc9af747b3415ea22c804228054a8a,feels,0.323934
uuid-4abc9af747b3415ea22c804228054a8a,immunotherapy,0.378871
uuid-4abc9af747b3415ea22c804228054a8a,option,0.586836
uuid-50651aecafa44a33820fbbc1043f76ac,pembro,0.37228
uuid-50651aecafa44a33820fbbc1043f76ac,RTL,0.421923
uuid-50651aecafa44a33820fbbc1043f76ac,BMS,0.624617
uuid-50651aecafa44a33820fbbc1043f76ac,trial,0.84804
uuid-50651aecafa44a33820fbbc1043f76ac,NTL,0.308582
uuid-50651aecafa44a33820fbbc1043f76ac,Merck,0.62007
uuid-50651aecafa44a33820fbbc1043f76ac,stated,0.317898
uuid-50651aecafa44a33820fbbc1043f76ac,OS,0.309172
uuid-50651aecafa44a33820fbbc1043f76ac,data,0.539796
uuid-50651aecafa44a33820fbbc1043f76ac,expressed,0.334793
uuid-50651aecafa44a33820fbbc1043f76ac,clinical trials,0.450633
uuid-50651aecafa44a33820fbbc1043f76ac,PFS,0.352593
uuid-50651aecafa44a33820fbbc1043f76ac,ORR,0.390728
uuid-50651aecafa44a33820fbbc1043f76ac,impressed,0.435748
uuid-4742744a577b4748bb3d6da9365339da,Nivo,0.372806
uuid-4742744a577b4748bb3d6da9365339da,patients,0.718956
uuid-4742744a577b4748bb3d6da9365339da,Opdivo,0.595596
uuid-4742744a577b4748bb3d6da9365339da,therapy,0.561081
uuid-4742744a577b4748bb3d6da9365339da,nivolumab,0.540954
uuid-4742744a577b4748bb3d6da9365339da,treated,0.499405
uuid-4742744a577b4748bb3d6da9365339da,pts,0.308793
uuid-4742744a577b4748bb3d6da9365339da,treatment,0.458874
uuid-4742744a577b4748bb3d6da9365339da,using nivo,0.405769
uuid-4742744a577b4748bb3d6da9365339da,cHL,0.666335
uuid-4742744a577b4748bb3d6da9365339da,progression,0.365971
uuid-a5bd1889547c4d56b7db9681b5b69258,lung,0.438637
uuid-a5bd1889547c4d56b7db9681b5b69258,NTL,0.31846
uuid-a5bd1889547c4d56b7db9681b5b69258,melanoma,0.373222
uuid-a5bd1889547c4d56b7db9681b5b69258,AI,0.520929
uuid-a5bd1889547c4d56b7db9681b5b69258,cHL,0.462217
uuid-a5bd1889547c4d56b7db9681b5b69258,NCCN,0.3957
uuid-c6884d98ece44a2da8449ff2544e7dd6,Opdivo,0.394188
uuid-c6884d98ece44a2da8449ff2544e7dd6,shared,0.407209
uuid-c6884d98ece44a2da8449ff2544e7dd6,RCC,0.490754
uuid-c6884d98ece44a2da8449ff2544e7dd6,TL stated,0.392996
uuid-c6884d98ece44a2da8449ff2544e7dd6,2L,0.339721
uuid-c6884d98ece44a2da8449ff2544e7dd6,Merck,0.381298
uuid-c6884d98ece44a2da8449ff2544e7dd6,approval,0.321245
uuid-c6884d98ece44a2da8449ff2544e7dd6,preferred,0.343717
uuid-c6884d98ece44a2da8449ff2544e7dd6,using nivo,0.342629
uuid-c6884d98ece44a2da8449ff2544e7dd6,approved,0.373002
uuid-c6884d98ece44a2da8449ff2544e7dd6,SCCHN,0.377258
uuid-c6884d98ece44a2da8449ff2544e7dd6,Keytruda,0.518924
uuid-c6884d98ece44a2da8449ff2544e7dd6,RTL stated,0.344828
uuid-9e65085eba55419f91e02e704794c0b3,pembro,0.539602
uuid-9e65085eba55419f91e02e704794c0b3,BMS,0.359122
uuid-9e65085eba55419f91e02e704794c0b3,1L,0.394265
uuid-9e65085eba55419f91e02e704794c0b3,PDL1,0.461005
uuid-9e65085eba55419f91e02e704794c0b3,trial,0.446572
uuid-9e65085eba55419f91e02e704794c0b3,efficacy,0.362483
uuid-9e65085eba55419f91e02e704794c0b3,commented,0.325673
uuid-9e65085eba55419f91e02e704794c0b3,2L,0.349776
uuid-9e65085eba55419f91e02e704794c0b3,agents,0.344675
uuid-9e65085eba55419f91e02e704794c0b3,Merck,0.373902
uuid-9e65085eba55419f91e02e704794c0b3,stated,0.337707
uuid-9e65085eba55419f91e02e704794c0b3,atezo,0.527863
uuid-9e65085eba55419f91e02e704794c0b3,preferred,0.345982
uuid-9e65085eba55419f91e02e704794c0b3,data,0.636599
uuid-9e65085eba55419f91e02e704794c0b3,clinical trials,0.394728
uuid-9e65085eba55419f91e02e704794c0b3,indication,0.433148
uuid-9e65085eba55419f91e02e704794c0b3,ORR,0.310375
uuid-9e65085eba55419f91e02e704794c0b3,approved,0.317063
uuid-9e65085eba55419f91e02e704794c0b3,SCCHN,0.36847
uuid-9e65085eba55419f91e02e704794c0b3,nivo and pembro,0.499994
uuid-9e65085eba55419f91e02e704794c0b3,impressed,0.386939
uuid-9e65085eba55419f91e02e704794c0b3,TLs,0.310597
uuid-9e65085eba55419f91e02e704794c0b3,feels,0.439927
uuid-9e65085eba55419f91e02e704794c0b3,PDL1 expression,0.470793
uuid-9e65085eba55419f91e02e704794c0b3,bladder,0.306429
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,patients,0.355385
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,dose,0.462467
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,nivolumab,0.330217
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,toxicity,0.544514
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,regimen,0.629068
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,treated,0.317922
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,combination,0.540734
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,chemo,0.372503
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,pts,0.325676
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,Ipi,0.618179
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,monotherapy,0.454352
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,combo,0.547069
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,chemotherapy,0.358928
uuid-bbdb8431cabe435a8b70e1c7bf344ab8,SCLC,0.311273
uuid-827bc89e8a0a46438732cbb444e713d2,lung,0.343791
uuid-827bc89e8a0a46438732cbb444e713d2,melanoma,0.339342
uuid-827bc89e8a0a46438732cbb444e713d2,RCC,0.570225
uuid-827bc89e8a0a46438732cbb444e713d2,TL stated,0.423215
uuid-827bc89e8a0a46438732cbb444e713d2,institution,0.424978
uuid-827bc89e8a0a46438732cbb444e713d2,PD-L1,0.304164
uuid-827bc89e8a0a46438732cbb444e713d2,approval,0.344012
uuid-827bc89e8a0a46438732cbb444e713d2,preferred,0.319551
uuid-827bc89e8a0a46438732cbb444e713d2,PD-L1 testing,0.400196
uuid-827bc89e8a0a46438732cbb444e713d2,testing,0.418548
uuid-827bc89e8a0a46438732cbb444e713d2,using nivo,0.319352
uuid-827bc89e8a0a46438732cbb444e713d2,PDL1 testing,0.500944
uuid-827bc89e8a0a46438732cbb444e713d2,NSCLC patients,0.428711
uuid-827bc89e8a0a46438732cbb444e713d2,approved,0.34317
uuid-827bc89e8a0a46438732cbb444e713d2,SCCHN,0.372147
uuid-827bc89e8a0a46438732cbb444e713d2,tumor types,0.349034
uuid-827bc89e8a0a46438732cbb444e713d2,oncologist,0.394104
uuid-827bc89e8a0a46438732cbb444e713d2,RTL stated,0.39691
uuid-827bc89e8a0a46438732cbb444e713d2,TL shared,0.354135
uuid-827bc89e8a0a46438732cbb444e713d2,bladder,0.345779
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,Nivo,0.538311
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,pembro,0.565513
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,dose,0.630629
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,trial,0.318647
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,regimen,0.368915
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,2L,0.327112
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,Ipi,0.578609
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,approval,0.309373
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,atezo,0.497496
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,preferred,0.355351
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,using nivo,0.397629
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,indication,0.345825
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,vs,0.483963
uuid-e7294cbde1ab4d3cbb78a00aabc85c3a,flat dosing,0.501187
uuid-b7a7fa79fdab43ae972766d4405e4916,TL,0.541566
uuid-b7a7fa79fdab43ae972766d4405e4916,pembro,0.37836
uuid-b7a7fa79fdab43ae972766d4405e4916,1L,0.324893
uuid-b7a7fa79fdab43ae972766d4405e4916,PDL1,0.572109
uuid-b7a7fa79fdab43ae972766d4405e4916,TL stated,0.344018
uuid-b7a7fa79fdab43ae972766d4405e4916,Merck,0.569087
uuid-b7a7fa79fdab43ae972766d4405e4916,PD-L1,0.754389
uuid-b7a7fa79fdab43ae972766d4405e4916,approval,0.311012
uuid-b7a7fa79fdab43ae972766d4405e4916,atezo,0.48054
uuid-b7a7fa79fdab43ae972766d4405e4916,PD-L1 testing,0.667214
uuid-b7a7fa79fdab43ae972766d4405e4916,testing,0.778162
uuid-b7a7fa79fdab43ae972766d4405e4916,PDL1 testing,0.621664
uuid-b7a7fa79fdab43ae972766d4405e4916,NSCLC patients,0.456412
uuid-b7a7fa79fdab43ae972766d4405e4916,nivo and pembro,0.304341
uuid-b7a7fa79fdab43ae972766d4405e4916,assay,0.861636
uuid-b7a7fa79fdab43ae972766d4405e4916,PDL1 expression,0.361272
uuid-b7a7fa79fdab43ae972766d4405e4916,biomarker,0.494898
uuid-49a6c59fec67450d9e1ccdd70d8621d8,BMS,0.637373
uuid-49a6c59fec67450d9e1ccdd70d8621d8,trial,0.54097
uuid-49a6c59fec67450d9e1ccdd70d8621d8,commented,0.409621
uuid-49a6c59fec67450d9e1ccdd70d8621d8,Merck,0.53654
uuid-49a6c59fec67450d9e1ccdd70d8621d8,stated,0.330089
uuid-49a6c59fec67450d9e1ccdd70d8621d8,OS,0.424083
uuid-49a6c59fec67450d9e1ccdd70d8621d8,data,0.676102
uuid-49a6c59fec67450d9e1ccdd70d8621d8,expressed,0.332616
uuid-49a6c59fec67450d9e1ccdd70d8621d8,clinical trials,0.33664
uuid-49a6c59fec67450d9e1ccdd70d8621d8,PFS,0.35535
uuid-49a6c59fec67450d9e1ccdd70d8621d8,ORR,0.423886
uuid-49a6c59fec67450d9e1ccdd70d8621d8,ASCO,0.346488
uuid-49a6c59fec67450d9e1ccdd70d8621d8,impressed,0.560929
uuid-49a6c59fec67450d9e1ccdd70d8621d8,feels,0.360594
uuid-b17177866141448abce0bae0c195f3d0,Nivo,0.3128
uuid-b17177866141448abce0bae0c195f3d0,patients,0.571358
uuid-b17177866141448abce0bae0c195f3d0,Opdivo,0.310927
uuid-b17177866141448abce0bae0c195f3d0,pembro,0.350569
uuid-b17177866141448abce0bae0c195f3d0,therapy,0.326107
uuid-b17177866141448abce0bae0c195f3d0,nivolumab,0.497464
uuid-b17177866141448abce0bae0c195f3d0,1L,0.530672
uuid-b17177866141448abce0bae0c195f3d0,regimen,0.397041
uuid-b17177866141448abce0bae0c195f3d0,treated,0.444288
uuid-b17177866141448abce0bae0c195f3d0,RCC,0.449888
uuid-b17177866141448abce0bae0c195f3d0,2L,0.627894
uuid-b17177866141448abce0bae0c195f3d0,pts,0.376742
uuid-b17177866141448abce0bae0c195f3d0,approval,0.429325
uuid-b17177866141448abce0bae0c195f3d0,atezo,0.30592
uuid-b17177866141448abce0bae0c195f3d0,preferred,0.722537
uuid-b17177866141448abce0bae0c195f3d0,monotherapy,0.577028
uuid-b17177866141448abce0bae0c195f3d0,treatment,0.400924
uuid-b17177866141448abce0bae0c195f3d0,using nivo,0.685634
uuid-b17177866141448abce0bae0c195f3d0,NSCLC patients,0.372737
uuid-b17177866141448abce0bae0c195f3d0,approved,0.444844
uuid-b17177866141448abce0bae0c195f3d0,SCCHN,0.451336
uuid-b17177866141448abce0bae0c195f3d0,tumor types,0.310087
uuid-b17177866141448abce0bae0c195f3d0,RTL stated,0.642495
uuid-b17177866141448abce0bae0c195f3d0,TL shared,0.367987
uuid-b17177866141448abce0bae0c195f3d0,option,0.631374
uuid-b17177866141448abce0bae0c195f3d0,bladder,0.312449
uuid-85af01ae3ae74b6fac8ca48537b9e66f,Nivo,0.416335
uuid-85af01ae3ae74b6fac8ca48537b9e66f,patients,0.871471
uuid-85af01ae3ae74b6fac8ca48537b9e66f,Opdivo,0.388876
uuid-85af01ae3ae74b6fac8ca48537b9e66f,therapy,0.759677
uuid-85af01ae3ae74b6fac8ca48537b9e66f,nivolumab,0.573711
uuid-85af01ae3ae74b6fac8ca48537b9e66f,regimen,0.547918
uuid-85af01ae3ae74b6fac8ca48537b9e66f,treated,0.63078
uuid-85af01ae3ae74b6fac8ca48537b9e66f,chemo,0.475979
uuid-85af01ae3ae74b6fac8ca48537b9e66f,pts,0.606757
uuid-85af01ae3ae74b6fac8ca48537b9e66f,monotherapy,0.460017
uuid-85af01ae3ae74b6fac8ca48537b9e66f,treatment,0.728799
uuid-85af01ae3ae74b6fac8ca48537b9e66f,using nivo,0.37018
uuid-85af01ae3ae74b6fac8ca48537b9e66f,response,0.558944
uuid-85af01ae3ae74b6fac8ca48537b9e66f,PD1,0.446813
uuid-85af01ae3ae74b6fac8ca48537b9e66f,cHL,0.449987
uuid-85af01ae3ae74b6fac8ca48537b9e66f,progression,0.739634
uuid-85af01ae3ae74b6fac8ca48537b9e66f,chemotherapy,0.527645
uuid-85af01ae3ae74b6fac8ca48537b9e66f,respond,0.515729
uuid-85af01ae3ae74b6fac8ca48537b9e66f,option,0.391235
uuid-da69b787a1d1415581ac83c7b4978d22,patients,0.34009
uuid-da69b787a1d1415581ac83c7b4978d22,BMS,0.307584
uuid-da69b787a1d1415581ac83c7b4978d22,trial,0.332664
uuid-da69b787a1d1415581ac83c7b4978d22,clinical trials,0.388758
uuid-da69b787a1d1415581ac83c7b4978d22,feels,0.373087
uuid-da69b787a1d1415581ac83c7b4978d22,bladder,0.420322
uuid-ce283e9035574a02bce9893a598d9638,Nivo,0.430524
uuid-ce283e9035574a02bce9893a598d9638,pembro,0.637442
uuid-ce283e9035574a02bce9893a598d9638,1L,0.682736
uuid-ce283e9035574a02bce9893a598d9638,RCC,0.408392
uuid-ce283e9035574a02bce9893a598d9638,combination,0.300087
uuid-ce283e9035574a02bce9893a598d9638,2L,0.736333
uuid-ce283e9035574a02bce9893a598d9638,agents,0.446897
uuid-ce283e9035574a02bce9893a598d9638,approval,0.398487
uuid-ce283e9035574a02bce9893a598d9638,atezo,0.641414
uuid-ce283e9035574a02bce9893a598d9638,preferred,0.701661
uuid-ce283e9035574a02bce9893a598d9638,monotherapy,0.576383
uuid-ce283e9035574a02bce9893a598d9638,using nivo,0.680507
uuid-ce283e9035574a02bce9893a598d9638,combo,0.360917
uuid-ce283e9035574a02bce9893a598d9638,indication,0.376219
uuid-ce283e9035574a02bce9893a598d9638,approved,0.479029
uuid-ce283e9035574a02bce9893a598d9638,SCCHN,0.478522
uuid-ce283e9035574a02bce9893a598d9638,nivo and pembro,0.365535
uuid-ce283e9035574a02bce9893a598d9638,believes,0.315514
uuid-ce283e9035574a02bce9893a598d9638,LTL,0.3178
uuid-ce283e9035574a02bce9893a598d9638,feels,0.542586
uuid-ce283e9035574a02bce9893a598d9638,RTL stated,0.593325
uuid-ce283e9035574a02bce9893a598d9638,option,0.590096
uuid-ce283e9035574a02bce9893a598d9638,bladder,0.370398
uuid-407554ed2a8d48a48096020e73727d26,Nivo,0.325244
uuid-407554ed2a8d48a48096020e73727d26,patients,0.335525
uuid-407554ed2a8d48a48096020e73727d26,pembro,0.359122
uuid-407554ed2a8d48a48096020e73727d26,nivolumab,0.301122
uuid-407554ed2a8d48a48096020e73727d26,trial,0.429981
uuid-407554ed2a8d48a48096020e73727d26,approval,0.395338
uuid-407554ed2a8d48a48096020e73727d26,preferred,0.35163
uuid-407554ed2a8d48a48096020e73727d26,using nivo,0.345282
uuid-407554ed2a8d48a48096020e73727d26,clinical trials,0.484578
uuid-407554ed2a8d48a48096020e73727d26,approved,0.389694
uuid-407554ed2a8d48a48096020e73727d26,SCCHN,0.302624
uuid-407554ed2a8d48a48096020e73727d26,feels,0.490603
uuid-407554ed2a8d48a48096020e73727d26,RTL stated,0.324101
uuid-407554ed2a8d48a48096020e73727d26,option,0.377678
uuid-79366c7d44a9405eafd3c02bc7a05430,patients,0.393064
uuid-79366c7d44a9405eafd3c02bc7a05430,treated,0.391298
uuid-79366c7d44a9405eafd3c02bc7a05430,commented,0.330462
uuid-79366c7d44a9405eafd3c02bc7a05430,approval,0.507424
uuid-79366c7d44a9405eafd3c02bc7a05430,using nivo,0.342767
uuid-79366c7d44a9405eafd3c02bc7a05430,NSCLC patients,0.336823
uuid-79366c7d44a9405eafd3c02bc7a05430,approved,0.362094
uuid-79366c7d44a9405eafd3c02bc7a05430,SCCHN,0.403938
uuid-79366c7d44a9405eafd3c02bc7a05430,tumor types,0.396932
uuid-79366c7d44a9405eafd3c02bc7a05430,label,0.341626
uuid-79366c7d44a9405eafd3c02bc7a05430,Regional TL,0.330848
uuid-79366c7d44a9405eafd3c02bc7a05430,RTL stated,0.347331
uuid-79366c7d44a9405eafd3c02bc7a05430,bladder,0.371563
uuid-b9b056e3b76c45d0a7735a8fb25c8602,Nivo,0.574353
uuid-b9b056e3b76c45d0a7735a8fb25c8602,pembro,0.433287
uuid-b9b056e3b76c45d0a7735a8fb25c8602,nivolumab,0.381962
uuid-b9b056e3b76c45d0a7735a8fb25c8602,1L,0.383653
uuid-b9b056e3b76c45d0a7735a8fb25c8602,trial,0.311227
uuid-b9b056e3b76c45d0a7735a8fb25c8602,commented,0.301768
uuid-b9b056e3b76c45d0a7735a8fb25c8602,RCC,0.36027
uuid-b9b056e3b76c45d0a7735a8fb25c8602,2L,0.414906
uuid-b9b056e3b76c45d0a7735a8fb25c8602,stated,0.341056
uuid-b9b056e3b76c45d0a7735a8fb25c8602,approval,0.421398
uuid-b9b056e3b76c45d0a7735a8fb25c8602,preferred,0.33679
uuid-b9b056e3b76c45d0a7735a8fb25c8602,monotherapy,0.374129
uuid-b9b056e3b76c45d0a7735a8fb25c8602,using nivo,0.561243
uuid-b9b056e3b76c45d0a7735a8fb25c8602,data,0.425273
uuid-b9b056e3b76c45d0a7735a8fb25c8602,approved,0.377239
uuid-b9b056e3b76c45d0a7735a8fb25c8602,SCCHN,0.42982
uuid-b9b056e3b76c45d0a7735a8fb25c8602,impressed,0.449852
uuid-b9b056e3b76c45d0a7735a8fb25c8602,LTL,0.340102
uuid-b9b056e3b76c45d0a7735a8fb25c8602,SCLC,0.410945
uuid-b9b056e3b76c45d0a7735a8fb25c8602,feels,0.383928
uuid-b9b056e3b76c45d0a7735a8fb25c8602,Regional TL,0.369837
uuid-b9b056e3b76c45d0a7735a8fb25c8602,RTL stated,0.531532
uuid-b9b056e3b76c45d0a7735a8fb25c8602,option,0.377377
uuid-b9b056e3b76c45d0a7735a8fb25c8602,bladder,0.410655
uuid-17bc79d29ab04a5aa3dee9b4ef010015,Nivo,0.494072
uuid-17bc79d29ab04a5aa3dee9b4ef010015,pembro,0.306323
uuid-17bc79d29ab04a5aa3dee9b4ef010015,therapy,0.324667
uuid-17bc79d29ab04a5aa3dee9b4ef010015,1L,0.386717
uuid-17bc79d29ab04a5aa3dee9b4ef010015,efficacy,0.311555
uuid-17bc79d29ab04a5aa3dee9b4ef010015,regimen,0.359954
uuid-17bc79d29ab04a5aa3dee9b4ef010015,RCC,0.337476
uuid-17bc79d29ab04a5aa3dee9b4ef010015,combination,0.440098
uuid-17bc79d29ab04a5aa3dee9b4ef010015,chemo,0.545816
uuid-17bc79d29ab04a5aa3dee9b4ef010015,2L,0.385752
uuid-17bc79d29ab04a5aa3dee9b4ef010015,pts,0.392179
uuid-17bc79d29ab04a5aa3dee9b4ef010015,agents,0.42383
uuid-17bc79d29ab04a5aa3dee9b4ef010015,monotherapy,0.581601
uuid-17bc79d29ab04a5aa3dee9b4ef010015,using nivo,0.391061
uuid-17bc79d29ab04a5aa3dee9b4ef010015,response,0.328179
uuid-17bc79d29ab04a5aa3dee9b4ef010015,combo,0.424889
uuid-17bc79d29ab04a5aa3dee9b4ef010015,PD1,0.574561
uuid-17bc79d29ab04a5aa3dee9b4ef010015,nivo and pembro,0.459355
uuid-17bc79d29ab04a5aa3dee9b4ef010015,believes,0.51554
uuid-17bc79d29ab04a5aa3dee9b4ef010015,chemotherapy,0.424109
uuid-17bc79d29ab04a5aa3dee9b4ef010015,respond,0.357545
uuid-17bc79d29ab04a5aa3dee9b4ef010015,feels,0.444515
uuid-17bc79d29ab04a5aa3dee9b4ef010015,RTL stated,0.314701
uuid-17bc79d29ab04a5aa3dee9b4ef010015,option,0.422589
uuid-1f6f5acf5ccb490ba520ebc1aaa44d60,Nivo,0.402655
uuid-1f6f5acf5ccb490ba520ebc1aaa44d60,pembro,0.351204
uuid-1f6f5acf5ccb490ba520ebc1aaa44d60,trial,0.395628
uuid-1f6f5acf5ccb490ba520ebc1aaa44d60,efficacy,0.428774
uuid-1f6f5acf5ccb490ba520ebc1aaa44d60,OS,0.652552
uuid-1f6f5acf5ccb490ba520ebc1aaa44d60,data,0.68594
uuid-1f6f5acf5ccb490ba520ebc1aaa44d60,PFS,0.571904
uuid-1f6f5acf5ccb490ba520ebc1aaa44d60,ORR,0.617189
uuid-1f6f5acf5ccb490ba520ebc1aaa44d60,nivo and pembro,0.373373
uuid-1f6f5acf5ccb490ba520ebc1aaa44d60,impressed,0.613559
uuid-1f6f5acf5ccb490ba520ebc1aaa44d60,feels,0.447578
uuid-5ebd78229d314ed18a00e16f2fe5d261,NTL,0.355866
uuid-5ebd78229d314ed18a00e16f2fe5d261,commented,0.32079
uuid-5ebd78229d314ed18a00e16f2fe5d261,approval,0.340605
uuid-5ebd78229d314ed18a00e16f2fe5d261,SCCHN,0.346476
uuid-5ebd78229d314ed18a00e16f2fe5d261,NCCN,0.388228
uuid-15b2fc0bb37c407db4940ac00618ec7e,Nivo,0.585122
uuid-15b2fc0bb37c407db4940ac00618ec7e,pembro,0.399141
uuid-15b2fc0bb37c407db4940ac00618ec7e,therapy,0.334604
uuid-15b2fc0bb37c407db4940ac00618ec7e,nivolumab,0.449374
uuid-15b2fc0bb37c407db4940ac00618ec7e,1L,0.413148
uuid-15b2fc0bb37c407db4940ac00618ec7e,toxicity,0.427856
uuid-15b2fc0bb37c407db4940ac00618ec7e,regimen,0.429729
uuid-15b2fc0bb37c407db4940ac00618ec7e,RCC,0.328734
uuid-15b2fc0bb37c407db4940ac00618ec7e,combination,0.617504
uuid-15b2fc0bb37c407db4940ac00618ec7e,chemo,0.420652
uuid-15b2fc0bb37c407db4940ac00618ec7e,2L,0.534371
uuid-15b2fc0bb37c407db4940ac00618ec7e,agents,0.552899
uuid-15b2fc0bb37c407db4940ac00618ec7e,Ipi,0.379932
uuid-15b2fc0bb37c407db4940ac00618ec7e,atezo,0.358709
uuid-15b2fc0bb37c407db4940ac00618ec7e,preferred,0.61491
uuid-15b2fc0bb37c407db4940ac00618ec7e,monotherapy,0.639264
uuid-15b2fc0bb37c407db4940ac00618ec7e,using nivo,0.530625
uuid-15b2fc0bb37c407db4940ac00618ec7e,combo,0.50094
uuid-15b2fc0bb37c407db4940ac00618ec7e,PD1,0.41513
uuid-15b2fc0bb37c407db4940ac00618ec7e,approved,0.325878
uuid-15b2fc0bb37c407db4940ac00618ec7e,chemotherapy,0.406703
uuid-15b2fc0bb37c407db4940ac00618ec7e,feels,0.339906
uuid-15b2fc0bb37c407db4940ac00618ec7e,RTL stated,0.491055
uuid-15b2fc0bb37c407db4940ac00618ec7e,option,0.540113
uuid-b376bf66203349239864afe6800ffd69,Opdivo,0.366501
uuid-b376bf66203349239864afe6800ffd69,physicians,0.821156
uuid-b376bf66203349239864afe6800ffd69,oncology,0.30858
uuid-343ab8baf1f748bcbc9e6396c44b4fe2,patients,0.651712
uuid-343ab8baf1f748bcbc9e6396c44b4fe2,Opdivo,0.540849
uuid-343ab8baf1f748bcbc9e6396c44b4fe2,dose,0.658386
uuid-343ab8baf1f748bcbc9e6396c44b4fe2,toxicity,0.570367
uuid-343ab8baf1f748bcbc9e6396c44b4fe2,regimen,0.519608
uuid-343ab8baf1f748bcbc9e6396c44b4fe2,treated,0.409109
uuid-343ab8baf1f748bcbc9e6396c44b4fe2,treatment,0.569836
uuid-343ab8baf1f748bcbc9e6396c44b4fe2,progression,0.397599
uuid-343ab8baf1f748bcbc9e6396c44b4fe2,respond,0.413207
uuid-343ab8baf1f748bcbc9e6396c44b4fe2,flat dosing,0.368528
uuid-1b25922832744af7837fba8df1b18505,1L,0.357059
uuid-1b25922832744af7837fba8df1b18505,efficacy,0.54834
uuid-1b25922832744af7837fba8df1b18505,combination,0.559036
uuid-1b25922832744af7837fba8df1b18505,chemo,0.506553
uuid-1b25922832744af7837fba8df1b18505,2L,0.30282
uuid-1b25922832744af7837fba8df1b18505,IO,0.569958
uuid-1b25922832744af7837fba8df1b18505,agents,0.548791
uuid-1b25922832744af7837fba8df1b18505,OS,0.308146
uuid-1b25922832744af7837fba8df1b18505,monotherapy,0.523215
uuid-1b25922832744af7837fba8df1b18505,response,0.306049
uuid-1b25922832744af7837fba8df1b18505,combo,0.590708
uuid-1b25922832744af7837fba8df1b18505,PD1,0.453023
uuid-1b25922832744af7837fba8df1b18505,ORR,0.366656
uuid-1b25922832744af7837fba8df1b18505,nivo and pembro,0.343616
uuid-1b25922832744af7837fba8df1b18505,believes,0.585549
uuid-1b25922832744af7837fba8df1b18505,chemotherapy,0.427566
uuid-1b25922832744af7837fba8df1b18505,TLs,0.32327
uuid-1b25922832744af7837fba8df1b18505,feels,0.412472
uuid-1b25922832744af7837fba8df1b18505,option,0.388299
uuid-ea9e29711ff14a4bb96aa63eecbfea23,Opdivo,0.333526
uuid-ea9e29711ff14a4bb96aa63eecbfea23,RTL,0.32159
uuid-ea9e29711ff14a4bb96aa63eecbfea23,shared,0.314808
uuid-ea9e29711ff14a4bb96aa63eecbfea23,stated,0.358647
uuid-ea9e29711ff14a4bb96aa63eecbfea23,physicians,0.537978
uuid-ea9e29711ff14a4bb96aa63eecbfea23,oncology,0.620887
uuid-ea9e29711ff14a4bb96aa63eecbfea23,LTL,0.381723
uuid-ea9e29711ff14a4bb96aa63eecbfea23,clinical,0.37744
uuid-ea9e29711ff14a4bb96aa63eecbfea23,academic,0.346875
uuid-ea9e29711ff14a4bb96aa63eecbfea23,Regional TL,0.414942
uuid-ea9e29711ff14a4bb96aa63eecbfea23,flat dosing,0.406994
uuid-443b1806f13748e8a7eb7894d87b6599,pembro,0.53969
uuid-443b1806f13748e8a7eb7894d87b6599,dose,0.592884
uuid-443b1806f13748e8a7eb7894d87b6599,BMS,0.381771
uuid-443b1806f13748e8a7eb7894d87b6599,efficacy,0.515604
uuid-443b1806f13748e8a7eb7894d87b6599,Merck,0.322905
uuid-443b1806f13748e8a7eb7894d87b6599,Ipi,0.399733
uuid-443b1806f13748e8a7eb7894d87b6599,atezo,0.620434
uuid-443b1806f13748e8a7eb7894d87b6599,regards,0.340011
uuid-443b1806f13748e8a7eb7894d87b6599,indication,0.512913
uuid-443b1806f13748e8a7eb7894d87b6599,approved,0.319078
uuid-443b1806f13748e8a7eb7894d87b6599,nivo and pembro,0.303283
uuid-443b1806f13748e8a7eb7894d87b6599,vs,0.553933
uuid-443b1806f13748e8a7eb7894d87b6599,Keytruda,0.365534
uuid-443b1806f13748e8a7eb7894d87b6599,TLs,0.368645
uuid-443b1806f13748e8a7eb7894d87b6599,flat dosing,0.614165
uuid-d2586a2cd5d6469c8704dbb02a8412b9,Nivo,0.395853
uuid-d2586a2cd5d6469c8704dbb02a8412b9,patients,0.506771
uuid-d2586a2cd5d6469c8704dbb02a8412b9,therapy,0.310413
uuid-d2586a2cd5d6469c8704dbb02a8412b9,nivolumab,0.494535
uuid-d2586a2cd5d6469c8704dbb02a8412b9,1L,0.319882
uuid-d2586a2cd5d6469c8704dbb02a8412b9,regimen,0.462066
uuid-d2586a2cd5d6469c8704dbb02a8412b9,treated,0.526506
uuid-d2586a2cd5d6469c8704dbb02a8412b9,RCC,0.506739
uuid-d2586a2cd5d6469c8704dbb02a8412b9,chemo,0.333891
uuid-d2586a2cd5d6469c8704dbb02a8412b9,2L,0.393147
uuid-d2586a2cd5d6469c8704dbb02a8412b9,pts,0.416288
uuid-d2586a2cd5d6469c8704dbb02a8412b9,preferred,0.304598
uuid-d2586a2cd5d6469c8704dbb02a8412b9,monotherapy,0.464985
uuid-d2586a2cd5d6469c8704dbb02a8412b9,treatment,0.408203
uuid-d2586a2cd5d6469c8704dbb02a8412b9,using nivo,0.53327
uuid-d2586a2cd5d6469c8704dbb02a8412b9,combo,0.34806
uuid-d2586a2cd5d6469c8704dbb02a8412b9,PD1,0.387879
uuid-d2586a2cd5d6469c8704dbb02a8412b9,SCCHN,0.338597
uuid-d2586a2cd5d6469c8704dbb02a8412b9,progression,0.418904
uuid-d2586a2cd5d6469c8704dbb02a8412b9,impressed,0.313861
uuid-d2586a2cd5d6469c8704dbb02a8412b9,respond,0.327934
uuid-d2586a2cd5d6469c8704dbb02a8412b9,SCLC,0.318396
uuid-d2586a2cd5d6469c8704dbb02a8412b9,feels,0.320095
uuid-d2586a2cd5d6469c8704dbb02a8412b9,RTL stated,0.489431
uuid-d2586a2cd5d6469c8704dbb02a8412b9,TL shared,0.378537
uuid-d2586a2cd5d6469c8704dbb02a8412b9,option,0.380749
uuid-d2586a2cd5d6469c8704dbb02a8412b9,bladder,0.323458
uuid-ea9e2f5f2c324c5889e927477a2e06e0,Nivo,0.47594
uuid-ea9e2f5f2c324c5889e927477a2e06e0,patients,0.87037
uuid-ea9e2f5f2c324c5889e927477a2e06e0,Opdivo,0.512745
uuid-ea9e2f5f2c324c5889e927477a2e06e0,therapy,0.648819
uuid-ea9e2f5f2c324c5889e927477a2e06e0,nivolumab,0.511717
uuid-ea9e2f5f2c324c5889e927477a2e06e0,regimen,0.497215
uuid-ea9e2f5f2c324c5889e927477a2e06e0,treated,0.514395
uuid-ea9e2f5f2c324c5889e927477a2e06e0,chemo,0.369285
uuid-ea9e2f5f2c324c5889e927477a2e06e0,pts,0.58356
uuid-ea9e2f5f2c324c5889e927477a2e06e0,monotherapy,0.355681
uuid-ea9e2f5f2c324c5889e927477a2e06e0,treatment,0.6724
uuid-ea9e2f5f2c324c5889e927477a2e06e0,using nivo,0.3378
uuid-ea9e2f5f2c324c5889e927477a2e06e0,response,0.427937
uuid-ea9e2f5f2c324c5889e927477a2e06e0,PD1,0.348268
uuid-ea9e2f5f2c324c5889e927477a2e06e0,cHL,0.440509
uuid-ea9e2f5f2c324c5889e927477a2e06e0,progression,0.684628
uuid-ea9e2f5f2c324c5889e927477a2e06e0,chemotherapy,0.413328
uuid-ea9e2f5f2c324c5889e927477a2e06e0,respond,0.526412
uuid-ea9e2f5f2c324c5889e927477a2e06e0,option,0.319589
uuid-160577311ce648029fea6dd12e8623dd,OS,0.485571
uuid-160577311ce648029fea6dd12e8623dd,data,0.384405
uuid-160577311ce648029fea6dd12e8623dd,PFS,0.438158
uuid-160577311ce648029fea6dd12e8623dd,ORR,0.406985
uuid-160577311ce648029fea6dd12e8623dd,nivo and pembro,0.402848
uuid-160577311ce648029fea6dd12e8623dd,believes,0.314567
uuid-160577311ce648029fea6dd12e8623dd,impressed,0.337582
uuid-160577311ce648029fea6dd12e8623dd,feels,0.460364
uuid-d12f05c6c4404daa865813787bf68c2c,Nivo,0.317466
uuid-d12f05c6c4404daa865813787bf68c2c,pembro,0.33932
uuid-d12f05c6c4404daa865813787bf68c2c,1L,0.544465
uuid-d12f05c6c4404daa865813787bf68c2c,RCC,0.515081
uuid-d12f05c6c4404daa865813787bf68c2c,TL stated,0.314967
uuid-d12f05c6c4404daa865813787bf68c2c,combination,0.338842
uuid-d12f05c6c4404daa865813787bf68c2c,chemo,0.338652
uuid-d12f05c6c4404daa865813787bf68c2c,2L,0.661103
uuid-d12f05c6c4404daa865813787bf68c2c,agents,0.626628
uuid-d12f05c6c4404daa865813787bf68c2c,atezo,0.403911
uuid-d12f05c6c4404daa865813787bf68c2c,preferred,0.651934
uuid-d12f05c6c4404daa865813787bf68c2c,monotherapy,0.541036
uuid-d12f05c6c4404daa865813787bf68c2c,using nivo,0.481839
uuid-d12f05c6c4404daa865813787bf68c2c,combo,0.391597
uuid-d12f05c6c4404daa865813787bf68c2c,PD1,0.340005
uuid-d12f05c6c4404daa865813787bf68c2c,approved,0.344777
uuid-d12f05c6c4404daa865813787bf68c2c,nivo and pembro,0.359716
uuid-d12f05c6c4404daa865813787bf68c2c,believes,0.408764
uuid-d12f05c6c4404daa865813787bf68c2c,feels,0.351345
uuid-d12f05c6c4404daa865813787bf68c2c,RTL stated,0.485963
uuid-d12f05c6c4404daa865813787bf68c2c,option,0.538578
uuid-50aa43d2f04147539069b4898f448c11,patients,0.503987
uuid-50aa43d2f04147539069b4898f448c11,dose,0.387016
uuid-50aa43d2f04147539069b4898f448c11,toxicity,0.622203
uuid-50aa43d2f04147539069b4898f448c11,regimen,0.583806
uuid-50aa43d2f04147539069b4898f448c11,treated,0.52741
uuid-50aa43d2f04147539069b4898f448c11,pts,0.312979
uuid-50aa43d2f04147539069b4898f448c11,treatment,0.558138
uuid-50aa43d2f04147539069b4898f448c11,progression,0.325682
uuid-50aa43d2f04147539069b4898f448c11,respond,0.450239
uuid-50aa43d2f04147539069b4898f448c11,TL shared,0.351764
uuid-05b06c8e037748a7995be6a89c491b06,patients,0.744669
uuid-05b06c8e037748a7995be6a89c491b06,Opdivo,0.545404
uuid-05b06c8e037748a7995be6a89c491b06,therapy,0.388522
uuid-05b06c8e037748a7995be6a89c491b06,nivolumab,0.320245
uuid-05b06c8e037748a7995be6a89c491b06,regimen,0.427506
uuid-05b06c8e037748a7995be6a89c491b06,treated,0.515676
uuid-05b06c8e037748a7995be6a89c491b06,pts,0.429366
uuid-05b06c8e037748a7995be6a89c491b06,physicians,0.397399
uuid-05b06c8e037748a7995be6a89c491b06,treatment,0.636785
uuid-05b06c8e037748a7995be6a89c491b06,NSCLC patients,0.340583
uuid-05b06c8e037748a7995be6a89c491b06,progression,0.499553
uuid-05b06c8e037748a7995be6a89c491b06,respond,0.405557
uuid-05b06c8e037748a7995be6a89c491b06,option,0.319321
uuid-68c9e8279bca435cb15907ccfe18ab7f,Nivo,0.414604
uuid-68c9e8279bca435cb15907ccfe18ab7f,patients,0.362758
uuid-68c9e8279bca435cb15907ccfe18ab7f,pembro,0.451571
uuid-68c9e8279bca435cb15907ccfe18ab7f,dose,0.454344
uuid-68c9e8279bca435cb15907ccfe18ab7f,1L,0.372412
uuid-68c9e8279bca435cb15907ccfe18ab7f,toxicity,0.379307
uuid-68c9e8279bca435cb15907ccfe18ab7f,regimen,0.394305
uuid-68c9e8279bca435cb15907ccfe18ab7f,chemo,0.349192
uuid-68c9e8279bca435cb15907ccfe18ab7f,2L,0.513162
uuid-68c9e8279bca435cb15907ccfe18ab7f,agents,0.383662
uuid-68c9e8279bca435cb15907ccfe18ab7f,Ipi,0.3084
uuid-68c9e8279bca435cb15907ccfe18ab7f,atezo,0.434126
uuid-68c9e8279bca435cb15907ccfe18ab7f,preferred,0.585036
uuid-68c9e8279bca435cb15907ccfe18ab7f,monotherapy,0.485206
uuid-68c9e8279bca435cb15907ccfe18ab7f,using nivo,0.453566
uuid-68c9e8279bca435cb15907ccfe18ab7f,vs,0.351637
uuid-68c9e8279bca435cb15907ccfe18ab7f,RTL stated,0.332559
uuid-68c9e8279bca435cb15907ccfe18ab7f,option,0.472134
uuid-58e9ba8bb0334fd3a277993cc8128cc9,Nivo,0.339714
uuid-58e9ba8bb0334fd3a277993cc8128cc9,patients,0.369154
uuid-58e9ba8bb0334fd3a277993cc8128cc9,pembro,0.358203
uuid-58e9ba8bb0334fd3a277993cc8128cc9,1L,0.377808
uuid-58e9ba8bb0334fd3a277993cc8128cc9,regimen,0.323325
uuid-58e9ba8bb0334fd3a277993cc8128cc9,2L,0.471535
uuid-58e9ba8bb0334fd3a277993cc8128cc9,atezo,0.335675
uuid-58e9ba8bb0334fd3a277993cc8128cc9,preferred,0.510178
uuid-58e9ba8bb0334fd3a277993cc8128cc9,monotherapy,0.395135
uuid-58e9ba8bb0334fd3a277993cc8128cc9,using nivo,0.460949
uuid-58e9ba8bb0334fd3a277993cc8128cc9,respond,0.322249
uuid-58e9ba8bb0334fd3a277993cc8128cc9,RTL stated,0.332134
uuid-58e9ba8bb0334fd3a277993cc8128cc9,option,0.444899
uuid-e903dbafcd224fb38adb673e38acbe1c,patients,0.610962
uuid-e903dbafcd224fb38adb673e38acbe1c,Opdivo,0.356762
uuid-e903dbafcd224fb38adb673e38acbe1c,therapy,0.618473
uuid-e903dbafcd224fb38adb673e38acbe1c,nivolumab,0.432061
uuid-e903dbafcd224fb38adb673e38acbe1c,treated,0.39756
uuid-e903dbafcd224fb38adb673e38acbe1c,treatment,0.414667
uuid-e903dbafcd224fb38adb673e38acbe1c,cHL,0.69793
uuid-e903dbafcd224fb38adb673e38acbe1c,progression,0.325632
uuid-5ef133f681cb41479a2eb1e06af83f8d,patients,0.406659
uuid-5ef133f681cb41479a2eb1e06af83f8d,therapy,0.421306
uuid-5ef133f681cb41479a2eb1e06af83f8d,mentioned,0.331815
uuid-5ef133f681cb41479a2eb1e06af83f8d,cHL,0.671021
uuid-aa208e62880a4818b39fe5273198364c,patients,0.66306
uuid-aa208e62880a4818b39fe5273198364c,Opdivo,0.345437
uuid-aa208e62880a4818b39fe5273198364c,therapy,0.552814
uuid-aa208e62880a4818b39fe5273198364c,nivolumab,0.431295
uuid-aa208e62880a4818b39fe5273198364c,treated,0.412831
uuid-aa208e62880a4818b39fe5273198364c,treatment,0.431144
uuid-aa208e62880a4818b39fe5273198364c,cHL,0.652522
uuid-aa208e62880a4818b39fe5273198364c,progression,0.371349
uuid-aa208e62880a4818b39fe5273198364c,respond,0.330283
uuid-96c330fe9c75478bbe689ebbdb29c1c7,Nivo,0.469104
uuid-96c330fe9c75478bbe689ebbdb29c1c7,patients,0.423749
uuid-96c330fe9c75478bbe689ebbdb29c1c7,therapy,0.389104
uuid-96c330fe9c75478bbe689ebbdb29c1c7,nivolumab,0.460565
uuid-96c330fe9c75478bbe689ebbdb29c1c7,approval,0.59454
uuid-96c330fe9c75478bbe689ebbdb29c1c7,using nivo,0.600766
uuid-96c330fe9c75478bbe689ebbdb29c1c7,mentioned,0.320144
uuid-96c330fe9c75478bbe689ebbdb29c1c7,approved,0.388267
uuid-96c330fe9c75478bbe689ebbdb29c1c7,cHL,0.615399
uuid-96c330fe9c75478bbe689ebbdb29c1c7,label,0.382542
uuid-40bb8a5a4fe64faea3d00cafb43e118a,Nivo,0.409131
uuid-40bb8a5a4fe64faea3d00cafb43e118a,pembro,0.379763
uuid-40bb8a5a4fe64faea3d00cafb43e118a,1L,0.470313
uuid-40bb8a5a4fe64faea3d00cafb43e118a,RCC,0.324381
uuid-40bb8a5a4fe64faea3d00cafb43e118a,chemo,0.382264
uuid-40bb8a5a4fe64faea3d00cafb43e118a,2L,0.500416
uuid-40bb8a5a4fe64faea3d00cafb43e118a,agents,0.465384
uuid-40bb8a5a4fe64faea3d00cafb43e118a,atezo,0.35679
uuid-40bb8a5a4fe64faea3d00cafb43e118a,preferred,0.38696
uuid-40bb8a5a4fe64faea3d00cafb43e118a,monotherapy,0.443496
uuid-40bb8a5a4fe64faea3d00cafb43e118a,using nivo,0.398454
uuid-40bb8a5a4fe64faea3d00cafb43e118a,combo,0.321031
uuid-40bb8a5a4fe64faea3d00cafb43e118a,PD1,0.359526
uuid-40bb8a5a4fe64faea3d00cafb43e118a,nivo and pembro,0.555937
uuid-40bb8a5a4fe64faea3d00cafb43e118a,believes,0.533069
uuid-40bb8a5a4fe64faea3d00cafb43e118a,feels,0.426038
uuid-40bb8a5a4fe64faea3d00cafb43e118a,RTL stated,0.300828
uuid-40bb8a5a4fe64faea3d00cafb43e118a,option,0.435938
uuid-45dcf5dd7a7941c3b09dd185cb840283,Nivo,0.59486
uuid-45dcf5dd7a7941c3b09dd185cb840283,patients,0.624573
uuid-45dcf5dd7a7941c3b09dd185cb840283,therapy,0.581419
uuid-45dcf5dd7a7941c3b09dd185cb840283,nivolumab,0.383189
uuid-45dcf5dd7a7941c3b09dd185cb840283,1L,0.396921
uuid-45dcf5dd7a7941c3b09dd185cb840283,toxicity,0.427609
uuid-45dcf5dd7a7941c3b09dd185cb840283,regimen,0.589146
uuid-45dcf5dd7a7941c3b09dd185cb840283,treated,0.315939
uuid-45dcf5dd7a7941c3b09dd185cb840283,combination,0.410742
uuid-45dcf5dd7a7941c3b09dd185cb840283,chemo,0.639816
uuid-45dcf5dd7a7941c3b09dd185cb840283,2L,0.440716
uuid-45dcf5dd7a7941c3b09dd185cb840283,pts,0.524635
uuid-45dcf5dd7a7941c3b09dd185cb840283,agents,0.35704
uuid-45dcf5dd7a7941c3b09dd185cb840283,Ipi,0.308214
uuid-45dcf5dd7a7941c3b09dd185cb840283,preferred,0.410132
uuid-45dcf5dd7a7941c3b09dd185cb840283,monotherapy,0.674616
uuid-45dcf5dd7a7941c3b09dd185cb840283,treatment,0.573247
uuid-45dcf5dd7a7941c3b09dd185cb840283,using nivo,0.417274
uuid-45dcf5dd7a7941c3b09dd185cb840283,response,0.448961
uuid-45dcf5dd7a7941c3b09dd185cb840283,combo,0.400762
uuid-45dcf5dd7a7941c3b09dd185cb840283,PD1,0.514452
uuid-45dcf5dd7a7941c3b09dd185cb840283,progression,0.565788
uuid-45dcf5dd7a7941c3b09dd185cb840283,believes,0.347198
uuid-45dcf5dd7a7941c3b09dd185cb840283,chemotherapy,0.532958
uuid-45dcf5dd7a7941c3b09dd185cb840283,respond,0.569179
uuid-45dcf5dd7a7941c3b09dd185cb840283,feels,0.35876
uuid-45dcf5dd7a7941c3b09dd185cb840283,option,0.601598
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,Nivo,0.483691
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,pembro,0.529136
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,1L,0.447086
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,toxicity,0.348796
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,regimen,0.310403
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,RCC,0.430176
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,combination,0.412167
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,chemo,0.372673
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,2L,0.537082
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,agents,0.46257
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,Ipi,0.436259
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,atezo,0.503098
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,preferred,0.619715
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,monotherapy,0.519889
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,using nivo,0.469915
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,combo,0.449364
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,nivo and pembro,0.378344
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,believes,0.305327
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,vs,0.387165
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,feels,0.415719
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,RTL stated,0.430246
uuid-9c8042dc031545b2a0b6a740f4ad7d7c,option,0.435363
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,Nivo,0.302048
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,patients,0.716314
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,Opdivo,0.400561
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,therapy,0.400055
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,dose,0.399188
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,nivolumab,0.419192
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,toxicity,0.432676
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,regimen,0.552874
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,treated,0.560164
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,pts,0.476121
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,treatment,0.666463
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,response,0.32443
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,progression,0.531854
uuid-5e5a2ba9f9a94e9d81e53cc101baa6f4,respond,0.564242
uuid-fb0de042d7244a79b0515e93715f9135,patients,0.443182
uuid-fb0de042d7244a79b0515e93715f9135,Opdivo,0.41737
uuid-fb0de042d7244a79b0515e93715f9135,dose,0.436899
uuid-fb0de042d7244a79b0515e93715f9135,toxicity,0.526361
uuid-fb0de042d7244a79b0515e93715f9135,regimen,0.534345
uuid-fb0de042d7244a79b0515e93715f9135,treated,0.411067
uuid-fb0de042d7244a79b0515e93715f9135,physicians,0.439137
uuid-fb0de042d7244a79b0515e93715f9135,treatment,0.616801
uuid-fb0de042d7244a79b0515e93715f9135,progression,0.317116
uuid-fb0de042d7244a79b0515e93715f9135,respond,0.398849
uuid-398664492cf84be1b5bfa0f88a059c02,patients,0.628401
uuid-398664492cf84be1b5bfa0f88a059c02,therapy,0.459591
uuid-398664492cf84be1b5bfa0f88a059c02,regimen,0.364352
uuid-398664492cf84be1b5bfa0f88a059c02,treated,0.480673
uuid-398664492cf84be1b5bfa0f88a059c02,chemo,0.501209
uuid-398664492cf84be1b5bfa0f88a059c02,tumor,0.577494
uuid-398664492cf84be1b5bfa0f88a059c02,pts,0.61204
uuid-398664492cf84be1b5bfa0f88a059c02,treatment,0.426154
uuid-398664492cf84be1b5bfa0f88a059c02,response,0.668221
uuid-398664492cf84be1b5bfa0f88a059c02,PD1,0.356114
uuid-398664492cf84be1b5bfa0f88a059c02,progression,0.573646
uuid-398664492cf84be1b5bfa0f88a059c02,chemotherapy,0.399461
uuid-398664492cf84be1b5bfa0f88a059c02,respond,0.474748
uuid-67e2172649f844168787c041cf8f92b8,patients,0.807732
uuid-67e2172649f844168787c041cf8f92b8,Opdivo,0.3724
uuid-67e2172649f844168787c041cf8f92b8,therapy,0.508953
uuid-67e2172649f844168787c041cf8f92b8,nivolumab,0.305933
uuid-67e2172649f844168787c041cf8f92b8,regimen,0.553353
uuid-67e2172649f844168787c041cf8f92b8,treated,0.624885
uuid-67e2172649f844168787c041cf8f92b8,pts,0.528367
uuid-67e2172649f844168787c041cf8f92b8,treatment,0.75725
uuid-67e2172649f844168787c041cf8f92b8,response,0.48368
uuid-67e2172649f844168787c041cf8f92b8,progression,0.745635
uuid-67e2172649f844168787c041cf8f92b8,respond,0.605006
uuid-b2101cf569eb4afc9c394354d647ee81,patients,0.319271
uuid-b2101cf569eb4afc9c394354d647ee81,Opdivo,0.318346
uuid-b2101cf569eb4afc9c394354d647ee81,dose,0.497802
uuid-b2101cf569eb4afc9c394354d647ee81,academic,0.313157
uuid-b2101cf569eb4afc9c394354d647ee81,flat dosing,0.501373
uuid-ccaf23d21648450ebaeb9c031a855721,oncology,0.510747
uuid-ccaf23d21648450ebaeb9c031a855721,ASCO,0.411008
uuid-fe90ae87e6f941fe8b8e251c6afeefb7,RTL,0.333988
uuid-fe90ae87e6f941fe8b8e251c6afeefb7,lung,0.357242
uuid-fe90ae87e6f941fe8b8e251c6afeefb7,NTL,0.370973
uuid-fe90ae87e6f941fe8b8e251c6afeefb7,discussed,0.322406
uuid-fe90ae87e6f941fe8b8e251c6afeefb7,melanoma,0.397777
uuid-fe90ae87e6f941fe8b8e251c6afeefb7,commented,0.367703
uuid-fe90ae87e6f941fe8b8e251c6afeefb7,stated,0.389895
uuid-fe90ae87e6f941fe8b8e251c6afeefb7,SCCHN,0.457551
uuid-fe90ae87e6f941fe8b8e251c6afeefb7,academic,0.31119
uuid-fe90ae87e6f941fe8b8e251c6afeefb7,Regional TL,0.373328
uuid-fe90ae87e6f941fe8b8e251c6afeefb7,NCCN,0.522036
uuid-014ee7dedcd34735864649dc6b11c458,pembro,0.310363
uuid-014ee7dedcd34735864649dc6b11c458,RTL,0.577352
uuid-014ee7dedcd34735864649dc6b11c458,BMS,0.403933
uuid-014ee7dedcd34735864649dc6b11c458,trial,0.504927
uuid-014ee7dedcd34735864649dc6b11c458,efficacy,0.357652
uuid-014ee7dedcd34735864649dc6b11c458,NTL,0.342763
uuid-014ee7dedcd34735864649dc6b11c458,shared,0.367058
uuid-014ee7dedcd34735864649dc6b11c458,commented,0.568955
uuid-014ee7dedcd34735864649dc6b11c458,Merck,0.33049
uuid-014ee7dedcd34735864649dc6b11c458,stated,0.588701
uuid-014ee7dedcd34735864649dc6b11c458,OS,0.44896
uuid-014ee7dedcd34735864649dc6b11c458,data,0.816806
uuid-014ee7dedcd34735864649dc6b11c458,expressed,0.487722
uuid-014ee7dedcd34735864649dc6b11c458,clinical trials,0.373784
uuid-014ee7dedcd34735864649dc6b11c458,PFS,0.417046
uuid-014ee7dedcd34735864649dc6b11c458,ORR,0.49182
uuid-014ee7dedcd34735864649dc6b11c458,SCCHN,0.418919
uuid-014ee7dedcd34735864649dc6b11c458,HCP,0.335256
uuid-014ee7dedcd34735864649dc6b11c458,nivo and pembro,0.342962
uuid-014ee7dedcd34735864649dc6b11c458,ASCO,0.385199
uuid-014ee7dedcd34735864649dc6b11c458,impressed,0.696487
uuid-014ee7dedcd34735864649dc6b11c458,LTL,0.518672
uuid-014ee7dedcd34735864649dc6b11c458,TLs,0.474273
uuid-014ee7dedcd34735864649dc6b11c458,SCLC,0.33385
uuid-014ee7dedcd34735864649dc6b11c458,feels,0.308637
uuid-014ee7dedcd34735864649dc6b11c458,Regional TL,0.49087
uuid-4b5f34b97a504973bcced726235784ef,pembro,0.337377
uuid-4b5f34b97a504973bcced726235784ef,BMS,0.374845
uuid-4b5f34b97a504973bcced726235784ef,PDL1,0.485803
uuid-4b5f34b97a504973bcced726235784ef,trial,0.69695
uuid-4b5f34b97a504973bcced726235784ef,efficacy,0.399092
uuid-4b5f34b97a504973bcced726235784ef,OS,0.469955
uuid-4b5f34b97a504973bcced726235784ef,data,0.535527
uuid-4b5f34b97a504973bcced726235784ef,clinical trials,0.387324
uuid-4b5f34b97a504973bcced726235784ef,PFS,0.535723
uuid-4b5f34b97a504973bcced726235784ef,ORR,0.565296
uuid-4b5f34b97a504973bcced726235784ef,nivo and pembro,0.395489
uuid-4b5f34b97a504973bcced726235784ef,impressed,0.38892
uuid-4b5f34b97a504973bcced726235784ef,feels,0.392185
uuid-4b5f34b97a504973bcced726235784ef,PDL1 expression,0.519649
uuid-4b5f34b97a504973bcced726235784ef,biomarker,0.322401
uuid-f3fdcefeb4824f46b164170a1c74eeef,pembro,0.312055
uuid-f3fdcefeb4824f46b164170a1c74eeef,BMS,0.34289
uuid-f3fdcefeb4824f46b164170a1c74eeef,trial,0.454393
uuid-f3fdcefeb4824f46b164170a1c74eeef,efficacy,0.391519
uuid-f3fdcefeb4824f46b164170a1c74eeef,agents,0.361424
uuid-f3fdcefeb4824f46b164170a1c74eeef,Merck,0.39166
uuid-f3fdcefeb4824f46b164170a1c74eeef,atezo,0.312559
uuid-f3fdcefeb4824f46b164170a1c74eeef,nivo and pembro,0.425323
uuid-922fca7a184445cba574b77457d98e1e,patients,0.498471
uuid-922fca7a184445cba574b77457d98e1e,Opdivo,0.702415
uuid-922fca7a184445cba574b77457d98e1e,therapy,0.337967
uuid-922fca7a184445cba574b77457d98e1e,nivolumab,0.350904
uuid-922fca7a184445cba574b77457d98e1e,regimen,0.474474
uuid-922fca7a184445cba574b77457d98e1e,treated,0.339276
uuid-922fca7a184445cba574b77457d98e1e,physicians,0.504081
uuid-922fca7a184445cba574b77457d98e1e,treatment,0.578882
uuid-922fca7a184445cba574b77457d98e1e,approved,0.372017
uuid-922fca7a184445cba574b77457d98e1e,progression,0.380788
uuid-922fca7a184445cba574b77457d98e1e,respond,0.324811
uuid-922fca7a184445cba574b77457d98e1e,Keytruda,0.310197
uuid-922fca7a184445cba574b77457d98e1e,option,0.367105
uuid-a29d3114e26e44f98c52676f76ec7bb8,Nivo,0.416465
uuid-a29d3114e26e44f98c52676f76ec7bb8,patients,0.344665
uuid-a29d3114e26e44f98c52676f76ec7bb8,therapy,0.380665
uuid-a29d3114e26e44f98c52676f76ec7bb8,chemo,0.421209
uuid-a29d3114e26e44f98c52676f76ec7bb8,treatment,0.30905
uuid-a29d3114e26e44f98c52676f76ec7bb8,response,0.491697
uuid-a29d3114e26e44f98c52676f76ec7bb8,PD1,0.31172
uuid-a29d3114e26e44f98c52676f76ec7bb8,progression,0.41392
uuid-a29d3114e26e44f98c52676f76ec7bb8,chemotherapy,0.338643
uuid-a29d3114e26e44f98c52676f76ec7bb8,respond,0.461399
uuid-a29d3114e26e44f98c52676f76ec7bb8,option,0.309638
uuid-a1e14788f5b14f4abddea1225db61568,Nivo,0.588109
uuid-a1e14788f5b14f4abddea1225db61568,patients,0.430065
uuid-a1e14788f5b14f4abddea1225db61568,pembro,0.320324
uuid-a1e14788f5b14f4abddea1225db61568,therapy,0.553605
uuid-a1e14788f5b14f4abddea1225db61568,nivolumab,0.449648
uuid-a1e14788f5b14f4abddea1225db61568,trial,0.418361
uuid-a1e14788f5b14f4abddea1225db61568,combination,0.340765
uuid-a1e14788f5b14f4abddea1225db61568,chemo,0.432592
uuid-a1e14788f5b14f4abddea1225db61568,monotherapy,0.383293
uuid-a1e14788f5b14f4abddea1225db61568,using nivo,0.397804
uuid-a1e14788f5b14f4abddea1225db61568,PD1,0.36594
uuid-a1e14788f5b14f4abddea1225db61568,cHL,0.439214
uuid-a1e14788f5b14f4abddea1225db61568,chemotherapy,0.499869
uuid-a1e14788f5b14f4abddea1225db61568,SCLC,0.334553
uuid-a1e14788f5b14f4abddea1225db61568,option,0.362373
uuid-ceafdcc77811401e84b2da40445b443b,Nivo,0.612112
uuid-ceafdcc77811401e84b2da40445b443b,patients,0.700679
uuid-ceafdcc77811401e84b2da40445b443b,therapy,0.671058
uuid-ceafdcc77811401e84b2da40445b443b,nivolumab,0.517097
uuid-ceafdcc77811401e84b2da40445b443b,1L,0.300176
uuid-ceafdcc77811401e84b2da40445b443b,regimen,0.473826
uuid-ceafdcc77811401e84b2da40445b443b,treated,0.436693
uuid-ceafdcc77811401e84b2da40445b443b,combination,0.349824
uuid-ceafdcc77811401e84b2da40445b443b,chemo,0.536473
uuid-ceafdcc77811401e84b2da40445b443b,2L,0.328882
uuid-ceafdcc77811401e84b2da40445b443b,pts,0.567976
uuid-ceafdcc77811401e84b2da40445b443b,monotherapy,0.565563
uuid-ceafdcc77811401e84b2da40445b443b,treatment,0.56314
uuid-ceafdcc77811401e84b2da40445b443b,using nivo,0.477735
uuid-ceafdcc77811401e84b2da40445b443b,response,0.576656
uuid-ceafdcc77811401e84b2da40445b443b,PD1,0.54936
uuid-ceafdcc77811401e84b2da40445b443b,cHL,0.400098
uuid-ceafdcc77811401e84b2da40445b443b,progression,0.629247
uuid-ceafdcc77811401e84b2da40445b443b,chemotherapy,0.474097
uuid-ceafdcc77811401e84b2da40445b443b,respond,0.539944
uuid-ceafdcc77811401e84b2da40445b443b,RTL stated,0.310566
uuid-ceafdcc77811401e84b2da40445b443b,option,0.480707
uuid-a42f7908f5c3445094b787703b7bd292,Nivo,0.660511
uuid-a42f7908f5c3445094b787703b7bd292,patients,0.659576
uuid-a42f7908f5c3445094b787703b7bd292,therapy,0.589806
uuid-a42f7908f5c3445094b787703b7bd292,nivolumab,0.388803
uuid-a42f7908f5c3445094b787703b7bd292,toxicity,0.382715
uuid-a42f7908f5c3445094b787703b7bd292,regimen,0.532667
uuid-a42f7908f5c3445094b787703b7bd292,treated,0.302126
uuid-a42f7908f5c3445094b787703b7bd292,combination,0.403513
uuid-a42f7908f5c3445094b787703b7bd292,chemo,0.661978
uuid-a42f7908f5c3445094b787703b7bd292,pts,0.587484
uuid-a42f7908f5c3445094b787703b7bd292,Ipi,0.320116
uuid-a42f7908f5c3445094b787703b7bd292,monotherapy,0.594169
uuid-a42f7908f5c3445094b787703b7bd292,treatment,0.516877
uuid-a42f7908f5c3445094b787703b7bd292,using nivo,0.318786
uuid-a42f7908f5c3445094b787703b7bd292,response,0.668845
uuid-a42f7908f5c3445094b787703b7bd292,combo,0.35763
uuid-a42f7908f5c3445094b787703b7bd292,PD1,0.534696
uuid-a42f7908f5c3445094b787703b7bd292,progression,0.640833
uuid-a42f7908f5c3445094b787703b7bd292,chemotherapy,0.55402
uuid-a42f7908f5c3445094b787703b7bd292,respond,0.599887
uuid-a42f7908f5c3445094b787703b7bd292,feels,0.329563
uuid-a42f7908f5c3445094b787703b7bd292,option,0.486491
uuid-898bdf86461f4b96873b98574962821d,Nivo,0.400045
uuid-898bdf86461f4b96873b98574962821d,pembro,0.688317
uuid-898bdf86461f4b96873b98574962821d,1L,0.440955
uuid-898bdf86461f4b96873b98574962821d,PDL1,0.598961
uuid-898bdf86461f4b96873b98574962821d,efficacy,0.432037
uuid-898bdf86461f4b96873b98574962821d,2L,0.427432
uuid-898bdf86461f4b96873b98574962821d,agents,0.380841
uuid-898bdf86461f4b96873b98574962821d,PD-L1,0.341938
uuid-898bdf86461f4b96873b98574962821d,atezo,0.651005
uuid-898bdf86461f4b96873b98574962821d,preferred,0.34337
uuid-898bdf86461f4b96873b98574962821d,nivo and pembro,0.680799
uuid-898bdf86461f4b96873b98574962821d,believes,0.486731
uuid-898bdf86461f4b96873b98574962821d,vs,0.518714
uuid-898bdf86461f4b96873b98574962821d,feels,0.385941
uuid-898bdf86461f4b96873b98574962821d,PDL1 expression,0.486145
uuid-898bdf86461f4b96873b98574962821d,option,0.302079
uuid-240a8fa1722040b0a91a895003624c9b,1L,0.343243
uuid-240a8fa1722040b0a91a895003624c9b,RCC,0.310575
uuid-240a8fa1722040b0a91a895003624c9b,2L,0.429938
uuid-240a8fa1722040b0a91a895003624c9b,agents,0.351901
uuid-240a8fa1722040b0a91a895003624c9b,atezo,0.348351
uuid-240a8fa1722040b0a91a895003624c9b,preferred,0.37426
uuid-240a8fa1722040b0a91a895003624c9b,monotherapy,0.332431
uuid-240a8fa1722040b0a91a895003624c9b,nivo and pembro,0.378117
uuid-240a8fa1722040b0a91a895003624c9b,believes,0.428656
uuid-240a8fa1722040b0a91a895003624c9b,feels,0.311417
uuid-240a8fa1722040b0a91a895003624c9b,option,0.302447
uuid-4b65df5737bd4c919fcf3cdac98c22a9,patients,0.68101
uuid-4b65df5737bd4c919fcf3cdac98c22a9,Opdivo,0.421108
uuid-4b65df5737bd4c919fcf3cdac98c22a9,therapy,0.41171
uuid-4b65df5737bd4c919fcf3cdac98c22a9,nivolumab,0.315256
uuid-4b65df5737bd4c919fcf3cdac98c22a9,toxicity,0.393733
uuid-4b65df5737bd4c919fcf3cdac98c22a9,regimen,0.481773
uuid-4b65df5737bd4c919fcf3cdac98c22a9,treated,0.58739
uuid-4b65df5737bd4c919fcf3cdac98c22a9,tumor,0.375388
uuid-4b65df5737bd4c919fcf3cdac98c22a9,pts,0.457048
uuid-4b65df5737bd4c919fcf3cdac98c22a9,treatment,0.715791
uuid-4b65df5737bd4c919fcf3cdac98c22a9,response,0.375558
uuid-4b65df5737bd4c919fcf3cdac98c22a9,progression,0.604148
uuid-4b65df5737bd4c919fcf3cdac98c22a9,respond,0.542698
uuid-a9ecfd48b5534d058100c2d1f63374c3,therapy,0.387149
uuid-a9ecfd48b5534d058100c2d1f63374c3,trial,0.347974
uuid-a9ecfd48b5534d058100c2d1f63374c3,combination,0.406492
uuid-a9ecfd48b5534d058100c2d1f63374c3,chemo,0.525489
uuid-a9ecfd48b5534d058100c2d1f63374c3,IO,0.341423
uuid-a9ecfd48b5534d058100c2d1f63374c3,OS,0.365125
uuid-a9ecfd48b5534d058100c2d1f63374c3,monotherapy,0.337445
uuid-a9ecfd48b5534d058100c2d1f63374c3,response,0.433337
uuid-a9ecfd48b5534d058100c2d1f63374c3,combo,0.332735
uuid-a9ecfd48b5534d058100c2d1f63374c3,PFS,0.392077
uuid-a9ecfd48b5534d058100c2d1f63374c3,PD1,0.476897
uuid-a9ecfd48b5534d058100c2d1f63374c3,ORR,0.372102
uuid-a9ecfd48b5534d058100c2d1f63374c3,progression,0.414141
uuid-a9ecfd48b5534d058100c2d1f63374c3,believes,0.335981
uuid-a9ecfd48b5534d058100c2d1f63374c3,chemotherapy,0.5714
uuid-a9ecfd48b5534d058100c2d1f63374c3,feels,0.363893
uuid-2dda0bc185b541d4ba69ca86c28b0118,TL,0.717447
uuid-2dda0bc185b541d4ba69ca86c28b0118,PDL1,0.3585
uuid-2dda0bc185b541d4ba69ca86c28b0118,TL stated,0.388471
uuid-2dda0bc185b541d4ba69ca86c28b0118,Merck,0.303417
uuid-2dda0bc185b541d4ba69ca86c28b0118,institution,0.38691
uuid-2dda0bc185b541d4ba69ca86c28b0118,PD-L1,0.819078
uuid-2dda0bc185b541d4ba69ca86c28b0118,PD-L1 testing,0.916534
uuid-2dda0bc185b541d4ba69ca86c28b0118,testing,0.87108
uuid-2dda0bc185b541d4ba69ca86c28b0118,PDL1 testing,0.652688
uuid-2dda0bc185b541d4ba69ca86c28b0118,NSCLC patients,0.594001
uuid-2dda0bc185b541d4ba69ca86c28b0118,assay,0.815198
uuid-2dda0bc185b541d4ba69ca86c28b0118,biomarker,0.331289
uuid-6b3f34c9dbad42d3a1c9b5d98a1c49a5,TL,0.770456
uuid-6b3f34c9dbad42d3a1c9b5d98a1c49a5,TL stated,0.383828
uuid-6b3f34c9dbad42d3a1c9b5d98a1c49a5,institution,0.361015
uuid-6b3f34c9dbad42d3a1c9b5d98a1c49a5,PD-L1,0.755657
uuid-6b3f34c9dbad42d3a1c9b5d98a1c49a5,PD-L1 testing,0.880161
uuid-6b3f34c9dbad42d3a1c9b5d98a1c49a5,testing,0.797359
uuid-6b3f34c9dbad42d3a1c9b5d98a1c49a5,PDL1 testing,0.588254
uuid-6b3f34c9dbad42d3a1c9b5d98a1c49a5,NSCLC patients,0.538799
uuid-6b3f34c9dbad42d3a1c9b5d98a1c49a5,assay,0.765976
uuid-5a508685be604bdc9dae6adc2e76c67b,Nivo,0.565324
uuid-5a508685be604bdc9dae6adc2e76c67b,patients,0.499467
uuid-5a508685be604bdc9dae6adc2e76c67b,Opdivo,0.378131
uuid-5a508685be604bdc9dae6adc2e76c67b,RTL,0.301318
uuid-5a508685be604bdc9dae6adc2e76c67b,therapy,0.473656
uuid-5a508685be604bdc9dae6adc2e76c67b,nivolumab,0.567303
uuid-5a508685be604bdc9dae6adc2e76c67b,regimen,0.316773
uuid-5a508685be604bdc9dae6adc2e76c67b,treated,0.320741
uuid-5a508685be604bdc9dae6adc2e76c67b,treatment,0.31651
uuid-5a508685be604bdc9dae6adc2e76c67b,using nivo,0.403558
uuid-5a508685be604bdc9dae6adc2e76c67b,cHL,0.586885
uuid-5a508685be604bdc9dae6adc2e76c67b,progression,0.326151
uuid-cde4e168092e48f69906459cd5bd0150,Opdivo,0.534927
uuid-cde4e168092e48f69906459cd5bd0150,dose,0.446879
uuid-cde4e168092e48f69906459cd5bd0150,indication,0.301989
uuid-cde4e168092e48f69906459cd5bd0150,drug,0.599171
uuid-cde4e168092e48f69906459cd5bd0150,Keytruda,0.72141
uuid-cde4e168092e48f69906459cd5bd0150,flat dosing,0.642376
uuid-7ba3aef494c4414591c57323910b6ab4,Opdivo,0.388691
uuid-7ba3aef494c4414591c57323910b6ab4,dose,0.791652
uuid-7ba3aef494c4414591c57323910b6ab4,toxicity,0.487024
uuid-7ba3aef494c4414591c57323910b6ab4,Ipi,0.375452
uuid-7ba3aef494c4414591c57323910b6ab4,vs,0.520867
uuid-7ba3aef494c4414591c57323910b6ab4,Keytruda,0.308496
uuid-7ba3aef494c4414591c57323910b6ab4,flat dosing,0.685253
uuid-ce09d16ce0b44da389b86ae8b485972d,TL,0.306381
uuid-ce09d16ce0b44da389b86ae8b485972d,BMS,0.525096
uuid-ce09d16ce0b44da389b86ae8b485972d,efficacy,0.42202
uuid-ce09d16ce0b44da389b86ae8b485972d,commented,0.45077
uuid-ce09d16ce0b44da389b86ae8b485972d,Merck,0.433333
uuid-ce09d16ce0b44da389b86ae8b485972d,stated,0.316409
uuid-ce09d16ce0b44da389b86ae8b485972d,atezo,0.330341
uuid-ce09d16ce0b44da389b86ae8b485972d,regards,0.402892
uuid-ce09d16ce0b44da389b86ae8b485972d,data,0.611498
uuid-ce09d16ce0b44da389b86ae8b485972d,expressed,0.37666
uuid-ce09d16ce0b44da389b86ae8b485972d,indication,0.35893
uuid-ce09d16ce0b44da389b86ae8b485972d,impressed,0.49259
uuid-ce09d16ce0b44da389b86ae8b485972d,LTL,0.316386
uuid-ce09d16ce0b44da389b86ae8b485972d,TLs,0.447213
uuid-ce09d16ce0b44da389b86ae8b485972d,flat dosing,0.460087
uuid-8a2da20068b7460294981b6d5b128231,pembro,0.300936
uuid-8a2da20068b7460294981b6d5b128231,PDL1,0.611595
uuid-8a2da20068b7460294981b6d5b128231,efficacy,0.559651
uuid-8a2da20068b7460294981b6d5b128231,Merck,0.373313
uuid-8a2da20068b7460294981b6d5b128231,PD-L1,0.359713
uuid-8a2da20068b7460294981b6d5b128231,OS,0.381403
uuid-8a2da20068b7460294981b6d5b128231,atezo,0.416131
uuid-8a2da20068b7460294981b6d5b128231,regards,0.43218
uuid-8a2da20068b7460294981b6d5b128231,data,0.450269
uuid-8a2da20068b7460294981b6d5b128231,PFS,0.4251
uuid-8a2da20068b7460294981b6d5b128231,ORR,0.389088
uuid-8a2da20068b7460294981b6d5b128231,nivo and pembro,0.598658
uuid-8a2da20068b7460294981b6d5b128231,believes,0.388941
uuid-8a2da20068b7460294981b6d5b128231,vs,0.311194
uuid-8a2da20068b7460294981b6d5b128231,TLs,0.410968
uuid-8a2da20068b7460294981b6d5b128231,assay,0.436882
uuid-8a2da20068b7460294981b6d5b128231,PDL1 expression,0.535614
uuid-8a2da20068b7460294981b6d5b128231,biomarker,0.390975
uuid-913a781280af489987f849c465d134cd,patients,0.474434
uuid-913a781280af489987f849c465d134cd,Opdivo,0.435793
uuid-913a781280af489987f849c465d134cd,pembro,0.382623
uuid-913a781280af489987f849c465d134cd,dose,0.312897
uuid-913a781280af489987f849c465d134cd,nivolumab,0.341475
uuid-913a781280af489987f849c465d134cd,1L,0.446722
uuid-913a781280af489987f849c465d134cd,regimen,0.325444
uuid-913a781280af489987f849c465d134cd,RCC,0.312966
uuid-913a781280af489987f849c465d134cd,2L,0.579918
uuid-913a781280af489987f849c465d134cd,agents,0.308834
uuid-913a781280af489987f849c465d134cd,approval,0.344283
uuid-913a781280af489987f849c465d134cd,atezo,0.395179
uuid-913a781280af489987f849c465d134cd,preferred,0.800154
uuid-913a781280af489987f849c465d134cd,monotherapy,0.496035
uuid-913a781280af489987f849c465d134cd,treatment,0.313722
uuid-913a781280af489987f849c465d134cd,using nivo,0.571097
uuid-913a781280af489987f849c465d134cd,indication,0.363632
uuid-913a781280af489987f849c465d134cd,approved,0.465368
uuid-913a781280af489987f849c465d134cd,SCCHN,0.346812
uuid-913a781280af489987f849c465d134cd,Keytruda,0.336251
uuid-913a781280af489987f849c465d134cd,feels,0.309786
uuid-913a781280af489987f849c465d134cd,RTL stated,0.49179
uuid-913a781280af489987f849c465d134cd,option,0.60604
uuid-d4a171b7912242c3a0001cbe18fea6b9,TL,0.330811
uuid-d4a171b7912242c3a0001cbe18fea6b9,pembro,0.360589
uuid-d4a171b7912242c3a0001cbe18fea6b9,1L,0.309506
uuid-d4a171b7912242c3a0001cbe18fea6b9,PDL1,0.552479
uuid-d4a171b7912242c3a0001cbe18fea6b9,Merck,0.443506
uuid-d4a171b7912242c3a0001cbe18fea6b9,PD-L1,0.703937
uuid-d4a171b7912242c3a0001cbe18fea6b9,atezo,0.427537
uuid-d4a171b7912242c3a0001cbe18fea6b9,PD-L1 testing,0.590182
uuid-d4a171b7912242c3a0001cbe18fea6b9,testing,0.705146
uuid-d4a171b7912242c3a0001cbe18fea6b9,PDL1 testing,0.555409
uuid-d4a171b7912242c3a0001cbe18fea6b9,NSCLC patients,0.474296
uuid-d4a171b7912242c3a0001cbe18fea6b9,assay,0.76627
uuid-d4a171b7912242c3a0001cbe18fea6b9,PDL1 expression,0.348675
uuid-d4a171b7912242c3a0001cbe18fea6b9,biomarker,0.418204
uuid-bbff29ab002f43988b25c8e0eb6021bf,PDL1,0.332423
uuid-bbff29ab002f43988b25c8e0eb6021bf,efficacy,0.367565
uuid-bbff29ab002f43988b25c8e0eb6021bf,chemo,0.338681
uuid-bbff29ab002f43988b25c8e0eb6021bf,OS,0.34059
uuid-bbff29ab002f43988b25c8e0eb6021bf,regards,0.326655
uuid-bbff29ab002f43988b25c8e0eb6021bf,PFS,0.377009
uuid-bbff29ab002f43988b25c8e0eb6021bf,AI,0.372749
uuid-bbff29ab002f43988b25c8e0eb6021bf,ORR,0.335483
uuid-bbff29ab002f43988b25c8e0eb6021bf,nivo and pembro,0.418695
uuid-bbff29ab002f43988b25c8e0eb6021bf,believes,0.435644
uuid-bbff29ab002f43988b25c8e0eb6021bf,respond,0.344078
uuid-bbff29ab002f43988b25c8e0eb6021bf,feels,0.359258
uuid-bbff29ab002f43988b25c8e0eb6021bf,PDL1 expression,0.322512
uuid-eef00beef6924d9d949b51e967a50d28,patients,0.8464
uuid-eef00beef6924d9d949b51e967a50d28,Opdivo,0.616739
uuid-eef00beef6924d9d949b51e967a50d28,therapy,0.513703
uuid-eef00beef6924d9d949b51e967a50d28,nivolumab,0.492016
uuid-eef00beef6924d9d949b51e967a50d28,regimen,0.421027
uuid-eef00beef6924d9d949b51e967a50d28,treated,0.583872
uuid-eef00beef6924d9d949b51e967a50d28,pts,0.470572
uuid-eef00beef6924d9d949b51e967a50d28,physicians,0.37877
uuid-eef00beef6924d9d949b51e967a50d28,treatment,0.691956
uuid-eef00beef6924d9d949b51e967a50d28,cHL,0.330422
uuid-eef00beef6924d9d949b51e967a50d28,progression,0.55804
uuid-eef00beef6924d9d949b51e967a50d28,respond,0.399639
uuid-eef00beef6924d9d949b51e967a50d28,option,0.318263
uuid-27e4006d06e94dcfa9355bc0337c493f,Nivo,0.431787
uuid-27e4006d06e94dcfa9355bc0337c493f,patients,0.622876
uuid-27e4006d06e94dcfa9355bc0337c493f,Opdivo,0.419285
uuid-27e4006d06e94dcfa9355bc0337c493f,therapy,0.65226
uuid-27e4006d06e94dcfa9355bc0337c493f,nivolumab,0.453547
uuid-27e4006d06e94dcfa9355bc0337c493f,regimen,0.421275
uuid-27e4006d06e94dcfa9355bc0337c493f,treated,0.429293
uuid-27e4006d06e94dcfa9355bc0337c493f,combination,0.327667
uuid-27e4006d06e94dcfa9355bc0337c493f,chemo,0.431632
uuid-27e4006d06e94dcfa9355bc0337c493f,2L,0.332512
uuid-27e4006d06e94dcfa9355bc0337c493f,pts,0.328222
uuid-27e4006d06e94dcfa9355bc0337c493f,agents,0.343612
uuid-27e4006d06e94dcfa9355bc0337c493f,preferred,0.44452
uuid-27e4006d06e94dcfa9355bc0337c493f,monotherapy,0.540508
uuid-27e4006d06e94dcfa9355bc0337c493f,treatment,0.644228
uuid-27e4006d06e94dcfa9355bc0337c493f,using nivo,0.353721
uuid-27e4006d06e94dcfa9355bc0337c493f,PD1,0.391873
uuid-27e4006d06e94dcfa9355bc0337c493f,cHL,0.353624
uuid-27e4006d06e94dcfa9355bc0337c493f,progression,0.398089
uuid-27e4006d06e94dcfa9355bc0337c493f,chemotherapy,0.541047
uuid-27e4006d06e94dcfa9355bc0337c493f,respond,0.316583
uuid-27e4006d06e94dcfa9355bc0337c493f,option,0.591323
uuid-ba23c6256b7f42ffb2258bef90fe1412,patients,0.564445
uuid-ba23c6256b7f42ffb2258bef90fe1412,Opdivo,0.379183
uuid-ba23c6256b7f42ffb2258bef90fe1412,therapy,0.408438
uuid-ba23c6256b7f42ffb2258bef90fe1412,treated,0.383499
uuid-ba23c6256b7f42ffb2258bef90fe1412,tumor,0.434529
uuid-ba23c6256b7f42ffb2258bef90fe1412,pts,0.386891
uuid-ba23c6256b7f42ffb2258bef90fe1412,treatment,0.477614
uuid-ba23c6256b7f42ffb2258bef90fe1412,response,0.375086
uuid-ba23c6256b7f42ffb2258bef90fe1412,cHL,0.378449
uuid-ba23c6256b7f42ffb2258bef90fe1412,progression,0.491249
uuid-ba23c6256b7f42ffb2258bef90fe1412,respond,0.34811
uuid-ad5272d3aa6d4930aa4392835b5b05b1,Nivo,0.325664
uuid-ad5272d3aa6d4930aa4392835b5b05b1,RTL,0.300537
uuid-ad5272d3aa6d4930aa4392835b5b05b1,trial,0.467492
uuid-ad5272d3aa6d4930aa4392835b5b05b1,efficacy,0.367946
uuid-ad5272d3aa6d4930aa4392835b5b05b1,OS,0.621173
uuid-ad5272d3aa6d4930aa4392835b5b05b1,data,0.551115
uuid-ad5272d3aa6d4930aa4392835b5b05b1,PFS,0.628425
uuid-ad5272d3aa6d4930aa4392835b5b05b1,ORR,0.61889
uuid-ad5272d3aa6d4930aa4392835b5b05b1,nivo and pembro,0.315681
uuid-ad5272d3aa6d4930aa4392835b5b05b1,ASCO,0.367824
uuid-ad5272d3aa6d4930aa4392835b5b05b1,impressed,0.639036
uuid-ad5272d3aa6d4930aa4392835b5b05b1,SCLC,0.310171
uuid-b42d049d0f0b4e4887acb5bf03882fcf,RTL,0.348035
uuid-b42d049d0f0b4e4887acb5bf03882fcf,trial,0.351225
uuid-b42d049d0f0b4e4887acb5bf03882fcf,NTL,0.411346
uuid-b42d049d0f0b4e4887acb5bf03882fcf,commented,0.365798
uuid-b42d049d0f0b4e4887acb5bf03882fcf,regards,0.310645
uuid-b42d049d0f0b4e4887acb5bf03882fcf,data,0.572629
uuid-b42d049d0f0b4e4887acb5bf03882fcf,mentioned,0.448239
uuid-b42d049d0f0b4e4887acb5bf03882fcf,ORR,0.312493
uuid-b42d049d0f0b4e4887acb5bf03882fcf,cHL,0.353069
uuid-b42d049d0f0b4e4887acb5bf03882fcf,ASCO,0.375137
uuid-b42d049d0f0b4e4887acb5bf03882fcf,impressed,0.456005
uuid-b42d049d0f0b4e4887acb5bf03882fcf,LTL,0.303103
uuid-fd0d09dca09c441d90bd9221cbcce9d3,patients,0.464839
uuid-fd0d09dca09c441d90bd9221cbcce9d3,therapy,0.306903
uuid-fd0d09dca09c441d90bd9221cbcce9d3,nivolumab,0.342615
uuid-fd0d09dca09c441d90bd9221cbcce9d3,1L,0.331545
uuid-fd0d09dca09c441d90bd9221cbcce9d3,regimen,0.412943
uuid-fd0d09dca09c441d90bd9221cbcce9d3,chemo,0.359582
uuid-fd0d09dca09c441d90bd9221cbcce9d3,2L,0.36662
uuid-fd0d09dca09c441d90bd9221cbcce9d3,preferred,0.673074
uuid-fd0d09dca09c441d90bd9221cbcce9d3,monotherapy,0.490854
uuid-fd0d09dca09c441d90bd9221cbcce9d3,treatment,0.34611
uuid-fd0d09dca09c441d90bd9221cbcce9d3,using nivo,0.419877
uuid-fd0d09dca09c441d90bd9221cbcce9d3,indication,0.344934
uuid-fd0d09dca09c441d90bd9221cbcce9d3,SCCHN,0.333608
uuid-fd0d09dca09c441d90bd9221cbcce9d3,chemotherapy,0.429694
uuid-fd0d09dca09c441d90bd9221cbcce9d3,RTL stated,0.388575
uuid-fd0d09dca09c441d90bd9221cbcce9d3,option,0.573473
uuid-a350625e408b41f893684c33d629d933,pembro,0.517713
uuid-a350625e408b41f893684c33d629d933,1L,0.443597
uuid-a350625e408b41f893684c33d629d933,PDL1,0.550181
uuid-a350625e408b41f893684c33d629d933,efficacy,0.367625
uuid-a350625e408b41f893684c33d629d933,2L,0.343763
uuid-a350625e408b41f893684c33d629d933,Merck,0.332882
uuid-a350625e408b41f893684c33d629d933,PD-L1,0.352294
uuid-a350625e408b41f893684c33d629d933,approval,0.34478
uuid-a350625e408b41f893684c33d629d933,atezo,0.443431
uuid-a350625e408b41f893684c33d629d933,data,0.41002
uuid-a350625e408b41f893684c33d629d933,indication,0.345467
uuid-a350625e408b41f893684c33d629d933,PFS,0.302893
uuid-a350625e408b41f893684c33d629d933,approved,0.423353
uuid-a350625e408b41f893684c33d629d933,nivo and pembro,0.391289
uuid-a350625e408b41f893684c33d629d933,feels,0.318322
uuid-a350625e408b41f893684c33d629d933,PDL1 expression,0.468589
uuid-a350625e408b41f893684c33d629d933,option,0.33683
uuid-bde78f8624834486a5e91930ec270c46,RTL,0.429677
uuid-bde78f8624834486a5e91930ec270c46,commented,0.370744
uuid-bde78f8624834486a5e91930ec270c46,stated,0.385441
uuid-bde78f8624834486a5e91930ec270c46,approval,0.35081
uuid-bde78f8624834486a5e91930ec270c46,SCCHN,0.411939
uuid-bde78f8624834486a5e91930ec270c46,impressed,0.539316
uuid-bde78f8624834486a5e91930ec270c46,LTL,0.415193
uuid-bde78f8624834486a5e91930ec270c46,Regional TL,0.463642
uuid-159af2f05c534f629732e6c90ecad58a,BMS,0.455522
uuid-159af2f05c534f629732e6c90ecad58a,trial,0.46126
uuid-159af2f05c534f629732e6c90ecad58a,efficacy,0.444197
uuid-159af2f05c534f629732e6c90ecad58a,discussed,0.40815
uuid-159af2f05c534f629732e6c90ecad58a,commented,0.561324
uuid-159af2f05c534f629732e6c90ecad58a,OS,0.520085
uuid-159af2f05c534f629732e6c90ecad58a,regards,0.460049
uuid-159af2f05c534f629732e6c90ecad58a,data,0.842958
uuid-159af2f05c534f629732e6c90ecad58a,expressed,0.31823
uuid-159af2f05c534f629732e6c90ecad58a,PFS,0.49575
uuid-159af2f05c534f629732e6c90ecad58a,ORR,0.561942
uuid-159af2f05c534f629732e6c90ecad58a,nivo and pembro,0.338439
uuid-159af2f05c534f629732e6c90ecad58a,ASCO,0.486859
uuid-159af2f05c534f629732e6c90ecad58a,impressed,0.611302
uuid-159af2f05c534f629732e6c90ecad58a,SCLC,0.310866
uuid-159af2f05c534f629732e6c90ecad58a,NCCN,0.407567
uuid-11aaf6803cbb447c92af97d0adea9f6a,patients,0.612324
uuid-11aaf6803cbb447c92af97d0adea9f6a,Opdivo,0.506095
uuid-11aaf6803cbb447c92af97d0adea9f6a,therapy,0.429707
uuid-11aaf6803cbb447c92af97d0adea9f6a,toxicity,0.3681
uuid-11aaf6803cbb447c92af97d0adea9f6a,regimen,0.36831
uuid-11aaf6803cbb447c92af97d0adea9f6a,chemo,0.325852
uuid-11aaf6803cbb447c92af97d0adea9f6a,pts,0.389912
uuid-11aaf6803cbb447c92af97d0adea9f6a,monotherapy,0.319775
uuid-11aaf6803cbb447c92af97d0adea9f6a,treatment,0.473382
uuid-11aaf6803cbb447c92af97d0adea9f6a,response,0.347094
uuid-11aaf6803cbb447c92af97d0adea9f6a,progression,0.527174
uuid-11aaf6803cbb447c92af97d0adea9f6a,chemotherapy,0.324695
uuid-11aaf6803cbb447c92af97d0adea9f6a,respond,0.417788
uuid-11aaf6803cbb447c92af97d0adea9f6a,drug,0.327267
uuid-11aaf6803cbb447c92af97d0adea9f6a,Keytruda,0.41245
uuid-11aaf6803cbb447c92af97d0adea9f6a,option,0.359443
uuid-82a41bab6f124952a96d4a454ad681df,1L,0.398515
uuid-82a41bab6f124952a96d4a454ad681df,PDL1,0.662644
uuid-82a41bab6f124952a96d4a454ad681df,efficacy,0.320209
uuid-82a41bab6f124952a96d4a454ad681df,2L,0.333125
uuid-82a41bab6f124952a96d4a454ad681df,agents,0.466006
uuid-82a41bab6f124952a96d4a454ad681df,Merck,0.324217
uuid-82a41bab6f124952a96d4a454ad681df,PD-L1,0.605725
uuid-82a41bab6f124952a96d4a454ad681df,atezo,0.408153
uuid-82a41bab6f124952a96d4a454ad681df,PD-L1 testing,0.350394
uuid-82a41bab6f124952a96d4a454ad681df,testing,0.57213
uuid-82a41bab6f124952a96d4a454ad681df,regards,0.327347
uuid-82a41bab6f124952a96d4a454ad681df,PDL1 testing,0.524374
uuid-82a41bab6f124952a96d4a454ad681df,NSCLC patients,0.346768
uuid-82a41bab6f124952a96d4a454ad681df,nivo and pembro,0.426916
uuid-82a41bab6f124952a96d4a454ad681df,believes,0.523534
uuid-82a41bab6f124952a96d4a454ad681df,assay,0.510791
uuid-82a41bab6f124952a96d4a454ad681df,PD-1,0.402477
uuid-82a41bab6f124952a96d4a454ad681df,PDL1 expression,0.492881
uuid-82a41bab6f124952a96d4a454ad681df,biomarker,0.625231
uuid-3252c09ffdf8436cb17e74911983fe2e,patients,0.66073
uuid-3252c09ffdf8436cb17e74911983fe2e,Opdivo,0.625111
uuid-3252c09ffdf8436cb17e74911983fe2e,therapy,0.313706
uuid-3252c09ffdf8436cb17e74911983fe2e,nivolumab,0.423467
uuid-3252c09ffdf8436cb17e74911983fe2e,treated,0.452388
uuid-3252c09ffdf8436cb17e74911983fe2e,stated,0.302219
uuid-3252c09ffdf8436cb17e74911983fe2e,physicians,0.481599
uuid-3252c09ffdf8436cb17e74911983fe2e,treatment,0.462651
uuid-3252c09ffdf8436cb17e74911983fe2e,using nivo,0.341891
uuid-3252c09ffdf8436cb17e74911983fe2e,HCP,0.31162
uuid-3252c09ffdf8436cb17e74911983fe2e,cHL,0.316524
uuid-3252c09ffdf8436cb17e74911983fe2e,progression,0.325949
uuid-9f385a225aca446093ab48e4fd7db6ca,patients,0.541888
uuid-9f385a225aca446093ab48e4fd7db6ca,Opdivo,0.498192
uuid-9f385a225aca446093ab48e4fd7db6ca,therapy,0.447309
uuid-9f385a225aca446093ab48e4fd7db6ca,regimen,0.316011
uuid-9f385a225aca446093ab48e4fd7db6ca,treated,0.480181
uuid-9f385a225aca446093ab48e4fd7db6ca,physicians,0.397293
uuid-9f385a225aca446093ab48e4fd7db6ca,treatment,0.584078
uuid-9f385a225aca446093ab48e4fd7db6ca,HCP,0.436397
uuid-9f385a225aca446093ab48e4fd7db6ca,cHL,0.321051
uuid-9f385a225aca446093ab48e4fd7db6ca,progression,0.461018
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,patients,0.451251
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,nivolumab,0.402215
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,regimen,0.487684
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,treated,0.328442
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,pts,0.31533
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,preferred,0.32648
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,monotherapy,0.376178
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,using nivo,0.349077
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,SCCHN,0.370467
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,LTL,0.301178
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,feels,0.424199
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,RTL stated,0.387441
uuid-8dc64bcfbef3453d9e52949df2b6e5c5,option,0.375856
uuid-dba6d87312c74c1198b052068ca0b68b,RTL,0.468259
uuid-dba6d87312c74c1198b052068ca0b68b,nivolumab,0.507707
uuid-dba6d87312c74c1198b052068ca0b68b,treated,0.3396
uuid-dba6d87312c74c1198b052068ca0b68b,NTL,0.30791
uuid-dba6d87312c74c1198b052068ca0b68b,shared,0.393996
uuid-dba6d87312c74c1198b052068ca0b68b,commented,0.436624
uuid-dba6d87312c74c1198b052068ca0b68b,stated,0.398079
uuid-dba6d87312c74c1198b052068ca0b68b,using nivo,0.304694
uuid-dba6d87312c74c1198b052068ca0b68b,data,0.372256
uuid-dba6d87312c74c1198b052068ca0b68b,clinical trials,0.319535
uuid-dba6d87312c74c1198b052068ca0b68b,SCCHN,0.347633
uuid-dba6d87312c74c1198b052068ca0b68b,ASCO,0.308975
uuid-dba6d87312c74c1198b052068ca0b68b,impressed,0.519689
uuid-dba6d87312c74c1198b052068ca0b68b,LTL,0.425306
uuid-dba6d87312c74c1198b052068ca0b68b,feels,0.410007
uuid-dba6d87312c74c1198b052068ca0b68b,Regional TL,0.461267
uuid-dba6d87312c74c1198b052068ca0b68b,RTL stated,0.371929
uuid-bc5d1837e96b4c159d74d662cbcfada5,Nivo,0.32766
uuid-bc5d1837e96b4c159d74d662cbcfada5,toxicity,0.427466
uuid-bc5d1837e96b4c159d74d662cbcfada5,efficacy,0.347798
uuid-bc5d1837e96b4c159d74d662cbcfada5,regimen,0.307358
uuid-bc5d1837e96b4c159d74d662cbcfada5,combination,0.378558
uuid-bc5d1837e96b4c159d74d662cbcfada5,chemo,0.328409
uuid-bc5d1837e96b4c159d74d662cbcfada5,agents,0.371955
uuid-bc5d1837e96b4c159d74d662cbcfada5,monotherapy,0.35637
uuid-bc5d1837e96b4c159d74d662cbcfada5,feels,0.495594
uuid-bc5d1837e96b4c159d74d662cbcfada5,option,0.34413
uuid-1e14817ed34046a29d4c3e73393d984e,BMS,0.427101
uuid-1e14817ed34046a29d4c3e73393d984e,PDL1,0.463058
uuid-1e14817ed34046a29d4c3e73393d984e,trial,0.394521
uuid-1e14817ed34046a29d4c3e73393d984e,efficacy,0.602084
uuid-1e14817ed34046a29d4c3e73393d984e,commented,0.402597
uuid-1e14817ed34046a29d4c3e73393d984e,stated,0.313505
uuid-1e14817ed34046a29d4c3e73393d984e,OS,0.595393
uuid-1e14817ed34046a29d4c3e73393d984e,regards,0.360558
uuid-1e14817ed34046a29d4c3e73393d984e,data,0.818259
uuid-1e14817ed34046a29d4c3e73393d984e,expressed,0.401114
uuid-1e14817ed34046a29d4c3e73393d984e,PFS,0.590866
uuid-1e14817ed34046a29d4c3e73393d984e,ORR,0.618845
uuid-1e14817ed34046a29d4c3e73393d984e,nivo and pembro,0.439073
uuid-1e14817ed34046a29d4c3e73393d984e,ASCO,0.302593
uuid-1e14817ed34046a29d4c3e73393d984e,impressed,0.629445
uuid-1e14817ed34046a29d4c3e73393d984e,TLs,0.302039
uuid-1e14817ed34046a29d4c3e73393d984e,feels,0.409283
uuid-1e14817ed34046a29d4c3e73393d984e,PDL1 expression,0.45499
uuid-b2f2d9ab23044ba89f0bcc793dfbf4c3,patients,0.605344
uuid-b2f2d9ab23044ba89f0bcc793dfbf4c3,therapy,0.386191
uuid-b2f2d9ab23044ba89f0bcc793dfbf4c3,nivolumab,0.318297
uuid-b2f2d9ab23044ba89f0bcc793dfbf4c3,toxicity,0.394025
uuid-b2f2d9ab23044ba89f0bcc793dfbf4c3,regimen,0.412399
uuid-b2f2d9ab23044ba89f0bcc793dfbf4c3,treated,0.678686
uuid-b2f2d9ab23044ba89f0bcc793dfbf4c3,pts,0.327568
uuid-b2f2d9ab23044ba89f0bcc793dfbf4c3,physicians,0.308865
uuid-b2f2d9ab23044ba89f0bcc793dfbf4c3,treatment,0.623353
uuid-b2f2d9ab23044ba89f0bcc793dfbf4c3,response,0.360621
uuid-b2f2d9ab23044ba89f0bcc793dfbf4c3,progression,0.446344
uuid-b2f2d9ab23044ba89f0bcc793dfbf4c3,respond,0.467756
uuid-bc66732742704ad6b696b69a32bee216,BMS,0.602478
uuid-bc66732742704ad6b696b69a32bee216,shared,0.328713
uuid-bc66732742704ad6b696b69a32bee216,Merck,0.338586
uuid-bc66732742704ad6b696b69a32bee216,physicians,0.554383
uuid-bc66732742704ad6b696b69a32bee216,regards,0.3456
uuid-bc66732742704ad6b696b69a32bee216,drug,0.379392
uuid-ff9753b0dc7d45aa8ecf068d6574a696,Opdivo,0.411487
uuid-ff9753b0dc7d45aa8ecf068d6574a696,physicians,0.415352
uuid-ff9753b0dc7d45aa8ecf068d6574a696,treatment,0.318329
uuid-ff9753b0dc7d45aa8ecf068d6574a696,HCP,0.303312
uuid-4abfe8b94a5543e4a59165869d8db3d5,patients,0.645056
uuid-4abfe8b94a5543e4a59165869d8db3d5,therapy,0.522838
uuid-4abfe8b94a5543e4a59165869d8db3d5,nivolumab,0.451814
uuid-4abfe8b94a5543e4a59165869d8db3d5,regimen,0.393276
uuid-4abfe8b94a5543e4a59165869d8db3d5,treated,0.484416
uuid-4abfe8b94a5543e4a59165869d8db3d5,chemo,0.386875
uuid-4abfe8b94a5543e4a59165869d8db3d5,pts,0.487442
uuid-4abfe8b94a5543e4a59165869d8db3d5,treatment,0.539364
uuid-4abfe8b94a5543e4a59165869d8db3d5,PD1,0.317312
uuid-4abfe8b94a5543e4a59165869d8db3d5,progression,0.50254
uuid-4abfe8b94a5543e4a59165869d8db3d5,chemotherapy,0.469348
uuid-4abfe8b94a5543e4a59165869d8db3d5,respond,0.343678
uuid-c429ecb37f974abfb1dc47ea9fe2e1bc,TL,0.508224
uuid-c429ecb37f974abfb1dc47ea9fe2e1bc,PDL1,0.385435
uuid-c429ecb37f974abfb1dc47ea9fe2e1bc,TL stated,0.421193
uuid-c429ecb37f974abfb1dc47ea9fe2e1bc,institution,0.497336
uuid-c429ecb37f974abfb1dc47ea9fe2e1bc,PD-L1,0.859435
uuid-c429ecb37f974abfb1dc47ea9fe2e1bc,PD-L1 testing,0.834852
uuid-c429ecb37f974abfb1dc47ea9fe2e1bc,testing,0.901418
uuid-c429ecb37f974abfb1dc47ea9fe2e1bc,PDL1 testing,0.719267
uuid-c429ecb37f974abfb1dc47ea9fe2e1bc,NSCLC patients,0.688682
uuid-c429ecb37f974abfb1dc47ea9fe2e1bc,assay,0.767505
uuid-c429ecb37f974abfb1dc47ea9fe2e1bc,biomarker,0.388289
uuid-c4376ab255724b1c999a5ee3aa324e8d,pembro,0.535903
uuid-c4376ab255724b1c999a5ee3aa324e8d,RTL,0.349542
uuid-c4376ab255724b1c999a5ee3aa324e8d,1L,0.499482
uuid-c4376ab255724b1c999a5ee3aa324e8d,PDL1,0.316542
uuid-c4376ab255724b1c999a5ee3aa324e8d,trial,0.40718
uuid-c4376ab255724b1c999a5ee3aa324e8d,commented,0.445054
uuid-c4376ab255724b1c999a5ee3aa324e8d,2L,0.442124
uuid-c4376ab255724b1c999a5ee3aa324e8d,stated,0.487076
uuid-c4376ab255724b1c999a5ee3aa324e8d,approval,0.448971
uuid-c4376ab255724b1c999a5ee3aa324e8d,atezo,0.48276
uuid-c4376ab255724b1c999a5ee3aa324e8d,preferred,0.337929
uuid-c4376ab255724b1c999a5ee3aa324e8d,using nivo,0.395309
uuid-c4376ab255724b1c999a5ee3aa324e8d,data,0.653731
uuid-c4376ab255724b1c999a5ee3aa324e8d,clinical trials,0.39311
uuid-c4376ab255724b1c999a5ee3aa324e8d,indication,0.394775
uuid-c4376ab255724b1c999a5ee3aa324e8d,ORR,0.313421
uuid-c4376ab255724b1c999a5ee3aa324e8d,approved,0.428179
uuid-c4376ab255724b1c999a5ee3aa324e8d,SCCHN,0.4908
uuid-c4376ab255724b1c999a5ee3aa324e8d,nivo and pembro,0.389926
uuid-c4376ab255724b1c999a5ee3aa324e8d,impressed,0.583555
uuid-c4376ab255724b1c999a5ee3aa324e8d,LTL,0.347179
uuid-c4376ab255724b1c999a5ee3aa324e8d,TLs,0.353886
uuid-c4376ab255724b1c999a5ee3aa324e8d,SCLC,0.346542
uuid-c4376ab255724b1c999a5ee3aa324e8d,feels,0.448526
uuid-c4376ab255724b1c999a5ee3aa324e8d,Regional TL,0.403902
uuid-c4376ab255724b1c999a5ee3aa324e8d,RTL stated,0.403189
uuid-c4376ab255724b1c999a5ee3aa324e8d,bladder,0.384942
uuid-557f0e8ad7d14679b45d58489bfd372c,Nivo,0.412347
uuid-557f0e8ad7d14679b45d58489bfd372c,patients,0.670889
uuid-557f0e8ad7d14679b45d58489bfd372c,therapy,0.40549
uuid-557f0e8ad7d14679b45d58489bfd372c,nivolumab,0.371348
uuid-557f0e8ad7d14679b45d58489bfd372c,1L,0.404046
uuid-557f0e8ad7d14679b45d58489bfd372c,regimen,0.405858
uuid-557f0e8ad7d14679b45d58489bfd372c,treated,0.4018
uuid-557f0e8ad7d14679b45d58489bfd372c,chemo,0.427662
uuid-557f0e8ad7d14679b45d58489bfd372c,2L,0.357226
uuid-557f0e8ad7d14679b45d58489bfd372c,pts,0.490367
uuid-557f0e8ad7d14679b45d58489bfd372c,preferred,0.378709
uuid-557f0e8ad7d14679b45d58489bfd372c,monotherapy,0.536056
uuid-557f0e8ad7d14679b45d58489bfd372c,treatment,0.435743
uuid-557f0e8ad7d14679b45d58489bfd372c,using nivo,0.473736
uuid-557f0e8ad7d14679b45d58489bfd372c,PD1,0.348627
uuid-557f0e8ad7d14679b45d58489bfd372c,SCCHN,0.378083
uuid-557f0e8ad7d14679b45d58489bfd372c,progression,0.463218
uuid-557f0e8ad7d14679b45d58489bfd372c,chemotherapy,0.446008
uuid-557f0e8ad7d14679b45d58489bfd372c,respond,0.329843
uuid-557f0e8ad7d14679b45d58489bfd372c,feels,0.365489
uuid-557f0e8ad7d14679b45d58489bfd372c,RTL stated,0.484004
uuid-557f0e8ad7d14679b45d58489bfd372c,option,0.561264
uuid-2ce017dfc59d44158e288b0e2898b3ea,patients,0.492903
uuid-2ce017dfc59d44158e288b0e2898b3ea,toxicity,0.490953
uuid-2ce017dfc59d44158e288b0e2898b3ea,regimen,0.410202
uuid-2ce017dfc59d44158e288b0e2898b3ea,treated,0.386174
uuid-2ce017dfc59d44158e288b0e2898b3ea,treatment,0.433729
uuid-2ce017dfc59d44158e288b0e2898b3ea,progression,0.419235
uuid-2ce017dfc59d44158e288b0e2898b3ea,oncologist,0.325868
uuid-2ce017dfc59d44158e288b0e2898b3ea,respond,0.567751
uuid-913d5e4eb78940b1b896df5a376491d1,RTL,0.515542
uuid-913d5e4eb78940b1b896df5a376491d1,1L,0.366419
uuid-913d5e4eb78940b1b896df5a376491d1,trial,0.491773
uuid-913d5e4eb78940b1b896df5a376491d1,shared,0.365891
uuid-913d5e4eb78940b1b896df5a376491d1,commented,0.308109
uuid-913d5e4eb78940b1b896df5a376491d1,RCC,0.466443
uuid-913d5e4eb78940b1b896df5a376491d1,combination,0.322289
uuid-913d5e4eb78940b1b896df5a376491d1,2L,0.330876
uuid-913d5e4eb78940b1b896df5a376491d1,stated,0.385078
uuid-913d5e4eb78940b1b896df5a376491d1,preferred,0.39129
uuid-913d5e4eb78940b1b896df5a376491d1,using nivo,0.33634
uuid-913d5e4eb78940b1b896df5a376491d1,combo,0.374232
uuid-913d5e4eb78940b1b896df5a376491d1,clinical trials,0.662313
uuid-913d5e4eb78940b1b896df5a376491d1,approved,0.303209
uuid-913d5e4eb78940b1b896df5a376491d1,SCCHN,0.583397
uuid-913d5e4eb78940b1b896df5a376491d1,impressed,0.319358
uuid-913d5e4eb78940b1b896df5a376491d1,LTL,0.345067
uuid-913d5e4eb78940b1b896df5a376491d1,TLs,0.445929
uuid-913d5e4eb78940b1b896df5a376491d1,academic,0.415911
uuid-913d5e4eb78940b1b896df5a376491d1,Regional TL,0.481236
uuid-913d5e4eb78940b1b896df5a376491d1,RTL stated,0.522728
uuid-913d5e4eb78940b1b896df5a376491d1,TL shared,0.339791
uuid-913d5e4eb78940b1b896df5a376491d1,bladder,0.440864
uuid-e6151b89413a467196dbf88e53bcb8f8,patients,0.321018
uuid-e6151b89413a467196dbf88e53bcb8f8,therapy,0.36921
uuid-e6151b89413a467196dbf88e53bcb8f8,lung,0.385616
uuid-e6151b89413a467196dbf88e53bcb8f8,regimen,0.438694
uuid-e6151b89413a467196dbf88e53bcb8f8,treated,0.326729
uuid-e6151b89413a467196dbf88e53bcb8f8,melanoma,0.484725
uuid-e6151b89413a467196dbf88e53bcb8f8,treatment,0.481095
uuid-e6151b89413a467196dbf88e53bcb8f8,AI,0.541834
uuid-e6151b89413a467196dbf88e53bcb8f8,cHL,0.336147
uuid-e6151b89413a467196dbf88e53bcb8f8,progression,0.402191
uuid-e6151b89413a467196dbf88e53bcb8f8,respond,0.362768
uuid-679ab94118ca4e918753de1742ee1b0f,BMS,0.312813
uuid-679ab94118ca4e918753de1742ee1b0f,PDL1,0.420089
uuid-679ab94118ca4e918753de1742ee1b0f,efficacy,0.350437
uuid-679ab94118ca4e918753de1742ee1b0f,OS,0.308353
uuid-679ab94118ca4e918753de1742ee1b0f,regards,0.488157
uuid-679ab94118ca4e918753de1742ee1b0f,data,0.496503
uuid-679ab94118ca4e918753de1742ee1b0f,indication,0.360773
uuid-679ab94118ca4e918753de1742ee1b0f,nivo and pembro,0.389491
uuid-679ab94118ca4e918753de1742ee1b0f,believes,0.33378
uuid-679ab94118ca4e918753de1742ee1b0f,PDL1 expression,0.391073
uuid-679ab94118ca4e918753de1742ee1b0f,NCCN,0.486984
uuid-b45de1aecc1b41db87c5c051190c7aeb,TL,0.483853
uuid-b45de1aecc1b41db87c5c051190c7aeb,pembro,0.423404
uuid-b45de1aecc1b41db87c5c051190c7aeb,1L,0.401016
uuid-b45de1aecc1b41db87c5c051190c7aeb,PDL1,0.367849
uuid-b45de1aecc1b41db87c5c051190c7aeb,TL stated,0.432824
uuid-b45de1aecc1b41db87c5c051190c7aeb,2L,0.387924
uuid-b45de1aecc1b41db87c5c051190c7aeb,institution,0.412467
uuid-b45de1aecc1b41db87c5c051190c7aeb,PD-L1,0.692153
uuid-b45de1aecc1b41db87c5c051190c7aeb,approval,0.428268
uuid-b45de1aecc1b41db87c5c051190c7aeb,atezo,0.431837
uuid-b45de1aecc1b41db87c5c051190c7aeb,PD-L1 testing,0.774975
uuid-b45de1aecc1b41db87c5c051190c7aeb,testing,0.810769
uuid-b45de1aecc1b41db87c5c051190c7aeb,using nivo,0.302173
uuid-b45de1aecc1b41db87c5c051190c7aeb,PDL1 testing,0.746254
uuid-b45de1aecc1b41db87c5c051190c7aeb,NSCLC patients,0.679585
uuid-b45de1aecc1b41db87c5c051190c7aeb,assay,0.573597
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,Nivo,0.412347
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,patients,0.670889
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,therapy,0.40549
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,nivolumab,0.371348
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,1L,0.404046
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,regimen,0.405858
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,treated,0.4018
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,chemo,0.427662
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,2L,0.357226
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,pts,0.490367
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,preferred,0.378709
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,monotherapy,0.536056
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,treatment,0.435743
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,using nivo,0.473736
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,PD1,0.348627
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,SCCHN,0.378083
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,progression,0.463218
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,chemotherapy,0.446008
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,respond,0.329843
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,feels,0.365489
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,RTL stated,0.484004
uuid-6f2c68bf3d094d8ea74eb16d96c999e7,option,0.561264
uuid-6762d37e289b44e287de88a84e152f2b,PDL1,0.324511
uuid-6762d37e289b44e287de88a84e152f2b,efficacy,0.407596
uuid-6762d37e289b44e287de88a84e152f2b,chemo,0.443522
uuid-6762d37e289b44e287de88a84e152f2b,OS,0.3829
uuid-6762d37e289b44e287de88a84e152f2b,monotherapy,0.343789
uuid-6762d37e289b44e287de88a84e152f2b,combo,0.300875
uuid-6762d37e289b44e287de88a84e152f2b,PFS,0.377678
uuid-6762d37e289b44e287de88a84e152f2b,ORR,0.368889
uuid-6762d37e289b44e287de88a84e152f2b,nivo and pembro,0.376648
uuid-6762d37e289b44e287de88a84e152f2b,believes,0.590427
uuid-6762d37e289b44e287de88a84e152f2b,chemotherapy,0.397883
uuid-6762d37e289b44e287de88a84e152f2b,feels,0.360401
uuid-6762d37e289b44e287de88a84e152f2b,option,0.353029
uuid-a62876309933411aa99c5a8f78311728,pembro,0.412446
uuid-a62876309933411aa99c5a8f78311728,RTL,0.478455
uuid-a62876309933411aa99c5a8f78311728,BMS,0.311491
uuid-a62876309933411aa99c5a8f78311728,trial,0.736542
uuid-a62876309933411aa99c5a8f78311728,NTL,0.399097
uuid-a62876309933411aa99c5a8f78311728,Merck,0.423462
uuid-a62876309933411aa99c5a8f78311728,approval,0.31438
uuid-a62876309933411aa99c5a8f78311728,atezo,0.307327
uuid-a62876309933411aa99c5a8f78311728,clinical trials,0.386478
uuid-a62876309933411aa99c5a8f78311728,SCCHN,0.367621
uuid-a62876309933411aa99c5a8f78311728,Regional TL,0.319377
uuid-a62876309933411aa99c5a8f78311728,bladder,0.349595
uuid-a1445169954344429a33b8bfc7bce751,Opdivo,0.767616
uuid-a1445169954344429a33b8bfc7bce751,dose,0.315551
uuid-a1445169954344429a33b8bfc7bce751,physicians,0.398733
uuid-a1445169954344429a33b8bfc7bce751,approved,0.321777
uuid-a1445169954344429a33b8bfc7bce751,drug,0.52845
uuid-a1445169954344429a33b8bfc7bce751,Keytruda,0.476063
uuid-a1445169954344429a33b8bfc7bce751,flat dosing,0.421879
uuid-bc65788fa6da4ae69d1944326b47d7ed,physicians,0.566143
uuid-bc65788fa6da4ae69d1944326b47d7ed,oncology,0.507099
uuid-bc65788fa6da4ae69d1944326b47d7ed,clinical,0.347087
uuid-badf4230fbb6416fb0b464d5466d3a31,1L,0.346802
uuid-badf4230fbb6416fb0b464d5466d3a31,PDL1,0.497539
uuid-badf4230fbb6416fb0b464d5466d3a31,efficacy,0.348601
uuid-badf4230fbb6416fb0b464d5466d3a31,PD-L1,0.35893
uuid-badf4230fbb6416fb0b464d5466d3a31,monotherapy,0.313266
uuid-badf4230fbb6416fb0b464d5466d3a31,believes,0.36825
uuid-badf4230fbb6416fb0b464d5466d3a31,feels,0.351394
uuid-badf4230fbb6416fb0b464d5466d3a31,PDL1 expression,0.334277
uuid-badf4230fbb6416fb0b464d5466d3a31,option,0.332516
uuid-bbee920195e243ddbadf66d6262ecc4f,oncology,0.440799
uuid-bbee920195e243ddbadf66d6262ecc4f,drug,0.519261
uuid-bbee920195e243ddbadf66d6262ecc4f,Keytruda,0.33398
uuid-bbee920195e243ddbadf66d6262ecc4f,clinical,0.377836
uuid-bbee920195e243ddbadf66d6262ecc4f,flat dosing,0.385408
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,Nivo,0.442884
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,pembro,0.70733
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,dose,0.578603
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,trial,0.313356
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,efficacy,0.498563
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,Ipi,0.390045
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,atezo,0.665559
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,preferred,0.358524
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,indication,0.440591
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,nivo and pembro,0.374154
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,vs,0.730869
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,Keytruda,0.414519
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,TLs,0.311674
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,feels,0.333029
uuid-d3a16bff37d2445c98cc0dfaf0ca82d0,flat dosing,0.549349
uuid-29565d1bd3d044c48431acf637f7816a,TL,0.326845
uuid-29565d1bd3d044c48431acf637f7816a,trial,0.675316
uuid-29565d1bd3d044c48431acf637f7816a,Merck,0.314961
uuid-29565d1bd3d044c48431acf637f7816a,clinical trials,0.340872
uuid-88572409844746b79eb66dd7bac28349,trial,0.504532
uuid-88572409844746b79eb66dd7bac28349,shared,0.402479
uuid-88572409844746b79eb66dd7bac28349,combination,0.373811
uuid-88572409844746b79eb66dd7bac28349,combo,0.343935
uuid-8fb42bc7129b41baaae700a11deb4129,Nivo,0.62766
uuid-8fb42bc7129b41baaae700a11deb4129,pembro,0.623474
uuid-8fb42bc7129b41baaae700a11deb4129,dose,0.515867
uuid-8fb42bc7129b41baaae700a11deb4129,1L,0.465307
uuid-8fb42bc7129b41baaae700a11deb4129,toxicity,0.355832
uuid-8fb42bc7129b41baaae700a11deb4129,efficacy,0.502328
uuid-8fb42bc7129b41baaae700a11deb4129,regimen,0.361651
uuid-8fb42bc7129b41baaae700a11deb4129,combination,0.366524
uuid-8fb42bc7129b41baaae700a11deb4129,chemo,0.42564
uuid-8fb42bc7129b41baaae700a11deb4129,2L,0.603441
uuid-8fb42bc7129b41baaae700a11deb4129,agents,0.515772
uuid-8fb42bc7129b41baaae700a11deb4129,Ipi,0.488052
uuid-8fb42bc7129b41baaae700a11deb4129,atezo,0.65974
uuid-8fb42bc7129b41baaae700a11deb4129,preferred,0.575649
uuid-8fb42bc7129b41baaae700a11deb4129,monotherapy,0.535226
uuid-8fb42bc7129b41baaae700a11deb4129,using nivo,0.436995
uuid-8fb42bc7129b41baaae700a11deb4129,combo,0.440656
uuid-8fb42bc7129b41baaae700a11deb4129,indication,0.300113
uuid-8fb42bc7129b41baaae700a11deb4129,approved,0.330182
uuid-8fb42bc7129b41baaae700a11deb4129,nivo and pembro,0.428234
uuid-8fb42bc7129b41baaae700a11deb4129,believes,0.358216
uuid-8fb42bc7129b41baaae700a11deb4129,vs,0.584775
uuid-8fb42bc7129b41baaae700a11deb4129,feels,0.412981
uuid-8fb42bc7129b41baaae700a11deb4129,option,0.486082
uuid-e5339ec5ce4b45598a17d314a3c91687,TL,0.368268
uuid-e5339ec5ce4b45598a17d314a3c91687,lung,0.662474
uuid-e5339ec5ce4b45598a17d314a3c91687,1L,0.304209
uuid-e5339ec5ce4b45598a17d314a3c91687,melanoma,0.454639
uuid-e5339ec5ce4b45598a17d314a3c91687,RCC,0.636104
uuid-e5339ec5ce4b45598a17d314a3c91687,TL stated,0.823963
uuid-e5339ec5ce4b45598a17d314a3c91687,2L,0.325997
uuid-e5339ec5ce4b45598a17d314a3c91687,institution,0.324688
uuid-e5339ec5ce4b45598a17d314a3c91687,stated,0.333773
uuid-e5339ec5ce4b45598a17d314a3c91687,PD-L1,0.336433
uuid-e5339ec5ce4b45598a17d314a3c91687,PD-L1 testing,0.494651
uuid-e5339ec5ce4b45598a17d314a3c91687,testing,0.55087
uuid-e5339ec5ce4b45598a17d314a3c91687,PDL1 testing,0.778561
uuid-e5339ec5ce4b45598a17d314a3c91687,NSCLC patients,0.530805
uuid-e5339ec5ce4b45598a17d314a3c91687,SCCHN,0.49397
uuid-e5339ec5ce4b45598a17d314a3c91687,tumor types,0.462866
uuid-e5339ec5ce4b45598a17d314a3c91687,TLs,0.396775
uuid-e5339ec5ce4b45598a17d314a3c91687,Regional TL,0.366691
uuid-e5339ec5ce4b45598a17d314a3c91687,RTL stated,0.476694
uuid-e5339ec5ce4b45598a17d314a3c91687,TL shared,0.547266
uuid-e5339ec5ce4b45598a17d314a3c91687,bladder,0.409308
uuid-4112b967fb984b178be6b37a743ceffc,Nivo,0.365224
uuid-4112b967fb984b178be6b37a743ceffc,pembro,0.485447
uuid-4112b967fb984b178be6b37a743ceffc,BMS,0.314248
uuid-4112b967fb984b178be6b37a743ceffc,1L,0.42321
uuid-4112b967fb984b178be6b37a743ceffc,PDL1,0.471043
uuid-4112b967fb984b178be6b37a743ceffc,trial,0.432531
uuid-4112b967fb984b178be6b37a743ceffc,efficacy,0.498809
uuid-4112b967fb984b178be6b37a743ceffc,2L,0.349564
uuid-4112b967fb984b178be6b37a743ceffc,stated,0.39869
uuid-4112b967fb984b178be6b37a743ceffc,OS,0.515673
uuid-4112b967fb984b178be6b37a743ceffc,atezo,0.439281
uuid-4112b967fb984b178be6b37a743ceffc,data,0.698959
uuid-4112b967fb984b178be6b37a743ceffc,clinical trials,0.302275
uuid-4112b967fb984b178be6b37a743ceffc,PFS,0.509514
uuid-4112b967fb984b178be6b37a743ceffc,ORR,0.537733
uuid-4112b967fb984b178be6b37a743ceffc,nivo and pembro,0.551944
uuid-4112b967fb984b178be6b37a743ceffc,believes,0.413694
uuid-4112b967fb984b178be6b37a743ceffc,impressed,0.532499
uuid-4112b967fb984b178be6b37a743ceffc,LTL,0.304144
uuid-4112b967fb984b178be6b37a743ceffc,TLs,0.321532
uuid-4112b967fb984b178be6b37a743ceffc,feels,0.547009
uuid-4112b967fb984b178be6b37a743ceffc,PDL1 expression,0.467286
uuid-d29c63285ce749029a5ab8943134a1ea,Nivo,0.577419
uuid-d29c63285ce749029a5ab8943134a1ea,pembro,0.706605
uuid-d29c63285ce749029a5ab8943134a1ea,1L,0.71949
uuid-d29c63285ce749029a5ab8943134a1ea,RCC,0.512565
uuid-d29c63285ce749029a5ab8943134a1ea,2L,0.776541
uuid-d29c63285ce749029a5ab8943134a1ea,agents,0.373499
uuid-d29c63285ce749029a5ab8943134a1ea,stated,0.334891
uuid-d29c63285ce749029a5ab8943134a1ea,approval,0.567796
uuid-d29c63285ce749029a5ab8943134a1ea,atezo,0.677499
uuid-d29c63285ce749029a5ab8943134a1ea,preferred,0.628356
uuid-d29c63285ce749029a5ab8943134a1ea,monotherapy,0.503395
uuid-d29c63285ce749029a5ab8943134a1ea,using nivo,0.724894
uuid-d29c63285ce749029a5ab8943134a1ea,combo,0.339694
uuid-d29c63285ce749029a5ab8943134a1ea,clinical trials,0.32489
uuid-d29c63285ce749029a5ab8943134a1ea,indication,0.472152
uuid-d29c63285ce749029a5ab8943134a1ea,approved,0.640345
uuid-d29c63285ce749029a5ab8943134a1ea,SCCHN,0.521202
uuid-d29c63285ce749029a5ab8943134a1ea,nivo and pembro,0.347227
uuid-d29c63285ce749029a5ab8943134a1ea,tumor types,0.392353
uuid-d29c63285ce749029a5ab8943134a1ea,label,0.373542
uuid-d29c63285ce749029a5ab8943134a1ea,SCLC,0.368552
uuid-d29c63285ce749029a5ab8943134a1ea,feels,0.335061
uuid-d29c63285ce749029a5ab8943134a1ea,RTL stated,0.613833
uuid-d29c63285ce749029a5ab8943134a1ea,option,0.519585
uuid-d29c63285ce749029a5ab8943134a1ea,bladder,0.514654
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,Nivo,0.380158
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,pembro,0.547042
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,dose,0.517403
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,BMS,0.439722
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,trial,0.451059
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,efficacy,0.528562
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,Merck,0.36294
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,Ipi,0.419488
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,atezo,0.542584
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,data,0.388745
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,nivo and pembro,0.310632
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,vs,0.675592
uuid-b345cdbe0101427b9cc0e2b4bc27bdc9,flat dosing,0.451295
uuid-ce89d09861054d038776452585eec3fd,Nivo,0.385677
uuid-ce89d09861054d038776452585eec3fd,pembro,0.314735
uuid-ce89d09861054d038776452585eec3fd,nivolumab,0.329128
uuid-ce89d09861054d038776452585eec3fd,1L,0.606886
uuid-ce89d09861054d038776452585eec3fd,toxicity,0.340412
uuid-ce89d09861054d038776452585eec3fd,regimen,0.489545
uuid-ce89d09861054d038776452585eec3fd,RCC,0.45459
uuid-ce89d09861054d038776452585eec3fd,combination,0.515684
uuid-ce89d09861054d038776452585eec3fd,chemo,0.493514
uuid-ce89d09861054d038776452585eec3fd,2L,0.681783
uuid-ce89d09861054d038776452585eec3fd,IO,0.337656
uuid-ce89d09861054d038776452585eec3fd,agents,0.708498
uuid-ce89d09861054d038776452585eec3fd,atezo,0.383767
uuid-ce89d09861054d038776452585eec3fd,preferred,0.719423
uuid-ce89d09861054d038776452585eec3fd,monotherapy,0.741233
uuid-ce89d09861054d038776452585eec3fd,using nivo,0.525447
uuid-ce89d09861054d038776452585eec3fd,combo,0.566152
uuid-ce89d09861054d038776452585eec3fd,PD1,0.488027
uuid-ce89d09861054d038776452585eec3fd,approved,0.452055
uuid-ce89d09861054d038776452585eec3fd,believes,0.43786
uuid-ce89d09861054d038776452585eec3fd,chemotherapy,0.410388
uuid-ce89d09861054d038776452585eec3fd,feels,0.372122
uuid-ce89d09861054d038776452585eec3fd,PD-1,0.330935
uuid-ce89d09861054d038776452585eec3fd,RTL stated,0.381871
uuid-ce89d09861054d038776452585eec3fd,option,0.749233
uuid-df10ef88baee4824897940680c45805f,patients,0.610211
uuid-df10ef88baee4824897940680c45805f,therapy,0.319661
uuid-df10ef88baee4824897940680c45805f,regimen,0.351175
uuid-df10ef88baee4824897940680c45805f,treated,0.586945
uuid-df10ef88baee4824897940680c45805f,chemo,0.312073
uuid-df10ef88baee4824897940680c45805f,tumor,0.512165
uuid-df10ef88baee4824897940680c45805f,pts,0.490043
uuid-df10ef88baee4824897940680c45805f,treatment,0.447157
uuid-df10ef88baee4824897940680c45805f,response,0.347226
uuid-df10ef88baee4824897940680c45805f,progression,0.483903
uuid-df10ef88baee4824897940680c45805f,respond,0.401623
uuid-8e0bda2e24e340f9afe3d510ba5167a3,pembro,0.324155
uuid-8e0bda2e24e340f9afe3d510ba5167a3,PDL1,0.587713
uuid-8e0bda2e24e340f9afe3d510ba5167a3,agents,0.32797
uuid-8e0bda2e24e340f9afe3d510ba5167a3,PD-L1,0.616618
uuid-8e0bda2e24e340f9afe3d510ba5167a3,atezo,0.457776
uuid-8e0bda2e24e340f9afe3d510ba5167a3,PD-L1 testing,0.386912
uuid-8e0bda2e24e340f9afe3d510ba5167a3,testing,0.531268
uuid-8e0bda2e24e340f9afe3d510ba5167a3,PDL1 testing,0.427124
uuid-8e0bda2e24e340f9afe3d510ba5167a3,NSCLC patients,0.318358
uuid-8e0bda2e24e340f9afe3d510ba5167a3,nivo and pembro,0.339226
uuid-8e0bda2e24e340f9afe3d510ba5167a3,believes,0.380665
uuid-8e0bda2e24e340f9afe3d510ba5167a3,assay,0.59433
uuid-8e0bda2e24e340f9afe3d510ba5167a3,PDL1 expression,0.504467
uuid-8e0bda2e24e340f9afe3d510ba5167a3,biomarker,0.499482
uuid-d9cfa3f0146243388700bd684089f237,Nivo,0.435321
uuid-d9cfa3f0146243388700bd684089f237,patients,0.345004
uuid-d9cfa3f0146243388700bd684089f237,pembro,0.559692
uuid-d9cfa3f0146243388700bd684089f237,nivolumab,0.324954
uuid-d9cfa3f0146243388700bd684089f237,1L,0.596621
uuid-d9cfa3f0146243388700bd684089f237,RCC,0.39071
uuid-d9cfa3f0146243388700bd684089f237,combination,0.30369
uuid-d9cfa3f0146243388700bd684089f237,chemo,0.337999
uuid-d9cfa3f0146243388700bd684089f237,2L,0.710933
uuid-d9cfa3f0146243388700bd684089f237,agents,0.474177
uuid-d9cfa3f0146243388700bd684089f237,approval,0.328031
uuid-d9cfa3f0146243388700bd684089f237,atezo,0.587836
uuid-d9cfa3f0146243388700bd684089f237,preferred,0.77221
uuid-d9cfa3f0146243388700bd684089f237,monotherapy,0.582447
uuid-d9cfa3f0146243388700bd684089f237,using nivo,0.585866
uuid-d9cfa3f0146243388700bd684089f237,combo,0.382803
uuid-d9cfa3f0146243388700bd684089f237,indication,0.346999
uuid-d9cfa3f0146243388700bd684089f237,NSCLC patients,0.305345
uuid-d9cfa3f0146243388700bd684089f237,PD1,0.339237
uuid-d9cfa3f0146243388700bd684089f237,approved,0.444349
uuid-d9cfa3f0146243388700bd684089f237,SCCHN,0.300893
uuid-d9cfa3f0146243388700bd684089f237,vs,0.36558
uuid-d9cfa3f0146243388700bd684089f237,feels,0.318979
uuid-d9cfa3f0146243388700bd684089f237,RTL stated,0.453372
uuid-d9cfa3f0146243388700bd684089f237,option,0.640502
uuid-d9cfa3f0146243388700bd684089f237,bladder,0.31559
uuid-2c47314c6c734fee850edd494510faa6,Nivo,0.669129
uuid-2c47314c6c734fee850edd494510faa6,pembro,0.487281
uuid-2c47314c6c734fee850edd494510faa6,trial,0.593812
uuid-2c47314c6c734fee850edd494510faa6,efficacy,0.579789
uuid-2c47314c6c734fee850edd494510faa6,combination,0.325554
uuid-2c47314c6c734fee850edd494510faa6,chemo,0.381653
uuid-2c47314c6c734fee850edd494510faa6,Ipi,0.469169
uuid-2c47314c6c734fee850edd494510faa6,OS,0.459921
uuid-2c47314c6c734fee850edd494510faa6,atezo,0.315504
uuid-2c47314c6c734fee850edd494510faa6,data,0.449333
uuid-2c47314c6c734fee850edd494510faa6,PFS,0.49766
uuid-2c47314c6c734fee850edd494510faa6,ORR,0.540188
uuid-2c47314c6c734fee850edd494510faa6,nivo and pembro,0.445559
uuid-2c47314c6c734fee850edd494510faa6,believes,0.311689
uuid-2c47314c6c734fee850edd494510faa6,chemotherapy,0.346882
uuid-2c47314c6c734fee850edd494510faa6,impressed,0.407507
uuid-2c47314c6c734fee850edd494510faa6,vs,0.446843
uuid-2c47314c6c734fee850edd494510faa6,feels,0.408865
uuid-e17dbc1231c04b0994c345195ab82835,RTL,0.346459
uuid-e17dbc1231c04b0994c345195ab82835,BMS,0.313421
uuid-e17dbc1231c04b0994c345195ab82835,PDL1,0.373302
uuid-e17dbc1231c04b0994c345195ab82835,trial,0.448904
uuid-e17dbc1231c04b0994c345195ab82835,efficacy,0.44481
uuid-e17dbc1231c04b0994c345195ab82835,NTL,0.349106
uuid-e17dbc1231c04b0994c345195ab82835,commented,0.34621
uuid-e17dbc1231c04b0994c345195ab82835,Merck,0.300215
uuid-e17dbc1231c04b0994c345195ab82835,OS,0.382046
uuid-e17dbc1231c04b0994c345195ab82835,regards,0.383721
uuid-e17dbc1231c04b0994c345195ab82835,data,0.556224
uuid-e17dbc1231c04b0994c345195ab82835,expressed,0.442509
uuid-e17dbc1231c04b0994c345195ab82835,mentioned,0.497404
uuid-e17dbc1231c04b0994c345195ab82835,PFS,0.443648
uuid-e17dbc1231c04b0994c345195ab82835,ORR,0.458685
uuid-e17dbc1231c04b0994c345195ab82835,nivo and pembro,0.432348
uuid-e17dbc1231c04b0994c345195ab82835,impressed,0.367233
uuid-e17dbc1231c04b0994c345195ab82835,TLs,0.38241
uuid-e17dbc1231c04b0994c345195ab82835,PDL1 expression,0.429233
uuid-61a49726faee49feab516a7e8c61031c,patients,0.338935
uuid-61a49726faee49feab516a7e8c61031c,toxicity,0.386668
uuid-61a49726faee49feab516a7e8c61031c,regimen,0.373615
uuid-61a49726faee49feab516a7e8c61031c,treatment,0.331939
uuid-61a49726faee49feab516a7e8c61031c,respond,0.426069
uuid-61a49726faee49feab516a7e8c61031c,feels,0.401749
uuid-509d3c8ec97948eebf806f240f6a47f8,patients,0.739377
uuid-509d3c8ec97948eebf806f240f6a47f8,Opdivo,0.423835
uuid-509d3c8ec97948eebf806f240f6a47f8,therapy,0.378344
uuid-509d3c8ec97948eebf806f240f6a47f8,regimen,0.352436
uuid-509d3c8ec97948eebf806f240f6a47f8,treated,0.360049
uuid-509d3c8ec97948eebf806f240f6a47f8,pts,0.467316
uuid-509d3c8ec97948eebf806f240f6a47f8,treatment,0.55025
uuid-509d3c8ec97948eebf806f240f6a47f8,progression,0.570781
uuid-509d3c8ec97948eebf806f240f6a47f8,respond,0.423482
uuid-3ede0133e58b4c1395b34443f9546930,pembro,0.567765
uuid-3ede0133e58b4c1395b34443f9546930,1L,0.443786
uuid-3ede0133e58b4c1395b34443f9546930,PDL1,0.39459
uuid-3ede0133e58b4c1395b34443f9546930,2L,0.435346
uuid-3ede0133e58b4c1395b34443f9546930,Merck,0.392371
uuid-3ede0133e58b4c1395b34443f9546930,PD-L1,0.618867
uuid-3ede0133e58b4c1395b34443f9546930,approval,0.497589
uuid-3ede0133e58b4c1395b34443f9546930,atezo,0.56829
uuid-3ede0133e58b4c1395b34443f9546930,preferred,0.41082
uuid-3ede0133e58b4c1395b34443f9546930,PD-L1 testing,0.539557
uuid-3ede0133e58b4c1395b34443f9546930,testing,0.654477
uuid-3ede0133e58b4c1395b34443f9546930,PDL1 testing,0.559505
uuid-3ede0133e58b4c1395b34443f9546930,indication,0.383415
uuid-3ede0133e58b4c1395b34443f9546930,NSCLC patients,0.525916
uuid-3ede0133e58b4c1395b34443f9546930,approved,0.534804
uuid-3ede0133e58b4c1395b34443f9546930,label,0.354771
uuid-3ede0133e58b4c1395b34443f9546930,Keytruda,0.530819
uuid-3ede0133e58b4c1395b34443f9546930,assay,0.48445
uuid-b6a13870f99242a08b71de24276d32f0,Nivo,0.333321
uuid-b6a13870f99242a08b71de24276d32f0,pembro,0.32493
uuid-b6a13870f99242a08b71de24276d32f0,dose,0.346232
uuid-b6a13870f99242a08b71de24276d32f0,BMS,0.340995
uuid-b6a13870f99242a08b71de24276d32f0,trial,0.623857
uuid-b6a13870f99242a08b71de24276d32f0,efficacy,0.55292
uuid-b6a13870f99242a08b71de24276d32f0,Ipi,0.729838
uuid-b6a13870f99242a08b71de24276d32f0,OS,0.439383
uuid-b6a13870f99242a08b71de24276d32f0,data,0.532983
uuid-b6a13870f99242a08b71de24276d32f0,PFS,0.423416
uuid-b6a13870f99242a08b71de24276d32f0,ORR,0.578035
uuid-b6a13870f99242a08b71de24276d32f0,impressed,0.475862
uuid-b6a13870f99242a08b71de24276d32f0,vs,0.45769
uuid-77997f5939c54f4189267e7460e80912,toxicity,0.460349
uuid-f624dd7f2664497c80e6c42972d61d74,patients,0.340267
uuid-f624dd7f2664497c80e6c42972d61d74,regimen,0.318167
uuid-f624dd7f2664497c80e6c42972d61d74,chemo,0.310768
uuid-f624dd7f2664497c80e6c42972d61d74,2L,0.321233
uuid-f624dd7f2664497c80e6c42972d61d74,preferred,0.607101
uuid-f624dd7f2664497c80e6c42972d61d74,monotherapy,0.376449
uuid-f624dd7f2664497c80e6c42972d61d74,treatment,0.334885
uuid-f624dd7f2664497c80e6c42972d61d74,using nivo,0.366791
uuid-f624dd7f2664497c80e6c42972d61d74,indication,0.32774
uuid-f624dd7f2664497c80e6c42972d61d74,SCCHN,0.335519
uuid-f624dd7f2664497c80e6c42972d61d74,chemotherapy,0.365508
uuid-f624dd7f2664497c80e6c42972d61d74,RTL stated,0.365949
uuid-f624dd7f2664497c80e6c42972d61d74,TL shared,0.30615
uuid-f624dd7f2664497c80e6c42972d61d74,option,0.510003
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,TL,0.504597
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,NSCLC,0.403568
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,1L,0.37931
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,RCC,0.428615
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,TL stated,0.626698
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,2L,0.310771
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,institution,0.337751
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,PD-L1,0.670419
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,approval,0.351643
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,PD-L1 testing,0.765795
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,testing,0.776726
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,PDL1 testing,0.770602
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,NSCLC patients,0.712738
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,SCCHN,0.429487
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,tumor types,0.34516
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,assay,0.414259
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,Regional TL,0.310381
uuid-4e0299b480cb4f9dbc3f2d05aa42c54e,RTL stated,0.405556
uuid-23c38b2d592a4a019550c6111f783e52,BMS,0.390061
uuid-23c38b2d592a4a019550c6111f783e52,PDL1,0.699072
uuid-23c38b2d592a4a019550c6111f783e52,trial,0.339665
uuid-23c38b2d592a4a019550c6111f783e52,efficacy,0.414486
uuid-23c38b2d592a4a019550c6111f783e52,discussed,0.355646
uuid-23c38b2d592a4a019550c6111f783e52,commented,0.395405
uuid-23c38b2d592a4a019550c6111f783e52,Merck,0.437044
uuid-23c38b2d592a4a019550c6111f783e52,PD-L1,0.41947
uuid-23c38b2d592a4a019550c6111f783e52,OS,0.471946
uuid-23c38b2d592a4a019550c6111f783e52,regards,0.450838
uuid-23c38b2d592a4a019550c6111f783e52,data,0.725889
uuid-23c38b2d592a4a019550c6111f783e52,expressed,0.302392
uuid-23c38b2d592a4a019550c6111f783e52,PFS,0.520375
uuid-23c38b2d592a4a019550c6111f783e52,ORR,0.50452
uuid-23c38b2d592a4a019550c6111f783e52,nivo and pembro,0.488195
uuid-23c38b2d592a4a019550c6111f783e52,impressed,0.364505
uuid-23c38b2d592a4a019550c6111f783e52,assay,0.478062
uuid-23c38b2d592a4a019550c6111f783e52,PDL1 expression,0.657054
uuid-23c38b2d592a4a019550c6111f783e52,biomarker,0.575792
uuid-3d65e357a32646738c7c321d96318ff2,patients,0.648116
uuid-3d65e357a32646738c7c321d96318ff2,Opdivo,0.432987
uuid-3d65e357a32646738c7c321d96318ff2,therapy,0.577877
uuid-3d65e357a32646738c7c321d96318ff2,nivolumab,0.505646
uuid-3d65e357a32646738c7c321d96318ff2,toxicity,0.306584
uuid-3d65e357a32646738c7c321d96318ff2,regimen,0.555315
uuid-3d65e357a32646738c7c321d96318ff2,treated,0.451498
uuid-3d65e357a32646738c7c321d96318ff2,RCC,0.339045
uuid-3d65e357a32646738c7c321d96318ff2,combination,0.373273
uuid-3d65e357a32646738c7c321d96318ff2,chemo,0.419995
uuid-3d65e357a32646738c7c321d96318ff2,2L,0.322053
uuid-3d65e357a32646738c7c321d96318ff2,pts,0.55317
uuid-3d65e357a32646738c7c321d96318ff2,IO,0.345959
uuid-3d65e357a32646738c7c321d96318ff2,preferred,0.309455
uuid-3d65e357a32646738c7c321d96318ff2,monotherapy,0.538231
uuid-3d65e357a32646738c7c321d96318ff2,treatment,0.611803
uuid-3d65e357a32646738c7c321d96318ff2,using nivo,0.377012
uuid-3d65e357a32646738c7c321d96318ff2,response,0.571192
uuid-3d65e357a32646738c7c321d96318ff2,combo,0.355569
uuid-3d65e357a32646738c7c321d96318ff2,PD1,0.498516
uuid-3d65e357a32646738c7c321d96318ff2,progression,0.72202
uuid-3d65e357a32646738c7c321d96318ff2,chemotherapy,0.374627
uuid-3d65e357a32646738c7c321d96318ff2,respond,0.518697
uuid-3d65e357a32646738c7c321d96318ff2,option,0.495131
uuid-86879863639c4158b00c7f8e77a446c8,Nivo,0.408487
uuid-86879863639c4158b00c7f8e77a446c8,patients,0.671921
uuid-86879863639c4158b00c7f8e77a446c8,Opdivo,0.45808
uuid-86879863639c4158b00c7f8e77a446c8,therapy,0.493145
uuid-86879863639c4158b00c7f8e77a446c8,nivolumab,0.574886
uuid-86879863639c4158b00c7f8e77a446c8,1L,0.346636
uuid-86879863639c4158b00c7f8e77a446c8,regimen,0.514554
uuid-86879863639c4158b00c7f8e77a446c8,treated,0.431957
uuid-86879863639c4158b00c7f8e77a446c8,2L,0.347591
uuid-86879863639c4158b00c7f8e77a446c8,pts,0.490182
uuid-86879863639c4158b00c7f8e77a446c8,approval,0.443608
uuid-86879863639c4158b00c7f8e77a446c8,preferred,0.344908
uuid-86879863639c4158b00c7f8e77a446c8,monotherapy,0.573087
uuid-86879863639c4158b00c7f8e77a446c8,treatment,0.438709
uuid-86879863639c4158b00c7f8e77a446c8,using nivo,0.555485
uuid-86879863639c4158b00c7f8e77a446c8,PD1,0.341836
uuid-86879863639c4158b00c7f8e77a446c8,approved,0.41555
uuid-86879863639c4158b00c7f8e77a446c8,cHL,0.345469
uuid-86879863639c4158b00c7f8e77a446c8,progression,0.439439
uuid-86879863639c4158b00c7f8e77a446c8,chemotherapy,0.357779
uuid-86879863639c4158b00c7f8e77a446c8,label,0.303465
uuid-86879863639c4158b00c7f8e77a446c8,respond,0.345531
uuid-86879863639c4158b00c7f8e77a446c8,SCLC,0.401768
uuid-86879863639c4158b00c7f8e77a446c8,RTL stated,0.40846
uuid-86879863639c4158b00c7f8e77a446c8,option,0.522778
uuid-eeecca121a3b48c6a5b2e6859cf7d69e,patients,0.349046
uuid-eeecca121a3b48c6a5b2e6859cf7d69e,nivolumab,0.307328
uuid-eeecca121a3b48c6a5b2e6859cf7d69e,pts,0.340466
uuid-eeecca121a3b48c6a5b2e6859cf7d69e,treatment,0.331732
uuid-eeecca121a3b48c6a5b2e6859cf7d69e,response,0.312977
uuid-eeecca121a3b48c6a5b2e6859cf7d69e,PD1,0.333611
uuid-eeecca121a3b48c6a5b2e6859cf7d69e,progression,0.39819
uuid-eeecca121a3b48c6a5b2e6859cf7d69e,ASCO,0.313124
uuid-196e7af26d04434f82d50662fab42a03,efficacy,0.477489
uuid-196e7af26d04434f82d50662fab42a03,OS,0.723576
uuid-196e7af26d04434f82d50662fab42a03,data,0.589964
uuid-196e7af26d04434f82d50662fab42a03,PFS,0.651432
uuid-196e7af26d04434f82d50662fab42a03,ORR,0.619708
uuid-196e7af26d04434f82d50662fab42a03,impressed,0.55509
uuid-196e7af26d04434f82d50662fab42a03,feels,0.321301
uuid-6bded813c9864bda89c434613e870af7,dose,0.378005
uuid-6bded813c9864bda89c434613e870af7,trial,0.386825
uuid-6bded813c9864bda89c434613e870af7,Ipi,0.36827
uuid-bf2390eed8b64592b499ea1d9e536226,patients,0.432577
uuid-bf2390eed8b64592b499ea1d9e536226,trial,0.304449
uuid-bf2390eed8b64592b499ea1d9e536226,regimen,0.344768
uuid-bf2390eed8b64592b499ea1d9e536226,treated,0.360264
uuid-bf2390eed8b64592b499ea1d9e536226,treatment,0.354594
uuid-bf2390eed8b64592b499ea1d9e536226,clinical trials,0.360567
uuid-bf2390eed8b64592b499ea1d9e536226,feels,0.332499
uuid-847b08d035d14b1387b04117f0456a9e,patients,0.359766
uuid-847b08d035d14b1387b04117f0456a9e,therapy,0.413044
uuid-847b08d035d14b1387b04117f0456a9e,nivolumab,0.321135
uuid-847b08d035d14b1387b04117f0456a9e,1L,0.300097
uuid-847b08d035d14b1387b04117f0456a9e,regimen,0.498009
uuid-847b08d035d14b1387b04117f0456a9e,treated,0.300637
uuid-847b08d035d14b1387b04117f0456a9e,combination,0.362442
uuid-847b08d035d14b1387b04117f0456a9e,chemo,0.348279
uuid-847b08d035d14b1387b04117f0456a9e,preferred,0.382393
uuid-847b08d035d14b1387b04117f0456a9e,monotherapy,0.515195
uuid-847b08d035d14b1387b04117f0456a9e,treatment,0.60653
uuid-847b08d035d14b1387b04117f0456a9e,using nivo,0.300843
uuid-847b08d035d14b1387b04117f0456a9e,combo,0.343768
uuid-847b08d035d14b1387b04117f0456a9e,PD1,0.348333
uuid-847b08d035d14b1387b04117f0456a9e,progression,0.356361
uuid-847b08d035d14b1387b04117f0456a9e,chemotherapy,0.452846
uuid-847b08d035d14b1387b04117f0456a9e,feels,0.340137
uuid-847b08d035d14b1387b04117f0456a9e,option,0.537374
uuid-8a7f76ce49c2482d8d5bca49c5de1575,Nivo,0.378929
uuid-8a7f76ce49c2482d8d5bca49c5de1575,pembro,0.310233
uuid-8a7f76ce49c2482d8d5bca49c5de1575,RTL,0.309704
uuid-8a7f76ce49c2482d8d5bca49c5de1575,dose,0.326655
uuid-8a7f76ce49c2482d8d5bca49c5de1575,1L,0.344364
uuid-8a7f76ce49c2482d8d5bca49c5de1575,toxicity,0.318771
uuid-8a7f76ce49c2482d8d5bca49c5de1575,efficacy,0.309419
uuid-8a7f76ce49c2482d8d5bca49c5de1575,regimen,0.445897
uuid-8a7f76ce49c2482d8d5bca49c5de1575,melanoma,0.364092
uuid-8a7f76ce49c2482d8d5bca49c5de1575,RCC,0.382811
uuid-8a7f76ce49c2482d8d5bca49c5de1575,combination,0.535137
uuid-8a7f76ce49c2482d8d5bca49c5de1575,chemo,0.35486
uuid-8a7f76ce49c2482d8d5bca49c5de1575,2L,0.367978
uuid-8a7f76ce49c2482d8d5bca49c5de1575,Ipi,0.651841
uuid-8a7f76ce49c2482d8d5bca49c5de1575,preferred,0.312952
uuid-8a7f76ce49c2482d8d5bca49c5de1575,monotherapy,0.492164
uuid-8a7f76ce49c2482d8d5bca49c5de1575,using nivo,0.349217
uuid-8a7f76ce49c2482d8d5bca49c5de1575,combo,0.608416
uuid-8a7f76ce49c2482d8d5bca49c5de1575,believes,0.318293
uuid-8a7f76ce49c2482d8d5bca49c5de1575,vs,0.310194
uuid-8a7f76ce49c2482d8d5bca49c5de1575,TLs,0.35118
uuid-8a7f76ce49c2482d8d5bca49c5de1575,SCLC,0.364105
uuid-8a7f76ce49c2482d8d5bca49c5de1575,RTL stated,0.352071
uuid-60bc4c9802bb438c926f08475619d99e,patients,0.320458
uuid-60bc4c9802bb438c926f08475619d99e,regimen,0.303099
uuid-60bc4c9802bb438c926f08475619d99e,treated,0.346147
uuid-b855365e09c94c9eb409ec0a6ff86a4d,RTL,0.313976
uuid-b855365e09c94c9eb409ec0a6ff86a4d,trial,0.418531
uuid-b855365e09c94c9eb409ec0a6ff86a4d,combination,0.305361
uuid-6c3ec9e2221b4c779ced26cdafca1a06,pembro,0.334582
uuid-6c3ec9e2221b4c779ced26cdafca1a06,lung,0.457122
uuid-6c3ec9e2221b4c779ced26cdafca1a06,1L,0.474954
uuid-6c3ec9e2221b4c779ced26cdafca1a06,treated,0.316907
uuid-6c3ec9e2221b4c779ced26cdafca1a06,melanoma,0.444683
uuid-6c3ec9e2221b4c779ced26cdafca1a06,RCC,0.680652
uuid-6c3ec9e2221b4c779ced26cdafca1a06,TL stated,0.650349
uuid-6c3ec9e2221b4c779ced26cdafca1a06,2L,0.597788
uuid-6c3ec9e2221b4c779ced26cdafca1a06,atezo,0.407817
uuid-6c3ec9e2221b4c779ced26cdafca1a06,preferred,0.542545
uuid-6c3ec9e2221b4c779ced26cdafca1a06,monotherapy,0.311837
uuid-6c3ec9e2221b4c779ced26cdafca1a06,using nivo,0.54636
uuid-6c3ec9e2221b4c779ced26cdafca1a06,PDL1 testing,0.504499
uuid-6c3ec9e2221b4c779ced26cdafca1a06,NSCLC patients,0.505683
uuid-6c3ec9e2221b4c779ced26cdafca1a06,approved,0.307039
uuid-6c3ec9e2221b4c779ced26cdafca1a06,SCCHN,0.545852
uuid-6c3ec9e2221b4c779ced26cdafca1a06,tumor types,0.405183
uuid-6c3ec9e2221b4c779ced26cdafca1a06,TLs,0.45509
uuid-6c3ec9e2221b4c779ced26cdafca1a06,academic,0.360639
uuid-6c3ec9e2221b4c779ced26cdafca1a06,Regional TL,0.342932
uuid-6c3ec9e2221b4c779ced26cdafca1a06,RTL stated,0.634041
uuid-6c3ec9e2221b4c779ced26cdafca1a06,TL shared,0.550089
uuid-6c3ec9e2221b4c779ced26cdafca1a06,bladder,0.506416
uuid-e21ce42af7df4b4fae178023b0530d2a,response,0.357704
uuid-e21ce42af7df4b4fae178023b0530d2a,PD-1,0.369457
uuid-6b65dedb1b6c4563af3fcb7ac191fe62,1L,0.339993
uuid-6b65dedb1b6c4563af3fcb7ac191fe62,PDL1,0.34434
uuid-6b65dedb1b6c4563af3fcb7ac191fe62,combination,0.315618
uuid-6b65dedb1b6c4563af3fcb7ac191fe62,agents,0.459367
uuid-6b65dedb1b6c4563af3fcb7ac191fe62,PD-L1,0.382349
uuid-6b65dedb1b6c4563af3fcb7ac191fe62,monotherapy,0.374478
uuid-6b65dedb1b6c4563af3fcb7ac191fe62,PD1,0.394549
uuid-6b65dedb1b6c4563af3fcb7ac191fe62,nivo and pembro,0.349377
uuid-6b65dedb1b6c4563af3fcb7ac191fe62,PD-1,0.695263
uuid-6b65dedb1b6c4563af3fcb7ac191fe62,option,0.307889
uuid-569a33b7358648cabf21e096fa67ab4e,lung,0.447582
uuid-569a33b7358648cabf21e096fa67ab4e,regards,0.407562
uuid-569a33b7358648cabf21e096fa67ab4e,expressed,0.391764
uuid-569a33b7358648cabf21e096fa67ab4e,indication,0.365031
uuid-569a33b7358648cabf21e096fa67ab4e,AI,0.705765
uuid-569a33b7358648cabf21e096fa67ab4e,oncology,0.363719
uuid-569a33b7358648cabf21e096fa67ab4e,clinical,0.315216
uuid-569a33b7358648cabf21e096fa67ab4e,NCCN,0.472278
uuid-84e8b59e57f74b43877d916913863c9e,TL,0.407317
uuid-84e8b59e57f74b43877d916913863c9e,pembro,0.452506
uuid-84e8b59e57f74b43877d916913863c9e,BMS,0.368328
uuid-84e8b59e57f74b43877d916913863c9e,NSCLC,0.302252
uuid-84e8b59e57f74b43877d916913863c9e,PDL1,0.626958
uuid-84e8b59e57f74b43877d916913863c9e,Merck,0.607845
uuid-84e8b59e57f74b43877d916913863c9e,PD-L1,0.622422
uuid-84e8b59e57f74b43877d916913863c9e,atezo,0.532728
uuid-84e8b59e57f74b43877d916913863c9e,PD-L1 testing,0.478769
uuid-84e8b59e57f74b43877d916913863c9e,testing,0.574332
uuid-84e8b59e57f74b43877d916913863c9e,PDL1 testing,0.456683
uuid-84e8b59e57f74b43877d916913863c9e,nivo and pembro,0.423975
uuid-84e8b59e57f74b43877d916913863c9e,assay,0.802387
uuid-84e8b59e57f74b43877d916913863c9e,PDL1 expression,0.422435
uuid-84e8b59e57f74b43877d916913863c9e,biomarker,0.436224
uuid-2c80ccd3620d4da285f099754312b330,Nivo,0.330888
uuid-2c80ccd3620d4da285f099754312b330,1L,0.321197
uuid-2c80ccd3620d4da285f099754312b330,PDL1,0.644525
uuid-2c80ccd3620d4da285f099754312b330,trial,0.331977
uuid-2c80ccd3620d4da285f099754312b330,efficacy,0.452734
uuid-2c80ccd3620d4da285f099754312b330,chemo,0.416613
uuid-2c80ccd3620d4da285f099754312b330,OS,0.641566
uuid-2c80ccd3620d4da285f099754312b330,data,0.368479
uuid-2c80ccd3620d4da285f099754312b330,PFS,0.667624
uuid-2c80ccd3620d4da285f099754312b330,ORR,0.609715
uuid-2c80ccd3620d4da285f099754312b330,nivo and pembro,0.652178
uuid-2c80ccd3620d4da285f099754312b330,believes,0.555032
uuid-2c80ccd3620d4da285f099754312b330,PDL1 expression,0.573531
uuid-2c80ccd3620d4da285f099754312b330,biomarker,0.420214
uuid-e9f04d3202b74a968cf9dfff67513635,Nivo,0.414234
uuid-e9f04d3202b74a968cf9dfff67513635,RTL,0.393391
uuid-e9f04d3202b74a968cf9dfff67513635,trial,0.422029
uuid-e9f04d3202b74a968cf9dfff67513635,OS,0.353994
uuid-e9f04d3202b74a968cf9dfff67513635,data,0.386587
uuid-e9f04d3202b74a968cf9dfff67513635,mentioned,0.354679
uuid-e9f04d3202b74a968cf9dfff67513635,PFS,0.455585
uuid-e9f04d3202b74a968cf9dfff67513635,ORR,0.351668
uuid-e9f04d3202b74a968cf9dfff67513635,cHL,0.616787
uuid-e9f04d3202b74a968cf9dfff67513635,impressed,0.384811
uuid-8636e13a4dd54912a93918d74d9c47e5,RTL,0.620894
uuid-8636e13a4dd54912a93918d74d9c47e5,nivolumab,0.3214
uuid-8636e13a4dd54912a93918d74d9c47e5,trial,0.504193
uuid-8636e13a4dd54912a93918d74d9c47e5,NTL,0.558912
uuid-8636e13a4dd54912a93918d74d9c47e5,commented,0.453934
uuid-8636e13a4dd54912a93918d74d9c47e5,stated,0.555644
uuid-8636e13a4dd54912a93918d74d9c47e5,data,0.38898
uuid-8636e13a4dd54912a93918d74d9c47e5,expressed,0.314443
uuid-8636e13a4dd54912a93918d74d9c47e5,mentioned,0.382557
uuid-8636e13a4dd54912a93918d74d9c47e5,clinical trials,0.380396
uuid-8636e13a4dd54912a93918d74d9c47e5,SCCHN,0.450343
uuid-8636e13a4dd54912a93918d74d9c47e5,HCP,0.310967
uuid-8636e13a4dd54912a93918d74d9c47e5,cHL,0.321746
uuid-8636e13a4dd54912a93918d74d9c47e5,ASCO,0.372674
uuid-8636e13a4dd54912a93918d74d9c47e5,impressed,0.545672
uuid-8636e13a4dd54912a93918d74d9c47e5,LTL,0.426363
uuid-8636e13a4dd54912a93918d74d9c47e5,SCLC,0.318653
uuid-8636e13a4dd54912a93918d74d9c47e5,Regional TL,0.62377
uuid-8636e13a4dd54912a93918d74d9c47e5,RTL stated,0.300415
uuid-8636e13a4dd54912a93918d74d9c47e5,bladder,0.332516
uuid-e3d972984da144d89e6bf08f68bdfdb1,pembro,0.349908
uuid-e3d972984da144d89e6bf08f68bdfdb1,BMS,0.759588
uuid-e3d972984da144d89e6bf08f68bdfdb1,PDL1,0.319256
uuid-e3d972984da144d89e6bf08f68bdfdb1,trial,0.533509
uuid-e3d972984da144d89e6bf08f68bdfdb1,efficacy,0.395414
uuid-e3d972984da144d89e6bf08f68bdfdb1,commented,0.36509
uuid-e3d972984da144d89e6bf08f68bdfdb1,Merck,0.591192
uuid-e3d972984da144d89e6bf08f68bdfdb1,stated,0.328652
uuid-e3d972984da144d89e6bf08f68bdfdb1,OS,0.407426
uuid-e3d972984da144d89e6bf08f68bdfdb1,regards,0.331902
uuid-e3d972984da144d89e6bf08f68bdfdb1,data,0.794722
uuid-e3d972984da144d89e6bf08f68bdfdb1,expressed,0.392155
uuid-e3d972984da144d89e6bf08f68bdfdb1,clinical trials,0.31843
uuid-e3d972984da144d89e6bf08f68bdfdb1,indication,0.338231
uuid-e3d972984da144d89e6bf08f68bdfdb1,PFS,0.376772
uuid-e3d972984da144d89e6bf08f68bdfdb1,ORR,0.407486
uuid-e3d972984da144d89e6bf08f68bdfdb1,nivo and pembro,0.407763
uuid-e3d972984da144d89e6bf08f68bdfdb1,impressed,0.528132
uuid-e3d972984da144d89e6bf08f68bdfdb1,feels,0.3725
uuid-24f1770e242c4caab5fab5b1bfed5295,Nivo,0.605664
uuid-24f1770e242c4caab5fab5b1bfed5295,pembro,0.474297
uuid-24f1770e242c4caab5fab5b1bfed5295,1L,0.314709
uuid-24f1770e242c4caab5fab5b1bfed5295,PDL1,0.490122
uuid-24f1770e242c4caab5fab5b1bfed5295,efficacy,0.58265
uuid-24f1770e242c4caab5fab5b1bfed5295,chemo,0.355791
uuid-24f1770e242c4caab5fab5b1bfed5295,agents,0.302856
uuid-24f1770e242c4caab5fab5b1bfed5295,OS,0.417907
uuid-24f1770e242c4caab5fab5b1bfed5295,atezo,0.44135
uuid-24f1770e242c4caab5fab5b1bfed5295,monotherapy,0.309018
uuid-24f1770e242c4caab5fab5b1bfed5295,data,0.459995
uuid-24f1770e242c4caab5fab5b1bfed5295,PFS,0.470212
uuid-24f1770e242c4caab5fab5b1bfed5295,ORR,0.480106
uuid-24f1770e242c4caab5fab5b1bfed5295,nivo and pembro,0.58258
uuid-24f1770e242c4caab5fab5b1bfed5295,believes,0.428846
uuid-24f1770e242c4caab5fab5b1bfed5295,vs,0.431823
uuid-24f1770e242c4caab5fab5b1bfed5295,feels,0.478233
uuid-24f1770e242c4caab5fab5b1bfed5295,PDL1 expression,0.47634
uuid-eeb95e24a99c4d58a3a6b99ae9329c8b,patients,0.437725
uuid-eeb95e24a99c4d58a3a6b99ae9329c8b,PD-L1,0.341574
uuid-eeb95e24a99c4d58a3a6b99ae9329c8b,PD-L1 testing,0.492248
uuid-eeb95e24a99c4d58a3a6b99ae9329c8b,testing,0.470151
uuid-eeb95e24a99c4d58a3a6b99ae9329c8b,PDL1 testing,0.40518
uuid-eeb95e24a99c4d58a3a6b99ae9329c8b,NSCLC patients,0.415243
uuid-eeb95e24a99c4d58a3a6b99ae9329c8b,lung cancer,0.334862
uuid-bde0bf8b7d364cb58659e01760bac5af,therapy,0.343287
uuid-bde0bf8b7d364cb58659e01760bac5af,treated,0.315935
uuid-bde0bf8b7d364cb58659e01760bac5af,chemo,0.419953
uuid-bde0bf8b7d364cb58659e01760bac5af,pts,0.429609
uuid-bde0bf8b7d364cb58659e01760bac5af,monotherapy,0.350209
uuid-bde0bf8b7d364cb58659e01760bac5af,treatment,0.326267
uuid-bde0bf8b7d364cb58659e01760bac5af,response,0.454857
uuid-bde0bf8b7d364cb58659e01760bac5af,PD1,0.525429
uuid-bde0bf8b7d364cb58659e01760bac5af,progression,0.548992
uuid-bde0bf8b7d364cb58659e01760bac5af,believes,0.42694
uuid-bde0bf8b7d364cb58659e01760bac5af,chemotherapy,0.36084
uuid-bde0bf8b7d364cb58659e01760bac5af,respond,0.380115
uuid-bde0bf8b7d364cb58659e01760bac5af,immunotherapy,0.350029
uuid-9fcf10b4307f4c05905c2da70ba216e9,Nivo,0.693348
uuid-9fcf10b4307f4c05905c2da70ba216e9,pembro,0.394524
uuid-9fcf10b4307f4c05905c2da70ba216e9,trial,0.383214
uuid-9fcf10b4307f4c05905c2da70ba216e9,efficacy,0.592427
uuid-9fcf10b4307f4c05905c2da70ba216e9,chemo,0.602727
uuid-9fcf10b4307f4c05905c2da70ba216e9,Ipi,0.412282
uuid-9fcf10b4307f4c05905c2da70ba216e9,OS,0.555834
uuid-9fcf10b4307f4c05905c2da70ba216e9,monotherapy,0.342396
uuid-9fcf10b4307f4c05905c2da70ba216e9,data,0.355323
uuid-9fcf10b4307f4c05905c2da70ba216e9,PFS,0.607656
uuid-9fcf10b4307f4c05905c2da70ba216e9,PD1,0.311464
uuid-9fcf10b4307f4c05905c2da70ba216e9,ORR,0.5894
uuid-9fcf10b4307f4c05905c2da70ba216e9,nivo and pembro,0.516705
uuid-9fcf10b4307f4c05905c2da70ba216e9,believes,0.399515
uuid-9fcf10b4307f4c05905c2da70ba216e9,chemotherapy,0.493539
uuid-9fcf10b4307f4c05905c2da70ba216e9,vs,0.417124
uuid-9fcf10b4307f4c05905c2da70ba216e9,feels,0.394293
uuid-9fcf10b4307f4c05905c2da70ba216e9,PDL1 expression,0.323481
uuid-87d5294dcee948538fd7a00a1d1b7022,TL,0.359572
uuid-87d5294dcee948538fd7a00a1d1b7022,RTL,0.325659
uuid-87d5294dcee948538fd7a00a1d1b7022,BMS,0.510554
uuid-87d5294dcee948538fd7a00a1d1b7022,trial,0.437996
uuid-87d5294dcee948538fd7a00a1d1b7022,NTL,0.317643
uuid-87d5294dcee948538fd7a00a1d1b7022,discussed,0.316654
uuid-87d5294dcee948538fd7a00a1d1b7022,commented,0.55143
uuid-87d5294dcee948538fd7a00a1d1b7022,Merck,0.650194
uuid-87d5294dcee948538fd7a00a1d1b7022,regards,0.544601
uuid-87d5294dcee948538fd7a00a1d1b7022,data,0.495638
uuid-87d5294dcee948538fd7a00a1d1b7022,expressed,0.426202
uuid-87d5294dcee948538fd7a00a1d1b7022,mentioned,0.478167
uuid-87d5294dcee948538fd7a00a1d1b7022,ASCO,0.319219
uuid-87d5294dcee948538fd7a00a1d1b7022,impressed,0.369793
uuid-87d5294dcee948538fd7a00a1d1b7022,assay,0.379196
uuid-4256ac54fdda4967acf918870adac5d2,Nivo,0.518985
uuid-4256ac54fdda4967acf918870adac5d2,pembro,0.54719
uuid-4256ac54fdda4967acf918870adac5d2,1L,0.418461
uuid-4256ac54fdda4967acf918870adac5d2,PDL1,0.557221
uuid-4256ac54fdda4967acf918870adac5d2,trial,0.394207
uuid-4256ac54fdda4967acf918870adac5d2,efficacy,0.724246
uuid-4256ac54fdda4967acf918870adac5d2,combination,0.36158
uuid-4256ac54fdda4967acf918870adac5d2,chemo,0.431431
uuid-4256ac54fdda4967acf918870adac5d2,2L,0.346737
uuid-4256ac54fdda4967acf918870adac5d2,agents,0.496365
uuid-4256ac54fdda4967acf918870adac5d2,Ipi,0.301858
uuid-4256ac54fdda4967acf918870adac5d2,OS,0.490654
uuid-4256ac54fdda4967acf918870adac5d2,atezo,0.521299
uuid-4256ac54fdda4967acf918870adac5d2,monotherapy,0.437864
uuid-4256ac54fdda4967acf918870adac5d2,data,0.521126
uuid-4256ac54fdda4967acf918870adac5d2,combo,0.413322
uuid-4256ac54fdda4967acf918870adac5d2,PFS,0.483047
uuid-4256ac54fdda4967acf918870adac5d2,PD1,0.483949
uuid-4256ac54fdda4967acf918870adac5d2,ORR,0.550453
uuid-4256ac54fdda4967acf918870adac5d2,nivo and pembro,0.729637
uuid-4256ac54fdda4967acf918870adac5d2,believes,0.574466
uuid-4256ac54fdda4967acf918870adac5d2,vs,0.435035
uuid-4256ac54fdda4967acf918870adac5d2,feels,0.402717
uuid-4256ac54fdda4967acf918870adac5d2,PD-1,0.306694
uuid-4256ac54fdda4967acf918870adac5d2,PDL1 expression,0.44968
uuid-c9117ab0d639443685be0fd819752658,RTL,0.371293
uuid-c9117ab0d639443685be0fd819752658,lung,0.302482
uuid-c9117ab0d639443685be0fd819752658,discussed,0.500124
uuid-c9117ab0d639443685be0fd819752658,melanoma,0.485356
uuid-c9117ab0d639443685be0fd819752658,SCCHN,0.403486
uuid-c9117ab0d639443685be0fd819752658,academic,0.586035
uuid-128d15cbdfcb494bb5feb616c34e0493,PDL1,0.331091
uuid-128d15cbdfcb494bb5feb616c34e0493,trial,0.353985
uuid-128d15cbdfcb494bb5feb616c34e0493,discussed,0.373409
uuid-128d15cbdfcb494bb5feb616c34e0493,OS,0.36782
uuid-128d15cbdfcb494bb5feb616c34e0493,data,0.397503
uuid-128d15cbdfcb494bb5feb616c34e0493,PFS,0.404861
uuid-128d15cbdfcb494bb5feb616c34e0493,ORR,0.400835
uuid-128d15cbdfcb494bb5feb616c34e0493,PDL1 expression,0.465854
uuid-128d15cbdfcb494bb5feb616c34e0493,biomarker,0.416085
uuid-ac1afee0c57445dd842bb599565556fb,pembro,0.373344
uuid-ac1afee0c57445dd842bb599565556fb,BMS,0.498179
uuid-ac1afee0c57445dd842bb599565556fb,PDL1,0.479202
uuid-ac1afee0c57445dd842bb599565556fb,trial,0.450267
uuid-ac1afee0c57445dd842bb599565556fb,efficacy,0.39469
uuid-ac1afee0c57445dd842bb599565556fb,commented,0.311907
uuid-ac1afee0c57445dd842bb599565556fb,Merck,0.360586
uuid-ac1afee0c57445dd842bb599565556fb,OS,0.446545
uuid-ac1afee0c57445dd842bb599565556fb,atezo,0.332812
uuid-ac1afee0c57445dd842bb599565556fb,regards,0.469729
uuid-ac1afee0c57445dd842bb599565556fb,data,0.587857
uuid-ac1afee0c57445dd842bb599565556fb,indication,0.320295
uuid-ac1afee0c57445dd842bb599565556fb,PFS,0.479564
uuid-ac1afee0c57445dd842bb599565556fb,AI,0.310121
uuid-ac1afee0c57445dd842bb599565556fb,ORR,0.451094
uuid-ac1afee0c57445dd842bb599565556fb,nivo and pembro,0.559294
uuid-ac1afee0c57445dd842bb599565556fb,impressed,0.334169
uuid-ac1afee0c57445dd842bb599565556fb,feels,0.309608
uuid-ac1afee0c57445dd842bb599565556fb,PDL1 expression,0.504901
uuid-ac1afee0c57445dd842bb599565556fb,NCCN,0.342302
uuid-e3168aa176564e2bb7de9469cd80ed2e,Nivo,0.562643
uuid-e3168aa176564e2bb7de9469cd80ed2e,pembro,0.793244
uuid-e3168aa176564e2bb7de9469cd80ed2e,1L,0.797036
uuid-e3168aa176564e2bb7de9469cd80ed2e,PDL1,0.36396
uuid-e3168aa176564e2bb7de9469cd80ed2e,RCC,0.34837
uuid-e3168aa176564e2bb7de9469cd80ed2e,chemo,0.301855
uuid-e3168aa176564e2bb7de9469cd80ed2e,2L,0.830326
uuid-e3168aa176564e2bb7de9469cd80ed2e,agents,0.485978
uuid-e3168aa176564e2bb7de9469cd80ed2e,approval,0.455381
uuid-e3168aa176564e2bb7de9469cd80ed2e,atezo,0.784117
uuid-e3168aa176564e2bb7de9469cd80ed2e,preferred,0.695584
uuid-e3168aa176564e2bb7de9469cd80ed2e,monotherapy,0.550706
uuid-e3168aa176564e2bb7de9469cd80ed2e,using nivo,0.611987
uuid-e3168aa176564e2bb7de9469cd80ed2e,combo,0.341614
uuid-e3168aa176564e2bb7de9469cd80ed2e,indication,0.482889
uuid-e3168aa176564e2bb7de9469cd80ed2e,approved,0.620528
uuid-e3168aa176564e2bb7de9469cd80ed2e,SCCHN,0.358735
uuid-e3168aa176564e2bb7de9469cd80ed2e,nivo and pembro,0.494338
uuid-e3168aa176564e2bb7de9469cd80ed2e,believes,0.322172
uuid-e3168aa176564e2bb7de9469cd80ed2e,tumor types,0.317503
uuid-e3168aa176564e2bb7de9469cd80ed2e,vs,0.3252
uuid-e3168aa176564e2bb7de9469cd80ed2e,label,0.339892
uuid-e3168aa176564e2bb7de9469cd80ed2e,feels,0.426756
uuid-e3168aa176564e2bb7de9469cd80ed2e,RTL stated,0.442256
uuid-e3168aa176564e2bb7de9469cd80ed2e,PDL1 expression,0.341755
uuid-e3168aa176564e2bb7de9469cd80ed2e,option,0.596414
uuid-e3168aa176564e2bb7de9469cd80ed2e,bladder,0.387006
uuid-b8402e381c314076a2abcfcfacac1b95,pembro,0.374804
uuid-b8402e381c314076a2abcfcfacac1b95,BMS,0.426756
uuid-b8402e381c314076a2abcfcfacac1b95,PDL1,0.607203
uuid-b8402e381c314076a2abcfcfacac1b95,trial,0.398908
uuid-b8402e381c314076a2abcfcfacac1b95,efficacy,0.702186
uuid-b8402e381c314076a2abcfcfacac1b95,Merck,0.342587
uuid-b8402e381c314076a2abcfcfacac1b95,OS,0.484157
uuid-b8402e381c314076a2abcfcfacac1b95,atezo,0.451528
uuid-b8402e381c314076a2abcfcfacac1b95,regards,0.434448
uuid-b8402e381c314076a2abcfcfacac1b95,data,0.726329
uuid-b8402e381c314076a2abcfcfacac1b95,expressed,0.361449
uuid-b8402e381c314076a2abcfcfacac1b95,PFS,0.496368
uuid-b8402e381c314076a2abcfcfacac1b95,ORR,0.566786
uuid-b8402e381c314076a2abcfcfacac1b95,nivo and pembro,0.661793
uuid-b8402e381c314076a2abcfcfacac1b95,believes,0.378047
uuid-b8402e381c314076a2abcfcfacac1b95,impressed,0.448458
uuid-b8402e381c314076a2abcfcfacac1b95,vs,0.333226
uuid-b8402e381c314076a2abcfcfacac1b95,TLs,0.435915
uuid-b8402e381c314076a2abcfcfacac1b95,feels,0.313333
uuid-b8402e381c314076a2abcfcfacac1b95,PDL1 expression,0.596645
uuid-b8402e381c314076a2abcfcfacac1b95,biomarker,0.424782
uuid-a11ef7ba77e74bdfaef657556f2acede,efficacy,0.474655
uuid-a11ef7ba77e74bdfaef657556f2acede,combination,0.426281
uuid-a11ef7ba77e74bdfaef657556f2acede,agents,0.35091
uuid-a11ef7ba77e74bdfaef657556f2acede,Ipi,0.329917
uuid-a11ef7ba77e74bdfaef657556f2acede,atezo,0.382306
uuid-a11ef7ba77e74bdfaef657556f2acede,combo,0.462101
uuid-a11ef7ba77e74bdfaef657556f2acede,clinical trials,0.378673
uuid-a11ef7ba77e74bdfaef657556f2acede,nivo and pembro,0.305082
uuid-a11ef7ba77e74bdfaef657556f2acede,believes,0.365562
uuid-a11ef7ba77e74bdfaef657556f2acede,TLs,0.583983
uuid-a11ef7ba77e74bdfaef657556f2acede,feels,0.427242
uuid-98034735122d415e8044d1dd4ecdcf07,Nivo,0.44033
uuid-98034735122d415e8044d1dd4ecdcf07,pembro,0.648324
uuid-98034735122d415e8044d1dd4ecdcf07,1L,0.331471
uuid-98034735122d415e8044d1dd4ecdcf07,PDL1,0.431188
uuid-98034735122d415e8044d1dd4ecdcf07,trial,0.31265
uuid-98034735122d415e8044d1dd4ecdcf07,efficacy,0.720131
uuid-98034735122d415e8044d1dd4ecdcf07,2L,0.398678
uuid-98034735122d415e8044d1dd4ecdcf07,agents,0.418071
uuid-98034735122d415e8044d1dd4ecdcf07,OS,0.31805
uuid-98034735122d415e8044d1dd4ecdcf07,atezo,0.748061
uuid-98034735122d415e8044d1dd4ecdcf07,regards,0.342169
uuid-98034735122d415e8044d1dd4ecdcf07,data,0.551837
uuid-98034735122d415e8044d1dd4ecdcf07,indication,0.436837
uuid-98034735122d415e8044d1dd4ecdcf07,PFS,0.302601
uuid-98034735122d415e8044d1dd4ecdcf07,ORR,0.373067
uuid-98034735122d415e8044d1dd4ecdcf07,nivo and pembro,0.669607
uuid-98034735122d415e8044d1dd4ecdcf07,believes,0.353095
uuid-98034735122d415e8044d1dd4ecdcf07,vs,0.563916
uuid-98034735122d415e8044d1dd4ecdcf07,TLs,0.419835
uuid-98034735122d415e8044d1dd4ecdcf07,feels,0.346809
uuid-98034735122d415e8044d1dd4ecdcf07,PDL1 expression,0.451375
uuid-5a98024b4a3047ebb40fd2707c31f127,RTL,0.406404
uuid-5a98024b4a3047ebb40fd2707c31f127,NTL,0.341821
uuid-5a98024b4a3047ebb40fd2707c31f127,discussed,0.573379
uuid-5a98024b4a3047ebb40fd2707c31f127,melanoma,0.454328
uuid-5a98024b4a3047ebb40fd2707c31f127,SCCHN,0.360381
uuid-5a98024b4a3047ebb40fd2707c31f127,academic,0.575358
uuid-3ac5dae26ae64320adcb59af6639dbc9,TL,0.387222
uuid-3ac5dae26ae64320adcb59af6639dbc9,RTL,0.467288
uuid-3ac5dae26ae64320adcb59af6639dbc9,lung,0.433449
uuid-3ac5dae26ae64320adcb59af6639dbc9,NSCLC,0.564962
uuid-3ac5dae26ae64320adcb59af6639dbc9,1L,0.334148
uuid-3ac5dae26ae64320adcb59af6639dbc9,treated,0.35697
uuid-3ac5dae26ae64320adcb59af6639dbc9,NTL,0.34862
uuid-3ac5dae26ae64320adcb59af6639dbc9,melanoma,0.366809
uuid-3ac5dae26ae64320adcb59af6639dbc9,shared,0.340321
uuid-3ac5dae26ae64320adcb59af6639dbc9,RCC,0.593872
uuid-3ac5dae26ae64320adcb59af6639dbc9,TL stated,0.621966
uuid-3ac5dae26ae64320adcb59af6639dbc9,2L,0.318602
uuid-3ac5dae26ae64320adcb59af6639dbc9,stated,0.468208
uuid-3ac5dae26ae64320adcb59af6639dbc9,approval,0.385553
uuid-3ac5dae26ae64320adcb59af6639dbc9,PD-L1 testing,0.442645
uuid-3ac5dae26ae64320adcb59af6639dbc9,testing,0.425387
uuid-3ac5dae26ae64320adcb59af6639dbc9,using nivo,0.405658
uuid-3ac5dae26ae64320adcb59af6639dbc9,PDL1 testing,0.592538
uuid-3ac5dae26ae64320adcb59af6639dbc9,NSCLC patients,0.516368
uuid-3ac5dae26ae64320adcb59af6639dbc9,SCCHN,0.650693
uuid-3ac5dae26ae64320adcb59af6639dbc9,HCP,0.311299
uuid-3ac5dae26ae64320adcb59af6639dbc9,tumor types,0.406371
uuid-3ac5dae26ae64320adcb59af6639dbc9,LTL,0.384524
uuid-3ac5dae26ae64320adcb59af6639dbc9,TLs,0.406013
uuid-3ac5dae26ae64320adcb59af6639dbc9,academic,0.426834
uuid-3ac5dae26ae64320adcb59af6639dbc9,Regional TL,0.573568
uuid-3ac5dae26ae64320adcb59af6639dbc9,RTL stated,0.623986
uuid-3ac5dae26ae64320adcb59af6639dbc9,TL shared,0.520285
uuid-3ac5dae26ae64320adcb59af6639dbc9,bladder,0.429819
uuid-62ebdced49564453be1ee325a34ef145,RTL,0.33031
uuid-62ebdced49564453be1ee325a34ef145,RCC,0.346104
uuid-62ebdced49564453be1ee325a34ef145,stated,0.375654
uuid-62ebdced49564453be1ee325a34ef145,data,0.341397
uuid-62ebdced49564453be1ee325a34ef145,SCCHN,0.300457
uuid-62ebdced49564453be1ee325a34ef145,impressed,0.468674
uuid-62ebdced49564453be1ee325a34ef145,TLs,0.324788
uuid-62ebdced49564453be1ee325a34ef145,Regional TL,0.368
uuid-62ebdced49564453be1ee325a34ef145,RTL stated,0.343969
uuid-62ebdced49564453be1ee325a34ef145,bladder,0.399174
uuid-9cc8a7d4bfde47b6805b2123961c7107,RTL,0.31055
uuid-9cc8a7d4bfde47b6805b2123961c7107,trial,0.316727
uuid-5407c82a317843f99707316c83b17c04,Nivo,0.310808
uuid-5407c82a317843f99707316c83b17c04,patients,0.33102
uuid-5407c82a317843f99707316c83b17c04,1L,0.428541
uuid-5407c82a317843f99707316c83b17c04,regimen,0.497261
uuid-5407c82a317843f99707316c83b17c04,chemo,0.452544
uuid-5407c82a317843f99707316c83b17c04,2L,0.352866
uuid-5407c82a317843f99707316c83b17c04,pts,0.457366
uuid-5407c82a317843f99707316c83b17c04,OS,0.319942
uuid-5407c82a317843f99707316c83b17c04,monotherapy,0.499502
uuid-5407c82a317843f99707316c83b17c04,response,0.350397
uuid-5407c82a317843f99707316c83b17c04,combo,0.398513
uuid-5407c82a317843f99707316c83b17c04,progression,0.411599
uuid-5407c82a317843f99707316c83b17c04,believes,0.309624
uuid-5407c82a317843f99707316c83b17c04,respond,0.401344
uuid-5407c82a317843f99707316c83b17c04,option,0.386701
uuid-8f4fc1fb06fd4446806806afd241fa97,therapy,0.331843
uuid-8f4fc1fb06fd4446806806afd241fa97,regimen,0.323906
uuid-8f4fc1fb06fd4446806806afd241fa97,treatment,0.502685
uuid-8f4fc1fb06fd4446806806afd241fa97,response,0.334779
uuid-8f4fc1fb06fd4446806806afd241fa97,PD1,0.339253
uuid-8f4fc1fb06fd4446806806afd241fa97,progression,0.40444
uuid-8f4fc1fb06fd4446806806afd241fa97,respond,0.34799
uuid-f57ebb1c3e734a8c9d516e8cc5989b1a,lung,0.687976
uuid-f57ebb1c3e734a8c9d516e8cc5989b1a,melanoma,0.558257
uuid-f57ebb1c3e734a8c9d516e8cc5989b1a,AI,0.790916
uuid-f57ebb1c3e734a8c9d516e8cc5989b1a,TL shared,0.410572
uuid-f57ebb1c3e734a8c9d516e8cc5989b1a,NCCN,0.377942
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,PDL1,0.545533
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,trial,0.321613
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,efficacy,0.422337
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,OS,0.594788
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,regards,0.411189
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,data,0.435668
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,PFS,0.634588
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,AI,0.455984
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,ORR,0.585413
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,nivo and pembro,0.603577
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,believes,0.47046
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,PDL1 expression,0.513476
uuid-44473ef56b7a49dc80ee8b75a38fd8d3,biomarker,0.38518
uuid-e55efbbdb01e459d8a0f010ad02f5d75,BMS,0.435001
uuid-e55efbbdb01e459d8a0f010ad02f5d75,trial,0.419263
uuid-e55efbbdb01e459d8a0f010ad02f5d75,efficacy,0.317127
uuid-e55efbbdb01e459d8a0f010ad02f5d75,combination,0.403552
uuid-e55efbbdb01e459d8a0f010ad02f5d75,OS,0.360171
uuid-e55efbbdb01e459d8a0f010ad02f5d75,data,0.542976
uuid-e55efbbdb01e459d8a0f010ad02f5d75,combo,0.387219
uuid-e55efbbdb01e459d8a0f010ad02f5d75,PFS,0.346152
uuid-e55efbbdb01e459d8a0f010ad02f5d75,ORR,0.378115
uuid-e55efbbdb01e459d8a0f010ad02f5d75,nivo and pembro,0.416883
uuid-e55efbbdb01e459d8a0f010ad02f5d75,believes,0.327217
uuid-e55efbbdb01e459d8a0f010ad02f5d75,impressed,0.33087
uuid-e55efbbdb01e459d8a0f010ad02f5d75,feels,0.508853
uuid-49602f40accb445892023b66cc60f2fc,BMS,0.313291
uuid-49602f40accb445892023b66cc60f2fc,lung,0.326412
uuid-49602f40accb445892023b66cc60f2fc,PDL1,0.496671
uuid-49602f40accb445892023b66cc60f2fc,trial,0.436244
uuid-49602f40accb445892023b66cc60f2fc,efficacy,0.397662
uuid-49602f40accb445892023b66cc60f2fc,OS,0.623518
uuid-49602f40accb445892023b66cc60f2fc,regards,0.486797
uuid-49602f40accb445892023b66cc60f2fc,data,0.498919
uuid-49602f40accb445892023b66cc60f2fc,expressed,0.314064
uuid-49602f40accb445892023b66cc60f2fc,PFS,0.704159
uuid-49602f40accb445892023b66cc60f2fc,AI,0.568575
uuid-49602f40accb445892023b66cc60f2fc,ORR,0.612104
uuid-49602f40accb445892023b66cc60f2fc,nivo and pembro,0.564902
uuid-49602f40accb445892023b66cc60f2fc,believes,0.31146
uuid-49602f40accb445892023b66cc60f2fc,PDL1 expression,0.522525
uuid-49602f40accb445892023b66cc60f2fc,biomarker,0.384518
uuid-61a232078ee745998b2a5fc89af66c87,TL,0.448848
uuid-61a232078ee745998b2a5fc89af66c87,PDL1,0.513185
uuid-61a232078ee745998b2a5fc89af66c87,Merck,0.309457
uuid-61a232078ee745998b2a5fc89af66c87,PD-L1,0.671414
uuid-61a232078ee745998b2a5fc89af66c87,PD-L1 testing,0.746666
uuid-61a232078ee745998b2a5fc89af66c87,testing,0.680033
uuid-61a232078ee745998b2a5fc89af66c87,PDL1 testing,0.454908
uuid-61a232078ee745998b2a5fc89af66c87,NSCLC patients,0.41201
uuid-61a232078ee745998b2a5fc89af66c87,assay,0.623519
uuid-61a232078ee745998b2a5fc89af66c87,PDL1 expression,0.331144
uuid-61a232078ee745998b2a5fc89af66c87,biomarker,0.437919
uuid-ce5a06a5029443d4b0f27cff2b0481d9,lung,0.389908
uuid-ce5a06a5029443d4b0f27cff2b0481d9,NSCLC,0.358324
uuid-ce5a06a5029443d4b0f27cff2b0481d9,PDL1,0.383768
uuid-ce5a06a5029443d4b0f27cff2b0481d9,OS,0.483113
uuid-ce5a06a5029443d4b0f27cff2b0481d9,regards,0.339401
uuid-ce5a06a5029443d4b0f27cff2b0481d9,PFS,0.520464
uuid-ce5a06a5029443d4b0f27cff2b0481d9,AI,0.678312
uuid-ce5a06a5029443d4b0f27cff2b0481d9,ORR,0.454658
uuid-ce5a06a5029443d4b0f27cff2b0481d9,nivo and pembro,0.456438
uuid-ce5a06a5029443d4b0f27cff2b0481d9,PDL1 expression,0.327729
uuid-ce5a06a5029443d4b0f27cff2b0481d9,NCCN,0.40896
uuid-6216e0065c274c6e90a2028ffae95aa7,TL,0.317301
uuid-6216e0065c274c6e90a2028ffae95aa7,RTL,0.433017
uuid-6216e0065c274c6e90a2028ffae95aa7,BMS,0.304891
uuid-6216e0065c274c6e90a2028ffae95aa7,NTL,0.348289
uuid-6216e0065c274c6e90a2028ffae95aa7,discussed,0.575082
uuid-6216e0065c274c6e90a2028ffae95aa7,shared,0.301067
uuid-6216e0065c274c6e90a2028ffae95aa7,commented,0.513143
uuid-6216e0065c274c6e90a2028ffae95aa7,stated,0.350581
uuid-6216e0065c274c6e90a2028ffae95aa7,physicians,0.319468
uuid-6216e0065c274c6e90a2028ffae95aa7,regards,0.311743
uuid-6216e0065c274c6e90a2028ffae95aa7,data,0.551691
uuid-6216e0065c274c6e90a2028ffae95aa7,ASCO,0.393622
uuid-6216e0065c274c6e90a2028ffae95aa7,impressed,0.449638
uuid-6216e0065c274c6e90a2028ffae95aa7,indicated,0.308628
uuid-6216e0065c274c6e90a2028ffae95aa7,LTL,0.435635
uuid-6216e0065c274c6e90a2028ffae95aa7,TLs,0.524871
uuid-6216e0065c274c6e90a2028ffae95aa7,clinical,0.336349
uuid-6216e0065c274c6e90a2028ffae95aa7,academic,0.427847
uuid-6216e0065c274c6e90a2028ffae95aa7,Regional TL,0.498682
uuid-ab116cbe2f9f4c24a1cbd880b7b0b47d,Opdivo,0.383874
uuid-ab116cbe2f9f4c24a1cbd880b7b0b47d,approved,0.408065
uuid-ab116cbe2f9f4c24a1cbd880b7b0b47d,label,0.3643
uuid-ab116cbe2f9f4c24a1cbd880b7b0b47d,flat dosing,0.425819
uuid-ba1d799fd9094f1a94263144362fa615,oncology,0.389793
uuid-ba1d799fd9094f1a94263144362fa615,oncologist,0.34992
uuid-ba1d799fd9094f1a94263144362fa615,indicated,0.41867
uuid-ba1d799fd9094f1a94263144362fa615,Regional TL,0.333109
uuid-8a8f6c872e1b493a8d9df9cddce88929,RTL,0.345859
uuid-8a8f6c872e1b493a8d9df9cddce88929,nivolumab,0.445349
uuid-8a8f6c872e1b493a8d9df9cddce88929,NTL,0.404346
uuid-8a8f6c872e1b493a8d9df9cddce88929,mentioned,0.345963
uuid-8a8f6c872e1b493a8d9df9cddce88929,cHL,0.426992
uuid-8a8f6c872e1b493a8d9df9cddce88929,Regional TL,0.373655
uuid-84aaf9e0e9db4c5bb15c76a2a4859cc6,Nivo,0.300513
uuid-84aaf9e0e9db4c5bb15c76a2a4859cc6,nivolumab,0.536724
uuid-84aaf9e0e9db4c5bb15c76a2a4859cc6,combination,0.35088
uuid-84aaf9e0e9db4c5bb15c76a2a4859cc6,cHL,0.357823
uuid-84aaf9e0e9db4c5bb15c76a2a4859cc6,chemotherapy,0.366298
uuid-8f7623b374bf4082bfe0935463963fdb,dose,0.335468
uuid-8f7623b374bf4082bfe0935463963fdb,toxicity,0.580765
uuid-8f7623b374bf4082bfe0935463963fdb,response,0.327778
uuid-552b54aa2e1e4701b2aba72dbd8c416e,Nivo,0.349613
uuid-552b54aa2e1e4701b2aba72dbd8c416e,patients,0.781316
uuid-552b54aa2e1e4701b2aba72dbd8c416e,Opdivo,0.393595
uuid-552b54aa2e1e4701b2aba72dbd8c416e,therapy,0.754501
uuid-552b54aa2e1e4701b2aba72dbd8c416e,nivolumab,0.535405
uuid-552b54aa2e1e4701b2aba72dbd8c416e,regimen,0.444394
uuid-552b54aa2e1e4701b2aba72dbd8c416e,treated,0.538858
uuid-552b54aa2e1e4701b2aba72dbd8c416e,chemo,0.357122
uuid-552b54aa2e1e4701b2aba72dbd8c416e,pts,0.533769
uuid-552b54aa2e1e4701b2aba72dbd8c416e,monotherapy,0.327182
uuid-552b54aa2e1e4701b2aba72dbd8c416e,treatment,0.688689
uuid-552b54aa2e1e4701b2aba72dbd8c416e,response,0.592239
uuid-552b54aa2e1e4701b2aba72dbd8c416e,PD1,0.441958
uuid-552b54aa2e1e4701b2aba72dbd8c416e,cHL,0.564619
uuid-552b54aa2e1e4701b2aba72dbd8c416e,progression,0.739083
uuid-552b54aa2e1e4701b2aba72dbd8c416e,chemotherapy,0.440013
uuid-552b54aa2e1e4701b2aba72dbd8c416e,respond,0.570014
uuid-fb871cc1bd8847a1a4d9f3548fca448a,patients,0.524055
uuid-fb871cc1bd8847a1a4d9f3548fca448a,therapy,0.365445
uuid-fb871cc1bd8847a1a4d9f3548fca448a,toxicity,0.302864
uuid-fb871cc1bd8847a1a4d9f3548fca448a,regimen,0.418533
uuid-fb871cc1bd8847a1a4d9f3548fca448a,treated,0.534772
uuid-fb871cc1bd8847a1a4d9f3548fca448a,chemo,0.327037
uuid-fb871cc1bd8847a1a4d9f3548fca448a,pts,0.575764
uuid-fb871cc1bd8847a1a4d9f3548fca448a,treatment,0.515223
uuid-fb871cc1bd8847a1a4d9f3548fca448a,response,0.718876
uuid-fb871cc1bd8847a1a4d9f3548fca448a,PD1,0.381554
uuid-fb871cc1bd8847a1a4d9f3548fca448a,progression,0.764643
uuid-fb871cc1bd8847a1a4d9f3548fca448a,respond,0.585809
uuid-5eb104d37f84427ca4fed8fd8c1238ab,RTL,0.41249
uuid-5eb104d37f84427ca4fed8fd8c1238ab,BMS,0.575314
uuid-5eb104d37f84427ca4fed8fd8c1238ab,trial,0.604304
uuid-5eb104d37f84427ca4fed8fd8c1238ab,efficacy,0.339419
uuid-5eb104d37f84427ca4fed8fd8c1238ab,NTL,0.311005
uuid-5eb104d37f84427ca4fed8fd8c1238ab,commented,0.453683
uuid-5eb104d37f84427ca4fed8fd8c1238ab,Merck,0.411265
uuid-5eb104d37f84427ca4fed8fd8c1238ab,OS,0.325311
uuid-5eb104d37f84427ca4fed8fd8c1238ab,regards,0.465985
uuid-5eb104d37f84427ca4fed8fd8c1238ab,data,0.503317
uuid-5eb104d37f84427ca4fed8fd8c1238ab,expressed,0.390952
uuid-5eb104d37f84427ca4fed8fd8c1238ab,PFS,0.337418
uuid-5eb104d37f84427ca4fed8fd8c1238ab,ORR,0.383493
uuid-5eb104d37f84427ca4fed8fd8c1238ab,nivo and pembro,0.316283
uuid-5eb104d37f84427ca4fed8fd8c1238ab,impressed,0.453348
uuid-5eb104d37f84427ca4fed8fd8c1238ab,LTL,0.303209
uuid-5eb104d37f84427ca4fed8fd8c1238ab,TLs,0.425666
uuid-daefa822d25a41828096d170c2fda821,RTL,0.400747
uuid-daefa822d25a41828096d170c2fda821,lung,0.558395
uuid-daefa822d25a41828096d170c2fda821,NTL,0.407327
uuid-daefa822d25a41828096d170c2fda821,melanoma,0.425464
uuid-daefa822d25a41828096d170c2fda821,commented,0.498574
uuid-daefa822d25a41828096d170c2fda821,RCC,0.439037
uuid-daefa822d25a41828096d170c2fda821,TL stated,0.33145
uuid-daefa822d25a41828096d170c2fda821,stated,0.474884
uuid-daefa822d25a41828096d170c2fda821,data,0.314535
uuid-daefa822d25a41828096d170c2fda821,expressed,0.348329
uuid-daefa822d25a41828096d170c2fda821,AI,0.418222
uuid-daefa822d25a41828096d170c2fda821,SCCHN,0.557228
uuid-daefa822d25a41828096d170c2fda821,ASCO,0.402232
uuid-daefa822d25a41828096d170c2fda821,impressed,0.369265
uuid-daefa822d25a41828096d170c2fda821,TLs,0.472423
uuid-daefa822d25a41828096d170c2fda821,SCLC,0.327175
uuid-daefa822d25a41828096d170c2fda821,Regional TL,0.564848
uuid-daefa822d25a41828096d170c2fda821,TL shared,0.366209
uuid-daefa822d25a41828096d170c2fda821,NCCN,0.617196
uuid-fca5ddad69374ee3862cbe30fca1e130,Nivo,0.313989
uuid-fca5ddad69374ee3862cbe30fca1e130,patients,0.754757
uuid-fca5ddad69374ee3862cbe30fca1e130,therapy,0.711163
uuid-fca5ddad69374ee3862cbe30fca1e130,toxicity,0.308882
uuid-fca5ddad69374ee3862cbe30fca1e130,regimen,0.536761
uuid-fca5ddad69374ee3862cbe30fca1e130,treated,0.387162
uuid-fca5ddad69374ee3862cbe30fca1e130,chemo,0.591958
uuid-fca5ddad69374ee3862cbe30fca1e130,pts,0.576155
uuid-fca5ddad69374ee3862cbe30fca1e130,monotherapy,0.44219
uuid-fca5ddad69374ee3862cbe30fca1e130,treatment,0.669008
uuid-fca5ddad69374ee3862cbe30fca1e130,response,0.62554
uuid-fca5ddad69374ee3862cbe30fca1e130,PD1,0.467023
uuid-fca5ddad69374ee3862cbe30fca1e130,progression,0.785961
uuid-fca5ddad69374ee3862cbe30fca1e130,chemotherapy,0.597361
uuid-fca5ddad69374ee3862cbe30fca1e130,respond,0.651695
uuid-fca5ddad69374ee3862cbe30fca1e130,option,0.367349
uuid-39f85291d26a4c6d9d33d4869e4e8e20,Nivo,0.35805
uuid-39f85291d26a4c6d9d33d4869e4e8e20,pembro,0.389262
uuid-39f85291d26a4c6d9d33d4869e4e8e20,1L,0.492976
uuid-39f85291d26a4c6d9d33d4869e4e8e20,efficacy,0.415281
uuid-39f85291d26a4c6d9d33d4869e4e8e20,combination,0.459567
uuid-39f85291d26a4c6d9d33d4869e4e8e20,chemo,0.425448
uuid-39f85291d26a4c6d9d33d4869e4e8e20,2L,0.544065
uuid-39f85291d26a4c6d9d33d4869e4e8e20,agents,0.867082
uuid-39f85291d26a4c6d9d33d4869e4e8e20,atezo,0.476107
uuid-39f85291d26a4c6d9d33d4869e4e8e20,preferred,0.581163
uuid-39f85291d26a4c6d9d33d4869e4e8e20,monotherapy,0.557067
uuid-39f85291d26a4c6d9d33d4869e4e8e20,combo,0.435498
uuid-39f85291d26a4c6d9d33d4869e4e8e20,indication,0.352124
uuid-39f85291d26a4c6d9d33d4869e4e8e20,PD1,0.432331
uuid-39f85291d26a4c6d9d33d4869e4e8e20,approved,0.355533
uuid-39f85291d26a4c6d9d33d4869e4e8e20,nivo and pembro,0.506117
uuid-39f85291d26a4c6d9d33d4869e4e8e20,believes,0.506723
uuid-39f85291d26a4c6d9d33d4869e4e8e20,chemotherapy,0.348802
uuid-39f85291d26a4c6d9d33d4869e4e8e20,feels,0.387392
uuid-39f85291d26a4c6d9d33d4869e4e8e20,PD-1,0.46891
uuid-39f85291d26a4c6d9d33d4869e4e8e20,option,0.607323
uuid-315740f0f65d445d80524d90f7b68e7c,RTL,0.654474
uuid-315740f0f65d445d80524d90f7b68e7c,trial,0.541255
uuid-315740f0f65d445d80524d90f7b68e7c,NTL,0.564688
uuid-315740f0f65d445d80524d90f7b68e7c,shared,0.304338
uuid-315740f0f65d445d80524d90f7b68e7c,commented,0.49454
uuid-315740f0f65d445d80524d90f7b68e7c,stated,0.53273
uuid-315740f0f65d445d80524d90f7b68e7c,data,0.499826
uuid-315740f0f65d445d80524d90f7b68e7c,expressed,0.421122
uuid-315740f0f65d445d80524d90f7b68e7c,mentioned,0.404225
uuid-315740f0f65d445d80524d90f7b68e7c,ORR,0.303386
uuid-315740f0f65d445d80524d90f7b68e7c,SCCHN,0.364606
uuid-315740f0f65d445d80524d90f7b68e7c,ASCO,0.437715
uuid-315740f0f65d445d80524d90f7b68e7c,impressed,0.567577
uuid-315740f0f65d445d80524d90f7b68e7c,LTL,0.421167
uuid-315740f0f65d445d80524d90f7b68e7c,TLs,0.316411
uuid-315740f0f65d445d80524d90f7b68e7c,SCLC,0.307843
uuid-315740f0f65d445d80524d90f7b68e7c,Regional TL,0.583676
uuid-7cab37c264474ffc81b2ceafb896285b,lung,0.403043
uuid-7cab37c264474ffc81b2ceafb896285b,discussed,0.33032
uuid-7cab37c264474ffc81b2ceafb896285b,melanoma,0.313894
uuid-7cab37c264474ffc81b2ceafb896285b,TL stated,0.451632
uuid-7cab37c264474ffc81b2ceafb896285b,academic,0.370293
uuid-7cab37c264474ffc81b2ceafb896285b,TL shared,0.319704
uuid-aab9c7e602954450bc1e727079f24498,toxicity,0.320083
uuid-aab9c7e602954450bc1e727079f24498,physicians,0.439713
uuid-aab9c7e602954450bc1e727079f24498,ASCO,0.310817
uuid-aab9c7e602954450bc1e727079f24498,respond,0.302211
uuid-72fe6ea340174b95976e2debe8f223ac,Nivo,0.347784
uuid-72fe6ea340174b95976e2debe8f223ac,therapy,0.415281
uuid-72fe6ea340174b95976e2debe8f223ac,nivolumab,0.352244
uuid-72fe6ea340174b95976e2debe8f223ac,using nivo,0.312014
uuid-72fe6ea340174b95976e2debe8f223ac,cHL,0.688234
uuid-4d1f5021efd5482eabce36d5e784f607,Nivo,0.405446
uuid-4d1f5021efd5482eabce36d5e784f607,patients,0.734439
uuid-4d1f5021efd5482eabce36d5e784f607,Opdivo,0.477599
uuid-4d1f5021efd5482eabce36d5e784f607,therapy,0.570805
uuid-4d1f5021efd5482eabce36d5e784f607,nivolumab,0.481795
uuid-4d1f5021efd5482eabce36d5e784f607,regimen,0.351981
uuid-4d1f5021efd5482eabce36d5e784f607,treated,0.427995
uuid-4d1f5021efd5482eabce36d5e784f607,pts,0.386436
uuid-4d1f5021efd5482eabce36d5e784f607,treatment,0.520944
uuid-4d1f5021efd5482eabce36d5e784f607,using nivo,0.352514
uuid-4d1f5021efd5482eabce36d5e784f607,cHL,0.602659
uuid-4d1f5021efd5482eabce36d5e784f607,progression,0.475297
uuid-4d1f5021efd5482eabce36d5e784f607,chemotherapy,0.33535
uuid-4d1f5021efd5482eabce36d5e784f607,respond,0.315189
uuid-e403b5995dda4809b81fded86212fc96,patients,0.676958
uuid-e403b5995dda4809b81fded86212fc96,Opdivo,0.373609
uuid-e403b5995dda4809b81fded86212fc96,therapy,0.518723
uuid-e403b5995dda4809b81fded86212fc96,nivolumab,0.416649
uuid-e403b5995dda4809b81fded86212fc96,1L,0.355165
uuid-e403b5995dda4809b81fded86212fc96,toxicity,0.319451
uuid-e403b5995dda4809b81fded86212fc96,regimen,0.579826
uuid-e403b5995dda4809b81fded86212fc96,treated,0.366942
uuid-e403b5995dda4809b81fded86212fc96,combination,0.310274
uuid-e403b5995dda4809b81fded86212fc96,chemo,0.406799
uuid-e403b5995dda4809b81fded86212fc96,2L,0.373065
uuid-e403b5995dda4809b81fded86212fc96,pts,0.522983
uuid-e403b5995dda4809b81fded86212fc96,preferred,0.404282
uuid-e403b5995dda4809b81fded86212fc96,monotherapy,0.573013
uuid-e403b5995dda4809b81fded86212fc96,treatment,0.568917
uuid-e403b5995dda4809b81fded86212fc96,using nivo,0.342832
uuid-e403b5995dda4809b81fded86212fc96,response,0.360709
uuid-e403b5995dda4809b81fded86212fc96,combo,0.335707
uuid-e403b5995dda4809b81fded86212fc96,PD1,0.378307
uuid-e403b5995dda4809b81fded86212fc96,progression,0.649265
uuid-e403b5995dda4809b81fded86212fc96,chemotherapy,0.383552
uuid-e403b5995dda4809b81fded86212fc96,respond,0.516649
uuid-e403b5995dda4809b81fded86212fc96,feels,0.343122
uuid-e403b5995dda4809b81fded86212fc96,option,0.569813
uuid-0efdd0bd962a475b80e183ca32c4610c,1L,0.420523
uuid-0efdd0bd962a475b80e183ca32c4610c,PDL1,0.339212
uuid-0efdd0bd962a475b80e183ca32c4610c,chemo,0.386931
uuid-0efdd0bd962a475b80e183ca32c4610c,tumor,0.380807
uuid-0efdd0bd962a475b80e183ca32c4610c,2L,0.304057
uuid-0efdd0bd962a475b80e183ca32c4610c,pts,0.341599
uuid-0efdd0bd962a475b80e183ca32c4610c,monotherapy,0.312335
uuid-0efdd0bd962a475b80e183ca32c4610c,believes,0.392471
uuid-0efdd0bd962a475b80e183ca32c4610c,feels,0.338093
uuid-0efdd0bd962a475b80e183ca32c4610c,option,0.434472
uuid-e7ba1c7d289a476d8739112fde8582bb,TL stated,0.408978
uuid-e7ba1c7d289a476d8739112fde8582bb,PD-L1,0.526956
uuid-e7ba1c7d289a476d8739112fde8582bb,PD-L1 testing,0.5354
uuid-e7ba1c7d289a476d8739112fde8582bb,testing,0.738292
uuid-e7ba1c7d289a476d8739112fde8582bb,PDL1 testing,0.712368
uuid-e7ba1c7d289a476d8739112fde8582bb,NSCLC patients,0.71105
uuid-e7ba1c7d289a476d8739112fde8582bb,tumor types,0.45336
uuid-e7ba1c7d289a476d8739112fde8582bb,biomarker,0.343366
uuid-24162b944e1847319c9749b53ea66181,PDL1,0.362401
uuid-24162b944e1847319c9749b53ea66181,PD-L1,0.372045
uuid-24162b944e1847319c9749b53ea66181,testing,0.34618
uuid-24162b944e1847319c9749b53ea66181,mentioned,0.313555
uuid-24162b944e1847319c9749b53ea66181,assay,0.300596
uuid-24162b944e1847319c9749b53ea66181,biomarker,0.32934
uuid-fd98160dd6964e83b016678c027e291d,TL,0.616741
uuid-fd98160dd6964e83b016678c027e291d,TL stated,0.375269
uuid-fd98160dd6964e83b016678c027e291d,institution,0.468698
uuid-fd98160dd6964e83b016678c027e291d,PD-L1,0.710782
uuid-fd98160dd6964e83b016678c027e291d,PD-L1 testing,0.945151
uuid-fd98160dd6964e83b016678c027e291d,testing,0.82037
uuid-fd98160dd6964e83b016678c027e291d,PDL1 testing,0.668093
uuid-fd98160dd6964e83b016678c027e291d,NSCLC patients,0.552795
uuid-fd98160dd6964e83b016678c027e291d,assay,0.678671
uuid-fd98160dd6964e83b016678c027e291d,biomarker,0.327869
uuid-ff969dc0faca45c09fc66b41235728b3,toxicity,0.431865
uuid-cedb68ac5a3047ec87f59ce20546f764,physicians,0.383878
uuid-155ab569787b4aafa8689580926c7649,toxicity,0.309099
uuid-155ab569787b4aafa8689580926c7649,efficacy,0.375319
uuid-155ab569787b4aafa8689580926c7649,regimen,0.403768
uuid-155ab569787b4aafa8689580926c7649,melanoma,0.318542
uuid-155ab569787b4aafa8689580926c7649,RCC,0.31367
uuid-155ab569787b4aafa8689580926c7649,combination,0.627573
uuid-155ab569787b4aafa8689580926c7649,chemo,0.374691
uuid-155ab569787b4aafa8689580926c7649,IO,0.353526
uuid-155ab569787b4aafa8689580926c7649,agents,0.348918
uuid-155ab569787b4aafa8689580926c7649,monotherapy,0.478225
uuid-155ab569787b4aafa8689580926c7649,response,0.350105
uuid-155ab569787b4aafa8689580926c7649,combo,0.630193
uuid-155ab569787b4aafa8689580926c7649,PD1,0.460268
uuid-155ab569787b4aafa8689580926c7649,believes,0.435892
uuid-155ab569787b4aafa8689580926c7649,chemotherapy,0.334082
uuid-155ab569787b4aafa8689580926c7649,impressed,0.363996
uuid-155ab569787b4aafa8689580926c7649,SCLC,0.335359
uuid-44ab9ee41c1b486891c81652c7df0fdb,NSCLC,0.341095
uuid-44ab9ee41c1b486891c81652c7df0fdb,1L,0.392826
uuid-44ab9ee41c1b486891c81652c7df0fdb,RCC,0.332813
uuid-44ab9ee41c1b486891c81652c7df0fdb,TL stated,0.397059
uuid-44ab9ee41c1b486891c81652c7df0fdb,IO,0.363124
uuid-44ab9ee41c1b486891c81652c7df0fdb,preferred,0.312435
uuid-44ab9ee41c1b486891c81652c7df0fdb,testing,0.301175
uuid-44ab9ee41c1b486891c81652c7df0fdb,PDL1 testing,0.503583
uuid-44ab9ee41c1b486891c81652c7df0fdb,NSCLC patients,0.493353
uuid-44ab9ee41c1b486891c81652c7df0fdb,lung cancer,0.347269
uuid-44ab9ee41c1b486891c81652c7df0fdb,tumor types,0.402276
uuid-44ab9ee41c1b486891c81652c7df0fdb,PD-1,0.436471
uuid-44ab9ee41c1b486891c81652c7df0fdb,RTL stated,0.356294
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,patients,0.357306
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,nivolumab,0.403921
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,treated,0.33237
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,commented,0.338217
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,RCC,0.358801
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,pts,0.360378
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,using nivo,0.440463
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,mentioned,0.337448
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,SCCHN,0.414758
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,ASCO,0.35034
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,impressed,0.435527
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,SCLC,0.764872
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,Regional TL,0.352484
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,RTL stated,0.38383
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,TL shared,0.316316
uuid-f2941984ba3b4e3c8ba8b5fbc2f24207,bladder,0.366228
uuid-e987ae9e4d374abcbcfb68ededbef53c,toxicity,0.627841
uuid-e987ae9e4d374abcbcfb68ededbef53c,regimen,0.46077
uuid-e987ae9e4d374abcbcfb68ededbef53c,combination,0.461625
uuid-e987ae9e4d374abcbcfb68ededbef53c,agents,0.334504
uuid-e987ae9e4d374abcbcfb68ededbef53c,combo,0.393865
uuid-46a244d954f1402fa859b024b7ac7c4d,patients,0.697755
uuid-46a244d954f1402fa859b024b7ac7c4d,Opdivo,0.338748
uuid-46a244d954f1402fa859b024b7ac7c4d,therapy,0.55005
uuid-46a244d954f1402fa859b024b7ac7c4d,nivolumab,0.51205
uuid-46a244d954f1402fa859b024b7ac7c4d,regimen,0.552207
uuid-46a244d954f1402fa859b024b7ac7c4d,treated,0.597
uuid-46a244d954f1402fa859b024b7ac7c4d,melanoma,0.483571
uuid-46a244d954f1402fa859b024b7ac7c4d,RCC,0.379649
uuid-46a244d954f1402fa859b024b7ac7c4d,pts,0.541358
uuid-46a244d954f1402fa859b024b7ac7c4d,monotherapy,0.364435
uuid-46a244d954f1402fa859b024b7ac7c4d,treatment,0.628592
uuid-46a244d954f1402fa859b024b7ac7c4d,using nivo,0.302632
uuid-46a244d954f1402fa859b024b7ac7c4d,response,0.490524
uuid-46a244d954f1402fa859b024b7ac7c4d,PD1,0.390156
uuid-46a244d954f1402fa859b024b7ac7c4d,cHL,0.391466
uuid-46a244d954f1402fa859b024b7ac7c4d,progression,0.680854
uuid-46a244d954f1402fa859b024b7ac7c4d,chemotherapy,0.354025
uuid-46a244d954f1402fa859b024b7ac7c4d,respond,0.459182
uuid-46a244d954f1402fa859b024b7ac7c4d,RTL stated,0.354789
uuid-46a244d954f1402fa859b024b7ac7c4d,TL shared,0.464943
uuid-2dcefe2a19124617be4576cd5ecd6b81,Nivo,0.372373
uuid-2dcefe2a19124617be4576cd5ecd6b81,pembro,0.304368
uuid-2dcefe2a19124617be4576cd5ecd6b81,dose,0.672801
uuid-2dcefe2a19124617be4576cd5ecd6b81,toxicity,0.503744
uuid-2dcefe2a19124617be4576cd5ecd6b81,efficacy,0.462516
uuid-2dcefe2a19124617be4576cd5ecd6b81,regimen,0.422655
uuid-2dcefe2a19124617be4576cd5ecd6b81,combination,0.373977
uuid-2dcefe2a19124617be4576cd5ecd6b81,Ipi,0.705479
uuid-2dcefe2a19124617be4576cd5ecd6b81,combo,0.418936
uuid-2dcefe2a19124617be4576cd5ecd6b81,vs,0.455539
uuid-2dcefe2a19124617be4576cd5ecd6b81,flat dosing,0.500428
uuid-51fd23f228db4c459e4f5c68baaa9710,patients,0.614118
uuid-51fd23f228db4c459e4f5c68baaa9710,toxicity,0.390764
uuid-51fd23f228db4c459e4f5c68baaa9710,regimen,0.468544
uuid-51fd23f228db4c459e4f5c68baaa9710,treated,0.460998
uuid-51fd23f228db4c459e4f5c68baaa9710,melanoma,0.306882
uuid-51fd23f228db4c459e4f5c68baaa9710,treatment,0.53511
uuid-51fd23f228db4c459e4f5c68baaa9710,progression,0.389186
uuid-51fd23f228db4c459e4f5c68baaa9710,TL shared,0.308764
uuid-e41cbd1b57284f6fad51e85743f7930a,RTL,0.365165
uuid-e41cbd1b57284f6fad51e85743f7930a,trial,0.348764
uuid-e41cbd1b57284f6fad51e85743f7930a,NTL,0.38944
uuid-e41cbd1b57284f6fad51e85743f7930a,OS,0.364762
uuid-e41cbd1b57284f6fad51e85743f7930a,data,0.500295
uuid-e41cbd1b57284f6fad51e85743f7930a,mentioned,0.5769
uuid-e41cbd1b57284f6fad51e85743f7930a,PFS,0.43437
uuid-e41cbd1b57284f6fad51e85743f7930a,ORR,0.327958
uuid-e41cbd1b57284f6fad51e85743f7930a,cHL,0.491352
uuid-e41cbd1b57284f6fad51e85743f7930a,impressed,0.359732
uuid-e41cbd1b57284f6fad51e85743f7930a,LTL,0.345324
uuid-dfe4c7778cab4caaba4585609dd65a4f,Nivo,0.4281
uuid-dfe4c7778cab4caaba4585609dd65a4f,patients,0.582942
uuid-dfe4c7778cab4caaba4585609dd65a4f,Opdivo,0.351826
uuid-dfe4c7778cab4caaba4585609dd65a4f,therapy,0.541168
uuid-dfe4c7778cab4caaba4585609dd65a4f,dose,0.412407
uuid-dfe4c7778cab4caaba4585609dd65a4f,nivolumab,0.447184
uuid-dfe4c7778cab4caaba4585609dd65a4f,regimen,0.457084
uuid-dfe4c7778cab4caaba4585609dd65a4f,combination,0.348115
uuid-dfe4c7778cab4caaba4585609dd65a4f,chemo,0.38255
uuid-dfe4c7778cab4caaba4585609dd65a4f,pts,0.378616
uuid-dfe4c7778cab4caaba4585609dd65a4f,Ipi,0.368363
uuid-dfe4c7778cab4caaba4585609dd65a4f,monotherapy,0.309825
uuid-dfe4c7778cab4caaba4585609dd65a4f,treatment,0.450611
uuid-dfe4c7778cab4caaba4585609dd65a4f,response,0.356587
uuid-dfe4c7778cab4caaba4585609dd65a4f,PD1,0.318448
uuid-dfe4c7778cab4caaba4585609dd65a4f,cHL,0.360243
uuid-dfe4c7778cab4caaba4585609dd65a4f,progression,0.447974
uuid-dfe4c7778cab4caaba4585609dd65a4f,chemotherapy,0.468005
uuid-dfe4c7778cab4caaba4585609dd65a4f,respond,0.308053
uuid-20241c71063f4bad8d5e711fe964e86a,RTL,0.344667
uuid-20241c71063f4bad8d5e711fe964e86a,BMS,0.611634
uuid-20241c71063f4bad8d5e711fe964e86a,trial,0.618805
uuid-20241c71063f4bad8d5e711fe964e86a,discussed,0.324871
uuid-20241c71063f4bad8d5e711fe964e86a,commented,0.508243
uuid-20241c71063f4bad8d5e711fe964e86a,Merck,0.503637
uuid-20241c71063f4bad8d5e711fe964e86a,stated,0.33301
uuid-20241c71063f4bad8d5e711fe964e86a,OS,0.443993
uuid-20241c71063f4bad8d5e711fe964e86a,regards,0.373878
uuid-20241c71063f4bad8d5e711fe964e86a,data,0.816976
uuid-20241c71063f4bad8d5e711fe964e86a,expressed,0.342986
uuid-20241c71063f4bad8d5e711fe964e86a,mentioned,0.365942
uuid-20241c71063f4bad8d5e711fe964e86a,indication,0.33188
uuid-20241c71063f4bad8d5e711fe964e86a,PFS,0.418526
uuid-20241c71063f4bad8d5e711fe964e86a,ORR,0.467072
uuid-20241c71063f4bad8d5e711fe964e86a,nivo and pembro,0.317879
uuid-20241c71063f4bad8d5e711fe964e86a,ASCO,0.380755
uuid-20241c71063f4bad8d5e711fe964e86a,impressed,0.599084
uuid-20241c71063f4bad8d5e711fe964e86a,LTL,0.311678
uuid-20241c71063f4bad8d5e711fe964e86a,feels,0.325712
uuid-6a5de2e0da5e4239bfea7251f90b17de,patients,0.471251
uuid-6a5de2e0da5e4239bfea7251f90b17de,Opdivo,0.506597
uuid-6a5de2e0da5e4239bfea7251f90b17de,nivolumab,0.489085
uuid-6a5de2e0da5e4239bfea7251f90b17de,treated,0.371731
uuid-6a5de2e0da5e4239bfea7251f90b17de,approval,0.36027
uuid-6a5de2e0da5e4239bfea7251f90b17de,preferred,0.414299
uuid-6a5de2e0da5e4239bfea7251f90b17de,treatment,0.377404
uuid-6a5de2e0da5e4239bfea7251f90b17de,using nivo,0.412504
uuid-6a5de2e0da5e4239bfea7251f90b17de,approved,0.444539
uuid-6a5de2e0da5e4239bfea7251f90b17de,HCP,0.310958
uuid-6a5de2e0da5e4239bfea7251f90b17de,RTL stated,0.307708
uuid-45b03eab5cba42d483b473b8880374bd,pembro,0.327545
uuid-45b03eab5cba42d483b473b8880374bd,BMS,0.310276
uuid-45b03eab5cba42d483b473b8880374bd,PDL1,0.722513
uuid-45b03eab5cba42d483b473b8880374bd,trial,0.316428
uuid-45b03eab5cba42d483b473b8880374bd,Merck,0.523355
uuid-45b03eab5cba42d483b473b8880374bd,PD-L1,0.640529
uuid-45b03eab5cba42d483b473b8880374bd,atezo,0.350339
uuid-45b03eab5cba42d483b473b8880374bd,PD-L1 testing,0.410642
uuid-45b03eab5cba42d483b473b8880374bd,testing,0.56701
uuid-45b03eab5cba42d483b473b8880374bd,data,0.368405
uuid-45b03eab5cba42d483b473b8880374bd,PDL1 testing,0.404337
uuid-45b03eab5cba42d483b473b8880374bd,nivo and pembro,0.452857
uuid-45b03eab5cba42d483b473b8880374bd,assay,0.64651
uuid-45b03eab5cba42d483b473b8880374bd,PDL1 expression,0.658231
uuid-45b03eab5cba42d483b473b8880374bd,biomarker,0.701639
uuid-98162abca59845d3ab28146feb76f3d6,Nivo,0.602392
uuid-98162abca59845d3ab28146feb76f3d6,patients,0.72864
uuid-98162abca59845d3ab28146feb76f3d6,pembro,0.33274
uuid-98162abca59845d3ab28146feb76f3d6,therapy,0.568074
uuid-98162abca59845d3ab28146feb76f3d6,nivolumab,0.387783
uuid-98162abca59845d3ab28146feb76f3d6,1L,0.469598
uuid-98162abca59845d3ab28146feb76f3d6,regimen,0.419062
uuid-98162abca59845d3ab28146feb76f3d6,chemo,0.580766
uuid-98162abca59845d3ab28146feb76f3d6,2L,0.46556
uuid-98162abca59845d3ab28146feb76f3d6,pts,0.580066
uuid-98162abca59845d3ab28146feb76f3d6,preferred,0.388285
uuid-98162abca59845d3ab28146feb76f3d6,monotherapy,0.619897
uuid-98162abca59845d3ab28146feb76f3d6,treatment,0.446079
uuid-98162abca59845d3ab28146feb76f3d6,using nivo,0.446937
uuid-98162abca59845d3ab28146feb76f3d6,response,0.318873
uuid-98162abca59845d3ab28146feb76f3d6,combo,0.340381
uuid-98162abca59845d3ab28146feb76f3d6,PD1,0.488513
uuid-98162abca59845d3ab28146feb76f3d6,progression,0.532981
uuid-98162abca59845d3ab28146feb76f3d6,believes,0.316407
uuid-98162abca59845d3ab28146feb76f3d6,chemotherapy,0.505902
uuid-98162abca59845d3ab28146feb76f3d6,respond,0.453798
uuid-98162abca59845d3ab28146feb76f3d6,feels,0.39003
uuid-98162abca59845d3ab28146feb76f3d6,option,0.613842
uuid-7bac4e164a37498dbe8de009849bc4f0,patients,0.321178
uuid-7bac4e164a37498dbe8de009849bc4f0,therapy,0.460173
uuid-7bac4e164a37498dbe8de009849bc4f0,nivolumab,0.313118
uuid-7bac4e164a37498dbe8de009849bc4f0,regimen,0.338415
uuid-7bac4e164a37498dbe8de009849bc4f0,treated,0.408146
uuid-7bac4e164a37498dbe8de009849bc4f0,pts,0.356282
uuid-7bac4e164a37498dbe8de009849bc4f0,treatment,0.502696
uuid-7bac4e164a37498dbe8de009849bc4f0,response,0.40933
uuid-7bac4e164a37498dbe8de009849bc4f0,progression,0.555576
uuid-7bac4e164a37498dbe8de009849bc4f0,respond,0.31946
uuid-ed7fb46d15fa4cb5aded81f5b5e9b02b,physicians,0.427978
uuid-0030270f27b7453f9d0d3021312912c0,Nivo,0.334025
uuid-0030270f27b7453f9d0d3021312912c0,pembro,0.337388
uuid-0030270f27b7453f9d0d3021312912c0,therapy,0.442668
uuid-0030270f27b7453f9d0d3021312912c0,nivolumab,0.416036
uuid-0030270f27b7453f9d0d3021312912c0,1L,0.654808
uuid-0030270f27b7453f9d0d3021312912c0,regimen,0.306375
uuid-0030270f27b7453f9d0d3021312912c0,RCC,0.378162
uuid-0030270f27b7453f9d0d3021312912c0,combination,0.496593
uuid-0030270f27b7453f9d0d3021312912c0,chemo,0.413301
uuid-0030270f27b7453f9d0d3021312912c0,2L,0.752506
uuid-0030270f27b7453f9d0d3021312912c0,agents,0.708304
uuid-0030270f27b7453f9d0d3021312912c0,atezo,0.414692
uuid-0030270f27b7453f9d0d3021312912c0,preferred,0.764996
uuid-0030270f27b7453f9d0d3021312912c0,monotherapy,0.698009
uuid-0030270f27b7453f9d0d3021312912c0,treatment,0.309896
uuid-0030270f27b7453f9d0d3021312912c0,using nivo,0.517411
uuid-0030270f27b7453f9d0d3021312912c0,combo,0.46722
uuid-0030270f27b7453f9d0d3021312912c0,PD1,0.527598
uuid-0030270f27b7453f9d0d3021312912c0,approved,0.484098
uuid-0030270f27b7453f9d0d3021312912c0,believes,0.321197
uuid-0030270f27b7453f9d0d3021312912c0,chemotherapy,0.362687
uuid-0030270f27b7453f9d0d3021312912c0,PD-1,0.499251
uuid-0030270f27b7453f9d0d3021312912c0,RTL stated,0.469356
uuid-0030270f27b7453f9d0d3021312912c0,option,0.695443
uuid-0b586bb7ffa149b4ba84e28d47b1a359,Nivo,0.383051
uuid-0b586bb7ffa149b4ba84e28d47b1a359,pembro,0.364957
uuid-0b586bb7ffa149b4ba84e28d47b1a359,RTL,0.300608
uuid-0b586bb7ffa149b4ba84e28d47b1a359,1L,0.510887
uuid-0b586bb7ffa149b4ba84e28d47b1a359,RCC,0.55237
uuid-0b586bb7ffa149b4ba84e28d47b1a359,combination,0.344232
uuid-0b586bb7ffa149b4ba84e28d47b1a359,2L,0.587303
uuid-0b586bb7ffa149b4ba84e28d47b1a359,agents,0.414195
uuid-0b586bb7ffa149b4ba84e28d47b1a359,stated,0.366783
uuid-0b586bb7ffa149b4ba84e28d47b1a359,approval,0.317409
uuid-0b586bb7ffa149b4ba84e28d47b1a359,atezo,0.418036
uuid-0b586bb7ffa149b4ba84e28d47b1a359,preferred,0.520909
uuid-0b586bb7ffa149b4ba84e28d47b1a359,monotherapy,0.479882
uuid-0b586bb7ffa149b4ba84e28d47b1a359,using nivo,0.532454
uuid-0b586bb7ffa149b4ba84e28d47b1a359,data,0.385951
uuid-0b586bb7ffa149b4ba84e28d47b1a359,combo,0.438274
uuid-0b586bb7ffa149b4ba84e28d47b1a359,indication,0.333981
uuid-0b586bb7ffa149b4ba84e28d47b1a359,approved,0.488225
uuid-0b586bb7ffa149b4ba84e28d47b1a359,SCCHN,0.467015
uuid-0b586bb7ffa149b4ba84e28d47b1a359,impressed,0.437673
uuid-0b586bb7ffa149b4ba84e28d47b1a359,LTL,0.323698
uuid-0b586bb7ffa149b4ba84e28d47b1a359,TLs,0.389446
uuid-0b586bb7ffa149b4ba84e28d47b1a359,SCLC,0.308069
uuid-0b586bb7ffa149b4ba84e28d47b1a359,feels,0.388474
uuid-0b586bb7ffa149b4ba84e28d47b1a359,Regional TL,0.38077
uuid-0b586bb7ffa149b4ba84e28d47b1a359,RTL stated,0.497159
uuid-0b586bb7ffa149b4ba84e28d47b1a359,option,0.483598
uuid-0b586bb7ffa149b4ba84e28d47b1a359,bladder,0.399108
uuid-83e237ea01874e539f1f35fcec6d1a52,TL,0.355532
uuid-83e237ea01874e539f1f35fcec6d1a52,PDL1,0.528044
uuid-83e237ea01874e539f1f35fcec6d1a52,PD-L1,0.814941
uuid-83e237ea01874e539f1f35fcec6d1a52,PD-L1 testing,0.704698
uuid-83e237ea01874e539f1f35fcec6d1a52,testing,0.837659
uuid-83e237ea01874e539f1f35fcec6d1a52,PDL1 testing,0.575598
uuid-83e237ea01874e539f1f35fcec6d1a52,NSCLC patients,0.572841
uuid-83e237ea01874e539f1f35fcec6d1a52,assay,0.679755
uuid-83e237ea01874e539f1f35fcec6d1a52,PDL1 expression,0.383159
uuid-83e237ea01874e539f1f35fcec6d1a52,biomarker,0.666869
uuid-703668e8d29043a1ad30f9d0b44f9563,BMS,0.533753
uuid-703668e8d29043a1ad30f9d0b44f9563,trial,0.770253
uuid-703668e8d29043a1ad30f9d0b44f9563,Merck,0.420776
uuid-703668e8d29043a1ad30f9d0b44f9563,OS,0.36762
uuid-703668e8d29043a1ad30f9d0b44f9563,data,0.522004
uuid-703668e8d29043a1ad30f9d0b44f9563,clinical trials,0.305718
uuid-703668e8d29043a1ad30f9d0b44f9563,PFS,0.379175
uuid-703668e8d29043a1ad30f9d0b44f9563,ORR,0.410239
uuid-703668e8d29043a1ad30f9d0b44f9563,impressed,0.413974
uuid-703668e8d29043a1ad30f9d0b44f9563,feels,0.331283
uuid-77823c4a7d5147b99f3d7b608830f1a6,lung,0.419168
uuid-77823c4a7d5147b99f3d7b608830f1a6,NSCLC,0.594257
uuid-77823c4a7d5147b99f3d7b608830f1a6,1L,0.472775
uuid-77823c4a7d5147b99f3d7b608830f1a6,melanoma,0.553525
uuid-77823c4a7d5147b99f3d7b608830f1a6,RCC,0.504634
uuid-77823c4a7d5147b99f3d7b608830f1a6,TL stated,0.33526
uuid-77823c4a7d5147b99f3d7b608830f1a6,combination,0.314844
uuid-77823c4a7d5147b99f3d7b608830f1a6,2L,0.463305
uuid-77823c4a7d5147b99f3d7b608830f1a6,IO,0.400809
uuid-77823c4a7d5147b99f3d7b608830f1a6,preferred,0.376087
uuid-77823c4a7d5147b99f3d7b608830f1a6,monotherapy,0.457914
uuid-77823c4a7d5147b99f3d7b608830f1a6,combo,0.447293
uuid-77823c4a7d5147b99f3d7b608830f1a6,PD1,0.385573
uuid-77823c4a7d5147b99f3d7b608830f1a6,SCCHN,0.340207
uuid-77823c4a7d5147b99f3d7b608830f1a6,believes,0.347503
uuid-77823c4a7d5147b99f3d7b608830f1a6,academic,0.304533
uuid-77823c4a7d5147b99f3d7b608830f1a6,SCLC,0.318986
uuid-77823c4a7d5147b99f3d7b608830f1a6,RTL stated,0.483368
uuid-77823c4a7d5147b99f3d7b608830f1a6,TL shared,0.441898
uuid-77823c4a7d5147b99f3d7b608830f1a6,option,0.361166
uuid-9662ca9fd5ef4522aef268a784be3038,patients,0.643719
uuid-9662ca9fd5ef4522aef268a784be3038,Opdivo,0.623591
uuid-9662ca9fd5ef4522aef268a784be3038,therapy,0.3674
uuid-9662ca9fd5ef4522aef268a784be3038,dose,0.495097
uuid-9662ca9fd5ef4522aef268a784be3038,nivolumab,0.301649
uuid-9662ca9fd5ef4522aef268a784be3038,toxicity,0.479884
uuid-9662ca9fd5ef4522aef268a784be3038,regimen,0.597767
uuid-9662ca9fd5ef4522aef268a784be3038,treated,0.371924
uuid-9662ca9fd5ef4522aef268a784be3038,pts,0.401618
uuid-9662ca9fd5ef4522aef268a784be3038,treatment,0.602185
uuid-9662ca9fd5ef4522aef268a784be3038,progression,0.516178
uuid-9662ca9fd5ef4522aef268a784be3038,respond,0.534578
uuid-94b8bf033afb47989c55356302e7df79,patients,0.601252
uuid-94b8bf033afb47989c55356302e7df79,pembro,0.362211
uuid-94b8bf033afb47989c55356302e7df79,1L,0.563988
uuid-94b8bf033afb47989c55356302e7df79,RCC,0.350747
uuid-94b8bf033afb47989c55356302e7df79,TL stated,0.454268
uuid-94b8bf033afb47989c55356302e7df79,2L,0.570467
uuid-94b8bf033afb47989c55356302e7df79,pts,0.439984
uuid-94b8bf033afb47989c55356302e7df79,PD-L1,0.375393
uuid-94b8bf033afb47989c55356302e7df79,approval,0.370103
uuid-94b8bf033afb47989c55356302e7df79,atezo,0.340568
uuid-94b8bf033afb47989c55356302e7df79,preferred,0.542428
uuid-94b8bf033afb47989c55356302e7df79,PD-L1 testing,0.382193
uuid-94b8bf033afb47989c55356302e7df79,testing,0.533985
uuid-94b8bf033afb47989c55356302e7df79,monotherapy,0.391697
uuid-94b8bf033afb47989c55356302e7df79,using nivo,0.525577
uuid-94b8bf033afb47989c55356302e7df79,PDL1 testing,0.587827
uuid-94b8bf033afb47989c55356302e7df79,NSCLC patients,0.716121
uuid-94b8bf033afb47989c55356302e7df79,approved,0.381298
uuid-94b8bf033afb47989c55356302e7df79,SCCHN,0.304686
uuid-94b8bf033afb47989c55356302e7df79,tumor types,0.450416
uuid-94b8bf033afb47989c55356302e7df79,RTL stated,0.444335
uuid-94b8bf033afb47989c55356302e7df79,option,0.480138
uuid-109c5787f89842f09646a88c2201e403,Nivo,0.430341
uuid-109c5787f89842f09646a88c2201e403,patients,0.532586
uuid-109c5787f89842f09646a88c2201e403,pembro,0.348041
uuid-109c5787f89842f09646a88c2201e403,therapy,0.454441
uuid-109c5787f89842f09646a88c2201e403,nivolumab,0.421766
uuid-109c5787f89842f09646a88c2201e403,1L,0.393543
uuid-109c5787f89842f09646a88c2201e403,trial,0.431165
uuid-109c5787f89842f09646a88c2201e403,regimen,0.369872
uuid-109c5787f89842f09646a88c2201e403,treated,0.304445
uuid-109c5787f89842f09646a88c2201e403,combination,0.539338
uuid-109c5787f89842f09646a88c2201e403,chemo,0.498421
uuid-109c5787f89842f09646a88c2201e403,2L,0.337963
uuid-109c5787f89842f09646a88c2201e403,pts,0.480199
uuid-109c5787f89842f09646a88c2201e403,Ipi,0.304058
uuid-109c5787f89842f09646a88c2201e403,preferred,0.357369
uuid-109c5787f89842f09646a88c2201e403,monotherapy,0.526052
uuid-109c5787f89842f09646a88c2201e403,treatment,0.33718
uuid-109c5787f89842f09646a88c2201e403,using nivo,0.392347
uuid-109c5787f89842f09646a88c2201e403,combo,0.509431
uuid-109c5787f89842f09646a88c2201e403,clinical trials,0.399774
uuid-109c5787f89842f09646a88c2201e403,PD1,0.396782
uuid-109c5787f89842f09646a88c2201e403,approved,0.364477
uuid-109c5787f89842f09646a88c2201e403,progression,0.377035
uuid-109c5787f89842f09646a88c2201e403,chemotherapy,0.515849
uuid-109c5787f89842f09646a88c2201e403,feels,0.397204
uuid-109c5787f89842f09646a88c2201e403,option,0.550863
uuid-e2fa8b006bc7409ea9ba314f98c75a48,TL,0.555467
uuid-e2fa8b006bc7409ea9ba314f98c75a48,PDL1,0.301494
uuid-e2fa8b006bc7409ea9ba314f98c75a48,TL stated,0.519446
uuid-e2fa8b006bc7409ea9ba314f98c75a48,institution,0.385832
uuid-e2fa8b006bc7409ea9ba314f98c75a48,PD-L1,0.767992
uuid-e2fa8b006bc7409ea9ba314f98c75a48,PD-L1 testing,0.819068
uuid-e2fa8b006bc7409ea9ba314f98c75a48,testing,0.888354
uuid-e2fa8b006bc7409ea9ba314f98c75a48,PDL1 testing,0.796517
uuid-e2fa8b006bc7409ea9ba314f98c75a48,NSCLC patients,0.73125
uuid-e2fa8b006bc7409ea9ba314f98c75a48,tumor types,0.316535
uuid-e2fa8b006bc7409ea9ba314f98c75a48,assay,0.601852
uuid-e2fa8b006bc7409ea9ba314f98c75a48,biomarker,0.376184
uuid-b0e021490a994531a4d51c7f98ea07bc,BMS,0.547513
uuid-b0e021490a994531a4d51c7f98ea07bc,PDL1,0.415586
uuid-b0e021490a994531a4d51c7f98ea07bc,trial,0.305306
uuid-b0e021490a994531a4d51c7f98ea07bc,commented,0.464128
uuid-b0e021490a994531a4d51c7f98ea07bc,Merck,0.544574
uuid-b0e021490a994531a4d51c7f98ea07bc,stated,0.456703
uuid-b0e021490a994531a4d51c7f98ea07bc,regards,0.372802
uuid-b0e021490a994531a4d51c7f98ea07bc,data,0.573098
uuid-b0e021490a994531a4d51c7f98ea07bc,expressed,0.38095
uuid-b0e021490a994531a4d51c7f98ea07bc,indication,0.346804
uuid-b0e021490a994531a4d51c7f98ea07bc,SCCHN,0.316522
uuid-b0e021490a994531a4d51c7f98ea07bc,nivo and pembro,0.337456
uuid-b0e021490a994531a4d51c7f98ea07bc,impressed,0.355572
uuid-b0e021490a994531a4d51c7f98ea07bc,label,0.310123
uuid-b0e021490a994531a4d51c7f98ea07bc,PDL1 expression,0.347839
uuid-b0e021490a994531a4d51c7f98ea07bc,NCCN,0.581663
uuid-2b7dd87eb8e749618c4eff784c74e142,pembro,0.468025
uuid-2b7dd87eb8e749618c4eff784c74e142,BMS,0.344635
uuid-2b7dd87eb8e749618c4eff784c74e142,1L,0.325354
uuid-2b7dd87eb8e749618c4eff784c74e142,PDL1,0.682542
uuid-2b7dd87eb8e749618c4eff784c74e142,trial,0.34096
uuid-2b7dd87eb8e749618c4eff784c74e142,efficacy,0.554776
uuid-2b7dd87eb8e749618c4eff784c74e142,OS,0.600628
uuid-2b7dd87eb8e749618c4eff784c74e142,atezo,0.408347
uuid-2b7dd87eb8e749618c4eff784c74e142,regards,0.315026
uuid-2b7dd87eb8e749618c4eff784c74e142,data,0.601902
uuid-2b7dd87eb8e749618c4eff784c74e142,PFS,0.605214
uuid-2b7dd87eb8e749618c4eff784c74e142,ORR,0.589154
uuid-2b7dd87eb8e749618c4eff784c74e142,nivo and pembro,0.764016
uuid-2b7dd87eb8e749618c4eff784c74e142,believes,0.547403
uuid-2b7dd87eb8e749618c4eff784c74e142,impressed,0.367801
uuid-2b7dd87eb8e749618c4eff784c74e142,feels,0.52062
uuid-2b7dd87eb8e749618c4eff784c74e142,PDL1 expression,0.554925
uuid-2b7dd87eb8e749618c4eff784c74e142,biomarker,0.302204
uuid-00523dd84a034a9fbea2341fe49e8202,patients,0.702554
uuid-00523dd84a034a9fbea2341fe49e8202,therapy,0.495255
uuid-00523dd84a034a9fbea2341fe49e8202,nivolumab,0.342755
uuid-00523dd84a034a9fbea2341fe49e8202,1L,0.315724
uuid-00523dd84a034a9fbea2341fe49e8202,toxicity,0.422255
uuid-00523dd84a034a9fbea2341fe49e8202,regimen,0.642725
uuid-00523dd84a034a9fbea2341fe49e8202,treated,0.413118
uuid-00523dd84a034a9fbea2341fe49e8202,combination,0.473394
uuid-00523dd84a034a9fbea2341fe49e8202,chemo,0.597624
uuid-00523dd84a034a9fbea2341fe49e8202,pts,0.674515
uuid-00523dd84a034a9fbea2341fe49e8202,IO,0.390224
uuid-00523dd84a034a9fbea2341fe49e8202,monotherapy,0.632129
uuid-00523dd84a034a9fbea2341fe49e8202,treatment,0.586618
uuid-00523dd84a034a9fbea2341fe49e8202,response,0.572943
uuid-00523dd84a034a9fbea2341fe49e8202,combo,0.492549
uuid-00523dd84a034a9fbea2341fe49e8202,PD1,0.47445
uuid-00523dd84a034a9fbea2341fe49e8202,progression,0.6471
uuid-00523dd84a034a9fbea2341fe49e8202,chemotherapy,0.533673
uuid-00523dd84a034a9fbea2341fe49e8202,respond,0.516183
uuid-00523dd84a034a9fbea2341fe49e8202,feels,0.310617
uuid-00523dd84a034a9fbea2341fe49e8202,option,0.544477
uuid-46bf3494683c409ca21fa61986006728,TL,0.461603
uuid-46bf3494683c409ca21fa61986006728,PDL1,0.467873
uuid-46bf3494683c409ca21fa61986006728,Merck,0.457919
uuid-46bf3494683c409ca21fa61986006728,institution,0.465423
uuid-46bf3494683c409ca21fa61986006728,PD-L1,0.654368
uuid-46bf3494683c409ca21fa61986006728,PD-L1 testing,0.668532
uuid-46bf3494683c409ca21fa61986006728,testing,0.688809
uuid-46bf3494683c409ca21fa61986006728,PDL1 testing,0.499568
uuid-46bf3494683c409ca21fa61986006728,AI,0.438407
uuid-46bf3494683c409ca21fa61986006728,NSCLC patients,0.319199
uuid-46bf3494683c409ca21fa61986006728,assay,0.849358
uuid-46bf3494683c409ca21fa61986006728,PDL1 expression,0.31173
uuid-46bf3494683c409ca21fa61986006728,biomarker,0.417444
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,patients,0.592629
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,Opdivo,0.331111
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,therapy,0.485677
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,nivolumab,0.374277
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,regimen,0.377232
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,treated,0.436813
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,chemo,0.306928
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,pts,0.41775
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,preferred,0.317296
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,monotherapy,0.369953
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,treatment,0.532275
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,using nivo,0.345621
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,progression,0.45253
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,chemotherapy,0.336829
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,respond,0.376293
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,RTL stated,0.30755
uuid-3c2101b1eeb342de85f39d1b8ed3ea00,option,0.416219
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,patients,0.624756
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,Opdivo,0.386668
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,therapy,0.305189
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,nivolumab,0.415464
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,toxicity,0.309897
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,regimen,0.49756
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,treated,0.616065
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,pts,0.41404
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,physicians,0.330258
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,treatment,0.450513
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,progression,0.438695
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,oncologist,0.327392
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,indicated,0.34546
uuid-7483ee7af3d6402584dbc1c74b1fd8b8,respond,0.385839
uuid-518fc8e1574541239a2eb043121d489d,Opdivo,0.390603
uuid-518fc8e1574541239a2eb043121d489d,pembro,0.300058
uuid-518fc8e1574541239a2eb043121d489d,nivolumab,0.334753
uuid-518fc8e1574541239a2eb043121d489d,shared,0.332223
uuid-518fc8e1574541239a2eb043121d489d,RCC,0.379853
uuid-518fc8e1574541239a2eb043121d489d,2L,0.408702
uuid-518fc8e1574541239a2eb043121d489d,stated,0.39191
uuid-518fc8e1574541239a2eb043121d489d,approval,0.495841
uuid-518fc8e1574541239a2eb043121d489d,atezo,0.384866
uuid-518fc8e1574541239a2eb043121d489d,preferred,0.433588
uuid-518fc8e1574541239a2eb043121d489d,using nivo,0.504615
uuid-518fc8e1574541239a2eb043121d489d,clinical trials,0.371046
uuid-518fc8e1574541239a2eb043121d489d,indication,0.475186
uuid-518fc8e1574541239a2eb043121d489d,approved,0.528573
uuid-518fc8e1574541239a2eb043121d489d,SCCHN,0.484828
uuid-518fc8e1574541239a2eb043121d489d,label,0.425403
uuid-518fc8e1574541239a2eb043121d489d,LTL,0.344875
uuid-518fc8e1574541239a2eb043121d489d,TLs,0.333206
uuid-518fc8e1574541239a2eb043121d489d,Regional TL,0.357291
uuid-518fc8e1574541239a2eb043121d489d,RTL stated,0.521344
uuid-518fc8e1574541239a2eb043121d489d,bladder,0.626253
uuid-518fc8e1574541239a2eb043121d489d,flat dosing,0.355281
uuid-499a33c68b4f470ea3c773fded3f6980,patients,0.488469
uuid-499a33c68b4f470ea3c773fded3f6980,Opdivo,0.458863
uuid-499a33c68b4f470ea3c773fded3f6980,dose,0.564679
uuid-499a33c68b4f470ea3c773fded3f6980,toxicity,0.43672
uuid-499a33c68b4f470ea3c773fded3f6980,regimen,0.411069
uuid-499a33c68b4f470ea3c773fded3f6980,treatment,0.442487
uuid-499a33c68b4f470ea3c773fded3f6980,progression,0.402483
uuid-499a33c68b4f470ea3c773fded3f6980,respond,0.324051
uuid-499a33c68b4f470ea3c773fded3f6980,drug,0.317642
uuid-499a33c68b4f470ea3c773fded3f6980,flat dosing,0.383204
uuid-90f7e7bb16f64003aab3c0d3faeba0e0,patients,0.678071
uuid-90f7e7bb16f64003aab3c0d3faeba0e0,Opdivo,0.398569
uuid-90f7e7bb16f64003aab3c0d3faeba0e0,toxicity,0.519825
uuid-90f7e7bb16f64003aab3c0d3faeba0e0,regimen,0.515291
uuid-90f7e7bb16f64003aab3c0d3faeba0e0,treated,0.603264
uuid-90f7e7bb16f64003aab3c0d3faeba0e0,physicians,0.349266
uuid-90f7e7bb16f64003aab3c0d3faeba0e0,treatment,0.651603
uuid-90f7e7bb16f64003aab3c0d3faeba0e0,progression,0.46009
uuid-90f7e7bb16f64003aab3c0d3faeba0e0,respond,0.511064
uuid-abd4586eb0734bf9bf984d334af9b324,RTL,0.325249
uuid-abd4586eb0734bf9bf984d334af9b324,lung,0.515707
uuid-abd4586eb0734bf9bf984d334af9b324,NTL,0.3898
uuid-abd4586eb0734bf9bf984d334af9b324,melanoma,0.523645
uuid-abd4586eb0734bf9bf984d334af9b324,shared,0.386174
uuid-abd4586eb0734bf9bf984d334af9b324,RCC,0.373288
uuid-abd4586eb0734bf9bf984d334af9b324,TL stated,0.342019
uuid-abd4586eb0734bf9bf984d334af9b324,institution,0.305455
uuid-abd4586eb0734bf9bf984d334af9b324,AI,0.320588
uuid-abd4586eb0734bf9bf984d334af9b324,SCCHN,0.412342
uuid-abd4586eb0734bf9bf984d334af9b324,Regional TL,0.363632
uuid-abd4586eb0734bf9bf984d334af9b324,TL shared,0.383708
uuid-abd4586eb0734bf9bf984d334af9b324,bladder,0.341722
uuid-abd4586eb0734bf9bf984d334af9b324,flat dosing,0.310694
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,Nivo,0.446628
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,pembro,0.497679
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,1L,0.500084
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,PDL1,0.437758
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,efficacy,0.541837
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,combination,0.353486
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,chemo,0.502936
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,2L,0.440484
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,agents,0.478099
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,Ipi,0.309998
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,OS,0.448046
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,atezo,0.458332
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,preferred,0.306063
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,monotherapy,0.513174
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,data,0.32648
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,combo,0.509759
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,PFS,0.405067
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,PD1,0.367824
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,ORR,0.448256
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,nivo and pembro,0.704912
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,believes,0.607882
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,chemotherapy,0.326742
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,vs,0.336272
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,feels,0.494789
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,PDL1 expression,0.367942
uuid-b680bdd6a0d642ec8af0d9d5e56dbe5a,option,0.407205
uuid-c4f0a3bce08f47e59209a1e8741e1573,BMS,0.462824
uuid-c4f0a3bce08f47e59209a1e8741e1573,PDL1,0.359223
uuid-c4f0a3bce08f47e59209a1e8741e1573,trial,0.462651
uuid-c4f0a3bce08f47e59209a1e8741e1573,efficacy,0.51593
uuid-c4f0a3bce08f47e59209a1e8741e1573,OS,0.581662
uuid-c4f0a3bce08f47e59209a1e8741e1573,data,0.618243
uuid-c4f0a3bce08f47e59209a1e8741e1573,PFS,0.57135
uuid-c4f0a3bce08f47e59209a1e8741e1573,ORR,0.56609
uuid-c4f0a3bce08f47e59209a1e8741e1573,nivo and pembro,0.330276
uuid-c4f0a3bce08f47e59209a1e8741e1573,believes,0.371389
uuid-c4f0a3bce08f47e59209a1e8741e1573,impressed,0.454358
uuid-c4f0a3bce08f47e59209a1e8741e1573,feels,0.464495
uuid-c4f0a3bce08f47e59209a1e8741e1573,PDL1 expression,0.31167
uuid-dfc15a0034df42d98ae2024338bea3ab,pembro,0.552632
uuid-dfc15a0034df42d98ae2024338bea3ab,1L,0.591452
uuid-dfc15a0034df42d98ae2024338bea3ab,PDL1,0.421882
uuid-dfc15a0034df42d98ae2024338bea3ab,RCC,0.362704
uuid-dfc15a0034df42d98ae2024338bea3ab,TL stated,0.319282
uuid-dfc15a0034df42d98ae2024338bea3ab,2L,0.598294
uuid-dfc15a0034df42d98ae2024338bea3ab,approval,0.35423
uuid-dfc15a0034df42d98ae2024338bea3ab,atezo,0.509365
uuid-dfc15a0034df42d98ae2024338bea3ab,preferred,0.488279
uuid-dfc15a0034df42d98ae2024338bea3ab,monotherapy,0.317513
uuid-dfc15a0034df42d98ae2024338bea3ab,using nivo,0.464864
uuid-dfc15a0034df42d98ae2024338bea3ab,PDL1 testing,0.414829
uuid-dfc15a0034df42d98ae2024338bea3ab,indication,0.437034
uuid-dfc15a0034df42d98ae2024338bea3ab,NSCLC patients,0.345213
uuid-dfc15a0034df42d98ae2024338bea3ab,approved,0.454264
uuid-dfc15a0034df42d98ae2024338bea3ab,nivo and pembro,0.412672
uuid-dfc15a0034df42d98ae2024338bea3ab,believes,0.303184
uuid-dfc15a0034df42d98ae2024338bea3ab,tumor types,0.382918
uuid-dfc15a0034df42d98ae2024338bea3ab,label,0.366364
uuid-dfc15a0034df42d98ae2024338bea3ab,feels,0.325319
uuid-dfc15a0034df42d98ae2024338bea3ab,RTL stated,0.341313
uuid-dfc15a0034df42d98ae2024338bea3ab,PDL1 expression,0.400141
uuid-dfc15a0034df42d98ae2024338bea3ab,option,0.436544
uuid-dfc15a0034df42d98ae2024338bea3ab,bladder,0.312432
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,RTL,0.430145
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,BMS,0.565987
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,PDL1,0.415331
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,trial,0.625657
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,efficacy,0.409
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,commented,0.540115
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,Merck,0.514335
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,stated,0.389324
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,OS,0.553884
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,regards,0.367505
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,data,0.90617
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,expressed,0.428675
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,PFS,0.532941
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,ORR,0.590197
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,nivo and pembro,0.382401
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,ASCO,0.413262
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,impressed,0.669485
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,LTL,0.307847
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,TLs,0.303312
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,Regional TL,0.324471
uuid-2a119f5d32d94e10b5ef1a6c03e60f5d,PDL1 expression,0.399505
uuid-ebee3c949e984170be8ee07820b228fc,RTL,0.353412
uuid-ebee3c949e984170be8ee07820b228fc,BMS,0.468346
uuid-ebee3c949e984170be8ee07820b228fc,PDL1,0.306642
uuid-ebee3c949e984170be8ee07820b228fc,trial,0.690746
uuid-ebee3c949e984170be8ee07820b228fc,efficacy,0.363067
uuid-ebee3c949e984170be8ee07820b228fc,commented,0.484809
uuid-ebee3c949e984170be8ee07820b228fc,Merck,0.430151
uuid-ebee3c949e984170be8ee07820b228fc,OS,0.496343
uuid-ebee3c949e984170be8ee07820b228fc,regards,0.387589
uuid-ebee3c949e984170be8ee07820b228fc,data,0.684509
uuid-ebee3c949e984170be8ee07820b228fc,expressed,0.361563
uuid-ebee3c949e984170be8ee07820b228fc,clinical trials,0.300734
uuid-ebee3c949e984170be8ee07820b228fc,PFS,0.508383
uuid-ebee3c949e984170be8ee07820b228fc,ORR,0.55907
uuid-ebee3c949e984170be8ee07820b228fc,nivo and pembro,0.361824
uuid-ebee3c949e984170be8ee07820b228fc,ASCO,0.319364
uuid-ebee3c949e984170be8ee07820b228fc,impressed,0.578216
uuid-ebee3c949e984170be8ee07820b228fc,PDL1 expression,0.315939
uuid-04b72a83b3a34f15b17f9bb2671ca885,Nivo,0.453025
uuid-04b72a83b3a34f15b17f9bb2671ca885,pembro,0.604772
uuid-04b72a83b3a34f15b17f9bb2671ca885,RTL,0.525373
uuid-04b72a83b3a34f15b17f9bb2671ca885,NTL,0.336203
uuid-04b72a83b3a34f15b17f9bb2671ca885,2L,0.382066
uuid-04b72a83b3a34f15b17f9bb2671ca885,Ipi,0.445655
uuid-04b72a83b3a34f15b17f9bb2671ca885,approval,0.35547
uuid-04b72a83b3a34f15b17f9bb2671ca885,atezo,0.554405
uuid-04b72a83b3a34f15b17f9bb2671ca885,preferred,0.384161
uuid-04b72a83b3a34f15b17f9bb2671ca885,using nivo,0.644743
uuid-04b72a83b3a34f15b17f9bb2671ca885,mentioned,0.510847
uuid-04b72a83b3a34f15b17f9bb2671ca885,indication,0.322535
uuid-04b72a83b3a34f15b17f9bb2671ca885,SCCHN,0.442698
uuid-04b72a83b3a34f15b17f9bb2671ca885,HCP,0.619414
uuid-04b72a83b3a34f15b17f9bb2671ca885,vs,0.386083
uuid-04b72a83b3a34f15b17f9bb2671ca885,LTL,0.520306
uuid-04b72a83b3a34f15b17f9bb2671ca885,TLs,0.366053
uuid-04b72a83b3a34f15b17f9bb2671ca885,SCLC,0.3691
uuid-04b72a83b3a34f15b17f9bb2671ca885,Regional TL,0.36355
uuid-04b72a83b3a34f15b17f9bb2671ca885,RTL stated,0.393484
uuid-04b72a83b3a34f15b17f9bb2671ca885,bladder,0.361313
uuid-965fda16de9e4578aa52280f1bd08f7f,patients,0.773478
uuid-965fda16de9e4578aa52280f1bd08f7f,Opdivo,0.378323
uuid-965fda16de9e4578aa52280f1bd08f7f,therapy,0.423541
uuid-965fda16de9e4578aa52280f1bd08f7f,nivolumab,0.313057
uuid-965fda16de9e4578aa52280f1bd08f7f,regimen,0.431239
uuid-965fda16de9e4578aa52280f1bd08f7f,treated,0.6434
uuid-965fda16de9e4578aa52280f1bd08f7f,pts,0.553723
uuid-965fda16de9e4578aa52280f1bd08f7f,treatment,0.706126
uuid-965fda16de9e4578aa52280f1bd08f7f,response,0.381733
uuid-965fda16de9e4578aa52280f1bd08f7f,progression,0.687661
uuid-965fda16de9e4578aa52280f1bd08f7f,respond,0.541796
uuid-4514d9f16672429291d4970bb0f56214,oncology,0.47017
uuid-4514d9f16672429291d4970bb0f56214,drug,0.474627
uuid-4514d9f16672429291d4970bb0f56214,Keytruda,0.322712
uuid-4514d9f16672429291d4970bb0f56214,clinical,0.453839
uuid-4514d9f16672429291d4970bb0f56214,flat dosing,0.356706
uuid-043c67a06b964c10b127e6c7b2398549,RTL,0.697286
uuid-043c67a06b964c10b127e6c7b2398549,BMS,0.316627
uuid-043c67a06b964c10b127e6c7b2398549,trial,0.460169
uuid-043c67a06b964c10b127e6c7b2398549,NTL,0.551372
uuid-043c67a06b964c10b127e6c7b2398549,discussed,0.34022
uuid-043c67a06b964c10b127e6c7b2398549,commented,0.59574
uuid-043c67a06b964c10b127e6c7b2398549,stated,0.416802
uuid-043c67a06b964c10b127e6c7b2398549,OS,0.413227
uuid-043c67a06b964c10b127e6c7b2398549,data,0.714731
uuid-043c67a06b964c10b127e6c7b2398549,expressed,0.511757
uuid-043c67a06b964c10b127e6c7b2398549,mentioned,0.628508
uuid-043c67a06b964c10b127e6c7b2398549,PFS,0.379771
uuid-043c67a06b964c10b127e6c7b2398549,ORR,0.408329
uuid-043c67a06b964c10b127e6c7b2398549,SCCHN,0.368333
uuid-043c67a06b964c10b127e6c7b2398549,HCP,0.557244
uuid-043c67a06b964c10b127e6c7b2398549,ASCO,0.55348
uuid-043c67a06b964c10b127e6c7b2398549,impressed,0.668534
uuid-043c67a06b964c10b127e6c7b2398549,LTL,0.536044
uuid-043c67a06b964c10b127e6c7b2398549,SCLC,0.368039
uuid-043c67a06b964c10b127e6c7b2398549,Regional TL,0.491256
uuid-8910c348c3954772840b58342a498352,RTL,0.478932
uuid-8910c348c3954772840b58342a498352,BMS,0.397226
uuid-8910c348c3954772840b58342a498352,trial,0.660687
uuid-8910c348c3954772840b58342a498352,NTL,0.317411
uuid-8910c348c3954772840b58342a498352,shared,0.33917
uuid-8910c348c3954772840b58342a498352,commented,0.335158
uuid-8910c348c3954772840b58342a498352,Merck,0.306002
uuid-8910c348c3954772840b58342a498352,stated,0.440442
uuid-8910c348c3954772840b58342a498352,clinical trials,0.521842
uuid-8910c348c3954772840b58342a498352,impressed,0.345811
uuid-8910c348c3954772840b58342a498352,LTL,0.302334
uuid-8910c348c3954772840b58342a498352,Regional TL,0.402066
uuid-5b3c1e6e6fb4447c92e71a682da55027,lung,0.376875
uuid-5b3c1e6e6fb4447c92e71a682da55027,1L,0.365777
uuid-5b3c1e6e6fb4447c92e71a682da55027,melanoma,0.324732
uuid-5b3c1e6e6fb4447c92e71a682da55027,combination,0.391656
uuid-5b3c1e6e6fb4447c92e71a682da55027,chemo,0.307233
uuid-5b3c1e6e6fb4447c92e71a682da55027,2L,0.374207
uuid-5b3c1e6e6fb4447c92e71a682da55027,agents,0.427352
uuid-5b3c1e6e6fb4447c92e71a682da55027,monotherapy,0.373675
uuid-5b3c1e6e6fb4447c92e71a682da55027,combo,0.48761
uuid-5b3c1e6e6fb4447c92e71a682da55027,AI,0.630491
uuid-5b3c1e6e6fb4447c92e71a682da55027,nivo and pembro,0.418443
uuid-5b3c1e6e6fb4447c92e71a682da55027,believes,0.413274
uuid-5b3c1e6e6fb4447c92e71a682da55027,option,0.318764
uuid-3657340004e2480182c36e40ebf93b7a,Nivo,0.322641
uuid-3657340004e2480182c36e40ebf93b7a,1L,0.308882
uuid-3657340004e2480182c36e40ebf93b7a,efficacy,0.341444
uuid-3657340004e2480182c36e40ebf93b7a,regimen,0.324372
uuid-3657340004e2480182c36e40ebf93b7a,OS,0.596256
uuid-3657340004e2480182c36e40ebf93b7a,monotherapy,0.382846
uuid-3657340004e2480182c36e40ebf93b7a,data,0.47925
uuid-3657340004e2480182c36e40ebf93b7a,PFS,0.480318
uuid-3657340004e2480182c36e40ebf93b7a,ORR,0.46335
uuid-3657340004e2480182c36e40ebf93b7a,impressed,0.50968
uuid-3657340004e2480182c36e40ebf93b7a,feels,0.397019
uuid-3657340004e2480182c36e40ebf93b7a,option,0.346904
uuid-2a6e8942df5d489f99c5f2343b23826d,patients,0.546356
uuid-2a6e8942df5d489f99c5f2343b23826d,Opdivo,0.312682
uuid-2a6e8942df5d489f99c5f2343b23826d,treated,0.529137
uuid-2a6e8942df5d489f99c5f2343b23826d,pts,0.348705
uuid-2a6e8942df5d489f99c5f2343b23826d,physicians,0.30124
uuid-2a6e8942df5d489f99c5f2343b23826d,PD-L1 testing,0.330718
uuid-2a6e8942df5d489f99c5f2343b23826d,testing,0.310026
uuid-2a6e8942df5d489f99c5f2343b23826d,treatment,0.394156
uuid-2a6e8942df5d489f99c5f2343b23826d,PDL1 testing,0.318928
uuid-2a6e8942df5d489f99c5f2343b23826d,NSCLC patients,0.406632
uuid-2a6e8942df5d489f99c5f2343b23826d,lung cancer,0.419729
uuid-2a6e8942df5d489f99c5f2343b23826d,progression,0.355224
uuid-2a6e8942df5d489f99c5f2343b23826d,respond,0.303336
uuid-81062618c5fe41e989b1282b4b16b32e,patients,0.351409
uuid-81062618c5fe41e989b1282b4b16b32e,therapy,0.41282
uuid-81062618c5fe41e989b1282b4b16b32e,treatment,0.470334
uuid-81062618c5fe41e989b1282b4b16b32e,response,0.313738
uuid-81062618c5fe41e989b1282b4b16b32e,PD1,0.328331
uuid-81062618c5fe41e989b1282b4b16b32e,progression,0.533541
uuid-81062618c5fe41e989b1282b4b16b32e,chemotherapy,0.320829
uuid-81062618c5fe41e989b1282b4b16b32e,respond,0.312052
uuid-044db80e69ee40b492b52547c5fc2f67,patients,0.459228
uuid-044db80e69ee40b492b52547c5fc2f67,1L,0.640791
uuid-044db80e69ee40b492b52547c5fc2f67,PDL1,0.391604
uuid-044db80e69ee40b492b52547c5fc2f67,RCC,0.392539
uuid-044db80e69ee40b492b52547c5fc2f67,TL stated,0.492258
uuid-044db80e69ee40b492b52547c5fc2f67,2L,0.56798
uuid-044db80e69ee40b492b52547c5fc2f67,pts,0.469464
uuid-044db80e69ee40b492b52547c5fc2f67,PD-L1,0.440599
uuid-044db80e69ee40b492b52547c5fc2f67,preferred,0.375885
uuid-044db80e69ee40b492b52547c5fc2f67,PD-L1 testing,0.330395
uuid-044db80e69ee40b492b52547c5fc2f67,testing,0.521506
uuid-044db80e69ee40b492b52547c5fc2f67,monotherapy,0.394294
uuid-044db80e69ee40b492b52547c5fc2f67,using nivo,0.425178
uuid-044db80e69ee40b492b52547c5fc2f67,PDL1 testing,0.599786
uuid-044db80e69ee40b492b52547c5fc2f67,NSCLC patients,0.638389
uuid-044db80e69ee40b492b52547c5fc2f67,approved,0.321983
uuid-044db80e69ee40b492b52547c5fc2f67,tumor types,0.510128
uuid-044db80e69ee40b492b52547c5fc2f67,RTL stated,0.410061
uuid-044db80e69ee40b492b52547c5fc2f67,TL shared,0.309702
uuid-044db80e69ee40b492b52547c5fc2f67,option,0.490674
uuid-044db80e69ee40b492b52547c5fc2f67,biomarker,0.333226
uuid-044db80e69ee40b492b52547c5fc2f67,bladder,0.311425
uuid-6c156e0f5384412d86d6f9c3157e379d,patients,0.322386
uuid-6c156e0f5384412d86d6f9c3157e379d,Opdivo,0.533807
uuid-6c156e0f5384412d86d6f9c3157e379d,dose,0.659977
uuid-6c156e0f5384412d86d6f9c3157e379d,oncology,0.325349
uuid-6c156e0f5384412d86d6f9c3157e379d,drug,0.408986
uuid-6c156e0f5384412d86d6f9c3157e379d,Keytruda,0.426338
uuid-6c156e0f5384412d86d6f9c3157e379d,flat dosing,0.753459
uuid-df401b92620f44c18cb0d860d1382f83,Opdivo,0.71545
uuid-df401b92620f44c18cb0d860d1382f83,physicians,0.346922
uuid-df401b92620f44c18cb0d860d1382f83,Keytruda,0.375043
uuid-f8f6a5480aa24201a10fbc73f3e5081c,oncology,0.477607
uuid-f8f6a5480aa24201a10fbc73f3e5081c,label,0.304894
uuid-f8f6a5480aa24201a10fbc73f3e5081c,flat dosing,0.373177
uuid-262c0d766c79410c829cfa4ff244ddef,patients,0.432953
uuid-262c0d766c79410c829cfa4ff244ddef,therapy,0.306978
uuid-262c0d766c79410c829cfa4ff244ddef,nivolumab,0.319354
uuid-262c0d766c79410c829cfa4ff244ddef,1L,0.418245
uuid-262c0d766c79410c829cfa4ff244ddef,regimen,0.325998
uuid-262c0d766c79410c829cfa4ff244ddef,treated,0.33029
uuid-262c0d766c79410c829cfa4ff244ddef,RCC,0.353348
uuid-262c0d766c79410c829cfa4ff244ddef,2L,0.472987
uuid-262c0d766c79410c829cfa4ff244ddef,agents,0.311633
uuid-262c0d766c79410c829cfa4ff244ddef,preferred,0.728325
uuid-262c0d766c79410c829cfa4ff244ddef,monotherapy,0.474009
uuid-262c0d766c79410c829cfa4ff244ddef,treatment,0.350465
uuid-262c0d766c79410c829cfa4ff244ddef,using nivo,0.507779
uuid-262c0d766c79410c829cfa4ff244ddef,SCCHN,0.43467
uuid-262c0d766c79410c829cfa4ff244ddef,chemotherapy,0.32065
uuid-262c0d766c79410c829cfa4ff244ddef,RTL stated,0.55156
uuid-262c0d766c79410c829cfa4ff244ddef,TL shared,0.365436
uuid-262c0d766c79410c829cfa4ff244ddef,option,0.601443
uuid-004e4232d7434e65a9d6c3f9e11cb655,Nivo,0.318096
uuid-004e4232d7434e65a9d6c3f9e11cb655,patients,0.688442
uuid-004e4232d7434e65a9d6c3f9e11cb655,therapy,0.538649
uuid-004e4232d7434e65a9d6c3f9e11cb655,nivolumab,0.327694
uuid-004e4232d7434e65a9d6c3f9e11cb655,toxicity,0.500261
uuid-004e4232d7434e65a9d6c3f9e11cb655,regimen,0.625511
uuid-004e4232d7434e65a9d6c3f9e11cb655,treated,0.489785
uuid-004e4232d7434e65a9d6c3f9e11cb655,chemo,0.440514
uuid-004e4232d7434e65a9d6c3f9e11cb655,pts,0.480925
uuid-004e4232d7434e65a9d6c3f9e11cb655,monotherapy,0.395393
uuid-004e4232d7434e65a9d6c3f9e11cb655,treatment,0.724448
uuid-004e4232d7434e65a9d6c3f9e11cb655,response,0.464416
uuid-004e4232d7434e65a9d6c3f9e11cb655,PD1,0.355429
uuid-004e4232d7434e65a9d6c3f9e11cb655,progression,0.63139
uuid-004e4232d7434e65a9d6c3f9e11cb655,chemotherapy,0.426657
uuid-004e4232d7434e65a9d6c3f9e11cb655,respond,0.652407
uuid-004e4232d7434e65a9d6c3f9e11cb655,option,0.308748
uuid-26332585cd524dcd91664c20b59e60be,Opdivo,0.423003
uuid-26332585cd524dcd91664c20b59e60be,therapy,0.356878
uuid-26332585cd524dcd91664c20b59e60be,nivolumab,0.459665
uuid-26332585cd524dcd91664c20b59e60be,approval,0.407167
uuid-26332585cd524dcd91664c20b59e60be,physicians,0.322338
uuid-26332585cd524dcd91664c20b59e60be,using nivo,0.30298
uuid-26332585cd524dcd91664c20b59e60be,mentioned,0.481854
uuid-26332585cd524dcd91664c20b59e60be,cHL,0.730958
uuid-26332585cd524dcd91664c20b59e60be,label,0.306157
uuid-26332585cd524dcd91664c20b59e60be,LTL,0.305294
uuid-2d5afdefee5e4ec5b3e5b3dcf2df3d8a,TL,0.478068
uuid-2d5afdefee5e4ec5b3e5b3dcf2df3d8a,RTL,0.459065
uuid-2d5afdefee5e4ec5b3e5b3dcf2df3d8a,lung,0.324735
uuid-2d5afdefee5e4ec5b3e5b3dcf2df3d8a,NTL,0.526022
uuid-2d5afdefee5e4ec5b3e5b3dcf2df3d8a,melanoma,0.341069
uuid-2d5afdefee5e4ec5b3e5b3dcf2df3d8a,shared,0.361968
uuid-2d5afdefee5e4ec5b3e5b3dcf2df3d8a,TL stated,0.302414
uuid-2d5afdefee5e4ec5b3e5b3dcf2df3d8a,institution,0.363527
uuid-2d5afdefee5e4ec5b3e5b3dcf2df3d8a,SCCHN,0.363408
uuid-2d5afdefee5e4ec5b3e5b3dcf2df3d8a,academic,0.342745
uuid-2d5afdefee5e4ec5b3e5b3dcf2df3d8a,Regional TL,0.410024
uuid-8d787d19974044ddb1356d01e9c9b55e,TL,0.329451
uuid-8d787d19974044ddb1356d01e9c9b55e,1L,0.440217
uuid-8d787d19974044ddb1356d01e9c9b55e,PDL1,0.533248
uuid-8d787d19974044ddb1356d01e9c9b55e,TL stated,0.431495
uuid-8d787d19974044ddb1356d01e9c9b55e,2L,0.319086
uuid-8d787d19974044ddb1356d01e9c9b55e,Merck,0.313588
uuid-8d787d19974044ddb1356d01e9c9b55e,PD-L1,0.569251
uuid-8d787d19974044ddb1356d01e9c9b55e,PD-L1 testing,0.420795
uuid-8d787d19974044ddb1356d01e9c9b55e,testing,0.592909
uuid-8d787d19974044ddb1356d01e9c9b55e,PDL1 testing,0.548026
uuid-8d787d19974044ddb1356d01e9c9b55e,NSCLC patients,0.494392
uuid-8d787d19974044ddb1356d01e9c9b55e,believes,0.386835
uuid-8d787d19974044ddb1356d01e9c9b55e,tumor types,0.413173
uuid-8d787d19974044ddb1356d01e9c9b55e,feels,0.308571
uuid-8d787d19974044ddb1356d01e9c9b55e,assay,0.384368
uuid-8d787d19974044ddb1356d01e9c9b55e,PDL1 expression,0.355408
uuid-8d787d19974044ddb1356d01e9c9b55e,biomarker,0.522355
uuid-4bfb3cacc39741469e509de819420109,PDL1,0.38296
uuid-4bfb3cacc39741469e509de819420109,efficacy,0.315582
uuid-4bfb3cacc39741469e509de819420109,agents,0.510517
uuid-4bfb3cacc39741469e509de819420109,PD-L1,0.390907
uuid-4bfb3cacc39741469e509de819420109,atezo,0.326989
uuid-4bfb3cacc39741469e509de819420109,PDL1 testing,0.3183
uuid-4bfb3cacc39741469e509de819420109,nivo and pembro,0.351185
uuid-4bfb3cacc39741469e509de819420109,believes,0.344205
uuid-4bfb3cacc39741469e509de819420109,assay,0.307483
uuid-4bfb3cacc39741469e509de819420109,PD-1,0.435775
uuid-4bfb3cacc39741469e509de819420109,PDL1 expression,0.31066
uuid-4bfb3cacc39741469e509de819420109,biomarker,0.368695
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,patients,0.598302
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,Opdivo,0.633649
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,nivolumab,0.489736
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,regimen,0.321064
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,treated,0.472553
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,RCC,0.3542
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,pts,0.32465
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,approval,0.506719
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,physicians,0.341147
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,preferred,0.32213
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,treatment,0.389617
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,using nivo,0.493971
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,clinical trials,0.371214
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,indication,0.32551
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,approved,0.419405
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,SCCHN,0.444275
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,HCP,0.357476
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,label,0.342754
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,Regional TL,0.339437
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,RTL stated,0.405113
uuid-4e7abdcb3ec64892b77b8fd4f88065ed,bladder,0.469276
uuid-10e7cf2584164853893b1d45db0dccfa,patients,0.603123
uuid-10e7cf2584164853893b1d45db0dccfa,therapy,0.385458
uuid-10e7cf2584164853893b1d45db0dccfa,nivolumab,0.340389
uuid-10e7cf2584164853893b1d45db0dccfa,1L,0.303114
uuid-10e7cf2584164853893b1d45db0dccfa,regimen,0.307447
uuid-10e7cf2584164853893b1d45db0dccfa,treated,0.335363
uuid-10e7cf2584164853893b1d45db0dccfa,RCC,0.336268
uuid-10e7cf2584164853893b1d45db0dccfa,2L,0.333464
uuid-10e7cf2584164853893b1d45db0dccfa,pts,0.406585
uuid-10e7cf2584164853893b1d45db0dccfa,monotherapy,0.366376
uuid-10e7cf2584164853893b1d45db0dccfa,treatment,0.44167
uuid-10e7cf2584164853893b1d45db0dccfa,using nivo,0.366128
uuid-10e7cf2584164853893b1d45db0dccfa,NSCLC patients,0.344362
uuid-10e7cf2584164853893b1d45db0dccfa,progression,0.460853
uuid-10e7cf2584164853893b1d45db0dccfa,respond,0.373133
uuid-10e7cf2584164853893b1d45db0dccfa,RTL stated,0.344445
uuid-10e7cf2584164853893b1d45db0dccfa,TL shared,0.362042
uuid-10e7cf2584164853893b1d45db0dccfa,option,0.408757
uuid-3af7683b309b4a9fb15c591af547c147,therapy,0.333066
uuid-3af7683b309b4a9fb15c591af547c147,nivolumab,0.395468
uuid-3af7683b309b4a9fb15c591af547c147,combination,0.317472
uuid-3af7683b309b4a9fb15c591af547c147,IO,0.45697
uuid-3af7683b309b4a9fb15c591af547c147,physicians,0.352931
uuid-3af7683b309b4a9fb15c591af547c147,preferred,0.387625
uuid-3af7683b309b4a9fb15c591af547c147,monotherapy,0.324353
uuid-3af7683b309b4a9fb15c591af547c147,using nivo,0.312368
uuid-3af7683b309b4a9fb15c591af547c147,option,0.378199
uuid-3986cdd5023d4508beacd01ee3b30ed5,preferred,0.333677
uuid-3986cdd5023d4508beacd01ee3b30ed5,SCCHN,0.315571
uuid-3986cdd5023d4508beacd01ee3b30ed5,feels,0.31289
uuid-3986cdd5023d4508beacd01ee3b30ed5,RTL stated,0.375419
uuid-ead93cab11104bd28ec9bf987022de58,Nivo,0.419072
uuid-ead93cab11104bd28ec9bf987022de58,patients,0.789515
uuid-ead93cab11104bd28ec9bf987022de58,therapy,0.588063
uuid-ead93cab11104bd28ec9bf987022de58,nivolumab,0.396487
uuid-ead93cab11104bd28ec9bf987022de58,regimen,0.486428
uuid-ead93cab11104bd28ec9bf987022de58,treated,0.556219
uuid-ead93cab11104bd28ec9bf987022de58,chemo,0.491882
uuid-ead93cab11104bd28ec9bf987022de58,pts,0.586538
uuid-ead93cab11104bd28ec9bf987022de58,monotherapy,0.41855
uuid-ead93cab11104bd28ec9bf987022de58,treatment,0.625501
uuid-ead93cab11104bd28ec9bf987022de58,response,0.433053
uuid-ead93cab11104bd28ec9bf987022de58,PD1,0.391805
uuid-ead93cab11104bd28ec9bf987022de58,cHL,0.310416
uuid-ead93cab11104bd28ec9bf987022de58,progression,0.59431
uuid-ead93cab11104bd28ec9bf987022de58,chemotherapy,0.457529
uuid-ead93cab11104bd28ec9bf987022de58,respond,0.656797
uuid-ead93cab11104bd28ec9bf987022de58,option,0.349001
uuid-f72e5b38da484940b4edee8cdff18ec5,patients,0.400649
uuid-f72e5b38da484940b4edee8cdff18ec5,Opdivo,0.534034
uuid-f72e5b38da484940b4edee8cdff18ec5,RTL,0.371396
uuid-f72e5b38da484940b4edee8cdff18ec5,nivolumab,0.383419
uuid-f72e5b38da484940b4edee8cdff18ec5,regimen,0.360611
uuid-f72e5b38da484940b4edee8cdff18ec5,treated,0.631922
uuid-f72e5b38da484940b4edee8cdff18ec5,shared,0.365993
uuid-f72e5b38da484940b4edee8cdff18ec5,commented,0.33771
uuid-f72e5b38da484940b4edee8cdff18ec5,stated,0.303254
uuid-f72e5b38da484940b4edee8cdff18ec5,physicians,0.559072
uuid-f72e5b38da484940b4edee8cdff18ec5,treatment,0.370607
uuid-f72e5b38da484940b4edee8cdff18ec5,SCCHN,0.368202
uuid-f72e5b38da484940b4edee8cdff18ec5,HCP,0.504098
uuid-f72e5b38da484940b4edee8cdff18ec5,lung cancer,0.386646
uuid-f72e5b38da484940b4edee8cdff18ec5,LTL,0.411099
uuid-f72e5b38da484940b4edee8cdff18ec5,academic,0.313921
uuid-f72e5b38da484940b4edee8cdff18ec5,Regional TL,0.478624
uuid-f72e5b38da484940b4edee8cdff18ec5,RTL stated,0.353944
uuid-f72e5b38da484940b4edee8cdff18ec5,TL shared,0.337354
uuid-a84d9cee2c5f40f4b2a0344881486c82,Nivo,0.553057
uuid-a84d9cee2c5f40f4b2a0344881486c82,patients,0.752538
uuid-a84d9cee2c5f40f4b2a0344881486c82,Opdivo,0.525759
uuid-a84d9cee2c5f40f4b2a0344881486c82,therapy,0.484793
uuid-a84d9cee2c5f40f4b2a0344881486c82,dose,0.522791
uuid-a84d9cee2c5f40f4b2a0344881486c82,nivolumab,0.45125
uuid-a84d9cee2c5f40f4b2a0344881486c82,toxicity,0.361624
uuid-a84d9cee2c5f40f4b2a0344881486c82,regimen,0.386146
uuid-a84d9cee2c5f40f4b2a0344881486c82,treated,0.317318
uuid-a84d9cee2c5f40f4b2a0344881486c82,pts,0.386344
uuid-a84d9cee2c5f40f4b2a0344881486c82,Ipi,0.364417
uuid-a84d9cee2c5f40f4b2a0344881486c82,treatment,0.457421
uuid-a84d9cee2c5f40f4b2a0344881486c82,using nivo,0.33396
uuid-a84d9cee2c5f40f4b2a0344881486c82,cHL,0.422764
uuid-a84d9cee2c5f40f4b2a0344881486c82,progression,0.407563
uuid-a84d9cee2c5f40f4b2a0344881486c82,chemotherapy,0.31961
uuid-a84d9cee2c5f40f4b2a0344881486c82,vs,0.335536
uuid-a84d9cee2c5f40f4b2a0344881486c82,respond,0.415954
uuid-b5005b642bb341059a4f4f0cde7e96ff,oncology,0.558872
uuid-b5005b642bb341059a4f4f0cde7e96ff,clinical,0.365838
uuid-c2849819a41b487abcd656a9f80ddc32,institution,0.326608
uuid-c2849819a41b487abcd656a9f80ddc32,indication,0.347403
uuid-c2849819a41b487abcd656a9f80ddc32,AI,0.451148
uuid-c2849819a41b487abcd656a9f80ddc32,oncology,0.356146
uuid-c2849819a41b487abcd656a9f80ddc32,approved,0.325081
uuid-c2849819a41b487abcd656a9f80ddc32,label,0.44701
uuid-c2849819a41b487abcd656a9f80ddc32,drug,0.332202
uuid-c2849819a41b487abcd656a9f80ddc32,NCCN,0.421155
uuid-c2849819a41b487abcd656a9f80ddc32,flat dosing,0.395337
uuid-160e88e588e846b28bb03bf6b2b21856,physicians,0.317505
uuid-160e88e588e846b28bb03bf6b2b21856,oncology,0.5053
uuid-160e88e588e846b28bb03bf6b2b21856,drug,0.340838
uuid-160e88e588e846b28bb03bf6b2b21856,clinical,0.353975
uuid-160e88e588e846b28bb03bf6b2b21856,flat dosing,0.318965
uuid-af599411d7b349e1abbcfc6663242061,toxicity,0.558799
uuid-af599411d7b349e1abbcfc6663242061,regimen,0.431765
uuid-af599411d7b349e1abbcfc6663242061,treated,0.355759
uuid-af599411d7b349e1abbcfc6663242061,melanoma,0.378258
uuid-af599411d7b349e1abbcfc6663242061,RTL stated,0.330477
uuid-af599411d7b349e1abbcfc6663242061,TL shared,0.455218
uuid-bc88f7dcda904937b775985cb8401bac,patients,0.328878
uuid-bc88f7dcda904937b775985cb8401bac,Opdivo,0.465131
uuid-bc88f7dcda904937b775985cb8401bac,dose,0.767262
uuid-bc88f7dcda904937b775985cb8401bac,nivolumab,0.317225
uuid-bc88f7dcda904937b775985cb8401bac,toxicity,0.392259
uuid-bc88f7dcda904937b775985cb8401bac,regimen,0.304614
uuid-bc88f7dcda904937b775985cb8401bac,Ipi,0.416665
uuid-bc88f7dcda904937b775985cb8401bac,HCP,0.336319
uuid-bc88f7dcda904937b775985cb8401bac,vs,0.420027
uuid-bc88f7dcda904937b775985cb8401bac,flat dosing,0.752062
uuid-7c56134ea6304b20b29343544886892d,Nivo,0.309043
uuid-7c56134ea6304b20b29343544886892d,patients,0.719835
uuid-7c56134ea6304b20b29343544886892d,Opdivo,0.368263
uuid-7c56134ea6304b20b29343544886892d,therapy,0.596486
uuid-7c56134ea6304b20b29343544886892d,nivolumab,0.543578
uuid-7c56134ea6304b20b29343544886892d,treated,0.598122
uuid-7c56134ea6304b20b29343544886892d,pts,0.367023
uuid-7c56134ea6304b20b29343544886892d,treatment,0.492892
uuid-7c56134ea6304b20b29343544886892d,using nivo,0.47661
uuid-7c56134ea6304b20b29343544886892d,cHL,0.661737
uuid-7c56134ea6304b20b29343544886892d,progression,0.399133
uuid-7c56134ea6304b20b29343544886892d,RTL stated,0.367778
uuid-0e47035179784c2b8c260e934f976e74,1L,0.305909
uuid-0e47035179784c2b8c260e934f976e74,PDL1,0.636371
uuid-0e47035179784c2b8c260e934f976e74,efficacy,0.388409
uuid-0e47035179784c2b8c260e934f976e74,combination,0.328718
uuid-0e47035179784c2b8c260e934f976e74,chemo,0.30969
uuid-0e47035179784c2b8c260e934f976e74,agents,0.513517
uuid-0e47035179784c2b8c260e934f976e74,PD-L1,0.457616
uuid-0e47035179784c2b8c260e934f976e74,monotherapy,0.357159
uuid-0e47035179784c2b8c260e934f976e74,PD1,0.421083
uuid-0e47035179784c2b8c260e934f976e74,nivo and pembro,0.460701
uuid-0e47035179784c2b8c260e934f976e74,believes,0.460117
uuid-0e47035179784c2b8c260e934f976e74,feels,0.308029
uuid-0e47035179784c2b8c260e934f976e74,assay,0.359356
uuid-0e47035179784c2b8c260e934f976e74,PD-1,0.541075
uuid-0e47035179784c2b8c260e934f976e74,PDL1 expression,0.385727
uuid-0e47035179784c2b8c260e934f976e74,biomarker,0.474793
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,Nivo,0.53805
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,patients,0.638924
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,therapy,0.522633
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,nivolumab,0.417272
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,toxicity,0.362277
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,regimen,0.516857
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,treated,0.393773
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,chemo,0.52735
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,2L,0.30839
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,pts,0.51382
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,monotherapy,0.490651
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,treatment,0.539465
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,using nivo,0.387805
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,response,0.348921
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,PD1,0.419598
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,progression,0.534477
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,chemotherapy,0.465912
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,respond,0.507147
uuid-75df18d6d71b4a0e8b6d23745a79ef0e,option,0.41305
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,PDL1,0.596992
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,PD-L1,0.493788
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,testing,0.421272
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,data,0.357227
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,PDL1 testing,0.366763
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,PFS,0.307143
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,NSCLC patients,0.362195
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,nivo and pembro,0.343393
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,believes,0.325684
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,feels,0.315675
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,assay,0.305005
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,PDL1 expression,0.51372
uuid-3bec7e9328b94722ba061bc3a4a1b4e6,biomarker,0.446046
uuid-ecce59781a874fa69514f977f0c041a3,patients,0.37708
uuid-ecce59781a874fa69514f977f0c041a3,Opdivo,0.497816
uuid-ecce59781a874fa69514f977f0c041a3,dose,0.381064
uuid-ecce59781a874fa69514f977f0c041a3,nivolumab,0.339384
uuid-ecce59781a874fa69514f977f0c041a3,toxicity,0.345685
uuid-ecce59781a874fa69514f977f0c041a3,regimen,0.342117
uuid-ecce59781a874fa69514f977f0c041a3,RCC,0.389251
uuid-ecce59781a874fa69514f977f0c041a3,preferred,0.372359
uuid-ecce59781a874fa69514f977f0c041a3,using nivo,0.475262
uuid-ecce59781a874fa69514f977f0c041a3,approved,0.327783
uuid-ecce59781a874fa69514f977f0c041a3,HCP,0.335309
uuid-ecce59781a874fa69514f977f0c041a3,label,0.318456
uuid-ecce59781a874fa69514f977f0c041a3,Keytruda,0.30993
uuid-ecce59781a874fa69514f977f0c041a3,flat dosing,0.393966
uuid-7ce4e9e06843496799d16772e6dac5f3,Opdivo,0.426339
uuid-7ce4e9e06843496799d16772e6dac5f3,dose,0.471131
uuid-7ce4e9e06843496799d16772e6dac5f3,preferred,0.408798
uuid-7ce4e9e06843496799d16772e6dac5f3,indication,0.353426
uuid-7ce4e9e06843496799d16772e6dac5f3,drug,0.418206
uuid-7ce4e9e06843496799d16772e6dac5f3,Keytruda,0.57754
uuid-7ce4e9e06843496799d16772e6dac5f3,flat dosing,0.568261
uuid-d118c11efebf4d9891601f9654d99278,Nivo,0.353917
uuid-d118c11efebf4d9891601f9654d99278,lung,0.379576
uuid-d118c11efebf4d9891601f9654d99278,1L,0.370968
uuid-d118c11efebf4d9891601f9654d99278,melanoma,0.399659
uuid-d118c11efebf4d9891601f9654d99278,chemo,0.32197
uuid-d118c11efebf4d9891601f9654d99278,2L,0.374664
uuid-d118c11efebf4d9891601f9654d99278,monotherapy,0.335718
uuid-d118c11efebf4d9891601f9654d99278,AI,0.393325
uuid-d118c11efebf4d9891601f9654d99278,believes,0.316433
uuid-d118c11efebf4d9891601f9654d99278,option,0.402351
uuid-76070237307145129748195a777db535,TL,0.446624
uuid-76070237307145129748195a777db535,TL stated,0.377625
uuid-76070237307145129748195a777db535,Merck,0.321622
uuid-76070237307145129748195a777db535,PD-L1,0.578831
uuid-76070237307145129748195a777db535,PD-L1 testing,0.58503
uuid-76070237307145129748195a777db535,testing,0.627703
uuid-76070237307145129748195a777db535,PDL1 testing,0.521442
uuid-76070237307145129748195a777db535,NSCLC patients,0.446821
uuid-76070237307145129748195a777db535,assay,0.578973
uuid-0a65e8b38ca64557bf596c79648c2c4d,regards,0.330587
uuid-0a65e8b38ca64557bf596c79648c2c4d,data,0.311666
uuid-0a65e8b38ca64557bf596c79648c2c4d,cHL,0.316864
uuid-0a65e8b38ca64557bf596c79648c2c4d,NCCN,0.528195
uuid-8819f6999557431c9137231123164ea5,patients,0.307053
uuid-8819f6999557431c9137231123164ea5,lung,0.336421
uuid-8819f6999557431c9137231123164ea5,1L,0.364011
uuid-8819f6999557431c9137231123164ea5,RCC,0.484203
uuid-8819f6999557431c9137231123164ea5,TL stated,0.414923
uuid-8819f6999557431c9137231123164ea5,2L,0.471222
uuid-8819f6999557431c9137231123164ea5,stated,0.301045
uuid-8819f6999557431c9137231123164ea5,physicians,0.315153
uuid-8819f6999557431c9137231123164ea5,preferred,0.536209
uuid-8819f6999557431c9137231123164ea5,using nivo,0.603095
uuid-8819f6999557431c9137231123164ea5,SCCHN,0.493184
uuid-8819f6999557431c9137231123164ea5,oncologist,0.437773
uuid-8819f6999557431c9137231123164ea5,indicated,0.365491
uuid-8819f6999557431c9137231123164ea5,LTL,0.341345
uuid-8819f6999557431c9137231123164ea5,TLs,0.432136
uuid-8819f6999557431c9137231123164ea5,Regional TL,0.434281
uuid-8819f6999557431c9137231123164ea5,RTL stated,0.499174
uuid-8819f6999557431c9137231123164ea5,TL shared,0.358964
uuid-8819f6999557431c9137231123164ea5,option,0.343037
uuid-8819f6999557431c9137231123164ea5,bladder,0.340462
uuid-e0e4edfcc30f42429ddecd3bb4757864,RTL,0.309087
uuid-e0e4edfcc30f42429ddecd3bb4757864,nivolumab,0.423169
uuid-e0e4edfcc30f42429ddecd3bb4757864,trial,0.578654
uuid-e0e4edfcc30f42429ddecd3bb4757864,NTL,0.301612
uuid-e0e4edfcc30f42429ddecd3bb4757864,combination,0.424546
uuid-e0e4edfcc30f42429ddecd3bb4757864,combo,0.392812
uuid-e0e4edfcc30f42429ddecd3bb4757864,clinical trials,0.409641
uuid-e0e4edfcc30f42429ddecd3bb4757864,chemotherapy,0.3402
uuid-e0e4edfcc30f42429ddecd3bb4757864,SCLC,0.340612
uuid-e0e4edfcc30f42429ddecd3bb4757864,bladder,0.460701
uuid-00aead1c53864a608b25908e8f956b3d,patients,0.512264
uuid-00aead1c53864a608b25908e8f956b3d,nivolumab,0.301833
uuid-00aead1c53864a608b25908e8f956b3d,treated,0.407513
uuid-00aead1c53864a608b25908e8f956b3d,tumor,0.607497
uuid-00aead1c53864a608b25908e8f956b3d,pts,0.414072
uuid-00aead1c53864a608b25908e8f956b3d,treatment,0.338606
uuid-00aead1c53864a608b25908e8f956b3d,response,0.30817
uuid-00aead1c53864a608b25908e8f956b3d,progression,0.388377
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,Nivo,0.629328
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,nivolumab,0.337766
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,toxicity,0.424338
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,efficacy,0.340928
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,regimen,0.485985
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,combination,0.497777
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,chemo,0.518535
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,2L,0.361304
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,pts,0.414502
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,agents,0.34202
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,Ipi,0.363313
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,preferred,0.312924
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,monotherapy,0.57136
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,using nivo,0.361625
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,response,0.406027
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,combo,0.461013
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,PD1,0.484166
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,progression,0.358391
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,believes,0.336297
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,chemotherapy,0.432769
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,respond,0.340544
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,feels,0.392215
uuid-d5c2d6d7db944f4fb31ee12eca22b6ce,option,0.434583
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,RTL,0.56784
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,BMS,0.472628
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,NTL,0.356647
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,shared,0.45675
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,commented,0.596085
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,RCC,0.345814
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,TL stated,0.414654
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,Merck,0.45356
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,stated,0.619002
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,approval,0.37386
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,data,0.466577
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,expressed,0.418853
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,mentioned,0.322156
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,clinical trials,0.348856
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,approved,0.305414
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,SCCHN,0.585261
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,HCP,0.331374
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,ASCO,0.306762
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,impressed,0.545917
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,LTL,0.462972
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,TLs,0.425847
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,academic,0.324528
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,Regional TL,0.555844
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,RTL stated,0.344136
uuid-4e9cc8ac58a44a62bfa4a58e193c7a9f,bladder,0.346303
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,Nivo,0.521355
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,patients,0.575302
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,Opdivo,0.334416
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,pembro,0.322579
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,therapy,0.392474
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,dose,0.557435
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,nivolumab,0.37458
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,1L,0.397901
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,toxicity,0.520288
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,regimen,0.649739
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,combination,0.435835
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,chemo,0.527195
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,2L,0.520655
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,pts,0.525889
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,agents,0.357278
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,Ipi,0.464526
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,atezo,0.341309
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,preferred,0.547197
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,monotherapy,0.614151
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,treatment,0.509923
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,using nivo,0.383383
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,response,0.324147
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,combo,0.463076
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,PD1,0.374671
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,approved,0.325095
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,progression,0.498516
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,chemotherapy,0.387797
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,vs,0.314555
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,respond,0.437437
uuid-52755e26798a4e6cb3d8d1ccb01ac9e3,option,0.544932
uuid-e6a2f13227d04d8c919ef5970b612c68,patients,0.320092
uuid-e6a2f13227d04d8c919ef5970b612c68,1L,0.382458
uuid-e6a2f13227d04d8c919ef5970b612c68,PDL1,0.370599
uuid-e6a2f13227d04d8c919ef5970b612c68,TL stated,0.445207
uuid-e6a2f13227d04d8c919ef5970b612c68,PD-L1,0.670157
uuid-e6a2f13227d04d8c919ef5970b612c68,PD-L1 testing,0.653805
uuid-e6a2f13227d04d8c919ef5970b612c68,testing,0.857338
uuid-e6a2f13227d04d8c919ef5970b612c68,PDL1 testing,0.79307
uuid-e6a2f13227d04d8c919ef5970b612c68,NSCLC patients,0.82306
uuid-e6a2f13227d04d8c919ef5970b612c68,tumor types,0.405923
uuid-e6a2f13227d04d8c919ef5970b612c68,assay,0.378235
uuid-e6a2f13227d04d8c919ef5970b612c68,biomarker,0.410082
uuid-7ba5b98b99734d10b78c1c2e8d809342,tumor,0.39387
uuid-7ba5b98b99734d10b78c1c2e8d809342,biomarker,0.329939
uuid-90d6370e99994fcfbd5200d14bad92f6,PDL1,0.677477
uuid-90d6370e99994fcfbd5200d14bad92f6,trial,0.318177
uuid-90d6370e99994fcfbd5200d14bad92f6,efficacy,0.308402
uuid-90d6370e99994fcfbd5200d14bad92f6,PD-L1,0.391954
uuid-90d6370e99994fcfbd5200d14bad92f6,OS,0.362682
uuid-90d6370e99994fcfbd5200d14bad92f6,data,0.340994
uuid-90d6370e99994fcfbd5200d14bad92f6,PFS,0.406609
uuid-90d6370e99994fcfbd5200d14bad92f6,ORR,0.455582
uuid-90d6370e99994fcfbd5200d14bad92f6,nivo and pembro,0.365096
uuid-90d6370e99994fcfbd5200d14bad92f6,PDL1 expression,0.650145
uuid-90d6370e99994fcfbd5200d14bad92f6,biomarker,0.416681
uuid-b5a91b6dea884d32ab81c729372ea2b5,patients,0.635772
uuid-b5a91b6dea884d32ab81c729372ea2b5,therapy,0.3949
uuid-b5a91b6dea884d32ab81c729372ea2b5,1L,0.522374
uuid-b5a91b6dea884d32ab81c729372ea2b5,PDL1,0.351884
uuid-b5a91b6dea884d32ab81c729372ea2b5,chemo,0.447639
uuid-b5a91b6dea884d32ab81c729372ea2b5,2L,0.402048
uuid-b5a91b6dea884d32ab81c729372ea2b5,pts,0.530619
uuid-b5a91b6dea884d32ab81c729372ea2b5,PD-L1,0.391197
uuid-b5a91b6dea884d32ab81c729372ea2b5,preferred,0.38739
uuid-b5a91b6dea884d32ab81c729372ea2b5,testing,0.415394
uuid-b5a91b6dea884d32ab81c729372ea2b5,monotherapy,0.514225
uuid-b5a91b6dea884d32ab81c729372ea2b5,treatment,0.38286
uuid-b5a91b6dea884d32ab81c729372ea2b5,PDL1 testing,0.37344
uuid-b5a91b6dea884d32ab81c729372ea2b5,NSCLC patients,0.586728
uuid-b5a91b6dea884d32ab81c729372ea2b5,PD1,0.342748
uuid-b5a91b6dea884d32ab81c729372ea2b5,progression,0.44803
uuid-b5a91b6dea884d32ab81c729372ea2b5,chemotherapy,0.37334
uuid-b5a91b6dea884d32ab81c729372ea2b5,tumor types,0.427651
uuid-b5a91b6dea884d32ab81c729372ea2b5,respond,0.406222
uuid-b5a91b6dea884d32ab81c729372ea2b5,PD-1,0.329194
uuid-b5a91b6dea884d32ab81c729372ea2b5,option,0.609675
uuid-8bf94eede1924e74aba0a9df488c16a0,RTL,0.337708
uuid-8bf94eede1924e74aba0a9df488c16a0,toxicity,0.366944
uuid-8bf94eede1924e74aba0a9df488c16a0,regimen,0.364349
uuid-8bf94eede1924e74aba0a9df488c16a0,treated,0.518704
uuid-8bf94eede1924e74aba0a9df488c16a0,shared,0.378294
uuid-8bf94eede1924e74aba0a9df488c16a0,commented,0.326922
uuid-8bf94eede1924e74aba0a9df488c16a0,physicians,0.564665
uuid-8bf94eede1924e74aba0a9df488c16a0,HCP,0.308928
uuid-8bf94eede1924e74aba0a9df488c16a0,LTL,0.320631
uuid-8bf94eede1924e74aba0a9df488c16a0,TLs,0.332144
uuid-8bf94eede1924e74aba0a9df488c16a0,academic,0.366497
uuid-8bf94eede1924e74aba0a9df488c16a0,Regional TL,0.388954
uuid-8bf94eede1924e74aba0a9df488c16a0,RTL stated,0.300557
uuid-8bf94eede1924e74aba0a9df488c16a0,TL shared,0.317339
uuid-d31819c90b4b4982891e086a15d88616,Merck,0.300138
uuid-d31819c90b4b4982891e086a15d88616,institution,0.370347
uuid-d31819c90b4b4982891e086a15d88616,stated,0.32352
uuid-d31819c90b4b4982891e086a15d88616,PDL1 testing,0.356468
uuid-d31819c90b4b4982891e086a15d88616,NCCN,0.427982
uuid-6f66de21902b49e79862b4a33869a2a5,discussed,0.411639
uuid-6f66de21902b49e79862b4a33869a2a5,oncology,0.61814
uuid-6f66de21902b49e79862b4a33869a2a5,clinical,0.334817
uuid-2dcd4bfd2eba49659e61a6d1f926a570,TL,0.371653
uuid-2dcd4bfd2eba49659e61a6d1f926a570,pembro,0.373329
uuid-2dcd4bfd2eba49659e61a6d1f926a570,PDL1,0.530285
uuid-2dcd4bfd2eba49659e61a6d1f926a570,Merck,0.566069
uuid-2dcd4bfd2eba49659e61a6d1f926a570,PD-L1,0.698713
uuid-2dcd4bfd2eba49659e61a6d1f926a570,approval,0.322041
uuid-2dcd4bfd2eba49659e61a6d1f926a570,atezo,0.439614
uuid-2dcd4bfd2eba49659e61a6d1f926a570,PD-L1 testing,0.633397
uuid-2dcd4bfd2eba49659e61a6d1f926a570,testing,0.778472
uuid-2dcd4bfd2eba49659e61a6d1f926a570,PDL1 testing,0.61982
uuid-2dcd4bfd2eba49659e61a6d1f926a570,NSCLC patients,0.508276
uuid-2dcd4bfd2eba49659e61a6d1f926a570,approved,0.321814
uuid-2dcd4bfd2eba49659e61a6d1f926a570,assay,0.669379
uuid-2dcd4bfd2eba49659e61a6d1f926a570,PDL1 expression,0.432402
uuid-2dcd4bfd2eba49659e61a6d1f926a570,biomarker,0.506079
uuid-4c0902c8c8ca4e90aa991883d84100fc,Nivo,0.471276
uuid-4c0902c8c8ca4e90aa991883d84100fc,pembro,0.549322
uuid-4c0902c8c8ca4e90aa991883d84100fc,dose,0.411458
uuid-4c0902c8c8ca4e90aa991883d84100fc,1L,0.37286
uuid-4c0902c8c8ca4e90aa991883d84100fc,efficacy,0.559891
uuid-4c0902c8c8ca4e90aa991883d84100fc,combination,0.354917
uuid-4c0902c8c8ca4e90aa991883d84100fc,2L,0.451384
uuid-4c0902c8c8ca4e90aa991883d84100fc,agents,0.490507
uuid-4c0902c8c8ca4e90aa991883d84100fc,Ipi,0.384399
uuid-4c0902c8c8ca4e90aa991883d84100fc,atezo,0.62752
uuid-4c0902c8c8ca4e90aa991883d84100fc,preferred,0.432482
uuid-4c0902c8c8ca4e90aa991883d84100fc,monotherapy,0.421766
uuid-4c0902c8c8ca4e90aa991883d84100fc,combo,0.438264
uuid-4c0902c8c8ca4e90aa991883d84100fc,indication,0.355107
uuid-4c0902c8c8ca4e90aa991883d84100fc,approved,0.370813
uuid-4c0902c8c8ca4e90aa991883d84100fc,nivo and pembro,0.374152
uuid-4c0902c8c8ca4e90aa991883d84100fc,believes,0.403701
uuid-4c0902c8c8ca4e90aa991883d84100fc,vs,0.517905
uuid-4c0902c8c8ca4e90aa991883d84100fc,Keytruda,0.359709
uuid-4c0902c8c8ca4e90aa991883d84100fc,option,0.383661
uuid-4c0902c8c8ca4e90aa991883d84100fc,flat dosing,0.395904
uuid-5f0a71eb231a48ee812a0808a5ce090d,Nivo,0.306905
uuid-5f0a71eb231a48ee812a0808a5ce090d,pembro,0.417151
uuid-5f0a71eb231a48ee812a0808a5ce090d,dose,0.534304
uuid-5f0a71eb231a48ee812a0808a5ce090d,trial,0.401186
uuid-5f0a71eb231a48ee812a0808a5ce090d,efficacy,0.519358
uuid-5f0a71eb231a48ee812a0808a5ce090d,Ipi,0.498518
uuid-5f0a71eb231a48ee812a0808a5ce090d,atezo,0.430268
uuid-5f0a71eb231a48ee812a0808a5ce090d,vs,0.707089
uuid-5f0a71eb231a48ee812a0808a5ce090d,TLs,0.329131
uuid-5f0a71eb231a48ee812a0808a5ce090d,flat dosing,0.451262
uuid-2d2df8c9be06435299ef6a9a3bb19356,Opdivo,0.490074
uuid-2d2df8c9be06435299ef6a9a3bb19356,dose,0.884526
uuid-2d2df8c9be06435299ef6a9a3bb19356,toxicity,0.552591
uuid-2d2df8c9be06435299ef6a9a3bb19356,regimen,0.37993
uuid-2d2df8c9be06435299ef6a9a3bb19356,Ipi,0.485237
uuid-2d2df8c9be06435299ef6a9a3bb19356,vs,0.460812
uuid-2d2df8c9be06435299ef6a9a3bb19356,drug,0.469757
uuid-2d2df8c9be06435299ef6a9a3bb19356,Keytruda,0.438016
uuid-2d2df8c9be06435299ef6a9a3bb19356,flat dosing,0.725608
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,RTL,0.590159
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,trial,0.562711
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,efficacy,0.334859
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,NTL,0.350606
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,commented,0.458541
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,OS,0.483578
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,data,0.592224
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,combo,0.337414
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,expressed,0.396424
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,mentioned,0.328009
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,PFS,0.442624
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,ORR,0.524651
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,ASCO,0.446053
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,impressed,0.69345
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,LTL,0.398513
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,TLs,0.363389
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,SCLC,0.314464
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,feels,0.318922
uuid-d3e48ed9db8b4a2991c0a0791bba8da5,Regional TL,0.359222
uuid-56b13a51682246e8ab724872107f772b,lung,0.407811
uuid-56b13a51682246e8ab724872107f772b,NTL,0.42362
uuid-56b13a51682246e8ab724872107f772b,melanoma,0.327775
uuid-56b13a51682246e8ab724872107f772b,RCC,0.307538
uuid-56b13a51682246e8ab724872107f772b,expressed,0.31616
uuid-56b13a51682246e8ab724872107f772b,ASCO,0.452716
uuid-56b13a51682246e8ab724872107f772b,SCLC,0.338691
uuid-56b13a51682246e8ab724872107f772b,Regional TL,0.409618
uuid-da73e8ee341b4c218cd11af58123bf15,Nivo,0.37428
uuid-da73e8ee341b4c218cd11af58123bf15,pembro,0.448912
uuid-da73e8ee341b4c218cd11af58123bf15,1L,0.355024
uuid-da73e8ee341b4c218cd11af58123bf15,PDL1,0.474404
uuid-da73e8ee341b4c218cd11af58123bf15,trial,0.450204
uuid-da73e8ee341b4c218cd11af58123bf15,efficacy,0.520729
uuid-da73e8ee341b4c218cd11af58123bf15,combination,0.313885
uuid-da73e8ee341b4c218cd11af58123bf15,2L,0.300392
uuid-da73e8ee341b4c218cd11af58123bf15,agents,0.308201
uuid-da73e8ee341b4c218cd11af58123bf15,OS,0.428638
uuid-da73e8ee341b4c218cd11af58123bf15,atezo,0.457442
uuid-da73e8ee341b4c218cd11af58123bf15,data,0.54994
uuid-da73e8ee341b4c218cd11af58123bf15,combo,0.31153
uuid-da73e8ee341b4c218cd11af58123bf15,PFS,0.393995
uuid-da73e8ee341b4c218cd11af58123bf15,ORR,0.458664
uuid-da73e8ee341b4c218cd11af58123bf15,nivo and pembro,0.521395
uuid-da73e8ee341b4c218cd11af58123bf15,believes,0.44541
uuid-da73e8ee341b4c218cd11af58123bf15,impressed,0.487831
uuid-da73e8ee341b4c218cd11af58123bf15,feels,0.328487
uuid-da73e8ee341b4c218cd11af58123bf15,PDL1 expression,0.429359
uuid-da73e8ee341b4c218cd11af58123bf15,biomarker,0.315408
uuid-da73e8ee341b4c218cd11af58123bf15,bladder,0.308902
uuid-614f670df7e74fe3b0b56cdcfdbc18e6,patients,0.331057
uuid-614f670df7e74fe3b0b56cdcfdbc18e6,dose,0.599275
uuid-614f670df7e74fe3b0b56cdcfdbc18e6,toxicity,0.670156
uuid-614f670df7e74fe3b0b56cdcfdbc18e6,regimen,0.486117
uuid-614f670df7e74fe3b0b56cdcfdbc18e6,treated,0.343483
uuid-614f670df7e74fe3b0b56cdcfdbc18e6,Ipi,0.337555
uuid-614f670df7e74fe3b0b56cdcfdbc18e6,treatment,0.455646
uuid-614f670df7e74fe3b0b56cdcfdbc18e6,respond,0.38677
uuid-a4fd4daf425e482281ab48814c290a6f,Nivo,0.479727
uuid-a4fd4daf425e482281ab48814c290a6f,pembro,0.428443
uuid-a4fd4daf425e482281ab48814c290a6f,1L,0.49592
uuid-a4fd4daf425e482281ab48814c290a6f,efficacy,0.539237
uuid-a4fd4daf425e482281ab48814c290a6f,combination,0.372976
uuid-a4fd4daf425e482281ab48814c290a6f,chemo,0.431951
uuid-a4fd4daf425e482281ab48814c290a6f,2L,0.466515
uuid-a4fd4daf425e482281ab48814c290a6f,agents,0.464293
uuid-a4fd4daf425e482281ab48814c290a6f,Ipi,0.309239
uuid-a4fd4daf425e482281ab48814c290a6f,OS,0.471573
uuid-a4fd4daf425e482281ab48814c290a6f,atezo,0.42234
uuid-a4fd4daf425e482281ab48814c290a6f,preferred,0.428868
uuid-a4fd4daf425e482281ab48814c290a6f,monotherapy,0.485643
uuid-a4fd4daf425e482281ab48814c290a6f,data,0.371204
uuid-a4fd4daf425e482281ab48814c290a6f,combo,0.50429
uuid-a4fd4daf425e482281ab48814c290a6f,indication,0.3192
uuid-a4fd4daf425e482281ab48814c290a6f,PFS,0.410814
uuid-a4fd4daf425e482281ab48814c290a6f,ORR,0.412504
uuid-a4fd4daf425e482281ab48814c290a6f,approved,0.376199
uuid-a4fd4daf425e482281ab48814c290a6f,nivo and pembro,0.438768
uuid-a4fd4daf425e482281ab48814c290a6f,believes,0.453582
uuid-a4fd4daf425e482281ab48814c290a6f,chemotherapy,0.330313
uuid-a4fd4daf425e482281ab48814c290a6f,impressed,0.34869
uuid-a4fd4daf425e482281ab48814c290a6f,feels,0.499419
uuid-a4fd4daf425e482281ab48814c290a6f,option,0.542662
uuid-6730cafd44b948c9beff841f863a5279,patients,0.621858
uuid-6730cafd44b948c9beff841f863a5279,Opdivo,0.319669
uuid-6730cafd44b948c9beff841f863a5279,dose,0.4978
uuid-6730cafd44b948c9beff841f863a5279,toxicity,0.492611
uuid-6730cafd44b948c9beff841f863a5279,regimen,0.443711
uuid-6730cafd44b948c9beff841f863a5279,treated,0.412418
uuid-6730cafd44b948c9beff841f863a5279,pts,0.396039
uuid-6730cafd44b948c9beff841f863a5279,treatment,0.500047
uuid-6730cafd44b948c9beff841f863a5279,progression,0.477695
uuid-6730cafd44b948c9beff841f863a5279,respond,0.429966
uuid-d91e1da4430a4a90ae8f9b405dce1e95,patients,0.461662
uuid-d91e1da4430a4a90ae8f9b405dce1e95,nivolumab,0.364496
uuid-d91e1da4430a4a90ae8f9b405dce1e95,trial,0.486232
uuid-d91e1da4430a4a90ae8f9b405dce1e95,combination,0.397909
uuid-d91e1da4430a4a90ae8f9b405dce1e95,chemo,0.31162
uuid-d91e1da4430a4a90ae8f9b405dce1e95,pts,0.43209
uuid-d91e1da4430a4a90ae8f9b405dce1e95,monotherapy,0.31182
uuid-d91e1da4430a4a90ae8f9b405dce1e95,combo,0.349614
uuid-d91e1da4430a4a90ae8f9b405dce1e95,clinical trials,0.536436
uuid-d91e1da4430a4a90ae8f9b405dce1e95,chemotherapy,0.364755
uuid-d91e1da4430a4a90ae8f9b405dce1e95,option,0.320614
uuid-956e28da2b5448859a09bf5f9237430c,Nivo,0.444581
uuid-956e28da2b5448859a09bf5f9237430c,pembro,0.382477
uuid-956e28da2b5448859a09bf5f9237430c,therapy,0.396402
uuid-956e28da2b5448859a09bf5f9237430c,nivolumab,0.355931
uuid-956e28da2b5448859a09bf5f9237430c,1L,0.682389
uuid-956e28da2b5448859a09bf5f9237430c,regimen,0.365107
uuid-956e28da2b5448859a09bf5f9237430c,RCC,0.493847
uuid-956e28da2b5448859a09bf5f9237430c,combination,0.487817
uuid-956e28da2b5448859a09bf5f9237430c,chemo,0.443845
uuid-956e28da2b5448859a09bf5f9237430c,2L,0.71983
uuid-956e28da2b5448859a09bf5f9237430c,agents,0.630529
uuid-956e28da2b5448859a09bf5f9237430c,atezo,0.417833
uuid-956e28da2b5448859a09bf5f9237430c,preferred,0.643888
uuid-956e28da2b5448859a09bf5f9237430c,monotherapy,0.700749
uuid-956e28da2b5448859a09bf5f9237430c,treatment,0.358838
uuid-956e28da2b5448859a09bf5f9237430c,using nivo,0.536575
uuid-956e28da2b5448859a09bf5f9237430c,combo,0.533134
uuid-956e28da2b5448859a09bf5f9237430c,PD1,0.494557
uuid-956e28da2b5448859a09bf5f9237430c,approved,0.517308
uuid-956e28da2b5448859a09bf5f9237430c,believes,0.371042
uuid-956e28da2b5448859a09bf5f9237430c,chemotherapy,0.417603
uuid-956e28da2b5448859a09bf5f9237430c,feels,0.307636
uuid-956e28da2b5448859a09bf5f9237430c,PD-1,0.365744
uuid-956e28da2b5448859a09bf5f9237430c,RTL stated,0.481062
uuid-956e28da2b5448859a09bf5f9237430c,option,0.724999
uuid-a3c2fb10844d4516ad69712e98c4c639,tumor,0.636095
uuid-41b8d20aa0b245e9b2fd329097e35c52,Nivo,0.40239
uuid-41b8d20aa0b245e9b2fd329097e35c52,patients,0.555154
uuid-41b8d20aa0b245e9b2fd329097e35c52,therapy,0.350814
uuid-41b8d20aa0b245e9b2fd329097e35c52,nivolumab,0.302827
uuid-41b8d20aa0b245e9b2fd329097e35c52,regimen,0.339553
uuid-41b8d20aa0b245e9b2fd329097e35c52,treated,0.31707
uuid-41b8d20aa0b245e9b2fd329097e35c52,combination,0.369371
uuid-41b8d20aa0b245e9b2fd329097e35c52,chemo,0.520182
uuid-41b8d20aa0b245e9b2fd329097e35c52,tumor,0.410209
uuid-41b8d20aa0b245e9b2fd329097e35c52,pts,0.605152
uuid-41b8d20aa0b245e9b2fd329097e35c52,monotherapy,0.433845
uuid-41b8d20aa0b245e9b2fd329097e35c52,response,0.472534
uuid-41b8d20aa0b245e9b2fd329097e35c52,combo,0.33755
uuid-41b8d20aa0b245e9b2fd329097e35c52,PD1,0.416966
uuid-41b8d20aa0b245e9b2fd329097e35c52,progression,0.519633
uuid-41b8d20aa0b245e9b2fd329097e35c52,chemotherapy,0.429434
uuid-41b8d20aa0b245e9b2fd329097e35c52,respond,0.312138
uuid-41b8d20aa0b245e9b2fd329097e35c52,feels,0.358256
uuid-41b8d20aa0b245e9b2fd329097e35c52,option,0.361764
uuid-98db96e58e544998a1bd49530f13c534,Nivo,0.547638
uuid-98db96e58e544998a1bd49530f13c534,pembro,0.479946
uuid-98db96e58e544998a1bd49530f13c534,therapy,0.325172
uuid-98db96e58e544998a1bd49530f13c534,1L,0.796002
uuid-98db96e58e544998a1bd49530f13c534,regimen,0.364288
uuid-98db96e58e544998a1bd49530f13c534,RCC,0.442762
uuid-98db96e58e544998a1bd49530f13c534,combination,0.368345
uuid-98db96e58e544998a1bd49530f13c534,chemo,0.52801
uuid-98db96e58e544998a1bd49530f13c534,2L,0.843981
uuid-98db96e58e544998a1bd49530f13c534,pts,0.359942
uuid-98db96e58e544998a1bd49530f13c534,agents,0.525054
uuid-98db96e58e544998a1bd49530f13c534,atezo,0.526194
uuid-98db96e58e544998a1bd49530f13c534,preferred,0.728154
uuid-98db96e58e544998a1bd49530f13c534,monotherapy,0.747328
uuid-98db96e58e544998a1bd49530f13c534,using nivo,0.623065
uuid-98db96e58e544998a1bd49530f13c534,combo,0.47302
uuid-98db96e58e544998a1bd49530f13c534,PD1,0.447601
uuid-98db96e58e544998a1bd49530f13c534,approved,0.511287
uuid-98db96e58e544998a1bd49530f13c534,nivo and pembro,0.349919
uuid-98db96e58e544998a1bd49530f13c534,believes,0.499996
uuid-98db96e58e544998a1bd49530f13c534,chemotherapy,0.394562
uuid-98db96e58e544998a1bd49530f13c534,feels,0.416462
uuid-98db96e58e544998a1bd49530f13c534,RTL stated,0.446622
uuid-98db96e58e544998a1bd49530f13c534,option,0.761564
uuid-c1d29f76e60740598fe9c78a3df97462,Nivo,0.45604
uuid-c1d29f76e60740598fe9c78a3df97462,pembro,0.548913
uuid-c1d29f76e60740598fe9c78a3df97462,BMS,0.36261
uuid-c1d29f76e60740598fe9c78a3df97462,PDL1,0.512805
uuid-c1d29f76e60740598fe9c78a3df97462,trial,0.459991
uuid-c1d29f76e60740598fe9c78a3df97462,efficacy,0.70273
uuid-c1d29f76e60740598fe9c78a3df97462,Merck,0.349878
uuid-c1d29f76e60740598fe9c78a3df97462,OS,0.667541
uuid-c1d29f76e60740598fe9c78a3df97462,atezo,0.431471
uuid-c1d29f76e60740598fe9c78a3df97462,data,0.72251
uuid-c1d29f76e60740598fe9c78a3df97462,PFS,0.623488
uuid-c1d29f76e60740598fe9c78a3df97462,ORR,0.662582
uuid-c1d29f76e60740598fe9c78a3df97462,nivo and pembro,0.560068
uuid-c1d29f76e60740598fe9c78a3df97462,impressed,0.506816
uuid-c1d29f76e60740598fe9c78a3df97462,vs,0.492341
uuid-c1d29f76e60740598fe9c78a3df97462,feels,0.409454
uuid-c1d29f76e60740598fe9c78a3df97462,PDL1 expression,0.456188
uuid-79877ef180a0402691a88ff7bc86a9d9,Nivo,0.470392
uuid-79877ef180a0402691a88ff7bc86a9d9,patients,0.791324
uuid-79877ef180a0402691a88ff7bc86a9d9,Opdivo,0.449212
uuid-79877ef180a0402691a88ff7bc86a9d9,therapy,0.561983
uuid-79877ef180a0402691a88ff7bc86a9d9,dose,0.452368
uuid-79877ef180a0402691a88ff7bc86a9d9,nivolumab,0.510114
uuid-79877ef180a0402691a88ff7bc86a9d9,regimen,0.487853
uuid-79877ef180a0402691a88ff7bc86a9d9,treated,0.435659
uuid-79877ef180a0402691a88ff7bc86a9d9,chemo,0.446017
uuid-79877ef180a0402691a88ff7bc86a9d9,pts,0.526545
uuid-79877ef180a0402691a88ff7bc86a9d9,Ipi,0.335871
uuid-79877ef180a0402691a88ff7bc86a9d9,monotherapy,0.379022
uuid-79877ef180a0402691a88ff7bc86a9d9,treatment,0.642854
uuid-79877ef180a0402691a88ff7bc86a9d9,using nivo,0.366203
uuid-79877ef180a0402691a88ff7bc86a9d9,response,0.34885
uuid-79877ef180a0402691a88ff7bc86a9d9,PD1,0.322065
uuid-79877ef180a0402691a88ff7bc86a9d9,progression,0.559603
uuid-79877ef180a0402691a88ff7bc86a9d9,chemotherapy,0.474602
uuid-79877ef180a0402691a88ff7bc86a9d9,respond,0.407397
uuid-79877ef180a0402691a88ff7bc86a9d9,option,0.392158
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,efficacy,0.601726
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,combination,0.320647
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,chemo,0.412952
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,IO,0.316565
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,OS,0.691333
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,response,0.491794
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,data,0.385863
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,PFS,0.64353
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,PD1,0.357567
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,ORR,0.657338
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,believes,0.432934
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,chemotherapy,0.354916
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,impressed,0.363821
uuid-fd47dc61f8794ba6b3604bf4dbdf8383,feels,0.42065
uuid-149d5d573642445b876fd8f6d6baa48b,Nivo,0.32375
uuid-149d5d573642445b876fd8f6d6baa48b,patients,0.319906
uuid-149d5d573642445b876fd8f6d6baa48b,regimen,0.329787
uuid-149d5d573642445b876fd8f6d6baa48b,chemo,0.331755
uuid-149d5d573642445b876fd8f6d6baa48b,pts,0.399431
uuid-149d5d573642445b876fd8f6d6baa48b,monotherapy,0.342903
uuid-149d5d573642445b876fd8f6d6baa48b,response,0.361619
uuid-149d5d573642445b876fd8f6d6baa48b,PD1,0.304792
uuid-149d5d573642445b876fd8f6d6baa48b,progression,0.373345
uuid-149d5d573642445b876fd8f6d6baa48b,chemotherapy,0.312006
uuid-d96b92d48c124ac198b1a6034058b9da,Nivo,0.567101
uuid-d96b92d48c124ac198b1a6034058b9da,pembro,0.316459
uuid-d96b92d48c124ac198b1a6034058b9da,therapy,0.43692
uuid-d96b92d48c124ac198b1a6034058b9da,combination,0.336953
uuid-d96b92d48c124ac198b1a6034058b9da,chemo,0.398924
uuid-d96b92d48c124ac198b1a6034058b9da,monotherapy,0.382725
uuid-d96b92d48c124ac198b1a6034058b9da,using nivo,0.402222
uuid-d96b92d48c124ac198b1a6034058b9da,PD1,0.387163
uuid-d96b92d48c124ac198b1a6034058b9da,cHL,0.466849
uuid-d96b92d48c124ac198b1a6034058b9da,chemotherapy,0.415813
uuid-d96b92d48c124ac198b1a6034058b9da,feels,0.393668
uuid-d96b92d48c124ac198b1a6034058b9da,option,0.374198
uuid-fb7fc721196f4e68b7f8ad23c5b70c29,nivolumab,0.340706
uuid-fb7fc721196f4e68b7f8ad23c5b70c29,NTL,0.377933
uuid-fb7fc721196f4e68b7f8ad23c5b70c29,discussed,0.37253
uuid-fb7fc721196f4e68b7f8ad23c5b70c29,mentioned,0.315405
uuid-fb7fc721196f4e68b7f8ad23c5b70c29,cHL,0.520525
uuid-0f04bb0d02dd49c799dfb680f5453586,patients,0.767411
uuid-0f04bb0d02dd49c799dfb680f5453586,Opdivo,0.371714
uuid-0f04bb0d02dd49c799dfb680f5453586,therapy,0.450718
uuid-0f04bb0d02dd49c799dfb680f5453586,nivolumab,0.420217
uuid-0f04bb0d02dd49c799dfb680f5453586,toxicity,0.45791
uuid-0f04bb0d02dd49c799dfb680f5453586,regimen,0.650063
uuid-0f04bb0d02dd49c799dfb680f5453586,treated,0.664236
uuid-0f04bb0d02dd49c799dfb680f5453586,pts,0.474471
uuid-0f04bb0d02dd49c799dfb680f5453586,treatment,0.731877
uuid-0f04bb0d02dd49c799dfb680f5453586,response,0.323806
uuid-0f04bb0d02dd49c799dfb680f5453586,progression,0.556901
uuid-0f04bb0d02dd49c799dfb680f5453586,respond,0.579252
uuid-7b69758cc1cc4a068751f1851a1754bc,patients,0.628132
uuid-7b69758cc1cc4a068751f1851a1754bc,Opdivo,0.682043
uuid-7b69758cc1cc4a068751f1851a1754bc,therapy,0.474988
uuid-7b69758cc1cc4a068751f1851a1754bc,nivolumab,0.536273
uuid-7b69758cc1cc4a068751f1851a1754bc,regimen,0.39084
uuid-7b69758cc1cc4a068751f1851a1754bc,treated,0.626966
uuid-7b69758cc1cc4a068751f1851a1754bc,pts,0.300393
uuid-7b69758cc1cc4a068751f1851a1754bc,approval,0.348996
uuid-7b69758cc1cc4a068751f1851a1754bc,treatment,0.536059
uuid-7b69758cc1cc4a068751f1851a1754bc,using nivo,0.403404
uuid-7b69758cc1cc4a068751f1851a1754bc,cHL,0.542292
uuid-7b69758cc1cc4a068751f1851a1754bc,progression,0.397849
uuid-7b69758cc1cc4a068751f1851a1754bc,respond,0.326449
uuid-8c45791178854cbbb64d9292b2c920c0,drug,0.353602
uuid-8c45791178854cbbb64d9292b2c920c0,PD-1,0.363907
uuid-8bce6e4fbc7749f6a24d687db835dd30,toxicity,0.643097
uuid-8bce6e4fbc7749f6a24d687db835dd30,regimen,0.458185
uuid-8bce6e4fbc7749f6a24d687db835dd30,treated,0.363076
uuid-8bce6e4fbc7749f6a24d687db835dd30,treatment,0.46918
uuid-8bce6e4fbc7749f6a24d687db835dd30,respond,0.490107
uuid-bf0c2b23113042568441924d83f9fab1,patients,0.601564
uuid-bf0c2b23113042568441924d83f9fab1,treated,0.34034
uuid-bf0c2b23113042568441924d83f9fab1,pts,0.392453
uuid-bf0c2b23113042568441924d83f9fab1,PD-L1,0.461588
uuid-bf0c2b23113042568441924d83f9fab1,approval,0.39655
uuid-bf0c2b23113042568441924d83f9fab1,PD-L1 testing,0.54684
uuid-bf0c2b23113042568441924d83f9fab1,testing,0.628792
uuid-bf0c2b23113042568441924d83f9fab1,treatment,0.367157
uuid-bf0c2b23113042568441924d83f9fab1,PDL1 testing,0.431835
uuid-bf0c2b23113042568441924d83f9fab1,NSCLC patients,0.670522
uuid-bf0c2b23113042568441924d83f9fab1,progression,0.335667
uuid-bf0c2b23113042568441924d83f9fab1,respond,0.304687
uuid-1e646c67f6cb4cbdb5615d82aa967071,patients,0.33897
uuid-1e646c67f6cb4cbdb5615d82aa967071,RTL,0.626976
uuid-1e646c67f6cb4cbdb5615d82aa967071,nivolumab,0.428832
uuid-1e646c67f6cb4cbdb5615d82aa967071,regimen,0.334632
uuid-1e646c67f6cb4cbdb5615d82aa967071,treated,0.381322
uuid-1e646c67f6cb4cbdb5615d82aa967071,NTL,0.32153
uuid-1e646c67f6cb4cbdb5615d82aa967071,commented,0.398858
uuid-1e646c67f6cb4cbdb5615d82aa967071,stated,0.39354
uuid-1e646c67f6cb4cbdb5615d82aa967071,physicians,0.319326
uuid-1e646c67f6cb4cbdb5615d82aa967071,mentioned,0.341457
uuid-1e646c67f6cb4cbdb5615d82aa967071,clinical trials,0.302314
uuid-1e646c67f6cb4cbdb5615d82aa967071,SCCHN,0.383495
uuid-1e646c67f6cb4cbdb5615d82aa967071,HCP,0.424394
uuid-1e646c67f6cb4cbdb5615d82aa967071,ASCO,0.449488
uuid-1e646c67f6cb4cbdb5615d82aa967071,impressed,0.536538
uuid-1e646c67f6cb4cbdb5615d82aa967071,LTL,0.47489
uuid-1e646c67f6cb4cbdb5615d82aa967071,TLs,0.304379
uuid-1e646c67f6cb4cbdb5615d82aa967071,academic,0.302024
uuid-1e646c67f6cb4cbdb5615d82aa967071,Regional TL,0.526695
uuid-1e646c67f6cb4cbdb5615d82aa967071,RTL stated,0.316261
uuid-9d4291578866400b8aac641ebcc4ff8f,BMS,0.324996
uuid-9d4291578866400b8aac641ebcc4ff8f,PDL1,0.72803
uuid-9d4291578866400b8aac641ebcc4ff8f,efficacy,0.410282
uuid-9d4291578866400b8aac641ebcc4ff8f,Merck,0.374897
uuid-9d4291578866400b8aac641ebcc4ff8f,PD-L1,0.487215
uuid-9d4291578866400b8aac641ebcc4ff8f,OS,0.395073
uuid-9d4291578866400b8aac641ebcc4ff8f,testing,0.350114
uuid-9d4291578866400b8aac641ebcc4ff8f,regards,0.360374
uuid-9d4291578866400b8aac641ebcc4ff8f,data,0.54355
uuid-9d4291578866400b8aac641ebcc4ff8f,expressed,0.311613
uuid-9d4291578866400b8aac641ebcc4ff8f,PFS,0.421447
uuid-9d4291578866400b8aac641ebcc4ff8f,ORR,0.455103
uuid-9d4291578866400b8aac641ebcc4ff8f,nivo and pembro,0.448513
uuid-9d4291578866400b8aac641ebcc4ff8f,believes,0.324619
uuid-9d4291578866400b8aac641ebcc4ff8f,impressed,0.303409
uuid-9d4291578866400b8aac641ebcc4ff8f,assay,0.464545
uuid-9d4291578866400b8aac641ebcc4ff8f,PDL1 expression,0.667767
uuid-9d4291578866400b8aac641ebcc4ff8f,biomarker,0.698268
uuid-c86865a45bb14ed5a761ba909bcf24bc,Opdivo,0.504191
uuid-c86865a45bb14ed5a761ba909bcf24bc,dose,0.705633
uuid-c86865a45bb14ed5a761ba909bcf24bc,Ipi,0.305066
uuid-c86865a45bb14ed5a761ba909bcf24bc,vs,0.417805
uuid-c86865a45bb14ed5a761ba909bcf24bc,Keytruda,0.352897
uuid-c86865a45bb14ed5a761ba909bcf24bc,flat dosing,0.644526
uuid-9870d87a045940238eea0821843db551,Opdivo,0.433643
uuid-9870d87a045940238eea0821843db551,physicians,0.328847
uuid-9870d87a045940238eea0821843db551,approved,0.310568
uuid-9870d87a045940238eea0821843db551,label,0.305711
uuid-9870d87a045940238eea0821843db551,drug,0.358129
uuid-9870d87a045940238eea0821843db551,Keytruda,0.328616
uuid-9870d87a045940238eea0821843db551,flat dosing,0.318907
uuid-3a61a88e9e0749b3b9d40657d8264ad1,patients,0.387391
uuid-3a61a88e9e0749b3b9d40657d8264ad1,Opdivo,0.304513
uuid-3a61a88e9e0749b3b9d40657d8264ad1,therapy,0.328512
uuid-3a61a88e9e0749b3b9d40657d8264ad1,dose,0.366535
uuid-3a61a88e9e0749b3b9d40657d8264ad1,toxicity,0.467495
uuid-3a61a88e9e0749b3b9d40657d8264ad1,regimen,0.507437
uuid-3a61a88e9e0749b3b9d40657d8264ad1,physicians,0.31212
uuid-3a61a88e9e0749b3b9d40657d8264ad1,treatment,0.533845
uuid-3a61a88e9e0749b3b9d40657d8264ad1,drug,0.312245
uuid-f78a88c0e54046efaf2763931504f4a6,TL,0.455456
uuid-f78a88c0e54046efaf2763931504f4a6,RTL,0.30844
uuid-f78a88c0e54046efaf2763931504f4a6,lung,0.359759
uuid-f78a88c0e54046efaf2763931504f4a6,treated,0.37845
uuid-f78a88c0e54046efaf2763931504f4a6,melanoma,0.342087
uuid-f78a88c0e54046efaf2763931504f4a6,shared,0.351041
uuid-f78a88c0e54046efaf2763931504f4a6,RCC,0.461559
uuid-f78a88c0e54046efaf2763931504f4a6,TL stated,0.568377
uuid-f78a88c0e54046efaf2763931504f4a6,institution,0.369555
uuid-f78a88c0e54046efaf2763931504f4a6,physicians,0.37605
uuid-f78a88c0e54046efaf2763931504f4a6,PD-L1 testing,0.51759
uuid-f78a88c0e54046efaf2763931504f4a6,testing,0.339311
uuid-f78a88c0e54046efaf2763931504f4a6,PDL1 testing,0.463334
uuid-f78a88c0e54046efaf2763931504f4a6,NSCLC patients,0.349521
uuid-f78a88c0e54046efaf2763931504f4a6,oncology,0.316073
uuid-f78a88c0e54046efaf2763931504f4a6,SCCHN,0.413691
uuid-f78a88c0e54046efaf2763931504f4a6,oncologist,0.371824
uuid-f78a88c0e54046efaf2763931504f4a6,TLs,0.337432
uuid-f78a88c0e54046efaf2763931504f4a6,academic,0.400804
uuid-f78a88c0e54046efaf2763931504f4a6,Regional TL,0.465994
uuid-f78a88c0e54046efaf2763931504f4a6,RTL stated,0.391756
uuid-f78a88c0e54046efaf2763931504f4a6,TL shared,0.404452
uuid-7c615964441c4fa38438774aca75989c,Nivo,0.69868
uuid-7c615964441c4fa38438774aca75989c,patients,0.358689
uuid-7c615964441c4fa38438774aca75989c,Opdivo,0.333937
uuid-7c615964441c4fa38438774aca75989c,therapy,0.617082
uuid-7c615964441c4fa38438774aca75989c,nivolumab,0.601159
uuid-7c615964441c4fa38438774aca75989c,approval,0.441481
uuid-7c615964441c4fa38438774aca75989c,monotherapy,0.319697
uuid-7c615964441c4fa38438774aca75989c,treatment,0.308536
uuid-7c615964441c4fa38438774aca75989c,using nivo,0.545668
uuid-7c615964441c4fa38438774aca75989c,PD1,0.353994
uuid-7c615964441c4fa38438774aca75989c,approved,0.333276
uuid-7c615964441c4fa38438774aca75989c,cHL,0.758952
uuid-7c615964441c4fa38438774aca75989c,chemotherapy,0.337815
uuid-7c615964441c4fa38438774aca75989c,RTL stated,0.339667
uuid-39eb7804c3444eabbf4fc1569e8ec636,patients,0.354018
uuid-39eb7804c3444eabbf4fc1569e8ec636,RTL,0.3783
uuid-39eb7804c3444eabbf4fc1569e8ec636,nivolumab,0.311299
uuid-39eb7804c3444eabbf4fc1569e8ec636,treated,0.47831
uuid-39eb7804c3444eabbf4fc1569e8ec636,physicians,0.554223
uuid-39eb7804c3444eabbf4fc1569e8ec636,treatment,0.323824
uuid-39eb7804c3444eabbf4fc1569e8ec636,SCCHN,0.396799
uuid-39eb7804c3444eabbf4fc1569e8ec636,oncologist,0.317066
uuid-39eb7804c3444eabbf4fc1569e8ec636,LTL,0.325734
uuid-39eb7804c3444eabbf4fc1569e8ec636,TLs,0.305984
uuid-39eb7804c3444eabbf4fc1569e8ec636,academic,0.6219
uuid-39eb7804c3444eabbf4fc1569e8ec636,Regional TL,0.432769
uuid-39eb7804c3444eabbf4fc1569e8ec636,RTL stated,0.370536
uuid-a4e83d6e7f62411fba5d8508357d8f1a,Nivo,0.31463
uuid-a4e83d6e7f62411fba5d8508357d8f1a,RTL,0.315462
uuid-a4e83d6e7f62411fba5d8508357d8f1a,nivolumab,0.378143
uuid-a4e83d6e7f62411fba5d8508357d8f1a,1L,0.329814
uuid-a4e83d6e7f62411fba5d8508357d8f1a,regimen,0.393066
uuid-a4e83d6e7f62411fba5d8508357d8f1a,treated,0.331937
uuid-a4e83d6e7f62411fba5d8508357d8f1a,RCC,0.366829
uuid-a4e83d6e7f62411fba5d8508357d8f1a,combination,0.49051
uuid-a4e83d6e7f62411fba5d8508357d8f1a,2L,0.325033
uuid-a4e83d6e7f62411fba5d8508357d8f1a,Ipi,0.362304
uuid-a4e83d6e7f62411fba5d8508357d8f1a,preferred,0.326347
uuid-a4e83d6e7f62411fba5d8508357d8f1a,monotherapy,0.473285
uuid-a4e83d6e7f62411fba5d8508357d8f1a,using nivo,0.434608
uuid-a4e83d6e7f62411fba5d8508357d8f1a,data,0.319987
uuid-a4e83d6e7f62411fba5d8508357d8f1a,combo,0.433002
uuid-a4e83d6e7f62411fba5d8508357d8f1a,approved,0.356451
uuid-a4e83d6e7f62411fba5d8508357d8f1a,SCCHN,0.39772
uuid-a4e83d6e7f62411fba5d8508357d8f1a,HCP,0.361889
uuid-a4e83d6e7f62411fba5d8508357d8f1a,impressed,0.414183
uuid-a4e83d6e7f62411fba5d8508357d8f1a,SCLC,0.717081
uuid-a4e83d6e7f62411fba5d8508357d8f1a,RTL stated,0.453094
uuid-a4e83d6e7f62411fba5d8508357d8f1a,TL shared,0.319787
uuid-a4e83d6e7f62411fba5d8508357d8f1a,option,0.336319
uuid-80f3fde2cd7945209f13741cc8f36142,patients,0.752568
uuid-80f3fde2cd7945209f13741cc8f36142,Opdivo,0.495316
uuid-80f3fde2cd7945209f13741cc8f36142,therapy,0.372254
uuid-80f3fde2cd7945209f13741cc8f36142,dose,0.497007
uuid-80f3fde2cd7945209f13741cc8f36142,nivolumab,0.369667
uuid-80f3fde2cd7945209f13741cc8f36142,toxicity,0.544506
uuid-80f3fde2cd7945209f13741cc8f36142,regimen,0.620504
uuid-80f3fde2cd7945209f13741cc8f36142,treated,0.581632
uuid-80f3fde2cd7945209f13741cc8f36142,pts,0.385155
uuid-80f3fde2cd7945209f13741cc8f36142,physicians,0.366285
uuid-80f3fde2cd7945209f13741cc8f36142,treatment,0.716312
uuid-80f3fde2cd7945209f13741cc8f36142,progression,0.495036
uuid-80f3fde2cd7945209f13741cc8f36142,respond,0.518237
uuid-cfcc6046bd3442b28be244402b3df8bc,patients,0.574801
uuid-cfcc6046bd3442b28be244402b3df8bc,Opdivo,0.402924
uuid-cfcc6046bd3442b28be244402b3df8bc,therapy,0.359747
uuid-cfcc6046bd3442b28be244402b3df8bc,nivolumab,0.593243
uuid-cfcc6046bd3442b28be244402b3df8bc,1L,0.303736
uuid-cfcc6046bd3442b28be244402b3df8bc,regimen,0.339385
uuid-cfcc6046bd3442b28be244402b3df8bc,treated,0.441997
uuid-cfcc6046bd3442b28be244402b3df8bc,RCC,0.406622
uuid-cfcc6046bd3442b28be244402b3df8bc,2L,0.340715
uuid-cfcc6046bd3442b28be244402b3df8bc,pts,0.380017
uuid-cfcc6046bd3442b28be244402b3df8bc,approval,0.49002
uuid-cfcc6046bd3442b28be244402b3df8bc,preferred,0.353354
uuid-cfcc6046bd3442b28be244402b3df8bc,monotherapy,0.360261
uuid-cfcc6046bd3442b28be244402b3df8bc,treatment,0.401241
uuid-cfcc6046bd3442b28be244402b3df8bc,using nivo,0.511192
uuid-cfcc6046bd3442b28be244402b3df8bc,approved,0.529575
uuid-cfcc6046bd3442b28be244402b3df8bc,SCCHN,0.335976
uuid-cfcc6046bd3442b28be244402b3df8bc,label,0.325365
uuid-cfcc6046bd3442b28be244402b3df8bc,SCLC,0.460581
uuid-cfcc6046bd3442b28be244402b3df8bc,RTL stated,0.436868
uuid-cfcc6046bd3442b28be244402b3df8bc,TL shared,0.320775
uuid-cfcc6046bd3442b28be244402b3df8bc,option,0.401664
uuid-f3f5bc6d9aaf4295b741d2421e109a83,efficacy,0.349462
uuid-f3f5bc6d9aaf4295b741d2421e109a83,commented,0.551471
uuid-f3f5bc6d9aaf4295b741d2421e109a83,OS,0.488638
uuid-f3f5bc6d9aaf4295b741d2421e109a83,regards,0.373964
uuid-f3f5bc6d9aaf4295b741d2421e109a83,data,0.673619
uuid-f3f5bc6d9aaf4295b741d2421e109a83,PFS,0.428725
uuid-f3f5bc6d9aaf4295b741d2421e109a83,ORR,0.484714
uuid-f3f5bc6d9aaf4295b741d2421e109a83,lung cancer,0.342476
uuid-f3f5bc6d9aaf4295b741d2421e109a83,ASCO,0.606879
uuid-f3f5bc6d9aaf4295b741d2421e109a83,impressed,0.62406
uuid-b4aef160e438443fb237b37298a0ba75,efficacy,0.349462
uuid-b4aef160e438443fb237b37298a0ba75,commented,0.551471
uuid-b4aef160e438443fb237b37298a0ba75,OS,0.488638
uuid-b4aef160e438443fb237b37298a0ba75,regards,0.373964
uuid-b4aef160e438443fb237b37298a0ba75,data,0.673619
uuid-b4aef160e438443fb237b37298a0ba75,PFS,0.428725
uuid-b4aef160e438443fb237b37298a0ba75,ORR,0.484714
uuid-b4aef160e438443fb237b37298a0ba75,lung cancer,0.342476
uuid-b4aef160e438443fb237b37298a0ba75,ASCO,0.606879
uuid-b4aef160e438443fb237b37298a0ba75,impressed,0.62406
uuid-2842a0a77c3e4bb4addf02ef2a37fc61,RTL,0.389926
uuid-2842a0a77c3e4bb4addf02ef2a37fc61,treated,0.397745
uuid-2842a0a77c3e4bb4addf02ef2a37fc61,commented,0.404996
uuid-2842a0a77c3e4bb4addf02ef2a37fc61,OS,0.404351
uuid-2842a0a77c3e4bb4addf02ef2a37fc61,data,0.586217
uuid-2842a0a77c3e4bb4addf02ef2a37fc61,PFS,0.350783
uuid-2842a0a77c3e4bb4addf02ef2a37fc61,ORR,0.479309
uuid-2842a0a77c3e4bb4addf02ef2a37fc61,ASCO,0.448986
uuid-2842a0a77c3e4bb4addf02ef2a37fc61,impressed,0.631406
uuid-2842a0a77c3e4bb4addf02ef2a37fc61,LTL,0.300624
uuid-2842a0a77c3e4bb4addf02ef2a37fc61,Regional TL,0.404997
uuid-222ecb95476f4f91a24640caa07684fd,response,0.371967
uuid-222ecb95476f4f91a24640caa07684fd,progression,0.329358
uuid-222ecb95476f4f91a24640caa07684fd,indicated,0.389685
uuid-222ecb95476f4f91a24640caa07684fd,respond,0.317131
uuid-f5ed1f5575f54696ba42587be5bfe843,TL,0.489625
uuid-f5ed1f5575f54696ba42587be5bfe843,PDL1,0.531029
uuid-f5ed1f5575f54696ba42587be5bfe843,TL stated,0.409545
uuid-f5ed1f5575f54696ba42587be5bfe843,Merck,0.353275
uuid-f5ed1f5575f54696ba42587be5bfe843,institution,0.319222
uuid-f5ed1f5575f54696ba42587be5bfe843,PD-L1,0.849547
uuid-f5ed1f5575f54696ba42587be5bfe843,PD-L1 testing,0.844536
uuid-f5ed1f5575f54696ba42587be5bfe843,testing,0.927987
uuid-f5ed1f5575f54696ba42587be5bfe843,PDL1 testing,0.737761
uuid-f5ed1f5575f54696ba42587be5bfe843,NSCLC patients,0.703276
uuid-f5ed1f5575f54696ba42587be5bfe843,assay,0.731968
uuid-f5ed1f5575f54696ba42587be5bfe843,PDL1 expression,0.331941
uuid-f5ed1f5575f54696ba42587be5bfe843,biomarker,0.468244
uuid-e8d5ed8f66ef41babfb87fa37265ce42,pembro,0.471052
uuid-e8d5ed8f66ef41babfb87fa37265ce42,RTL,0.43798
uuid-e8d5ed8f66ef41babfb87fa37265ce42,BMS,0.469294
uuid-e8d5ed8f66ef41babfb87fa37265ce42,trial,0.486134
uuid-e8d5ed8f66ef41babfb87fa37265ce42,shared,0.505841
uuid-e8d5ed8f66ef41babfb87fa37265ce42,commented,0.475848
uuid-e8d5ed8f66ef41babfb87fa37265ce42,Merck,0.406606
uuid-e8d5ed8f66ef41babfb87fa37265ce42,stated,0.577417
uuid-e8d5ed8f66ef41babfb87fa37265ce42,approval,0.453723
uuid-e8d5ed8f66ef41babfb87fa37265ce42,atezo,0.399633
uuid-e8d5ed8f66ef41babfb87fa37265ce42,using nivo,0.318507
uuid-e8d5ed8f66ef41babfb87fa37265ce42,data,0.68667
uuid-e8d5ed8f66ef41babfb87fa37265ce42,expressed,0.381889
uuid-e8d5ed8f66ef41babfb87fa37265ce42,clinical trials,0.464982
uuid-e8d5ed8f66ef41babfb87fa37265ce42,indication,0.388101
uuid-e8d5ed8f66ef41babfb87fa37265ce42,approved,0.447111
uuid-e8d5ed8f66ef41babfb87fa37265ce42,SCCHN,0.481161
uuid-e8d5ed8f66ef41babfb87fa37265ce42,impressed,0.611719
uuid-e8d5ed8f66ef41babfb87fa37265ce42,LTL,0.488244
uuid-e8d5ed8f66ef41babfb87fa37265ce42,TLs,0.399069
uuid-e8d5ed8f66ef41babfb87fa37265ce42,SCLC,0.374679
uuid-e8d5ed8f66ef41babfb87fa37265ce42,feels,0.363314
uuid-e8d5ed8f66ef41babfb87fa37265ce42,Regional TL,0.474431
uuid-e8d5ed8f66ef41babfb87fa37265ce42,RTL stated,0.314311
uuid-e8d5ed8f66ef41babfb87fa37265ce42,bladder,0.384379
uuid-421d5c86d1f447d4b91427287fb517ba,Nivo,0.556833
uuid-421d5c86d1f447d4b91427287fb517ba,patients,0.489308
uuid-421d5c86d1f447d4b91427287fb517ba,Opdivo,0.325795
uuid-421d5c86d1f447d4b91427287fb517ba,pembro,0.393498
uuid-421d5c86d1f447d4b91427287fb517ba,nivolumab,0.483004
uuid-421d5c86d1f447d4b91427287fb517ba,regimen,0.34976
uuid-421d5c86d1f447d4b91427287fb517ba,2L,0.350958
uuid-421d5c86d1f447d4b91427287fb517ba,pts,0.382677
uuid-421d5c86d1f447d4b91427287fb517ba,stated,0.308571
uuid-421d5c86d1f447d4b91427287fb517ba,approval,0.40287
uuid-421d5c86d1f447d4b91427287fb517ba,preferred,0.333549
uuid-421d5c86d1f447d4b91427287fb517ba,monotherapy,0.4218
uuid-421d5c86d1f447d4b91427287fb517ba,using nivo,0.52988
uuid-421d5c86d1f447d4b91427287fb517ba,data,0.311663
uuid-421d5c86d1f447d4b91427287fb517ba,clinical trials,0.312251
uuid-421d5c86d1f447d4b91427287fb517ba,indication,0.316053
uuid-421d5c86d1f447d4b91427287fb517ba,approved,0.404467
uuid-421d5c86d1f447d4b91427287fb517ba,SCCHN,0.357858
uuid-421d5c86d1f447d4b91427287fb517ba,HCP,0.329755
uuid-421d5c86d1f447d4b91427287fb517ba,chemotherapy,0.322566
uuid-421d5c86d1f447d4b91427287fb517ba,impressed,0.402027
uuid-421d5c86d1f447d4b91427287fb517ba,LTL,0.323396
uuid-421d5c86d1f447d4b91427287fb517ba,SCLC,0.369367
uuid-421d5c86d1f447d4b91427287fb517ba,feels,0.386651
uuid-421d5c86d1f447d4b91427287fb517ba,RTL stated,0.383738
uuid-421d5c86d1f447d4b91427287fb517ba,option,0.45851
uuid-421d5c86d1f447d4b91427287fb517ba,bladder,0.322585
uuid-f1121da3cd14417291810296775ee1fa,pembro,0.570225
uuid-f1121da3cd14417291810296775ee1fa,RTL,0.479676
uuid-f1121da3cd14417291810296775ee1fa,1L,0.341589
uuid-f1121da3cd14417291810296775ee1fa,PDL1,0.339375
uuid-f1121da3cd14417291810296775ee1fa,trial,0.397337
uuid-f1121da3cd14417291810296775ee1fa,commented,0.378828
uuid-f1121da3cd14417291810296775ee1fa,Merck,0.334479
uuid-f1121da3cd14417291810296775ee1fa,stated,0.417829
uuid-f1121da3cd14417291810296775ee1fa,approval,0.51502
uuid-f1121da3cd14417291810296775ee1fa,atezo,0.488676
uuid-f1121da3cd14417291810296775ee1fa,using nivo,0.371711
uuid-f1121da3cd14417291810296775ee1fa,data,0.541863
uuid-f1121da3cd14417291810296775ee1fa,expressed,0.354344
uuid-f1121da3cd14417291810296775ee1fa,mentioned,0.300491
uuid-f1121da3cd14417291810296775ee1fa,clinical trials,0.385869
uuid-f1121da3cd14417291810296775ee1fa,indication,0.466168
uuid-f1121da3cd14417291810296775ee1fa,approved,0.449749
uuid-f1121da3cd14417291810296775ee1fa,SCCHN,0.506992
uuid-f1121da3cd14417291810296775ee1fa,HCP,0.337691
uuid-f1121da3cd14417291810296775ee1fa,nivo and pembro,0.370639
uuid-f1121da3cd14417291810296775ee1fa,impressed,0.449582
uuid-f1121da3cd14417291810296775ee1fa,label,0.48579
uuid-f1121da3cd14417291810296775ee1fa,LTL,0.391173
uuid-f1121da3cd14417291810296775ee1fa,TLs,0.35153
uuid-f1121da3cd14417291810296775ee1fa,SCLC,0.346542
uuid-f1121da3cd14417291810296775ee1fa,Regional TL,0.347963
uuid-f1121da3cd14417291810296775ee1fa,PDL1 expression,0.417037
uuid-f1121da3cd14417291810296775ee1fa,bladder,0.368323
uuid-26bceb9aa75a430eb1229c0be37ba13a,patients,0.494421
uuid-26bceb9aa75a430eb1229c0be37ba13a,pembro,0.349003
uuid-26bceb9aa75a430eb1229c0be37ba13a,1L,0.318375
uuid-26bceb9aa75a430eb1229c0be37ba13a,regimen,0.362708
uuid-26bceb9aa75a430eb1229c0be37ba13a,combination,0.30596
uuid-26bceb9aa75a430eb1229c0be37ba13a,2L,0.321563
uuid-26bceb9aa75a430eb1229c0be37ba13a,preferred,0.498993
uuid-26bceb9aa75a430eb1229c0be37ba13a,monotherapy,0.398437
uuid-26bceb9aa75a430eb1229c0be37ba13a,treatment,0.316108
uuid-26bceb9aa75a430eb1229c0be37ba13a,clinical trials,0.451974
uuid-26bceb9aa75a430eb1229c0be37ba13a,indication,0.406848
uuid-26bceb9aa75a430eb1229c0be37ba13a,approved,0.351394
uuid-26bceb9aa75a430eb1229c0be37ba13a,chemotherapy,0.443989
uuid-26bceb9aa75a430eb1229c0be37ba13a,option,0.52566
uuid-d03e67f78cea4d85b1805433898124a8,Nivo,0.366105
uuid-d03e67f78cea4d85b1805433898124a8,patients,0.347081
uuid-d03e67f78cea4d85b1805433898124a8,Opdivo,0.338072
uuid-d03e67f78cea4d85b1805433898124a8,pembro,0.508685
uuid-d03e67f78cea4d85b1805433898124a8,dose,0.461091
uuid-d03e67f78cea4d85b1805433898124a8,nivolumab,0.312919
uuid-d03e67f78cea4d85b1805433898124a8,trial,0.466345
uuid-d03e67f78cea4d85b1805433898124a8,Ipi,0.388983
uuid-d03e67f78cea4d85b1805433898124a8,approval,0.459009
uuid-d03e67f78cea4d85b1805433898124a8,atezo,0.329916
uuid-d03e67f78cea4d85b1805433898124a8,clinical trials,0.463945
uuid-d03e67f78cea4d85b1805433898124a8,indication,0.380301
uuid-d03e67f78cea4d85b1805433898124a8,approved,0.456594
uuid-d03e67f78cea4d85b1805433898124a8,vs,0.396326
uuid-d03e67f78cea4d85b1805433898124a8,label,0.35241
uuid-d03e67f78cea4d85b1805433898124a8,feels,0.331287
uuid-d03e67f78cea4d85b1805433898124a8,flat dosing,0.478856
uuid-03c96bbbe8014832a39f0d24c45c87e3,Nivo,0.347898
uuid-03c96bbbe8014832a39f0d24c45c87e3,patients,0.311374
uuid-03c96bbbe8014832a39f0d24c45c87e3,pembro,0.327074
uuid-03c96bbbe8014832a39f0d24c45c87e3,1L,0.474162
uuid-03c96bbbe8014832a39f0d24c45c87e3,PDL1,0.368684
uuid-03c96bbbe8014832a39f0d24c45c87e3,chemo,0.459019
uuid-03c96bbbe8014832a39f0d24c45c87e3,2L,0.383989
uuid-03c96bbbe8014832a39f0d24c45c87e3,pts,0.401814
uuid-03c96bbbe8014832a39f0d24c45c87e3,preferred,0.318607
uuid-03c96bbbe8014832a39f0d24c45c87e3,monotherapy,0.481635
uuid-03c96bbbe8014832a39f0d24c45c87e3,using nivo,0.301323
uuid-03c96bbbe8014832a39f0d24c45c87e3,PD1,0.313753
uuid-03c96bbbe8014832a39f0d24c45c87e3,nivo and pembro,0.437568
uuid-03c96bbbe8014832a39f0d24c45c87e3,believes,0.48718
uuid-03c96bbbe8014832a39f0d24c45c87e3,chemotherapy,0.352455
uuid-03c96bbbe8014832a39f0d24c45c87e3,respond,0.362962
uuid-03c96bbbe8014832a39f0d24c45c87e3,feels,0.417875
uuid-03c96bbbe8014832a39f0d24c45c87e3,option,0.491511
uuid-0e6b5c1a1b334681ba7d45b08c14a188,patients,0.438135
uuid-0e6b5c1a1b334681ba7d45b08c14a188,TL,0.310736
uuid-0e6b5c1a1b334681ba7d45b08c14a188,treated,0.302105
uuid-0e6b5c1a1b334681ba7d45b08c14a188,TL stated,0.376035
uuid-0e6b5c1a1b334681ba7d45b08c14a188,pts,0.303256
uuid-0e6b5c1a1b334681ba7d45b08c14a188,PD-L1,0.491026
uuid-0e6b5c1a1b334681ba7d45b08c14a188,approval,0.365577
uuid-0e6b5c1a1b334681ba7d45b08c14a188,PD-L1 testing,0.544613
uuid-0e6b5c1a1b334681ba7d45b08c14a188,testing,0.662194
uuid-0e6b5c1a1b334681ba7d45b08c14a188,using nivo,0.308787
uuid-0e6b5c1a1b334681ba7d45b08c14a188,PDL1 testing,0.595962
uuid-0e6b5c1a1b334681ba7d45b08c14a188,NSCLC patients,0.725697
uuid-0e6b5c1a1b334681ba7d45b08c14a188,SCCHN,0.35382
uuid-0e6b5c1a1b334681ba7d45b08c14a188,tumor types,0.438723
uuid-0e6b5c1a1b334681ba7d45b08c14a188,RTL stated,0.381706
uuid-0e6b5c1a1b334681ba7d45b08c14a188,bladder,0.335804
uuid-4435c6c23e974ccd90e303a55de85946,TL,0.559758
uuid-4435c6c23e974ccd90e303a55de85946,RTL,0.582979
uuid-4435c6c23e974ccd90e303a55de85946,NTL,0.377128
uuid-4435c6c23e974ccd90e303a55de85946,TL stated,0.530504
uuid-4435c6c23e974ccd90e303a55de85946,institution,0.314911
uuid-4435c6c23e974ccd90e303a55de85946,stated,0.376674
uuid-4435c6c23e974ccd90e303a55de85946,PD-L1,0.603317
uuid-4435c6c23e974ccd90e303a55de85946,approval,0.311393
uuid-4435c6c23e974ccd90e303a55de85946,PD-L1 testing,0.675927
uuid-4435c6c23e974ccd90e303a55de85946,testing,0.728259
uuid-4435c6c23e974ccd90e303a55de85946,expressed,0.30764
uuid-4435c6c23e974ccd90e303a55de85946,PDL1 testing,0.673617
uuid-4435c6c23e974ccd90e303a55de85946,NSCLC patients,0.645357
uuid-4435c6c23e974ccd90e303a55de85946,SCCHN,0.45654
uuid-4435c6c23e974ccd90e303a55de85946,HCP,0.373854
uuid-4435c6c23e974ccd90e303a55de85946,LTL,0.429451
uuid-4435c6c23e974ccd90e303a55de85946,TLs,0.306149
uuid-4435c6c23e974ccd90e303a55de85946,academic,0.313403
uuid-4435c6c23e974ccd90e303a55de85946,assay,0.437851
uuid-4435c6c23e974ccd90e303a55de85946,Regional TL,0.421563
uuid-4435c6c23e974ccd90e303a55de85946,RTL stated,0.341895
uuid-4435c6c23e974ccd90e303a55de85946,bladder,0.31157
uuid-7405933a8f4a48f389792ee2ab01307f,1L,0.317676
uuid-7405933a8f4a48f389792ee2ab01307f,PDL1,0.707473
uuid-7405933a8f4a48f389792ee2ab01307f,efficacy,0.359701
uuid-7405933a8f4a48f389792ee2ab01307f,PD-L1,0.562389
uuid-7405933a8f4a48f389792ee2ab01307f,testing,0.479047
uuid-7405933a8f4a48f389792ee2ab01307f,PDL1 testing,0.345433
uuid-7405933a8f4a48f389792ee2ab01307f,NSCLC patients,0.411453
uuid-7405933a8f4a48f389792ee2ab01307f,ORR,0.326096
uuid-7405933a8f4a48f389792ee2ab01307f,nivo and pembro,0.406104
uuid-7405933a8f4a48f389792ee2ab01307f,believes,0.376936
uuid-7405933a8f4a48f389792ee2ab01307f,tumor types,0.370802
uuid-7405933a8f4a48f389792ee2ab01307f,assay,0.352758
uuid-7405933a8f4a48f389792ee2ab01307f,PDL1 expression,0.604078
uuid-7405933a8f4a48f389792ee2ab01307f,biomarker,0.651463
uuid-392ca6d28bec4758a9589c6aae357139,RTL,0.433631
uuid-392ca6d28bec4758a9589c6aae357139,lung,0.460649
uuid-392ca6d28bec4758a9589c6aae357139,regimen,0.304287
uuid-392ca6d28bec4758a9589c6aae357139,treated,0.320423
uuid-392ca6d28bec4758a9589c6aae357139,NTL,0.342069
uuid-392ca6d28bec4758a9589c6aae357139,discussed,0.339796
uuid-392ca6d28bec4758a9589c6aae357139,melanoma,0.694434
uuid-392ca6d28bec4758a9589c6aae357139,shared,0.456954
uuid-392ca6d28bec4758a9589c6aae357139,RCC,0.499588
uuid-392ca6d28bec4758a9589c6aae357139,SCCHN,0.520852
uuid-392ca6d28bec4758a9589c6aae357139,TLs,0.41283
uuid-392ca6d28bec4758a9589c6aae357139,academic,0.800191
uuid-392ca6d28bec4758a9589c6aae357139,Regional TL,0.425324
uuid-392ca6d28bec4758a9589c6aae357139,RTL stated,0.525261
uuid-392ca6d28bec4758a9589c6aae357139,TL shared,0.562277
uuid-9a0fd649a8df405d86bd1fc03192c550,dose,0.539243
uuid-9a0fd649a8df405d86bd1fc03192c550,toxicity,0.607352
uuid-9a0fd649a8df405d86bd1fc03192c550,regimen,0.377201
uuid-9a0fd649a8df405d86bd1fc03192c550,academic,0.312952
uuid-9a0fd649a8df405d86bd1fc03192c550,flat dosing,0.301041
uuid-73e205f642e246ef86fd6072ba88f7dc,NSCLC,0.425623
uuid-73e205f642e246ef86fd6072ba88f7dc,data,0.463407
uuid-73e205f642e246ef86fd6072ba88f7dc,NCCN,0.473124
uuid-8a8518230627401d8208c0d29ee3459d,NSCLC,0.460928
uuid-8a8518230627401d8208c0d29ee3459d,data,0.325525
uuid-8a8518230627401d8208c0d29ee3459d,NCCN,0.536764
uuid-a768cdba0cc34955b73585ef1f594362,NSCLC,0.438868
uuid-a768cdba0cc34955b73585ef1f594362,data,0.303457
uuid-a768cdba0cc34955b73585ef1f594362,NCCN,0.531073
uuid-d62349874acb4ad581dd17e2ed854346,Nivo,0.353023
uuid-d62349874acb4ad581dd17e2ed854346,patients,0.540439
uuid-d62349874acb4ad581dd17e2ed854346,therapy,0.509242
uuid-d62349874acb4ad581dd17e2ed854346,1L,0.406672
uuid-d62349874acb4ad581dd17e2ed854346,chemo,0.436509
uuid-d62349874acb4ad581dd17e2ed854346,2L,0.335493
uuid-d62349874acb4ad581dd17e2ed854346,pts,0.442687
uuid-d62349874acb4ad581dd17e2ed854346,preferred,0.338492
uuid-d62349874acb4ad581dd17e2ed854346,monotherapy,0.424968
uuid-d62349874acb4ad581dd17e2ed854346,treatment,0.364883
uuid-d62349874acb4ad581dd17e2ed854346,using nivo,0.309566
uuid-d62349874acb4ad581dd17e2ed854346,NSCLC patients,0.320404
uuid-d62349874acb4ad581dd17e2ed854346,PD1,0.342515
uuid-d62349874acb4ad581dd17e2ed854346,progression,0.451613
uuid-d62349874acb4ad581dd17e2ed854346,chemotherapy,0.396743
uuid-d62349874acb4ad581dd17e2ed854346,respond,0.406221
uuid-d62349874acb4ad581dd17e2ed854346,option,0.484865
uuid-0d47f38471d6444e960f1c6ff50bea7d,BMS,0.314001
uuid-0d47f38471d6444e960f1c6ff50bea7d,PDL1,0.518835
uuid-0d47f38471d6444e960f1c6ff50bea7d,trial,0.38499
uuid-0d47f38471d6444e960f1c6ff50bea7d,efficacy,0.525501
uuid-0d47f38471d6444e960f1c6ff50bea7d,discussed,0.374475
uuid-0d47f38471d6444e960f1c6ff50bea7d,commented,0.393893
uuid-0d47f38471d6444e960f1c6ff50bea7d,OS,0.742442
uuid-0d47f38471d6444e960f1c6ff50bea7d,regards,0.395582
uuid-0d47f38471d6444e960f1c6ff50bea7d,data,0.791775
uuid-0d47f38471d6444e960f1c6ff50bea7d,PFS,0.718155
uuid-0d47f38471d6444e960f1c6ff50bea7d,ORR,0.723413
uuid-0d47f38471d6444e960f1c6ff50bea7d,nivo and pembro,0.482559
uuid-0d47f38471d6444e960f1c6ff50bea7d,ASCO,0.320331
uuid-0d47f38471d6444e960f1c6ff50bea7d,believes,0.316204
uuid-0d47f38471d6444e960f1c6ff50bea7d,impressed,0.542134
uuid-0d47f38471d6444e960f1c6ff50bea7d,feels,0.371526
uuid-0d47f38471d6444e960f1c6ff50bea7d,PDL1 expression,0.525855
uuid-7a1b8491aba74eb68f60deead5d4e19d,RTL,0.423318
uuid-7a1b8491aba74eb68f60deead5d4e19d,BMS,0.475135
uuid-7a1b8491aba74eb68f60deead5d4e19d,lung,0.426793
uuid-7a1b8491aba74eb68f60deead5d4e19d,NTL,0.348833
uuid-7a1b8491aba74eb68f60deead5d4e19d,discussed,0.329999
uuid-7a1b8491aba74eb68f60deead5d4e19d,shared,0.401451
uuid-7a1b8491aba74eb68f60deead5d4e19d,commented,0.551393
uuid-7a1b8491aba74eb68f60deead5d4e19d,RCC,0.309097
uuid-7a1b8491aba74eb68f60deead5d4e19d,TL stated,0.407697
uuid-7a1b8491aba74eb68f60deead5d4e19d,Merck,0.532259
uuid-7a1b8491aba74eb68f60deead5d4e19d,stated,0.496707
uuid-7a1b8491aba74eb68f60deead5d4e19d,data,0.494286
uuid-7a1b8491aba74eb68f60deead5d4e19d,expressed,0.372561
uuid-7a1b8491aba74eb68f60deead5d4e19d,SCCHN,0.482526
uuid-7a1b8491aba74eb68f60deead5d4e19d,ASCO,0.324883
uuid-7a1b8491aba74eb68f60deead5d4e19d,impressed,0.420047
uuid-7a1b8491aba74eb68f60deead5d4e19d,LTL,0.404278
uuid-7a1b8491aba74eb68f60deead5d4e19d,TLs,0.43995
uuid-7a1b8491aba74eb68f60deead5d4e19d,Regional TL,0.462323
uuid-7a1b8491aba74eb68f60deead5d4e19d,bladder,0.313202
uuid-63638aa0c0174056911c8f4ff7cebf49,BMS,0.628315
uuid-63638aa0c0174056911c8f4ff7cebf49,trial,0.463756
uuid-63638aa0c0174056911c8f4ff7cebf49,commented,0.428579
uuid-63638aa0c0174056911c8f4ff7cebf49,Merck,0.540214
uuid-63638aa0c0174056911c8f4ff7cebf49,regards,0.318683
uuid-63638aa0c0174056911c8f4ff7cebf49,data,0.485592
uuid-63638aa0c0174056911c8f4ff7cebf49,expressed,0.506671
uuid-63638aa0c0174056911c8f4ff7cebf49,impressed,0.446178
uuid-663223ac46304fb8b4f12a92837e0ee6,TL,0.386412
uuid-663223ac46304fb8b4f12a92837e0ee6,pembro,0.486332
uuid-663223ac46304fb8b4f12a92837e0ee6,1L,0.511384
uuid-663223ac46304fb8b4f12a92837e0ee6,PDL1,0.637004
uuid-663223ac46304fb8b4f12a92837e0ee6,TL stated,0.510111
uuid-663223ac46304fb8b4f12a92837e0ee6,2L,0.402228
uuid-663223ac46304fb8b4f12a92837e0ee6,Merck,0.389552
uuid-663223ac46304fb8b4f12a92837e0ee6,PD-L1,0.765047
uuid-663223ac46304fb8b4f12a92837e0ee6,approval,0.358888
uuid-663223ac46304fb8b4f12a92837e0ee6,atezo,0.489198
uuid-663223ac46304fb8b4f12a92837e0ee6,PD-L1 testing,0.627681
uuid-663223ac46304fb8b4f12a92837e0ee6,testing,0.803678
uuid-663223ac46304fb8b4f12a92837e0ee6,PDL1 testing,0.775664
uuid-663223ac46304fb8b4f12a92837e0ee6,NSCLC patients,0.723801
uuid-663223ac46304fb8b4f12a92837e0ee6,nivo and pembro,0.362946
uuid-663223ac46304fb8b4f12a92837e0ee6,tumor types,0.335484
uuid-663223ac46304fb8b4f12a92837e0ee6,assay,0.586852
uuid-663223ac46304fb8b4f12a92837e0ee6,PDL1 expression,0.447995
uuid-663223ac46304fb8b4f12a92837e0ee6,biomarker,0.460711
uuid-95881daf9bf744409562230bc080d765,Nivo,0.521232
uuid-95881daf9bf744409562230bc080d765,patients,0.459103
uuid-95881daf9bf744409562230bc080d765,pembro,0.459795
uuid-95881daf9bf744409562230bc080d765,therapy,0.367133
uuid-95881daf9bf744409562230bc080d765,nivolumab,0.429966
uuid-95881daf9bf744409562230bc080d765,1L,0.601986
uuid-95881daf9bf744409562230bc080d765,regimen,0.3449
uuid-95881daf9bf744409562230bc080d765,treated,0.339256
uuid-95881daf9bf744409562230bc080d765,RCC,0.495572
uuid-95881daf9bf744409562230bc080d765,chemo,0.353547
uuid-95881daf9bf744409562230bc080d765,2L,0.700196
uuid-95881daf9bf744409562230bc080d765,agents,0.382014
uuid-95881daf9bf744409562230bc080d765,approval,0.440596
uuid-95881daf9bf744409562230bc080d765,atezo,0.435577
uuid-95881daf9bf744409562230bc080d765,preferred,0.741606
uuid-95881daf9bf744409562230bc080d765,monotherapy,0.597396
uuid-95881daf9bf744409562230bc080d765,treatment,0.384851
uuid-95881daf9bf744409562230bc080d765,using nivo,0.719123
uuid-95881daf9bf744409562230bc080d765,approved,0.469673
uuid-95881daf9bf744409562230bc080d765,SCCHN,0.411039
uuid-95881daf9bf744409562230bc080d765,chemotherapy,0.322066
uuid-95881daf9bf744409562230bc080d765,RTL stated,0.654868
uuid-95881daf9bf744409562230bc080d765,TL shared,0.349999
uuid-95881daf9bf744409562230bc080d765,option,0.635684
uuid-388fcead4ca64d8783945131acc6f352,pembro,0.317426
uuid-388fcead4ca64d8783945131acc6f352,BMS,0.390864
uuid-388fcead4ca64d8783945131acc6f352,PDL1,0.55908
uuid-388fcead4ca64d8783945131acc6f352,trial,0.495484
uuid-388fcead4ca64d8783945131acc6f352,efficacy,0.487978
uuid-388fcead4ca64d8783945131acc6f352,Merck,0.304235
uuid-388fcead4ca64d8783945131acc6f352,OS,0.547284
uuid-388fcead4ca64d8783945131acc6f352,regards,0.346592
uuid-388fcead4ca64d8783945131acc6f352,data,0.66576
uuid-388fcead4ca64d8783945131acc6f352,PFS,0.58724
uuid-388fcead4ca64d8783945131acc6f352,ORR,0.558718
uuid-388fcead4ca64d8783945131acc6f352,nivo and pembro,0.614505
uuid-388fcead4ca64d8783945131acc6f352,believes,0.448801
uuid-388fcead4ca64d8783945131acc6f352,impressed,0.35405
uuid-388fcead4ca64d8783945131acc6f352,feels,0.482828
uuid-388fcead4ca64d8783945131acc6f352,PDL1 expression,0.523422
uuid-388fcead4ca64d8783945131acc6f352,biomarker,0.33308
uuid-c294f7f61d50415c9df3749b1afe2ac8,NSCLC,0.327166
uuid-c294f7f61d50415c9df3749b1afe2ac8,PDL1,0.368705
uuid-c294f7f61d50415c9df3749b1afe2ac8,trial,0.386712
uuid-c294f7f61d50415c9df3749b1afe2ac8,efficacy,0.491806
uuid-c294f7f61d50415c9df3749b1afe2ac8,commented,0.320704
uuid-c294f7f61d50415c9df3749b1afe2ac8,OS,0.652483
uuid-c294f7f61d50415c9df3749b1afe2ac8,regards,0.365449
uuid-c294f7f61d50415c9df3749b1afe2ac8,data,0.66076
uuid-c294f7f61d50415c9df3749b1afe2ac8,PFS,0.672686
uuid-c294f7f61d50415c9df3749b1afe2ac8,ORR,0.672302
uuid-c294f7f61d50415c9df3749b1afe2ac8,nivo and pembro,0.383018
uuid-c294f7f61d50415c9df3749b1afe2ac8,impressed,0.47775
uuid-c294f7f61d50415c9df3749b1afe2ac8,PDL1 expression,0.323658
uuid-c294f7f61d50415c9df3749b1afe2ac8,NCCN,0.338341
uuid-d73bdf269b7b47a099245636b8b05d3c,drug,0.308942
uuid-c149fb06020f4d6faac4d25229f3975c,toxicity,0.335812
uuid-c149fb06020f4d6faac4d25229f3975c,efficacy,0.319537
uuid-c149fb06020f4d6faac4d25229f3975c,regimen,0.444636
uuid-c149fb06020f4d6faac4d25229f3975c,chemo,0.335143
uuid-c149fb06020f4d6faac4d25229f3975c,OS,0.41314
uuid-c149fb06020f4d6faac4d25229f3975c,treatment,0.387227
uuid-c149fb06020f4d6faac4d25229f3975c,response,0.471364
uuid-c149fb06020f4d6faac4d25229f3975c,PFS,0.349389
uuid-c149fb06020f4d6faac4d25229f3975c,ORR,0.360222
uuid-c149fb06020f4d6faac4d25229f3975c,progression,0.401068
uuid-c149fb06020f4d6faac4d25229f3975c,believes,0.343105
uuid-c149fb06020f4d6faac4d25229f3975c,respond,0.484486
uuid-c149fb06020f4d6faac4d25229f3975c,feels,0.34895
uuid-3ec274d97b864c178b023f84cba715ea,TL,0.446014
uuid-3ec274d97b864c178b023f84cba715ea,lung,0.308493
uuid-3ec274d97b864c178b023f84cba715ea,1L,0.311623
uuid-3ec274d97b864c178b023f84cba715ea,RCC,0.378804
uuid-3ec274d97b864c178b023f84cba715ea,TL stated,0.592308
uuid-3ec274d97b864c178b023f84cba715ea,institution,0.386444
uuid-3ec274d97b864c178b023f84cba715ea,PD-L1,0.66741
uuid-3ec274d97b864c178b023f84cba715ea,PD-L1 testing,0.732639
uuid-3ec274d97b864c178b023f84cba715ea,testing,0.774293
uuid-3ec274d97b864c178b023f84cba715ea,PDL1 testing,0.783208
uuid-3ec274d97b864c178b023f84cba715ea,NSCLC patients,0.654729
uuid-3ec274d97b864c178b023f84cba715ea,tumor types,0.323101
uuid-3ec274d97b864c178b023f84cba715ea,assay,0.513982
uuid-3ec274d97b864c178b023f84cba715ea,biomarker,0.344751
uuid-68e4b93bb6df413e9309c427fd9ee60c,Nivo,0.341944
uuid-68e4b93bb6df413e9309c427fd9ee60c,pembro,0.50731
uuid-68e4b93bb6df413e9309c427fd9ee60c,BMS,0.405586
uuid-68e4b93bb6df413e9309c427fd9ee60c,1L,0.440364
uuid-68e4b93bb6df413e9309c427fd9ee60c,2L,0.478235
uuid-68e4b93bb6df413e9309c427fd9ee60c,agents,0.460538
uuid-68e4b93bb6df413e9309c427fd9ee60c,atezo,0.495883
uuid-68e4b93bb6df413e9309c427fd9ee60c,preferred,0.427633
uuid-68e4b93bb6df413e9309c427fd9ee60c,monotherapy,0.33319
uuid-68e4b93bb6df413e9309c427fd9ee60c,using nivo,0.317272
uuid-68e4b93bb6df413e9309c427fd9ee60c,combo,0.353478
uuid-68e4b93bb6df413e9309c427fd9ee60c,approved,0.407718
uuid-68e4b93bb6df413e9309c427fd9ee60c,nivo and pembro,0.346295
uuid-68e4b93bb6df413e9309c427fd9ee60c,believes,0.334977
uuid-68e4b93bb6df413e9309c427fd9ee60c,feels,0.516361
uuid-68e4b93bb6df413e9309c427fd9ee60c,option,0.387845
uuid-55244eff039c46bb83c2a1c5427be929,Nivo,0.465959
uuid-55244eff039c46bb83c2a1c5427be929,pembro,0.670931
uuid-55244eff039c46bb83c2a1c5427be929,1L,0.335012
uuid-55244eff039c46bb83c2a1c5427be929,trial,0.517604
uuid-55244eff039c46bb83c2a1c5427be929,efficacy,0.493408
uuid-55244eff039c46bb83c2a1c5427be929,2L,0.38323
uuid-55244eff039c46bb83c2a1c5427be929,Ipi,0.401501
uuid-55244eff039c46bb83c2a1c5427be929,atezo,0.661357
uuid-55244eff039c46bb83c2a1c5427be929,regards,0.318201
uuid-55244eff039c46bb83c2a1c5427be929,data,0.445994
uuid-55244eff039c46bb83c2a1c5427be929,indication,0.325578
uuid-55244eff039c46bb83c2a1c5427be929,PFS,0.303897
uuid-55244eff039c46bb83c2a1c5427be929,ORR,0.331155
uuid-55244eff039c46bb83c2a1c5427be929,nivo and pembro,0.594773
uuid-55244eff039c46bb83c2a1c5427be929,believes,0.321941
uuid-55244eff039c46bb83c2a1c5427be929,impressed,0.349809
uuid-55244eff039c46bb83c2a1c5427be929,vs,0.535511
uuid-55244eff039c46bb83c2a1c5427be929,TLs,0.445628
uuid-55244eff039c46bb83c2a1c5427be929,feels,0.376601
uuid-c232978cbf9044089bea2de0da46e568,Nivo,0.412045
uuid-c232978cbf9044089bea2de0da46e568,patients,0.386272
uuid-c232978cbf9044089bea2de0da46e568,Opdivo,0.385132
uuid-c232978cbf9044089bea2de0da46e568,pembro,0.426086
uuid-c232978cbf9044089bea2de0da46e568,dose,0.80615
uuid-c232978cbf9044089bea2de0da46e568,toxicity,0.338604
uuid-c232978cbf9044089bea2de0da46e568,efficacy,0.331798
uuid-c232978cbf9044089bea2de0da46e568,Ipi,0.468614
uuid-c232978cbf9044089bea2de0da46e568,atezo,0.450081
uuid-c232978cbf9044089bea2de0da46e568,preferred,0.332929
uuid-c232978cbf9044089bea2de0da46e568,vs,0.642068
uuid-c232978cbf9044089bea2de0da46e568,Keytruda,0.358895
uuid-c232978cbf9044089bea2de0da46e568,flat dosing,0.56318
uuid-124f230d23d641ea898305e1a4fdddbe,PDL1,0.397156
uuid-124f230d23d641ea898305e1a4fdddbe,trial,0.44632
uuid-124f230d23d641ea898305e1a4fdddbe,efficacy,0.445152
uuid-124f230d23d641ea898305e1a4fdddbe,commented,0.373927
uuid-124f230d23d641ea898305e1a4fdddbe,OS,0.710767
uuid-124f230d23d641ea898305e1a4fdddbe,data,0.611638
uuid-124f230d23d641ea898305e1a4fdddbe,PFS,0.704947
uuid-124f230d23d641ea898305e1a4fdddbe,ORR,0.702059
uuid-124f230d23d641ea898305e1a4fdddbe,nivo and pembro,0.359701
uuid-124f230d23d641ea898305e1a4fdddbe,impressed,0.563171
uuid-124f230d23d641ea898305e1a4fdddbe,feels,0.419657
uuid-124f230d23d641ea898305e1a4fdddbe,PDL1 expression,0.368862
uuid-228d926de7a341e184d08b6c061a4484,Nivo,0.443093
uuid-228d926de7a341e184d08b6c061a4484,pembro,0.408543
uuid-228d926de7a341e184d08b6c061a4484,dose,0.806813
uuid-228d926de7a341e184d08b6c061a4484,toxicity,0.374758
uuid-228d926de7a341e184d08b6c061a4484,efficacy,0.30092
uuid-228d926de7a341e184d08b6c061a4484,regimen,0.400539
uuid-228d926de7a341e184d08b6c061a4484,Ipi,0.769168
uuid-228d926de7a341e184d08b6c061a4484,atezo,0.354821
uuid-228d926de7a341e184d08b6c061a4484,combo,0.313956
uuid-228d926de7a341e184d08b6c061a4484,indication,0.304331
uuid-228d926de7a341e184d08b6c061a4484,vs,0.505142
uuid-228d926de7a341e184d08b6c061a4484,flat dosing,0.614162
uuid-2dea7239cfdc456e9c6aae41a4dacb93,RTL,0.519157
uuid-2dea7239cfdc456e9c6aae41a4dacb93,NTL,0.319577
uuid-2dea7239cfdc456e9c6aae41a4dacb93,shared,0.412643
uuid-2dea7239cfdc456e9c6aae41a4dacb93,commented,0.528861
uuid-2dea7239cfdc456e9c6aae41a4dacb93,institution,0.3485
uuid-2dea7239cfdc456e9c6aae41a4dacb93,stated,0.529787
uuid-2dea7239cfdc456e9c6aae41a4dacb93,approval,0.362556
uuid-2dea7239cfdc456e9c6aae41a4dacb93,data,0.388963
uuid-2dea7239cfdc456e9c6aae41a4dacb93,expressed,0.376509
uuid-2dea7239cfdc456e9c6aae41a4dacb93,clinical trials,0.384852
uuid-2dea7239cfdc456e9c6aae41a4dacb93,indication,0.362644
uuid-2dea7239cfdc456e9c6aae41a4dacb93,SCCHN,0.585894
uuid-2dea7239cfdc456e9c6aae41a4dacb93,impressed,0.435031
uuid-2dea7239cfdc456e9c6aae41a4dacb93,LTL,0.448138
uuid-2dea7239cfdc456e9c6aae41a4dacb93,TLs,0.546921
uuid-2dea7239cfdc456e9c6aae41a4dacb93,academic,0.401342
uuid-2dea7239cfdc456e9c6aae41a4dacb93,Regional TL,0.569647
uuid-2dea7239cfdc456e9c6aae41a4dacb93,bladder,0.314442
uuid-15f6e84d23e9439f87392e824f156a66,RTL,0.447253
uuid-15f6e84d23e9439f87392e824f156a66,BMS,0.530816
uuid-15f6e84d23e9439f87392e824f156a66,trial,0.618311
uuid-15f6e84d23e9439f87392e824f156a66,Merck,0.487332
uuid-15f6e84d23e9439f87392e824f156a66,stated,0.341224
uuid-15f6e84d23e9439f87392e824f156a66,mentioned,0.410244
uuid-15f6e84d23e9439f87392e824f156a66,clinical trials,0.418594
uuid-ca79738a42004f19812dae2b06a561dc,patients,0.3356
uuid-ca79738a42004f19812dae2b06a561dc,trial,0.452195
uuid-ca79738a42004f19812dae2b06a561dc,chemo,0.318006
uuid-ca79738a42004f19812dae2b06a561dc,pts,0.332176
uuid-ca79738a42004f19812dae2b06a561dc,response,0.411112
uuid-ca79738a42004f19812dae2b06a561dc,chemotherapy,0.305793
uuid-ca79738a42004f19812dae2b06a561dc,respond,0.32737
uuid-ca79738a42004f19812dae2b06a561dc,feels,0.426334
uuid-23c219befe3b48079f21065d6d9ade18,Nivo,0.409249
uuid-23c219befe3b48079f21065d6d9ade18,pembro,0.498423
uuid-23c219befe3b48079f21065d6d9ade18,1L,0.344587
uuid-23c219befe3b48079f21065d6d9ade18,PDL1,0.592999
uuid-23c219befe3b48079f21065d6d9ade18,trial,0.300572
uuid-23c219befe3b48079f21065d6d9ade18,efficacy,0.575721
uuid-23c219befe3b48079f21065d6d9ade18,2L,0.324133
uuid-23c219befe3b48079f21065d6d9ade18,agents,0.307069
uuid-23c219befe3b48079f21065d6d9ade18,OS,0.426379
uuid-23c219befe3b48079f21065d6d9ade18,atezo,0.552659
uuid-23c219befe3b48079f21065d6d9ade18,regards,0.324863
uuid-23c219befe3b48079f21065d6d9ade18,data,0.403699
uuid-23c219befe3b48079f21065d6d9ade18,PFS,0.465927
uuid-23c219befe3b48079f21065d6d9ade18,AI,0.370683
uuid-23c219befe3b48079f21065d6d9ade18,ORR,0.454505
uuid-23c219befe3b48079f21065d6d9ade18,nivo and pembro,0.758657
uuid-23c219befe3b48079f21065d6d9ade18,believes,0.475567
uuid-23c219befe3b48079f21065d6d9ade18,vs,0.380944
uuid-23c219befe3b48079f21065d6d9ade18,feels,0.354846
uuid-23c219befe3b48079f21065d6d9ade18,PDL1 expression,0.546025
uuid-23c219befe3b48079f21065d6d9ade18,biomarker,0.30286
uuid-6224de71a3d04474b04c35c0b111b3a2,patients,0.443052
uuid-6224de71a3d04474b04c35c0b111b3a2,Opdivo,0.330998
uuid-6224de71a3d04474b04c35c0b111b3a2,dose,0.641541
uuid-6224de71a3d04474b04c35c0b111b3a2,Ipi,0.316763
uuid-6224de71a3d04474b04c35c0b111b3a2,preferred,0.33749
uuid-6224de71a3d04474b04c35c0b111b3a2,using nivo,0.344528
uuid-6224de71a3d04474b04c35c0b111b3a2,vs,0.405565
uuid-6224de71a3d04474b04c35c0b111b3a2,flat dosing,0.529998
uuid-2106c64f52b64150906437f365aac840,nivolumab,0.321805
uuid-2106c64f52b64150906437f365aac840,trial,0.390078
uuid-2106c64f52b64150906437f365aac840,discussed,0.306298
uuid-2106c64f52b64150906437f365aac840,data,0.418337
uuid-2106c64f52b64150906437f365aac840,PFS,0.327409
uuid-2106c64f52b64150906437f365aac840,ORR,0.309487
uuid-2106c64f52b64150906437f365aac840,cHL,0.42627
uuid-2106c64f52b64150906437f365aac840,ASCO,0.394178
uuid-2106c64f52b64150906437f365aac840,impressed,0.407038
uuid-05f1ed4f7aa748cc901750b583a56b0c,Nivo,0.597563
uuid-05f1ed4f7aa748cc901750b583a56b0c,Opdivo,0.317586
uuid-05f1ed4f7aa748cc901750b583a56b0c,pembro,0.600503
uuid-05f1ed4f7aa748cc901750b583a56b0c,dose,0.640104
uuid-05f1ed4f7aa748cc901750b583a56b0c,nivolumab,0.329929
uuid-05f1ed4f7aa748cc901750b583a56b0c,efficacy,0.308434
uuid-05f1ed4f7aa748cc901750b583a56b0c,regimen,0.345528
uuid-05f1ed4f7aa748cc901750b583a56b0c,combination,0.332499
uuid-05f1ed4f7aa748cc901750b583a56b0c,2L,0.380063
uuid-05f1ed4f7aa748cc901750b583a56b0c,pts,0.351658
uuid-05f1ed4f7aa748cc901750b583a56b0c,Ipi,0.578155
uuid-05f1ed4f7aa748cc901750b583a56b0c,atezo,0.524884
uuid-05f1ed4f7aa748cc901750b583a56b0c,preferred,0.371657
uuid-05f1ed4f7aa748cc901750b583a56b0c,monotherapy,0.364194
uuid-05f1ed4f7aa748cc901750b583a56b0c,using nivo,0.384246
uuid-05f1ed4f7aa748cc901750b583a56b0c,combo,0.380363
uuid-05f1ed4f7aa748cc901750b583a56b0c,approved,0.314693
uuid-05f1ed4f7aa748cc901750b583a56b0c,vs,0.556596
uuid-05f1ed4f7aa748cc901750b583a56b0c,feels,0.316466
uuid-05f1ed4f7aa748cc901750b583a56b0c,flat dosing,0.482254
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,patients,0.651886
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,therapy,0.605353
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,nivolumab,0.340028
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,toxicity,0.338094
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,regimen,0.456251
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,treated,0.530367
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,combination,0.333811
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,chemo,0.469902
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,tumor,0.384742
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,pts,0.591138
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,monotherapy,0.308086
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,treatment,0.672317
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,response,0.752357
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,PD1,0.45218
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,progression,0.753179
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,chemotherapy,0.451688
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,respond,0.584705
uuid-7bf1aa3d5a214dc8aa74bc7199e8116e,immunotherapy,0.429091
uuid-8704401906324c00b1e4e0bc9b7bc251,pembro,0.475896
uuid-8704401906324c00b1e4e0bc9b7bc251,1L,0.532877
uuid-8704401906324c00b1e4e0bc9b7bc251,PDL1,0.590257
uuid-8704401906324c00b1e4e0bc9b7bc251,2L,0.441889
uuid-8704401906324c00b1e4e0bc9b7bc251,Merck,0.356678
uuid-8704401906324c00b1e4e0bc9b7bc251,PD-L1,0.617996
uuid-8704401906324c00b1e4e0bc9b7bc251,approval,0.351387
uuid-8704401906324c00b1e4e0bc9b7bc251,atezo,0.46553
uuid-8704401906324c00b1e4e0bc9b7bc251,PD-L1 testing,0.431125
uuid-8704401906324c00b1e4e0bc9b7bc251,testing,0.60419
uuid-8704401906324c00b1e4e0bc9b7bc251,PDL1 testing,0.539177
uuid-8704401906324c00b1e4e0bc9b7bc251,NSCLC patients,0.537618
uuid-8704401906324c00b1e4e0bc9b7bc251,approved,0.302853
uuid-8704401906324c00b1e4e0bc9b7bc251,nivo and pembro,0.424114
uuid-8704401906324c00b1e4e0bc9b7bc251,assay,0.469882
uuid-8704401906324c00b1e4e0bc9b7bc251,PDL1 expression,0.384822
uuid-8704401906324c00b1e4e0bc9b7bc251,biomarker,0.387753
uuid-81815f4e3af84d34b6bec9986a79dde3,RTL,0.335996
uuid-81815f4e3af84d34b6bec9986a79dde3,NTL,0.482761
uuid-81815f4e3af84d34b6bec9986a79dde3,physicians,0.396096
uuid-81815f4e3af84d34b6bec9986a79dde3,mentioned,0.312481
uuid-81815f4e3af84d34b6bec9986a79dde3,oncology,0.380952
uuid-81815f4e3af84d34b6bec9986a79dde3,oncologist,0.395169
uuid-81815f4e3af84d34b6bec9986a79dde3,indicated,0.426542
uuid-81815f4e3af84d34b6bec9986a79dde3,Regional TL,0.373622
uuid-5703d4ed620d40e285e046c0b275481c,patients,0.551239
uuid-5703d4ed620d40e285e046c0b275481c,Opdivo,0.368006
uuid-5703d4ed620d40e285e046c0b275481c,nivolumab,0.394053
uuid-5703d4ed620d40e285e046c0b275481c,treated,0.630547
uuid-5703d4ed620d40e285e046c0b275481c,shared,0.353306
uuid-5703d4ed620d40e285e046c0b275481c,pts,0.302701
uuid-5703d4ed620d40e285e046c0b275481c,physicians,0.415871
uuid-5703d4ed620d40e285e046c0b275481c,treatment,0.376397
uuid-5703d4ed620d40e285e046c0b275481c,academic,0.337264
uuid-5703d4ed620d40e285e046c0b275481c,Regional TL,0.335128
uuid-d4b8f86c8f8c4ecfae3f252a3bc6e9be,Nivo,0.301921
uuid-d4b8f86c8f8c4ecfae3f252a3bc6e9be,patients,0.495545
uuid-d4b8f86c8f8c4ecfae3f252a3bc6e9be,therapy,0.376287
uuid-d4b8f86c8f8c4ecfae3f252a3bc6e9be,dose,0.372679
uuid-d4b8f86c8f8c4ecfae3f252a3bc6e9be,toxicity,0.359681
uuid-d4b8f86c8f8c4ecfae3f252a3bc6e9be,treatment,0.377555
uuid-d4b8f86c8f8c4ecfae3f252a3bc6e9be,progression,0.304628
uuid-44db9e5d830940c88a7be7402ef4f7c4,NSCLC,0.489043
uuid-44db9e5d830940c88a7be7402ef4f7c4,data,0.449483
uuid-44db9e5d830940c88a7be7402ef4f7c4,NCCN,0.595453
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,Nivo,0.344224
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,pembro,0.400468
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,1L,0.472732
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,PDL1,0.378244
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,chemo,0.374273
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,2L,0.469475
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,agents,0.374963
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,atezo,0.371497
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,preferred,0.428984
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,testing,0.301965
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,monotherapy,0.390833
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,using nivo,0.30611
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,PDL1 testing,0.344981
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,NSCLC patients,0.345713
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,nivo and pembro,0.415569
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,believes,0.457628
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,feels,0.402195
uuid-4b87e3eae32c4158aed0958c1ec1e5b9,option,0.477596
uuid-9c80ae21c20743f5a426dfcdac64cf8b,RTL,0.37295
uuid-9c80ae21c20743f5a426dfcdac64cf8b,BMS,0.628338
uuid-9c80ae21c20743f5a426dfcdac64cf8b,trial,0.507038
uuid-9c80ae21c20743f5a426dfcdac64cf8b,shared,0.303278
uuid-9c80ae21c20743f5a426dfcdac64cf8b,commented,0.572289
uuid-9c80ae21c20743f5a426dfcdac64cf8b,Merck,0.524382
uuid-9c80ae21c20743f5a426dfcdac64cf8b,stated,0.454943
uuid-9c80ae21c20743f5a426dfcdac64cf8b,OS,0.454694
uuid-9c80ae21c20743f5a426dfcdac64cf8b,regards,0.369971
uuid-9c80ae21c20743f5a426dfcdac64cf8b,data,0.851769
uuid-9c80ae21c20743f5a426dfcdac64cf8b,expressed,0.432135
uuid-9c80ae21c20743f5a426dfcdac64cf8b,PFS,0.398103
uuid-9c80ae21c20743f5a426dfcdac64cf8b,ORR,0.460992
uuid-9c80ae21c20743f5a426dfcdac64cf8b,ASCO,0.474579
uuid-9c80ae21c20743f5a426dfcdac64cf8b,impressed,0.655678
uuid-9c80ae21c20743f5a426dfcdac64cf8b,LTL,0.316623
uuid-9c80ae21c20743f5a426dfcdac64cf8b,TLs,0.360599
uuid-9c80ae21c20743f5a426dfcdac64cf8b,Regional TL,0.341403
uuid-fcb78d3a103c4e10af7e18ee0c6878ca,NSCLC,0.498684
uuid-fcb78d3a103c4e10af7e18ee0c6878ca,PDL1,0.408741
uuid-fcb78d3a103c4e10af7e18ee0c6878ca,trial,0.331535
uuid-fcb78d3a103c4e10af7e18ee0c6878ca,data,0.467553
uuid-fcb78d3a103c4e10af7e18ee0c6878ca,PFS,0.326028
uuid-fcb78d3a103c4e10af7e18ee0c6878ca,ORR,0.332212
uuid-fcb78d3a103c4e10af7e18ee0c6878ca,NCCN,0.470756
uuid-dd355e0ae9fd4bb89b262a9637dc4831,NSCLC,0.439016
uuid-dd355e0ae9fd4bb89b262a9637dc4831,NTL,0.336684
uuid-dd355e0ae9fd4bb89b262a9637dc4831,commented,0.353507
uuid-dd355e0ae9fd4bb89b262a9637dc4831,data,0.323419
uuid-dd355e0ae9fd4bb89b262a9637dc4831,oncology,0.308387
uuid-dd355e0ae9fd4bb89b262a9637dc4831,Regional TL,0.38451
uuid-dd355e0ae9fd4bb89b262a9637dc4831,NCCN,0.610492
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,Nivo,0.548232
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,patients,0.455376
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,pembro,0.620589
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,1L,0.464765
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,chemo,0.30864
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,2L,0.473125
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,pts,0.34439
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,approval,0.499321
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,atezo,0.422896
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,preferred,0.385363
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,monotherapy,0.381693
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,using nivo,0.555404
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,clinical trials,0.300577
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,approved,0.474777
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,feels,0.4853
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,RTL stated,0.377585
uuid-bc74ba5fd3fa47b688e46ec995ab00c5,option,0.435359
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,pembro,0.392458
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,PDL1,0.64519
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,Merck,0.407995
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,PD-L1,0.618554
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,atezo,0.347283
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,PD-L1 testing,0.475783
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,testing,0.61684
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,PDL1 testing,0.495227
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,NSCLC patients,0.451711
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,nivo and pembro,0.325364
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,assay,0.540232
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,PDL1 expression,0.471832
uuid-3b258cf9263b4e4ab7f1648f5d9316ff,biomarker,0.367889
uuid-4c8628485e774262a8fd40df0ef48d89,dose,0.360542
uuid-4c8628485e774262a8fd40df0ef48d89,lung,0.335583
uuid-4c8628485e774262a8fd40df0ef48d89,toxicity,0.455606
uuid-4c8628485e774262a8fd40df0ef48d89,regimen,0.389929
uuid-4c8628485e774262a8fd40df0ef48d89,melanoma,0.306797
uuid-4c8628485e774262a8fd40df0ef48d89,RCC,0.373016
uuid-4c8628485e774262a8fd40df0ef48d89,TL stated,0.332196
uuid-4c8628485e774262a8fd40df0ef48d89,combination,0.470566
uuid-4c8628485e774262a8fd40df0ef48d89,chemo,0.307781
uuid-4c8628485e774262a8fd40df0ef48d89,2L,0.394668
uuid-4c8628485e774262a8fd40df0ef48d89,IO,0.409159
uuid-4c8628485e774262a8fd40df0ef48d89,agents,0.521526
uuid-4c8628485e774262a8fd40df0ef48d89,Ipi,0.320665
uuid-4c8628485e774262a8fd40df0ef48d89,preferred,0.396845
uuid-4c8628485e774262a8fd40df0ef48d89,monotherapy,0.433075
uuid-4c8628485e774262a8fd40df0ef48d89,combo,0.586753
uuid-4c8628485e774262a8fd40df0ef48d89,PD1,0.300718
uuid-4c8628485e774262a8fd40df0ef48d89,vs,0.306826
uuid-4c8628485e774262a8fd40df0ef48d89,option,0.30895
uuid-7d047e0b6c8943e494d8732a72c6ab8c,lung,0.310565
uuid-7d047e0b6c8943e494d8732a72c6ab8c,melanoma,0.304365
uuid-7d047e0b6c8943e494d8732a72c6ab8c,RCC,0.401085
uuid-7d047e0b6c8943e494d8732a72c6ab8c,2L,0.350814
uuid-7d047e0b6c8943e494d8732a72c6ab8c,stated,0.433747
uuid-7d047e0b6c8943e494d8732a72c6ab8c,approval,0.571057
uuid-7d047e0b6c8943e494d8732a72c6ab8c,preferred,0.361743
uuid-7d047e0b6c8943e494d8732a72c6ab8c,using nivo,0.415192
uuid-7d047e0b6c8943e494d8732a72c6ab8c,indication,0.533118
uuid-7d047e0b6c8943e494d8732a72c6ab8c,AI,0.329658
uuid-7d047e0b6c8943e494d8732a72c6ab8c,approved,0.621183
uuid-7d047e0b6c8943e494d8732a72c6ab8c,SCCHN,0.486433
uuid-7d047e0b6c8943e494d8732a72c6ab8c,tumor types,0.358218
uuid-7d047e0b6c8943e494d8732a72c6ab8c,label,0.589088
uuid-7d047e0b6c8943e494d8732a72c6ab8c,SCLC,0.392521
uuid-7d047e0b6c8943e494d8732a72c6ab8c,Regional TL,0.322841
uuid-7d047e0b6c8943e494d8732a72c6ab8c,RTL stated,0.343672
uuid-7d047e0b6c8943e494d8732a72c6ab8c,NCCN,0.562459
uuid-7d047e0b6c8943e494d8732a72c6ab8c,bladder,0.342312
uuid-7d047e0b6c8943e494d8732a72c6ab8c,flat dosing,0.305316
uuid-927164ac206b4f7bba06b7e3bb22f7f7,patients,0.551617
uuid-927164ac206b4f7bba06b7e3bb22f7f7,pts,0.353305
uuid-927164ac206b4f7bba06b7e3bb22f7f7,PD-L1,0.515992
uuid-927164ac206b4f7bba06b7e3bb22f7f7,PD-L1 testing,0.590626
uuid-927164ac206b4f7bba06b7e3bb22f7f7,testing,0.646014
uuid-927164ac206b4f7bba06b7e3bb22f7f7,PDL1 testing,0.561096
uuid-927164ac206b4f7bba06b7e3bb22f7f7,NSCLC patients,0.62426
uuid-65a005da632c44129978db6876109f7d,pembro,0.314816
uuid-65a005da632c44129978db6876109f7d,dose,0.622191
uuid-65a005da632c44129978db6876109f7d,BMS,0.447645
uuid-65a005da632c44129978db6876109f7d,efficacy,0.394862
uuid-65a005da632c44129978db6876109f7d,Merck,0.303309
uuid-65a005da632c44129978db6876109f7d,Ipi,0.352675
uuid-65a005da632c44129978db6876109f7d,atezo,0.348911
uuid-65a005da632c44129978db6876109f7d,regards,0.319664
uuid-65a005da632c44129978db6876109f7d,indication,0.322397
uuid-65a005da632c44129978db6876109f7d,vs,0.509565
uuid-65a005da632c44129978db6876109f7d,flat dosing,0.579659
uuid-4ed3e002336040fc929dd816660af945,pembro,0.377921
uuid-4ed3e002336040fc929dd816660af945,BMS,0.380602
uuid-4ed3e002336040fc929dd816660af945,trial,0.502334
uuid-4ed3e002336040fc929dd816660af945,efficacy,0.317218
uuid-4ed3e002336040fc929dd816660af945,Merck,0.409928
uuid-4ed3e002336040fc929dd816660af945,atezo,0.389529
uuid-4ed3e002336040fc929dd816660af945,data,0.401474
uuid-4ed3e002336040fc929dd816660af945,expressed,0.313172
uuid-4ed3e002336040fc929dd816660af945,nivo and pembro,0.409874
uuid-4ed3e002336040fc929dd816660af945,Regional TL,0.339978
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,Nivo,0.669266
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,pembro,0.67836
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,dose,0.483152
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,1L,0.32884
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,2L,0.482059
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,Ipi,0.547147
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,approval,0.427023
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,atezo,0.642524
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,preferred,0.499522
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,monotherapy,0.338687
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,using nivo,0.528701
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,indication,0.423126
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,approved,0.46162
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,vs,0.568117
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,feels,0.34935
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,RTL stated,0.330472
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,option,0.335488
uuid-58304af2ccac4f088fc0a83a1f2cd4d0,flat dosing,0.421936
uuid-b737426a4ab24eabbb7a10d2cc003480,lung,0.511032
uuid-b737426a4ab24eabbb7a10d2cc003480,regards,0.370681
uuid-b737426a4ab24eabbb7a10d2cc003480,AI,0.854251
uuid-b737426a4ab24eabbb7a10d2cc003480,nivo and pembro,0.557017
uuid-b737426a4ab24eabbb7a10d2cc003480,NCCN,0.396104
uuid-73f097bc7c0642e594d56558570f84aa,lung,0.464771
uuid-73f097bc7c0642e594d56558570f84aa,melanoma,0.33249
uuid-73f097bc7c0642e594d56558570f84aa,regards,0.487072
uuid-73f097bc7c0642e594d56558570f84aa,indication,0.388627
uuid-73f097bc7c0642e594d56558570f84aa,AI,0.708145
uuid-73f097bc7c0642e594d56558570f84aa,nivo and pembro,0.345092
uuid-73f097bc7c0642e594d56558570f84aa,label,0.339737
uuid-73f097bc7c0642e594d56558570f84aa,SCLC,0.349487
uuid-73f097bc7c0642e594d56558570f84aa,NCCN,0.738899
uuid-18ad1712e36d4889ac8e150fd7b49d90,patients,0.511063
uuid-18ad1712e36d4889ac8e150fd7b49d90,toxicity,0.347181
uuid-18ad1712e36d4889ac8e150fd7b49d90,regimen,0.540206
uuid-18ad1712e36d4889ac8e150fd7b49d90,combination,0.319037
uuid-18ad1712e36d4889ac8e150fd7b49d90,chemo,0.425039
uuid-18ad1712e36d4889ac8e150fd7b49d90,2L,0.302217
uuid-18ad1712e36d4889ac8e150fd7b49d90,preferred,0.590072
uuid-18ad1712e36d4889ac8e150fd7b49d90,monotherapy,0.504635
uuid-18ad1712e36d4889ac8e150fd7b49d90,treatment,0.352733
uuid-18ad1712e36d4889ac8e150fd7b49d90,using nivo,0.350037
uuid-18ad1712e36d4889ac8e150fd7b49d90,indication,0.318719
uuid-18ad1712e36d4889ac8e150fd7b49d90,chemotherapy,0.438808
uuid-18ad1712e36d4889ac8e150fd7b49d90,feels,0.365843
uuid-18ad1712e36d4889ac8e150fd7b49d90,option,0.557484
uuid-f568e06287c44db08f804ed2a2348501,patients,0.487577
uuid-f568e06287c44db08f804ed2a2348501,Opdivo,0.670606
uuid-f568e06287c44db08f804ed2a2348501,therapy,0.394862
uuid-f568e06287c44db08f804ed2a2348501,nivolumab,0.487735
uuid-f568e06287c44db08f804ed2a2348501,treated,0.453391
uuid-f568e06287c44db08f804ed2a2348501,stated,0.310819
uuid-f568e06287c44db08f804ed2a2348501,approval,0.315156
uuid-f568e06287c44db08f804ed2a2348501,treatment,0.366258
uuid-f568e06287c44db08f804ed2a2348501,using nivo,0.406653
uuid-f568e06287c44db08f804ed2a2348501,mentioned,0.326899
uuid-f568e06287c44db08f804ed2a2348501,cHL,0.625937
uuid-f568e06287c44db08f804ed2a2348501,progression,0.319937
uuid-f568e06287c44db08f804ed2a2348501,LTL,0.3465
uuid-f568e06287c44db08f804ed2a2348501,RTL stated,0.349376
uuid-5dcc90da8d594009a7b15045efe8c08a,patients,0.318529
uuid-5dcc90da8d594009a7b15045efe8c08a,Opdivo,0.541926
uuid-5dcc90da8d594009a7b15045efe8c08a,treated,0.37169
uuid-5dcc90da8d594009a7b15045efe8c08a,stated,0.415627
uuid-5dcc90da8d594009a7b15045efe8c08a,cHL,0.407539
uuid-d2bea212b4f4470899b1dbb4304eceb0,Opdivo,0.403689
uuid-d2bea212b4f4470899b1dbb4304eceb0,NSCLC,0.319977
uuid-d2bea212b4f4470899b1dbb4304eceb0,1L,0.300373
uuid-d2bea212b4f4470899b1dbb4304eceb0,shared,0.375564
uuid-d2bea212b4f4470899b1dbb4304eceb0,RCC,0.397442
uuid-d2bea212b4f4470899b1dbb4304eceb0,TL stated,0.522587
uuid-d2bea212b4f4470899b1dbb4304eceb0,2L,0.3277
uuid-d2bea212b4f4470899b1dbb4304eceb0,stated,0.561033
uuid-d2bea212b4f4470899b1dbb4304eceb0,approval,0.374693
uuid-d2bea212b4f4470899b1dbb4304eceb0,physicians,0.341015
uuid-d2bea212b4f4470899b1dbb4304eceb0,preferred,0.330382
uuid-d2bea212b4f4470899b1dbb4304eceb0,testing,0.324196
uuid-d2bea212b4f4470899b1dbb4304eceb0,using nivo,0.346411
uuid-d2bea212b4f4470899b1dbb4304eceb0,PDL1 testing,0.532039
uuid-d2bea212b4f4470899b1dbb4304eceb0,NSCLC patients,0.382103
uuid-d2bea212b4f4470899b1dbb4304eceb0,approved,0.38842
uuid-d2bea212b4f4470899b1dbb4304eceb0,SCCHN,0.466993
uuid-d2bea212b4f4470899b1dbb4304eceb0,HCP,0.329925
uuid-d2bea212b4f4470899b1dbb4304eceb0,tumor types,0.418642
uuid-d2bea212b4f4470899b1dbb4304eceb0,LTL,0.378988
uuid-d2bea212b4f4470899b1dbb4304eceb0,Keytruda,0.32267
uuid-d2bea212b4f4470899b1dbb4304eceb0,TLs,0.345273
uuid-d2bea212b4f4470899b1dbb4304eceb0,Regional TL,0.39192
uuid-d2bea212b4f4470899b1dbb4304eceb0,RTL stated,0.471371
uuid-58bba15d20a04193b270ff6a85462dc2,patients,0.506225
uuid-58bba15d20a04193b270ff6a85462dc2,pts,0.340713
uuid-58bba15d20a04193b270ff6a85462dc2,stated,0.322399
uuid-58bba15d20a04193b270ff6a85462dc2,approval,0.311087
uuid-58bba15d20a04193b270ff6a85462dc2,preferred,0.310909
uuid-58bba15d20a04193b270ff6a85462dc2,treatment,0.303614
uuid-58bba15d20a04193b270ff6a85462dc2,using nivo,0.418404
uuid-58bba15d20a04193b270ff6a85462dc2,approved,0.300637
uuid-58bba15d20a04193b270ff6a85462dc2,SCCHN,0.427756
uuid-58bba15d20a04193b270ff6a85462dc2,impressed,0.323763
uuid-58bba15d20a04193b270ff6a85462dc2,feels,0.309941
uuid-58bba15d20a04193b270ff6a85462dc2,Regional TL,0.320199
uuid-58bba15d20a04193b270ff6a85462dc2,option,0.47368
uuid-4c289d3711a94f2786e168087a9c3c95,efficacy,0.3353
uuid-4c289d3711a94f2786e168087a9c3c95,regimen,0.31001
uuid-4c289d3711a94f2786e168087a9c3c95,combination,0.417678
uuid-4c289d3711a94f2786e168087a9c3c95,chemo,0.452935
uuid-4c289d3711a94f2786e168087a9c3c95,IO,0.443814
uuid-4c289d3711a94f2786e168087a9c3c95,OS,0.558089
uuid-4c289d3711a94f2786e168087a9c3c95,monotherapy,0.302497
uuid-4c289d3711a94f2786e168087a9c3c95,response,0.53099
uuid-4c289d3711a94f2786e168087a9c3c95,combo,0.388947
uuid-4c289d3711a94f2786e168087a9c3c95,PFS,0.517688
uuid-4c289d3711a94f2786e168087a9c3c95,PD1,0.380023
uuid-4c289d3711a94f2786e168087a9c3c95,ORR,0.489302
uuid-4c289d3711a94f2786e168087a9c3c95,progression,0.401676
uuid-4c289d3711a94f2786e168087a9c3c95,believes,0.327131
uuid-4c289d3711a94f2786e168087a9c3c95,chemotherapy,0.508327
uuid-4c289d3711a94f2786e168087a9c3c95,feels,0.318352
uuid-22b969cb259641a58512f216e5a22f1c,Nivo,0.301683
uuid-22b969cb259641a58512f216e5a22f1c,patients,0.543232
uuid-22b969cb259641a58512f216e5a22f1c,Opdivo,0.445989
uuid-22b969cb259641a58512f216e5a22f1c,pembro,0.32928
uuid-22b969cb259641a58512f216e5a22f1c,nivolumab,0.442089
uuid-22b969cb259641a58512f216e5a22f1c,1L,0.382438
uuid-22b969cb259641a58512f216e5a22f1c,RCC,0.31224
uuid-22b969cb259641a58512f216e5a22f1c,2L,0.469928
uuid-22b969cb259641a58512f216e5a22f1c,pts,0.357744
uuid-22b969cb259641a58512f216e5a22f1c,stated,0.451776
uuid-22b969cb259641a58512f216e5a22f1c,approval,0.645765
uuid-22b969cb259641a58512f216e5a22f1c,preferred,0.453438
uuid-22b969cb259641a58512f216e5a22f1c,using nivo,0.61226
uuid-22b969cb259641a58512f216e5a22f1c,indication,0.345538
uuid-22b969cb259641a58512f216e5a22f1c,approved,0.682837
uuid-22b969cb259641a58512f216e5a22f1c,SCCHN,0.409892
uuid-22b969cb259641a58512f216e5a22f1c,tumor types,0.35551
uuid-22b969cb259641a58512f216e5a22f1c,label,0.481887
uuid-22b969cb259641a58512f216e5a22f1c,LTL,0.30095
uuid-22b969cb259641a58512f216e5a22f1c,SCLC,0.345854
uuid-22b969cb259641a58512f216e5a22f1c,RTL stated,0.429286
uuid-22b969cb259641a58512f216e5a22f1c,option,0.454372
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,Nivo,0.469221
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,pembro,0.430378
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,1L,0.525743
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,PDL1,0.369821
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,efficacy,0.434043
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,combination,0.300467
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,chemo,0.390617
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,2L,0.449254
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,agents,0.459758
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,OS,0.422196
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,atezo,0.380471
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,preferred,0.402878
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,monotherapy,0.479869
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,using nivo,0.32148
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,data,0.525099
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,combo,0.329735
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,PFS,0.395647
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,PD1,0.309529
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,ORR,0.426049
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,approved,0.303609
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,nivo and pembro,0.491982
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,believes,0.437678
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,chemotherapy,0.33237
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,impressed,0.381318
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,feels,0.569468
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,PDL1 expression,0.320918
uuid-ebfd8a7bf939495ba776ba76d7e1adc3,option,0.510449
uuid-dc687a368e914e4caea2e2e8c2baa4aa,Nivo,0.654404
uuid-dc687a368e914e4caea2e2e8c2baa4aa,pembro,0.642632
uuid-dc687a368e914e4caea2e2e8c2baa4aa,therapy,0.366595
uuid-dc687a368e914e4caea2e2e8c2baa4aa,nivolumab,0.32108
uuid-dc687a368e914e4caea2e2e8c2baa4aa,1L,0.532581
uuid-dc687a368e914e4caea2e2e8c2baa4aa,combination,0.314991
uuid-dc687a368e914e4caea2e2e8c2baa4aa,chemo,0.378892
uuid-dc687a368e914e4caea2e2e8c2baa4aa,2L,0.613522
uuid-dc687a368e914e4caea2e2e8c2baa4aa,agents,0.470844
uuid-dc687a368e914e4caea2e2e8c2baa4aa,approval,0.412385
uuid-dc687a368e914e4caea2e2e8c2baa4aa,atezo,0.58069
uuid-dc687a368e914e4caea2e2e8c2baa4aa,preferred,0.62952
uuid-dc687a368e914e4caea2e2e8c2baa4aa,monotherapy,0.541431
uuid-dc687a368e914e4caea2e2e8c2baa4aa,using nivo,0.596873
uuid-dc687a368e914e4caea2e2e8c2baa4aa,indication,0.49452
uuid-dc687a368e914e4caea2e2e8c2baa4aa,approved,0.533347
uuid-dc687a368e914e4caea2e2e8c2baa4aa,nivo and pembro,0.321231
uuid-dc687a368e914e4caea2e2e8c2baa4aa,chemotherapy,0.361452
uuid-dc687a368e914e4caea2e2e8c2baa4aa,vs,0.323969
uuid-dc687a368e914e4caea2e2e8c2baa4aa,label,0.307532
uuid-dc687a368e914e4caea2e2e8c2baa4aa,feels,0.432178
uuid-dc687a368e914e4caea2e2e8c2baa4aa,RTL stated,0.332866
uuid-dc687a368e914e4caea2e2e8c2baa4aa,option,0.637618
uuid-56efdc9b735b4d778488e0b7a1217e49,Nivo,0.350349
uuid-56efdc9b735b4d778488e0b7a1217e49,pembro,0.509299
uuid-56efdc9b735b4d778488e0b7a1217e49,1L,0.434464
uuid-56efdc9b735b4d778488e0b7a1217e49,PDL1,0.310224
uuid-56efdc9b735b4d778488e0b7a1217e49,2L,0.382035
uuid-56efdc9b735b4d778488e0b7a1217e49,approval,0.415646
uuid-56efdc9b735b4d778488e0b7a1217e49,atezo,0.395517
uuid-56efdc9b735b4d778488e0b7a1217e49,using nivo,0.34364
uuid-56efdc9b735b4d778488e0b7a1217e49,data,0.523875
uuid-56efdc9b735b4d778488e0b7a1217e49,indication,0.370497
uuid-56efdc9b735b4d778488e0b7a1217e49,approved,0.415291
uuid-56efdc9b735b4d778488e0b7a1217e49,nivo and pembro,0.340692
uuid-56efdc9b735b4d778488e0b7a1217e49,impressed,0.327277
uuid-56efdc9b735b4d778488e0b7a1217e49,feels,0.360814
uuid-56efdc9b735b4d778488e0b7a1217e49,option,0.365432
uuid-e1776070bfd3429cbd8eab42c44e6f09,PDL1,0.395678
uuid-e1776070bfd3429cbd8eab42c44e6f09,efficacy,0.413229
uuid-e1776070bfd3429cbd8eab42c44e6f09,OS,0.409457
uuid-e1776070bfd3429cbd8eab42c44e6f09,data,0.385341
uuid-e1776070bfd3429cbd8eab42c44e6f09,PFS,0.458644
uuid-e1776070bfd3429cbd8eab42c44e6f09,ORR,0.450869
uuid-e1776070bfd3429cbd8eab42c44e6f09,feels,0.40514
uuid-e1776070bfd3429cbd8eab42c44e6f09,PDL1 expression,0.372588
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,PDL1,0.464243
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,trial,0.312418
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,efficacy,0.308931
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,agents,0.363963
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,Merck,0.325261
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,PD-L1,0.435715
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,data,0.351225
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,lung cancer,0.389183
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,nivo and pembro,0.414088
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,assay,0.315612
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,PD-1,0.504232
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,PDL1 expression,0.306753
uuid-28efd475ca5d4f9c9f58492f1d2e7d95,biomarker,0.347574
uuid-20b332aa15574375bd7ffb092c3fd863,patients,0.50517
uuid-20b332aa15574375bd7ffb092c3fd863,Opdivo,0.301259
uuid-20b332aa15574375bd7ffb092c3fd863,toxicity,0.661938
uuid-20b332aa15574375bd7ffb092c3fd863,regimen,0.611941
uuid-20b332aa15574375bd7ffb092c3fd863,treated,0.435084
uuid-20b332aa15574375bd7ffb092c3fd863,pts,0.305133
uuid-20b332aa15574375bd7ffb092c3fd863,treatment,0.536621
uuid-20b332aa15574375bd7ffb092c3fd863,progression,0.430759
uuid-20b332aa15574375bd7ffb092c3fd863,respond,0.504178
uuid-e71101e6aada437d9aba0e9696d405ec,BMS,0.336201
uuid-e71101e6aada437d9aba0e9696d405ec,PDL1,0.409444
uuid-e71101e6aada437d9aba0e9696d405ec,trial,0.435817
uuid-e71101e6aada437d9aba0e9696d405ec,efficacy,0.601123
uuid-e71101e6aada437d9aba0e9696d405ec,discussed,0.36904
uuid-e71101e6aada437d9aba0e9696d405ec,commented,0.349976
uuid-e71101e6aada437d9aba0e9696d405ec,OS,0.751035
uuid-e71101e6aada437d9aba0e9696d405ec,regards,0.46254
uuid-e71101e6aada437d9aba0e9696d405ec,data,0.726224
uuid-e71101e6aada437d9aba0e9696d405ec,expressed,0.316118
uuid-e71101e6aada437d9aba0e9696d405ec,PFS,0.783033
uuid-e71101e6aada437d9aba0e9696d405ec,ORR,0.736124
uuid-e71101e6aada437d9aba0e9696d405ec,nivo and pembro,0.532768
uuid-e71101e6aada437d9aba0e9696d405ec,ASCO,0.359274
uuid-e71101e6aada437d9aba0e9696d405ec,impressed,0.512171
uuid-e71101e6aada437d9aba0e9696d405ec,PDL1 expression,0.419917
uuid-4bb303a9b3d54117a95404a26adde5b4,feels,0.326005
uuid-af365617d4264efaa6b8d317246da0dd,toxicity,0.528736
uuid-af365617d4264efaa6b8d317246da0dd,regimen,0.354057
uuid-af365617d4264efaa6b8d317246da0dd,treatment,0.307024
uuid-af365617d4264efaa6b8d317246da0dd,response,0.339828
uuid-af365617d4264efaa6b8d317246da0dd,respond,0.407394
uuid-7af8492bcc4a44efb4c4f91bfca6d5b2,TL,0.541832
uuid-7af8492bcc4a44efb4c4f91bfca6d5b2,PDL1,0.381849
uuid-7af8492bcc4a44efb4c4f91bfca6d5b2,TL stated,0.385123
uuid-7af8492bcc4a44efb4c4f91bfca6d5b2,institution,0.309026
uuid-7af8492bcc4a44efb4c4f91bfca6d5b2,PD-L1,0.731116
uuid-7af8492bcc4a44efb4c4f91bfca6d5b2,PD-L1 testing,0.852384
uuid-7af8492bcc4a44efb4c4f91bfca6d5b2,testing,0.807687
uuid-7af8492bcc4a44efb4c4f91bfca6d5b2,PDL1 testing,0.615517
uuid-7af8492bcc4a44efb4c4f91bfca6d5b2,NSCLC patients,0.545974
uuid-7af8492bcc4a44efb4c4f91bfca6d5b2,assay,0.679115
uuid-7af8492bcc4a44efb4c4f91bfca6d5b2,biomarker,0.391538
uuid-33e0c9ec414647eeb2e27f95c3545c7f,pembro,0.51422
uuid-33e0c9ec414647eeb2e27f95c3545c7f,BMS,0.472865
uuid-33e0c9ec414647eeb2e27f95c3545c7f,1L,0.408574
uuid-33e0c9ec414647eeb2e27f95c3545c7f,PDL1,0.433203
uuid-33e0c9ec414647eeb2e27f95c3545c7f,trial,0.454611
uuid-33e0c9ec414647eeb2e27f95c3545c7f,efficacy,0.333417
uuid-33e0c9ec414647eeb2e27f95c3545c7f,commented,0.444741
uuid-33e0c9ec414647eeb2e27f95c3545c7f,2L,0.318912
uuid-33e0c9ec414647eeb2e27f95c3545c7f,Merck,0.482845
uuid-33e0c9ec414647eeb2e27f95c3545c7f,stated,0.342368
uuid-33e0c9ec414647eeb2e27f95c3545c7f,OS,0.310339
uuid-33e0c9ec414647eeb2e27f95c3545c7f,atezo,0.474802
uuid-33e0c9ec414647eeb2e27f95c3545c7f,data,0.647981
uuid-33e0c9ec414647eeb2e27f95c3545c7f,expressed,0.386774
uuid-33e0c9ec414647eeb2e27f95c3545c7f,clinical trials,0.312409
uuid-33e0c9ec414647eeb2e27f95c3545c7f,indication,0.334066
uuid-33e0c9ec414647eeb2e27f95c3545c7f,ORR,0.320716
uuid-33e0c9ec414647eeb2e27f95c3545c7f,SCCHN,0.301851
uuid-33e0c9ec414647eeb2e27f95c3545c7f,nivo and pembro,0.441612
uuid-33e0c9ec414647eeb2e27f95c3545c7f,impressed,0.514942
uuid-33e0c9ec414647eeb2e27f95c3545c7f,TLs,0.414152
uuid-33e0c9ec414647eeb2e27f95c3545c7f,feels,0.423579
uuid-33e0c9ec414647eeb2e27f95c3545c7f,PDL1 expression,0.337444
uuid-33e0c9ec414647eeb2e27f95c3545c7f,bladder,0.317454
uuid-5b251f3d1e624ae78f9a63b80260f2a1,patients,0.714123
uuid-5b251f3d1e624ae78f9a63b80260f2a1,therapy,0.420754
uuid-5b251f3d1e624ae78f9a63b80260f2a1,nivolumab,0.422752
uuid-5b251f3d1e624ae78f9a63b80260f2a1,regimen,0.383376
uuid-5b251f3d1e624ae78f9a63b80260f2a1,treated,0.556057
uuid-5b251f3d1e624ae78f9a63b80260f2a1,RCC,0.356911
uuid-5b251f3d1e624ae78f9a63b80260f2a1,chemo,0.307028
uuid-5b251f3d1e624ae78f9a63b80260f2a1,pts,0.459165
uuid-5b251f3d1e624ae78f9a63b80260f2a1,treatment,0.544443
uuid-5b251f3d1e624ae78f9a63b80260f2a1,using nivo,0.404156
uuid-5b251f3d1e624ae78f9a63b80260f2a1,progression,0.463585
uuid-5b251f3d1e624ae78f9a63b80260f2a1,chemotherapy,0.321219
uuid-5b251f3d1e624ae78f9a63b80260f2a1,respond,0.361984
uuid-5b251f3d1e624ae78f9a63b80260f2a1,RTL stated,0.377422
uuid-5b251f3d1e624ae78f9a63b80260f2a1,TL shared,0.362343
uuid-5b251f3d1e624ae78f9a63b80260f2a1,option,0.377362
uuid-236b0756f4cd403fabf97d0e707ab222,Nivo,0.324606
uuid-236b0756f4cd403fabf97d0e707ab222,patients,0.725635
uuid-236b0756f4cd403fabf97d0e707ab222,therapy,0.388997
uuid-236b0756f4cd403fabf97d0e707ab222,1L,0.354703
uuid-236b0756f4cd403fabf97d0e707ab222,regimen,0.307437
uuid-236b0756f4cd403fabf97d0e707ab222,treated,0.359102
uuid-236b0756f4cd403fabf97d0e707ab222,chemo,0.459137
uuid-236b0756f4cd403fabf97d0e707ab222,tumor,0.384356
uuid-236b0756f4cd403fabf97d0e707ab222,2L,0.362489
uuid-236b0756f4cd403fabf97d0e707ab222,pts,0.578075
uuid-236b0756f4cd403fabf97d0e707ab222,preferred,0.396272
uuid-236b0756f4cd403fabf97d0e707ab222,monotherapy,0.406339
uuid-236b0756f4cd403fabf97d0e707ab222,treatment,0.41859
uuid-236b0756f4cd403fabf97d0e707ab222,using nivo,0.389938
uuid-236b0756f4cd403fabf97d0e707ab222,NSCLC patients,0.370604
uuid-236b0756f4cd403fabf97d0e707ab222,progression,0.444749
uuid-236b0756f4cd403fabf97d0e707ab222,chemotherapy,0.364878
uuid-236b0756f4cd403fabf97d0e707ab222,respond,0.373963
uuid-236b0756f4cd403fabf97d0e707ab222,option,0.49452
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,Nivo,0.606305
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,pembro,0.71857
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,dose,0.454563
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,1L,0.592268
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,combination,0.438776
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,chemo,0.315108
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,2L,0.712128
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,agents,0.441744
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,Ipi,0.568045
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,approval,0.333217
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,atezo,0.73052
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,preferred,0.628874
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,monotherapy,0.559786
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,using nivo,0.551811
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,combo,0.580215
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,approved,0.486106
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,nivo and pembro,0.326892
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,vs,0.531446
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,feels,0.371781
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,RTL stated,0.381776
uuid-21f7a8474f0c4aba82e0dbe95ae83fe5,option,0.49656
uuid-1d2372b26adb45f1aac8df91bdf0236d,Nivo,0.337569
uuid-1d2372b26adb45f1aac8df91bdf0236d,Opdivo,0.304283
uuid-1d2372b26adb45f1aac8df91bdf0236d,pembro,0.335549
uuid-1d2372b26adb45f1aac8df91bdf0236d,dose,0.841489
uuid-1d2372b26adb45f1aac8df91bdf0236d,toxicity,0.345582
uuid-1d2372b26adb45f1aac8df91bdf0236d,regimen,0.30777
uuid-1d2372b26adb45f1aac8df91bdf0236d,Ipi,0.582444
uuid-1d2372b26adb45f1aac8df91bdf0236d,atezo,0.322805
uuid-1d2372b26adb45f1aac8df91bdf0236d,vs,0.550713
uuid-1d2372b26adb45f1aac8df91bdf0236d,Keytruda,0.36517
uuid-1d2372b26adb45f1aac8df91bdf0236d,flat dosing,0.657876
uuid-dfaa7b2934814aa984f86987e47f1587,BMS,0.36021
uuid-dfaa7b2934814aa984f86987e47f1587,PDL1,0.682
uuid-dfaa7b2934814aa984f86987e47f1587,trial,0.423714
uuid-dfaa7b2934814aa984f86987e47f1587,efficacy,0.437189
uuid-dfaa7b2934814aa984f86987e47f1587,Merck,0.386829
uuid-dfaa7b2934814aa984f86987e47f1587,PD-L1,0.454035
uuid-dfaa7b2934814aa984f86987e47f1587,OS,0.449203
uuid-dfaa7b2934814aa984f86987e47f1587,data,0.406171
uuid-dfaa7b2934814aa984f86987e47f1587,PFS,0.50064
uuid-dfaa7b2934814aa984f86987e47f1587,ORR,0.512656
uuid-dfaa7b2934814aa984f86987e47f1587,nivo and pembro,0.413252
uuid-dfaa7b2934814aa984f86987e47f1587,believes,0.342837
uuid-dfaa7b2934814aa984f86987e47f1587,feels,0.302136
uuid-dfaa7b2934814aa984f86987e47f1587,assay,0.463349
uuid-dfaa7b2934814aa984f86987e47f1587,PDL1 expression,0.577072
uuid-dfaa7b2934814aa984f86987e47f1587,biomarker,0.469418
uuid-d2d4e68e81c74387b425ee2ff870a4d4,PD-L1,0.305955
uuid-d2d4e68e81c74387b425ee2ff870a4d4,PD-L1 testing,0.358007
uuid-d2d4e68e81c74387b425ee2ff870a4d4,testing,0.344653
uuid-d2d4e68e81c74387b425ee2ff870a4d4,lung cancer,0.659875
uuid-58e74ba3ae8248648e20246ff0f6b57b,lung cancer,0.733044
uuid-3589237f2e1f4969bc54d23c10a028d4,lung cancer,0.585159
uuid-3589237f2e1f4969bc54d23c10a028d4,NCCN,0.304305
uuid-8bdd612719fd4a839da88b81aa9c6777,PD-L1,0.340393
uuid-8bdd612719fd4a839da88b81aa9c6777,PD-L1 testing,0.328583
uuid-8bdd612719fd4a839da88b81aa9c6777,testing,0.349709
uuid-8bdd612719fd4a839da88b81aa9c6777,lung cancer,0.745259
uuid-8bdd612719fd4a839da88b81aa9c6777,assay,0.348352
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,Nivo,0.400005
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,patients,0.663257
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,therapy,0.690438
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,1L,0.337168
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,regimen,0.536848
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,treated,0.344601
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,combination,0.342239
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,chemo,0.603814
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,2L,0.305868
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,pts,0.618547
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,IO,0.346422
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,monotherapy,0.536618
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,treatment,0.661355
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,response,0.620019
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,combo,0.342934
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,PD1,0.542326
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,progression,0.84298
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,chemotherapy,0.53145
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,respond,0.593555
uuid-c182b1ac6a4a43d8a7e2cdf30a06ca05,option,0.495056
uuid-bd96e7e6cb4e48c8a525953194de336f,RTL,0.335958
uuid-bd96e7e6cb4e48c8a525953194de336f,efficacy,0.371932
uuid-bd96e7e6cb4e48c8a525953194de336f,commented,0.384758
uuid-bd96e7e6cb4e48c8a525953194de336f,stated,0.407157
uuid-bd96e7e6cb4e48c8a525953194de336f,OS,0.389505
uuid-bd96e7e6cb4e48c8a525953194de336f,data,0.683021
uuid-bd96e7e6cb4e48c8a525953194de336f,clinical trials,0.333579
uuid-bd96e7e6cb4e48c8a525953194de336f,PFS,0.360063
uuid-bd96e7e6cb4e48c8a525953194de336f,ORR,0.400436
uuid-bd96e7e6cb4e48c8a525953194de336f,impressed,0.604021
uuid-bd96e7e6cb4e48c8a525953194de336f,LTL,0.356215
uuid-bd96e7e6cb4e48c8a525953194de336f,TLs,0.426681
uuid-bd96e7e6cb4e48c8a525953194de336f,feels,0.420313
uuid-bd96e7e6cb4e48c8a525953194de336f,Regional TL,0.326766
uuid-e4d2ec5cfe9a4c2b97fec084eeca8c51,PDL1,0.518637
uuid-e4d2ec5cfe9a4c2b97fec084eeca8c51,PD-L1,0.57589
uuid-e4d2ec5cfe9a4c2b97fec084eeca8c51,PD-L1 testing,0.413135
uuid-e4d2ec5cfe9a4c2b97fec084eeca8c51,testing,0.644332
uuid-e4d2ec5cfe9a4c2b97fec084eeca8c51,PDL1 testing,0.483111
uuid-e4d2ec5cfe9a4c2b97fec084eeca8c51,NSCLC patients,0.514423
uuid-e4d2ec5cfe9a4c2b97fec084eeca8c51,tumor types,0.346721
uuid-e4d2ec5cfe9a4c2b97fec084eeca8c51,assay,0.384646
uuid-e4d2ec5cfe9a4c2b97fec084eeca8c51,PDL1 expression,0.330263
uuid-e4d2ec5cfe9a4c2b97fec084eeca8c51,biomarker,0.633638
uuid-597848e3bbfb4f6e90569b2c3dbb5f24,PDL1,0.424819
uuid-597848e3bbfb4f6e90569b2c3dbb5f24,OS,0.361616
uuid-597848e3bbfb4f6e90569b2c3dbb5f24,PFS,0.379679
uuid-597848e3bbfb4f6e90569b2c3dbb5f24,AI,0.448048
uuid-597848e3bbfb4f6e90569b2c3dbb5f24,nivo and pembro,0.328359
uuid-597848e3bbfb4f6e90569b2c3dbb5f24,believes,0.367887
uuid-597848e3bbfb4f6e90569b2c3dbb5f24,immunotherapy,0.36949
uuid-597848e3bbfb4f6e90569b2c3dbb5f24,PDL1 expression,0.430106
uuid-597848e3bbfb4f6e90569b2c3dbb5f24,biomarker,0.447487
uuid-64320a20f9754398ba062c0d4f8c8026,TL,0.456271
uuid-64320a20f9754398ba062c0d4f8c8026,RTL,0.461344
uuid-64320a20f9754398ba062c0d4f8c8026,lung,0.333564
uuid-64320a20f9754398ba062c0d4f8c8026,1L,0.310091
uuid-64320a20f9754398ba062c0d4f8c8026,shared,0.392873
uuid-64320a20f9754398ba062c0d4f8c8026,RCC,0.479811
uuid-64320a20f9754398ba062c0d4f8c8026,TL stated,0.650709
uuid-64320a20f9754398ba062c0d4f8c8026,institution,0.410629
uuid-64320a20f9754398ba062c0d4f8c8026,stated,0.352039
uuid-64320a20f9754398ba062c0d4f8c8026,PD-L1,0.587014
uuid-64320a20f9754398ba062c0d4f8c8026,approval,0.301537
uuid-64320a20f9754398ba062c0d4f8c8026,PD-L1 testing,0.642144
uuid-64320a20f9754398ba062c0d4f8c8026,testing,0.690254
uuid-64320a20f9754398ba062c0d4f8c8026,PDL1 testing,0.721294
uuid-64320a20f9754398ba062c0d4f8c8026,NSCLC patients,0.697316
uuid-64320a20f9754398ba062c0d4f8c8026,SCCHN,0.503674
uuid-64320a20f9754398ba062c0d4f8c8026,tumor types,0.414964
uuid-64320a20f9754398ba062c0d4f8c8026,LTL,0.340957
uuid-64320a20f9754398ba062c0d4f8c8026,TLs,0.35639
uuid-64320a20f9754398ba062c0d4f8c8026,academic,0.373121
uuid-64320a20f9754398ba062c0d4f8c8026,assay,0.327405
uuid-64320a20f9754398ba062c0d4f8c8026,Regional TL,0.381118
uuid-64320a20f9754398ba062c0d4f8c8026,RTL stated,0.442625
uuid-64320a20f9754398ba062c0d4f8c8026,TL shared,0.358163
uuid-64320a20f9754398ba062c0d4f8c8026,bladder,0.375526
uuid-2a2678a83b824ea78d55076db140d2f2,Nivo,0.404106
uuid-2a2678a83b824ea78d55076db140d2f2,pembro,0.499456
uuid-2a2678a83b824ea78d55076db140d2f2,1L,0.367775
uuid-2a2678a83b824ea78d55076db140d2f2,PDL1,0.669749
uuid-2a2678a83b824ea78d55076db140d2f2,trial,0.403966
uuid-2a2678a83b824ea78d55076db140d2f2,efficacy,0.664343
uuid-2a2678a83b824ea78d55076db140d2f2,chemo,0.300732
uuid-2a2678a83b824ea78d55076db140d2f2,OS,0.610129
uuid-2a2678a83b824ea78d55076db140d2f2,atezo,0.461942
uuid-2a2678a83b824ea78d55076db140d2f2,data,0.694356
uuid-2a2678a83b824ea78d55076db140d2f2,PFS,0.628054
uuid-2a2678a83b824ea78d55076db140d2f2,ORR,0.634712
uuid-2a2678a83b824ea78d55076db140d2f2,nivo and pembro,0.667919
uuid-2a2678a83b824ea78d55076db140d2f2,believes,0.497772
uuid-2a2678a83b824ea78d55076db140d2f2,impressed,0.4178
uuid-2a2678a83b824ea78d55076db140d2f2,vs,0.32848
uuid-2a2678a83b824ea78d55076db140d2f2,feels,0.48094
uuid-2a2678a83b824ea78d55076db140d2f2,PDL1 expression,0.616411
uuid-2a2678a83b824ea78d55076db140d2f2,biomarker,0.350865
uuid-122bf536909d44ef8423c7ac93447a61,Nivo,0.324189
uuid-122bf536909d44ef8423c7ac93447a61,lung,0.386452
uuid-122bf536909d44ef8423c7ac93447a61,PDL1,0.427217
uuid-122bf536909d44ef8423c7ac93447a61,efficacy,0.397289
uuid-122bf536909d44ef8423c7ac93447a61,OS,0.503522
uuid-122bf536909d44ef8423c7ac93447a61,regards,0.400674
uuid-122bf536909d44ef8423c7ac93447a61,PFS,0.600396
uuid-122bf536909d44ef8423c7ac93447a61,AI,0.703056
uuid-122bf536909d44ef8423c7ac93447a61,ORR,0.49241
uuid-122bf536909d44ef8423c7ac93447a61,nivo and pembro,0.638351
uuid-122bf536909d44ef8423c7ac93447a61,believes,0.329222
uuid-122bf536909d44ef8423c7ac93447a61,PDL1 expression,0.461419
uuid-2cb49690450c41e9ba1ac92a4c86d17d,Nivo,0.42326
uuid-2cb49690450c41e9ba1ac92a4c86d17d,therapy,0.321735
uuid-2cb49690450c41e9ba1ac92a4c86d17d,lung,0.381008
uuid-2cb49690450c41e9ba1ac92a4c86d17d,chemo,0.379578
uuid-2cb49690450c41e9ba1ac92a4c86d17d,PFS,0.301518
uuid-2cb49690450c41e9ba1ac92a4c86d17d,AI,0.655743
uuid-2cb49690450c41e9ba1ac92a4c86d17d,nivo and pembro,0.367482
uuid-2cb49690450c41e9ba1ac92a4c86d17d,chemotherapy,0.3283
uuid-db6ebe25e0ca4db8ac59b4a23424b13e,RTL,0.535767
uuid-db6ebe25e0ca4db8ac59b4a23424b13e,trial,0.366736
uuid-db6ebe25e0ca4db8ac59b4a23424b13e,NTL,0.554203
uuid-db6ebe25e0ca4db8ac59b4a23424b13e,data,0.30255
uuid-db6ebe25e0ca4db8ac59b4a23424b13e,expressed,0.516846
uuid-db6ebe25e0ca4db8ac59b4a23424b13e,mentioned,0.513175
uuid-db6ebe25e0ca4db8ac59b4a23424b13e,HCP,0.658559
uuid-db6ebe25e0ca4db8ac59b4a23424b13e,impressed,0.321476
uuid-db6ebe25e0ca4db8ac59b4a23424b13e,LTL,0.369687
uuid-db6ebe25e0ca4db8ac59b4a23424b13e,SCLC,0.311113
uuid-01cc30bcb0194765b1609fb6b1746667,NSCLC,0.411971
uuid-01cc30bcb0194765b1609fb6b1746667,1L,0.353147
uuid-01cc30bcb0194765b1609fb6b1746667,pts,0.323838
uuid-01cc30bcb0194765b1609fb6b1746667,monotherapy,0.303726
uuid-01cc30bcb0194765b1609fb6b1746667,HCP,0.326933
uuid-01cc30bcb0194765b1609fb6b1746667,chemotherapy,0.314759
uuid-01cc30bcb0194765b1609fb6b1746667,bladder,0.310294
uuid-165c2d10ef4a41879b08645ac633c2c5,RTL,0.407858
uuid-165c2d10ef4a41879b08645ac633c2c5,PDL1,0.385182
uuid-165c2d10ef4a41879b08645ac633c2c5,trial,0.505738
uuid-165c2d10ef4a41879b08645ac633c2c5,efficacy,0.468152
uuid-165c2d10ef4a41879b08645ac633c2c5,commented,0.319566
uuid-165c2d10ef4a41879b08645ac633c2c5,OS,0.823683
uuid-165c2d10ef4a41879b08645ac633c2c5,data,0.685382
uuid-165c2d10ef4a41879b08645ac633c2c5,expressed,0.33092
uuid-165c2d10ef4a41879b08645ac633c2c5,PFS,0.811371
uuid-165c2d10ef4a41879b08645ac633c2c5,ORR,0.771147
uuid-165c2d10ef4a41879b08645ac633c2c5,nivo and pembro,0.321263
uuid-165c2d10ef4a41879b08645ac633c2c5,impressed,0.61596
uuid-165c2d10ef4a41879b08645ac633c2c5,PDL1 expression,0.389662
uuid-9d0a364af0954871abdce96ccb40734f,Nivo,0.323564
uuid-9d0a364af0954871abdce96ccb40734f,patients,0.552408
uuid-9d0a364af0954871abdce96ccb40734f,pembro,0.460967
uuid-9d0a364af0954871abdce96ccb40734f,nivolumab,0.386074
uuid-9d0a364af0954871abdce96ccb40734f,1L,0.462503
uuid-9d0a364af0954871abdce96ccb40734f,trial,0.322197
uuid-9d0a364af0954871abdce96ccb40734f,treated,0.346887
uuid-9d0a364af0954871abdce96ccb40734f,2L,0.437742
uuid-9d0a364af0954871abdce96ccb40734f,pts,0.473192
uuid-9d0a364af0954871abdce96ccb40734f,approval,0.516697
uuid-9d0a364af0954871abdce96ccb40734f,preferred,0.474509
uuid-9d0a364af0954871abdce96ccb40734f,monotherapy,0.452845
uuid-9d0a364af0954871abdce96ccb40734f,using nivo,0.493355
uuid-9d0a364af0954871abdce96ccb40734f,combo,0.300969
uuid-9d0a364af0954871abdce96ccb40734f,clinical trials,0.422876
uuid-9d0a364af0954871abdce96ccb40734f,NSCLC patients,0.342845
uuid-9d0a364af0954871abdce96ccb40734f,approved,0.485518
uuid-9d0a364af0954871abdce96ccb40734f,SCCHN,0.332402
uuid-9d0a364af0954871abdce96ccb40734f,feels,0.319301
uuid-9d0a364af0954871abdce96ccb40734f,RTL stated,0.44006
uuid-9d0a364af0954871abdce96ccb40734f,option,0.498863
uuid-9d0a364af0954871abdce96ccb40734f,bladder,0.311034
uuid-e7c2a1ec08634ce0aeac9d699d1e6a61,TL,0.382255
uuid-e7c2a1ec08634ce0aeac9d699d1e6a61,mentioned,0.419995
uuid-e7c2a1ec08634ce0aeac9d699d1e6a61,HCP,0.368788
uuid-e7c2a1ec08634ce0aeac9d699d1e6a61,assay,0.388191
uuid-c200f5d181db4d5c93922c7e6e4c8c06,TL,0.628312
uuid-c200f5d181db4d5c93922c7e6e4c8c06,PDL1,0.436213
uuid-c200f5d181db4d5c93922c7e6e4c8c06,Merck,0.386456
uuid-c200f5d181db4d5c93922c7e6e4c8c06,institution,0.308099
uuid-c200f5d181db4d5c93922c7e6e4c8c06,PD-L1,0.746919
uuid-c200f5d181db4d5c93922c7e6e4c8c06,PD-L1 testing,0.767102
uuid-c200f5d181db4d5c93922c7e6e4c8c06,testing,0.715628
uuid-c200f5d181db4d5c93922c7e6e4c8c06,PDL1 testing,0.439203
uuid-c200f5d181db4d5c93922c7e6e4c8c06,NSCLC patients,0.383028
uuid-c200f5d181db4d5c93922c7e6e4c8c06,assay,0.822272
uuid-c200f5d181db4d5c93922c7e6e4c8c06,biomarker,0.416778
uuid-b6019f8d11214940aa0745439ea1d0bc,RTL,0.63268
uuid-b6019f8d11214940aa0745439ea1d0bc,NTL,0.466204
uuid-b6019f8d11214940aa0745439ea1d0bc,shared,0.309269
uuid-b6019f8d11214940aa0745439ea1d0bc,commented,0.416603
uuid-b6019f8d11214940aa0745439ea1d0bc,RCC,0.350713
uuid-b6019f8d11214940aa0745439ea1d0bc,stated,0.486106
uuid-b6019f8d11214940aa0745439ea1d0bc,approval,0.375623
uuid-b6019f8d11214940aa0745439ea1d0bc,using nivo,0.467194
uuid-b6019f8d11214940aa0745439ea1d0bc,data,0.395046
uuid-b6019f8d11214940aa0745439ea1d0bc,expressed,0.389134
uuid-b6019f8d11214940aa0745439ea1d0bc,mentioned,0.496922
uuid-b6019f8d11214940aa0745439ea1d0bc,clinical trials,0.347437
uuid-b6019f8d11214940aa0745439ea1d0bc,SCCHN,0.659627
uuid-b6019f8d11214940aa0745439ea1d0bc,HCP,0.596069
uuid-b6019f8d11214940aa0745439ea1d0bc,impressed,0.369359
uuid-b6019f8d11214940aa0745439ea1d0bc,LTL,0.586089
uuid-b6019f8d11214940aa0745439ea1d0bc,academic,0.376188
uuid-b6019f8d11214940aa0745439ea1d0bc,SCLC,0.334155
uuid-b6019f8d11214940aa0745439ea1d0bc,Regional TL,0.533172
uuid-b6019f8d11214940aa0745439ea1d0bc,RTL stated,0.495773
uuid-b6019f8d11214940aa0745439ea1d0bc,bladder,0.366852
uuid-3a80078d295c43debad466ed54cc44f1,Nivo,0.332946
uuid-3a80078d295c43debad466ed54cc44f1,pembro,0.44442
uuid-3a80078d295c43debad466ed54cc44f1,RTL,0.305806
uuid-3a80078d295c43debad466ed54cc44f1,BMS,0.348308
uuid-3a80078d295c43debad466ed54cc44f1,1L,0.300442
uuid-3a80078d295c43debad466ed54cc44f1,trial,0.387681
uuid-3a80078d295c43debad466ed54cc44f1,commented,0.409557
uuid-3a80078d295c43debad466ed54cc44f1,2L,0.314255
uuid-3a80078d295c43debad466ed54cc44f1,Merck,0.325894
uuid-3a80078d295c43debad466ed54cc44f1,stated,0.397674
uuid-3a80078d295c43debad466ed54cc44f1,approval,0.348577
uuid-3a80078d295c43debad466ed54cc44f1,atezo,0.379208
uuid-3a80078d295c43debad466ed54cc44f1,preferred,0.300681
uuid-3a80078d295c43debad466ed54cc44f1,using nivo,0.32689
uuid-3a80078d295c43debad466ed54cc44f1,data,0.640348
uuid-3a80078d295c43debad466ed54cc44f1,indication,0.361449
uuid-3a80078d295c43debad466ed54cc44f1,approved,0.378739
uuid-3a80078d295c43debad466ed54cc44f1,SCCHN,0.383859
uuid-3a80078d295c43debad466ed54cc44f1,impressed,0.586391
uuid-3a80078d295c43debad466ed54cc44f1,LTL,0.392031
uuid-3a80078d295c43debad466ed54cc44f1,SCLC,0.323521
uuid-3a80078d295c43debad466ed54cc44f1,feels,0.510762
uuid-3a80078d295c43debad466ed54cc44f1,Regional TL,0.33664
uuid-3a80078d295c43debad466ed54cc44f1,RTL stated,0.350329
uuid-3a80078d295c43debad466ed54cc44f1,bladder,0.303167
uuid-921a92a377374b7297d7a9dc863d520c,RTL,0.49002
uuid-921a92a377374b7297d7a9dc863d520c,BMS,0.497831
uuid-921a92a377374b7297d7a9dc863d520c,trial,0.434148
uuid-921a92a377374b7297d7a9dc863d520c,NTL,0.395947
uuid-921a92a377374b7297d7a9dc863d520c,discussed,0.43325
uuid-921a92a377374b7297d7a9dc863d520c,shared,0.324186
uuid-921a92a377374b7297d7a9dc863d520c,commented,0.713996
uuid-921a92a377374b7297d7a9dc863d520c,Merck,0.437683
uuid-921a92a377374b7297d7a9dc863d520c,stated,0.499952
uuid-921a92a377374b7297d7a9dc863d520c,OS,0.452833
uuid-921a92a377374b7297d7a9dc863d520c,regards,0.429495
uuid-921a92a377374b7297d7a9dc863d520c,data,0.818655
uuid-921a92a377374b7297d7a9dc863d520c,expressed,0.463651
uuid-921a92a377374b7297d7a9dc863d520c,mentioned,0.321647
uuid-921a92a377374b7297d7a9dc863d520c,PFS,0.390482
uuid-921a92a377374b7297d7a9dc863d520c,ORR,0.447571
uuid-921a92a377374b7297d7a9dc863d520c,SCCHN,0.330724
uuid-921a92a377374b7297d7a9dc863d520c,ASCO,0.685109
uuid-921a92a377374b7297d7a9dc863d520c,impressed,0.738685
uuid-921a92a377374b7297d7a9dc863d520c,LTL,0.391365
uuid-921a92a377374b7297d7a9dc863d520c,TLs,0.434799
uuid-921a92a377374b7297d7a9dc863d520c,Regional TL,0.515319
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,pembro,0.309662
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,nivolumab,0.316218
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,1L,0.504886
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,regimen,0.397232
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,treated,0.302878
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,shared,0.32625
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,RCC,0.417803
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,combination,0.305006
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,2L,0.568316
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,agents,0.34112
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,atezo,0.324762
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,preferred,0.727086
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,monotherapy,0.543291
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,using nivo,0.565996
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,combo,0.314123
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,approved,0.346189
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,SCCHN,0.447842
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,tumor types,0.316996
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,RTL stated,0.576778
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,TL shared,0.372111
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,option,0.564071
uuid-4b93e156eb7f49a6812f9d9b4bb4863e,bladder,0.302344
uuid-42a465c1150141959773963f686217df,RTL,0.385178
uuid-42a465c1150141959773963f686217df,BMS,0.329323
uuid-42a465c1150141959773963f686217df,trial,0.502496
uuid-42a465c1150141959773963f686217df,commented,0.369902
uuid-42a465c1150141959773963f686217df,OS,0.402137
uuid-42a465c1150141959773963f686217df,data,0.64983
uuid-42a465c1150141959773963f686217df,expressed,0.37886
uuid-42a465c1150141959773963f686217df,clinical trials,0.344659
uuid-42a465c1150141959773963f686217df,PFS,0.399492
uuid-42a465c1150141959773963f686217df,ORR,0.430359
uuid-42a465c1150141959773963f686217df,SCCHN,0.325093
uuid-42a465c1150141959773963f686217df,impressed,0.561641
uuid-42a465c1150141959773963f686217df,feels,0.356335
uuid-42a465c1150141959773963f686217df,Regional TL,0.313719
uuid-6ac5db793d314837aef656ca40cc2e20,trial,0.310527
uuid-6c8f4720d53a4ef6bcd57b77e1ce5f29,NSCLC,0.384818
uuid-6c8f4720d53a4ef6bcd57b77e1ce5f29,trial,0.383949
uuid-6c8f4720d53a4ef6bcd57b77e1ce5f29,shared,0.318209
uuid-6c8f4720d53a4ef6bcd57b77e1ce5f29,approval,0.356098
uuid-6c8f4720d53a4ef6bcd57b77e1ce5f29,preferred,0.312365
uuid-6c8f4720d53a4ef6bcd57b77e1ce5f29,clinical trials,0.452356
uuid-6c8f4720d53a4ef6bcd57b77e1ce5f29,SCCHN,0.395877
uuid-6c8f4720d53a4ef6bcd57b77e1ce5f29,tumor types,0.300231
uuid-6c8f4720d53a4ef6bcd57b77e1ce5f29,RTL stated,0.306838
uuid-6c8f4720d53a4ef6bcd57b77e1ce5f29,bladder,0.488559
uuid-3fc4b542b7b3418aaeaa187471b7a7e6,patients,0.455635
uuid-3fc4b542b7b3418aaeaa187471b7a7e6,therapy,0.353736
uuid-3fc4b542b7b3418aaeaa187471b7a7e6,trial,0.352917
uuid-3fc4b542b7b3418aaeaa187471b7a7e6,clinical trials,0.341563
uuid-3fc4b542b7b3418aaeaa187471b7a7e6,chemotherapy,0.384794
uuid-1c4342dce6754823a5d7decb8d27d837,Nivo,0.414208
uuid-1c4342dce6754823a5d7decb8d27d837,pembro,0.686482
uuid-1c4342dce6754823a5d7decb8d27d837,dose,0.500715
uuid-1c4342dce6754823a5d7decb8d27d837,1L,0.539887
uuid-1c4342dce6754823a5d7decb8d27d837,TL stated,0.323412
uuid-1c4342dce6754823a5d7decb8d27d837,2L,0.701648
uuid-1c4342dce6754823a5d7decb8d27d837,agents,0.497718
uuid-1c4342dce6754823a5d7decb8d27d837,Ipi,0.370295
uuid-1c4342dce6754823a5d7decb8d27d837,atezo,0.812337
uuid-1c4342dce6754823a5d7decb8d27d837,preferred,0.64933
uuid-1c4342dce6754823a5d7decb8d27d837,monotherapy,0.369352
uuid-1c4342dce6754823a5d7decb8d27d837,using nivo,0.430063
uuid-1c4342dce6754823a5d7decb8d27d837,combo,0.381379
uuid-1c4342dce6754823a5d7decb8d27d837,PDL1 testing,0.307544
uuid-1c4342dce6754823a5d7decb8d27d837,indication,0.377757
uuid-1c4342dce6754823a5d7decb8d27d837,approved,0.458128
uuid-1c4342dce6754823a5d7decb8d27d837,nivo and pembro,0.41182
uuid-1c4342dce6754823a5d7decb8d27d837,vs,0.557165
uuid-1c4342dce6754823a5d7decb8d27d837,TLs,0.351798
uuid-1c4342dce6754823a5d7decb8d27d837,RTL stated,0.314864
uuid-1c4342dce6754823a5d7decb8d27d837,option,0.373236
uuid-1c4342dce6754823a5d7decb8d27d837,flat dosing,0.400747
uuid-e43801cc4a9c419096475046e879ae68,BMS,0.485106
uuid-e43801cc4a9c419096475046e879ae68,lung,0.33957
uuid-e43801cc4a9c419096475046e879ae68,commented,0.320031
uuid-e43801cc4a9c419096475046e879ae68,TL stated,0.335117
uuid-e43801cc4a9c419096475046e879ae68,Merck,0.442681
uuid-e43801cc4a9c419096475046e879ae68,regards,0.36991
uuid-e43801cc4a9c419096475046e879ae68,expressed,0.34499
uuid-e43801cc4a9c419096475046e879ae68,clinical trials,0.337912
uuid-e43801cc4a9c419096475046e879ae68,indication,0.333828
uuid-e43801cc4a9c419096475046e879ae68,believes,0.32314
uuid-e43801cc4a9c419096475046e879ae68,tumor types,0.303668
uuid-e43801cc4a9c419096475046e879ae68,TLs,0.459882
uuid-e43801cc4a9c419096475046e879ae68,feels,0.324953
uuid-e43801cc4a9c419096475046e879ae68,biomarker,0.343228
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,Nivo,0.657897
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,pembro,0.478543
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,1L,0.511511
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,efficacy,0.400052
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,regimen,0.317643
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,combination,0.36604
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,chemo,0.618773
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,2L,0.545925
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,pts,0.374089
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,agents,0.38837
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,Ipi,0.38909
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,atezo,0.464256
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,preferred,0.393897
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,monotherapy,0.554152
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,using nivo,0.354147
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,combo,0.468468
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,PD1,0.38493
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,nivo and pembro,0.46946
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,believes,0.45705
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,chemotherapy,0.394057
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,vs,0.357091
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,feels,0.384762
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,PDL1 expression,0.323067
uuid-c5c3570ca1e848e2a9bbf0fafeb6aa9a,option,0.454057
uuid-51b905f8a22a47d7acee4826ba9d8ce3,Nivo,0.312218
uuid-51b905f8a22a47d7acee4826ba9d8ce3,pembro,0.397903
uuid-51b905f8a22a47d7acee4826ba9d8ce3,1L,0.329636
uuid-51b905f8a22a47d7acee4826ba9d8ce3,PDL1,0.455503
uuid-51b905f8a22a47d7acee4826ba9d8ce3,trial,0.581779
uuid-51b905f8a22a47d7acee4826ba9d8ce3,efficacy,0.531262
uuid-51b905f8a22a47d7acee4826ba9d8ce3,chemo,0.36211
uuid-51b905f8a22a47d7acee4826ba9d8ce3,OS,0.633591
uuid-51b905f8a22a47d7acee4826ba9d8ce3,monotherapy,0.306638
uuid-51b905f8a22a47d7acee4826ba9d8ce3,data,0.671374
uuid-51b905f8a22a47d7acee4826ba9d8ce3,combo,0.358961
uuid-51b905f8a22a47d7acee4826ba9d8ce3,PFS,0.636935
uuid-51b905f8a22a47d7acee4826ba9d8ce3,ORR,0.659511
uuid-51b905f8a22a47d7acee4826ba9d8ce3,nivo and pembro,0.555077
uuid-51b905f8a22a47d7acee4826ba9d8ce3,believes,0.426589
uuid-51b905f8a22a47d7acee4826ba9d8ce3,impressed,0.558143
uuid-51b905f8a22a47d7acee4826ba9d8ce3,feels,0.493914
uuid-51b905f8a22a47d7acee4826ba9d8ce3,PDL1 expression,0.428281
uuid-b5b590792f5e49c0afbfac782001b9bd,RTL,0.308884
uuid-b5b590792f5e49c0afbfac782001b9bd,BMS,0.438795
uuid-b5b590792f5e49c0afbfac782001b9bd,trial,0.388811
uuid-b5b590792f5e49c0afbfac782001b9bd,commented,0.625018
uuid-b5b590792f5e49c0afbfac782001b9bd,stated,0.563688
uuid-b5b590792f5e49c0afbfac782001b9bd,OS,0.455856
uuid-b5b590792f5e49c0afbfac782001b9bd,regards,0.43964
uuid-b5b590792f5e49c0afbfac782001b9bd,data,0.778356
uuid-b5b590792f5e49c0afbfac782001b9bd,expressed,0.425863
uuid-b5b590792f5e49c0afbfac782001b9bd,indication,0.313848
uuid-b5b590792f5e49c0afbfac782001b9bd,PFS,0.40343
uuid-b5b590792f5e49c0afbfac782001b9bd,ORR,0.458238
uuid-b5b590792f5e49c0afbfac782001b9bd,SCCHN,0.349374
uuid-b5b590792f5e49c0afbfac782001b9bd,nivo and pembro,0.30625
uuid-b5b590792f5e49c0afbfac782001b9bd,ASCO,0.397338
uuid-b5b590792f5e49c0afbfac782001b9bd,impressed,0.64349
uuid-b5b590792f5e49c0afbfac782001b9bd,TLs,0.300967
uuid-b5b590792f5e49c0afbfac782001b9bd,SCLC,0.380824
uuid-b5b590792f5e49c0afbfac782001b9bd,feels,0.361199
uuid-b5b590792f5e49c0afbfac782001b9bd,Regional TL,0.372073
uuid-b5b590792f5e49c0afbfac782001b9bd,NCCN,0.455305
uuid-ea5af305948a4bc09170034a24afd886,RTL,0.377095
uuid-ea5af305948a4bc09170034a24afd886,BMS,0.481415
uuid-ea5af305948a4bc09170034a24afd886,trial,0.556846
uuid-ea5af305948a4bc09170034a24afd886,NTL,0.315428
uuid-ea5af305948a4bc09170034a24afd886,commented,0.477686
uuid-ea5af305948a4bc09170034a24afd886,Merck,0.418962
uuid-ea5af305948a4bc09170034a24afd886,stated,0.410582
uuid-ea5af305948a4bc09170034a24afd886,regards,0.318823
uuid-ea5af305948a4bc09170034a24afd886,data,0.401962
uuid-ea5af305948a4bc09170034a24afd886,expressed,0.42098
uuid-ea5af305948a4bc09170034a24afd886,mentioned,0.308188
uuid-ea5af305948a4bc09170034a24afd886,clinical trials,0.378579
uuid-ea5af305948a4bc09170034a24afd886,SCCHN,0.311632
uuid-ea5af305948a4bc09170034a24afd886,impressed,0.413729
uuid-ea5af305948a4bc09170034a24afd886,TLs,0.300219
uuid-ea5af305948a4bc09170034a24afd886,feels,0.36509
uuid-ea5af305948a4bc09170034a24afd886,Regional TL,0.405334
uuid-7d2b52a7403949beb723894d45804925,Nivo,0.371443
uuid-7d2b52a7403949beb723894d45804925,pembro,0.494013
uuid-7d2b52a7403949beb723894d45804925,dose,0.351228
uuid-7d2b52a7403949beb723894d45804925,1L,0.415246
uuid-7d2b52a7403949beb723894d45804925,2L,0.546751
uuid-7d2b52a7403949beb723894d45804925,agents,0.335177
uuid-7d2b52a7403949beb723894d45804925,Ipi,0.314765
uuid-7d2b52a7403949beb723894d45804925,atezo,0.605049
uuid-7d2b52a7403949beb723894d45804925,preferred,0.553059
uuid-7d2b52a7403949beb723894d45804925,monotherapy,0.307134
uuid-7d2b52a7403949beb723894d45804925,using nivo,0.400575
uuid-7d2b52a7403949beb723894d45804925,indication,0.393824
uuid-7d2b52a7403949beb723894d45804925,approved,0.357838
uuid-7d2b52a7403949beb723894d45804925,tumor types,0.301875
uuid-7d2b52a7403949beb723894d45804925,vs,0.344247
uuid-7d2b52a7403949beb723894d45804925,TLs,0.312357
uuid-7d2b52a7403949beb723894d45804925,feels,0.334324
uuid-7d2b52a7403949beb723894d45804925,RTL stated,0.33097
uuid-7d2b52a7403949beb723894d45804925,option,0.381997
uuid-e1901caaefd0497fb175ceef43be8e1b,dose,0.317912
uuid-e1901caaefd0497fb175ceef43be8e1b,toxicity,0.681895
uuid-e1901caaefd0497fb175ceef43be8e1b,efficacy,0.4852
uuid-e1901caaefd0497fb175ceef43be8e1b,regimen,0.459062
uuid-e1901caaefd0497fb175ceef43be8e1b,chemo,0.4202
uuid-e1901caaefd0497fb175ceef43be8e1b,Ipi,0.32734
uuid-e1901caaefd0497fb175ceef43be8e1b,believes,0.323629
uuid-e1901caaefd0497fb175ceef43be8e1b,respond,0.39555
uuid-e1901caaefd0497fb175ceef43be8e1b,feels,0.383883
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,Nivo,0.528386
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,pembro,0.773765
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,1L,0.535415
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,PDL1,0.328377
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,trial,0.33177
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,2L,0.577829
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,agents,0.393104
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,approval,0.375826
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,atezo,0.708187
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,preferred,0.499336
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,monotherapy,0.34781
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,using nivo,0.454419
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,indication,0.356527
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,approved,0.420364
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,nivo and pembro,0.675794
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,vs,0.406325
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,label,0.315716
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,feels,0.386529
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,PDL1 expression,0.325067
uuid-68da7a1ff2e443bfa34a14f234b1cdf3,option,0.391054
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,toxicity,0.317579
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,efficacy,0.49829
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,regimen,0.440727
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,combination,0.464653
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,chemo,0.377113
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,IO,0.327822
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,agents,0.374204
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,Ipi,0.427913
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,atezo,0.315136
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,preferred,0.325746
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,monotherapy,0.421412
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,combo,0.543573
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,believes,0.403816
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,impressed,0.336312
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,feels,0.492809
uuid-4f458a6b3c8a4b5788c608b02e9b8c9a,option,0.36941
uuid-3c401ba37cce4444aa0ecf84f890c651,TL,0.616706
uuid-3c401ba37cce4444aa0ecf84f890c651,PDL1,0.437166
uuid-3c401ba37cce4444aa0ecf84f890c651,TL stated,0.449382
uuid-3c401ba37cce4444aa0ecf84f890c651,institution,0.384617
uuid-3c401ba37cce4444aa0ecf84f890c651,PD-L1,0.833039
uuid-3c401ba37cce4444aa0ecf84f890c651,PD-L1 testing,0.873749
uuid-3c401ba37cce4444aa0ecf84f890c651,testing,0.902917
uuid-3c401ba37cce4444aa0ecf84f890c651,PDL1 testing,0.690237
uuid-3c401ba37cce4444aa0ecf84f890c651,NSCLC patients,0.600059
uuid-3c401ba37cce4444aa0ecf84f890c651,assay,0.814347
uuid-3c401ba37cce4444aa0ecf84f890c651,biomarker,0.481061
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,pembro,0.668329
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,1L,0.666973
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,PDL1,0.671028
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,2L,0.573797
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,agents,0.335568
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,Merck,0.330152
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,PD-L1,0.666787
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,approval,0.378453
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,atezo,0.669078
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,preferred,0.408994
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,PD-L1 testing,0.41746
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,testing,0.613064
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,monotherapy,0.313106
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,using nivo,0.324451
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,PDL1 testing,0.502226
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,NSCLC patients,0.530378
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,approved,0.38434
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,nivo and pembro,0.505068
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,believes,0.353426
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,assay,0.594496
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,PD-1,0.305997
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,PDL1 expression,0.492256
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,option,0.363627
uuid-3e3ec6fd9f60403eb8f1053ab8e57710,biomarker,0.408612
uuid-4bd1de162198488fb1da9ab76b9fff52,Nivo,0.659035
uuid-4bd1de162198488fb1da9ab76b9fff52,pembro,0.763922
uuid-4bd1de162198488fb1da9ab76b9fff52,dose,0.550956
uuid-4bd1de162198488fb1da9ab76b9fff52,1L,0.377877
uuid-4bd1de162198488fb1da9ab76b9fff52,efficacy,0.492188
uuid-4bd1de162198488fb1da9ab76b9fff52,2L,0.544041
uuid-4bd1de162198488fb1da9ab76b9fff52,agents,0.33304
uuid-4bd1de162198488fb1da9ab76b9fff52,Ipi,0.462314
uuid-4bd1de162198488fb1da9ab76b9fff52,approval,0.316097
uuid-4bd1de162198488fb1da9ab76b9fff52,atezo,0.826173
uuid-4bd1de162198488fb1da9ab76b9fff52,preferred,0.473658
uuid-4bd1de162198488fb1da9ab76b9fff52,monotherapy,0.330142
uuid-4bd1de162198488fb1da9ab76b9fff52,using nivo,0.470019
uuid-4bd1de162198488fb1da9ab76b9fff52,indication,0.382781
uuid-4bd1de162198488fb1da9ab76b9fff52,approved,0.372283
uuid-4bd1de162198488fb1da9ab76b9fff52,nivo and pembro,0.460585
uuid-4bd1de162198488fb1da9ab76b9fff52,vs,0.695188
uuid-4bd1de162198488fb1da9ab76b9fff52,TLs,0.340228
uuid-4bd1de162198488fb1da9ab76b9fff52,feels,0.317089
uuid-4bd1de162198488fb1da9ab76b9fff52,option,0.312926
uuid-4bd1de162198488fb1da9ab76b9fff52,flat dosing,0.415805
uuid-4acc60a9feb9481db3041610ad0e6823,TL,0.457885
uuid-4acc60a9feb9481db3041610ad0e6823,RTL,0.506618
uuid-4acc60a9feb9481db3041610ad0e6823,NTL,0.44829
uuid-4acc60a9feb9481db3041610ad0e6823,shared,0.359961
uuid-4acc60a9feb9481db3041610ad0e6823,Merck,0.412122
uuid-4acc60a9feb9481db3041610ad0e6823,stated,0.400903
uuid-4acc60a9feb9481db3041610ad0e6823,approval,0.374414
uuid-4acc60a9feb9481db3041610ad0e6823,mentioned,0.371058
uuid-4acc60a9feb9481db3041610ad0e6823,clinical trials,0.378021
uuid-4acc60a9feb9481db3041610ad0e6823,SCCHN,0.344619
uuid-4acc60a9feb9481db3041610ad0e6823,LTL,0.430358
uuid-4acc60a9feb9481db3041610ad0e6823,academic,0.347187
uuid-4acc60a9feb9481db3041610ad0e6823,Regional TL,0.548034
uuid-17b88e55dcf148e5a8e111d9bdaa5965,RTL,0.370292
uuid-17b88e55dcf148e5a8e111d9bdaa5965,therapy,0.382931
uuid-17b88e55dcf148e5a8e111d9bdaa5965,nivolumab,0.416359
uuid-17b88e55dcf148e5a8e111d9bdaa5965,combination,0.428956
uuid-17b88e55dcf148e5a8e111d9bdaa5965,preferred,0.310911
uuid-17b88e55dcf148e5a8e111d9bdaa5965,monotherapy,0.392873
uuid-17b88e55dcf148e5a8e111d9bdaa5965,using nivo,0.418966
uuid-17b88e55dcf148e5a8e111d9bdaa5965,mentioned,0.364525
uuid-17b88e55dcf148e5a8e111d9bdaa5965,PD1,0.300059
uuid-17b88e55dcf148e5a8e111d9bdaa5965,SCCHN,0.344213
uuid-17b88e55dcf148e5a8e111d9bdaa5965,HCP,0.365011
uuid-17b88e55dcf148e5a8e111d9bdaa5965,cHL,0.326144
uuid-17b88e55dcf148e5a8e111d9bdaa5965,chemotherapy,0.320337
uuid-17b88e55dcf148e5a8e111d9bdaa5965,LTL,0.310324
uuid-17b88e55dcf148e5a8e111d9bdaa5965,SCLC,0.311985
uuid-17b88e55dcf148e5a8e111d9bdaa5965,RTL stated,0.401174
uuid-17b88e55dcf148e5a8e111d9bdaa5965,option,0.343786
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,Nivo,0.35385
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,patients,0.514582
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,pembro,0.593765
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,1L,0.602481
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,PDL1,0.366936
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,chemo,0.326207
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,2L,0.611497
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,pts,0.389095
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,PD-L1,0.472286
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,approval,0.338069
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,atezo,0.568995
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,preferred,0.526414
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,PD-L1 testing,0.355173
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,testing,0.507338
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,monotherapy,0.43588
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,using nivo,0.433066
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,PDL1 testing,0.465146
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,NSCLC patients,0.596159
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,approved,0.339122
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,vs,0.378917
uuid-58a8a0e41e0949d78b68ab1a576cd6f6,option,0.471857
uuid-a1a4f52a1391420db7849c0978911598,pembro,0.434439
uuid-a1a4f52a1391420db7849c0978911598,trial,0.465804
uuid-a1a4f52a1391420db7849c0978911598,approval,0.45243
uuid-a1a4f52a1391420db7849c0978911598,atezo,0.31837
uuid-a1a4f52a1391420db7849c0978911598,preferred,0.381102
uuid-a1a4f52a1391420db7849c0978911598,clinical trials,0.46288
uuid-a1a4f52a1391420db7849c0978911598,indication,0.375517
uuid-a1a4f52a1391420db7849c0978911598,approved,0.364854
uuid-a1a4f52a1391420db7849c0978911598,SCCHN,0.346321
uuid-a1a4f52a1391420db7849c0978911598,RTL stated,0.321195
uuid-a1a4f52a1391420db7849c0978911598,option,0.32375
uuid-a1a4f52a1391420db7849c0978911598,bladder,0.38906
uuid-d17d07c96e6d48548af8c8744b66ef87,Nivo,0.345601
uuid-d17d07c96e6d48548af8c8744b66ef87,pembro,0.412833
uuid-d17d07c96e6d48548af8c8744b66ef87,lung,0.436031
uuid-d17d07c96e6d48548af8c8744b66ef87,1L,0.529076
uuid-d17d07c96e6d48548af8c8744b66ef87,trial,0.302743
uuid-d17d07c96e6d48548af8c8744b66ef87,melanoma,0.318619
uuid-d17d07c96e6d48548af8c8744b66ef87,RCC,0.495176
uuid-d17d07c96e6d48548af8c8744b66ef87,combination,0.420958
uuid-d17d07c96e6d48548af8c8744b66ef87,2L,0.499945
uuid-d17d07c96e6d48548af8c8744b66ef87,agents,0.414546
uuid-d17d07c96e6d48548af8c8744b66ef87,atezo,0.377313
uuid-d17d07c96e6d48548af8c8744b66ef87,preferred,0.312496
uuid-d17d07c96e6d48548af8c8744b66ef87,monotherapy,0.453508
uuid-d17d07c96e6d48548af8c8744b66ef87,using nivo,0.406878
uuid-d17d07c96e6d48548af8c8744b66ef87,data,0.443899
uuid-d17d07c96e6d48548af8c8744b66ef87,combo,0.50476
uuid-d17d07c96e6d48548af8c8744b66ef87,PD1,0.347411
uuid-d17d07c96e6d48548af8c8744b66ef87,SCCHN,0.369626
uuid-d17d07c96e6d48548af8c8744b66ef87,nivo and pembro,0.455493
uuid-d17d07c96e6d48548af8c8744b66ef87,impressed,0.412777
uuid-d17d07c96e6d48548af8c8744b66ef87,TLs,0.30627
uuid-d17d07c96e6d48548af8c8744b66ef87,SCLC,0.436498
uuid-d17d07c96e6d48548af8c8744b66ef87,feels,0.310977
uuid-d17d07c96e6d48548af8c8744b66ef87,RTL stated,0.433042
uuid-d17d07c96e6d48548af8c8744b66ef87,TL shared,0.3842
uuid-d17d07c96e6d48548af8c8744b66ef87,option,0.347783
uuid-d17d07c96e6d48548af8c8744b66ef87,bladder,0.386524
uuid-5b49d4b06b0841d98a79be8d463f58e2,BMS,0.663839
uuid-5b49d4b06b0841d98a79be8d463f58e2,PDL1,0.368809
uuid-5b49d4b06b0841d98a79be8d463f58e2,trial,0.453996
uuid-5b49d4b06b0841d98a79be8d463f58e2,efficacy,0.476797
uuid-5b49d4b06b0841d98a79be8d463f58e2,commented,0.302093
uuid-5b49d4b06b0841d98a79be8d463f58e2,Merck,0.419559
uuid-5b49d4b06b0841d98a79be8d463f58e2,OS,0.444252
uuid-5b49d4b06b0841d98a79be8d463f58e2,regards,0.490672
uuid-5b49d4b06b0841d98a79be8d463f58e2,data,0.491553
uuid-5b49d4b06b0841d98a79be8d463f58e2,PFS,0.477788
uuid-5b49d4b06b0841d98a79be8d463f58e2,ORR,0.434247
uuid-5b49d4b06b0841d98a79be8d463f58e2,nivo and pembro,0.376115
uuid-5b49d4b06b0841d98a79be8d463f58e2,believes,0.351079
uuid-5b49d4b06b0841d98a79be8d463f58e2,impressed,0.321718
uuid-5b49d4b06b0841d98a79be8d463f58e2,feels,0.453096
uuid-5b49d4b06b0841d98a79be8d463f58e2,PDL1 expression,0.335662
uuid-6537068e6664402b8b5c99ebdeb00658,pembro,0.360159
uuid-6537068e6664402b8b5c99ebdeb00658,BMS,0.365817
uuid-6537068e6664402b8b5c99ebdeb00658,PDL1,0.493526
uuid-6537068e6664402b8b5c99ebdeb00658,trial,0.372373
uuid-6537068e6664402b8b5c99ebdeb00658,efficacy,0.402202
uuid-6537068e6664402b8b5c99ebdeb00658,commented,0.394613
uuid-6537068e6664402b8b5c99ebdeb00658,Merck,0.351625
uuid-6537068e6664402b8b5c99ebdeb00658,OS,0.403023
uuid-6537068e6664402b8b5c99ebdeb00658,atezo,0.335399
uuid-6537068e6664402b8b5c99ebdeb00658,regards,0.366296
uuid-6537068e6664402b8b5c99ebdeb00658,data,0.756006
uuid-6537068e6664402b8b5c99ebdeb00658,expressed,0.303547
uuid-6537068e6664402b8b5c99ebdeb00658,indication,0.322057
uuid-6537068e6664402b8b5c99ebdeb00658,PFS,0.399628
uuid-6537068e6664402b8b5c99ebdeb00658,ORR,0.420844
uuid-6537068e6664402b8b5c99ebdeb00658,nivo and pembro,0.454415
uuid-6537068e6664402b8b5c99ebdeb00658,impressed,0.478241
uuid-6537068e6664402b8b5c99ebdeb00658,PDL1 expression,0.451649
uuid-6537068e6664402b8b5c99ebdeb00658,biomarker,0.319668
uuid-55df53118a7048958fc6f45a33d24053,regards,0.389365
uuid-55df53118a7048958fc6f45a33d24053,indicated,0.372563
uuid-55df53118a7048958fc6f45a33d24053,clinical,0.327303
uuid-55df53118a7048958fc6f45a33d24053,PDL1 expression,0.42426
uuid-55df53118a7048958fc6f45a33d24053,biomarker,0.340589
uuid-2b6ff2bfaa6a40af8fd58f027c1724c8,physicians,0.580406
uuid-2b6ff2bfaa6a40af8fd58f027c1724c8,oncology,0.375755
uuid-2b6ff2bfaa6a40af8fd58f027c1724c8,drug,0.348167
uuid-2b6ff2bfaa6a40af8fd58f027c1724c8,clinical,0.347898
uuid-2a0d1c71577b47d9babeb67c53889767,lung,0.352145
uuid-2a0d1c71577b47d9babeb67c53889767,AI,0.480478
uuid-2a0d1c71577b47d9babeb67c53889767,lung cancer,0.578834
uuid-b9ab8f6048514cf2bbf33f4fbb026482,pembro,0.352204
uuid-b9ab8f6048514cf2bbf33f4fbb026482,2L,0.305423
uuid-b9ab8f6048514cf2bbf33f4fbb026482,atezo,0.399693
uuid-b9ab8f6048514cf2bbf33f4fbb026482,lung cancer,0.586386
uuid-b9ab8f6048514cf2bbf33f4fbb026482,nivo and pembro,0.362842
uuid-de864020a71e4ea79b56ae86af5815a3,pembro,0.321561
uuid-de864020a71e4ea79b56ae86af5815a3,nivolumab,0.303281
uuid-de864020a71e4ea79b56ae86af5815a3,1L,0.363615
uuid-de864020a71e4ea79b56ae86af5815a3,shared,0.393999
uuid-de864020a71e4ea79b56ae86af5815a3,RCC,0.429024
uuid-de864020a71e4ea79b56ae86af5815a3,2L,0.427076
uuid-de864020a71e4ea79b56ae86af5815a3,stated,0.518696
uuid-de864020a71e4ea79b56ae86af5815a3,approval,0.600095
uuid-de864020a71e4ea79b56ae86af5815a3,preferred,0.376214
uuid-de864020a71e4ea79b56ae86af5815a3,using nivo,0.499391
uuid-de864020a71e4ea79b56ae86af5815a3,clinical trials,0.493936
uuid-de864020a71e4ea79b56ae86af5815a3,indication,0.385786
uuid-de864020a71e4ea79b56ae86af5815a3,approved,0.664308
uuid-de864020a71e4ea79b56ae86af5815a3,SCCHN,0.418507
uuid-de864020a71e4ea79b56ae86af5815a3,impressed,0.313618
uuid-de864020a71e4ea79b56ae86af5815a3,tumor types,0.384538
uuid-de864020a71e4ea79b56ae86af5815a3,label,0.437536
uuid-de864020a71e4ea79b56ae86af5815a3,SCLC,0.337503
uuid-de864020a71e4ea79b56ae86af5815a3,Regional TL,0.343209
uuid-de864020a71e4ea79b56ae86af5815a3,RTL stated,0.432603
uuid-de864020a71e4ea79b56ae86af5815a3,bladder,0.417618
uuid-ca223458f4cf4e8fa974b7857707ac05,patients,0.618621
uuid-ca223458f4cf4e8fa974b7857707ac05,therapy,0.440705
uuid-ca223458f4cf4e8fa974b7857707ac05,nivolumab,0.469442
uuid-ca223458f4cf4e8fa974b7857707ac05,toxicity,0.357619
uuid-ca223458f4cf4e8fa974b7857707ac05,regimen,0.502363
uuid-ca223458f4cf4e8fa974b7857707ac05,treated,0.668615
uuid-ca223458f4cf4e8fa974b7857707ac05,melanoma,0.37877
uuid-ca223458f4cf4e8fa974b7857707ac05,pts,0.582808
uuid-ca223458f4cf4e8fa974b7857707ac05,treatment,0.631636
uuid-ca223458f4cf4e8fa974b7857707ac05,response,0.553242
uuid-ca223458f4cf4e8fa974b7857707ac05,PD1,0.328
uuid-ca223458f4cf4e8fa974b7857707ac05,progression,0.702986
uuid-ca223458f4cf4e8fa974b7857707ac05,respond,0.510438
uuid-ca223458f4cf4e8fa974b7857707ac05,TL shared,0.431297
uuid-b3a4e2737ec2492a9b7fa5a72d5a1fd4,trial,0.385122
uuid-93f49e38f66b4af38793448cbc94992f,Nivo,0.350858
uuid-93f49e38f66b4af38793448cbc94992f,patients,0.561481
uuid-93f49e38f66b4af38793448cbc94992f,therapy,0.527333
uuid-93f49e38f66b4af38793448cbc94992f,nivolumab,0.377708
uuid-93f49e38f66b4af38793448cbc94992f,regimen,0.489197
uuid-93f49e38f66b4af38793448cbc94992f,treated,0.428052
uuid-93f49e38f66b4af38793448cbc94992f,combination,0.413849
uuid-93f49e38f66b4af38793448cbc94992f,chemo,0.54348
uuid-93f49e38f66b4af38793448cbc94992f,pts,0.625459
uuid-93f49e38f66b4af38793448cbc94992f,IO,0.371262
uuid-93f49e38f66b4af38793448cbc94992f,monotherapy,0.500997
uuid-93f49e38f66b4af38793448cbc94992f,treatment,0.477472
uuid-93f49e38f66b4af38793448cbc94992f,response,0.793726
uuid-93f49e38f66b4af38793448cbc94992f,combo,0.366781
uuid-93f49e38f66b4af38793448cbc94992f,PD1,0.551672
uuid-93f49e38f66b4af38793448cbc94992f,progression,0.698275
uuid-93f49e38f66b4af38793448cbc94992f,chemotherapy,0.465982
uuid-93f49e38f66b4af38793448cbc94992f,respond,0.553568
uuid-93f49e38f66b4af38793448cbc94992f,option,0.343053
uuid-99e7db2561364f15a7e7f02d9c96b488,toxicity,0.411566
uuid-99e7db2561364f15a7e7f02d9c96b488,physicians,0.431846
uuid-99e7db2561364f15a7e7f02d9c96b488,feels,0.340371
uuid-5bbec1d94ea74801a82d96a933bec95f,Nivo,0.34713
uuid-5bbec1d94ea74801a82d96a933bec95f,pembro,0.49174
uuid-5bbec1d94ea74801a82d96a933bec95f,dose,0.571727
uuid-5bbec1d94ea74801a82d96a933bec95f,trial,0.363329
uuid-5bbec1d94ea74801a82d96a933bec95f,efficacy,0.612429
uuid-5bbec1d94ea74801a82d96a933bec95f,Ipi,0.477464
uuid-5bbec1d94ea74801a82d96a933bec95f,atezo,0.401343
uuid-5bbec1d94ea74801a82d96a933bec95f,data,0.458281
uuid-5bbec1d94ea74801a82d96a933bec95f,ORR,0.320365
uuid-5bbec1d94ea74801a82d96a933bec95f,nivo and pembro,0.341403
uuid-5bbec1d94ea74801a82d96a933bec95f,impressed,0.353749
uuid-5bbec1d94ea74801a82d96a933bec95f,vs,0.721187
uuid-5bbec1d94ea74801a82d96a933bec95f,TLs,0.344476
uuid-5bbec1d94ea74801a82d96a933bec95f,flat dosing,0.506234
uuid-ef0f17d14ca84352b6353f5249e2d18b,Nivo,0.407858
uuid-ef0f17d14ca84352b6353f5249e2d18b,pembro,0.459341
uuid-ef0f17d14ca84352b6353f5249e2d18b,BMS,0.326492
uuid-ef0f17d14ca84352b6353f5249e2d18b,PDL1,0.341014
uuid-ef0f17d14ca84352b6353f5249e2d18b,trial,0.354945
uuid-ef0f17d14ca84352b6353f5249e2d18b,efficacy,0.564018
uuid-ef0f17d14ca84352b6353f5249e2d18b,agents,0.314547
uuid-ef0f17d14ca84352b6353f5249e2d18b,Ipi,0.342285
uuid-ef0f17d14ca84352b6353f5249e2d18b,OS,0.361504
uuid-ef0f17d14ca84352b6353f5249e2d18b,atezo,0.463671
uuid-ef0f17d14ca84352b6353f5249e2d18b,regards,0.403526
uuid-ef0f17d14ca84352b6353f5249e2d18b,data,0.301786
uuid-ef0f17d14ca84352b6353f5249e2d18b,combo,0.35617
uuid-ef0f17d14ca84352b6353f5249e2d18b,PFS,0.403733
uuid-ef0f17d14ca84352b6353f5249e2d18b,AI,0.499926
uuid-ef0f17d14ca84352b6353f5249e2d18b,ORR,0.379931
uuid-ef0f17d14ca84352b6353f5249e2d18b,nivo and pembro,0.635334
uuid-ef0f17d14ca84352b6353f5249e2d18b,believes,0.466925
uuid-ef0f17d14ca84352b6353f5249e2d18b,vs,0.435008
uuid-ef0f17d14ca84352b6353f5249e2d18b,PDL1 expression,0.329499
uuid-8a20422175c74a10b18aae79f020e2a4,Nivo,0.313718
uuid-8a20422175c74a10b18aae79f020e2a4,PDL1,0.4867
uuid-8a20422175c74a10b18aae79f020e2a4,efficacy,0.496593
uuid-8a20422175c74a10b18aae79f020e2a4,chemo,0.337812
uuid-8a20422175c74a10b18aae79f020e2a4,OS,0.563781
uuid-8a20422175c74a10b18aae79f020e2a4,regards,0.391352
uuid-8a20422175c74a10b18aae79f020e2a4,PFS,0.647036
uuid-8a20422175c74a10b18aae79f020e2a4,AI,0.551162
uuid-8a20422175c74a10b18aae79f020e2a4,ORR,0.562372
uuid-8a20422175c74a10b18aae79f020e2a4,nivo and pembro,0.662312
uuid-8a20422175c74a10b18aae79f020e2a4,believes,0.472546
uuid-8a20422175c74a10b18aae79f020e2a4,PDL1 expression,0.510622
uuid-8a20422175c74a10b18aae79f020e2a4,biomarker,0.302445
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,PDL1,0.509193
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,efficacy,0.502744
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,chemo,0.365637
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,OS,0.562354
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,regards,0.338308
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,response,0.302517
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,PFS,0.606962
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,AI,0.484347
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,ORR,0.519376
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,nivo and pembro,0.505055
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,believes,0.476241
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,PDL1 expression,0.44845
uuid-468a5b69e1bd4e72b5305481e9b1a0d2,biomarker,0.358966
uuid-a174986113fa47e19b1a17fa331af402,therapy,0.348031
uuid-a174986113fa47e19b1a17fa331af402,lung,0.408412
uuid-a174986113fa47e19b1a17fa331af402,regimen,0.376461
uuid-a174986113fa47e19b1a17fa331af402,melanoma,0.392735
uuid-a174986113fa47e19b1a17fa331af402,combination,0.46067
uuid-a174986113fa47e19b1a17fa331af402,chemo,0.405462
uuid-a174986113fa47e19b1a17fa331af402,IO,0.40781
uuid-a174986113fa47e19b1a17fa331af402,monotherapy,0.373936
uuid-a174986113fa47e19b1a17fa331af402,response,0.402653
uuid-a174986113fa47e19b1a17fa331af402,combo,0.469023
uuid-a174986113fa47e19b1a17fa331af402,AI,0.50984
uuid-a174986113fa47e19b1a17fa331af402,PD1,0.464273
uuid-a174986113fa47e19b1a17fa331af402,progression,0.323442
uuid-a174986113fa47e19b1a17fa331af402,chemotherapy,0.356182
uuid-a174986113fa47e19b1a17fa331af402,SCLC,0.481319
uuid-a174986113fa47e19b1a17fa331af402,immunotherapy,0.364514
uuid-a174986113fa47e19b1a17fa331af402,TL shared,0.301883
uuid-62c0facf409f4d0bb41f7e17e4ee43cd,Opdivo,0.314379
uuid-62c0facf409f4d0bb41f7e17e4ee43cd,toxicity,0.386779
uuid-62c0facf409f4d0bb41f7e17e4ee43cd,drug,0.446894
uuid-909aa65f5fb946b5b437a131097ba73f,Nivo,0.32784
uuid-909aa65f5fb946b5b437a131097ba73f,patients,0.606499
uuid-909aa65f5fb946b5b437a131097ba73f,therapy,0.683587
uuid-909aa65f5fb946b5b437a131097ba73f,nivolumab,0.647865
uuid-909aa65f5fb946b5b437a131097ba73f,regimen,0.393456
uuid-909aa65f5fb946b5b437a131097ba73f,treated,0.512542
uuid-909aa65f5fb946b5b437a131097ba73f,combination,0.440938
uuid-909aa65f5fb946b5b437a131097ba73f,chemo,0.422474
uuid-909aa65f5fb946b5b437a131097ba73f,pts,0.37266
uuid-909aa65f5fb946b5b437a131097ba73f,preferred,0.322135
uuid-909aa65f5fb946b5b437a131097ba73f,monotherapy,0.492436
uuid-909aa65f5fb946b5b437a131097ba73f,treatment,0.532616
uuid-909aa65f5fb946b5b437a131097ba73f,using nivo,0.389812
uuid-909aa65f5fb946b5b437a131097ba73f,PD1,0.477352
uuid-909aa65f5fb946b5b437a131097ba73f,cHL,0.393354
uuid-909aa65f5fb946b5b437a131097ba73f,progression,0.42068
uuid-909aa65f5fb946b5b437a131097ba73f,chemotherapy,0.566002
uuid-909aa65f5fb946b5b437a131097ba73f,PD-1,0.30787
uuid-909aa65f5fb946b5b437a131097ba73f,RTL stated,0.31874
uuid-909aa65f5fb946b5b437a131097ba73f,option,0.4392
uuid-f305a56a076741f0b1ec409594d8668e,Nivo,0.40736
uuid-f305a56a076741f0b1ec409594d8668e,patients,0.330125
uuid-f305a56a076741f0b1ec409594d8668e,pembro,0.716057
uuid-f305a56a076741f0b1ec409594d8668e,1L,0.706579
uuid-f305a56a076741f0b1ec409594d8668e,RCC,0.325786
uuid-f305a56a076741f0b1ec409594d8668e,2L,0.726787
uuid-f305a56a076741f0b1ec409594d8668e,agents,0.369984
uuid-f305a56a076741f0b1ec409594d8668e,PD-L1,0.371521
uuid-f305a56a076741f0b1ec409594d8668e,approval,0.60434
uuid-f305a56a076741f0b1ec409594d8668e,atezo,0.637453
uuid-f305a56a076741f0b1ec409594d8668e,preferred,0.649568
uuid-f305a56a076741f0b1ec409594d8668e,testing,0.42185
uuid-f305a56a076741f0b1ec409594d8668e,monotherapy,0.461024
uuid-f305a56a076741f0b1ec409594d8668e,using nivo,0.63267
uuid-f305a56a076741f0b1ec409594d8668e,PDL1 testing,0.455568
uuid-f305a56a076741f0b1ec409594d8668e,indication,0.423223
uuid-f305a56a076741f0b1ec409594d8668e,NSCLC patients,0.524086
uuid-f305a56a076741f0b1ec409594d8668e,approved,0.681181
uuid-f305a56a076741f0b1ec409594d8668e,nivo and pembro,0.302645
uuid-f305a56a076741f0b1ec409594d8668e,tumor types,0.361712
uuid-f305a56a076741f0b1ec409594d8668e,label,0.429377
uuid-f305a56a076741f0b1ec409594d8668e,RTL stated,0.405186
uuid-f305a56a076741f0b1ec409594d8668e,option,0.578679
uuid-f85022996bff4179b2f2319af43b7b41,Nivo,0.393112
uuid-f85022996bff4179b2f2319af43b7b41,patients,0.699274
uuid-f85022996bff4179b2f2319af43b7b41,Opdivo,0.303261
uuid-f85022996bff4179b2f2319af43b7b41,therapy,0.448174
uuid-f85022996bff4179b2f2319af43b7b41,dose,0.427395
uuid-f85022996bff4179b2f2319af43b7b41,nivolumab,0.359571
uuid-f85022996bff4179b2f2319af43b7b41,toxicity,0.332078
uuid-f85022996bff4179b2f2319af43b7b41,regimen,0.459037
uuid-f85022996bff4179b2f2319af43b7b41,treated,0.359125
uuid-f85022996bff4179b2f2319af43b7b41,chemo,0.45545
uuid-f85022996bff4179b2f2319af43b7b41,pts,0.488284
uuid-f85022996bff4179b2f2319af43b7b41,Ipi,0.351327
uuid-f85022996bff4179b2f2319af43b7b41,monotherapy,0.376029
uuid-f85022996bff4179b2f2319af43b7b41,treatment,0.45695
uuid-f85022996bff4179b2f2319af43b7b41,response,0.434733
uuid-f85022996bff4179b2f2319af43b7b41,PD1,0.361471
uuid-f85022996bff4179b2f2319af43b7b41,progression,0.613609
uuid-f85022996bff4179b2f2319af43b7b41,chemotherapy,0.350738
uuid-f85022996bff4179b2f2319af43b7b41,vs,0.346555
uuid-f85022996bff4179b2f2319af43b7b41,respond,0.512042
uuid-54ae855f35c5458a88fefea85372aa71,TL,0.389946
uuid-54ae855f35c5458a88fefea85372aa71,PDL1,0.419379
uuid-54ae855f35c5458a88fefea85372aa71,TL stated,0.473804
uuid-54ae855f35c5458a88fefea85372aa71,PD-L1,0.783977
uuid-54ae855f35c5458a88fefea85372aa71,PD-L1 testing,0.741893
uuid-54ae855f35c5458a88fefea85372aa71,testing,0.89753
uuid-54ae855f35c5458a88fefea85372aa71,PDL1 testing,0.773283
uuid-54ae855f35c5458a88fefea85372aa71,NSCLC patients,0.773636
uuid-54ae855f35c5458a88fefea85372aa71,tumor types,0.368702
uuid-54ae855f35c5458a88fefea85372aa71,assay,0.525835
uuid-54ae855f35c5458a88fefea85372aa71,biomarker,0.518205
uuid-6bd48026f84c48938f3d3f0e86253928,patients,0.621121
uuid-6bd48026f84c48938f3d3f0e86253928,1L,0.373029
uuid-6bd48026f84c48938f3d3f0e86253928,regimen,0.372331
uuid-6bd48026f84c48938f3d3f0e86253928,treated,0.305986
uuid-6bd48026f84c48938f3d3f0e86253928,chemo,0.456754
uuid-6bd48026f84c48938f3d3f0e86253928,pts,0.532706
uuid-6bd48026f84c48938f3d3f0e86253928,preferred,0.317324
uuid-6bd48026f84c48938f3d3f0e86253928,monotherapy,0.461918
uuid-6bd48026f84c48938f3d3f0e86253928,treatment,0.309065
uuid-6bd48026f84c48938f3d3f0e86253928,NSCLC patients,0.314523
uuid-6bd48026f84c48938f3d3f0e86253928,progression,0.383253
uuid-6bd48026f84c48938f3d3f0e86253928,chemotherapy,0.389433
uuid-6bd48026f84c48938f3d3f0e86253928,respond,0.348228
uuid-6bd48026f84c48938f3d3f0e86253928,feels,0.422068
uuid-6bd48026f84c48938f3d3f0e86253928,option,0.495956
uuid-13495dabc997471d9aefefbf52d36345,Nivo,0.528467
uuid-13495dabc997471d9aefefbf52d36345,patients,0.380624
uuid-13495dabc997471d9aefefbf52d36345,chemo,0.521297
uuid-13495dabc997471d9aefefbf52d36345,Ipi,0.309718
uuid-13495dabc997471d9aefefbf52d36345,monotherapy,0.37313
uuid-13495dabc997471d9aefefbf52d36345,PFS,0.321022
uuid-13495dabc997471d9aefefbf52d36345,chemotherapy,0.456683
uuid-13495dabc997471d9aefefbf52d36345,vs,0.346702
uuid-13495dabc997471d9aefefbf52d36345,feels,0.619466
uuid-13495dabc997471d9aefefbf52d36345,option,0.348021
uuid-8a1711f558d64ce5a3c1faa1c2b0f70c,patients,0.57541
uuid-8a1711f558d64ce5a3c1faa1c2b0f70c,regimen,0.347033
uuid-8a1711f558d64ce5a3c1faa1c2b0f70c,chemo,0.323667
uuid-8a1711f558d64ce5a3c1faa1c2b0f70c,pts,0.437844
uuid-8a1711f558d64ce5a3c1faa1c2b0f70c,OS,0.311747
uuid-8a1711f558d64ce5a3c1faa1c2b0f70c,treatment,0.390382
uuid-8a1711f558d64ce5a3c1faa1c2b0f70c,response,0.433716
uuid-8a1711f558d64ce5a3c1faa1c2b0f70c,PFS,0.330833
uuid-8a1711f558d64ce5a3c1faa1c2b0f70c,progression,0.581283
uuid-8a1711f558d64ce5a3c1faa1c2b0f70c,chemotherapy,0.32038
uuid-8a1711f558d64ce5a3c1faa1c2b0f70c,respond,0.470957
uuid-8a1711f558d64ce5a3c1faa1c2b0f70c,feels,0.424208
uuid-1886deb4007c4f80b128db7f79af1bf9,BMS,0.352026
uuid-1886deb4007c4f80b128db7f79af1bf9,PDL1,0.603741
uuid-1886deb4007c4f80b128db7f79af1bf9,trial,0.533033
uuid-1886deb4007c4f80b128db7f79af1bf9,efficacy,0.482116
uuid-1886deb4007c4f80b128db7f79af1bf9,commented,0.32782
uuid-1886deb4007c4f80b128db7f79af1bf9,OS,0.678892
uuid-1886deb4007c4f80b128db7f79af1bf9,data,0.671183
uuid-1886deb4007c4f80b128db7f79af1bf9,PFS,0.714354
uuid-1886deb4007c4f80b128db7f79af1bf9,ORR,0.728844
uuid-1886deb4007c4f80b128db7f79af1bf9,nivo and pembro,0.46755
uuid-1886deb4007c4f80b128db7f79af1bf9,impressed,0.460566
uuid-1886deb4007c4f80b128db7f79af1bf9,PDL1 expression,0.619804
uuid-1886deb4007c4f80b128db7f79af1bf9,biomarker,0.344676
uuid-21e6191f33964ce098dc86005aca863a,patients,0.459335
uuid-21e6191f33964ce098dc86005aca863a,1L,0.485875
uuid-21e6191f33964ce098dc86005aca863a,PDL1,0.315512
uuid-21e6191f33964ce098dc86005aca863a,TL stated,0.327726
uuid-21e6191f33964ce098dc86005aca863a,2L,0.414125
uuid-21e6191f33964ce098dc86005aca863a,PD-L1,0.634459
uuid-21e6191f33964ce098dc86005aca863a,preferred,0.430664
uuid-21e6191f33964ce098dc86005aca863a,PD-L1 testing,0.573123
uuid-21e6191f33964ce098dc86005aca863a,testing,0.717943
uuid-21e6191f33964ce098dc86005aca863a,using nivo,0.32584
uuid-21e6191f33964ce098dc86005aca863a,PDL1 testing,0.642098
uuid-21e6191f33964ce098dc86005aca863a,NSCLC patients,0.733814
uuid-21e6191f33964ce098dc86005aca863a,approved,0.300467
uuid-21e6191f33964ce098dc86005aca863a,tumor types,0.384859
uuid-21e6191f33964ce098dc86005aca863a,option,0.43989
uuid-21e6191f33964ce098dc86005aca863a,biomarker,0.331441
uuid-5a54def5cffd4773a596b309edb2f819,TL,0.412822
uuid-5a54def5cffd4773a596b309edb2f819,RTL,0.310296
uuid-5a54def5cffd4773a596b309edb2f819,commented,0.313849
uuid-5a54def5cffd4773a596b309edb2f819,RCC,0.36842
uuid-5a54def5cffd4773a596b309edb2f819,TL stated,0.520152
uuid-5a54def5cffd4773a596b309edb2f819,stated,0.457631
uuid-5a54def5cffd4773a596b309edb2f819,PD-L1,0.529774
uuid-5a54def5cffd4773a596b309edb2f819,approval,0.370596
uuid-5a54def5cffd4773a596b309edb2f819,PD-L1 testing,0.52413
uuid-5a54def5cffd4773a596b309edb2f819,testing,0.593221
uuid-5a54def5cffd4773a596b309edb2f819,PDL1 testing,0.607709
uuid-5a54def5cffd4773a596b309edb2f819,NSCLC patients,0.620814
uuid-5a54def5cffd4773a596b309edb2f819,SCCHN,0.476708
uuid-5a54def5cffd4773a596b309edb2f819,tumor types,0.420969
uuid-5a54def5cffd4773a596b309edb2f819,Regional TL,0.472562
uuid-5a54def5cffd4773a596b309edb2f819,RTL stated,0.382512
uuid-5a54def5cffd4773a596b309edb2f819,TL shared,0.308352
uuid-5a54def5cffd4773a596b309edb2f819,bladder,0.316504
uuid-eb93b766208f4ddfb8f28a7306c371c8,Nivo,0.408138
uuid-eb93b766208f4ddfb8f28a7306c371c8,patients,0.400841
uuid-eb93b766208f4ddfb8f28a7306c371c8,pembro,0.571752
uuid-eb93b766208f4ddfb8f28a7306c371c8,NSCLC,0.395635
uuid-eb93b766208f4ddfb8f28a7306c371c8,1L,0.560974
uuid-eb93b766208f4ddfb8f28a7306c371c8,chemo,0.320752
uuid-eb93b766208f4ddfb8f28a7306c371c8,2L,0.521299
uuid-eb93b766208f4ddfb8f28a7306c371c8,approval,0.355636
uuid-eb93b766208f4ddfb8f28a7306c371c8,atezo,0.443194
uuid-eb93b766208f4ddfb8f28a7306c371c8,preferred,0.527297
uuid-eb93b766208f4ddfb8f28a7306c371c8,monotherapy,0.5155
uuid-eb93b766208f4ddfb8f28a7306c371c8,using nivo,0.581745
uuid-eb93b766208f4ddfb8f28a7306c371c8,NSCLC patients,0.311009
uuid-eb93b766208f4ddfb8f28a7306c371c8,approved,0.35728
uuid-eb93b766208f4ddfb8f28a7306c371c8,chemotherapy,0.32231
uuid-eb93b766208f4ddfb8f28a7306c371c8,RTL stated,0.383234
uuid-eb93b766208f4ddfb8f28a7306c371c8,option,0.554622
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,patients,0.624411
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,therapy,0.37091
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,1L,0.373277
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,regimen,0.409626
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,treated,0.377633
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,RCC,0.414008
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,TL stated,0.311018
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,chemo,0.445255
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,2L,0.355967
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,pts,0.591712
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,monotherapy,0.47268
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,treatment,0.418391
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,using nivo,0.329552
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,response,0.447818
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,PD1,0.334929
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,progression,0.553711
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,chemotherapy,0.380729
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,tumor types,0.365868
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,respond,0.408842
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,RTL stated,0.300358
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,TL shared,0.32526
uuid-1b8e36f8e3cc4d528f4400edf56f6d97,option,0.427085
uuid-ef103fbc10d540fe80f8084cc4c1a81d,Opdivo,0.465861
uuid-ef103fbc10d540fe80f8084cc4c1a81d,dose,0.554967
uuid-ef103fbc10d540fe80f8084cc4c1a81d,approval,0.394845
uuid-ef103fbc10d540fe80f8084cc4c1a81d,indication,0.346319
uuid-ef103fbc10d540fe80f8084cc4c1a81d,approved,0.417408
uuid-ef103fbc10d540fe80f8084cc4c1a81d,label,0.440758
uuid-ef103fbc10d540fe80f8084cc4c1a81d,drug,0.319079
uuid-ef103fbc10d540fe80f8084cc4c1a81d,Keytruda,0.314449
uuid-ef103fbc10d540fe80f8084cc4c1a81d,flat dosing,0.674303
uuid-8ed2edacfc9e45c5b7c66a982ab22118,Nivo,0.560801
uuid-8ed2edacfc9e45c5b7c66a982ab22118,pembro,0.637631
uuid-8ed2edacfc9e45c5b7c66a982ab22118,dose,0.502822
uuid-8ed2edacfc9e45c5b7c66a982ab22118,1L,0.31269
uuid-8ed2edacfc9e45c5b7c66a982ab22118,2L,0.461261
uuid-8ed2edacfc9e45c5b7c66a982ab22118,Ipi,0.401175
uuid-8ed2edacfc9e45c5b7c66a982ab22118,approval,0.353495
uuid-8ed2edacfc9e45c5b7c66a982ab22118,atezo,0.618626
uuid-8ed2edacfc9e45c5b7c66a982ab22118,preferred,0.456688
uuid-8ed2edacfc9e45c5b7c66a982ab22118,monotherapy,0.325565
uuid-8ed2edacfc9e45c5b7c66a982ab22118,using nivo,0.50127
uuid-8ed2edacfc9e45c5b7c66a982ab22118,indication,0.382954
uuid-8ed2edacfc9e45c5b7c66a982ab22118,approved,0.414999
uuid-8ed2edacfc9e45c5b7c66a982ab22118,SCCHN,0.302597
uuid-8ed2edacfc9e45c5b7c66a982ab22118,vs,0.55296
uuid-8ed2edacfc9e45c5b7c66a982ab22118,TLs,0.416307
uuid-8ed2edacfc9e45c5b7c66a982ab22118,feels,0.349153
uuid-8ed2edacfc9e45c5b7c66a982ab22118,RTL stated,0.317238
uuid-8ed2edacfc9e45c5b7c66a982ab22118,option,0.345542
uuid-8ed2edacfc9e45c5b7c66a982ab22118,flat dosing,0.490323
uuid-95c48a7c1c614f509b098987f05f7ac3,pembro,0.308534
uuid-95c48a7c1c614f509b098987f05f7ac3,RTL,0.359819
uuid-95c48a7c1c614f509b098987f05f7ac3,BMS,0.352942
uuid-95c48a7c1c614f509b098987f05f7ac3,PDL1,0.318754
uuid-95c48a7c1c614f509b098987f05f7ac3,trial,0.359714
uuid-95c48a7c1c614f509b098987f05f7ac3,commented,0.483376
uuid-95c48a7c1c614f509b098987f05f7ac3,Merck,0.314148
uuid-95c48a7c1c614f509b098987f05f7ac3,stated,0.484451
uuid-95c48a7c1c614f509b098987f05f7ac3,OS,0.390565
uuid-95c48a7c1c614f509b098987f05f7ac3,atezo,0.301132
uuid-95c48a7c1c614f509b098987f05f7ac3,regards,0.301152
uuid-95c48a7c1c614f509b098987f05f7ac3,data,0.689036
uuid-95c48a7c1c614f509b098987f05f7ac3,expressed,0.36184
uuid-95c48a7c1c614f509b098987f05f7ac3,PFS,0.343857
uuid-95c48a7c1c614f509b098987f05f7ac3,ORR,0.386552
uuid-95c48a7c1c614f509b098987f05f7ac3,SCCHN,0.373883
uuid-95c48a7c1c614f509b098987f05f7ac3,nivo and pembro,0.334162
uuid-95c48a7c1c614f509b098987f05f7ac3,ASCO,0.318626
uuid-95c48a7c1c614f509b098987f05f7ac3,impressed,0.632066
uuid-95c48a7c1c614f509b098987f05f7ac3,LTL,0.367761
uuid-95c48a7c1c614f509b098987f05f7ac3,TLs,0.499223
uuid-95c48a7c1c614f509b098987f05f7ac3,feels,0.387035
uuid-95c48a7c1c614f509b098987f05f7ac3,Regional TL,0.419134
uuid-95c48a7c1c614f509b098987f05f7ac3,bladder,0.337735
uuid-ec76286319314188b2a376717e21ab4f,patients,0.345588
uuid-ec76286319314188b2a376717e21ab4f,TL,0.410495
uuid-ec76286319314188b2a376717e21ab4f,lung,0.344366
uuid-ec76286319314188b2a376717e21ab4f,treated,0.364698
uuid-ec76286319314188b2a376717e21ab4f,RCC,0.446676
uuid-ec76286319314188b2a376717e21ab4f,TL stated,0.604784
uuid-ec76286319314188b2a376717e21ab4f,stated,0.3108
uuid-ec76286319314188b2a376717e21ab4f,PD-L1,0.432115
uuid-ec76286319314188b2a376717e21ab4f,PD-L1 testing,0.482506
uuid-ec76286319314188b2a376717e21ab4f,testing,0.600167
uuid-ec76286319314188b2a376717e21ab4f,PDL1 testing,0.641871
uuid-ec76286319314188b2a376717e21ab4f,NSCLC patients,0.702794
uuid-ec76286319314188b2a376717e21ab4f,SCCHN,0.455333
uuid-ec76286319314188b2a376717e21ab4f,tumor types,0.501059
uuid-ec76286319314188b2a376717e21ab4f,Regional TL,0.379868
uuid-ec76286319314188b2a376717e21ab4f,RTL stated,0.429358
uuid-ec76286319314188b2a376717e21ab4f,TL shared,0.441468
uuid-ec76286319314188b2a376717e21ab4f,bladder,0.396812
uuid-9d9626c1ca2f401d8d9fcc32943a4a8d,patients,0.568675
uuid-9d9626c1ca2f401d8d9fcc32943a4a8d,Opdivo,0.567788
uuid-9d9626c1ca2f401d8d9fcc32943a4a8d,dose,0.302205
uuid-9d9626c1ca2f401d8d9fcc32943a4a8d,regimen,0.338359
uuid-9d9626c1ca2f401d8d9fcc32943a4a8d,treated,0.343837
uuid-9d9626c1ca2f401d8d9fcc32943a4a8d,pts,0.309896
uuid-9d9626c1ca2f401d8d9fcc32943a4a8d,treatment,0.3271
uuid-9d9626c1ca2f401d8d9fcc32943a4a8d,progression,0.377862
uuid-9d9626c1ca2f401d8d9fcc32943a4a8d,Keytruda,0.308737
uuid-9d9626c1ca2f401d8d9fcc32943a4a8d,flat dosing,0.300077
uuid-c16d0704f77d4b129731310c68121095,patients,0.354485
uuid-c16d0704f77d4b129731310c68121095,Opdivo,0.342939
uuid-c16d0704f77d4b129731310c68121095,therapy,0.476834
uuid-c16d0704f77d4b129731310c68121095,nivolumab,0.452005
uuid-c16d0704f77d4b129731310c68121095,treated,0.307967
uuid-c16d0704f77d4b129731310c68121095,mentioned,0.337734
uuid-c16d0704f77d4b129731310c68121095,cHL,0.732973
uuid-99b03e756cc148d6b02971d248fdc1fc,pembro,0.319934
uuid-99b03e756cc148d6b02971d248fdc1fc,RTL,0.437932
uuid-99b03e756cc148d6b02971d248fdc1fc,BMS,0.444263
uuid-99b03e756cc148d6b02971d248fdc1fc,trial,0.694501
uuid-99b03e756cc148d6b02971d248fdc1fc,commented,0.467525
uuid-99b03e756cc148d6b02971d248fdc1fc,Merck,0.39596
uuid-99b03e756cc148d6b02971d248fdc1fc,stated,0.429697
uuid-99b03e756cc148d6b02971d248fdc1fc,approval,0.420211
uuid-99b03e756cc148d6b02971d248fdc1fc,OS,0.582775
uuid-99b03e756cc148d6b02971d248fdc1fc,data,0.750768
uuid-99b03e756cc148d6b02971d248fdc1fc,expressed,0.359627
uuid-99b03e756cc148d6b02971d248fdc1fc,clinical trials,0.346353
uuid-99b03e756cc148d6b02971d248fdc1fc,indication,0.373382
uuid-99b03e756cc148d6b02971d248fdc1fc,PFS,0.52244
uuid-99b03e756cc148d6b02971d248fdc1fc,ORR,0.564081
uuid-99b03e756cc148d6b02971d248fdc1fc,SCCHN,0.384469
uuid-99b03e756cc148d6b02971d248fdc1fc,ASCO,0.383988
uuid-99b03e756cc148d6b02971d248fdc1fc,impressed,0.659534
uuid-99b03e756cc148d6b02971d248fdc1fc,SCLC,0.361013
uuid-99b03e756cc148d6b02971d248fdc1fc,Regional TL,0.345428
uuid-99b03e756cc148d6b02971d248fdc1fc,bladder,0.318668
uuid-93af5cb9f61d49bda031158e36121230,patients,0.61571
uuid-93af5cb9f61d49bda031158e36121230,toxicity,0.353599
uuid-93af5cb9f61d49bda031158e36121230,regimen,0.415189
uuid-93af5cb9f61d49bda031158e36121230,pts,0.433574
uuid-93af5cb9f61d49bda031158e36121230,treatment,0.437505
uuid-93af5cb9f61d49bda031158e36121230,progression,0.48202
uuid-93af5cb9f61d49bda031158e36121230,respond,0.395445
uuid-5bd61e05d58f4e0fbf028474f5cfd69b,NTL,0.480999
uuid-5bd61e05d58f4e0fbf028474f5cfd69b,commented,0.453666
uuid-5bd61e05d58f4e0fbf028474f5cfd69b,Merck,0.344017
uuid-5bd61e05d58f4e0fbf028474f5cfd69b,stated,0.310741
uuid-5bd61e05d58f4e0fbf028474f5cfd69b,data,0.478729
uuid-5bd61e05d58f4e0fbf028474f5cfd69b,expressed,0.342959
uuid-5bd61e05d58f4e0fbf028474f5cfd69b,indication,0.391021
uuid-5bd61e05d58f4e0fbf028474f5cfd69b,lung cancer,0.611322
uuid-5bd61e05d58f4e0fbf028474f5cfd69b,ASCO,0.420787
uuid-5bd61e05d58f4e0fbf028474f5cfd69b,impressed,0.394749
uuid-5bd61e05d58f4e0fbf028474f5cfd69b,Regional TL,0.357825
uuid-16eae106dac84732b6021d94644c2361,Nivo,0.42544
uuid-16eae106dac84732b6021d94644c2361,patients,0.810136
uuid-16eae106dac84732b6021d94644c2361,Opdivo,0.371971
uuid-16eae106dac84732b6021d94644c2361,pembro,0.339018
uuid-16eae106dac84732b6021d94644c2361,therapy,0.460374
uuid-16eae106dac84732b6021d94644c2361,nivolumab,0.426425
uuid-16eae106dac84732b6021d94644c2361,1L,0.525926
uuid-16eae106dac84732b6021d94644c2361,regimen,0.379585
uuid-16eae106dac84732b6021d94644c2361,treated,0.40842
uuid-16eae106dac84732b6021d94644c2361,RCC,0.332424
uuid-16eae106dac84732b6021d94644c2361,chemo,0.351951
uuid-16eae106dac84732b6021d94644c2361,2L,0.519098
uuid-16eae106dac84732b6021d94644c2361,pts,0.55156
uuid-16eae106dac84732b6021d94644c2361,approval,0.479405
uuid-16eae106dac84732b6021d94644c2361,preferred,0.491627
uuid-16eae106dac84732b6021d94644c2361,monotherapy,0.523734
uuid-16eae106dac84732b6021d94644c2361,treatment,0.472406
uuid-16eae106dac84732b6021d94644c2361,using nivo,0.583736
uuid-16eae106dac84732b6021d94644c2361,NSCLC patients,0.502121
uuid-16eae106dac84732b6021d94644c2361,approved,0.448048
uuid-16eae106dac84732b6021d94644c2361,progression,0.427584
uuid-16eae106dac84732b6021d94644c2361,chemotherapy,0.338838
uuid-16eae106dac84732b6021d94644c2361,respond,0.390481
uuid-16eae106dac84732b6021d94644c2361,RTL stated,0.441148
uuid-16eae106dac84732b6021d94644c2361,option,0.549936
uuid-3c0bf37f8cd94daba130c0a8643fd58a,TL,0.355902
uuid-3c0bf37f8cd94daba130c0a8643fd58a,pembro,0.333232
uuid-3c0bf37f8cd94daba130c0a8643fd58a,RTL,0.379531
uuid-3c0bf37f8cd94daba130c0a8643fd58a,trial,0.430606
uuid-3c0bf37f8cd94daba130c0a8643fd58a,approval,0.471306
uuid-3c0bf37f8cd94daba130c0a8643fd58a,atezo,0.301055
uuid-3c0bf37f8cd94daba130c0a8643fd58a,preferred,0.39238
uuid-3c0bf37f8cd94daba130c0a8643fd58a,using nivo,0.325866
uuid-3c0bf37f8cd94daba130c0a8643fd58a,clinical trials,0.426015
uuid-3c0bf37f8cd94daba130c0a8643fd58a,indication,0.345517
uuid-3c0bf37f8cd94daba130c0a8643fd58a,approved,0.39088
uuid-3c0bf37f8cd94daba130c0a8643fd58a,SCCHN,0.468454
uuid-3c0bf37f8cd94daba130c0a8643fd58a,impressed,0.34681
uuid-3c0bf37f8cd94daba130c0a8643fd58a,LTL,0.32711
uuid-3c0bf37f8cd94daba130c0a8643fd58a,Regional TL,0.440602
uuid-3c0bf37f8cd94daba130c0a8643fd58a,RTL stated,0.429173
uuid-3c0bf37f8cd94daba130c0a8643fd58a,bladder,0.444254
uuid-aa7563a220d64239af2e7eb9fd5af5b6,patients,0.445162
uuid-aa7563a220d64239af2e7eb9fd5af5b6,pembro,0.41967
uuid-aa7563a220d64239af2e7eb9fd5af5b6,1L,0.644841
uuid-aa7563a220d64239af2e7eb9fd5af5b6,PDL1,0.334902
uuid-aa7563a220d64239af2e7eb9fd5af5b6,treated,0.302319
uuid-aa7563a220d64239af2e7eb9fd5af5b6,RCC,0.306964
uuid-aa7563a220d64239af2e7eb9fd5af5b6,2L,0.527183
uuid-aa7563a220d64239af2e7eb9fd5af5b6,pts,0.425345
uuid-aa7563a220d64239af2e7eb9fd5af5b6,PD-L1,0.460655
uuid-aa7563a220d64239af2e7eb9fd5af5b6,approval,0.431771
uuid-aa7563a220d64239af2e7eb9fd5af5b6,atezo,0.317704
uuid-aa7563a220d64239af2e7eb9fd5af5b6,preferred,0.487572
uuid-aa7563a220d64239af2e7eb9fd5af5b6,PD-L1 testing,0.347993
uuid-aa7563a220d64239af2e7eb9fd5af5b6,testing,0.487221
uuid-aa7563a220d64239af2e7eb9fd5af5b6,monotherapy,0.459493
uuid-aa7563a220d64239af2e7eb9fd5af5b6,using nivo,0.478786
uuid-aa7563a220d64239af2e7eb9fd5af5b6,PDL1 testing,0.441752
uuid-aa7563a220d64239af2e7eb9fd5af5b6,NSCLC patients,0.65384
uuid-aa7563a220d64239af2e7eb9fd5af5b6,approved,0.381093
uuid-aa7563a220d64239af2e7eb9fd5af5b6,SCCHN,0.316745
uuid-aa7563a220d64239af2e7eb9fd5af5b6,tumor types,0.338609
uuid-aa7563a220d64239af2e7eb9fd5af5b6,RTL stated,0.489556
uuid-aa7563a220d64239af2e7eb9fd5af5b6,option,0.526186
uuid-6472f898590c43e3935625f4ed6b32f8,drug,0.303448
uuid-f72609fc40674c5c91989799a998e5a6,Nivo,0.349095
uuid-f72609fc40674c5c91989799a998e5a6,patients,0.303633
uuid-f72609fc40674c5c91989799a998e5a6,pembro,0.416209
uuid-f72609fc40674c5c91989799a998e5a6,nivolumab,0.402784
uuid-f72609fc40674c5c91989799a998e5a6,1L,0.591852
uuid-f72609fc40674c5c91989799a998e5a6,regimen,0.309585
uuid-f72609fc40674c5c91989799a998e5a6,RCC,0.576912
uuid-f72609fc40674c5c91989799a998e5a6,2L,0.690946
uuid-f72609fc40674c5c91989799a998e5a6,agents,0.420886
uuid-f72609fc40674c5c91989799a998e5a6,approval,0.438347
uuid-f72609fc40674c5c91989799a998e5a6,atezo,0.440283
uuid-f72609fc40674c5c91989799a998e5a6,preferred,0.806479
uuid-f72609fc40674c5c91989799a998e5a6,monotherapy,0.568196
uuid-f72609fc40674c5c91989799a998e5a6,using nivo,0.638025
uuid-f72609fc40674c5c91989799a998e5a6,PDL1 testing,0.316151
uuid-f72609fc40674c5c91989799a998e5a6,indication,0.455689
uuid-f72609fc40674c5c91989799a998e5a6,approved,0.577954
uuid-f72609fc40674c5c91989799a998e5a6,SCCHN,0.433168
uuid-f72609fc40674c5c91989799a998e5a6,label,0.332729
uuid-f72609fc40674c5c91989799a998e5a6,RTL stated,0.597081
uuid-f72609fc40674c5c91989799a998e5a6,TL shared,0.391299
uuid-f72609fc40674c5c91989799a998e5a6,option,0.655604
uuid-f72609fc40674c5c91989799a998e5a6,bladder,0.361546
uuid-65eb8513c0d04301a6be05978be885d5,pembro,0.47995
uuid-65eb8513c0d04301a6be05978be885d5,1L,0.383042
uuid-65eb8513c0d04301a6be05978be885d5,trial,0.518551
uuid-65eb8513c0d04301a6be05978be885d5,2L,0.345254
uuid-65eb8513c0d04301a6be05978be885d5,approval,0.421912
uuid-65eb8513c0d04301a6be05978be885d5,atezo,0.338512
uuid-65eb8513c0d04301a6be05978be885d5,preferred,0.411647
uuid-65eb8513c0d04301a6be05978be885d5,using nivo,0.370716
uuid-65eb8513c0d04301a6be05978be885d5,clinical trials,0.55873
uuid-65eb8513c0d04301a6be05978be885d5,indication,0.315618
uuid-65eb8513c0d04301a6be05978be885d5,approved,0.437614
uuid-65eb8513c0d04301a6be05978be885d5,SCCHN,0.319249
uuid-65eb8513c0d04301a6be05978be885d5,feels,0.346007
uuid-65eb8513c0d04301a6be05978be885d5,RTL stated,0.342218
uuid-65eb8513c0d04301a6be05978be885d5,option,0.361633
uuid-65eb8513c0d04301a6be05978be885d5,bladder,0.344427
uuid-96ec2cd8d2074d2a9d7f0ae1db840201,Opdivo,0.353181
uuid-96ec2cd8d2074d2a9d7f0ae1db840201,dose,0.692823
uuid-96ec2cd8d2074d2a9d7f0ae1db840201,Ipi,0.300963
uuid-96ec2cd8d2074d2a9d7f0ae1db840201,vs,0.347342
uuid-96ec2cd8d2074d2a9d7f0ae1db840201,drug,0.449511
uuid-96ec2cd8d2074d2a9d7f0ae1db840201,Keytruda,0.448834
uuid-96ec2cd8d2074d2a9d7f0ae1db840201,flat dosing,0.761794
uuid-593c19f94b854255a4574a5033bde490,pembro,0.446699
uuid-593c19f94b854255a4574a5033bde490,NSCLC,0.374732
uuid-593c19f94b854255a4574a5033bde490,PDL1,0.483716
uuid-593c19f94b854255a4574a5033bde490,trial,0.49637
uuid-593c19f94b854255a4574a5033bde490,efficacy,0.491095
uuid-593c19f94b854255a4574a5033bde490,discussed,0.361789
uuid-593c19f94b854255a4574a5033bde490,commented,0.352803
uuid-593c19f94b854255a4574a5033bde490,OS,0.505937
uuid-593c19f94b854255a4574a5033bde490,atezo,0.399702
uuid-593c19f94b854255a4574a5033bde490,data,0.653502
uuid-593c19f94b854255a4574a5033bde490,PFS,0.484206
uuid-593c19f94b854255a4574a5033bde490,ORR,0.540055
uuid-593c19f94b854255a4574a5033bde490,nivo and pembro,0.456697
uuid-593c19f94b854255a4574a5033bde490,impressed,0.453701
uuid-593c19f94b854255a4574a5033bde490,vs,0.407094
uuid-593c19f94b854255a4574a5033bde490,TLs,0.333605
uuid-593c19f94b854255a4574a5033bde490,PDL1 expression,0.481898
uuid-593c19f94b854255a4574a5033bde490,biomarker,0.318393
uuid-5c04bf962c904ca7a73880ebda349345,shared,0.47841
uuid-5c04bf962c904ca7a73880ebda349345,preferred,0.366076
uuid-5c04bf962c904ca7a73880ebda349345,expressed,0.319969
uuid-5c04bf962c904ca7a73880ebda349345,approved,0.341574
uuid-5c04bf962c904ca7a73880ebda349345,HCP,0.318209
uuid-5c04bf962c904ca7a73880ebda349345,drug,0.444141
uuid-5c04bf962c904ca7a73880ebda349345,RTL stated,0.320311
uuid-d0a5343002594de6b9e2767a90a4c292,patients,0.750341
uuid-d0a5343002594de6b9e2767a90a4c292,Opdivo,0.31226
uuid-d0a5343002594de6b9e2767a90a4c292,therapy,0.522239
uuid-d0a5343002594de6b9e2767a90a4c292,nivolumab,0.351408
uuid-d0a5343002594de6b9e2767a90a4c292,regimen,0.437757
uuid-d0a5343002594de6b9e2767a90a4c292,treated,0.590917
uuid-d0a5343002594de6b9e2767a90a4c292,pts,0.525469
uuid-d0a5343002594de6b9e2767a90a4c292,treatment,0.672657
uuid-d0a5343002594de6b9e2767a90a4c292,response,0.444122
uuid-d0a5343002594de6b9e2767a90a4c292,progression,0.611428
uuid-d0a5343002594de6b9e2767a90a4c292,chemotherapy,0.36878
uuid-d0a5343002594de6b9e2767a90a4c292,respond,0.490164
uuid-2c90a4d5c6304341bf0f4fde3dd5c857,patients,0.525348
uuid-2c90a4d5c6304341bf0f4fde3dd5c857,Opdivo,0.324167
uuid-2c90a4d5c6304341bf0f4fde3dd5c857,testing,0.392493
uuid-2c90a4d5c6304341bf0f4fde3dd5c857,treatment,0.459409
uuid-2c90a4d5c6304341bf0f4fde3dd5c857,PDL1 testing,0.376729
uuid-2c90a4d5c6304341bf0f4fde3dd5c857,NSCLC patients,0.39059
uuid-2c90a4d5c6304341bf0f4fde3dd5c857,progression,0.326197
uuid-2c90a4d5c6304341bf0f4fde3dd5c857,option,0.321652
uuid-4daba53c6ccc45a29c51a202b60a08f7,patients,0.424642
uuid-4daba53c6ccc45a29c51a202b60a08f7,therapy,0.433829
uuid-4daba53c6ccc45a29c51a202b60a08f7,treated,0.336814
uuid-4daba53c6ccc45a29c51a202b60a08f7,chemo,0.425363
uuid-4daba53c6ccc45a29c51a202b60a08f7,tumor,0.630149
uuid-4daba53c6ccc45a29c51a202b60a08f7,pts,0.446868
uuid-4daba53c6ccc45a29c51a202b60a08f7,treatment,0.39198
uuid-4daba53c6ccc45a29c51a202b60a08f7,response,0.525044
uuid-4daba53c6ccc45a29c51a202b60a08f7,PD1,0.337085
uuid-4daba53c6ccc45a29c51a202b60a08f7,progression,0.462386
uuid-4daba53c6ccc45a29c51a202b60a08f7,chemotherapy,0.412436
uuid-4daba53c6ccc45a29c51a202b60a08f7,respond,0.364476
uuid-4daba53c6ccc45a29c51a202b60a08f7,immunotherapy,0.401686
uuid-9f3b21ac835a4cd18105452f053e5f79,discussed,0.310481
uuid-9f3b21ac835a4cd18105452f053e5f79,shared,0.330294
uuid-9f3b21ac835a4cd18105452f053e5f79,oncology,0.567326
uuid-9f3b21ac835a4cd18105452f053e5f79,clinical,0.350553
uuid-ae846bd905a04d6d81887a7c148e8333,efficacy,0.331918
uuid-ae846bd905a04d6d81887a7c148e8333,shared,0.368547
uuid-ae846bd905a04d6d81887a7c148e8333,commented,0.348645
uuid-ae846bd905a04d6d81887a7c148e8333,HCP,0.340982
uuid-ae846bd905a04d6d81887a7c148e8333,LTL,0.339192
uuid-ae846bd905a04d6d81887a7c148e8333,TLs,0.347935
uuid-83f1b20ecd9e40f18e632c317df19797,patients,0.309657
uuid-83f1b20ecd9e40f18e632c317df19797,Opdivo,0.516911
uuid-83f1b20ecd9e40f18e632c317df19797,nivolumab,0.341333
uuid-83f1b20ecd9e40f18e632c317df19797,toxicity,0.304492
uuid-83f1b20ecd9e40f18e632c317df19797,regimen,0.568652
uuid-83f1b20ecd9e40f18e632c317df19797,combination,0.300918
uuid-83f1b20ecd9e40f18e632c317df19797,pts,0.317121
uuid-83f1b20ecd9e40f18e632c317df19797,monotherapy,0.330824
uuid-83f1b20ecd9e40f18e632c317df19797,combo,0.31416
uuid-83f1b20ecd9e40f18e632c317df19797,HCP,0.395362
uuid-83f1b20ecd9e40f18e632c317df19797,impressed,0.300099
uuid-83f1b20ecd9e40f18e632c317df19797,respond,0.316937
uuid-83f1b20ecd9e40f18e632c317df19797,SCLC,0.307103
uuid-83f1b20ecd9e40f18e632c317df19797,feels,0.426246
uuid-dab615dae6ea436791182672bbdbe423,TL,0.416153
uuid-dab615dae6ea436791182672bbdbe423,RCC,0.301998
uuid-dab615dae6ea436791182672bbdbe423,TL stated,0.538464
uuid-dab615dae6ea436791182672bbdbe423,institution,0.399612
uuid-dab615dae6ea436791182672bbdbe423,PD-L1,0.637422
uuid-dab615dae6ea436791182672bbdbe423,PD-L1 testing,0.695456
uuid-dab615dae6ea436791182672bbdbe423,testing,0.798072
uuid-dab615dae6ea436791182672bbdbe423,PDL1 testing,0.773922
uuid-dab615dae6ea436791182672bbdbe423,NSCLC patients,0.676099
uuid-dab615dae6ea436791182672bbdbe423,SCCHN,0.372498
uuid-dab615dae6ea436791182672bbdbe423,tumor types,0.49039
uuid-dab615dae6ea436791182672bbdbe423,assay,0.419703
uuid-dab615dae6ea436791182672bbdbe423,RTL stated,0.31001
uuid-dab615dae6ea436791182672bbdbe423,biomarker,0.395258
uuid-dab615dae6ea436791182672bbdbe423,bladder,0.332632
uuid-f67a0eb74a4f44648f2a489c69ca5ab8,data,0.314532
uuid-f67a0eb74a4f44648f2a489c69ca5ab8,impressed,0.303658
uuid-5b9a0adea6054813a02c364546683e54,Nivo,0.326892
uuid-5b9a0adea6054813a02c364546683e54,therapy,0.343378
uuid-5b9a0adea6054813a02c364546683e54,nivolumab,0.514807
uuid-5b9a0adea6054813a02c364546683e54,trial,0.342704
uuid-5b9a0adea6054813a02c364546683e54,data,0.302883
uuid-5b9a0adea6054813a02c364546683e54,PD1,0.30194
uuid-5b9a0adea6054813a02c364546683e54,cHL,0.534575
uuid-5b9a0adea6054813a02c364546683e54,chemotherapy,0.342121
uuid-e0207568487d46acaeb10c28df42e339,patients,0.498196
uuid-e0207568487d46acaeb10c28df42e339,RTL,0.403596
uuid-e0207568487d46acaeb10c28df42e339,nivolumab,0.36092
uuid-e0207568487d46acaeb10c28df42e339,regimen,0.46655
uuid-e0207568487d46acaeb10c28df42e339,treated,0.536
uuid-e0207568487d46acaeb10c28df42e339,melanoma,0.311363
uuid-e0207568487d46acaeb10c28df42e339,RCC,0.414757
uuid-e0207568487d46acaeb10c28df42e339,pts,0.497306
uuid-e0207568487d46acaeb10c28df42e339,monotherapy,0.347579
uuid-e0207568487d46acaeb10c28df42e339,using nivo,0.346752
uuid-e0207568487d46acaeb10c28df42e339,response,0.324804
uuid-e0207568487d46acaeb10c28df42e339,SCCHN,0.362952
uuid-e0207568487d46acaeb10c28df42e339,progression,0.427927
uuid-e0207568487d46acaeb10c28df42e339,impressed,0.348782
uuid-e0207568487d46acaeb10c28df42e339,LTL,0.308365
uuid-e0207568487d46acaeb10c28df42e339,Regional TL,0.370445
uuid-e0207568487d46acaeb10c28df42e339,RTL stated,0.436626
uuid-e0207568487d46acaeb10c28df42e339,TL shared,0.397826
uuid-88968817e48d4726a28d7bf1eb1a6ec2,RTL,0.360699
uuid-88968817e48d4726a28d7bf1eb1a6ec2,BMS,0.509951
uuid-88968817e48d4726a28d7bf1eb1a6ec2,trial,0.555377
uuid-88968817e48d4726a28d7bf1eb1a6ec2,commented,0.342207
uuid-88968817e48d4726a28d7bf1eb1a6ec2,Merck,0.472946
uuid-88968817e48d4726a28d7bf1eb1a6ec2,stated,0.371653
uuid-88968817e48d4726a28d7bf1eb1a6ec2,data,0.371177
uuid-88968817e48d4726a28d7bf1eb1a6ec2,mentioned,0.301734
uuid-88968817e48d4726a28d7bf1eb1a6ec2,clinical trials,0.307427
uuid-88968817e48d4726a28d7bf1eb1a6ec2,impressed,0.432727
uuid-88968817e48d4726a28d7bf1eb1a6ec2,Regional TL,0.312228
uuid-39f730a583ab47f7bbd96735e6688746,PDL1,0.329986
uuid-39f730a583ab47f7bbd96735e6688746,efficacy,0.342034
uuid-39f730a583ab47f7bbd96735e6688746,agents,0.40801
uuid-39f730a583ab47f7bbd96735e6688746,data,0.508597
uuid-39f730a583ab47f7bbd96735e6688746,feels,0.343496
uuid-0c41f03bcd5a40aea34905eefaac0052,TL,0.596482
uuid-0c41f03bcd5a40aea34905eefaac0052,PDL1,0.357387
uuid-0c41f03bcd5a40aea34905eefaac0052,Merck,0.327115
uuid-0c41f03bcd5a40aea34905eefaac0052,institution,0.406763
uuid-0c41f03bcd5a40aea34905eefaac0052,PD-L1,0.764579
uuid-0c41f03bcd5a40aea34905eefaac0052,PD-L1 testing,0.901669
uuid-0c41f03bcd5a40aea34905eefaac0052,testing,0.796441
uuid-0c41f03bcd5a40aea34905eefaac0052,PDL1 testing,0.52971
uuid-0c41f03bcd5a40aea34905eefaac0052,NSCLC patients,0.459868
uuid-0c41f03bcd5a40aea34905eefaac0052,assay,0.78177
uuid-0c41f03bcd5a40aea34905eefaac0052,biomarker,0.358869
uuid-64188b3d07104628a2ac98bf869b4c22,TL,0.519226
uuid-64188b3d07104628a2ac98bf869b4c22,IO,0.361189
uuid-64188b3d07104628a2ac98bf869b4c22,PD-L1,0.478534
uuid-64188b3d07104628a2ac98bf869b4c22,PD-L1 testing,0.515116
uuid-64188b3d07104628a2ac98bf869b4c22,testing,0.457116
uuid-64188b3d07104628a2ac98bf869b4c22,indicated,0.314402
uuid-64188b3d07104628a2ac98bf869b4c22,clinical,0.366362
uuid-64188b3d07104628a2ac98bf869b4c22,assay,0.421423
uuid-64188b3d07104628a2ac98bf869b4c22,biomarker,0.425023
uuid-a4b33c580c214981851a2ae61dbc8264,TL,0.629602
uuid-a4b33c580c214981851a2ae61dbc8264,PDL1,0.399632
uuid-a4b33c580c214981851a2ae61dbc8264,TL stated,0.450779
uuid-a4b33c580c214981851a2ae61dbc8264,Merck,0.418838
uuid-a4b33c580c214981851a2ae61dbc8264,PD-L1,0.703727
uuid-a4b33c580c214981851a2ae61dbc8264,PD-L1 testing,0.731791
uuid-a4b33c580c214981851a2ae61dbc8264,testing,0.759032
uuid-a4b33c580c214981851a2ae61dbc8264,PDL1 testing,0.660512
uuid-a4b33c580c214981851a2ae61dbc8264,NSCLC patients,0.500154
uuid-a4b33c580c214981851a2ae61dbc8264,assay,0.710485
uuid-a4b33c580c214981851a2ae61dbc8264,biomarker,0.349544
uuid-5954992db859427d8adac1307c10674c,BMS,0.524621
uuid-5954992db859427d8adac1307c10674c,trial,0.370974
uuid-5954992db859427d8adac1307c10674c,Merck,0.543888
uuid-0b1a1104a5c34696bc1281bcbd68ddff,1L,0.342414
uuid-0b1a1104a5c34696bc1281bcbd68ddff,PDL1,0.346242
uuid-0b1a1104a5c34696bc1281bcbd68ddff,TL stated,0.474105
uuid-0b1a1104a5c34696bc1281bcbd68ddff,PD-L1,0.632583
uuid-0b1a1104a5c34696bc1281bcbd68ddff,PD-L1 testing,0.569506
uuid-0b1a1104a5c34696bc1281bcbd68ddff,testing,0.779949
uuid-0b1a1104a5c34696bc1281bcbd68ddff,PDL1 testing,0.712432
uuid-0b1a1104a5c34696bc1281bcbd68ddff,NSCLC patients,0.817336
uuid-0b1a1104a5c34696bc1281bcbd68ddff,tumor types,0.471469
uuid-0b1a1104a5c34696bc1281bcbd68ddff,assay,0.3292
uuid-0b1a1104a5c34696bc1281bcbd68ddff,biomarker,0.39411
uuid-b59cf3fb8e0f445881bdf51abc135de2,RTL,0.632774
uuid-b59cf3fb8e0f445881bdf51abc135de2,trial,0.319912
uuid-b59cf3fb8e0f445881bdf51abc135de2,NTL,0.313751
uuid-b59cf3fb8e0f445881bdf51abc135de2,shared,0.342968
uuid-b59cf3fb8e0f445881bdf51abc135de2,commented,0.500218
uuid-b59cf3fb8e0f445881bdf51abc135de2,RCC,0.371293
uuid-b59cf3fb8e0f445881bdf51abc135de2,stated,0.527769
uuid-b59cf3fb8e0f445881bdf51abc135de2,data,0.549867
uuid-b59cf3fb8e0f445881bdf51abc135de2,expressed,0.334193
uuid-b59cf3fb8e0f445881bdf51abc135de2,clinical trials,0.372563
uuid-b59cf3fb8e0f445881bdf51abc135de2,SCCHN,0.481772
uuid-b59cf3fb8e0f445881bdf51abc135de2,HCP,0.347964
uuid-b59cf3fb8e0f445881bdf51abc135de2,ASCO,0.387014
uuid-b59cf3fb8e0f445881bdf51abc135de2,impressed,0.694498
uuid-b59cf3fb8e0f445881bdf51abc135de2,LTL,0.546359
uuid-b59cf3fb8e0f445881bdf51abc135de2,TLs,0.489596
uuid-b59cf3fb8e0f445881bdf51abc135de2,academic,0.343594
uuid-b59cf3fb8e0f445881bdf51abc135de2,feels,0.394241
uuid-b59cf3fb8e0f445881bdf51abc135de2,Regional TL,0.592253
uuid-b59cf3fb8e0f445881bdf51abc135de2,RTL stated,0.435314
uuid-b59cf3fb8e0f445881bdf51abc135de2,bladder,0.37355
uuid-7a1039efb2ff4c3f802685eae7ff5748,Nivo,0.408138
uuid-7a1039efb2ff4c3f802685eae7ff5748,patients,0.400841
uuid-7a1039efb2ff4c3f802685eae7ff5748,pembro,0.571752
uuid-7a1039efb2ff4c3f802685eae7ff5748,NSCLC,0.395635
uuid-7a1039efb2ff4c3f802685eae7ff5748,1L,0.560974
uuid-7a1039efb2ff4c3f802685eae7ff5748,chemo,0.320752
uuid-7a1039efb2ff4c3f802685eae7ff5748,2L,0.521299
uuid-7a1039efb2ff4c3f802685eae7ff5748,approval,0.355636
uuid-7a1039efb2ff4c3f802685eae7ff5748,atezo,0.443194
uuid-7a1039efb2ff4c3f802685eae7ff5748,preferred,0.527297
uuid-7a1039efb2ff4c3f802685eae7ff5748,monotherapy,0.5155
uuid-7a1039efb2ff4c3f802685eae7ff5748,using nivo,0.581745
uuid-7a1039efb2ff4c3f802685eae7ff5748,NSCLC patients,0.311009
uuid-7a1039efb2ff4c3f802685eae7ff5748,approved,0.35728
uuid-7a1039efb2ff4c3f802685eae7ff5748,chemotherapy,0.32231
uuid-7a1039efb2ff4c3f802685eae7ff5748,RTL stated,0.383234
uuid-7a1039efb2ff4c3f802685eae7ff5748,option,0.554622
uuid-5b540de25c4f4142ae83d3197bd4b044,Nivo,0.503763
uuid-5b540de25c4f4142ae83d3197bd4b044,dose,0.339375
uuid-5b540de25c4f4142ae83d3197bd4b044,nivolumab,0.423114
uuid-5b540de25c4f4142ae83d3197bd4b044,1L,0.333062
uuid-5b540de25c4f4142ae83d3197bd4b044,toxicity,0.337858
uuid-5b540de25c4f4142ae83d3197bd4b044,regimen,0.446366
uuid-5b540de25c4f4142ae83d3197bd4b044,melanoma,0.313503
uuid-5b540de25c4f4142ae83d3197bd4b044,RCC,0.468007
uuid-5b540de25c4f4142ae83d3197bd4b044,combination,0.562537
uuid-5b540de25c4f4142ae83d3197bd4b044,chemo,0.36314
uuid-5b540de25c4f4142ae83d3197bd4b044,2L,0.434038
uuid-5b540de25c4f4142ae83d3197bd4b044,agents,0.361575
uuid-5b540de25c4f4142ae83d3197bd4b044,Ipi,0.565093
uuid-5b540de25c4f4142ae83d3197bd4b044,atezo,0.314986
uuid-5b540de25c4f4142ae83d3197bd4b044,preferred,0.438677
uuid-5b540de25c4f4142ae83d3197bd4b044,monotherapy,0.500168
uuid-5b540de25c4f4142ae83d3197bd4b044,using nivo,0.414639
uuid-5b540de25c4f4142ae83d3197bd4b044,combo,0.603923
uuid-5b540de25c4f4142ae83d3197bd4b044,approved,0.336256
uuid-5b540de25c4f4142ae83d3197bd4b044,chemotherapy,0.306237
uuid-5b540de25c4f4142ae83d3197bd4b044,SCLC,0.32605
uuid-5b540de25c4f4142ae83d3197bd4b044,RTL stated,0.390026
uuid-5b540de25c4f4142ae83d3197bd4b044,TL shared,0.31699
uuid-5b540de25c4f4142ae83d3197bd4b044,option,0.36861
uuid-5b540de25c4f4142ae83d3197bd4b044,bladder,0.369011
uuid-de42801e02f54f61aa4d7f0a263423dd,Nivo,0.518549
uuid-de42801e02f54f61aa4d7f0a263423dd,patients,0.362398
uuid-de42801e02f54f61aa4d7f0a263423dd,pembro,0.370022
uuid-de42801e02f54f61aa4d7f0a263423dd,therapy,0.378477
uuid-de42801e02f54f61aa4d7f0a263423dd,1L,0.393837
uuid-de42801e02f54f61aa4d7f0a263423dd,efficacy,0.369301
uuid-de42801e02f54f61aa4d7f0a263423dd,regimen,0.446763
uuid-de42801e02f54f61aa4d7f0a263423dd,combination,0.38069
uuid-de42801e02f54f61aa4d7f0a263423dd,chemo,0.567739
uuid-de42801e02f54f61aa4d7f0a263423dd,2L,0.327294
uuid-de42801e02f54f61aa4d7f0a263423dd,pts,0.424444
uuid-de42801e02f54f61aa4d7f0a263423dd,Ipi,0.320869
uuid-de42801e02f54f61aa4d7f0a263423dd,preferred,0.326929
uuid-de42801e02f54f61aa4d7f0a263423dd,monotherapy,0.521234
uuid-de42801e02f54f61aa4d7f0a263423dd,treatment,0.350844
uuid-de42801e02f54f61aa4d7f0a263423dd,combo,0.406531
uuid-de42801e02f54f61aa4d7f0a263423dd,PD1,0.362681
uuid-de42801e02f54f61aa4d7f0a263423dd,progression,0.346277
uuid-de42801e02f54f61aa4d7f0a263423dd,chemotherapy,0.605624
uuid-de42801e02f54f61aa4d7f0a263423dd,feels,0.316662
uuid-de42801e02f54f61aa4d7f0a263423dd,option,0.523051
uuid-29d931ee2c794b488ad4d18a4b00e96f,Nivo,0.398217
uuid-29d931ee2c794b488ad4d18a4b00e96f,patients,0.59093
uuid-29d931ee2c794b488ad4d18a4b00e96f,Opdivo,0.357771
uuid-29d931ee2c794b488ad4d18a4b00e96f,therapy,0.449816
uuid-29d931ee2c794b488ad4d18a4b00e96f,nivolumab,0.527642
uuid-29d931ee2c794b488ad4d18a4b00e96f,1L,0.440716
uuid-29d931ee2c794b488ad4d18a4b00e96f,regimen,0.567214
uuid-29d931ee2c794b488ad4d18a4b00e96f,treated,0.451251
uuid-29d931ee2c794b488ad4d18a4b00e96f,RCC,0.521544
uuid-29d931ee2c794b488ad4d18a4b00e96f,TL stated,0.30808
uuid-29d931ee2c794b488ad4d18a4b00e96f,combination,0.364285
uuid-29d931ee2c794b488ad4d18a4b00e96f,chemo,0.41707
uuid-29d931ee2c794b488ad4d18a4b00e96f,2L,0.573217
uuid-29d931ee2c794b488ad4d18a4b00e96f,pts,0.479112
uuid-29d931ee2c794b488ad4d18a4b00e96f,agents,0.302008
uuid-29d931ee2c794b488ad4d18a4b00e96f,preferred,0.501691
uuid-29d931ee2c794b488ad4d18a4b00e96f,monotherapy,0.580622
uuid-29d931ee2c794b488ad4d18a4b00e96f,treatment,0.574062
uuid-29d931ee2c794b488ad4d18a4b00e96f,using nivo,0.548117
uuid-29d931ee2c794b488ad4d18a4b00e96f,combo,0.422242
uuid-29d931ee2c794b488ad4d18a4b00e96f,PD1,0.407943
uuid-29d931ee2c794b488ad4d18a4b00e96f,approved,0.307164
uuid-29d931ee2c794b488ad4d18a4b00e96f,progression,0.498641
uuid-29d931ee2c794b488ad4d18a4b00e96f,chemotherapy,0.365171
uuid-29d931ee2c794b488ad4d18a4b00e96f,respond,0.344641
uuid-29d931ee2c794b488ad4d18a4b00e96f,RTL stated,0.492373
uuid-29d931ee2c794b488ad4d18a4b00e96f,TL shared,0.411191
uuid-29d931ee2c794b488ad4d18a4b00e96f,option,0.536911
uuid-18253b83a51e4deabb3076162ebb1b84,BMS,0.39699
uuid-18253b83a51e4deabb3076162ebb1b84,PDL1,0.354478
uuid-18253b83a51e4deabb3076162ebb1b84,trial,0.365756
uuid-18253b83a51e4deabb3076162ebb1b84,efficacy,0.335131
uuid-18253b83a51e4deabb3076162ebb1b84,discussed,0.401748
uuid-18253b83a51e4deabb3076162ebb1b84,commented,0.562931
uuid-18253b83a51e4deabb3076162ebb1b84,Merck,0.372578
uuid-18253b83a51e4deabb3076162ebb1b84,stated,0.310382
uuid-18253b83a51e4deabb3076162ebb1b84,OS,0.508851
uuid-18253b83a51e4deabb3076162ebb1b84,regards,0.515018
uuid-18253b83a51e4deabb3076162ebb1b84,data,0.749559
uuid-18253b83a51e4deabb3076162ebb1b84,expressed,0.438997
uuid-18253b83a51e4deabb3076162ebb1b84,PFS,0.480519
uuid-18253b83a51e4deabb3076162ebb1b84,ORR,0.51261
uuid-18253b83a51e4deabb3076162ebb1b84,nivo and pembro,0.358828
uuid-18253b83a51e4deabb3076162ebb1b84,ASCO,0.513012
uuid-18253b83a51e4deabb3076162ebb1b84,impressed,0.597388
uuid-18253b83a51e4deabb3076162ebb1b84,TLs,0.446764
uuid-18253b83a51e4deabb3076162ebb1b84,Regional TL,0.334216
uuid-18253b83a51e4deabb3076162ebb1b84,PDL1 expression,0.329545
uuid-18253b83a51e4deabb3076162ebb1b84,biomarker,0.302689
uuid-ea070e2363c4425ca3918d4dd60a774e,Nivo,0.413545
uuid-ea070e2363c4425ca3918d4dd60a774e,patients,0.722409
uuid-ea070e2363c4425ca3918d4dd60a774e,Opdivo,0.391898
uuid-ea070e2363c4425ca3918d4dd60a774e,pembro,0.322131
uuid-ea070e2363c4425ca3918d4dd60a774e,therapy,0.500645
uuid-ea070e2363c4425ca3918d4dd60a774e,nivolumab,0.538272
uuid-ea070e2363c4425ca3918d4dd60a774e,1L,0.385947
uuid-ea070e2363c4425ca3918d4dd60a774e,regimen,0.372533
uuid-ea070e2363c4425ca3918d4dd60a774e,treated,0.41644
uuid-ea070e2363c4425ca3918d4dd60a774e,chemo,0.33068
uuid-ea070e2363c4425ca3918d4dd60a774e,2L,0.483319
uuid-ea070e2363c4425ca3918d4dd60a774e,pts,0.40279
uuid-ea070e2363c4425ca3918d4dd60a774e,approval,0.382743
uuid-ea070e2363c4425ca3918d4dd60a774e,preferred,0.633199
uuid-ea070e2363c4425ca3918d4dd60a774e,monotherapy,0.491865
uuid-ea070e2363c4425ca3918d4dd60a774e,treatment,0.492708
uuid-ea070e2363c4425ca3918d4dd60a774e,using nivo,0.66464
uuid-ea070e2363c4425ca3918d4dd60a774e,approved,0.38805
uuid-ea070e2363c4425ca3918d4dd60a774e,SCCHN,0.317115
uuid-ea070e2363c4425ca3918d4dd60a774e,cHL,0.309014
uuid-ea070e2363c4425ca3918d4dd60a774e,progression,0.328838
uuid-ea070e2363c4425ca3918d4dd60a774e,chemotherapy,0.383985
uuid-ea070e2363c4425ca3918d4dd60a774e,RTL stated,0.474194
uuid-ea070e2363c4425ca3918d4dd60a774e,option,0.594389
uuid-5441afeeaea14d72831d909f29584b49,patients,0.629908
uuid-5441afeeaea14d72831d909f29584b49,therapy,0.414309
uuid-5441afeeaea14d72831d909f29584b49,nivolumab,0.448967
uuid-5441afeeaea14d72831d909f29584b49,trial,0.318699
uuid-5441afeeaea14d72831d909f29584b49,treated,0.466424
uuid-5441afeeaea14d72831d909f29584b49,pts,0.477974
uuid-5441afeeaea14d72831d909f29584b49,approval,0.30004
uuid-5441afeeaea14d72831d909f29584b49,treatment,0.411932
uuid-5441afeeaea14d72831d909f29584b49,clinical trials,0.463836
uuid-5441afeeaea14d72831d909f29584b49,progression,0.356144
uuid-5441afeeaea14d72831d909f29584b49,chemotherapy,0.375139
uuid-ed9e13ec31a442688028f0849b879a08,1L,0.326493
uuid-ed9e13ec31a442688028f0849b879a08,combination,0.540279
uuid-ed9e13ec31a442688028f0849b879a08,chemo,0.366744
uuid-ed9e13ec31a442688028f0849b879a08,2L,0.30139
uuid-ed9e13ec31a442688028f0849b879a08,IO,0.406541
uuid-ed9e13ec31a442688028f0849b879a08,agents,0.677201
uuid-ed9e13ec31a442688028f0849b879a08,preferred,0.33429
uuid-ed9e13ec31a442688028f0849b879a08,monotherapy,0.40191
uuid-ed9e13ec31a442688028f0849b879a08,combo,0.541912
uuid-ed9e13ec31a442688028f0849b879a08,PD1,0.406492
uuid-ed9e13ec31a442688028f0849b879a08,believes,0.401155
uuid-ed9e13ec31a442688028f0849b879a08,chemotherapy,0.355801
uuid-ed9e13ec31a442688028f0849b879a08,PD-1,0.512048
uuid-ed9e13ec31a442688028f0849b879a08,option,0.416239
uuid-a3b5be2141944ae4be619217d7f7a852,Nivo,0.302221
uuid-a3b5be2141944ae4be619217d7f7a852,patients,0.726981
uuid-a3b5be2141944ae4be619217d7f7a852,Opdivo,0.371162
uuid-a3b5be2141944ae4be619217d7f7a852,therapy,0.819401
uuid-a3b5be2141944ae4be619217d7f7a852,nivolumab,0.634329
uuid-a3b5be2141944ae4be619217d7f7a852,regimen,0.450349
uuid-a3b5be2141944ae4be619217d7f7a852,treated,0.606112
uuid-a3b5be2141944ae4be619217d7f7a852,chemo,0.322451
uuid-a3b5be2141944ae4be619217d7f7a852,pts,0.412303
uuid-a3b5be2141944ae4be619217d7f7a852,monotherapy,0.382838
uuid-a3b5be2141944ae4be619217d7f7a852,treatment,0.669167
uuid-a3b5be2141944ae4be619217d7f7a852,using nivo,0.325184
uuid-a3b5be2141944ae4be619217d7f7a852,response,0.465482
uuid-a3b5be2141944ae4be619217d7f7a852,PD1,0.473801
uuid-a3b5be2141944ae4be619217d7f7a852,cHL,0.642597
uuid-a3b5be2141944ae4be619217d7f7a852,progression,0.627883
uuid-a3b5be2141944ae4be619217d7f7a852,chemotherapy,0.466302
uuid-a3b5be2141944ae4be619217d7f7a852,respond,0.433354
uuid-3ec4ae3144a848c594a599a05f5f1554,TL,0.399492
uuid-3ec4ae3144a848c594a599a05f5f1554,1L,0.311982
uuid-3ec4ae3144a848c594a599a05f5f1554,PDL1,0.571422
uuid-3ec4ae3144a848c594a599a05f5f1554,TL stated,0.433577
uuid-3ec4ae3144a848c594a599a05f5f1554,PD-L1,0.801817
uuid-3ec4ae3144a848c594a599a05f5f1554,PD-L1 testing,0.726282
uuid-3ec4ae3144a848c594a599a05f5f1554,testing,0.896312
uuid-3ec4ae3144a848c594a599a05f5f1554,PDL1 testing,0.760118
uuid-3ec4ae3144a848c594a599a05f5f1554,NSCLC patients,0.742842
uuid-3ec4ae3144a848c594a599a05f5f1554,assay,0.602141
uuid-3ec4ae3144a848c594a599a05f5f1554,PDL1 expression,0.378882
uuid-3ec4ae3144a848c594a599a05f5f1554,biomarker,0.505603
uuid-9285a5030c1a4af0867a06b2bdc4e279,pembro,0.300934
uuid-9285a5030c1a4af0867a06b2bdc4e279,RTL,0.524656
uuid-9285a5030c1a4af0867a06b2bdc4e279,trial,0.561389
uuid-9285a5030c1a4af0867a06b2bdc4e279,commented,0.502655
uuid-9285a5030c1a4af0867a06b2bdc4e279,RCC,0.322509
uuid-9285a5030c1a4af0867a06b2bdc4e279,stated,0.442388
uuid-9285a5030c1a4af0867a06b2bdc4e279,OS,0.339195
uuid-9285a5030c1a4af0867a06b2bdc4e279,data,0.643229
uuid-9285a5030c1a4af0867a06b2bdc4e279,combo,0.301427
uuid-9285a5030c1a4af0867a06b2bdc4e279,expressed,0.306946
uuid-9285a5030c1a4af0867a06b2bdc4e279,clinical trials,0.469945
uuid-9285a5030c1a4af0867a06b2bdc4e279,PFS,0.30809
uuid-9285a5030c1a4af0867a06b2bdc4e279,ORR,0.394501
uuid-9285a5030c1a4af0867a06b2bdc4e279,SCCHN,0.474653
uuid-9285a5030c1a4af0867a06b2bdc4e279,ASCO,0.357833
uuid-9285a5030c1a4af0867a06b2bdc4e279,impressed,0.655926
uuid-9285a5030c1a4af0867a06b2bdc4e279,LTL,0.40723
uuid-9285a5030c1a4af0867a06b2bdc4e279,TLs,0.398966
uuid-9285a5030c1a4af0867a06b2bdc4e279,SCLC,0.321051
uuid-9285a5030c1a4af0867a06b2bdc4e279,feels,0.387272
uuid-9285a5030c1a4af0867a06b2bdc4e279,Regional TL,0.494497
uuid-9285a5030c1a4af0867a06b2bdc4e279,RTL stated,0.341067
uuid-9285a5030c1a4af0867a06b2bdc4e279,bladder,0.454443
uuid-62148cc55035474ba9d6b42c3c1473ab,RTL,0.385597
uuid-62148cc55035474ba9d6b42c3c1473ab,NTL,0.470921
uuid-62148cc55035474ba9d6b42c3c1473ab,oncologist,0.339376
uuid-62148cc55035474ba9d6b42c3c1473ab,indicated,0.59643
uuid-62148cc55035474ba9d6b42c3c1473ab,Regional TL,0.361107
uuid-334c3c9b295246ef8ebdef01ed8651a1,RTL,0.587468
uuid-334c3c9b295246ef8ebdef01ed8651a1,trial,0.403843
uuid-334c3c9b295246ef8ebdef01ed8651a1,NTL,0.656887
uuid-334c3c9b295246ef8ebdef01ed8651a1,shared,0.31462
uuid-334c3c9b295246ef8ebdef01ed8651a1,commented,0.318735
uuid-334c3c9b295246ef8ebdef01ed8651a1,stated,0.306074
uuid-334c3c9b295246ef8ebdef01ed8651a1,mentioned,0.4482
uuid-334c3c9b295246ef8ebdef01ed8651a1,oncologist,0.343444
uuid-334c3c9b295246ef8ebdef01ed8651a1,indicated,0.493642
uuid-334c3c9b295246ef8ebdef01ed8651a1,LTL,0.404658
uuid-334c3c9b295246ef8ebdef01ed8651a1,TLs,0.347306
uuid-334c3c9b295246ef8ebdef01ed8651a1,Regional TL,0.560189
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,patients,0.870004
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,Opdivo,0.571677
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,therapy,0.555168
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,nivolumab,0.508681
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,regimen,0.381414
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,treated,0.584749
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,pts,0.522483
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,treatment,0.604274
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,using nivo,0.379019
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,cHL,0.390443
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,progression,0.588476
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,chemotherapy,0.332598
uuid-3b4ed0bad3f54a2ebcabd1cfa6e604a3,respond,0.391702
uuid-5ee41f35b9cd41b89705d8cf6a607a67,TL,0.353961
uuid-5ee41f35b9cd41b89705d8cf6a607a67,pembro,0.413417
uuid-5ee41f35b9cd41b89705d8cf6a607a67,1L,0.377725
uuid-5ee41f35b9cd41b89705d8cf6a607a67,PDL1,0.683183
uuid-5ee41f35b9cd41b89705d8cf6a607a67,2L,0.316527
uuid-5ee41f35b9cd41b89705d8cf6a607a67,Merck,0.310081
uuid-5ee41f35b9cd41b89705d8cf6a607a67,PD-L1,0.610266
uuid-5ee41f35b9cd41b89705d8cf6a607a67,atezo,0.473568
uuid-5ee41f35b9cd41b89705d8cf6a607a67,PD-L1 testing,0.343802
uuid-5ee41f35b9cd41b89705d8cf6a607a67,testing,0.497935
uuid-5ee41f35b9cd41b89705d8cf6a607a67,data,0.345725
uuid-5ee41f35b9cd41b89705d8cf6a607a67,PDL1 testing,0.396708
uuid-5ee41f35b9cd41b89705d8cf6a607a67,NSCLC patients,0.352914
uuid-5ee41f35b9cd41b89705d8cf6a607a67,nivo and pembro,0.387036
uuid-5ee41f35b9cd41b89705d8cf6a607a67,believes,0.38036
uuid-5ee41f35b9cd41b89705d8cf6a607a67,assay,0.494175
uuid-5ee41f35b9cd41b89705d8cf6a607a67,PDL1 expression,0.584394
uuid-5ee41f35b9cd41b89705d8cf6a607a67,biomarker,0.472497
uuid-5ee41f35b9cd41b89705d8cf6a607a67,bladder,0.306137
uuid-c62b77588d174d3fba85b6c9b95b3f9d,patients,0.452577
uuid-c62b77588d174d3fba85b6c9b95b3f9d,nivolumab,0.401015
uuid-c62b77588d174d3fba85b6c9b95b3f9d,1L,0.332629
uuid-c62b77588d174d3fba85b6c9b95b3f9d,toxicity,0.448199
uuid-c62b77588d174d3fba85b6c9b95b3f9d,regimen,0.548908
uuid-c62b77588d174d3fba85b6c9b95b3f9d,treated,0.423275
uuid-c62b77588d174d3fba85b6c9b95b3f9d,melanoma,0.326886
uuid-c62b77588d174d3fba85b6c9b95b3f9d,RCC,0.524446
uuid-c62b77588d174d3fba85b6c9b95b3f9d,TL stated,0.352575
uuid-c62b77588d174d3fba85b6c9b95b3f9d,combination,0.32111
uuid-c62b77588d174d3fba85b6c9b95b3f9d,2L,0.492744
uuid-c62b77588d174d3fba85b6c9b95b3f9d,pts,0.309911
uuid-c62b77588d174d3fba85b6c9b95b3f9d,preferred,0.527869
uuid-c62b77588d174d3fba85b6c9b95b3f9d,monotherapy,0.501997
uuid-c62b77588d174d3fba85b6c9b95b3f9d,treatment,0.345835
uuid-c62b77588d174d3fba85b6c9b95b3f9d,using nivo,0.537615
uuid-c62b77588d174d3fba85b6c9b95b3f9d,combo,0.373109
uuid-c62b77588d174d3fba85b6c9b95b3f9d,SCCHN,0.366344
uuid-c62b77588d174d3fba85b6c9b95b3f9d,RTL stated,0.518969
uuid-c62b77588d174d3fba85b6c9b95b3f9d,TL shared,0.473252
uuid-c62b77588d174d3fba85b6c9b95b3f9d,option,0.388477
uuid-c62b77588d174d3fba85b6c9b95b3f9d,bladder,0.422039
uuid-ab5b593990904ee29fdf97f71871e9cf,TL,0.59004
uuid-ab5b593990904ee29fdf97f71871e9cf,institution,0.498657
uuid-ab5b593990904ee29fdf97f71871e9cf,PD-L1,0.733772
uuid-ab5b593990904ee29fdf97f71871e9cf,approval,0.334655
uuid-ab5b593990904ee29fdf97f71871e9cf,PD-L1 testing,0.884854
uuid-ab5b593990904ee29fdf97f71871e9cf,testing,0.793933
uuid-ab5b593990904ee29fdf97f71871e9cf,PDL1 testing,0.532555
uuid-ab5b593990904ee29fdf97f71871e9cf,NSCLC patients,0.539818
uuid-ab5b593990904ee29fdf97f71871e9cf,assay,0.761131
uuid-7d2f6656ffd4491c98b55dfc2186071f,RTL,0.394605
uuid-7d2f6656ffd4491c98b55dfc2186071f,nivolumab,0.306829
uuid-7d2f6656ffd4491c98b55dfc2186071f,trial,0.498046
uuid-7d2f6656ffd4491c98b55dfc2186071f,treated,0.461598
uuid-7d2f6656ffd4491c98b55dfc2186071f,commented,0.325277
uuid-7d2f6656ffd4491c98b55dfc2186071f,clinical trials,0.492806
uuid-7d2f6656ffd4491c98b55dfc2186071f,SCCHN,0.346042
uuid-7d2f6656ffd4491c98b55dfc2186071f,impressed,0.372711
uuid-7d2f6656ffd4491c98b55dfc2186071f,Regional TL,0.457545
uuid-7d2f6656ffd4491c98b55dfc2186071f,RTL stated,0.300958
uuid-7d2f6656ffd4491c98b55dfc2186071f,bladder,0.405688
uuid-b71921190253412cbb120b13599705f1,patients,0.454882
uuid-b71921190253412cbb120b13599705f1,Opdivo,0.382134
uuid-b71921190253412cbb120b13599705f1,nivolumab,0.35668
uuid-b71921190253412cbb120b13599705f1,toxicity,0.369301
uuid-b71921190253412cbb120b13599705f1,regimen,0.409019
uuid-b71921190253412cbb120b13599705f1,treated,0.50846
uuid-b71921190253412cbb120b13599705f1,RCC,0.422285
uuid-b71921190253412cbb120b13599705f1,2L,0.391519
uuid-b71921190253412cbb120b13599705f1,physicians,0.308825
uuid-b71921190253412cbb120b13599705f1,preferred,0.578265
uuid-b71921190253412cbb120b13599705f1,monotherapy,0.366149
uuid-b71921190253412cbb120b13599705f1,treatment,0.46517
uuid-b71921190253412cbb120b13599705f1,using nivo,0.456909
uuid-b71921190253412cbb120b13599705f1,RTL stated,0.48268
uuid-b71921190253412cbb120b13599705f1,TL shared,0.420439
uuid-b71921190253412cbb120b13599705f1,option,0.409422
uuid-15ba9977adf94a89809aff6039d2c0ef,TL stated,0.423181
uuid-15ba9977adf94a89809aff6039d2c0ef,PD-L1,0.523664
uuid-15ba9977adf94a89809aff6039d2c0ef,PD-L1 testing,0.418421
uuid-15ba9977adf94a89809aff6039d2c0ef,testing,0.715666
uuid-15ba9977adf94a89809aff6039d2c0ef,PDL1 testing,0.685327
uuid-15ba9977adf94a89809aff6039d2c0ef,NSCLC patients,0.784329
uuid-15ba9977adf94a89809aff6039d2c0ef,tumor types,0.446615
uuid-15ba9977adf94a89809aff6039d2c0ef,PD-1,0.314757
uuid-15ba9977adf94a89809aff6039d2c0ef,biomarker,0.379195
uuid-31ecd10e433b4e6980bf5f49204636b3,patients,0.853682
uuid-31ecd10e433b4e6980bf5f49204636b3,Opdivo,0.538396
uuid-31ecd10e433b4e6980bf5f49204636b3,therapy,0.453978
uuid-31ecd10e433b4e6980bf5f49204636b3,dose,0.470948
uuid-31ecd10e433b4e6980bf5f49204636b3,nivolumab,0.495302
uuid-31ecd10e433b4e6980bf5f49204636b3,toxicity,0.390616
uuid-31ecd10e433b4e6980bf5f49204636b3,regimen,0.58889
uuid-31ecd10e433b4e6980bf5f49204636b3,treated,0.646181
uuid-31ecd10e433b4e6980bf5f49204636b3,chemo,0.317944
uuid-31ecd10e433b4e6980bf5f49204636b3,pts,0.552571
uuid-31ecd10e433b4e6980bf5f49204636b3,preferred,0.323497
uuid-31ecd10e433b4e6980bf5f49204636b3,monotherapy,0.382675
uuid-31ecd10e433b4e6980bf5f49204636b3,treatment,0.647477
uuid-31ecd10e433b4e6980bf5f49204636b3,using nivo,0.350581
uuid-31ecd10e433b4e6980bf5f49204636b3,progression,0.545731
uuid-31ecd10e433b4e6980bf5f49204636b3,chemotherapy,0.328313
uuid-31ecd10e433b4e6980bf5f49204636b3,respond,0.473236
uuid-31ecd10e433b4e6980bf5f49204636b3,option,0.360649
uuid-0b1f91fa09a1416082fd3a861aef4cc8,Nivo,0.636957
uuid-0b1f91fa09a1416082fd3a861aef4cc8,pembro,0.50457
uuid-0b1f91fa09a1416082fd3a861aef4cc8,dose,0.485233
uuid-0b1f91fa09a1416082fd3a861aef4cc8,nivolumab,0.402364
uuid-0b1f91fa09a1416082fd3a861aef4cc8,efficacy,0.318937
uuid-0b1f91fa09a1416082fd3a861aef4cc8,regimen,0.392289
uuid-0b1f91fa09a1416082fd3a861aef4cc8,combination,0.42396
uuid-0b1f91fa09a1416082fd3a861aef4cc8,2L,0.382668
uuid-0b1f91fa09a1416082fd3a861aef4cc8,Ipi,0.605934
uuid-0b1f91fa09a1416082fd3a861aef4cc8,atezo,0.417274
uuid-0b1f91fa09a1416082fd3a861aef4cc8,preferred,0.45765
uuid-0b1f91fa09a1416082fd3a861aef4cc8,monotherapy,0.43237
uuid-0b1f91fa09a1416082fd3a861aef4cc8,using nivo,0.501422
uuid-0b1f91fa09a1416082fd3a861aef4cc8,combo,0.379459
uuid-0b1f91fa09a1416082fd3a861aef4cc8,indication,0.315885
uuid-0b1f91fa09a1416082fd3a861aef4cc8,approved,0.329802
uuid-0b1f91fa09a1416082fd3a861aef4cc8,vs,0.438342
uuid-0b1f91fa09a1416082fd3a861aef4cc8,SCLC,0.349587
uuid-0b1f91fa09a1416082fd3a861aef4cc8,RTL stated,0.353698
uuid-0b1f91fa09a1416082fd3a861aef4cc8,option,0.384031
uuid-0b1f91fa09a1416082fd3a861aef4cc8,flat dosing,0.309923
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,Nivo,0.48215
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,pembro,0.551905
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,dose,0.309512
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,1L,0.309961
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,efficacy,0.520252
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,2L,0.425197
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,agents,0.360321
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,Ipi,0.320561
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,atezo,0.597577
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,preferred,0.436419
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,monotherapy,0.313878
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,using nivo,0.350601
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,data,0.358031
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,clinical trials,0.338983
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,indication,0.451395
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,approved,0.449857
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,nivo and pembro,0.341855
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,impressed,0.30114
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,vs,0.478279
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,TLs,0.419609
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,feels,0.331022
uuid-a30ee757bb65420ab8fa4aeeeaa36ffa,flat dosing,0.393437
uuid-11f47b6453fd40fcaa72d5be0648bdda,TL,0.339386
uuid-11f47b6453fd40fcaa72d5be0648bdda,lung,0.33117
uuid-11f47b6453fd40fcaa72d5be0648bdda,1L,0.399733
uuid-11f47b6453fd40fcaa72d5be0648bdda,RCC,0.369277
uuid-11f47b6453fd40fcaa72d5be0648bdda,TL stated,0.605066
uuid-11f47b6453fd40fcaa72d5be0648bdda,2L,0.376924
uuid-11f47b6453fd40fcaa72d5be0648bdda,institution,0.42982
uuid-11f47b6453fd40fcaa72d5be0648bdda,PD-L1,0.546193
uuid-11f47b6453fd40fcaa72d5be0648bdda,approval,0.370012
uuid-11f47b6453fd40fcaa72d5be0648bdda,preferred,0.34173
uuid-11f47b6453fd40fcaa72d5be0648bdda,PD-L1 testing,0.645588
uuid-11f47b6453fd40fcaa72d5be0648bdda,testing,0.760822
uuid-11f47b6453fd40fcaa72d5be0648bdda,using nivo,0.305151
uuid-11f47b6453fd40fcaa72d5be0648bdda,PDL1 testing,0.813211
uuid-11f47b6453fd40fcaa72d5be0648bdda,NSCLC patients,0.722116
uuid-11f47b6453fd40fcaa72d5be0648bdda,SCCHN,0.358869
uuid-11f47b6453fd40fcaa72d5be0648bdda,tumor types,0.4151
uuid-11f47b6453fd40fcaa72d5be0648bdda,assay,0.35472
uuid-11f47b6453fd40fcaa72d5be0648bdda,RTL stated,0.422809
uuid-11f47b6453fd40fcaa72d5be0648bdda,TL shared,0.342474
uuid-a8f4fe630a264ac699cc20f69ea68682,pembro,0.364436
uuid-a8f4fe630a264ac699cc20f69ea68682,RTL,0.365963
uuid-a8f4fe630a264ac699cc20f69ea68682,PDL1,0.314508
uuid-a8f4fe630a264ac699cc20f69ea68682,trial,0.540016
uuid-a8f4fe630a264ac699cc20f69ea68682,efficacy,0.364473
uuid-a8f4fe630a264ac699cc20f69ea68682,NTL,0.306318
uuid-a8f4fe630a264ac699cc20f69ea68682,OS,0.355798
uuid-a8f4fe630a264ac699cc20f69ea68682,data,0.389617
uuid-a8f4fe630a264ac699cc20f69ea68682,clinical trials,0.308943
uuid-a8f4fe630a264ac699cc20f69ea68682,PFS,0.367382
uuid-a8f4fe630a264ac699cc20f69ea68682,ORR,0.432113
uuid-a8f4fe630a264ac699cc20f69ea68682,impressed,0.369964
uuid-a8f4fe630a264ac699cc20f69ea68682,feels,0.324802
uuid-a8f4fe630a264ac699cc20f69ea68682,PDL1 expression,0.359995
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,patients,0.44819
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,1L,0.314938
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,treated,0.483149
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,RCC,0.370448
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,TL stated,0.523527
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,2L,0.306155
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,PD-L1,0.349312
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,preferred,0.30954
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,PD-L1 testing,0.508777
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,testing,0.580845
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,treatment,0.324535
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,PDL1 testing,0.671843
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,NSCLC patients,0.673315
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,lung cancer,0.355572
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,tumor types,0.390712
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,oncologist,0.313637
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,RTL stated,0.390355
uuid-e4b67fb7ae5a4838b8ba636e9d62803e,TL shared,0.374228
uuid-a37206664118479cac77ee418c8324a1,PD-L1,0.342406
uuid-a37206664118479cac77ee418c8324a1,testing,0.429714
uuid-a37206664118479cac77ee418c8324a1,PDL1 testing,0.413045
uuid-a37206664118479cac77ee418c8324a1,NSCLC patients,0.642646
uuid-a37206664118479cac77ee418c8324a1,tumor types,0.361256
uuid-a37206664118479cac77ee418c8324a1,PD-1,0.347764
uuid-1e053081de2e4ada88103f24c22b5bdd,pembro,0.457581
uuid-1e053081de2e4ada88103f24c22b5bdd,RTL,0.360712
uuid-1e053081de2e4ada88103f24c22b5bdd,dose,0.664014
uuid-1e053081de2e4ada88103f24c22b5bdd,NTL,0.344323
uuid-1e053081de2e4ada88103f24c22b5bdd,shared,0.320066
uuid-1e053081de2e4ada88103f24c22b5bdd,Ipi,0.43028
uuid-1e053081de2e4ada88103f24c22b5bdd,approval,0.332314
uuid-1e053081de2e4ada88103f24c22b5bdd,atezo,0.42945
uuid-1e053081de2e4ada88103f24c22b5bdd,using nivo,0.317047
uuid-1e053081de2e4ada88103f24c22b5bdd,mentioned,0.369084
uuid-1e053081de2e4ada88103f24c22b5bdd,approved,0.30003
uuid-1e053081de2e4ada88103f24c22b5bdd,SCCHN,0.310943
uuid-1e053081de2e4ada88103f24c22b5bdd,HCP,0.349824
uuid-1e053081de2e4ada88103f24c22b5bdd,vs,0.462235
uuid-1e053081de2e4ada88103f24c22b5bdd,LTL,0.330095
uuid-1e053081de2e4ada88103f24c22b5bdd,Keytruda,0.307312
uuid-1e053081de2e4ada88103f24c22b5bdd,TLs,0.317699
uuid-1e053081de2e4ada88103f24c22b5bdd,flat dosing,0.68617
uuid-0c095dff8e1d45509e88d508020ef5dd,Nivo,0.308682
uuid-0c095dff8e1d45509e88d508020ef5dd,patients,0.563716
uuid-0c095dff8e1d45509e88d508020ef5dd,therapy,0.455219
uuid-0c095dff8e1d45509e88d508020ef5dd,1L,0.32214
uuid-0c095dff8e1d45509e88d508020ef5dd,regimen,0.406975
uuid-0c095dff8e1d45509e88d508020ef5dd,combination,0.327506
uuid-0c095dff8e1d45509e88d508020ef5dd,chemo,0.586698
uuid-0c095dff8e1d45509e88d508020ef5dd,2L,0.305888
uuid-0c095dff8e1d45509e88d508020ef5dd,pts,0.429884
uuid-0c095dff8e1d45509e88d508020ef5dd,IO,0.348602
uuid-0c095dff8e1d45509e88d508020ef5dd,monotherapy,0.474471
uuid-0c095dff8e1d45509e88d508020ef5dd,treatment,0.395912
uuid-0c095dff8e1d45509e88d508020ef5dd,response,0.417377
uuid-0c095dff8e1d45509e88d508020ef5dd,combo,0.317029
uuid-0c095dff8e1d45509e88d508020ef5dd,PD1,0.349264
uuid-0c095dff8e1d45509e88d508020ef5dd,progression,0.501769
uuid-0c095dff8e1d45509e88d508020ef5dd,believes,0.309182
uuid-0c095dff8e1d45509e88d508020ef5dd,chemotherapy,0.530244
uuid-0c095dff8e1d45509e88d508020ef5dd,respond,0.409869
uuid-0c095dff8e1d45509e88d508020ef5dd,option,0.444055
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,patients,0.304147
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,TL,0.444791
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,lung,0.36891
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,treated,0.358938
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,RCC,0.439003
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,TL stated,0.572748
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,PD-L1,0.36542
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,approval,0.418438
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,PD-L1 testing,0.529187
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,testing,0.519459
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,using nivo,0.326032
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,PDL1 testing,0.540499
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,NSCLC patients,0.581055
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,SCCHN,0.463521
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,tumor types,0.317768
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,oncologist,0.319345
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,Regional TL,0.384902
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,RTL stated,0.382486
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,TL shared,0.427362
uuid-a9f6505c72c24cd59ae8ef389e9ea0c3,bladder,0.346439
uuid-ac46460cef224d558f9212252871749a,Nivo,0.336337
uuid-ac46460cef224d558f9212252871749a,pembro,0.420085
uuid-ac46460cef224d558f9212252871749a,dose,0.419741
uuid-ac46460cef224d558f9212252871749a,1L,0.409171
uuid-ac46460cef224d558f9212252871749a,2L,0.52229
uuid-ac46460cef224d558f9212252871749a,agents,0.430598
uuid-ac46460cef224d558f9212252871749a,atezo,0.559326
uuid-ac46460cef224d558f9212252871749a,preferred,0.600871
uuid-ac46460cef224d558f9212252871749a,monotherapy,0.366797
uuid-ac46460cef224d558f9212252871749a,indication,0.444129
uuid-ac46460cef224d558f9212252871749a,approved,0.448204
uuid-ac46460cef224d558f9212252871749a,vs,0.301413
uuid-ac46460cef224d558f9212252871749a,drug,0.413639
uuid-ac46460cef224d558f9212252871749a,Keytruda,0.52812
uuid-ac46460cef224d558f9212252871749a,option,0.476076
uuid-ac46460cef224d558f9212252871749a,flat dosing,0.425303
uuid-768fe22359d84ca7a5dba484d407f215,Nivo,0.414512
uuid-768fe22359d84ca7a5dba484d407f215,Opdivo,0.347487
uuid-768fe22359d84ca7a5dba484d407f215,pembro,0.500841
uuid-768fe22359d84ca7a5dba484d407f215,dose,0.799573
uuid-768fe22359d84ca7a5dba484d407f215,Ipi,0.537888
uuid-768fe22359d84ca7a5dba484d407f215,atezo,0.516756
uuid-768fe22359d84ca7a5dba484d407f215,vs,0.642551
uuid-768fe22359d84ca7a5dba484d407f215,Keytruda,0.360419
uuid-768fe22359d84ca7a5dba484d407f215,flat dosing,0.693242
uuid-942cb3d6763645328e9008506b41d87b,patients,0.605248
uuid-942cb3d6763645328e9008506b41d87b,RTL,0.342639
uuid-942cb3d6763645328e9008506b41d87b,nivolumab,0.458265
uuid-942cb3d6763645328e9008506b41d87b,toxicity,0.435764
uuid-942cb3d6763645328e9008506b41d87b,regimen,0.570069
uuid-942cb3d6763645328e9008506b41d87b,treated,0.479455
uuid-942cb3d6763645328e9008506b41d87b,RCC,0.313098
uuid-942cb3d6763645328e9008506b41d87b,combination,0.373664
uuid-942cb3d6763645328e9008506b41d87b,pts,0.517739
uuid-942cb3d6763645328e9008506b41d87b,monotherapy,0.453288
uuid-942cb3d6763645328e9008506b41d87b,treatment,0.394218
uuid-942cb3d6763645328e9008506b41d87b,using nivo,0.35726
uuid-942cb3d6763645328e9008506b41d87b,combo,0.360355
uuid-942cb3d6763645328e9008506b41d87b,SCCHN,0.312038
uuid-942cb3d6763645328e9008506b41d87b,progression,0.442898
uuid-942cb3d6763645328e9008506b41d87b,respond,0.341544
uuid-942cb3d6763645328e9008506b41d87b,SCLC,0.390785
uuid-942cb3d6763645328e9008506b41d87b,RTL stated,0.40933
uuid-942cb3d6763645328e9008506b41d87b,TL shared,0.352902
uuid-942cb3d6763645328e9008506b41d87b,option,0.317289
uuid-1c582d3a8acb44f794a07d1496691c20,1L,0.572476
uuid-1c582d3a8acb44f794a07d1496691c20,toxicity,0.440663
uuid-1c582d3a8acb44f794a07d1496691c20,regimen,0.464201
uuid-1c582d3a8acb44f794a07d1496691c20,RCC,0.404564
uuid-1c582d3a8acb44f794a07d1496691c20,combination,0.701529
uuid-1c582d3a8acb44f794a07d1496691c20,chemo,0.587725
uuid-1c582d3a8acb44f794a07d1496691c20,2L,0.556329
uuid-1c582d3a8acb44f794a07d1496691c20,IO,0.487661
uuid-1c582d3a8acb44f794a07d1496691c20,agents,0.682444
uuid-1c582d3a8acb44f794a07d1496691c20,preferred,0.473724
uuid-1c582d3a8acb44f794a07d1496691c20,monotherapy,0.73866
uuid-1c582d3a8acb44f794a07d1496691c20,combo,0.779858
uuid-1c582d3a8acb44f794a07d1496691c20,PD1,0.576825
uuid-1c582d3a8acb44f794a07d1496691c20,believes,0.496936
uuid-1c582d3a8acb44f794a07d1496691c20,chemotherapy,0.468222
uuid-1c582d3a8acb44f794a07d1496691c20,feels,0.367805
uuid-1c582d3a8acb44f794a07d1496691c20,PD-1,0.378813
uuid-1c582d3a8acb44f794a07d1496691c20,RTL stated,0.343151
uuid-1c582d3a8acb44f794a07d1496691c20,option,0.574101
uuid-e13e1d5d9c6842e793432ddb884f9754,Nivo,0.707914
uuid-e13e1d5d9c6842e793432ddb884f9754,pembro,0.654646
uuid-e13e1d5d9c6842e793432ddb884f9754,dose,0.462113
uuid-e13e1d5d9c6842e793432ddb884f9754,1L,0.410241
uuid-e13e1d5d9c6842e793432ddb884f9754,efficacy,0.427715
uuid-e13e1d5d9c6842e793432ddb884f9754,chemo,0.33183
uuid-e13e1d5d9c6842e793432ddb884f9754,2L,0.527618
uuid-e13e1d5d9c6842e793432ddb884f9754,agents,0.393435
uuid-e13e1d5d9c6842e793432ddb884f9754,Ipi,0.441544
uuid-e13e1d5d9c6842e793432ddb884f9754,atezo,0.596741
uuid-e13e1d5d9c6842e793432ddb884f9754,preferred,0.549426
uuid-e13e1d5d9c6842e793432ddb884f9754,monotherapy,0.47176
uuid-e13e1d5d9c6842e793432ddb884f9754,using nivo,0.495524
uuid-e13e1d5d9c6842e793432ddb884f9754,combo,0.335888
uuid-e13e1d5d9c6842e793432ddb884f9754,indication,0.384226
uuid-e13e1d5d9c6842e793432ddb884f9754,approved,0.443518
uuid-e13e1d5d9c6842e793432ddb884f9754,nivo and pembro,0.333879
uuid-e13e1d5d9c6842e793432ddb884f9754,vs,0.578076
uuid-e13e1d5d9c6842e793432ddb884f9754,feels,0.398791
uuid-e13e1d5d9c6842e793432ddb884f9754,option,0.573001
uuid-e13e1d5d9c6842e793432ddb884f9754,flat dosing,0.339929
uuid-7643cd5488474fc080600ae44b5ba7da,1L,0.354386
uuid-7643cd5488474fc080600ae44b5ba7da,PDL1,0.535277
uuid-7643cd5488474fc080600ae44b5ba7da,TL stated,0.477051
uuid-7643cd5488474fc080600ae44b5ba7da,PD-L1,0.719933
uuid-7643cd5488474fc080600ae44b5ba7da,PD-L1 testing,0.579529
uuid-7643cd5488474fc080600ae44b5ba7da,testing,0.830271
uuid-7643cd5488474fc080600ae44b5ba7da,PDL1 testing,0.780342
uuid-7643cd5488474fc080600ae44b5ba7da,NSCLC patients,0.797701
uuid-7643cd5488474fc080600ae44b5ba7da,tumor types,0.369594
uuid-7643cd5488474fc080600ae44b5ba7da,assay,0.40813
uuid-7643cd5488474fc080600ae44b5ba7da,PDL1 expression,0.365896
uuid-7643cd5488474fc080600ae44b5ba7da,biomarker,0.538373
uuid-10d612f994b744b4bdbde694f076bdfb,institution,0.341061
uuid-10d612f994b744b4bdbde694f076bdfb,regards,0.356112
uuid-10d612f994b744b4bdbde694f076bdfb,indication,0.303352
uuid-10d612f994b744b4bdbde694f076bdfb,AI,0.533798
uuid-10d612f994b744b4bdbde694f076bdfb,oncology,0.379698
uuid-10d612f994b744b4bdbde694f076bdfb,drug,0.36133
uuid-10d612f994b744b4bdbde694f076bdfb,NCCN,0.484761
uuid-10d612f994b744b4bdbde694f076bdfb,flat dosing,0.440294
uuid-26d06d60ae4b405d82544a7904896fbe,RTL,0.440293
uuid-26d06d60ae4b405d82544a7904896fbe,BMS,0.50658
uuid-26d06d60ae4b405d82544a7904896fbe,trial,0.42176
uuid-26d06d60ae4b405d82544a7904896fbe,NTL,0.387306
uuid-26d06d60ae4b405d82544a7904896fbe,shared,0.314923
uuid-26d06d60ae4b405d82544a7904896fbe,commented,0.593421
uuid-26d06d60ae4b405d82544a7904896fbe,Merck,0.406292
uuid-26d06d60ae4b405d82544a7904896fbe,stated,0.600447
uuid-26d06d60ae4b405d82544a7904896fbe,approval,0.385422
uuid-26d06d60ae4b405d82544a7904896fbe,regards,0.408945
uuid-26d06d60ae4b405d82544a7904896fbe,data,0.507604
uuid-26d06d60ae4b405d82544a7904896fbe,expressed,0.368459
uuid-26d06d60ae4b405d82544a7904896fbe,clinical trials,0.413537
uuid-26d06d60ae4b405d82544a7904896fbe,indication,0.338669
uuid-26d06d60ae4b405d82544a7904896fbe,approved,0.308799
uuid-26d06d60ae4b405d82544a7904896fbe,SCCHN,0.472602
uuid-26d06d60ae4b405d82544a7904896fbe,ASCO,0.3414
uuid-26d06d60ae4b405d82544a7904896fbe,impressed,0.461201
uuid-26d06d60ae4b405d82544a7904896fbe,label,0.362444
uuid-26d06d60ae4b405d82544a7904896fbe,SCLC,0.315212
uuid-26d06d60ae4b405d82544a7904896fbe,Regional TL,0.429569
uuid-26d06d60ae4b405d82544a7904896fbe,NCCN,0.431213
uuid-26d06d60ae4b405d82544a7904896fbe,bladder,0.311112
uuid-cd0d4764afad40fa8ea18d90d5dde435,Nivo,0.346298
uuid-cd0d4764afad40fa8ea18d90d5dde435,pembro,0.379194
uuid-cd0d4764afad40fa8ea18d90d5dde435,1L,0.423678
uuid-cd0d4764afad40fa8ea18d90d5dde435,PDL1,0.40509
uuid-cd0d4764afad40fa8ea18d90d5dde435,trial,0.529903
uuid-cd0d4764afad40fa8ea18d90d5dde435,efficacy,0.566393
uuid-cd0d4764afad40fa8ea18d90d5dde435,combination,0.479885
uuid-cd0d4764afad40fa8ea18d90d5dde435,chemo,0.465134
uuid-cd0d4764afad40fa8ea18d90d5dde435,IO,0.367593
uuid-cd0d4764afad40fa8ea18d90d5dde435,agents,0.3365
uuid-cd0d4764afad40fa8ea18d90d5dde435,Ipi,0.36242
uuid-cd0d4764afad40fa8ea18d90d5dde435,OS,0.491242
uuid-cd0d4764afad40fa8ea18d90d5dde435,atezo,0.317843
uuid-cd0d4764afad40fa8ea18d90d5dde435,monotherapy,0.468218
uuid-cd0d4764afad40fa8ea18d90d5dde435,data,0.521717
uuid-cd0d4764afad40fa8ea18d90d5dde435,combo,0.583453
uuid-cd0d4764afad40fa8ea18d90d5dde435,PFS,0.466562
uuid-cd0d4764afad40fa8ea18d90d5dde435,PD1,0.337735
uuid-cd0d4764afad40fa8ea18d90d5dde435,ORR,0.550848
uuid-cd0d4764afad40fa8ea18d90d5dde435,nivo and pembro,0.477365
uuid-cd0d4764afad40fa8ea18d90d5dde435,believes,0.571977
uuid-cd0d4764afad40fa8ea18d90d5dde435,chemotherapy,0.375416
uuid-cd0d4764afad40fa8ea18d90d5dde435,impressed,0.389147
uuid-cd0d4764afad40fa8ea18d90d5dde435,feels,0.472329
uuid-cd0d4764afad40fa8ea18d90d5dde435,PDL1 expression,0.367085
uuid-cd0d4764afad40fa8ea18d90d5dde435,option,0.329208
uuid-63fc6db3a0b44a9097a3cd7d79d14795,patients,0.461819
uuid-63fc6db3a0b44a9097a3cd7d79d14795,toxicity,0.577676
uuid-63fc6db3a0b44a9097a3cd7d79d14795,regimen,0.509217
uuid-63fc6db3a0b44a9097a3cd7d79d14795,treated,0.444658
uuid-63fc6db3a0b44a9097a3cd7d79d14795,combination,0.341616
uuid-63fc6db3a0b44a9097a3cd7d79d14795,pts,0.33955
uuid-63fc6db3a0b44a9097a3cd7d79d14795,monotherapy,0.309674
uuid-63fc6db3a0b44a9097a3cd7d79d14795,treatment,0.385279
uuid-63fc6db3a0b44a9097a3cd7d79d14795,combo,0.356463
uuid-63fc6db3a0b44a9097a3cd7d79d14795,progression,0.356125
uuid-3d2f2627184247a097be3b64b084678a,agents,0.306864
uuid-3d2f2627184247a097be3b64b084678a,preferred,0.377773
uuid-3d2f2627184247a097be3b64b084678a,oncology,0.474712
uuid-3d2f2627184247a097be3b64b084678a,drug,0.432909
uuid-3d2f2627184247a097be3b64b084678a,clinical,0.430583
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,pembro,0.35936
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,BMS,0.570476
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,PDL1,0.457827
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,trial,0.715269
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,efficacy,0.419559
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,commented,0.393137
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,Merck,0.433404
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,stated,0.326811
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,OS,0.607539
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,data,0.814908
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,expressed,0.343766
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,clinical trials,0.334378
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,PFS,0.596861
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,ORR,0.653561
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,nivo and pembro,0.456203
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,impressed,0.621661
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,feels,0.389625
uuid-ae16d6fd4bfe4a6bb13bae1d97658fae,PDL1 expression,0.443536
uuid-6f63edb293c74f8bae278ae0c41636d3,PDL1,0.334849
uuid-6f63edb293c74f8bae278ae0c41636d3,efficacy,0.358484
uuid-6f63edb293c74f8bae278ae0c41636d3,tumor,0.336985
uuid-6f63edb293c74f8bae278ae0c41636d3,response,0.303249
uuid-6f63edb293c74f8bae278ae0c41636d3,PDL1 expression,0.386357
uuid-6f63edb293c74f8bae278ae0c41636d3,biomarker,0.412501
uuid-e48d59978a6f45f4ace7b9a18fc7f661,TL shared,0.32035
uuid-e48d59978a6f45f4ace7b9a18fc7f661,biomarker,0.355401
uuid-d95441940d1240bbaff9620b31422c8d,Nivo,0.593368
uuid-d95441940d1240bbaff9620b31422c8d,pembro,0.735768
uuid-d95441940d1240bbaff9620b31422c8d,dose,0.476111
uuid-d95441940d1240bbaff9620b31422c8d,1L,0.500657
uuid-d95441940d1240bbaff9620b31422c8d,efficacy,0.366001
uuid-d95441940d1240bbaff9620b31422c8d,combination,0.321219
uuid-d95441940d1240bbaff9620b31422c8d,chemo,0.35235
uuid-d95441940d1240bbaff9620b31422c8d,2L,0.659885
uuid-d95441940d1240bbaff9620b31422c8d,agents,0.518129
uuid-d95441940d1240bbaff9620b31422c8d,Ipi,0.40796
uuid-d95441940d1240bbaff9620b31422c8d,atezo,0.764914
uuid-d95441940d1240bbaff9620b31422c8d,preferred,0.672447
uuid-d95441940d1240bbaff9620b31422c8d,monotherapy,0.547253
uuid-d95441940d1240bbaff9620b31422c8d,using nivo,0.496366
uuid-d95441940d1240bbaff9620b31422c8d,combo,0.36968
uuid-d95441940d1240bbaff9620b31422c8d,indication,0.313686
uuid-d95441940d1240bbaff9620b31422c8d,approved,0.350889
uuid-d95441940d1240bbaff9620b31422c8d,nivo and pembro,0.459677
uuid-d95441940d1240bbaff9620b31422c8d,believes,0.330311
uuid-d95441940d1240bbaff9620b31422c8d,vs,0.59149
uuid-d95441940d1240bbaff9620b31422c8d,feels,0.344593
uuid-d95441940d1240bbaff9620b31422c8d,RTL stated,0.377036
uuid-d95441940d1240bbaff9620b31422c8d,option,0.49535
uuid-f31b92340c8647b2acf8f6024c4fe354,patients,0.657676
uuid-f31b92340c8647b2acf8f6024c4fe354,therapy,0.503347
uuid-f31b92340c8647b2acf8f6024c4fe354,toxicity,0.301808
uuid-f31b92340c8647b2acf8f6024c4fe354,regimen,0.347992
uuid-f31b92340c8647b2acf8f6024c4fe354,treated,0.363548
uuid-f31b92340c8647b2acf8f6024c4fe354,pts,0.49922
uuid-f31b92340c8647b2acf8f6024c4fe354,treatment,0.592212
uuid-f31b92340c8647b2acf8f6024c4fe354,response,0.508255
uuid-f31b92340c8647b2acf8f6024c4fe354,progression,0.69395
uuid-f31b92340c8647b2acf8f6024c4fe354,respond,0.56169
uuid-4e3e74011d1c43cf86abc13d1d606cc9,combination,0.533485
uuid-4e3e74011d1c43cf86abc13d1d606cc9,chemo,0.394782
uuid-4e3e74011d1c43cf86abc13d1d606cc9,tumor,0.324609
uuid-4e3e74011d1c43cf86abc13d1d606cc9,pts,0.347409
uuid-4e3e74011d1c43cf86abc13d1d606cc9,IO,0.396238
uuid-4e3e74011d1c43cf86abc13d1d606cc9,monotherapy,0.323187
uuid-4e3e74011d1c43cf86abc13d1d606cc9,response,0.424033
uuid-4e3e74011d1c43cf86abc13d1d606cc9,combo,0.445941
uuid-4e3e74011d1c43cf86abc13d1d606cc9,PD1,0.366578
uuid-4e3e74011d1c43cf86abc13d1d606cc9,progression,0.310822
uuid-4e3e74011d1c43cf86abc13d1d606cc9,believes,0.363787
uuid-4e3e74011d1c43cf86abc13d1d606cc9,chemotherapy,0.303849
uuid-4e3e74011d1c43cf86abc13d1d606cc9,PD-1,0.33751
uuid-c8bab3cf3ce542d79660e172c01ed1be,patients,0.699651
uuid-c8bab3cf3ce542d79660e172c01ed1be,Opdivo,0.423733
uuid-c8bab3cf3ce542d79660e172c01ed1be,therapy,0.303448
uuid-c8bab3cf3ce542d79660e172c01ed1be,dose,0.368729
uuid-c8bab3cf3ce542d79660e172c01ed1be,nivolumab,0.47311
uuid-c8bab3cf3ce542d79660e172c01ed1be,toxicity,0.376918
uuid-c8bab3cf3ce542d79660e172c01ed1be,regimen,0.550207
uuid-c8bab3cf3ce542d79660e172c01ed1be,treated,0.620572
uuid-c8bab3cf3ce542d79660e172c01ed1be,pts,0.363407
uuid-c8bab3cf3ce542d79660e172c01ed1be,physicians,0.368659
uuid-c8bab3cf3ce542d79660e172c01ed1be,preferred,0.307138
uuid-c8bab3cf3ce542d79660e172c01ed1be,monotherapy,0.313006
uuid-c8bab3cf3ce542d79660e172c01ed1be,treatment,0.57287
uuid-c8bab3cf3ce542d79660e172c01ed1be,using nivo,0.363299
uuid-c8bab3cf3ce542d79660e172c01ed1be,progression,0.398622
uuid-c8bab3cf3ce542d79660e172c01ed1be,respond,0.374934
uuid-c8bab3cf3ce542d79660e172c01ed1be,RTL stated,0.354389
uuid-0105dedda4884ad5a318640f7ea2f142,Nivo,0.509121
uuid-0105dedda4884ad5a318640f7ea2f142,patients,0.754536
uuid-0105dedda4884ad5a318640f7ea2f142,Opdivo,0.332257
uuid-0105dedda4884ad5a318640f7ea2f142,therapy,0.611177
uuid-0105dedda4884ad5a318640f7ea2f142,nivolumab,0.533515
uuid-0105dedda4884ad5a318640f7ea2f142,regimen,0.432373
uuid-0105dedda4884ad5a318640f7ea2f142,treated,0.543037
uuid-0105dedda4884ad5a318640f7ea2f142,chemo,0.467175
uuid-0105dedda4884ad5a318640f7ea2f142,pts,0.552212
uuid-0105dedda4884ad5a318640f7ea2f142,monotherapy,0.403056
uuid-0105dedda4884ad5a318640f7ea2f142,treatment,0.586394
uuid-0105dedda4884ad5a318640f7ea2f142,using nivo,0.462407
uuid-0105dedda4884ad5a318640f7ea2f142,response,0.385497
uuid-0105dedda4884ad5a318640f7ea2f142,PD1,0.380107
uuid-0105dedda4884ad5a318640f7ea2f142,cHL,0.432745
uuid-0105dedda4884ad5a318640f7ea2f142,progression,0.53396
uuid-0105dedda4884ad5a318640f7ea2f142,chemotherapy,0.439647
uuid-0105dedda4884ad5a318640f7ea2f142,respond,0.50135
uuid-0105dedda4884ad5a318640f7ea2f142,SCLC,0.328353
uuid-0105dedda4884ad5a318640f7ea2f142,RTL stated,0.300072
uuid-0105dedda4884ad5a318640f7ea2f142,option,0.397454
uuid-9ba76801be6947f292e77ad6a5d1fcbc,Nivo,0.326769
uuid-9ba76801be6947f292e77ad6a5d1fcbc,patients,0.534243
uuid-9ba76801be6947f292e77ad6a5d1fcbc,therapy,0.499493
uuid-9ba76801be6947f292e77ad6a5d1fcbc,toxicity,0.367091
uuid-9ba76801be6947f292e77ad6a5d1fcbc,regimen,0.47456
uuid-9ba76801be6947f292e77ad6a5d1fcbc,chemo,0.443555
uuid-9ba76801be6947f292e77ad6a5d1fcbc,pts,0.445058
uuid-9ba76801be6947f292e77ad6a5d1fcbc,treatment,0.445048
uuid-9ba76801be6947f292e77ad6a5d1fcbc,response,0.564211
uuid-9ba76801be6947f292e77ad6a5d1fcbc,PD1,0.385152
uuid-9ba76801be6947f292e77ad6a5d1fcbc,progression,0.584742
uuid-9ba76801be6947f292e77ad6a5d1fcbc,chemotherapy,0.420308
uuid-9ba76801be6947f292e77ad6a5d1fcbc,respond,0.548483
uuid-329f01321879400d80cc2ba7c8fddd2b,Nivo,0.466057
uuid-329f01321879400d80cc2ba7c8fddd2b,patients,0.854464
uuid-329f01321879400d80cc2ba7c8fddd2b,Opdivo,0.473102
uuid-329f01321879400d80cc2ba7c8fddd2b,therapy,0.734136
uuid-329f01321879400d80cc2ba7c8fddd2b,nivolumab,0.56433
uuid-329f01321879400d80cc2ba7c8fddd2b,regimen,0.360995
uuid-329f01321879400d80cc2ba7c8fddd2b,treated,0.486724
uuid-329f01321879400d80cc2ba7c8fddd2b,chemo,0.360118
uuid-329f01321879400d80cc2ba7c8fddd2b,pts,0.46016
uuid-329f01321879400d80cc2ba7c8fddd2b,monotherapy,0.355866
uuid-329f01321879400d80cc2ba7c8fddd2b,treatment,0.617203
uuid-329f01321879400d80cc2ba7c8fddd2b,using nivo,0.405224
uuid-329f01321879400d80cc2ba7c8fddd2b,response,0.339536
uuid-329f01321879400d80cc2ba7c8fddd2b,PD1,0.362586
uuid-329f01321879400d80cc2ba7c8fddd2b,cHL,0.615028
uuid-329f01321879400d80cc2ba7c8fddd2b,progression,0.572948
uuid-329f01321879400d80cc2ba7c8fddd2b,chemotherapy,0.468142
uuid-329f01321879400d80cc2ba7c8fddd2b,respond,0.404799
uuid-329f01321879400d80cc2ba7c8fddd2b,option,0.371443
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,RTL,0.315641
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,BMS,0.574661
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,trial,0.319389
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,efficacy,0.321755
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,commented,0.496394
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,Merck,0.321743
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,stated,0.365707
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,OS,0.508781
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,regards,0.30441
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,data,0.663584
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,expressed,0.369183
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,PFS,0.430736
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,ORR,0.503561
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,ASCO,0.384881
uuid-0a5fd01a54fa4d599c8dcc6f8ffa2342,impressed,0.713649
uuid-4c8aeba024c74c4d8f1ca62bf735d1f9,patients,0.447329
uuid-4c8aeba024c74c4d8f1ca62bf735d1f9,regimen,0.349263
uuid-4c8aeba024c74c4d8f1ca62bf735d1f9,treated,0.484978
uuid-4c8aeba024c74c4d8f1ca62bf735d1f9,melanoma,0.429327
uuid-4c8aeba024c74c4d8f1ca62bf735d1f9,RCC,0.318954
uuid-4c8aeba024c74c4d8f1ca62bf735d1f9,tumor,0.674405
uuid-4c8aeba024c74c4d8f1ca62bf735d1f9,pts,0.436284
uuid-4c8aeba024c74c4d8f1ca62bf735d1f9,treatment,0.345414
uuid-4c8aeba024c74c4d8f1ca62bf735d1f9,progression,0.375864
uuid-4c8aeba024c74c4d8f1ca62bf735d1f9,RTL stated,0.319659
uuid-4c8aeba024c74c4d8f1ca62bf735d1f9,TL shared,0.380319
uuid-2336103cd2c64dcd98d7f2b1437a8edd,TL,0.445652
uuid-2336103cd2c64dcd98d7f2b1437a8edd,NSCLC,0.364704
uuid-2336103cd2c64dcd98d7f2b1437a8edd,1L,0.396157
uuid-2336103cd2c64dcd98d7f2b1437a8edd,PDL1,0.367966
uuid-2336103cd2c64dcd98d7f2b1437a8edd,RCC,0.346474
uuid-2336103cd2c64dcd98d7f2b1437a8edd,TL stated,0.49837
uuid-2336103cd2c64dcd98d7f2b1437a8edd,2L,0.302731
uuid-2336103cd2c64dcd98d7f2b1437a8edd,PD-L1,0.693321
uuid-2336103cd2c64dcd98d7f2b1437a8edd,PD-L1 testing,0.65555
uuid-2336103cd2c64dcd98d7f2b1437a8edd,testing,0.700625
uuid-2336103cd2c64dcd98d7f2b1437a8edd,PDL1 testing,0.655202
uuid-2336103cd2c64dcd98d7f2b1437a8edd,NSCLC patients,0.541066
uuid-2336103cd2c64dcd98d7f2b1437a8edd,assay,0.506156
uuid-2336103cd2c64dcd98d7f2b1437a8edd,PD-1,0.35619
uuid-2336103cd2c64dcd98d7f2b1437a8edd,biomarker,0.670552
uuid-b3e4eda292b04da68d67f4ce29cc1871,pembro,0.484298
uuid-b3e4eda292b04da68d67f4ce29cc1871,BMS,0.657653
uuid-b3e4eda292b04da68d67f4ce29cc1871,PDL1,0.407726
uuid-b3e4eda292b04da68d67f4ce29cc1871,trial,0.703588
uuid-b3e4eda292b04da68d67f4ce29cc1871,efficacy,0.511432
uuid-b3e4eda292b04da68d67f4ce29cc1871,Merck,0.578248
uuid-b3e4eda292b04da68d67f4ce29cc1871,OS,0.519262
uuid-b3e4eda292b04da68d67f4ce29cc1871,atezo,0.372968
uuid-b3e4eda292b04da68d67f4ce29cc1871,data,0.628287
uuid-b3e4eda292b04da68d67f4ce29cc1871,expressed,0.305568
uuid-b3e4eda292b04da68d67f4ce29cc1871,PFS,0.537634
uuid-b3e4eda292b04da68d67f4ce29cc1871,ORR,0.542971
uuid-b3e4eda292b04da68d67f4ce29cc1871,nivo and pembro,0.569512
uuid-b3e4eda292b04da68d67f4ce29cc1871,impressed,0.401202
uuid-b3e4eda292b04da68d67f4ce29cc1871,vs,0.391766
uuid-b3e4eda292b04da68d67f4ce29cc1871,feels,0.334996
uuid-b3e4eda292b04da68d67f4ce29cc1871,PDL1 expression,0.427607
uuid-13af8f180251412e81eac29de759186a,oncology,0.410976
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,TL,0.301835
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,lung,0.600233
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,1L,0.39618
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,PDL1,0.318053
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,melanoma,0.334581
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,RCC,0.375981
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,TL stated,0.588425
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,2L,0.33293
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,institution,0.514457
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,PD-L1,0.559979
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,PD-L1 testing,0.633002
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,testing,0.719531
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,PDL1 testing,0.778921
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,AI,0.391336
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,NSCLC patients,0.567913
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,SCCHN,0.307778
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,tumor types,0.425159
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,assay,0.425415
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,TL shared,0.350535
uuid-0b8fa105eeb34754b4ea2c1f1e66c694,biomarker,0.457986
uuid-e5136b2062904c6291d3dc10700215fb,Nivo,0.376792
uuid-e5136b2062904c6291d3dc10700215fb,pembro,0.481394
uuid-e5136b2062904c6291d3dc10700215fb,trial,0.583576
uuid-e5136b2062904c6291d3dc10700215fb,efficacy,0.565705
uuid-e5136b2062904c6291d3dc10700215fb,combination,0.384071
uuid-e5136b2062904c6291d3dc10700215fb,Ipi,0.56755
uuid-e5136b2062904c6291d3dc10700215fb,OS,0.376885
uuid-e5136b2062904c6291d3dc10700215fb,atezo,0.409934
uuid-e5136b2062904c6291d3dc10700215fb,data,0.681538
uuid-e5136b2062904c6291d3dc10700215fb,combo,0.410041
uuid-e5136b2062904c6291d3dc10700215fb,indication,0.300466
uuid-e5136b2062904c6291d3dc10700215fb,PFS,0.305268
uuid-e5136b2062904c6291d3dc10700215fb,ORR,0.499872
uuid-e5136b2062904c6291d3dc10700215fb,nivo and pembro,0.377374
uuid-e5136b2062904c6291d3dc10700215fb,impressed,0.590749
uuid-e5136b2062904c6291d3dc10700215fb,vs,0.362286
uuid-e5136b2062904c6291d3dc10700215fb,SCLC,0.462573
uuid-e5136b2062904c6291d3dc10700215fb,feels,0.310085
uuid-c009cb85f1a049888b4cb8fb7f219d5a,tumor,0.336138
uuid-1ed3f11b03f1485e989afc705452f4c8,Nivo,0.304975
uuid-1ed3f11b03f1485e989afc705452f4c8,PDL1,0.325775
uuid-1ed3f11b03f1485e989afc705452f4c8,trial,0.345489
uuid-1ed3f11b03f1485e989afc705452f4c8,efficacy,0.519891
uuid-1ed3f11b03f1485e989afc705452f4c8,discussed,0.346615
uuid-1ed3f11b03f1485e989afc705452f4c8,OS,0.605257
uuid-1ed3f11b03f1485e989afc705452f4c8,regards,0.350567
uuid-1ed3f11b03f1485e989afc705452f4c8,data,0.528932
uuid-1ed3f11b03f1485e989afc705452f4c8,PFS,0.607204
uuid-1ed3f11b03f1485e989afc705452f4c8,ORR,0.59391
uuid-1ed3f11b03f1485e989afc705452f4c8,nivo and pembro,0.391159
uuid-1ed3f11b03f1485e989afc705452f4c8,impressed,0.380869
uuid-1ed3f11b03f1485e989afc705452f4c8,PDL1 expression,0.378205
uuid-dcb420f9f8b148bfaa4b461269c48c6c,TL,0.668531
uuid-dcb420f9f8b148bfaa4b461269c48c6c,PDL1,0.426815
uuid-dcb420f9f8b148bfaa4b461269c48c6c,TL stated,0.306956
uuid-dcb420f9f8b148bfaa4b461269c48c6c,Merck,0.379015
uuid-dcb420f9f8b148bfaa4b461269c48c6c,institution,0.323736
uuid-dcb420f9f8b148bfaa4b461269c48c6c,PD-L1,0.79469
uuid-dcb420f9f8b148bfaa4b461269c48c6c,approval,0.312767
uuid-dcb420f9f8b148bfaa4b461269c48c6c,atezo,0.342532
uuid-dcb420f9f8b148bfaa4b461269c48c6c,PD-L1 testing,0.806523
uuid-dcb420f9f8b148bfaa4b461269c48c6c,testing,0.791393
uuid-dcb420f9f8b148bfaa4b461269c48c6c,PDL1 testing,0.535318
uuid-dcb420f9f8b148bfaa4b461269c48c6c,NSCLC patients,0.506016
uuid-dcb420f9f8b148bfaa4b461269c48c6c,assay,0.880243
uuid-dcb420f9f8b148bfaa4b461269c48c6c,biomarker,0.304611
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,Nivo,0.370322
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,patients,0.648815
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,nivolumab,0.366088
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,regimen,0.341299
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,treated,0.37979
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,pts,0.489331
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,monotherapy,0.322199
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,treatment,0.346544
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,using nivo,0.419443
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,progression,0.382966
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,chemotherapy,0.328788
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,RTL stated,0.344014
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,option,0.300267
uuid-4e8ae766e1ee4ed3a466bd32ab5813ba,bladder,0.444453
uuid-dd050258c1ca4682a9320f5c4ec5a753,TL,0.425988
uuid-dd050258c1ca4682a9320f5c4ec5a753,commented,0.389761
uuid-dd050258c1ca4682a9320f5c4ec5a753,TL stated,0.471528
uuid-dd050258c1ca4682a9320f5c4ec5a753,PD-L1,0.565642
uuid-dd050258c1ca4682a9320f5c4ec5a753,PD-L1 testing,0.642224
uuid-dd050258c1ca4682a9320f5c4ec5a753,testing,0.638918
uuid-dd050258c1ca4682a9320f5c4ec5a753,PDL1 testing,0.636454
uuid-dd050258c1ca4682a9320f5c4ec5a753,NSCLC patients,0.607876
uuid-dd050258c1ca4682a9320f5c4ec5a753,SCCHN,0.440936
uuid-dd050258c1ca4682a9320f5c4ec5a753,tumor types,0.369883
uuid-dd050258c1ca4682a9320f5c4ec5a753,assay,0.365162
uuid-dd050258c1ca4682a9320f5c4ec5a753,Regional TL,0.437612
uuid-dd050258c1ca4682a9320f5c4ec5a753,biomarker,0.375837
uuid-598de71a5472497982d3ca711aefc6b4,Nivo,0.629791
uuid-598de71a5472497982d3ca711aefc6b4,pembro,0.519784
uuid-598de71a5472497982d3ca711aefc6b4,dose,0.629032
uuid-598de71a5472497982d3ca711aefc6b4,toxicity,0.431688
uuid-598de71a5472497982d3ca711aefc6b4,efficacy,0.418497
uuid-598de71a5472497982d3ca711aefc6b4,regimen,0.391465
uuid-598de71a5472497982d3ca711aefc6b4,combination,0.516679
uuid-598de71a5472497982d3ca711aefc6b4,chemo,0.346779
uuid-598de71a5472497982d3ca711aefc6b4,2L,0.312239
uuid-598de71a5472497982d3ca711aefc6b4,Ipi,0.839157
uuid-598de71a5472497982d3ca711aefc6b4,atezo,0.443441
uuid-598de71a5472497982d3ca711aefc6b4,preferred,0.350179
uuid-598de71a5472497982d3ca711aefc6b4,monotherapy,0.447824
uuid-598de71a5472497982d3ca711aefc6b4,using nivo,0.394141
uuid-598de71a5472497982d3ca711aefc6b4,combo,0.503538
uuid-598de71a5472497982d3ca711aefc6b4,vs,0.563209
uuid-598de71a5472497982d3ca711aefc6b4,SCLC,0.334668
uuid-598de71a5472497982d3ca711aefc6b4,flat dosing,0.4086
uuid-42f93b8f24ed4454a171fef8a01c75e1,trial,0.475555
uuid-42f93b8f24ed4454a171fef8a01c75e1,efficacy,0.343362
uuid-42f93b8f24ed4454a171fef8a01c75e1,chemo,0.30244
uuid-42f93b8f24ed4454a171fef8a01c75e1,OS,0.672152
uuid-42f93b8f24ed4454a171fef8a01c75e1,data,0.478327
uuid-42f93b8f24ed4454a171fef8a01c75e1,PFS,0.703478
uuid-42f93b8f24ed4454a171fef8a01c75e1,ORR,0.612867
uuid-42f93b8f24ed4454a171fef8a01c75e1,chemotherapy,0.360884
uuid-42f93b8f24ed4454a171fef8a01c75e1,impressed,0.401536
uuid-42f93b8f24ed4454a171fef8a01c75e1,feels,0.301928
uuid-b4cb5308a2dc4040a693b04181cbef24,RTL,0.628324
uuid-b4cb5308a2dc4040a693b04181cbef24,nivolumab,0.349579
uuid-b4cb5308a2dc4040a693b04181cbef24,BMS,0.431797
uuid-b4cb5308a2dc4040a693b04181cbef24,trial,0.548216
uuid-b4cb5308a2dc4040a693b04181cbef24,NTL,0.420225
uuid-b4cb5308a2dc4040a693b04181cbef24,shared,0.330817
uuid-b4cb5308a2dc4040a693b04181cbef24,commented,0.312722
uuid-b4cb5308a2dc4040a693b04181cbef24,stated,0.518929
uuid-b4cb5308a2dc4040a693b04181cbef24,mentioned,0.309627
uuid-b4cb5308a2dc4040a693b04181cbef24,clinical trials,0.487149
uuid-b4cb5308a2dc4040a693b04181cbef24,SCCHN,0.405289
uuid-b4cb5308a2dc4040a693b04181cbef24,impressed,0.436239
uuid-b4cb5308a2dc4040a693b04181cbef24,LTL,0.403795
uuid-b4cb5308a2dc4040a693b04181cbef24,Regional TL,0.461945
uuid-b4cb5308a2dc4040a693b04181cbef24,RTL stated,0.359519
uuid-b4cb5308a2dc4040a693b04181cbef24,bladder,0.370321
uuid-dcdf2d15ceee4f41bb05625d319228d5,RTL,0.307425
uuid-dcdf2d15ceee4f41bb05625d319228d5,lung,0.526149
uuid-dcdf2d15ceee4f41bb05625d319228d5,NTL,0.342355
uuid-dcdf2d15ceee4f41bb05625d319228d5,melanoma,0.418552
uuid-dcdf2d15ceee4f41bb05625d319228d5,commented,0.389596
uuid-dcdf2d15ceee4f41bb05625d319228d5,RCC,0.465624
uuid-dcdf2d15ceee4f41bb05625d319228d5,TL stated,0.436381
uuid-dcdf2d15ceee4f41bb05625d319228d5,stated,0.456596
uuid-dcdf2d15ceee4f41bb05625d319228d5,SCCHN,0.413081
uuid-dcdf2d15ceee4f41bb05625d319228d5,ASCO,0.439165
uuid-dcdf2d15ceee4f41bb05625d319228d5,impressed,0.391782
uuid-dcdf2d15ceee4f41bb05625d319228d5,TLs,0.35432
uuid-dcdf2d15ceee4f41bb05625d319228d5,SCLC,0.338886
uuid-dcdf2d15ceee4f41bb05625d319228d5,Regional TL,0.46041
uuid-dcdf2d15ceee4f41bb05625d319228d5,TL shared,0.363089
uuid-dcdf2d15ceee4f41bb05625d319228d5,bladder,0.43079
uuid-0c1287ebb5644254abe2786c8c5eb0f3,therapy,0.302318
uuid-0c1287ebb5644254abe2786c8c5eb0f3,treated,0.431949
uuid-0c1287ebb5644254abe2786c8c5eb0f3,treatment,0.400555
uuid-0c1287ebb5644254abe2786c8c5eb0f3,RTL stated,0.343122
uuid-0c1287ebb5644254abe2786c8c5eb0f3,bladder,0.313766
uuid-ba55ae65a50647f8a3b19bdd7619317e,pembro,0.384102
uuid-ba55ae65a50647f8a3b19bdd7619317e,lung,0.369357
uuid-ba55ae65a50647f8a3b19bdd7619317e,1L,0.613909
uuid-ba55ae65a50647f8a3b19bdd7619317e,regimen,0.302304
uuid-ba55ae65a50647f8a3b19bdd7619317e,RCC,0.52666
uuid-ba55ae65a50647f8a3b19bdd7619317e,TL stated,0.467536
uuid-ba55ae65a50647f8a3b19bdd7619317e,2L,0.68457
uuid-ba55ae65a50647f8a3b19bdd7619317e,agents,0.483532
uuid-ba55ae65a50647f8a3b19bdd7619317e,atezo,0.429793
uuid-ba55ae65a50647f8a3b19bdd7619317e,preferred,0.696865
uuid-ba55ae65a50647f8a3b19bdd7619317e,monotherapy,0.516996
uuid-ba55ae65a50647f8a3b19bdd7619317e,using nivo,0.489058
uuid-ba55ae65a50647f8a3b19bdd7619317e,combo,0.32609
uuid-ba55ae65a50647f8a3b19bdd7619317e,PDL1 testing,0.414441
uuid-ba55ae65a50647f8a3b19bdd7619317e,NSCLC patients,0.324055
uuid-ba55ae65a50647f8a3b19bdd7619317e,approved,0.399215
uuid-ba55ae65a50647f8a3b19bdd7619317e,SCCHN,0.35492
uuid-ba55ae65a50647f8a3b19bdd7619317e,tumor types,0.344448
uuid-ba55ae65a50647f8a3b19bdd7619317e,RTL stated,0.532703
uuid-ba55ae65a50647f8a3b19bdd7619317e,TL shared,0.450435
uuid-ba55ae65a50647f8a3b19bdd7619317e,option,0.551796
uuid-49644533475a4610a7579acd3b7c3a03,patients,0.441939
uuid-49644533475a4610a7579acd3b7c3a03,pembro,0.36506
uuid-49644533475a4610a7579acd3b7c3a03,1L,0.587451
uuid-49644533475a4610a7579acd3b7c3a03,RCC,0.311585
uuid-49644533475a4610a7579acd3b7c3a03,TL stated,0.306874
uuid-49644533475a4610a7579acd3b7c3a03,2L,0.569046
uuid-49644533475a4610a7579acd3b7c3a03,pts,0.349364
uuid-49644533475a4610a7579acd3b7c3a03,agents,0.303476
uuid-49644533475a4610a7579acd3b7c3a03,PD-L1,0.451958
uuid-49644533475a4610a7579acd3b7c3a03,approval,0.424198
uuid-49644533475a4610a7579acd3b7c3a03,atezo,0.347532
uuid-49644533475a4610a7579acd3b7c3a03,preferred,0.563617
uuid-49644533475a4610a7579acd3b7c3a03,PD-L1 testing,0.346938
uuid-49644533475a4610a7579acd3b7c3a03,testing,0.494684
uuid-49644533475a4610a7579acd3b7c3a03,monotherapy,0.449834
uuid-49644533475a4610a7579acd3b7c3a03,using nivo,0.451033
uuid-49644533475a4610a7579acd3b7c3a03,PDL1 testing,0.534883
uuid-49644533475a4610a7579acd3b7c3a03,NSCLC patients,0.604579
uuid-49644533475a4610a7579acd3b7c3a03,approved,0.49145
uuid-49644533475a4610a7579acd3b7c3a03,tumor types,0.382369
uuid-49644533475a4610a7579acd3b7c3a03,label,0.324363
uuid-49644533475a4610a7579acd3b7c3a03,PD-1,0.33193
uuid-49644533475a4610a7579acd3b7c3a03,RTL stated,0.377057
uuid-49644533475a4610a7579acd3b7c3a03,option,0.541436
uuid-6c16f0a7cc7747e89b791ccc97764789,lung,0.332524
uuid-6c16f0a7cc7747e89b791ccc97764789,NSCLC,0.40375
uuid-6c16f0a7cc7747e89b791ccc97764789,1L,0.622218
uuid-6c16f0a7cc7747e89b791ccc97764789,regimen,0.411166
uuid-6c16f0a7cc7747e89b791ccc97764789,RCC,0.529933
uuid-6c16f0a7cc7747e89b791ccc97764789,TL stated,0.413776
uuid-6c16f0a7cc7747e89b791ccc97764789,combination,0.569108
uuid-6c16f0a7cc7747e89b791ccc97764789,chemo,0.466575
uuid-6c16f0a7cc7747e89b791ccc97764789,2L,0.579763
uuid-6c16f0a7cc7747e89b791ccc97764789,IO,0.664754
uuid-6c16f0a7cc7747e89b791ccc97764789,agents,0.506126
uuid-6c16f0a7cc7747e89b791ccc97764789,preferred,0.490722
uuid-6c16f0a7cc7747e89b791ccc97764789,monotherapy,0.638328
uuid-6c16f0a7cc7747e89b791ccc97764789,using nivo,0.34856
uuid-6c16f0a7cc7747e89b791ccc97764789,combo,0.677808
uuid-6c16f0a7cc7747e89b791ccc97764789,PD1,0.448814
uuid-6c16f0a7cc7747e89b791ccc97764789,believes,0.372671
uuid-6c16f0a7cc7747e89b791ccc97764789,chemotherapy,0.34873
uuid-6c16f0a7cc7747e89b791ccc97764789,PD-1,0.304648
uuid-6c16f0a7cc7747e89b791ccc97764789,RTL stated,0.443563
uuid-6c16f0a7cc7747e89b791ccc97764789,TL shared,0.371036
uuid-6c16f0a7cc7747e89b791ccc97764789,option,0.500255
uuid-e5d2e46a990f46ba8f40d9b6537c0cfa,RTL stated,0.417188
uuid-e5d2e46a990f46ba8f40d9b6537c0cfa,bladder,0.379999
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,Nivo,0.481435
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,patients,0.764192
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,Opdivo,0.356282
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,therapy,0.510735
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,nivolumab,0.675778
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,1L,0.30977
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,regimen,0.526914
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,treated,0.641912
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,RCC,0.322077
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,combination,0.455012
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,chemo,0.44854
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,2L,0.386355
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,pts,0.567456
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,approval,0.31216
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,preferred,0.405138
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,monotherapy,0.538986
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,treatment,0.548178
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,using nivo,0.532719
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,combo,0.37295
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,PD1,0.392232
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,approved,0.333695
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,progression,0.500471
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,chemotherapy,0.449912
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,respond,0.370331
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,RTL stated,0.46865
uuid-b2c0a254a2ed4f0dad3c8104b486ee14,option,0.445082
uuid-ba26614262514bb680d2aeee61957031,RTL,0.300329
uuid-ba26614262514bb680d2aeee61957031,lung,0.323403
uuid-ba26614262514bb680d2aeee61957031,NTL,0.301268
uuid-ba26614262514bb680d2aeee61957031,commented,0.458596
uuid-ba26614262514bb680d2aeee61957031,OS,0.692958
uuid-ba26614262514bb680d2aeee61957031,regards,0.313138
uuid-ba26614262514bb680d2aeee61957031,data,0.577893
uuid-ba26614262514bb680d2aeee61957031,expressed,0.332713
uuid-ba26614262514bb680d2aeee61957031,PFS,0.645077
uuid-ba26614262514bb680d2aeee61957031,ORR,0.56389
uuid-ba26614262514bb680d2aeee61957031,ASCO,0.509803
uuid-ba26614262514bb680d2aeee61957031,impressed,0.574778
uuid-6c1a73acca3f47d39f4c6443d7539d6b,Nivo,0.567486
uuid-6c1a73acca3f47d39f4c6443d7539d6b,pembro,0.335012
uuid-6c1a73acca3f47d39f4c6443d7539d6b,toxicity,0.400295
uuid-6c1a73acca3f47d39f4c6443d7539d6b,efficacy,0.680857
uuid-6c1a73acca3f47d39f4c6443d7539d6b,regimen,0.455625
uuid-6c1a73acca3f47d39f4c6443d7539d6b,combination,0.460125
uuid-6c1a73acca3f47d39f4c6443d7539d6b,chemo,0.664746
uuid-6c1a73acca3f47d39f4c6443d7539d6b,agents,0.42744
uuid-6c1a73acca3f47d39f4c6443d7539d6b,Ipi,0.419289
uuid-6c1a73acca3f47d39f4c6443d7539d6b,OS,0.440714
uuid-6c1a73acca3f47d39f4c6443d7539d6b,monotherapy,0.516739
uuid-6c1a73acca3f47d39f4c6443d7539d6b,response,0.300507
uuid-6c1a73acca3f47d39f4c6443d7539d6b,data,0.33227
uuid-6c1a73acca3f47d39f4c6443d7539d6b,combo,0.447884
uuid-6c1a73acca3f47d39f4c6443d7539d6b,PFS,0.435433
uuid-6c1a73acca3f47d39f4c6443d7539d6b,PD1,0.415687
uuid-6c1a73acca3f47d39f4c6443d7539d6b,ORR,0.485497
uuid-6c1a73acca3f47d39f4c6443d7539d6b,nivo and pembro,0.446634
uuid-6c1a73acca3f47d39f4c6443d7539d6b,believes,0.463502
uuid-6c1a73acca3f47d39f4c6443d7539d6b,chemotherapy,0.578546
uuid-6c1a73acca3f47d39f4c6443d7539d6b,impressed,0.306933
uuid-6c1a73acca3f47d39f4c6443d7539d6b,vs,0.389185
uuid-6c1a73acca3f47d39f4c6443d7539d6b,feels,0.544967
uuid-6c1a73acca3f47d39f4c6443d7539d6b,option,0.403887
uuid-8abb1191425f46f68a18f086d1b9b9da,tumor,0.547805
uuid-f6b665865efc44b7a64414510d40b41a,chemo,0.311068
uuid-f6b665865efc44b7a64414510d40b41a,tumor,0.762841
uuid-f6b665865efc44b7a64414510d40b41a,pts,0.341315
uuid-f6b665865efc44b7a64414510d40b41a,tumor types,0.324029
uuid-b926a72f62ed408c967aa26db1054fbc,patients,0.706127
uuid-b926a72f62ed408c967aa26db1054fbc,Opdivo,0.416885
uuid-b926a72f62ed408c967aa26db1054fbc,therapy,0.350597
uuid-b926a72f62ed408c967aa26db1054fbc,nivolumab,0.357022
uuid-b926a72f62ed408c967aa26db1054fbc,treated,0.398674
uuid-b926a72f62ed408c967aa26db1054fbc,pts,0.487742
uuid-b926a72f62ed408c967aa26db1054fbc,treatment,0.405438
uuid-b926a72f62ed408c967aa26db1054fbc,cHL,0.416893
uuid-b926a72f62ed408c967aa26db1054fbc,progression,0.505521
uuid-b926a72f62ed408c967aa26db1054fbc,respond,0.352381
uuid-dc55de3950e949ce94250e717e396868,RTL,0.365527
uuid-dc55de3950e949ce94250e717e396868,BMS,0.526439
uuid-dc55de3950e949ce94250e717e396868,trial,0.558569
uuid-dc55de3950e949ce94250e717e396868,efficacy,0.300085
uuid-dc55de3950e949ce94250e717e396868,discussed,0.382358
uuid-dc55de3950e949ce94250e717e396868,commented,0.519132
uuid-dc55de3950e949ce94250e717e396868,Merck,0.428812
uuid-dc55de3950e949ce94250e717e396868,stated,0.432543
uuid-dc55de3950e949ce94250e717e396868,OS,0.473817
uuid-dc55de3950e949ce94250e717e396868,regards,0.373067
uuid-dc55de3950e949ce94250e717e396868,data,0.683313
uuid-dc55de3950e949ce94250e717e396868,expressed,0.39771
uuid-dc55de3950e949ce94250e717e396868,PFS,0.405932
uuid-dc55de3950e949ce94250e717e396868,ORR,0.440663
uuid-dc55de3950e949ce94250e717e396868,SCCHN,0.306982
uuid-dc55de3950e949ce94250e717e396868,nivo and pembro,0.310274
uuid-dc55de3950e949ce94250e717e396868,ASCO,0.390728
uuid-dc55de3950e949ce94250e717e396868,impressed,0.609194
uuid-dc55de3950e949ce94250e717e396868,TLs,0.324617
uuid-dc55de3950e949ce94250e717e396868,feels,0.412316
uuid-dc55de3950e949ce94250e717e396868,Regional TL,0.331834
uuid-ff581d114f3f437bbc6297371f055124,PDL1,0.338289
uuid-ff581d114f3f437bbc6297371f055124,PD-L1,0.324502
uuid-ff581d114f3f437bbc6297371f055124,PD-L1 testing,0.361664
uuid-ff581d114f3f437bbc6297371f055124,testing,0.398486
uuid-ff581d114f3f437bbc6297371f055124,PDL1 testing,0.341561
uuid-1ca63c9ba57c43bca0c937dbbdd629b1,TL,0.318776
uuid-1ca63c9ba57c43bca0c937dbbdd629b1,TL stated,0.382404
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,TL,0.408417
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,PDL1,0.632359
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,commented,0.362896
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,Merck,0.482845
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,PD-L1,0.608377
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,OS,0.375329
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,PD-L1 testing,0.424383
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,testing,0.493489
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,data,0.636566
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,PDL1 testing,0.352056
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,PFS,0.334785
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,NSCLC patients,0.355568
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,ORR,0.353605
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,nivo and pembro,0.300206
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,impressed,0.442956
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,assay,0.543947
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,PDL1 expression,0.474997
uuid-9bcceae8a6bd4c7aaf5579c4e8296623,biomarker,0.449978
uuid-82d4c48502ba425b9d35369c847df1e8,patients,0.466511
uuid-82d4c48502ba425b9d35369c847df1e8,Opdivo,0.36064
uuid-82d4c48502ba425b9d35369c847df1e8,therapy,0.310975
uuid-82d4c48502ba425b9d35369c847df1e8,nivolumab,0.456456
uuid-82d4c48502ba425b9d35369c847df1e8,treated,0.467113
uuid-82d4c48502ba425b9d35369c847df1e8,pts,0.413272
uuid-82d4c48502ba425b9d35369c847df1e8,stated,0.352134
uuid-82d4c48502ba425b9d35369c847df1e8,treatment,0.345657
uuid-82d4c48502ba425b9d35369c847df1e8,response,0.382469
uuid-82d4c48502ba425b9d35369c847df1e8,progression,0.414382
uuid-cc97516b8dba4a129b86deada30e95ba,patients,0.407108
uuid-cc97516b8dba4a129b86deada30e95ba,toxicity,0.493415
uuid-cc97516b8dba4a129b86deada30e95ba,regimen,0.378322
uuid-cc97516b8dba4a129b86deada30e95ba,treated,0.512026
uuid-cc97516b8dba4a129b86deada30e95ba,treatment,0.520891
uuid-cc97516b8dba4a129b86deada30e95ba,progression,0.394944
uuid-cc97516b8dba4a129b86deada30e95ba,respond,0.401657
uuid-cc97516b8dba4a129b86deada30e95ba,TL shared,0.305841
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,RTL,0.399013
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,BMS,0.500507
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,trial,0.756061
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,NTL,0.340037
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,shared,0.380545
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,commented,0.330345
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,Merck,0.516286
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,stated,0.343718
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,approval,0.331836
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,data,0.310514
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,mentioned,0.348031
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,clinical trials,0.505778
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,impressed,0.311474
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,Regional TL,0.330554
uuid-f9203a26c6f84a88b8b8dd0a3995e00a,bladder,0.38782
uuid-ef198b1ef9a448bebe53bfadb03cbff8,Nivo,0.346833
uuid-ef198b1ef9a448bebe53bfadb03cbff8,patients,0.664381
uuid-ef198b1ef9a448bebe53bfadb03cbff8,therapy,0.348499
uuid-ef198b1ef9a448bebe53bfadb03cbff8,regimen,0.386034
uuid-ef198b1ef9a448bebe53bfadb03cbff8,treated,0.328403
uuid-ef198b1ef9a448bebe53bfadb03cbff8,chemo,0.427873
uuid-ef198b1ef9a448bebe53bfadb03cbff8,pts,0.547879
uuid-ef198b1ef9a448bebe53bfadb03cbff8,monotherapy,0.386095
uuid-ef198b1ef9a448bebe53bfadb03cbff8,treatment,0.465208
uuid-ef198b1ef9a448bebe53bfadb03cbff8,response,0.354975
uuid-ef198b1ef9a448bebe53bfadb03cbff8,progression,0.469313
uuid-ef198b1ef9a448bebe53bfadb03cbff8,chemotherapy,0.404681
uuid-ef198b1ef9a448bebe53bfadb03cbff8,respond,0.440469
uuid-ef198b1ef9a448bebe53bfadb03cbff8,feels,0.426177
uuid-ef198b1ef9a448bebe53bfadb03cbff8,option,0.466334
uuid-49acd39ca5d441cab52c7a54f9920bfe,Nivo,0.373445
uuid-49acd39ca5d441cab52c7a54f9920bfe,dose,0.387671
uuid-49acd39ca5d441cab52c7a54f9920bfe,regimen,0.375425
uuid-49acd39ca5d441cab52c7a54f9920bfe,combination,0.489882
uuid-49acd39ca5d441cab52c7a54f9920bfe,chemo,0.430203
uuid-49acd39ca5d441cab52c7a54f9920bfe,IO,0.453381
uuid-49acd39ca5d441cab52c7a54f9920bfe,agents,0.300433
uuid-49acd39ca5d441cab52c7a54f9920bfe,Ipi,0.530005
uuid-49acd39ca5d441cab52c7a54f9920bfe,preferred,0.325019
uuid-49acd39ca5d441cab52c7a54f9920bfe,monotherapy,0.396906
uuid-49acd39ca5d441cab52c7a54f9920bfe,combo,0.489575
uuid-49acd39ca5d441cab52c7a54f9920bfe,believes,0.300032
uuid-49acd39ca5d441cab52c7a54f9920bfe,chemotherapy,0.394663
uuid-49acd39ca5d441cab52c7a54f9920bfe,vs,0.432079
uuid-49acd39ca5d441cab52c7a54f9920bfe,feels,0.365468
uuid-49acd39ca5d441cab52c7a54f9920bfe,option,0.340637
uuid-eba1e44cc420478d8b53a31eaa3e3674,patients,0.64548
uuid-eba1e44cc420478d8b53a31eaa3e3674,Opdivo,0.4778
uuid-eba1e44cc420478d8b53a31eaa3e3674,therapy,0.453525
uuid-eba1e44cc420478d8b53a31eaa3e3674,nivolumab,0.54089
uuid-eba1e44cc420478d8b53a31eaa3e3674,regimen,0.369073
uuid-eba1e44cc420478d8b53a31eaa3e3674,treated,0.452498
uuid-eba1e44cc420478d8b53a31eaa3e3674,combination,0.364345
uuid-eba1e44cc420478d8b53a31eaa3e3674,2L,0.326616
uuid-eba1e44cc420478d8b53a31eaa3e3674,pts,0.506599
uuid-eba1e44cc420478d8b53a31eaa3e3674,stated,0.313048
uuid-eba1e44cc420478d8b53a31eaa3e3674,approval,0.327156
uuid-eba1e44cc420478d8b53a31eaa3e3674,preferred,0.342498
uuid-eba1e44cc420478d8b53a31eaa3e3674,monotherapy,0.437159
uuid-eba1e44cc420478d8b53a31eaa3e3674,treatment,0.470696
uuid-eba1e44cc420478d8b53a31eaa3e3674,using nivo,0.441043
uuid-eba1e44cc420478d8b53a31eaa3e3674,combo,0.305097
uuid-eba1e44cc420478d8b53a31eaa3e3674,PD1,0.313541
uuid-eba1e44cc420478d8b53a31eaa3e3674,approved,0.355491
uuid-eba1e44cc420478d8b53a31eaa3e3674,progression,0.495011
uuid-eba1e44cc420478d8b53a31eaa3e3674,chemotherapy,0.309317
uuid-eba1e44cc420478d8b53a31eaa3e3674,RTL stated,0.391778
uuid-eba1e44cc420478d8b53a31eaa3e3674,option,0.485823
uuid-b89a214cf8154505992799a82acafe9c,Nivo,0.421172
uuid-b89a214cf8154505992799a82acafe9c,pembro,0.51774
uuid-b89a214cf8154505992799a82acafe9c,dose,0.822299
uuid-b89a214cf8154505992799a82acafe9c,efficacy,0.402497
uuid-b89a214cf8154505992799a82acafe9c,Ipi,0.536354
uuid-b89a214cf8154505992799a82acafe9c,atezo,0.575673
uuid-b89a214cf8154505992799a82acafe9c,preferred,0.348827
uuid-b89a214cf8154505992799a82acafe9c,vs,0.722363
uuid-b89a214cf8154505992799a82acafe9c,Keytruda,0.351014
uuid-b89a214cf8154505992799a82acafe9c,flat dosing,0.638072
uuid-46b30df0b95541938f492f2e214cd2a9,BMS,0.362976
uuid-46b30df0b95541938f492f2e214cd2a9,PDL1,0.365149
uuid-46b30df0b95541938f492f2e214cd2a9,trial,0.446253
uuid-46b30df0b95541938f492f2e214cd2a9,efficacy,0.499402
uuid-46b30df0b95541938f492f2e214cd2a9,commented,0.448957
uuid-46b30df0b95541938f492f2e214cd2a9,stated,0.383662
uuid-46b30df0b95541938f492f2e214cd2a9,OS,0.612315
uuid-46b30df0b95541938f492f2e214cd2a9,data,0.859884
uuid-46b30df0b95541938f492f2e214cd2a9,PFS,0.56878
uuid-46b30df0b95541938f492f2e214cd2a9,ORR,0.621223
uuid-46b30df0b95541938f492f2e214cd2a9,nivo and pembro,0.429346
uuid-46b30df0b95541938f492f2e214cd2a9,ASCO,0.357363
uuid-46b30df0b95541938f492f2e214cd2a9,impressed,0.694654
uuid-46b30df0b95541938f492f2e214cd2a9,feels,0.515914
uuid-46b30df0b95541938f492f2e214cd2a9,PDL1 expression,0.308177
uuid-2dd0d9921114439dae81cc64e56bf4c1,patients,0.632619
uuid-2dd0d9921114439dae81cc64e56bf4c1,Opdivo,0.362511
uuid-2dd0d9921114439dae81cc64e56bf4c1,toxicity,0.520216
uuid-2dd0d9921114439dae81cc64e56bf4c1,regimen,0.454317
uuid-2dd0d9921114439dae81cc64e56bf4c1,treated,0.459783
uuid-2dd0d9921114439dae81cc64e56bf4c1,pts,0.316502
uuid-2dd0d9921114439dae81cc64e56bf4c1,treatment,0.627398
uuid-2dd0d9921114439dae81cc64e56bf4c1,progression,0.453372
uuid-2dd0d9921114439dae81cc64e56bf4c1,respond,0.449012
uuid-85fda3b6de88417390cccca80d9d2ce3,pembro,0.57493
uuid-85fda3b6de88417390cccca80d9d2ce3,RTL,0.4688
uuid-85fda3b6de88417390cccca80d9d2ce3,trial,0.303007
uuid-85fda3b6de88417390cccca80d9d2ce3,shared,0.383146
uuid-85fda3b6de88417390cccca80d9d2ce3,commented,0.4649
uuid-85fda3b6de88417390cccca80d9d2ce3,RCC,0.36523
uuid-85fda3b6de88417390cccca80d9d2ce3,2L,0.357935
uuid-85fda3b6de88417390cccca80d9d2ce3,Ipi,0.301526
uuid-85fda3b6de88417390cccca80d9d2ce3,stated,0.545373
uuid-85fda3b6de88417390cccca80d9d2ce3,approval,0.534616
uuid-85fda3b6de88417390cccca80d9d2ce3,atezo,0.545005
uuid-85fda3b6de88417390cccca80d9d2ce3,preferred,0.366046
uuid-85fda3b6de88417390cccca80d9d2ce3,using nivo,0.490788
uuid-85fda3b6de88417390cccca80d9d2ce3,data,0.501041
uuid-85fda3b6de88417390cccca80d9d2ce3,expressed,0.318797
uuid-85fda3b6de88417390cccca80d9d2ce3,mentioned,0.347623
uuid-85fda3b6de88417390cccca80d9d2ce3,clinical trials,0.366785
uuid-85fda3b6de88417390cccca80d9d2ce3,indication,0.58427
uuid-85fda3b6de88417390cccca80d9d2ce3,approved,0.473204
uuid-85fda3b6de88417390cccca80d9d2ce3,SCCHN,0.626132
uuid-85fda3b6de88417390cccca80d9d2ce3,HCP,0.374896
uuid-85fda3b6de88417390cccca80d9d2ce3,impressed,0.514622
uuid-85fda3b6de88417390cccca80d9d2ce3,label,0.38261
uuid-85fda3b6de88417390cccca80d9d2ce3,LTL,0.5774
uuid-85fda3b6de88417390cccca80d9d2ce3,TLs,0.524812
uuid-85fda3b6de88417390cccca80d9d2ce3,SCLC,0.367623
uuid-85fda3b6de88417390cccca80d9d2ce3,Regional TL,0.526295
uuid-85fda3b6de88417390cccca80d9d2ce3,RTL stated,0.421709
uuid-85fda3b6de88417390cccca80d9d2ce3,bladder,0.466183
uuid-85fda3b6de88417390cccca80d9d2ce3,flat dosing,0.444309
uuid-426cc31762c94915b0a4211127fc49b8,feels,0.333984
uuid-426cc31762c94915b0a4211127fc49b8,PDL1 expression,0.347696
uuid-426cc31762c94915b0a4211127fc49b8,bladder,0.363472
uuid-5f1bc7f2d9f1409582d5bd02c26d21ab,patients,0.388166
uuid-5f1bc7f2d9f1409582d5bd02c26d21ab,Opdivo,0.460152
uuid-5f1bc7f2d9f1409582d5bd02c26d21ab,therapy,0.330277
uuid-5f1bc7f2d9f1409582d5bd02c26d21ab,nivolumab,0.319861
uuid-5f1bc7f2d9f1409582d5bd02c26d21ab,stated,0.302086
uuid-5f1bc7f2d9f1409582d5bd02c26d21ab,using nivo,0.356295
uuid-5f1bc7f2d9f1409582d5bd02c26d21ab,cHL,0.361659
uuid-5f1bc7f2d9f1409582d5bd02c26d21ab,Keytruda,0.324083
uuid-6424e49e8c604a98905f23cf705c5cb5,Nivo,0.423631
uuid-6424e49e8c604a98905f23cf705c5cb5,patients,0.486985
uuid-6424e49e8c604a98905f23cf705c5cb5,pembro,0.452378
uuid-6424e49e8c604a98905f23cf705c5cb5,therapy,0.485774
uuid-6424e49e8c604a98905f23cf705c5cb5,nivolumab,0.385349
uuid-6424e49e8c604a98905f23cf705c5cb5,1L,0.639637
uuid-6424e49e8c604a98905f23cf705c5cb5,regimen,0.300781
uuid-6424e49e8c604a98905f23cf705c5cb5,RCC,0.311829
uuid-6424e49e8c604a98905f23cf705c5cb5,chemo,0.4647
uuid-6424e49e8c604a98905f23cf705c5cb5,2L,0.679953
uuid-6424e49e8c604a98905f23cf705c5cb5,pts,0.358511
uuid-6424e49e8c604a98905f23cf705c5cb5,agents,0.461969
uuid-6424e49e8c604a98905f23cf705c5cb5,approval,0.355229
uuid-6424e49e8c604a98905f23cf705c5cb5,atezo,0.401619
uuid-6424e49e8c604a98905f23cf705c5cb5,preferred,0.721016
uuid-6424e49e8c604a98905f23cf705c5cb5,monotherapy,0.641949
uuid-6424e49e8c604a98905f23cf705c5cb5,treatment,0.376287
uuid-6424e49e8c604a98905f23cf705c5cb5,using nivo,0.609883
uuid-6424e49e8c604a98905f23cf705c5cb5,PDL1 testing,0.320508
uuid-6424e49e8c604a98905f23cf705c5cb5,NSCLC patients,0.386716
uuid-6424e49e8c604a98905f23cf705c5cb5,PD1,0.407097
uuid-6424e49e8c604a98905f23cf705c5cb5,approved,0.436006
uuid-6424e49e8c604a98905f23cf705c5cb5,chemotherapy,0.396806
uuid-6424e49e8c604a98905f23cf705c5cb5,feels,0.359958
uuid-6424e49e8c604a98905f23cf705c5cb5,PD-1,0.33401
uuid-6424e49e8c604a98905f23cf705c5cb5,RTL stated,0.514452
uuid-6424e49e8c604a98905f23cf705c5cb5,option,0.697215
uuid-d7b115d3afbc4902906b1707a14e9d25,RTL,0.589933
uuid-d7b115d3afbc4902906b1707a14e9d25,BMS,0.350191
uuid-d7b115d3afbc4902906b1707a14e9d25,trial,0.385515
uuid-d7b115d3afbc4902906b1707a14e9d25,NTL,0.557131
uuid-d7b115d3afbc4902906b1707a14e9d25,discussed,0.406756
uuid-d7b115d3afbc4902906b1707a14e9d25,shared,0.345872
uuid-d7b115d3afbc4902906b1707a14e9d25,commented,0.693702
uuid-d7b115d3afbc4902906b1707a14e9d25,stated,0.553803
uuid-d7b115d3afbc4902906b1707a14e9d25,OS,0.385171
uuid-d7b115d3afbc4902906b1707a14e9d25,data,0.698723
uuid-d7b115d3afbc4902906b1707a14e9d25,expressed,0.460035
uuid-d7b115d3afbc4902906b1707a14e9d25,mentioned,0.352491
uuid-d7b115d3afbc4902906b1707a14e9d25,PFS,0.314537
uuid-d7b115d3afbc4902906b1707a14e9d25,ORR,0.395993
uuid-d7b115d3afbc4902906b1707a14e9d25,SCCHN,0.431307
uuid-d7b115d3afbc4902906b1707a14e9d25,ASCO,0.653724
uuid-d7b115d3afbc4902906b1707a14e9d25,impressed,0.766268
uuid-d7b115d3afbc4902906b1707a14e9d25,LTL,0.449987
uuid-d7b115d3afbc4902906b1707a14e9d25,TLs,0.452937
uuid-d7b115d3afbc4902906b1707a14e9d25,Regional TL,0.649663
uuid-decf5552c87343f1b8d7f8b258ed30cf,Nivo,0.335598
uuid-decf5552c87343f1b8d7f8b258ed30cf,patients,0.325963
uuid-decf5552c87343f1b8d7f8b258ed30cf,nivolumab,0.302653
uuid-decf5552c87343f1b8d7f8b258ed30cf,pts,0.461707
uuid-decf5552c87343f1b8d7f8b258ed30cf,stated,0.369537
uuid-decf5552c87343f1b8d7f8b258ed30cf,OS,0.32772
uuid-decf5552c87343f1b8d7f8b258ed30cf,PFS,0.318992
uuid-decf5552c87343f1b8d7f8b258ed30cf,ORR,0.403882
uuid-decf5552c87343f1b8d7f8b258ed30cf,impressed,0.439343
uuid-8ffa53ea38b942afa92d56f6af36ed42,Nivo,0.433795
uuid-8ffa53ea38b942afa92d56f6af36ed42,patients,0.344864
uuid-8ffa53ea38b942afa92d56f6af36ed42,nivolumab,0.325072
uuid-8ffa53ea38b942afa92d56f6af36ed42,toxicity,0.321832
uuid-8ffa53ea38b942afa92d56f6af36ed42,regimen,0.410333
uuid-8ffa53ea38b942afa92d56f6af36ed42,combination,0.460153
uuid-8ffa53ea38b942afa92d56f6af36ed42,chemo,0.537299
uuid-8ffa53ea38b942afa92d56f6af36ed42,pts,0.34918
uuid-8ffa53ea38b942afa92d56f6af36ed42,monotherapy,0.394189
uuid-8ffa53ea38b942afa92d56f6af36ed42,response,0.374548
uuid-8ffa53ea38b942afa92d56f6af36ed42,combo,0.363316
uuid-8ffa53ea38b942afa92d56f6af36ed42,PD1,0.335685
uuid-8ffa53ea38b942afa92d56f6af36ed42,chemotherapy,0.538005
uuid-8ffa53ea38b942afa92d56f6af36ed42,option,0.301091
uuid-8ffa53ea38b942afa92d56f6af36ed42,bladder,0.32145
uuid-beb3cc2be820429a92a7419680b327fa,pembro,0.506102
uuid-beb3cc2be820429a92a7419680b327fa,PDL1,0.706247
uuid-beb3cc2be820429a92a7419680b327fa,trial,0.448752
uuid-beb3cc2be820429a92a7419680b327fa,efficacy,0.37553
uuid-beb3cc2be820429a92a7419680b327fa,Merck,0.374898
uuid-beb3cc2be820429a92a7419680b327fa,PD-L1,0.450695
uuid-beb3cc2be820429a92a7419680b327fa,OS,0.369432
uuid-beb3cc2be820429a92a7419680b327fa,atezo,0.412567
uuid-beb3cc2be820429a92a7419680b327fa,testing,0.346832
uuid-beb3cc2be820429a92a7419680b327fa,data,0.419695
uuid-beb3cc2be820429a92a7419680b327fa,PFS,0.399597
uuid-beb3cc2be820429a92a7419680b327fa,NSCLC patients,0.303161
uuid-beb3cc2be820429a92a7419680b327fa,ORR,0.396239
uuid-beb3cc2be820429a92a7419680b327fa,nivo and pembro,0.633818
uuid-beb3cc2be820429a92a7419680b327fa,believes,0.373231
uuid-beb3cc2be820429a92a7419680b327fa,vs,0.370563
uuid-beb3cc2be820429a92a7419680b327fa,assay,0.372711
uuid-beb3cc2be820429a92a7419680b327fa,PDL1 expression,0.613648
uuid-beb3cc2be820429a92a7419680b327fa,biomarker,0.383428
uuid-47a7fcb6c1864d81a996c951dfdb0ab2,patients,0.310862
uuid-47a7fcb6c1864d81a996c951dfdb0ab2,Opdivo,0.387741
uuid-47a7fcb6c1864d81a996c951dfdb0ab2,dose,0.783461
uuid-47a7fcb6c1864d81a996c951dfdb0ab2,toxicity,0.610729
uuid-47a7fcb6c1864d81a996c951dfdb0ab2,regimen,0.401997
uuid-47a7fcb6c1864d81a996c951dfdb0ab2,Ipi,0.3436
uuid-47a7fcb6c1864d81a996c951dfdb0ab2,treatment,0.305509
uuid-47a7fcb6c1864d81a996c951dfdb0ab2,flat dosing,0.536583
uuid-4b9d8d005afa4f2d95f42b44415bb4eb,oncology,0.369639
uuid-4b9d8d005afa4f2d95f42b44415bb4eb,NCCN,0.339938
uuid-8a369a8db1d84264bfee346069844c53,physicians,0.338501
uuid-8a369a8db1d84264bfee346069844c53,preferred,0.404634
uuid-8a369a8db1d84264bfee346069844c53,indication,0.41251
uuid-8a369a8db1d84264bfee346069844c53,oncology,0.31471
uuid-8a369a8db1d84264bfee346069844c53,approved,0.406815
uuid-8a369a8db1d84264bfee346069844c53,option,0.333068
uuid-d29a84ee0a744dddb856cd4e42afab08,pembro,0.412381
uuid-d29a84ee0a744dddb856cd4e42afab08,RTL,0.312618
uuid-d29a84ee0a744dddb856cd4e42afab08,nivolumab,0.428489
uuid-d29a84ee0a744dddb856cd4e42afab08,1L,0.608378
uuid-d29a84ee0a744dddb856cd4e42afab08,regimen,0.310957
uuid-d29a84ee0a744dddb856cd4e42afab08,RCC,0.608577
uuid-d29a84ee0a744dddb856cd4e42afab08,TL stated,0.366988
uuid-d29a84ee0a744dddb856cd4e42afab08,combination,0.50156
uuid-d29a84ee0a744dddb856cd4e42afab08,2L,0.731497
uuid-d29a84ee0a744dddb856cd4e42afab08,agents,0.484046
uuid-d29a84ee0a744dddb856cd4e42afab08,approval,0.305766
uuid-d29a84ee0a744dddb856cd4e42afab08,atezo,0.485046
uuid-d29a84ee0a744dddb856cd4e42afab08,preferred,0.685552
uuid-d29a84ee0a744dddb856cd4e42afab08,monotherapy,0.622495
uuid-d29a84ee0a744dddb856cd4e42afab08,using nivo,0.608314
uuid-d29a84ee0a744dddb856cd4e42afab08,combo,0.540071
uuid-d29a84ee0a744dddb856cd4e42afab08,clinical trials,0.320523
uuid-d29a84ee0a744dddb856cd4e42afab08,PD1,0.334871
uuid-d29a84ee0a744dddb856cd4e42afab08,approved,0.425011
uuid-d29a84ee0a744dddb856cd4e42afab08,SCCHN,0.512411
uuid-d29a84ee0a744dddb856cd4e42afab08,LTL,0.346521
uuid-d29a84ee0a744dddb856cd4e42afab08,TLs,0.467582
uuid-d29a84ee0a744dddb856cd4e42afab08,academic,0.44056
uuid-d29a84ee0a744dddb856cd4e42afab08,Regional TL,0.420866
uuid-d29a84ee0a744dddb856cd4e42afab08,RTL stated,0.70215
uuid-d29a84ee0a744dddb856cd4e42afab08,TL shared,0.37961
uuid-d29a84ee0a744dddb856cd4e42afab08,option,0.491258
uuid-d29a84ee0a744dddb856cd4e42afab08,bladder,0.416406
uuid-925a28aba2df4001a2b52950d46950b4,Nivo,0.32668
uuid-925a28aba2df4001a2b52950d46950b4,patients,0.550732
uuid-925a28aba2df4001a2b52950d46950b4,Opdivo,0.441497
uuid-925a28aba2df4001a2b52950d46950b4,therapy,0.5701
uuid-925a28aba2df4001a2b52950d46950b4,nivolumab,0.453617
uuid-925a28aba2df4001a2b52950d46950b4,treated,0.322712
uuid-925a28aba2df4001a2b52950d46950b4,treatment,0.315952
uuid-925a28aba2df4001a2b52950d46950b4,using nivo,0.309063
uuid-925a28aba2df4001a2b52950d46950b4,cHL,0.794577
uuid-8b42b9bb2e424310a7e70b7f6fe74566,shared,0.572782
uuid-8b42b9bb2e424310a7e70b7f6fe74566,institution,0.681952
uuid-8b42b9bb2e424310a7e70b7f6fe74566,stated,0.357654
uuid-8b42b9bb2e424310a7e70b7f6fe74566,clinical,0.313862
uuid-c2f9c4b6cef94a5d8edc07877834600d,patients,0.327157
uuid-c2f9c4b6cef94a5d8edc07877834600d,physicians,0.31791
uuid-c2f9c4b6cef94a5d8edc07877834600d,lung cancer,0.344853
uuid-c2f9c4b6cef94a5d8edc07877834600d,progression,0.303613
uuid-c2f9c4b6cef94a5d8edc07877834600d,tumor types,0.369121
uuid-448ed129f7824da99896318ae65ac16b,toxicity,0.328909
uuid-448ed129f7824da99896318ae65ac16b,regimen,0.454081
uuid-448ed129f7824da99896318ae65ac16b,combination,0.308468
uuid-448ed129f7824da99896318ae65ac16b,chemo,0.340322
uuid-448ed129f7824da99896318ae65ac16b,preferred,0.370237
uuid-448ed129f7824da99896318ae65ac16b,monotherapy,0.441309
uuid-448ed129f7824da99896318ae65ac16b,treatment,0.317588
uuid-448ed129f7824da99896318ae65ac16b,combo,0.376938
uuid-448ed129f7824da99896318ae65ac16b,chemotherapy,0.387082
uuid-448ed129f7824da99896318ae65ac16b,option,0.497113
uuid-ada1c5518edf4c8397e641a11aabb8dd,patients,0.626418
uuid-ada1c5518edf4c8397e641a11aabb8dd,therapy,0.487687
uuid-ada1c5518edf4c8397e641a11aabb8dd,nivolumab,0.300252
uuid-ada1c5518edf4c8397e641a11aabb8dd,toxicity,0.362196
uuid-ada1c5518edf4c8397e641a11aabb8dd,regimen,0.514445
uuid-ada1c5518edf4c8397e641a11aabb8dd,treated,0.550382
uuid-ada1c5518edf4c8397e641a11aabb8dd,chemo,0.455339
uuid-ada1c5518edf4c8397e641a11aabb8dd,pts,0.512932
uuid-ada1c5518edf4c8397e641a11aabb8dd,IO,0.400524
uuid-ada1c5518edf4c8397e641a11aabb8dd,monotherapy,0.424118
uuid-ada1c5518edf4c8397e641a11aabb8dd,treatment,0.651584
uuid-ada1c5518edf4c8397e641a11aabb8dd,response,0.570578
uuid-ada1c5518edf4c8397e641a11aabb8dd,PD1,0.39133
uuid-ada1c5518edf4c8397e641a11aabb8dd,progression,0.641055
uuid-ada1c5518edf4c8397e641a11aabb8dd,chemotherapy,0.388849
uuid-ada1c5518edf4c8397e641a11aabb8dd,respond,0.618067
uuid-ada1c5518edf4c8397e641a11aabb8dd,option,0.370179
uuid-a4a772e6ba694ec5bacdc2b42a661c99,patients,0.870386
uuid-a4a772e6ba694ec5bacdc2b42a661c99,Opdivo,0.589178
uuid-a4a772e6ba694ec5bacdc2b42a661c99,therapy,0.606345
uuid-a4a772e6ba694ec5bacdc2b42a661c99,nivolumab,0.42537
uuid-a4a772e6ba694ec5bacdc2b42a661c99,toxicity,0.355965
uuid-a4a772e6ba694ec5bacdc2b42a661c99,regimen,0.578957
uuid-a4a772e6ba694ec5bacdc2b42a661c99,treated,0.520933
uuid-a4a772e6ba694ec5bacdc2b42a661c99,chemo,0.319161
uuid-a4a772e6ba694ec5bacdc2b42a661c99,pts,0.569556
uuid-a4a772e6ba694ec5bacdc2b42a661c99,monotherapy,0.334323
uuid-a4a772e6ba694ec5bacdc2b42a661c99,treatment,0.809423
uuid-a4a772e6ba694ec5bacdc2b42a661c99,response,0.462205
uuid-a4a772e6ba694ec5bacdc2b42a661c99,PD1,0.306446
uuid-a4a772e6ba694ec5bacdc2b42a661c99,cHL,0.309564
uuid-a4a772e6ba694ec5bacdc2b42a661c99,progression,0.755878
uuid-a4a772e6ba694ec5bacdc2b42a661c99,chemotherapy,0.379891
uuid-a4a772e6ba694ec5bacdc2b42a661c99,respond,0.641486
uuid-a4a772e6ba694ec5bacdc2b42a661c99,option,0.318762
uuid-dcacddcf85b24bd2bb8355fe7704108a,RTL,0.308071
uuid-dcacddcf85b24bd2bb8355fe7704108a,nivolumab,0.303038
uuid-dcacddcf85b24bd2bb8355fe7704108a,1L,0.385863
uuid-dcacddcf85b24bd2bb8355fe7704108a,regimen,0.412775
uuid-dcacddcf85b24bd2bb8355fe7704108a,RCC,0.336399
uuid-dcacddcf85b24bd2bb8355fe7704108a,combination,0.537443
uuid-dcacddcf85b24bd2bb8355fe7704108a,2L,0.396742
uuid-dcacddcf85b24bd2bb8355fe7704108a,IO,0.425657
uuid-dcacddcf85b24bd2bb8355fe7704108a,Ipi,0.373425
uuid-dcacddcf85b24bd2bb8355fe7704108a,preferred,0.365646
uuid-dcacddcf85b24bd2bb8355fe7704108a,monotherapy,0.527185
uuid-dcacddcf85b24bd2bb8355fe7704108a,using nivo,0.438398
uuid-dcacddcf85b24bd2bb8355fe7704108a,combo,0.636249
uuid-dcacddcf85b24bd2bb8355fe7704108a,PD1,0.325517
uuid-dcacddcf85b24bd2bb8355fe7704108a,believes,0.369201
uuid-dcacddcf85b24bd2bb8355fe7704108a,TLs,0.464577
uuid-dcacddcf85b24bd2bb8355fe7704108a,feels,0.388093
uuid-dcacddcf85b24bd2bb8355fe7704108a,Regional TL,0.345404
uuid-dcacddcf85b24bd2bb8355fe7704108a,RTL stated,0.34161
uuid-dcacddcf85b24bd2bb8355fe7704108a,option,0.358218
uuid-f0b005ccfeec432ea7ca2f722416a41e,1L,0.314641
uuid-f0b005ccfeec432ea7ca2f722416a41e,2L,0.430715
uuid-f0b005ccfeec432ea7ca2f722416a41e,agents,0.420285
uuid-f0b005ccfeec432ea7ca2f722416a41e,physicians,0.347393
uuid-f0b005ccfeec432ea7ca2f722416a41e,preferred,0.480044
uuid-f0b005ccfeec432ea7ca2f722416a41e,monotherapy,0.31799
uuid-f0b005ccfeec432ea7ca2f722416a41e,using nivo,0.328566
uuid-f0b005ccfeec432ea7ca2f722416a41e,approved,0.372638
uuid-f0b005ccfeec432ea7ca2f722416a41e,oncologist,0.395182
uuid-f0b005ccfeec432ea7ca2f722416a41e,feels,0.307605
uuid-f0b005ccfeec432ea7ca2f722416a41e,option,0.433326
uuid-286b94c2e57c48b8bf672cdde1a3b289,lung,0.302624
uuid-286b94c2e57c48b8bf672cdde1a3b289,NSCLC,0.300348
uuid-286b94c2e57c48b8bf672cdde1a3b289,1L,0.347729
uuid-286b94c2e57c48b8bf672cdde1a3b289,PDL1,0.462464
uuid-286b94c2e57c48b8bf672cdde1a3b289,TL stated,0.340387
uuid-286b94c2e57c48b8bf672cdde1a3b289,stated,0.300034
uuid-286b94c2e57c48b8bf672cdde1a3b289,PDL1 testing,0.389495
uuid-286b94c2e57c48b8bf672cdde1a3b289,nivo and pembro,0.334599
uuid-286b94c2e57c48b8bf672cdde1a3b289,believes,0.398936
uuid-286b94c2e57c48b8bf672cdde1a3b289,feels,0.365036
uuid-286b94c2e57c48b8bf672cdde1a3b289,PDL1 expression,0.306404
uuid-286b94c2e57c48b8bf672cdde1a3b289,biomarker,0.359268
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,1L,0.484549
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,PDL1,0.4953
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,TL stated,0.304988
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,2L,0.381351
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,PD-L1,0.580844
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,preferred,0.321613
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,PD-L1 testing,0.47649
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,testing,0.62597
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,PDL1 testing,0.554088
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,NSCLC patients,0.486531
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,believes,0.379986
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,assay,0.344547
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,PD-1,0.317764
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,option,0.403194
uuid-cd80fb6b9fa84f3f8fbf364ec93aa1d8,biomarker,0.507928
uuid-e6aff845228b4d3aa5c4abe8b51de654,PDL1,0.310197
uuid-e6aff845228b4d3aa5c4abe8b51de654,efficacy,0.454819
uuid-e6aff845228b4d3aa5c4abe8b51de654,OS,0.47877
uuid-e6aff845228b4d3aa5c4abe8b51de654,data,0.323396
uuid-e6aff845228b4d3aa5c4abe8b51de654,PFS,0.537403
uuid-e6aff845228b4d3aa5c4abe8b51de654,ORR,0.500994
uuid-e6aff845228b4d3aa5c4abe8b51de654,nivo and pembro,0.375893
uuid-e6aff845228b4d3aa5c4abe8b51de654,believes,0.339335
uuid-e6aff845228b4d3aa5c4abe8b51de654,immunotherapy,0.363431
uuid-e6aff845228b4d3aa5c4abe8b51de654,PDL1 expression,0.315618
uuid-9a9186dd524d4a7791566a3eb6c5acf8,patients,0.418072
uuid-9a9186dd524d4a7791566a3eb6c5acf8,Opdivo,0.330351
uuid-9a9186dd524d4a7791566a3eb6c5acf8,physicians,0.383135
uuid-9a9186dd524d4a7791566a3eb6c5acf8,clinical trials,0.36851
uuid-9a9186dd524d4a7791566a3eb6c5acf8,academic,0.314365
uuid-879496dcc8694965aff26e74f437965b,Nivo,0.389909
uuid-879496dcc8694965aff26e74f437965b,patients,0.473374
uuid-879496dcc8694965aff26e74f437965b,Opdivo,0.553409
uuid-879496dcc8694965aff26e74f437965b,dose,0.563712
uuid-879496dcc8694965aff26e74f437965b,nivolumab,0.323505
uuid-879496dcc8694965aff26e74f437965b,regimen,0.407174
uuid-879496dcc8694965aff26e74f437965b,chemo,0.303556
uuid-879496dcc8694965aff26e74f437965b,2L,0.34741
uuid-879496dcc8694965aff26e74f437965b,preferred,0.454717
uuid-879496dcc8694965aff26e74f437965b,monotherapy,0.409432
uuid-879496dcc8694965aff26e74f437965b,treatment,0.350607
uuid-879496dcc8694965aff26e74f437965b,approved,0.333312
uuid-879496dcc8694965aff26e74f437965b,vs,0.360478
uuid-879496dcc8694965aff26e74f437965b,drug,0.329538
uuid-879496dcc8694965aff26e74f437965b,Keytruda,0.396066
uuid-879496dcc8694965aff26e74f437965b,feels,0.307799
uuid-879496dcc8694965aff26e74f437965b,option,0.42189
uuid-879496dcc8694965aff26e74f437965b,flat dosing,0.443966
uuid-e9002e8dc9df45778c58a155441809b9,pembro,0.306524
uuid-e9002e8dc9df45778c58a155441809b9,BMS,0.32193
uuid-e9002e8dc9df45778c58a155441809b9,PDL1,0.317138
uuid-e9002e8dc9df45778c58a155441809b9,trial,0.645022
uuid-e9002e8dc9df45778c58a155441809b9,data,0.314801
uuid-e9002e8dc9df45778c58a155441809b9,combo,0.332107
uuid-e9002e8dc9df45778c58a155441809b9,clinical trials,0.447143
uuid-e9002e8dc9df45778c58a155441809b9,ORR,0.318947
uuid-e9002e8dc9df45778c58a155441809b9,impressed,0.342715
uuid-e9002e8dc9df45778c58a155441809b9,feels,0.439312
uuid-4aff56069cac4f7ba46afbbf0677d217,patients,0.76632
uuid-4aff56069cac4f7ba46afbbf0677d217,therapy,0.466205
uuid-4aff56069cac4f7ba46afbbf0677d217,nivolumab,0.378642
uuid-4aff56069cac4f7ba46afbbf0677d217,regimen,0.535635
uuid-4aff56069cac4f7ba46afbbf0677d217,treated,0.418543
uuid-4aff56069cac4f7ba46afbbf0677d217,combination,0.370351
uuid-4aff56069cac4f7ba46afbbf0677d217,chemo,0.433149
uuid-4aff56069cac4f7ba46afbbf0677d217,pts,0.590152
uuid-4aff56069cac4f7ba46afbbf0677d217,Ipi,0.39264
uuid-4aff56069cac4f7ba46afbbf0677d217,monotherapy,0.448682
uuid-4aff56069cac4f7ba46afbbf0677d217,treatment,0.514426
uuid-4aff56069cac4f7ba46afbbf0677d217,response,0.381058
uuid-4aff56069cac4f7ba46afbbf0677d217,combo,0.442947
uuid-4aff56069cac4f7ba46afbbf0677d217,PD1,0.334002
uuid-4aff56069cac4f7ba46afbbf0677d217,progression,0.579664
uuid-4aff56069cac4f7ba46afbbf0677d217,chemotherapy,0.470999
uuid-4aff56069cac4f7ba46afbbf0677d217,respond,0.439656
uuid-4aff56069cac4f7ba46afbbf0677d217,option,0.370976
uuid-f7bda02b78e340868c1069d49eea8aac,Nivo,0.364057
uuid-f7bda02b78e340868c1069d49eea8aac,patients,0.631964
uuid-f7bda02b78e340868c1069d49eea8aac,therapy,0.334121
uuid-f7bda02b78e340868c1069d49eea8aac,dose,0.378469
uuid-f7bda02b78e340868c1069d49eea8aac,toxicity,0.382735
uuid-f7bda02b78e340868c1069d49eea8aac,regimen,0.525769
uuid-f7bda02b78e340868c1069d49eea8aac,treated,0.356275
uuid-f7bda02b78e340868c1069d49eea8aac,combination,0.360497
uuid-f7bda02b78e340868c1069d49eea8aac,chemo,0.420279
uuid-f7bda02b78e340868c1069d49eea8aac,pts,0.437594
uuid-f7bda02b78e340868c1069d49eea8aac,Ipi,0.525362
uuid-f7bda02b78e340868c1069d49eea8aac,monotherapy,0.33627
uuid-f7bda02b78e340868c1069d49eea8aac,treatment,0.429168
uuid-f7bda02b78e340868c1069d49eea8aac,combo,0.374985
uuid-f7bda02b78e340868c1069d49eea8aac,progression,0.395713
uuid-f7bda02b78e340868c1069d49eea8aac,chemotherapy,0.478476
uuid-f7bda02b78e340868c1069d49eea8aac,respond,0.363623
uuid-581f47219cbf4aac9bf8ab473cb7607c,Nivo,0.465703
uuid-581f47219cbf4aac9bf8ab473cb7607c,patients,0.756067
uuid-581f47219cbf4aac9bf8ab473cb7607c,Opdivo,0.522747
uuid-581f47219cbf4aac9bf8ab473cb7607c,pembro,0.306565
uuid-581f47219cbf4aac9bf8ab473cb7607c,therapy,0.569697
uuid-581f47219cbf4aac9bf8ab473cb7607c,nivolumab,0.580046
uuid-581f47219cbf4aac9bf8ab473cb7607c,treated,0.420376
uuid-581f47219cbf4aac9bf8ab473cb7607c,pts,0.415014
uuid-581f47219cbf4aac9bf8ab473cb7607c,approval,0.535548
uuid-581f47219cbf4aac9bf8ab473cb7607c,preferred,0.306723
uuid-581f47219cbf4aac9bf8ab473cb7607c,monotherapy,0.334633
uuid-581f47219cbf4aac9bf8ab473cb7607c,treatment,0.436628
uuid-581f47219cbf4aac9bf8ab473cb7607c,using nivo,0.500611
uuid-581f47219cbf4aac9bf8ab473cb7607c,approved,0.417476
uuid-581f47219cbf4aac9bf8ab473cb7607c,cHL,0.543934
uuid-581f47219cbf4aac9bf8ab473cb7607c,progression,0.320402
uuid-581f47219cbf4aac9bf8ab473cb7607c,chemotherapy,0.358859
uuid-581f47219cbf4aac9bf8ab473cb7607c,label,0.435171
uuid-581f47219cbf4aac9bf8ab473cb7607c,option,0.396055
uuid-42bbb192043444a69d73dca3436d64e6,pembro,0.539541
uuid-42bbb192043444a69d73dca3436d64e6,1L,0.532213
uuid-42bbb192043444a69d73dca3436d64e6,TL stated,0.379451
uuid-42bbb192043444a69d73dca3436d64e6,2L,0.573628
uuid-42bbb192043444a69d73dca3436d64e6,agents,0.309854
uuid-42bbb192043444a69d73dca3436d64e6,Merck,0.37376
uuid-42bbb192043444a69d73dca3436d64e6,stated,0.357614
uuid-42bbb192043444a69d73dca3436d64e6,PD-L1,0.384139
uuid-42bbb192043444a69d73dca3436d64e6,approval,0.474847
uuid-42bbb192043444a69d73dca3436d64e6,atezo,0.53984
uuid-42bbb192043444a69d73dca3436d64e6,preferred,0.57985
uuid-42bbb192043444a69d73dca3436d64e6,PD-L1 testing,0.328393
uuid-42bbb192043444a69d73dca3436d64e6,testing,0.44566
uuid-42bbb192043444a69d73dca3436d64e6,using nivo,0.463263
uuid-42bbb192043444a69d73dca3436d64e6,PDL1 testing,0.557989
uuid-42bbb192043444a69d73dca3436d64e6,indication,0.391811
uuid-42bbb192043444a69d73dca3436d64e6,NSCLC patients,0.435593
uuid-42bbb192043444a69d73dca3436d64e6,approved,0.52461
uuid-42bbb192043444a69d73dca3436d64e6,SCCHN,0.353683
uuid-42bbb192043444a69d73dca3436d64e6,tumor types,0.381981
uuid-42bbb192043444a69d73dca3436d64e6,feels,0.353916
uuid-42bbb192043444a69d73dca3436d64e6,RTL stated,0.408652
uuid-42bbb192043444a69d73dca3436d64e6,option,0.391111
uuid-3621039576da4f5d9287c92d90f2b500,patients,0.567805
uuid-3621039576da4f5d9287c92d90f2b500,Opdivo,0.398613
uuid-3621039576da4f5d9287c92d90f2b500,therapy,0.353144
uuid-3621039576da4f5d9287c92d90f2b500,nivolumab,0.520902
uuid-3621039576da4f5d9287c92d90f2b500,treated,0.399078
uuid-3621039576da4f5d9287c92d90f2b500,treatment,0.31566
uuid-3621039576da4f5d9287c92d90f2b500,using nivo,0.303191
uuid-3621039576da4f5d9287c92d90f2b500,mentioned,0.318991
uuid-3621039576da4f5d9287c92d90f2b500,cHL,0.469376
uuid-fb87e5d2d6494b9583f0194dd0e1a435,PDL1,0.648117
uuid-fb87e5d2d6494b9583f0194dd0e1a435,efficacy,0.52855
uuid-fb87e5d2d6494b9583f0194dd0e1a435,chemo,0.301165
uuid-fb87e5d2d6494b9583f0194dd0e1a435,PD-L1,0.357953
uuid-fb87e5d2d6494b9583f0194dd0e1a435,OS,0.360624
uuid-fb87e5d2d6494b9583f0194dd0e1a435,data,0.336605
uuid-fb87e5d2d6494b9583f0194dd0e1a435,PFS,0.37389
uuid-fb87e5d2d6494b9583f0194dd0e1a435,ORR,0.409545
uuid-fb87e5d2d6494b9583f0194dd0e1a435,nivo and pembro,0.496999
uuid-fb87e5d2d6494b9583f0194dd0e1a435,believes,0.460079
uuid-fb87e5d2d6494b9583f0194dd0e1a435,feels,0.522949
uuid-fb87e5d2d6494b9583f0194dd0e1a435,PDL1 expression,0.680746
uuid-fb87e5d2d6494b9583f0194dd0e1a435,option,0.323876
uuid-fb87e5d2d6494b9583f0194dd0e1a435,biomarker,0.426418
uuid-fa55ee6efb944c219772e9e7caeee9fb,patients,0.301146
uuid-fa55ee6efb944c219772e9e7caeee9fb,dose,0.59175
uuid-fa55ee6efb944c219772e9e7caeee9fb,nivolumab,0.31381
uuid-fa55ee6efb944c219772e9e7caeee9fb,toxicity,0.404396
uuid-fa55ee6efb944c219772e9e7caeee9fb,regimen,0.453435
uuid-fa55ee6efb944c219772e9e7caeee9fb,treated,0.439726
uuid-fa55ee6efb944c219772e9e7caeee9fb,melanoma,0.46992
uuid-fa55ee6efb944c219772e9e7caeee9fb,combination,0.366836
uuid-fa55ee6efb944c219772e9e7caeee9fb,Ipi,0.419988
uuid-fa55ee6efb944c219772e9e7caeee9fb,treatment,0.341596
uuid-fa55ee6efb944c219772e9e7caeee9fb,combo,0.353646
uuid-fa55ee6efb944c219772e9e7caeee9fb,TL shared,0.347937
uuid-fa55ee6efb944c219772e9e7caeee9fb,flat dosing,0.370603
uuid-3437613f66ee4c86a9294c0cc528624e,patients,0.375874
uuid-3437613f66ee4c86a9294c0cc528624e,Opdivo,0.429149
uuid-3437613f66ee4c86a9294c0cc528624e,dose,0.445113
uuid-3437613f66ee4c86a9294c0cc528624e,toxicity,0.495633
uuid-3437613f66ee4c86a9294c0cc528624e,regimen,0.541315
uuid-3437613f66ee4c86a9294c0cc528624e,treated,0.318245
uuid-3437613f66ee4c86a9294c0cc528624e,shared,0.411697
uuid-3437613f66ee4c86a9294c0cc528624e,physicians,0.563465
uuid-3437613f66ee4c86a9294c0cc528624e,treatment,0.361531
uuid-3437613f66ee4c86a9294c0cc528624e,drug,0.327728
uuid-3437613f66ee4c86a9294c0cc528624e,flat dosing,0.32274
uuid-09e921230ae04d7085fa2bbcb3ab984f,Nivo,0.769707
uuid-09e921230ae04d7085fa2bbcb3ab984f,patients,0.335133
uuid-09e921230ae04d7085fa2bbcb3ab984f,pembro,0.469938
uuid-09e921230ae04d7085fa2bbcb3ab984f,therapy,0.348171
uuid-09e921230ae04d7085fa2bbcb3ab984f,1L,0.35945
uuid-09e921230ae04d7085fa2bbcb3ab984f,efficacy,0.54455
uuid-09e921230ae04d7085fa2bbcb3ab984f,chemo,0.650833
uuid-09e921230ae04d7085fa2bbcb3ab984f,2L,0.312131
uuid-09e921230ae04d7085fa2bbcb3ab984f,pts,0.313775
uuid-09e921230ae04d7085fa2bbcb3ab984f,Ipi,0.399427
uuid-09e921230ae04d7085fa2bbcb3ab984f,OS,0.541842
uuid-09e921230ae04d7085fa2bbcb3ab984f,atezo,0.319392
uuid-09e921230ae04d7085fa2bbcb3ab984f,monotherapy,0.498291
uuid-09e921230ae04d7085fa2bbcb3ab984f,using nivo,0.300196
uuid-09e921230ae04d7085fa2bbcb3ab984f,response,0.325947
uuid-09e921230ae04d7085fa2bbcb3ab984f,combo,0.334355
uuid-09e921230ae04d7085fa2bbcb3ab984f,PFS,0.555288
uuid-09e921230ae04d7085fa2bbcb3ab984f,PD1,0.397995
uuid-09e921230ae04d7085fa2bbcb3ab984f,ORR,0.511175
uuid-09e921230ae04d7085fa2bbcb3ab984f,nivo and pembro,0.455412
uuid-09e921230ae04d7085fa2bbcb3ab984f,progression,0.319877
uuid-09e921230ae04d7085fa2bbcb3ab984f,believes,0.393435
uuid-09e921230ae04d7085fa2bbcb3ab984f,chemotherapy,0.553224
uuid-09e921230ae04d7085fa2bbcb3ab984f,vs,0.489574
uuid-09e921230ae04d7085fa2bbcb3ab984f,feels,0.443141
uuid-09e921230ae04d7085fa2bbcb3ab984f,option,0.443199
uuid-7c0ce4ca369d472ba95520451fa9432f,patients,0.378344
uuid-7c0ce4ca369d472ba95520451fa9432f,Opdivo,0.448535
uuid-7c0ce4ca369d472ba95520451fa9432f,therapy,0.371841
uuid-7c0ce4ca369d472ba95520451fa9432f,nivolumab,0.424839
uuid-7c0ce4ca369d472ba95520451fa9432f,toxicity,0.316553
uuid-7c0ce4ca369d472ba95520451fa9432f,treated,0.345241
uuid-7c0ce4ca369d472ba95520451fa9432f,mentioned,0.326228
uuid-7c0ce4ca369d472ba95520451fa9432f,cHL,0.711586
uuid-f0c063c545b743f6b48f43899cf28a84,Nivo,0.319719
uuid-f0c063c545b743f6b48f43899cf28a84,trial,0.306775
uuid-f0c063c545b743f6b48f43899cf28a84,pts,0.377364
uuid-f0c063c545b743f6b48f43899cf28a84,stated,0.414537
uuid-f0c063c545b743f6b48f43899cf28a84,OS,0.334712
uuid-f0c063c545b743f6b48f43899cf28a84,data,0.339903
uuid-f0c063c545b743f6b48f43899cf28a84,combo,0.323574
uuid-f0c063c545b743f6b48f43899cf28a84,progression,0.308341
uuid-f0c063c545b743f6b48f43899cf28a84,impressed,0.470538
uuid-f0c063c545b743f6b48f43899cf28a84,feels,0.419303
uuid-c90cd1acc3b948b4866adc141f8a7128,patients,0.668431
uuid-c90cd1acc3b948b4866adc141f8a7128,therapy,0.356915
uuid-c90cd1acc3b948b4866adc141f8a7128,toxicity,0.522645
uuid-c90cd1acc3b948b4866adc141f8a7128,regimen,0.475164
uuid-c90cd1acc3b948b4866adc141f8a7128,treated,0.413219
uuid-c90cd1acc3b948b4866adc141f8a7128,pts,0.404005
uuid-c90cd1acc3b948b4866adc141f8a7128,treatment,0.587087
uuid-c90cd1acc3b948b4866adc141f8a7128,response,0.44946
uuid-c90cd1acc3b948b4866adc141f8a7128,progression,0.55489
uuid-c90cd1acc3b948b4866adc141f8a7128,respond,0.605939
uuid-e4521dd8d5084d0ca557461f6d6433e9,therapy,0.302008
uuid-e4521dd8d5084d0ca557461f6d6433e9,1L,0.457249
uuid-e4521dd8d5084d0ca557461f6d6433e9,regimen,0.350705
uuid-e4521dd8d5084d0ca557461f6d6433e9,RCC,0.326294
uuid-e4521dd8d5084d0ca557461f6d6433e9,combination,0.500456
uuid-e4521dd8d5084d0ca557461f6d6433e9,chemo,0.31797
uuid-e4521dd8d5084d0ca557461f6d6433e9,2L,0.441759
uuid-e4521dd8d5084d0ca557461f6d6433e9,IO,0.524114
uuid-e4521dd8d5084d0ca557461f6d6433e9,agents,0.415652
uuid-e4521dd8d5084d0ca557461f6d6433e9,preferred,0.483302
uuid-e4521dd8d5084d0ca557461f6d6433e9,monotherapy,0.618259
uuid-e4521dd8d5084d0ca557461f6d6433e9,using nivo,0.307826
uuid-e4521dd8d5084d0ca557461f6d6433e9,combo,0.473378
uuid-e4521dd8d5084d0ca557461f6d6433e9,PD1,0.33654
uuid-e4521dd8d5084d0ca557461f6d6433e9,believes,0.311694
uuid-e4521dd8d5084d0ca557461f6d6433e9,chemotherapy,0.357142
uuid-e4521dd8d5084d0ca557461f6d6433e9,RTL stated,0.451881
uuid-e4521dd8d5084d0ca557461f6d6433e9,option,0.572823
uuid-23ec39c6aec44b209e1f19caa0eacec4,patients,0.582731
uuid-23ec39c6aec44b209e1f19caa0eacec4,Opdivo,0.437913
uuid-23ec39c6aec44b209e1f19caa0eacec4,therapy,0.459894
uuid-23ec39c6aec44b209e1f19caa0eacec4,nivolumab,0.351319
uuid-23ec39c6aec44b209e1f19caa0eacec4,regimen,0.586696
uuid-23ec39c6aec44b209e1f19caa0eacec4,treated,0.475969
uuid-23ec39c6aec44b209e1f19caa0eacec4,pts,0.335473
uuid-23ec39c6aec44b209e1f19caa0eacec4,physicians,0.401353
uuid-23ec39c6aec44b209e1f19caa0eacec4,monotherapy,0.487542
uuid-23ec39c6aec44b209e1f19caa0eacec4,treatment,0.675452
uuid-23ec39c6aec44b209e1f19caa0eacec4,progression,0.470143
uuid-23ec39c6aec44b209e1f19caa0eacec4,chemotherapy,0.328571
uuid-23ec39c6aec44b209e1f19caa0eacec4,respond,0.436538
uuid-23ec39c6aec44b209e1f19caa0eacec4,feels,0.394939
uuid-23ec39c6aec44b209e1f19caa0eacec4,option,0.444621
uuid-d6200f8841ba408ea78d0e5195155df1,Opdivo,0.490516
uuid-d6200f8841ba408ea78d0e5195155df1,physicians,0.376295
uuid-78458c0ff434442fad4f691bb40ec063,Nivo,0.522544
uuid-78458c0ff434442fad4f691bb40ec063,patients,0.468633
uuid-78458c0ff434442fad4f691bb40ec063,pembro,0.355432
uuid-78458c0ff434442fad4f691bb40ec063,nivolumab,0.321068
uuid-78458c0ff434442fad4f691bb40ec063,1L,0.464901
uuid-78458c0ff434442fad4f691bb40ec063,regimen,0.375979
uuid-78458c0ff434442fad4f691bb40ec063,combination,0.34427
uuid-78458c0ff434442fad4f691bb40ec063,chemo,0.474886
uuid-78458c0ff434442fad4f691bb40ec063,2L,0.406139
uuid-78458c0ff434442fad4f691bb40ec063,pts,0.524367
uuid-78458c0ff434442fad4f691bb40ec063,monotherapy,0.530637
uuid-78458c0ff434442fad4f691bb40ec063,using nivo,0.408152
uuid-78458c0ff434442fad4f691bb40ec063,response,0.361965
uuid-78458c0ff434442fad4f691bb40ec063,combo,0.425999
uuid-78458c0ff434442fad4f691bb40ec063,PD1,0.393529
uuid-78458c0ff434442fad4f691bb40ec063,approved,0.357584
uuid-78458c0ff434442fad4f691bb40ec063,progression,0.409179
uuid-78458c0ff434442fad4f691bb40ec063,believes,0.327617
uuid-78458c0ff434442fad4f691bb40ec063,chemotherapy,0.344145
uuid-78458c0ff434442fad4f691bb40ec063,impressed,0.391249
uuid-78458c0ff434442fad4f691bb40ec063,respond,0.363396
uuid-78458c0ff434442fad4f691bb40ec063,feels,0.511521
uuid-78458c0ff434442fad4f691bb40ec063,option,0.495675
uuid-31380544e50a430a9fa395aac44dbe71,patients,0.785289
uuid-31380544e50a430a9fa395aac44dbe71,therapy,0.626429
uuid-31380544e50a430a9fa395aac44dbe71,nivolumab,0.334471
uuid-31380544e50a430a9fa395aac44dbe71,regimen,0.542771
uuid-31380544e50a430a9fa395aac44dbe71,treated,0.477699
uuid-31380544e50a430a9fa395aac44dbe71,chemo,0.62561
uuid-31380544e50a430a9fa395aac44dbe71,pts,0.59795
uuid-31380544e50a430a9fa395aac44dbe71,monotherapy,0.448395
uuid-31380544e50a430a9fa395aac44dbe71,treatment,0.735989
uuid-31380544e50a430a9fa395aac44dbe71,response,0.571326
uuid-31380544e50a430a9fa395aac44dbe71,PD1,0.439071
uuid-31380544e50a430a9fa395aac44dbe71,progression,0.775193
uuid-31380544e50a430a9fa395aac44dbe71,chemotherapy,0.575293
uuid-31380544e50a430a9fa395aac44dbe71,respond,0.556064
uuid-31380544e50a430a9fa395aac44dbe71,option,0.466832
uuid-5d1426002eb54e0da4bcc0b5b9200f32,patients,0.606943
uuid-5d1426002eb54e0da4bcc0b5b9200f32,therapy,0.319551
uuid-5d1426002eb54e0da4bcc0b5b9200f32,toxicity,0.623591
uuid-5d1426002eb54e0da4bcc0b5b9200f32,regimen,0.488103
uuid-5d1426002eb54e0da4bcc0b5b9200f32,treated,0.457109
uuid-5d1426002eb54e0da4bcc0b5b9200f32,pts,0.338511
uuid-5d1426002eb54e0da4bcc0b5b9200f32,treatment,0.5938
uuid-5d1426002eb54e0da4bcc0b5b9200f32,progression,0.510079
uuid-5d1426002eb54e0da4bcc0b5b9200f32,respond,0.398856
uuid-c38931eaa8b74712a227ba1ac79e50af,patients,0.542879
uuid-c38931eaa8b74712a227ba1ac79e50af,therapy,0.653907
uuid-c38931eaa8b74712a227ba1ac79e50af,nivolumab,0.344378
uuid-c38931eaa8b74712a227ba1ac79e50af,regimen,0.451219
uuid-c38931eaa8b74712a227ba1ac79e50af,treated,0.414995
uuid-c38931eaa8b74712a227ba1ac79e50af,combination,0.312137
uuid-c38931eaa8b74712a227ba1ac79e50af,chemo,0.470876
uuid-c38931eaa8b74712a227ba1ac79e50af,pts,0.471911
uuid-c38931eaa8b74712a227ba1ac79e50af,IO,0.30343
uuid-c38931eaa8b74712a227ba1ac79e50af,monotherapy,0.411631
uuid-c38931eaa8b74712a227ba1ac79e50af,treatment,0.647487
uuid-c38931eaa8b74712a227ba1ac79e50af,response,0.576671
uuid-c38931eaa8b74712a227ba1ac79e50af,PD1,0.476334
uuid-c38931eaa8b74712a227ba1ac79e50af,progression,0.687062
uuid-c38931eaa8b74712a227ba1ac79e50af,chemotherapy,0.464986
uuid-c38931eaa8b74712a227ba1ac79e50af,respond,0.525964
uuid-c38931eaa8b74712a227ba1ac79e50af,option,0.385605
uuid-f49f3aeca09e4a5c88c7677cd7a9fdcc,trial,0.351026
uuid-f49f3aeca09e4a5c88c7677cd7a9fdcc,clinical trials,0.345309
uuid-f49f3aeca09e4a5c88c7677cd7a9fdcc,impressed,0.350241
uuid-f49f3aeca09e4a5c88c7677cd7a9fdcc,respond,0.316893
uuid-f49f3aeca09e4a5c88c7677cd7a9fdcc,feels,0.350424
uuid-22217aa5982646de81ec0d7866f00a2f,Nivo,0.339873
uuid-22217aa5982646de81ec0d7866f00a2f,Opdivo,0.439463
uuid-22217aa5982646de81ec0d7866f00a2f,pembro,0.444969
uuid-22217aa5982646de81ec0d7866f00a2f,dose,0.90716
uuid-22217aa5982646de81ec0d7866f00a2f,efficacy,0.312518
uuid-22217aa5982646de81ec0d7866f00a2f,Ipi,0.55074
uuid-22217aa5982646de81ec0d7866f00a2f,atezo,0.451363
uuid-22217aa5982646de81ec0d7866f00a2f,vs,0.631994
uuid-22217aa5982646de81ec0d7866f00a2f,Keytruda,0.48116
uuid-22217aa5982646de81ec0d7866f00a2f,flat dosing,0.796041
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,commented,0.383306
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,stated,0.383318
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,atezo,0.328158
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,regards,0.428093
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,data,0.330155
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,expressed,0.423544
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,indication,0.520672
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,approved,0.392948
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,SCCHN,0.350961
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,impressed,0.314434
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,TLs,0.439613
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,Regional TL,0.333258
uuid-c4bcbf2c4c394ab2a8854edf5648b3d0,NCCN,0.321174
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,patients,0.367204
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,therapy,0.47875
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,nivolumab,0.312779
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,toxicity,0.702495
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,regimen,0.617646
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,treated,0.403805
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,combination,0.474589
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,chemo,0.453916
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,pts,0.30498
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,IO,0.311121
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,agents,0.32275
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,monotherapy,0.463355
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,treatment,0.595842
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,response,0.425896
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,combo,0.385106
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,PD1,0.499562
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,progression,0.518096
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,believes,0.31754
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,chemotherapy,0.459565
uuid-0f98107a8e9c4f3aa8cc77fcc0ec1a0f,respond,0.495572
uuid-d88ed5526ea14a23a4fddebd5a9a2501,toxicity,0.454427
uuid-d88ed5526ea14a23a4fddebd5a9a2501,physicians,0.316435
uuid-d88ed5526ea14a23a4fddebd5a9a2501,oncology,0.300188
uuid-d88ed5526ea14a23a4fddebd5a9a2501,drug,0.327791
uuid-d88ed5526ea14a23a4fddebd5a9a2501,clinical,0.375012
uuid-4affc1f3261340f4b25a253a4b3a4446,Nivo,0.300614
uuid-4affc1f3261340f4b25a253a4b3a4446,pembro,0.3549
uuid-4affc1f3261340f4b25a253a4b3a4446,RTL,0.389403
uuid-4affc1f3261340f4b25a253a4b3a4446,trial,0.309285
uuid-4affc1f3261340f4b25a253a4b3a4446,using nivo,0.372371
uuid-4affc1f3261340f4b25a253a4b3a4446,mentioned,0.439651
uuid-4affc1f3261340f4b25a253a4b3a4446,HCP,0.678077
uuid-4affc1f3261340f4b25a253a4b3a4446,impressed,0.405997
uuid-4affc1f3261340f4b25a253a4b3a4446,LTL,0.399109
uuid-4affc1f3261340f4b25a253a4b3a4446,feels,0.431812
uuid-aa52720dfca7400895cd9de92d35cf33,Nivo,0.401342
uuid-aa52720dfca7400895cd9de92d35cf33,patients,0.399462
uuid-aa52720dfca7400895cd9de92d35cf33,therapy,0.693068
uuid-aa52720dfca7400895cd9de92d35cf33,nivolumab,0.514305
uuid-aa52720dfca7400895cd9de92d35cf33,cHL,0.817307
uuid-aa52720dfca7400895cd9de92d35cf33,chemotherapy,0.387508
uuid-306a202d2c54470aa576c36f77fb25f4,Opdivo,0.543289
uuid-306a202d2c54470aa576c36f77fb25f4,pembro,0.300056
uuid-306a202d2c54470aa576c36f77fb25f4,dose,0.838204
uuid-306a202d2c54470aa576c36f77fb25f4,toxicity,0.305015
uuid-306a202d2c54470aa576c36f77fb25f4,Ipi,0.432752
uuid-306a202d2c54470aa576c36f77fb25f4,vs,0.436931
uuid-306a202d2c54470aa576c36f77fb25f4,Keytruda,0.529338
uuid-306a202d2c54470aa576c36f77fb25f4,flat dosing,0.804011
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,patients,0.363807
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,TL,0.358779
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,1L,0.419619
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,RCC,0.386229
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,TL stated,0.605528
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,2L,0.335573
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,pts,0.309235
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,PD-L1,0.659325
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,approval,0.321812
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,PD-L1 testing,0.657893
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,testing,0.788218
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,PDL1 testing,0.738301
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,NSCLC patients,0.828329
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,tumor types,0.453534
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,assay,0.383218
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,RTL stated,0.34284
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,TL shared,0.382173
uuid-6d9cd729c7f04e5d82aff16d8e3f1fc0,biomarker,0.30169
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,Nivo,0.659846
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,pembro,0.767306
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,dose,0.405663
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,1L,0.323134
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,efficacy,0.510338
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,2L,0.445693
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,agents,0.309583
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,Ipi,0.477093
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,atezo,0.737435
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,preferred,0.403699
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,using nivo,0.480269
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,data,0.35195
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,indication,0.394066
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,approved,0.361378
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,HCP,0.342355
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,nivo and pembro,0.504245
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,vs,0.627337
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,feels,0.350016
uuid-f88fca1d48dd406ab23f6ea9f9f93e72,flat dosing,0.347961
uuid-ccce22d0fa9243dcae6e9102703beff8,Nivo,0.404609
uuid-ccce22d0fa9243dcae6e9102703beff8,RTL,0.447119
uuid-ccce22d0fa9243dcae6e9102703beff8,nivolumab,0.337322
uuid-ccce22d0fa9243dcae6e9102703beff8,trial,0.32848
uuid-ccce22d0fa9243dcae6e9102703beff8,regimen,0.302094
uuid-ccce22d0fa9243dcae6e9102703beff8,combination,0.348893
uuid-ccce22d0fa9243dcae6e9102703beff8,Ipi,0.599258
uuid-ccce22d0fa9243dcae6e9102703beff8,using nivo,0.406507
uuid-ccce22d0fa9243dcae6e9102703beff8,combo,0.313549
uuid-ccce22d0fa9243dcae6e9102703beff8,mentioned,0.359327
uuid-ccce22d0fa9243dcae6e9102703beff8,HCP,0.472221
uuid-ccce22d0fa9243dcae6e9102703beff8,SCLC,0.572253
uuid-e303265465a847f8b976f429ca4571c8,Nivo,0.431259
uuid-e303265465a847f8b976f429ca4571c8,patients,0.424201
uuid-e303265465a847f8b976f429ca4571c8,RTL,0.454873
uuid-e303265465a847f8b976f429ca4571c8,nivolumab,0.476577
uuid-e303265465a847f8b976f429ca4571c8,regimen,0.427986
uuid-e303265465a847f8b976f429ca4571c8,combination,0.434965
uuid-e303265465a847f8b976f429ca4571c8,2L,0.303125
uuid-e303265465a847f8b976f429ca4571c8,pts,0.370332
uuid-e303265465a847f8b976f429ca4571c8,Ipi,0.580693
uuid-e303265465a847f8b976f429ca4571c8,preferred,0.342001
uuid-e303265465a847f8b976f429ca4571c8,monotherapy,0.435795
uuid-e303265465a847f8b976f429ca4571c8,using nivo,0.601118
uuid-e303265465a847f8b976f429ca4571c8,combo,0.414635
uuid-e303265465a847f8b976f429ca4571c8,mentioned,0.361433
uuid-e303265465a847f8b976f429ca4571c8,SCCHN,0.324843
uuid-e303265465a847f8b976f429ca4571c8,HCP,0.532116
uuid-e303265465a847f8b976f429ca4571c8,LTL,0.361797
uuid-e303265465a847f8b976f429ca4571c8,SCLC,0.477091
uuid-e303265465a847f8b976f429ca4571c8,RTL stated,0.390912
uuid-e303265465a847f8b976f429ca4571c8,option,0.348393
uuid-0870530715714d758d237cf5de9b3b87,TL,0.351307
uuid-0870530715714d758d237cf5de9b3b87,PDL1,0.33316
uuid-0870530715714d758d237cf5de9b3b87,tumor,0.492974
uuid-0870530715714d758d237cf5de9b3b87,PD-L1,0.569259
uuid-0870530715714d758d237cf5de9b3b87,PD-L1 testing,0.473601
uuid-0870530715714d758d237cf5de9b3b87,testing,0.521951
uuid-0870530715714d758d237cf5de9b3b87,PDL1 testing,0.306379
uuid-0870530715714d758d237cf5de9b3b87,NSCLC patients,0.408662
uuid-0870530715714d758d237cf5de9b3b87,HCP,0.37017
uuid-0870530715714d758d237cf5de9b3b87,assay,0.545433
uuid-0870530715714d758d237cf5de9b3b87,PDL1 expression,0.31468
uuid-0870530715714d758d237cf5de9b3b87,biomarker,0.328827
uuid-c23b061e28554103abb9c27102d3afcd,Nivo,0.373732
uuid-c23b061e28554103abb9c27102d3afcd,patients,0.627879
uuid-c23b061e28554103abb9c27102d3afcd,Opdivo,0.398204
uuid-c23b061e28554103abb9c27102d3afcd,therapy,0.702073
uuid-c23b061e28554103abb9c27102d3afcd,nivolumab,0.51586
uuid-c23b061e28554103abb9c27102d3afcd,treated,0.378863
uuid-c23b061e28554103abb9c27102d3afcd,treatment,0.453162
uuid-c23b061e28554103abb9c27102d3afcd,using nivo,0.30135
uuid-c23b061e28554103abb9c27102d3afcd,cHL,0.796117
uuid-c23b061e28554103abb9c27102d3afcd,progression,0.415319
uuid-c23b061e28554103abb9c27102d3afcd,chemotherapy,0.346169
uuid-25ecf2238ff946d994b7d0f76c5cebe9,patients,0.464203
uuid-25ecf2238ff946d994b7d0f76c5cebe9,therapy,0.33378
uuid-25ecf2238ff946d994b7d0f76c5cebe9,nivolumab,0.331255
uuid-25ecf2238ff946d994b7d0f76c5cebe9,treated,0.327169
uuid-25ecf2238ff946d994b7d0f76c5cebe9,treatment,0.415334
uuid-25ecf2238ff946d994b7d0f76c5cebe9,progression,0.446316
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,patients,0.592488
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,Opdivo,0.305145
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,therapy,0.359488
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,nivolumab,0.408055
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,trial,0.315922
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,regimen,0.300576
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,treated,0.518764
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,pts,0.419539
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,treatment,0.386843
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,cHL,0.340321
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,progression,0.381076
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,chemotherapy,0.332955
uuid-78f9d1560ecc48c2a9fba78a6cb8a083,respond,0.311723
uuid-2ffe1d995fe14c11858548e6f9acef40,patients,0.441735
uuid-2ffe1d995fe14c11858548e6f9acef40,Opdivo,0.543161
uuid-2ffe1d995fe14c11858548e6f9acef40,dose,0.429432
uuid-2ffe1d995fe14c11858548e6f9acef40,physicians,0.301684
uuid-2ffe1d995fe14c11858548e6f9acef40,treatment,0.322699
uuid-2ffe1d995fe14c11858548e6f9acef40,label,0.335715
uuid-2ffe1d995fe14c11858548e6f9acef40,flat dosing,0.555761
uuid-16a9f323398f48078ef0858a4825fc15,preferred,0.388478
uuid-16a9f323398f48078ef0858a4825fc15,using nivo,0.316662
uuid-16a9f323398f48078ef0858a4825fc15,feels,0.323202
uuid-16a9f323398f48078ef0858a4825fc15,RTL stated,0.350587
uuid-14586d96c91345d7a0ccf6472d437899,pembro,0.505592
uuid-14586d96c91345d7a0ccf6472d437899,1L,0.50378
uuid-14586d96c91345d7a0ccf6472d437899,PDL1,0.361494
uuid-14586d96c91345d7a0ccf6472d437899,TL stated,0.376992
uuid-14586d96c91345d7a0ccf6472d437899,2L,0.46953
uuid-14586d96c91345d7a0ccf6472d437899,Merck,0.373015
uuid-14586d96c91345d7a0ccf6472d437899,institution,0.435932
uuid-14586d96c91345d7a0ccf6472d437899,stated,0.442663
uuid-14586d96c91345d7a0ccf6472d437899,PD-L1,0.486976
uuid-14586d96c91345d7a0ccf6472d437899,approval,0.498956
uuid-14586d96c91345d7a0ccf6472d437899,atezo,0.467732
uuid-14586d96c91345d7a0ccf6472d437899,preferred,0.354037
uuid-14586d96c91345d7a0ccf6472d437899,PD-L1 testing,0.52084
uuid-14586d96c91345d7a0ccf6472d437899,testing,0.571793
uuid-14586d96c91345d7a0ccf6472d437899,using nivo,0.443995
uuid-14586d96c91345d7a0ccf6472d437899,PDL1 testing,0.602888
uuid-14586d96c91345d7a0ccf6472d437899,NSCLC patients,0.506328
uuid-14586d96c91345d7a0ccf6472d437899,approved,0.41515
uuid-14586d96c91345d7a0ccf6472d437899,SCCHN,0.413525
uuid-14586d96c91345d7a0ccf6472d437899,tumor types,0.327139
uuid-14586d96c91345d7a0ccf6472d437899,assay,0.346828
uuid-14586d96c91345d7a0ccf6472d437899,RTL stated,0.397243
uuid-14586d96c91345d7a0ccf6472d437899,bladder,0.342374
uuid-e9d3467c410c47dbbf89290e5d4f8d16,drug,0.379219
uuid-13461b887fbc478dbe5858e5e54149d0,Nivo,0.660007
uuid-13461b887fbc478dbe5858e5e54149d0,patients,0.333784
uuid-13461b887fbc478dbe5858e5e54149d0,pembro,0.471402
uuid-13461b887fbc478dbe5858e5e54149d0,nivolumab,0.333554
uuid-13461b887fbc478dbe5858e5e54149d0,1L,0.352906
uuid-13461b887fbc478dbe5858e5e54149d0,2L,0.39389
uuid-13461b887fbc478dbe5858e5e54149d0,approval,0.554846
uuid-13461b887fbc478dbe5858e5e54149d0,atezo,0.34191
uuid-13461b887fbc478dbe5858e5e54149d0,preferred,0.311099
uuid-13461b887fbc478dbe5858e5e54149d0,using nivo,0.552874
uuid-13461b887fbc478dbe5858e5e54149d0,approved,0.410967
uuid-13461b887fbc478dbe5858e5e54149d0,cHL,0.326107
uuid-13461b887fbc478dbe5858e5e54149d0,RTL stated,0.335378
uuid-85b66a9bfac64f70be62b34d7995ddc8,RTL,0.586545
uuid-85b66a9bfac64f70be62b34d7995ddc8,commented,0.394198
uuid-85b66a9bfac64f70be62b34d7995ddc8,RCC,0.317482
uuid-85b66a9bfac64f70be62b34d7995ddc8,stated,0.55735
uuid-85b66a9bfac64f70be62b34d7995ddc8,approval,0.391529
uuid-85b66a9bfac64f70be62b34d7995ddc8,preferred,0.363808
uuid-85b66a9bfac64f70be62b34d7995ddc8,using nivo,0.434419
uuid-85b66a9bfac64f70be62b34d7995ddc8,data,0.528122
uuid-85b66a9bfac64f70be62b34d7995ddc8,expressed,0.337395
uuid-85b66a9bfac64f70be62b34d7995ddc8,mentioned,0.320318
uuid-85b66a9bfac64f70be62b34d7995ddc8,clinical trials,0.381552
uuid-85b66a9bfac64f70be62b34d7995ddc8,indication,0.40315
uuid-85b66a9bfac64f70be62b34d7995ddc8,approved,0.337955
uuid-85b66a9bfac64f70be62b34d7995ddc8,SCCHN,0.66858
uuid-85b66a9bfac64f70be62b34d7995ddc8,HCP,0.34461
uuid-85b66a9bfac64f70be62b34d7995ddc8,impressed,0.618442
uuid-85b66a9bfac64f70be62b34d7995ddc8,LTL,0.542415
uuid-85b66a9bfac64f70be62b34d7995ddc8,TLs,0.340387
uuid-85b66a9bfac64f70be62b34d7995ddc8,SCLC,0.306288
uuid-85b66a9bfac64f70be62b34d7995ddc8,feels,0.338935
uuid-85b66a9bfac64f70be62b34d7995ddc8,Regional TL,0.549998
uuid-85b66a9bfac64f70be62b34d7995ddc8,RTL stated,0.530566
uuid-85b66a9bfac64f70be62b34d7995ddc8,bladder,0.378307
uuid-ca3936667a6047d282624fa3eca28128,TL,0.502798
uuid-ca3936667a6047d282624fa3eca28128,TL stated,0.378982
uuid-ca3936667a6047d282624fa3eca28128,institution,0.354818
uuid-ca3936667a6047d282624fa3eca28128,PD-L1,0.574869
uuid-ca3936667a6047d282624fa3eca28128,PD-L1 testing,0.820319
uuid-ca3936667a6047d282624fa3eca28128,testing,0.718257
uuid-ca3936667a6047d282624fa3eca28128,PDL1 testing,0.613275
uuid-ca3936667a6047d282624fa3eca28128,NSCLC patients,0.46962
uuid-ca3936667a6047d282624fa3eca28128,assay,0.481696
uuid-3a25d400f9b8486e84c53d1554324007,shared,0.519074
uuid-3a25d400f9b8486e84c53d1554324007,RCC,0.328466
uuid-3a25d400f9b8486e84c53d1554324007,TL stated,0.45251
uuid-3a25d400f9b8486e84c53d1554324007,pts,0.309908
uuid-3a25d400f9b8486e84c53d1554324007,institution,0.371183
uuid-3a25d400f9b8486e84c53d1554324007,stated,0.385587
uuid-3a25d400f9b8486e84c53d1554324007,PD-L1 testing,0.406255
uuid-3a25d400f9b8486e84c53d1554324007,testing,0.445033
uuid-3a25d400f9b8486e84c53d1554324007,clinical trials,0.312064
uuid-3a25d400f9b8486e84c53d1554324007,PDL1 testing,0.56917
uuid-3a25d400f9b8486e84c53d1554324007,NSCLC patients,0.457524
uuid-3a25d400f9b8486e84c53d1554324007,SCCHN,0.356488
uuid-3a25d400f9b8486e84c53d1554324007,tumor types,0.398674
uuid-3a25d400f9b8486e84c53d1554324007,RTL stated,0.381757
uuid-b6d0ca65783943ae95ad52d758eff801,patients,0.472227
uuid-b6d0ca65783943ae95ad52d758eff801,therapy,0.411749
uuid-b6d0ca65783943ae95ad52d758eff801,toxicity,0.496293
uuid-b6d0ca65783943ae95ad52d758eff801,regimen,0.508252
uuid-b6d0ca65783943ae95ad52d758eff801,treated,0.509721
uuid-b6d0ca65783943ae95ad52d758eff801,physicians,0.316147
uuid-b6d0ca65783943ae95ad52d758eff801,treatment,0.70206
uuid-b6d0ca65783943ae95ad52d758eff801,response,0.404732
uuid-b6d0ca65783943ae95ad52d758eff801,progression,0.490862
uuid-b6d0ca65783943ae95ad52d758eff801,chemotherapy,0.338154
uuid-b6d0ca65783943ae95ad52d758eff801,respond,0.454655
uuid-b6d0ca65783943ae95ad52d758eff801,immunotherapy,0.419991
uuid-dfb56c58d40e48ba9aac3b60800bf1b3,patients,0.305679
uuid-dfb56c58d40e48ba9aac3b60800bf1b3,therapy,0.403796
uuid-dfb56c58d40e48ba9aac3b60800bf1b3,PDL1,0.344436
uuid-dfb56c58d40e48ba9aac3b60800bf1b3,response,0.46067
uuid-dfb56c58d40e48ba9aac3b60800bf1b3,PD1,0.304294
uuid-dfb56c58d40e48ba9aac3b60800bf1b3,cHL,0.322722
uuid-dfb56c58d40e48ba9aac3b60800bf1b3,progression,0.335605
uuid-dfb56c58d40e48ba9aac3b60800bf1b3,biomarker,0.317829
uuid-1a19c310454143249667af750377f407,NSCLC,0.381893
uuid-1a19c310454143249667af750377f407,discussed,0.683812
uuid-1a19c310454143249667af750377f407,IO,0.48771
uuid-1a19c310454143249667af750377f407,TLs,0.361752
uuid-1a19c310454143249667af750377f407,academic,0.569732
uuid-1a19c310454143249667af750377f407,feels,0.314415
uuid-22a8e96ba1654bfeb3b8df5bbb199911,BMS,0.315161
uuid-22a8e96ba1654bfeb3b8df5bbb199911,NTL,0.30041
uuid-22a8e96ba1654bfeb3b8df5bbb199911,discussed,0.830144
uuid-22a8e96ba1654bfeb3b8df5bbb199911,commented,0.372081
uuid-22a8e96ba1654bfeb3b8df5bbb199911,OS,0.31949
uuid-22a8e96ba1654bfeb3b8df5bbb199911,regards,0.342177
uuid-22a8e96ba1654bfeb3b8df5bbb199911,data,0.486174
uuid-22a8e96ba1654bfeb3b8df5bbb199911,PFS,0.31675
uuid-22a8e96ba1654bfeb3b8df5bbb199911,impressed,0.307981
uuid-22a8e96ba1654bfeb3b8df5bbb199911,TLs,0.398536
uuid-22a8e96ba1654bfeb3b8df5bbb199911,academic,0.603674
uuid-2f5765d2d22b4183b99e60c88b7049f2,RTL,0.478955
uuid-2f5765d2d22b4183b99e60c88b7049f2,lung,0.333909
uuid-2f5765d2d22b4183b99e60c88b7049f2,1L,0.310244
uuid-2f5765d2d22b4183b99e60c88b7049f2,NTL,0.316722
uuid-2f5765d2d22b4183b99e60c88b7049f2,commented,0.392754
uuid-2f5765d2d22b4183b99e60c88b7049f2,RCC,0.530604
uuid-2f5765d2d22b4183b99e60c88b7049f2,TL stated,0.325941
uuid-2f5765d2d22b4183b99e60c88b7049f2,2L,0.317537
uuid-2f5765d2d22b4183b99e60c88b7049f2,stated,0.45082
uuid-2f5765d2d22b4183b99e60c88b7049f2,using nivo,0.397471
uuid-2f5765d2d22b4183b99e60c88b7049f2,data,0.307831
uuid-2f5765d2d22b4183b99e60c88b7049f2,expressed,0.359266
uuid-2f5765d2d22b4183b99e60c88b7049f2,SCCHN,0.567143
uuid-2f5765d2d22b4183b99e60c88b7049f2,impressed,0.497444
uuid-2f5765d2d22b4183b99e60c88b7049f2,LTL,0.399957
uuid-2f5765d2d22b4183b99e60c88b7049f2,TLs,0.458034
uuid-2f5765d2d22b4183b99e60c88b7049f2,SCLC,0.323318
uuid-2f5765d2d22b4183b99e60c88b7049f2,Regional TL,0.618412
uuid-2f5765d2d22b4183b99e60c88b7049f2,RTL stated,0.50824
uuid-2f5765d2d22b4183b99e60c88b7049f2,TL shared,0.38017
uuid-2f5765d2d22b4183b99e60c88b7049f2,bladder,0.382702
uuid-40b3431925e44a7e85a954f1d44ff2d5,Nivo,0.329318
uuid-40b3431925e44a7e85a954f1d44ff2d5,trial,0.479872
uuid-40b3431925e44a7e85a954f1d44ff2d5,efficacy,0.368905
uuid-40b3431925e44a7e85a954f1d44ff2d5,OS,0.626986
uuid-40b3431925e44a7e85a954f1d44ff2d5,data,0.454709
uuid-40b3431925e44a7e85a954f1d44ff2d5,PFS,0.721187
uuid-40b3431925e44a7e85a954f1d44ff2d5,ORR,0.628948
uuid-40b3431925e44a7e85a954f1d44ff2d5,nivo and pembro,0.322845
uuid-40b3431925e44a7e85a954f1d44ff2d5,impressed,0.439208
uuid-7ec230a47ebe4db7b22312a0057daa7d,PDL1,0.463035
uuid-7ec230a47ebe4db7b22312a0057daa7d,PD-L1,0.722782
uuid-7ec230a47ebe4db7b22312a0057daa7d,PD-L1 testing,0.627041
uuid-7ec230a47ebe4db7b22312a0057daa7d,testing,0.785642
uuid-7ec230a47ebe4db7b22312a0057daa7d,PDL1 testing,0.648647
uuid-7ec230a47ebe4db7b22312a0057daa7d,NSCLC patients,0.534921
uuid-7ec230a47ebe4db7b22312a0057daa7d,assay,0.55101
uuid-7ec230a47ebe4db7b22312a0057daa7d,PDL1 expression,0.351032
uuid-7ec230a47ebe4db7b22312a0057daa7d,biomarker,0.613974
uuid-322ccfdeec6c4fe9b5cb8718a27c0cd2,Nivo,0.305398
uuid-322ccfdeec6c4fe9b5cb8718a27c0cd2,patients,0.326642
uuid-322ccfdeec6c4fe9b5cb8718a27c0cd2,Opdivo,0.428818
uuid-322ccfdeec6c4fe9b5cb8718a27c0cd2,pembro,0.418625
uuid-322ccfdeec6c4fe9b5cb8718a27c0cd2,dose,0.368298
uuid-322ccfdeec6c4fe9b5cb8718a27c0cd2,atezo,0.3287
uuid-322ccfdeec6c4fe9b5cb8718a27c0cd2,indication,0.390728
uuid-322ccfdeec6c4fe9b5cb8718a27c0cd2,approved,0.304466
uuid-322ccfdeec6c4fe9b5cb8718a27c0cd2,vs,0.31606
uuid-322ccfdeec6c4fe9b5cb8718a27c0cd2,Keytruda,0.417888
uuid-322ccfdeec6c4fe9b5cb8718a27c0cd2,feels,0.335583
uuid-322ccfdeec6c4fe9b5cb8718a27c0cd2,flat dosing,0.308609
uuid-6cd4ea7b3e184ed8bb04de8a4250bc41,patients,0.59139
uuid-6cd4ea7b3e184ed8bb04de8a4250bc41,Opdivo,0.354258
uuid-6cd4ea7b3e184ed8bb04de8a4250bc41,therapy,0.401626
uuid-6cd4ea7b3e184ed8bb04de8a4250bc41,regimen,0.434691
uuid-6cd4ea7b3e184ed8bb04de8a4250bc41,treated,0.430095
uuid-6cd4ea7b3e184ed8bb04de8a4250bc41,pts,0.494718
uuid-6cd4ea7b3e184ed8bb04de8a4250bc41,treatment,0.621798
uuid-6cd4ea7b3e184ed8bb04de8a4250bc41,response,0.546876
uuid-6cd4ea7b3e184ed8bb04de8a4250bc41,progression,0.717001
uuid-6cd4ea7b3e184ed8bb04de8a4250bc41,respond,0.600319
uuid-7020006ab50f4714936dc45e952459af,commented,0.425509
uuid-7020006ab50f4714936dc45e952459af,response,0.362603
uuid-7020006ab50f4714936dc45e952459af,ASCO,0.332524
uuid-59d215b836de48e2a052de7ea1f5889f,TL,0.482897
uuid-59d215b836de48e2a052de7ea1f5889f,pembro,0.398242
uuid-59d215b836de48e2a052de7ea1f5889f,1L,0.327072
uuid-59d215b836de48e2a052de7ea1f5889f,PDL1,0.703374
uuid-59d215b836de48e2a052de7ea1f5889f,Merck,0.432644
uuid-59d215b836de48e2a052de7ea1f5889f,PD-L1,0.759172
uuid-59d215b836de48e2a052de7ea1f5889f,atezo,0.438769
uuid-59d215b836de48e2a052de7ea1f5889f,PD-L1 testing,0.548326
uuid-59d215b836de48e2a052de7ea1f5889f,testing,0.667824
uuid-59d215b836de48e2a052de7ea1f5889f,PDL1 testing,0.451952
uuid-59d215b836de48e2a052de7ea1f5889f,NSCLC patients,0.480799
uuid-59d215b836de48e2a052de7ea1f5889f,nivo and pembro,0.37579
uuid-59d215b836de48e2a052de7ea1f5889f,assay,0.785507
uuid-59d215b836de48e2a052de7ea1f5889f,PDL1 expression,0.508806
uuid-59d215b836de48e2a052de7ea1f5889f,biomarker,0.4583
uuid-f9853dfd3b2143008449bf4c570d2fdc,Nivo,0.350355
uuid-f9853dfd3b2143008449bf4c570d2fdc,patients,0.582231
uuid-f9853dfd3b2143008449bf4c570d2fdc,therapy,0.400198
uuid-f9853dfd3b2143008449bf4c570d2fdc,nivolumab,0.470943
uuid-f9853dfd3b2143008449bf4c570d2fdc,regimen,0.610058
uuid-f9853dfd3b2143008449bf4c570d2fdc,treated,0.445935
uuid-f9853dfd3b2143008449bf4c570d2fdc,combination,0.555996
uuid-f9853dfd3b2143008449bf4c570d2fdc,chemo,0.397283
uuid-f9853dfd3b2143008449bf4c570d2fdc,pts,0.682258
uuid-f9853dfd3b2143008449bf4c570d2fdc,IO,0.302144
uuid-f9853dfd3b2143008449bf4c570d2fdc,Ipi,0.442495
uuid-f9853dfd3b2143008449bf4c570d2fdc,monotherapy,0.520283
uuid-f9853dfd3b2143008449bf4c570d2fdc,treatment,0.439226
uuid-f9853dfd3b2143008449bf4c570d2fdc,using nivo,0.328977
uuid-f9853dfd3b2143008449bf4c570d2fdc,response,0.424807
uuid-f9853dfd3b2143008449bf4c570d2fdc,combo,0.535644
uuid-f9853dfd3b2143008449bf4c570d2fdc,PD1,0.398072
uuid-f9853dfd3b2143008449bf4c570d2fdc,progression,0.551497
uuid-f9853dfd3b2143008449bf4c570d2fdc,chemotherapy,0.41008
uuid-f9853dfd3b2143008449bf4c570d2fdc,respond,0.437739
uuid-f9853dfd3b2143008449bf4c570d2fdc,SCLC,0.334973
uuid-f9853dfd3b2143008449bf4c570d2fdc,option,0.398254
uuid-2196d82445a448aebdad6d2fe0d2ed38,Nivo,0.391981
uuid-2196d82445a448aebdad6d2fe0d2ed38,pembro,0.52785
uuid-2196d82445a448aebdad6d2fe0d2ed38,BMS,0.315477
uuid-2196d82445a448aebdad6d2fe0d2ed38,PDL1,0.530722
uuid-2196d82445a448aebdad6d2fe0d2ed38,trial,0.503857
uuid-2196d82445a448aebdad6d2fe0d2ed38,efficacy,0.757183
uuid-2196d82445a448aebdad6d2fe0d2ed38,Ipi,0.314799
uuid-2196d82445a448aebdad6d2fe0d2ed38,OS,0.58139
uuid-2196d82445a448aebdad6d2fe0d2ed38,atezo,0.488222
uuid-2196d82445a448aebdad6d2fe0d2ed38,data,0.666074
uuid-2196d82445a448aebdad6d2fe0d2ed38,PFS,0.576973
uuid-2196d82445a448aebdad6d2fe0d2ed38,ORR,0.629407
uuid-2196d82445a448aebdad6d2fe0d2ed38,nivo and pembro,0.662783
uuid-2196d82445a448aebdad6d2fe0d2ed38,believes,0.464649
uuid-2196d82445a448aebdad6d2fe0d2ed38,impressed,0.414504
uuid-2196d82445a448aebdad6d2fe0d2ed38,vs,0.574565
uuid-2196d82445a448aebdad6d2fe0d2ed38,feels,0.407826
uuid-2196d82445a448aebdad6d2fe0d2ed38,PDL1 expression,0.475513
uuid-5c3c116c439b40b58fe9485752f15ca5,Nivo,0.375126
uuid-5c3c116c439b40b58fe9485752f15ca5,patients,0.351157
uuid-5c3c116c439b40b58fe9485752f15ca5,pembro,0.576516
uuid-5c3c116c439b40b58fe9485752f15ca5,dose,0.384548
uuid-5c3c116c439b40b58fe9485752f15ca5,1L,0.447738
uuid-5c3c116c439b40b58fe9485752f15ca5,2L,0.566341
uuid-5c3c116c439b40b58fe9485752f15ca5,agents,0.314161
uuid-5c3c116c439b40b58fe9485752f15ca5,approval,0.393336
uuid-5c3c116c439b40b58fe9485752f15ca5,atezo,0.573074
uuid-5c3c116c439b40b58fe9485752f15ca5,preferred,0.763166
uuid-5c3c116c439b40b58fe9485752f15ca5,monotherapy,0.423127
uuid-5c3c116c439b40b58fe9485752f15ca5,using nivo,0.542577
uuid-5c3c116c439b40b58fe9485752f15ca5,indication,0.404214
uuid-5c3c116c439b40b58fe9485752f15ca5,NSCLC patients,0.30824
uuid-5c3c116c439b40b58fe9485752f15ca5,approved,0.466743
uuid-5c3c116c439b40b58fe9485752f15ca5,SCCHN,0.353587
uuid-5c3c116c439b40b58fe9485752f15ca5,vs,0.36122
uuid-5c3c116c439b40b58fe9485752f15ca5,RTL stated,0.490423
uuid-5c3c116c439b40b58fe9485752f15ca5,option,0.536949
uuid-7cf3333c26d84408af187b85b45ceba2,patients,0.342787
uuid-7cf3333c26d84408af187b85b45ceba2,pembro,0.314215
uuid-7cf3333c26d84408af187b85b45ceba2,regimen,0.348865
uuid-7cf3333c26d84408af187b85b45ceba2,treated,0.325061
uuid-7cf3333c26d84408af187b85b45ceba2,pts,0.536036
uuid-7cf3333c26d84408af187b85b45ceba2,monotherapy,0.330208
uuid-7cf3333c26d84408af187b85b45ceba2,feels,0.46428
uuid-c06376b22a484727b84ca71f95007b25,NSCLC,0.339305
uuid-c06376b22a484727b84ca71f95007b25,PDL1,0.522928
uuid-c06376b22a484727b84ca71f95007b25,trial,0.478308
uuid-c06376b22a484727b84ca71f95007b25,efficacy,0.447821
uuid-c06376b22a484727b84ca71f95007b25,IO,0.364737
uuid-c06376b22a484727b84ca71f95007b25,OS,0.482066
uuid-c06376b22a484727b84ca71f95007b25,data,0.5267
uuid-c06376b22a484727b84ca71f95007b25,PFS,0.52367
uuid-c06376b22a484727b84ca71f95007b25,ORR,0.524309
uuid-c06376b22a484727b84ca71f95007b25,nivo and pembro,0.490265
uuid-c06376b22a484727b84ca71f95007b25,believes,0.411922
uuid-c06376b22a484727b84ca71f95007b25,impressed,0.317423
uuid-c06376b22a484727b84ca71f95007b25,feels,0.420986
uuid-c06376b22a484727b84ca71f95007b25,PDL1 expression,0.411528
uuid-3b3e0ab3180c449c8b36e29c9dcb0d7e,dose,0.380382
uuid-3b3e0ab3180c449c8b36e29c9dcb0d7e,toxicity,0.394833
uuid-3b3e0ab3180c449c8b36e29c9dcb0d7e,oncology,0.335775
uuid-3b3e0ab3180c449c8b36e29c9dcb0d7e,drug,0.477566
uuid-3b3e0ab3180c449c8b36e29c9dcb0d7e,clinical,0.334207
uuid-3b3e0ab3180c449c8b36e29c9dcb0d7e,flat dosing,0.486401
uuid-67ce1dff16db45498cbfdfcfe816a192,RTL,0.320343
uuid-67ce1dff16db45498cbfdfcfe816a192,NTL,0.318534
uuid-67ce1dff16db45498cbfdfcfe816a192,melanoma,0.408111
uuid-67ce1dff16db45498cbfdfcfe816a192,RCC,0.331387
uuid-67ce1dff16db45498cbfdfcfe816a192,SCCHN,0.32822
uuid-67ce1dff16db45498cbfdfcfe816a192,lung cancer,0.361946
uuid-67ce1dff16db45498cbfdfcfe816a192,TL shared,0.402066
uuid-18f58f5a166b4406bb7b3ac114250ad5,patients,0.834397
uuid-18f58f5a166b4406bb7b3ac114250ad5,Opdivo,0.499662
uuid-18f58f5a166b4406bb7b3ac114250ad5,therapy,0.595167
uuid-18f58f5a166b4406bb7b3ac114250ad5,nivolumab,0.513868
uuid-18f58f5a166b4406bb7b3ac114250ad5,regimen,0.587717
uuid-18f58f5a166b4406bb7b3ac114250ad5,treated,0.626125
uuid-18f58f5a166b4406bb7b3ac114250ad5,chemo,0.372628
uuid-18f58f5a166b4406bb7b3ac114250ad5,pts,0.543761
uuid-18f58f5a166b4406bb7b3ac114250ad5,monotherapy,0.390206
uuid-18f58f5a166b4406bb7b3ac114250ad5,treatment,0.762328
uuid-18f58f5a166b4406bb7b3ac114250ad5,response,0.443977
uuid-18f58f5a166b4406bb7b3ac114250ad5,PD1,0.309274
uuid-18f58f5a166b4406bb7b3ac114250ad5,progression,0.691795
uuid-18f58f5a166b4406bb7b3ac114250ad5,chemotherapy,0.492751
uuid-18f58f5a166b4406bb7b3ac114250ad5,respond,0.497192
uuid-18f58f5a166b4406bb7b3ac114250ad5,option,0.377589
uuid-2af8869b8e674dc1b7a3e77f79b32c50,Nivo,0.507822
uuid-2af8869b8e674dc1b7a3e77f79b32c50,pembro,0.627405
uuid-2af8869b8e674dc1b7a3e77f79b32c50,dose,0.52485
uuid-2af8869b8e674dc1b7a3e77f79b32c50,trial,0.620942
uuid-2af8869b8e674dc1b7a3e77f79b32c50,efficacy,0.351987
uuid-2af8869b8e674dc1b7a3e77f79b32c50,Ipi,0.53073
uuid-2af8869b8e674dc1b7a3e77f79b32c50,approval,0.340313
uuid-2af8869b8e674dc1b7a3e77f79b32c50,atezo,0.528937
uuid-2af8869b8e674dc1b7a3e77f79b32c50,using nivo,0.302705
uuid-2af8869b8e674dc1b7a3e77f79b32c50,clinical trials,0.34506
uuid-2af8869b8e674dc1b7a3e77f79b32c50,indication,0.401726
uuid-2af8869b8e674dc1b7a3e77f79b32c50,approved,0.35993
uuid-2af8869b8e674dc1b7a3e77f79b32c50,vs,0.566381
uuid-2af8869b8e674dc1b7a3e77f79b32c50,Keytruda,0.30096
uuid-2af8869b8e674dc1b7a3e77f79b32c50,flat dosing,0.521907
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,Nivo,0.488503
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,pembro,0.559564
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,PDL1,0.459611
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,trial,0.371313
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,efficacy,0.729639
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,agents,0.392159
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,Ipi,0.324095
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,OS,0.400704
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,atezo,0.57751
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,regards,0.308342
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,data,0.460103
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,indication,0.330025
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,PFS,0.411664
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,ORR,0.45341
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,nivo and pembro,0.644283
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,believes,0.49583
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,vs,0.56397
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,feels,0.360996
uuid-877bf9df0fcf4252bbfdb1f44e4d92f1,PDL1 expression,0.450653
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,RTL,0.3373
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,BMS,0.328142
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,trial,0.581764
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,efficacy,0.437889
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,discussed,0.35551
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,commented,0.36174
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,OS,0.725856
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,regards,0.334232
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,data,0.68093
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,PFS,0.747337
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,ORR,0.706691
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,nivo and pembro,0.373697
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,ASCO,0.323983
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,impressed,0.56231
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,feels,0.318016
uuid-e0b0076cbbbc4fcf9f9644408cda77a9,PDL1 expression,0.310915
uuid-4200681b3a2545f290ac8167e38029c8,TL,0.678748
uuid-4200681b3a2545f290ac8167e38029c8,PDL1,0.34039
uuid-4200681b3a2545f290ac8167e38029c8,TL stated,0.379121
uuid-4200681b3a2545f290ac8167e38029c8,institution,0.404142
uuid-4200681b3a2545f290ac8167e38029c8,PD-L1,0.801336
uuid-4200681b3a2545f290ac8167e38029c8,PD-L1 testing,0.912645
uuid-4200681b3a2545f290ac8167e38029c8,testing,0.871234
uuid-4200681b3a2545f290ac8167e38029c8,PDL1 testing,0.640516
uuid-4200681b3a2545f290ac8167e38029c8,NSCLC patients,0.601276
uuid-4200681b3a2545f290ac8167e38029c8,assay,0.785761
uuid-4200681b3a2545f290ac8167e38029c8,biomarker,0.367363
uuid-e97eba13664846d98d58684a7300ee83,pembro,0.315012
uuid-e97eba13664846d98d58684a7300ee83,BMS,0.330213
uuid-e97eba13664846d98d58684a7300ee83,1L,0.389228
uuid-e97eba13664846d98d58684a7300ee83,PDL1,0.335413
uuid-e97eba13664846d98d58684a7300ee83,TL stated,0.370974
uuid-e97eba13664846d98d58684a7300ee83,2L,0.382807
uuid-e97eba13664846d98d58684a7300ee83,Merck,0.369966
uuid-e97eba13664846d98d58684a7300ee83,stated,0.505776
uuid-e97eba13664846d98d58684a7300ee83,approval,0.417891
uuid-e97eba13664846d98d58684a7300ee83,atezo,0.342159
uuid-e97eba13664846d98d58684a7300ee83,testing,0.403702
uuid-e97eba13664846d98d58684a7300ee83,PDL1 testing,0.522005
uuid-e97eba13664846d98d58684a7300ee83,indication,0.313213
uuid-e97eba13664846d98d58684a7300ee83,NSCLC patients,0.328182
uuid-e97eba13664846d98d58684a7300ee83,approved,0.475531
uuid-e97eba13664846d98d58684a7300ee83,tumor types,0.361179
uuid-e97eba13664846d98d58684a7300ee83,LTL,0.310493
uuid-0839bd75bd434001adac6002578ddfda,BMS,0.333348
uuid-0839bd75bd434001adac6002578ddfda,trial,0.531706
uuid-0839bd75bd434001adac6002578ddfda,commented,0.320085
uuid-0839bd75bd434001adac6002578ddfda,clinical trials,0.337382
uuid-9eb3026be12b423d9423871a3f5a6ccf,TL,0.36954
uuid-9eb3026be12b423d9423871a3f5a6ccf,1L,0.409406
uuid-9eb3026be12b423d9423871a3f5a6ccf,PDL1,0.381619
uuid-9eb3026be12b423d9423871a3f5a6ccf,RCC,0.350285
uuid-9eb3026be12b423d9423871a3f5a6ccf,TL stated,0.525397
uuid-9eb3026be12b423d9423871a3f5a6ccf,2L,0.345258
uuid-9eb3026be12b423d9423871a3f5a6ccf,stated,0.412869
uuid-9eb3026be12b423d9423871a3f5a6ccf,PD-L1,0.530843
uuid-9eb3026be12b423d9423871a3f5a6ccf,approval,0.409568
uuid-9eb3026be12b423d9423871a3f5a6ccf,PD-L1 testing,0.502372
uuid-9eb3026be12b423d9423871a3f5a6ccf,testing,0.612219
uuid-9eb3026be12b423d9423871a3f5a6ccf,PDL1 testing,0.661322
uuid-9eb3026be12b423d9423871a3f5a6ccf,NSCLC patients,0.576041
uuid-9eb3026be12b423d9423871a3f5a6ccf,SCCHN,0.440519
uuid-9eb3026be12b423d9423871a3f5a6ccf,tumor types,0.346596
uuid-9eb3026be12b423d9423871a3f5a6ccf,assay,0.385916
uuid-9eb3026be12b423d9423871a3f5a6ccf,Regional TL,0.430506
uuid-9eb3026be12b423d9423871a3f5a6ccf,RTL stated,0.345929
uuid-9eb3026be12b423d9423871a3f5a6ccf,bladder,0.327513
uuid-acb6e95c2b524453a2f72bb41f204bff,PDL1,0.324304
uuid-acb6e95c2b524453a2f72bb41f204bff,efficacy,0.451557
uuid-acb6e95c2b524453a2f72bb41f204bff,chemo,0.498442
uuid-acb6e95c2b524453a2f72bb41f204bff,IO,0.394635
uuid-acb6e95c2b524453a2f72bb41f204bff,OS,0.726731
uuid-acb6e95c2b524453a2f72bb41f204bff,monotherapy,0.306006
uuid-acb6e95c2b524453a2f72bb41f204bff,response,0.402884
uuid-acb6e95c2b524453a2f72bb41f204bff,PFS,0.663002
uuid-acb6e95c2b524453a2f72bb41f204bff,ORR,0.549637
uuid-acb6e95c2b524453a2f72bb41f204bff,progression,0.370257
uuid-acb6e95c2b524453a2f72bb41f204bff,believes,0.444147
uuid-acb6e95c2b524453a2f72bb41f204bff,chemotherapy,0.35792
uuid-acb6e95c2b524453a2f72bb41f204bff,feels,0.458913
uuid-97e422d7d9604893973ae5ae5bfce6c4,1L,0.522468
uuid-97e422d7d9604893973ae5ae5bfce6c4,RCC,0.371416
uuid-97e422d7d9604893973ae5ae5bfce6c4,TL stated,0.443011
uuid-97e422d7d9604893973ae5ae5bfce6c4,2L,0.396274
uuid-97e422d7d9604893973ae5ae5bfce6c4,stated,0.38208
uuid-97e422d7d9604893973ae5ae5bfce6c4,PD-L1,0.428922
uuid-97e422d7d9604893973ae5ae5bfce6c4,approval,0.324599
uuid-97e422d7d9604893973ae5ae5bfce6c4,preferred,0.410209
uuid-97e422d7d9604893973ae5ae5bfce6c4,PD-L1 testing,0.425186
uuid-97e422d7d9604893973ae5ae5bfce6c4,testing,0.575706
uuid-97e422d7d9604893973ae5ae5bfce6c4,using nivo,0.379574
uuid-97e422d7d9604893973ae5ae5bfce6c4,PDL1 testing,0.640797
uuid-97e422d7d9604893973ae5ae5bfce6c4,NSCLC patients,0.675252
uuid-97e422d7d9604893973ae5ae5bfce6c4,SCCHN,0.472586
uuid-97e422d7d9604893973ae5ae5bfce6c4,tumor types,0.463527
uuid-97e422d7d9604893973ae5ae5bfce6c4,RTL stated,0.535123
uuid-97e422d7d9604893973ae5ae5bfce6c4,TL shared,0.337299
uuid-97e422d7d9604893973ae5ae5bfce6c4,option,0.380759
uuid-9e58ab30c8054ea8b395442abcc5d0a5,Nivo,0.764858
uuid-9e58ab30c8054ea8b395442abcc5d0a5,patients,0.383638
uuid-9e58ab30c8054ea8b395442abcc5d0a5,Opdivo,0.331414
uuid-9e58ab30c8054ea8b395442abcc5d0a5,pembro,0.75412
uuid-9e58ab30c8054ea8b395442abcc5d0a5,dose,0.489819
uuid-9e58ab30c8054ea8b395442abcc5d0a5,nivolumab,0.327268
uuid-9e58ab30c8054ea8b395442abcc5d0a5,1L,0.474543
uuid-9e58ab30c8054ea8b395442abcc5d0a5,chemo,0.353278
uuid-9e58ab30c8054ea8b395442abcc5d0a5,2L,0.599825
uuid-9e58ab30c8054ea8b395442abcc5d0a5,agents,0.337001
uuid-9e58ab30c8054ea8b395442abcc5d0a5,Ipi,0.502616
uuid-9e58ab30c8054ea8b395442abcc5d0a5,approval,0.460521
uuid-9e58ab30c8054ea8b395442abcc5d0a5,atezo,0.679552
uuid-9e58ab30c8054ea8b395442abcc5d0a5,preferred,0.562517
uuid-9e58ab30c8054ea8b395442abcc5d0a5,monotherapy,0.482691
uuid-9e58ab30c8054ea8b395442abcc5d0a5,using nivo,0.589903
uuid-9e58ab30c8054ea8b395442abcc5d0a5,indication,0.403774
uuid-9e58ab30c8054ea8b395442abcc5d0a5,approved,0.53478
uuid-9e58ab30c8054ea8b395442abcc5d0a5,vs,0.513089
uuid-9e58ab30c8054ea8b395442abcc5d0a5,label,0.363761
uuid-9e58ab30c8054ea8b395442abcc5d0a5,Keytruda,0.31279
uuid-9e58ab30c8054ea8b395442abcc5d0a5,option,0.487127
uuid-9e58ab30c8054ea8b395442abcc5d0a5,flat dosing,0.348509
uuid-e1731a7e61ee432a851040e6d99bac42,Nivo,0.513561
uuid-e1731a7e61ee432a851040e6d99bac42,pembro,0.59478
uuid-e1731a7e61ee432a851040e6d99bac42,RTL,0.302611
uuid-e1731a7e61ee432a851040e6d99bac42,trial,0.479572
uuid-e1731a7e61ee432a851040e6d99bac42,2L,0.334599
uuid-e1731a7e61ee432a851040e6d99bac42,Ipi,0.334143
uuid-e1731a7e61ee432a851040e6d99bac42,stated,0.43245
uuid-e1731a7e61ee432a851040e6d99bac42,approval,0.511534
uuid-e1731a7e61ee432a851040e6d99bac42,atezo,0.466884
uuid-e1731a7e61ee432a851040e6d99bac42,using nivo,0.428876
uuid-e1731a7e61ee432a851040e6d99bac42,data,0.458583
uuid-e1731a7e61ee432a851040e6d99bac42,clinical trials,0.381554
uuid-e1731a7e61ee432a851040e6d99bac42,indication,0.440532
uuid-e1731a7e61ee432a851040e6d99bac42,approved,0.524343
uuid-e1731a7e61ee432a851040e6d99bac42,SCCHN,0.354892
uuid-e1731a7e61ee432a851040e6d99bac42,impressed,0.462494
uuid-e1731a7e61ee432a851040e6d99bac42,vs,0.338321
uuid-e1731a7e61ee432a851040e6d99bac42,label,0.36056
uuid-e1731a7e61ee432a851040e6d99bac42,LTL,0.326125
uuid-e1731a7e61ee432a851040e6d99bac42,SCLC,0.350265
uuid-e1731a7e61ee432a851040e6d99bac42,feels,0.337708
uuid-e1731a7e61ee432a851040e6d99bac42,bladder,0.391928
uuid-e1731a7e61ee432a851040e6d99bac42,flat dosing,0.312173
uuid-82dd6c2579364d5882d7624b6475bd2c,oncology,0.48207
uuid-82dd6c2579364d5882d7624b6475bd2c,drug,0.320123
uuid-82dd6c2579364d5882d7624b6475bd2c,clinical,0.447729
uuid-82dd6c2579364d5882d7624b6475bd2c,biomarker,0.353528
uuid-1f4ab7b36f894254b7d93c82f10d795d,Nivo,0.363382
uuid-1f4ab7b36f894254b7d93c82f10d795d,patients,0.605755
uuid-1f4ab7b36f894254b7d93c82f10d795d,Opdivo,0.583515
uuid-1f4ab7b36f894254b7d93c82f10d795d,therapy,0.649155
uuid-1f4ab7b36f894254b7d93c82f10d795d,nivolumab,0.574643
uuid-1f4ab7b36f894254b7d93c82f10d795d,regimen,0.347426
uuid-1f4ab7b36f894254b7d93c82f10d795d,treated,0.403774
uuid-1f4ab7b36f894254b7d93c82f10d795d,treatment,0.499778
uuid-1f4ab7b36f894254b7d93c82f10d795d,using nivo,0.328359
uuid-1f4ab7b36f894254b7d93c82f10d795d,PD1,0.307967
uuid-1f4ab7b36f894254b7d93c82f10d795d,cHL,0.637248
uuid-1f4ab7b36f894254b7d93c82f10d795d,progression,0.473532
uuid-1f4ab7b36f894254b7d93c82f10d795d,chemotherapy,0.378655
uuid-1f4ab7b36f894254b7d93c82f10d795d,respond,0.306185
uuid-919c67b597a3404abdc39b12e4abfd0b,Nivo,0.381557
uuid-919c67b597a3404abdc39b12e4abfd0b,pembro,0.598567
uuid-919c67b597a3404abdc39b12e4abfd0b,BMS,0.329063
uuid-919c67b597a3404abdc39b12e4abfd0b,1L,0.341444
uuid-919c67b597a3404abdc39b12e4abfd0b,PDL1,0.530604
uuid-919c67b597a3404abdc39b12e4abfd0b,trial,0.458981
uuid-919c67b597a3404abdc39b12e4abfd0b,efficacy,0.557223
uuid-919c67b597a3404abdc39b12e4abfd0b,Merck,0.32139
uuid-919c67b597a3404abdc39b12e4abfd0b,OS,0.484391
uuid-919c67b597a3404abdc39b12e4abfd0b,atezo,0.606546
uuid-919c67b597a3404abdc39b12e4abfd0b,data,0.813465
uuid-919c67b597a3404abdc39b12e4abfd0b,indication,0.309539
uuid-919c67b597a3404abdc39b12e4abfd0b,PFS,0.45218
uuid-919c67b597a3404abdc39b12e4abfd0b,ORR,0.551643
uuid-919c67b597a3404abdc39b12e4abfd0b,nivo and pembro,0.613151
uuid-919c67b597a3404abdc39b12e4abfd0b,impressed,0.490665
uuid-919c67b597a3404abdc39b12e4abfd0b,vs,0.391882
uuid-919c67b597a3404abdc39b12e4abfd0b,TLs,0.373832
uuid-919c67b597a3404abdc39b12e4abfd0b,feels,0.325701
uuid-919c67b597a3404abdc39b12e4abfd0b,PDL1 expression,0.474814
uuid-aea0f533e6654fa299ef2f30b0331096,lung,0.396248
uuid-aea0f533e6654fa299ef2f30b0331096,PDL1 testing,0.320688
uuid-aea0f533e6654fa299ef2f30b0331096,AI,0.488963
uuid-aea0f533e6654fa299ef2f30b0331096,oncology,0.355498
uuid-aea0f533e6654fa299ef2f30b0331096,SCCHN,0.300201
uuid-aea0f533e6654fa299ef2f30b0331096,label,0.350153
uuid-aea0f533e6654fa299ef2f30b0331096,NCCN,0.475015
uuid-0d327e3c14304cc7b0bc0ca61510ec3e,TL,0.639136
uuid-0d327e3c14304cc7b0bc0ca61510ec3e,TL stated,0.503719
uuid-0d327e3c14304cc7b0bc0ca61510ec3e,PD-L1 testing,0.461677
uuid-0d327e3c14304cc7b0bc0ca61510ec3e,testing,0.388268
uuid-0d327e3c14304cc7b0bc0ca61510ec3e,PDL1 testing,0.465337
uuid-0d327e3c14304cc7b0bc0ca61510ec3e,SCCHN,0.321715
uuid-0d327e3c14304cc7b0bc0ca61510ec3e,Regional TL,0.429571
uuid-f5ee37626d13418aab341a7e4ecedffd,RTL,0.649504
uuid-f5ee37626d13418aab341a7e4ecedffd,lung,0.311311
uuid-f5ee37626d13418aab341a7e4ecedffd,trial,0.343774
uuid-f5ee37626d13418aab341a7e4ecedffd,NTL,0.592687
uuid-f5ee37626d13418aab341a7e4ecedffd,shared,0.52862
uuid-f5ee37626d13418aab341a7e4ecedffd,commented,0.5069
uuid-f5ee37626d13418aab341a7e4ecedffd,RCC,0.309576
uuid-f5ee37626d13418aab341a7e4ecedffd,institution,0.305931
uuid-f5ee37626d13418aab341a7e4ecedffd,stated,0.709277
uuid-f5ee37626d13418aab341a7e4ecedffd,approval,0.398477
uuid-f5ee37626d13418aab341a7e4ecedffd,using nivo,0.315312
uuid-f5ee37626d13418aab341a7e4ecedffd,data,0.327417
uuid-f5ee37626d13418aab341a7e4ecedffd,expressed,0.337037
uuid-f5ee37626d13418aab341a7e4ecedffd,mentioned,0.326332
uuid-f5ee37626d13418aab341a7e4ecedffd,clinical trials,0.358853
uuid-f5ee37626d13418aab341a7e4ecedffd,SCCHN,0.558306
uuid-f5ee37626d13418aab341a7e4ecedffd,HCP,0.305702
uuid-f5ee37626d13418aab341a7e4ecedffd,ASCO,0.329364
uuid-f5ee37626d13418aab341a7e4ecedffd,impressed,0.438309
uuid-f5ee37626d13418aab341a7e4ecedffd,LTL,0.532277
uuid-f5ee37626d13418aab341a7e4ecedffd,TLs,0.492544
uuid-f5ee37626d13418aab341a7e4ecedffd,academic,0.360527
uuid-f5ee37626d13418aab341a7e4ecedffd,Regional TL,0.742621
uuid-f5ee37626d13418aab341a7e4ecedffd,RTL stated,0.332011
uuid-f5ee37626d13418aab341a7e4ecedffd,bladder,0.347025
uuid-add81acd3ef84b3490eb0da0ba1e41bf,pembro,0.424953
uuid-add81acd3ef84b3490eb0da0ba1e41bf,BMS,0.53501
uuid-add81acd3ef84b3490eb0da0ba1e41bf,PDL1,0.388501
uuid-add81acd3ef84b3490eb0da0ba1e41bf,trial,0.54235
uuid-add81acd3ef84b3490eb0da0ba1e41bf,efficacy,0.425049
uuid-add81acd3ef84b3490eb0da0ba1e41bf,commented,0.324924
uuid-add81acd3ef84b3490eb0da0ba1e41bf,Merck,0.468846
uuid-add81acd3ef84b3490eb0da0ba1e41bf,OS,0.410472
uuid-add81acd3ef84b3490eb0da0ba1e41bf,atezo,0.417052
uuid-add81acd3ef84b3490eb0da0ba1e41bf,regards,0.41044
uuid-add81acd3ef84b3490eb0da0ba1e41bf,data,0.556153
uuid-add81acd3ef84b3490eb0da0ba1e41bf,PFS,0.410656
uuid-add81acd3ef84b3490eb0da0ba1e41bf,ORR,0.39885
uuid-add81acd3ef84b3490eb0da0ba1e41bf,nivo and pembro,0.53445
uuid-add81acd3ef84b3490eb0da0ba1e41bf,believes,0.406048
uuid-add81acd3ef84b3490eb0da0ba1e41bf,impressed,0.352264
uuid-add81acd3ef84b3490eb0da0ba1e41bf,vs,0.418606
uuid-add81acd3ef84b3490eb0da0ba1e41bf,TLs,0.320016
uuid-add81acd3ef84b3490eb0da0ba1e41bf,feels,0.446681
uuid-add81acd3ef84b3490eb0da0ba1e41bf,PDL1 expression,0.319625
uuid-220aa4d9716d4780b4b5f0a6e237e74f,Nivo,0.655787
uuid-220aa4d9716d4780b4b5f0a6e237e74f,pembro,0.569069
uuid-220aa4d9716d4780b4b5f0a6e237e74f,1L,0.535342
uuid-220aa4d9716d4780b4b5f0a6e237e74f,trial,0.411709
uuid-220aa4d9716d4780b4b5f0a6e237e74f,efficacy,0.396106
uuid-220aa4d9716d4780b4b5f0a6e237e74f,RCC,0.332249
uuid-220aa4d9716d4780b4b5f0a6e237e74f,combination,0.387882
uuid-220aa4d9716d4780b4b5f0a6e237e74f,chemo,0.382593
uuid-220aa4d9716d4780b4b5f0a6e237e74f,2L,0.545984
uuid-220aa4d9716d4780b4b5f0a6e237e74f,agents,0.387108
uuid-220aa4d9716d4780b4b5f0a6e237e74f,Ipi,0.361917
uuid-220aa4d9716d4780b4b5f0a6e237e74f,approval,0.377708
uuid-220aa4d9716d4780b4b5f0a6e237e74f,atezo,0.524255
uuid-220aa4d9716d4780b4b5f0a6e237e74f,preferred,0.333802
uuid-220aa4d9716d4780b4b5f0a6e237e74f,monotherapy,0.475026
uuid-220aa4d9716d4780b4b5f0a6e237e74f,using nivo,0.458117
uuid-220aa4d9716d4780b4b5f0a6e237e74f,data,0.446461
uuid-220aa4d9716d4780b4b5f0a6e237e74f,combo,0.473462
uuid-220aa4d9716d4780b4b5f0a6e237e74f,PD1,0.381738
uuid-220aa4d9716d4780b4b5f0a6e237e74f,ORR,0.358781
uuid-220aa4d9716d4780b4b5f0a6e237e74f,approved,0.491535
uuid-220aa4d9716d4780b4b5f0a6e237e74f,nivo and pembro,0.479616
uuid-220aa4d9716d4780b4b5f0a6e237e74f,believes,0.467406
uuid-220aa4d9716d4780b4b5f0a6e237e74f,impressed,0.449079
uuid-220aa4d9716d4780b4b5f0a6e237e74f,SCLC,0.342467
uuid-220aa4d9716d4780b4b5f0a6e237e74f,feels,0.463401
uuid-220aa4d9716d4780b4b5f0a6e237e74f,RTL stated,0.349613
uuid-220aa4d9716d4780b4b5f0a6e237e74f,option,0.406545
uuid-220aa4d9716d4780b4b5f0a6e237e74f,bladder,0.381859
uuid-6297a232cc884969a7e6da1bef9d42c6,RTL,0.394442
uuid-6297a232cc884969a7e6da1bef9d42c6,lung,0.31357
uuid-6297a232cc884969a7e6da1bef9d42c6,melanoma,0.357496
uuid-6297a232cc884969a7e6da1bef9d42c6,shared,0.556469
uuid-6297a232cc884969a7e6da1bef9d42c6,commented,0.411237
uuid-6297a232cc884969a7e6da1bef9d42c6,RCC,0.364296
uuid-6297a232cc884969a7e6da1bef9d42c6,institution,0.427442
uuid-6297a232cc884969a7e6da1bef9d42c6,stated,0.544856
uuid-6297a232cc884969a7e6da1bef9d42c6,approval,0.354461
uuid-6297a232cc884969a7e6da1bef9d42c6,data,0.383894
uuid-6297a232cc884969a7e6da1bef9d42c6,clinical trials,0.304748
uuid-6297a232cc884969a7e6da1bef9d42c6,SCCHN,0.509157
uuid-6297a232cc884969a7e6da1bef9d42c6,impressed,0.425156
uuid-6297a232cc884969a7e6da1bef9d42c6,LTL,0.350639
uuid-6297a232cc884969a7e6da1bef9d42c6,TLs,0.324812
uuid-6297a232cc884969a7e6da1bef9d42c6,SCLC,0.326167
uuid-6297a232cc884969a7e6da1bef9d42c6,Regional TL,0.457716
uuid-6297a232cc884969a7e6da1bef9d42c6,RTL stated,0.425851
uuid-6297a232cc884969a7e6da1bef9d42c6,TL shared,0.306756
uuid-6297a232cc884969a7e6da1bef9d42c6,NCCN,0.376392
uuid-6297a232cc884969a7e6da1bef9d42c6,bladder,0.337815
uuid-8557c179afce4aa6b5590dfce5b06f51,NSCLC,0.341404
uuid-8557c179afce4aa6b5590dfce5b06f51,preferred,0.503936
uuid-8557c179afce4aa6b5590dfce5b06f51,using nivo,0.31531
uuid-8557c179afce4aa6b5590dfce5b06f51,feels,0.367285
uuid-8557c179afce4aa6b5590dfce5b06f51,RTL stated,0.403021
uuid-8557c179afce4aa6b5590dfce5b06f51,option,0.31773
uuid-8d9dc7cff96444fa80d151669fc672b3,patients,0.442695
uuid-8d9dc7cff96444fa80d151669fc672b3,therapy,0.327322
uuid-8d9dc7cff96444fa80d151669fc672b3,1L,0.354344
uuid-8d9dc7cff96444fa80d151669fc672b3,regimen,0.427384
uuid-8d9dc7cff96444fa80d151669fc672b3,combination,0.333961
uuid-8d9dc7cff96444fa80d151669fc672b3,chemo,0.41044
uuid-8d9dc7cff96444fa80d151669fc672b3,2L,0.385443
uuid-8d9dc7cff96444fa80d151669fc672b3,pts,0.407287
uuid-8d9dc7cff96444fa80d151669fc672b3,IO,0.359374
uuid-8d9dc7cff96444fa80d151669fc672b3,preferred,0.319067
uuid-8d9dc7cff96444fa80d151669fc672b3,monotherapy,0.487749
uuid-8d9dc7cff96444fa80d151669fc672b3,treatment,0.344555
uuid-8d9dc7cff96444fa80d151669fc672b3,combo,0.406629
uuid-8d9dc7cff96444fa80d151669fc672b3,PD1,0.36595
uuid-8d9dc7cff96444fa80d151669fc672b3,progression,0.442052
uuid-8d9dc7cff96444fa80d151669fc672b3,chemotherapy,0.312824
uuid-8d9dc7cff96444fa80d151669fc672b3,respond,0.33483
uuid-8d9dc7cff96444fa80d151669fc672b3,option,0.43845
uuid-1c138fc4a67146afa079fd568a4de29d,Nivo,0.517983
uuid-1c138fc4a67146afa079fd568a4de29d,patients,0.57443
uuid-1c138fc4a67146afa079fd568a4de29d,therapy,0.539126
uuid-1c138fc4a67146afa079fd568a4de29d,nivolumab,0.462545
uuid-1c138fc4a67146afa079fd568a4de29d,1L,0.680042
uuid-1c138fc4a67146afa079fd568a4de29d,regimen,0.539611
uuid-1c138fc4a67146afa079fd568a4de29d,treated,0.328902
uuid-1c138fc4a67146afa079fd568a4de29d,RCC,0.44413
uuid-1c138fc4a67146afa079fd568a4de29d,combination,0.488464
uuid-1c138fc4a67146afa079fd568a4de29d,chemo,0.626472
uuid-1c138fc4a67146afa079fd568a4de29d,2L,0.699793
uuid-1c138fc4a67146afa079fd568a4de29d,pts,0.592188
uuid-1c138fc4a67146afa079fd568a4de29d,IO,0.363738
uuid-1c138fc4a67146afa079fd568a4de29d,agents,0.480804
uuid-1c138fc4a67146afa079fd568a4de29d,preferred,0.593841
uuid-1c138fc4a67146afa079fd568a4de29d,monotherapy,0.780753
uuid-1c138fc4a67146afa079fd568a4de29d,treatment,0.502035
uuid-1c138fc4a67146afa079fd568a4de29d,using nivo,0.554303
uuid-1c138fc4a67146afa079fd568a4de29d,response,0.444466
uuid-1c138fc4a67146afa079fd568a4de29d,combo,0.521848
uuid-1c138fc4a67146afa079fd568a4de29d,PD1,0.589501
uuid-1c138fc4a67146afa079fd568a4de29d,approved,0.427801
uuid-1c138fc4a67146afa079fd568a4de29d,progression,0.566721
uuid-1c138fc4a67146afa079fd568a4de29d,believes,0.329141
uuid-1c138fc4a67146afa079fd568a4de29d,chemotherapy,0.480332
uuid-1c138fc4a67146afa079fd568a4de29d,respond,0.437938
uuid-1c138fc4a67146afa079fd568a4de29d,feels,0.318733
uuid-1c138fc4a67146afa079fd568a4de29d,PD-1,0.322361
uuid-1c138fc4a67146afa079fd568a4de29d,RTL stated,0.472835
uuid-1c138fc4a67146afa079fd568a4de29d,option,0.706249
uuid-b96b7985041a4872a663afe986f52689,patients,0.302771
uuid-b96b7985041a4872a663afe986f52689,toxicity,0.322274
uuid-b96b7985041a4872a663afe986f52689,regimen,0.484657
uuid-b96b7985041a4872a663afe986f52689,shared,0.349586
uuid-b96b7985041a4872a663afe986f52689,combination,0.415735
uuid-b96b7985041a4872a663afe986f52689,chemo,0.300904
uuid-b96b7985041a4872a663afe986f52689,Ipi,0.428511
uuid-b96b7985041a4872a663afe986f52689,monotherapy,0.427589
uuid-b96b7985041a4872a663afe986f52689,combo,0.492051
uuid-b96b7985041a4872a663afe986f52689,clinical trials,0.351517
uuid-b96b7985041a4872a663afe986f52689,chemotherapy,0.349144
uuid-b96b7985041a4872a663afe986f52689,impressed,0.383026
uuid-b96b7985041a4872a663afe986f52689,feels,0.457387
uuid-b96b7985041a4872a663afe986f52689,option,0.419831
uuid-9db64bd474224763beeded22d4e3755c,pembro,0.303899
uuid-9db64bd474224763beeded22d4e3755c,RTL,0.335983
uuid-9db64bd474224763beeded22d4e3755c,dose,0.32862
uuid-9db64bd474224763beeded22d4e3755c,BMS,0.350794
uuid-9db64bd474224763beeded22d4e3755c,trial,0.496642
uuid-9db64bd474224763beeded22d4e3755c,efficacy,0.36067
uuid-9db64bd474224763beeded22d4e3755c,shared,0.58494
uuid-9db64bd474224763beeded22d4e3755c,commented,0.373165
uuid-9db64bd474224763beeded22d4e3755c,combination,0.338088
uuid-9db64bd474224763beeded22d4e3755c,Ipi,0.489964
uuid-9db64bd474224763beeded22d4e3755c,data,0.471633
uuid-9db64bd474224763beeded22d4e3755c,combo,0.3611
uuid-9db64bd474224763beeded22d4e3755c,clinical trials,0.326682
uuid-9db64bd474224763beeded22d4e3755c,impressed,0.464085
uuid-9db64bd474224763beeded22d4e3755c,LTL,0.321159
uuid-9db64bd474224763beeded22d4e3755c,TLs,0.313538
uuid-9db64bd474224763beeded22d4e3755c,SCLC,0.320213
uuid-9db64bd474224763beeded22d4e3755c,flat dosing,0.354768
uuid-8154a8ad318f472b8dba70d128edb9fa,BMS,0.430434
uuid-8154a8ad318f472b8dba70d128edb9fa,PDL1,0.454327
uuid-8154a8ad318f472b8dba70d128edb9fa,trial,0.468869
uuid-8154a8ad318f472b8dba70d128edb9fa,efficacy,0.534299
uuid-8154a8ad318f472b8dba70d128edb9fa,OS,0.684144
uuid-8154a8ad318f472b8dba70d128edb9fa,regards,0.524264
uuid-8154a8ad318f472b8dba70d128edb9fa,data,0.572636
uuid-8154a8ad318f472b8dba70d128edb9fa,expressed,0.372613
uuid-8154a8ad318f472b8dba70d128edb9fa,PFS,0.768147
uuid-8154a8ad318f472b8dba70d128edb9fa,AI,0.547086
uuid-8154a8ad318f472b8dba70d128edb9fa,ORR,0.684995
uuid-8154a8ad318f472b8dba70d128edb9fa,nivo and pembro,0.600935
uuid-8154a8ad318f472b8dba70d128edb9fa,believes,0.300998
uuid-8154a8ad318f472b8dba70d128edb9fa,impressed,0.376307
uuid-8154a8ad318f472b8dba70d128edb9fa,PDL1 expression,0.505883
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,Nivo,0.545914
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,patients,0.656293
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,therapy,0.705683
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,nivolumab,0.5868
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,1L,0.397024
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,toxicity,0.4219
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,regimen,0.703049
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,treated,0.425413
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,combination,0.648274
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,chemo,0.640872
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,2L,0.417327
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,pts,0.537574
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,IO,0.351268
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,agents,0.358891
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,Ipi,0.437012
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,preferred,0.404127
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,monotherapy,0.78466
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,treatment,0.603982
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,using nivo,0.475864
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,response,0.423671
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,combo,0.578459
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,PD1,0.639193
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,progression,0.583824
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,chemotherapy,0.656788
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,respond,0.399178
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,RTL stated,0.335659
uuid-4ec5d3d7f44242f9b3719b7e83263b4b,option,0.623026
uuid-e64d728981d0425f9f5c9419fa5d2b68,RTL,0.380875
uuid-e64d728981d0425f9f5c9419fa5d2b68,trial,0.620367
uuid-e64d728981d0425f9f5c9419fa5d2b68,clinical trials,0.324551
uuid-e64d728981d0425f9f5c9419fa5d2b68,Regional TL,0.319035
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,patients,0.417959
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,Opdivo,0.321077
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,therapy,0.355506
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,nivolumab,0.366651
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,1L,0.394264
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,treated,0.300933
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,RCC,0.446665
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,2L,0.435625
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,approval,0.415378
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,preferred,0.428822
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,monotherapy,0.413356
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,treatment,0.305296
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,using nivo,0.563897
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,indication,0.390639
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,approved,0.342471
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,SCCHN,0.356114
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,cHL,0.317574
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,RTL stated,0.420764
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,TL shared,0.347759
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,option,0.440894
uuid-11cafd69dd9e40e2b9cdbe244cd84b8e,bladder,0.311548
uuid-9ef0b105c6b04c57a25026d4399146f2,patients,0.546724
uuid-9ef0b105c6b04c57a25026d4399146f2,Opdivo,0.622524
uuid-9ef0b105c6b04c57a25026d4399146f2,treated,0.30535
uuid-9ef0b105c6b04c57a25026d4399146f2,pts,0.307112
uuid-9ef0b105c6b04c57a25026d4399146f2,physicians,0.47812
uuid-9ef0b105c6b04c57a25026d4399146f2,treatment,0.426071
uuid-9ef0b105c6b04c57a25026d4399146f2,progression,0.417696
uuid-9ef0b105c6b04c57a25026d4399146f2,respond,0.398133
uuid-9ef0b105c6b04c57a25026d4399146f2,feels,0.304087
uuid-b94fbe619c6d4d899b1f3da86b995578,Nivo,0.416511
uuid-b94fbe619c6d4d899b1f3da86b995578,pembro,0.326752
uuid-b94fbe619c6d4d899b1f3da86b995578,BMS,0.367812
uuid-b94fbe619c6d4d899b1f3da86b995578,PDL1,0.301906
uuid-b94fbe619c6d4d899b1f3da86b995578,trial,0.570701
uuid-b94fbe619c6d4d899b1f3da86b995578,efficacy,0.490706
uuid-b94fbe619c6d4d899b1f3da86b995578,OS,0.605033
uuid-b94fbe619c6d4d899b1f3da86b995578,data,0.84756
uuid-b94fbe619c6d4d899b1f3da86b995578,PFS,0.577841
uuid-b94fbe619c6d4d899b1f3da86b995578,ORR,0.647816
uuid-b94fbe619c6d4d899b1f3da86b995578,nivo and pembro,0.439662
uuid-b94fbe619c6d4d899b1f3da86b995578,ASCO,0.30934
uuid-b94fbe619c6d4d899b1f3da86b995578,impressed,0.618941
uuid-b94fbe619c6d4d899b1f3da86b995578,feels,0.405355
uuid-61b330f595a943cca2625db32d1b270a,Nivo,0.403445
uuid-61b330f595a943cca2625db32d1b270a,patients,0.526938
uuid-61b330f595a943cca2625db32d1b270a,therapy,0.793394
uuid-61b330f595a943cca2625db32d1b270a,nivolumab,0.60766
uuid-61b330f595a943cca2625db32d1b270a,treated,0.381839
uuid-61b330f595a943cca2625db32d1b270a,combination,0.368606
uuid-61b330f595a943cca2625db32d1b270a,chemo,0.361985
uuid-61b330f595a943cca2625db32d1b270a,monotherapy,0.395253
uuid-61b330f595a943cca2625db32d1b270a,treatment,0.447657
uuid-61b330f595a943cca2625db32d1b270a,using nivo,0.36812
uuid-61b330f595a943cca2625db32d1b270a,response,0.312809
uuid-61b330f595a943cca2625db32d1b270a,PD1,0.490467
uuid-61b330f595a943cca2625db32d1b270a,cHL,0.6719
uuid-61b330f595a943cca2625db32d1b270a,progression,0.402746
uuid-61b330f595a943cca2625db32d1b270a,chemotherapy,0.503688
uuid-61b330f595a943cca2625db32d1b270a,option,0.337626
uuid-4f929b23af384cfebd9b977dbb89949c,Nivo,0.309815
uuid-4f929b23af384cfebd9b977dbb89949c,patients,0.37911
uuid-4f929b23af384cfebd9b977dbb89949c,Opdivo,0.372434
uuid-4f929b23af384cfebd9b977dbb89949c,therapy,0.514854
uuid-4f929b23af384cfebd9b977dbb89949c,nivolumab,0.458906
uuid-4f929b23af384cfebd9b977dbb89949c,toxicity,0.406497
uuid-4f929b23af384cfebd9b977dbb89949c,regimen,0.31717
uuid-4f929b23af384cfebd9b977dbb89949c,treatment,0.35513
uuid-4f929b23af384cfebd9b977dbb89949c,PD1,0.344982
uuid-4f929b23af384cfebd9b977dbb89949c,cHL,0.522932
uuid-34cf7515a3934eb4ac8c6c310874237f,patients,0.557863
uuid-34cf7515a3934eb4ac8c6c310874237f,therapy,0.395545
uuid-34cf7515a3934eb4ac8c6c310874237f,1L,0.423735
uuid-34cf7515a3934eb4ac8c6c310874237f,PDL1,0.327067
uuid-34cf7515a3934eb4ac8c6c310874237f,treated,0.35001
uuid-34cf7515a3934eb4ac8c6c310874237f,chemo,0.318289
uuid-34cf7515a3934eb4ac8c6c310874237f,2L,0.337993
uuid-34cf7515a3934eb4ac8c6c310874237f,pts,0.499541
uuid-34cf7515a3934eb4ac8c6c310874237f,PD-L1,0.363946
uuid-34cf7515a3934eb4ac8c6c310874237f,testing,0.415859
uuid-34cf7515a3934eb4ac8c6c310874237f,monotherapy,0.4206
uuid-34cf7515a3934eb4ac8c6c310874237f,treatment,0.452943
uuid-34cf7515a3934eb4ac8c6c310874237f,response,0.304004
uuid-34cf7515a3934eb4ac8c6c310874237f,PDL1 testing,0.385675
uuid-34cf7515a3934eb4ac8c6c310874237f,NSCLC patients,0.539909
uuid-34cf7515a3934eb4ac8c6c310874237f,PD1,0.38293
uuid-34cf7515a3934eb4ac8c6c310874237f,progression,0.470622
uuid-34cf7515a3934eb4ac8c6c310874237f,tumor types,0.310947
uuid-34cf7515a3934eb4ac8c6c310874237f,respond,0.412232
uuid-34cf7515a3934eb4ac8c6c310874237f,feels,0.300553
uuid-34cf7515a3934eb4ac8c6c310874237f,PD-1,0.326243
uuid-34cf7515a3934eb4ac8c6c310874237f,option,0.445796
uuid-e8bb6e374401419ba590b1c1509c5079,Nivo,0.359201
uuid-e8bb6e374401419ba590b1c1509c5079,toxicity,0.475051
uuid-e8bb6e374401419ba590b1c1509c5079,efficacy,0.684065
uuid-e8bb6e374401419ba590b1c1509c5079,regimen,0.496946
uuid-e8bb6e374401419ba590b1c1509c5079,chemo,0.436871
uuid-e8bb6e374401419ba590b1c1509c5079,Ipi,0.34315
uuid-e8bb6e374401419ba590b1c1509c5079,OS,0.555549
uuid-e8bb6e374401419ba590b1c1509c5079,monotherapy,0.306301
uuid-e8bb6e374401419ba590b1c1509c5079,response,0.460618
uuid-e8bb6e374401419ba590b1c1509c5079,PFS,0.538235
uuid-e8bb6e374401419ba590b1c1509c5079,ORR,0.60919
uuid-e8bb6e374401419ba590b1c1509c5079,progression,0.39099
uuid-e8bb6e374401419ba590b1c1509c5079,chemotherapy,0.444227
uuid-e8bb6e374401419ba590b1c1509c5079,impressed,0.301949
uuid-e8bb6e374401419ba590b1c1509c5079,respond,0.372602
uuid-e8bb6e374401419ba590b1c1509c5079,feels,0.363247
uuid-ec6e5c9cb1c84f0387654e1834139569,Nivo,0.310112
uuid-ec6e5c9cb1c84f0387654e1834139569,dose,0.686937
uuid-ec6e5c9cb1c84f0387654e1834139569,toxicity,0.705077
uuid-ec6e5c9cb1c84f0387654e1834139569,efficacy,0.498996
uuid-ec6e5c9cb1c84f0387654e1834139569,regimen,0.528376
uuid-ec6e5c9cb1c84f0387654e1834139569,Ipi,0.564404
uuid-ec6e5c9cb1c84f0387654e1834139569,combo,0.306064
uuid-ec6e5c9cb1c84f0387654e1834139569,vs,0.417286
uuid-ec6e5c9cb1c84f0387654e1834139569,flat dosing,0.430643
uuid-74b7d1609c3b40cab62cb55e3b2dad68,Nivo,0.488956
uuid-74b7d1609c3b40cab62cb55e3b2dad68,Ipi,0.507822
uuid-74b7d1609c3b40cab62cb55e3b2dad68,approval,0.352569
uuid-74b7d1609c3b40cab62cb55e3b2dad68,using nivo,0.368432
uuid-74b7d1609c3b40cab62cb55e3b2dad68,mentioned,0.368654
uuid-74b7d1609c3b40cab62cb55e3b2dad68,indication,0.335431
uuid-74b7d1609c3b40cab62cb55e3b2dad68,approved,0.36433
uuid-74b7d1609c3b40cab62cb55e3b2dad68,HCP,0.39363
uuid-74b7d1609c3b40cab62cb55e3b2dad68,label,0.330879
uuid-74b7d1609c3b40cab62cb55e3b2dad68,SCLC,0.628109
uuid-3345eb8d42a446109c2f076b814a99d8,therapy,0.312424
uuid-3345eb8d42a446109c2f076b814a99d8,mentioned,0.358797
uuid-3345eb8d42a446109c2f076b814a99d8,cHL,0.663891
uuid-2fd56ddb1ce24b83894117d86a437654,patients,0.830808
uuid-2fd56ddb1ce24b83894117d86a437654,Opdivo,0.490425
uuid-2fd56ddb1ce24b83894117d86a437654,therapy,0.619865
uuid-2fd56ddb1ce24b83894117d86a437654,nivolumab,0.489593
uuid-2fd56ddb1ce24b83894117d86a437654,regimen,0.57542
uuid-2fd56ddb1ce24b83894117d86a437654,treated,0.670204
uuid-2fd56ddb1ce24b83894117d86a437654,chemo,0.328044
uuid-2fd56ddb1ce24b83894117d86a437654,pts,0.609134
uuid-2fd56ddb1ce24b83894117d86a437654,monotherapy,0.402327
uuid-2fd56ddb1ce24b83894117d86a437654,treatment,0.830043
uuid-2fd56ddb1ce24b83894117d86a437654,using nivo,0.317669
uuid-2fd56ddb1ce24b83894117d86a437654,response,0.440122
uuid-2fd56ddb1ce24b83894117d86a437654,PD1,0.35446
uuid-2fd56ddb1ce24b83894117d86a437654,cHL,0.304392
uuid-2fd56ddb1ce24b83894117d86a437654,progression,0.709935
uuid-2fd56ddb1ce24b83894117d86a437654,chemotherapy,0.368048
uuid-2fd56ddb1ce24b83894117d86a437654,respond,0.609119
uuid-2fd56ddb1ce24b83894117d86a437654,option,0.407756
uuid-6769af14b5134794a6161a1c66f2ddd5,Nivo,0.306485
uuid-6769af14b5134794a6161a1c66f2ddd5,patients,0.503217
uuid-6769af14b5134794a6161a1c66f2ddd5,Opdivo,0.483746
uuid-6769af14b5134794a6161a1c66f2ddd5,therapy,0.593448
uuid-6769af14b5134794a6161a1c66f2ddd5,nivolumab,0.461391
uuid-6769af14b5134794a6161a1c66f2ddd5,treated,0.31063
uuid-6769af14b5134794a6161a1c66f2ddd5,treatment,0.339342
uuid-6769af14b5134794a6161a1c66f2ddd5,cHL,0.810917
uuid-90feea0c9a0a47e4828a3e0b88839cf6,TL,0.445186
uuid-90feea0c9a0a47e4828a3e0b88839cf6,RTL,0.50495
uuid-90feea0c9a0a47e4828a3e0b88839cf6,NTL,0.504949
uuid-90feea0c9a0a47e4828a3e0b88839cf6,commented,0.366085
uuid-90feea0c9a0a47e4828a3e0b88839cf6,stated,0.375205
uuid-90feea0c9a0a47e4828a3e0b88839cf6,physicians,0.37877
uuid-90feea0c9a0a47e4828a3e0b88839cf6,mentioned,0.373011
uuid-90feea0c9a0a47e4828a3e0b88839cf6,oncology,0.356056
uuid-90feea0c9a0a47e4828a3e0b88839cf6,indicated,0.384484
uuid-90feea0c9a0a47e4828a3e0b88839cf6,LTL,0.40156
uuid-90feea0c9a0a47e4828a3e0b88839cf6,TLs,0.355713
uuid-90feea0c9a0a47e4828a3e0b88839cf6,clinical,0.343059
uuid-90feea0c9a0a47e4828a3e0b88839cf6,academic,0.348838
uuid-90feea0c9a0a47e4828a3e0b88839cf6,Regional TL,0.564722
uuid-28c70fdddbb042ba947a1c9ec8cd869a,lung,0.423431
uuid-28c70fdddbb042ba947a1c9ec8cd869a,PDL1,0.490834
uuid-28c70fdddbb042ba947a1c9ec8cd869a,efficacy,0.345689
uuid-28c70fdddbb042ba947a1c9ec8cd869a,atezo,0.300402
uuid-28c70fdddbb042ba947a1c9ec8cd869a,regards,0.443346
uuid-28c70fdddbb042ba947a1c9ec8cd869a,PFS,0.338924
uuid-28c70fdddbb042ba947a1c9ec8cd869a,AI,0.723892
uuid-28c70fdddbb042ba947a1c9ec8cd869a,nivo and pembro,0.628423
uuid-28c70fdddbb042ba947a1c9ec8cd869a,believes,0.389396
uuid-28c70fdddbb042ba947a1c9ec8cd869a,PDL1 expression,0.437343
uuid-28c70fdddbb042ba947a1c9ec8cd869a,biomarker,0.322332
uuid-28c70fdddbb042ba947a1c9ec8cd869a,NCCN,0.420178
uuid-302616e473ac4351a8a003dbb5c980fa,lung,0.429842
uuid-302616e473ac4351a8a003dbb5c980fa,trial,0.346449
uuid-302616e473ac4351a8a003dbb5c980fa,melanoma,0.428504
uuid-302616e473ac4351a8a003dbb5c980fa,OS,0.343317
uuid-302616e473ac4351a8a003dbb5c980fa,regards,0.448885
uuid-302616e473ac4351a8a003dbb5c980fa,PFS,0.378955
uuid-302616e473ac4351a8a003dbb5c980fa,AI,0.758343
uuid-302616e473ac4351a8a003dbb5c980fa,ORR,0.34332
uuid-302616e473ac4351a8a003dbb5c980fa,nivo and pembro,0.365812
uuid-302616e473ac4351a8a003dbb5c980fa,SCLC,0.3478
uuid-302616e473ac4351a8a003dbb5c980fa,NCCN,0.509363
uuid-1b8154afff6145adb7a1305903b634f3,lung,0.350847
uuid-1b8154afff6145adb7a1305903b634f3,institution,0.327864
uuid-1b8154afff6145adb7a1305903b634f3,regards,0.32633
uuid-1b8154afff6145adb7a1305903b634f3,AI,0.706031
uuid-1b8154afff6145adb7a1305903b634f3,oncology,0.423092
uuid-1b8154afff6145adb7a1305903b634f3,clinical,0.343072
uuid-1b8154afff6145adb7a1305903b634f3,NCCN,0.333331
uuid-9722c0ff6345416dbbd7c8acf3efbe92,patients,0.340023
uuid-9722c0ff6345416dbbd7c8acf3efbe92,progression,0.357039
uuid-a32be019cb3545d989d9d0093b68b252,patients,0.445157
uuid-a32be019cb3545d989d9d0093b68b252,Opdivo,0.335918
uuid-a32be019cb3545d989d9d0093b68b252,nivolumab,0.359145
uuid-a32be019cb3545d989d9d0093b68b252,physicians,0.362596
uuid-a32be019cb3545d989d9d0093b68b252,clinical trials,0.315096
uuid-500cecf655234851885e5e88e628f1e0,patients,0.496765
uuid-500cecf655234851885e5e88e628f1e0,nivolumab,0.303144
uuid-500cecf655234851885e5e88e628f1e0,lung,0.47525
uuid-500cecf655234851885e5e88e628f1e0,1L,0.639424
uuid-500cecf655234851885e5e88e628f1e0,regimen,0.349902
uuid-500cecf655234851885e5e88e628f1e0,treated,0.351666
uuid-500cecf655234851885e5e88e628f1e0,melanoma,0.418567
uuid-500cecf655234851885e5e88e628f1e0,RCC,0.641533
uuid-500cecf655234851885e5e88e628f1e0,TL stated,0.509963
uuid-500cecf655234851885e5e88e628f1e0,chemo,0.333383
uuid-500cecf655234851885e5e88e628f1e0,2L,0.649178
uuid-500cecf655234851885e5e88e628f1e0,pts,0.476205
uuid-500cecf655234851885e5e88e628f1e0,preferred,0.511186
uuid-500cecf655234851885e5e88e628f1e0,monotherapy,0.532678
uuid-500cecf655234851885e5e88e628f1e0,using nivo,0.570902
uuid-500cecf655234851885e5e88e628f1e0,combo,0.380706
uuid-500cecf655234851885e5e88e628f1e0,PDL1 testing,0.397556
uuid-500cecf655234851885e5e88e628f1e0,NSCLC patients,0.418925
uuid-500cecf655234851885e5e88e628f1e0,approved,0.352937
uuid-500cecf655234851885e5e88e628f1e0,SCCHN,0.442896
uuid-500cecf655234851885e5e88e628f1e0,progression,0.33086
uuid-500cecf655234851885e5e88e628f1e0,tumor types,0.494826
uuid-500cecf655234851885e5e88e628f1e0,RTL stated,0.591673
uuid-500cecf655234851885e5e88e628f1e0,TL shared,0.551453
uuid-500cecf655234851885e5e88e628f1e0,option,0.546479
uuid-500cecf655234851885e5e88e628f1e0,bladder,0.439192
uuid-83a45724c4ba403c80fb7f926bc39a63,toxicity,0.51117
uuid-83a45724c4ba403c80fb7f926bc39a63,regimen,0.358873
uuid-83a45724c4ba403c80fb7f926bc39a63,combination,0.320977
uuid-83a45724c4ba403c80fb7f926bc39a63,IO,0.350267
uuid-83a45724c4ba403c80fb7f926bc39a63,physicians,0.427042
uuid-83a45724c4ba403c80fb7f926bc39a63,combo,0.366627
uuid-83a45724c4ba403c80fb7f926bc39a63,oncology,0.357086
uuid-83a45724c4ba403c80fb7f926bc39a63,TLs,0.336774
uuid-83a45724c4ba403c80fb7f926bc39a63,academic,0.349611
uuid-8f900930a17d4255af9dfbe2e7e840e5,lung,0.303817
uuid-8f900930a17d4255af9dfbe2e7e840e5,1L,0.416827
uuid-8f900930a17d4255af9dfbe2e7e840e5,RCC,0.349001
uuid-8f900930a17d4255af9dfbe2e7e840e5,2L,0.426206
uuid-8f900930a17d4255af9dfbe2e7e840e5,stated,0.485622
uuid-8f900930a17d4255af9dfbe2e7e840e5,approval,0.382926
uuid-8f900930a17d4255af9dfbe2e7e840e5,preferred,0.39055
uuid-8f900930a17d4255af9dfbe2e7e840e5,using nivo,0.342737
uuid-8f900930a17d4255af9dfbe2e7e840e5,expressed,0.309415
uuid-8f900930a17d4255af9dfbe2e7e840e5,indication,0.452873
uuid-8f900930a17d4255af9dfbe2e7e840e5,approved,0.483253
uuid-8f900930a17d4255af9dfbe2e7e840e5,SCCHN,0.399102
uuid-8f900930a17d4255af9dfbe2e7e840e5,tumor types,0.312962
uuid-8f900930a17d4255af9dfbe2e7e840e5,label,0.420169
uuid-8f900930a17d4255af9dfbe2e7e840e5,RTL stated,0.324389
uuid-8f900930a17d4255af9dfbe2e7e840e5,option,0.331133
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,BMS,0.41435
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,PDL1,0.519711
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,trial,0.574975
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,efficacy,0.529896
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,OS,0.704521
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,regards,0.339319
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,data,0.656596
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,PFS,0.737446
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,ORR,0.684187
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,nivo and pembro,0.621302
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,believes,0.346397
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,impressed,0.43664
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,feels,0.348139
uuid-8b0b00cfa97845e7a64ac002b6a0d1ba,PDL1 expression,0.439821
uuid-a8493e86204e4c43b1a07a7699255401,oncology,0.530257
uuid-a8493e86204e4c43b1a07a7699255401,drug,0.61349
uuid-a8493e86204e4c43b1a07a7699255401,clinical,0.435506
uuid-8eeeca4f08a24d24b56c2fa164c948ab,Nivo,0.568902
uuid-8eeeca4f08a24d24b56c2fa164c948ab,therapy,0.39103
uuid-8eeeca4f08a24d24b56c2fa164c948ab,efficacy,0.455894
uuid-8eeeca4f08a24d24b56c2fa164c948ab,chemo,0.64162
uuid-8eeeca4f08a24d24b56c2fa164c948ab,OS,0.446313
uuid-8eeeca4f08a24d24b56c2fa164c948ab,monotherapy,0.345388
uuid-8eeeca4f08a24d24b56c2fa164c948ab,response,0.501756
uuid-8eeeca4f08a24d24b56c2fa164c948ab,PFS,0.504457
uuid-8eeeca4f08a24d24b56c2fa164c948ab,PD1,0.386355
uuid-8eeeca4f08a24d24b56c2fa164c948ab,ORR,0.421333
uuid-8eeeca4f08a24d24b56c2fa164c948ab,nivo and pembro,0.402946
uuid-8eeeca4f08a24d24b56c2fa164c948ab,progression,0.337911
uuid-8eeeca4f08a24d24b56c2fa164c948ab,believes,0.457358
uuid-8eeeca4f08a24d24b56c2fa164c948ab,chemotherapy,0.504458
uuid-8eeeca4f08a24d24b56c2fa164c948ab,respond,0.372472
uuid-8eeeca4f08a24d24b56c2fa164c948ab,feels,0.371752
uuid-8eeeca4f08a24d24b56c2fa164c948ab,option,0.342691
uuid-594682ecb354470487803ed6cbf0632e,approval,0.332875
uuid-594682ecb354470487803ed6cbf0632e,clinical trials,0.334678
uuid-594682ecb354470487803ed6cbf0632e,indication,0.515523
uuid-594682ecb354470487803ed6cbf0632e,approved,0.54617
uuid-594682ecb354470487803ed6cbf0632e,label,0.507105
uuid-594682ecb354470487803ed6cbf0632e,drug,0.323409
uuid-39e1a03991914ecc9c1d900fde972d15,patients,0.529542
uuid-39e1a03991914ecc9c1d900fde972d15,pts,0.304502
uuid-39e1a03991914ecc9c1d900fde972d15,clinical trials,0.391149
uuid-7f9130d0f44a437192de248c34a75bdd,patients,0.488458
uuid-7f9130d0f44a437192de248c34a75bdd,Opdivo,0.518754
uuid-7f9130d0f44a437192de248c34a75bdd,nivolumab,0.46321
uuid-7f9130d0f44a437192de248c34a75bdd,treated,0.356498
uuid-7f9130d0f44a437192de248c34a75bdd,pts,0.384749
uuid-7f9130d0f44a437192de248c34a75bdd,approval,0.421232
uuid-7f9130d0f44a437192de248c34a75bdd,treatment,0.347353
uuid-7f9130d0f44a437192de248c34a75bdd,using nivo,0.393946
uuid-7f9130d0f44a437192de248c34a75bdd,SCCHN,0.434661
uuid-7f9130d0f44a437192de248c34a75bdd,cHL,0.348855
uuid-7f9130d0f44a437192de248c34a75bdd,RTL stated,0.333093
uuid-f598c60ff8b444eb833620e27a00528c,Nivo,0.367042
uuid-f598c60ff8b444eb833620e27a00528c,patients,0.732865
uuid-f598c60ff8b444eb833620e27a00528c,Opdivo,0.580366
uuid-f598c60ff8b444eb833620e27a00528c,therapy,0.435128
uuid-f598c60ff8b444eb833620e27a00528c,nivolumab,0.551422
uuid-f598c60ff8b444eb833620e27a00528c,regimen,0.465655
uuid-f598c60ff8b444eb833620e27a00528c,treated,0.608243
uuid-f598c60ff8b444eb833620e27a00528c,pts,0.456944
uuid-f598c60ff8b444eb833620e27a00528c,approval,0.426504
uuid-f598c60ff8b444eb833620e27a00528c,monotherapy,0.326863
uuid-f598c60ff8b444eb833620e27a00528c,treatment,0.544716
uuid-f598c60ff8b444eb833620e27a00528c,using nivo,0.463055
uuid-f598c60ff8b444eb833620e27a00528c,approved,0.311808
uuid-f598c60ff8b444eb833620e27a00528c,SCCHN,0.324972
uuid-f598c60ff8b444eb833620e27a00528c,cHL,0.364311
uuid-f598c60ff8b444eb833620e27a00528c,progression,0.443816
uuid-f598c60ff8b444eb833620e27a00528c,respond,0.348484
uuid-f598c60ff8b444eb833620e27a00528c,RTL stated,0.384853
uuid-f598c60ff8b444eb833620e27a00528c,option,0.344146
uuid-3def7826d6024ae99db9b1ef6395a245,Nivo,0.301202
uuid-3def7826d6024ae99db9b1ef6395a245,Opdivo,0.444715
uuid-3def7826d6024ae99db9b1ef6395a245,pembro,0.530744
uuid-3def7826d6024ae99db9b1ef6395a245,dose,0.347934
uuid-3def7826d6024ae99db9b1ef6395a245,2L,0.412206
uuid-3def7826d6024ae99db9b1ef6395a245,approval,0.337491
uuid-3def7826d6024ae99db9b1ef6395a245,atezo,0.517559
uuid-3def7826d6024ae99db9b1ef6395a245,preferred,0.55308
uuid-3def7826d6024ae99db9b1ef6395a245,using nivo,0.370148
uuid-3def7826d6024ae99db9b1ef6395a245,indication,0.503997
uuid-3def7826d6024ae99db9b1ef6395a245,approved,0.432115
uuid-3def7826d6024ae99db9b1ef6395a245,vs,0.341802
uuid-3def7826d6024ae99db9b1ef6395a245,label,0.306533
uuid-3def7826d6024ae99db9b1ef6395a245,Keytruda,0.501044
uuid-3def7826d6024ae99db9b1ef6395a245,feels,0.349285
uuid-3def7826d6024ae99db9b1ef6395a245,option,0.407907
uuid-3def7826d6024ae99db9b1ef6395a245,flat dosing,0.385623
uuid-e5efea130bbd482d854a5c5a3c1145fb,lung,0.393257
uuid-e5efea130bbd482d854a5c5a3c1145fb,discussed,0.381907
uuid-e5efea130bbd482d854a5c5a3c1145fb,commented,0.44971
uuid-e5efea130bbd482d854a5c5a3c1145fb,RCC,0.31357
uuid-e5efea130bbd482d854a5c5a3c1145fb,stated,0.357325
uuid-e5efea130bbd482d854a5c5a3c1145fb,regards,0.451892
uuid-e5efea130bbd482d854a5c5a3c1145fb,data,0.390419
uuid-e5efea130bbd482d854a5c5a3c1145fb,expressed,0.386486
uuid-e5efea130bbd482d854a5c5a3c1145fb,indication,0.514724
uuid-e5efea130bbd482d854a5c5a3c1145fb,approved,0.303088
uuid-e5efea130bbd482d854a5c5a3c1145fb,SCCHN,0.447407
uuid-e5efea130bbd482d854a5c5a3c1145fb,impressed,0.329482
uuid-e5efea130bbd482d854a5c5a3c1145fb,indicated,0.356226
uuid-e5efea130bbd482d854a5c5a3c1145fb,LTL,0.301897
uuid-e5efea130bbd482d854a5c5a3c1145fb,TLs,0.516329
uuid-e5efea130bbd482d854a5c5a3c1145fb,Regional TL,0.360382
uuid-9f7ef38f43874708b0dded2cd3a35478,BMS,0.34605
uuid-9f7ef38f43874708b0dded2cd3a35478,efficacy,0.484292
uuid-9f7ef38f43874708b0dded2cd3a35478,agents,0.532221
uuid-9f7ef38f43874708b0dded2cd3a35478,atezo,0.329914
uuid-9f7ef38f43874708b0dded2cd3a35478,regards,0.418951
uuid-9f7ef38f43874708b0dded2cd3a35478,data,0.358881
uuid-9f7ef38f43874708b0dded2cd3a35478,expressed,0.328036
uuid-9f7ef38f43874708b0dded2cd3a35478,indication,0.375644
uuid-9f7ef38f43874708b0dded2cd3a35478,nivo and pembro,0.394901
uuid-9f7ef38f43874708b0dded2cd3a35478,believes,0.363175
uuid-9f7ef38f43874708b0dded2cd3a35478,TLs,0.405734
uuid-9f7ef38f43874708b0dded2cd3a35478,clinical,0.406818
uuid-9f7ef38f43874708b0dded2cd3a35478,feels,0.309861
uuid-b05d74a2c5594a4cb2e33b3c019ee153,pembro,0.507491
uuid-b05d74a2c5594a4cb2e33b3c019ee153,lung,0.537252
uuid-b05d74a2c5594a4cb2e33b3c019ee153,1L,0.56377
uuid-b05d74a2c5594a4cb2e33b3c019ee153,commented,0.336658
uuid-b05d74a2c5594a4cb2e33b3c019ee153,RCC,0.551338
uuid-b05d74a2c5594a4cb2e33b3c019ee153,TL stated,0.567375
uuid-b05d74a2c5594a4cb2e33b3c019ee153,2L,0.619841
uuid-b05d74a2c5594a4cb2e33b3c019ee153,stated,0.38749
uuid-b05d74a2c5594a4cb2e33b3c019ee153,approval,0.372698
uuid-b05d74a2c5594a4cb2e33b3c019ee153,atezo,0.579478
uuid-b05d74a2c5594a4cb2e33b3c019ee153,preferred,0.420799
uuid-b05d74a2c5594a4cb2e33b3c019ee153,using nivo,0.514258
uuid-b05d74a2c5594a4cb2e33b3c019ee153,data,0.325785
uuid-b05d74a2c5594a4cb2e33b3c019ee153,PDL1 testing,0.463712
uuid-b05d74a2c5594a4cb2e33b3c019ee153,indication,0.364946
uuid-b05d74a2c5594a4cb2e33b3c019ee153,approved,0.375637
uuid-b05d74a2c5594a4cb2e33b3c019ee153,SCCHN,0.54945
uuid-b05d74a2c5594a4cb2e33b3c019ee153,nivo and pembro,0.361495
uuid-b05d74a2c5594a4cb2e33b3c019ee153,tumor types,0.315788
uuid-b05d74a2c5594a4cb2e33b3c019ee153,LTL,0.345095
uuid-b05d74a2c5594a4cb2e33b3c019ee153,TLs,0.542454
uuid-b05d74a2c5594a4cb2e33b3c019ee153,Regional TL,0.398
uuid-b05d74a2c5594a4cb2e33b3c019ee153,RTL stated,0.52726
uuid-b05d74a2c5594a4cb2e33b3c019ee153,TL shared,0.37381
uuid-b05d74a2c5594a4cb2e33b3c019ee153,bladder,0.463465
uuid-ca37b95c23d14c10b2a8fd57371b1301,TL,0.367989
uuid-ca37b95c23d14c10b2a8fd57371b1301,RTL,0.391651
uuid-ca37b95c23d14c10b2a8fd57371b1301,shared,0.429917
uuid-ca37b95c23d14c10b2a8fd57371b1301,RCC,0.41223
uuid-ca37b95c23d14c10b2a8fd57371b1301,TL stated,0.489621
uuid-ca37b95c23d14c10b2a8fd57371b1301,institution,0.576436
uuid-ca37b95c23d14c10b2a8fd57371b1301,stated,0.430708
uuid-ca37b95c23d14c10b2a8fd57371b1301,PD-L1,0.508977
uuid-ca37b95c23d14c10b2a8fd57371b1301,approval,0.42467
uuid-ca37b95c23d14c10b2a8fd57371b1301,PD-L1 testing,0.606844
uuid-ca37b95c23d14c10b2a8fd57371b1301,testing,0.605583
uuid-ca37b95c23d14c10b2a8fd57371b1301,PDL1 testing,0.587825
uuid-ca37b95c23d14c10b2a8fd57371b1301,NSCLC patients,0.584499
uuid-ca37b95c23d14c10b2a8fd57371b1301,SCCHN,0.478938
uuid-ca37b95c23d14c10b2a8fd57371b1301,tumor types,0.387764
uuid-ca37b95c23d14c10b2a8fd57371b1301,LTL,0.30978
uuid-ca37b95c23d14c10b2a8fd57371b1301,Regional TL,0.371282
uuid-ca37b95c23d14c10b2a8fd57371b1301,RTL stated,0.38439
uuid-ca37b95c23d14c10b2a8fd57371b1301,bladder,0.311551
uuid-e2b11138af1d4364b6cae1e58a208566,NTL,0.430652
uuid-e2b11138af1d4364b6cae1e58a208566,discussed,0.318225
uuid-e2b11138af1d4364b6cae1e58a208566,commented,0.434419
uuid-e2b11138af1d4364b6cae1e58a208566,physicians,0.384807
uuid-e2b11138af1d4364b6cae1e58a208566,regards,0.472798
uuid-e2b11138af1d4364b6cae1e58a208566,mentioned,0.31601
uuid-e2b11138af1d4364b6cae1e58a208566,oncology,0.316183
uuid-e2b11138af1d4364b6cae1e58a208566,ASCO,0.318215
uuid-e2b11138af1d4364b6cae1e58a208566,clinical,0.404713
uuid-06485d411eb249c3a3998d4b70e0b0bb,Nivo,0.348342
uuid-06485d411eb249c3a3998d4b70e0b0bb,RTL,0.33455
uuid-06485d411eb249c3a3998d4b70e0b0bb,nivolumab,0.344115
uuid-06485d411eb249c3a3998d4b70e0b0bb,trial,0.610862
uuid-06485d411eb249c3a3998d4b70e0b0bb,OS,0.342495
uuid-06485d411eb249c3a3998d4b70e0b0bb,response,0.340988
uuid-06485d411eb249c3a3998d4b70e0b0bb,data,0.370043
uuid-06485d411eb249c3a3998d4b70e0b0bb,PFS,0.382122
uuid-06485d411eb249c3a3998d4b70e0b0bb,ORR,0.435279
uuid-06485d411eb249c3a3998d4b70e0b0bb,chemotherapy,0.337508
uuid-06485d411eb249c3a3998d4b70e0b0bb,impressed,0.440719
uuid-8d1eef53f04c45939343c54a4d247071,shared,0.539883
uuid-8d1eef53f04c45939343c54a4d247071,institution,0.75561
uuid-083f7919c613448c839ac51ab8c6dbee,trial,0.371091
uuid-083f7919c613448c839ac51ab8c6dbee,response,0.366656
uuid-083f7919c613448c839ac51ab8c6dbee,ORR,0.34055
uuid-7eb770318f0049fda19fab8f09d4d3b9,therapy,0.452003
uuid-7eb770318f0049fda19fab8f09d4d3b9,nivolumab,0.305503
uuid-7eb770318f0049fda19fab8f09d4d3b9,tumor,0.354597
uuid-7eb770318f0049fda19fab8f09d4d3b9,response,0.373741
uuid-7eb770318f0049fda19fab8f09d4d3b9,cHL,0.498177
uuid-7eb770318f0049fda19fab8f09d4d3b9,immunotherapy,0.324973
uuid-f4287ef0c6b54521861b100c3b3c2a71,NSCLC,0.437209
uuid-f4287ef0c6b54521861b100c3b3c2a71,1L,0.495045
uuid-f4287ef0c6b54521861b100c3b3c2a71,RCC,0.316891
uuid-f4287ef0c6b54521861b100c3b3c2a71,TL stated,0.325481
uuid-f4287ef0c6b54521861b100c3b3c2a71,2L,0.398945
uuid-f4287ef0c6b54521861b100c3b3c2a71,pts,0.457618
uuid-f4287ef0c6b54521861b100c3b3c2a71,IO,0.370032
uuid-f4287ef0c6b54521861b100c3b3c2a71,PD-L1,0.405636
uuid-f4287ef0c6b54521861b100c3b3c2a71,preferred,0.431799
uuid-f4287ef0c6b54521861b100c3b3c2a71,PD-L1 testing,0.424108
uuid-f4287ef0c6b54521861b100c3b3c2a71,testing,0.425066
uuid-f4287ef0c6b54521861b100c3b3c2a71,monotherapy,0.423889
uuid-f4287ef0c6b54521861b100c3b3c2a71,combo,0.338101
uuid-f4287ef0c6b54521861b100c3b3c2a71,PDL1 testing,0.41654
uuid-f4287ef0c6b54521861b100c3b3c2a71,NSCLC patients,0.503804
uuid-f4287ef0c6b54521861b100c3b3c2a71,RTL stated,0.379374
uuid-f4287ef0c6b54521861b100c3b3c2a71,option,0.448742
uuid-2a6ce043ebe5428499aee8b3c5fbf770,Opdivo,0.683488
uuid-2a6ce043ebe5428499aee8b3c5fbf770,dose,0.536679
uuid-2a6ce043ebe5428499aee8b3c5fbf770,indication,0.364822
uuid-2a6ce043ebe5428499aee8b3c5fbf770,approved,0.300591
uuid-2a6ce043ebe5428499aee8b3c5fbf770,label,0.383651
uuid-2a6ce043ebe5428499aee8b3c5fbf770,Keytruda,0.552707
uuid-2a6ce043ebe5428499aee8b3c5fbf770,flat dosing,0.756388
uuid-a1c852e7c3784c6b92911782db9af02b,therapy,0.481213
uuid-a1c852e7c3784c6b92911782db9af02b,nivolumab,0.534007
uuid-a1c852e7c3784c6b92911782db9af02b,regimen,0.354913
uuid-a1c852e7c3784c6b92911782db9af02b,combination,0.707261
uuid-a1c852e7c3784c6b92911782db9af02b,chemo,0.555144
uuid-a1c852e7c3784c6b92911782db9af02b,pts,0.424233
uuid-a1c852e7c3784c6b92911782db9af02b,IO,0.383881
uuid-a1c852e7c3784c6b92911782db9af02b,agents,0.340317
uuid-a1c852e7c3784c6b92911782db9af02b,monotherapy,0.547407
uuid-a1c852e7c3784c6b92911782db9af02b,response,0.562763
uuid-a1c852e7c3784c6b92911782db9af02b,combo,0.562833
uuid-a1c852e7c3784c6b92911782db9af02b,PD1,0.75562
uuid-a1c852e7c3784c6b92911782db9af02b,progression,0.465582
uuid-a1c852e7c3784c6b92911782db9af02b,believes,0.310302
uuid-a1c852e7c3784c6b92911782db9af02b,chemotherapy,0.505678
uuid-a1c852e7c3784c6b92911782db9af02b,immunotherapy,0.317994
uuid-a1c852e7c3784c6b92911782db9af02b,PD-1,0.447482
uuid-a1c852e7c3784c6b92911782db9af02b,option,0.334231
uuid-ef9912552fff448b98033f9cea7fc8ff,Nivo,0.454428
uuid-ef9912552fff448b98033f9cea7fc8ff,pembro,0.602031
uuid-ef9912552fff448b98033f9cea7fc8ff,dose,0.625719
uuid-ef9912552fff448b98033f9cea7fc8ff,efficacy,0.491888
uuid-ef9912552fff448b98033f9cea7fc8ff,Ipi,0.431818
uuid-ef9912552fff448b98033f9cea7fc8ff,atezo,0.620942
uuid-ef9912552fff448b98033f9cea7fc8ff,preferred,0.336823
uuid-ef9912552fff448b98033f9cea7fc8ff,indication,0.378077
uuid-ef9912552fff448b98033f9cea7fc8ff,nivo and pembro,0.339948
uuid-ef9912552fff448b98033f9cea7fc8ff,vs,0.661453
uuid-ef9912552fff448b98033f9cea7fc8ff,Keytruda,0.490633
uuid-ef9912552fff448b98033f9cea7fc8ff,flat dosing,0.611955
uuid-b51205e2a2db4209b609998c2d4d3195,NSCLC,0.428722
uuid-b51205e2a2db4209b609998c2d4d3195,PDL1,0.46847
uuid-b51205e2a2db4209b609998c2d4d3195,TL stated,0.388949
uuid-b51205e2a2db4209b609998c2d4d3195,PD-L1,0.717816
uuid-b51205e2a2db4209b609998c2d4d3195,PD-L1 testing,0.642578
uuid-b51205e2a2db4209b609998c2d4d3195,testing,0.720148
uuid-b51205e2a2db4209b609998c2d4d3195,PDL1 testing,0.605789
uuid-b51205e2a2db4209b609998c2d4d3195,NSCLC patients,0.606997
uuid-b51205e2a2db4209b609998c2d4d3195,assay,0.438035
uuid-b51205e2a2db4209b609998c2d4d3195,biomarker,0.509643
uuid-b717103dca5f442da3dc1f50871fd0d0,pembro,0.587909
uuid-b717103dca5f442da3dc1f50871fd0d0,1L,0.538021
uuid-b717103dca5f442da3dc1f50871fd0d0,PDL1,0.657681
uuid-b717103dca5f442da3dc1f50871fd0d0,TL stated,0.300533
uuid-b717103dca5f442da3dc1f50871fd0d0,2L,0.485911
uuid-b717103dca5f442da3dc1f50871fd0d0,agents,0.30496
uuid-b717103dca5f442da3dc1f50871fd0d0,Merck,0.379409
uuid-b717103dca5f442da3dc1f50871fd0d0,PD-L1,0.655528
uuid-b717103dca5f442da3dc1f50871fd0d0,approval,0.334076
uuid-b717103dca5f442da3dc1f50871fd0d0,atezo,0.600803
uuid-b717103dca5f442da3dc1f50871fd0d0,preferred,0.376481
uuid-b717103dca5f442da3dc1f50871fd0d0,PD-L1 testing,0.343748
uuid-b717103dca5f442da3dc1f50871fd0d0,testing,0.547965
uuid-b717103dca5f442da3dc1f50871fd0d0,data,0.31837
uuid-b717103dca5f442da3dc1f50871fd0d0,expressed,0.372637
uuid-b717103dca5f442da3dc1f50871fd0d0,PDL1 testing,0.505719
uuid-b717103dca5f442da3dc1f50871fd0d0,indication,0.384265
uuid-b717103dca5f442da3dc1f50871fd0d0,NSCLC patients,0.456271
uuid-b717103dca5f442da3dc1f50871fd0d0,approved,0.419635
uuid-b717103dca5f442da3dc1f50871fd0d0,nivo and pembro,0.49392
uuid-b717103dca5f442da3dc1f50871fd0d0,tumor types,0.397464
uuid-b717103dca5f442da3dc1f50871fd0d0,assay,0.461349
uuid-b717103dca5f442da3dc1f50871fd0d0,PDL1 expression,0.535985
uuid-b717103dca5f442da3dc1f50871fd0d0,biomarker,0.434749
uuid-b717103dca5f442da3dc1f50871fd0d0,bladder,0.306938
uuid-888bdb52ff044c45a1516aa8bacb1b24,PDL1,0.333475
uuid-888bdb52ff044c45a1516aa8bacb1b24,efficacy,0.31453
uuid-888bdb52ff044c45a1516aa8bacb1b24,commented,0.32489
uuid-888bdb52ff044c45a1516aa8bacb1b24,expressed,0.458928
uuid-888bdb52ff044c45a1516aa8bacb1b24,HCP,0.389089
uuid-888bdb52ff044c45a1516aa8bacb1b24,lung cancer,0.427371
uuid-888bdb52ff044c45a1516aa8bacb1b24,TLs,0.310652
uuid-9f5bc9b76c1d498f8383bc1a0e4bf8af,TL,0.456694
uuid-9f5bc9b76c1d498f8383bc1a0e4bf8af,TL stated,0.449038
uuid-9f5bc9b76c1d498f8383bc1a0e4bf8af,PD-L1,0.681578
uuid-9f5bc9b76c1d498f8383bc1a0e4bf8af,PD-L1 testing,0.67382
uuid-9f5bc9b76c1d498f8383bc1a0e4bf8af,testing,0.797958
uuid-9f5bc9b76c1d498f8383bc1a0e4bf8af,PDL1 testing,0.68129
uuid-9f5bc9b76c1d498f8383bc1a0e4bf8af,NSCLC patients,0.724553
uuid-9f5bc9b76c1d498f8383bc1a0e4bf8af,tumor types,0.391128
uuid-9f5bc9b76c1d498f8383bc1a0e4bf8af,assay,0.462557
uuid-9f5bc9b76c1d498f8383bc1a0e4bf8af,biomarker,0.353604
uuid-02920fee00a046ab8f8f73ba24c9604b,TL,0.374914
uuid-02920fee00a046ab8f8f73ba24c9604b,lung,0.322476
uuid-02920fee00a046ab8f8f73ba24c9604b,RCC,0.318652
uuid-02920fee00a046ab8f8f73ba24c9604b,TL stated,0.359971
uuid-02920fee00a046ab8f8f73ba24c9604b,PD-L1,0.533354
uuid-02920fee00a046ab8f8f73ba24c9604b,PD-L1 testing,0.536891
uuid-02920fee00a046ab8f8f73ba24c9604b,testing,0.501291
uuid-02920fee00a046ab8f8f73ba24c9604b,PDL1 testing,0.427408
uuid-02920fee00a046ab8f8f73ba24c9604b,NSCLC patients,0.479715
uuid-02920fee00a046ab8f8f73ba24c9604b,SCCHN,0.318471
uuid-02920fee00a046ab8f8f73ba24c9604b,oncologist,0.531037
uuid-02920fee00a046ab8f8f73ba24c9604b,indicated,0.68272
uuid-02920fee00a046ab8f8f73ba24c9604b,TLs,0.315468
uuid-e804081678044e6e9efccee03b8dfdbf,TL,0.343313
uuid-e804081678044e6e9efccee03b8dfdbf,TL stated,0.346913
uuid-e804081678044e6e9efccee03b8dfdbf,PD-L1,0.366695
uuid-e804081678044e6e9efccee03b8dfdbf,PD-L1 testing,0.603283
uuid-e804081678044e6e9efccee03b8dfdbf,testing,0.48784
uuid-e804081678044e6e9efccee03b8dfdbf,PDL1 testing,0.428778
uuid-e804081678044e6e9efccee03b8dfdbf,NSCLC patients,0.36684
uuid-e804081678044e6e9efccee03b8dfdbf,assay,0.346501
uuid-e3c109ee5d2d40eeab83742430778fc3,TL,0.70439
uuid-e3c109ee5d2d40eeab83742430778fc3,TL stated,0.392972
uuid-e3c109ee5d2d40eeab83742430778fc3,institution,0.357633
uuid-e3c109ee5d2d40eeab83742430778fc3,PD-L1,0.681402
uuid-e3c109ee5d2d40eeab83742430778fc3,PD-L1 testing,0.91114
uuid-e3c109ee5d2d40eeab83742430778fc3,testing,0.812567
uuid-e3c109ee5d2d40eeab83742430778fc3,PDL1 testing,0.641718
uuid-e3c109ee5d2d40eeab83742430778fc3,NSCLC patients,0.525133
uuid-e3c109ee5d2d40eeab83742430778fc3,clinical,0.325215
uuid-e3c109ee5d2d40eeab83742430778fc3,assay,0.665183
uuid-e3c109ee5d2d40eeab83742430778fc3,biomarker,0.306366
uuid-eb65dde1a51f4dedb0425308e6e5df92,Nivo,0.6645
uuid-eb65dde1a51f4dedb0425308e6e5df92,patients,0.332467
uuid-eb65dde1a51f4dedb0425308e6e5df92,therapy,0.576953
uuid-eb65dde1a51f4dedb0425308e6e5df92,nivolumab,0.468538
uuid-eb65dde1a51f4dedb0425308e6e5df92,regimen,0.373136
uuid-eb65dde1a51f4dedb0425308e6e5df92,combination,0.698775
uuid-eb65dde1a51f4dedb0425308e6e5df92,chemo,0.568986
uuid-eb65dde1a51f4dedb0425308e6e5df92,pts,0.314338
uuid-eb65dde1a51f4dedb0425308e6e5df92,IO,0.309858
uuid-eb65dde1a51f4dedb0425308e6e5df92,agents,0.433609
uuid-eb65dde1a51f4dedb0425308e6e5df92,Ipi,0.390842
uuid-eb65dde1a51f4dedb0425308e6e5df92,monotherapy,0.555653
uuid-eb65dde1a51f4dedb0425308e6e5df92,treatment,0.34341
uuid-eb65dde1a51f4dedb0425308e6e5df92,response,0.388479
uuid-eb65dde1a51f4dedb0425308e6e5df92,combo,0.511268
uuid-eb65dde1a51f4dedb0425308e6e5df92,PD1,0.570018
uuid-eb65dde1a51f4dedb0425308e6e5df92,cHL,0.300155
uuid-eb65dde1a51f4dedb0425308e6e5df92,progression,0.368273
uuid-eb65dde1a51f4dedb0425308e6e5df92,chemotherapy,0.578345
uuid-eb65dde1a51f4dedb0425308e6e5df92,feels,0.338006
uuid-eb65dde1a51f4dedb0425308e6e5df92,option,0.42391
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,pembro,0.302501
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,BMS,0.323558
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,trial,0.393875
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,efficacy,0.505724
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,commented,0.374832
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,stated,0.309653
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,OS,0.548362
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,data,0.863
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,indication,0.360791
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,PFS,0.488032
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,ORR,0.55956
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,nivo and pembro,0.307484
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,ASCO,0.395716
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,impressed,0.652182
uuid-3df59fb210eb4b9aaadfe9bdb29ba307,PDL1 expression,0.302783
uuid-802c08f5e09445cf9fb79bdc1da9788f,Nivo,0.301441
uuid-802c08f5e09445cf9fb79bdc1da9788f,pembro,0.504952
uuid-802c08f5e09445cf9fb79bdc1da9788f,1L,0.364032
uuid-802c08f5e09445cf9fb79bdc1da9788f,trial,0.32829
uuid-802c08f5e09445cf9fb79bdc1da9788f,2L,0.380238
uuid-802c08f5e09445cf9fb79bdc1da9788f,agents,0.308237
uuid-802c08f5e09445cf9fb79bdc1da9788f,approval,0.313026
uuid-802c08f5e09445cf9fb79bdc1da9788f,atezo,0.4096
uuid-802c08f5e09445cf9fb79bdc1da9788f,preferred,0.370594
uuid-802c08f5e09445cf9fb79bdc1da9788f,monotherapy,0.318334
uuid-802c08f5e09445cf9fb79bdc1da9788f,data,0.332217
uuid-802c08f5e09445cf9fb79bdc1da9788f,clinical trials,0.310207
uuid-802c08f5e09445cf9fb79bdc1da9788f,indication,0.345548
uuid-802c08f5e09445cf9fb79bdc1da9788f,approved,0.425939
uuid-802c08f5e09445cf9fb79bdc1da9788f,nivo and pembro,0.332746
uuid-802c08f5e09445cf9fb79bdc1da9788f,tumor types,0.301601
uuid-802c08f5e09445cf9fb79bdc1da9788f,feels,0.315584
uuid-802c08f5e09445cf9fb79bdc1da9788f,RTL stated,0.303092
uuid-802c08f5e09445cf9fb79bdc1da9788f,option,0.351739
uuid-2861051980a34bb5910d20085bf8e8bf,Opdivo,0.516688
uuid-2861051980a34bb5910d20085bf8e8bf,dose,0.563555
uuid-2861051980a34bb5910d20085bf8e8bf,physicians,0.44449
uuid-2861051980a34bb5910d20085bf8e8bf,oncology,0.321661
uuid-2861051980a34bb5910d20085bf8e8bf,indicated,0.32404
uuid-2861051980a34bb5910d20085bf8e8bf,Keytruda,0.468338
uuid-2861051980a34bb5910d20085bf8e8bf,flat dosing,0.662901
uuid-4bd8f9538fc4454c8ca96042a51c1515,patients,0.791308
uuid-4bd8f9538fc4454c8ca96042a51c1515,Opdivo,0.634159
uuid-4bd8f9538fc4454c8ca96042a51c1515,therapy,0.654541
uuid-4bd8f9538fc4454c8ca96042a51c1515,nivolumab,0.537421
uuid-4bd8f9538fc4454c8ca96042a51c1515,regimen,0.520853
uuid-4bd8f9538fc4454c8ca96042a51c1515,treated,0.592044
uuid-4bd8f9538fc4454c8ca96042a51c1515,pts,0.441871
uuid-4bd8f9538fc4454c8ca96042a51c1515,physicians,0.424882
uuid-4bd8f9538fc4454c8ca96042a51c1515,treatment,0.74487
uuid-4bd8f9538fc4454c8ca96042a51c1515,response,0.307574
uuid-4bd8f9538fc4454c8ca96042a51c1515,cHL,0.402927
uuid-4bd8f9538fc4454c8ca96042a51c1515,progression,0.636201
uuid-4bd8f9538fc4454c8ca96042a51c1515,chemotherapy,0.32784
uuid-4bd8f9538fc4454c8ca96042a51c1515,respond,0.425882
uuid-ee0e4aa6cf374a0585b4420efeabe938,Opdivo,0.388826
uuid-ee0e4aa6cf374a0585b4420efeabe938,physicians,0.5205
uuid-ee0e4aa6cf374a0585b4420efeabe938,preferred,0.494209
uuid-ee0e4aa6cf374a0585b4420efeabe938,PDL1 testing,0.323822
uuid-ee0e4aa6cf374a0585b4420efeabe938,indication,0.341605
uuid-ee0e4aa6cf374a0585b4420efeabe938,approved,0.375466
uuid-ee0e4aa6cf374a0585b4420efeabe938,drug,0.316217
uuid-ee0e4aa6cf374a0585b4420efeabe938,Keytruda,0.348376
uuid-3a32512e2fd04124be6b301898a2b3b2,Opdivo,0.345069
uuid-3a32512e2fd04124be6b301898a2b3b2,shared,0.327488
uuid-3a32512e2fd04124be6b301898a2b3b2,physicians,0.699017
uuid-3a32512e2fd04124be6b301898a2b3b2,oncology,0.307081
uuid-3a32512e2fd04124be6b301898a2b3b2,indicated,0.338862
uuid-3a32512e2fd04124be6b301898a2b3b2,clinical,0.330396
uuid-f8fa313caa6c4823a3d87d67af1ffc22,Opdivo,0.545594
uuid-f8fa313caa6c4823a3d87d67af1ffc22,dose,0.776276
uuid-f8fa313caa6c4823a3d87d67af1ffc22,toxicity,0.32515
uuid-f8fa313caa6c4823a3d87d67af1ffc22,Ipi,0.355543
uuid-f8fa313caa6c4823a3d87d67af1ffc22,vs,0.359497
uuid-f8fa313caa6c4823a3d87d67af1ffc22,drug,0.335533
uuid-f8fa313caa6c4823a3d87d67af1ffc22,Keytruda,0.523067
uuid-f8fa313caa6c4823a3d87d67af1ffc22,flat dosing,0.768037
uuid-5847ea3a8cad468ea3808d366ca4fa7c,Nivo,0.401324
uuid-5847ea3a8cad468ea3808d366ca4fa7c,pembro,0.311161
uuid-5847ea3a8cad468ea3808d366ca4fa7c,trial,0.305119
uuid-5847ea3a8cad468ea3808d366ca4fa7c,efficacy,0.452201
uuid-5847ea3a8cad468ea3808d366ca4fa7c,Ipi,0.308133
uuid-5847ea3a8cad468ea3808d366ca4fa7c,OS,0.527322
uuid-5847ea3a8cad468ea3808d366ca4fa7c,data,0.375989
uuid-5847ea3a8cad468ea3808d366ca4fa7c,PFS,0.463812
uuid-5847ea3a8cad468ea3808d366ca4fa7c,ORR,0.488839
uuid-5847ea3a8cad468ea3808d366ca4fa7c,nivo and pembro,0.417396
uuid-5847ea3a8cad468ea3808d366ca4fa7c,believes,0.407537
uuid-5847ea3a8cad468ea3808d366ca4fa7c,impressed,0.417468
uuid-5847ea3a8cad468ea3808d366ca4fa7c,feels,0.417331
uuid-dba435bb61e14f749882be542578f9d2,patients,0.315178
uuid-dba435bb61e14f749882be542578f9d2,1L,0.430518
uuid-dba435bb61e14f749882be542578f9d2,2L,0.370721
uuid-dba435bb61e14f749882be542578f9d2,preferred,0.403763
uuid-dba435bb61e14f749882be542578f9d2,monotherapy,0.360434
uuid-dba435bb61e14f749882be542578f9d2,using nivo,0.323202
uuid-dba435bb61e14f749882be542578f9d2,NSCLC patients,0.43232
uuid-dba435bb61e14f749882be542578f9d2,tumor types,0.51403
uuid-dba435bb61e14f749882be542578f9d2,feels,0.358731
uuid-dba435bb61e14f749882be542578f9d2,RTL stated,0.407068
uuid-dba435bb61e14f749882be542578f9d2,option,0.414913
uuid-0ecc41c871584bb8a25a7df40ba09367,discussed,0.337542
uuid-0ecc41c871584bb8a25a7df40ba09367,physicians,0.7395
uuid-0ecc41c871584bb8a25a7df40ba09367,oncologist,0.307814
uuid-0ecc41c871584bb8a25a7df40ba09367,indicated,0.340561
uuid-0ecc41c871584bb8a25a7df40ba09367,clinical,0.346983
uuid-0ecc41c871584bb8a25a7df40ba09367,academic,0.374263
uuid-b9b25d279a92488abef0317508762384,patients,0.666289
uuid-b9b25d279a92488abef0317508762384,Opdivo,0.54173
uuid-b9b25d279a92488abef0317508762384,nivolumab,0.483225
uuid-b9b25d279a92488abef0317508762384,regimen,0.309265
uuid-b9b25d279a92488abef0317508762384,treated,0.642797
uuid-b9b25d279a92488abef0317508762384,pts,0.331822
uuid-b9b25d279a92488abef0317508762384,approval,0.367164
uuid-b9b25d279a92488abef0317508762384,physicians,0.304182
uuid-b9b25d279a92488abef0317508762384,treatment,0.482765
uuid-b9b25d279a92488abef0317508762384,using nivo,0.332491
uuid-b9b25d279a92488abef0317508762384,SCCHN,0.309183
uuid-b9b25d279a92488abef0317508762384,cHL,0.306932
uuid-b9b25d279a92488abef0317508762384,progression,0.309318
uuid-b9b25d279a92488abef0317508762384,RTL stated,0.332942
uuid-b9b25d279a92488abef0317508762384,bladder,0.327132
uuid-a400c4e328c24addbd564848abba68ab,patients,0.37554
uuid-a400c4e328c24addbd564848abba68ab,Opdivo,0.38713
uuid-a400c4e328c24addbd564848abba68ab,dose,0.709308
uuid-a400c4e328c24addbd564848abba68ab,toxicity,0.597238
uuid-a400c4e328c24addbd564848abba68ab,regimen,0.502274
uuid-a400c4e328c24addbd564848abba68ab,treated,0.316632
uuid-a400c4e328c24addbd564848abba68ab,Ipi,0.325389
uuid-a400c4e328c24addbd564848abba68ab,physicians,0.359984
uuid-a400c4e328c24addbd564848abba68ab,treatment,0.457805
uuid-a400c4e328c24addbd564848abba68ab,respond,0.339803
uuid-a400c4e328c24addbd564848abba68ab,flat dosing,0.387131
uuid-9bd0959728f44e0b86bad015fcf077b2,Nivo,0.373433
uuid-9bd0959728f44e0b86bad015fcf077b2,patients,0.774932
uuid-9bd0959728f44e0b86bad015fcf077b2,Opdivo,0.360751
uuid-9bd0959728f44e0b86bad015fcf077b2,therapy,0.651471
uuid-9bd0959728f44e0b86bad015fcf077b2,nivolumab,0.538481
uuid-9bd0959728f44e0b86bad015fcf077b2,1L,0.36779
uuid-9bd0959728f44e0b86bad015fcf077b2,toxicity,0.409221
uuid-9bd0959728f44e0b86bad015fcf077b2,regimen,0.732583
uuid-9bd0959728f44e0b86bad015fcf077b2,treated,0.561866
uuid-9bd0959728f44e0b86bad015fcf077b2,RCC,0.335604
uuid-9bd0959728f44e0b86bad015fcf077b2,combination,0.47199
uuid-9bd0959728f44e0b86bad015fcf077b2,chemo,0.534513
uuid-9bd0959728f44e0b86bad015fcf077b2,2L,0.406624
uuid-9bd0959728f44e0b86bad015fcf077b2,pts,0.596425
uuid-9bd0959728f44e0b86bad015fcf077b2,preferred,0.472534
uuid-9bd0959728f44e0b86bad015fcf077b2,monotherapy,0.674596
uuid-9bd0959728f44e0b86bad015fcf077b2,treatment,0.695956
uuid-9bd0959728f44e0b86bad015fcf077b2,using nivo,0.441854
uuid-9bd0959728f44e0b86bad015fcf077b2,response,0.355717
uuid-9bd0959728f44e0b86bad015fcf077b2,combo,0.448445
uuid-9bd0959728f44e0b86bad015fcf077b2,PD1,0.479731
uuid-9bd0959728f44e0b86bad015fcf077b2,progression,0.64214
uuid-9bd0959728f44e0b86bad015fcf077b2,chemotherapy,0.555473
uuid-9bd0959728f44e0b86bad015fcf077b2,respond,0.475828
uuid-9bd0959728f44e0b86bad015fcf077b2,RTL stated,0.404719
uuid-9bd0959728f44e0b86bad015fcf077b2,TL shared,0.356191
uuid-9bd0959728f44e0b86bad015fcf077b2,option,0.611024
uuid-eaf0e9ccc6614c05b3b332e822198e05,pembro,0.456456
uuid-eaf0e9ccc6614c05b3b332e822198e05,1L,0.35886
uuid-eaf0e9ccc6614c05b3b332e822198e05,PDL1,0.769544
uuid-eaf0e9ccc6614c05b3b332e822198e05,efficacy,0.393225
uuid-eaf0e9ccc6614c05b3b332e822198e05,agents,0.375331
uuid-eaf0e9ccc6614c05b3b332e822198e05,Merck,0.381742
uuid-eaf0e9ccc6614c05b3b332e822198e05,PD-L1,0.804313
uuid-eaf0e9ccc6614c05b3b332e822198e05,atezo,0.548099
uuid-eaf0e9ccc6614c05b3b332e822198e05,PD-L1 testing,0.44781
uuid-eaf0e9ccc6614c05b3b332e822198e05,testing,0.615725
uuid-eaf0e9ccc6614c05b3b332e822198e05,PDL1 testing,0.410424
uuid-eaf0e9ccc6614c05b3b332e822198e05,NSCLC patients,0.425299
uuid-eaf0e9ccc6614c05b3b332e822198e05,nivo and pembro,0.534575
uuid-eaf0e9ccc6614c05b3b332e822198e05,believes,0.35284
uuid-eaf0e9ccc6614c05b3b332e822198e05,assay,0.771352
uuid-eaf0e9ccc6614c05b3b332e822198e05,PD-1,0.337475
uuid-eaf0e9ccc6614c05b3b332e822198e05,PDL1 expression,0.586114
uuid-eaf0e9ccc6614c05b3b332e822198e05,biomarker,0.540894
uuid-071123bbe3af4487999d35125fd4a828,pembro,0.336418
uuid-071123bbe3af4487999d35125fd4a828,lung,0.51177
uuid-071123bbe3af4487999d35125fd4a828,efficacy,0.337389
uuid-071123bbe3af4487999d35125fd4a828,melanoma,0.313167
uuid-071123bbe3af4487999d35125fd4a828,atezo,0.398318
uuid-071123bbe3af4487999d35125fd4a828,regards,0.421127
uuid-071123bbe3af4487999d35125fd4a828,AI,0.834767
uuid-071123bbe3af4487999d35125fd4a828,nivo and pembro,0.568439
uuid-071123bbe3af4487999d35125fd4a828,NCCN,0.41402
uuid-4dbddea5d9ca48509274ff0ada18447d,PD-L1,0.331135
uuid-4dbddea5d9ca48509274ff0ada18447d,testing,0.529359
uuid-4dbddea5d9ca48509274ff0ada18447d,PDL1 testing,0.509478
uuid-4dbddea5d9ca48509274ff0ada18447d,NSCLC patients,0.65379
uuid-4dbddea5d9ca48509274ff0ada18447d,tumor types,0.366402
uuid-45688b5f0d2041a6b7b689806a9f1913,RTL,0.303683
uuid-45688b5f0d2041a6b7b689806a9f1913,trial,0.656681
uuid-45688b5f0d2041a6b7b689806a9f1913,combination,0.535384
uuid-45688b5f0d2041a6b7b689806a9f1913,Ipi,0.309823
uuid-45688b5f0d2041a6b7b689806a9f1913,data,0.340777
uuid-45688b5f0d2041a6b7b689806a9f1913,combo,0.397406
uuid-45688b5f0d2041a6b7b689806a9f1913,PD1,0.319524
uuid-45688b5f0d2041a6b7b689806a9f1913,ORR,0.342537
uuid-45688b5f0d2041a6b7b689806a9f1913,impressed,0.382697
uuid-45688b5f0d2041a6b7b689806a9f1913,SCLC,0.410805
uuid-9a928c6d08484c93a665fd1d56642692,patients,0.664629
uuid-9a928c6d08484c93a665fd1d56642692,Opdivo,0.372656
uuid-9a928c6d08484c93a665fd1d56642692,therapy,0.3464
uuid-9a928c6d08484c93a665fd1d56642692,nivolumab,0.391051
uuid-9a928c6d08484c93a665fd1d56642692,toxicity,0.373452
uuid-9a928c6d08484c93a665fd1d56642692,regimen,0.646135
uuid-9a928c6d08484c93a665fd1d56642692,treated,0.486351
uuid-9a928c6d08484c93a665fd1d56642692,pts,0.491706
uuid-9a928c6d08484c93a665fd1d56642692,monotherapy,0.427537
uuid-9a928c6d08484c93a665fd1d56642692,treatment,0.543904
uuid-9a928c6d08484c93a665fd1d56642692,using nivo,0.304522
uuid-9a928c6d08484c93a665fd1d56642692,combo,0.314736
uuid-9a928c6d08484c93a665fd1d56642692,lung cancer,0.359696
uuid-9a928c6d08484c93a665fd1d56642692,progression,0.483432
uuid-9a928c6d08484c93a665fd1d56642692,chemotherapy,0.355439
uuid-9a928c6d08484c93a665fd1d56642692,respond,0.390501
uuid-9a928c6d08484c93a665fd1d56642692,option,0.346041
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,Nivo,0.301628
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,nivolumab,0.308748
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,1L,0.312394
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,regimen,0.403582
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,RCC,0.30175
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,2L,0.357072
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,Ipi,0.346386
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,approval,0.453625
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,monotherapy,0.363936
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,using nivo,0.429767
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,combo,0.326813
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,indication,0.340313
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,approved,0.487148
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,impressed,0.301695
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,label,0.373737
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,SCLC,0.496584
uuid-c6ee4c3cee154a4dad6b733a02cc2d67,option,0.345336
uuid-1b8c9102ad474e4fae1c59b08a3c7678,patients,0.607975
uuid-1b8c9102ad474e4fae1c59b08a3c7678,Opdivo,0.42407
uuid-1b8c9102ad474e4fae1c59b08a3c7678,therapy,0.317077
uuid-1b8c9102ad474e4fae1c59b08a3c7678,regimen,0.360721
uuid-1b8c9102ad474e4fae1c59b08a3c7678,treated,0.482734
uuid-1b8c9102ad474e4fae1c59b08a3c7678,physicians,0.539654
uuid-1b8c9102ad474e4fae1c59b08a3c7678,treatment,0.62469
uuid-1b8c9102ad474e4fae1c59b08a3c7678,progression,0.33215
uuid-1b8c9102ad474e4fae1c59b08a3c7678,respond,0.339513
uuid-09e9326c1ed74fef9de4995b6e94664e,Nivo,0.377474
uuid-09e9326c1ed74fef9de4995b6e94664e,pembro,0.575079
uuid-09e9326c1ed74fef9de4995b6e94664e,1L,0.798686
uuid-09e9326c1ed74fef9de4995b6e94664e,PDL1,0.481075
uuid-09e9326c1ed74fef9de4995b6e94664e,chemo,0.40387
uuid-09e9326c1ed74fef9de4995b6e94664e,2L,0.742882
uuid-09e9326c1ed74fef9de4995b6e94664e,agents,0.591443
uuid-09e9326c1ed74fef9de4995b6e94664e,PD-L1,0.395888
uuid-09e9326c1ed74fef9de4995b6e94664e,atezo,0.617994
uuid-09e9326c1ed74fef9de4995b6e94664e,preferred,0.69443
uuid-09e9326c1ed74fef9de4995b6e94664e,monotherapy,0.635323
uuid-09e9326c1ed74fef9de4995b6e94664e,using nivo,0.419062
uuid-09e9326c1ed74fef9de4995b6e94664e,combo,0.37923
uuid-09e9326c1ed74fef9de4995b6e94664e,PDL1 testing,0.349573
uuid-09e9326c1ed74fef9de4995b6e94664e,indication,0.366889
uuid-09e9326c1ed74fef9de4995b6e94664e,NSCLC patients,0.328256
uuid-09e9326c1ed74fef9de4995b6e94664e,approved,0.457905
uuid-09e9326c1ed74fef9de4995b6e94664e,nivo and pembro,0.469773
uuid-09e9326c1ed74fef9de4995b6e94664e,believes,0.468385
uuid-09e9326c1ed74fef9de4995b6e94664e,chemotherapy,0.303903
uuid-09e9326c1ed74fef9de4995b6e94664e,feels,0.398245
uuid-09e9326c1ed74fef9de4995b6e94664e,PD-1,0.329099
uuid-09e9326c1ed74fef9de4995b6e94664e,RTL stated,0.320107
uuid-09e9326c1ed74fef9de4995b6e94664e,PDL1 expression,0.405586
uuid-09e9326c1ed74fef9de4995b6e94664e,option,0.685031
uuid-461422f44b1f43478feeb6ebfaa4f933,NSCLC,0.51794
uuid-461422f44b1f43478feeb6ebfaa4f933,1L,0.41343
uuid-461422f44b1f43478feeb6ebfaa4f933,efficacy,0.372564
uuid-461422f44b1f43478feeb6ebfaa4f933,regimen,0.323591
uuid-461422f44b1f43478feeb6ebfaa4f933,combination,0.570552
uuid-461422f44b1f43478feeb6ebfaa4f933,chemo,0.458374
uuid-461422f44b1f43478feeb6ebfaa4f933,2L,0.354058
uuid-461422f44b1f43478feeb6ebfaa4f933,IO,0.762889
uuid-461422f44b1f43478feeb6ebfaa4f933,agents,0.469662
uuid-461422f44b1f43478feeb6ebfaa4f933,preferred,0.336656
uuid-461422f44b1f43478feeb6ebfaa4f933,monotherapy,0.582457
uuid-461422f44b1f43478feeb6ebfaa4f933,combo,0.655126
uuid-461422f44b1f43478feeb6ebfaa4f933,PD1,0.379914
uuid-461422f44b1f43478feeb6ebfaa4f933,believes,0.536369
uuid-461422f44b1f43478feeb6ebfaa4f933,chemotherapy,0.358041
uuid-461422f44b1f43478feeb6ebfaa4f933,vs,0.326011
uuid-461422f44b1f43478feeb6ebfaa4f933,feels,0.361311
uuid-461422f44b1f43478feeb6ebfaa4f933,option,0.441348
uuid-4237fd8829ee429a8525c355ee5f39d5,TL,0.407792
uuid-4237fd8829ee429a8525c355ee5f39d5,pembro,0.33402
uuid-4237fd8829ee429a8525c355ee5f39d5,1L,0.472641
uuid-4237fd8829ee429a8525c355ee5f39d5,PDL1,0.655646
uuid-4237fd8829ee429a8525c355ee5f39d5,TL stated,0.323839
uuid-4237fd8829ee429a8525c355ee5f39d5,2L,0.35501
uuid-4237fd8829ee429a8525c355ee5f39d5,Merck,0.40537
uuid-4237fd8829ee429a8525c355ee5f39d5,PD-L1,0.713373
uuid-4237fd8829ee429a8525c355ee5f39d5,atezo,0.417512
uuid-4237fd8829ee429a8525c355ee5f39d5,PD-L1 testing,0.564829
uuid-4237fd8829ee429a8525c355ee5f39d5,testing,0.737354
uuid-4237fd8829ee429a8525c355ee5f39d5,PDL1 testing,0.633535
uuid-4237fd8829ee429a8525c355ee5f39d5,NSCLC patients,0.549777
uuid-4237fd8829ee429a8525c355ee5f39d5,nivo and pembro,0.370936
uuid-4237fd8829ee429a8525c355ee5f39d5,believes,0.327427
uuid-4237fd8829ee429a8525c355ee5f39d5,assay,0.593204
uuid-4237fd8829ee429a8525c355ee5f39d5,PDL1 expression,0.485866
uuid-4237fd8829ee429a8525c355ee5f39d5,biomarker,0.5581
uuid-25c21513c2154894bb5035c2c13fa59a,Nivo,0.370653
uuid-25c21513c2154894bb5035c2c13fa59a,patients,0.354445
uuid-25c21513c2154894bb5035c2c13fa59a,pembro,0.459251
uuid-25c21513c2154894bb5035c2c13fa59a,1L,0.669383
uuid-25c21513c2154894bb5035c2c13fa59a,regimen,0.341839
uuid-25c21513c2154894bb5035c2c13fa59a,chemo,0.431029
uuid-25c21513c2154894bb5035c2c13fa59a,2L,0.696582
uuid-25c21513c2154894bb5035c2c13fa59a,pts,0.391808
uuid-25c21513c2154894bb5035c2c13fa59a,IO,0.317877
uuid-25c21513c2154894bb5035c2c13fa59a,agents,0.390298
uuid-25c21513c2154894bb5035c2c13fa59a,atezo,0.514547
uuid-25c21513c2154894bb5035c2c13fa59a,preferred,0.590042
uuid-25c21513c2154894bb5035c2c13fa59a,monotherapy,0.659411
uuid-25c21513c2154894bb5035c2c13fa59a,using nivo,0.465536
uuid-25c21513c2154894bb5035c2c13fa59a,combo,0.404585
uuid-25c21513c2154894bb5035c2c13fa59a,PD1,0.37238
uuid-25c21513c2154894bb5035c2c13fa59a,approved,0.35949
uuid-25c21513c2154894bb5035c2c13fa59a,believes,0.405229
uuid-25c21513c2154894bb5035c2c13fa59a,feels,0.323697
uuid-25c21513c2154894bb5035c2c13fa59a,option,0.595782
uuid-85e0632bca7f4ef8b75d6a8352606741,TL,0.476854
uuid-85e0632bca7f4ef8b75d6a8352606741,pembro,0.473707
uuid-85e0632bca7f4ef8b75d6a8352606741,PDL1,0.307509
uuid-85e0632bca7f4ef8b75d6a8352606741,efficacy,0.355357
uuid-85e0632bca7f4ef8b75d6a8352606741,PD-L1,0.306563
uuid-85e0632bca7f4ef8b75d6a8352606741,atezo,0.468439
uuid-85e0632bca7f4ef8b75d6a8352606741,nivo and pembro,0.425853
uuid-85e0632bca7f4ef8b75d6a8352606741,vs,0.301042
uuid-85e0632bca7f4ef8b75d6a8352606741,assay,0.460464
uuid-87024396f39144ec9cfceba95af79ee4,TL,0.364977
uuid-87024396f39144ec9cfceba95af79ee4,BMS,0.313687
uuid-87024396f39144ec9cfceba95af79ee4,trial,0.433441
uuid-87024396f39144ec9cfceba95af79ee4,efficacy,0.490487
uuid-87024396f39144ec9cfceba95af79ee4,commented,0.345649
uuid-87024396f39144ec9cfceba95af79ee4,OS,0.331057
uuid-87024396f39144ec9cfceba95af79ee4,regards,0.452416
uuid-87024396f39144ec9cfceba95af79ee4,data,0.519644
uuid-87024396f39144ec9cfceba95af79ee4,indication,0.372395
uuid-87024396f39144ec9cfceba95af79ee4,PFS,0.315351
uuid-87024396f39144ec9cfceba95af79ee4,ORR,0.413379
uuid-87024396f39144ec9cfceba95af79ee4,impressed,0.441304
uuid-3cc95a05f0d34e5b8225f9fa830e5800,BMS,0.57468
uuid-3cc95a05f0d34e5b8225f9fa830e5800,trial,0.476567
uuid-3cc95a05f0d34e5b8225f9fa830e5800,commented,0.406533
uuid-3cc95a05f0d34e5b8225f9fa830e5800,Merck,0.457178
uuid-3cc95a05f0d34e5b8225f9fa830e5800,stated,0.31465
uuid-3cc95a05f0d34e5b8225f9fa830e5800,data,0.466406
uuid-3cc95a05f0d34e5b8225f9fa830e5800,expressed,0.337379
uuid-3cc95a05f0d34e5b8225f9fa830e5800,clinical trials,0.372164
uuid-3cc95a05f0d34e5b8225f9fa830e5800,impressed,0.454406
uuid-3cc95a05f0d34e5b8225f9fa830e5800,feels,0.341445
uuid-4055976e19f3415e806af58a13293467,Nivo,0.325953
uuid-4055976e19f3415e806af58a13293467,patients,0.341306
uuid-4055976e19f3415e806af58a13293467,efficacy,0.317909
uuid-4055976e19f3415e806af58a13293467,chemo,0.353731
uuid-4055976e19f3415e806af58a13293467,pts,0.325784
uuid-4055976e19f3415e806af58a13293467,OS,0.567255
uuid-4055976e19f3415e806af58a13293467,response,0.439976
uuid-4055976e19f3415e806af58a13293467,PFS,0.59222
uuid-4055976e19f3415e806af58a13293467,ORR,0.478805
uuid-4055976e19f3415e806af58a13293467,progression,0.506413
uuid-4055976e19f3415e806af58a13293467,chemotherapy,0.343889
uuid-4055976e19f3415e806af58a13293467,respond,0.306782
uuid-d968a1907d094f228ed2dca02e4222b7,preferred,0.419105
uuid-d968a1907d094f228ed2dca02e4222b7,using nivo,0.324202
uuid-d968a1907d094f228ed2dca02e4222b7,SCCHN,0.331372
uuid-d968a1907d094f228ed2dca02e4222b7,LTL,0.35666
uuid-d968a1907d094f228ed2dca02e4222b7,feels,0.434842
uuid-d968a1907d094f228ed2dca02e4222b7,Regional TL,0.315532
uuid-93f5b82ea53740c98988f52826358161,Opdivo,0.420427
uuid-93f5b82ea53740c98988f52826358161,Keytruda,0.357671
uuid-93f5b82ea53740c98988f52826358161,flat dosing,0.56015
uuid-36fee8c23e7a4cbf9ed2048dff127038,Nivo,0.351769
uuid-36fee8c23e7a4cbf9ed2048dff127038,patients,0.437928
uuid-36fee8c23e7a4cbf9ed2048dff127038,pembro,0.303939
uuid-36fee8c23e7a4cbf9ed2048dff127038,therapy,0.345431
uuid-36fee8c23e7a4cbf9ed2048dff127038,nivolumab,0.350394
uuid-36fee8c23e7a4cbf9ed2048dff127038,1L,0.499267
uuid-36fee8c23e7a4cbf9ed2048dff127038,regimen,0.332048
uuid-36fee8c23e7a4cbf9ed2048dff127038,RCC,0.342002
uuid-36fee8c23e7a4cbf9ed2048dff127038,chemo,0.387891
uuid-36fee8c23e7a4cbf9ed2048dff127038,2L,0.555169
uuid-36fee8c23e7a4cbf9ed2048dff127038,agents,0.387256
uuid-36fee8c23e7a4cbf9ed2048dff127038,preferred,0.821654
uuid-36fee8c23e7a4cbf9ed2048dff127038,monotherapy,0.555627
uuid-36fee8c23e7a4cbf9ed2048dff127038,treatment,0.313136
uuid-36fee8c23e7a4cbf9ed2048dff127038,using nivo,0.550973
uuid-36fee8c23e7a4cbf9ed2048dff127038,indication,0.333155
uuid-36fee8c23e7a4cbf9ed2048dff127038,approved,0.330666
uuid-36fee8c23e7a4cbf9ed2048dff127038,SCCHN,0.384356
uuid-36fee8c23e7a4cbf9ed2048dff127038,chemotherapy,0.404131
uuid-36fee8c23e7a4cbf9ed2048dff127038,RTL stated,0.520901
uuid-36fee8c23e7a4cbf9ed2048dff127038,option,0.683029
uuid-686be2d8044043ff9f4ec18b8ca89f65,trial,0.330455
uuid-686be2d8044043ff9f4ec18b8ca89f65,efficacy,0.402543
uuid-686be2d8044043ff9f4ec18b8ca89f65,commented,0.363613
uuid-686be2d8044043ff9f4ec18b8ca89f65,OS,0.601696
uuid-686be2d8044043ff9f4ec18b8ca89f65,data,0.642137
uuid-686be2d8044043ff9f4ec18b8ca89f65,PFS,0.623906
uuid-686be2d8044043ff9f4ec18b8ca89f65,ORR,0.670736
uuid-686be2d8044043ff9f4ec18b8ca89f65,ASCO,0.379418
uuid-686be2d8044043ff9f4ec18b8ca89f65,impressed,0.560183
uuid-71394e2740df4a2ea980d64af8d2319c,RTL,0.417529
uuid-71394e2740df4a2ea980d64af8d2319c,BMS,0.311336
uuid-71394e2740df4a2ea980d64af8d2319c,trial,0.580219
uuid-71394e2740df4a2ea980d64af8d2319c,NTL,0.313132
uuid-71394e2740df4a2ea980d64af8d2319c,Merck,0.358549
uuid-71394e2740df4a2ea980d64af8d2319c,Ipi,0.305933
uuid-71394e2740df4a2ea980d64af8d2319c,stated,0.339636
uuid-71394e2740df4a2ea980d64af8d2319c,clinical trials,0.308684
uuid-202a6d2bd5064763a52827730f8abc99,TL,0.525306
uuid-202a6d2bd5064763a52827730f8abc99,RTL,0.322306
uuid-202a6d2bd5064763a52827730f8abc99,TL stated,0.580265
uuid-202a6d2bd5064763a52827730f8abc99,institution,0.412445
uuid-202a6d2bd5064763a52827730f8abc99,stated,0.470389
uuid-202a6d2bd5064763a52827730f8abc99,PD-L1,0.564628
uuid-202a6d2bd5064763a52827730f8abc99,approval,0.350855
uuid-202a6d2bd5064763a52827730f8abc99,PD-L1 testing,0.725607
uuid-202a6d2bd5064763a52827730f8abc99,testing,0.755087
uuid-202a6d2bd5064763a52827730f8abc99,PDL1 testing,0.778123
uuid-202a6d2bd5064763a52827730f8abc99,NSCLC patients,0.641396
uuid-202a6d2bd5064763a52827730f8abc99,SCCHN,0.468516
uuid-202a6d2bd5064763a52827730f8abc99,tumor types,0.367395
uuid-202a6d2bd5064763a52827730f8abc99,LTL,0.32033
uuid-202a6d2bd5064763a52827730f8abc99,assay,0.374814
uuid-202a6d2bd5064763a52827730f8abc99,Regional TL,0.416302
uuid-202a6d2bd5064763a52827730f8abc99,RTL stated,0.348474
uuid-033314f80c26437699c14293fbda448b,BMS,0.542182
uuid-033314f80c26437699c14293fbda448b,Merck,0.368029
uuid-033314f80c26437699c14293fbda448b,indication,0.338984
uuid-033314f80c26437699c14293fbda448b,approved,0.403592
uuid-033314f80c26437699c14293fbda448b,drug,0.452324
uuid-033314f80c26437699c14293fbda448b,feels,0.331256
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,Nivo,0.468397
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,patients,0.692127
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,Opdivo,0.313051
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,therapy,0.426282
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,nivolumab,0.325224
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,regimen,0.46659
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,treated,0.360595
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,chemo,0.411059
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,pts,0.541484
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,monotherapy,0.358785
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,treatment,0.493261
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,response,0.485747
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,PD1,0.339597
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,progression,0.608389
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,chemotherapy,0.393184
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,respond,0.55465
uuid-3cedb7a8a1eb4194a804ff1bd3e21872,feels,0.40752
uuid-163156145fca41cea9402d9120b81690,Nivo,0.466698
uuid-163156145fca41cea9402d9120b81690,pembro,0.485161
uuid-163156145fca41cea9402d9120b81690,dose,0.655594
uuid-163156145fca41cea9402d9120b81690,trial,0.450992
uuid-163156145fca41cea9402d9120b81690,efficacy,0.369556
uuid-163156145fca41cea9402d9120b81690,combination,0.31907
uuid-163156145fca41cea9402d9120b81690,Ipi,0.795591
uuid-163156145fca41cea9402d9120b81690,atezo,0.406834
uuid-163156145fca41cea9402d9120b81690,combo,0.383852
uuid-163156145fca41cea9402d9120b81690,indication,0.333755
uuid-163156145fca41cea9402d9120b81690,approved,0.333395
uuid-163156145fca41cea9402d9120b81690,vs,0.453402
uuid-163156145fca41cea9402d9120b81690,label,0.31855
uuid-163156145fca41cea9402d9120b81690,SCLC,0.44525
uuid-163156145fca41cea9402d9120b81690,flat dosing,0.532695
uuid-fb9e4327803e4d44ad25bdb797c7ed49,PDL1,0.368541
uuid-fb9e4327803e4d44ad25bdb797c7ed49,TL stated,0.361786
uuid-fb9e4327803e4d44ad25bdb797c7ed49,PD-L1,0.57569
uuid-fb9e4327803e4d44ad25bdb797c7ed49,PD-L1 testing,0.471657
uuid-fb9e4327803e4d44ad25bdb797c7ed49,testing,0.743137
uuid-fb9e4327803e4d44ad25bdb797c7ed49,PDL1 testing,0.700522
uuid-fb9e4327803e4d44ad25bdb797c7ed49,NSCLC patients,0.749329
uuid-fb9e4327803e4d44ad25bdb797c7ed49,tumor types,0.358505
uuid-fb9e4327803e4d44ad25bdb797c7ed49,biomarker,0.469801
uuid-80ee2759d21d47e7b91ccf4fbcdcf704,patients,0.499015
uuid-80ee2759d21d47e7b91ccf4fbcdcf704,Opdivo,0.502149
uuid-80ee2759d21d47e7b91ccf4fbcdcf704,nivolumab,0.30028
uuid-80ee2759d21d47e7b91ccf4fbcdcf704,treated,0.377904
uuid-80ee2759d21d47e7b91ccf4fbcdcf704,shared,0.309693
uuid-80ee2759d21d47e7b91ccf4fbcdcf704,approval,0.506425
uuid-80ee2759d21d47e7b91ccf4fbcdcf704,clinical trials,0.312813
uuid-80ee2759d21d47e7b91ccf4fbcdcf704,approved,0.388627
uuid-80ee2759d21d47e7b91ccf4fbcdcf704,tumor types,0.318909
uuid-80ee2759d21d47e7b91ccf4fbcdcf704,label,0.339773
uuid-29791919909c4c83a5f0d931bf9231df,BMS,0.367888
uuid-29791919909c4c83a5f0d931bf9231df,PDL1,0.618443
uuid-29791919909c4c83a5f0d931bf9231df,trial,0.348587
uuid-29791919909c4c83a5f0d931bf9231df,efficacy,0.368219
uuid-29791919909c4c83a5f0d931bf9231df,commented,0.338693
uuid-29791919909c4c83a5f0d931bf9231df,Merck,0.395927
uuid-29791919909c4c83a5f0d931bf9231df,PD-L1,0.397262
uuid-29791919909c4c83a5f0d931bf9231df,OS,0.311562
uuid-29791919909c4c83a5f0d931bf9231df,data,0.574602
uuid-29791919909c4c83a5f0d931bf9231df,expressed,0.346301
uuid-29791919909c4c83a5f0d931bf9231df,PFS,0.358618
uuid-29791919909c4c83a5f0d931bf9231df,ORR,0.390104
uuid-29791919909c4c83a5f0d931bf9231df,nivo and pembro,0.401632
uuid-29791919909c4c83a5f0d931bf9231df,impressed,0.413963
uuid-29791919909c4c83a5f0d931bf9231df,TLs,0.334143
uuid-29791919909c4c83a5f0d931bf9231df,assay,0.393904
uuid-29791919909c4c83a5f0d931bf9231df,PDL1 expression,0.56106
uuid-29791919909c4c83a5f0d931bf9231df,biomarker,0.443803
uuid-7360da2a9c73435da37b4273a66110d1,TL,0.45695
uuid-7360da2a9c73435da37b4273a66110d1,lung,0.307301
uuid-7360da2a9c73435da37b4273a66110d1,1L,0.349505
uuid-7360da2a9c73435da37b4273a66110d1,PDL1,0.34578
uuid-7360da2a9c73435da37b4273a66110d1,RCC,0.410123
uuid-7360da2a9c73435da37b4273a66110d1,TL stated,0.631238
uuid-7360da2a9c73435da37b4273a66110d1,tumor,0.353282
uuid-7360da2a9c73435da37b4273a66110d1,2L,0.318692
uuid-7360da2a9c73435da37b4273a66110d1,stated,0.369699
uuid-7360da2a9c73435da37b4273a66110d1,PD-L1,0.641158
uuid-7360da2a9c73435da37b4273a66110d1,PD-L1 testing,0.599629
uuid-7360da2a9c73435da37b4273a66110d1,testing,0.715132
uuid-7360da2a9c73435da37b4273a66110d1,PDL1 testing,0.724065
uuid-7360da2a9c73435da37b4273a66110d1,NSCLC patients,0.633088
uuid-7360da2a9c73435da37b4273a66110d1,SCCHN,0.390872
uuid-7360da2a9c73435da37b4273a66110d1,tumor types,0.487296
uuid-7360da2a9c73435da37b4273a66110d1,TLs,0.303782
uuid-7360da2a9c73435da37b4273a66110d1,assay,0.449781
uuid-7360da2a9c73435da37b4273a66110d1,RTL stated,0.363719
uuid-7360da2a9c73435da37b4273a66110d1,biomarker,0.449501
uuid-7360da2a9c73435da37b4273a66110d1,bladder,0.45435
uuid-e4bc2c607f9147dfafe404d66202a13f,biomarker,0.37149
uuid-61e0c1de87794295b2239cbc2a27b0c7,patients,0.556608
uuid-61e0c1de87794295b2239cbc2a27b0c7,therapy,0.364182
uuid-61e0c1de87794295b2239cbc2a27b0c7,toxicity,0.585209
uuid-61e0c1de87794295b2239cbc2a27b0c7,regimen,0.484498
uuid-61e0c1de87794295b2239cbc2a27b0c7,treated,0.366721
uuid-61e0c1de87794295b2239cbc2a27b0c7,chemo,0.315031
uuid-61e0c1de87794295b2239cbc2a27b0c7,pts,0.391542
uuid-61e0c1de87794295b2239cbc2a27b0c7,treatment,0.571443
uuid-61e0c1de87794295b2239cbc2a27b0c7,response,0.487454
uuid-61e0c1de87794295b2239cbc2a27b0c7,progression,0.562267
uuid-61e0c1de87794295b2239cbc2a27b0c7,chemotherapy,0.34888
uuid-61e0c1de87794295b2239cbc2a27b0c7,respond,0.619819
uuid-82c8e993171f4c85a5efb7921c23fc67,TL,0.71412
uuid-82c8e993171f4c85a5efb7921c23fc67,PDL1,0.305663
uuid-82c8e993171f4c85a5efb7921c23fc67,TL stated,0.404557
uuid-82c8e993171f4c85a5efb7921c23fc67,institution,0.415328
uuid-82c8e993171f4c85a5efb7921c23fc67,PD-L1,0.771167
uuid-82c8e993171f4c85a5efb7921c23fc67,approval,0.320616
uuid-82c8e993171f4c85a5efb7921c23fc67,PD-L1 testing,0.894469
uuid-82c8e993171f4c85a5efb7921c23fc67,testing,0.85435
uuid-82c8e993171f4c85a5efb7921c23fc67,PDL1 testing,0.636004
uuid-82c8e993171f4c85a5efb7921c23fc67,NSCLC patients,0.588374
uuid-82c8e993171f4c85a5efb7921c23fc67,assay,0.835861
uuid-c9403149cc8e4084be97981228136b66,TL,0.55529
uuid-c9403149cc8e4084be97981228136b66,PDL1,0.451772
uuid-c9403149cc8e4084be97981228136b66,trial,0.311229
uuid-c9403149cc8e4084be97981228136b66,Merck,0.441184
uuid-c9403149cc8e4084be97981228136b66,PD-L1,0.468251
uuid-c9403149cc8e4084be97981228136b66,OS,0.410919
uuid-c9403149cc8e4084be97981228136b66,PD-L1 testing,0.41367
uuid-c9403149cc8e4084be97981228136b66,testing,0.367159
uuid-c9403149cc8e4084be97981228136b66,regards,0.309592
uuid-c9403149cc8e4084be97981228136b66,data,0.564551
uuid-c9403149cc8e4084be97981228136b66,PFS,0.414955
uuid-c9403149cc8e4084be97981228136b66,ORR,0.419439
uuid-c9403149cc8e4084be97981228136b66,nivo and pembro,0.318459
uuid-c9403149cc8e4084be97981228136b66,ASCO,0.30344
uuid-c9403149cc8e4084be97981228136b66,impressed,0.382556
uuid-c9403149cc8e4084be97981228136b66,assay,0.668712
uuid-c9403149cc8e4084be97981228136b66,PDL1 expression,0.314302
uuid-c5adc605416e404a8dba3c7f84e95ae4,toxicity,0.343855
uuid-c5adc605416e404a8dba3c7f84e95ae4,physicians,0.630421
uuid-c5adc605416e404a8dba3c7f84e95ae4,treatment,0.357606
uuid-138970db358b4a819ca05a5b526e8999,pembro,0.412186
uuid-138970db358b4a819ca05a5b526e8999,lung,0.328996
uuid-138970db358b4a819ca05a5b526e8999,1L,0.380679
uuid-138970db358b4a819ca05a5b526e8999,PDL1,0.718216
uuid-138970db358b4a819ca05a5b526e8999,TL stated,0.31137
uuid-138970db358b4a819ca05a5b526e8999,Merck,0.402527
uuid-138970db358b4a819ca05a5b526e8999,PD-L1,0.647386
uuid-138970db358b4a819ca05a5b526e8999,atezo,0.477605
uuid-138970db358b4a819ca05a5b526e8999,PD-L1 testing,0.4423
uuid-138970db358b4a819ca05a5b526e8999,testing,0.612671
uuid-138970db358b4a819ca05a5b526e8999,data,0.304908
uuid-138970db358b4a819ca05a5b526e8999,PDL1 testing,0.568806
uuid-138970db358b4a819ca05a5b526e8999,AI,0.42669
uuid-138970db358b4a819ca05a5b526e8999,NSCLC patients,0.398634
uuid-138970db358b4a819ca05a5b526e8999,nivo and pembro,0.538704
uuid-138970db358b4a819ca05a5b526e8999,assay,0.637924
uuid-138970db358b4a819ca05a5b526e8999,PDL1 expression,0.610208
uuid-138970db358b4a819ca05a5b526e8999,biomarker,0.569304
uuid-138970db358b4a819ca05a5b526e8999,NCCN,0.313055
uuid-3dcb347c723748208a7a7ee80445d393,Nivo,0.407418
uuid-3dcb347c723748208a7a7ee80445d393,pembro,0.333387
uuid-3dcb347c723748208a7a7ee80445d393,1L,0.496338
uuid-3dcb347c723748208a7a7ee80445d393,PDL1,0.424648
uuid-3dcb347c723748208a7a7ee80445d393,efficacy,0.525827
uuid-3dcb347c723748208a7a7ee80445d393,combination,0.344869
uuid-3dcb347c723748208a7a7ee80445d393,chemo,0.487346
uuid-3dcb347c723748208a7a7ee80445d393,2L,0.410543
uuid-3dcb347c723748208a7a7ee80445d393,IO,0.32451
uuid-3dcb347c723748208a7a7ee80445d393,agents,0.461899
uuid-3dcb347c723748208a7a7ee80445d393,OS,0.432747
uuid-3dcb347c723748208a7a7ee80445d393,atezo,0.367852
uuid-3dcb347c723748208a7a7ee80445d393,monotherapy,0.482918
uuid-3dcb347c723748208a7a7ee80445d393,combo,0.527114
uuid-3dcb347c723748208a7a7ee80445d393,PFS,0.440661
uuid-3dcb347c723748208a7a7ee80445d393,AI,0.445867
uuid-3dcb347c723748208a7a7ee80445d393,PD1,0.375096
uuid-3dcb347c723748208a7a7ee80445d393,ORR,0.404541
uuid-3dcb347c723748208a7a7ee80445d393,nivo and pembro,0.649814
uuid-3dcb347c723748208a7a7ee80445d393,believes,0.617687
uuid-3dcb347c723748208a7a7ee80445d393,chemotherapy,0.346426
uuid-3dcb347c723748208a7a7ee80445d393,PDL1 expression,0.354733
uuid-3dcb347c723748208a7a7ee80445d393,option,0.407245
uuid-0945d2d958bb48f5971edd9bf3ae474e,Nivo,0.327697
uuid-0945d2d958bb48f5971edd9bf3ae474e,patients,0.846098
uuid-0945d2d958bb48f5971edd9bf3ae474e,Opdivo,0.528235
uuid-0945d2d958bb48f5971edd9bf3ae474e,therapy,0.647723
uuid-0945d2d958bb48f5971edd9bf3ae474e,nivolumab,0.55116
uuid-0945d2d958bb48f5971edd9bf3ae474e,regimen,0.33022
uuid-0945d2d958bb48f5971edd9bf3ae474e,treated,0.463068
uuid-0945d2d958bb48f5971edd9bf3ae474e,pts,0.470413
uuid-0945d2d958bb48f5971edd9bf3ae474e,approval,0.320056
uuid-0945d2d958bb48f5971edd9bf3ae474e,treatment,0.597779
uuid-0945d2d958bb48f5971edd9bf3ae474e,using nivo,0.330272
uuid-0945d2d958bb48f5971edd9bf3ae474e,response,0.355918
uuid-0945d2d958bb48f5971edd9bf3ae474e,cHL,0.593011
uuid-0945d2d958bb48f5971edd9bf3ae474e,progression,0.601142
uuid-0945d2d958bb48f5971edd9bf3ae474e,chemotherapy,0.338832
uuid-0945d2d958bb48f5971edd9bf3ae474e,respond,0.433187
uuid-7527c85843744bf3b63c9cbf6b9f70ee,BMS,0.451023
uuid-7527c85843744bf3b63c9cbf6b9f70ee,PDL1,0.533194
uuid-7527c85843744bf3b63c9cbf6b9f70ee,trial,0.520812
uuid-7527c85843744bf3b63c9cbf6b9f70ee,efficacy,0.511868
uuid-7527c85843744bf3b63c9cbf6b9f70ee,commented,0.328748
uuid-7527c85843744bf3b63c9cbf6b9f70ee,Merck,0.422838
uuid-7527c85843744bf3b63c9cbf6b9f70ee,OS,0.624769
uuid-7527c85843744bf3b63c9cbf6b9f70ee,data,0.897545
uuid-7527c85843744bf3b63c9cbf6b9f70ee,PFS,0.614416
uuid-7527c85843744bf3b63c9cbf6b9f70ee,ORR,0.638107
uuid-7527c85843744bf3b63c9cbf6b9f70ee,nivo and pembro,0.495981
uuid-7527c85843744bf3b63c9cbf6b9f70ee,ASCO,0.327419
uuid-7527c85843744bf3b63c9cbf6b9f70ee,impressed,0.495823
uuid-7527c85843744bf3b63c9cbf6b9f70ee,PDL1 expression,0.481784
uuid-7527c85843744bf3b63c9cbf6b9f70ee,biomarker,0.30792
uuid-b216f89ea9754308809f1554050154e7,Nivo,0.338125
uuid-b216f89ea9754308809f1554050154e7,pembro,0.507519
uuid-b216f89ea9754308809f1554050154e7,BMS,0.385242
uuid-b216f89ea9754308809f1554050154e7,PDL1,0.466319
uuid-b216f89ea9754308809f1554050154e7,trial,0.707571
uuid-b216f89ea9754308809f1554050154e7,efficacy,0.563347
uuid-b216f89ea9754308809f1554050154e7,agents,0.426727
uuid-b216f89ea9754308809f1554050154e7,Merck,0.347437
uuid-b216f89ea9754308809f1554050154e7,OS,0.482535
uuid-b216f89ea9754308809f1554050154e7,atezo,0.424812
uuid-b216f89ea9754308809f1554050154e7,data,0.594755
uuid-b216f89ea9754308809f1554050154e7,combo,0.34083
uuid-b216f89ea9754308809f1554050154e7,PFS,0.515366
uuid-b216f89ea9754308809f1554050154e7,ORR,0.554384
uuid-b216f89ea9754308809f1554050154e7,nivo and pembro,0.728526
uuid-b216f89ea9754308809f1554050154e7,believes,0.508359
uuid-b216f89ea9754308809f1554050154e7,impressed,0.338781
uuid-b216f89ea9754308809f1554050154e7,vs,0.383507
uuid-b216f89ea9754308809f1554050154e7,feels,0.405886
uuid-b216f89ea9754308809f1554050154e7,PDL1 expression,0.424136
uuid-dad0e7bafb444295a41ec40e1c06a943,Nivo,0.693677
uuid-dad0e7bafb444295a41ec40e1c06a943,pembro,0.80536
uuid-dad0e7bafb444295a41ec40e1c06a943,1L,0.594373
uuid-dad0e7bafb444295a41ec40e1c06a943,efficacy,0.323114
uuid-dad0e7bafb444295a41ec40e1c06a943,chemo,0.347564
uuid-dad0e7bafb444295a41ec40e1c06a943,2L,0.657551
uuid-dad0e7bafb444295a41ec40e1c06a943,agents,0.508458
uuid-dad0e7bafb444295a41ec40e1c06a943,Ipi,0.312158
uuid-dad0e7bafb444295a41ec40e1c06a943,approval,0.347393
uuid-dad0e7bafb444295a41ec40e1c06a943,atezo,0.754552
uuid-dad0e7bafb444295a41ec40e1c06a943,preferred,0.642806
uuid-dad0e7bafb444295a41ec40e1c06a943,monotherapy,0.479909
uuid-dad0e7bafb444295a41ec40e1c06a943,using nivo,0.562195
uuid-dad0e7bafb444295a41ec40e1c06a943,indication,0.380224
uuid-dad0e7bafb444295a41ec40e1c06a943,approved,0.418266
uuid-dad0e7bafb444295a41ec40e1c06a943,nivo and pembro,0.557075
uuid-dad0e7bafb444295a41ec40e1c06a943,vs,0.498409
uuid-dad0e7bafb444295a41ec40e1c06a943,feels,0.43714
uuid-dad0e7bafb444295a41ec40e1c06a943,RTL stated,0.372885
uuid-dad0e7bafb444295a41ec40e1c06a943,option,0.520324
uuid-7f0025b1ec19462496e023b60bdf3962,pembro,0.515176
uuid-7f0025b1ec19462496e023b60bdf3962,1L,0.495012
uuid-7f0025b1ec19462496e023b60bdf3962,PDL1,0.48576
uuid-7f0025b1ec19462496e023b60bdf3962,2L,0.47939
uuid-7f0025b1ec19462496e023b60bdf3962,agents,0.39769
uuid-7f0025b1ec19462496e023b60bdf3962,PD-L1,0.420531
uuid-7f0025b1ec19462496e023b60bdf3962,approval,0.315333
uuid-7f0025b1ec19462496e023b60bdf3962,atezo,0.517562
uuid-7f0025b1ec19462496e023b60bdf3962,preferred,0.40503
uuid-7f0025b1ec19462496e023b60bdf3962,testing,0.39228
uuid-7f0025b1ec19462496e023b60bdf3962,PDL1 testing,0.391279
uuid-7f0025b1ec19462496e023b60bdf3962,indication,0.378135
uuid-7f0025b1ec19462496e023b60bdf3962,NSCLC patients,0.305171
uuid-7f0025b1ec19462496e023b60bdf3962,approved,0.31015
uuid-7f0025b1ec19462496e023b60bdf3962,nivo and pembro,0.496602
uuid-7f0025b1ec19462496e023b60bdf3962,believes,0.30666
uuid-7f0025b1ec19462496e023b60bdf3962,assay,0.393261
uuid-7f0025b1ec19462496e023b60bdf3962,PDL1 expression,0.379033
uuid-7f0025b1ec19462496e023b60bdf3962,option,0.332221
uuid-7f0025b1ec19462496e023b60bdf3962,biomarker,0.313106
uuid-ddc85cd274d5492f991bc8f234400b30,Nivo,0.322929
uuid-ddc85cd274d5492f991bc8f234400b30,pembro,0.404369
uuid-ddc85cd274d5492f991bc8f234400b30,RTL,0.354877
uuid-ddc85cd274d5492f991bc8f234400b30,1L,0.525903
uuid-ddc85cd274d5492f991bc8f234400b30,RCC,0.371205
uuid-ddc85cd274d5492f991bc8f234400b30,chemo,0.313454
uuid-ddc85cd274d5492f991bc8f234400b30,2L,0.427016
uuid-ddc85cd274d5492f991bc8f234400b30,OS,0.395702
uuid-ddc85cd274d5492f991bc8f234400b30,atezo,0.327372
uuid-ddc85cd274d5492f991bc8f234400b30,preferred,0.368928
uuid-ddc85cd274d5492f991bc8f234400b30,monotherapy,0.476067
uuid-ddc85cd274d5492f991bc8f234400b30,using nivo,0.350506
uuid-ddc85cd274d5492f991bc8f234400b30,data,0.407386
uuid-ddc85cd274d5492f991bc8f234400b30,combo,0.395539
uuid-ddc85cd274d5492f991bc8f234400b30,ORR,0.343906
uuid-ddc85cd274d5492f991bc8f234400b30,SCCHN,0.388901
uuid-ddc85cd274d5492f991bc8f234400b30,believes,0.305724
uuid-ddc85cd274d5492f991bc8f234400b30,impressed,0.439603
uuid-ddc85cd274d5492f991bc8f234400b30,feels,0.314586
uuid-ddc85cd274d5492f991bc8f234400b30,RTL stated,0.387425
uuid-ddc85cd274d5492f991bc8f234400b30,option,0.401456
uuid-ddc85cd274d5492f991bc8f234400b30,bladder,0.310611
uuid-5572a60560584389a1bbf6247e09e9d1,regimen,0.316985
uuid-5572a60560584389a1bbf6247e09e9d1,shared,0.404742
uuid-5572a60560584389a1bbf6247e09e9d1,commented,0.338337
uuid-5572a60560584389a1bbf6247e09e9d1,physicians,0.600163
uuid-5572a60560584389a1bbf6247e09e9d1,preferred,0.35679
uuid-5572a60560584389a1bbf6247e09e9d1,SCCHN,0.419041
uuid-5572a60560584389a1bbf6247e09e9d1,oncologist,0.344451
uuid-5572a60560584389a1bbf6247e09e9d1,indicated,0.313953
uuid-5572a60560584389a1bbf6247e09e9d1,LTL,0.315477
uuid-5572a60560584389a1bbf6247e09e9d1,TLs,0.35315
uuid-5572a60560584389a1bbf6247e09e9d1,Regional TL,0.469779
uuid-5572a60560584389a1bbf6247e09e9d1,RTL stated,0.337449
uuid-9535744cb79240e59ffb71b55913f026,Nivo,0.425428
uuid-9535744cb79240e59ffb71b55913f026,pembro,0.470306
uuid-9535744cb79240e59ffb71b55913f026,1L,0.622267
uuid-9535744cb79240e59ffb71b55913f026,RCC,0.398863
uuid-9535744cb79240e59ffb71b55913f026,chemo,0.340448
uuid-9535744cb79240e59ffb71b55913f026,2L,0.621728
uuid-9535744cb79240e59ffb71b55913f026,agents,0.430461
uuid-9535744cb79240e59ffb71b55913f026,approval,0.359413
uuid-9535744cb79240e59ffb71b55913f026,atezo,0.450533
uuid-9535744cb79240e59ffb71b55913f026,preferred,0.556492
uuid-9535744cb79240e59ffb71b55913f026,monotherapy,0.441881
uuid-9535744cb79240e59ffb71b55913f026,using nivo,0.524104
uuid-9535744cb79240e59ffb71b55913f026,data,0.314033
uuid-9535744cb79240e59ffb71b55913f026,combo,0.361517
uuid-9535744cb79240e59ffb71b55913f026,indication,0.366681
uuid-9535744cb79240e59ffb71b55913f026,approved,0.508445
uuid-9535744cb79240e59ffb71b55913f026,SCCHN,0.319194
uuid-9535744cb79240e59ffb71b55913f026,nivo and pembro,0.407768
uuid-9535744cb79240e59ffb71b55913f026,believes,0.426912
uuid-9535744cb79240e59ffb71b55913f026,impressed,0.364256
uuid-9535744cb79240e59ffb71b55913f026,feels,0.500899
uuid-9535744cb79240e59ffb71b55913f026,RTL stated,0.35956
uuid-9535744cb79240e59ffb71b55913f026,option,0.542681
uuid-0f4d97f3b007439ab8981a5affbd565d,pembro,0.364521
uuid-0f4d97f3b007439ab8981a5affbd565d,RTL,0.317186
uuid-0f4d97f3b007439ab8981a5affbd565d,dose,0.345697
uuid-0f4d97f3b007439ab8981a5affbd565d,trial,0.479086
uuid-0f4d97f3b007439ab8981a5affbd565d,NTL,0.304301
uuid-0f4d97f3b007439ab8981a5affbd565d,shared,0.452281
uuid-0f4d97f3b007439ab8981a5affbd565d,institution,0.354952
uuid-0f4d97f3b007439ab8981a5affbd565d,Ipi,0.403405
uuid-0f4d97f3b007439ab8981a5affbd565d,atezo,0.309119
uuid-0f4d97f3b007439ab8981a5affbd565d,clinical trials,0.359736
uuid-0f4d97f3b007439ab8981a5affbd565d,SCCHN,0.313874
uuid-0f4d97f3b007439ab8981a5affbd565d,bladder,0.386569
uuid-0f4d97f3b007439ab8981a5affbd565d,flat dosing,0.411158
uuid-28725516564a44cc9f9f5ea669ebf623,Nivo,0.433012
uuid-28725516564a44cc9f9f5ea669ebf623,patients,0.490192
uuid-28725516564a44cc9f9f5ea669ebf623,therapy,0.441353
uuid-28725516564a44cc9f9f5ea669ebf623,nivolumab,0.559637
uuid-28725516564a44cc9f9f5ea669ebf623,1L,0.564245
uuid-28725516564a44cc9f9f5ea669ebf623,regimen,0.396978
uuid-28725516564a44cc9f9f5ea669ebf623,treated,0.384721
uuid-28725516564a44cc9f9f5ea669ebf623,RCC,0.598325
uuid-28725516564a44cc9f9f5ea669ebf623,TL stated,0.373568
uuid-28725516564a44cc9f9f5ea669ebf623,combination,0.393998
uuid-28725516564a44cc9f9f5ea669ebf623,chemo,0.441929
uuid-28725516564a44cc9f9f5ea669ebf623,2L,0.615109
uuid-28725516564a44cc9f9f5ea669ebf623,pts,0.492796
uuid-28725516564a44cc9f9f5ea669ebf623,preferred,0.499573
uuid-28725516564a44cc9f9f5ea669ebf623,monotherapy,0.607444
uuid-28725516564a44cc9f9f5ea669ebf623,treatment,0.355176
uuid-28725516564a44cc9f9f5ea669ebf623,using nivo,0.635178
uuid-28725516564a44cc9f9f5ea669ebf623,response,0.309766
uuid-28725516564a44cc9f9f5ea669ebf623,combo,0.392935
uuid-28725516564a44cc9f9f5ea669ebf623,PD1,0.44002
uuid-28725516564a44cc9f9f5ea669ebf623,approved,0.368089
uuid-28725516564a44cc9f9f5ea669ebf623,SCCHN,0.363397
uuid-28725516564a44cc9f9f5ea669ebf623,progression,0.432296
uuid-28725516564a44cc9f9f5ea669ebf623,chemotherapy,0.338711
uuid-28725516564a44cc9f9f5ea669ebf623,RTL stated,0.604236
uuid-28725516564a44cc9f9f5ea669ebf623,TL shared,0.40768
uuid-28725516564a44cc9f9f5ea669ebf623,option,0.518995
uuid-28725516564a44cc9f9f5ea669ebf623,bladder,0.348125
uuid-96fb338bf58844b1b5a9eef1c3490dc9,patients,0.747009
uuid-96fb338bf58844b1b5a9eef1c3490dc9,Opdivo,0.307756
uuid-96fb338bf58844b1b5a9eef1c3490dc9,therapy,0.515408
uuid-96fb338bf58844b1b5a9eef1c3490dc9,toxicity,0.406357
uuid-96fb338bf58844b1b5a9eef1c3490dc9,regimen,0.566865
uuid-96fb338bf58844b1b5a9eef1c3490dc9,treated,0.512256
uuid-96fb338bf58844b1b5a9eef1c3490dc9,chemo,0.377299
uuid-96fb338bf58844b1b5a9eef1c3490dc9,pts,0.568825
uuid-96fb338bf58844b1b5a9eef1c3490dc9,treatment,0.795226
uuid-96fb338bf58844b1b5a9eef1c3490dc9,response,0.634634
uuid-96fb338bf58844b1b5a9eef1c3490dc9,PD1,0.3369
uuid-96fb338bf58844b1b5a9eef1c3490dc9,progression,0.821063
uuid-96fb338bf58844b1b5a9eef1c3490dc9,chemotherapy,0.390375
uuid-96fb338bf58844b1b5a9eef1c3490dc9,respond,0.701057
uuid-b8b0d271e8314ef3b66af915f00f4eb4,Nivo,0.515274
uuid-b8b0d271e8314ef3b66af915f00f4eb4,pembro,0.512906
uuid-b8b0d271e8314ef3b66af915f00f4eb4,lung,0.343817
uuid-b8b0d271e8314ef3b66af915f00f4eb4,1L,0.705373
uuid-b8b0d271e8314ef3b66af915f00f4eb4,RCC,0.665748
uuid-b8b0d271e8314ef3b66af915f00f4eb4,TL stated,0.335369
uuid-b8b0d271e8314ef3b66af915f00f4eb4,combination,0.334742
uuid-b8b0d271e8314ef3b66af915f00f4eb4,chemo,0.336277
uuid-b8b0d271e8314ef3b66af915f00f4eb4,2L,0.801377
uuid-b8b0d271e8314ef3b66af915f00f4eb4,agents,0.520278
uuid-b8b0d271e8314ef3b66af915f00f4eb4,approval,0.342276
uuid-b8b0d271e8314ef3b66af915f00f4eb4,atezo,0.55461
uuid-b8b0d271e8314ef3b66af915f00f4eb4,preferred,0.652421
uuid-b8b0d271e8314ef3b66af915f00f4eb4,monotherapy,0.565513
uuid-b8b0d271e8314ef3b66af915f00f4eb4,using nivo,0.668574
uuid-b8b0d271e8314ef3b66af915f00f4eb4,combo,0.449292
uuid-b8b0d271e8314ef3b66af915f00f4eb4,indication,0.335513
uuid-b8b0d271e8314ef3b66af915f00f4eb4,PD1,0.329039
uuid-b8b0d271e8314ef3b66af915f00f4eb4,approved,0.509029
uuid-b8b0d271e8314ef3b66af915f00f4eb4,SCCHN,0.400076
uuid-b8b0d271e8314ef3b66af915f00f4eb4,nivo and pembro,0.414834
uuid-b8b0d271e8314ef3b66af915f00f4eb4,believes,0.377911
uuid-b8b0d271e8314ef3b66af915f00f4eb4,TLs,0.328341
uuid-b8b0d271e8314ef3b66af915f00f4eb4,SCLC,0.326924
uuid-b8b0d271e8314ef3b66af915f00f4eb4,RTL stated,0.578222
uuid-b8b0d271e8314ef3b66af915f00f4eb4,TL shared,0.353559
uuid-b8b0d271e8314ef3b66af915f00f4eb4,option,0.490944
uuid-b8b0d271e8314ef3b66af915f00f4eb4,bladder,0.383917
uuid-6e56047261bf419ba13d16cc15091b0d,Nivo,0.323544
uuid-6e56047261bf419ba13d16cc15091b0d,patients,0.676095
uuid-6e56047261bf419ba13d16cc15091b0d,Opdivo,0.39766
uuid-6e56047261bf419ba13d16cc15091b0d,therapy,0.486495
uuid-6e56047261bf419ba13d16cc15091b0d,nivolumab,0.457387
uuid-6e56047261bf419ba13d16cc15091b0d,toxicity,0.419228
uuid-6e56047261bf419ba13d16cc15091b0d,regimen,0.812923
uuid-6e56047261bf419ba13d16cc15091b0d,treated,0.494129
uuid-6e56047261bf419ba13d16cc15091b0d,combination,0.37524
uuid-6e56047261bf419ba13d16cc15091b0d,chemo,0.421137
uuid-6e56047261bf419ba13d16cc15091b0d,pts,0.507615
uuid-6e56047261bf419ba13d16cc15091b0d,monotherapy,0.531627
uuid-6e56047261bf419ba13d16cc15091b0d,treatment,0.601028
uuid-6e56047261bf419ba13d16cc15091b0d,response,0.404324
uuid-6e56047261bf419ba13d16cc15091b0d,combo,0.366381
uuid-6e56047261bf419ba13d16cc15091b0d,PD1,0.37761
uuid-6e56047261bf419ba13d16cc15091b0d,progression,0.565121
uuid-6e56047261bf419ba13d16cc15091b0d,chemotherapy,0.461104
uuid-6e56047261bf419ba13d16cc15091b0d,respond,0.54522
uuid-6e56047261bf419ba13d16cc15091b0d,option,0.3984
uuid-6744717180e6497394e03c6b00f725c8,RTL,0.398375
uuid-6744717180e6497394e03c6b00f725c8,NTL,0.370126
uuid-6744717180e6497394e03c6b00f725c8,shared,0.331438
uuid-6744717180e6497394e03c6b00f725c8,commented,0.546911
uuid-6744717180e6497394e03c6b00f725c8,stated,0.315184
uuid-6744717180e6497394e03c6b00f725c8,physicians,0.336778
uuid-6744717180e6497394e03c6b00f725c8,data,0.324761
uuid-6744717180e6497394e03c6b00f725c8,expressed,0.505086
uuid-6744717180e6497394e03c6b00f725c8,mentioned,0.354583
uuid-6744717180e6497394e03c6b00f725c8,HCP,0.345327
uuid-6744717180e6497394e03c6b00f725c8,lung cancer,0.300153
uuid-6744717180e6497394e03c6b00f725c8,ASCO,0.511881
uuid-6744717180e6497394e03c6b00f725c8,impressed,0.468069
uuid-6744717180e6497394e03c6b00f725c8,Regional TL,0.519363
uuid-6399fbed18e8419e8f8e4a553df64409,Nivo,0.321941
uuid-6399fbed18e8419e8f8e4a553df64409,patients,0.606664
uuid-6399fbed18e8419e8f8e4a553df64409,therapy,0.678957
uuid-6399fbed18e8419e8f8e4a553df64409,nivolumab,0.58636
uuid-6399fbed18e8419e8f8e4a553df64409,1L,0.434552
uuid-6399fbed18e8419e8f8e4a553df64409,regimen,0.484845
uuid-6399fbed18e8419e8f8e4a553df64409,treated,0.527421
uuid-6399fbed18e8419e8f8e4a553df64409,RCC,0.391032
uuid-6399fbed18e8419e8f8e4a553df64409,combination,0.479423
uuid-6399fbed18e8419e8f8e4a553df64409,chemo,0.446319
uuid-6399fbed18e8419e8f8e4a553df64409,2L,0.491818
uuid-6399fbed18e8419e8f8e4a553df64409,pts,0.414758
uuid-6399fbed18e8419e8f8e4a553df64409,agents,0.367614
uuid-6399fbed18e8419e8f8e4a553df64409,approval,0.321016
uuid-6399fbed18e8419e8f8e4a553df64409,preferred,0.55594
uuid-6399fbed18e8419e8f8e4a553df64409,monotherapy,0.588681
uuid-6399fbed18e8419e8f8e4a553df64409,treatment,0.617732
uuid-6399fbed18e8419e8f8e4a553df64409,using nivo,0.482982
uuid-6399fbed18e8419e8f8e4a553df64409,combo,0.392585
uuid-6399fbed18e8419e8f8e4a553df64409,PD1,0.450456
uuid-6399fbed18e8419e8f8e4a553df64409,approved,0.385706
uuid-6399fbed18e8419e8f8e4a553df64409,progression,0.458844
uuid-6399fbed18e8419e8f8e4a553df64409,chemotherapy,0.565831
uuid-6399fbed18e8419e8f8e4a553df64409,RTL stated,0.493774
uuid-6399fbed18e8419e8f8e4a553df64409,option,0.63445
uuid-1003988d0c8d4b3d93c39d32318bab97,Nivo,0.366301
uuid-1003988d0c8d4b3d93c39d32318bab97,patients,0.473149
uuid-1003988d0c8d4b3d93c39d32318bab97,therapy,0.420352
uuid-1003988d0c8d4b3d93c39d32318bab97,regimen,0.328448
uuid-1003988d0c8d4b3d93c39d32318bab97,chemo,0.434128
uuid-1003988d0c8d4b3d93c39d32318bab97,pts,0.488182
uuid-1003988d0c8d4b3d93c39d32318bab97,OS,0.502064
uuid-1003988d0c8d4b3d93c39d32318bab97,treatment,0.398172
uuid-1003988d0c8d4b3d93c39d32318bab97,response,0.505207
uuid-1003988d0c8d4b3d93c39d32318bab97,PFS,0.518502
uuid-1003988d0c8d4b3d93c39d32318bab97,PD1,0.339008
uuid-1003988d0c8d4b3d93c39d32318bab97,ORR,0.419735
uuid-1003988d0c8d4b3d93c39d32318bab97,progression,0.592216
uuid-1003988d0c8d4b3d93c39d32318bab97,chemotherapy,0.419434
uuid-1003988d0c8d4b3d93c39d32318bab97,respond,0.489637
uuid-ca168f8ebadc48a1b23e68215449411f,patients,0.695695
uuid-ca168f8ebadc48a1b23e68215449411f,Opdivo,0.386009
uuid-ca168f8ebadc48a1b23e68215449411f,therapy,0.603112
uuid-ca168f8ebadc48a1b23e68215449411f,nivolumab,0.337649
uuid-ca168f8ebadc48a1b23e68215449411f,regimen,0.465148
uuid-ca168f8ebadc48a1b23e68215449411f,treated,0.440033
uuid-ca168f8ebadc48a1b23e68215449411f,chemo,0.375768
uuid-ca168f8ebadc48a1b23e68215449411f,pts,0.454637
uuid-ca168f8ebadc48a1b23e68215449411f,treatment,0.82171
uuid-ca168f8ebadc48a1b23e68215449411f,response,0.440983
uuid-ca168f8ebadc48a1b23e68215449411f,progression,0.653003
uuid-ca168f8ebadc48a1b23e68215449411f,chemotherapy,0.421542
uuid-ca168f8ebadc48a1b23e68215449411f,respond,0.551304
uuid-ca168f8ebadc48a1b23e68215449411f,option,0.337976
uuid-3841c284fe93453489eb9bb6295939f9,Nivo,0.332469
uuid-3841c284fe93453489eb9bb6295939f9,pembro,0.383088
uuid-3841c284fe93453489eb9bb6295939f9,trial,0.574987
uuid-3841c284fe93453489eb9bb6295939f9,combination,0.313641
uuid-3841c284fe93453489eb9bb6295939f9,chemo,0.400382
uuid-3841c284fe93453489eb9bb6295939f9,clinical trials,0.357744
uuid-3841c284fe93453489eb9bb6295939f9,nivo and pembro,0.305571
uuid-3841c284fe93453489eb9bb6295939f9,chemotherapy,0.420908
uuid-3841c284fe93453489eb9bb6295939f9,feels,0.359635
uuid-6b584af782094928b7fe216752747165,pembro,0.333587
uuid-6b584af782094928b7fe216752747165,1L,0.414845
uuid-6b584af782094928b7fe216752747165,PDL1,0.34714
uuid-6b584af782094928b7fe216752747165,2L,0.398981
uuid-6b584af782094928b7fe216752747165,agents,0.435714
uuid-6b584af782094928b7fe216752747165,PD-L1,0.307699
uuid-6b584af782094928b7fe216752747165,atezo,0.370291
uuid-6b584af782094928b7fe216752747165,preferred,0.467855
uuid-6b584af782094928b7fe216752747165,monotherapy,0.45322
uuid-6b584af782094928b7fe216752747165,indication,0.320482
uuid-6b584af782094928b7fe216752747165,approved,0.341136
uuid-6b584af782094928b7fe216752747165,chemotherapy,0.343972
uuid-6b584af782094928b7fe216752747165,feels,0.327458
uuid-6b584af782094928b7fe216752747165,PDL1 expression,0.327868
uuid-6b584af782094928b7fe216752747165,option,0.584917
uuid-9b2adb94264a4f81a5ba50f638b40b4c,Nivo,0.325036
uuid-9b2adb94264a4f81a5ba50f638b40b4c,patients,0.926965
uuid-9b2adb94264a4f81a5ba50f638b40b4c,Opdivo,0.352477
uuid-9b2adb94264a4f81a5ba50f638b40b4c,therapy,0.70309
uuid-9b2adb94264a4f81a5ba50f638b40b4c,nivolumab,0.43381
uuid-9b2adb94264a4f81a5ba50f638b40b4c,regimen,0.537849
uuid-9b2adb94264a4f81a5ba50f638b40b4c,treated,0.557359
uuid-9b2adb94264a4f81a5ba50f638b40b4c,chemo,0.525656
uuid-9b2adb94264a4f81a5ba50f638b40b4c,pts,0.590166
uuid-9b2adb94264a4f81a5ba50f638b40b4c,monotherapy,0.482437
uuid-9b2adb94264a4f81a5ba50f638b40b4c,treatment,0.753812
uuid-9b2adb94264a4f81a5ba50f638b40b4c,using nivo,0.316609
uuid-9b2adb94264a4f81a5ba50f638b40b4c,response,0.414755
uuid-9b2adb94264a4f81a5ba50f638b40b4c,PD1,0.396688
uuid-9b2adb94264a4f81a5ba50f638b40b4c,progression,0.699108
uuid-9b2adb94264a4f81a5ba50f638b40b4c,chemotherapy,0.575323
uuid-9b2adb94264a4f81a5ba50f638b40b4c,respond,0.540776
uuid-9b2adb94264a4f81a5ba50f638b40b4c,option,0.496957
uuid-1bb2fc4e38be4d1ab7336706cb11269e,TL,0.34995
uuid-1bb2fc4e38be4d1ab7336706cb11269e,PDL1,0.339656
uuid-1bb2fc4e38be4d1ab7336706cb11269e,Merck,0.304606
uuid-1bb2fc4e38be4d1ab7336706cb11269e,PD-L1,0.607152
uuid-1bb2fc4e38be4d1ab7336706cb11269e,PD-L1 testing,0.639653
uuid-1bb2fc4e38be4d1ab7336706cb11269e,testing,0.787582
uuid-1bb2fc4e38be4d1ab7336706cb11269e,PDL1 testing,0.599543
uuid-1bb2fc4e38be4d1ab7336706cb11269e,NSCLC patients,0.58869
uuid-1bb2fc4e38be4d1ab7336706cb11269e,assay,0.482728
uuid-1bb2fc4e38be4d1ab7336706cb11269e,biomarker,0.454954
uuid-76246a36ff944cd9b0dfe37913c2c6a3,therapy,0.392721
uuid-76246a36ff944cd9b0dfe37913c2c6a3,nivolumab,0.322181
uuid-76246a36ff944cd9b0dfe37913c2c6a3,toxicity,0.371758
uuid-76246a36ff944cd9b0dfe37913c2c6a3,regimen,0.359657
uuid-76246a36ff944cd9b0dfe37913c2c6a3,combination,0.67884
uuid-76246a36ff944cd9b0dfe37913c2c6a3,chemo,0.478864
uuid-76246a36ff944cd9b0dfe37913c2c6a3,IO,0.395415
uuid-76246a36ff944cd9b0dfe37913c2c6a3,agents,0.470721
uuid-76246a36ff944cd9b0dfe37913c2c6a3,monotherapy,0.460814
uuid-76246a36ff944cd9b0dfe37913c2c6a3,treatment,0.351651
uuid-76246a36ff944cd9b0dfe37913c2c6a3,combo,0.544316
uuid-76246a36ff944cd9b0dfe37913c2c6a3,PD1,0.464328
uuid-76246a36ff944cd9b0dfe37913c2c6a3,progression,0.315936
uuid-76246a36ff944cd9b0dfe37913c2c6a3,chemotherapy,0.539065
uuid-76246a36ff944cd9b0dfe37913c2c6a3,immunotherapy,0.368213
uuid-76246a36ff944cd9b0dfe37913c2c6a3,PD-1,0.305568
uuid-76246a36ff944cd9b0dfe37913c2c6a3,option,0.417849
uuid-81fd9b8fcd444397964bf8f14ac783d4,trial,0.480349
uuid-81fd9b8fcd444397964bf8f14ac783d4,efficacy,0.423144
uuid-81fd9b8fcd444397964bf8f14ac783d4,commented,0.429754
uuid-81fd9b8fcd444397964bf8f14ac783d4,OS,0.685792
uuid-81fd9b8fcd444397964bf8f14ac783d4,data,0.746708
uuid-81fd9b8fcd444397964bf8f14ac783d4,PFS,0.659054
uuid-81fd9b8fcd444397964bf8f14ac783d4,ORR,0.75523
uuid-81fd9b8fcd444397964bf8f14ac783d4,nivo and pembro,0.316407
uuid-81fd9b8fcd444397964bf8f14ac783d4,ASCO,0.424999
uuid-81fd9b8fcd444397964bf8f14ac783d4,impressed,0.679903
uuid-995182df286242de92080f3c9c4f5d4d,patients,0.602259
uuid-995182df286242de92080f3c9c4f5d4d,therapy,0.448141
uuid-995182df286242de92080f3c9c4f5d4d,toxicity,0.322133
uuid-995182df286242de92080f3c9c4f5d4d,regimen,0.330366
uuid-995182df286242de92080f3c9c4f5d4d,treated,0.360386
uuid-995182df286242de92080f3c9c4f5d4d,chemo,0.382491
uuid-995182df286242de92080f3c9c4f5d4d,tumor,0.422265
uuid-995182df286242de92080f3c9c4f5d4d,pts,0.515051
uuid-995182df286242de92080f3c9c4f5d4d,treatment,0.498045
uuid-995182df286242de92080f3c9c4f5d4d,response,0.431738
uuid-995182df286242de92080f3c9c4f5d4d,progression,0.554375
uuid-995182df286242de92080f3c9c4f5d4d,chemotherapy,0.494866
uuid-995182df286242de92080f3c9c4f5d4d,respond,0.331578
uuid-995182df286242de92080f3c9c4f5d4d,immunotherapy,0.322564
uuid-b905d42e4cf34d0a96b7371ba8481464,NTL,0.358639
uuid-b905d42e4cf34d0a96b7371ba8481464,lung cancer,0.930864
uuid-34dd209a6000481995e24fdec168948c,TL,0.383384
uuid-34dd209a6000481995e24fdec168948c,PDL1,0.408194
uuid-34dd209a6000481995e24fdec168948c,Merck,0.313757
uuid-34dd209a6000481995e24fdec168948c,PD-L1,0.580713
uuid-34dd209a6000481995e24fdec168948c,PD-L1 testing,0.476866
uuid-34dd209a6000481995e24fdec168948c,testing,0.492381
uuid-34dd209a6000481995e24fdec168948c,indicated,0.373959
uuid-34dd209a6000481995e24fdec168948c,Keytruda,0.398532
uuid-34dd209a6000481995e24fdec168948c,assay,0.543343
uuid-34dd209a6000481995e24fdec168948c,PDL1 expression,0.333817
uuid-34dd209a6000481995e24fdec168948c,biomarker,0.306677
uuid-f3c6d1ad7dd6455086baa48b137af08e,TL,0.769921
uuid-f3c6d1ad7dd6455086baa48b137af08e,TL stated,0.329823
uuid-f3c6d1ad7dd6455086baa48b137af08e,Merck,0.30674
uuid-f3c6d1ad7dd6455086baa48b137af08e,institution,0.364009
uuid-f3c6d1ad7dd6455086baa48b137af08e,PD-L1,0.702165
uuid-f3c6d1ad7dd6455086baa48b137af08e,PD-L1 testing,0.822436
uuid-f3c6d1ad7dd6455086baa48b137af08e,testing,0.736263
uuid-f3c6d1ad7dd6455086baa48b137af08e,PDL1 testing,0.496314
uuid-f3c6d1ad7dd6455086baa48b137af08e,NSCLC patients,0.428717
uuid-f3c6d1ad7dd6455086baa48b137af08e,assay,0.858134
uuid-a4e4700f69a54123b2c011f945363ed1,patients,0.44021
uuid-a4e4700f69a54123b2c011f945363ed1,TL,0.351617
uuid-a4e4700f69a54123b2c011f945363ed1,pembro,0.476721
uuid-a4e4700f69a54123b2c011f945363ed1,therapy,0.341596
uuid-a4e4700f69a54123b2c011f945363ed1,nivolumab,0.315444
uuid-a4e4700f69a54123b2c011f945363ed1,1L,0.548192
uuid-a4e4700f69a54123b2c011f945363ed1,RCC,0.34142
uuid-a4e4700f69a54123b2c011f945363ed1,2L,0.556284
uuid-a4e4700f69a54123b2c011f945363ed1,approval,0.631379
uuid-a4e4700f69a54123b2c011f945363ed1,atezo,0.39346
uuid-a4e4700f69a54123b2c011f945363ed1,preferred,0.489865
uuid-a4e4700f69a54123b2c011f945363ed1,PD-L1 testing,0.393623
uuid-a4e4700f69a54123b2c011f945363ed1,testing,0.405832
uuid-a4e4700f69a54123b2c011f945363ed1,monotherapy,0.338737
uuid-a4e4700f69a54123b2c011f945363ed1,using nivo,0.597609
uuid-a4e4700f69a54123b2c011f945363ed1,PDL1 testing,0.41184
uuid-a4e4700f69a54123b2c011f945363ed1,NSCLC patients,0.490194
uuid-a4e4700f69a54123b2c011f945363ed1,approved,0.508339
uuid-a4e4700f69a54123b2c011f945363ed1,SCCHN,0.326712
uuid-a4e4700f69a54123b2c011f945363ed1,label,0.328125
uuid-a4e4700f69a54123b2c011f945363ed1,RTL stated,0.426769
uuid-a4e4700f69a54123b2c011f945363ed1,option,0.44249
uuid-a4e4700f69a54123b2c011f945363ed1,bladder,0.33014
uuid-a4c4f12ddee84b3fadcaa6d635fb60ac,preferred,0.332598
uuid-a4c4f12ddee84b3fadcaa6d635fb60ac,using nivo,0.302698
uuid-a4c4f12ddee84b3fadcaa6d635fb60ac,data,0.379849
uuid-a4c4f12ddee84b3fadcaa6d635fb60ac,SCCHN,0.326108
uuid-a4c4f12ddee84b3fadcaa6d635fb60ac,impressed,0.350452
uuid-a4c4f12ddee84b3fadcaa6d635fb60ac,LTL,0.422119
uuid-a4c4f12ddee84b3fadcaa6d635fb60ac,feels,0.503908
uuid-a4c4f12ddee84b3fadcaa6d635fb60ac,RTL stated,0.309984
uuid-eaeab174962a46479fc00b2fbf1d89fd,patients,0.411237
uuid-eaeab174962a46479fc00b2fbf1d89fd,therapy,0.557383
uuid-eaeab174962a46479fc00b2fbf1d89fd,treated,0.306916
uuid-eaeab174962a46479fc00b2fbf1d89fd,chemo,0.333593
uuid-eaeab174962a46479fc00b2fbf1d89fd,treatment,0.382359
uuid-eaeab174962a46479fc00b2fbf1d89fd,PD1,0.341025
uuid-eaeab174962a46479fc00b2fbf1d89fd,cHL,0.409863
uuid-eaeab174962a46479fc00b2fbf1d89fd,progression,0.394899
uuid-eaeab174962a46479fc00b2fbf1d89fd,chemotherapy,0.4258
uuid-eaeab174962a46479fc00b2fbf1d89fd,option,0.331713
uuid-c369f0e50e0644528ed1a5356564055f,TL,0.538134
uuid-c369f0e50e0644528ed1a5356564055f,PDL1,0.388236
uuid-c369f0e50e0644528ed1a5356564055f,TL stated,0.365103
uuid-c369f0e50e0644528ed1a5356564055f,PD-L1,0.808429
uuid-c369f0e50e0644528ed1a5356564055f,PD-L1 testing,0.810646
uuid-c369f0e50e0644528ed1a5356564055f,testing,0.88457
uuid-c369f0e50e0644528ed1a5356564055f,PDL1 testing,0.660461
uuid-c369f0e50e0644528ed1a5356564055f,NSCLC patients,0.714859
uuid-c369f0e50e0644528ed1a5356564055f,assay,0.701775
uuid-c369f0e50e0644528ed1a5356564055f,biomarker,0.359702
uuid-e9187252d6bb452ca7cf18bbd2b123fc,PDL1,0.364426
uuid-e9187252d6bb452ca7cf18bbd2b123fc,combination,0.377201
uuid-e9187252d6bb452ca7cf18bbd2b123fc,chemo,0.537425
uuid-e9187252d6bb452ca7cf18bbd2b123fc,pts,0.50931
uuid-e9187252d6bb452ca7cf18bbd2b123fc,monotherapy,0.365507
uuid-e9187252d6bb452ca7cf18bbd2b123fc,response,0.439656
uuid-e9187252d6bb452ca7cf18bbd2b123fc,combo,0.381378
uuid-e9187252d6bb452ca7cf18bbd2b123fc,PD1,0.369226
uuid-e9187252d6bb452ca7cf18bbd2b123fc,progression,0.316968
uuid-e9187252d6bb452ca7cf18bbd2b123fc,believes,0.453982
uuid-e9187252d6bb452ca7cf18bbd2b123fc,chemotherapy,0.414115
uuid-e9187252d6bb452ca7cf18bbd2b123fc,respond,0.405159
uuid-e9187252d6bb452ca7cf18bbd2b123fc,feels,0.368731
uuid-e9187252d6bb452ca7cf18bbd2b123fc,immunotherapy,0.35017
uuid-e9187252d6bb452ca7cf18bbd2b123fc,PDL1 expression,0.370828
uuid-e9187252d6bb452ca7cf18bbd2b123fc,option,0.332628
uuid-e9187252d6bb452ca7cf18bbd2b123fc,biomarker,0.300592
uuid-4f7132a4d33e4656b46725f16bcb2f44,patients,0.413166
uuid-4f7132a4d33e4656b46725f16bcb2f44,therapy,0.630129
uuid-4f7132a4d33e4656b46725f16bcb2f44,nivolumab,0.316815
uuid-4f7132a4d33e4656b46725f16bcb2f44,regimen,0.418769
uuid-4f7132a4d33e4656b46725f16bcb2f44,treated,0.407082
uuid-4f7132a4d33e4656b46725f16bcb2f44,combination,0.369272
uuid-4f7132a4d33e4656b46725f16bcb2f44,chemo,0.544779
uuid-4f7132a4d33e4656b46725f16bcb2f44,pts,0.475129
uuid-4f7132a4d33e4656b46725f16bcb2f44,IO,0.370116
uuid-4f7132a4d33e4656b46725f16bcb2f44,monotherapy,0.325076
uuid-4f7132a4d33e4656b46725f16bcb2f44,treatment,0.589436
uuid-4f7132a4d33e4656b46725f16bcb2f44,response,0.817651
uuid-4f7132a4d33e4656b46725f16bcb2f44,PD1,0.543499
uuid-4f7132a4d33e4656b46725f16bcb2f44,progression,0.743038
uuid-4f7132a4d33e4656b46725f16bcb2f44,chemotherapy,0.555796
uuid-4f7132a4d33e4656b46725f16bcb2f44,respond,0.543361
uuid-4f7132a4d33e4656b46725f16bcb2f44,immunotherapy,0.501433
uuid-d34fe6802d5d4d209a2514fa66cbb369,pembro,0.450521
uuid-d34fe6802d5d4d209a2514fa66cbb369,RTL,0.392386
uuid-d34fe6802d5d4d209a2514fa66cbb369,atezo,0.356425
uuid-d34fe6802d5d4d209a2514fa66cbb369,using nivo,0.331413
uuid-d34fe6802d5d4d209a2514fa66cbb369,data,0.446608
uuid-d34fe6802d5d4d209a2514fa66cbb369,mentioned,0.316077
uuid-d34fe6802d5d4d209a2514fa66cbb369,SCCHN,0.338489
uuid-d34fe6802d5d4d209a2514fa66cbb369,HCP,0.334341
uuid-d34fe6802d5d4d209a2514fa66cbb369,nivo and pembro,0.310254
uuid-d34fe6802d5d4d209a2514fa66cbb369,impressed,0.364597
uuid-d34fe6802d5d4d209a2514fa66cbb369,LTL,0.510171
uuid-d34fe6802d5d4d209a2514fa66cbb369,feels,0.353656
uuid-cc5dedafaa844bef99c67eaaf93887cd,shared,0.414775
uuid-cc5dedafaa844bef99c67eaaf93887cd,physicians,0.711294
uuid-cc5dedafaa844bef99c67eaaf93887cd,oncology,0.458335
uuid-cc5dedafaa844bef99c67eaaf93887cd,clinical,0.472234
uuid-cc5dedafaa844bef99c67eaaf93887cd,academic,0.368289
uuid-91350c38a1e54b38b1fbdbb354af0e7c,TL,0.300538
uuid-91350c38a1e54b38b1fbdbb354af0e7c,pembro,0.309543
uuid-91350c38a1e54b38b1fbdbb354af0e7c,1L,0.472249
uuid-91350c38a1e54b38b1fbdbb354af0e7c,shared,0.418218
uuid-91350c38a1e54b38b1fbdbb354af0e7c,RCC,0.339256
uuid-91350c38a1e54b38b1fbdbb354af0e7c,TL stated,0.380812
uuid-91350c38a1e54b38b1fbdbb354af0e7c,2L,0.460986
uuid-91350c38a1e54b38b1fbdbb354af0e7c,institution,0.359335
uuid-91350c38a1e54b38b1fbdbb354af0e7c,PD-L1,0.4995
uuid-91350c38a1e54b38b1fbdbb354af0e7c,approval,0.430017
uuid-91350c38a1e54b38b1fbdbb354af0e7c,atezo,0.377077
uuid-91350c38a1e54b38b1fbdbb354af0e7c,preferred,0.45913
uuid-91350c38a1e54b38b1fbdbb354af0e7c,PD-L1 testing,0.516529
uuid-91350c38a1e54b38b1fbdbb354af0e7c,testing,0.586763
uuid-91350c38a1e54b38b1fbdbb354af0e7c,using nivo,0.325717
uuid-91350c38a1e54b38b1fbdbb354af0e7c,PDL1 testing,0.627419
uuid-91350c38a1e54b38b1fbdbb354af0e7c,NSCLC patients,0.506462
uuid-91350c38a1e54b38b1fbdbb354af0e7c,approved,0.45211
uuid-91350c38a1e54b38b1fbdbb354af0e7c,SCCHN,0.395184
uuid-91350c38a1e54b38b1fbdbb354af0e7c,tumor types,0.328292
uuid-91350c38a1e54b38b1fbdbb354af0e7c,academic,0.379704
uuid-91350c38a1e54b38b1fbdbb354af0e7c,assay,0.335764
uuid-91350c38a1e54b38b1fbdbb354af0e7c,RTL stated,0.469495
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,pembro,0.350331
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,RTL,0.494083
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,1L,0.330049
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,trial,0.419634
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,melanoma,0.316878
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,shared,0.638628
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,commented,0.368815
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,RCC,0.467311
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,combination,0.369507
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,2L,0.41516
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,stated,0.441732
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,approval,0.35963
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,atezo,0.32736
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,preferred,0.440213
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,monotherapy,0.303729
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,using nivo,0.458193
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,combo,0.393649
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,clinical trials,0.535802
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,approved,0.381539
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,SCCHN,0.550167
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,impressed,0.3947
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,LTL,0.451026
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,TLs,0.392681
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,academic,0.410213
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,SCLC,0.334765
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,feels,0.410783
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,Regional TL,0.483811
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,RTL stated,0.568834
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,TL shared,0.327729
uuid-7bb8628fa3c0455e8c5b4ed7faf1ca4e,bladder,0.414258
uuid-8807719da202421983d594cd13d3ba18,Nivo,0.309432
uuid-8807719da202421983d594cd13d3ba18,patients,0.358891
uuid-8807719da202421983d594cd13d3ba18,1L,0.301827
uuid-8807719da202421983d594cd13d3ba18,toxicity,0.311362
uuid-8807719da202421983d594cd13d3ba18,regimen,0.38641
uuid-8807719da202421983d594cd13d3ba18,chemo,0.334019
uuid-8807719da202421983d594cd13d3ba18,2L,0.392992
uuid-8807719da202421983d594cd13d3ba18,agents,0.381367
uuid-8807719da202421983d594cd13d3ba18,preferred,0.706523
uuid-8807719da202421983d594cd13d3ba18,monotherapy,0.466403
uuid-8807719da202421983d594cd13d3ba18,treatment,0.359061
uuid-8807719da202421983d594cd13d3ba18,using nivo,0.402624
uuid-8807719da202421983d594cd13d3ba18,indication,0.305827
uuid-8807719da202421983d594cd13d3ba18,SCCHN,0.306402
uuid-8807719da202421983d594cd13d3ba18,chemotherapy,0.380676
uuid-8807719da202421983d594cd13d3ba18,RTL stated,0.425845
uuid-8807719da202421983d594cd13d3ba18,option,0.567618
uuid-3d35233010aa4069bd2c78c1f2c46266,lung,0.380495
uuid-3d35233010aa4069bd2c78c1f2c46266,1L,0.30523
uuid-3d35233010aa4069bd2c78c1f2c46266,melanoma,0.328394
uuid-3d35233010aa4069bd2c78c1f2c46266,RCC,0.318448
uuid-3d35233010aa4069bd2c78c1f2c46266,2L,0.41735
uuid-3d35233010aa4069bd2c78c1f2c46266,institution,0.492561
uuid-3d35233010aa4069bd2c78c1f2c46266,preferred,0.364538
uuid-3d35233010aa4069bd2c78c1f2c46266,PDL1 testing,0.300501
uuid-3d35233010aa4069bd2c78c1f2c46266,AI,0.520911
uuid-3d35233010aa4069bd2c78c1f2c46266,oncology,0.333447
uuid-6800dc0ea91647c180a6a5972b868f7d,Nivo,0.452914
uuid-6800dc0ea91647c180a6a5972b868f7d,pembro,0.641111
uuid-6800dc0ea91647c180a6a5972b868f7d,1L,0.474232
uuid-6800dc0ea91647c180a6a5972b868f7d,PDL1,0.51754
uuid-6800dc0ea91647c180a6a5972b868f7d,trial,0.396017
uuid-6800dc0ea91647c180a6a5972b868f7d,efficacy,0.513219
uuid-6800dc0ea91647c180a6a5972b868f7d,2L,0.405606
uuid-6800dc0ea91647c180a6a5972b868f7d,approval,0.340393
uuid-6800dc0ea91647c180a6a5972b868f7d,OS,0.492093
uuid-6800dc0ea91647c180a6a5972b868f7d,atezo,0.580782
uuid-6800dc0ea91647c180a6a5972b868f7d,using nivo,0.345346
uuid-6800dc0ea91647c180a6a5972b868f7d,data,0.609517
uuid-6800dc0ea91647c180a6a5972b868f7d,PFS,0.464056
uuid-6800dc0ea91647c180a6a5972b868f7d,ORR,0.500726
uuid-6800dc0ea91647c180a6a5972b868f7d,nivo and pembro,0.550911
uuid-6800dc0ea91647c180a6a5972b868f7d,believes,0.314919
uuid-6800dc0ea91647c180a6a5972b868f7d,impressed,0.483621
uuid-6800dc0ea91647c180a6a5972b868f7d,vs,0.35725
uuid-6800dc0ea91647c180a6a5972b868f7d,feels,0.385638
uuid-6800dc0ea91647c180a6a5972b868f7d,PDL1 expression,0.440148
uuid-ee43744c796c4737b781bbb2c88ff3bb,patients,0.325699
uuid-ee43744c796c4737b781bbb2c88ff3bb,therapy,0.380124
uuid-ee43744c796c4737b781bbb2c88ff3bb,nivolumab,0.480057
uuid-ee43744c796c4737b781bbb2c88ff3bb,1L,0.356242
uuid-ee43744c796c4737b781bbb2c88ff3bb,treated,0.400654
uuid-ee43744c796c4737b781bbb2c88ff3bb,RCC,0.435093
uuid-ee43744c796c4737b781bbb2c88ff3bb,combination,0.31157
uuid-ee43744c796c4737b781bbb2c88ff3bb,chemo,0.306426
uuid-ee43744c796c4737b781bbb2c88ff3bb,2L,0.333541
uuid-ee43744c796c4737b781bbb2c88ff3bb,approval,0.312638
uuid-ee43744c796c4737b781bbb2c88ff3bb,preferred,0.570416
uuid-ee43744c796c4737b781bbb2c88ff3bb,monotherapy,0.384033
uuid-ee43744c796c4737b781bbb2c88ff3bb,treatment,0.325262
uuid-ee43744c796c4737b781bbb2c88ff3bb,using nivo,0.478083
uuid-ee43744c796c4737b781bbb2c88ff3bb,SCCHN,0.50489
uuid-ee43744c796c4737b781bbb2c88ff3bb,chemotherapy,0.406701
uuid-ee43744c796c4737b781bbb2c88ff3bb,RTL stated,0.565472
uuid-ee43744c796c4737b781bbb2c88ff3bb,TL shared,0.37742
uuid-ee43744c796c4737b781bbb2c88ff3bb,option,0.50933
uuid-ee43744c796c4737b781bbb2c88ff3bb,bladder,0.376965
uuid-2a0a4f0ef5954fe08d59fd56a4473682,Nivo,0.739855
uuid-2a0a4f0ef5954fe08d59fd56a4473682,pembro,0.674834
uuid-2a0a4f0ef5954fe08d59fd56a4473682,1L,0.449637
uuid-2a0a4f0ef5954fe08d59fd56a4473682,efficacy,0.365868
uuid-2a0a4f0ef5954fe08d59fd56a4473682,combination,0.303001
uuid-2a0a4f0ef5954fe08d59fd56a4473682,2L,0.565368
uuid-2a0a4f0ef5954fe08d59fd56a4473682,agents,0.414378
uuid-2a0a4f0ef5954fe08d59fd56a4473682,Ipi,0.368155
uuid-2a0a4f0ef5954fe08d59fd56a4473682,atezo,0.660721
uuid-2a0a4f0ef5954fe08d59fd56a4473682,preferred,0.574635
uuid-2a0a4f0ef5954fe08d59fd56a4473682,monotherapy,0.430176
uuid-2a0a4f0ef5954fe08d59fd56a4473682,using nivo,0.585754
uuid-2a0a4f0ef5954fe08d59fd56a4473682,indication,0.334273
uuid-2a0a4f0ef5954fe08d59fd56a4473682,approved,0.339095
uuid-2a0a4f0ef5954fe08d59fd56a4473682,nivo and pembro,0.443481
uuid-2a0a4f0ef5954fe08d59fd56a4473682,vs,0.478032
uuid-2a0a4f0ef5954fe08d59fd56a4473682,feels,0.50988
uuid-2a0a4f0ef5954fe08d59fd56a4473682,RTL stated,0.411881
uuid-2a0a4f0ef5954fe08d59fd56a4473682,option,0.451846
uuid-f04ba83a5edb49049174fd0582640ec3,Nivo,0.399032
uuid-f04ba83a5edb49049174fd0582640ec3,pembro,0.423859
uuid-f04ba83a5edb49049174fd0582640ec3,dose,0.327404
uuid-f04ba83a5edb49049174fd0582640ec3,nivolumab,0.302928
uuid-f04ba83a5edb49049174fd0582640ec3,1L,0.502281
uuid-f04ba83a5edb49049174fd0582640ec3,regimen,0.331936
uuid-f04ba83a5edb49049174fd0582640ec3,RCC,0.430016
uuid-f04ba83a5edb49049174fd0582640ec3,combination,0.657265
uuid-f04ba83a5edb49049174fd0582640ec3,chemo,0.439867
uuid-f04ba83a5edb49049174fd0582640ec3,2L,0.605848
uuid-f04ba83a5edb49049174fd0582640ec3,IO,0.401975
uuid-f04ba83a5edb49049174fd0582640ec3,agents,0.636085
uuid-f04ba83a5edb49049174fd0582640ec3,Ipi,0.459116
uuid-f04ba83a5edb49049174fd0582640ec3,atezo,0.531485
uuid-f04ba83a5edb49049174fd0582640ec3,preferred,0.560043
uuid-f04ba83a5edb49049174fd0582640ec3,monotherapy,0.58544
uuid-f04ba83a5edb49049174fd0582640ec3,using nivo,0.38008
uuid-f04ba83a5edb49049174fd0582640ec3,combo,0.678123
uuid-f04ba83a5edb49049174fd0582640ec3,PD1,0.363519
uuid-f04ba83a5edb49049174fd0582640ec3,approved,0.327188
uuid-f04ba83a5edb49049174fd0582640ec3,believes,0.436058
uuid-f04ba83a5edb49049174fd0582640ec3,chemotherapy,0.346097
uuid-f04ba83a5edb49049174fd0582640ec3,vs,0.371448
uuid-f04ba83a5edb49049174fd0582640ec3,TLs,0.314173
uuid-f04ba83a5edb49049174fd0582640ec3,RTL stated,0.429449
uuid-f04ba83a5edb49049174fd0582640ec3,option,0.447048
uuid-f04ba83a5edb49049174fd0582640ec3,bladder,0.347204
uuid-b13ad6ef78d946e3b6a7f46be81eba50,nivolumab,0.307633
uuid-b13ad6ef78d946e3b6a7f46be81eba50,trial,0.655299
uuid-b13ad6ef78d946e3b6a7f46be81eba50,combination,0.490434
uuid-b13ad6ef78d946e3b6a7f46be81eba50,combo,0.322903
uuid-b13ad6ef78d946e3b6a7f46be81eba50,clinical trials,0.423651
uuid-b13ad6ef78d946e3b6a7f46be81eba50,chemotherapy,0.322281
uuid-b13ad6ef78d946e3b6a7f46be81eba50,bladder,0.334274
uuid-2cfa54f7b12e45299825b7fc4ccad321,NSCLC,0.435016
uuid-2cfa54f7b12e45299825b7fc4ccad321,trial,0.339842
uuid-2cfa54f7b12e45299825b7fc4ccad321,combination,0.400124
uuid-2cfa54f7b12e45299825b7fc4ccad321,chemo,0.301056
uuid-2cfa54f7b12e45299825b7fc4ccad321,IO,0.584325
uuid-2cfa54f7b12e45299825b7fc4ccad321,OS,0.323182
uuid-2cfa54f7b12e45299825b7fc4ccad321,combo,0.419565
uuid-2cfa54f7b12e45299825b7fc4ccad321,PFS,0.330672
uuid-2cfa54f7b12e45299825b7fc4ccad321,ORR,0.329151
uuid-2cfa54f7b12e45299825b7fc4ccad321,believes,0.391041
uuid-33229df3396e47c582885b8e5ea2fa26,patients,0.787616
uuid-33229df3396e47c582885b8e5ea2fa26,Opdivo,0.69273
uuid-33229df3396e47c582885b8e5ea2fa26,therapy,0.402506
uuid-33229df3396e47c582885b8e5ea2fa26,nivolumab,0.554099
uuid-33229df3396e47c582885b8e5ea2fa26,regimen,0.332945
uuid-33229df3396e47c582885b8e5ea2fa26,treated,0.505203
uuid-33229df3396e47c582885b8e5ea2fa26,pts,0.470348
uuid-33229df3396e47c582885b8e5ea2fa26,approval,0.418159
uuid-33229df3396e47c582885b8e5ea2fa26,treatment,0.503843
uuid-33229df3396e47c582885b8e5ea2fa26,using nivo,0.466123
uuid-33229df3396e47c582885b8e5ea2fa26,approved,0.365355
uuid-33229df3396e47c582885b8e5ea2fa26,cHL,0.357655
uuid-33229df3396e47c582885b8e5ea2fa26,progression,0.416742
uuid-33229df3396e47c582885b8e5ea2fa26,RTL stated,0.356706
uuid-33229df3396e47c582885b8e5ea2fa26,option,0.308697
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,patients,0.360408
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,pembro,0.304729
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,1L,0.579777
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,PDL1,0.408565
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,regimen,0.308899
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,chemo,0.465752
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,2L,0.489202
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,pts,0.437532
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,agents,0.322366
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,PD-L1,0.340904
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,atezo,0.307445
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,preferred,0.376053
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,monotherapy,0.557971
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,combo,0.453445
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,PDL1 testing,0.310938
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,NSCLC patients,0.430179
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,PD1,0.4307
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,progression,0.390239
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,believes,0.457781
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,chemotherapy,0.368212
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,feels,0.459946
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,option,0.521664
uuid-c8a1312f0fdc4086bf3e6e96129c2e98,biomarker,0.324117
uuid-d6b59001d134406ba1ff30ddeee8eb52,dose,0.334889
uuid-d6b59001d134406ba1ff30ddeee8eb52,toxicity,0.68075
uuid-d6b59001d134406ba1ff30ddeee8eb52,efficacy,0.444713
uuid-d6b59001d134406ba1ff30ddeee8eb52,regimen,0.653974
uuid-d6b59001d134406ba1ff30ddeee8eb52,combination,0.308896
uuid-d6b59001d134406ba1ff30ddeee8eb52,Ipi,0.307995
uuid-d6b59001d134406ba1ff30ddeee8eb52,physicians,0.313973
uuid-d6b59001d134406ba1ff30ddeee8eb52,treatment,0.324799
uuid-d6b59001d134406ba1ff30ddeee8eb52,combo,0.333174
uuid-d6b59001d134406ba1ff30ddeee8eb52,believes,0.300928
uuid-d6b59001d134406ba1ff30ddeee8eb52,respond,0.328178
uuid-d6b59001d134406ba1ff30ddeee8eb52,feels,0.346152
uuid-0af55769c35d4d8796e3b4113148010b,efficacy,0.374839
uuid-0af55769c35d4d8796e3b4113148010b,regimen,0.464952
uuid-0af55769c35d4d8796e3b4113148010b,combination,0.382141
uuid-0af55769c35d4d8796e3b4113148010b,chemo,0.342432
uuid-0af55769c35d4d8796e3b4113148010b,IO,0.340074
uuid-0af55769c35d4d8796e3b4113148010b,OS,0.357668
uuid-0af55769c35d4d8796e3b4113148010b,monotherapy,0.38431
uuid-0af55769c35d4d8796e3b4113148010b,response,0.346759
uuid-0af55769c35d4d8796e3b4113148010b,data,0.421977
uuid-0af55769c35d4d8796e3b4113148010b,combo,0.403965
uuid-0af55769c35d4d8796e3b4113148010b,PFS,0.316034
uuid-0af55769c35d4d8796e3b4113148010b,PD1,0.361811
uuid-0af55769c35d4d8796e3b4113148010b,ORR,0.354044
uuid-0af55769c35d4d8796e3b4113148010b,progression,0.387463
uuid-0af55769c35d4d8796e3b4113148010b,believes,0.36836
uuid-0af55769c35d4d8796e3b4113148010b,chemotherapy,0.325933
uuid-0af55769c35d4d8796e3b4113148010b,impressed,0.450925
uuid-0af55769c35d4d8796e3b4113148010b,respond,0.326086
uuid-0af55769c35d4d8796e3b4113148010b,feels,0.62148
uuid-a6086223d00647bda54829da8fee6aea,PDL1,0.490848
uuid-a6086223d00647bda54829da8fee6aea,Merck,0.426227
uuid-a6086223d00647bda54829da8fee6aea,PD-L1,0.503021
uuid-a6086223d00647bda54829da8fee6aea,PD-L1 testing,0.35336
uuid-a6086223d00647bda54829da8fee6aea,testing,0.49504
uuid-a6086223d00647bda54829da8fee6aea,PDL1 testing,0.368756
uuid-a6086223d00647bda54829da8fee6aea,assay,0.539604
uuid-a6086223d00647bda54829da8fee6aea,PDL1 expression,0.348888
uuid-a6086223d00647bda54829da8fee6aea,biomarker,0.413257
uuid-6ccd092e02be4e92b61fe731ff473c2a,Nivo,0.319814
uuid-6ccd092e02be4e92b61fe731ff473c2a,Opdivo,0.374556
uuid-6ccd092e02be4e92b61fe731ff473c2a,dose,0.905338
uuid-6ccd092e02be4e92b61fe731ff473c2a,toxicity,0.543299
uuid-6ccd092e02be4e92b61fe731ff473c2a,regimen,0.460637
uuid-6ccd092e02be4e92b61fe731ff473c2a,Ipi,0.56229
uuid-6ccd092e02be4e92b61fe731ff473c2a,treatment,0.304774
uuid-6ccd092e02be4e92b61fe731ff473c2a,vs,0.544424
uuid-6ccd092e02be4e92b61fe731ff473c2a,flat dosing,0.574403
uuid-862861b5ab604dafb79450216447333c,TL,0.571924
uuid-862861b5ab604dafb79450216447333c,RTL,0.326456
uuid-862861b5ab604dafb79450216447333c,lung,0.313371
uuid-862861b5ab604dafb79450216447333c,commented,0.385043
uuid-862861b5ab604dafb79450216447333c,TL stated,0.461717
uuid-862861b5ab604dafb79450216447333c,PD-L1,0.333961
uuid-862861b5ab604dafb79450216447333c,PD-L1 testing,0.439081
uuid-862861b5ab604dafb79450216447333c,testing,0.381411
uuid-862861b5ab604dafb79450216447333c,PDL1 testing,0.319806
uuid-862861b5ab604dafb79450216447333c,SCCHN,0.342161
uuid-862861b5ab604dafb79450216447333c,assay,0.429409
uuid-862861b5ab604dafb79450216447333c,Regional TL,0.358259
uuid-862861b5ab604dafb79450216447333c,TL shared,0.383496
uuid-c27f6b821f274d019f4be5c8016d3550,patients,0.491879
uuid-c27f6b821f274d019f4be5c8016d3550,1L,0.359873
uuid-c27f6b821f274d019f4be5c8016d3550,treated,0.331691
uuid-c27f6b821f274d019f4be5c8016d3550,RCC,0.309397
uuid-c27f6b821f274d019f4be5c8016d3550,TL stated,0.475242
uuid-c27f6b821f274d019f4be5c8016d3550,2L,0.332783
uuid-c27f6b821f274d019f4be5c8016d3550,PD-L1,0.371822
uuid-c27f6b821f274d019f4be5c8016d3550,preferred,0.369258
uuid-c27f6b821f274d019f4be5c8016d3550,PD-L1 testing,0.462257
uuid-c27f6b821f274d019f4be5c8016d3550,testing,0.58754
uuid-c27f6b821f274d019f4be5c8016d3550,treatment,0.331364
uuid-c27f6b821f274d019f4be5c8016d3550,using nivo,0.353833
uuid-c27f6b821f274d019f4be5c8016d3550,PDL1 testing,0.667142
uuid-c27f6b821f274d019f4be5c8016d3550,NSCLC patients,0.725976
uuid-c27f6b821f274d019f4be5c8016d3550,SCCHN,0.392839
uuid-c27f6b821f274d019f4be5c8016d3550,tumor types,0.419427
uuid-c27f6b821f274d019f4be5c8016d3550,RTL stated,0.385385
uuid-c037082532894d77bead523e37608089,patients,0.541764
uuid-c037082532894d77bead523e37608089,therapy,0.395942
uuid-c037082532894d77bead523e37608089,nivolumab,0.483946
uuid-c037082532894d77bead523e37608089,toxicity,0.550399
uuid-c037082532894d77bead523e37608089,regimen,0.598137
uuid-c037082532894d77bead523e37608089,treated,0.424991
uuid-c037082532894d77bead523e37608089,combination,0.47316
uuid-c037082532894d77bead523e37608089,chemo,0.359021
uuid-c037082532894d77bead523e37608089,pts,0.380379
uuid-c037082532894d77bead523e37608089,Ipi,0.311265
uuid-c037082532894d77bead523e37608089,monotherapy,0.407013
uuid-c037082532894d77bead523e37608089,treatment,0.515073
uuid-c037082532894d77bead523e37608089,combo,0.398404
uuid-c037082532894d77bead523e37608089,PD1,0.340439
uuid-c037082532894d77bead523e37608089,progression,0.424369
uuid-c037082532894d77bead523e37608089,chemotherapy,0.440091
uuid-c037082532894d77bead523e37608089,respond,0.386294
uuid-3d751576da8d4cd1aad2422159cf72a3,Nivo,0.337986
uuid-3d751576da8d4cd1aad2422159cf72a3,pembro,0.579436
uuid-3d751576da8d4cd1aad2422159cf72a3,dose,0.740288
uuid-3d751576da8d4cd1aad2422159cf72a3,trial,0.31071
uuid-3d751576da8d4cd1aad2422159cf72a3,efficacy,0.581386
uuid-3d751576da8d4cd1aad2422159cf72a3,Ipi,0.498591
uuid-3d751576da8d4cd1aad2422159cf72a3,atezo,0.50811
uuid-3d751576da8d4cd1aad2422159cf72a3,nivo and pembro,0.336663
uuid-3d751576da8d4cd1aad2422159cf72a3,vs,0.806673
uuid-3d751576da8d4cd1aad2422159cf72a3,flat dosing,0.59593
uuid-1503afed5c11418bafbbff20b3593c3d,patients,0.523267
uuid-1503afed5c11418bafbbff20b3593c3d,Opdivo,0.336735
uuid-1503afed5c11418bafbbff20b3593c3d,regimen,0.319478
uuid-1503afed5c11418bafbbff20b3593c3d,treated,0.547656
uuid-1503afed5c11418bafbbff20b3593c3d,shared,0.356745
uuid-1503afed5c11418bafbbff20b3593c3d,physicians,0.462721
uuid-1503afed5c11418bafbbff20b3593c3d,treatment,0.415903
uuid-1503afed5c11418bafbbff20b3593c3d,clinical trials,0.335936
uuid-8f7be2426091489ba5424435f550a9c3,patients,0.78375
uuid-8f7be2426091489ba5424435f550a9c3,therapy,0.523249
uuid-8f7be2426091489ba5424435f550a9c3,nivolumab,0.519264
uuid-8f7be2426091489ba5424435f550a9c3,regimen,0.564401
uuid-8f7be2426091489ba5424435f550a9c3,treated,0.602767
uuid-8f7be2426091489ba5424435f550a9c3,RCC,0.322215
uuid-8f7be2426091489ba5424435f550a9c3,combination,0.394918
uuid-8f7be2426091489ba5424435f550a9c3,chemo,0.406178
uuid-8f7be2426091489ba5424435f550a9c3,pts,0.650125
uuid-8f7be2426091489ba5424435f550a9c3,IO,0.356923
uuid-8f7be2426091489ba5424435f550a9c3,monotherapy,0.510384
uuid-8f7be2426091489ba5424435f550a9c3,treatment,0.580588
uuid-8f7be2426091489ba5424435f550a9c3,using nivo,0.358773
uuid-8f7be2426091489ba5424435f550a9c3,response,0.475772
uuid-8f7be2426091489ba5424435f550a9c3,combo,0.410859
uuid-8f7be2426091489ba5424435f550a9c3,PD1,0.426913
uuid-8f7be2426091489ba5424435f550a9c3,progression,0.697287
uuid-8f7be2426091489ba5424435f550a9c3,chemotherapy,0.435158
uuid-8f7be2426091489ba5424435f550a9c3,respond,0.446678
uuid-8f7be2426091489ba5424435f550a9c3,RTL stated,0.342699
uuid-8f7be2426091489ba5424435f550a9c3,TL shared,0.333857
uuid-8f7be2426091489ba5424435f550a9c3,option,0.403153
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,patients,0.474828
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,Opdivo,0.303596
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,therapy,0.443121
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,nivolumab,0.569036
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,1L,0.401916
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,treated,0.364474
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,RCC,0.354891
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,combination,0.314957
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,2L,0.447261
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,approval,0.434214
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,preferred,0.629585
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,monotherapy,0.468735
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,treatment,0.38191
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,using nivo,0.540155
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,approved,0.507603
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,SCCHN,0.371903
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,chemotherapy,0.370889
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,tumor types,0.305705
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,label,0.31827
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,RTL stated,0.526776
uuid-7bbe0ea34e3b4d2c9964491bcbad869f,option,0.5993
uuid-61b9dfa313c446ae8691d0d40ebd4002,Nivo,0.550037
uuid-61b9dfa313c446ae8691d0d40ebd4002,pembro,0.706424
uuid-61b9dfa313c446ae8691d0d40ebd4002,dose,0.715616
uuid-61b9dfa313c446ae8691d0d40ebd4002,trial,0.331169
uuid-61b9dfa313c446ae8691d0d40ebd4002,efficacy,0.483709
uuid-61b9dfa313c446ae8691d0d40ebd4002,Ipi,0.555063
uuid-61b9dfa313c446ae8691d0d40ebd4002,atezo,0.585252
uuid-61b9dfa313c446ae8691d0d40ebd4002,preferred,0.340413
uuid-61b9dfa313c446ae8691d0d40ebd4002,nivo and pembro,0.308027
uuid-61b9dfa313c446ae8691d0d40ebd4002,vs,0.802545
uuid-61b9dfa313c446ae8691d0d40ebd4002,flat dosing,0.50177
uuid-fa13985fb3bb41c8a640afeec582e31c,Nivo,0.334238
uuid-fa13985fb3bb41c8a640afeec582e31c,therapy,0.328573
uuid-fa13985fb3bb41c8a640afeec582e31c,toxicity,0.46024
uuid-fa13985fb3bb41c8a640afeec582e31c,efficacy,0.39624
uuid-fa13985fb3bb41c8a640afeec582e31c,regimen,0.590598
uuid-fa13985fb3bb41c8a640afeec582e31c,combination,0.49045
uuid-fa13985fb3bb41c8a640afeec582e31c,chemo,0.537365
uuid-fa13985fb3bb41c8a640afeec582e31c,pts,0.324656
uuid-fa13985fb3bb41c8a640afeec582e31c,IO,0.362706
uuid-fa13985fb3bb41c8a640afeec582e31c,Ipi,0.393743
uuid-fa13985fb3bb41c8a640afeec582e31c,OS,0.308531
uuid-fa13985fb3bb41c8a640afeec582e31c,monotherapy,0.547699
uuid-fa13985fb3bb41c8a640afeec582e31c,treatment,0.307047
uuid-fa13985fb3bb41c8a640afeec582e31c,response,0.425595
uuid-fa13985fb3bb41c8a640afeec582e31c,combo,0.50013
uuid-fa13985fb3bb41c8a640afeec582e31c,PD1,0.452098
uuid-fa13985fb3bb41c8a640afeec582e31c,ORR,0.302114
uuid-fa13985fb3bb41c8a640afeec582e31c,progression,0.419155
uuid-fa13985fb3bb41c8a640afeec582e31c,believes,0.446766
uuid-fa13985fb3bb41c8a640afeec582e31c,chemotherapy,0.477003
uuid-fa13985fb3bb41c8a640afeec582e31c,impressed,0.341911
uuid-fa13985fb3bb41c8a640afeec582e31c,respond,0.340792
uuid-fa13985fb3bb41c8a640afeec582e31c,feels,0.410994
uuid-fa13985fb3bb41c8a640afeec582e31c,option,0.335509
uuid-f61e7a9a12d6432fba639e681db359da,TL,0.368392
uuid-f61e7a9a12d6432fba639e681db359da,pembro,0.400661
uuid-f61e7a9a12d6432fba639e681db359da,1L,0.372298
uuid-f61e7a9a12d6432fba639e681db359da,PDL1,0.555583
uuid-f61e7a9a12d6432fba639e681db359da,TL stated,0.325476
uuid-f61e7a9a12d6432fba639e681db359da,Merck,0.338898
uuid-f61e7a9a12d6432fba639e681db359da,PD-L1,0.763104
uuid-f61e7a9a12d6432fba639e681db359da,atezo,0.406518
uuid-f61e7a9a12d6432fba639e681db359da,PD-L1 testing,0.711776
uuid-f61e7a9a12d6432fba639e681db359da,testing,0.85143
uuid-f61e7a9a12d6432fba639e681db359da,PDL1 testing,0.661434
uuid-f61e7a9a12d6432fba639e681db359da,NSCLC patients,0.674135
uuid-f61e7a9a12d6432fba639e681db359da,assay,0.641553
uuid-f61e7a9a12d6432fba639e681db359da,PDL1 expression,0.390387
uuid-f61e7a9a12d6432fba639e681db359da,biomarker,0.439911
uuid-450afc6a43d647b8bc04ca74d7a671de,RTL,0.475153
uuid-450afc6a43d647b8bc04ca74d7a671de,nivolumab,0.378857
uuid-450afc6a43d647b8bc04ca74d7a671de,trial,0.406789
uuid-450afc6a43d647b8bc04ca74d7a671de,NTL,0.44203
uuid-450afc6a43d647b8bc04ca74d7a671de,commented,0.306977
uuid-450afc6a43d647b8bc04ca74d7a671de,stated,0.347923
uuid-450afc6a43d647b8bc04ca74d7a671de,approval,0.337635
uuid-450afc6a43d647b8bc04ca74d7a671de,preferred,0.364322
uuid-450afc6a43d647b8bc04ca74d7a671de,using nivo,0.432862
uuid-450afc6a43d647b8bc04ca74d7a671de,mentioned,0.494918
uuid-450afc6a43d647b8bc04ca74d7a671de,clinical trials,0.421308
uuid-450afc6a43d647b8bc04ca74d7a671de,indication,0.384155
uuid-450afc6a43d647b8bc04ca74d7a671de,SCCHN,0.498894
uuid-450afc6a43d647b8bc04ca74d7a671de,HCP,0.309118
uuid-450afc6a43d647b8bc04ca74d7a671de,LTL,0.410462
uuid-450afc6a43d647b8bc04ca74d7a671de,SCLC,0.305562
uuid-450afc6a43d647b8bc04ca74d7a671de,Regional TL,0.478409
uuid-450afc6a43d647b8bc04ca74d7a671de,RTL stated,0.434379
uuid-450afc6a43d647b8bc04ca74d7a671de,bladder,0.406469
uuid-3d37b07b4586485e97b045231b64006b,patients,0.398298
uuid-3d37b07b4586485e97b045231b64006b,Opdivo,0.541852
uuid-3d37b07b4586485e97b045231b64006b,lung cancer,0.490813
uuid-3d37b07b4586485e97b045231b64006b,flat dosing,0.377481
uuid-048bc071cf3e4db1b8c0c8bcce290e79,response,0.323538
uuid-048bc071cf3e4db1b8c0c8bcce290e79,progression,0.353368
uuid-844cef8152d145edb49416df68c92692,pembro,0.434334
uuid-844cef8152d145edb49416df68c92692,1L,0.541247
uuid-844cef8152d145edb49416df68c92692,RCC,0.398322
uuid-844cef8152d145edb49416df68c92692,2L,0.65265
uuid-844cef8152d145edb49416df68c92692,agents,0.36894
uuid-844cef8152d145edb49416df68c92692,approval,0.321054
uuid-844cef8152d145edb49416df68c92692,atezo,0.504534
uuid-844cef8152d145edb49416df68c92692,preferred,0.732811
uuid-844cef8152d145edb49416df68c92692,monotherapy,0.365554
uuid-844cef8152d145edb49416df68c92692,using nivo,0.538532
uuid-844cef8152d145edb49416df68c92692,PDL1 testing,0.396738
uuid-844cef8152d145edb49416df68c92692,indication,0.418252
uuid-844cef8152d145edb49416df68c92692,approved,0.403267
uuid-844cef8152d145edb49416df68c92692,SCCHN,0.462076
uuid-844cef8152d145edb49416df68c92692,RTL stated,0.570387
uuid-844cef8152d145edb49416df68c92692,option,0.493402
uuid-2b2c4962e17d44bc86c68569a4e9a576,patients,0.437816
uuid-2b2c4962e17d44bc86c68569a4e9a576,Opdivo,0.486866
uuid-2b2c4962e17d44bc86c68569a4e9a576,dose,0.703835
uuid-2b2c4962e17d44bc86c68569a4e9a576,toxicity,0.369504
uuid-2b2c4962e17d44bc86c68569a4e9a576,regimen,0.348067
uuid-2b2c4962e17d44bc86c68569a4e9a576,treated,0.381722
uuid-2b2c4962e17d44bc86c68569a4e9a576,Ipi,0.338943
uuid-2b2c4962e17d44bc86c68569a4e9a576,vs,0.408265
uuid-2b2c4962e17d44bc86c68569a4e9a576,flat dosing,0.61531
uuid-be65a8fe35a74969bb089a2b41663995,pembro,0.424253
uuid-be65a8fe35a74969bb089a2b41663995,BMS,0.317799
uuid-be65a8fe35a74969bb089a2b41663995,PDL1,0.707081
uuid-be65a8fe35a74969bb089a2b41663995,efficacy,0.411565
uuid-be65a8fe35a74969bb089a2b41663995,Merck,0.436622
uuid-be65a8fe35a74969bb089a2b41663995,PD-L1,0.478696
uuid-be65a8fe35a74969bb089a2b41663995,OS,0.376849
uuid-be65a8fe35a74969bb089a2b41663995,atezo,0.452287
uuid-be65a8fe35a74969bb089a2b41663995,testing,0.315723
uuid-be65a8fe35a74969bb089a2b41663995,data,0.569917
uuid-be65a8fe35a74969bb089a2b41663995,PFS,0.381722
uuid-be65a8fe35a74969bb089a2b41663995,ORR,0.365186
uuid-be65a8fe35a74969bb089a2b41663995,nivo and pembro,0.677027
uuid-be65a8fe35a74969bb089a2b41663995,believes,0.399607
uuid-be65a8fe35a74969bb089a2b41663995,assay,0.586024
uuid-be65a8fe35a74969bb089a2b41663995,PDL1 expression,0.545096
uuid-be65a8fe35a74969bb089a2b41663995,biomarker,0.401817
uuid-4a1d6fd4af9d413c9ad43ad1d9bf3076,TL,0.432166
uuid-4a1d6fd4af9d413c9ad43ad1d9bf3076,PDL1,0.55566
uuid-4a1d6fd4af9d413c9ad43ad1d9bf3076,Merck,0.526452
uuid-4a1d6fd4af9d413c9ad43ad1d9bf3076,PD-L1,0.610341
uuid-4a1d6fd4af9d413c9ad43ad1d9bf3076,PD-L1 testing,0.47106
uuid-4a1d6fd4af9d413c9ad43ad1d9bf3076,testing,0.540282
uuid-4a1d6fd4af9d413c9ad43ad1d9bf3076,data,0.40314
uuid-4a1d6fd4af9d413c9ad43ad1d9bf3076,PDL1 testing,0.312115
uuid-4a1d6fd4af9d413c9ad43ad1d9bf3076,nivo and pembro,0.349247
uuid-4a1d6fd4af9d413c9ad43ad1d9bf3076,assay,0.781608
uuid-4a1d6fd4af9d413c9ad43ad1d9bf3076,PDL1 expression,0.419048
uuid-4a1d6fd4af9d413c9ad43ad1d9bf3076,biomarker,0.44648
uuid-047f10433dba416dbe3371c6652cedd1,patients,0.772561
uuid-047f10433dba416dbe3371c6652cedd1,Opdivo,0.375276
uuid-047f10433dba416dbe3371c6652cedd1,therapy,0.37338
uuid-047f10433dba416dbe3371c6652cedd1,nivolumab,0.396716
uuid-047f10433dba416dbe3371c6652cedd1,1L,0.343353
uuid-047f10433dba416dbe3371c6652cedd1,regimen,0.483037
uuid-047f10433dba416dbe3371c6652cedd1,treated,0.424938
uuid-047f10433dba416dbe3371c6652cedd1,chemo,0.310565
uuid-047f10433dba416dbe3371c6652cedd1,2L,0.381348
uuid-047f10433dba416dbe3371c6652cedd1,pts,0.511746
uuid-047f10433dba416dbe3371c6652cedd1,approval,0.312804
uuid-047f10433dba416dbe3371c6652cedd1,preferred,0.369209
uuid-047f10433dba416dbe3371c6652cedd1,monotherapy,0.422686
uuid-047f10433dba416dbe3371c6652cedd1,treatment,0.519483
uuid-047f10433dba416dbe3371c6652cedd1,using nivo,0.439904
uuid-047f10433dba416dbe3371c6652cedd1,approved,0.358391
uuid-047f10433dba416dbe3371c6652cedd1,progression,0.510337
uuid-047f10433dba416dbe3371c6652cedd1,respond,0.342468
uuid-047f10433dba416dbe3371c6652cedd1,RTL stated,0.303775
uuid-047f10433dba416dbe3371c6652cedd1,option,0.479452
uuid-42d7cef1ad3a49a59beb581f4af18bd4,TL,0.316106
uuid-42d7cef1ad3a49a59beb581f4af18bd4,RTL,0.328664
uuid-42d7cef1ad3a49a59beb581f4af18bd4,treated,0.442021
uuid-42d7cef1ad3a49a59beb581f4af18bd4,physicians,0.443914
uuid-42d7cef1ad3a49a59beb581f4af18bd4,oncologist,0.329495
uuid-42d7cef1ad3a49a59beb581f4af18bd4,academic,0.43211
uuid-42d7cef1ad3a49a59beb581f4af18bd4,Regional TL,0.374163
uuid-42d7cef1ad3a49a59beb581f4af18bd4,flat dosing,0.312557
uuid-1116fd5733294b41a9476aa6cec6715b,therapy,0.377207
uuid-1116fd5733294b41a9476aa6cec6715b,nivolumab,0.314689
uuid-1116fd5733294b41a9476aa6cec6715b,mentioned,0.532355
uuid-1116fd5733294b41a9476aa6cec6715b,cHL,0.636287
uuid-7c73952af15e44d6acf1bcf3b54c933c,Nivo,0.324895
uuid-7c73952af15e44d6acf1bcf3b54c933c,patients,0.855525
uuid-7c73952af15e44d6acf1bcf3b54c933c,Opdivo,0.338561
uuid-7c73952af15e44d6acf1bcf3b54c933c,therapy,0.651702
uuid-7c73952af15e44d6acf1bcf3b54c933c,nivolumab,0.410871
uuid-7c73952af15e44d6acf1bcf3b54c933c,toxicity,0.501974
uuid-7c73952af15e44d6acf1bcf3b54c933c,regimen,0.608109
uuid-7c73952af15e44d6acf1bcf3b54c933c,treated,0.496616
uuid-7c73952af15e44d6acf1bcf3b54c933c,combination,0.338554
uuid-7c73952af15e44d6acf1bcf3b54c933c,chemo,0.561807
uuid-7c73952af15e44d6acf1bcf3b54c933c,pts,0.540772
uuid-7c73952af15e44d6acf1bcf3b54c933c,monotherapy,0.505078
uuid-7c73952af15e44d6acf1bcf3b54c933c,treatment,0.70946
uuid-7c73952af15e44d6acf1bcf3b54c933c,response,0.428378
uuid-7c73952af15e44d6acf1bcf3b54c933c,PD1,0.407374
uuid-7c73952af15e44d6acf1bcf3b54c933c,progression,0.675946
uuid-7c73952af15e44d6acf1bcf3b54c933c,chemotherapy,0.596454
uuid-7c73952af15e44d6acf1bcf3b54c933c,respond,0.476554
uuid-7c73952af15e44d6acf1bcf3b54c933c,option,0.468064
uuid-2edec2fc160f472fa4ad84c7fbabb543,Opdivo,0.511015
uuid-2edec2fc160f472fa4ad84c7fbabb543,physicians,0.639626
uuid-2edec2fc160f472fa4ad84c7fbabb543,oncology,0.461585
uuid-2edec2fc160f472fa4ad84c7fbabb543,drug,0.488524
uuid-2edec2fc160f472fa4ad84c7fbabb543,clinical,0.352177
uuid-2edec2fc160f472fa4ad84c7fbabb543,flat dosing,0.347252
uuid-6d7baa1b74304a978d3dec5bc5cf3ad4,TL,0.762468
uuid-6d7baa1b74304a978d3dec5bc5cf3ad4,TL stated,0.401182
uuid-6d7baa1b74304a978d3dec5bc5cf3ad4,institution,0.384335
uuid-6d7baa1b74304a978d3dec5bc5cf3ad4,PD-L1,0.565943
uuid-6d7baa1b74304a978d3dec5bc5cf3ad4,PD-L1 testing,0.889642
uuid-6d7baa1b74304a978d3dec5bc5cf3ad4,testing,0.708356
uuid-6d7baa1b74304a978d3dec5bc5cf3ad4,PDL1 testing,0.556448
uuid-6d7baa1b74304a978d3dec5bc5cf3ad4,NSCLC patients,0.453233
uuid-6d7baa1b74304a978d3dec5bc5cf3ad4,assay,0.602542
uuid-48e6f849e16241c7911f2bbc3d67999c,TL,0.673455
uuid-48e6f849e16241c7911f2bbc3d67999c,TL stated,0.3924
uuid-48e6f849e16241c7911f2bbc3d67999c,institution,0.363925
uuid-48e6f849e16241c7911f2bbc3d67999c,PD-L1,0.735108
uuid-48e6f849e16241c7911f2bbc3d67999c,PD-L1 testing,0.929512
uuid-48e6f849e16241c7911f2bbc3d67999c,testing,0.853244
uuid-48e6f849e16241c7911f2bbc3d67999c,PDL1 testing,0.665879
uuid-48e6f849e16241c7911f2bbc3d67999c,NSCLC patients,0.562739
uuid-48e6f849e16241c7911f2bbc3d67999c,assay,0.688792
uuid-48e6f849e16241c7911f2bbc3d67999c,biomarker,0.331069
uuid-be4849a509194f16bd5bd07acf4d3646,TL,0.554587
uuid-be4849a509194f16bd5bd07acf4d3646,PDL1,0.374237
uuid-be4849a509194f16bd5bd07acf4d3646,TL stated,0.475931
uuid-be4849a509194f16bd5bd07acf4d3646,PD-L1,0.798339
uuid-be4849a509194f16bd5bd07acf4d3646,PD-L1 testing,0.783018
uuid-be4849a509194f16bd5bd07acf4d3646,testing,0.91754
uuid-be4849a509194f16bd5bd07acf4d3646,PDL1 testing,0.76763
uuid-be4849a509194f16bd5bd07acf4d3646,NSCLC patients,0.763728
uuid-be4849a509194f16bd5bd07acf4d3646,assay,0.676582
uuid-be4849a509194f16bd5bd07acf4d3646,PD-1,0.340375
uuid-be4849a509194f16bd5bd07acf4d3646,biomarker,0.442029
uuid-a710db6a60c84653badab05ed4267905,Nivo,0.447877
uuid-a710db6a60c84653badab05ed4267905,patients,0.450049
uuid-a710db6a60c84653badab05ed4267905,therapy,0.317471
uuid-a710db6a60c84653badab05ed4267905,nivolumab,0.378842
uuid-a710db6a60c84653badab05ed4267905,trial,0.396873
uuid-a710db6a60c84653badab05ed4267905,approval,0.512311
uuid-a710db6a60c84653badab05ed4267905,clinical trials,0.342114
uuid-a710db6a60c84653badab05ed4267905,indication,0.433996
uuid-a710db6a60c84653badab05ed4267905,approved,0.485417
uuid-a710db6a60c84653badab05ed4267905,chemotherapy,0.385651
uuid-a710db6a60c84653badab05ed4267905,label,0.41601
uuid-a710db6a60c84653badab05ed4267905,SCLC,0.378361
uuid-a710db6a60c84653badab05ed4267905,option,0.354814
uuid-b06000deb06d4bcc86fedeb047f4461c,TL,0.634986
uuid-b06000deb06d4bcc86fedeb047f4461c,PDL1,0.313247
uuid-b06000deb06d4bcc86fedeb047f4461c,TL stated,0.313328
uuid-b06000deb06d4bcc86fedeb047f4461c,Merck,0.31596
uuid-b06000deb06d4bcc86fedeb047f4461c,institution,0.470103
uuid-b06000deb06d4bcc86fedeb047f4461c,PD-L1,0.750718
uuid-b06000deb06d4bcc86fedeb047f4461c,PD-L1 testing,0.885502
uuid-b06000deb06d4bcc86fedeb047f4461c,testing,0.827689
uuid-b06000deb06d4bcc86fedeb047f4461c,PDL1 testing,0.566848
uuid-b06000deb06d4bcc86fedeb047f4461c,NSCLC patients,0.513186
uuid-b06000deb06d4bcc86fedeb047f4461c,assay,0.859976
uuid-f9c3863af1e547b799b10a7c0ff6a27d,TL,0.673176
uuid-f9c3863af1e547b799b10a7c0ff6a27d,TL stated,0.40441
uuid-f9c3863af1e547b799b10a7c0ff6a27d,institution,0.42118
uuid-f9c3863af1e547b799b10a7c0ff6a27d,PD-L1,0.67932
uuid-f9c3863af1e547b799b10a7c0ff6a27d,PD-L1 testing,0.907829
uuid-f9c3863af1e547b799b10a7c0ff6a27d,testing,0.764474
uuid-f9c3863af1e547b799b10a7c0ff6a27d,PDL1 testing,0.586692
uuid-f9c3863af1e547b799b10a7c0ff6a27d,NSCLC patients,0.453481
uuid-f9c3863af1e547b799b10a7c0ff6a27d,assay,0.689774
uuid-f9c3863af1e547b799b10a7c0ff6a27d,biomarker,0.318937
uuid-3826f67a22464607b2d78e1bcfdf2f44,agents,0.324108
uuid-3826f67a22464607b2d78e1bcfdf2f44,physicians,0.514084
uuid-3826f67a22464607b2d78e1bcfdf2f44,preferred,0.346246
uuid-3826f67a22464607b2d78e1bcfdf2f44,TLs,0.314537
uuid-82a420a5234949d6bdf365570983d497,BMS,0.674723
uuid-82a420a5234949d6bdf365570983d497,shared,0.339735
uuid-82a420a5234949d6bdf365570983d497,Merck,0.50613
uuid-82a420a5234949d6bdf365570983d497,physicians,0.411773
uuid-82a420a5234949d6bdf365570983d497,indication,0.319077
uuid-82a420a5234949d6bdf365570983d497,drug,0.431107
uuid-562c845ce2804b709b1520f993aab5df,therapy,0.47771
uuid-562c845ce2804b709b1520f993aab5df,PDL1,0.379623
uuid-562c845ce2804b709b1520f993aab5df,PD-L1,0.593136
uuid-562c845ce2804b709b1520f993aab5df,PD-L1 testing,0.395898
uuid-562c845ce2804b709b1520f993aab5df,testing,0.533616
uuid-562c845ce2804b709b1520f993aab5df,treatment,0.338669
uuid-562c845ce2804b709b1520f993aab5df,PDL1 testing,0.319872
uuid-562c845ce2804b709b1520f993aab5df,NSCLC patients,0.434916
uuid-562c845ce2804b709b1520f993aab5df,progression,0.305743
uuid-562c845ce2804b709b1520f993aab5df,assay,0.402133
uuid-562c845ce2804b709b1520f993aab5df,PD-1,0.439582
uuid-562c845ce2804b709b1520f993aab5df,PDL1 expression,0.312756
uuid-562c845ce2804b709b1520f993aab5df,option,0.354177
uuid-562c845ce2804b709b1520f993aab5df,biomarker,0.545882
uuid-b0b86453241f4638a67aabcafa81ccca,Nivo,0.348753
uuid-b0b86453241f4638a67aabcafa81ccca,patients,0.712936
uuid-b0b86453241f4638a67aabcafa81ccca,Opdivo,0.431309
uuid-b0b86453241f4638a67aabcafa81ccca,therapy,0.489002
uuid-b0b86453241f4638a67aabcafa81ccca,nivolumab,0.642752
uuid-b0b86453241f4638a67aabcafa81ccca,regimen,0.355969
uuid-b0b86453241f4638a67aabcafa81ccca,treated,0.673202
uuid-b0b86453241f4638a67aabcafa81ccca,RCC,0.349066
uuid-b0b86453241f4638a67aabcafa81ccca,pts,0.493463
uuid-b0b86453241f4638a67aabcafa81ccca,approval,0.417031
uuid-b0b86453241f4638a67aabcafa81ccca,treatment,0.538052
uuid-b0b86453241f4638a67aabcafa81ccca,using nivo,0.465617
uuid-b0b86453241f4638a67aabcafa81ccca,SCCHN,0.337683
uuid-b0b86453241f4638a67aabcafa81ccca,cHL,0.498148
uuid-b0b86453241f4638a67aabcafa81ccca,progression,0.465734
uuid-b0b86453241f4638a67aabcafa81ccca,respond,0.306237
uuid-b0b86453241f4638a67aabcafa81ccca,RTL stated,0.433947
uuid-b0b86453241f4638a67aabcafa81ccca,TL shared,0.35938
uuid-e6808312a78d41bd99f4eb6fc7443b38,RTL,0.34414
uuid-e6808312a78d41bd99f4eb6fc7443b38,commented,0.364415
uuid-e6808312a78d41bd99f4eb6fc7443b38,stated,0.328802
uuid-e6808312a78d41bd99f4eb6fc7443b38,preferred,0.401376
uuid-e6808312a78d41bd99f4eb6fc7443b38,using nivo,0.414603
uuid-e6808312a78d41bd99f4eb6fc7443b38,mentioned,0.530406
uuid-e6808312a78d41bd99f4eb6fc7443b38,indication,0.42333
uuid-e6808312a78d41bd99f4eb6fc7443b38,SCCHN,0.483549
uuid-e6808312a78d41bd99f4eb6fc7443b38,HCP,0.330084
uuid-e6808312a78d41bd99f4eb6fc7443b38,oncologist,0.339823
uuid-e6808312a78d41bd99f4eb6fc7443b38,LTL,0.449576
uuid-e6808312a78d41bd99f4eb6fc7443b38,Regional TL,0.50016
uuid-e6808312a78d41bd99f4eb6fc7443b38,RTL stated,0.353156
uuid-e6808312a78d41bd99f4eb6fc7443b38,option,0.338238
uuid-feeef423cf624fa4ab6126b96d9d518e,TL,0.340084
uuid-feeef423cf624fa4ab6126b96d9d518e,BMS,0.324393
uuid-feeef423cf624fa4ab6126b96d9d518e,shared,0.310519
uuid-feeef423cf624fa4ab6126b96d9d518e,commented,0.393133
uuid-feeef423cf624fa4ab6126b96d9d518e,Merck,0.473941
uuid-feeef423cf624fa4ab6126b96d9d518e,stated,0.360916
uuid-feeef423cf624fa4ab6126b96d9d518e,mentioned,0.436182
uuid-feeef423cf624fa4ab6126b96d9d518e,LTL,0.350711
uuid-8262cd9f4d02446e9a11a5776cc45241,patients,0.605422
uuid-8262cd9f4d02446e9a11a5776cc45241,Opdivo,0.468642
uuid-8262cd9f4d02446e9a11a5776cc45241,pts,0.314443
uuid-8262cd9f4d02446e9a11a5776cc45241,approval,0.353866
uuid-8262cd9f4d02446e9a11a5776cc45241,mentioned,0.331539
uuid-66202f18e7124b9ab80c8c7496be24d3,patients,0.642532
uuid-66202f18e7124b9ab80c8c7496be24d3,therapy,0.476455
uuid-66202f18e7124b9ab80c8c7496be24d3,nivolumab,0.319036
uuid-66202f18e7124b9ab80c8c7496be24d3,1L,0.324654
uuid-66202f18e7124b9ab80c8c7496be24d3,regimen,0.455552
uuid-66202f18e7124b9ab80c8c7496be24d3,treated,0.38397
uuid-66202f18e7124b9ab80c8c7496be24d3,chemo,0.402586
uuid-66202f18e7124b9ab80c8c7496be24d3,2L,0.303158
uuid-66202f18e7124b9ab80c8c7496be24d3,pts,0.486785
uuid-66202f18e7124b9ab80c8c7496be24d3,IO,0.339397
uuid-66202f18e7124b9ab80c8c7496be24d3,preferred,0.353902
uuid-66202f18e7124b9ab80c8c7496be24d3,monotherapy,0.4952
uuid-66202f18e7124b9ab80c8c7496be24d3,treatment,0.47948
uuid-66202f18e7124b9ab80c8c7496be24d3,NSCLC patients,0.347944
uuid-66202f18e7124b9ab80c8c7496be24d3,PD1,0.334308
uuid-66202f18e7124b9ab80c8c7496be24d3,progression,0.500892
uuid-66202f18e7124b9ab80c8c7496be24d3,chemotherapy,0.351194
uuid-66202f18e7124b9ab80c8c7496be24d3,respond,0.340102
uuid-66202f18e7124b9ab80c8c7496be24d3,option,0.511659
uuid-5645937d2d0a4516b8bd2dabde34e911,lung,0.516713
uuid-5645937d2d0a4516b8bd2dabde34e911,1L,0.335609
uuid-5645937d2d0a4516b8bd2dabde34e911,regimen,0.40285
uuid-5645937d2d0a4516b8bd2dabde34e911,melanoma,0.498067
uuid-5645937d2d0a4516b8bd2dabde34e911,RCC,0.570843
uuid-5645937d2d0a4516b8bd2dabde34e911,TL stated,0.491593
uuid-5645937d2d0a4516b8bd2dabde34e911,2L,0.402957
uuid-5645937d2d0a4516b8bd2dabde34e911,monotherapy,0.34988
uuid-5645937d2d0a4516b8bd2dabde34e911,combo,0.373064
uuid-5645937d2d0a4516b8bd2dabde34e911,AI,0.349139
uuid-5645937d2d0a4516b8bd2dabde34e911,RTL stated,0.35378
uuid-5645937d2d0a4516b8bd2dabde34e911,TL shared,0.457882
uuid-d361de8c869a40b0bb8a083989a182a8,patients,0.762343
uuid-d361de8c869a40b0bb8a083989a182a8,Opdivo,0.355
uuid-d361de8c869a40b0bb8a083989a182a8,therapy,0.571725
uuid-d361de8c869a40b0bb8a083989a182a8,nivolumab,0.513669
uuid-d361de8c869a40b0bb8a083989a182a8,regimen,0.4734
uuid-d361de8c869a40b0bb8a083989a182a8,treated,0.580992
uuid-d361de8c869a40b0bb8a083989a182a8,pts,0.438986
uuid-d361de8c869a40b0bb8a083989a182a8,treatment,0.663953
uuid-d361de8c869a40b0bb8a083989a182a8,response,0.428307
uuid-d361de8c869a40b0bb8a083989a182a8,progression,0.61273
uuid-d361de8c869a40b0bb8a083989a182a8,chemotherapy,0.371354
uuid-d361de8c869a40b0bb8a083989a182a8,respond,0.453044
uuid-c44427bf88154a2fad9a11c4ae059a4b,patients,0.46517
uuid-c44427bf88154a2fad9a11c4ae059a4b,pts,0.33458
uuid-c44427bf88154a2fad9a11c4ae059a4b,stated,0.355834
uuid-c44427bf88154a2fad9a11c4ae059a4b,treatment,0.316955
uuid-c44427bf88154a2fad9a11c4ae059a4b,clinical trials,0.391071
uuid-c44427bf88154a2fad9a11c4ae059a4b,approved,0.321099
uuid-c44427bf88154a2fad9a11c4ae059a4b,progression,0.307098
uuid-c44427bf88154a2fad9a11c4ae059a4b,option,0.333216
uuid-6eec07dfd32846509962066defa2868e,patients,0.522531
uuid-6eec07dfd32846509962066defa2868e,therapy,0.325915
uuid-6eec07dfd32846509962066defa2868e,dose,0.302065
uuid-6eec07dfd32846509962066defa2868e,nivolumab,0.319591
uuid-6eec07dfd32846509962066defa2868e,regimen,0.393332
uuid-6eec07dfd32846509962066defa2868e,treated,0.36336
uuid-6eec07dfd32846509962066defa2868e,combination,0.438562
uuid-6eec07dfd32846509962066defa2868e,chemo,0.346512
uuid-6eec07dfd32846509962066defa2868e,pts,0.327303
uuid-6eec07dfd32846509962066defa2868e,Ipi,0.332267
uuid-6eec07dfd32846509962066defa2868e,monotherapy,0.318379
uuid-6eec07dfd32846509962066defa2868e,treatment,0.398651
uuid-6eec07dfd32846509962066defa2868e,combo,0.33335
uuid-6eec07dfd32846509962066defa2868e,progression,0.362361
uuid-6eec07dfd32846509962066defa2868e,chemotherapy,0.400814
uuid-e5f6aec1a6364e61b13d045f5762b0a1,Nivo,0.302196
uuid-e5f6aec1a6364e61b13d045f5762b0a1,patients,0.637316
uuid-e5f6aec1a6364e61b13d045f5762b0a1,therapy,0.487906
uuid-e5f6aec1a6364e61b13d045f5762b0a1,regimen,0.372824
uuid-e5f6aec1a6364e61b13d045f5762b0a1,combination,0.33434
uuid-e5f6aec1a6364e61b13d045f5762b0a1,chemo,0.494346
uuid-e5f6aec1a6364e61b13d045f5762b0a1,2L,0.301812
uuid-e5f6aec1a6364e61b13d045f5762b0a1,pts,0.370319
uuid-e5f6aec1a6364e61b13d045f5762b0a1,agents,0.30066
uuid-e5f6aec1a6364e61b13d045f5762b0a1,preferred,0.455658
uuid-e5f6aec1a6364e61b13d045f5762b0a1,monotherapy,0.487652
uuid-e5f6aec1a6364e61b13d045f5762b0a1,treatment,0.538732
uuid-e5f6aec1a6364e61b13d045f5762b0a1,progression,0.405424
uuid-e5f6aec1a6364e61b13d045f5762b0a1,chemotherapy,0.542547
uuid-e5f6aec1a6364e61b13d045f5762b0a1,respond,0.314194
uuid-e5f6aec1a6364e61b13d045f5762b0a1,feels,0.367334
uuid-e5f6aec1a6364e61b13d045f5762b0a1,option,0.632057
uuid-e9302c646ac14a40a4a480aacb49636a,tumor,0.49348
uuid-c4b025a87cd04b438e436115bbe7cd53,patients,0.539672
uuid-c4b025a87cd04b438e436115bbe7cd53,therapy,0.338312
uuid-c4b025a87cd04b438e436115bbe7cd53,nivolumab,0.362031
uuid-c4b025a87cd04b438e436115bbe7cd53,toxicity,0.606843
uuid-c4b025a87cd04b438e436115bbe7cd53,regimen,0.746348
uuid-c4b025a87cd04b438e436115bbe7cd53,treated,0.598592
uuid-c4b025a87cd04b438e436115bbe7cd53,combination,0.410171
uuid-c4b025a87cd04b438e436115bbe7cd53,chemo,0.338956
uuid-c4b025a87cd04b438e436115bbe7cd53,pts,0.41323
uuid-c4b025a87cd04b438e436115bbe7cd53,IO,0.310064
uuid-c4b025a87cd04b438e436115bbe7cd53,monotherapy,0.462202
uuid-c4b025a87cd04b438e436115bbe7cd53,treatment,0.586181
uuid-c4b025a87cd04b438e436115bbe7cd53,response,0.335765
uuid-c4b025a87cd04b438e436115bbe7cd53,combo,0.358431
uuid-c4b025a87cd04b438e436115bbe7cd53,PD1,0.341516
uuid-c4b025a87cd04b438e436115bbe7cd53,progression,0.472727
uuid-c4b025a87cd04b438e436115bbe7cd53,chemotherapy,0.353264
uuid-c4b025a87cd04b438e436115bbe7cd53,respond,0.460789
uuid-c4b025a87cd04b438e436115bbe7cd53,feels,0.332693
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,Nivo,0.320612
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,Opdivo,0.374501
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,pembro,0.40225
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,dose,0.459728
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,regimen,0.311399
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,2L,0.342091
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,Ipi,0.304058
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,approval,0.416848
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,atezo,0.410642
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,preferred,0.460972
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,using nivo,0.319453
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,indication,0.560926
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,approved,0.467306
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,label,0.364316
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,Keytruda,0.310147
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,option,0.342821
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,bladder,0.325953
uuid-00dfdfc4876645dab98b1a05bfe4ac7e,flat dosing,0.414193
uuid-5775b8b146b34611b3c4771ea4136b3f,patients,0.401582
uuid-5775b8b146b34611b3c4771ea4136b3f,Opdivo,0.344442
uuid-5775b8b146b34611b3c4771ea4136b3f,treated,0.331226
uuid-5775b8b146b34611b3c4771ea4136b3f,treatment,0.300966
uuid-bd658857eb824af4b753a38163ec7606,patients,0.532651
uuid-bd658857eb824af4b753a38163ec7606,Opdivo,0.365517
uuid-bd658857eb824af4b753a38163ec7606,treated,0.461518
uuid-bd658857eb824af4b753a38163ec7606,physicians,0.434164
uuid-bd658857eb824af4b753a38163ec7606,treatment,0.475422
uuid-e4e3b61af4514219b9dac473745311f0,physicians,0.303495
uuid-f29001bd61c74fc388711a9715678265,dose,0.472868
uuid-f29001bd61c74fc388711a9715678265,AI,0.499628
uuid-f29001bd61c74fc388711a9715678265,drug,0.443397
uuid-f29001bd61c74fc388711a9715678265,Keytruda,0.584303
uuid-f29001bd61c74fc388711a9715678265,flat dosing,0.606402
uuid-74b83eac2c984f8683d2632da4193949,pembro,0.336418
uuid-74b83eac2c984f8683d2632da4193949,lung,0.51177
uuid-74b83eac2c984f8683d2632da4193949,efficacy,0.337389
uuid-74b83eac2c984f8683d2632da4193949,melanoma,0.313167
uuid-74b83eac2c984f8683d2632da4193949,atezo,0.398318
uuid-74b83eac2c984f8683d2632da4193949,regards,0.421127
uuid-74b83eac2c984f8683d2632da4193949,AI,0.834767
uuid-74b83eac2c984f8683d2632da4193949,nivo and pembro,0.568439
uuid-74b83eac2c984f8683d2632da4193949,NCCN,0.41402
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,RTL,0.429281
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,BMS,0.500912
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,trial,0.576816
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,efficacy,0.320493
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,commented,0.658563
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,Merck,0.351281
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,stated,0.407351
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,OS,0.63672
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,regards,0.329088
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,data,0.843227
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,expressed,0.386102
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,clinical trials,0.324828
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,PFS,0.571984
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,ORR,0.625847
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,ASCO,0.604467
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,impressed,0.799014
uuid-05968b56aa7c4e34b3d48e1451d0dbaa,Regional TL,0.404371
uuid-33b9e3761691410a8dbd6e3d414d5056,Nivo,0.713931
uuid-33b9e3761691410a8dbd6e3d414d5056,pembro,0.506441
uuid-33b9e3761691410a8dbd6e3d414d5056,therapy,0.476207
uuid-33b9e3761691410a8dbd6e3d414d5056,nivolumab,0.340993
uuid-33b9e3761691410a8dbd6e3d414d5056,1L,0.410954
uuid-33b9e3761691410a8dbd6e3d414d5056,efficacy,0.315076
uuid-33b9e3761691410a8dbd6e3d414d5056,combination,0.63635
uuid-33b9e3761691410a8dbd6e3d414d5056,chemo,0.541048
uuid-33b9e3761691410a8dbd6e3d414d5056,2L,0.453744
uuid-33b9e3761691410a8dbd6e3d414d5056,agents,0.599868
uuid-33b9e3761691410a8dbd6e3d414d5056,Ipi,0.39577
uuid-33b9e3761691410a8dbd6e3d414d5056,atezo,0.431443
uuid-33b9e3761691410a8dbd6e3d414d5056,preferred,0.488306
uuid-33b9e3761691410a8dbd6e3d414d5056,monotherapy,0.619901
uuid-33b9e3761691410a8dbd6e3d414d5056,using nivo,0.363819
uuid-33b9e3761691410a8dbd6e3d414d5056,combo,0.491877
uuid-33b9e3761691410a8dbd6e3d414d5056,PD1,0.516194
uuid-33b9e3761691410a8dbd6e3d414d5056,nivo and pembro,0.386845
uuid-33b9e3761691410a8dbd6e3d414d5056,believes,0.340838
uuid-33b9e3761691410a8dbd6e3d414d5056,chemotherapy,0.524977
uuid-33b9e3761691410a8dbd6e3d414d5056,vs,0.340885
uuid-33b9e3761691410a8dbd6e3d414d5056,feels,0.313219
uuid-33b9e3761691410a8dbd6e3d414d5056,PD-1,0.34947
uuid-33b9e3761691410a8dbd6e3d414d5056,option,0.541857
uuid-cb04870e35f84939bbb5e3992ca96bb8,Nivo,0.473942
uuid-cb04870e35f84939bbb5e3992ca96bb8,patients,0.616251
uuid-cb04870e35f84939bbb5e3992ca96bb8,Opdivo,0.45553
uuid-cb04870e35f84939bbb5e3992ca96bb8,therapy,0.667822
uuid-cb04870e35f84939bbb5e3992ca96bb8,nivolumab,0.570135
uuid-cb04870e35f84939bbb5e3992ca96bb8,treated,0.39176
uuid-cb04870e35f84939bbb5e3992ca96bb8,treatment,0.467191
uuid-cb04870e35f84939bbb5e3992ca96bb8,using nivo,0.384363
uuid-cb04870e35f84939bbb5e3992ca96bb8,cHL,0.777984
uuid-cb04870e35f84939bbb5e3992ca96bb8,progression,0.389657
uuid-cb04870e35f84939bbb5e3992ca96bb8,chemotherapy,0.347081
uuid-3f297c6714794127a48d3f2a53328d06,patients,0.305851
uuid-3f297c6714794127a48d3f2a53328d06,dose,0.309656
uuid-3f297c6714794127a48d3f2a53328d06,nivolumab,0.30537
uuid-3f297c6714794127a48d3f2a53328d06,regimen,0.406513
uuid-3f297c6714794127a48d3f2a53328d06,treated,0.339973
uuid-3f297c6714794127a48d3f2a53328d06,shared,0.319282
uuid-3f297c6714794127a48d3f2a53328d06,physicians,0.3719
uuid-3f297c6714794127a48d3f2a53328d06,treatment,0.308454
uuid-3f297c6714794127a48d3f2a53328d06,respond,0.31587
uuid-0b9c6c36137f4f1287e038c250689036,Nivo,0.473241
uuid-0b9c6c36137f4f1287e038c250689036,patients,0.443325
uuid-0b9c6c36137f4f1287e038c250689036,pembro,0.381016
uuid-0b9c6c36137f4f1287e038c250689036,nivolumab,0.425373
uuid-0b9c6c36137f4f1287e038c250689036,1L,0.65284
uuid-0b9c6c36137f4f1287e038c250689036,regimen,0.512264
uuid-0b9c6c36137f4f1287e038c250689036,RCC,0.539795
uuid-0b9c6c36137f4f1287e038c250689036,combination,0.499482
uuid-0b9c6c36137f4f1287e038c250689036,chemo,0.481406
uuid-0b9c6c36137f4f1287e038c250689036,2L,0.691613
uuid-0b9c6c36137f4f1287e038c250689036,pts,0.452384
uuid-0b9c6c36137f4f1287e038c250689036,IO,0.341104
uuid-0b9c6c36137f4f1287e038c250689036,agents,0.36546
uuid-0b9c6c36137f4f1287e038c250689036,Ipi,0.345621
uuid-0b9c6c36137f4f1287e038c250689036,approval,0.334675
uuid-0b9c6c36137f4f1287e038c250689036,atezo,0.349639
uuid-0b9c6c36137f4f1287e038c250689036,preferred,0.596251
uuid-0b9c6c36137f4f1287e038c250689036,monotherapy,0.717665
uuid-0b9c6c36137f4f1287e038c250689036,treatment,0.314177
uuid-0b9c6c36137f4f1287e038c250689036,using nivo,0.624087
uuid-0b9c6c36137f4f1287e038c250689036,combo,0.592555
uuid-0b9c6c36137f4f1287e038c250689036,clinical trials,0.301817
uuid-0b9c6c36137f4f1287e038c250689036,PD1,0.399479
uuid-0b9c6c36137f4f1287e038c250689036,approved,0.499242
uuid-0b9c6c36137f4f1287e038c250689036,SCCHN,0.382276
uuid-0b9c6c36137f4f1287e038c250689036,progression,0.318545
uuid-0b9c6c36137f4f1287e038c250689036,believes,0.333421
uuid-0b9c6c36137f4f1287e038c250689036,chemotherapy,0.376721
uuid-0b9c6c36137f4f1287e038c250689036,feels,0.435466
uuid-0b9c6c36137f4f1287e038c250689036,RTL stated,0.565083
uuid-0b9c6c36137f4f1287e038c250689036,option,0.647371
uuid-0b9c6c36137f4f1287e038c250689036,bladder,0.379734
uuid-b2120cd98db249b1a1a571f000620117,RTL,0.313959
uuid-b2120cd98db249b1a1a571f000620117,trial,0.575552
uuid-b2120cd98db249b1a1a571f000620117,stated,0.352381
uuid-b2120cd98db249b1a1a571f000620117,approval,0.352718
uuid-b2120cd98db249b1a1a571f000620117,data,0.307008
uuid-b2120cd98db249b1a1a571f000620117,clinical trials,0.426178
uuid-b2120cd98db249b1a1a571f000620117,bladder,0.362678
uuid-b42294b0c0604b1798cfb219c55d1030,Nivo,0.510117
uuid-b42294b0c0604b1798cfb219c55d1030,patients,0.519754
uuid-b42294b0c0604b1798cfb219c55d1030,pembro,0.490782
uuid-b42294b0c0604b1798cfb219c55d1030,dose,0.576279
uuid-b42294b0c0604b1798cfb219c55d1030,1L,0.3212
uuid-b42294b0c0604b1798cfb219c55d1030,toxicity,0.360933
uuid-b42294b0c0604b1798cfb219c55d1030,regimen,0.418706
uuid-b42294b0c0604b1798cfb219c55d1030,chemo,0.331216
uuid-b42294b0c0604b1798cfb219c55d1030,2L,0.473044
uuid-b42294b0c0604b1798cfb219c55d1030,pts,0.345542
uuid-b42294b0c0604b1798cfb219c55d1030,Ipi,0.41176
uuid-b42294b0c0604b1798cfb219c55d1030,atezo,0.493458
uuid-b42294b0c0604b1798cfb219c55d1030,preferred,0.527129
uuid-b42294b0c0604b1798cfb219c55d1030,monotherapy,0.468819
uuid-b42294b0c0604b1798cfb219c55d1030,using nivo,0.446538
uuid-b42294b0c0604b1798cfb219c55d1030,approved,0.30661
uuid-b42294b0c0604b1798cfb219c55d1030,vs,0.525661
uuid-b42294b0c0604b1798cfb219c55d1030,RTL stated,0.313009
uuid-b42294b0c0604b1798cfb219c55d1030,option,0.440039
uuid-b42294b0c0604b1798cfb219c55d1030,flat dosing,0.317844
uuid-c4e54b8269204424b39cb7f6f84b44af,patients,0.64177
uuid-c4e54b8269204424b39cb7f6f84b44af,therapy,0.494493
uuid-c4e54b8269204424b39cb7f6f84b44af,regimen,0.332448
uuid-c4e54b8269204424b39cb7f6f84b44af,treated,0.320136
uuid-c4e54b8269204424b39cb7f6f84b44af,chemo,0.352486
uuid-c4e54b8269204424b39cb7f6f84b44af,pts,0.46292
uuid-c4e54b8269204424b39cb7f6f84b44af,treatment,0.49152
uuid-c4e54b8269204424b39cb7f6f84b44af,progression,0.543643
uuid-c4e54b8269204424b39cb7f6f84b44af,chemotherapy,0.350953
uuid-c4e54b8269204424b39cb7f6f84b44af,respond,0.471922
uuid-c4e54b8269204424b39cb7f6f84b44af,option,0.392595
uuid-bf7ca68f02ea4db2b360147c90d91772,RTL,0.508495
uuid-bf7ca68f02ea4db2b360147c90d91772,lung,0.500912
uuid-bf7ca68f02ea4db2b360147c90d91772,1L,0.351893
uuid-bf7ca68f02ea4db2b360147c90d91772,NTL,0.310533
uuid-bf7ca68f02ea4db2b360147c90d91772,discussed,0.345954
uuid-bf7ca68f02ea4db2b360147c90d91772,melanoma,0.565759
uuid-bf7ca68f02ea4db2b360147c90d91772,shared,0.454936
uuid-bf7ca68f02ea4db2b360147c90d91772,RCC,0.712889
uuid-bf7ca68f02ea4db2b360147c90d91772,TL stated,0.463778
uuid-bf7ca68f02ea4db2b360147c90d91772,2L,0.434688
uuid-bf7ca68f02ea4db2b360147c90d91772,stated,0.381331
uuid-bf7ca68f02ea4db2b360147c90d91772,preferred,0.36391
uuid-bf7ca68f02ea4db2b360147c90d91772,using nivo,0.489778
uuid-bf7ca68f02ea4db2b360147c90d91772,clinical trials,0.359344
uuid-bf7ca68f02ea4db2b360147c90d91772,PDL1 testing,0.365119
uuid-bf7ca68f02ea4db2b360147c90d91772,SCCHN,0.687075
uuid-bf7ca68f02ea4db2b360147c90d91772,LTL,0.41811
uuid-bf7ca68f02ea4db2b360147c90d91772,TLs,0.573824
uuid-bf7ca68f02ea4db2b360147c90d91772,academic,0.78578
uuid-bf7ca68f02ea4db2b360147c90d91772,Regional TL,0.551122
uuid-bf7ca68f02ea4db2b360147c90d91772,RTL stated,0.758046
uuid-bf7ca68f02ea4db2b360147c90d91772,TL shared,0.595387
uuid-bf7ca68f02ea4db2b360147c90d91772,bladder,0.393728
uuid-7c9117d336a748f8b40c990d8ab9dbd2,Nivo,0.560157
uuid-7c9117d336a748f8b40c990d8ab9dbd2,pembro,0.585301
uuid-7c9117d336a748f8b40c990d8ab9dbd2,1L,0.490391
uuid-7c9117d336a748f8b40c990d8ab9dbd2,PDL1,0.454451
uuid-7c9117d336a748f8b40c990d8ab9dbd2,efficacy,0.508215
uuid-7c9117d336a748f8b40c990d8ab9dbd2,chemo,0.414106
uuid-7c9117d336a748f8b40c990d8ab9dbd2,2L,0.472825
uuid-7c9117d336a748f8b40c990d8ab9dbd2,agents,0.387154
uuid-7c9117d336a748f8b40c990d8ab9dbd2,OS,0.33574
uuid-7c9117d336a748f8b40c990d8ab9dbd2,atezo,0.527969
uuid-7c9117d336a748f8b40c990d8ab9dbd2,preferred,0.349113
uuid-7c9117d336a748f8b40c990d8ab9dbd2,monotherapy,0.456005
uuid-7c9117d336a748f8b40c990d8ab9dbd2,using nivo,0.335511
uuid-7c9117d336a748f8b40c990d8ab9dbd2,data,0.449439
uuid-7c9117d336a748f8b40c990d8ab9dbd2,combo,0.32767
uuid-7c9117d336a748f8b40c990d8ab9dbd2,ORR,0.364561
uuid-7c9117d336a748f8b40c990d8ab9dbd2,approved,0.361029
uuid-7c9117d336a748f8b40c990d8ab9dbd2,nivo and pembro,0.476136
uuid-7c9117d336a748f8b40c990d8ab9dbd2,believes,0.455028
uuid-7c9117d336a748f8b40c990d8ab9dbd2,impressed,0.341357
uuid-7c9117d336a748f8b40c990d8ab9dbd2,vs,0.404864
uuid-7c9117d336a748f8b40c990d8ab9dbd2,feels,0.466947
uuid-7c9117d336a748f8b40c990d8ab9dbd2,PDL1 expression,0.374189
uuid-7c9117d336a748f8b40c990d8ab9dbd2,option,0.437088
uuid-5ad22bb5d9a945cf9f2dc9216a32de94,physicians,0.533862
uuid-5ad22bb5d9a945cf9f2dc9216a32de94,oncology,0.434267
uuid-5ad22bb5d9a945cf9f2dc9216a32de94,drug,0.458063
uuid-5ad22bb5d9a945cf9f2dc9216a32de94,clinical,0.519028
uuid-a96cff517aa54af1904baa628a4aea06,Nivo,0.362482
uuid-a96cff517aa54af1904baa628a4aea06,pembro,0.577419
uuid-a96cff517aa54af1904baa628a4aea06,BMS,0.328252
uuid-a96cff517aa54af1904baa628a4aea06,1L,0.433382
uuid-a96cff517aa54af1904baa628a4aea06,trial,0.462585
uuid-a96cff517aa54af1904baa628a4aea06,efficacy,0.305082
uuid-a96cff517aa54af1904baa628a4aea06,commented,0.378415
uuid-a96cff517aa54af1904baa628a4aea06,2L,0.422699
uuid-a96cff517aa54af1904baa628a4aea06,Merck,0.348277
uuid-a96cff517aa54af1904baa628a4aea06,stated,0.33444
uuid-a96cff517aa54af1904baa628a4aea06,approval,0.423988
uuid-a96cff517aa54af1904baa628a4aea06,atezo,0.536557
uuid-a96cff517aa54af1904baa628a4aea06,preferred,0.42437
uuid-a96cff517aa54af1904baa628a4aea06,using nivo,0.385136
uuid-a96cff517aa54af1904baa628a4aea06,data,0.604517
uuid-a96cff517aa54af1904baa628a4aea06,expressed,0.332332
uuid-a96cff517aa54af1904baa628a4aea06,clinical trials,0.408827
uuid-a96cff517aa54af1904baa628a4aea06,indication,0.455699
uuid-a96cff517aa54af1904baa628a4aea06,approved,0.466513
uuid-a96cff517aa54af1904baa628a4aea06,SCCHN,0.493012
uuid-a96cff517aa54af1904baa628a4aea06,nivo and pembro,0.432058
uuid-a96cff517aa54af1904baa628a4aea06,impressed,0.51649
uuid-a96cff517aa54af1904baa628a4aea06,LTL,0.307353
uuid-a96cff517aa54af1904baa628a4aea06,TLs,0.330042
uuid-a96cff517aa54af1904baa628a4aea06,SCLC,0.362737
uuid-a96cff517aa54af1904baa628a4aea06,feels,0.423308
uuid-a96cff517aa54af1904baa628a4aea06,Regional TL,0.325545
uuid-a96cff517aa54af1904baa628a4aea06,RTL stated,0.423774
uuid-a96cff517aa54af1904baa628a4aea06,option,0.310792
uuid-a96cff517aa54af1904baa628a4aea06,bladder,0.518226
uuid-6be41a77af894c6c82484b5d8eda85fd,Nivo,0.353785
uuid-6be41a77af894c6c82484b5d8eda85fd,patients,0.360187
uuid-6be41a77af894c6c82484b5d8eda85fd,Opdivo,0.31821
uuid-6be41a77af894c6c82484b5d8eda85fd,pembro,0.349986
uuid-6be41a77af894c6c82484b5d8eda85fd,dose,0.656181
uuid-6be41a77af894c6c82484b5d8eda85fd,regimen,0.339446
uuid-6be41a77af894c6c82484b5d8eda85fd,2L,0.327663
uuid-6be41a77af894c6c82484b5d8eda85fd,Ipi,0.397925
uuid-6be41a77af894c6c82484b5d8eda85fd,atezo,0.379444
uuid-6be41a77af894c6c82484b5d8eda85fd,preferred,0.517769
uuid-6be41a77af894c6c82484b5d8eda85fd,monotherapy,0.324358
uuid-6be41a77af894c6c82484b5d8eda85fd,using nivo,0.331609
uuid-6be41a77af894c6c82484b5d8eda85fd,indication,0.300416
uuid-6be41a77af894c6c82484b5d8eda85fd,vs,0.479386
uuid-6be41a77af894c6c82484b5d8eda85fd,option,0.364374
uuid-6be41a77af894c6c82484b5d8eda85fd,flat dosing,0.550644
uuid-202df675e0dd411a9e9333575a7c51c0,BMS,0.336965
uuid-202df675e0dd411a9e9333575a7c51c0,discussed,0.33493
uuid-202df675e0dd411a9e9333575a7c51c0,shared,0.320288
uuid-202df675e0dd411a9e9333575a7c51c0,physicians,0.312343
uuid-202df675e0dd411a9e9333575a7c51c0,regards,0.325816
uuid-202df675e0dd411a9e9333575a7c51c0,oncology,0.455414
uuid-202df675e0dd411a9e9333575a7c51c0,drug,0.329484
uuid-202df675e0dd411a9e9333575a7c51c0,clinical,0.537856
uuid-817072cb72b1458d906d5b825b241682,Nivo,0.533116
uuid-817072cb72b1458d906d5b825b241682,patients,0.519125
uuid-817072cb72b1458d906d5b825b241682,pembro,0.455959
uuid-817072cb72b1458d906d5b825b241682,nivolumab,0.442137
uuid-817072cb72b1458d906d5b825b241682,1L,0.373861
uuid-817072cb72b1458d906d5b825b241682,treated,0.353168
uuid-817072cb72b1458d906d5b825b241682,RCC,0.332882
uuid-817072cb72b1458d906d5b825b241682,2L,0.418592
uuid-817072cb72b1458d906d5b825b241682,pts,0.418308
uuid-817072cb72b1458d906d5b825b241682,stated,0.386836
uuid-817072cb72b1458d906d5b825b241682,approval,0.565365
uuid-817072cb72b1458d906d5b825b241682,monotherapy,0.340207
uuid-817072cb72b1458d906d5b825b241682,using nivo,0.557857
uuid-817072cb72b1458d906d5b825b241682,approved,0.499525
uuid-817072cb72b1458d906d5b825b241682,SCCHN,0.374164
uuid-817072cb72b1458d906d5b825b241682,label,0.368606
uuid-817072cb72b1458d906d5b825b241682,SCLC,0.431283
uuid-817072cb72b1458d906d5b825b241682,RTL stated,0.439802
uuid-817072cb72b1458d906d5b825b241682,option,0.368373
uuid-817072cb72b1458d906d5b825b241682,bladder,0.371965
uuid-873955a7d34a46d5ae99e8de487abcee,toxicity,0.365795
uuid-ee592a75fe89482ca4a5ba95e436518e,BMS,0.396496
uuid-ee592a75fe89482ca4a5ba95e436518e,PDL1,0.48489
uuid-ee592a75fe89482ca4a5ba95e436518e,Merck,0.47471
uuid-ee592a75fe89482ca4a5ba95e436518e,institution,0.309995
uuid-ee592a75fe89482ca4a5ba95e436518e,PD-L1,0.354036
uuid-ee592a75fe89482ca4a5ba95e436518e,testing,0.334882
uuid-ee592a75fe89482ca4a5ba95e436518e,regards,0.438539
uuid-ee592a75fe89482ca4a5ba95e436518e,PFS,0.349404
uuid-ee592a75fe89482ca4a5ba95e436518e,AI,0.585618
uuid-ee592a75fe89482ca4a5ba95e436518e,nivo and pembro,0.385587
uuid-ee592a75fe89482ca4a5ba95e436518e,assay,0.616345
uuid-ee592a75fe89482ca4a5ba95e436518e,PDL1 expression,0.420822
uuid-ee592a75fe89482ca4a5ba95e436518e,biomarker,0.441177
uuid-ee592a75fe89482ca4a5ba95e436518e,NCCN,0.337022
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,TL,0.336481
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,lung,0.357912
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,NSCLC,0.555645
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,TL stated,0.410822
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,institution,0.600766
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,PD-L1,0.528644
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,PD-L1 testing,0.650487
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,testing,0.619971
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,PDL1 testing,0.55666
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,AI,0.365425
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,NSCLC patients,0.454695
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,assay,0.472079
uuid-8a9d4bf4c2ef44559a2552b7cdbcf7fd,NCCN,0.339419
uuid-483ff58ccf22493a8abc217aee48732f,TL,0.622338
uuid-483ff58ccf22493a8abc217aee48732f,PDL1,0.456837
uuid-483ff58ccf22493a8abc217aee48732f,TL stated,0.301785
uuid-483ff58ccf22493a8abc217aee48732f,Merck,0.344192
uuid-483ff58ccf22493a8abc217aee48732f,institution,0.338671
uuid-483ff58ccf22493a8abc217aee48732f,PD-L1,0.828491
uuid-483ff58ccf22493a8abc217aee48732f,PD-L1 testing,0.826061
uuid-483ff58ccf22493a8abc217aee48732f,testing,0.865199
uuid-483ff58ccf22493a8abc217aee48732f,PDL1 testing,0.569872
uuid-483ff58ccf22493a8abc217aee48732f,NSCLC patients,0.541611
uuid-483ff58ccf22493a8abc217aee48732f,assay,0.929673
uuid-483ff58ccf22493a8abc217aee48732f,biomarker,0.428717
uuid-bfe812ca768a4267be922e85bb8c6331,patients,0.574359
uuid-bfe812ca768a4267be922e85bb8c6331,therapy,0.445695
uuid-bfe812ca768a4267be922e85bb8c6331,toxicity,0.551104
uuid-bfe812ca768a4267be922e85bb8c6331,regimen,0.5728
uuid-bfe812ca768a4267be922e85bb8c6331,treated,0.656637
uuid-bfe812ca768a4267be922e85bb8c6331,pts,0.327485
uuid-bfe812ca768a4267be922e85bb8c6331,treatment,0.73459
uuid-bfe812ca768a4267be922e85bb8c6331,response,0.397118
uuid-bfe812ca768a4267be922e85bb8c6331,progression,0.521862
uuid-bfe812ca768a4267be922e85bb8c6331,respond,0.608649
uuid-c59f531ae4b64106a195ae95ba534838,discussed,0.380531
uuid-c59f531ae4b64106a195ae95ba534838,physicians,0.48169
uuid-c59f531ae4b64106a195ae95ba534838,clinical,0.321263
uuid-c59f531ae4b64106a195ae95ba534838,academic,0.418561
uuid-a11105bf475a4069aae43a34ce4151ee,patients,0.433139
uuid-a11105bf475a4069aae43a34ce4151ee,therapy,0.376025
uuid-a11105bf475a4069aae43a34ce4151ee,treated,0.336726
uuid-a11105bf475a4069aae43a34ce4151ee,treatment,0.387955
uuid-a11105bf475a4069aae43a34ce4151ee,using nivo,0.332233
uuid-a11105bf475a4069aae43a34ce4151ee,progression,0.30375
uuid-a11105bf475a4069aae43a34ce4151ee,RTL stated,0.339221
uuid-a11105bf475a4069aae43a34ce4151ee,TL shared,0.342401
uuid-7d5f1122e11345a186c4a3a69137c739,Opdivo,0.502892
uuid-7d5f1122e11345a186c4a3a69137c739,physicians,0.549192
uuid-7d5f1122e11345a186c4a3a69137c739,oncology,0.307351
uuid-7d5f1122e11345a186c4a3a69137c739,drug,0.331771
uuid-7d5f1122e11345a186c4a3a69137c739,flat dosing,0.481149
uuid-2436645db3e9498a8e2743b7d3fbd67c,patients,0.858545
uuid-2436645db3e9498a8e2743b7d3fbd67c,Opdivo,0.635197
uuid-2436645db3e9498a8e2743b7d3fbd67c,therapy,0.567023
uuid-2436645db3e9498a8e2743b7d3fbd67c,nivolumab,0.429307
uuid-2436645db3e9498a8e2743b7d3fbd67c,regimen,0.457847
uuid-2436645db3e9498a8e2743b7d3fbd67c,treated,0.585928
uuid-2436645db3e9498a8e2743b7d3fbd67c,pts,0.560104
uuid-2436645db3e9498a8e2743b7d3fbd67c,treatment,0.750177
uuid-2436645db3e9498a8e2743b7d3fbd67c,response,0.385453
uuid-2436645db3e9498a8e2743b7d3fbd67c,cHL,0.404723
uuid-2436645db3e9498a8e2743b7d3fbd67c,progression,0.691785
uuid-2436645db3e9498a8e2743b7d3fbd67c,respond,0.584398
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,RTL,0.321061
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,BMS,0.433384
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,shared,0.585866
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,commented,0.394277
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,stated,0.499719
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,data,0.462524
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,expressed,0.413472
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,clinical trials,0.388046
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,impressed,0.514733
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,LTL,0.386508
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,TLs,0.389736
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,feels,0.468813
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,Regional TL,0.325979
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,RTL stated,0.301947
uuid-51f9c290f98c4d56bd42cc88a6ef0f0d,bladder,0.313808
uuid-ca32394fd5714e27b0e590c68879bf71,patients,0.567511
uuid-ca32394fd5714e27b0e590c68879bf71,therapy,0.318551
uuid-ca32394fd5714e27b0e590c68879bf71,chemo,0.341947
uuid-ca32394fd5714e27b0e590c68879bf71,pts,0.34886
uuid-ca32394fd5714e27b0e590c68879bf71,treatment,0.357809
uuid-ca32394fd5714e27b0e590c68879bf71,response,0.315723
uuid-ca32394fd5714e27b0e590c68879bf71,progression,0.336775
uuid-ca32394fd5714e27b0e590c68879bf71,chemotherapy,0.36227
uuid-ca32394fd5714e27b0e590c68879bf71,respond,0.335441
uuid-ca32394fd5714e27b0e590c68879bf71,option,0.319327
uuid-0ffaf89ab8d34912a669774899813e85,lung,0.386247
uuid-0ffaf89ab8d34912a669774899813e85,efficacy,0.327287
uuid-0ffaf89ab8d34912a669774899813e85,OS,0.495719
uuid-0ffaf89ab8d34912a669774899813e85,regards,0.465934
uuid-0ffaf89ab8d34912a669774899813e85,data,0.339162
uuid-0ffaf89ab8d34912a669774899813e85,expressed,0.336696
uuid-0ffaf89ab8d34912a669774899813e85,PFS,0.553474
uuid-0ffaf89ab8d34912a669774899813e85,AI,0.802905
uuid-0ffaf89ab8d34912a669774899813e85,ORR,0.471281
uuid-0ffaf89ab8d34912a669774899813e85,nivo and pembro,0.381571
uuid-0ffaf89ab8d34912a669774899813e85,NCCN,0.474859
uuid-28d9f78eb22a406aaf37730995cfc702,toxicity,0.462559
uuid-28d9f78eb22a406aaf37730995cfc702,physicians,0.472587
uuid-28d9f78eb22a406aaf37730995cfc702,drug,0.413263
uuid-830e60ae3ffa4a83baa9726ba8cc26ac,TL,0.361171
uuid-830e60ae3ffa4a83baa9726ba8cc26ac,PDL1,0.333957
uuid-830e60ae3ffa4a83baa9726ba8cc26ac,TL stated,0.444713
uuid-830e60ae3ffa4a83baa9726ba8cc26ac,PD-L1,0.685623
uuid-830e60ae3ffa4a83baa9726ba8cc26ac,PD-L1 testing,0.641848
uuid-830e60ae3ffa4a83baa9726ba8cc26ac,testing,0.841943
uuid-830e60ae3ffa4a83baa9726ba8cc26ac,PDL1 testing,0.716489
uuid-830e60ae3ffa4a83baa9726ba8cc26ac,NSCLC patients,0.76941
uuid-830e60ae3ffa4a83baa9726ba8cc26ac,tumor types,0.322877
uuid-830e60ae3ffa4a83baa9726ba8cc26ac,assay,0.443558
uuid-830e60ae3ffa4a83baa9726ba8cc26ac,biomarker,0.477811
uuid-f2aa8395e1fa400e9b5afb995147db08,Nivo,0.306039
uuid-f2aa8395e1fa400e9b5afb995147db08,pembro,0.413549
uuid-f2aa8395e1fa400e9b5afb995147db08,1L,0.447228
uuid-f2aa8395e1fa400e9b5afb995147db08,efficacy,0.503278
uuid-f2aa8395e1fa400e9b5afb995147db08,combination,0.374531
uuid-f2aa8395e1fa400e9b5afb995147db08,chemo,0.320055
uuid-f2aa8395e1fa400e9b5afb995147db08,2L,0.410761
uuid-f2aa8395e1fa400e9b5afb995147db08,IO,0.396486
uuid-f2aa8395e1fa400e9b5afb995147db08,agents,0.486178
uuid-f2aa8395e1fa400e9b5afb995147db08,OS,0.317603
uuid-f2aa8395e1fa400e9b5afb995147db08,atezo,0.456788
uuid-f2aa8395e1fa400e9b5afb995147db08,preferred,0.427662
uuid-f2aa8395e1fa400e9b5afb995147db08,monotherapy,0.433368
uuid-f2aa8395e1fa400e9b5afb995147db08,data,0.511737
uuid-f2aa8395e1fa400e9b5afb995147db08,combo,0.44933
uuid-f2aa8395e1fa400e9b5afb995147db08,indication,0.31336
uuid-f2aa8395e1fa400e9b5afb995147db08,nivo and pembro,0.426793
uuid-f2aa8395e1fa400e9b5afb995147db08,believes,0.510502
uuid-f2aa8395e1fa400e9b5afb995147db08,impressed,0.425547
uuid-f2aa8395e1fa400e9b5afb995147db08,TLs,0.426913
uuid-f2aa8395e1fa400e9b5afb995147db08,feels,0.515401
uuid-f2aa8395e1fa400e9b5afb995147db08,option,0.394803
uuid-1a194365820842ff8c6a2508b2e1f92c,Opdivo,0.336453
uuid-1a194365820842ff8c6a2508b2e1f92c,physicians,0.759797
uuid-8fb6ff08044341a6844a1626c4c3fcc7,Nivo,0.341275
uuid-8fb6ff08044341a6844a1626c4c3fcc7,patients,0.323366
uuid-8fb6ff08044341a6844a1626c4c3fcc7,dose,0.769778
uuid-8fb6ff08044341a6844a1626c4c3fcc7,toxicity,0.540302
uuid-8fb6ff08044341a6844a1626c4c3fcc7,regimen,0.544723
uuid-8fb6ff08044341a6844a1626c4c3fcc7,Ipi,0.522037
uuid-8fb6ff08044341a6844a1626c4c3fcc7,treatment,0.372329
uuid-8fb6ff08044341a6844a1626c4c3fcc7,vs,0.420207
uuid-8fb6ff08044341a6844a1626c4c3fcc7,respond,0.337315
uuid-8fb6ff08044341a6844a1626c4c3fcc7,flat dosing,0.389707
uuid-61776a8ce82a480da4460db404d807fc,patients,0.540775
uuid-61776a8ce82a480da4460db404d807fc,therapy,0.377475
uuid-61776a8ce82a480da4460db404d807fc,nivolumab,0.388356
uuid-61776a8ce82a480da4460db404d807fc,treated,0.453689
uuid-61776a8ce82a480da4460db404d807fc,tumor,0.337356
uuid-61776a8ce82a480da4460db404d807fc,pts,0.438154
uuid-61776a8ce82a480da4460db404d807fc,treatment,0.479431
uuid-61776a8ce82a480da4460db404d807fc,response,0.393352
uuid-61776a8ce82a480da4460db404d807fc,cHL,0.416366
uuid-61776a8ce82a480da4460db404d807fc,progression,0.366201
uuid-61776a8ce82a480da4460db404d807fc,respond,0.371583
uuid-c02842b2bfe248fba22f7aeac70b076a,Nivo,0.305677
uuid-c02842b2bfe248fba22f7aeac70b076a,patients,0.489803
uuid-c02842b2bfe248fba22f7aeac70b076a,therapy,0.562759
uuid-c02842b2bfe248fba22f7aeac70b076a,nivolumab,0.485373
uuid-c02842b2bfe248fba22f7aeac70b076a,toxicity,0.315929
uuid-c02842b2bfe248fba22f7aeac70b076a,regimen,0.459607
uuid-c02842b2bfe248fba22f7aeac70b076a,treated,0.408363
uuid-c02842b2bfe248fba22f7aeac70b076a,combination,0.496103
uuid-c02842b2bfe248fba22f7aeac70b076a,chemo,0.405765
uuid-c02842b2bfe248fba22f7aeac70b076a,pts,0.453814
uuid-c02842b2bfe248fba22f7aeac70b076a,monotherapy,0.505605
uuid-c02842b2bfe248fba22f7aeac70b076a,treatment,0.56404
uuid-c02842b2bfe248fba22f7aeac70b076a,response,0.437452
uuid-c02842b2bfe248fba22f7aeac70b076a,combo,0.439452
uuid-c02842b2bfe248fba22f7aeac70b076a,PD1,0.62094
uuid-c02842b2bfe248fba22f7aeac70b076a,progression,0.552316
uuid-c02842b2bfe248fba22f7aeac70b076a,chemotherapy,0.384415
uuid-c02842b2bfe248fba22f7aeac70b076a,respond,0.44896
uuid-c02842b2bfe248fba22f7aeac70b076a,PD-1,0.438164
uuid-c02842b2bfe248fba22f7aeac70b076a,option,0.359905
uuid-8fbf04a0654043cc9d4229b4df281ab6,Opdivo,0.407215
uuid-8fbf04a0654043cc9d4229b4df281ab6,physicians,0.617288
uuid-8fbf04a0654043cc9d4229b4df281ab6,oncology,0.33847
uuid-8fbf04a0654043cc9d4229b4df281ab6,drug,0.487972
uuid-8fbf04a0654043cc9d4229b4df281ab6,clinical,0.36228
uuid-8fbf04a0654043cc9d4229b4df281ab6,flat dosing,0.377417
uuid-ab42a309a3ba4ba9a9aaafd0b6026d55,dose,0.500587
uuid-ab42a309a3ba4ba9a9aaafd0b6026d55,toxicity,0.409036
uuid-ab42a309a3ba4ba9a9aaafd0b6026d55,regimen,0.352369
uuid-ab42a309a3ba4ba9a9aaafd0b6026d55,physicians,0.557695
uuid-ab42a309a3ba4ba9a9aaafd0b6026d55,treatment,0.399903
uuid-861ef6d95128474b8045bb387519b802,therapy,0.32003
uuid-861ef6d95128474b8045bb387519b802,nivolumab,0.302569
uuid-861ef6d95128474b8045bb387519b802,regimen,0.49863
uuid-861ef6d95128474b8045bb387519b802,combination,0.620676
uuid-861ef6d95128474b8045bb387519b802,chemo,0.450582
uuid-861ef6d95128474b8045bb387519b802,IO,0.790717
uuid-861ef6d95128474b8045bb387519b802,agents,0.419807
uuid-861ef6d95128474b8045bb387519b802,preferred,0.356735
uuid-861ef6d95128474b8045bb387519b802,monotherapy,0.602227
uuid-861ef6d95128474b8045bb387519b802,combo,0.586305
uuid-861ef6d95128474b8045bb387519b802,PD1,0.392747
uuid-861ef6d95128474b8045bb387519b802,progression,0.332532
uuid-861ef6d95128474b8045bb387519b802,believes,0.337649
uuid-861ef6d95128474b8045bb387519b802,chemotherapy,0.444298
uuid-861ef6d95128474b8045bb387519b802,feels,0.366924
uuid-861ef6d95128474b8045bb387519b802,RTL stated,0.329501
uuid-861ef6d95128474b8045bb387519b802,option,0.445273
uuid-a580156acad949dc8edc62b1766dbdbf,BMS,0.612872
uuid-a580156acad949dc8edc62b1766dbdbf,PDL1,0.413458
uuid-a580156acad949dc8edc62b1766dbdbf,trial,0.551682
uuid-a580156acad949dc8edc62b1766dbdbf,efficacy,0.418544
uuid-a580156acad949dc8edc62b1766dbdbf,Merck,0.471989
uuid-a580156acad949dc8edc62b1766dbdbf,OS,0.316985
uuid-a580156acad949dc8edc62b1766dbdbf,regards,0.356866
uuid-a580156acad949dc8edc62b1766dbdbf,data,0.523164
uuid-a580156acad949dc8edc62b1766dbdbf,PFS,0.347324
uuid-a580156acad949dc8edc62b1766dbdbf,ORR,0.393
uuid-a580156acad949dc8edc62b1766dbdbf,nivo and pembro,0.358877
uuid-a580156acad949dc8edc62b1766dbdbf,believes,0.303625
uuid-a580156acad949dc8edc62b1766dbdbf,impressed,0.342361
uuid-a580156acad949dc8edc62b1766dbdbf,feels,0.529936
uuid-a580156acad949dc8edc62b1766dbdbf,PDL1 expression,0.411321
uuid-a580156acad949dc8edc62b1766dbdbf,biomarker,0.369259
uuid-0071a978f84c43c2aba73a351100b5aa,Opdivo,0.328454
uuid-0071a978f84c43c2aba73a351100b5aa,dose,0.597527
uuid-0071a978f84c43c2aba73a351100b5aa,efficacy,0.367819
uuid-0071a978f84c43c2aba73a351100b5aa,Ipi,0.328558
uuid-0071a978f84c43c2aba73a351100b5aa,vs,0.372057
uuid-0071a978f84c43c2aba73a351100b5aa,drug,0.380354
uuid-0071a978f84c43c2aba73a351100b5aa,Keytruda,0.522419
uuid-0071a978f84c43c2aba73a351100b5aa,flat dosing,0.630339
uuid-ef350dfd603048e0a5a3f5a85642aa28,patients,0.490499
uuid-ef350dfd603048e0a5a3f5a85642aa28,pts,0.308912
uuid-ef350dfd603048e0a5a3f5a85642aa28,physicians,0.321629
uuid-ef350dfd603048e0a5a3f5a85642aa28,treatment,0.337391
uuid-ef350dfd603048e0a5a3f5a85642aa28,clinical trials,0.371747
uuid-ef350dfd603048e0a5a3f5a85642aa28,feels,0.620437
uuid-ef350dfd603048e0a5a3f5a85642aa28,option,0.314712
uuid-21c284b742f446a2b00cf9dc28ddd1e8,trial,0.380448
uuid-21c284b742f446a2b00cf9dc28ddd1e8,efficacy,0.381873
uuid-21c284b742f446a2b00cf9dc28ddd1e8,commented,0.381005
uuid-21c284b742f446a2b00cf9dc28ddd1e8,OS,0.599272
uuid-21c284b742f446a2b00cf9dc28ddd1e8,data,0.561462
uuid-21c284b742f446a2b00cf9dc28ddd1e8,PFS,0.522278
uuid-21c284b742f446a2b00cf9dc28ddd1e8,ORR,0.58764
uuid-21c284b742f446a2b00cf9dc28ddd1e8,ASCO,0.319049
uuid-21c284b742f446a2b00cf9dc28ddd1e8,impressed,0.64132
uuid-3ddc0df76072409d8412e742742448dc,nivolumab,0.333279
uuid-3ddc0df76072409d8412e742742448dc,1L,0.407629
uuid-3ddc0df76072409d8412e742742448dc,trial,0.326948
uuid-3ddc0df76072409d8412e742742448dc,RCC,0.336057
uuid-3ddc0df76072409d8412e742742448dc,combination,0.34666
uuid-3ddc0df76072409d8412e742742448dc,chemo,0.325004
uuid-3ddc0df76072409d8412e742742448dc,2L,0.361813
uuid-3ddc0df76072409d8412e742742448dc,approval,0.352759
uuid-3ddc0df76072409d8412e742742448dc,preferred,0.448765
uuid-3ddc0df76072409d8412e742742448dc,monotherapy,0.338809
uuid-3ddc0df76072409d8412e742742448dc,using nivo,0.378854
uuid-3ddc0df76072409d8412e742742448dc,combo,0.305907
uuid-3ddc0df76072409d8412e742742448dc,clinical trials,0.373488
uuid-3ddc0df76072409d8412e742742448dc,indication,0.393474
uuid-3ddc0df76072409d8412e742742448dc,approved,0.353182
uuid-3ddc0df76072409d8412e742742448dc,SCCHN,0.424272
uuid-3ddc0df76072409d8412e742742448dc,chemotherapy,0.407256
uuid-3ddc0df76072409d8412e742742448dc,feels,0.313648
uuid-3ddc0df76072409d8412e742742448dc,RTL stated,0.417028
uuid-3ddc0df76072409d8412e742742448dc,option,0.470246
uuid-3ddc0df76072409d8412e742742448dc,bladder,0.474386
uuid-b7d3ba68c0ec4708ad14d8b86de72292,efficacy,0.387614
uuid-b7d3ba68c0ec4708ad14d8b86de72292,oncology,0.364203
uuid-b7d3ba68c0ec4708ad14d8b86de72292,clinical,0.359084
uuid-bc88357614fc4fbd981599dcaab43330,RTL,0.422781
uuid-bc88357614fc4fbd981599dcaab43330,lung,0.495328
uuid-bc88357614fc4fbd981599dcaab43330,1L,0.344496
uuid-bc88357614fc4fbd981599dcaab43330,treated,0.38598
uuid-bc88357614fc4fbd981599dcaab43330,discussed,0.301322
uuid-bc88357614fc4fbd981599dcaab43330,melanoma,0.468388
uuid-bc88357614fc4fbd981599dcaab43330,commented,0.415306
uuid-bc88357614fc4fbd981599dcaab43330,RCC,0.631522
uuid-bc88357614fc4fbd981599dcaab43330,TL stated,0.454956
uuid-bc88357614fc4fbd981599dcaab43330,2L,0.329334
uuid-bc88357614fc4fbd981599dcaab43330,stated,0.442451
uuid-bc88357614fc4fbd981599dcaab43330,using nivo,0.390108
uuid-bc88357614fc4fbd981599dcaab43330,clinical trials,0.320566
uuid-bc88357614fc4fbd981599dcaab43330,SCCHN,0.555673
uuid-bc88357614fc4fbd981599dcaab43330,impressed,0.384686
uuid-bc88357614fc4fbd981599dcaab43330,tumor types,0.319826
uuid-bc88357614fc4fbd981599dcaab43330,LTL,0.343462
uuid-bc88357614fc4fbd981599dcaab43330,TLs,0.492794
uuid-bc88357614fc4fbd981599dcaab43330,academic,0.429034
uuid-bc88357614fc4fbd981599dcaab43330,feels,0.309275
uuid-bc88357614fc4fbd981599dcaab43330,Regional TL,0.49738
uuid-bc88357614fc4fbd981599dcaab43330,RTL stated,0.58762
uuid-bc88357614fc4fbd981599dcaab43330,TL shared,0.567712
uuid-bc88357614fc4fbd981599dcaab43330,bladder,0.375539
uuid-7c394535600949308bb10dad3ce21094,TL,0.779392
uuid-7c394535600949308bb10dad3ce21094,TL stated,0.323249
uuid-7c394535600949308bb10dad3ce21094,Merck,0.385786
uuid-7c394535600949308bb10dad3ce21094,institution,0.388428
uuid-7c394535600949308bb10dad3ce21094,PD-L1,0.683694
uuid-7c394535600949308bb10dad3ce21094,PD-L1 testing,0.818948
uuid-7c394535600949308bb10dad3ce21094,testing,0.750512
uuid-7c394535600949308bb10dad3ce21094,PDL1 testing,0.496467
uuid-7c394535600949308bb10dad3ce21094,NSCLC patients,0.402209
uuid-7c394535600949308bb10dad3ce21094,assay,0.833028
uuid-7c394535600949308bb10dad3ce21094,biomarker,0.346445
uuid-45b5b8a295fb4037a0e322bdb9c0f856,toxicity,0.480484
uuid-45b5b8a295fb4037a0e322bdb9c0f856,regimen,0.363584
uuid-45b5b8a295fb4037a0e322bdb9c0f856,treated,0.309504
uuid-45b5b8a295fb4037a0e322bdb9c0f856,treatment,0.383534
uuid-45b5b8a295fb4037a0e322bdb9c0f856,response,0.359685
uuid-45b5b8a295fb4037a0e322bdb9c0f856,progression,0.342718
uuid-45b5b8a295fb4037a0e322bdb9c0f856,respond,0.352339
uuid-45b5b8a295fb4037a0e322bdb9c0f856,immunotherapy,0.336617
uuid-a42f71b693454cf6bd7a46057ef0edba,TL,0.682898
uuid-a42f71b693454cf6bd7a46057ef0edba,PDL1,0.301472
uuid-a42f71b693454cf6bd7a46057ef0edba,TL stated,0.327661
uuid-a42f71b693454cf6bd7a46057ef0edba,institution,0.410947
uuid-a42f71b693454cf6bd7a46057ef0edba,PD-L1,0.744248
uuid-a42f71b693454cf6bd7a46057ef0edba,PD-L1 testing,0.856958
uuid-a42f71b693454cf6bd7a46057ef0edba,testing,0.761222
uuid-a42f71b693454cf6bd7a46057ef0edba,PDL1 testing,0.55843
uuid-a42f71b693454cf6bd7a46057ef0edba,NSCLC patients,0.478836
uuid-a42f71b693454cf6bd7a46057ef0edba,indicated,0.373614
uuid-a42f71b693454cf6bd7a46057ef0edba,assay,0.731481
uuid-d0da69a0f849410cbf3750cb7ad43e98,nivolumab,0.307722
uuid-d0da69a0f849410cbf3750cb7ad43e98,regimen,0.340241
uuid-d0da69a0f849410cbf3750cb7ad43e98,shared,0.498794
uuid-d0da69a0f849410cbf3750cb7ad43e98,combination,0.722237
uuid-d0da69a0f849410cbf3750cb7ad43e98,chemo,0.302408
uuid-d0da69a0f849410cbf3750cb7ad43e98,IO,0.486134
uuid-d0da69a0f849410cbf3750cb7ad43e98,agents,0.413045
uuid-d0da69a0f849410cbf3750cb7ad43e98,Ipi,0.340812
uuid-d0da69a0f849410cbf3750cb7ad43e98,monotherapy,0.44582
uuid-d0da69a0f849410cbf3750cb7ad43e98,combo,0.661129
uuid-d0da69a0f849410cbf3750cb7ad43e98,PD1,0.357072
uuid-d0da69a0f849410cbf3750cb7ad43e98,chemotherapy,0.363538
uuid-dc3e9404197a4c31900f316b8b091559,Nivo,0.316042
uuid-dc3e9404197a4c31900f316b8b091559,patients,0.350971
uuid-dc3e9404197a4c31900f316b8b091559,Opdivo,0.457284
uuid-dc3e9404197a4c31900f316b8b091559,pembro,0.332013
uuid-dc3e9404197a4c31900f316b8b091559,dose,0.883634
uuid-dc3e9404197a4c31900f316b8b091559,toxicity,0.41034
uuid-dc3e9404197a4c31900f316b8b091559,regimen,0.433656
uuid-dc3e9404197a4c31900f316b8b091559,Ipi,0.613308
uuid-dc3e9404197a4c31900f316b8b091559,combo,0.307898
uuid-dc3e9404197a4c31900f316b8b091559,vs,0.517938
uuid-dc3e9404197a4c31900f316b8b091559,Keytruda,0.35785
uuid-dc3e9404197a4c31900f316b8b091559,flat dosing,0.704281
uuid-edd247175bd4428c9ab9840815321eda,physicians,0.673106
uuid-edd247175bd4428c9ab9840815321eda,oncology,0.399174
uuid-edd247175bd4428c9ab9840815321eda,drug,0.389457
uuid-edd247175bd4428c9ab9840815321eda,clinical,0.462876
uuid-f8654e100e5444e888912f34bdf234fd,physicians,0.572363
uuid-f8654e100e5444e888912f34bdf234fd,oncology,0.390217
uuid-f8654e100e5444e888912f34bdf234fd,clinical,0.360644
uuid-dadbe278c14c4f7fa8549807f757c012,pembro,0.327282
uuid-dadbe278c14c4f7fa8549807f757c012,lung,0.464104
uuid-dadbe278c14c4f7fa8549807f757c012,1L,0.398821
uuid-dadbe278c14c4f7fa8549807f757c012,PDL1,0.394571
uuid-dadbe278c14c4f7fa8549807f757c012,2L,0.314593
uuid-dadbe278c14c4f7fa8549807f757c012,atezo,0.310832
uuid-dadbe278c14c4f7fa8549807f757c012,regards,0.412339
uuid-dadbe278c14c4f7fa8549807f757c012,indication,0.319964
uuid-dadbe278c14c4f7fa8549807f757c012,AI,0.611894
uuid-dadbe278c14c4f7fa8549807f757c012,nivo and pembro,0.514753
uuid-dadbe278c14c4f7fa8549807f757c012,PDL1 expression,0.316903
uuid-dadbe278c14c4f7fa8549807f757c012,NCCN,0.358342
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,patients,0.574061
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,Opdivo,0.374632
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,therapy,0.519935
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,nivolumab,0.398874
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,regimen,0.57667
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,treated,0.46143
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,pts,0.546771
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,monotherapy,0.387407
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,treatment,0.675278
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,response,0.38639
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,PD1,0.374435
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,progression,0.682858
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,chemotherapy,0.319386
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,respond,0.446292
uuid-16dc01ed0b734f2aa59d2fd6b1f0b72a,option,0.309882
uuid-c312c3567ddc4423a435a385d9d8153c,pembro,0.312841
uuid-c312c3567ddc4423a435a385d9d8153c,BMS,0.480434
uuid-c312c3567ddc4423a435a385d9d8153c,1L,0.403226
uuid-c312c3567ddc4423a435a385d9d8153c,PDL1,0.487257
uuid-c312c3567ddc4423a435a385d9d8153c,trial,0.475259
uuid-c312c3567ddc4423a435a385d9d8153c,efficacy,0.537187
uuid-c312c3567ddc4423a435a385d9d8153c,chemo,0.312953
uuid-c312c3567ddc4423a435a385d9d8153c,OS,0.676206
uuid-c312c3567ddc4423a435a385d9d8153c,data,0.661078
uuid-c312c3567ddc4423a435a385d9d8153c,combo,0.371498
uuid-c312c3567ddc4423a435a385d9d8153c,PFS,0.665113
uuid-c312c3567ddc4423a435a385d9d8153c,ORR,0.651562
uuid-c312c3567ddc4423a435a385d9d8153c,nivo and pembro,0.566562
uuid-c312c3567ddc4423a435a385d9d8153c,believes,0.495847
uuid-c312c3567ddc4423a435a385d9d8153c,impressed,0.517763
uuid-c312c3567ddc4423a435a385d9d8153c,TLs,0.309793
uuid-c312c3567ddc4423a435a385d9d8153c,feels,0.534509
uuid-c312c3567ddc4423a435a385d9d8153c,PDL1 expression,0.443827
uuid-34ae058e7dd6438fb31ee05174f56c9c,pembro,0.366162
uuid-34ae058e7dd6438fb31ee05174f56c9c,BMS,0.609284
uuid-34ae058e7dd6438fb31ee05174f56c9c,trial,0.593501
uuid-34ae058e7dd6438fb31ee05174f56c9c,shared,0.355171
uuid-34ae058e7dd6438fb31ee05174f56c9c,Merck,0.673743
uuid-34ae058e7dd6438fb31ee05174f56c9c,institution,0.344036
uuid-34ae058e7dd6438fb31ee05174f56c9c,stated,0.413126
uuid-34ae058e7dd6438fb31ee05174f56c9c,approval,0.429031
uuid-34ae058e7dd6438fb31ee05174f56c9c,data,0.364926
uuid-34ae058e7dd6438fb31ee05174f56c9c,clinical trials,0.37794
uuid-34ae058e7dd6438fb31ee05174f56c9c,indication,0.328026
uuid-34ae058e7dd6438fb31ee05174f56c9c,approved,0.398404
uuid-34ae058e7dd6438fb31ee05174f56c9c,label,0.365322
uuid-4469965e5eb2426d99461a544dc2b3f6,tumor,0.389502
uuid-4469965e5eb2426d99461a544dc2b3f6,physicians,0.426745
uuid-4469965e5eb2426d99461a544dc2b3f6,response,0.3056
uuid-4469965e5eb2426d99461a544dc2b3f6,progression,0.309822
uuid-f338c45134ce49959b164a34d9f3b56e,patients,0.782463
uuid-f338c45134ce49959b164a34d9f3b56e,Opdivo,0.364509
uuid-f338c45134ce49959b164a34d9f3b56e,therapy,0.483147
uuid-f338c45134ce49959b164a34d9f3b56e,nivolumab,0.38658
uuid-f338c45134ce49959b164a34d9f3b56e,toxicity,0.358564
uuid-f338c45134ce49959b164a34d9f3b56e,regimen,0.519819
uuid-f338c45134ce49959b164a34d9f3b56e,treated,0.5635
uuid-f338c45134ce49959b164a34d9f3b56e,chemo,0.307718
uuid-f338c45134ce49959b164a34d9f3b56e,pts,0.647976
uuid-f338c45134ce49959b164a34d9f3b56e,treatment,0.702101
uuid-f338c45134ce49959b164a34d9f3b56e,response,0.573507
uuid-f338c45134ce49959b164a34d9f3b56e,progression,0.769995
uuid-f338c45134ce49959b164a34d9f3b56e,chemotherapy,0.324672
uuid-f338c45134ce49959b164a34d9f3b56e,respond,0.621143
uuid-bf17376baed1444e8aa3fb188bb662df,institution,0.38317
uuid-bf17376baed1444e8aa3fb188bb662df,AI,0.627794
uuid-bf17376baed1444e8aa3fb188bb662df,oncology,0.746412
uuid-bf17376baed1444e8aa3fb188bb662df,drug,0.341337
uuid-bf17376baed1444e8aa3fb188bb662df,clinical,0.398709
uuid-bf17376baed1444e8aa3fb188bb662df,NCCN,0.36558
uuid-8607a98376f64c19abb9b00d26bebff2,patients,0.397889
uuid-8607a98376f64c19abb9b00d26bebff2,toxicity,0.387031
uuid-8607a98376f64c19abb9b00d26bebff2,regimen,0.315828
uuid-8607a98376f64c19abb9b00d26bebff2,pts,0.375826
uuid-8607a98376f64c19abb9b00d26bebff2,clinical trials,0.330538
uuid-8607a98376f64c19abb9b00d26bebff2,impressed,0.30446
uuid-8607a98376f64c19abb9b00d26bebff2,feels,0.376566
uuid-8607a98376f64c19abb9b00d26bebff2,TL shared,0.313382
uuid-7a8faa260b414821a74c668ed6d06dd1,patients,0.340453
uuid-7a8faa260b414821a74c668ed6d06dd1,pts,0.345683
uuid-7a8faa260b414821a74c668ed6d06dd1,OS,0.301574
uuid-7a8faa260b414821a74c668ed6d06dd1,data,0.403587
uuid-7a8faa260b414821a74c668ed6d06dd1,ORR,0.339066
uuid-7a8faa260b414821a74c668ed6d06dd1,impressed,0.462254
uuid-7a8faa260b414821a74c668ed6d06dd1,feels,0.530587
uuid-741078c84099434991a1e33ec1cd391b,Nivo,0.360885
uuid-741078c84099434991a1e33ec1cd391b,BMS,0.306866
uuid-741078c84099434991a1e33ec1cd391b,trial,0.586683
uuid-741078c84099434991a1e33ec1cd391b,efficacy,0.547583
uuid-741078c84099434991a1e33ec1cd391b,combination,0.591064
uuid-741078c84099434991a1e33ec1cd391b,chemo,0.440063
uuid-741078c84099434991a1e33ec1cd391b,agents,0.410433
uuid-741078c84099434991a1e33ec1cd391b,Ipi,0.357049
uuid-741078c84099434991a1e33ec1cd391b,OS,0.371982
uuid-741078c84099434991a1e33ec1cd391b,monotherapy,0.367042
uuid-741078c84099434991a1e33ec1cd391b,data,0.4609
uuid-741078c84099434991a1e33ec1cd391b,combo,0.560666
uuid-741078c84099434991a1e33ec1cd391b,PFS,0.376005
uuid-741078c84099434991a1e33ec1cd391b,ORR,0.449189
uuid-741078c84099434991a1e33ec1cd391b,nivo and pembro,0.388913
uuid-741078c84099434991a1e33ec1cd391b,believes,0.485258
uuid-741078c84099434991a1e33ec1cd391b,chemotherapy,0.38434
uuid-741078c84099434991a1e33ec1cd391b,impressed,0.395036
uuid-741078c84099434991a1e33ec1cd391b,feels,0.591521
uuid-c33541361e1f4e6286db4aac16bce94b,trial,0.379207
uuid-c33541361e1f4e6286db4aac16bce94b,efficacy,0.493787
uuid-c33541361e1f4e6286db4aac16bce94b,combination,0.408885
uuid-c33541361e1f4e6286db4aac16bce94b,chemo,0.334788
uuid-c33541361e1f4e6286db4aac16bce94b,IO,0.37877
uuid-c33541361e1f4e6286db4aac16bce94b,OS,0.573089
uuid-c33541361e1f4e6286db4aac16bce94b,monotherapy,0.333171
uuid-c33541361e1f4e6286db4aac16bce94b,response,0.327927
uuid-c33541361e1f4e6286db4aac16bce94b,data,0.599486
uuid-c33541361e1f4e6286db4aac16bce94b,combo,0.479572
uuid-c33541361e1f4e6286db4aac16bce94b,PFS,0.518835
uuid-c33541361e1f4e6286db4aac16bce94b,ORR,0.637456
uuid-c33541361e1f4e6286db4aac16bce94b,nivo and pembro,0.321439
uuid-c33541361e1f4e6286db4aac16bce94b,believes,0.434234
uuid-c33541361e1f4e6286db4aac16bce94b,impressed,0.569582
uuid-c33541361e1f4e6286db4aac16bce94b,feels,0.498673
uuid-7bdc1a24f5d94d5888d0d90b75932df9,Nivo,0.54584
uuid-7bdc1a24f5d94d5888d0d90b75932df9,pembro,0.370214
uuid-7bdc1a24f5d94d5888d0d90b75932df9,trial,0.354116
uuid-7bdc1a24f5d94d5888d0d90b75932df9,efficacy,0.690951
uuid-7bdc1a24f5d94d5888d0d90b75932df9,chemo,0.391844
uuid-7bdc1a24f5d94d5888d0d90b75932df9,Ipi,0.345048
uuid-7bdc1a24f5d94d5888d0d90b75932df9,OS,0.619901
uuid-7bdc1a24f5d94d5888d0d90b75932df9,data,0.52248
uuid-7bdc1a24f5d94d5888d0d90b75932df9,PFS,0.608135
uuid-7bdc1a24f5d94d5888d0d90b75932df9,ORR,0.641555
uuid-7bdc1a24f5d94d5888d0d90b75932df9,nivo and pembro,0.400896
uuid-7bdc1a24f5d94d5888d0d90b75932df9,believes,0.300273
uuid-7bdc1a24f5d94d5888d0d90b75932df9,chemotherapy,0.352871
uuid-7bdc1a24f5d94d5888d0d90b75932df9,impressed,0.475999
uuid-7bdc1a24f5d94d5888d0d90b75932df9,vs,0.490445
uuid-7bdc1a24f5d94d5888d0d90b75932df9,feels,0.560789
uuid-274a71cf9ff5462ab53a3d627c68bfde,TL,0.702213
uuid-274a71cf9ff5462ab53a3d627c68bfde,TL stated,0.364754
uuid-274a71cf9ff5462ab53a3d627c68bfde,institution,0.370796
uuid-274a71cf9ff5462ab53a3d627c68bfde,PD-L1,0.750064
uuid-274a71cf9ff5462ab53a3d627c68bfde,PD-L1 testing,0.887882
uuid-274a71cf9ff5462ab53a3d627c68bfde,testing,0.818189
uuid-274a71cf9ff5462ab53a3d627c68bfde,PDL1 testing,0.579099
uuid-274a71cf9ff5462ab53a3d627c68bfde,NSCLC patients,0.513425
uuid-274a71cf9ff5462ab53a3d627c68bfde,assay,0.818659
uuid-2db0a7f3d0d44cfda87c2c0655f658bf,RTL,0.32673
uuid-2db0a7f3d0d44cfda87c2c0655f658bf,commented,0.432399
uuid-2db0a7f3d0d44cfda87c2c0655f658bf,stated,0.360262
uuid-2db0a7f3d0d44cfda87c2c0655f658bf,OS,0.306431
uuid-2db0a7f3d0d44cfda87c2c0655f658bf,data,0.434189
uuid-2db0a7f3d0d44cfda87c2c0655f658bf,expressed,0.355585
uuid-2db0a7f3d0d44cfda87c2c0655f658bf,ASCO,0.380092
uuid-2db0a7f3d0d44cfda87c2c0655f658bf,impressed,0.456161
uuid-c663daf87b28404dbbed35214d493979,Opdivo,0.336697
uuid-c663daf87b28404dbbed35214d493979,dose,0.605151
uuid-c663daf87b28404dbbed35214d493979,toxicity,0.420416
uuid-c663daf87b28404dbbed35214d493979,efficacy,0.329032
uuid-c663daf87b28404dbbed35214d493979,regimen,0.334184
uuid-c663daf87b28404dbbed35214d493979,agents,0.312364
uuid-c663daf87b28404dbbed35214d493979,atezo,0.307236
uuid-c663daf87b28404dbbed35214d493979,physicians,0.422646
uuid-c663daf87b28404dbbed35214d493979,preferred,0.370652
uuid-c663daf87b28404dbbed35214d493979,vs,0.313414
uuid-c663daf87b28404dbbed35214d493979,drug,0.356497
uuid-c663daf87b28404dbbed35214d493979,flat dosing,0.521069
uuid-9899fb5b6bff45a4aea78cbe2d7e3c72,BMS,0.631642
uuid-9899fb5b6bff45a4aea78cbe2d7e3c72,Merck,0.498023
uuid-9899fb5b6bff45a4aea78cbe2d7e3c72,regards,0.353534
uuid-9899fb5b6bff45a4aea78cbe2d7e3c72,expressed,0.618699
uuid-29ed37c74df749a0bcaf321e3e5cdbf5,dose,0.553449
uuid-29ed37c74df749a0bcaf321e3e5cdbf5,toxicity,0.505037
uuid-29ed37c74df749a0bcaf321e3e5cdbf5,regimen,0.33043
uuid-29ed37c74df749a0bcaf321e3e5cdbf5,physicians,0.476341
uuid-29ed37c74df749a0bcaf321e3e5cdbf5,treatment,0.333719
uuid-cf2ba40a71b1457bb5658488bd1515a6,Opdivo,0.543062
uuid-cf2ba40a71b1457bb5658488bd1515a6,dose,0.32981
uuid-cf2ba40a71b1457bb5658488bd1515a6,physicians,0.430673
uuid-cf2ba40a71b1457bb5658488bd1515a6,expressed,0.325315
uuid-cf2ba40a71b1457bb5658488bd1515a6,oncology,0.367316
uuid-cf2ba40a71b1457bb5658488bd1515a6,drug,0.409445
uuid-cf2ba40a71b1457bb5658488bd1515a6,Keytruda,0.412156
uuid-cf2ba40a71b1457bb5658488bd1515a6,flat dosing,0.594433
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,PDL1,0.438266
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,efficacy,0.490931
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,chemo,0.402954
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,OS,0.805488
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,response,0.330499
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,data,0.451959
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,PFS,0.801016
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,PD1,0.303287
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,ORR,0.672401
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,nivo and pembro,0.451735
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,believes,0.527681
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,chemotherapy,0.360129
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,impressed,0.352273
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,feels,0.388093
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,PDL1 expression,0.342248
uuid-a1eeb06f1cbb4cc495d90467b1b2b557,biomarker,0.300737
uuid-bfbb6bf555024950befeb15e2fd818d4,Opdivo,0.425846
uuid-bfbb6bf555024950befeb15e2fd818d4,BMS,0.411082
uuid-bfbb6bf555024950befeb15e2fd818d4,shared,0.467794
uuid-bfbb6bf555024950befeb15e2fd818d4,Merck,0.311395
uuid-bfbb6bf555024950befeb15e2fd818d4,physicians,0.391492
uuid-bfbb6bf555024950befeb15e2fd818d4,clinical trials,0.305611
uuid-bfbb6bf555024950befeb15e2fd818d4,indication,0.304148
uuid-bfbb6bf555024950befeb15e2fd818d4,approved,0.343758
uuid-bfbb6bf555024950befeb15e2fd818d4,label,0.305389
uuid-bfbb6bf555024950befeb15e2fd818d4,drug,0.602138
uuid-bfbb6bf555024950befeb15e2fd818d4,Keytruda,0.399384
uuid-bfbb6bf555024950befeb15e2fd818d4,flat dosing,0.453012
uuid-6056797ab74d4bc4a66c52aacfb39719,Nivo,0.435478
uuid-6056797ab74d4bc4a66c52aacfb39719,patients,0.70288
uuid-6056797ab74d4bc4a66c52aacfb39719,Opdivo,0.366342
uuid-6056797ab74d4bc4a66c52aacfb39719,therapy,0.556618
uuid-6056797ab74d4bc4a66c52aacfb39719,nivolumab,0.442329
uuid-6056797ab74d4bc4a66c52aacfb39719,toxicity,0.425535
uuid-6056797ab74d4bc4a66c52aacfb39719,regimen,0.593499
uuid-6056797ab74d4bc4a66c52aacfb39719,treated,0.425208
uuid-6056797ab74d4bc4a66c52aacfb39719,combination,0.379421
uuid-6056797ab74d4bc4a66c52aacfb39719,chemo,0.46537
uuid-6056797ab74d4bc4a66c52aacfb39719,pts,0.689896
uuid-6056797ab74d4bc4a66c52aacfb39719,monotherapy,0.55017
uuid-6056797ab74d4bc4a66c52aacfb39719,treatment,0.59825
uuid-6056797ab74d4bc4a66c52aacfb39719,using nivo,0.306437
uuid-6056797ab74d4bc4a66c52aacfb39719,response,0.490536
uuid-6056797ab74d4bc4a66c52aacfb39719,combo,0.401739
uuid-6056797ab74d4bc4a66c52aacfb39719,PD1,0.514559
uuid-6056797ab74d4bc4a66c52aacfb39719,progression,0.727271
uuid-6056797ab74d4bc4a66c52aacfb39719,chemotherapy,0.416557
uuid-6056797ab74d4bc4a66c52aacfb39719,respond,0.583393
uuid-6056797ab74d4bc4a66c52aacfb39719,option,0.423183
uuid-c2deb0f2a5a74333b6d0b98a50df479a,Nivo,0.387948
uuid-c2deb0f2a5a74333b6d0b98a50df479a,NSCLC,0.32819
uuid-c2deb0f2a5a74333b6d0b98a50df479a,1L,0.563024
uuid-c2deb0f2a5a74333b6d0b98a50df479a,efficacy,0.344799
uuid-c2deb0f2a5a74333b6d0b98a50df479a,regimen,0.391372
uuid-c2deb0f2a5a74333b6d0b98a50df479a,combination,0.658572
uuid-c2deb0f2a5a74333b6d0b98a50df479a,chemo,0.62722
uuid-c2deb0f2a5a74333b6d0b98a50df479a,2L,0.488904
uuid-c2deb0f2a5a74333b6d0b98a50df479a,pts,0.347143
uuid-c2deb0f2a5a74333b6d0b98a50df479a,IO,0.649153
uuid-c2deb0f2a5a74333b6d0b98a50df479a,agents,0.542489
uuid-c2deb0f2a5a74333b6d0b98a50df479a,Ipi,0.332447
uuid-c2deb0f2a5a74333b6d0b98a50df479a,preferred,0.401091
uuid-c2deb0f2a5a74333b6d0b98a50df479a,monotherapy,0.71682
uuid-c2deb0f2a5a74333b6d0b98a50df479a,response,0.353359
uuid-c2deb0f2a5a74333b6d0b98a50df479a,combo,0.727871
uuid-c2deb0f2a5a74333b6d0b98a50df479a,PD1,0.577408
uuid-c2deb0f2a5a74333b6d0b98a50df479a,nivo and pembro,0.310607
uuid-c2deb0f2a5a74333b6d0b98a50df479a,progression,0.303866
uuid-c2deb0f2a5a74333b6d0b98a50df479a,believes,0.59049
uuid-c2deb0f2a5a74333b6d0b98a50df479a,chemotherapy,0.470178
uuid-c2deb0f2a5a74333b6d0b98a50df479a,feels,0.615777
uuid-c2deb0f2a5a74333b6d0b98a50df479a,option,0.576912
uuid-b4663cf9c9c4447eb59cb41092a7c8c2,tumor,0.379888
uuid-b4663cf9c9c4447eb59cb41092a7c8c2,PD-L1,0.322186
uuid-b4663cf9c9c4447eb59cb41092a7c8c2,testing,0.333459
uuid-b4663cf9c9c4447eb59cb41092a7c8c2,ASCO,0.318479
uuid-b4663cf9c9c4447eb59cb41092a7c8c2,biomarker,0.396802
uuid-b57d40d071ff4702924a2362eba78668,Nivo,0.342794
uuid-b57d40d071ff4702924a2362eba78668,patients,0.556395
uuid-b57d40d071ff4702924a2362eba78668,therapy,0.421967
uuid-b57d40d071ff4702924a2362eba78668,1L,0.508749
uuid-b57d40d071ff4702924a2362eba78668,regimen,0.469693
uuid-b57d40d071ff4702924a2362eba78668,combination,0.368711
uuid-b57d40d071ff4702924a2362eba78668,chemo,0.588116
uuid-b57d40d071ff4702924a2362eba78668,2L,0.439808
uuid-b57d40d071ff4702924a2362eba78668,pts,0.522877
uuid-b57d40d071ff4702924a2362eba78668,IO,0.494792
uuid-b57d40d071ff4702924a2362eba78668,agents,0.324179
uuid-b57d40d071ff4702924a2362eba78668,preferred,0.355148
uuid-b57d40d071ff4702924a2362eba78668,monotherapy,0.671021
uuid-b57d40d071ff4702924a2362eba78668,treatment,0.420066
uuid-b57d40d071ff4702924a2362eba78668,using nivo,0.329509
uuid-b57d40d071ff4702924a2362eba78668,response,0.409684
uuid-b57d40d071ff4702924a2362eba78668,combo,0.460738
uuid-b57d40d071ff4702924a2362eba78668,PD1,0.445714
uuid-b57d40d071ff4702924a2362eba78668,progression,0.520857
uuid-b57d40d071ff4702924a2362eba78668,believes,0.486847
uuid-b57d40d071ff4702924a2362eba78668,chemotherapy,0.494411
uuid-b57d40d071ff4702924a2362eba78668,respond,0.527431
uuid-b57d40d071ff4702924a2362eba78668,feels,0.463099
uuid-b57d40d071ff4702924a2362eba78668,option,0.62738
uuid-6d85a0d4c0fa49919007cc40ce263671,pembro,0.337533
uuid-6d85a0d4c0fa49919007cc40ce263671,BMS,0.467338
uuid-6d85a0d4c0fa49919007cc40ce263671,trial,0.466637
uuid-6d85a0d4c0fa49919007cc40ce263671,efficacy,0.538706
uuid-6d85a0d4c0fa49919007cc40ce263671,commented,0.425358
uuid-6d85a0d4c0fa49919007cc40ce263671,Merck,0.362554
uuid-6d85a0d4c0fa49919007cc40ce263671,OS,0.42765
uuid-6d85a0d4c0fa49919007cc40ce263671,regards,0.485662
uuid-6d85a0d4c0fa49919007cc40ce263671,data,0.705772
uuid-6d85a0d4c0fa49919007cc40ce263671,expressed,0.357411
uuid-6d85a0d4c0fa49919007cc40ce263671,mentioned,0.332393
uuid-6d85a0d4c0fa49919007cc40ce263671,indication,0.520105
uuid-6d85a0d4c0fa49919007cc40ce263671,PFS,0.405443
uuid-6d85a0d4c0fa49919007cc40ce263671,ORR,0.458093
uuid-6d85a0d4c0fa49919007cc40ce263671,nivo and pembro,0.325322
uuid-6d85a0d4c0fa49919007cc40ce263671,impressed,0.571655
uuid-6d85a0d4c0fa49919007cc40ce263671,label,0.317212
uuid-48058cfdb68946acaad153f94711c87e,Nivo,0.499574
uuid-48058cfdb68946acaad153f94711c87e,patients,0.563114
uuid-48058cfdb68946acaad153f94711c87e,pembro,0.320008
uuid-48058cfdb68946acaad153f94711c87e,therapy,0.516078
uuid-48058cfdb68946acaad153f94711c87e,nivolumab,0.57155
uuid-48058cfdb68946acaad153f94711c87e,1L,0.383253
uuid-48058cfdb68946acaad153f94711c87e,trial,0.324282
uuid-48058cfdb68946acaad153f94711c87e,regimen,0.390787
uuid-48058cfdb68946acaad153f94711c87e,treated,0.338899
uuid-48058cfdb68946acaad153f94711c87e,combination,0.497829
uuid-48058cfdb68946acaad153f94711c87e,chemo,0.527123
uuid-48058cfdb68946acaad153f94711c87e,2L,0.375948
uuid-48058cfdb68946acaad153f94711c87e,pts,0.453855
uuid-48058cfdb68946acaad153f94711c87e,preferred,0.400525
uuid-48058cfdb68946acaad153f94711c87e,monotherapy,0.585899
uuid-48058cfdb68946acaad153f94711c87e,treatment,0.363983
uuid-48058cfdb68946acaad153f94711c87e,using nivo,0.50081
uuid-48058cfdb68946acaad153f94711c87e,combo,0.421278
uuid-48058cfdb68946acaad153f94711c87e,clinical trials,0.37068
uuid-48058cfdb68946acaad153f94711c87e,PD1,0.453817
uuid-48058cfdb68946acaad153f94711c87e,approved,0.321672
uuid-48058cfdb68946acaad153f94711c87e,progression,0.334033
uuid-48058cfdb68946acaad153f94711c87e,chemotherapy,0.631259
uuid-48058cfdb68946acaad153f94711c87e,feels,0.493802
uuid-48058cfdb68946acaad153f94711c87e,RTL stated,0.396884
uuid-48058cfdb68946acaad153f94711c87e,option,0.612351
uuid-05154c17ad504af2b6ea2c5e8e5f5607,patients,0.783956
uuid-05154c17ad504af2b6ea2c5e8e5f5607,Opdivo,0.343337
uuid-05154c17ad504af2b6ea2c5e8e5f5607,therapy,0.552217
uuid-05154c17ad504af2b6ea2c5e8e5f5607,nivolumab,0.607116
uuid-05154c17ad504af2b6ea2c5e8e5f5607,regimen,0.461591
uuid-05154c17ad504af2b6ea2c5e8e5f5607,treated,0.57
uuid-05154c17ad504af2b6ea2c5e8e5f5607,RCC,0.377083
uuid-05154c17ad504af2b6ea2c5e8e5f5607,chemo,0.342724
uuid-05154c17ad504af2b6ea2c5e8e5f5607,2L,0.323198
uuid-05154c17ad504af2b6ea2c5e8e5f5607,pts,0.469279
uuid-05154c17ad504af2b6ea2c5e8e5f5607,preferred,0.346582
uuid-05154c17ad504af2b6ea2c5e8e5f5607,monotherapy,0.440435
uuid-05154c17ad504af2b6ea2c5e8e5f5607,treatment,0.691958
uuid-05154c17ad504af2b6ea2c5e8e5f5607,using nivo,0.419359
uuid-05154c17ad504af2b6ea2c5e8e5f5607,PD1,0.319532
uuid-05154c17ad504af2b6ea2c5e8e5f5607,progression,0.549624
uuid-05154c17ad504af2b6ea2c5e8e5f5607,chemotherapy,0.400835
uuid-05154c17ad504af2b6ea2c5e8e5f5607,respond,0.361261
uuid-05154c17ad504af2b6ea2c5e8e5f5607,RTL stated,0.416071
uuid-05154c17ad504af2b6ea2c5e8e5f5607,TL shared,0.401763
uuid-05154c17ad504af2b6ea2c5e8e5f5607,option,0.470227
uuid-b91e49985eef499282dee6ff5e0e21a2,Opdivo,0.476933
uuid-83b519da9b66476ca1f2a13c4dc5a28a,Nivo,0.352229
uuid-83b519da9b66476ca1f2a13c4dc5a28a,pembro,0.379006
uuid-83b519da9b66476ca1f2a13c4dc5a28a,RTL,0.442879
uuid-83b519da9b66476ca1f2a13c4dc5a28a,BMS,0.347129
uuid-83b519da9b66476ca1f2a13c4dc5a28a,trial,0.764877
uuid-83b519da9b66476ca1f2a13c4dc5a28a,efficacy,0.427106
uuid-83b519da9b66476ca1f2a13c4dc5a28a,combination,0.337219
uuid-83b519da9b66476ca1f2a13c4dc5a28a,Ipi,0.396848
uuid-83b519da9b66476ca1f2a13c4dc5a28a,OS,0.374478
uuid-83b519da9b66476ca1f2a13c4dc5a28a,data,0.519571
uuid-83b519da9b66476ca1f2a13c4dc5a28a,clinical trials,0.338967
uuid-83b519da9b66476ca1f2a13c4dc5a28a,PFS,0.391976
uuid-83b519da9b66476ca1f2a13c4dc5a28a,ORR,0.467366
uuid-83b519da9b66476ca1f2a13c4dc5a28a,nivo and pembro,0.354223
uuid-83b519da9b66476ca1f2a13c4dc5a28a,impressed,0.477344
uuid-83b519da9b66476ca1f2a13c4dc5a28a,vs,0.324838
uuid-d1c9833ac23d4459bb6b546d2f7d78be,BMS,0.339717
uuid-d1c9833ac23d4459bb6b546d2f7d78be,combination,0.53891
uuid-d1c9833ac23d4459bb6b546d2f7d78be,IO,0.59985
uuid-d1c9833ac23d4459bb6b546d2f7d78be,agents,0.369276
uuid-d1c9833ac23d4459bb6b546d2f7d78be,combo,0.47979
uuid-d1c9833ac23d4459bb6b546d2f7d78be,believes,0.408999
uuid-d1c9833ac23d4459bb6b546d2f7d78be,feels,0.333133
uuid-071a1ddc37e54067b0c38f92d5c4ead5,RTL,0.463746
uuid-071a1ddc37e54067b0c38f92d5c4ead5,trial,0.347707
uuid-071a1ddc37e54067b0c38f92d5c4ead5,NTL,0.401811
uuid-071a1ddc37e54067b0c38f92d5c4ead5,commented,0.530968
uuid-071a1ddc37e54067b0c38f92d5c4ead5,stated,0.456026
uuid-071a1ddc37e54067b0c38f92d5c4ead5,OS,0.402922
uuid-071a1ddc37e54067b0c38f92d5c4ead5,data,0.58117
uuid-071a1ddc37e54067b0c38f92d5c4ead5,expressed,0.385597
uuid-071a1ddc37e54067b0c38f92d5c4ead5,mentioned,0.357592
uuid-071a1ddc37e54067b0c38f92d5c4ead5,indication,0.425844
uuid-071a1ddc37e54067b0c38f92d5c4ead5,PFS,0.331582
uuid-071a1ddc37e54067b0c38f92d5c4ead5,ORR,0.38022
uuid-071a1ddc37e54067b0c38f92d5c4ead5,SCCHN,0.488326
uuid-071a1ddc37e54067b0c38f92d5c4ead5,HCP,0.337129
uuid-071a1ddc37e54067b0c38f92d5c4ead5,ASCO,0.428322
uuid-071a1ddc37e54067b0c38f92d5c4ead5,impressed,0.665217
uuid-071a1ddc37e54067b0c38f92d5c4ead5,LTL,0.392596
uuid-071a1ddc37e54067b0c38f92d5c4ead5,SCLC,0.359152
uuid-071a1ddc37e54067b0c38f92d5c4ead5,feels,0.338307
uuid-071a1ddc37e54067b0c38f92d5c4ead5,Regional TL,0.496972
uuid-071a1ddc37e54067b0c38f92d5c4ead5,bladder,0.322602
uuid-33cbf90968ff464180dbc8f386392c53,Opdivo,0.648502
uuid-33cbf90968ff464180dbc8f386392c53,dose,0.363786
uuid-33cbf90968ff464180dbc8f386392c53,regimen,0.362438
uuid-33cbf90968ff464180dbc8f386392c53,preferred,0.365499
uuid-33cbf90968ff464180dbc8f386392c53,indication,0.369729
uuid-33cbf90968ff464180dbc8f386392c53,approved,0.500591
uuid-33cbf90968ff464180dbc8f386392c53,label,0.337035
uuid-33cbf90968ff464180dbc8f386392c53,drug,0.497183
uuid-33cbf90968ff464180dbc8f386392c53,Keytruda,0.461702
uuid-33cbf90968ff464180dbc8f386392c53,option,0.337474
uuid-33cbf90968ff464180dbc8f386392c53,flat dosing,0.389317
uuid-a59394f982fd4fd29e1b442fb60b3f10,Nivo,0.496442
uuid-a59394f982fd4fd29e1b442fb60b3f10,toxicity,0.301024
uuid-a59394f982fd4fd29e1b442fb60b3f10,trial,0.431254
uuid-a59394f982fd4fd29e1b442fb60b3f10,efficacy,0.674803
uuid-a59394f982fd4fd29e1b442fb60b3f10,regimen,0.370046
uuid-a59394f982fd4fd29e1b442fb60b3f10,combination,0.591256
uuid-a59394f982fd4fd29e1b442fb60b3f10,chemo,0.498665
uuid-a59394f982fd4fd29e1b442fb60b3f10,IO,0.366273
uuid-a59394f982fd4fd29e1b442fb60b3f10,agents,0.356429
uuid-a59394f982fd4fd29e1b442fb60b3f10,Ipi,0.551425
uuid-a59394f982fd4fd29e1b442fb60b3f10,OS,0.522909
uuid-a59394f982fd4fd29e1b442fb60b3f10,monotherapy,0.470033
uuid-a59394f982fd4fd29e1b442fb60b3f10,data,0.386242
uuid-a59394f982fd4fd29e1b442fb60b3f10,combo,0.697521
uuid-a59394f982fd4fd29e1b442fb60b3f10,PFS,0.47548
uuid-a59394f982fd4fd29e1b442fb60b3f10,PD1,0.380422
uuid-a59394f982fd4fd29e1b442fb60b3f10,ORR,0.552744
uuid-a59394f982fd4fd29e1b442fb60b3f10,nivo and pembro,0.398382
uuid-a59394f982fd4fd29e1b442fb60b3f10,believes,0.491473
uuid-a59394f982fd4fd29e1b442fb60b3f10,chemotherapy,0.419329
uuid-a59394f982fd4fd29e1b442fb60b3f10,impressed,0.359515
uuid-a59394f982fd4fd29e1b442fb60b3f10,vs,0.332795
uuid-a59394f982fd4fd29e1b442fb60b3f10,feels,0.439855
uuid-a59394f982fd4fd29e1b442fb60b3f10,option,0.322097
uuid-a072b2d919a740d0a26e4782368661b9,Nivo,0.404268
uuid-a072b2d919a740d0a26e4782368661b9,pembro,0.353324
uuid-a072b2d919a740d0a26e4782368661b9,dose,0.324691
uuid-a072b2d919a740d0a26e4782368661b9,toxicity,0.300581
uuid-a072b2d919a740d0a26e4782368661b9,efficacy,0.66029
uuid-a072b2d919a740d0a26e4782368661b9,regimen,0.300272
uuid-a072b2d919a740d0a26e4782368661b9,combination,0.308954
uuid-a072b2d919a740d0a26e4782368661b9,chemo,0.35939
uuid-a072b2d919a740d0a26e4782368661b9,agents,0.387523
uuid-a072b2d919a740d0a26e4782368661b9,Ipi,0.398075
uuid-a072b2d919a740d0a26e4782368661b9,atezo,0.367845
uuid-a072b2d919a740d0a26e4782368661b9,monotherapy,0.319378
uuid-a072b2d919a740d0a26e4782368661b9,data,0.389363
uuid-a072b2d919a740d0a26e4782368661b9,combo,0.327426
uuid-a072b2d919a740d0a26e4782368661b9,indication,0.350516
uuid-a072b2d919a740d0a26e4782368661b9,believes,0.394158
uuid-a072b2d919a740d0a26e4782368661b9,impressed,0.350635
uuid-a072b2d919a740d0a26e4782368661b9,vs,0.384373
uuid-a072b2d919a740d0a26e4782368661b9,feels,0.454337
uuid-b6970402a27e4ff08eb0b353b231749e,Nivo,0.429817
uuid-b6970402a27e4ff08eb0b353b231749e,patients,0.369322
uuid-b6970402a27e4ff08eb0b353b231749e,therapy,0.576085
uuid-b6970402a27e4ff08eb0b353b231749e,nivolumab,0.351212
uuid-b6970402a27e4ff08eb0b353b231749e,toxicity,0.49909
uuid-b6970402a27e4ff08eb0b353b231749e,efficacy,0.334739
uuid-b6970402a27e4ff08eb0b353b231749e,regimen,0.48021
uuid-b6970402a27e4ff08eb0b353b231749e,combination,0.519417
uuid-b6970402a27e4ff08eb0b353b231749e,chemo,0.496564
uuid-b6970402a27e4ff08eb0b353b231749e,pts,0.300526
uuid-b6970402a27e4ff08eb0b353b231749e,Ipi,0.33072
uuid-b6970402a27e4ff08eb0b353b231749e,monotherapy,0.471191
uuid-b6970402a27e4ff08eb0b353b231749e,treatment,0.410403
uuid-b6970402a27e4ff08eb0b353b231749e,response,0.54126
uuid-b6970402a27e4ff08eb0b353b231749e,combo,0.368653
uuid-b6970402a27e4ff08eb0b353b231749e,PD1,0.551649
uuid-b6970402a27e4ff08eb0b353b231749e,cHL,0.319573
uuid-b6970402a27e4ff08eb0b353b231749e,progression,0.511716
uuid-b6970402a27e4ff08eb0b353b231749e,chemotherapy,0.545222
uuid-b6970402a27e4ff08eb0b353b231749e,respond,0.360383
uuid-b6970402a27e4ff08eb0b353b231749e,option,0.306631
uuid-8c817b50c4d04350ab7c2f646f617c27,patients,0.36127
uuid-8c817b50c4d04350ab7c2f646f617c27,Opdivo,0.568488
uuid-8c817b50c4d04350ab7c2f646f617c27,dose,0.800228
uuid-8c817b50c4d04350ab7c2f646f617c27,toxicity,0.365531
uuid-8c817b50c4d04350ab7c2f646f617c27,Ipi,0.315903
uuid-8c817b50c4d04350ab7c2f646f617c27,indication,0.311734
uuid-8c817b50c4d04350ab7c2f646f617c27,vs,0.376087
uuid-8c817b50c4d04350ab7c2f646f617c27,drug,0.361627
uuid-8c817b50c4d04350ab7c2f646f617c27,Keytruda,0.519433
uuid-8c817b50c4d04350ab7c2f646f617c27,flat dosing,0.814123
uuid-5ac03a5383ff4c3590057a5eadddb1dd,Nivo,0.335636
uuid-5ac03a5383ff4c3590057a5eadddb1dd,patients,0.75837
uuid-5ac03a5383ff4c3590057a5eadddb1dd,Opdivo,0.446328
uuid-5ac03a5383ff4c3590057a5eadddb1dd,therapy,0.400382
uuid-5ac03a5383ff4c3590057a5eadddb1dd,dose,0.358266
uuid-5ac03a5383ff4c3590057a5eadddb1dd,nivolumab,0.36686
uuid-5ac03a5383ff4c3590057a5eadddb1dd,regimen,0.592261
uuid-5ac03a5383ff4c3590057a5eadddb1dd,treated,0.397535
uuid-5ac03a5383ff4c3590057a5eadddb1dd,chemo,0.40273
uuid-5ac03a5383ff4c3590057a5eadddb1dd,pts,0.592909
uuid-5ac03a5383ff4c3590057a5eadddb1dd,monotherapy,0.434103
uuid-5ac03a5383ff4c3590057a5eadddb1dd,treatment,0.512123
uuid-5ac03a5383ff4c3590057a5eadddb1dd,response,0.302175
uuid-5ac03a5383ff4c3590057a5eadddb1dd,progression,0.573366
uuid-5ac03a5383ff4c3590057a5eadddb1dd,chemotherapy,0.357709
uuid-5ac03a5383ff4c3590057a5eadddb1dd,respond,0.46353
uuid-5ac03a5383ff4c3590057a5eadddb1dd,option,0.426805
uuid-46f1297c9dd44c6e872c72ff878c0d7f,pembro,0.401444
uuid-46f1297c9dd44c6e872c72ff878c0d7f,BMS,0.664736
uuid-46f1297c9dd44c6e872c72ff878c0d7f,PDL1,0.383424
uuid-46f1297c9dd44c6e872c72ff878c0d7f,trial,0.875715
uuid-46f1297c9dd44c6e872c72ff878c0d7f,efficacy,0.454558
uuid-46f1297c9dd44c6e872c72ff878c0d7f,Merck,0.537834
uuid-46f1297c9dd44c6e872c72ff878c0d7f,OS,0.474496
uuid-46f1297c9dd44c6e872c72ff878c0d7f,data,0.56622
uuid-46f1297c9dd44c6e872c72ff878c0d7f,clinical trials,0.36253
uuid-46f1297c9dd44c6e872c72ff878c0d7f,PFS,0.512808
uuid-46f1297c9dd44c6e872c72ff878c0d7f,ORR,0.532244
uuid-46f1297c9dd44c6e872c72ff878c0d7f,nivo and pembro,0.442439
uuid-46f1297c9dd44c6e872c72ff878c0d7f,impressed,0.399965
uuid-46f1297c9dd44c6e872c72ff878c0d7f,feels,0.373583
uuid-46f1297c9dd44c6e872c72ff878c0d7f,PDL1 expression,0.371655
uuid-75d37836f6bc45029e82507440bfcced,tumor,0.343583
uuid-75d37836f6bc45029e82507440bfcced,believes,0.348894
uuid-75d37836f6bc45029e82507440bfcced,immunotherapy,0.448639
uuid-75d37836f6bc45029e82507440bfcced,PDL1 expression,0.333344
uuid-75d37836f6bc45029e82507440bfcced,biomarker,0.423443
uuid-09beaa672b2d42b680332549c62ec354,lung,0.329322
uuid-09beaa672b2d42b680332549c62ec354,chemo,0.348034
uuid-09beaa672b2d42b680332549c62ec354,OS,0.472756
uuid-09beaa672b2d42b680332549c62ec354,response,0.397435
uuid-09beaa672b2d42b680332549c62ec354,PFS,0.531907
uuid-09beaa672b2d42b680332549c62ec354,AI,0.637109
uuid-09beaa672b2d42b680332549c62ec354,ORR,0.448157
uuid-09beaa672b2d42b680332549c62ec354,nivo and pembro,0.383596
uuid-0ca76554d0d64bce984802f6756944df,patients,0.678182
uuid-0ca76554d0d64bce984802f6756944df,therapy,0.581226
uuid-0ca76554d0d64bce984802f6756944df,nivolumab,0.347078
uuid-0ca76554d0d64bce984802f6756944df,NSCLC,0.318882
uuid-0ca76554d0d64bce984802f6756944df,1L,0.484578
uuid-0ca76554d0d64bce984802f6756944df,regimen,0.495944
uuid-0ca76554d0d64bce984802f6756944df,treated,0.441225
uuid-0ca76554d0d64bce984802f6756944df,combination,0.372497
uuid-0ca76554d0d64bce984802f6756944df,chemo,0.632762
uuid-0ca76554d0d64bce984802f6756944df,2L,0.398843
uuid-0ca76554d0d64bce984802f6756944df,pts,0.586423
uuid-0ca76554d0d64bce984802f6756944df,IO,0.480831
uuid-0ca76554d0d64bce984802f6756944df,preferred,0.323514
uuid-0ca76554d0d64bce984802f6756944df,monotherapy,0.600548
uuid-0ca76554d0d64bce984802f6756944df,treatment,0.567848
uuid-0ca76554d0d64bce984802f6756944df,using nivo,0.343989
uuid-0ca76554d0d64bce984802f6756944df,response,0.507538
uuid-0ca76554d0d64bce984802f6756944df,combo,0.415197
uuid-0ca76554d0d64bce984802f6756944df,PD1,0.521091
uuid-0ca76554d0d64bce984802f6756944df,progression,0.684505
uuid-0ca76554d0d64bce984802f6756944df,chemotherapy,0.573727
uuid-0ca76554d0d64bce984802f6756944df,respond,0.451388
uuid-0ca76554d0d64bce984802f6756944df,RTL stated,0.312858
uuid-0ca76554d0d64bce984802f6756944df,option,0.557891
uuid-4e65d46afb6c459a8e4733f9a1e85549,patients,0.570668
uuid-4e65d46afb6c459a8e4733f9a1e85549,Opdivo,0.337622
uuid-4e65d46afb6c459a8e4733f9a1e85549,therapy,0.348643
uuid-4e65d46afb6c459a8e4733f9a1e85549,nivolumab,0.367484
uuid-4e65d46afb6c459a8e4733f9a1e85549,regimen,0.449559
uuid-4e65d46afb6c459a8e4733f9a1e85549,treated,0.669292
uuid-4e65d46afb6c459a8e4733f9a1e85549,physicians,0.435804
uuid-4e65d46afb6c459a8e4733f9a1e85549,treatment,0.631399
uuid-4e65d46afb6c459a8e4733f9a1e85549,progression,0.446186
uuid-4e65d46afb6c459a8e4733f9a1e85549,oncologist,0.335882
uuid-4e65d46afb6c459a8e4733f9a1e85549,respond,0.334933
uuid-cf9739ce7a57490a8fbda3a9e81e4009,Nivo,0.319811
uuid-cf9739ce7a57490a8fbda3a9e81e4009,pembro,0.562145
uuid-cf9739ce7a57490a8fbda3a9e81e4009,BMS,0.347621
uuid-cf9739ce7a57490a8fbda3a9e81e4009,PDL1,0.494934
uuid-cf9739ce7a57490a8fbda3a9e81e4009,trial,0.404457
uuid-cf9739ce7a57490a8fbda3a9e81e4009,efficacy,0.658196
uuid-cf9739ce7a57490a8fbda3a9e81e4009,agents,0.337093
uuid-cf9739ce7a57490a8fbda3a9e81e4009,OS,0.338966
uuid-cf9739ce7a57490a8fbda3a9e81e4009,atezo,0.569419
uuid-cf9739ce7a57490a8fbda3a9e81e4009,data,0.522436
uuid-cf9739ce7a57490a8fbda3a9e81e4009,PFS,0.336256
uuid-cf9739ce7a57490a8fbda3a9e81e4009,ORR,0.393847
uuid-cf9739ce7a57490a8fbda3a9e81e4009,nivo and pembro,0.646972
uuid-cf9739ce7a57490a8fbda3a9e81e4009,believes,0.443424
uuid-cf9739ce7a57490a8fbda3a9e81e4009,vs,0.580775
uuid-cf9739ce7a57490a8fbda3a9e81e4009,feels,0.408672
uuid-cf9739ce7a57490a8fbda3a9e81e4009,PDL1 expression,0.504333
uuid-a8e460e767e946d49da1f9651c1c5694,patients,0.612831
uuid-a8e460e767e946d49da1f9651c1c5694,therapy,0.350855
uuid-a8e460e767e946d49da1f9651c1c5694,regimen,0.571534
uuid-a8e460e767e946d49da1f9651c1c5694,treated,0.399483
uuid-a8e460e767e946d49da1f9651c1c5694,chemo,0.456386
uuid-a8e460e767e946d49da1f9651c1c5694,pts,0.496019
uuid-a8e460e767e946d49da1f9651c1c5694,monotherapy,0.410534
uuid-a8e460e767e946d49da1f9651c1c5694,treatment,0.509625
uuid-a8e460e767e946d49da1f9651c1c5694,response,0.398663
uuid-a8e460e767e946d49da1f9651c1c5694,progression,0.568709
uuid-a8e460e767e946d49da1f9651c1c5694,chemotherapy,0.396539
uuid-a8e460e767e946d49da1f9651c1c5694,respond,0.498666
uuid-a8e460e767e946d49da1f9651c1c5694,feels,0.360805
uuid-a8e460e767e946d49da1f9651c1c5694,option,0.389208
uuid-22b18701f8d34be1976dcdd698af2610,Nivo,0.340959
uuid-22b18701f8d34be1976dcdd698af2610,pembro,0.538181
uuid-22b18701f8d34be1976dcdd698af2610,dose,0.560488
uuid-22b18701f8d34be1976dcdd698af2610,trial,0.611725
uuid-22b18701f8d34be1976dcdd698af2610,combination,0.306132
uuid-22b18701f8d34be1976dcdd698af2610,Ipi,0.550654
uuid-22b18701f8d34be1976dcdd698af2610,atezo,0.347572
uuid-22b18701f8d34be1976dcdd698af2610,combo,0.341729
uuid-22b18701f8d34be1976dcdd698af2610,clinical trials,0.347876
uuid-22b18701f8d34be1976dcdd698af2610,vs,0.616951
uuid-22b18701f8d34be1976dcdd698af2610,flat dosing,0.439355
uuid-ae29b8a788f74d55a3424eb21c7056a3,Nivo,0.385597
uuid-ae29b8a788f74d55a3424eb21c7056a3,patients,0.837004
uuid-ae29b8a788f74d55a3424eb21c7056a3,Opdivo,0.315772
uuid-ae29b8a788f74d55a3424eb21c7056a3,therapy,0.682158
uuid-ae29b8a788f74d55a3424eb21c7056a3,nivolumab,0.511735
uuid-ae29b8a788f74d55a3424eb21c7056a3,toxicity,0.32103
uuid-ae29b8a788f74d55a3424eb21c7056a3,regimen,0.664158
uuid-ae29b8a788f74d55a3424eb21c7056a3,treated,0.545056
uuid-ae29b8a788f74d55a3424eb21c7056a3,combination,0.355299
uuid-ae29b8a788f74d55a3424eb21c7056a3,chemo,0.542848
uuid-ae29b8a788f74d55a3424eb21c7056a3,pts,0.694778
uuid-ae29b8a788f74d55a3424eb21c7056a3,monotherapy,0.535413
uuid-ae29b8a788f74d55a3424eb21c7056a3,treatment,0.726788
uuid-ae29b8a788f74d55a3424eb21c7056a3,response,0.630013
uuid-ae29b8a788f74d55a3424eb21c7056a3,combo,0.300469
uuid-ae29b8a788f74d55a3424eb21c7056a3,PD1,0.500472
uuid-ae29b8a788f74d55a3424eb21c7056a3,progression,0.813941
uuid-ae29b8a788f74d55a3424eb21c7056a3,chemotherapy,0.53489
uuid-ae29b8a788f74d55a3424eb21c7056a3,respond,0.611693
uuid-ae29b8a788f74d55a3424eb21c7056a3,option,0.424045
uuid-407e9c286c5d48dca736c9251656428e,therapy,0.301198
uuid-407e9c286c5d48dca736c9251656428e,toxicity,0.44872
uuid-407e9c286c5d48dca736c9251656428e,efficacy,0.348326
uuid-407e9c286c5d48dca736c9251656428e,regimen,0.381324
uuid-407e9c286c5d48dca736c9251656428e,combination,0.643646
uuid-407e9c286c5d48dca736c9251656428e,chemo,0.531491
uuid-407e9c286c5d48dca736c9251656428e,IO,0.383684
uuid-407e9c286c5d48dca736c9251656428e,agents,0.36089
uuid-407e9c286c5d48dca736c9251656428e,Ipi,0.319917
uuid-407e9c286c5d48dca736c9251656428e,monotherapy,0.510763
uuid-407e9c286c5d48dca736c9251656428e,response,0.515382
uuid-407e9c286c5d48dca736c9251656428e,combo,0.562966
uuid-407e9c286c5d48dca736c9251656428e,PD1,0.660351
uuid-407e9c286c5d48dca736c9251656428e,progression,0.451727
uuid-407e9c286c5d48dca736c9251656428e,believes,0.428163
uuid-407e9c286c5d48dca736c9251656428e,chemotherapy,0.48078
uuid-407e9c286c5d48dca736c9251656428e,respond,0.339201
uuid-407e9c286c5d48dca736c9251656428e,PD-1,0.320146
uuid-fdf116b13bb446d1a1b69ee258ee02c5,Nivo,0.430104
uuid-fdf116b13bb446d1a1b69ee258ee02c5,PDL1,0.445817
uuid-fdf116b13bb446d1a1b69ee258ee02c5,trial,0.365283
uuid-fdf116b13bb446d1a1b69ee258ee02c5,efficacy,0.644381
uuid-fdf116b13bb446d1a1b69ee258ee02c5,chemo,0.313731
uuid-fdf116b13bb446d1a1b69ee258ee02c5,OS,0.865311
uuid-fdf116b13bb446d1a1b69ee258ee02c5,data,0.594081
uuid-fdf116b13bb446d1a1b69ee258ee02c5,PFS,0.882312
uuid-fdf116b13bb446d1a1b69ee258ee02c5,ORR,0.815304
uuid-fdf116b13bb446d1a1b69ee258ee02c5,nivo and pembro,0.554568
uuid-fdf116b13bb446d1a1b69ee258ee02c5,believes,0.423018
uuid-fdf116b13bb446d1a1b69ee258ee02c5,impressed,0.493108
uuid-fdf116b13bb446d1a1b69ee258ee02c5,feels,0.410079
uuid-fdf116b13bb446d1a1b69ee258ee02c5,PDL1 expression,0.418409
uuid-6cb7c36024a44b069bb8ca5613463238,PD-L1,0.362051
uuid-6cb7c36024a44b069bb8ca5613463238,PD-L1 testing,0.446048
uuid-6cb7c36024a44b069bb8ca5613463238,testing,0.454361
uuid-6cb7c36024a44b069bb8ca5613463238,assay,0.366502
uuid-6cb7c36024a44b069bb8ca5613463238,biomarker,0.36531
uuid-413c043f1c894043bebe98612c1b7b96,Nivo,0.38383
uuid-413c043f1c894043bebe98612c1b7b96,patients,0.833033
uuid-413c043f1c894043bebe98612c1b7b96,Opdivo,0.310416
uuid-413c043f1c894043bebe98612c1b7b96,therapy,0.657174
uuid-413c043f1c894043bebe98612c1b7b96,nivolumab,0.500993
uuid-413c043f1c894043bebe98612c1b7b96,toxicity,0.357145
uuid-413c043f1c894043bebe98612c1b7b96,regimen,0.703759
uuid-413c043f1c894043bebe98612c1b7b96,treated,0.52609
uuid-413c043f1c894043bebe98612c1b7b96,combination,0.391599
uuid-413c043f1c894043bebe98612c1b7b96,chemo,0.56037
uuid-413c043f1c894043bebe98612c1b7b96,pts,0.687372
uuid-413c043f1c894043bebe98612c1b7b96,monotherapy,0.567559
uuid-413c043f1c894043bebe98612c1b7b96,treatment,0.723554
uuid-413c043f1c894043bebe98612c1b7b96,response,0.609111
uuid-413c043f1c894043bebe98612c1b7b96,combo,0.343292
uuid-413c043f1c894043bebe98612c1b7b96,PD1,0.495301
uuid-413c043f1c894043bebe98612c1b7b96,progression,0.794776
uuid-413c043f1c894043bebe98612c1b7b96,chemotherapy,0.545224
uuid-413c043f1c894043bebe98612c1b7b96,respond,0.600573
uuid-413c043f1c894043bebe98612c1b7b96,option,0.461321
uuid-279be1575a4642ea9e668e616d73605d,RTL,0.3044
uuid-279be1575a4642ea9e668e616d73605d,BMS,0.454498
uuid-279be1575a4642ea9e668e616d73605d,shared,0.349995
uuid-279be1575a4642ea9e668e616d73605d,commented,0.310707
uuid-279be1575a4642ea9e668e616d73605d,physicians,0.503729
uuid-279be1575a4642ea9e668e616d73605d,academic,0.304324
uuid-d441395ecb6144e79e4c54fcadb95db6,Nivo,0.482788
uuid-d441395ecb6144e79e4c54fcadb95db6,pembro,0.432915
uuid-d441395ecb6144e79e4c54fcadb95db6,dose,0.55412
uuid-d441395ecb6144e79e4c54fcadb95db6,trial,0.601988
uuid-d441395ecb6144e79e4c54fcadb95db6,efficacy,0.532171
uuid-d441395ecb6144e79e4c54fcadb95db6,combination,0.445974
uuid-d441395ecb6144e79e4c54fcadb95db6,chemo,0.315822
uuid-d441395ecb6144e79e4c54fcadb95db6,Ipi,0.707347
uuid-d441395ecb6144e79e4c54fcadb95db6,atezo,0.304579
uuid-d441395ecb6144e79e4c54fcadb95db6,combo,0.481964
uuid-d441395ecb6144e79e4c54fcadb95db6,ORR,0.316209
uuid-d441395ecb6144e79e4c54fcadb95db6,vs,0.553637
uuid-d441395ecb6144e79e4c54fcadb95db6,feels,0.340391
uuid-d441395ecb6144e79e4c54fcadb95db6,flat dosing,0.344149
uuid-f5d1757e8e49403fb8bbee19ece64499,Opdivo,0.337519
uuid-f5d1757e8e49403fb8bbee19ece64499,dose,0.567614
uuid-f5d1757e8e49403fb8bbee19ece64499,indication,0.372627
uuid-f5d1757e8e49403fb8bbee19ece64499,AI,0.488611
uuid-f5d1757e8e49403fb8bbee19ece64499,drug,0.460278
uuid-f5d1757e8e49403fb8bbee19ece64499,Keytruda,0.490228
uuid-f5d1757e8e49403fb8bbee19ece64499,flat dosing,0.674004
uuid-601f33f6e21a4b879bbd6fbf42478b47,patients,0.589383
uuid-601f33f6e21a4b879bbd6fbf42478b47,nivolumab,0.30323
uuid-601f33f6e21a4b879bbd6fbf42478b47,lung,0.394066
uuid-601f33f6e21a4b879bbd6fbf42478b47,regimen,0.420696
uuid-601f33f6e21a4b879bbd6fbf42478b47,treated,0.702189
uuid-601f33f6e21a4b879bbd6fbf42478b47,melanoma,0.468077
uuid-601f33f6e21a4b879bbd6fbf42478b47,RCC,0.446705
uuid-601f33f6e21a4b879bbd6fbf42478b47,TL stated,0.338489
uuid-601f33f6e21a4b879bbd6fbf42478b47,pts,0.456592
uuid-601f33f6e21a4b879bbd6fbf42478b47,treatment,0.541146
uuid-601f33f6e21a4b879bbd6fbf42478b47,progression,0.48542
uuid-601f33f6e21a4b879bbd6fbf42478b47,respond,0.389125
uuid-601f33f6e21a4b879bbd6fbf42478b47,RTL stated,0.381422
uuid-601f33f6e21a4b879bbd6fbf42478b47,TL shared,0.591912
uuid-e7c8c7a5c9a74853b66f7457df8bb03d,TL,0.51852
uuid-e7c8c7a5c9a74853b66f7457df8bb03d,1L,0.346161
uuid-e7c8c7a5c9a74853b66f7457df8bb03d,TL stated,0.589332
uuid-e7c8c7a5c9a74853b66f7457df8bb03d,PD-L1,0.647174
uuid-e7c8c7a5c9a74853b66f7457df8bb03d,PD-L1 testing,0.774834
uuid-e7c8c7a5c9a74853b66f7457df8bb03d,testing,0.784529
uuid-e7c8c7a5c9a74853b66f7457df8bb03d,PDL1 testing,0.721067
uuid-e7c8c7a5c9a74853b66f7457df8bb03d,NSCLC patients,0.697661
uuid-e7c8c7a5c9a74853b66f7457df8bb03d,assay,0.46553
uuid-e7c8c7a5c9a74853b66f7457df8bb03d,RTL stated,0.306714
uuid-bfbd96f95f6b41e4853395bdb05add92,patients,0.364276
uuid-5954d4d4caad4b24b0cfd634f5e4193d,patients,0.575416
uuid-5954d4d4caad4b24b0cfd634f5e4193d,therapy,0.475814
uuid-5954d4d4caad4b24b0cfd634f5e4193d,treated,0.392895
uuid-5954d4d4caad4b24b0cfd634f5e4193d,tumor,0.456288
uuid-5954d4d4caad4b24b0cfd634f5e4193d,pts,0.537474
uuid-5954d4d4caad4b24b0cfd634f5e4193d,treatment,0.480858
uuid-5954d4d4caad4b24b0cfd634f5e4193d,response,0.70497
uuid-5954d4d4caad4b24b0cfd634f5e4193d,PD1,0.314219
uuid-5954d4d4caad4b24b0cfd634f5e4193d,progression,0.702877
uuid-5954d4d4caad4b24b0cfd634f5e4193d,respond,0.492121
uuid-b365eb5949a244b1b067dd33f3f1e7ef,Nivo,0.426475
uuid-b365eb5949a244b1b067dd33f3f1e7ef,pembro,0.437267
uuid-b365eb5949a244b1b067dd33f3f1e7ef,BMS,0.334893
uuid-b365eb5949a244b1b067dd33f3f1e7ef,1L,0.348356
uuid-b365eb5949a244b1b067dd33f3f1e7ef,PDL1,0.302617
uuid-b365eb5949a244b1b067dd33f3f1e7ef,trial,0.435907
uuid-b365eb5949a244b1b067dd33f3f1e7ef,efficacy,0.533708
uuid-b365eb5949a244b1b067dd33f3f1e7ef,combination,0.373241
uuid-b365eb5949a244b1b067dd33f3f1e7ef,2L,0.342666
uuid-b365eb5949a244b1b067dd33f3f1e7ef,agents,0.458709
uuid-b365eb5949a244b1b067dd33f3f1e7ef,stated,0.312204
uuid-b365eb5949a244b1b067dd33f3f1e7ef,OS,0.424446
uuid-b365eb5949a244b1b067dd33f3f1e7ef,atezo,0.407028
uuid-b365eb5949a244b1b067dd33f3f1e7ef,monotherapy,0.337728
uuid-b365eb5949a244b1b067dd33f3f1e7ef,data,0.761755
uuid-b365eb5949a244b1b067dd33f3f1e7ef,combo,0.381354
uuid-b365eb5949a244b1b067dd33f3f1e7ef,clinical trials,0.301276
uuid-b365eb5949a244b1b067dd33f3f1e7ef,indication,0.301178
uuid-b365eb5949a244b1b067dd33f3f1e7ef,PFS,0.362749
uuid-b365eb5949a244b1b067dd33f3f1e7ef,PD1,0.321696
uuid-b365eb5949a244b1b067dd33f3f1e7ef,ORR,0.476761
uuid-b365eb5949a244b1b067dd33f3f1e7ef,approved,0.349216
uuid-b365eb5949a244b1b067dd33f3f1e7ef,nivo and pembro,0.48659
uuid-b365eb5949a244b1b067dd33f3f1e7ef,believes,0.384553
uuid-b365eb5949a244b1b067dd33f3f1e7ef,impressed,0.572407
uuid-b365eb5949a244b1b067dd33f3f1e7ef,SCLC,0.352556
uuid-b365eb5949a244b1b067dd33f3f1e7ef,feels,0.505041
uuid-b365eb5949a244b1b067dd33f3f1e7ef,option,0.323368
uuid-ae912380905548c6a5a91c340bf0004a,dose,0.640818
uuid-ae912380905548c6a5a91c340bf0004a,Ipi,0.363757
uuid-ae912380905548c6a5a91c340bf0004a,vs,0.363725
uuid-ae912380905548c6a5a91c340bf0004a,NCCN,0.354881
uuid-ae912380905548c6a5a91c340bf0004a,flat dosing,0.544852
uuid-46ebd4c965cc47ce82d13cd3338fce1c,Nivo,0.461874
uuid-46ebd4c965cc47ce82d13cd3338fce1c,patients,0.391835
uuid-46ebd4c965cc47ce82d13cd3338fce1c,therapy,0.368758
uuid-46ebd4c965cc47ce82d13cd3338fce1c,toxicity,0.305475
uuid-46ebd4c965cc47ce82d13cd3338fce1c,efficacy,0.380674
uuid-46ebd4c965cc47ce82d13cd3338fce1c,regimen,0.416582
uuid-46ebd4c965cc47ce82d13cd3338fce1c,chemo,0.633353
uuid-46ebd4c965cc47ce82d13cd3338fce1c,pts,0.447185
uuid-46ebd4c965cc47ce82d13cd3338fce1c,IO,0.33734
uuid-46ebd4c965cc47ce82d13cd3338fce1c,OS,0.390494
uuid-46ebd4c965cc47ce82d13cd3338fce1c,monotherapy,0.430877
uuid-46ebd4c965cc47ce82d13cd3338fce1c,treatment,0.354431
uuid-46ebd4c965cc47ce82d13cd3338fce1c,response,0.646479
uuid-46ebd4c965cc47ce82d13cd3338fce1c,PFS,0.371343
uuid-46ebd4c965cc47ce82d13cd3338fce1c,PD1,0.44176
uuid-46ebd4c965cc47ce82d13cd3338fce1c,ORR,0.355248
uuid-46ebd4c965cc47ce82d13cd3338fce1c,progression,0.572651
uuid-46ebd4c965cc47ce82d13cd3338fce1c,believes,0.462648
uuid-46ebd4c965cc47ce82d13cd3338fce1c,chemotherapy,0.466231
uuid-46ebd4c965cc47ce82d13cd3338fce1c,respond,0.584512
uuid-46ebd4c965cc47ce82d13cd3338fce1c,feels,0.482028
uuid-46ebd4c965cc47ce82d13cd3338fce1c,option,0.315918
uuid-5552589ccc8f413c9bf6d890a15da19e,Nivo,0.511469
uuid-5552589ccc8f413c9bf6d890a15da19e,pembro,0.657339
uuid-5552589ccc8f413c9bf6d890a15da19e,1L,0.500499
uuid-5552589ccc8f413c9bf6d890a15da19e,PDL1,0.461384
uuid-5552589ccc8f413c9bf6d890a15da19e,efficacy,0.708484
uuid-5552589ccc8f413c9bf6d890a15da19e,chemo,0.327813
uuid-5552589ccc8f413c9bf6d890a15da19e,2L,0.573976
uuid-5552589ccc8f413c9bf6d890a15da19e,agents,0.621929
uuid-5552589ccc8f413c9bf6d890a15da19e,atezo,0.751694
uuid-5552589ccc8f413c9bf6d890a15da19e,preferred,0.490976
uuid-5552589ccc8f413c9bf6d890a15da19e,monotherapy,0.412979
uuid-5552589ccc8f413c9bf6d890a15da19e,data,0.381234
uuid-5552589ccc8f413c9bf6d890a15da19e,combo,0.357659
uuid-5552589ccc8f413c9bf6d890a15da19e,indication,0.445251
uuid-5552589ccc8f413c9bf6d890a15da19e,ORR,0.307487
uuid-5552589ccc8f413c9bf6d890a15da19e,approved,0.375551
uuid-5552589ccc8f413c9bf6d890a15da19e,nivo and pembro,0.641829
uuid-5552589ccc8f413c9bf6d890a15da19e,believes,0.495791
uuid-5552589ccc8f413c9bf6d890a15da19e,vs,0.530573
uuid-5552589ccc8f413c9bf6d890a15da19e,TLs,0.332265
uuid-5552589ccc8f413c9bf6d890a15da19e,feels,0.492003
uuid-5552589ccc8f413c9bf6d890a15da19e,PDL1 expression,0.455113
uuid-5552589ccc8f413c9bf6d890a15da19e,option,0.427917
uuid-cfda5b4aacad41a18008dce96b8205cb,Nivo,0.456907
uuid-cfda5b4aacad41a18008dce96b8205cb,pembro,0.472577
uuid-cfda5b4aacad41a18008dce96b8205cb,NSCLC,0.362056
uuid-cfda5b4aacad41a18008dce96b8205cb,1L,0.514056
uuid-cfda5b4aacad41a18008dce96b8205cb,PDL1,0.331731
uuid-cfda5b4aacad41a18008dce96b8205cb,efficacy,0.553898
uuid-cfda5b4aacad41a18008dce96b8205cb,combination,0.466357
uuid-cfda5b4aacad41a18008dce96b8205cb,chemo,0.499776
uuid-cfda5b4aacad41a18008dce96b8205cb,2L,0.426872
uuid-cfda5b4aacad41a18008dce96b8205cb,IO,0.520013
uuid-cfda5b4aacad41a18008dce96b8205cb,agents,0.461519
uuid-cfda5b4aacad41a18008dce96b8205cb,Ipi,0.353253
uuid-cfda5b4aacad41a18008dce96b8205cb,OS,0.314067
uuid-cfda5b4aacad41a18008dce96b8205cb,atezo,0.486369
uuid-cfda5b4aacad41a18008dce96b8205cb,preferred,0.362151
uuid-cfda5b4aacad41a18008dce96b8205cb,monotherapy,0.566021
uuid-cfda5b4aacad41a18008dce96b8205cb,data,0.365509
uuid-cfda5b4aacad41a18008dce96b8205cb,combo,0.555989
uuid-cfda5b4aacad41a18008dce96b8205cb,PD1,0.348153
uuid-cfda5b4aacad41a18008dce96b8205cb,ORR,0.344655
uuid-cfda5b4aacad41a18008dce96b8205cb,nivo and pembro,0.428992
uuid-cfda5b4aacad41a18008dce96b8205cb,believes,0.478858
uuid-cfda5b4aacad41a18008dce96b8205cb,chemotherapy,0.367571
uuid-cfda5b4aacad41a18008dce96b8205cb,vs,0.42897
uuid-cfda5b4aacad41a18008dce96b8205cb,feels,0.441312
uuid-cfda5b4aacad41a18008dce96b8205cb,option,0.472483
uuid-1250e262cfbd42748818c8edabf99b70,pembro,0.621481
uuid-1250e262cfbd42748818c8edabf99b70,trial,0.375426
uuid-1250e262cfbd42748818c8edabf99b70,Merck,0.498957
uuid-1250e262cfbd42748818c8edabf99b70,approval,0.463534
uuid-1250e262cfbd42748818c8edabf99b70,atezo,0.563517
uuid-1250e262cfbd42748818c8edabf99b70,data,0.342388
uuid-1250e262cfbd42748818c8edabf99b70,indication,0.481899
uuid-1250e262cfbd42748818c8edabf99b70,approved,0.469438
uuid-1250e262cfbd42748818c8edabf99b70,vs,0.376165
uuid-1250e262cfbd42748818c8edabf99b70,label,0.374175
uuid-1250e262cfbd42748818c8edabf99b70,Keytruda,0.341393
uuid-1250e262cfbd42748818c8edabf99b70,assay,0.365734
uuid-f7523928b8fd49dcb8320cd61e06169f,BMS,0.542243
uuid-f7523928b8fd49dcb8320cd61e06169f,PDL1,0.37714
uuid-f7523928b8fd49dcb8320cd61e06169f,trial,0.703488
uuid-f7523928b8fd49dcb8320cd61e06169f,efficacy,0.410226
uuid-f7523928b8fd49dcb8320cd61e06169f,commented,0.374026
uuid-f7523928b8fd49dcb8320cd61e06169f,Merck,0.402342
uuid-f7523928b8fd49dcb8320cd61e06169f,OS,0.491985
uuid-f7523928b8fd49dcb8320cd61e06169f,regards,0.415258
uuid-f7523928b8fd49dcb8320cd61e06169f,data,0.614245
uuid-f7523928b8fd49dcb8320cd61e06169f,expressed,0.333308
uuid-f7523928b8fd49dcb8320cd61e06169f,clinical trials,0.353191
uuid-f7523928b8fd49dcb8320cd61e06169f,PFS,0.552705
uuid-f7523928b8fd49dcb8320cd61e06169f,ORR,0.544441
uuid-f7523928b8fd49dcb8320cd61e06169f,nivo and pembro,0.397447
uuid-f7523928b8fd49dcb8320cd61e06169f,impressed,0.417265
uuid-f7523928b8fd49dcb8320cd61e06169f,TLs,0.314276
uuid-f7523928b8fd49dcb8320cd61e06169f,PDL1 expression,0.507005
uuid-3671bb011d3c4c73bb0f7f48676ba16d,Nivo,0.389264
uuid-3671bb011d3c4c73bb0f7f48676ba16d,pembro,0.498968
uuid-3671bb011d3c4c73bb0f7f48676ba16d,PDL1,0.305725
uuid-3671bb011d3c4c73bb0f7f48676ba16d,trial,0.552495
uuid-3671bb011d3c4c73bb0f7f48676ba16d,efficacy,0.597147
uuid-3671bb011d3c4c73bb0f7f48676ba16d,Ipi,0.344243
uuid-3671bb011d3c4c73bb0f7f48676ba16d,OS,0.415443
uuid-3671bb011d3c4c73bb0f7f48676ba16d,atezo,0.401954
uuid-3671bb011d3c4c73bb0f7f48676ba16d,regards,0.306129
uuid-3671bb011d3c4c73bb0f7f48676ba16d,data,0.514389
uuid-3671bb011d3c4c73bb0f7f48676ba16d,indication,0.335302
uuid-3671bb011d3c4c73bb0f7f48676ba16d,PFS,0.42136
uuid-3671bb011d3c4c73bb0f7f48676ba16d,ORR,0.479439
uuid-3671bb011d3c4c73bb0f7f48676ba16d,nivo and pembro,0.459545
uuid-3671bb011d3c4c73bb0f7f48676ba16d,impressed,0.425225
uuid-3671bb011d3c4c73bb0f7f48676ba16d,vs,0.498214
uuid-3671bb011d3c4c73bb0f7f48676ba16d,feels,0.413975
uuid-3671bb011d3c4c73bb0f7f48676ba16d,PDL1 expression,0.322201
uuid-2e447a2695964b2fa3c8b6cd67616726,nivolumab,0.326464
uuid-2e447a2695964b2fa3c8b6cd67616726,PD1,0.333261
uuid-739fc35496ac448ea50f169e186c5be2,patients,0.496238
uuid-739fc35496ac448ea50f169e186c5be2,TL,0.329509
uuid-739fc35496ac448ea50f169e186c5be2,approval,0.366106
uuid-739fc35496ac448ea50f169e186c5be2,PD-L1 testing,0.425826
uuid-739fc35496ac448ea50f169e186c5be2,using nivo,0.380138
uuid-739fc35496ac448ea50f169e186c5be2,NSCLC patients,0.309556
uuid-739fc35496ac448ea50f169e186c5be2,SCCHN,0.348159
uuid-739fc35496ac448ea50f169e186c5be2,indicated,0.319774
uuid-739fc35496ac448ea50f169e186c5be2,Regional TL,0.347258
uuid-db382fdb0ce24d83811575d2d2dbea6b,PDL1,0.497262
uuid-db382fdb0ce24d83811575d2d2dbea6b,PD-L1,0.540287
uuid-db382fdb0ce24d83811575d2d2dbea6b,PD-L1 testing,0.305244
uuid-db382fdb0ce24d83811575d2d2dbea6b,testing,0.395546
uuid-db382fdb0ce24d83811575d2d2dbea6b,NSCLC patients,0.339596
uuid-db382fdb0ce24d83811575d2d2dbea6b,assay,0.419514
uuid-db382fdb0ce24d83811575d2d2dbea6b,PDL1 expression,0.450546
uuid-db382fdb0ce24d83811575d2d2dbea6b,biomarker,0.399408
uuid-69eb0f38db124221ad45d583103e9fd1,TL,0.722237
uuid-69eb0f38db124221ad45d583103e9fd1,shared,0.310428
uuid-69eb0f38db124221ad45d583103e9fd1,TL stated,0.440165
uuid-69eb0f38db124221ad45d583103e9fd1,Merck,0.319369
uuid-69eb0f38db124221ad45d583103e9fd1,institution,0.644274
uuid-69eb0f38db124221ad45d583103e9fd1,PD-L1,0.673784
uuid-69eb0f38db124221ad45d583103e9fd1,PD-L1 testing,0.842293
uuid-69eb0f38db124221ad45d583103e9fd1,testing,0.728362
uuid-69eb0f38db124221ad45d583103e9fd1,PDL1 testing,0.610759
uuid-69eb0f38db124221ad45d583103e9fd1,NSCLC patients,0.445257
uuid-69eb0f38db124221ad45d583103e9fd1,assay,0.647659
uuid-69eb0f38db124221ad45d583103e9fd1,biomarker,0.342632
uuid-329ba621cc924c11bac582e0b294c15a,patients,0.351002
uuid-329ba621cc924c11bac582e0b294c15a,Opdivo,0.341249
uuid-329ba621cc924c11bac582e0b294c15a,therapy,0.498096
uuid-329ba621cc924c11bac582e0b294c15a,nivolumab,0.38812
uuid-329ba621cc924c11bac582e0b294c15a,cHL,0.693109
uuid-9f1f9a1d3e71481fac1716195c310a74,patients,0.676842
uuid-9f1f9a1d3e71481fac1716195c310a74,Opdivo,0.663004
uuid-9f1f9a1d3e71481fac1716195c310a74,dose,0.588707
uuid-9f1f9a1d3e71481fac1716195c310a74,nivolumab,0.42267
uuid-9f1f9a1d3e71481fac1716195c310a74,regimen,0.424986
uuid-9f1f9a1d3e71481fac1716195c310a74,treated,0.425353
uuid-9f1f9a1d3e71481fac1716195c310a74,pts,0.353093
uuid-9f1f9a1d3e71481fac1716195c310a74,treatment,0.503452
uuid-9f1f9a1d3e71481fac1716195c310a74,progression,0.350056
uuid-9f1f9a1d3e71481fac1716195c310a74,flat dosing,0.565504
uuid-c612b515c1684baeaff6e172c332c9a1,patients,0.342897
uuid-c612b515c1684baeaff6e172c332c9a1,Opdivo,0.648393
uuid-c612b515c1684baeaff6e172c332c9a1,dose,0.718736
uuid-c612b515c1684baeaff6e172c332c9a1,toxicity,0.40646
uuid-c612b515c1684baeaff6e172c332c9a1,regimen,0.32929
uuid-c612b515c1684baeaff6e172c332c9a1,drug,0.442451
uuid-c612b515c1684baeaff6e172c332c9a1,Keytruda,0.58531
uuid-c612b515c1684baeaff6e172c332c9a1,flat dosing,0.70692
uuid-34a22f2bcf2e4c529635aadc411aa224,patients,0.858187
uuid-34a22f2bcf2e4c529635aadc411aa224,Opdivo,0.47635
uuid-34a22f2bcf2e4c529635aadc411aa224,therapy,0.401593
uuid-34a22f2bcf2e4c529635aadc411aa224,nivolumab,0.369042
uuid-34a22f2bcf2e4c529635aadc411aa224,regimen,0.436799
uuid-34a22f2bcf2e4c529635aadc411aa224,treated,0.524231
uuid-34a22f2bcf2e4c529635aadc411aa224,pts,0.588782
uuid-34a22f2bcf2e4c529635aadc411aa224,treatment,0.580548
uuid-34a22f2bcf2e4c529635aadc411aa224,response,0.304592
uuid-34a22f2bcf2e4c529635aadc411aa224,progression,0.605177
uuid-34a22f2bcf2e4c529635aadc411aa224,respond,0.492265
uuid-e9b0184d23c7428186a78ccb1bc17f2b,RTL,0.30582
uuid-e9b0184d23c7428186a78ccb1bc17f2b,nivolumab,0.420017
uuid-e9b0184d23c7428186a78ccb1bc17f2b,treated,0.326051
uuid-e9b0184d23c7428186a78ccb1bc17f2b,impressed,0.305894
uuid-e9b0184d23c7428186a78ccb1bc17f2b,Regional TL,0.328983
uuid-e7f307c30f62463da24094e525526dac,oncology,0.458369
uuid-e7f307c30f62463da24094e525526dac,drug,0.355493
uuid-e7f307c30f62463da24094e525526dac,clinical,0.324704
uuid-e7f307c30f62463da24094e525526dac,flat dosing,0.331544
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,Nivo,0.357723
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,pembro,0.363809
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,1L,0.350003
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,PDL1,0.399137
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,efficacy,0.33478
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,agents,0.364714
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,atezo,0.315847
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,monotherapy,0.331154
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,data,0.495623
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,indication,0.316834
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,ORR,0.331328
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,nivo and pembro,0.494916
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,feels,0.318857
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,PDL1 expression,0.422745
uuid-96e8a878e2fd404d9b4e7b7bbadf5d1e,option,0.324197
uuid-1ca7a599fcbd4987a5f2fa95a9d688d7,Opdivo,0.509588
uuid-1ca7a599fcbd4987a5f2fa95a9d688d7,dose,0.564658
uuid-1ca7a599fcbd4987a5f2fa95a9d688d7,physicians,0.442378
uuid-1ca7a599fcbd4987a5f2fa95a9d688d7,indication,0.304798
uuid-1ca7a599fcbd4987a5f2fa95a9d688d7,drug,0.65619
uuid-1ca7a599fcbd4987a5f2fa95a9d688d7,Keytruda,0.537587
uuid-1ca7a599fcbd4987a5f2fa95a9d688d7,flat dosing,0.681695
uuid-dc0baef182d0454ca21c3c9a5d81d5fb,nivolumab,0.460018
uuid-dc0baef182d0454ca21c3c9a5d81d5fb,trial,0.334575
uuid-dc0baef182d0454ca21c3c9a5d81d5fb,combination,0.339848
uuid-dc0baef182d0454ca21c3c9a5d81d5fb,PD1,0.481182
uuid-dc0baef182d0454ca21c3c9a5d81d5fb,PD-1,0.338998
uuid-6d9c4059283343478dcd479a20672d67,tumor,0.601628
uuid-1a61a49a80a840f082e95356f65fb8c4,BMS,0.506943
uuid-1a61a49a80a840f082e95356f65fb8c4,PDL1,0.352031
uuid-1a61a49a80a840f082e95356f65fb8c4,trial,0.515673
uuid-1a61a49a80a840f082e95356f65fb8c4,efficacy,0.560343
uuid-1a61a49a80a840f082e95356f65fb8c4,commented,0.40859
uuid-1a61a49a80a840f082e95356f65fb8c4,Merck,0.347407
uuid-1a61a49a80a840f082e95356f65fb8c4,OS,0.615526
uuid-1a61a49a80a840f082e95356f65fb8c4,regards,0.362538
uuid-1a61a49a80a840f082e95356f65fb8c4,data,0.781881
uuid-1a61a49a80a840f082e95356f65fb8c4,expressed,0.308843
uuid-1a61a49a80a840f082e95356f65fb8c4,PFS,0.584809
uuid-1a61a49a80a840f082e95356f65fb8c4,ORR,0.60292
uuid-1a61a49a80a840f082e95356f65fb8c4,nivo and pembro,0.469599
uuid-1a61a49a80a840f082e95356f65fb8c4,believes,0.328869
uuid-1a61a49a80a840f082e95356f65fb8c4,impressed,0.596495
uuid-1a61a49a80a840f082e95356f65fb8c4,feels,0.469267
uuid-1a61a49a80a840f082e95356f65fb8c4,PDL1 expression,0.338561
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,Nivo,0.458399
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,pembro,0.406085
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,1L,0.399158
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,trial,0.386841
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,efficacy,0.307507
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,combination,0.363832
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,chemo,0.447405
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,OS,0.345358
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,preferred,0.343285
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,monotherapy,0.448372
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,data,0.433993
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,combo,0.331535
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,PFS,0.340041
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,ORR,0.358315
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,approved,0.310495
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,chemotherapy,0.461938
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,impressed,0.335716
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,feels,0.509535
uuid-ac4cf66ede1e4f6c936e4a2b482512c7,option,0.528569
uuid-6e537a22770a4d0a983a6775f0c2f6b7,TL,0.538019
uuid-6e537a22770a4d0a983a6775f0c2f6b7,RTL,0.392022
uuid-6e537a22770a4d0a983a6775f0c2f6b7,nivolumab,0.306378
uuid-6e537a22770a4d0a983a6775f0c2f6b7,NTL,0.304131
uuid-6e537a22770a4d0a983a6775f0c2f6b7,PD-L1 testing,0.469912
uuid-6e537a22770a4d0a983a6775f0c2f6b7,testing,0.303093
uuid-6e537a22770a4d0a983a6775f0c2f6b7,oncology,0.348331
uuid-6e537a22770a4d0a983a6775f0c2f6b7,SCCHN,0.369318
uuid-6e537a22770a4d0a983a6775f0c2f6b7,LTL,0.361666
uuid-6e537a22770a4d0a983a6775f0c2f6b7,clinical,0.343169
uuid-6e537a22770a4d0a983a6775f0c2f6b7,academic,0.332226
uuid-6e537a22770a4d0a983a6775f0c2f6b7,Regional TL,0.476668
uuid-6e537a22770a4d0a983a6775f0c2f6b7,RTL stated,0.323878
uuid-bd22228406b34a75aa7d86099e448ea4,RTL,0.356717
uuid-bd22228406b34a75aa7d86099e448ea4,BMS,0.601784
uuid-bd22228406b34a75aa7d86099e448ea4,trial,0.391579
uuid-bd22228406b34a75aa7d86099e448ea4,NTL,0.321103
uuid-bd22228406b34a75aa7d86099e448ea4,shared,0.310272
uuid-bd22228406b34a75aa7d86099e448ea4,commented,0.55115
uuid-bd22228406b34a75aa7d86099e448ea4,Merck,0.541317
uuid-bd22228406b34a75aa7d86099e448ea4,stated,0.517806
uuid-bd22228406b34a75aa7d86099e448ea4,regards,0.359978
uuid-bd22228406b34a75aa7d86099e448ea4,data,0.575892
uuid-bd22228406b34a75aa7d86099e448ea4,expressed,0.422858
uuid-bd22228406b34a75aa7d86099e448ea4,ASCO,0.348532
uuid-bd22228406b34a75aa7d86099e448ea4,impressed,0.516424
uuid-bd22228406b34a75aa7d86099e448ea4,LTL,0.306006
uuid-bd22228406b34a75aa7d86099e448ea4,TLs,0.359534
uuid-bd22228406b34a75aa7d86099e448ea4,Regional TL,0.498215
uuid-97ef554138fd4c849c3e000e2874df70,patients,0.351792
uuid-97ef554138fd4c849c3e000e2874df70,tumor,0.657103
uuid-97ef554138fd4c849c3e000e2874df70,progression,0.315897
uuid-c7963cf8f7d34d69a954050813c0b23d,Nivo,0.372137
uuid-c7963cf8f7d34d69a954050813c0b23d,patients,0.480754
uuid-c7963cf8f7d34d69a954050813c0b23d,Opdivo,0.545749
uuid-c7963cf8f7d34d69a954050813c0b23d,dose,0.82315
uuid-c7963cf8f7d34d69a954050813c0b23d,nivolumab,0.368637
uuid-c7963cf8f7d34d69a954050813c0b23d,toxicity,0.415225
uuid-c7963cf8f7d34d69a954050813c0b23d,regimen,0.48478
uuid-c7963cf8f7d34d69a954050813c0b23d,Ipi,0.514403
uuid-c7963cf8f7d34d69a954050813c0b23d,treatment,0.343734
uuid-c7963cf8f7d34d69a954050813c0b23d,vs,0.430983
uuid-c7963cf8f7d34d69a954050813c0b23d,flat dosing,0.652664
uuid-8c72388fe9e843fb991418b3ee25fea8,Nivo,0.506437
uuid-8c72388fe9e843fb991418b3ee25fea8,pembro,0.424183
uuid-8c72388fe9e843fb991418b3ee25fea8,PDL1,0.496361
uuid-8c72388fe9e843fb991418b3ee25fea8,trial,0.375816
uuid-8c72388fe9e843fb991418b3ee25fea8,efficacy,0.661002
uuid-8c72388fe9e843fb991418b3ee25fea8,OS,0.56862
uuid-8c72388fe9e843fb991418b3ee25fea8,atezo,0.320165
uuid-8c72388fe9e843fb991418b3ee25fea8,data,0.423281
uuid-8c72388fe9e843fb991418b3ee25fea8,PFS,0.654229
uuid-8c72388fe9e843fb991418b3ee25fea8,ORR,0.600983
uuid-8c72388fe9e843fb991418b3ee25fea8,nivo and pembro,0.560159
uuid-8c72388fe9e843fb991418b3ee25fea8,vs,0.527597
uuid-8c72388fe9e843fb991418b3ee25fea8,PDL1 expression,0.480524
uuid-6a691c86443142928c29d00e9646272c,oncology,0.58727
uuid-6a691c86443142928c29d00e9646272c,clinical,0.60194
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,Nivo,0.516707
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,patients,0.302831
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,therapy,0.457254
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,1L,0.356969
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,PDL1,0.407365
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,efficacy,0.474708
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,regimen,0.314869
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,combination,0.360615
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,chemo,0.70098
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,pts,0.432941
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,agents,0.315399
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,OS,0.429522
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,monotherapy,0.512201
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,response,0.452993
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,combo,0.38491
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,PFS,0.475178
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,PD1,0.529586
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,ORR,0.448179
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,nivo and pembro,0.480707
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,progression,0.437956
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,believes,0.568341
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,chemotherapy,0.602135
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,respond,0.409029
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,feels,0.373147
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,PDL1 expression,0.393974
uuid-ef672dd23c75463bbdd6bf9c16fdc7ac,option,0.427806
uuid-26064ee289944ba68a3d7369002e4727,Nivo,0.621581
uuid-26064ee289944ba68a3d7369002e4727,pembro,0.610899
uuid-26064ee289944ba68a3d7369002e4727,1L,0.49119
uuid-26064ee289944ba68a3d7369002e4727,PDL1,0.453929
uuid-26064ee289944ba68a3d7369002e4727,trial,0.373881
uuid-26064ee289944ba68a3d7369002e4727,efficacy,0.607569
uuid-26064ee289944ba68a3d7369002e4727,chemo,0.423708
uuid-26064ee289944ba68a3d7369002e4727,2L,0.450987
uuid-26064ee289944ba68a3d7369002e4727,agents,0.367886
uuid-26064ee289944ba68a3d7369002e4727,Ipi,0.312517
uuid-26064ee289944ba68a3d7369002e4727,OS,0.450473
uuid-26064ee289944ba68a3d7369002e4727,atezo,0.534854
uuid-26064ee289944ba68a3d7369002e4727,preferred,0.316524
uuid-26064ee289944ba68a3d7369002e4727,monotherapy,0.450405
uuid-26064ee289944ba68a3d7369002e4727,data,0.471233
uuid-26064ee289944ba68a3d7369002e4727,combo,0.356437
uuid-26064ee289944ba68a3d7369002e4727,indication,0.332282
uuid-26064ee289944ba68a3d7369002e4727,PFS,0.450044
uuid-26064ee289944ba68a3d7369002e4727,PD1,0.334928
uuid-26064ee289944ba68a3d7369002e4727,ORR,0.495524
uuid-26064ee289944ba68a3d7369002e4727,approved,0.347103
uuid-26064ee289944ba68a3d7369002e4727,nivo and pembro,0.615071
uuid-26064ee289944ba68a3d7369002e4727,believes,0.509849
uuid-26064ee289944ba68a3d7369002e4727,chemotherapy,0.30092
uuid-26064ee289944ba68a3d7369002e4727,impressed,0.375164
uuid-26064ee289944ba68a3d7369002e4727,vs,0.374057
uuid-26064ee289944ba68a3d7369002e4727,feels,0.547961
uuid-26064ee289944ba68a3d7369002e4727,PDL1 expression,0.464692
uuid-26064ee289944ba68a3d7369002e4727,option,0.466307
uuid-a841fda607884fa091c0a6c58fb15136,lung,0.33389
uuid-a841fda607884fa091c0a6c58fb15136,1L,0.365594
uuid-a841fda607884fa091c0a6c58fb15136,PDL1,0.407756
uuid-a841fda607884fa091c0a6c58fb15136,chemo,0.362522
uuid-a841fda607884fa091c0a6c58fb15136,OS,0.358204
uuid-a841fda607884fa091c0a6c58fb15136,monotherapy,0.337271
uuid-a841fda607884fa091c0a6c58fb15136,PFS,0.372434
uuid-a841fda607884fa091c0a6c58fb15136,ORR,0.30291
uuid-a841fda607884fa091c0a6c58fb15136,nivo and pembro,0.338715
uuid-a841fda607884fa091c0a6c58fb15136,progression,0.355803
uuid-a841fda607884fa091c0a6c58fb15136,believes,0.309089
uuid-a841fda607884fa091c0a6c58fb15136,PDL1 expression,0.333846
uuid-a841fda607884fa091c0a6c58fb15136,option,0.344245
uuid-1b80750f01eb4027b5f951030266e16e,pembro,0.371439
uuid-1b80750f01eb4027b5f951030266e16e,1L,0.383249
uuid-1b80750f01eb4027b5f951030266e16e,PDL1,0.369903
uuid-1b80750f01eb4027b5f951030266e16e,trial,0.445272
uuid-1b80750f01eb4027b5f951030266e16e,efficacy,0.449024
uuid-1b80750f01eb4027b5f951030266e16e,OS,0.416123
uuid-1b80750f01eb4027b5f951030266e16e,atezo,0.344795
uuid-1b80750f01eb4027b5f951030266e16e,monotherapy,0.367845
uuid-1b80750f01eb4027b5f951030266e16e,data,0.582441
uuid-1b80750f01eb4027b5f951030266e16e,combo,0.375819
uuid-1b80750f01eb4027b5f951030266e16e,indication,0.324403
uuid-1b80750f01eb4027b5f951030266e16e,PFS,0.361297
uuid-1b80750f01eb4027b5f951030266e16e,ORR,0.446836
uuid-1b80750f01eb4027b5f951030266e16e,nivo and pembro,0.362773
uuid-1b80750f01eb4027b5f951030266e16e,believes,0.367209
uuid-1b80750f01eb4027b5f951030266e16e,impressed,0.397522
uuid-1b80750f01eb4027b5f951030266e16e,feels,0.365463
uuid-1b80750f01eb4027b5f951030266e16e,PDL1 expression,0.372055
uuid-1b80750f01eb4027b5f951030266e16e,option,0.349714
uuid-5c34ed18e4c048c084d77f7597cdfd14,ASCO,0.361719
uuid-5c34ed18e4c048c084d77f7597cdfd14,immunotherapy,0.306937
uuid-c955f197a01542268a9c6ffa0e0656ff,dose,0.356354
uuid-c955f197a01542268a9c6ffa0e0656ff,toxicity,0.551899
uuid-f3f7926cc9cc4ba1aec30e42ef5f729a,Opdivo,0.341953
uuid-f3f7926cc9cc4ba1aec30e42ef5f729a,dose,0.554173
uuid-f3f7926cc9cc4ba1aec30e42ef5f729a,indication,0.378261
uuid-f3f7926cc9cc4ba1aec30e42ef5f729a,AI,0.494313
uuid-f3f7926cc9cc4ba1aec30e42ef5f729a,label,0.308736
uuid-f3f7926cc9cc4ba1aec30e42ef5f729a,drug,0.469529
uuid-f3f7926cc9cc4ba1aec30e42ef5f729a,Keytruda,0.48382
uuid-f3f7926cc9cc4ba1aec30e42ef5f729a,flat dosing,0.682798
uuid-350f625a51e942009aa49281e0302ecf,patients,0.544036
uuid-350f625a51e942009aa49281e0302ecf,Opdivo,0.32491
uuid-350f625a51e942009aa49281e0302ecf,therapy,0.396048
uuid-350f625a51e942009aa49281e0302ecf,regimen,0.463241
uuid-350f625a51e942009aa49281e0302ecf,treated,0.493624
uuid-350f625a51e942009aa49281e0302ecf,chemo,0.350545
uuid-350f625a51e942009aa49281e0302ecf,pts,0.512879
uuid-350f625a51e942009aa49281e0302ecf,treatment,0.566894
uuid-350f625a51e942009aa49281e0302ecf,response,0.468768
uuid-350f625a51e942009aa49281e0302ecf,progression,0.650785
uuid-350f625a51e942009aa49281e0302ecf,chemotherapy,0.308016
uuid-350f625a51e942009aa49281e0302ecf,respond,0.568161
uuid-350f625a51e942009aa49281e0302ecf,feels,0.31997
uuid-b84afa28880747a09391ac178024e5dc,Nivo,0.346639
uuid-b84afa28880747a09391ac178024e5dc,pembro,0.351863
uuid-b84afa28880747a09391ac178024e5dc,1L,0.410575
uuid-b84afa28880747a09391ac178024e5dc,efficacy,0.408093
uuid-b84afa28880747a09391ac178024e5dc,regimen,0.343089
uuid-b84afa28880747a09391ac178024e5dc,RCC,0.32413
uuid-b84afa28880747a09391ac178024e5dc,2L,0.39186
uuid-b84afa28880747a09391ac178024e5dc,OS,0.43719
uuid-b84afa28880747a09391ac178024e5dc,atezo,0.312134
uuid-b84afa28880747a09391ac178024e5dc,monotherapy,0.443695
uuid-b84afa28880747a09391ac178024e5dc,data,0.446856
uuid-b84afa28880747a09391ac178024e5dc,combo,0.328384
uuid-b84afa28880747a09391ac178024e5dc,PFS,0.328388
uuid-b84afa28880747a09391ac178024e5dc,ORR,0.389354
uuid-b84afa28880747a09391ac178024e5dc,approved,0.32958
uuid-b84afa28880747a09391ac178024e5dc,nivo and pembro,0.328935
uuid-b84afa28880747a09391ac178024e5dc,impressed,0.49267
uuid-b84afa28880747a09391ac178024e5dc,feels,0.382104
uuid-b84afa28880747a09391ac178024e5dc,option,0.323897
uuid-5c7eb277fbd84199b62d65037a4ee271,pembro,0.342791
uuid-5c7eb277fbd84199b62d65037a4ee271,BMS,0.312369
uuid-5c7eb277fbd84199b62d65037a4ee271,2L,0.378683
uuid-5c7eb277fbd84199b62d65037a4ee271,approval,0.530476
uuid-5c7eb277fbd84199b62d65037a4ee271,atezo,0.329814
uuid-5c7eb277fbd84199b62d65037a4ee271,preferred,0.461071
uuid-5c7eb277fbd84199b62d65037a4ee271,using nivo,0.41833
uuid-5c7eb277fbd84199b62d65037a4ee271,clinical trials,0.35318
uuid-5c7eb277fbd84199b62d65037a4ee271,indication,0.399552
uuid-5c7eb277fbd84199b62d65037a4ee271,approved,0.57095
uuid-5c7eb277fbd84199b62d65037a4ee271,SCCHN,0.343353
uuid-5c7eb277fbd84199b62d65037a4ee271,label,0.399598
uuid-5c7eb277fbd84199b62d65037a4ee271,RTL stated,0.34805
uuid-5c7eb277fbd84199b62d65037a4ee271,option,0.352848
uuid-a1301db99a5e468a8e1b0a3356a7e202,tumor,0.520642
uuid-a1301db99a5e468a8e1b0a3356a7e202,response,0.41544
uuid-a1301db99a5e468a8e1b0a3356a7e202,immunotherapy,0.324549
uuid-36c0473e092142e697f74bfb8e6ac435,TL,0.619302
uuid-36c0473e092142e697f74bfb8e6ac435,PDL1,0.346774
uuid-36c0473e092142e697f74bfb8e6ac435,TL stated,0.382984
uuid-36c0473e092142e697f74bfb8e6ac435,Merck,0.317515
uuid-36c0473e092142e697f74bfb8e6ac435,PD-L1,0.716608
uuid-36c0473e092142e697f74bfb8e6ac435,PD-L1 testing,0.783833
uuid-36c0473e092142e697f74bfb8e6ac435,testing,0.755683
uuid-36c0473e092142e697f74bfb8e6ac435,PDL1 testing,0.534134
uuid-36c0473e092142e697f74bfb8e6ac435,NSCLC patients,0.548562
uuid-36c0473e092142e697f74bfb8e6ac435,assay,0.663429
uuid-36c0473e092142e697f74bfb8e6ac435,biomarker,0.340807
uuid-df13fe1fc42043f7b7331830ea126b93,Nivo,0.452902
uuid-df13fe1fc42043f7b7331830ea126b93,patients,0.756662
uuid-df13fe1fc42043f7b7331830ea126b93,Opdivo,0.449112
uuid-df13fe1fc42043f7b7331830ea126b93,therapy,0.475469
uuid-df13fe1fc42043f7b7331830ea126b93,dose,0.328611
uuid-df13fe1fc42043f7b7331830ea126b93,nivolumab,0.338738
uuid-df13fe1fc42043f7b7331830ea126b93,toxicity,0.462616
uuid-df13fe1fc42043f7b7331830ea126b93,regimen,0.582715
uuid-df13fe1fc42043f7b7331830ea126b93,chemo,0.415365
uuid-df13fe1fc42043f7b7331830ea126b93,pts,0.459278
uuid-df13fe1fc42043f7b7331830ea126b93,monotherapy,0.428082
uuid-df13fe1fc42043f7b7331830ea126b93,treatment,0.540422
uuid-df13fe1fc42043f7b7331830ea126b93,response,0.363014
uuid-df13fe1fc42043f7b7331830ea126b93,progression,0.54053
uuid-df13fe1fc42043f7b7331830ea126b93,chemotherapy,0.494735
uuid-df13fe1fc42043f7b7331830ea126b93,respond,0.46242
uuid-df13fe1fc42043f7b7331830ea126b93,option,0.425164
uuid-20ed6a6685cd4070a8c371987bdcb053,Nivo,0.470386
uuid-20ed6a6685cd4070a8c371987bdcb053,pembro,0.562355
uuid-20ed6a6685cd4070a8c371987bdcb053,BMS,0.38763
uuid-20ed6a6685cd4070a8c371987bdcb053,PDL1,0.334496
uuid-20ed6a6685cd4070a8c371987bdcb053,trial,0.727876
uuid-20ed6a6685cd4070a8c371987bdcb053,efficacy,0.507198
uuid-20ed6a6685cd4070a8c371987bdcb053,stated,0.331999
uuid-20ed6a6685cd4070a8c371987bdcb053,OS,0.480096
uuid-20ed6a6685cd4070a8c371987bdcb053,atezo,0.445463
uuid-20ed6a6685cd4070a8c371987bdcb053,data,0.717639
uuid-20ed6a6685cd4070a8c371987bdcb053,clinical trials,0.386708
uuid-20ed6a6685cd4070a8c371987bdcb053,indication,0.375375
uuid-20ed6a6685cd4070a8c371987bdcb053,PFS,0.50264
uuid-20ed6a6685cd4070a8c371987bdcb053,ORR,0.56882
uuid-20ed6a6685cd4070a8c371987bdcb053,nivo and pembro,0.519647
uuid-20ed6a6685cd4070a8c371987bdcb053,impressed,0.515513
uuid-20ed6a6685cd4070a8c371987bdcb053,vs,0.330954
uuid-20ed6a6685cd4070a8c371987bdcb053,LTL,0.30058
uuid-20ed6a6685cd4070a8c371987bdcb053,feels,0.415911
uuid-20ed6a6685cd4070a8c371987bdcb053,PDL1 expression,0.432443
uuid-78823aabc7a4435ea620b20246ac8193,Nivo,0.440096
uuid-78823aabc7a4435ea620b20246ac8193,Opdivo,0.337811
uuid-78823aabc7a4435ea620b20246ac8193,pembro,0.586571
uuid-78823aabc7a4435ea620b20246ac8193,RTL,0.346709
uuid-78823aabc7a4435ea620b20246ac8193,dose,0.48665
uuid-78823aabc7a4435ea620b20246ac8193,2L,0.414074
uuid-78823aabc7a4435ea620b20246ac8193,Ipi,0.40923
uuid-78823aabc7a4435ea620b20246ac8193,stated,0.508117
uuid-78823aabc7a4435ea620b20246ac8193,approval,0.472861
uuid-78823aabc7a4435ea620b20246ac8193,atezo,0.527883
uuid-78823aabc7a4435ea620b20246ac8193,preferred,0.415277
uuid-78823aabc7a4435ea620b20246ac8193,using nivo,0.540224
uuid-78823aabc7a4435ea620b20246ac8193,mentioned,0.318557
uuid-78823aabc7a4435ea620b20246ac8193,indication,0.47769
uuid-78823aabc7a4435ea620b20246ac8193,approved,0.511754
uuid-78823aabc7a4435ea620b20246ac8193,SCCHN,0.434376
uuid-78823aabc7a4435ea620b20246ac8193,HCP,0.385859
uuid-78823aabc7a4435ea620b20246ac8193,vs,0.393298
uuid-78823aabc7a4435ea620b20246ac8193,label,0.384979
uuid-78823aabc7a4435ea620b20246ac8193,LTL,0.525123
uuid-78823aabc7a4435ea620b20246ac8193,TLs,0.368871
uuid-78823aabc7a4435ea620b20246ac8193,Regional TL,0.300407
uuid-78823aabc7a4435ea620b20246ac8193,RTL stated,0.395687
uuid-78823aabc7a4435ea620b20246ac8193,bladder,0.339489
uuid-78823aabc7a4435ea620b20246ac8193,flat dosing,0.590045
uuid-97b188d529ab4749bd23e042a9ae0e11,Nivo,0.306451
uuid-97b188d529ab4749bd23e042a9ae0e11,pembro,0.65208
uuid-97b188d529ab4749bd23e042a9ae0e11,NSCLC,0.430864
uuid-97b188d529ab4749bd23e042a9ae0e11,1L,0.669864
uuid-97b188d529ab4749bd23e042a9ae0e11,RCC,0.358697
uuid-97b188d529ab4749bd23e042a9ae0e11,TL stated,0.31046
uuid-97b188d529ab4749bd23e042a9ae0e11,2L,0.628002
uuid-97b188d529ab4749bd23e042a9ae0e11,stated,0.459141
uuid-97b188d529ab4749bd23e042a9ae0e11,approval,0.517084
uuid-97b188d529ab4749bd23e042a9ae0e11,atezo,0.615666
uuid-97b188d529ab4749bd23e042a9ae0e11,preferred,0.528233
uuid-97b188d529ab4749bd23e042a9ae0e11,monotherapy,0.344101
uuid-97b188d529ab4749bd23e042a9ae0e11,using nivo,0.558281
uuid-97b188d529ab4749bd23e042a9ae0e11,data,0.386662
uuid-97b188d529ab4749bd23e042a9ae0e11,PDL1 testing,0.381677
uuid-97b188d529ab4749bd23e042a9ae0e11,indication,0.354469
uuid-97b188d529ab4749bd23e042a9ae0e11,NSCLC patients,0.316938
uuid-97b188d529ab4749bd23e042a9ae0e11,approved,0.522671
uuid-97b188d529ab4749bd23e042a9ae0e11,SCCHN,0.503106
uuid-97b188d529ab4749bd23e042a9ae0e11,nivo and pembro,0.301285
uuid-97b188d529ab4749bd23e042a9ae0e11,impressed,0.312378
uuid-97b188d529ab4749bd23e042a9ae0e11,LTL,0.406274
uuid-97b188d529ab4749bd23e042a9ae0e11,TLs,0.332993
uuid-97b188d529ab4749bd23e042a9ae0e11,feels,0.327898
uuid-97b188d529ab4749bd23e042a9ae0e11,Regional TL,0.369521
uuid-97b188d529ab4749bd23e042a9ae0e11,RTL stated,0.500494
uuid-97b188d529ab4749bd23e042a9ae0e11,option,0.398374
uuid-97b188d529ab4749bd23e042a9ae0e11,bladder,0.350771
uuid-31ff5d7ba3bb40939f229751fd678b82,Nivo,0.523148
uuid-31ff5d7ba3bb40939f229751fd678b82,pembro,0.315216
uuid-31ff5d7ba3bb40939f229751fd678b82,therapy,0.379588
uuid-31ff5d7ba3bb40939f229751fd678b82,nivolumab,0.308963
uuid-31ff5d7ba3bb40939f229751fd678b82,1L,0.517074
uuid-31ff5d7ba3bb40939f229751fd678b82,efficacy,0.43775
uuid-31ff5d7ba3bb40939f229751fd678b82,regimen,0.46902
uuid-31ff5d7ba3bb40939f229751fd678b82,combination,0.851519
uuid-31ff5d7ba3bb40939f229751fd678b82,chemo,0.706477
uuid-31ff5d7ba3bb40939f229751fd678b82,2L,0.475434
uuid-31ff5d7ba3bb40939f229751fd678b82,pts,0.311699
uuid-31ff5d7ba3bb40939f229751fd678b82,IO,0.524168
uuid-31ff5d7ba3bb40939f229751fd678b82,agents,0.650785
uuid-31ff5d7ba3bb40939f229751fd678b82,Ipi,0.451258
uuid-31ff5d7ba3bb40939f229751fd678b82,preferred,0.385995
uuid-31ff5d7ba3bb40939f229751fd678b82,monotherapy,0.781434
uuid-31ff5d7ba3bb40939f229751fd678b82,response,0.370397
uuid-31ff5d7ba3bb40939f229751fd678b82,combo,0.815377
uuid-31ff5d7ba3bb40939f229751fd678b82,PD1,0.631884
uuid-31ff5d7ba3bb40939f229751fd678b82,nivo and pembro,0.334544
uuid-31ff5d7ba3bb40939f229751fd678b82,progression,0.318757
uuid-31ff5d7ba3bb40939f229751fd678b82,believes,0.523141
uuid-31ff5d7ba3bb40939f229751fd678b82,chemotherapy,0.643674
uuid-31ff5d7ba3bb40939f229751fd678b82,feels,0.408004
uuid-31ff5d7ba3bb40939f229751fd678b82,PD-1,0.31698
uuid-31ff5d7ba3bb40939f229751fd678b82,option,0.605196
uuid-bcb9daae86a343bb9bca7b531faad8ac,Nivo,0.466501
uuid-bcb9daae86a343bb9bca7b531faad8ac,patients,0.480665
uuid-bcb9daae86a343bb9bca7b531faad8ac,pembro,0.361775
uuid-bcb9daae86a343bb9bca7b531faad8ac,1L,0.428501
uuid-bcb9daae86a343bb9bca7b531faad8ac,efficacy,0.347487
uuid-bcb9daae86a343bb9bca7b531faad8ac,regimen,0.443499
uuid-bcb9daae86a343bb9bca7b531faad8ac,combination,0.364326
uuid-bcb9daae86a343bb9bca7b531faad8ac,chemo,0.557581
uuid-bcb9daae86a343bb9bca7b531faad8ac,2L,0.394938
uuid-bcb9daae86a343bb9bca7b531faad8ac,pts,0.559459
uuid-bcb9daae86a343bb9bca7b531faad8ac,agents,0.313942
uuid-bcb9daae86a343bb9bca7b531faad8ac,preferred,0.386843
uuid-bcb9daae86a343bb9bca7b531faad8ac,monotherapy,0.594497
uuid-bcb9daae86a343bb9bca7b531faad8ac,response,0.374495
uuid-bcb9daae86a343bb9bca7b531faad8ac,combo,0.366749
uuid-bcb9daae86a343bb9bca7b531faad8ac,PD1,0.383133
uuid-bcb9daae86a343bb9bca7b531faad8ac,progression,0.393363
uuid-bcb9daae86a343bb9bca7b531faad8ac,believes,0.336933
uuid-bcb9daae86a343bb9bca7b531faad8ac,chemotherapy,0.436617
uuid-bcb9daae86a343bb9bca7b531faad8ac,respond,0.41586
uuid-bcb9daae86a343bb9bca7b531faad8ac,feels,0.492078
uuid-bcb9daae86a343bb9bca7b531faad8ac,option,0.554546
uuid-db338e00b74c42f99df2332be53a058d,TL,0.354676
uuid-db338e00b74c42f99df2332be53a058d,pembro,0.318056
uuid-db338e00b74c42f99df2332be53a058d,RTL,0.383221
uuid-db338e00b74c42f99df2332be53a058d,lung,0.346689
uuid-db338e00b74c42f99df2332be53a058d,1L,0.558526
uuid-db338e00b74c42f99df2332be53a058d,commented,0.308488
uuid-db338e00b74c42f99df2332be53a058d,RCC,0.685364
uuid-db338e00b74c42f99df2332be53a058d,TL stated,0.621067
uuid-db338e00b74c42f99df2332be53a058d,2L,0.626248
uuid-db338e00b74c42f99df2332be53a058d,stated,0.546568
uuid-db338e00b74c42f99df2332be53a058d,approval,0.444731
uuid-db338e00b74c42f99df2332be53a058d,atezo,0.363472
uuid-db338e00b74c42f99df2332be53a058d,preferred,0.550317
uuid-db338e00b74c42f99df2332be53a058d,using nivo,0.629767
uuid-db338e00b74c42f99df2332be53a058d,PDL1 testing,0.507792
uuid-db338e00b74c42f99df2332be53a058d,NSCLC patients,0.409135
uuid-db338e00b74c42f99df2332be53a058d,approved,0.442206
uuid-db338e00b74c42f99df2332be53a058d,SCCHN,0.63377
uuid-db338e00b74c42f99df2332be53a058d,tumor types,0.436728
uuid-db338e00b74c42f99df2332be53a058d,LTL,0.443666
uuid-db338e00b74c42f99df2332be53a058d,TLs,0.479359
uuid-db338e00b74c42f99df2332be53a058d,Regional TL,0.570469
uuid-db338e00b74c42f99df2332be53a058d,RTL stated,0.678947
uuid-db338e00b74c42f99df2332be53a058d,TL shared,0.429293
uuid-db338e00b74c42f99df2332be53a058d,option,0.322786
uuid-db338e00b74c42f99df2332be53a058d,bladder,0.466801
uuid-37c9ee5de3e947c39d965dfb8f58d223,pembro,0.424915
uuid-37c9ee5de3e947c39d965dfb8f58d223,lung,0.310762
uuid-37c9ee5de3e947c39d965dfb8f58d223,1L,0.336462
uuid-37c9ee5de3e947c39d965dfb8f58d223,RCC,0.359066
uuid-37c9ee5de3e947c39d965dfb8f58d223,TL stated,0.441658
uuid-37c9ee5de3e947c39d965dfb8f58d223,2L,0.427941
uuid-37c9ee5de3e947c39d965dfb8f58d223,atezo,0.500548
uuid-37c9ee5de3e947c39d965dfb8f58d223,preferred,0.363872
uuid-37c9ee5de3e947c39d965dfb8f58d223,using nivo,0.322515
uuid-37c9ee5de3e947c39d965dfb8f58d223,PDL1 testing,0.326094
uuid-37c9ee5de3e947c39d965dfb8f58d223,NSCLC patients,0.358352
uuid-37c9ee5de3e947c39d965dfb8f58d223,nivo and pembro,0.374251
uuid-37c9ee5de3e947c39d965dfb8f58d223,tumor types,0.401383
uuid-37c9ee5de3e947c39d965dfb8f58d223,TLs,0.418739
uuid-37c9ee5de3e947c39d965dfb8f58d223,RTL stated,0.339198
uuid-37c9ee5de3e947c39d965dfb8f58d223,bladder,0.303714
uuid-4e825238b1964e46a167a9d6fa561e72,Nivo,0.4495
uuid-4e825238b1964e46a167a9d6fa561e72,Opdivo,0.438251
uuid-4e825238b1964e46a167a9d6fa561e72,pembro,0.627256
uuid-4e825238b1964e46a167a9d6fa561e72,dose,0.756021
uuid-4e825238b1964e46a167a9d6fa561e72,2L,0.363435
uuid-4e825238b1964e46a167a9d6fa561e72,Ipi,0.49222
uuid-4e825238b1964e46a167a9d6fa561e72,approval,0.401963
uuid-4e825238b1964e46a167a9d6fa561e72,atezo,0.605307
uuid-4e825238b1964e46a167a9d6fa561e72,preferred,0.418369
uuid-4e825238b1964e46a167a9d6fa561e72,using nivo,0.35212
uuid-4e825238b1964e46a167a9d6fa561e72,indication,0.437659
uuid-4e825238b1964e46a167a9d6fa561e72,approved,0.453406
uuid-4e825238b1964e46a167a9d6fa561e72,vs,0.545324
uuid-4e825238b1964e46a167a9d6fa561e72,label,0.37187
uuid-4e825238b1964e46a167a9d6fa561e72,Keytruda,0.497614
uuid-4e825238b1964e46a167a9d6fa561e72,flat dosing,0.784205
uuid-d18472edc4ca48239e45777e6c352e9b,pembro,0.346484
uuid-d18472edc4ca48239e45777e6c352e9b,BMS,0.361081
uuid-d18472edc4ca48239e45777e6c352e9b,PDL1,0.564394
uuid-d18472edc4ca48239e45777e6c352e9b,trial,0.319016
uuid-d18472edc4ca48239e45777e6c352e9b,efficacy,0.398799
uuid-d18472edc4ca48239e45777e6c352e9b,Merck,0.41411
uuid-d18472edc4ca48239e45777e6c352e9b,PD-L1,0.315546
uuid-d18472edc4ca48239e45777e6c352e9b,OS,0.35136
uuid-d18472edc4ca48239e45777e6c352e9b,atezo,0.403781
uuid-d18472edc4ca48239e45777e6c352e9b,regards,0.414645
uuid-d18472edc4ca48239e45777e6c352e9b,data,0.325598
uuid-d18472edc4ca48239e45777e6c352e9b,indication,0.302798
uuid-d18472edc4ca48239e45777e6c352e9b,PFS,0.414555
uuid-d18472edc4ca48239e45777e6c352e9b,AI,0.581994
uuid-d18472edc4ca48239e45777e6c352e9b,ORR,0.336021
uuid-d18472edc4ca48239e45777e6c352e9b,nivo and pembro,0.615835
uuid-d18472edc4ca48239e45777e6c352e9b,assay,0.489844
uuid-d18472edc4ca48239e45777e6c352e9b,PDL1 expression,0.529205
uuid-d18472edc4ca48239e45777e6c352e9b,biomarker,0.389331
uuid-34aec7b61b3a4033a382f69462a375e5,mentioned,0.559719
uuid-34aec7b61b3a4033a382f69462a375e5,cHL,0.53639
uuid-c9b55672f35a40dea5ad7c1ce3d206ba,patients,0.671919
uuid-c9b55672f35a40dea5ad7c1ce3d206ba,Opdivo,0.392403
uuid-c9b55672f35a40dea5ad7c1ce3d206ba,therapy,0.615669
uuid-c9b55672f35a40dea5ad7c1ce3d206ba,nivolumab,0.469625
uuid-c9b55672f35a40dea5ad7c1ce3d206ba,treated,0.417293
uuid-c9b55672f35a40dea5ad7c1ce3d206ba,treatment,0.48674
uuid-c9b55672f35a40dea5ad7c1ce3d206ba,cHL,0.612386
uuid-c9b55672f35a40dea5ad7c1ce3d206ba,progression,0.43672
uuid-c9b55672f35a40dea5ad7c1ce3d206ba,chemotherapy,0.366089
uuid-6d22fd12ef014843acb459a22745cb1a,RTL,0.45974
uuid-6d22fd12ef014843acb459a22745cb1a,nivolumab,0.463895
uuid-6d22fd12ef014843acb459a22745cb1a,stated,0.467338
uuid-6d22fd12ef014843acb459a22745cb1a,clinical trials,0.323792
uuid-6d22fd12ef014843acb459a22745cb1a,SCCHN,0.315148
uuid-6d22fd12ef014843acb459a22745cb1a,cHL,0.389727
uuid-6d22fd12ef014843acb459a22745cb1a,impressed,0.389277
uuid-6d22fd12ef014843acb459a22745cb1a,LTL,0.41507
uuid-6d22fd12ef014843acb459a22745cb1a,academic,0.355384
uuid-6d22fd12ef014843acb459a22745cb1a,Regional TL,0.452926
uuid-6d22fd12ef014843acb459a22745cb1a,RTL stated,0.318358
uuid-3637163002e940698d0bfd14c4db3b2c,Opdivo,0.345306
uuid-3637163002e940698d0bfd14c4db3b2c,pembro,0.349771
uuid-3637163002e940698d0bfd14c4db3b2c,dose,0.371946
uuid-3637163002e940698d0bfd14c4db3b2c,shared,0.470493
uuid-3637163002e940698d0bfd14c4db3b2c,RCC,0.321718
uuid-3637163002e940698d0bfd14c4db3b2c,2L,0.390058
uuid-3637163002e940698d0bfd14c4db3b2c,institution,0.467984
uuid-3637163002e940698d0bfd14c4db3b2c,Ipi,0.321119
uuid-3637163002e940698d0bfd14c4db3b2c,stated,0.481906
uuid-3637163002e940698d0bfd14c4db3b2c,approval,0.460883
uuid-3637163002e940698d0bfd14c4db3b2c,atezo,0.369028
uuid-3637163002e940698d0bfd14c4db3b2c,preferred,0.382048
uuid-3637163002e940698d0bfd14c4db3b2c,using nivo,0.509643
uuid-3637163002e940698d0bfd14c4db3b2c,indication,0.309185
uuid-3637163002e940698d0bfd14c4db3b2c,approved,0.447371
uuid-3637163002e940698d0bfd14c4db3b2c,SCCHN,0.404199
uuid-3637163002e940698d0bfd14c4db3b2c,label,0.304949
uuid-3637163002e940698d0bfd14c4db3b2c,SCLC,0.309906
uuid-3637163002e940698d0bfd14c4db3b2c,RTL stated,0.402921
uuid-3637163002e940698d0bfd14c4db3b2c,flat dosing,0.414144
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,pembro,0.40098
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,BMS,0.486678
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,PDL1,0.453428
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,trial,0.787919
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,efficacy,0.450291
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,Merck,0.512747
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,OS,0.416018
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,atezo,0.318184
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,regards,0.325547
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,data,0.598663
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,expressed,0.325952
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,clinical trials,0.384773
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,PFS,0.460198
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,ORR,0.495034
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,nivo and pembro,0.45733
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,impressed,0.351599
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,PDL1 expression,0.493512
uuid-ddc4b8084be24ac8b4cde2c78d4fd47b,biomarker,0.326875
uuid-591596a507f54ad9aa53d27c62c902a8,PD-L1 testing,0.43196
uuid-7aed5b68a76b4020989629c4bbe932e5,Nivo,0.303159
uuid-7aed5b68a76b4020989629c4bbe932e5,BMS,0.530804
uuid-7aed5b68a76b4020989629c4bbe932e5,PDL1,0.314349
uuid-7aed5b68a76b4020989629c4bbe932e5,trial,0.471543
uuid-7aed5b68a76b4020989629c4bbe932e5,efficacy,0.610461
uuid-7aed5b68a76b4020989629c4bbe932e5,commented,0.337896
uuid-7aed5b68a76b4020989629c4bbe932e5,OS,0.496908
uuid-7aed5b68a76b4020989629c4bbe932e5,regards,0.338937
uuid-7aed5b68a76b4020989629c4bbe932e5,data,0.69438
uuid-7aed5b68a76b4020989629c4bbe932e5,PFS,0.49564
uuid-7aed5b68a76b4020989629c4bbe932e5,ORR,0.505435
uuid-7aed5b68a76b4020989629c4bbe932e5,nivo and pembro,0.395519
uuid-7aed5b68a76b4020989629c4bbe932e5,impressed,0.550294
uuid-7aed5b68a76b4020989629c4bbe932e5,vs,0.351007
uuid-7aed5b68a76b4020989629c4bbe932e5,feels,0.577583
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,RTL,0.459828
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,BMS,0.447516
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,PDL1,0.343538
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,trial,0.664505
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,commented,0.486853
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,Merck,0.467443
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,stated,0.390574
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,OS,0.445714
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,data,0.737036
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,expressed,0.363421
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,clinical trials,0.341175
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,PFS,0.451085
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,ORR,0.48144
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,ASCO,0.358038
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,impressed,0.589513
uuid-500af2c3ddd7457d9cf78e7f5b59cea5,Regional TL,0.388034
uuid-b0f86acd73284d84b90e26a2b307cc1d,patients,0.72664
uuid-b0f86acd73284d84b90e26a2b307cc1d,Opdivo,0.482195
uuid-b0f86acd73284d84b90e26a2b307cc1d,therapy,0.545631
uuid-b0f86acd73284d84b90e26a2b307cc1d,nivolumab,0.700697
uuid-b0f86acd73284d84b90e26a2b307cc1d,regimen,0.55231
uuid-b0f86acd73284d84b90e26a2b307cc1d,treated,0.715635
uuid-b0f86acd73284d84b90e26a2b307cc1d,RCC,0.335067
uuid-b0f86acd73284d84b90e26a2b307cc1d,combination,0.35497
uuid-b0f86acd73284d84b90e26a2b307cc1d,chemo,0.322055
uuid-b0f86acd73284d84b90e26a2b307cc1d,pts,0.577238
uuid-b0f86acd73284d84b90e26a2b307cc1d,monotherapy,0.446472
uuid-b0f86acd73284d84b90e26a2b307cc1d,treatment,0.638131
uuid-b0f86acd73284d84b90e26a2b307cc1d,using nivo,0.344674
uuid-b0f86acd73284d84b90e26a2b307cc1d,response,0.416241
uuid-b0f86acd73284d84b90e26a2b307cc1d,PD1,0.357899
uuid-b0f86acd73284d84b90e26a2b307cc1d,progression,0.591319
uuid-b0f86acd73284d84b90e26a2b307cc1d,chemotherapy,0.388275
uuid-b0f86acd73284d84b90e26a2b307cc1d,respond,0.428218
uuid-b0f86acd73284d84b90e26a2b307cc1d,RTL stated,0.392655
uuid-b0f86acd73284d84b90e26a2b307cc1d,TL shared,0.362431
uuid-b0f86acd73284d84b90e26a2b307cc1d,option,0.325842
uuid-905ba495df384a2388b45cb4b18e1027,patients,0.734598
uuid-905ba495df384a2388b45cb4b18e1027,Opdivo,0.609654
uuid-905ba495df384a2388b45cb4b18e1027,therapy,0.492012
uuid-905ba495df384a2388b45cb4b18e1027,dose,0.491455
uuid-905ba495df384a2388b45cb4b18e1027,nivolumab,0.622831
uuid-905ba495df384a2388b45cb4b18e1027,toxicity,0.453293
uuid-905ba495df384a2388b45cb4b18e1027,regimen,0.69631
uuid-905ba495df384a2388b45cb4b18e1027,treated,0.633136
uuid-905ba495df384a2388b45cb4b18e1027,combination,0.459242
uuid-905ba495df384a2388b45cb4b18e1027,chemo,0.309464
uuid-905ba495df384a2388b45cb4b18e1027,pts,0.48733
uuid-905ba495df384a2388b45cb4b18e1027,Ipi,0.382489
uuid-905ba495df384a2388b45cb4b18e1027,monotherapy,0.466449
uuid-905ba495df384a2388b45cb4b18e1027,treatment,0.677733
uuid-905ba495df384a2388b45cb4b18e1027,using nivo,0.332873
uuid-905ba495df384a2388b45cb4b18e1027,combo,0.40967
uuid-905ba495df384a2388b45cb4b18e1027,PD1,0.305321
uuid-905ba495df384a2388b45cb4b18e1027,progression,0.529073
uuid-905ba495df384a2388b45cb4b18e1027,chemotherapy,0.395955
uuid-905ba495df384a2388b45cb4b18e1027,respond,0.382112
uuid-905ba495df384a2388b45cb4b18e1027,option,0.345931
uuid-00548f57c94f47b6a8592378fcf203de,patients,0.792497
uuid-00548f57c94f47b6a8592378fcf203de,therapy,0.414987
uuid-00548f57c94f47b6a8592378fcf203de,1L,0.364379
uuid-00548f57c94f47b6a8592378fcf203de,regimen,0.375659
uuid-00548f57c94f47b6a8592378fcf203de,treated,0.340398
uuid-00548f57c94f47b6a8592378fcf203de,chemo,0.375718
uuid-00548f57c94f47b6a8592378fcf203de,pts,0.563628
uuid-00548f57c94f47b6a8592378fcf203de,monotherapy,0.433356
uuid-00548f57c94f47b6a8592378fcf203de,treatment,0.499025
uuid-00548f57c94f47b6a8592378fcf203de,NSCLC patients,0.445409
uuid-00548f57c94f47b6a8592378fcf203de,progression,0.494792
uuid-00548f57c94f47b6a8592378fcf203de,chemotherapy,0.373375
uuid-00548f57c94f47b6a8592378fcf203de,respond,0.389529
uuid-00548f57c94f47b6a8592378fcf203de,option,0.527362
uuid-8e165cbc2b124833a0856cea4ae9cb9b,Nivo,0.335777
uuid-8e165cbc2b124833a0856cea4ae9cb9b,pembro,0.368195
uuid-8e165cbc2b124833a0856cea4ae9cb9b,dose,0.516864
uuid-8e165cbc2b124833a0856cea4ae9cb9b,regimen,0.347472
uuid-8e165cbc2b124833a0856cea4ae9cb9b,2L,0.307134
uuid-8e165cbc2b124833a0856cea4ae9cb9b,Ipi,0.341828
uuid-8e165cbc2b124833a0856cea4ae9cb9b,atezo,0.371624
uuid-8e165cbc2b124833a0856cea4ae9cb9b,preferred,0.447046
uuid-8e165cbc2b124833a0856cea4ae9cb9b,monotherapy,0.306781
uuid-8e165cbc2b124833a0856cea4ae9cb9b,vs,0.392594
uuid-8e165cbc2b124833a0856cea4ae9cb9b,feels,0.360903
uuid-16d76336e11b4896a968f3d79f851fc0,lung,0.394765
uuid-16d76336e11b4896a968f3d79f851fc0,efficacy,0.363646
uuid-16d76336e11b4896a968f3d79f851fc0,discussed,0.481891
uuid-16d76336e11b4896a968f3d79f851fc0,melanoma,0.347605
uuid-16d76336e11b4896a968f3d79f851fc0,OS,0.331967
uuid-16d76336e11b4896a968f3d79f851fc0,atezo,0.324156
uuid-16d76336e11b4896a968f3d79f851fc0,regards,0.459688
uuid-16d76336e11b4896a968f3d79f851fc0,data,0.401663
uuid-16d76336e11b4896a968f3d79f851fc0,PFS,0.327951
uuid-16d76336e11b4896a968f3d79f851fc0,AI,0.5469
uuid-16d76336e11b4896a968f3d79f851fc0,nivo and pembro,0.446616
uuid-16d76336e11b4896a968f3d79f851fc0,NCCN,0.329712
uuid-8f94dc377d18427e95aa4a35b7d3edaf,regimen,0.425525
uuid-8f94dc377d18427e95aa4a35b7d3edaf,melanoma,0.349991
uuid-8f94dc377d18427e95aa4a35b7d3edaf,Ipi,0.350589
uuid-8f94dc377d18427e95aa4a35b7d3edaf,OS,0.319002
uuid-8f94dc377d18427e95aa4a35b7d3edaf,regards,0.319184
uuid-8f94dc377d18427e95aa4a35b7d3edaf,response,0.356325
uuid-8f94dc377d18427e95aa4a35b7d3edaf,combo,0.322379
uuid-8f94dc377d18427e95aa4a35b7d3edaf,PFS,0.304097
uuid-8f94dc377d18427e95aa4a35b7d3edaf,ORR,0.347182
uuid-8f94dc377d18427e95aa4a35b7d3edaf,impressed,0.394426
uuid-8f94dc377d18427e95aa4a35b7d3edaf,respond,0.32021
uuid-8f94dc377d18427e95aa4a35b7d3edaf,SCLC,0.525696
uuid-1f8d92319cdf407a84c8d68f647b6f62,patients,0.331534
uuid-1f8d92319cdf407a84c8d68f647b6f62,1L,0.374561
uuid-1f8d92319cdf407a84c8d68f647b6f62,PDL1,0.320942
uuid-1f8d92319cdf407a84c8d68f647b6f62,PD-L1,0.592295
uuid-1f8d92319cdf407a84c8d68f647b6f62,PD-L1 testing,0.628866
uuid-1f8d92319cdf407a84c8d68f647b6f62,testing,0.730925
uuid-1f8d92319cdf407a84c8d68f647b6f62,PDL1 testing,0.644316
uuid-1f8d92319cdf407a84c8d68f647b6f62,NSCLC patients,0.619704
uuid-1f8d92319cdf407a84c8d68f647b6f62,assay,0.373938
uuid-1f8d92319cdf407a84c8d68f647b6f62,option,0.30662
uuid-1f8d92319cdf407a84c8d68f647b6f62,biomarker,0.328641
uuid-bac198bcd4974bccae76b2a4a7003000,tumor,0.693613
uuid-bac198bcd4974bccae76b2a4a7003000,tumor types,0.371279
uuid-6ad315f4297b470cac442d855c371343,RTL,0.554348
uuid-6ad315f4297b470cac442d855c371343,BMS,0.367364
uuid-6ad315f4297b470cac442d855c371343,NTL,0.344038
uuid-6ad315f4297b470cac442d855c371343,shared,0.767307
uuid-6ad315f4297b470cac442d855c371343,commented,0.588765
uuid-6ad315f4297b470cac442d855c371343,RCC,0.378888
uuid-6ad315f4297b470cac442d855c371343,stated,0.63741
uuid-6ad315f4297b470cac442d855c371343,data,0.550435
uuid-6ad315f4297b470cac442d855c371343,expressed,0.421548
uuid-6ad315f4297b470cac442d855c371343,clinical trials,0.421005
uuid-6ad315f4297b470cac442d855c371343,SCCHN,0.469452
uuid-6ad315f4297b470cac442d855c371343,HCP,0.350258
uuid-6ad315f4297b470cac442d855c371343,ASCO,0.329725
uuid-6ad315f4297b470cac442d855c371343,impressed,0.611931
uuid-6ad315f4297b470cac442d855c371343,LTL,0.618227
uuid-6ad315f4297b470cac442d855c371343,TLs,0.55983
uuid-6ad315f4297b470cac442d855c371343,academic,0.373542
uuid-6ad315f4297b470cac442d855c371343,SCLC,0.302737
uuid-6ad315f4297b470cac442d855c371343,feels,0.307363
uuid-6ad315f4297b470cac442d855c371343,Regional TL,0.581472
uuid-6ad315f4297b470cac442d855c371343,RTL stated,0.353595
uuid-6ad315f4297b470cac442d855c371343,bladder,0.309783
uuid-3a2c07741e6a47559b68d6d2b85eaadf,BMS,0.316043
uuid-3a2c07741e6a47559b68d6d2b85eaadf,PDL1,0.317057
uuid-3a2c07741e6a47559b68d6d2b85eaadf,trial,0.564907
uuid-3a2c07741e6a47559b68d6d2b85eaadf,efficacy,0.614525
uuid-3a2c07741e6a47559b68d6d2b85eaadf,OS,0.719065
uuid-3a2c07741e6a47559b68d6d2b85eaadf,data,0.696325
uuid-3a2c07741e6a47559b68d6d2b85eaadf,PFS,0.697953
uuid-3a2c07741e6a47559b68d6d2b85eaadf,ORR,0.826385
uuid-3a2c07741e6a47559b68d6d2b85eaadf,nivo and pembro,0.452807
uuid-3a2c07741e6a47559b68d6d2b85eaadf,ASCO,0.30731
uuid-3a2c07741e6a47559b68d6d2b85eaadf,impressed,0.698725
uuid-3a2c07741e6a47559b68d6d2b85eaadf,feels,0.366052
uuid-3a2c07741e6a47559b68d6d2b85eaadf,PDL1 expression,0.372754
uuid-8e44dab646c54ccb8bd06b3684df7d16,BMS,0.358769
uuid-8e44dab646c54ccb8bd06b3684df7d16,trial,0.305492
uuid-8e44dab646c54ccb8bd06b3684df7d16,efficacy,0.376552
uuid-8e44dab646c54ccb8bd06b3684df7d16,commented,0.396634
uuid-8e44dab646c54ccb8bd06b3684df7d16,OS,0.777542
uuid-8e44dab646c54ccb8bd06b3684df7d16,data,0.664503
uuid-8e44dab646c54ccb8bd06b3684df7d16,PFS,0.692102
uuid-8e44dab646c54ccb8bd06b3684df7d16,ORR,0.65378
uuid-8e44dab646c54ccb8bd06b3684df7d16,ASCO,0.422642
uuid-8e44dab646c54ccb8bd06b3684df7d16,impressed,0.690323
uuid-8e44dab646c54ccb8bd06b3684df7d16,feels,0.328549
uuid-3839f4f1da2c4cc68e0c95642571c2a7,trial,0.476842
uuid-3839f4f1da2c4cc68e0c95642571c2a7,combination,0.516714
uuid-3839f4f1da2c4cc68e0c95642571c2a7,chemo,0.473428
uuid-3839f4f1da2c4cc68e0c95642571c2a7,IO,0.342965
uuid-3839f4f1da2c4cc68e0c95642571c2a7,monotherapy,0.368538
uuid-3839f4f1da2c4cc68e0c95642571c2a7,response,0.36538
uuid-3839f4f1da2c4cc68e0c95642571c2a7,data,0.322049
uuid-3839f4f1da2c4cc68e0c95642571c2a7,combo,0.457224
uuid-3839f4f1da2c4cc68e0c95642571c2a7,PD1,0.422193
uuid-3839f4f1da2c4cc68e0c95642571c2a7,ORR,0.366692
uuid-3839f4f1da2c4cc68e0c95642571c2a7,chemotherapy,0.456382
uuid-3839f4f1da2c4cc68e0c95642571c2a7,impressed,0.380582
uuid-6d6db13d7ffe437fa4256ac87ef294d7,RTL,0.309136
uuid-6d6db13d7ffe437fa4256ac87ef294d7,BMS,0.324475
uuid-6d6db13d7ffe437fa4256ac87ef294d7,trial,0.715532
uuid-6d6db13d7ffe437fa4256ac87ef294d7,data,0.445608
uuid-6d6db13d7ffe437fa4256ac87ef294d7,clinical trials,0.44222
uuid-6d6db13d7ffe437fa4256ac87ef294d7,PFS,0.309018
uuid-6d6db13d7ffe437fa4256ac87ef294d7,ORR,0.389159
uuid-6d6db13d7ffe437fa4256ac87ef294d7,impressed,0.417035
uuid-ebc0afaa595545549ca6030d824bce0c,1L,0.4616
uuid-ebc0afaa595545549ca6030d824bce0c,PDL1,0.401441
uuid-ebc0afaa595545549ca6030d824bce0c,2L,0.317405
uuid-ebc0afaa595545549ca6030d824bce0c,testing,0.376614
uuid-ebc0afaa595545549ca6030d824bce0c,PDL1 testing,0.443163
uuid-ebc0afaa595545549ca6030d824bce0c,NSCLC patients,0.459884
uuid-ebc0afaa595545549ca6030d824bce0c,believes,0.302166
uuid-ebc0afaa595545549ca6030d824bce0c,feels,0.37529
uuid-ebc0afaa595545549ca6030d824bce0c,PDL1 expression,0.31419
uuid-ebc0afaa595545549ca6030d824bce0c,option,0.315367
uuid-e883fa904b844c49939ae937f2b9c50f,patients,0.454228
uuid-e883fa904b844c49939ae937f2b9c50f,Opdivo,0.334671
uuid-e883fa904b844c49939ae937f2b9c50f,therapy,0.381826
uuid-e883fa904b844c49939ae937f2b9c50f,nivolumab,0.301087
uuid-e883fa904b844c49939ae937f2b9c50f,treated,0.39969
uuid-e883fa904b844c49939ae937f2b9c50f,treatment,0.319277
uuid-e883fa904b844c49939ae937f2b9c50f,mentioned,0.437383
uuid-e883fa904b844c49939ae937f2b9c50f,cHL,0.688411
uuid-eb6008dfc61f422b8c1795d4e6e2f029,TL,0.49124
uuid-eb6008dfc61f422b8c1795d4e6e2f029,RTL,0.319795
uuid-eb6008dfc61f422b8c1795d4e6e2f029,NTL,0.392524
uuid-eb6008dfc61f422b8c1795d4e6e2f029,commented,0.461653
uuid-eb6008dfc61f422b8c1795d4e6e2f029,TL stated,0.413468
uuid-eb6008dfc61f422b8c1795d4e6e2f029,Merck,0.431509
uuid-eb6008dfc61f422b8c1795d4e6e2f029,physicians,0.46739
uuid-eb6008dfc61f422b8c1795d4e6e2f029,expressed,0.337102
uuid-eb6008dfc61f422b8c1795d4e6e2f029,mentioned,0.427379
uuid-eb6008dfc61f422b8c1795d4e6e2f029,ASCO,0.405541
uuid-eb6008dfc61f422b8c1795d4e6e2f029,Regional TL,0.439624
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,pembro,0.311874
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,RTL,0.546241
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,BMS,0.402439
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,trial,0.736751
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,NTL,0.411273
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,shared,0.306374
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,commented,0.565681
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,Merck,0.399418
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,stated,0.428348
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,approval,0.337176
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,OS,0.347448
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,data,0.620393
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,expressed,0.370018
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,clinical trials,0.387365
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,PFS,0.320656
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,ORR,0.385303
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,SCCHN,0.407385
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,ASCO,0.456539
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,impressed,0.645612
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,LTL,0.343325
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,TLs,0.332719
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,SCLC,0.376205
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,Regional TL,0.504239
uuid-a0e3d2ef64b74a0ca1df0910d9a9b0d7,bladder,0.334877
uuid-7cbe6ccd763b474b9124187d60e5f523,patients,0.370918
uuid-7cbe6ccd763b474b9124187d60e5f523,dose,0.319088
uuid-7cbe6ccd763b474b9124187d60e5f523,toxicity,0.430185
uuid-7cbe6ccd763b474b9124187d60e5f523,regimen,0.314279
uuid-7cbe6ccd763b474b9124187d60e5f523,treated,0.325353
uuid-7cbe6ccd763b474b9124187d60e5f523,physicians,0.450361
uuid-7cbe6ccd763b474b9124187d60e5f523,treatment,0.558434
uuid-7cbe6ccd763b474b9124187d60e5f523,progression,0.302331
uuid-7cbe6ccd763b474b9124187d60e5f523,respond,0.392717
uuid-dd13de6349cd4840862d2cf85f8198e1,chemo,0.366146
uuid-dd13de6349cd4840862d2cf85f8198e1,pts,0.335164
uuid-dd13de6349cd4840862d2cf85f8198e1,NSCLC patients,0.305703
uuid-dd13de6349cd4840862d2cf85f8198e1,tumor types,0.385333
uuid-dd13de6349cd4840862d2cf85f8198e1,biomarker,0.337451
uuid-e96d7278182742c885923e731cb0c4e1,patients,0.374625
uuid-e96d7278182742c885923e731cb0c4e1,trial,0.354286
uuid-e96d7278182742c885923e731cb0c4e1,pts,0.329682
uuid-e96d7278182742c885923e731cb0c4e1,clinical trials,0.389237
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,Nivo,0.382765
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,patients,0.584722
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,Opdivo,0.440592
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,therapy,0.412766
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,nivolumab,0.352639
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,1L,0.411694
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,regimen,0.491615
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,treated,0.314836
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,chemo,0.350435
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,2L,0.413235
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,pts,0.430078
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,preferred,0.424289
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,monotherapy,0.537958
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,treatment,0.503325
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,using nivo,0.440299
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,indication,0.322983
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,approved,0.366547
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,progression,0.402488
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,chemotherapy,0.391769
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,respond,0.416447
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,feels,0.32818
uuid-4ae53c610eb747ef8ccd5caf3e67ea23,option,0.586674
uuid-557bbf9614b84e76820017402bbd963e,patients,0.851087
uuid-557bbf9614b84e76820017402bbd963e,Opdivo,0.568443
uuid-557bbf9614b84e76820017402bbd963e,therapy,0.474274
uuid-557bbf9614b84e76820017402bbd963e,dose,0.373562
uuid-557bbf9614b84e76820017402bbd963e,nivolumab,0.404932
uuid-557bbf9614b84e76820017402bbd963e,toxicity,0.526693
uuid-557bbf9614b84e76820017402bbd963e,regimen,0.661052
uuid-557bbf9614b84e76820017402bbd963e,treated,0.451905
uuid-557bbf9614b84e76820017402bbd963e,chemo,0.360009
uuid-557bbf9614b84e76820017402bbd963e,pts,0.551045
uuid-557bbf9614b84e76820017402bbd963e,monotherapy,0.4506
uuid-557bbf9614b84e76820017402bbd963e,treatment,0.650435
uuid-557bbf9614b84e76820017402bbd963e,response,0.311296
uuid-557bbf9614b84e76820017402bbd963e,progression,0.551091
uuid-557bbf9614b84e76820017402bbd963e,chemotherapy,0.389871
uuid-557bbf9614b84e76820017402bbd963e,respond,0.476534
uuid-557bbf9614b84e76820017402bbd963e,option,0.409509
uuid-53e2060232d942a085a0a52604a80c01,Nivo,0.338616
uuid-53e2060232d942a085a0a52604a80c01,patients,0.36612
uuid-53e2060232d942a085a0a52604a80c01,therapy,0.613129
uuid-53e2060232d942a085a0a52604a80c01,nivolumab,0.431597
uuid-53e2060232d942a085a0a52604a80c01,1L,0.382578
uuid-53e2060232d942a085a0a52604a80c01,toxicity,0.442989
uuid-53e2060232d942a085a0a52604a80c01,regimen,0.562318
uuid-53e2060232d942a085a0a52604a80c01,treated,0.401323
uuid-53e2060232d942a085a0a52604a80c01,combination,0.673411
uuid-53e2060232d942a085a0a52604a80c01,chemo,0.579928
uuid-53e2060232d942a085a0a52604a80c01,2L,0.380754
uuid-53e2060232d942a085a0a52604a80c01,pts,0.458627
uuid-53e2060232d942a085a0a52604a80c01,IO,0.504824
uuid-53e2060232d942a085a0a52604a80c01,agents,0.484003
uuid-53e2060232d942a085a0a52604a80c01,preferred,0.341492
uuid-53e2060232d942a085a0a52604a80c01,monotherapy,0.763076
uuid-53e2060232d942a085a0a52604a80c01,treatment,0.442541
uuid-53e2060232d942a085a0a52604a80c01,response,0.408092
uuid-53e2060232d942a085a0a52604a80c01,combo,0.617107
uuid-53e2060232d942a085a0a52604a80c01,PD1,0.692106
uuid-53e2060232d942a085a0a52604a80c01,progression,0.472117
uuid-53e2060232d942a085a0a52604a80c01,believes,0.357859
uuid-53e2060232d942a085a0a52604a80c01,chemotherapy,0.558285
uuid-53e2060232d942a085a0a52604a80c01,respond,0.344325
uuid-53e2060232d942a085a0a52604a80c01,PD-1,0.43728
uuid-53e2060232d942a085a0a52604a80c01,option,0.557788
uuid-6133ea95185c4e43895f5082d3e71f7d,BMS,0.426752
uuid-6133ea95185c4e43895f5082d3e71f7d,PDL1,0.484109
uuid-6133ea95185c4e43895f5082d3e71f7d,trial,0.383831
uuid-6133ea95185c4e43895f5082d3e71f7d,efficacy,0.550534
uuid-6133ea95185c4e43895f5082d3e71f7d,commented,0.434772
uuid-6133ea95185c4e43895f5082d3e71f7d,Merck,0.305171
uuid-6133ea95185c4e43895f5082d3e71f7d,OS,0.511789
uuid-6133ea95185c4e43895f5082d3e71f7d,regards,0.435054
uuid-6133ea95185c4e43895f5082d3e71f7d,data,0.740901
uuid-6133ea95185c4e43895f5082d3e71f7d,expressed,0.471487
uuid-6133ea95185c4e43895f5082d3e71f7d,PFS,0.496735
uuid-6133ea95185c4e43895f5082d3e71f7d,ORR,0.577289
uuid-6133ea95185c4e43895f5082d3e71f7d,nivo and pembro,0.381115
uuid-6133ea95185c4e43895f5082d3e71f7d,ASCO,0.340421
uuid-6133ea95185c4e43895f5082d3e71f7d,believes,0.348083
uuid-6133ea95185c4e43895f5082d3e71f7d,impressed,0.593087
uuid-6133ea95185c4e43895f5082d3e71f7d,TLs,0.364466
uuid-6133ea95185c4e43895f5082d3e71f7d,feels,0.336207
uuid-6133ea95185c4e43895f5082d3e71f7d,PDL1 expression,0.479661
uuid-6133ea95185c4e43895f5082d3e71f7d,biomarker,0.348216
uuid-0ff7166589644a0ea44082d5b65e6bf2,patients,0.493939
uuid-0ff7166589644a0ea44082d5b65e6bf2,Opdivo,0.354765
uuid-0ff7166589644a0ea44082d5b65e6bf2,toxicity,0.516146
uuid-0ff7166589644a0ea44082d5b65e6bf2,regimen,0.51227
uuid-0ff7166589644a0ea44082d5b65e6bf2,treated,0.526454
uuid-0ff7166589644a0ea44082d5b65e6bf2,shared,0.40276
uuid-0ff7166589644a0ea44082d5b65e6bf2,physicians,0.417763
uuid-0ff7166589644a0ea44082d5b65e6bf2,treatment,0.449901
uuid-0ff7166589644a0ea44082d5b65e6bf2,progression,0.325951
uuid-0ff7166589644a0ea44082d5b65e6bf2,respond,0.33249
uuid-0ff7166589644a0ea44082d5b65e6bf2,TL shared,0.3373
uuid-0f8a2e50926d4158a795659831fdea69,Nivo,0.382312
uuid-0f8a2e50926d4158a795659831fdea69,regimen,0.400785
uuid-0f8a2e50926d4158a795659831fdea69,shared,0.369144
uuid-0f8a2e50926d4158a795659831fdea69,combination,0.527984
uuid-0f8a2e50926d4158a795659831fdea69,IO,0.300525
uuid-0f8a2e50926d4158a795659831fdea69,Ipi,0.493068
uuid-0f8a2e50926d4158a795659831fdea69,monotherapy,0.428828
uuid-0f8a2e50926d4158a795659831fdea69,combo,0.544884
uuid-0f8a2e50926d4158a795659831fdea69,impressed,0.323846
uuid-0f8a2e50926d4158a795659831fdea69,SCLC,0.313968
uuid-0f8a2e50926d4158a795659831fdea69,feels,0.317947
uuid-0f8a2e50926d4158a795659831fdea69,RTL stated,0.342276
uuid-0f8a2e50926d4158a795659831fdea69,option,0.30415
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,RTL,0.445716
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,lung,0.307235
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,NSCLC,0.376703
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,NTL,0.567936
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,discussed,0.377252
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,commented,0.370199
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,OS,0.323243
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,PFS,0.326932
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,ASCO,0.32588
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,impressed,0.370236
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,indicated,0.442808
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,TLs,0.399332
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,academic,0.340565
uuid-c97cccec2a5c4d9e951cd2f280f75cd2,Regional TL,0.442218
uuid-7a1beda251e44af2bcb2a9bdf07a9a0e,Nivo,0.360204
uuid-7a1beda251e44af2bcb2a9bdf07a9a0e,patients,0.537859
uuid-7a1beda251e44af2bcb2a9bdf07a9a0e,Opdivo,0.373301
uuid-7a1beda251e44af2bcb2a9bdf07a9a0e,therapy,0.547778
uuid-7a1beda251e44af2bcb2a9bdf07a9a0e,nivolumab,0.571661
uuid-7a1beda251e44af2bcb2a9bdf07a9a0e,treated,0.464581
uuid-7a1beda251e44af2bcb2a9bdf07a9a0e,approval,0.484929
uuid-7a1beda251e44af2bcb2a9bdf07a9a0e,treatment,0.411369
uuid-7a1beda251e44af2bcb2a9bdf07a9a0e,using nivo,0.449412
uuid-7a1beda251e44af2bcb2a9bdf07a9a0e,cHL,0.580086
uuid-7a1beda251e44af2bcb2a9bdf07a9a0e,progression,0.319569
uuid-7a1beda251e44af2bcb2a9bdf07a9a0e,RTL stated,0.323994
uuid-d98da9c47f2e421ba2ad90c326deeb80,Nivo,0.429598
uuid-d98da9c47f2e421ba2ad90c326deeb80,pembro,0.424088
uuid-d98da9c47f2e421ba2ad90c326deeb80,dose,0.763363
uuid-d98da9c47f2e421ba2ad90c326deeb80,toxicity,0.522413
uuid-d98da9c47f2e421ba2ad90c326deeb80,efficacy,0.366514
uuid-d98da9c47f2e421ba2ad90c326deeb80,regimen,0.372084
uuid-d98da9c47f2e421ba2ad90c326deeb80,combination,0.359435
uuid-d98da9c47f2e421ba2ad90c326deeb80,Ipi,0.697121
uuid-d98da9c47f2e421ba2ad90c326deeb80,atezo,0.421601
uuid-d98da9c47f2e421ba2ad90c326deeb80,preferred,0.383403
uuid-d98da9c47f2e421ba2ad90c326deeb80,combo,0.355441
uuid-d98da9c47f2e421ba2ad90c326deeb80,indication,0.343977
uuid-d98da9c47f2e421ba2ad90c326deeb80,vs,0.521746
uuid-d98da9c47f2e421ba2ad90c326deeb80,flat dosing,0.535708
uuid-f97118edd42e442cb070c5dd8151c89c,combination,0.318835
uuid-f97118edd42e442cb070c5dd8151c89c,response,0.313699
uuid-f97118edd42e442cb070c5dd8151c89c,PD1,0.465041
uuid-f97118edd42e442cb070c5dd8151c89c,ORR,0.329938
uuid-f97118edd42e442cb070c5dd8151c89c,believes,0.336774
uuid-5255a077d75e42ee8790377e3ba6f3d2,chemo,0.368634
uuid-5255a077d75e42ee8790377e3ba6f3d2,tumor,0.459791
uuid-5255a077d75e42ee8790377e3ba6f3d2,pts,0.362003
uuid-5255a077d75e42ee8790377e3ba6f3d2,response,0.547387
uuid-5121ee3a575d4888bbb9154a8f85c36a,patients,0.57478
uuid-5121ee3a575d4888bbb9154a8f85c36a,Opdivo,0.36348
uuid-5121ee3a575d4888bbb9154a8f85c36a,dose,0.465145
uuid-5121ee3a575d4888bbb9154a8f85c36a,nivolumab,0.327215
uuid-5121ee3a575d4888bbb9154a8f85c36a,regimen,0.361722
uuid-5121ee3a575d4888bbb9154a8f85c36a,treated,0.367469
uuid-5121ee3a575d4888bbb9154a8f85c36a,pts,0.343284
uuid-5121ee3a575d4888bbb9154a8f85c36a,Ipi,0.344512
uuid-5121ee3a575d4888bbb9154a8f85c36a,treatment,0.37335
uuid-5121ee3a575d4888bbb9154a8f85c36a,clinical trials,0.352167
uuid-5121ee3a575d4888bbb9154a8f85c36a,flat dosing,0.308
uuid-1cc6520c6d22492b9663f2b0f9bc287d,patients,0.405057
uuid-1cc6520c6d22492b9663f2b0f9bc287d,Opdivo,0.518167
uuid-1cc6520c6d22492b9663f2b0f9bc287d,2L,0.311928
uuid-1cc6520c6d22492b9663f2b0f9bc287d,approval,0.475979
uuid-1cc6520c6d22492b9663f2b0f9bc287d,physicians,0.316701
uuid-1cc6520c6d22492b9663f2b0f9bc287d,preferred,0.411077
uuid-1cc6520c6d22492b9663f2b0f9bc287d,using nivo,0.379608
uuid-1cc6520c6d22492b9663f2b0f9bc287d,clinical trials,0.314864
uuid-1cc6520c6d22492b9663f2b0f9bc287d,indication,0.360514
uuid-1cc6520c6d22492b9663f2b0f9bc287d,approved,0.525286
uuid-1cc6520c6d22492b9663f2b0f9bc287d,tumor types,0.333158
uuid-1cc6520c6d22492b9663f2b0f9bc287d,label,0.402655
uuid-1cc6520c6d22492b9663f2b0f9bc287d,Keytruda,0.312941
uuid-1cc6520c6d22492b9663f2b0f9bc287d,option,0.349964
uuid-b8a2fcad49b244b68c36997eaa50e244,patients,0.784034
uuid-b8a2fcad49b244b68c36997eaa50e244,Opdivo,0.393645
uuid-b8a2fcad49b244b68c36997eaa50e244,therapy,0.564118
uuid-b8a2fcad49b244b68c36997eaa50e244,nivolumab,0.526377
uuid-b8a2fcad49b244b68c36997eaa50e244,regimen,0.458783
uuid-b8a2fcad49b244b68c36997eaa50e244,treated,0.604395
uuid-b8a2fcad49b244b68c36997eaa50e244,pts,0.466472
uuid-b8a2fcad49b244b68c36997eaa50e244,monotherapy,0.366886
uuid-b8a2fcad49b244b68c36997eaa50e244,treatment,0.621946
uuid-b8a2fcad49b244b68c36997eaa50e244,using nivo,0.409163
uuid-b8a2fcad49b244b68c36997eaa50e244,cHL,0.343319
uuid-b8a2fcad49b244b68c36997eaa50e244,progression,0.561361
uuid-b8a2fcad49b244b68c36997eaa50e244,chemotherapy,0.350697
uuid-b8a2fcad49b244b68c36997eaa50e244,respond,0.414624
uuid-b8a2fcad49b244b68c36997eaa50e244,option,0.363801
uuid-a1abc2713ee9492b80cad08410636fbf,patients,0.509878
uuid-a1abc2713ee9492b80cad08410636fbf,chemo,0.360629
uuid-a1abc2713ee9492b80cad08410636fbf,pts,0.393734
uuid-a1abc2713ee9492b80cad08410636fbf,response,0.330967
uuid-a1abc2713ee9492b80cad08410636fbf,NSCLC patients,0.431995
uuid-a1abc2713ee9492b80cad08410636fbf,progression,0.405715
uuid-a1abc2713ee9492b80cad08410636fbf,tumor types,0.323528
uuid-a1abc2713ee9492b80cad08410636fbf,respond,0.409132
uuid-04d5769b45ca4e029ba992efcbf4d440,patients,0.51267
uuid-04d5769b45ca4e029ba992efcbf4d440,therapy,0.36417
uuid-04d5769b45ca4e029ba992efcbf4d440,1L,0.324847
uuid-04d5769b45ca4e029ba992efcbf4d440,toxicity,0.390713
uuid-04d5769b45ca4e029ba992efcbf4d440,regimen,0.591371
uuid-04d5769b45ca4e029ba992efcbf4d440,combination,0.489078
uuid-04d5769b45ca4e029ba992efcbf4d440,chemo,0.60378
uuid-04d5769b45ca4e029ba992efcbf4d440,pts,0.618469
uuid-04d5769b45ca4e029ba992efcbf4d440,IO,0.421364
uuid-04d5769b45ca4e029ba992efcbf4d440,monotherapy,0.619941
uuid-04d5769b45ca4e029ba992efcbf4d440,treatment,0.369547
uuid-04d5769b45ca4e029ba992efcbf4d440,response,0.560019
uuid-04d5769b45ca4e029ba992efcbf4d440,combo,0.517627
uuid-04d5769b45ca4e029ba992efcbf4d440,PD1,0.515424
uuid-04d5769b45ca4e029ba992efcbf4d440,progression,0.62349
uuid-04d5769b45ca4e029ba992efcbf4d440,believes,0.3356
uuid-04d5769b45ca4e029ba992efcbf4d440,chemotherapy,0.475364
uuid-04d5769b45ca4e029ba992efcbf4d440,respond,0.458183
uuid-04d5769b45ca4e029ba992efcbf4d440,feels,0.428108
uuid-04d5769b45ca4e029ba992efcbf4d440,option,0.464937
uuid-aefceb44726d491e981b85483d0e937f,patients,0.641074
uuid-aefceb44726d491e981b85483d0e937f,Opdivo,0.319134
uuid-aefceb44726d491e981b85483d0e937f,toxicity,0.587681
uuid-aefceb44726d491e981b85483d0e937f,regimen,0.554179
uuid-aefceb44726d491e981b85483d0e937f,treated,0.394474
uuid-aefceb44726d491e981b85483d0e937f,chemo,0.314187
uuid-aefceb44726d491e981b85483d0e937f,pts,0.413189
uuid-aefceb44726d491e981b85483d0e937f,treatment,0.65855
uuid-aefceb44726d491e981b85483d0e937f,response,0.375954
uuid-aefceb44726d491e981b85483d0e937f,progression,0.542093
uuid-aefceb44726d491e981b85483d0e937f,respond,0.605399
uuid-8f05faf5929b4a95b090b0240418bb7a,Nivo,0.500734
uuid-8f05faf5929b4a95b090b0240418bb7a,patients,0.573705
uuid-8f05faf5929b4a95b090b0240418bb7a,Opdivo,0.345986
uuid-8f05faf5929b4a95b090b0240418bb7a,therapy,0.300333
uuid-8f05faf5929b4a95b090b0240418bb7a,dose,0.328624
uuid-8f05faf5929b4a95b090b0240418bb7a,nivolumab,0.522056
uuid-8f05faf5929b4a95b090b0240418bb7a,trial,0.306122
uuid-8f05faf5929b4a95b090b0240418bb7a,regimen,0.488164
uuid-8f05faf5929b4a95b090b0240418bb7a,treated,0.349946
uuid-8f05faf5929b4a95b090b0240418bb7a,combination,0.371833
uuid-8f05faf5929b4a95b090b0240418bb7a,chemo,0.306155
uuid-8f05faf5929b4a95b090b0240418bb7a,pts,0.447151
uuid-8f05faf5929b4a95b090b0240418bb7a,Ipi,0.544815
uuid-8f05faf5929b4a95b090b0240418bb7a,monotherapy,0.352937
uuid-8f05faf5929b4a95b090b0240418bb7a,treatment,0.331473
uuid-8f05faf5929b4a95b090b0240418bb7a,using nivo,0.339088
uuid-8f05faf5929b4a95b090b0240418bb7a,combo,0.345325
uuid-8f05faf5929b4a95b090b0240418bb7a,progression,0.392057
uuid-8f05faf5929b4a95b090b0240418bb7a,chemotherapy,0.363582
uuid-8f05faf5929b4a95b090b0240418bb7a,impressed,0.301945
uuid-8f05faf5929b4a95b090b0240418bb7a,respond,0.31941
uuid-8f05faf5929b4a95b090b0240418bb7a,SCLC,0.303307
uuid-baf51ec03e7d44a18074faeedf6eb9d3,dose,0.330843
uuid-baf51ec03e7d44a18074faeedf6eb9d3,toxicity,0.375006
uuid-baf51ec03e7d44a18074faeedf6eb9d3,efficacy,0.387047
uuid-baf51ec03e7d44a18074faeedf6eb9d3,combination,0.404987
uuid-baf51ec03e7d44a18074faeedf6eb9d3,chemo,0.459418
uuid-baf51ec03e7d44a18074faeedf6eb9d3,tumor,0.475381
uuid-baf51ec03e7d44a18074faeedf6eb9d3,IO,0.459676
uuid-baf51ec03e7d44a18074faeedf6eb9d3,Ipi,0.338117
uuid-baf51ec03e7d44a18074faeedf6eb9d3,response,0.46358
uuid-baf51ec03e7d44a18074faeedf6eb9d3,combo,0.408822
uuid-baf51ec03e7d44a18074faeedf6eb9d3,progression,0.325267
uuid-baf51ec03e7d44a18074faeedf6eb9d3,believes,0.347668
uuid-baf51ec03e7d44a18074faeedf6eb9d3,chemotherapy,0.313162
uuid-baf51ec03e7d44a18074faeedf6eb9d3,vs,0.362959
uuid-b3a2921e61a34cbcb855279345ee9afe,patients,0.620169
uuid-b3a2921e61a34cbcb855279345ee9afe,Opdivo,0.442243
uuid-b3a2921e61a34cbcb855279345ee9afe,therapy,0.317277
uuid-b3a2921e61a34cbcb855279345ee9afe,dose,0.323093
uuid-b3a2921e61a34cbcb855279345ee9afe,nivolumab,0.313232
uuid-b3a2921e61a34cbcb855279345ee9afe,toxicity,0.568056
uuid-b3a2921e61a34cbcb855279345ee9afe,regimen,0.580943
uuid-b3a2921e61a34cbcb855279345ee9afe,treated,0.383029
uuid-b3a2921e61a34cbcb855279345ee9afe,chemo,0.313848
uuid-b3a2921e61a34cbcb855279345ee9afe,2L,0.34538
uuid-b3a2921e61a34cbcb855279345ee9afe,pts,0.367661
uuid-b3a2921e61a34cbcb855279345ee9afe,preferred,0.539437
uuid-b3a2921e61a34cbcb855279345ee9afe,monotherapy,0.520037
uuid-b3a2921e61a34cbcb855279345ee9afe,treatment,0.557124
uuid-b3a2921e61a34cbcb855279345ee9afe,using nivo,0.311658
uuid-b3a2921e61a34cbcb855279345ee9afe,progression,0.354737
uuid-b3a2921e61a34cbcb855279345ee9afe,respond,0.405218
uuid-b3a2921e61a34cbcb855279345ee9afe,option,0.552383
uuid-1012c66c998b4eb9ae93b7a37211d78d,combination,0.516294
uuid-1012c66c998b4eb9ae93b7a37211d78d,IO,0.492478
uuid-1012c66c998b4eb9ae93b7a37211d78d,agents,0.482753
uuid-1012c66c998b4eb9ae93b7a37211d78d,preferred,0.33644
uuid-1012c66c998b4eb9ae93b7a37211d78d,combo,0.452162
uuid-1012c66c998b4eb9ae93b7a37211d78d,believes,0.322367
uuid-1012c66c998b4eb9ae93b7a37211d78d,feels,0.355644
uuid-1012c66c998b4eb9ae93b7a37211d78d,option,0.361632
uuid-84a19ee021ab4679a4f230c84b0b9854,patients,0.778834
uuid-84a19ee021ab4679a4f230c84b0b9854,Opdivo,0.469568
uuid-84a19ee021ab4679a4f230c84b0b9854,therapy,0.618598
uuid-84a19ee021ab4679a4f230c84b0b9854,nivolumab,0.477763
uuid-84a19ee021ab4679a4f230c84b0b9854,regimen,0.429737
uuid-84a19ee021ab4679a4f230c84b0b9854,treated,0.610526
uuid-84a19ee021ab4679a4f230c84b0b9854,pts,0.430932
uuid-84a19ee021ab4679a4f230c84b0b9854,treatment,0.66284
uuid-84a19ee021ab4679a4f230c84b0b9854,response,0.434381
uuid-84a19ee021ab4679a4f230c84b0b9854,cHL,0.498037
uuid-84a19ee021ab4679a4f230c84b0b9854,progression,0.652542
uuid-84a19ee021ab4679a4f230c84b0b9854,respond,0.512797
uuid-9ff301e0e46c4759b3b08fe315ea3df6,combination,0.461304
uuid-9ff301e0e46c4759b3b08fe315ea3df6,agents,0.383336
uuid-9ff301e0e46c4759b3b08fe315ea3df6,immunotherapy,0.409542
uuid-adf654284459457da7fec1b540c3bdad,patients,0.302656
uuid-adf654284459457da7fec1b540c3bdad,therapy,0.322874
uuid-adf654284459457da7fec1b540c3bdad,toxicity,0.370566
uuid-adf654284459457da7fec1b540c3bdad,combination,0.340273
uuid-adf654284459457da7fec1b540c3bdad,chemo,0.36453
uuid-adf654284459457da7fec1b540c3bdad,treatment,0.319198
uuid-adf654284459457da7fec1b540c3bdad,chemotherapy,0.412432
uuid-adf654284459457da7fec1b540c3bdad,option,0.363614
uuid-4a52622f152e46a6823635a066b22b17,tumor,0.596002
uuid-4a52622f152e46a6823635a066b22b17,response,0.345292
uuid-4a52622f152e46a6823635a066b22b17,immunotherapy,0.382763
uuid-e31b1e2b684a4ff6b2373b71ca3ac614,OS,0.391316
uuid-e31b1e2b684a4ff6b2373b71ca3ac614,PFS,0.344423
uuid-e31b1e2b684a4ff6b2373b71ca3ac614,ORR,0.306612
uuid-21b6fd98f047464eb74377609820cfba,BMS,0.319321
uuid-21b6fd98f047464eb74377609820cfba,trial,0.384012
uuid-21b6fd98f047464eb74377609820cfba,efficacy,0.375589
uuid-21b6fd98f047464eb74377609820cfba,commented,0.63087
uuid-21b6fd98f047464eb74377609820cfba,stated,0.308841
uuid-21b6fd98f047464eb74377609820cfba,OS,0.630241
uuid-21b6fd98f047464eb74377609820cfba,regards,0.386302
uuid-21b6fd98f047464eb74377609820cfba,data,0.794532
uuid-21b6fd98f047464eb74377609820cfba,expressed,0.375059
uuid-21b6fd98f047464eb74377609820cfba,PFS,0.574241
uuid-21b6fd98f047464eb74377609820cfba,ORR,0.660281
uuid-21b6fd98f047464eb74377609820cfba,ASCO,0.511214
uuid-21b6fd98f047464eb74377609820cfba,impressed,0.727588
uuid-21b6fd98f047464eb74377609820cfba,TLs,0.320751
uuid-21b6fd98f047464eb74377609820cfba,SCLC,0.335385
uuid-21b6fd98f047464eb74377609820cfba,Regional TL,0.310735
uuid-21b6fd98f047464eb74377609820cfba,NCCN,0.310927
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,patients,0.584967
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,1L,0.472633
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,treated,0.300888
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,TL stated,0.338615
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,2L,0.411777
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,pts,0.399965
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,PD-L1,0.424197
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,approval,0.406705
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,preferred,0.442943
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,PD-L1 testing,0.566569
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,testing,0.598705
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,treatment,0.353682
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,using nivo,0.38269
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,PDL1 testing,0.556675
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,NSCLC patients,0.645472
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,approved,0.306151
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,progression,0.324291
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,RTL stated,0.337905
uuid-98706ae1f1fc4dc6a1027bdb2aa522a5,option,0.44305
uuid-eee69aa9291f42239d2b1084ba31da27,TL,0.427002
uuid-eee69aa9291f42239d2b1084ba31da27,pembro,0.404817
uuid-eee69aa9291f42239d2b1084ba31da27,PDL1,0.603121
uuid-eee69aa9291f42239d2b1084ba31da27,Merck,0.488294
uuid-eee69aa9291f42239d2b1084ba31da27,PD-L1,0.646454
uuid-eee69aa9291f42239d2b1084ba31da27,atezo,0.441976
uuid-eee69aa9291f42239d2b1084ba31da27,PD-L1 testing,0.521037
uuid-eee69aa9291f42239d2b1084ba31da27,testing,0.613234
uuid-eee69aa9291f42239d2b1084ba31da27,data,0.384101
uuid-eee69aa9291f42239d2b1084ba31da27,PDL1 testing,0.485883
uuid-eee69aa9291f42239d2b1084ba31da27,NSCLC patients,0.35783
uuid-eee69aa9291f42239d2b1084ba31da27,nivo and pembro,0.488895
uuid-eee69aa9291f42239d2b1084ba31da27,assay,0.692031
uuid-eee69aa9291f42239d2b1084ba31da27,PDL1 expression,0.43929
uuid-eee69aa9291f42239d2b1084ba31da27,biomarker,0.453791
uuid-9eb16ac8cef84ae3994dffa4a3855e98,patients,0.39304
uuid-9eb16ac8cef84ae3994dffa4a3855e98,dose,0.422506
uuid-9eb16ac8cef84ae3994dffa4a3855e98,toxicity,0.61733
uuid-9eb16ac8cef84ae3994dffa4a3855e98,regimen,0.464434
uuid-9eb16ac8cef84ae3994dffa4a3855e98,physicians,0.369315
uuid-9eb16ac8cef84ae3994dffa4a3855e98,treatment,0.442505
uuid-9eb16ac8cef84ae3994dffa4a3855e98,progression,0.36107
uuid-9eb16ac8cef84ae3994dffa4a3855e98,respond,0.400052
uuid-9dc8ae80a336443890054dd3f8d3f618,patients,0.326647
uuid-9dc8ae80a336443890054dd3f8d3f618,Opdivo,0.441087
uuid-9dc8ae80a336443890054dd3f8d3f618,BMS,0.395183
uuid-9dc8ae80a336443890054dd3f8d3f618,physicians,0.390714
uuid-c51022ac758a4a3db975abc8da95d66c,drug,0.365994
uuid-181061f01e744dc0849b7a0f7999739d,Opdivo,0.347065
uuid-181061f01e744dc0849b7a0f7999739d,stated,0.412922
uuid-181061f01e744dc0849b7a0f7999739d,approval,0.508409
uuid-181061f01e744dc0849b7a0f7999739d,preferred,0.302902
uuid-181061f01e744dc0849b7a0f7999739d,using nivo,0.423131
uuid-181061f01e744dc0849b7a0f7999739d,clinical trials,0.447411
uuid-181061f01e744dc0849b7a0f7999739d,indication,0.489564
uuid-181061f01e744dc0849b7a0f7999739d,approved,0.539408
uuid-181061f01e744dc0849b7a0f7999739d,SCCHN,0.325745
uuid-181061f01e744dc0849b7a0f7999739d,tumor types,0.304205
uuid-181061f01e744dc0849b7a0f7999739d,label,0.412039
uuid-181061f01e744dc0849b7a0f7999739d,bladder,0.376063
uuid-bf857c8e7f1245daad8ff061ddc439a0,patients,0.679075
uuid-bf857c8e7f1245daad8ff061ddc439a0,Opdivo,0.339685
uuid-bf857c8e7f1245daad8ff061ddc439a0,therapy,0.352744
uuid-bf857c8e7f1245daad8ff061ddc439a0,nivolumab,0.419392
uuid-bf857c8e7f1245daad8ff061ddc439a0,toxicity,0.456822
uuid-bf857c8e7f1245daad8ff061ddc439a0,regimen,0.648311
uuid-bf857c8e7f1245daad8ff061ddc439a0,treated,0.703023
uuid-bf857c8e7f1245daad8ff061ddc439a0,melanoma,0.442913
uuid-bf857c8e7f1245daad8ff061ddc439a0,RCC,0.410712
uuid-bf857c8e7f1245daad8ff061ddc439a0,pts,0.508462
uuid-bf857c8e7f1245daad8ff061ddc439a0,monotherapy,0.375328
uuid-bf857c8e7f1245daad8ff061ddc439a0,treatment,0.633269
uuid-bf857c8e7f1245daad8ff061ddc439a0,progression,0.544902
uuid-bf857c8e7f1245daad8ff061ddc439a0,respond,0.40338
uuid-bf857c8e7f1245daad8ff061ddc439a0,RTL stated,0.414139
uuid-bf857c8e7f1245daad8ff061ddc439a0,TL shared,0.510575
uuid-377a87af71744bbabf5dade510f75efd,RTL,0.578701
uuid-377a87af71744bbabf5dade510f75efd,lung,0.489802
uuid-377a87af71744bbabf5dade510f75efd,NTL,0.514396
uuid-377a87af71744bbabf5dade510f75efd,discussed,0.6637
uuid-377a87af71744bbabf5dade510f75efd,melanoma,0.437318
uuid-377a87af71744bbabf5dade510f75efd,shared,0.582763
uuid-377a87af71744bbabf5dade510f75efd,commented,0.608134
uuid-377a87af71744bbabf5dade510f75efd,RCC,0.404794
uuid-377a87af71744bbabf5dade510f75efd,stated,0.504471
uuid-377a87af71744bbabf5dade510f75efd,data,0.46059
uuid-377a87af71744bbabf5dade510f75efd,expressed,0.386735
uuid-377a87af71744bbabf5dade510f75efd,SCCHN,0.599821
uuid-377a87af71744bbabf5dade510f75efd,ASCO,0.449973
uuid-377a87af71744bbabf5dade510f75efd,impressed,0.489394
uuid-377a87af71744bbabf5dade510f75efd,LTL,0.484011
uuid-377a87af71744bbabf5dade510f75efd,TLs,0.512558
uuid-377a87af71744bbabf5dade510f75efd,academic,0.664588
uuid-377a87af71744bbabf5dade510f75efd,Regional TL,0.624167
uuid-377a87af71744bbabf5dade510f75efd,RTL stated,0.37623
uuid-377a87af71744bbabf5dade510f75efd,TL shared,0.430191
uuid-0c22f39cc19b4788b262417317d8c76b,patients,0.504704
uuid-0c22f39cc19b4788b262417317d8c76b,Opdivo,0.319226
uuid-0c22f39cc19b4788b262417317d8c76b,nivolumab,0.461665
uuid-0c22f39cc19b4788b262417317d8c76b,regimen,0.602508
uuid-0c22f39cc19b4788b262417317d8c76b,treated,0.534798
uuid-0c22f39cc19b4788b262417317d8c76b,melanoma,0.374418
uuid-0c22f39cc19b4788b262417317d8c76b,RCC,0.414842
uuid-0c22f39cc19b4788b262417317d8c76b,pts,0.407569
uuid-0c22f39cc19b4788b262417317d8c76b,monotherapy,0.313487
uuid-0c22f39cc19b4788b262417317d8c76b,treatment,0.403719
uuid-0c22f39cc19b4788b262417317d8c76b,using nivo,0.385553
uuid-0c22f39cc19b4788b262417317d8c76b,SCCHN,0.332922
uuid-0c22f39cc19b4788b262417317d8c76b,progression,0.345188
uuid-0c22f39cc19b4788b262417317d8c76b,Regional TL,0.355536
uuid-0c22f39cc19b4788b262417317d8c76b,RTL stated,0.39476
uuid-0c22f39cc19b4788b262417317d8c76b,TL shared,0.407299
uuid-5158edf6d1484e22b8e48dabf7e2acf3,therapy,0.40843
uuid-5158edf6d1484e22b8e48dabf7e2acf3,treatment,0.374208
uuid-5158edf6d1484e22b8e48dabf7e2acf3,PD1,0.485219
uuid-5158edf6d1484e22b8e48dabf7e2acf3,immunotherapy,0.384937
uuid-5158edf6d1484e22b8e48dabf7e2acf3,PD-1,0.441739
uuid-539a83766b2b4952b8017fce0d1d152d,patients,0.854485
uuid-539a83766b2b4952b8017fce0d1d152d,Opdivo,0.606131
uuid-539a83766b2b4952b8017fce0d1d152d,therapy,0.618229
uuid-539a83766b2b4952b8017fce0d1d152d,nivolumab,0.610733
uuid-539a83766b2b4952b8017fce0d1d152d,regimen,0.549
uuid-539a83766b2b4952b8017fce0d1d152d,treated,0.649987
uuid-539a83766b2b4952b8017fce0d1d152d,pts,0.513981
uuid-539a83766b2b4952b8017fce0d1d152d,monotherapy,0.355632
uuid-539a83766b2b4952b8017fce0d1d152d,treatment,0.694985
uuid-539a83766b2b4952b8017fce0d1d152d,using nivo,0.407718
uuid-539a83766b2b4952b8017fce0d1d152d,PD1,0.304504
uuid-539a83766b2b4952b8017fce0d1d152d,cHL,0.509706
uuid-539a83766b2b4952b8017fce0d1d152d,progression,0.624868
uuid-539a83766b2b4952b8017fce0d1d152d,chemotherapy,0.347867
uuid-539a83766b2b4952b8017fce0d1d152d,respond,0.435821
uuid-539a83766b2b4952b8017fce0d1d152d,RTL stated,0.301233
uuid-539a83766b2b4952b8017fce0d1d152d,option,0.304591
uuid-f4c4d042ad5849a6b6fcedecda946109,RTL,0.375946
uuid-f4c4d042ad5849a6b6fcedecda946109,lung,0.745615
uuid-f4c4d042ad5849a6b6fcedecda946109,NTL,0.440443
uuid-f4c4d042ad5849a6b6fcedecda946109,melanoma,0.648141
uuid-f4c4d042ad5849a6b6fcedecda946109,shared,0.330629
uuid-f4c4d042ad5849a6b6fcedecda946109,commented,0.504014
uuid-f4c4d042ad5849a6b6fcedecda946109,RCC,0.611505
uuid-f4c4d042ad5849a6b6fcedecda946109,TL stated,0.611528
uuid-f4c4d042ad5849a6b6fcedecda946109,stated,0.318772
uuid-f4c4d042ad5849a6b6fcedecda946109,expressed,0.3612
uuid-f4c4d042ad5849a6b6fcedecda946109,PDL1 testing,0.425838
uuid-f4c4d042ad5849a6b6fcedecda946109,AI,0.310546
uuid-f4c4d042ad5849a6b6fcedecda946109,SCCHN,0.539957
uuid-f4c4d042ad5849a6b6fcedecda946109,ASCO,0.505445
uuid-f4c4d042ad5849a6b6fcedecda946109,tumor types,0.346344
uuid-f4c4d042ad5849a6b6fcedecda946109,TLs,0.466596
uuid-f4c4d042ad5849a6b6fcedecda946109,academic,0.322547
uuid-f4c4d042ad5849a6b6fcedecda946109,SCLC,0.318543
uuid-f4c4d042ad5849a6b6fcedecda946109,Regional TL,0.535395
uuid-f4c4d042ad5849a6b6fcedecda946109,RTL stated,0.420247
uuid-f4c4d042ad5849a6b6fcedecda946109,TL shared,0.63174
uuid-f4c4d042ad5849a6b6fcedecda946109,NCCN,0.391929
uuid-f4c4d042ad5849a6b6fcedecda946109,bladder,0.451941
uuid-d39786e479ef4c6d83be89f36a3e9e10,testing,0.327065
uuid-d39786e479ef4c6d83be89f36a3e9e10,PDL1 testing,0.339824
uuid-27a2e6fa313d45b3858a0575aabede77,patients,0.681675
uuid-27a2e6fa313d45b3858a0575aabede77,Opdivo,0.345814
uuid-27a2e6fa313d45b3858a0575aabede77,therapy,0.35849
uuid-27a2e6fa313d45b3858a0575aabede77,regimen,0.421345
uuid-27a2e6fa313d45b3858a0575aabede77,treated,0.419114
uuid-27a2e6fa313d45b3858a0575aabede77,chemo,0.374545
uuid-27a2e6fa313d45b3858a0575aabede77,pts,0.48202
uuid-27a2e6fa313d45b3858a0575aabede77,monotherapy,0.326714
uuid-27a2e6fa313d45b3858a0575aabede77,treatment,0.494144
uuid-27a2e6fa313d45b3858a0575aabede77,progression,0.534812
uuid-27a2e6fa313d45b3858a0575aabede77,chemotherapy,0.413514
uuid-27a2e6fa313d45b3858a0575aabede77,respond,0.354408
uuid-27a2e6fa313d45b3858a0575aabede77,option,0.361412
uuid-84fc96e16b7344ccb70718179c953d68,PDL1,0.366743
uuid-84fc96e16b7344ccb70718179c953d68,tumor,0.488109
uuid-84fc96e16b7344ccb70718179c953d68,PD-L1,0.571762
uuid-84fc96e16b7344ccb70718179c953d68,PD-L1 testing,0.390052
uuid-84fc96e16b7344ccb70718179c953d68,testing,0.529501
uuid-84fc96e16b7344ccb70718179c953d68,PDL1 testing,0.308389
uuid-84fc96e16b7344ccb70718179c953d68,NSCLC patients,0.411122
uuid-84fc96e16b7344ccb70718179c953d68,assay,0.427035
uuid-84fc96e16b7344ccb70718179c953d68,PDL1 expression,0.31167
uuid-84fc96e16b7344ccb70718179c953d68,biomarker,0.455894
uuid-f71df85b656c488e854408d832f1c1cb,patients,0.329085
uuid-f71df85b656c488e854408d832f1c1cb,Opdivo,0.302582
uuid-f71df85b656c488e854408d832f1c1cb,Merck,0.335003
uuid-f71df85b656c488e854408d832f1c1cb,preferred,0.497648
uuid-f71df85b656c488e854408d832f1c1cb,approved,0.369904
uuid-f71df85b656c488e854408d832f1c1cb,label,0.377137
uuid-f71df85b656c488e854408d832f1c1cb,option,0.301898
uuid-4e21e807203240fa8d19a8d2baec3da5,patients,0.400146
uuid-4e21e807203240fa8d19a8d2baec3da5,Opdivo,0.470026
uuid-4e21e807203240fa8d19a8d2baec3da5,dose,0.396213
uuid-4e21e807203240fa8d19a8d2baec3da5,toxicity,0.458743
uuid-4e21e807203240fa8d19a8d2baec3da5,regimen,0.372402
uuid-4e21e807203240fa8d19a8d2baec3da5,physicians,0.507107
uuid-4e21e807203240fa8d19a8d2baec3da5,treatment,0.394758
uuid-4e21e807203240fa8d19a8d2baec3da5,drug,0.33112
uuid-4e21e807203240fa8d19a8d2baec3da5,flat dosing,0.395786
uuid-b6190f6046b34d6582d13c45aaa64965,pembro,0.546171
uuid-b6190f6046b34d6582d13c45aaa64965,dose,0.578083
uuid-b6190f6046b34d6582d13c45aaa64965,efficacy,0.311373
uuid-b6190f6046b34d6582d13c45aaa64965,shared,0.460779
uuid-b6190f6046b34d6582d13c45aaa64965,RCC,0.354398
uuid-b6190f6046b34d6582d13c45aaa64965,2L,0.475607
uuid-b6190f6046b34d6582d13c45aaa64965,Ipi,0.483431
uuid-b6190f6046b34d6582d13c45aaa64965,atezo,0.654554
uuid-b6190f6046b34d6582d13c45aaa64965,preferred,0.42077
uuid-b6190f6046b34d6582d13c45aaa64965,using nivo,0.368595
uuid-b6190f6046b34d6582d13c45aaa64965,combo,0.359233
uuid-b6190f6046b34d6582d13c45aaa64965,indication,0.361162
uuid-b6190f6046b34d6582d13c45aaa64965,approved,0.31781
uuid-b6190f6046b34d6582d13c45aaa64965,nivo and pembro,0.312764
uuid-b6190f6046b34d6582d13c45aaa64965,vs,0.507275
uuid-b6190f6046b34d6582d13c45aaa64965,TLs,0.489664
uuid-b6190f6046b34d6582d13c45aaa64965,flat dosing,0.550924
uuid-94014394458a4300991106d89eac6cfe,patients,0.861436
uuid-94014394458a4300991106d89eac6cfe,Opdivo,0.391169
uuid-94014394458a4300991106d89eac6cfe,therapy,0.638302
uuid-94014394458a4300991106d89eac6cfe,nivolumab,0.435794
uuid-94014394458a4300991106d89eac6cfe,toxicity,0.304484
uuid-94014394458a4300991106d89eac6cfe,regimen,0.591058
uuid-94014394458a4300991106d89eac6cfe,treated,0.5902
uuid-94014394458a4300991106d89eac6cfe,chemo,0.427973
uuid-94014394458a4300991106d89eac6cfe,pts,0.645547
uuid-94014394458a4300991106d89eac6cfe,monotherapy,0.439253
uuid-94014394458a4300991106d89eac6cfe,treatment,0.798522
uuid-94014394458a4300991106d89eac6cfe,response,0.53543
uuid-94014394458a4300991106d89eac6cfe,PD1,0.408984
uuid-94014394458a4300991106d89eac6cfe,progression,0.819807
uuid-94014394458a4300991106d89eac6cfe,chemotherapy,0.460326
uuid-94014394458a4300991106d89eac6cfe,respond,0.608831
uuid-94014394458a4300991106d89eac6cfe,option,0.401101
uuid-1b24e1bce265404b81152b37b7cc7ee5,patients,0.326615
uuid-1b24e1bce265404b81152b37b7cc7ee5,Opdivo,0.683931
uuid-1b24e1bce265404b81152b37b7cc7ee5,dose,0.822299
uuid-1b24e1bce265404b81152b37b7cc7ee5,toxicity,0.367813
uuid-1b24e1bce265404b81152b37b7cc7ee5,regimen,0.336157
uuid-1b24e1bce265404b81152b37b7cc7ee5,Ipi,0.386354
uuid-1b24e1bce265404b81152b37b7cc7ee5,vs,0.409795
uuid-1b24e1bce265404b81152b37b7cc7ee5,drug,0.437041
uuid-1b24e1bce265404b81152b37b7cc7ee5,Keytruda,0.537845
uuid-1b24e1bce265404b81152b37b7cc7ee5,flat dosing,0.777295
uuid-e2ac4aac010b4719b0e51117ebcacf11,Nivo,0.44413
uuid-e2ac4aac010b4719b0e51117ebcacf11,pembro,0.522022
uuid-e2ac4aac010b4719b0e51117ebcacf11,dose,0.473181
uuid-e2ac4aac010b4719b0e51117ebcacf11,efficacy,0.424975
uuid-e2ac4aac010b4719b0e51117ebcacf11,Ipi,0.324501
uuid-e2ac4aac010b4719b0e51117ebcacf11,atezo,0.476364
uuid-e2ac4aac010b4719b0e51117ebcacf11,preferred,0.352995
uuid-e2ac4aac010b4719b0e51117ebcacf11,indication,0.304862
uuid-e2ac4aac010b4719b0e51117ebcacf11,nivo and pembro,0.32214
uuid-e2ac4aac010b4719b0e51117ebcacf11,vs,0.601965
uuid-e2ac4aac010b4719b0e51117ebcacf11,feels,0.50832
uuid-e2ac4aac010b4719b0e51117ebcacf11,flat dosing,0.395606
uuid-aa5aac11a0e24477bb924e88c3af41e0,institution,0.444494
uuid-aa5aac11a0e24477bb924e88c3af41e0,approval,0.363821
uuid-aa5aac11a0e24477bb924e88c3af41e0,physicians,0.406292
uuid-aa5aac11a0e24477bb924e88c3af41e0,PD-L1 testing,0.441162
uuid-aa5aac11a0e24477bb924e88c3af41e0,testing,0.40446
uuid-aa5aac11a0e24477bb924e88c3af41e0,PDL1 testing,0.368801
uuid-aa5aac11a0e24477bb924e88c3af41e0,oncology,0.492196
uuid-aa5aac11a0e24477bb924e88c3af41e0,approved,0.363818
uuid-aa5aac11a0e24477bb924e88c3af41e0,label,0.351033
uuid-aa5aac11a0e24477bb924e88c3af41e0,oncologist,0.310804
uuid-aa5aac11a0e24477bb924e88c3af41e0,drug,0.418395
uuid-aa5aac11a0e24477bb924e88c3af41e0,clinical,0.360044
uuid-314ec54354d6460fb4d0b06212f1f5f8,patients,0.530592
uuid-314ec54354d6460fb4d0b06212f1f5f8,treated,0.427451
uuid-314ec54354d6460fb4d0b06212f1f5f8,pts,0.305968
uuid-314ec54354d6460fb4d0b06212f1f5f8,PD-L1 testing,0.408217
uuid-314ec54354d6460fb4d0b06212f1f5f8,treatment,0.409707
uuid-314ec54354d6460fb4d0b06212f1f5f8,NSCLC patients,0.318044
uuid-314ec54354d6460fb4d0b06212f1f5f8,progression,0.344555
uuid-6a32925e66b5471da8f54a73e1fd3419,Nivo,0.331467
uuid-6a32925e66b5471da8f54a73e1fd3419,pembro,0.40153
uuid-6a32925e66b5471da8f54a73e1fd3419,BMS,0.357424
uuid-6a32925e66b5471da8f54a73e1fd3419,PDL1,0.582432
uuid-6a32925e66b5471da8f54a73e1fd3419,trial,0.574489
uuid-6a32925e66b5471da8f54a73e1fd3419,efficacy,0.609025
uuid-6a32925e66b5471da8f54a73e1fd3419,OS,0.595717
uuid-6a32925e66b5471da8f54a73e1fd3419,atezo,0.360387
uuid-6a32925e66b5471da8f54a73e1fd3419,regards,0.353971
uuid-6a32925e66b5471da8f54a73e1fd3419,data,0.673311
uuid-6a32925e66b5471da8f54a73e1fd3419,expressed,0.457229
uuid-6a32925e66b5471da8f54a73e1fd3419,PFS,0.602212
uuid-6a32925e66b5471da8f54a73e1fd3419,ORR,0.646758
uuid-6a32925e66b5471da8f54a73e1fd3419,nivo and pembro,0.602011
uuid-6a32925e66b5471da8f54a73e1fd3419,believes,0.38552
uuid-6a32925e66b5471da8f54a73e1fd3419,impressed,0.497082
uuid-6a32925e66b5471da8f54a73e1fd3419,feels,0.33696
uuid-6a32925e66b5471da8f54a73e1fd3419,PDL1 expression,0.555177
uuid-6a32925e66b5471da8f54a73e1fd3419,biomarker,0.320015
uuid-54fc53897d874762b79d702b11350a94,RTL,0.484908
uuid-54fc53897d874762b79d702b11350a94,BMS,0.40178
uuid-54fc53897d874762b79d702b11350a94,trial,0.455681
uuid-54fc53897d874762b79d702b11350a94,NTL,0.344646
uuid-54fc53897d874762b79d702b11350a94,shared,0.31292
uuid-54fc53897d874762b79d702b11350a94,commented,0.585336
uuid-54fc53897d874762b79d702b11350a94,stated,0.510668
uuid-54fc53897d874762b79d702b11350a94,OS,0.4097
uuid-54fc53897d874762b79d702b11350a94,regards,0.311036
uuid-54fc53897d874762b79d702b11350a94,data,0.826245
uuid-54fc53897d874762b79d702b11350a94,expressed,0.456924
uuid-54fc53897d874762b79d702b11350a94,PFS,0.342012
uuid-54fc53897d874762b79d702b11350a94,ORR,0.436141
uuid-54fc53897d874762b79d702b11350a94,SCCHN,0.383785
uuid-54fc53897d874762b79d702b11350a94,ASCO,0.549361
uuid-54fc53897d874762b79d702b11350a94,impressed,0.741584
uuid-54fc53897d874762b79d702b11350a94,LTL,0.414616
uuid-54fc53897d874762b79d702b11350a94,TLs,0.418696
uuid-54fc53897d874762b79d702b11350a94,SCLC,0.420253
uuid-54fc53897d874762b79d702b11350a94,feels,0.308433
uuid-54fc53897d874762b79d702b11350a94,Regional TL,0.490452
uuid-54fc53897d874762b79d702b11350a94,bladder,0.358676
uuid-f6490f41dd5440d5b02b3aee45396845,patients,0.8906
uuid-f6490f41dd5440d5b02b3aee45396845,Opdivo,0.535547
uuid-f6490f41dd5440d5b02b3aee45396845,therapy,0.506256
uuid-f6490f41dd5440d5b02b3aee45396845,nivolumab,0.505763
uuid-f6490f41dd5440d5b02b3aee45396845,regimen,0.498997
uuid-f6490f41dd5440d5b02b3aee45396845,treated,0.659652
uuid-f6490f41dd5440d5b02b3aee45396845,pts,0.598227
uuid-f6490f41dd5440d5b02b3aee45396845,monotherapy,0.307045
uuid-f6490f41dd5440d5b02b3aee45396845,treatment,0.687231
uuid-f6490f41dd5440d5b02b3aee45396845,using nivo,0.3805
uuid-f6490f41dd5440d5b02b3aee45396845,response,0.334004
uuid-f6490f41dd5440d5b02b3aee45396845,cHL,0.324559
uuid-f6490f41dd5440d5b02b3aee45396845,progression,0.649969
uuid-f6490f41dd5440d5b02b3aee45396845,respond,0.519751
uuid-554c8084b9ae4546ae0be31621b36ea8,Nivo,0.364117
uuid-554c8084b9ae4546ae0be31621b36ea8,patients,0.692704
uuid-554c8084b9ae4546ae0be31621b36ea8,pembro,0.403727
uuid-554c8084b9ae4546ae0be31621b36ea8,1L,0.398569
uuid-554c8084b9ae4546ae0be31621b36ea8,chemo,0.301443
uuid-554c8084b9ae4546ae0be31621b36ea8,2L,0.393986
uuid-554c8084b9ae4546ae0be31621b36ea8,pts,0.477081
uuid-554c8084b9ae4546ae0be31621b36ea8,approval,0.343947
uuid-554c8084b9ae4546ae0be31621b36ea8,preferred,0.361336
uuid-554c8084b9ae4546ae0be31621b36ea8,monotherapy,0.354917
uuid-554c8084b9ae4546ae0be31621b36ea8,treatment,0.301611
uuid-554c8084b9ae4546ae0be31621b36ea8,using nivo,0.427909
uuid-554c8084b9ae4546ae0be31621b36ea8,NSCLC patients,0.328551
uuid-554c8084b9ae4546ae0be31621b36ea8,approved,0.33178
uuid-554c8084b9ae4546ae0be31621b36ea8,progression,0.329151
uuid-554c8084b9ae4546ae0be31621b36ea8,feels,0.365074
uuid-554c8084b9ae4546ae0be31621b36ea8,option,0.479645
uuid-fc70b90fa6df40bba5210db6a9599aa2,lung,0.450047
uuid-fc70b90fa6df40bba5210db6a9599aa2,1L,0.317176
uuid-fc70b90fa6df40bba5210db6a9599aa2,melanoma,0.464727
uuid-fc70b90fa6df40bba5210db6a9599aa2,shared,0.336905
uuid-fc70b90fa6df40bba5210db6a9599aa2,RCC,0.471183
uuid-fc70b90fa6df40bba5210db6a9599aa2,2L,0.400478
uuid-fc70b90fa6df40bba5210db6a9599aa2,institution,0.436368
uuid-fc70b90fa6df40bba5210db6a9599aa2,stated,0.329902
uuid-fc70b90fa6df40bba5210db6a9599aa2,approval,0.344604
uuid-fc70b90fa6df40bba5210db6a9599aa2,preferred,0.406489
uuid-fc70b90fa6df40bba5210db6a9599aa2,using nivo,0.416214
uuid-fc70b90fa6df40bba5210db6a9599aa2,PDL1 testing,0.331891
uuid-fc70b90fa6df40bba5210db6a9599aa2,AI,0.344346
uuid-fc70b90fa6df40bba5210db6a9599aa2,approved,0.344905
uuid-fc70b90fa6df40bba5210db6a9599aa2,SCCHN,0.540208
uuid-fc70b90fa6df40bba5210db6a9599aa2,academic,0.422945
uuid-fc70b90fa6df40bba5210db6a9599aa2,Regional TL,0.322055
uuid-fc70b90fa6df40bba5210db6a9599aa2,RTL stated,0.467111
uuid-fc70b90fa6df40bba5210db6a9599aa2,TL shared,0.388819
uuid-fc70b90fa6df40bba5210db6a9599aa2,NCCN,0.370689
uuid-f3c5eaa61faa48beb01f1df15e751d66,therapy,0.449625
uuid-f3c5eaa61faa48beb01f1df15e751d66,combination,0.366814
uuid-f3c5eaa61faa48beb01f1df15e751d66,chemo,0.417143
uuid-f3c5eaa61faa48beb01f1df15e751d66,pts,0.352438
uuid-f3c5eaa61faa48beb01f1df15e751d66,response,0.637995
uuid-f3c5eaa61faa48beb01f1df15e751d66,PD1,0.356725
uuid-f3c5eaa61faa48beb01f1df15e751d66,progression,0.336752
uuid-f3c5eaa61faa48beb01f1df15e751d66,believes,0.31141
uuid-f3c5eaa61faa48beb01f1df15e751d66,chemotherapy,0.305925
uuid-f3c5eaa61faa48beb01f1df15e751d66,respond,0.40806
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,patients,0.481912
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,therapy,0.527073
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,nivolumab,0.606975
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,treated,0.406928
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,combination,0.347631
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,chemo,0.423683
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,pts,0.43738
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,treatment,0.372536
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,response,0.532689
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,PD1,0.395575
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,cHL,0.31791
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,progression,0.429313
uuid-08b398c6d43f42f9a6ccf7341b4dc10e,chemotherapy,0.388371
uuid-cee5f18167114574a04f6cdc92a88399,discussed,0.42176
uuid-85140c60951742daac357be5b3b0247d,TL,0.754034
uuid-85140c60951742daac357be5b3b0247d,institution,0.330044
uuid-85140c60951742daac357be5b3b0247d,PD-L1,0.66597
uuid-85140c60951742daac357be5b3b0247d,PD-L1 testing,0.753664
uuid-85140c60951742daac357be5b3b0247d,testing,0.684714
uuid-85140c60951742daac357be5b3b0247d,PDL1 testing,0.405323
uuid-85140c60951742daac357be5b3b0247d,NSCLC patients,0.385788
uuid-85140c60951742daac357be5b3b0247d,assay,0.790533
uuid-a4d3cb066cb9432d85c447678b61cc72,TL,0.59038
uuid-a4d3cb066cb9432d85c447678b61cc72,pembro,0.340018
uuid-a4d3cb066cb9432d85c447678b61cc72,1L,0.32843
uuid-a4d3cb066cb9432d85c447678b61cc72,PDL1,0.314876
uuid-a4d3cb066cb9432d85c447678b61cc72,TL stated,0.473729
uuid-a4d3cb066cb9432d85c447678b61cc72,institution,0.329794
uuid-a4d3cb066cb9432d85c447678b61cc72,PD-L1,0.725722
uuid-a4d3cb066cb9432d85c447678b61cc72,approval,0.393308
uuid-a4d3cb066cb9432d85c447678b61cc72,atezo,0.375877
uuid-a4d3cb066cb9432d85c447678b61cc72,PD-L1 testing,0.810881
uuid-a4d3cb066cb9432d85c447678b61cc72,testing,0.826192
uuid-a4d3cb066cb9432d85c447678b61cc72,PDL1 testing,0.657141
uuid-a4d3cb066cb9432d85c447678b61cc72,NSCLC patients,0.655365
uuid-a4d3cb066cb9432d85c447678b61cc72,assay,0.781443
uuid-41e30450f976422c9f5d4546752d924a,TL,0.517031
uuid-41e30450f976422c9f5d4546752d924a,PDL1,0.379657
uuid-41e30450f976422c9f5d4546752d924a,TL stated,0.385136
uuid-41e30450f976422c9f5d4546752d924a,tumor,0.539752
uuid-41e30450f976422c9f5d4546752d924a,PD-L1,0.622188
uuid-41e30450f976422c9f5d4546752d924a,PD-L1 testing,0.607107
uuid-41e30450f976422c9f5d4546752d924a,testing,0.585827
uuid-41e30450f976422c9f5d4546752d924a,PDL1 testing,0.449668
uuid-41e30450f976422c9f5d4546752d924a,NSCLC patients,0.362619
uuid-41e30450f976422c9f5d4546752d924a,assay,0.556147
uuid-41e30450f976422c9f5d4546752d924a,PDL1 expression,0.31663
uuid-41e30450f976422c9f5d4546752d924a,biomarker,0.392985
uuid-5901258d386240dcbc36eae53259b260,TL,0.367531
uuid-5901258d386240dcbc36eae53259b260,TL stated,0.387548
uuid-5901258d386240dcbc36eae53259b260,tumor,0.536988
uuid-5901258d386240dcbc36eae53259b260,PD-L1,0.579213
uuid-5901258d386240dcbc36eae53259b260,PD-L1 testing,0.615098
uuid-5901258d386240dcbc36eae53259b260,testing,0.619128
uuid-5901258d386240dcbc36eae53259b260,PDL1 testing,0.479798
uuid-5901258d386240dcbc36eae53259b260,NSCLC patients,0.366937
uuid-5901258d386240dcbc36eae53259b260,assay,0.517907
uuid-5901258d386240dcbc36eae53259b260,biomarker,0.371987
uuid-298eff92b48c462cbe313c371dc4493a,TL,0.73038
uuid-298eff92b48c462cbe313c371dc4493a,TL stated,0.394915
uuid-298eff92b48c462cbe313c371dc4493a,institution,0.469561
uuid-298eff92b48c462cbe313c371dc4493a,PD-L1,0.770719
uuid-298eff92b48c462cbe313c371dc4493a,PD-L1 testing,0.884269
uuid-298eff92b48c462cbe313c371dc4493a,testing,0.849086
uuid-298eff92b48c462cbe313c371dc4493a,PDL1 testing,0.631351
uuid-298eff92b48c462cbe313c371dc4493a,NSCLC patients,0.571211
uuid-298eff92b48c462cbe313c371dc4493a,assay,0.747856
uuid-298eff92b48c462cbe313c371dc4493a,biomarker,0.358465
uuid-3658971aa93f4e81ba00bcac1f2a352c,TL,0.672532
uuid-3658971aa93f4e81ba00bcac1f2a352c,PDL1,0.300449
uuid-3658971aa93f4e81ba00bcac1f2a352c,TL stated,0.322035
uuid-3658971aa93f4e81ba00bcac1f2a352c,institution,0.367124
uuid-3658971aa93f4e81ba00bcac1f2a352c,PD-L1,0.699722
uuid-3658971aa93f4e81ba00bcac1f2a352c,PD-L1 testing,0.854195
uuid-3658971aa93f4e81ba00bcac1f2a352c,testing,0.787421
uuid-3658971aa93f4e81ba00bcac1f2a352c,PDL1 testing,0.582465
uuid-3658971aa93f4e81ba00bcac1f2a352c,NSCLC patients,0.435757
uuid-3658971aa93f4e81ba00bcac1f2a352c,assay,0.72671
uuid-3658971aa93f4e81ba00bcac1f2a352c,biomarker,0.322833
uuid-da56e9f34350483bada6e13847e7bf72,PD-L1 testing,0.31712
uuid-da56e9f34350483bada6e13847e7bf72,assay,0.320202
uuid-07dcd82adace4eee8a9039c0d5fbf47b,TL,0.582465
uuid-07dcd82adace4eee8a9039c0d5fbf47b,PDL1,0.314805
uuid-07dcd82adace4eee8a9039c0d5fbf47b,TL stated,0.412607
uuid-07dcd82adace4eee8a9039c0d5fbf47b,institution,0.410474
uuid-07dcd82adace4eee8a9039c0d5fbf47b,PD-L1,0.707493
uuid-07dcd82adace4eee8a9039c0d5fbf47b,PD-L1 testing,0.869318
uuid-07dcd82adace4eee8a9039c0d5fbf47b,testing,0.830774
uuid-07dcd82adace4eee8a9039c0d5fbf47b,PDL1 testing,0.687036
uuid-07dcd82adace4eee8a9039c0d5fbf47b,NSCLC patients,0.523234
uuid-07dcd82adace4eee8a9039c0d5fbf47b,assay,0.669425
uuid-07dcd82adace4eee8a9039c0d5fbf47b,biomarker,0.337957
uuid-97e7de008933421990d0e695c898b6e0,TL,0.396701
uuid-97e7de008933421990d0e695c898b6e0,institution,0.636893
uuid-97e7de008933421990d0e695c898b6e0,PD-L1,0.636096
uuid-97e7de008933421990d0e695c898b6e0,PD-L1 testing,0.712857
uuid-97e7de008933421990d0e695c898b6e0,testing,0.676566
uuid-97e7de008933421990d0e695c898b6e0,PDL1 testing,0.532221
uuid-97e7de008933421990d0e695c898b6e0,NSCLC patients,0.515775
uuid-97e7de008933421990d0e695c898b6e0,Keytruda,0.37802
uuid-97e7de008933421990d0e695c898b6e0,assay,0.497636
uuid-1d289d4d98b84ed88ba55af70582d0b2,TL,0.831599
uuid-1d289d4d98b84ed88ba55af70582d0b2,TL stated,0.440951
uuid-1d289d4d98b84ed88ba55af70582d0b2,Merck,0.301385
uuid-1d289d4d98b84ed88ba55af70582d0b2,institution,0.414071
uuid-1d289d4d98b84ed88ba55af70582d0b2,PD-L1,0.612188
uuid-1d289d4d98b84ed88ba55af70582d0b2,PD-L1 testing,0.805588
uuid-1d289d4d98b84ed88ba55af70582d0b2,testing,0.682203
uuid-1d289d4d98b84ed88ba55af70582d0b2,PDL1 testing,0.512613
uuid-1d289d4d98b84ed88ba55af70582d0b2,NSCLC patients,0.400127
uuid-1d289d4d98b84ed88ba55af70582d0b2,assay,0.72609
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,lung,0.536498
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,1L,0.56908
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,melanoma,0.50632
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,RCC,0.911228
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,TL stated,0.646937
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,2L,0.626249
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,stated,0.326224
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,approval,0.415874
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,preferred,0.519736
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,monotherapy,0.340256
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,using nivo,0.620756
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,PDL1 testing,0.533387
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,NSCLC patients,0.499948
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,approved,0.423946
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,SCCHN,0.669019
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,tumor types,0.544401
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,oncologist,0.308694
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,TLs,0.360205
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,Regional TL,0.450876
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,RTL stated,0.698565
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,TL shared,0.6392
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,option,0.360829
uuid-e32ea6dfb86e445dbf4ef4dd11464d9d,bladder,0.563694
uuid-fb4cb88d916647b182e4cbde09c8d7f9,patients,0.901557
uuid-fb4cb88d916647b182e4cbde09c8d7f9,Opdivo,0.55627
uuid-fb4cb88d916647b182e4cbde09c8d7f9,therapy,0.562342
uuid-fb4cb88d916647b182e4cbde09c8d7f9,nivolumab,0.614125
uuid-fb4cb88d916647b182e4cbde09c8d7f9,toxicity,0.305344
uuid-fb4cb88d916647b182e4cbde09c8d7f9,regimen,0.549694
uuid-fb4cb88d916647b182e4cbde09c8d7f9,treated,0.728319
uuid-fb4cb88d916647b182e4cbde09c8d7f9,pts,0.582929
uuid-fb4cb88d916647b182e4cbde09c8d7f9,monotherapy,0.340182
uuid-fb4cb88d916647b182e4cbde09c8d7f9,treatment,0.686805
uuid-fb4cb88d916647b182e4cbde09c8d7f9,using nivo,0.33679
uuid-fb4cb88d916647b182e4cbde09c8d7f9,response,0.330001
uuid-fb4cb88d916647b182e4cbde09c8d7f9,cHL,0.427913
uuid-fb4cb88d916647b182e4cbde09c8d7f9,progression,0.64181
uuid-fb4cb88d916647b182e4cbde09c8d7f9,chemotherapy,0.349469
uuid-fb4cb88d916647b182e4cbde09c8d7f9,respond,0.454432
uuid-fc2a9cad974649b7bbc30d5e4452e440,lung,0.740347
uuid-fc2a9cad974649b7bbc30d5e4452e440,1L,0.424883
uuid-fc2a9cad974649b7bbc30d5e4452e440,melanoma,0.604709
uuid-fc2a9cad974649b7bbc30d5e4452e440,shared,0.327182
uuid-fc2a9cad974649b7bbc30d5e4452e440,RCC,0.709722
uuid-fc2a9cad974649b7bbc30d5e4452e440,TL stated,0.721012
uuid-fc2a9cad974649b7bbc30d5e4452e440,2L,0.431703
uuid-fc2a9cad974649b7bbc30d5e4452e440,institution,0.52677
uuid-fc2a9cad974649b7bbc30d5e4452e440,stated,0.303641
uuid-fc2a9cad974649b7bbc30d5e4452e440,PD-L1,0.39784
uuid-fc2a9cad974649b7bbc30d5e4452e440,approval,0.318729
uuid-fc2a9cad974649b7bbc30d5e4452e440,PD-L1 testing,0.493018
uuid-fc2a9cad974649b7bbc30d5e4452e440,testing,0.543206
uuid-fc2a9cad974649b7bbc30d5e4452e440,using nivo,0.37121
uuid-fc2a9cad974649b7bbc30d5e4452e440,PDL1 testing,0.729789
uuid-fc2a9cad974649b7bbc30d5e4452e440,AI,0.387415
uuid-fc2a9cad974649b7bbc30d5e4452e440,NSCLC patients,0.558741
uuid-fc2a9cad974649b7bbc30d5e4452e440,SCCHN,0.554251
uuid-fc2a9cad974649b7bbc30d5e4452e440,tumor types,0.454475
uuid-fc2a9cad974649b7bbc30d5e4452e440,TLs,0.329404
uuid-fc2a9cad974649b7bbc30d5e4452e440,Regional TL,0.336314
uuid-fc2a9cad974649b7bbc30d5e4452e440,RTL stated,0.52616
uuid-fc2a9cad974649b7bbc30d5e4452e440,TL shared,0.625814
uuid-fc2a9cad974649b7bbc30d5e4452e440,NCCN,0.304678
uuid-fc2a9cad974649b7bbc30d5e4452e440,bladder,0.428642
uuid-b5bc79aabc6646aca550320c646e9a5a,Nivo,0.309266
uuid-b5bc79aabc6646aca550320c646e9a5a,patients,0.914561
uuid-b5bc79aabc6646aca550320c646e9a5a,Opdivo,0.525846
uuid-b5bc79aabc6646aca550320c646e9a5a,therapy,0.621675
uuid-b5bc79aabc6646aca550320c646e9a5a,nivolumab,0.53777
uuid-b5bc79aabc6646aca550320c646e9a5a,toxicity,0.364953
uuid-b5bc79aabc6646aca550320c646e9a5a,regimen,0.588821
uuid-b5bc79aabc6646aca550320c646e9a5a,treated,0.593205
uuid-b5bc79aabc6646aca550320c646e9a5a,chemo,0.358509
uuid-b5bc79aabc6646aca550320c646e9a5a,pts,0.596338
uuid-b5bc79aabc6646aca550320c646e9a5a,monotherapy,0.347406
uuid-b5bc79aabc6646aca550320c646e9a5a,treatment,0.759241
uuid-b5bc79aabc6646aca550320c646e9a5a,response,0.441667
uuid-b5bc79aabc6646aca550320c646e9a5a,cHL,0.382953
uuid-b5bc79aabc6646aca550320c646e9a5a,progression,0.660582
uuid-b5bc79aabc6646aca550320c646e9a5a,chemotherapy,0.389591
uuid-b5bc79aabc6646aca550320c646e9a5a,respond,0.550185
uuid-b5bc79aabc6646aca550320c646e9a5a,option,0.315813
uuid-52f860811d2e42bcbf8e50315921806f,tumor,0.618566
uuid-52f860811d2e42bcbf8e50315921806f,bladder,0.343789
uuid-af911c243abc4cc59076f9b569ad2bcd,RTL,0.433354
uuid-af911c243abc4cc59076f9b569ad2bcd,commented,0.312112
uuid-af911c243abc4cc59076f9b569ad2bcd,RCC,0.430565
uuid-af911c243abc4cc59076f9b569ad2bcd,TL stated,0.500618
uuid-af911c243abc4cc59076f9b569ad2bcd,stated,0.494503
uuid-af911c243abc4cc59076f9b569ad2bcd,approval,0.358437
uuid-af911c243abc4cc59076f9b569ad2bcd,preferred,0.309826
uuid-af911c243abc4cc59076f9b569ad2bcd,PD-L1 testing,0.301838
uuid-af911c243abc4cc59076f9b569ad2bcd,using nivo,0.464887
uuid-af911c243abc4cc59076f9b569ad2bcd,PDL1 testing,0.442833
uuid-af911c243abc4cc59076f9b569ad2bcd,NSCLC patients,0.368198
uuid-af911c243abc4cc59076f9b569ad2bcd,SCCHN,0.571979
uuid-af911c243abc4cc59076f9b569ad2bcd,tumor types,0.334047
uuid-af911c243abc4cc59076f9b569ad2bcd,oncologist,0.416903
uuid-af911c243abc4cc59076f9b569ad2bcd,LTL,0.415718
uuid-af911c243abc4cc59076f9b569ad2bcd,TLs,0.331842
uuid-af911c243abc4cc59076f9b569ad2bcd,Regional TL,0.52244
uuid-af911c243abc4cc59076f9b569ad2bcd,RTL stated,0.488829
uuid-af911c243abc4cc59076f9b569ad2bcd,TL shared,0.345345
uuid-af911c243abc4cc59076f9b569ad2bcd,bladder,0.321144
uuid-8381a0b20231435cbf785b8206ace85c,RTL,0.649655
uuid-8381a0b20231435cbf785b8206ace85c,NTL,0.420619
uuid-8381a0b20231435cbf785b8206ace85c,shared,0.467631
uuid-8381a0b20231435cbf785b8206ace85c,commented,0.316039
uuid-8381a0b20231435cbf785b8206ace85c,stated,0.51951
uuid-8381a0b20231435cbf785b8206ace85c,approval,0.365787
uuid-8381a0b20231435cbf785b8206ace85c,using nivo,0.360517
uuid-8381a0b20231435cbf785b8206ace85c,mentioned,0.401757
uuid-8381a0b20231435cbf785b8206ace85c,clinical trials,0.527434
uuid-8381a0b20231435cbf785b8206ace85c,SCCHN,0.569222
uuid-8381a0b20231435cbf785b8206ace85c,HCP,0.316587
uuid-8381a0b20231435cbf785b8206ace85c,LTL,0.518568
uuid-8381a0b20231435cbf785b8206ace85c,TLs,0.42028
uuid-8381a0b20231435cbf785b8206ace85c,academic,0.521578
uuid-8381a0b20231435cbf785b8206ace85c,Regional TL,0.611133
uuid-8381a0b20231435cbf785b8206ace85c,RTL stated,0.439762
uuid-8381a0b20231435cbf785b8206ace85c,bladder,0.334138
uuid-87101b38ef1f4051abe4541407e9a3b9,RTL,0.347694
uuid-87101b38ef1f4051abe4541407e9a3b9,trial,0.576988
uuid-87101b38ef1f4051abe4541407e9a3b9,clinical trials,0.371187
uuid-70477e64e59543d2b6537a21b178372e,patients,0.390773
uuid-70477e64e59543d2b6537a21b178372e,Opdivo,0.533293
uuid-70477e64e59543d2b6537a21b178372e,nivolumab,0.383557
uuid-70477e64e59543d2b6537a21b178372e,treated,0.321411
uuid-70477e64e59543d2b6537a21b178372e,RCC,0.342347
uuid-70477e64e59543d2b6537a21b178372e,2L,0.35144
uuid-70477e64e59543d2b6537a21b178372e,stated,0.304066
uuid-70477e64e59543d2b6537a21b178372e,approval,0.523425
uuid-70477e64e59543d2b6537a21b178372e,physicians,0.369022
uuid-70477e64e59543d2b6537a21b178372e,preferred,0.522723
uuid-70477e64e59543d2b6537a21b178372e,using nivo,0.46235
uuid-70477e64e59543d2b6537a21b178372e,clinical trials,0.350926
uuid-70477e64e59543d2b6537a21b178372e,indication,0.432096
uuid-70477e64e59543d2b6537a21b178372e,approved,0.527549
uuid-70477e64e59543d2b6537a21b178372e,SCCHN,0.451618
uuid-70477e64e59543d2b6537a21b178372e,label,0.37641
uuid-70477e64e59543d2b6537a21b178372e,Keytruda,0.306556
uuid-70477e64e59543d2b6537a21b178372e,Regional TL,0.301841
uuid-70477e64e59543d2b6537a21b178372e,RTL stated,0.377033
uuid-70477e64e59543d2b6537a21b178372e,option,0.333411
uuid-70477e64e59543d2b6537a21b178372e,bladder,0.321159
uuid-70477e64e59543d2b6537a21b178372e,flat dosing,0.30938
uuid-f63108b23feb45ab967725f3faa0417f,TL,0.636056
uuid-f63108b23feb45ab967725f3faa0417f,PDL1,0.500717
uuid-f63108b23feb45ab967725f3faa0417f,TL stated,0.393407
uuid-f63108b23feb45ab967725f3faa0417f,Merck,0.457468
uuid-f63108b23feb45ab967725f3faa0417f,PD-L1,0.844878
uuid-f63108b23feb45ab967725f3faa0417f,approval,0.307389
uuid-f63108b23feb45ab967725f3faa0417f,atezo,0.340746
uuid-f63108b23feb45ab967725f3faa0417f,PD-L1 testing,0.804691
uuid-f63108b23feb45ab967725f3faa0417f,testing,0.883227
uuid-f63108b23feb45ab967725f3faa0417f,PDL1 testing,0.663552
uuid-f63108b23feb45ab967725f3faa0417f,NSCLC patients,0.623899
uuid-f63108b23feb45ab967725f3faa0417f,assay,0.854485
uuid-f63108b23feb45ab967725f3faa0417f,biomarker,0.397692
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,patients,0.619101
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,Opdivo,0.406253
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,therapy,0.348196
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,nivolumab,0.341366
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,toxicity,0.360988
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,regimen,0.440689
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,treated,0.617484
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,melanoma,0.406956
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,pts,0.333623
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,treatment,0.643864
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,progression,0.502234
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,respond,0.407874
uuid-4b6f0a7b19b147efb1b3ae3e0e04826d,TL shared,0.417667
uuid-3de9d7874cd6460eab30548aefde841d,TL,0.436377
uuid-3de9d7874cd6460eab30548aefde841d,PDL1,0.426022
uuid-3de9d7874cd6460eab30548aefde841d,commented,0.361533
uuid-3de9d7874cd6460eab30548aefde841d,TL stated,0.397749
uuid-3de9d7874cd6460eab30548aefde841d,Merck,0.429324
uuid-3de9d7874cd6460eab30548aefde841d,PD-L1,0.616441
uuid-3de9d7874cd6460eab30548aefde841d,approval,0.356082
uuid-3de9d7874cd6460eab30548aefde841d,PD-L1 testing,0.518154
uuid-3de9d7874cd6460eab30548aefde841d,testing,0.656362
uuid-3de9d7874cd6460eab30548aefde841d,PDL1 testing,0.568506
uuid-3de9d7874cd6460eab30548aefde841d,NSCLC patients,0.498939
uuid-3de9d7874cd6460eab30548aefde841d,tumor types,0.306185
uuid-3de9d7874cd6460eab30548aefde841d,assay,0.488261
uuid-3de9d7874cd6460eab30548aefde841d,biomarker,0.401816
uuid-4171fd0b7aac420a89b32c80599b7b8a,TL,0.357111
uuid-4171fd0b7aac420a89b32c80599b7b8a,RTL,0.341466
uuid-4171fd0b7aac420a89b32c80599b7b8a,NSCLC,0.353149
uuid-4171fd0b7aac420a89b32c80599b7b8a,physicians,0.450613
uuid-4171fd0b7aac420a89b32c80599b7b8a,PD-L1 testing,0.307496
uuid-4171fd0b7aac420a89b32c80599b7b8a,using nivo,0.338825
uuid-4171fd0b7aac420a89b32c80599b7b8a,oncology,0.305262
uuid-4171fd0b7aac420a89b32c80599b7b8a,SCCHN,0.377765
uuid-4171fd0b7aac420a89b32c80599b7b8a,oncologist,0.418073
uuid-4171fd0b7aac420a89b32c80599b7b8a,indicated,0.508387
uuid-4171fd0b7aac420a89b32c80599b7b8a,LTL,0.34981
uuid-4171fd0b7aac420a89b32c80599b7b8a,TLs,0.30823
uuid-4171fd0b7aac420a89b32c80599b7b8a,academic,0.345714
uuid-4171fd0b7aac420a89b32c80599b7b8a,Regional TL,0.499725
uuid-5e45ccc146d64748b57daeeb5ffa0e65,patients,0.3287
uuid-5e45ccc146d64748b57daeeb5ffa0e65,Opdivo,0.372316
uuid-5e45ccc146d64748b57daeeb5ffa0e65,dose,0.604728
uuid-5e45ccc146d64748b57daeeb5ffa0e65,toxicity,0.509
uuid-5e45ccc146d64748b57daeeb5ffa0e65,regimen,0.465493
uuid-5e45ccc146d64748b57daeeb5ffa0e65,treated,0.34275
uuid-5e45ccc146d64748b57daeeb5ffa0e65,physicians,0.421998
uuid-5e45ccc146d64748b57daeeb5ffa0e65,treatment,0.503293
uuid-5e45ccc146d64748b57daeeb5ffa0e65,respond,0.359825
uuid-f4b2485b53774be39344c6c801c71e65,patients,0.498748
uuid-f4b2485b53774be39344c6c801c71e65,Opdivo,0.616767
uuid-f4b2485b53774be39344c6c801c71e65,dose,0.599907
uuid-f4b2485b53774be39344c6c801c71e65,toxicity,0.38337
uuid-f4b2485b53774be39344c6c801c71e65,regimen,0.328463
uuid-f4b2485b53774be39344c6c801c71e65,treatment,0.344575
uuid-f4b2485b53774be39344c6c801c71e65,drug,0.410749
uuid-f4b2485b53774be39344c6c801c71e65,Keytruda,0.479748
uuid-f4b2485b53774be39344c6c801c71e65,flat dosing,0.59603
uuid-b32f64ba8b654fbd86d46e4fa19db5c1,Opdivo,0.368987
uuid-b32f64ba8b654fbd86d46e4fa19db5c1,RTL,0.301551
uuid-b32f64ba8b654fbd86d46e4fa19db5c1,BMS,0.419507
uuid-b32f64ba8b654fbd86d46e4fa19db5c1,shared,0.34167
uuid-b32f64ba8b654fbd86d46e4fa19db5c1,commented,0.30251
uuid-b32f64ba8b654fbd86d46e4fa19db5c1,stated,0.363326
uuid-b32f64ba8b654fbd86d46e4fa19db5c1,physicians,0.532825
uuid-b32f64ba8b654fbd86d46e4fa19db5c1,clinical trials,0.363094
uuid-b32f64ba8b654fbd86d46e4fa19db5c1,HCP,0.310967
uuid-b32f64ba8b654fbd86d46e4fa19db5c1,LTL,0.35996
uuid-e40a65af396443f9b797d36ddc88254f,patients,0.832677
uuid-e40a65af396443f9b797d36ddc88254f,Opdivo,0.483245
uuid-e40a65af396443f9b797d36ddc88254f,therapy,0.44514
uuid-e40a65af396443f9b797d36ddc88254f,dose,0.379363
uuid-e40a65af396443f9b797d36ddc88254f,nivolumab,0.610951
uuid-e40a65af396443f9b797d36ddc88254f,toxicity,0.379215
uuid-e40a65af396443f9b797d36ddc88254f,regimen,0.576524
uuid-e40a65af396443f9b797d36ddc88254f,treated,0.654912
uuid-e40a65af396443f9b797d36ddc88254f,chemo,0.350603
uuid-e40a65af396443f9b797d36ddc88254f,pts,0.607268
uuid-e40a65af396443f9b797d36ddc88254f,monotherapy,0.403692
uuid-e40a65af396443f9b797d36ddc88254f,treatment,0.62726
uuid-e40a65af396443f9b797d36ddc88254f,using nivo,0.329416
uuid-e40a65af396443f9b797d36ddc88254f,response,0.42471
uuid-e40a65af396443f9b797d36ddc88254f,progression,0.583234
uuid-e40a65af396443f9b797d36ddc88254f,chemotherapy,0.329829
uuid-e40a65af396443f9b797d36ddc88254f,respond,0.458073
uuid-e40a65af396443f9b797d36ddc88254f,option,0.312891
uuid-6eaced1538714e089c963ad17fa43a5a,Nivo,0.324302
uuid-6eaced1538714e089c963ad17fa43a5a,Opdivo,0.31508
uuid-6eaced1538714e089c963ad17fa43a5a,pembro,0.431474
uuid-6eaced1538714e089c963ad17fa43a5a,dose,0.91048
uuid-6eaced1538714e089c963ad17fa43a5a,Ipi,0.615115
uuid-6eaced1538714e089c963ad17fa43a5a,atezo,0.367009
uuid-6eaced1538714e089c963ad17fa43a5a,vs,0.623217
uuid-6eaced1538714e089c963ad17fa43a5a,Keytruda,0.331856
uuid-6eaced1538714e089c963ad17fa43a5a,flat dosing,0.694526
uuid-798268301a80405ab4a05fe430af60fd,BMS,0.60218
uuid-798268301a80405ab4a05fe430af60fd,commented,0.304562
uuid-798268301a80405ab4a05fe430af60fd,Merck,0.341461
uuid-798268301a80405ab4a05fe430af60fd,physicians,0.321177
uuid-798268301a80405ab4a05fe430af60fd,clinical trials,0.387785
uuid-17dfc03354d840d1a64d5c0ab4763a97,pembro,0.314913
uuid-17dfc03354d840d1a64d5c0ab4763a97,RTL,0.435807
uuid-17dfc03354d840d1a64d5c0ab4763a97,BMS,0.332728
uuid-17dfc03354d840d1a64d5c0ab4763a97,trial,0.765373
uuid-17dfc03354d840d1a64d5c0ab4763a97,efficacy,0.302398
uuid-17dfc03354d840d1a64d5c0ab4763a97,commented,0.389618
uuid-17dfc03354d840d1a64d5c0ab4763a97,Merck,0.320516
uuid-17dfc03354d840d1a64d5c0ab4763a97,stated,0.332748
uuid-17dfc03354d840d1a64d5c0ab4763a97,approval,0.355025
uuid-17dfc03354d840d1a64d5c0ab4763a97,OS,0.484235
uuid-17dfc03354d840d1a64d5c0ab4763a97,data,0.639979
uuid-17dfc03354d840d1a64d5c0ab4763a97,expressed,0.312829
uuid-17dfc03354d840d1a64d5c0ab4763a97,clinical trials,0.361851
uuid-17dfc03354d840d1a64d5c0ab4763a97,PFS,0.467368
uuid-17dfc03354d840d1a64d5c0ab4763a97,ORR,0.530549
uuid-17dfc03354d840d1a64d5c0ab4763a97,ASCO,0.330517
uuid-17dfc03354d840d1a64d5c0ab4763a97,impressed,0.677605
uuid-17dfc03354d840d1a64d5c0ab4763a97,SCLC,0.367382
uuid-17dfc03354d840d1a64d5c0ab4763a97,Regional TL,0.32077
uuid-0bb347bddd124c1ab8ff3b938157b480,patients,0.302214
uuid-0bb347bddd124c1ab8ff3b938157b480,treated,0.405371
uuid-0bb347bddd124c1ab8ff3b938157b480,commented,0.407033
uuid-0bb347bddd124c1ab8ff3b938157b480,physicians,0.35879
uuid-0bb347bddd124c1ab8ff3b938157b480,ASCO,0.384387
uuid-0bb347bddd124c1ab8ff3b938157b480,impressed,0.39726
uuid-0bb347bddd124c1ab8ff3b938157b480,TL shared,0.328828
uuid-b81db273538e42f8a147a0024d785467,Nivo,0.623027
uuid-b81db273538e42f8a147a0024d785467,patients,0.649643
uuid-b81db273538e42f8a147a0024d785467,pembro,0.502229
uuid-b81db273538e42f8a147a0024d785467,therapy,0.400907
uuid-b81db273538e42f8a147a0024d785467,nivolumab,0.4267
uuid-b81db273538e42f8a147a0024d785467,1L,0.675822
uuid-b81db273538e42f8a147a0024d785467,regimen,0.371215
uuid-b81db273538e42f8a147a0024d785467,RCC,0.407417
uuid-b81db273538e42f8a147a0024d785467,combination,0.309937
uuid-b81db273538e42f8a147a0024d785467,chemo,0.481806
uuid-b81db273538e42f8a147a0024d785467,2L,0.701934
uuid-b81db273538e42f8a147a0024d785467,pts,0.540962
uuid-b81db273538e42f8a147a0024d785467,agents,0.302332
uuid-b81db273538e42f8a147a0024d785467,approval,0.389762
uuid-b81db273538e42f8a147a0024d785467,atezo,0.426519
uuid-b81db273538e42f8a147a0024d785467,preferred,0.562307
uuid-b81db273538e42f8a147a0024d785467,monotherapy,0.640582
uuid-b81db273538e42f8a147a0024d785467,treatment,0.37053
uuid-b81db273538e42f8a147a0024d785467,using nivo,0.638927
uuid-b81db273538e42f8a147a0024d785467,combo,0.404827
uuid-b81db273538e42f8a147a0024d785467,NSCLC patients,0.334889
uuid-b81db273538e42f8a147a0024d785467,PD1,0.382004
uuid-b81db273538e42f8a147a0024d785467,approved,0.50126
uuid-b81db273538e42f8a147a0024d785467,progression,0.383511
uuid-b81db273538e42f8a147a0024d785467,chemotherapy,0.37381
uuid-b81db273538e42f8a147a0024d785467,tumor types,0.337096
uuid-b81db273538e42f8a147a0024d785467,RTL stated,0.487778
uuid-b81db273538e42f8a147a0024d785467,option,0.632049
uuid-b81db273538e42f8a147a0024d785467,bladder,0.329374
uuid-173fce82af6042d9be6072cd04550967,RTL,0.45441
uuid-173fce82af6042d9be6072cd04550967,lung,0.481599
uuid-173fce82af6042d9be6072cd04550967,NTL,0.406963
uuid-173fce82af6042d9be6072cd04550967,melanoma,0.482605
uuid-173fce82af6042d9be6072cd04550967,shared,0.523976
uuid-173fce82af6042d9be6072cd04550967,commented,0.420301
uuid-173fce82af6042d9be6072cd04550967,RCC,0.575006
uuid-173fce82af6042d9be6072cd04550967,TL stated,0.510077
uuid-173fce82af6042d9be6072cd04550967,stated,0.419338
uuid-173fce82af6042d9be6072cd04550967,physicians,0.515414
uuid-173fce82af6042d9be6072cd04550967,using nivo,0.363231
uuid-173fce82af6042d9be6072cd04550967,mentioned,0.321819
uuid-173fce82af6042d9be6072cd04550967,SCCHN,0.53507
uuid-173fce82af6042d9be6072cd04550967,HCP,0.331978
uuid-173fce82af6042d9be6072cd04550967,oncologist,0.387339
uuid-173fce82af6042d9be6072cd04550967,indicated,0.312454
uuid-173fce82af6042d9be6072cd04550967,LTL,0.404818
uuid-173fce82af6042d9be6072cd04550967,TLs,0.566102
uuid-173fce82af6042d9be6072cd04550967,academic,0.391182
uuid-173fce82af6042d9be6072cd04550967,Regional TL,0.585049
uuid-173fce82af6042d9be6072cd04550967,RTL stated,0.454213
uuid-173fce82af6042d9be6072cd04550967,TL shared,0.468753
uuid-173fce82af6042d9be6072cd04550967,bladder,0.323595
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,patients,0.863634
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,Opdivo,0.395865
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,therapy,0.457434
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,nivolumab,0.40356
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,toxicity,0.35921
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,regimen,0.545568
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,treated,0.528546
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,pts,0.619278
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,monotherapy,0.392195
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,treatment,0.595874
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,using nivo,0.306643
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,response,0.311139
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,NSCLC patients,0.328454
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,progression,0.599942
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,chemotherapy,0.324603
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,respond,0.443919
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,TL shared,0.376261
uuid-a24e26a2e8ab4958962ce365b2bfb1a8,option,0.375931
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,Nivo,0.4073
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,patients,0.710539
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,therapy,0.440892
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,nivolumab,0.439033
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,regimen,0.382043
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,treated,0.464516
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,chemo,0.316621
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,pts,0.492896
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,monotherapy,0.330639
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,treatment,0.517812
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,using nivo,0.347864
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,response,0.35963
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,cHL,0.30806
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,progression,0.521105
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,chemotherapy,0.344494
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,respond,0.399538
uuid-6fdca7a3e76f472e8c9a88977b7cbde6,RTL stated,0.334075
uuid-c9c386477ee64ac4942949fd9316b8d1,RTL,0.456264
uuid-c9c386477ee64ac4942949fd9316b8d1,toxicity,0.365077
uuid-c9c386477ee64ac4942949fd9316b8d1,trial,0.350473
uuid-c9c386477ee64ac4942949fd9316b8d1,regimen,0.404023
uuid-c9c386477ee64ac4942949fd9316b8d1,mentioned,0.318236
uuid-c9c386477ee64ac4942949fd9316b8d1,HCP,0.359858
uuid-c9c386477ee64ac4942949fd9316b8d1,impressed,0.404219
uuid-c9c386477ee64ac4942949fd9316b8d1,LTL,0.327325
uuid-3cacd30d1bb34b209c4f0abe8ee76679,PD-L1,0.332746
uuid-3cacd30d1bb34b209c4f0abe8ee76679,assay,0.321038
uuid-3cacd30d1bb34b209c4f0abe8ee76679,PDL1 expression,0.408456
uuid-3cacd30d1bb34b209c4f0abe8ee76679,biomarker,0.451348
uuid-c72fcd7b3d184237b119a42a2fa30c6f,toxicity,0.492076
uuid-c72fcd7b3d184237b119a42a2fa30c6f,efficacy,0.538078
uuid-c72fcd7b3d184237b119a42a2fa30c6f,regimen,0.35664
uuid-c72fcd7b3d184237b119a42a2fa30c6f,OS,0.349269
uuid-c72fcd7b3d184237b119a42a2fa30c6f,PFS,0.316068
uuid-c72fcd7b3d184237b119a42a2fa30c6f,ORR,0.414747
uuid-c72fcd7b3d184237b119a42a2fa30c6f,impressed,0.302784
uuid-c72fcd7b3d184237b119a42a2fa30c6f,feels,0.382648
uuid-a85525005ee04f4693cf054cb027bcf4,Nivo,0.376085
uuid-a85525005ee04f4693cf054cb027bcf4,patients,0.713271
uuid-a85525005ee04f4693cf054cb027bcf4,Opdivo,0.309941
uuid-a85525005ee04f4693cf054cb027bcf4,therapy,0.373382
uuid-a85525005ee04f4693cf054cb027bcf4,dose,0.386362
uuid-a85525005ee04f4693cf054cb027bcf4,nivolumab,0.362513
uuid-a85525005ee04f4693cf054cb027bcf4,toxicity,0.559322
uuid-a85525005ee04f4693cf054cb027bcf4,regimen,0.698953
uuid-a85525005ee04f4693cf054cb027bcf4,treated,0.449736
uuid-a85525005ee04f4693cf054cb027bcf4,chemo,0.428356
uuid-a85525005ee04f4693cf054cb027bcf4,pts,0.447718
uuid-a85525005ee04f4693cf054cb027bcf4,Ipi,0.382447
uuid-a85525005ee04f4693cf054cb027bcf4,preferred,0.352513
uuid-a85525005ee04f4693cf054cb027bcf4,monotherapy,0.466051
uuid-a85525005ee04f4693cf054cb027bcf4,treatment,0.637724
uuid-a85525005ee04f4693cf054cb027bcf4,using nivo,0.330817
uuid-a85525005ee04f4693cf054cb027bcf4,progression,0.496661
uuid-a85525005ee04f4693cf054cb027bcf4,chemotherapy,0.368125
uuid-a85525005ee04f4693cf054cb027bcf4,respond,0.546528
uuid-a85525005ee04f4693cf054cb027bcf4,option,0.426274
uuid-0bd0f2e3037a47aaa3958f36190c4254,patients,0.39387
uuid-0bd0f2e3037a47aaa3958f36190c4254,toxicity,0.520833
uuid-0bd0f2e3037a47aaa3958f36190c4254,regimen,0.393038
uuid-0bd0f2e3037a47aaa3958f36190c4254,treated,0.393228
uuid-0bd0f2e3037a47aaa3958f36190c4254,treatment,0.453432
uuid-0bd0f2e3037a47aaa3958f36190c4254,progression,0.344104
uuid-0bd0f2e3037a47aaa3958f36190c4254,respond,0.409824
uuid-98b4b67fdb1c4160b70d7e0b09a4478b,RTL,0.372868
uuid-98b4b67fdb1c4160b70d7e0b09a4478b,trial,0.312582
uuid-98b4b67fdb1c4160b70d7e0b09a4478b,NTL,0.43043
uuid-98b4b67fdb1c4160b70d7e0b09a4478b,commented,0.330905
uuid-98b4b67fdb1c4160b70d7e0b09a4478b,data,0.448204
uuid-98b4b67fdb1c4160b70d7e0b09a4478b,mentioned,0.325365
uuid-98b4b67fdb1c4160b70d7e0b09a4478b,cHL,0.42668
uuid-98b4b67fdb1c4160b70d7e0b09a4478b,ASCO,0.432312
uuid-98b4b67fdb1c4160b70d7e0b09a4478b,impressed,0.398682
uuid-98b4b67fdb1c4160b70d7e0b09a4478b,Regional TL,0.311382
uuid-1dbf3fb3fff54bda81cf797228c399b1,patients,0.63202
uuid-1dbf3fb3fff54bda81cf797228c399b1,therapy,0.607083
uuid-1dbf3fb3fff54bda81cf797228c399b1,nivolumab,0.43597
uuid-1dbf3fb3fff54bda81cf797228c399b1,toxicity,0.497621
uuid-1dbf3fb3fff54bda81cf797228c399b1,regimen,0.587495
uuid-1dbf3fb3fff54bda81cf797228c399b1,treated,0.556195
uuid-1dbf3fb3fff54bda81cf797228c399b1,combination,0.445589
uuid-1dbf3fb3fff54bda81cf797228c399b1,chemo,0.576827
uuid-1dbf3fb3fff54bda81cf797228c399b1,pts,0.492546
uuid-1dbf3fb3fff54bda81cf797228c399b1,IO,0.339356
uuid-1dbf3fb3fff54bda81cf797228c399b1,monotherapy,0.44975
uuid-1dbf3fb3fff54bda81cf797228c399b1,treatment,0.734397
uuid-1dbf3fb3fff54bda81cf797228c399b1,response,0.594719
uuid-1dbf3fb3fff54bda81cf797228c399b1,combo,0.32562
uuid-1dbf3fb3fff54bda81cf797228c399b1,PD1,0.49831
uuid-1dbf3fb3fff54bda81cf797228c399b1,progression,0.717157
uuid-1dbf3fb3fff54bda81cf797228c399b1,chemotherapy,0.59866
uuid-1dbf3fb3fff54bda81cf797228c399b1,respond,0.55258
uuid-1dbf3fb3fff54bda81cf797228c399b1,immunotherapy,0.3909
uuid-1dbf3fb3fff54bda81cf797228c399b1,option,0.382713
uuid-770cad8920b641e0a99d4930c92d0e20,TL,0.471621
uuid-770cad8920b641e0a99d4930c92d0e20,PDL1,0.319986
uuid-770cad8920b641e0a99d4930c92d0e20,TL stated,0.429171
uuid-770cad8920b641e0a99d4930c92d0e20,PD-L1,0.660235
uuid-770cad8920b641e0a99d4930c92d0e20,PD-L1 testing,0.696428
uuid-770cad8920b641e0a99d4930c92d0e20,testing,0.764015
uuid-770cad8920b641e0a99d4930c92d0e20,PDL1 testing,0.671853
uuid-770cad8920b641e0a99d4930c92d0e20,NSCLC patients,0.678317
uuid-770cad8920b641e0a99d4930c92d0e20,assay,0.485674
uuid-770cad8920b641e0a99d4930c92d0e20,biomarker,0.354473
uuid-0b5489e90a3b491e83e1c3c424e0bc2e,PD-L1,0.361595
uuid-0b5489e90a3b491e83e1c3c424e0bc2e,testing,0.371467
uuid-0b5489e90a3b491e83e1c3c424e0bc2e,NSCLC patients,0.334782
uuid-0b5489e90a3b491e83e1c3c424e0bc2e,biomarker,0.397861
uuid-7c6ec8d4418e42dca9117ec1fe1dab9d,trial,0.356133
uuid-7c6ec8d4418e42dca9117ec1fe1dab9d,commented,0.310535
uuid-7c6ec8d4418e42dca9117ec1fe1dab9d,impressed,0.35665
uuid-7c6ec8d4418e42dca9117ec1fe1dab9d,respond,0.331802
uuid-61297bb3f1c44b30bb53df8eff73a8d3,stated,0.40757
uuid-f5fef1f423274af992f87810cdd9cf71,TL,0.467476
uuid-f5fef1f423274af992f87810cdd9cf71,Merck,0.327024
uuid-f5fef1f423274af992f87810cdd9cf71,PD-L1,0.3764
uuid-f5fef1f423274af992f87810cdd9cf71,PD-L1 testing,0.375794
uuid-f5fef1f423274af992f87810cdd9cf71,testing,0.335851
uuid-f5fef1f423274af992f87810cdd9cf71,indicated,0.481169
uuid-f5fef1f423274af992f87810cdd9cf71,assay,0.461378
uuid-6851ce061b8441938792d4bba5fa438d,patients,0.592071
uuid-6851ce061b8441938792d4bba5fa438d,therapy,0.642684
uuid-6851ce061b8441938792d4bba5fa438d,regimen,0.390998
uuid-6851ce061b8441938792d4bba5fa438d,chemo,0.434312
uuid-6851ce061b8441938792d4bba5fa438d,pts,0.344748
uuid-6851ce061b8441938792d4bba5fa438d,monotherapy,0.302347
uuid-6851ce061b8441938792d4bba5fa438d,treatment,0.638921
uuid-6851ce061b8441938792d4bba5fa438d,response,0.44815
uuid-6851ce061b8441938792d4bba5fa438d,PD1,0.365931
uuid-6851ce061b8441938792d4bba5fa438d,progression,0.628006
uuid-6851ce061b8441938792d4bba5fa438d,chemotherapy,0.469881
uuid-6851ce061b8441938792d4bba5fa438d,respond,0.534492
uuid-6851ce061b8441938792d4bba5fa438d,drug,0.384637
uuid-6851ce061b8441938792d4bba5fa438d,option,0.365694
uuid-de287e53f61147d2a0dbae8f29692dc5,BMS,0.455087
uuid-de287e53f61147d2a0dbae8f29692dc5,PDL1,0.360661
uuid-de287e53f61147d2a0dbae8f29692dc5,trial,0.379381
uuid-de287e53f61147d2a0dbae8f29692dc5,efficacy,0.523408
uuid-de287e53f61147d2a0dbae8f29692dc5,OS,0.839977
uuid-de287e53f61147d2a0dbae8f29692dc5,data,0.534728
uuid-de287e53f61147d2a0dbae8f29692dc5,PFS,0.819007
uuid-de287e53f61147d2a0dbae8f29692dc5,ORR,0.705409
uuid-de287e53f61147d2a0dbae8f29692dc5,nivo and pembro,0.384348
uuid-de287e53f61147d2a0dbae8f29692dc5,believes,0.364546
uuid-de287e53f61147d2a0dbae8f29692dc5,impressed,0.417051
uuid-de287e53f61147d2a0dbae8f29692dc5,feels,0.301839
uuid-de287e53f61147d2a0dbae8f29692dc5,PDL1 expression,0.336052
uuid-c10a0340cdd04ed9a138fbe6135a104d,Nivo,0.359235
uuid-c10a0340cdd04ed9a138fbe6135a104d,dose,0.45481
uuid-c10a0340cdd04ed9a138fbe6135a104d,toxicity,0.495873
uuid-c10a0340cdd04ed9a138fbe6135a104d,efficacy,0.674416
uuid-c10a0340cdd04ed9a138fbe6135a104d,regimen,0.522126
uuid-c10a0340cdd04ed9a138fbe6135a104d,combination,0.586959
uuid-c10a0340cdd04ed9a138fbe6135a104d,chemo,0.506402
uuid-c10a0340cdd04ed9a138fbe6135a104d,IO,0.408088
uuid-c10a0340cdd04ed9a138fbe6135a104d,agents,0.512776
uuid-c10a0340cdd04ed9a138fbe6135a104d,Ipi,0.521355
uuid-c10a0340cdd04ed9a138fbe6135a104d,monotherapy,0.526944
uuid-c10a0340cdd04ed9a138fbe6135a104d,combo,0.608653
uuid-c10a0340cdd04ed9a138fbe6135a104d,PD1,0.40608
uuid-c10a0340cdd04ed9a138fbe6135a104d,believes,0.472045
uuid-c10a0340cdd04ed9a138fbe6135a104d,chemotherapy,0.427074
uuid-c10a0340cdd04ed9a138fbe6135a104d,vs,0.466126
uuid-c10a0340cdd04ed9a138fbe6135a104d,feels,0.361014
uuid-c10a0340cdd04ed9a138fbe6135a104d,option,0.360697
uuid-7e651d20661a4549a5291142e5065b62,BMS,0.53093
uuid-7e651d20661a4549a5291142e5065b62,shared,0.302554
uuid-7e651d20661a4549a5291142e5065b62,commented,0.383113
uuid-7e651d20661a4549a5291142e5065b62,Merck,0.375828
uuid-7e651d20661a4549a5291142e5065b62,stated,0.304146
uuid-7e651d20661a4549a5291142e5065b62,physicians,0.31733
uuid-7e651d20661a4549a5291142e5065b62,regards,0.379508
uuid-7e651d20661a4549a5291142e5065b62,expressed,0.333481
uuid-7e651d20661a4549a5291142e5065b62,AI,0.310424
uuid-7e651d20661a4549a5291142e5065b62,drug,0.390624
uuid-fd43e9ea2f104885a9e7260b835d7513,Nivo,0.457589
uuid-fd43e9ea2f104885a9e7260b835d7513,patients,0.302918
uuid-fd43e9ea2f104885a9e7260b835d7513,Opdivo,0.473206
uuid-fd43e9ea2f104885a9e7260b835d7513,pembro,0.330843
uuid-fd43e9ea2f104885a9e7260b835d7513,dose,0.773618
uuid-fd43e9ea2f104885a9e7260b835d7513,toxicity,0.315554
uuid-fd43e9ea2f104885a9e7260b835d7513,efficacy,0.350472
uuid-fd43e9ea2f104885a9e7260b835d7513,regimen,0.300115
uuid-fd43e9ea2f104885a9e7260b835d7513,Ipi,0.529276
uuid-fd43e9ea2f104885a9e7260b835d7513,indication,0.408813
uuid-fd43e9ea2f104885a9e7260b835d7513,vs,0.451649
uuid-fd43e9ea2f104885a9e7260b835d7513,label,0.343672
uuid-fd43e9ea2f104885a9e7260b835d7513,Keytruda,0.357413
uuid-fd43e9ea2f104885a9e7260b835d7513,flat dosing,0.73802
uuid-f2d6f19318964071a717748e81ede329,TL,0.356244
uuid-f2d6f19318964071a717748e81ede329,TL stated,0.345924
uuid-f2d6f19318964071a717748e81ede329,PD-L1,0.507584
uuid-f2d6f19318964071a717748e81ede329,approval,0.32703
uuid-f2d6f19318964071a717748e81ede329,physicians,0.340507
uuid-f2d6f19318964071a717748e81ede329,preferred,0.377772
uuid-f2d6f19318964071a717748e81ede329,PD-L1 testing,0.528602
uuid-f2d6f19318964071a717748e81ede329,testing,0.621275
uuid-f2d6f19318964071a717748e81ede329,PDL1 testing,0.542976
uuid-f2d6f19318964071a717748e81ede329,NSCLC patients,0.525776
uuid-f2d6f19318964071a717748e81ede329,approved,0.325268
uuid-f2d6f19318964071a717748e81ede329,tumor types,0.317976
uuid-f2d6f19318964071a717748e81ede329,assay,0.333129
uuid-d8696547956d4b67a003ffc290c18ddc,oncology,0.46351
uuid-d8696547956d4b67a003ffc290c18ddc,drug,0.379878
uuid-d8696547956d4b67a003ffc290c18ddc,flat dosing,0.399045
uuid-c73ce1116644434ba2fe0267db6c07f6,Nivo,0.356335
uuid-c73ce1116644434ba2fe0267db6c07f6,toxicity,0.538279
uuid-c73ce1116644434ba2fe0267db6c07f6,efficacy,0.599341
uuid-c73ce1116644434ba2fe0267db6c07f6,regimen,0.548132
uuid-c73ce1116644434ba2fe0267db6c07f6,combination,0.781975
uuid-c73ce1116644434ba2fe0267db6c07f6,chemo,0.533366
uuid-c73ce1116644434ba2fe0267db6c07f6,IO,0.420138
uuid-c73ce1116644434ba2fe0267db6c07f6,agents,0.531255
uuid-c73ce1116644434ba2fe0267db6c07f6,Ipi,0.451271
uuid-c73ce1116644434ba2fe0267db6c07f6,monotherapy,0.562507
uuid-c73ce1116644434ba2fe0267db6c07f6,response,0.335612
uuid-c73ce1116644434ba2fe0267db6c07f6,combo,0.692309
uuid-c73ce1116644434ba2fe0267db6c07f6,PD1,0.530956
uuid-c73ce1116644434ba2fe0267db6c07f6,believes,0.514058
uuid-c73ce1116644434ba2fe0267db6c07f6,chemotherapy,0.520905
uuid-c73ce1116644434ba2fe0267db6c07f6,feels,0.429748
uuid-c73ce1116644434ba2fe0267db6c07f6,option,0.371643
uuid-43f7c5cf38974aa0919135a2d165b294,Nivo,0.438083
uuid-43f7c5cf38974aa0919135a2d165b294,Opdivo,0.333664
uuid-43f7c5cf38974aa0919135a2d165b294,pembro,0.378151
uuid-43f7c5cf38974aa0919135a2d165b294,dose,0.829406
uuid-43f7c5cf38974aa0919135a2d165b294,nivolumab,0.336427
uuid-43f7c5cf38974aa0919135a2d165b294,toxicity,0.407663
uuid-43f7c5cf38974aa0919135a2d165b294,regimen,0.393458
uuid-43f7c5cf38974aa0919135a2d165b294,combination,0.408313
uuid-43f7c5cf38974aa0919135a2d165b294,Ipi,0.756639
uuid-43f7c5cf38974aa0919135a2d165b294,atezo,0.357342
uuid-43f7c5cf38974aa0919135a2d165b294,combo,0.406912
uuid-43f7c5cf38974aa0919135a2d165b294,vs,0.537486
uuid-43f7c5cf38974aa0919135a2d165b294,TLs,0.319692
uuid-43f7c5cf38974aa0919135a2d165b294,flat dosing,0.689116
uuid-aa4afd7f52cd499eb33d79454e527b1d,Nivo,0.604422
uuid-aa4afd7f52cd499eb33d79454e527b1d,patients,0.434434
uuid-aa4afd7f52cd499eb33d79454e527b1d,therapy,0.597506
uuid-aa4afd7f52cd499eb33d79454e527b1d,nivolumab,0.42443
uuid-aa4afd7f52cd499eb33d79454e527b1d,toxicity,0.566688
uuid-aa4afd7f52cd499eb33d79454e527b1d,regimen,0.542748
uuid-aa4afd7f52cd499eb33d79454e527b1d,combination,0.504414
uuid-aa4afd7f52cd499eb33d79454e527b1d,chemo,0.545883
uuid-aa4afd7f52cd499eb33d79454e527b1d,2L,0.319673
uuid-aa4afd7f52cd499eb33d79454e527b1d,pts,0.321514
uuid-aa4afd7f52cd499eb33d79454e527b1d,agents,0.340699
uuid-aa4afd7f52cd499eb33d79454e527b1d,Ipi,0.411286
uuid-aa4afd7f52cd499eb33d79454e527b1d,monotherapy,0.644855
uuid-aa4afd7f52cd499eb33d79454e527b1d,treatment,0.426882
uuid-aa4afd7f52cd499eb33d79454e527b1d,using nivo,0.30376
uuid-aa4afd7f52cd499eb33d79454e527b1d,response,0.462493
uuid-aa4afd7f52cd499eb33d79454e527b1d,combo,0.431462
uuid-aa4afd7f52cd499eb33d79454e527b1d,PD1,0.624935
uuid-aa4afd7f52cd499eb33d79454e527b1d,cHL,0.339101
uuid-aa4afd7f52cd499eb33d79454e527b1d,progression,0.511432
uuid-aa4afd7f52cd499eb33d79454e527b1d,believes,0.303966
uuid-aa4afd7f52cd499eb33d79454e527b1d,chemotherapy,0.554124
uuid-aa4afd7f52cd499eb33d79454e527b1d,respond,0.384874
uuid-aa4afd7f52cd499eb33d79454e527b1d,option,0.447371
uuid-1d65b2af92d4427cb225e5a867f54a7e,trial,0.353627
uuid-1d65b2af92d4427cb225e5a867f54a7e,chemo,0.304626
uuid-1d65b2af92d4427cb225e5a867f54a7e,tumor,0.55008
uuid-1d65b2af92d4427cb225e5a867f54a7e,tumor types,0.324658
uuid-1d65b2af92d4427cb225e5a867f54a7e,PDL1 expression,0.376819
uuid-225408ccbaeb436996d98ef5d83da954,RTL,0.485396
uuid-225408ccbaeb436996d98ef5d83da954,commented,0.385759
uuid-225408ccbaeb436996d98ef5d83da954,data,0.314929
uuid-225408ccbaeb436996d98ef5d83da954,mentioned,0.301392
uuid-225408ccbaeb436996d98ef5d83da954,HCP,0.326119
uuid-225408ccbaeb436996d98ef5d83da954,ASCO,0.41453
uuid-225408ccbaeb436996d98ef5d83da954,impressed,0.552195
uuid-225408ccbaeb436996d98ef5d83da954,LTL,0.316774
uuid-225408ccbaeb436996d98ef5d83da954,Regional TL,0.348367
uuid-225408ccbaeb436996d98ef5d83da954,flat dosing,0.325942
uuid-89d9f20e11864a52bb4df684ca0db3be,Nivo,0.400953
uuid-89d9f20e11864a52bb4df684ca0db3be,pembro,0.367659
uuid-89d9f20e11864a52bb4df684ca0db3be,RTL,0.393606
uuid-89d9f20e11864a52bb4df684ca0db3be,BMS,0.319564
uuid-89d9f20e11864a52bb4df684ca0db3be,trial,0.588725
uuid-89d9f20e11864a52bb4df684ca0db3be,efficacy,0.52544
uuid-89d9f20e11864a52bb4df684ca0db3be,commented,0.397007
uuid-89d9f20e11864a52bb4df684ca0db3be,combination,0.400943
uuid-89d9f20e11864a52bb4df684ca0db3be,Ipi,0.381188
uuid-89d9f20e11864a52bb4df684ca0db3be,stated,0.370267
uuid-89d9f20e11864a52bb4df684ca0db3be,OS,0.458583
uuid-89d9f20e11864a52bb4df684ca0db3be,atezo,0.308564
uuid-89d9f20e11864a52bb4df684ca0db3be,data,0.768811
uuid-89d9f20e11864a52bb4df684ca0db3be,combo,0.406469
uuid-89d9f20e11864a52bb4df684ca0db3be,expressed,0.326417
uuid-89d9f20e11864a52bb4df684ca0db3be,clinical trials,0.319753
uuid-89d9f20e11864a52bb4df684ca0db3be,PFS,0.417097
uuid-89d9f20e11864a52bb4df684ca0db3be,ORR,0.55179
uuid-89d9f20e11864a52bb4df684ca0db3be,nivo and pembro,0.40375
uuid-89d9f20e11864a52bb4df684ca0db3be,ASCO,0.337395
uuid-89d9f20e11864a52bb4df684ca0db3be,impressed,0.664138
uuid-89d9f20e11864a52bb4df684ca0db3be,LTL,0.342658
uuid-89d9f20e11864a52bb4df684ca0db3be,TLs,0.377572
uuid-89d9f20e11864a52bb4df684ca0db3be,SCLC,0.396294
uuid-89d9f20e11864a52bb4df684ca0db3be,feels,0.402123
uuid-89d9f20e11864a52bb4df684ca0db3be,Regional TL,0.33939
uuid-89d9f20e11864a52bb4df684ca0db3be,bladder,0.350943
uuid-1aff57053c09414196293603ea8e601c,TL,0.454061
uuid-1aff57053c09414196293603ea8e601c,pembro,0.355784
uuid-1aff57053c09414196293603ea8e601c,RTL,0.309468
uuid-1aff57053c09414196293603ea8e601c,lung,0.573555
uuid-1aff57053c09414196293603ea8e601c,1L,0.396611
uuid-1aff57053c09414196293603ea8e601c,melanoma,0.397554
uuid-1aff57053c09414196293603ea8e601c,shared,0.478801
uuid-1aff57053c09414196293603ea8e601c,RCC,0.555096
uuid-1aff57053c09414196293603ea8e601c,TL stated,0.671691
uuid-1aff57053c09414196293603ea8e601c,2L,0.477759
uuid-1aff57053c09414196293603ea8e601c,Merck,0.461138
uuid-1aff57053c09414196293603ea8e601c,institution,0.414252
uuid-1aff57053c09414196293603ea8e601c,stated,0.342747
uuid-1aff57053c09414196293603ea8e601c,PD-L1,0.353469
uuid-1aff57053c09414196293603ea8e601c,approval,0.38358
uuid-1aff57053c09414196293603ea8e601c,atezo,0.500547
uuid-1aff57053c09414196293603ea8e601c,preferred,0.408136
uuid-1aff57053c09414196293603ea8e601c,PD-L1 testing,0.448011
uuid-1aff57053c09414196293603ea8e601c,testing,0.437115
uuid-1aff57053c09414196293603ea8e601c,using nivo,0.376809
uuid-1aff57053c09414196293603ea8e601c,expressed,0.36355
uuid-1aff57053c09414196293603ea8e601c,PDL1 testing,0.637189
uuid-1aff57053c09414196293603ea8e601c,NSCLC patients,0.336711
uuid-1aff57053c09414196293603ea8e601c,approved,0.32837
uuid-1aff57053c09414196293603ea8e601c,SCCHN,0.541402
uuid-1aff57053c09414196293603ea8e601c,tumor types,0.339789
uuid-1aff57053c09414196293603ea8e601c,LTL,0.35877
uuid-1aff57053c09414196293603ea8e601c,TLs,0.554249
uuid-1aff57053c09414196293603ea8e601c,academic,0.327146
uuid-1aff57053c09414196293603ea8e601c,assay,0.381164
uuid-1aff57053c09414196293603ea8e601c,Regional TL,0.417334
uuid-1aff57053c09414196293603ea8e601c,RTL stated,0.459938
uuid-1aff57053c09414196293603ea8e601c,TL shared,0.443342
uuid-1aff57053c09414196293603ea8e601c,bladder,0.470084
uuid-0aea23521ebd42b39f447dff0b4384b9,Nivo,0.613266
uuid-0aea23521ebd42b39f447dff0b4384b9,patients,0.695921
uuid-0aea23521ebd42b39f447dff0b4384b9,Opdivo,0.451659
uuid-0aea23521ebd42b39f447dff0b4384b9,pembro,0.308274
uuid-0aea23521ebd42b39f447dff0b4384b9,therapy,0.427096
uuid-0aea23521ebd42b39f447dff0b4384b9,dose,0.362897
uuid-0aea23521ebd42b39f447dff0b4384b9,nivolumab,0.576462
uuid-0aea23521ebd42b39f447dff0b4384b9,toxicity,0.323065
uuid-0aea23521ebd42b39f447dff0b4384b9,regimen,0.495397
uuid-0aea23521ebd42b39f447dff0b4384b9,treated,0.43881
uuid-0aea23521ebd42b39f447dff0b4384b9,2L,0.343909
uuid-0aea23521ebd42b39f447dff0b4384b9,pts,0.40637
uuid-0aea23521ebd42b39f447dff0b4384b9,Ipi,0.471832
uuid-0aea23521ebd42b39f447dff0b4384b9,approval,0.337337
uuid-0aea23521ebd42b39f447dff0b4384b9,preferred,0.334049
uuid-0aea23521ebd42b39f447dff0b4384b9,monotherapy,0.447113
uuid-0aea23521ebd42b39f447dff0b4384b9,treatment,0.418625
uuid-0aea23521ebd42b39f447dff0b4384b9,using nivo,0.642264
uuid-0aea23521ebd42b39f447dff0b4384b9,cHL,0.431697
uuid-0aea23521ebd42b39f447dff0b4384b9,progression,0.354397
uuid-0aea23521ebd42b39f447dff0b4384b9,chemotherapy,0.313752
uuid-0aea23521ebd42b39f447dff0b4384b9,respond,0.34728
uuid-0aea23521ebd42b39f447dff0b4384b9,RTL stated,0.414164
uuid-0aea23521ebd42b39f447dff0b4384b9,option,0.330025
uuid-ee484913bfc4427ab74876bcd1af9534,patients,0.758891
uuid-ee484913bfc4427ab74876bcd1af9534,therapy,0.493522
uuid-ee484913bfc4427ab74876bcd1af9534,nivolumab,0.562665
uuid-ee484913bfc4427ab74876bcd1af9534,regimen,0.484029
uuid-ee484913bfc4427ab74876bcd1af9534,treated,0.646431
uuid-ee484913bfc4427ab74876bcd1af9534,pts,0.5513
uuid-ee484913bfc4427ab74876bcd1af9534,monotherapy,0.4466
uuid-ee484913bfc4427ab74876bcd1af9534,treatment,0.524724
uuid-ee484913bfc4427ab74876bcd1af9534,using nivo,0.382523
uuid-ee484913bfc4427ab74876bcd1af9534,NSCLC patients,0.328469
uuid-ee484913bfc4427ab74876bcd1af9534,progression,0.453921
uuid-ee484913bfc4427ab74876bcd1af9534,chemotherapy,0.330641
uuid-ee484913bfc4427ab74876bcd1af9534,respond,0.300118
uuid-ee484913bfc4427ab74876bcd1af9534,RTL stated,0.403873
uuid-ee484913bfc4427ab74876bcd1af9534,TL shared,0.344313
uuid-ee484913bfc4427ab74876bcd1af9534,option,0.329058
uuid-b739d3793d2342e68d569998eded7ca3,1L,0.365336
uuid-b739d3793d2342e68d569998eded7ca3,RCC,0.348858
uuid-b739d3793d2342e68d569998eded7ca3,2L,0.355543
uuid-b739d3793d2342e68d569998eded7ca3,agents,0.307796
uuid-b739d3793d2342e68d569998eded7ca3,preferred,0.633468
uuid-b739d3793d2342e68d569998eded7ca3,monotherapy,0.340191
uuid-b739d3793d2342e68d569998eded7ca3,using nivo,0.356523
uuid-b739d3793d2342e68d569998eded7ca3,indication,0.364502
uuid-b739d3793d2342e68d569998eded7ca3,SCCHN,0.482324
uuid-b739d3793d2342e68d569998eded7ca3,feels,0.321084
uuid-b739d3793d2342e68d569998eded7ca3,RTL stated,0.465684
uuid-b739d3793d2342e68d569998eded7ca3,TL shared,0.358554
uuid-b739d3793d2342e68d569998eded7ca3,option,0.51479
uuid-663d0a20d518429abedac1c8d5369d51,pembro,0.33047
uuid-663d0a20d518429abedac1c8d5369d51,1L,0.527705
uuid-663d0a20d518429abedac1c8d5369d51,PDL1,0.420624
uuid-663d0a20d518429abedac1c8d5369d51,chemo,0.332324
uuid-663d0a20d518429abedac1c8d5369d51,2L,0.476557
uuid-663d0a20d518429abedac1c8d5369d51,agents,0.379962
uuid-663d0a20d518429abedac1c8d5369d51,PD-L1,0.535031
uuid-663d0a20d518429abedac1c8d5369d51,atezo,0.405429
uuid-663d0a20d518429abedac1c8d5369d51,preferred,0.526014
uuid-663d0a20d518429abedac1c8d5369d51,PD-L1 testing,0.39096
uuid-663d0a20d518429abedac1c8d5369d51,testing,0.54559
uuid-663d0a20d518429abedac1c8d5369d51,monotherapy,0.357139
uuid-663d0a20d518429abedac1c8d5369d51,PDL1 testing,0.487749
uuid-663d0a20d518429abedac1c8d5369d51,NSCLC patients,0.498653
uuid-663d0a20d518429abedac1c8d5369d51,believes,0.364057
uuid-663d0a20d518429abedac1c8d5369d51,tumor types,0.327227
uuid-663d0a20d518429abedac1c8d5369d51,assay,0.326445
uuid-663d0a20d518429abedac1c8d5369d51,PDL1 expression,0.339558
uuid-663d0a20d518429abedac1c8d5369d51,option,0.55133
uuid-663d0a20d518429abedac1c8d5369d51,biomarker,0.464674
uuid-65a81d0054094dc280987a08d5e2c615,dose,0.340723
uuid-65a81d0054094dc280987a08d5e2c615,toxicity,0.451266
uuid-65a81d0054094dc280987a08d5e2c615,regimen,0.359183
uuid-65a81d0054094dc280987a08d5e2c615,treated,0.371453
uuid-65a81d0054094dc280987a08d5e2c615,physicians,0.4156
uuid-65a81d0054094dc280987a08d5e2c615,treatment,0.433454
uuid-b1f2b0fe6904439a8fe158bc4bedc257,Nivo,0.432586
uuid-b1f2b0fe6904439a8fe158bc4bedc257,patients,0.644275
uuid-b1f2b0fe6904439a8fe158bc4bedc257,Opdivo,0.500636
uuid-b1f2b0fe6904439a8fe158bc4bedc257,pembro,0.323893
uuid-b1f2b0fe6904439a8fe158bc4bedc257,therapy,0.416087
uuid-b1f2b0fe6904439a8fe158bc4bedc257,nivolumab,0.555475
uuid-b1f2b0fe6904439a8fe158bc4bedc257,1L,0.356885
uuid-b1f2b0fe6904439a8fe158bc4bedc257,regimen,0.451568
uuid-b1f2b0fe6904439a8fe158bc4bedc257,treated,0.453531
uuid-b1f2b0fe6904439a8fe158bc4bedc257,RCC,0.329398
uuid-b1f2b0fe6904439a8fe158bc4bedc257,combination,0.346887
uuid-b1f2b0fe6904439a8fe158bc4bedc257,chemo,0.315554
uuid-b1f2b0fe6904439a8fe158bc4bedc257,2L,0.450121
uuid-b1f2b0fe6904439a8fe158bc4bedc257,pts,0.398918
uuid-b1f2b0fe6904439a8fe158bc4bedc257,approval,0.434796
uuid-b1f2b0fe6904439a8fe158bc4bedc257,preferred,0.554447
uuid-b1f2b0fe6904439a8fe158bc4bedc257,monotherapy,0.527284
uuid-b1f2b0fe6904439a8fe158bc4bedc257,treatment,0.447081
uuid-b1f2b0fe6904439a8fe158bc4bedc257,using nivo,0.569368
uuid-b1f2b0fe6904439a8fe158bc4bedc257,combo,0.318579
uuid-b1f2b0fe6904439a8fe158bc4bedc257,clinical trials,0.337469
uuid-b1f2b0fe6904439a8fe158bc4bedc257,indication,0.320409
uuid-b1f2b0fe6904439a8fe158bc4bedc257,approved,0.508856
uuid-b1f2b0fe6904439a8fe158bc4bedc257,SCCHN,0.335752
uuid-b1f2b0fe6904439a8fe158bc4bedc257,chemotherapy,0.413957
uuid-b1f2b0fe6904439a8fe158bc4bedc257,feels,0.303962
uuid-b1f2b0fe6904439a8fe158bc4bedc257,RTL stated,0.459822
uuid-b1f2b0fe6904439a8fe158bc4bedc257,option,0.561295
uuid-b1f2b0fe6904439a8fe158bc4bedc257,bladder,0.314555
uuid-3a7afaac54a44ea6ba61ff21ed149066,Nivo,0.337698
uuid-3a7afaac54a44ea6ba61ff21ed149066,pembro,0.399771
uuid-3a7afaac54a44ea6ba61ff21ed149066,dose,0.549591
uuid-3a7afaac54a44ea6ba61ff21ed149066,efficacy,0.470099
uuid-3a7afaac54a44ea6ba61ff21ed149066,agents,0.470411
uuid-3a7afaac54a44ea6ba61ff21ed149066,atezo,0.47664
uuid-3a7afaac54a44ea6ba61ff21ed149066,preferred,0.473444
uuid-3a7afaac54a44ea6ba61ff21ed149066,indication,0.419334
uuid-3a7afaac54a44ea6ba61ff21ed149066,approved,0.334644
uuid-3a7afaac54a44ea6ba61ff21ed149066,vs,0.449241
uuid-3a7afaac54a44ea6ba61ff21ed149066,drug,0.507036
uuid-3a7afaac54a44ea6ba61ff21ed149066,Keytruda,0.464357
uuid-3a7afaac54a44ea6ba61ff21ed149066,option,0.363037
uuid-3a7afaac54a44ea6ba61ff21ed149066,flat dosing,0.477734
uuid-ed689010e84b43babd170411c7819d94,patients,0.325182
uuid-ed689010e84b43babd170411c7819d94,dose,0.337209
uuid-ed689010e84b43babd170411c7819d94,feels,0.339048
uuid-2332739eb745462b95c09914cf94b26c,toxicity,0.349893
uuid-2332739eb745462b95c09914cf94b26c,physicians,0.348047
uuid-2332739eb745462b95c09914cf94b26c,treatment,0.335668
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,efficacy,0.467067
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,regimen,0.315901
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,combination,0.327717
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,chemo,0.315563
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,OS,0.412757
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,data,0.363252
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,combo,0.331151
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,PFS,0.39209
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,ORR,0.368529
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,believes,0.328524
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,chemotherapy,0.336984
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,impressed,0.314041
uuid-da0810cd7e5e4477a1bd57bd6bbb9c2f,feels,0.327915
uuid-f0da82033f35426991934260b2f94f40,Nivo,0.461954
uuid-f0da82033f35426991934260b2f94f40,patients,0.306119
uuid-f0da82033f35426991934260b2f94f40,pembro,0.607888
uuid-f0da82033f35426991934260b2f94f40,dose,0.464396
uuid-f0da82033f35426991934260b2f94f40,1L,0.398491
uuid-f0da82033f35426991934260b2f94f40,2L,0.556676
uuid-f0da82033f35426991934260b2f94f40,Ipi,0.389967
uuid-f0da82033f35426991934260b2f94f40,approval,0.384937
uuid-f0da82033f35426991934260b2f94f40,atezo,0.643034
uuid-f0da82033f35426991934260b2f94f40,preferred,0.582796
uuid-f0da82033f35426991934260b2f94f40,monotherapy,0.357887
uuid-f0da82033f35426991934260b2f94f40,using nivo,0.501514
uuid-f0da82033f35426991934260b2f94f40,indication,0.373381
uuid-f0da82033f35426991934260b2f94f40,approved,0.430146
uuid-f0da82033f35426991934260b2f94f40,vs,0.45809
uuid-f0da82033f35426991934260b2f94f40,RTL stated,0.336626
uuid-f0da82033f35426991934260b2f94f40,option,0.400202
uuid-f0da82033f35426991934260b2f94f40,flat dosing,0.338127
uuid-b10ab6cbac2649db8e045a3a21f04038,1L,0.311254
uuid-b10ab6cbac2649db8e045a3a21f04038,PDL1,0.589755
uuid-b10ab6cbac2649db8e045a3a21f04038,agents,0.325346
uuid-b10ab6cbac2649db8e045a3a21f04038,Merck,0.374182
uuid-b10ab6cbac2649db8e045a3a21f04038,PD-L1,0.58843
uuid-b10ab6cbac2649db8e045a3a21f04038,atezo,0.331044
uuid-b10ab6cbac2649db8e045a3a21f04038,PD-L1 testing,0.355558
uuid-b10ab6cbac2649db8e045a3a21f04038,testing,0.542797
uuid-b10ab6cbac2649db8e045a3a21f04038,PDL1 testing,0.414051
uuid-b10ab6cbac2649db8e045a3a21f04038,NSCLC patients,0.314125
uuid-b10ab6cbac2649db8e045a3a21f04038,nivo and pembro,0.355497
uuid-b10ab6cbac2649db8e045a3a21f04038,believes,0.387894
uuid-b10ab6cbac2649db8e045a3a21f04038,assay,0.60565
uuid-b10ab6cbac2649db8e045a3a21f04038,PDL1 expression,0.456801
uuid-b10ab6cbac2649db8e045a3a21f04038,biomarker,0.617313
uuid-3e3ae268d3d645359f0af8016439ca9f,PDL1,0.522763
uuid-3e3ae268d3d645359f0af8016439ca9f,efficacy,0.35305
uuid-3e3ae268d3d645359f0af8016439ca9f,chemo,0.30036
uuid-3e3ae268d3d645359f0af8016439ca9f,OS,0.327071
uuid-3e3ae268d3d645359f0af8016439ca9f,PFS,0.371873
uuid-3e3ae268d3d645359f0af8016439ca9f,ORR,0.322445
uuid-3e3ae268d3d645359f0af8016439ca9f,nivo and pembro,0.556264
uuid-3e3ae268d3d645359f0af8016439ca9f,believes,0.533667
uuid-3e3ae268d3d645359f0af8016439ca9f,feels,0.353344
uuid-3e3ae268d3d645359f0af8016439ca9f,PDL1 expression,0.42058
uuid-6f33b6486b66406994ec642e21a17daf,Opdivo,0.318865
uuid-6f33b6486b66406994ec642e21a17daf,BMS,0.421777
uuid-6f33b6486b66406994ec642e21a17daf,Merck,0.323915
uuid-6f33b6486b66406994ec642e21a17daf,physicians,0.358021
uuid-6f33b6486b66406994ec642e21a17daf,approved,0.434047
uuid-6f33b6486b66406994ec642e21a17daf,drug,0.414136
uuid-8d873c6d2a154a45829625f30627e127,pembro,0.334641
uuid-8d873c6d2a154a45829625f30627e127,1L,0.420706
uuid-8d873c6d2a154a45829625f30627e127,PDL1,0.520497
uuid-8d873c6d2a154a45829625f30627e127,chemo,0.339186
uuid-8d873c6d2a154a45829625f30627e127,2L,0.37949
uuid-8d873c6d2a154a45829625f30627e127,agents,0.545224
uuid-8d873c6d2a154a45829625f30627e127,PD-L1,0.49289
uuid-8d873c6d2a154a45829625f30627e127,atezo,0.392981
uuid-8d873c6d2a154a45829625f30627e127,preferred,0.38019
uuid-8d873c6d2a154a45829625f30627e127,testing,0.341187
uuid-8d873c6d2a154a45829625f30627e127,monotherapy,0.404341
uuid-8d873c6d2a154a45829625f30627e127,NSCLC patients,0.319977
uuid-8d873c6d2a154a45829625f30627e127,nivo and pembro,0.433253
uuid-8d873c6d2a154a45829625f30627e127,believes,0.369244
uuid-8d873c6d2a154a45829625f30627e127,assay,0.3204
uuid-8d873c6d2a154a45829625f30627e127,PD-1,0.415044
uuid-8d873c6d2a154a45829625f30627e127,PDL1 expression,0.476047
uuid-8d873c6d2a154a45829625f30627e127,option,0.424918
uuid-8d873c6d2a154a45829625f30627e127,biomarker,0.417924
uuid-f4fb543dc96d4d30ba16a2b0eb333290,commented,0.344904
uuid-f4fb543dc96d4d30ba16a2b0eb333290,institution,0.326909
uuid-f4fb543dc96d4d30ba16a2b0eb333290,regards,0.359195
uuid-f4fb543dc96d4d30ba16a2b0eb333290,indication,0.309647
uuid-f4fb543dc96d4d30ba16a2b0eb333290,NCCN,0.678528
uuid-1b7b23f525f94a979f58bb4a884a5679,patients,0.852975
uuid-1b7b23f525f94a979f58bb4a884a5679,Opdivo,0.393932
uuid-1b7b23f525f94a979f58bb4a884a5679,therapy,0.699127
uuid-1b7b23f525f94a979f58bb4a884a5679,nivolumab,0.414518
uuid-1b7b23f525f94a979f58bb4a884a5679,toxicity,0.381618
uuid-1b7b23f525f94a979f58bb4a884a5679,regimen,0.611834
uuid-1b7b23f525f94a979f58bb4a884a5679,treated,0.553066
uuid-1b7b23f525f94a979f58bb4a884a5679,chemo,0.427514
uuid-1b7b23f525f94a979f58bb4a884a5679,pts,0.543617
uuid-1b7b23f525f94a979f58bb4a884a5679,monotherapy,0.422027
uuid-1b7b23f525f94a979f58bb4a884a5679,treatment,0.867164
uuid-1b7b23f525f94a979f58bb4a884a5679,response,0.481866
uuid-1b7b23f525f94a979f58bb4a884a5679,PD1,0.384467
uuid-1b7b23f525f94a979f58bb4a884a5679,progression,0.795396
uuid-1b7b23f525f94a979f58bb4a884a5679,chemotherapy,0.496882
uuid-1b7b23f525f94a979f58bb4a884a5679,respond,0.592352
uuid-1b7b23f525f94a979f58bb4a884a5679,option,0.434881
uuid-3f5b58736e1047b488bde4645db50638,Nivo,0.419837
uuid-3f5b58736e1047b488bde4645db50638,patients,0.770657
uuid-3f5b58736e1047b488bde4645db50638,Opdivo,0.610643
uuid-3f5b58736e1047b488bde4645db50638,therapy,0.43082
uuid-3f5b58736e1047b488bde4645db50638,dose,0.512605
uuid-3f5b58736e1047b488bde4645db50638,nivolumab,0.502385
uuid-3f5b58736e1047b488bde4645db50638,regimen,0.453364
uuid-3f5b58736e1047b488bde4645db50638,treated,0.367887
uuid-3f5b58736e1047b488bde4645db50638,2L,0.315082
uuid-3f5b58736e1047b488bde4645db50638,pts,0.472499
uuid-3f5b58736e1047b488bde4645db50638,approval,0.323249
uuid-3f5b58736e1047b488bde4645db50638,preferred,0.425743
uuid-3f5b58736e1047b488bde4645db50638,monotherapy,0.383086
uuid-3f5b58736e1047b488bde4645db50638,treatment,0.525597
uuid-3f5b58736e1047b488bde4645db50638,using nivo,0.437087
uuid-3f5b58736e1047b488bde4645db50638,approved,0.379875
uuid-3f5b58736e1047b488bde4645db50638,progression,0.416606
uuid-3f5b58736e1047b488bde4645db50638,respond,0.382253
uuid-3f5b58736e1047b488bde4645db50638,option,0.437895
uuid-3f5b58736e1047b488bde4645db50638,flat dosing,0.424866
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,TL,0.507279
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,PDL1,0.389989
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,TL stated,0.384102
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,Merck,0.497812
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,institution,0.329336
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,PD-L1,0.653254
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,PD-L1 testing,0.69557
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,testing,0.655771
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,PDL1 testing,0.596282
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,NSCLC patients,0.46518
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,TLs,0.303
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,assay,0.562208
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,PDL1 expression,0.339783
uuid-c5556ea1c2c24decb9b8f2acc2ed2b9a,biomarker,0.315039
uuid-f73e805cb59444be8fe4890693605a93,Nivo,0.41792
uuid-f73e805cb59444be8fe4890693605a93,pembro,0.595064
uuid-f73e805cb59444be8fe4890693605a93,1L,0.69878
uuid-f73e805cb59444be8fe4890693605a93,PDL1,0.588829
uuid-f73e805cb59444be8fe4890693605a93,efficacy,0.373253
uuid-f73e805cb59444be8fe4890693605a93,chemo,0.349054
uuid-f73e805cb59444be8fe4890693605a93,2L,0.642555
uuid-f73e805cb59444be8fe4890693605a93,agents,0.538779
uuid-f73e805cb59444be8fe4890693605a93,PD-L1,0.37187
uuid-f73e805cb59444be8fe4890693605a93,atezo,0.634462
uuid-f73e805cb59444be8fe4890693605a93,preferred,0.528024
uuid-f73e805cb59444be8fe4890693605a93,monotherapy,0.481834
uuid-f73e805cb59444be8fe4890693605a93,using nivo,0.350286
uuid-f73e805cb59444be8fe4890693605a93,combo,0.317155
uuid-f73e805cb59444be8fe4890693605a93,PDL1 testing,0.330489
uuid-f73e805cb59444be8fe4890693605a93,indication,0.308768
uuid-f73e805cb59444be8fe4890693605a93,approved,0.382549
uuid-f73e805cb59444be8fe4890693605a93,nivo and pembro,0.581805
uuid-f73e805cb59444be8fe4890693605a93,believes,0.481268
uuid-f73e805cb59444be8fe4890693605a93,feels,0.459376
uuid-f73e805cb59444be8fe4890693605a93,PDL1 expression,0.516819
uuid-f73e805cb59444be8fe4890693605a93,option,0.542216
uuid-f73e805cb59444be8fe4890693605a93,biomarker,0.384593
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,pembro,0.392138
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,RTL,0.300637
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,lung,0.596671
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,1L,0.353164
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,melanoma,0.619132
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,shared,0.31403
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,RCC,0.64443
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,TL stated,0.558944
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,2L,0.527654
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,atezo,0.475654
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,preferred,0.512525
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,using nivo,0.500815
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,PDL1 testing,0.380361
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,SCCHN,0.635894
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,TLs,0.487417
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,academic,0.36481
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,Regional TL,0.357363
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,RTL stated,0.666632
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,TL shared,0.566515
uuid-2e08ea389f4a4a018f5e36ce4e90fb65,bladder,0.416448
uuid-44aedb50f00a45d78fa6ba82eb49f08c,Nivo,0.327276
uuid-44aedb50f00a45d78fa6ba82eb49f08c,pembro,0.428304
uuid-44aedb50f00a45d78fa6ba82eb49f08c,RTL,0.393887
uuid-44aedb50f00a45d78fa6ba82eb49f08c,trial,0.695949
uuid-44aedb50f00a45d78fa6ba82eb49f08c,combination,0.583684
uuid-44aedb50f00a45d78fa6ba82eb49f08c,agents,0.341547
uuid-44aedb50f00a45d78fa6ba82eb49f08c,Ipi,0.386207
uuid-44aedb50f00a45d78fa6ba82eb49f08c,atezo,0.315483
uuid-44aedb50f00a45d78fa6ba82eb49f08c,preferred,0.351869
uuid-44aedb50f00a45d78fa6ba82eb49f08c,monotherapy,0.366862
uuid-44aedb50f00a45d78fa6ba82eb49f08c,data,0.346956
uuid-44aedb50f00a45d78fa6ba82eb49f08c,combo,0.489294
uuid-44aedb50f00a45d78fa6ba82eb49f08c,clinical trials,0.415316
uuid-44aedb50f00a45d78fa6ba82eb49f08c,SCCHN,0.324984
uuid-44aedb50f00a45d78fa6ba82eb49f08c,chemotherapy,0.316381
uuid-44aedb50f00a45d78fa6ba82eb49f08c,impressed,0.333027
uuid-44aedb50f00a45d78fa6ba82eb49f08c,feels,0.424682
uuid-44aedb50f00a45d78fa6ba82eb49f08c,RTL stated,0.338559
uuid-44aedb50f00a45d78fa6ba82eb49f08c,bladder,0.319399
uuid-7842ef7093b34aeb84160d8ac3720b9f,combination,0.709928
uuid-7842ef7093b34aeb84160d8ac3720b9f,chemo,0.435393
uuid-7842ef7093b34aeb84160d8ac3720b9f,IO,0.570114
uuid-7842ef7093b34aeb84160d8ac3720b9f,agents,0.463032
uuid-7842ef7093b34aeb84160d8ac3720b9f,monotherapy,0.552517
uuid-7842ef7093b34aeb84160d8ac3720b9f,combo,0.603937
uuid-7842ef7093b34aeb84160d8ac3720b9f,PD1,0.458578
uuid-7842ef7093b34aeb84160d8ac3720b9f,believes,0.427913
uuid-7842ef7093b34aeb84160d8ac3720b9f,chemotherapy,0.390818
uuid-7842ef7093b34aeb84160d8ac3720b9f,feels,0.423404
uuid-7842ef7093b34aeb84160d8ac3720b9f,PD-1,0.332625
uuid-7842ef7093b34aeb84160d8ac3720b9f,option,0.369085
uuid-41317af48e434313be29b6b13a91ff53,Nivo,0.659586
uuid-41317af48e434313be29b6b13a91ff53,pembro,0.618152
uuid-41317af48e434313be29b6b13a91ff53,1L,0.383823
uuid-41317af48e434313be29b6b13a91ff53,trial,0.44874
uuid-41317af48e434313be29b6b13a91ff53,efficacy,0.417413
uuid-41317af48e434313be29b6b13a91ff53,combination,0.33498
uuid-41317af48e434313be29b6b13a91ff53,chemo,0.399081
uuid-41317af48e434313be29b6b13a91ff53,2L,0.404457
uuid-41317af48e434313be29b6b13a91ff53,agents,0.32683
uuid-41317af48e434313be29b6b13a91ff53,Ipi,0.329494
uuid-41317af48e434313be29b6b13a91ff53,approval,0.347167
uuid-41317af48e434313be29b6b13a91ff53,OS,0.30036
uuid-41317af48e434313be29b6b13a91ff53,atezo,0.479911
uuid-41317af48e434313be29b6b13a91ff53,preferred,0.321842
uuid-41317af48e434313be29b6b13a91ff53,monotherapy,0.393578
uuid-41317af48e434313be29b6b13a91ff53,using nivo,0.403193
uuid-41317af48e434313be29b6b13a91ff53,data,0.396472
uuid-41317af48e434313be29b6b13a91ff53,combo,0.341748
uuid-41317af48e434313be29b6b13a91ff53,indication,0.324309
uuid-41317af48e434313be29b6b13a91ff53,PD1,0.314659
uuid-41317af48e434313be29b6b13a91ff53,ORR,0.317302
uuid-41317af48e434313be29b6b13a91ff53,approved,0.410196
uuid-41317af48e434313be29b6b13a91ff53,nivo and pembro,0.438956
uuid-41317af48e434313be29b6b13a91ff53,believes,0.351538
uuid-41317af48e434313be29b6b13a91ff53,chemotherapy,0.313569
uuid-41317af48e434313be29b6b13a91ff53,impressed,0.382812
uuid-41317af48e434313be29b6b13a91ff53,vs,0.365289
uuid-41317af48e434313be29b6b13a91ff53,feels,0.568233
uuid-41317af48e434313be29b6b13a91ff53,option,0.396314
uuid-baafa8d1e0364e71ad8cbda5f4108de2,1L,0.349828
uuid-baafa8d1e0364e71ad8cbda5f4108de2,PDL1,0.496798
uuid-baafa8d1e0364e71ad8cbda5f4108de2,agents,0.338069
uuid-baafa8d1e0364e71ad8cbda5f4108de2,PD-L1,0.458425
uuid-baafa8d1e0364e71ad8cbda5f4108de2,testing,0.449667
uuid-baafa8d1e0364e71ad8cbda5f4108de2,PDL1 testing,0.400913
uuid-baafa8d1e0364e71ad8cbda5f4108de2,NSCLC patients,0.313813
uuid-baafa8d1e0364e71ad8cbda5f4108de2,believes,0.394418
uuid-baafa8d1e0364e71ad8cbda5f4108de2,feels,0.301339
uuid-baafa8d1e0364e71ad8cbda5f4108de2,assay,0.32402
uuid-baafa8d1e0364e71ad8cbda5f4108de2,PDL1 expression,0.366203
uuid-baafa8d1e0364e71ad8cbda5f4108de2,biomarker,0.528816
uuid-6e0bc0daa1e04100a916c5d2375ae30f,patients,0.370126
uuid-6e0bc0daa1e04100a916c5d2375ae30f,TL,0.563527
uuid-6e0bc0daa1e04100a916c5d2375ae30f,TL stated,0.413307
uuid-6e0bc0daa1e04100a916c5d2375ae30f,PD-L1,0.578617
uuid-6e0bc0daa1e04100a916c5d2375ae30f,approval,0.320491
uuid-6e0bc0daa1e04100a916c5d2375ae30f,PD-L1 testing,0.719006
uuid-6e0bc0daa1e04100a916c5d2375ae30f,testing,0.741781
uuid-6e0bc0daa1e04100a916c5d2375ae30f,PDL1 testing,0.624784
uuid-6e0bc0daa1e04100a916c5d2375ae30f,NSCLC patients,0.705582
uuid-6e0bc0daa1e04100a916c5d2375ae30f,assay,0.420567
uuid-0559488aa0be4e1d97d1f5d97bdc159a,TL,0.348383
uuid-0559488aa0be4e1d97d1f5d97bdc159a,RTL,0.346626
uuid-0559488aa0be4e1d97d1f5d97bdc159a,toxicity,0.352972
uuid-0559488aa0be4e1d97d1f5d97bdc159a,NTL,0.356907
uuid-0559488aa0be4e1d97d1f5d97bdc159a,TL stated,0.323346
uuid-0559488aa0be4e1d97d1f5d97bdc159a,TL shared,0.337337
uuid-b4beb5007ba1429aac236f3423cc16ce,Nivo,0.564741
uuid-b4beb5007ba1429aac236f3423cc16ce,patients,0.345419
uuid-b4beb5007ba1429aac236f3423cc16ce,pembro,0.604139
uuid-b4beb5007ba1429aac236f3423cc16ce,nivolumab,0.391606
uuid-b4beb5007ba1429aac236f3423cc16ce,1L,0.599267
uuid-b4beb5007ba1429aac236f3423cc16ce,RCC,0.46741
uuid-b4beb5007ba1429aac236f3423cc16ce,2L,0.682019
uuid-b4beb5007ba1429aac236f3423cc16ce,pts,0.321477
uuid-b4beb5007ba1429aac236f3423cc16ce,stated,0.417868
uuid-b4beb5007ba1429aac236f3423cc16ce,approval,0.555661
uuid-b4beb5007ba1429aac236f3423cc16ce,atezo,0.531239
uuid-b4beb5007ba1429aac236f3423cc16ce,preferred,0.56567
uuid-b4beb5007ba1429aac236f3423cc16ce,monotherapy,0.517284
uuid-b4beb5007ba1429aac236f3423cc16ce,using nivo,0.711598
uuid-b4beb5007ba1429aac236f3423cc16ce,clinical trials,0.350741
uuid-b4beb5007ba1429aac236f3423cc16ce,indication,0.391102
uuid-b4beb5007ba1429aac236f3423cc16ce,approved,0.596029
uuid-b4beb5007ba1429aac236f3423cc16ce,SCCHN,0.543981
uuid-b4beb5007ba1429aac236f3423cc16ce,impressed,0.33716
uuid-b4beb5007ba1429aac236f3423cc16ce,tumor types,0.329835
uuid-b4beb5007ba1429aac236f3423cc16ce,label,0.348121
uuid-b4beb5007ba1429aac236f3423cc16ce,LTL,0.386255
uuid-b4beb5007ba1429aac236f3423cc16ce,SCLC,0.384705
uuid-b4beb5007ba1429aac236f3423cc16ce,feels,0.408206
uuid-b4beb5007ba1429aac236f3423cc16ce,Regional TL,0.334521
uuid-b4beb5007ba1429aac236f3423cc16ce,RTL stated,0.625235
uuid-b4beb5007ba1429aac236f3423cc16ce,option,0.5168
uuid-b4beb5007ba1429aac236f3423cc16ce,bladder,0.512996
uuid-1212675d720a4bb2883e97c818147976,Nivo,0.608532
uuid-1212675d720a4bb2883e97c818147976,pembro,0.522744
uuid-1212675d720a4bb2883e97c818147976,nivolumab,0.411559
uuid-1212675d720a4bb2883e97c818147976,1L,0.566052
uuid-1212675d720a4bb2883e97c818147976,RCC,0.486615
uuid-1212675d720a4bb2883e97c818147976,combination,0.495398
uuid-1212675d720a4bb2883e97c818147976,chemo,0.348778
uuid-1212675d720a4bb2883e97c818147976,2L,0.667771
uuid-1212675d720a4bb2883e97c818147976,agents,0.443981
uuid-1212675d720a4bb2883e97c818147976,Ipi,0.366676
uuid-1212675d720a4bb2883e97c818147976,stated,0.320139
uuid-1212675d720a4bb2883e97c818147976,approval,0.383875
uuid-1212675d720a4bb2883e97c818147976,atezo,0.477876
uuid-1212675d720a4bb2883e97c818147976,preferred,0.639118
uuid-1212675d720a4bb2883e97c818147976,monotherapy,0.607647
uuid-1212675d720a4bb2883e97c818147976,using nivo,0.706626
uuid-1212675d720a4bb2883e97c818147976,combo,0.476639
uuid-1212675d720a4bb2883e97c818147976,PD1,0.328034
uuid-1212675d720a4bb2883e97c818147976,approved,0.493011
uuid-1212675d720a4bb2883e97c818147976,SCCHN,0.460666
uuid-1212675d720a4bb2883e97c818147976,LTL,0.443387
uuid-1212675d720a4bb2883e97c818147976,SCLC,0.339516
uuid-1212675d720a4bb2883e97c818147976,feels,0.484348
uuid-1212675d720a4bb2883e97c818147976,RTL stated,0.659486
uuid-1212675d720a4bb2883e97c818147976,option,0.553422
uuid-1212675d720a4bb2883e97c818147976,bladder,0.354554
uuid-4dcab07874d64f97afdd316c3832aa4d,RTL,0.492194
uuid-4dcab07874d64f97afdd316c3832aa4d,trial,0.31807
uuid-4dcab07874d64f97afdd316c3832aa4d,NTL,0.405809
uuid-4dcab07874d64f97afdd316c3832aa4d,discussed,0.347651
uuid-4dcab07874d64f97afdd316c3832aa4d,commented,0.58883
uuid-4dcab07874d64f97afdd316c3832aa4d,regards,0.460764
uuid-4dcab07874d64f97afdd316c3832aa4d,data,0.48304
uuid-4dcab07874d64f97afdd316c3832aa4d,expressed,0.511984
uuid-4dcab07874d64f97afdd316c3832aa4d,mentioned,0.658244
uuid-4dcab07874d64f97afdd316c3832aa4d,HCP,0.361382
uuid-4dcab07874d64f97afdd316c3832aa4d,ASCO,0.427767
uuid-4dcab07874d64f97afdd316c3832aa4d,impressed,0.52029
uuid-4dcab07874d64f97afdd316c3832aa4d,LTL,0.429286
uuid-4dcab07874d64f97afdd316c3832aa4d,TLs,0.317108
uuid-4dcab07874d64f97afdd316c3832aa4d,Regional TL,0.442365
uuid-60f4fd308fc144cf83c2eddf1bad0dbe,BMS,0.616578
uuid-60f4fd308fc144cf83c2eddf1bad0dbe,shared,0.383536
uuid-60f4fd308fc144cf83c2eddf1bad0dbe,Merck,0.590542
uuid-60f4fd308fc144cf83c2eddf1bad0dbe,physicians,0.427297
uuid-60f4fd308fc144cf83c2eddf1bad0dbe,drug,0.491679
uuid-60f4fd308fc144cf83c2eddf1bad0dbe,Keytruda,0.329667
uuid-f47510a511a64bc89cdfc2a9c2c75c50,Nivo,0.730192
uuid-f47510a511a64bc89cdfc2a9c2c75c50,patients,0.53776
uuid-f47510a511a64bc89cdfc2a9c2c75c50,pembro,0.400411
uuid-f47510a511a64bc89cdfc2a9c2c75c50,therapy,0.410239
uuid-f47510a511a64bc89cdfc2a9c2c75c50,dose,0.664244
uuid-f47510a511a64bc89cdfc2a9c2c75c50,nivolumab,0.457989
uuid-f47510a511a64bc89cdfc2a9c2c75c50,toxicity,0.3779
uuid-f47510a511a64bc89cdfc2a9c2c75c50,regimen,0.517458
uuid-f47510a511a64bc89cdfc2a9c2c75c50,combination,0.45512
uuid-f47510a511a64bc89cdfc2a9c2c75c50,chemo,0.455658
uuid-f47510a511a64bc89cdfc2a9c2c75c50,pts,0.419965
uuid-f47510a511a64bc89cdfc2a9c2c75c50,Ipi,0.73733
uuid-f47510a511a64bc89cdfc2a9c2c75c50,preferred,0.301815
uuid-f47510a511a64bc89cdfc2a9c2c75c50,monotherapy,0.459303
uuid-f47510a511a64bc89cdfc2a9c2c75c50,treatment,0.348257
uuid-f47510a511a64bc89cdfc2a9c2c75c50,using nivo,0.366718
uuid-f47510a511a64bc89cdfc2a9c2c75c50,response,0.312686
uuid-f47510a511a64bc89cdfc2a9c2c75c50,combo,0.382088
uuid-f47510a511a64bc89cdfc2a9c2c75c50,progression,0.323147
uuid-f47510a511a64bc89cdfc2a9c2c75c50,chemotherapy,0.403652
uuid-f47510a511a64bc89cdfc2a9c2c75c50,vs,0.490024
uuid-f47510a511a64bc89cdfc2a9c2c75c50,option,0.339242
uuid-f47510a511a64bc89cdfc2a9c2c75c50,flat dosing,0.355591
uuid-1708e4e8bc364223a24305c7d542a77f,patients,0.604721
uuid-1708e4e8bc364223a24305c7d542a77f,therapy,0.461599
uuid-1708e4e8bc364223a24305c7d542a77f,nivolumab,0.312834
uuid-1708e4e8bc364223a24305c7d542a77f,toxicity,0.522451
uuid-1708e4e8bc364223a24305c7d542a77f,regimen,0.577583
uuid-1708e4e8bc364223a24305c7d542a77f,treated,0.586602
uuid-1708e4e8bc364223a24305c7d542a77f,chemo,0.343911
uuid-1708e4e8bc364223a24305c7d542a77f,pts,0.348883
uuid-1708e4e8bc364223a24305c7d542a77f,monotherapy,0.345295
uuid-1708e4e8bc364223a24305c7d542a77f,treatment,0.686034
uuid-1708e4e8bc364223a24305c7d542a77f,progression,0.465219
uuid-1708e4e8bc364223a24305c7d542a77f,chemotherapy,0.383215
uuid-1708e4e8bc364223a24305c7d542a77f,respond,0.491659
uuid-21eb7a078c7c40b79e2d08343abe346c,BMS,0.418679
uuid-21eb7a078c7c40b79e2d08343abe346c,PDL1,0.388321
uuid-21eb7a078c7c40b79e2d08343abe346c,trial,0.343787
uuid-21eb7a078c7c40b79e2d08343abe346c,efficacy,0.545651
uuid-21eb7a078c7c40b79e2d08343abe346c,OS,0.906269
uuid-21eb7a078c7c40b79e2d08343abe346c,data,0.536244
uuid-21eb7a078c7c40b79e2d08343abe346c,PFS,0.870192
uuid-21eb7a078c7c40b79e2d08343abe346c,ORR,0.746105
uuid-21eb7a078c7c40b79e2d08343abe346c,nivo and pembro,0.363684
uuid-21eb7a078c7c40b79e2d08343abe346c,believes,0.342519
uuid-21eb7a078c7c40b79e2d08343abe346c,impressed,0.423322
uuid-21eb7a078c7c40b79e2d08343abe346c,feels,0.343873
uuid-21eb7a078c7c40b79e2d08343abe346c,PDL1 expression,0.33934
uuid-ff55a3bce28f461bbd50605b5f5a8269,patients,0.629782
uuid-ff55a3bce28f461bbd50605b5f5a8269,Opdivo,0.409277
uuid-ff55a3bce28f461bbd50605b5f5a8269,dose,0.357232
uuid-ff55a3bce28f461bbd50605b5f5a8269,pts,0.349059
uuid-ff55a3bce28f461bbd50605b5f5a8269,treatment,0.397357
uuid-ff55a3bce28f461bbd50605b5f5a8269,using nivo,0.339281
uuid-ff55a3bce28f461bbd50605b5f5a8269,progression,0.360792
uuid-ff55a3bce28f461bbd50605b5f5a8269,respond,0.344073
uuid-ad978155092d48e5b06e8e9df9dfadca,Nivo,0.379578
uuid-ad978155092d48e5b06e8e9df9dfadca,pembro,0.462581
uuid-ad978155092d48e5b06e8e9df9dfadca,trial,0.432372
uuid-ad978155092d48e5b06e8e9df9dfadca,commented,0.347079
uuid-ad978155092d48e5b06e8e9df9dfadca,stated,0.510057
uuid-ad978155092d48e5b06e8e9df9dfadca,approval,0.435934
uuid-ad978155092d48e5b06e8e9df9dfadca,OS,0.348612
uuid-ad978155092d48e5b06e8e9df9dfadca,atezo,0.36029
uuid-ad978155092d48e5b06e8e9df9dfadca,using nivo,0.335106
uuid-ad978155092d48e5b06e8e9df9dfadca,data,0.612588
uuid-ad978155092d48e5b06e8e9df9dfadca,indication,0.308359
uuid-ad978155092d48e5b06e8e9df9dfadca,PFS,0.334554
uuid-ad978155092d48e5b06e8e9df9dfadca,ORR,0.347834
uuid-ad978155092d48e5b06e8e9df9dfadca,approved,0.383964
uuid-ad978155092d48e5b06e8e9df9dfadca,SCCHN,0.367776
uuid-ad978155092d48e5b06e8e9df9dfadca,nivo and pembro,0.368336
uuid-ad978155092d48e5b06e8e9df9dfadca,impressed,0.514548
uuid-ad978155092d48e5b06e8e9df9dfadca,label,0.319099
uuid-ad978155092d48e5b06e8e9df9dfadca,SCLC,0.420423
uuid-ad978155092d48e5b06e8e9df9dfadca,feels,0.376418
uuid-ad978155092d48e5b06e8e9df9dfadca,Regional TL,0.301417
uuid-ad978155092d48e5b06e8e9df9dfadca,NCCN,0.340618
uuid-7cbd4d8ecc294b4ba53edb4d52d2bca2,PDL1,0.405063
uuid-7cbd4d8ecc294b4ba53edb4d52d2bca2,OS,0.347481
uuid-7cbd4d8ecc294b4ba53edb4d52d2bca2,PFS,0.343556
uuid-7cbd4d8ecc294b4ba53edb4d52d2bca2,ORR,0.308703
uuid-7cbd4d8ecc294b4ba53edb4d52d2bca2,believes,0.434438
uuid-7cbd4d8ecc294b4ba53edb4d52d2bca2,feels,0.571252
uuid-7cbd4d8ecc294b4ba53edb4d52d2bca2,PDL1 expression,0.309525
uuid-7cbd4d8ecc294b4ba53edb4d52d2bca2,biomarker,0.30157
uuid-1654591d5d72439d8d7ce7e908d43e27,Opdivo,0.426185
uuid-1654591d5d72439d8d7ce7e908d43e27,dose,0.478742
uuid-1654591d5d72439d8d7ce7e908d43e27,drug,0.638793
uuid-1654591d5d72439d8d7ce7e908d43e27,Keytruda,0.339455
uuid-1654591d5d72439d8d7ce7e908d43e27,flat dosing,0.508522
uuid-b87e00864b6942c79af010fe48e8de69,Opdivo,0.303705
uuid-b87e00864b6942c79af010fe48e8de69,dose,0.588209
uuid-b87e00864b6942c79af010fe48e8de69,toxicity,0.569857
uuid-b87e00864b6942c79af010fe48e8de69,regimen,0.444272
uuid-b87e00864b6942c79af010fe48e8de69,treated,0.353538
uuid-b87e00864b6942c79af010fe48e8de69,physicians,0.438715
uuid-b87e00864b6942c79af010fe48e8de69,treatment,0.421424
uuid-b87e00864b6942c79af010fe48e8de69,respond,0.301448
uuid-9864a39801f647329c30787371b84717,RTL,0.332099
uuid-9864a39801f647329c30787371b84717,BMS,0.393475
uuid-9864a39801f647329c30787371b84717,shared,0.417322
uuid-9864a39801f647329c30787371b84717,commented,0.368635
uuid-9864a39801f647329c30787371b84717,stated,0.537582
uuid-9864a39801f647329c30787371b84717,physicians,0.381212
uuid-9864a39801f647329c30787371b84717,clinical trials,0.384436
uuid-9864a39801f647329c30787371b84717,SCCHN,0.30204
uuid-9864a39801f647329c30787371b84717,impressed,0.34764
uuid-9864a39801f647329c30787371b84717,LTL,0.302835
uuid-9864a39801f647329c30787371b84717,Regional TL,0.432827
uuid-9864a39801f647329c30787371b84717,flat dosing,0.330353
uuid-3d6d9956f98340bd8147630470bafb44,Nivo,0.412058
uuid-3d6d9956f98340bd8147630470bafb44,patients,0.670597
uuid-3d6d9956f98340bd8147630470bafb44,therapy,0.382828
uuid-3d6d9956f98340bd8147630470bafb44,nivolumab,0.311595
uuid-3d6d9956f98340bd8147630470bafb44,1L,0.365034
uuid-3d6d9956f98340bd8147630470bafb44,regimen,0.312621
uuid-3d6d9956f98340bd8147630470bafb44,treated,0.305123
uuid-3d6d9956f98340bd8147630470bafb44,chemo,0.337517
uuid-3d6d9956f98340bd8147630470bafb44,2L,0.302152
uuid-3d6d9956f98340bd8147630470bafb44,pts,0.608821
uuid-3d6d9956f98340bd8147630470bafb44,monotherapy,0.408906
uuid-3d6d9956f98340bd8147630470bafb44,using nivo,0.369396
uuid-3d6d9956f98340bd8147630470bafb44,response,0.388
uuid-3d6d9956f98340bd8147630470bafb44,NSCLC patients,0.346775
uuid-3d6d9956f98340bd8147630470bafb44,PD1,0.316612
uuid-3d6d9956f98340bd8147630470bafb44,progression,0.513882
uuid-3d6d9956f98340bd8147630470bafb44,respond,0.387558
uuid-3d6d9956f98340bd8147630470bafb44,option,0.336576
uuid-5ff9146f486d4bcaac775d4a68f70434,patients,0.61548
uuid-5ff9146f486d4bcaac775d4a68f70434,Opdivo,0.676565
uuid-5ff9146f486d4bcaac775d4a68f70434,therapy,0.351002
uuid-5ff9146f486d4bcaac775d4a68f70434,nivolumab,0.321164
uuid-5ff9146f486d4bcaac775d4a68f70434,regimen,0.355404
uuid-5ff9146f486d4bcaac775d4a68f70434,treated,0.35695
uuid-5ff9146f486d4bcaac775d4a68f70434,pts,0.337119
uuid-5ff9146f486d4bcaac775d4a68f70434,treatment,0.421524
uuid-5ff9146f486d4bcaac775d4a68f70434,mentioned,0.310774
uuid-5ff9146f486d4bcaac775d4a68f70434,cHL,0.323061
uuid-5ff9146f486d4bcaac775d4a68f70434,progression,0.418832
uuid-5ff9146f486d4bcaac775d4a68f70434,Keytruda,0.332224
uuid-048f2edda4904e049bf1827b6480413d,Opdivo,0.423558
uuid-048f2edda4904e049bf1827b6480413d,TL,0.346513
uuid-048f2edda4904e049bf1827b6480413d,commented,0.408668
uuid-048f2edda4904e049bf1827b6480413d,TL stated,0.342719
uuid-048f2edda4904e049bf1827b6480413d,physicians,0.43688
uuid-048f2edda4904e049bf1827b6480413d,mentioned,0.498962
uuid-048f2edda4904e049bf1827b6480413d,ASCO,0.337591
uuid-048f2edda4904e049bf1827b6480413d,Keytruda,0.328248
uuid-048f2edda4904e049bf1827b6480413d,Regional TL,0.306751
uuid-f62eb685e8164af49afa504303946814,patients,0.425726
uuid-f62eb685e8164af49afa504303946814,1L,0.351572
uuid-f62eb685e8164af49afa504303946814,TL stated,0.310042
uuid-f62eb685e8164af49afa504303946814,2L,0.321836
uuid-f62eb685e8164af49afa504303946814,PD-L1,0.430136
uuid-f62eb685e8164af49afa504303946814,approval,0.312317
uuid-f62eb685e8164af49afa504303946814,preferred,0.320905
uuid-f62eb685e8164af49afa504303946814,PD-L1 testing,0.421141
uuid-f62eb685e8164af49afa504303946814,testing,0.550641
uuid-f62eb685e8164af49afa504303946814,PDL1 testing,0.519378
uuid-f62eb685e8164af49afa504303946814,NSCLC patients,0.589186
uuid-f62eb685e8164af49afa504303946814,approved,0.362368
uuid-f62eb685e8164af49afa504303946814,tumor types,0.448573
uuid-f62eb685e8164af49afa504303946814,option,0.420047
uuid-e2d2e97744d44e23b49e073c5673f526,nivolumab,0.501713
uuid-e2d2e97744d44e23b49e073c5673f526,lung,0.335564
uuid-e2d2e97744d44e23b49e073c5673f526,1L,0.528539
uuid-e2d2e97744d44e23b49e073c5673f526,RCC,0.759828
uuid-e2d2e97744d44e23b49e073c5673f526,TL stated,0.445641
uuid-e2d2e97744d44e23b49e073c5673f526,combination,0.347226
uuid-e2d2e97744d44e23b49e073c5673f526,2L,0.654511
uuid-e2d2e97744d44e23b49e073c5673f526,agents,0.40992
uuid-e2d2e97744d44e23b49e073c5673f526,approval,0.357187
uuid-e2d2e97744d44e23b49e073c5673f526,preferred,0.668905
uuid-e2d2e97744d44e23b49e073c5673f526,monotherapy,0.512687
uuid-e2d2e97744d44e23b49e073c5673f526,using nivo,0.706754
uuid-e2d2e97744d44e23b49e073c5673f526,combo,0.342547
uuid-e2d2e97744d44e23b49e073c5673f526,PDL1 testing,0.319436
uuid-e2d2e97744d44e23b49e073c5673f526,approved,0.45066
uuid-e2d2e97744d44e23b49e073c5673f526,SCCHN,0.56495
uuid-e2d2e97744d44e23b49e073c5673f526,tumor types,0.356017
uuid-e2d2e97744d44e23b49e073c5673f526,oncologist,0.317893
uuid-e2d2e97744d44e23b49e073c5673f526,LTL,0.324155
uuid-e2d2e97744d44e23b49e073c5673f526,TLs,0.312732
uuid-e2d2e97744d44e23b49e073c5673f526,Regional TL,0.445335
uuid-e2d2e97744d44e23b49e073c5673f526,RTL stated,0.72324
uuid-e2d2e97744d44e23b49e073c5673f526,TL shared,0.468689
uuid-e2d2e97744d44e23b49e073c5673f526,option,0.49884
uuid-e2d2e97744d44e23b49e073c5673f526,bladder,0.442945
uuid-95d5728f63334c249b93d19add4e520c,lung,0.526934
uuid-95d5728f63334c249b93d19add4e520c,melanoma,0.398749
uuid-95d5728f63334c249b93d19add4e520c,institution,0.480219
uuid-95d5728f63334c249b93d19add4e520c,AI,0.703441
uuid-95d5728f63334c249b93d19add4e520c,oncology,0.566534
uuid-95d5728f63334c249b93d19add4e520c,clinical,0.377582
uuid-95d5728f63334c249b93d19add4e520c,NCCN,0.359809
uuid-88a363fdc17e4487b20dfeb129ddae23,Opdivo,0.427725
uuid-88a363fdc17e4487b20dfeb129ddae23,dose,0.370674
uuid-88a363fdc17e4487b20dfeb129ddae23,approval,0.438132
uuid-88a363fdc17e4487b20dfeb129ddae23,indication,0.406192
uuid-88a363fdc17e4487b20dfeb129ddae23,approved,0.531283
uuid-88a363fdc17e4487b20dfeb129ddae23,label,0.413527
uuid-88a363fdc17e4487b20dfeb129ddae23,Keytruda,0.32453
uuid-88a363fdc17e4487b20dfeb129ddae23,flat dosing,0.608343
uuid-06b6c1ebb1c94f95966972ce32d16ac2,Opdivo,0.436513
uuid-06b6c1ebb1c94f95966972ce32d16ac2,nivolumab,0.349451
uuid-06b6c1ebb1c94f95966972ce32d16ac2,regimen,0.319181
uuid-06b6c1ebb1c94f95966972ce32d16ac2,treated,0.345683
uuid-06b6c1ebb1c94f95966972ce32d16ac2,shared,0.370257
uuid-06b6c1ebb1c94f95966972ce32d16ac2,RCC,0.382762
uuid-06b6c1ebb1c94f95966972ce32d16ac2,stated,0.340254
uuid-06b6c1ebb1c94f95966972ce32d16ac2,physicians,0.490639
uuid-06b6c1ebb1c94f95966972ce32d16ac2,preferred,0.393662
uuid-06b6c1ebb1c94f95966972ce32d16ac2,treatment,0.324248
uuid-06b6c1ebb1c94f95966972ce32d16ac2,using nivo,0.358495
uuid-06b6c1ebb1c94f95966972ce32d16ac2,approved,0.305432
uuid-06b6c1ebb1c94f95966972ce32d16ac2,SCCHN,0.349215
uuid-06b6c1ebb1c94f95966972ce32d16ac2,LTL,0.303075
uuid-06b6c1ebb1c94f95966972ce32d16ac2,Regional TL,0.332393
uuid-06b6c1ebb1c94f95966972ce32d16ac2,RTL stated,0.41983
uuid-06b6c1ebb1c94f95966972ce32d16ac2,TL shared,0.315116
uuid-06b6c1ebb1c94f95966972ce32d16ac2,option,0.340918
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,Nivo,0.397562
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,pembro,0.438655
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,BMS,0.488759
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,PDL1,0.452896
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,trial,0.442952
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,efficacy,0.542531
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,agents,0.355743
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,Merck,0.311971
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,OS,0.424509
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,atezo,0.391736
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,data,0.560373
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,expressed,0.326322
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,PFS,0.448544
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,ORR,0.467832
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,nivo and pembro,0.570829
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,believes,0.394817
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,impressed,0.442596
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,feels,0.706718
uuid-9b8386cdec834c5f8abdc9fbdd9c9d5b,PDL1 expression,0.448912
uuid-dad6e360eb0c4ab887c0898871d0df3a,patients,0.345484
uuid-dad6e360eb0c4ab887c0898871d0df3a,therapy,0.460203
uuid-dad6e360eb0c4ab887c0898871d0df3a,nivolumab,0.419023
uuid-dad6e360eb0c4ab887c0898871d0df3a,regimen,0.35132
uuid-dad6e360eb0c4ab887c0898871d0df3a,treated,0.413541
uuid-dad6e360eb0c4ab887c0898871d0df3a,melanoma,0.406702
uuid-dad6e360eb0c4ab887c0898871d0df3a,RCC,0.449042
uuid-dad6e360eb0c4ab887c0898871d0df3a,combination,0.351788
uuid-dad6e360eb0c4ab887c0898871d0df3a,stated,0.300584
uuid-dad6e360eb0c4ab887c0898871d0df3a,monotherapy,0.312256
uuid-dad6e360eb0c4ab887c0898871d0df3a,treatment,0.438383
uuid-dad6e360eb0c4ab887c0898871d0df3a,using nivo,0.337246
uuid-dad6e360eb0c4ab887c0898871d0df3a,combo,0.314861
uuid-dad6e360eb0c4ab887c0898871d0df3a,PD1,0.373762
uuid-dad6e360eb0c4ab887c0898871d0df3a,SCCHN,0.3797
uuid-dad6e360eb0c4ab887c0898871d0df3a,progression,0.327099
uuid-dad6e360eb0c4ab887c0898871d0df3a,chemotherapy,0.380462
uuid-dad6e360eb0c4ab887c0898871d0df3a,tumor types,0.300652
uuid-dad6e360eb0c4ab887c0898871d0df3a,RTL stated,0.421206
uuid-dad6e360eb0c4ab887c0898871d0df3a,TL shared,0.31444
uuid-dad6e360eb0c4ab887c0898871d0df3a,option,0.388222
uuid-dad6e360eb0c4ab887c0898871d0df3a,bladder,0.328119
uuid-96b077e9c2d34c25a40387e570b1fca8,patients,0.750852
uuid-96b077e9c2d34c25a40387e570b1fca8,Opdivo,0.475797
uuid-96b077e9c2d34c25a40387e570b1fca8,therapy,0.378178
uuid-96b077e9c2d34c25a40387e570b1fca8,toxicity,0.349002
uuid-96b077e9c2d34c25a40387e570b1fca8,regimen,0.475275
uuid-96b077e9c2d34c25a40387e570b1fca8,treated,0.488755
uuid-96b077e9c2d34c25a40387e570b1fca8,pts,0.369304
uuid-96b077e9c2d34c25a40387e570b1fca8,physicians,0.438621
uuid-96b077e9c2d34c25a40387e570b1fca8,treatment,0.746883
uuid-96b077e9c2d34c25a40387e570b1fca8,progression,0.523895
uuid-96b077e9c2d34c25a40387e570b1fca8,respond,0.544234
uuid-3b410831a4d04e0ca5773e3e93cfbecb,patients,0.642042
uuid-3b410831a4d04e0ca5773e3e93cfbecb,therapy,0.685045
uuid-3b410831a4d04e0ca5773e3e93cfbecb,nivolumab,0.479817
uuid-3b410831a4d04e0ca5773e3e93cfbecb,regimen,0.317342
uuid-3b410831a4d04e0ca5773e3e93cfbecb,treated,0.385099
uuid-3b410831a4d04e0ca5773e3e93cfbecb,combination,0.316081
uuid-3b410831a4d04e0ca5773e3e93cfbecb,chemo,0.384294
uuid-3b410831a4d04e0ca5773e3e93cfbecb,pts,0.390074
uuid-3b410831a4d04e0ca5773e3e93cfbecb,monotherapy,0.357963
uuid-3b410831a4d04e0ca5773e3e93cfbecb,treatment,0.534304
uuid-3b410831a4d04e0ca5773e3e93cfbecb,response,0.490064
uuid-3b410831a4d04e0ca5773e3e93cfbecb,PD1,0.385069
uuid-3b410831a4d04e0ca5773e3e93cfbecb,cHL,0.379457
uuid-3b410831a4d04e0ca5773e3e93cfbecb,progression,0.559566
uuid-3b410831a4d04e0ca5773e3e93cfbecb,chemotherapy,0.492354
uuid-3b410831a4d04e0ca5773e3e93cfbecb,respond,0.328904
uuid-3b410831a4d04e0ca5773e3e93cfbecb,option,0.353763
uuid-29895acaf8a04797bc0035d98a23665c,patients,0.952418
uuid-29895acaf8a04797bc0035d98a23665c,Opdivo,0.583903
uuid-29895acaf8a04797bc0035d98a23665c,therapy,0.56208
uuid-29895acaf8a04797bc0035d98a23665c,nivolumab,0.492398
uuid-29895acaf8a04797bc0035d98a23665c,regimen,0.538718
uuid-29895acaf8a04797bc0035d98a23665c,treated,0.595962
uuid-29895acaf8a04797bc0035d98a23665c,chemo,0.345202
uuid-29895acaf8a04797bc0035d98a23665c,pts,0.612252
uuid-29895acaf8a04797bc0035d98a23665c,monotherapy,0.377345
uuid-29895acaf8a04797bc0035d98a23665c,treatment,0.714615
uuid-29895acaf8a04797bc0035d98a23665c,using nivo,0.300019
uuid-29895acaf8a04797bc0035d98a23665c,response,0.370097
uuid-29895acaf8a04797bc0035d98a23665c,cHL,0.308994
uuid-29895acaf8a04797bc0035d98a23665c,progression,0.673926
uuid-29895acaf8a04797bc0035d98a23665c,chemotherapy,0.388081
uuid-29895acaf8a04797bc0035d98a23665c,respond,0.510353
uuid-29895acaf8a04797bc0035d98a23665c,option,0.37061
uuid-5238731c426c4b7bba444cd23d07c0fd,patients,0.381337
uuid-5238731c426c4b7bba444cd23d07c0fd,toxicity,0.365777
uuid-5238731c426c4b7bba444cd23d07c0fd,physicians,0.338675
uuid-5238731c426c4b7bba444cd23d07c0fd,treatment,0.322342
uuid-7b810c666158410aa0f6fe14614adb3d,Nivo,0.670769
uuid-7b810c666158410aa0f6fe14614adb3d,patients,0.573468
uuid-7b810c666158410aa0f6fe14614adb3d,pembro,0.40571
uuid-7b810c666158410aa0f6fe14614adb3d,therapy,0.371351
uuid-7b810c666158410aa0f6fe14614adb3d,nivolumab,0.484505
uuid-7b810c666158410aa0f6fe14614adb3d,regimen,0.425594
uuid-7b810c666158410aa0f6fe14614adb3d,combination,0.357176
uuid-7b810c666158410aa0f6fe14614adb3d,chemo,0.358647
uuid-7b810c666158410aa0f6fe14614adb3d,2L,0.327777
uuid-7b810c666158410aa0f6fe14614adb3d,pts,0.468507
uuid-7b810c666158410aa0f6fe14614adb3d,Ipi,0.611962
uuid-7b810c666158410aa0f6fe14614adb3d,approval,0.370046
uuid-7b810c666158410aa0f6fe14614adb3d,monotherapy,0.461221
uuid-7b810c666158410aa0f6fe14614adb3d,treatment,0.309603
uuid-7b810c666158410aa0f6fe14614adb3d,using nivo,0.543923
uuid-7b810c666158410aa0f6fe14614adb3d,combo,0.336486
uuid-7b810c666158410aa0f6fe14614adb3d,PD1,0.311178
uuid-7b810c666158410aa0f6fe14614adb3d,approved,0.333548
uuid-7b810c666158410aa0f6fe14614adb3d,progression,0.335425
uuid-7b810c666158410aa0f6fe14614adb3d,chemotherapy,0.347716
uuid-7b810c666158410aa0f6fe14614adb3d,SCLC,0.533714
uuid-7b810c666158410aa0f6fe14614adb3d,RTL stated,0.327635
uuid-7b810c666158410aa0f6fe14614adb3d,option,0.385941
uuid-7ba98bfeef3d45a6b77e285c6328b160,Nivo,0.318316
uuid-7ba98bfeef3d45a6b77e285c6328b160,pembro,0.43965
uuid-7ba98bfeef3d45a6b77e285c6328b160,trial,0.508322
uuid-7ba98bfeef3d45a6b77e285c6328b160,efficacy,0.494926
uuid-7ba98bfeef3d45a6b77e285c6328b160,Ipi,0.353316
uuid-7ba98bfeef3d45a6b77e285c6328b160,OS,0.370973
uuid-7ba98bfeef3d45a6b77e285c6328b160,atezo,0.451426
uuid-7ba98bfeef3d45a6b77e285c6328b160,data,0.413366
uuid-7ba98bfeef3d45a6b77e285c6328b160,clinical trials,0.378095
uuid-7ba98bfeef3d45a6b77e285c6328b160,indication,0.38652
uuid-7ba98bfeef3d45a6b77e285c6328b160,PFS,0.344655
uuid-7ba98bfeef3d45a6b77e285c6328b160,ORR,0.412801
uuid-7ba98bfeef3d45a6b77e285c6328b160,nivo and pembro,0.373551
uuid-7ba98bfeef3d45a6b77e285c6328b160,impressed,0.33433
uuid-7ba98bfeef3d45a6b77e285c6328b160,vs,0.374651
uuid-7ba98bfeef3d45a6b77e285c6328b160,TLs,0.403895
uuid-7ba98bfeef3d45a6b77e285c6328b160,bladder,0.358514
uuid-14c5da8a64734c418e377a6635b8c223,Nivo,0.382053
uuid-14c5da8a64734c418e377a6635b8c223,patients,0.701574
uuid-14c5da8a64734c418e377a6635b8c223,Opdivo,0.361385
uuid-14c5da8a64734c418e377a6635b8c223,therapy,0.477503
uuid-14c5da8a64734c418e377a6635b8c223,nivolumab,0.497679
uuid-14c5da8a64734c418e377a6635b8c223,toxicity,0.364373
uuid-14c5da8a64734c418e377a6635b8c223,regimen,0.554768
uuid-14c5da8a64734c418e377a6635b8c223,treated,0.497918
uuid-14c5da8a64734c418e377a6635b8c223,chemo,0.353271
uuid-14c5da8a64734c418e377a6635b8c223,pts,0.421367
uuid-14c5da8a64734c418e377a6635b8c223,monotherapy,0.419843
uuid-14c5da8a64734c418e377a6635b8c223,treatment,0.571277
uuid-14c5da8a64734c418e377a6635b8c223,using nivo,0.349632
uuid-14c5da8a64734c418e377a6635b8c223,cHL,0.426217
uuid-14c5da8a64734c418e377a6635b8c223,progression,0.397997
uuid-14c5da8a64734c418e377a6635b8c223,chemotherapy,0.450838
uuid-14c5da8a64734c418e377a6635b8c223,respond,0.326117
uuid-14c5da8a64734c418e377a6635b8c223,option,0.395806
uuid-89137e9cdbff40cd9567903654edad03,patients,0.685938
uuid-89137e9cdbff40cd9567903654edad03,Opdivo,0.792565
uuid-89137e9cdbff40cd9567903654edad03,therapy,0.362253
uuid-89137e9cdbff40cd9567903654edad03,nivolumab,0.487911
uuid-89137e9cdbff40cd9567903654edad03,regimen,0.309465
uuid-89137e9cdbff40cd9567903654edad03,treated,0.444338
uuid-89137e9cdbff40cd9567903654edad03,pts,0.399955
uuid-89137e9cdbff40cd9567903654edad03,approval,0.436618
uuid-89137e9cdbff40cd9567903654edad03,preferred,0.318803
uuid-89137e9cdbff40cd9567903654edad03,treatment,0.47106
uuid-89137e9cdbff40cd9567903654edad03,using nivo,0.424661
uuid-89137e9cdbff40cd9567903654edad03,approved,0.432085
uuid-89137e9cdbff40cd9567903654edad03,cHL,0.356211
uuid-89137e9cdbff40cd9567903654edad03,progression,0.303762
uuid-89137e9cdbff40cd9567903654edad03,label,0.38257
uuid-89137e9cdbff40cd9567903654edad03,Keytruda,0.535693
uuid-89137e9cdbff40cd9567903654edad03,option,0.329772
uuid-89137e9cdbff40cd9567903654edad03,flat dosing,0.306224
uuid-9354c805a0cd4904919c2bac4f31fe14,patients,0.671933
uuid-9354c805a0cd4904919c2bac4f31fe14,Opdivo,0.34032
uuid-9354c805a0cd4904919c2bac4f31fe14,therapy,0.683467
uuid-9354c805a0cd4904919c2bac4f31fe14,nivolumab,0.45527
uuid-9354c805a0cd4904919c2bac4f31fe14,regimen,0.532163
uuid-9354c805a0cd4904919c2bac4f31fe14,treated,0.543984
uuid-9354c805a0cd4904919c2bac4f31fe14,melanoma,0.320619
uuid-9354c805a0cd4904919c2bac4f31fe14,chemo,0.379563
uuid-9354c805a0cd4904919c2bac4f31fe14,pts,0.590241
uuid-9354c805a0cd4904919c2bac4f31fe14,monotherapy,0.43488
uuid-9354c805a0cd4904919c2bac4f31fe14,treatment,0.729719
uuid-9354c805a0cd4904919c2bac4f31fe14,response,0.577873
uuid-9354c805a0cd4904919c2bac4f31fe14,PD1,0.534007
uuid-9354c805a0cd4904919c2bac4f31fe14,cHL,0.337949
uuid-9354c805a0cd4904919c2bac4f31fe14,progression,0.805418
uuid-9354c805a0cd4904919c2bac4f31fe14,chemotherapy,0.422551
uuid-9354c805a0cd4904919c2bac4f31fe14,respond,0.572246
uuid-9354c805a0cd4904919c2bac4f31fe14,TL shared,0.332822
uuid-9354c805a0cd4904919c2bac4f31fe14,option,0.342863
uuid-f2542af115fe49c0a92da21737a6e221,BMS,0.360511
uuid-f2542af115fe49c0a92da21737a6e221,1L,0.316722
uuid-f2542af115fe49c0a92da21737a6e221,PDL1,0.638025
uuid-f2542af115fe49c0a92da21737a6e221,efficacy,0.397454
uuid-f2542af115fe49c0a92da21737a6e221,commented,0.341287
uuid-f2542af115fe49c0a92da21737a6e221,Merck,0.321645
uuid-f2542af115fe49c0a92da21737a6e221,OS,0.460006
uuid-f2542af115fe49c0a92da21737a6e221,data,0.686162
uuid-f2542af115fe49c0a92da21737a6e221,PFS,0.426359
uuid-f2542af115fe49c0a92da21737a6e221,ORR,0.422704
uuid-f2542af115fe49c0a92da21737a6e221,nivo and pembro,0.462505
uuid-f2542af115fe49c0a92da21737a6e221,believes,0.40226
uuid-f2542af115fe49c0a92da21737a6e221,impressed,0.429027
uuid-f2542af115fe49c0a92da21737a6e221,feels,0.42853
uuid-f2542af115fe49c0a92da21737a6e221,PDL1 expression,0.491466
uuid-f2542af115fe49c0a92da21737a6e221,biomarker,0.412202
uuid-be81d4f2c2e540f692436eacbfeee74d,patients,0.351721
uuid-be81d4f2c2e540f692436eacbfeee74d,therapy,0.365942
uuid-be81d4f2c2e540f692436eacbfeee74d,chemo,0.358774
uuid-be81d4f2c2e540f692436eacbfeee74d,PD1,0.33378
uuid-be81d4f2c2e540f692436eacbfeee74d,progression,0.42455
uuid-be81d4f2c2e540f692436eacbfeee74d,chemotherapy,0.364188
uuid-be81d4f2c2e540f692436eacbfeee74d,vs,0.343461
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,1L,0.461853
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,PDL1,0.804222
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,TL stated,0.374474
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,2L,0.319923
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,PD-L1,0.611081
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,testing,0.513805
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,PDL1 testing,0.515289
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,NSCLC patients,0.460995
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,nivo and pembro,0.436689
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,believes,0.384298
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,tumor types,0.43628
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,assay,0.376394
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,PDL1 expression,0.688346
uuid-655ed8e1183a45d19fe86ecbc7d6bae0,biomarker,0.666615
uuid-7bf14be176554f67abf9059cc2259270,lung,0.448692
uuid-7bf14be176554f67abf9059cc2259270,1L,0.546109
uuid-7bf14be176554f67abf9059cc2259270,regimen,0.318897
uuid-7bf14be176554f67abf9059cc2259270,melanoma,0.31317
uuid-7bf14be176554f67abf9059cc2259270,RCC,0.454179
uuid-7bf14be176554f67abf9059cc2259270,TL stated,0.390709
uuid-7bf14be176554f67abf9059cc2259270,chemo,0.35016
uuid-7bf14be176554f67abf9059cc2259270,2L,0.479853
uuid-7bf14be176554f67abf9059cc2259270,agents,0.346108
uuid-7bf14be176554f67abf9059cc2259270,preferred,0.371621
uuid-7bf14be176554f67abf9059cc2259270,monotherapy,0.484325
uuid-7bf14be176554f67abf9059cc2259270,combo,0.411844
uuid-7bf14be176554f67abf9059cc2259270,PDL1 testing,0.327045
uuid-7bf14be176554f67abf9059cc2259270,AI,0.330796
uuid-7bf14be176554f67abf9059cc2259270,believes,0.353499
uuid-7bf14be176554f67abf9059cc2259270,chemotherapy,0.340371
uuid-7bf14be176554f67abf9059cc2259270,tumor types,0.321979
uuid-7bf14be176554f67abf9059cc2259270,TL shared,0.353801
uuid-7bf14be176554f67abf9059cc2259270,option,0.552324
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,Nivo,0.413443
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,patients,0.314094
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,pembro,0.415064
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,1L,0.499892
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,chemo,0.497268
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,2L,0.520531
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,pts,0.340942
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,agents,0.384964
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,atezo,0.381489
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,preferred,0.415438
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,monotherapy,0.490189
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,using nivo,0.394282
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,combo,0.445683
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,PD1,0.430158
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,nivo and pembro,0.38744
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,believes,0.441632
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,chemotherapy,0.341664
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,vs,0.330464
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,respond,0.306815
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,feels,0.465119
uuid-b4e6ca28aeb44d10a52c675ed3a37b22,option,0.550011
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,patients,0.561451
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,Opdivo,0.330762
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,therapy,0.49379
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,dose,0.313184
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,toxicity,0.569473
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,regimen,0.743275
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,treated,0.417302
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,combination,0.405261
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,chemo,0.477275
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,pts,0.413731
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,IO,0.348105
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,monotherapy,0.521075
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,treatment,0.724624
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,response,0.452372
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,combo,0.38153
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,PD1,0.385446
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,progression,0.602463
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,chemotherapy,0.476448
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,respond,0.637425
uuid-e68acb9aae0b42a5bd9f3a549c8b9bc7,option,0.444547
uuid-91e4ab9f83c346a0a0411640b45fbd60,Nivo,0.312504
uuid-91e4ab9f83c346a0a0411640b45fbd60,BMS,0.302905
uuid-91e4ab9f83c346a0a0411640b45fbd60,trial,0.784402
uuid-91e4ab9f83c346a0a0411640b45fbd60,combination,0.431985
uuid-91e4ab9f83c346a0a0411640b45fbd60,Ipi,0.342479
uuid-91e4ab9f83c346a0a0411640b45fbd60,combo,0.34422
uuid-91e4ab9f83c346a0a0411640b45fbd60,clinical trials,0.387408
uuid-91e4ab9f83c346a0a0411640b45fbd60,chemotherapy,0.36637
uuid-91e4ab9f83c346a0a0411640b45fbd60,feels,0.328966
uuid-6505e41f220b472782312c88504f8b86,BMS,0.763618
uuid-6505e41f220b472782312c88504f8b86,trial,0.741081
uuid-6505e41f220b472782312c88504f8b86,commented,0.305004
uuid-6505e41f220b472782312c88504f8b86,Merck,0.724356
uuid-6505e41f220b472782312c88504f8b86,data,0.495656
uuid-6505e41f220b472782312c88504f8b86,expressed,0.343183
uuid-6505e41f220b472782312c88504f8b86,clinical trials,0.438328
uuid-6505e41f220b472782312c88504f8b86,indication,0.307539
uuid-6505e41f220b472782312c88504f8b86,impressed,0.364285
uuid-8b8f7cc1800a4dad94191e189ef69712,Nivo,0.50904
uuid-8b8f7cc1800a4dad94191e189ef69712,pembro,0.440997
uuid-8b8f7cc1800a4dad94191e189ef69712,PDL1,0.472056
uuid-8b8f7cc1800a4dad94191e189ef69712,trial,0.451462
uuid-8b8f7cc1800a4dad94191e189ef69712,efficacy,0.733221
uuid-8b8f7cc1800a4dad94191e189ef69712,chemo,0.347741
uuid-8b8f7cc1800a4dad94191e189ef69712,OS,0.687559
uuid-8b8f7cc1800a4dad94191e189ef69712,atezo,0.377988
uuid-8b8f7cc1800a4dad94191e189ef69712,data,0.716614
uuid-8b8f7cc1800a4dad94191e189ef69712,PFS,0.641275
uuid-8b8f7cc1800a4dad94191e189ef69712,ORR,0.689065
uuid-8b8f7cc1800a4dad94191e189ef69712,nivo and pembro,0.600125
uuid-8b8f7cc1800a4dad94191e189ef69712,believes,0.465809
uuid-8b8f7cc1800a4dad94191e189ef69712,impressed,0.52727
uuid-8b8f7cc1800a4dad94191e189ef69712,vs,0.351644
uuid-8b8f7cc1800a4dad94191e189ef69712,feels,0.44474
uuid-8b8f7cc1800a4dad94191e189ef69712,PDL1 expression,0.400841
uuid-3a9fd1903db24ce983cf7cc514e9f69a,patients,0.845607
uuid-3a9fd1903db24ce983cf7cc514e9f69a,Opdivo,0.676077
uuid-3a9fd1903db24ce983cf7cc514e9f69a,therapy,0.430384
uuid-3a9fd1903db24ce983cf7cc514e9f69a,nivolumab,0.428134
uuid-3a9fd1903db24ce983cf7cc514e9f69a,regimen,0.378694
uuid-3a9fd1903db24ce983cf7cc514e9f69a,treated,0.526647
uuid-3a9fd1903db24ce983cf7cc514e9f69a,pts,0.515998
uuid-3a9fd1903db24ce983cf7cc514e9f69a,approval,0.309887
uuid-3a9fd1903db24ce983cf7cc514e9f69a,treatment,0.581734
uuid-3a9fd1903db24ce983cf7cc514e9f69a,cHL,0.39976
uuid-3a9fd1903db24ce983cf7cc514e9f69a,progression,0.566903
uuid-3a9fd1903db24ce983cf7cc514e9f69a,respond,0.449663
uuid-2b78fcca70ed4a70a4d77faab03f6868,Nivo,0.492303
uuid-2b78fcca70ed4a70a4d77faab03f6868,pembro,0.620625
uuid-2b78fcca70ed4a70a4d77faab03f6868,dose,0.301279
uuid-2b78fcca70ed4a70a4d77faab03f6868,trial,0.307667
uuid-2b78fcca70ed4a70a4d77faab03f6868,efficacy,0.358156
uuid-2b78fcca70ed4a70a4d77faab03f6868,2L,0.342163
uuid-2b78fcca70ed4a70a4d77faab03f6868,Ipi,0.309985
uuid-2b78fcca70ed4a70a4d77faab03f6868,atezo,0.601411
uuid-2b78fcca70ed4a70a4d77faab03f6868,preferred,0.405619
uuid-2b78fcca70ed4a70a4d77faab03f6868,nivo and pembro,0.574967
uuid-2b78fcca70ed4a70a4d77faab03f6868,vs,0.57942
uuid-2b78fcca70ed4a70a4d77faab03f6868,feels,0.364254
uuid-cf42ec4899d0472cb7a2d97ad21d860b,pembro,0.322235
uuid-cf42ec4899d0472cb7a2d97ad21d860b,PDL1,0.694934
uuid-cf42ec4899d0472cb7a2d97ad21d860b,Merck,0.353738
uuid-cf42ec4899d0472cb7a2d97ad21d860b,PD-L1,0.536397
uuid-cf42ec4899d0472cb7a2d97ad21d860b,atezo,0.359674
uuid-cf42ec4899d0472cb7a2d97ad21d860b,PD-L1 testing,0.306118
uuid-cf42ec4899d0472cb7a2d97ad21d860b,testing,0.43724
uuid-cf42ec4899d0472cb7a2d97ad21d860b,PDL1 testing,0.382656
uuid-cf42ec4899d0472cb7a2d97ad21d860b,nivo and pembro,0.45896
uuid-cf42ec4899d0472cb7a2d97ad21d860b,assay,0.462272
uuid-cf42ec4899d0472cb7a2d97ad21d860b,PDL1 expression,0.653277
uuid-cf42ec4899d0472cb7a2d97ad21d860b,biomarker,0.443635
uuid-7593c054a7fd4c8da550fd41aa10750a,RTL,0.431729
uuid-7593c054a7fd4c8da550fd41aa10750a,shared,0.348841
uuid-7593c054a7fd4c8da550fd41aa10750a,combination,0.328618
uuid-7593c054a7fd4c8da550fd41aa10750a,combo,0.358152
uuid-7593c054a7fd4c8da550fd41aa10750a,expressed,0.353977
uuid-7593c054a7fd4c8da550fd41aa10750a,LTL,0.313437
uuid-7593c054a7fd4c8da550fd41aa10750a,TLs,0.389642
uuid-394c943563ba4c3399fb2aee58b30a9b,TL,0.492718
uuid-394c943563ba4c3399fb2aee58b30a9b,shared,0.319609
uuid-394c943563ba4c3399fb2aee58b30a9b,TL stated,0.476593
uuid-394c943563ba4c3399fb2aee58b30a9b,institution,0.549702
uuid-394c943563ba4c3399fb2aee58b30a9b,PD-L1,0.630749
uuid-394c943563ba4c3399fb2aee58b30a9b,PD-L1 testing,0.796674
uuid-394c943563ba4c3399fb2aee58b30a9b,testing,0.716521
uuid-394c943563ba4c3399fb2aee58b30a9b,PDL1 testing,0.665596
uuid-394c943563ba4c3399fb2aee58b30a9b,NSCLC patients,0.611953
uuid-394c943563ba4c3399fb2aee58b30a9b,SCCHN,0.332453
uuid-394c943563ba4c3399fb2aee58b30a9b,academic,0.366331
uuid-394c943563ba4c3399fb2aee58b30a9b,assay,0.444541
uuid-34c5f93273ab4532855631554959ffa1,BMS,0.418781
uuid-34c5f93273ab4532855631554959ffa1,efficacy,0.308834
uuid-34c5f93273ab4532855631554959ffa1,regards,0.356965
uuid-34c5f93273ab4532855631554959ffa1,indicated,0.442098
uuid-fba944e718df4220ba9292b531f6a137,patients,0.62663
uuid-fba944e718df4220ba9292b531f6a137,Opdivo,0.730506
uuid-fba944e718df4220ba9292b531f6a137,nivolumab,0.327937
uuid-fba944e718df4220ba9292b531f6a137,regimen,0.312996
uuid-fba944e718df4220ba9292b531f6a137,treated,0.39281
uuid-fba944e718df4220ba9292b531f6a137,pts,0.388547
uuid-fba944e718df4220ba9292b531f6a137,approval,0.313506
uuid-fba944e718df4220ba9292b531f6a137,treatment,0.420806
uuid-fba944e718df4220ba9292b531f6a137,progression,0.348948
uuid-fba944e718df4220ba9292b531f6a137,respond,0.343134
uuid-31848fc3efb24fdab5bbd037704143cc,TL,0.547397
uuid-31848fc3efb24fdab5bbd037704143cc,PDL1,0.529323
uuid-31848fc3efb24fdab5bbd037704143cc,Merck,0.46699
uuid-31848fc3efb24fdab5bbd037704143cc,PD-L1,0.684904
uuid-31848fc3efb24fdab5bbd037704143cc,PD-L1 testing,0.579734
uuid-31848fc3efb24fdab5bbd037704143cc,testing,0.6131
uuid-31848fc3efb24fdab5bbd037704143cc,data,0.314636
uuid-31848fc3efb24fdab5bbd037704143cc,PDL1 testing,0.342974
uuid-31848fc3efb24fdab5bbd037704143cc,assay,0.902097
uuid-31848fc3efb24fdab5bbd037704143cc,PDL1 expression,0.355281
uuid-31848fc3efb24fdab5bbd037704143cc,biomarker,0.491572
uuid-10179758a8cc44e2ba1db1f2d1a0ead3,BMS,0.696634
uuid-10179758a8cc44e2ba1db1f2d1a0ead3,Merck,0.464866
uuid-10179758a8cc44e2ba1db1f2d1a0ead3,clinical trials,0.321198
uuid-3741687ff5c842d498e009ae6f62d2b1,patients,0.363655
uuid-3741687ff5c842d498e009ae6f62d2b1,trial,0.388367
uuid-3741687ff5c842d498e009ae6f62d2b1,treated,0.334465
uuid-3741687ff5c842d498e009ae6f62d2b1,treatment,0.326636
uuid-3741687ff5c842d498e009ae6f62d2b1,chemotherapy,0.330651
uuid-b7b7661bc5564d03bfc11cf61cd5c6af,Nivo,0.573725
uuid-b7b7661bc5564d03bfc11cf61cd5c6af,RTL,0.303866
uuid-b7b7661bc5564d03bfc11cf61cd5c6af,therapy,0.337869
uuid-b7b7661bc5564d03bfc11cf61cd5c6af,nivolumab,0.466818
uuid-b7b7661bc5564d03bfc11cf61cd5c6af,NTL,0.314497
uuid-b7b7661bc5564d03bfc11cf61cd5c6af,approval,0.310513
uuid-b7b7661bc5564d03bfc11cf61cd5c6af,using nivo,0.498086
uuid-b7b7661bc5564d03bfc11cf61cd5c6af,PD1,0.369419
uuid-b7b7661bc5564d03bfc11cf61cd5c6af,cHL,0.619606
uuid-b7b7661bc5564d03bfc11cf61cd5c6af,RTL stated,0.434566
uuid-c14fd1c3d108412a9258467e81b82df3,therapy,0.360199
uuid-c14fd1c3d108412a9258467e81b82df3,nivolumab,0.371411
uuid-c14fd1c3d108412a9258467e81b82df3,cHL,0.481518
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,Opdivo,0.470214
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,pembro,0.386469
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,dose,0.755489
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,shared,0.421758
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,Ipi,0.412913
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,atezo,0.365333
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,preferred,0.363556
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,indication,0.333288
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,approved,0.306426
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,vs,0.389524
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,drug,0.318167
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,Keytruda,0.491668
uuid-eb8ac47cd5e84ed68cb516acff5d61fe,flat dosing,0.781657
uuid-5dee538170f94b75aa03bed3ace986be,PDL1,0.331587
uuid-5dee538170f94b75aa03bed3ace986be,PD-L1,0.420214
uuid-5dee538170f94b75aa03bed3ace986be,testing,0.537616
uuid-5dee538170f94b75aa03bed3ace986be,PDL1 testing,0.501102
uuid-5dee538170f94b75aa03bed3ace986be,NSCLC patients,0.655711
uuid-5dee538170f94b75aa03bed3ace986be,tumor types,0.374637
uuid-5dee538170f94b75aa03bed3ace986be,PD-1,0.323956
uuid-5dee538170f94b75aa03bed3ace986be,biomarker,0.43245
uuid-e5e8217f2b434e3cb52d4e35df76fc6a,Nivo,0.461742
uuid-e5e8217f2b434e3cb52d4e35df76fc6a,patients,0.354487
uuid-e5e8217f2b434e3cb52d4e35df76fc6a,RTL,0.301761
uuid-e5e8217f2b434e3cb52d4e35df76fc6a,regimen,0.358511
uuid-e5e8217f2b434e3cb52d4e35df76fc6a,pts,0.334726
uuid-e5e8217f2b434e3cb52d4e35df76fc6a,Ipi,0.49523
uuid-e5e8217f2b434e3cb52d4e35df76fc6a,monotherapy,0.314244
uuid-e5e8217f2b434e3cb52d4e35df76fc6a,using nivo,0.419327
uuid-e5e8217f2b434e3cb52d4e35df76fc6a,mentioned,0.386181
uuid-e5e8217f2b434e3cb52d4e35df76fc6a,HCP,0.593055
uuid-e5e8217f2b434e3cb52d4e35df76fc6a,impressed,0.307404
uuid-e5e8217f2b434e3cb52d4e35df76fc6a,SCLC,0.357496
uuid-517c644de0f243deb62845714d107d2f,patients,0.594319
uuid-517c644de0f243deb62845714d107d2f,Opdivo,0.469938
uuid-517c644de0f243deb62845714d107d2f,therapy,0.451483
uuid-517c644de0f243deb62845714d107d2f,nivolumab,0.603936
uuid-517c644de0f243deb62845714d107d2f,toxicity,0.48111
uuid-517c644de0f243deb62845714d107d2f,regimen,0.530203
uuid-517c644de0f243deb62845714d107d2f,treated,0.620815
uuid-517c644de0f243deb62845714d107d2f,physicians,0.409312
uuid-517c644de0f243deb62845714d107d2f,treatment,0.627001
uuid-517c644de0f243deb62845714d107d2f,HCP,0.313881
uuid-517c644de0f243deb62845714d107d2f,cHL,0.355289
uuid-517c644de0f243deb62845714d107d2f,progression,0.420832
uuid-bea5ab2c398d4e71ab1c350ab8096cc4,Nivo,0.331974
uuid-bea5ab2c398d4e71ab1c350ab8096cc4,pembro,0.480436
uuid-bea5ab2c398d4e71ab1c350ab8096cc4,dose,0.873918
uuid-bea5ab2c398d4e71ab1c350ab8096cc4,Ipi,0.581693
uuid-bea5ab2c398d4e71ab1c350ab8096cc4,atezo,0.479536
uuid-bea5ab2c398d4e71ab1c350ab8096cc4,vs,0.684479
uuid-bea5ab2c398d4e71ab1c350ab8096cc4,Keytruda,0.319424
uuid-bea5ab2c398d4e71ab1c350ab8096cc4,flat dosing,0.764154
uuid-732928b22bde4b4ab65f94580d743c7e,Opdivo,0.509511
uuid-732928b22bde4b4ab65f94580d743c7e,dose,0.617606
uuid-732928b22bde4b4ab65f94580d743c7e,shared,0.411054
uuid-732928b22bde4b4ab65f94580d743c7e,Ipi,0.309577
uuid-732928b22bde4b4ab65f94580d743c7e,approval,0.340359
uuid-732928b22bde4b4ab65f94580d743c7e,indication,0.324389
uuid-732928b22bde4b4ab65f94580d743c7e,approved,0.375324
uuid-732928b22bde4b4ab65f94580d743c7e,HCP,0.306947
uuid-732928b22bde4b4ab65f94580d743c7e,label,0.398031
uuid-732928b22bde4b4ab65f94580d743c7e,Keytruda,0.370726
uuid-732928b22bde4b4ab65f94580d743c7e,flat dosing,0.776661
uuid-a0590fb0d91448259e69f40f122078af,Nivo,0.504791
uuid-a0590fb0d91448259e69f40f122078af,pembro,0.712697
uuid-a0590fb0d91448259e69f40f122078af,dose,0.354813
uuid-a0590fb0d91448259e69f40f122078af,BMS,0.305661
uuid-a0590fb0d91448259e69f40f122078af,1L,0.314169
uuid-a0590fb0d91448259e69f40f122078af,trial,0.462968
uuid-a0590fb0d91448259e69f40f122078af,efficacy,0.577853
uuid-a0590fb0d91448259e69f40f122078af,2L,0.362418
uuid-a0590fb0d91448259e69f40f122078af,Ipi,0.471889
uuid-a0590fb0d91448259e69f40f122078af,OS,0.315189
uuid-a0590fb0d91448259e69f40f122078af,atezo,0.628242
uuid-a0590fb0d91448259e69f40f122078af,data,0.602625
uuid-a0590fb0d91448259e69f40f122078af,combo,0.368981
uuid-a0590fb0d91448259e69f40f122078af,indication,0.351166
uuid-a0590fb0d91448259e69f40f122078af,ORR,0.349563
uuid-a0590fb0d91448259e69f40f122078af,approved,0.336009
uuid-a0590fb0d91448259e69f40f122078af,nivo and pembro,0.466659
uuid-a0590fb0d91448259e69f40f122078af,impressed,0.468171
uuid-a0590fb0d91448259e69f40f122078af,vs,0.588649
uuid-a0590fb0d91448259e69f40f122078af,TLs,0.331365
uuid-a0590fb0d91448259e69f40f122078af,feels,0.389549
uuid-a0590fb0d91448259e69f40f122078af,flat dosing,0.336097
uuid-a4fe8b879bee467ebec6c36fb2fa5079,Nivo,0.348179
uuid-a4fe8b879bee467ebec6c36fb2fa5079,pembro,0.360016
uuid-a4fe8b879bee467ebec6c36fb2fa5079,dose,0.349726
uuid-a4fe8b879bee467ebec6c36fb2fa5079,nivolumab,0.457305
uuid-a4fe8b879bee467ebec6c36fb2fa5079,1L,0.435513
uuid-a4fe8b879bee467ebec6c36fb2fa5079,toxicity,0.338378
uuid-a4fe8b879bee467ebec6c36fb2fa5079,regimen,0.519217
uuid-a4fe8b879bee467ebec6c36fb2fa5079,shared,0.317079
uuid-a4fe8b879bee467ebec6c36fb2fa5079,RCC,0.513531
uuid-a4fe8b879bee467ebec6c36fb2fa5079,combination,0.533814
uuid-a4fe8b879bee467ebec6c36fb2fa5079,chemo,0.302446
uuid-a4fe8b879bee467ebec6c36fb2fa5079,2L,0.586205
uuid-a4fe8b879bee467ebec6c36fb2fa5079,agents,0.373845
uuid-a4fe8b879bee467ebec6c36fb2fa5079,Ipi,0.445758
uuid-a4fe8b879bee467ebec6c36fb2fa5079,approval,0.368902
uuid-a4fe8b879bee467ebec6c36fb2fa5079,atezo,0.378749
uuid-a4fe8b879bee467ebec6c36fb2fa5079,preferred,0.636329
uuid-a4fe8b879bee467ebec6c36fb2fa5079,monotherapy,0.557403
uuid-a4fe8b879bee467ebec6c36fb2fa5079,using nivo,0.534924
uuid-a4fe8b879bee467ebec6c36fb2fa5079,combo,0.564143
uuid-a4fe8b879bee467ebec6c36fb2fa5079,clinical trials,0.403812
uuid-a4fe8b879bee467ebec6c36fb2fa5079,indication,0.354748
uuid-a4fe8b879bee467ebec6c36fb2fa5079,approved,0.548982
uuid-a4fe8b879bee467ebec6c36fb2fa5079,SCCHN,0.378725
uuid-a4fe8b879bee467ebec6c36fb2fa5079,chemotherapy,0.31146
uuid-a4fe8b879bee467ebec6c36fb2fa5079,RTL stated,0.494341
uuid-a4fe8b879bee467ebec6c36fb2fa5079,option,0.518401
uuid-a4fe8b879bee467ebec6c36fb2fa5079,bladder,0.419471
uuid-ba630801b81d4388a456a5e05c5bf98b,therapy,0.429456
uuid-ba630801b81d4388a456a5e05c5bf98b,dose,0.403185
uuid-ba630801b81d4388a456a5e05c5bf98b,nivolumab,0.399277
uuid-ba630801b81d4388a456a5e05c5bf98b,toxicity,0.310271
uuid-ba630801b81d4388a456a5e05c5bf98b,PD1,0.393325
uuid-ba630801b81d4388a456a5e05c5bf98b,cHL,0.39245
uuid-ba630801b81d4388a456a5e05c5bf98b,PD-1,0.379061
uuid-9c14ab2ee2554e1789fceffaefb40c57,patients,0.775145
uuid-9c14ab2ee2554e1789fceffaefb40c57,Opdivo,0.68084
uuid-9c14ab2ee2554e1789fceffaefb40c57,therapy,0.377262
uuid-9c14ab2ee2554e1789fceffaefb40c57,dose,0.321816
uuid-9c14ab2ee2554e1789fceffaefb40c57,nivolumab,0.408188
uuid-9c14ab2ee2554e1789fceffaefb40c57,toxicity,0.531408
uuid-9c14ab2ee2554e1789fceffaefb40c57,regimen,0.535876
uuid-9c14ab2ee2554e1789fceffaefb40c57,treated,0.503353
uuid-9c14ab2ee2554e1789fceffaefb40c57,pts,0.445523
uuid-9c14ab2ee2554e1789fceffaefb40c57,treatment,0.603202
uuid-9c14ab2ee2554e1789fceffaefb40c57,lung cancer,0.347467
uuid-9c14ab2ee2554e1789fceffaefb40c57,progression,0.514879
uuid-9c14ab2ee2554e1789fceffaefb40c57,respond,0.425273
uuid-504c41f0781d4e509481888050813726,BMS,0.48327
uuid-504c41f0781d4e509481888050813726,commented,0.409826
uuid-504c41f0781d4e509481888050813726,Merck,0.374486
uuid-504c41f0781d4e509481888050813726,OS,0.332835
uuid-504c41f0781d4e509481888050813726,data,0.381673
uuid-504c41f0781d4e509481888050813726,expressed,0.424257
uuid-504c41f0781d4e509481888050813726,mentioned,0.542169
uuid-504c41f0781d4e509481888050813726,PFS,0.370469
uuid-504c41f0781d4e509481888050813726,impressed,0.346586
uuid-504c41f0781d4e509481888050813726,LTL,0.333423
uuid-dc5ac04d31a84ca9a2eeb4cc562585fa,institution,0.499275
uuid-dc5ac04d31a84ca9a2eeb4cc562585fa,AI,0.683444
uuid-dc5ac04d31a84ca9a2eeb4cc562585fa,oncology,0.519567
uuid-dc5ac04d31a84ca9a2eeb4cc562585fa,drug,0.426594
uuid-dc5ac04d31a84ca9a2eeb4cc562585fa,NCCN,0.386288
uuid-657c622df54145959e72d4e722b8591e,Nivo,0.390347
uuid-657c622df54145959e72d4e722b8591e,trial,0.526494
uuid-657c622df54145959e72d4e722b8591e,efficacy,0.514683
uuid-657c622df54145959e72d4e722b8591e,combination,0.450945
uuid-657c622df54145959e72d4e722b8591e,chemo,0.318591
uuid-657c622df54145959e72d4e722b8591e,agents,0.30523
uuid-657c622df54145959e72d4e722b8591e,Ipi,0.380516
uuid-657c622df54145959e72d4e722b8591e,OS,0.488806
uuid-657c622df54145959e72d4e722b8591e,regards,0.328327
uuid-657c622df54145959e72d4e722b8591e,data,0.433052
uuid-657c622df54145959e72d4e722b8591e,combo,0.447455
uuid-657c622df54145959e72d4e722b8591e,PFS,0.444789
uuid-657c622df54145959e72d4e722b8591e,ORR,0.491674
uuid-657c622df54145959e72d4e722b8591e,nivo and pembro,0.438458
uuid-657c622df54145959e72d4e722b8591e,believes,0.492678
uuid-657c622df54145959e72d4e722b8591e,impressed,0.430901
uuid-657c622df54145959e72d4e722b8591e,SCLC,0.335514
uuid-657c622df54145959e72d4e722b8591e,feels,0.393878
uuid-c6f96f428da44b94bd51bc8fa6158996,patients,0.605766
uuid-c6f96f428da44b94bd51bc8fa6158996,Opdivo,0.33936
uuid-c6f96f428da44b94bd51bc8fa6158996,therapy,0.321815
uuid-c6f96f428da44b94bd51bc8fa6158996,toxicity,0.594313
uuid-c6f96f428da44b94bd51bc8fa6158996,regimen,0.436371
uuid-c6f96f428da44b94bd51bc8fa6158996,treated,0.43908
uuid-c6f96f428da44b94bd51bc8fa6158996,treatment,0.48692
uuid-c6f96f428da44b94bd51bc8fa6158996,progression,0.391899
uuid-c6f96f428da44b94bd51bc8fa6158996,respond,0.427652
uuid-e1d06d0f7eee488cb7b360cf56e9b947,patients,0.579966
uuid-e1d06d0f7eee488cb7b360cf56e9b947,therapy,0.718372
uuid-e1d06d0f7eee488cb7b360cf56e9b947,nivolumab,0.459422
uuid-e1d06d0f7eee488cb7b360cf56e9b947,treated,0.35765
uuid-e1d06d0f7eee488cb7b360cf56e9b947,chemo,0.318057
uuid-e1d06d0f7eee488cb7b360cf56e9b947,treatment,0.533315
uuid-e1d06d0f7eee488cb7b360cf56e9b947,response,0.375565
uuid-e1d06d0f7eee488cb7b360cf56e9b947,PD1,0.573309
uuid-e1d06d0f7eee488cb7b360cf56e9b947,cHL,0.516227
uuid-e1d06d0f7eee488cb7b360cf56e9b947,progression,0.51784
uuid-e1d06d0f7eee488cb7b360cf56e9b947,chemotherapy,0.412464
uuid-e1d06d0f7eee488cb7b360cf56e9b947,respond,0.382477
uuid-e1d06d0f7eee488cb7b360cf56e9b947,immunotherapy,0.315287
uuid-e1d06d0f7eee488cb7b360cf56e9b947,PD-1,0.470075
uuid-e51cf48a58bb4825a7abb98fac66f077,pembro,0.302495
uuid-e51cf48a58bb4825a7abb98fac66f077,BMS,0.479916
uuid-e51cf48a58bb4825a7abb98fac66f077,PDL1,0.750111
uuid-e51cf48a58bb4825a7abb98fac66f077,trial,0.458847
uuid-e51cf48a58bb4825a7abb98fac66f077,efficacy,0.608644
uuid-e51cf48a58bb4825a7abb98fac66f077,Merck,0.460606
uuid-e51cf48a58bb4825a7abb98fac66f077,PD-L1,0.378863
uuid-e51cf48a58bb4825a7abb98fac66f077,OS,0.598587
uuid-e51cf48a58bb4825a7abb98fac66f077,atezo,0.319446
uuid-e51cf48a58bb4825a7abb98fac66f077,regards,0.374082
uuid-e51cf48a58bb4825a7abb98fac66f077,data,0.613933
uuid-e51cf48a58bb4825a7abb98fac66f077,PFS,0.605251
uuid-e51cf48a58bb4825a7abb98fac66f077,ORR,0.599278
uuid-e51cf48a58bb4825a7abb98fac66f077,nivo and pembro,0.585539
uuid-e51cf48a58bb4825a7abb98fac66f077,believes,0.440552
uuid-e51cf48a58bb4825a7abb98fac66f077,impressed,0.35262
uuid-e51cf48a58bb4825a7abb98fac66f077,feels,0.346016
uuid-e51cf48a58bb4825a7abb98fac66f077,assay,0.424943
uuid-e51cf48a58bb4825a7abb98fac66f077,PDL1 expression,0.635006
uuid-e51cf48a58bb4825a7abb98fac66f077,biomarker,0.512886
uuid-5531555417b04271afcd6954839a9ddc,Nivo,0.565034
uuid-5531555417b04271afcd6954839a9ddc,patients,0.301373
uuid-5531555417b04271afcd6954839a9ddc,pembro,0.638644
uuid-5531555417b04271afcd6954839a9ddc,dose,0.483924
uuid-5531555417b04271afcd6954839a9ddc,1L,0.539943
uuid-5531555417b04271afcd6954839a9ddc,efficacy,0.306026
uuid-5531555417b04271afcd6954839a9ddc,regimen,0.362315
uuid-5531555417b04271afcd6954839a9ddc,combination,0.345066
uuid-5531555417b04271afcd6954839a9ddc,chemo,0.330147
uuid-5531555417b04271afcd6954839a9ddc,2L,0.666596
uuid-5531555417b04271afcd6954839a9ddc,agents,0.407353
uuid-5531555417b04271afcd6954839a9ddc,Ipi,0.443221
uuid-5531555417b04271afcd6954839a9ddc,approval,0.352737
uuid-5531555417b04271afcd6954839a9ddc,atezo,0.659968
uuid-5531555417b04271afcd6954839a9ddc,preferred,0.669545
uuid-5531555417b04271afcd6954839a9ddc,monotherapy,0.55078
uuid-5531555417b04271afcd6954839a9ddc,using nivo,0.573202
uuid-5531555417b04271afcd6954839a9ddc,combo,0.429106
uuid-5531555417b04271afcd6954839a9ddc,indication,0.359156
uuid-5531555417b04271afcd6954839a9ddc,approved,0.489943
uuid-5531555417b04271afcd6954839a9ddc,vs,0.495091
uuid-5531555417b04271afcd6954839a9ddc,feels,0.358933
uuid-5531555417b04271afcd6954839a9ddc,RTL stated,0.338697
uuid-5531555417b04271afcd6954839a9ddc,option,0.544439
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,patients,0.546024
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,therapy,0.336691
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,nivolumab,0.381354
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,lung,0.301436
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,1L,0.47488
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,regimen,0.514423
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,treated,0.487039
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,melanoma,0.363521
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,RCC,0.566264
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,TL stated,0.460103
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,2L,0.479748
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,pts,0.440365
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,preferred,0.519508
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,monotherapy,0.523062
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,treatment,0.446052
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,using nivo,0.459422
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,combo,0.334799
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,PDL1 testing,0.351294
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,NSCLC patients,0.34041
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,SCCHN,0.438446
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,progression,0.386632
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,RTL stated,0.562165
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,TL shared,0.538385
uuid-240512bd6b72434ebcfd5dbdc1e84ab0,option,0.490461
uuid-7653a4ca726442d0b0b273cd9e16423d,TL,0.339196
uuid-7653a4ca726442d0b0b273cd9e16423d,PDL1,0.331931
uuid-7653a4ca726442d0b0b273cd9e16423d,TL stated,0.357761
uuid-7653a4ca726442d0b0b273cd9e16423d,tumor,0.497493
uuid-7653a4ca726442d0b0b273cd9e16423d,PD-L1,0.588648
uuid-7653a4ca726442d0b0b273cd9e16423d,PD-L1 testing,0.471193
uuid-7653a4ca726442d0b0b273cd9e16423d,testing,0.622581
uuid-7653a4ca726442d0b0b273cd9e16423d,PDL1 testing,0.415256
uuid-7653a4ca726442d0b0b273cd9e16423d,NSCLC patients,0.505163
uuid-7653a4ca726442d0b0b273cd9e16423d,assay,0.440161
uuid-7653a4ca726442d0b0b273cd9e16423d,biomarker,0.456909
uuid-46eb5a084d234e798e317d4f0b379158,patients,0.772924
uuid-46eb5a084d234e798e317d4f0b379158,therapy,0.5911
uuid-46eb5a084d234e798e317d4f0b379158,nivolumab,0.304092
uuid-46eb5a084d234e798e317d4f0b379158,1L,0.315374
uuid-46eb5a084d234e798e317d4f0b379158,regimen,0.382842
uuid-46eb5a084d234e798e317d4f0b379158,treated,0.361368
uuid-46eb5a084d234e798e317d4f0b379158,chemo,0.385402
uuid-46eb5a084d234e798e317d4f0b379158,pts,0.573126
uuid-46eb5a084d234e798e317d4f0b379158,monotherapy,0.458941
uuid-46eb5a084d234e798e317d4f0b379158,treatment,0.540143
uuid-46eb5a084d234e798e317d4f0b379158,progression,0.548001
uuid-46eb5a084d234e798e317d4f0b379158,chemotherapy,0.431072
uuid-46eb5a084d234e798e317d4f0b379158,respond,0.323416
uuid-46eb5a084d234e798e317d4f0b379158,option,0.502633
uuid-ed213927ac444977b702b18ea0b246a0,Nivo,0.440074
uuid-ed213927ac444977b702b18ea0b246a0,pembro,0.334343
uuid-ed213927ac444977b702b18ea0b246a0,NSCLC,0.353693
uuid-ed213927ac444977b702b18ea0b246a0,1L,0.610058
uuid-ed213927ac444977b702b18ea0b246a0,regimen,0.421501
uuid-ed213927ac444977b702b18ea0b246a0,RCC,0.495182
uuid-ed213927ac444977b702b18ea0b246a0,combination,0.485321
uuid-ed213927ac444977b702b18ea0b246a0,chemo,0.448035
uuid-ed213927ac444977b702b18ea0b246a0,2L,0.670977
uuid-ed213927ac444977b702b18ea0b246a0,IO,0.533551
uuid-ed213927ac444977b702b18ea0b246a0,agents,0.485257
uuid-ed213927ac444977b702b18ea0b246a0,Ipi,0.337044
uuid-ed213927ac444977b702b18ea0b246a0,atezo,0.429251
uuid-ed213927ac444977b702b18ea0b246a0,preferred,0.593859
uuid-ed213927ac444977b702b18ea0b246a0,monotherapy,0.667449
uuid-ed213927ac444977b702b18ea0b246a0,using nivo,0.432786
uuid-ed213927ac444977b702b18ea0b246a0,combo,0.608415
uuid-ed213927ac444977b702b18ea0b246a0,PD1,0.38783
uuid-ed213927ac444977b702b18ea0b246a0,believes,0.445228
uuid-ed213927ac444977b702b18ea0b246a0,TLs,0.319158
uuid-ed213927ac444977b702b18ea0b246a0,feels,0.349155
uuid-ed213927ac444977b702b18ea0b246a0,RTL stated,0.406347
uuid-ed213927ac444977b702b18ea0b246a0,option,0.539272
uuid-1ebbe9d2fbae461eacf06557c2ca3977,regimen,0.310309
uuid-1ebbe9d2fbae461eacf06557c2ca3977,treated,0.340563
uuid-1ebbe9d2fbae461eacf06557c2ca3977,treatment,0.354313
uuid-1ebbe9d2fbae461eacf06557c2ca3977,respond,0.360344
uuid-7c1828c2b300417d9dec2e382af479e7,patients,0.397333
uuid-7c1828c2b300417d9dec2e382af479e7,therapy,0.306804
uuid-7c1828c2b300417d9dec2e382af479e7,regimen,0.399946
uuid-7c1828c2b300417d9dec2e382af479e7,chemo,0.468259
uuid-7c1828c2b300417d9dec2e382af479e7,pts,0.514127
uuid-7c1828c2b300417d9dec2e382af479e7,OS,0.303923
uuid-7c1828c2b300417d9dec2e382af479e7,treatment,0.33795
uuid-7c1828c2b300417d9dec2e382af479e7,response,0.70698
uuid-7c1828c2b300417d9dec2e382af479e7,PD1,0.364255
uuid-7c1828c2b300417d9dec2e382af479e7,progression,0.684063
uuid-7c1828c2b300417d9dec2e382af479e7,believes,0.334728
uuid-7c1828c2b300417d9dec2e382af479e7,chemotherapy,0.301906
uuid-7c1828c2b300417d9dec2e382af479e7,respond,0.578053
uuid-0549a2129bd84c7d82bd6f6374fe4995,patients,0.755607
uuid-0549a2129bd84c7d82bd6f6374fe4995,Opdivo,0.485799
uuid-0549a2129bd84c7d82bd6f6374fe4995,therapy,0.314786
uuid-0549a2129bd84c7d82bd6f6374fe4995,treated,0.387343
uuid-0549a2129bd84c7d82bd6f6374fe4995,pts,0.439604
uuid-0549a2129bd84c7d82bd6f6374fe4995,PD-L1 testing,0.381938
uuid-0549a2129bd84c7d82bd6f6374fe4995,testing,0.371872
uuid-0549a2129bd84c7d82bd6f6374fe4995,treatment,0.472539
uuid-0549a2129bd84c7d82bd6f6374fe4995,NSCLC patients,0.429513
uuid-0549a2129bd84c7d82bd6f6374fe4995,progression,0.475311
uuid-0549a2129bd84c7d82bd6f6374fe4995,respond,0.410169
uuid-4ac3aef773a9414ba2029dddf9583591,patients,0.670167
uuid-4ac3aef773a9414ba2029dddf9583591,Opdivo,0.701635
uuid-4ac3aef773a9414ba2029dddf9583591,therapy,0.415713
uuid-4ac3aef773a9414ba2029dddf9583591,dose,0.375297
uuid-4ac3aef773a9414ba2029dddf9583591,nivolumab,0.423286
uuid-4ac3aef773a9414ba2029dddf9583591,toxicity,0.43537
uuid-4ac3aef773a9414ba2029dddf9583591,regimen,0.435459
uuid-4ac3aef773a9414ba2029dddf9583591,treated,0.473637
uuid-4ac3aef773a9414ba2029dddf9583591,pts,0.316205
uuid-4ac3aef773a9414ba2029dddf9583591,physicians,0.375487
uuid-4ac3aef773a9414ba2029dddf9583591,treatment,0.565136
uuid-4ac3aef773a9414ba2029dddf9583591,cHL,0.347307
uuid-4ac3aef773a9414ba2029dddf9583591,progression,0.38512
uuid-4ac3aef773a9414ba2029dddf9583591,respond,0.384329
uuid-4ac3aef773a9414ba2029dddf9583591,flat dosing,0.329545
uuid-9827f4c0c4a4479b8b9c41b2d9ec546c,Opdivo,0.571022
uuid-9827f4c0c4a4479b8b9c41b2d9ec546c,TL,0.389656
uuid-9827f4c0c4a4479b8b9c41b2d9ec546c,TL stated,0.346386
uuid-9827f4c0c4a4479b8b9c41b2d9ec546c,approval,0.328717
uuid-9827f4c0c4a4479b8b9c41b2d9ec546c,physicians,0.475347
uuid-9827f4c0c4a4479b8b9c41b2d9ec546c,PD-L1 testing,0.39722
uuid-9827f4c0c4a4479b8b9c41b2d9ec546c,testing,0.314313
uuid-9827f4c0c4a4479b8b9c41b2d9ec546c,PDL1 testing,0.36024
uuid-9827f4c0c4a4479b8b9c41b2d9ec546c,HCP,0.321279
uuid-7ca10cbba4154156b2c31d1e5e8f9f6f,Opdivo,0.342434
uuid-7ca10cbba4154156b2c31d1e5e8f9f6f,approval,0.444876
uuid-7ca10cbba4154156b2c31d1e5e8f9f6f,preferred,0.402192
uuid-7ca10cbba4154156b2c31d1e5e8f9f6f,using nivo,0.328951
uuid-7ca10cbba4154156b2c31d1e5e8f9f6f,clinical trials,0.351029
uuid-7ca10cbba4154156b2c31d1e5e8f9f6f,PDL1 testing,0.349814
uuid-7ca10cbba4154156b2c31d1e5e8f9f6f,approved,0.453472
uuid-7ca10cbba4154156b2c31d1e5e8f9f6f,label,0.457581
uuid-7ca10cbba4154156b2c31d1e5e8f9f6f,RTL stated,0.303085
uuid-4e79f1eda73943169e67e3b0170dbb05,Opdivo,0.527369
uuid-4e79f1eda73943169e67e3b0170dbb05,shared,0.311837
uuid-4e79f1eda73943169e67e3b0170dbb05,commented,0.391335
uuid-4e79f1eda73943169e67e3b0170dbb05,TL stated,0.387767
uuid-4e79f1eda73943169e67e3b0170dbb05,stated,0.391885
uuid-4e79f1eda73943169e67e3b0170dbb05,approval,0.372471
uuid-4e79f1eda73943169e67e3b0170dbb05,physicians,0.402359
uuid-4e79f1eda73943169e67e3b0170dbb05,using nivo,0.325151
uuid-4e79f1eda73943169e67e3b0170dbb05,mentioned,0.327718
uuid-4e79f1eda73943169e67e3b0170dbb05,SCCHN,0.368679
uuid-4e79f1eda73943169e67e3b0170dbb05,HCP,0.350664
uuid-4e79f1eda73943169e67e3b0170dbb05,impressed,0.306653
uuid-4e79f1eda73943169e67e3b0170dbb05,LTL,0.374012
uuid-4e79f1eda73943169e67e3b0170dbb05,TLs,0.3613
uuid-4e79f1eda73943169e67e3b0170dbb05,Regional TL,0.366028
uuid-647cb7dd521442d78f0a15d135ca0fe3,Nivo,0.303902
uuid-647cb7dd521442d78f0a15d135ca0fe3,patients,0.645176
uuid-647cb7dd521442d78f0a15d135ca0fe3,therapy,0.38703
uuid-647cb7dd521442d78f0a15d135ca0fe3,nivolumab,0.379635
uuid-647cb7dd521442d78f0a15d135ca0fe3,toxicity,0.565678
uuid-647cb7dd521442d78f0a15d135ca0fe3,regimen,0.722323
uuid-647cb7dd521442d78f0a15d135ca0fe3,treated,0.4394
uuid-647cb7dd521442d78f0a15d135ca0fe3,combination,0.371461
uuid-647cb7dd521442d78f0a15d135ca0fe3,chemo,0.429989
uuid-647cb7dd521442d78f0a15d135ca0fe3,pts,0.525453
uuid-647cb7dd521442d78f0a15d135ca0fe3,Ipi,0.351591
uuid-647cb7dd521442d78f0a15d135ca0fe3,monotherapy,0.438603
uuid-647cb7dd521442d78f0a15d135ca0fe3,treatment,0.590611
uuid-647cb7dd521442d78f0a15d135ca0fe3,response,0.377884
uuid-647cb7dd521442d78f0a15d135ca0fe3,combo,0.393798
uuid-647cb7dd521442d78f0a15d135ca0fe3,PD1,0.367693
uuid-647cb7dd521442d78f0a15d135ca0fe3,progression,0.586919
uuid-647cb7dd521442d78f0a15d135ca0fe3,chemotherapy,0.407934
uuid-647cb7dd521442d78f0a15d135ca0fe3,respond,0.577293
uuid-647cb7dd521442d78f0a15d135ca0fe3,option,0.317742
uuid-b36c5e9aaf4e48779d1917a2bfd631ba,Nivo,0.337769
uuid-b36c5e9aaf4e48779d1917a2bfd631ba,PDL1,0.363963
uuid-b36c5e9aaf4e48779d1917a2bfd631ba,efficacy,0.348111
uuid-b36c5e9aaf4e48779d1917a2bfd631ba,chemo,0.420465
uuid-b36c5e9aaf4e48779d1917a2bfd631ba,pts,0.365711
uuid-b36c5e9aaf4e48779d1917a2bfd631ba,response,0.415862
uuid-b36c5e9aaf4e48779d1917a2bfd631ba,PDL1 expression,0.38353
uuid-e31fb90cf9404ea78dca7163cfafec28,patients,0.655619
uuid-e31fb90cf9404ea78dca7163cfafec28,therapy,0.446274
uuid-e31fb90cf9404ea78dca7163cfafec28,1L,0.372422
uuid-e31fb90cf9404ea78dca7163cfafec28,treated,0.327239
uuid-e31fb90cf9404ea78dca7163cfafec28,chemo,0.397126
uuid-e31fb90cf9404ea78dca7163cfafec28,2L,0.304662
uuid-e31fb90cf9404ea78dca7163cfafec28,pts,0.606414
uuid-e31fb90cf9404ea78dca7163cfafec28,monotherapy,0.340751
uuid-e31fb90cf9404ea78dca7163cfafec28,treatment,0.439392
uuid-e31fb90cf9404ea78dca7163cfafec28,using nivo,0.329491
uuid-e31fb90cf9404ea78dca7163cfafec28,response,0.395742
uuid-e31fb90cf9404ea78dca7163cfafec28,NSCLC patients,0.386555
uuid-e31fb90cf9404ea78dca7163cfafec28,PD1,0.310262
uuid-e31fb90cf9404ea78dca7163cfafec28,progression,0.551099
uuid-e31fb90cf9404ea78dca7163cfafec28,chemotherapy,0.311006
uuid-e31fb90cf9404ea78dca7163cfafec28,respond,0.43342
uuid-e31fb90cf9404ea78dca7163cfafec28,option,0.436116
uuid-80f1063224fa4466b80ba745a72e847a,patients,0.305793
uuid-80f1063224fa4466b80ba745a72e847a,therapy,0.504628
uuid-80f1063224fa4466b80ba745a72e847a,regimen,0.442194
uuid-80f1063224fa4466b80ba745a72e847a,combination,0.343088
uuid-80f1063224fa4466b80ba745a72e847a,chemo,0.500652
uuid-80f1063224fa4466b80ba745a72e847a,pts,0.42541
uuid-80f1063224fa4466b80ba745a72e847a,IO,0.375936
uuid-80f1063224fa4466b80ba745a72e847a,monotherapy,0.424112
uuid-80f1063224fa4466b80ba745a72e847a,treatment,0.483864
uuid-80f1063224fa4466b80ba745a72e847a,response,0.667832
uuid-80f1063224fa4466b80ba745a72e847a,combo,0.340878
uuid-80f1063224fa4466b80ba745a72e847a,AI,0.304979
uuid-80f1063224fa4466b80ba745a72e847a,PD1,0.546118
uuid-80f1063224fa4466b80ba745a72e847a,progression,0.616388
uuid-80f1063224fa4466b80ba745a72e847a,believes,0.356905
uuid-80f1063224fa4466b80ba745a72e847a,chemotherapy,0.457325
uuid-80f1063224fa4466b80ba745a72e847a,respond,0.531427
uuid-80f1063224fa4466b80ba745a72e847a,immunotherapy,0.368471
uuid-80f1063224fa4466b80ba745a72e847a,PD-1,0.343471
uuid-3415ab5c4b6548aba5b72c049ceb279f,dose,0.341914
uuid-3415ab5c4b6548aba5b72c049ceb279f,BMS,0.341961
uuid-3415ab5c4b6548aba5b72c049ceb279f,efficacy,0.401238
uuid-3415ab5c4b6548aba5b72c049ceb279f,discussed,0.407695
uuid-3415ab5c4b6548aba5b72c049ceb279f,commented,0.344693
uuid-3415ab5c4b6548aba5b72c049ceb279f,regards,0.434171
uuid-3415ab5c4b6548aba5b72c049ceb279f,data,0.348933
uuid-3415ab5c4b6548aba5b72c049ceb279f,expressed,0.303775
uuid-3415ab5c4b6548aba5b72c049ceb279f,indication,0.305439
uuid-3415ab5c4b6548aba5b72c049ceb279f,impressed,0.313199
uuid-3415ab5c4b6548aba5b72c049ceb279f,vs,0.32677
uuid-3415ab5c4b6548aba5b72c049ceb279f,TLs,0.506908
uuid-3415ab5c4b6548aba5b72c049ceb279f,flat dosing,0.333673
uuid-3412dd4ef0214c9497f873dd214d3323,PDL1,0.494323
uuid-3412dd4ef0214c9497f873dd214d3323,efficacy,0.466352
uuid-3412dd4ef0214c9497f873dd214d3323,chemo,0.404323
uuid-3412dd4ef0214c9497f873dd214d3323,OS,0.750042
uuid-3412dd4ef0214c9497f873dd214d3323,response,0.466297
uuid-3412dd4ef0214c9497f873dd214d3323,data,0.351356
uuid-3412dd4ef0214c9497f873dd214d3323,PFS,0.718414
uuid-3412dd4ef0214c9497f873dd214d3323,ORR,0.639041
uuid-3412dd4ef0214c9497f873dd214d3323,nivo and pembro,0.412278
uuid-3412dd4ef0214c9497f873dd214d3323,progression,0.321543
uuid-3412dd4ef0214c9497f873dd214d3323,believes,0.424609
uuid-3412dd4ef0214c9497f873dd214d3323,chemotherapy,0.310964
uuid-3412dd4ef0214c9497f873dd214d3323,respond,0.328642
uuid-3412dd4ef0214c9497f873dd214d3323,PDL1 expression,0.419145
uuid-3412dd4ef0214c9497f873dd214d3323,biomarker,0.333023
uuid-ef347461a28e4fc4971fe0a3ad236a32,Nivo,0.302963
uuid-ef347461a28e4fc4971fe0a3ad236a32,patients,0.331644
uuid-ef347461a28e4fc4971fe0a3ad236a32,1L,0.462743
uuid-ef347461a28e4fc4971fe0a3ad236a32,regimen,0.324895
uuid-ef347461a28e4fc4971fe0a3ad236a32,melanoma,0.334608
uuid-ef347461a28e4fc4971fe0a3ad236a32,RCC,0.491444
uuid-ef347461a28e4fc4971fe0a3ad236a32,TL stated,0.300474
uuid-ef347461a28e4fc4971fe0a3ad236a32,chemo,0.33011
uuid-ef347461a28e4fc4971fe0a3ad236a32,2L,0.411294
uuid-ef347461a28e4fc4971fe0a3ad236a32,pts,0.47571
uuid-ef347461a28e4fc4971fe0a3ad236a32,stated,0.321208
uuid-ef347461a28e4fc4971fe0a3ad236a32,monotherapy,0.456571
uuid-ef347461a28e4fc4971fe0a3ad236a32,using nivo,0.42758
uuid-ef347461a28e4fc4971fe0a3ad236a32,combo,0.330174
uuid-ef347461a28e4fc4971fe0a3ad236a32,PD1,0.384499
uuid-ef347461a28e4fc4971fe0a3ad236a32,SCCHN,0.391107
uuid-ef347461a28e4fc4971fe0a3ad236a32,progression,0.375834
uuid-ef347461a28e4fc4971fe0a3ad236a32,believes,0.335229
uuid-ef347461a28e4fc4971fe0a3ad236a32,impressed,0.402542
uuid-ef347461a28e4fc4971fe0a3ad236a32,respond,0.317014
uuid-ef347461a28e4fc4971fe0a3ad236a32,SCLC,0.315632
uuid-ef347461a28e4fc4971fe0a3ad236a32,feels,0.419204
uuid-ef347461a28e4fc4971fe0a3ad236a32,RTL stated,0.455874
uuid-ef347461a28e4fc4971fe0a3ad236a32,TL shared,0.388161
uuid-ef347461a28e4fc4971fe0a3ad236a32,option,0.374938
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,Nivo,0.330094
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,pembro,0.47668
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,BMS,0.348178
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,1L,0.361117
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,RCC,0.33177
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,2L,0.455691
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,Merck,0.322514
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,stated,0.497318
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,approval,0.634095
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,atezo,0.387931
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,preferred,0.42038
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,using nivo,0.563068
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,mentioned,0.309761
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,clinical trials,0.381634
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,indication,0.44769
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,approved,0.603627
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,SCCHN,0.5211
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,label,0.449292
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,LTL,0.343342
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,Regional TL,0.339853
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,RTL stated,0.456868
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,option,0.31283
uuid-b7b88b4c70d84adf981f4d61e8e64dc0,bladder,0.377812
uuid-d55599173dd546ceb2b8a7230ca0aa9f,patients,0.38142
uuid-d55599173dd546ceb2b8a7230ca0aa9f,TL,0.30581
uuid-d55599173dd546ceb2b8a7230ca0aa9f,1L,0.382531
uuid-d55599173dd546ceb2b8a7230ca0aa9f,TL stated,0.372853
uuid-d55599173dd546ceb2b8a7230ca0aa9f,PD-L1,0.609706
uuid-d55599173dd546ceb2b8a7230ca0aa9f,approval,0.383683
uuid-d55599173dd546ceb2b8a7230ca0aa9f,PD-L1 testing,0.714772
uuid-d55599173dd546ceb2b8a7230ca0aa9f,testing,0.767688
uuid-d55599173dd546ceb2b8a7230ca0aa9f,PDL1 testing,0.687436
uuid-d55599173dd546ceb2b8a7230ca0aa9f,NSCLC patients,0.719804
uuid-d55599173dd546ceb2b8a7230ca0aa9f,assay,0.367437
uuid-1c780c192e6a47a5a734f50525b80080,patients,0.416786
uuid-1c780c192e6a47a5a734f50525b80080,lung,0.314508
uuid-1c780c192e6a47a5a734f50525b80080,treated,0.415772
uuid-1c780c192e6a47a5a734f50525b80080,melanoma,0.342625
uuid-1c780c192e6a47a5a734f50525b80080,pts,0.310809
uuid-1c780c192e6a47a5a734f50525b80080,treatment,0.383095
uuid-1c780c192e6a47a5a734f50525b80080,response,0.376373
uuid-1c780c192e6a47a5a734f50525b80080,AI,0.311008
uuid-1c780c192e6a47a5a734f50525b80080,progression,0.435054
uuid-1c780c192e6a47a5a734f50525b80080,respond,0.358085
uuid-1c780c192e6a47a5a734f50525b80080,TL shared,0.366642
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,1L,0.507
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,PDL1,0.327735
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,chemo,0.334519
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,2L,0.474149
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,agents,0.484721
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,PD-L1,0.330106
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,atezo,0.334754
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,preferred,0.559941
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,testing,0.36151
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,monotherapy,0.436218
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,PDL1 testing,0.347978
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,NSCLC patients,0.33276
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,believes,0.431981
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,feels,0.445545
uuid-dbd8daca38ac42109d3f6aa23cf5c0f5,option,0.586958
uuid-06ebe32b57874c2782bf259803c0f33c,PDL1,0.317068
uuid-06ebe32b57874c2782bf259803c0f33c,trial,0.382725
uuid-06ebe32b57874c2782bf259803c0f33c,efficacy,0.468821
uuid-06ebe32b57874c2782bf259803c0f33c,OS,0.88062
uuid-06ebe32b57874c2782bf259803c0f33c,regards,0.333604
uuid-06ebe32b57874c2782bf259803c0f33c,data,0.529439
uuid-06ebe32b57874c2782bf259803c0f33c,PFS,0.881537
uuid-06ebe32b57874c2782bf259803c0f33c,ORR,0.762017
uuid-06ebe32b57874c2782bf259803c0f33c,nivo and pembro,0.342344
uuid-06ebe32b57874c2782bf259803c0f33c,impressed,0.494129
uuid-83a4c7cefcdb4ee2861e402609559338,RTL,0.372783
uuid-83a4c7cefcdb4ee2861e402609559338,commented,0.455241
uuid-83a4c7cefcdb4ee2861e402609559338,stated,0.316998
uuid-83a4c7cefcdb4ee2861e402609559338,OS,0.614502
uuid-83a4c7cefcdb4ee2861e402609559338,data,0.50757
uuid-83a4c7cefcdb4ee2861e402609559338,PFS,0.5659
uuid-83a4c7cefcdb4ee2861e402609559338,ORR,0.515669
uuid-83a4c7cefcdb4ee2861e402609559338,ASCO,0.562334
uuid-83a4c7cefcdb4ee2861e402609559338,impressed,0.694949
uuid-83a4c7cefcdb4ee2861e402609559338,Regional TL,0.352869
uuid-796864ee004d4bebb93a03c634f574fd,TL,0.35923
uuid-796864ee004d4bebb93a03c634f574fd,RTL,0.371096
uuid-796864ee004d4bebb93a03c634f574fd,lung,0.389061
uuid-796864ee004d4bebb93a03c634f574fd,commented,0.544126
uuid-796864ee004d4bebb93a03c634f574fd,TL stated,0.595442
uuid-796864ee004d4bebb93a03c634f574fd,Merck,0.432763
uuid-796864ee004d4bebb93a03c634f574fd,stated,0.410296
uuid-796864ee004d4bebb93a03c634f574fd,PD-L1,0.300359
uuid-796864ee004d4bebb93a03c634f574fd,PD-L1 testing,0.391064
uuid-796864ee004d4bebb93a03c634f574fd,testing,0.431886
uuid-796864ee004d4bebb93a03c634f574fd,data,0.328528
uuid-796864ee004d4bebb93a03c634f574fd,expressed,0.408177
uuid-796864ee004d4bebb93a03c634f574fd,mentioned,0.437175
uuid-796864ee004d4bebb93a03c634f574fd,PDL1 testing,0.575677
uuid-796864ee004d4bebb93a03c634f574fd,NSCLC patients,0.33946
uuid-796864ee004d4bebb93a03c634f574fd,SCCHN,0.409658
uuid-796864ee004d4bebb93a03c634f574fd,ASCO,0.386392
uuid-796864ee004d4bebb93a03c634f574fd,impressed,0.36953
uuid-796864ee004d4bebb93a03c634f574fd,LTL,0.30794
uuid-796864ee004d4bebb93a03c634f574fd,TLs,0.325134
uuid-796864ee004d4bebb93a03c634f574fd,Regional TL,0.440246
uuid-796864ee004d4bebb93a03c634f574fd,bladder,0.326805
uuid-61a135b41edc4ebcacdc845dfca72695,TL,0.49278
uuid-61a135b41edc4ebcacdc845dfca72695,1L,0.305901
uuid-61a135b41edc4ebcacdc845dfca72695,PDL1,0.461518
uuid-61a135b41edc4ebcacdc845dfca72695,TL stated,0.533705
uuid-61a135b41edc4ebcacdc845dfca72695,Merck,0.350797
uuid-61a135b41edc4ebcacdc845dfca72695,institution,0.323195
uuid-61a135b41edc4ebcacdc845dfca72695,PD-L1,0.753938
uuid-61a135b41edc4ebcacdc845dfca72695,PD-L1 testing,0.765626
uuid-61a135b41edc4ebcacdc845dfca72695,testing,0.869983
uuid-61a135b41edc4ebcacdc845dfca72695,PDL1 testing,0.820922
uuid-61a135b41edc4ebcacdc845dfca72695,NSCLC patients,0.677998
uuid-61a135b41edc4ebcacdc845dfca72695,tumor types,0.316422
uuid-61a135b41edc4ebcacdc845dfca72695,assay,0.601209
uuid-61a135b41edc4ebcacdc845dfca72695,PDL1 expression,0.304486
uuid-61a135b41edc4ebcacdc845dfca72695,biomarker,0.462734
uuid-826c971b2b234f69b60385bc284e3cd6,therapy,0.425505
uuid-826c971b2b234f69b60385bc284e3cd6,nivolumab,0.383499
uuid-826c971b2b234f69b60385bc284e3cd6,toxicity,0.507674
uuid-826c971b2b234f69b60385bc284e3cd6,regimen,0.374241
uuid-826c971b2b234f69b60385bc284e3cd6,treated,0.432181
uuid-826c971b2b234f69b60385bc284e3cd6,combination,0.368783
uuid-826c971b2b234f69b60385bc284e3cd6,treatment,0.54702
uuid-826c971b2b234f69b60385bc284e3cd6,PD1,0.421155
uuid-826c971b2b234f69b60385bc284e3cd6,progression,0.394991
uuid-826c971b2b234f69b60385bc284e3cd6,chemotherapy,0.400174
uuid-826c971b2b234f69b60385bc284e3cd6,immunotherapy,0.416054
uuid-5f2467d4a6b344969df6033c857d099c,patients,0.429845
uuid-5f2467d4a6b344969df6033c857d099c,Opdivo,0.585051
uuid-5f2467d4a6b344969df6033c857d099c,dose,0.697881
uuid-5f2467d4a6b344969df6033c857d099c,nivolumab,0.33958
uuid-5f2467d4a6b344969df6033c857d099c,toxicity,0.463993
uuid-5f2467d4a6b344969df6033c857d099c,regimen,0.477818
uuid-5f2467d4a6b344969df6033c857d099c,Ipi,0.330069
uuid-5f2467d4a6b344969df6033c857d099c,preferred,0.472869
uuid-5f2467d4a6b344969df6033c857d099c,monotherapy,0.344678
uuid-5f2467d4a6b344969df6033c857d099c,treatment,0.352551
uuid-5f2467d4a6b344969df6033c857d099c,drug,0.409854
uuid-5f2467d4a6b344969df6033c857d099c,Keytruda,0.541434
uuid-5f2467d4a6b344969df6033c857d099c,option,0.323639
uuid-5f2467d4a6b344969df6033c857d099c,flat dosing,0.586077
uuid-a988da9226f44c428ff129e8fcda09ea,patients,0.680962
uuid-a988da9226f44c428ff129e8fcda09ea,Opdivo,0.453773
uuid-a988da9226f44c428ff129e8fcda09ea,nivolumab,0.30987
uuid-a988da9226f44c428ff129e8fcda09ea,1L,0.424779
uuid-a988da9226f44c428ff129e8fcda09ea,regimen,0.355623
uuid-a988da9226f44c428ff129e8fcda09ea,2L,0.478232
uuid-a988da9226f44c428ff129e8fcda09ea,pts,0.482519
uuid-a988da9226f44c428ff129e8fcda09ea,approval,0.305367
uuid-a988da9226f44c428ff129e8fcda09ea,preferred,0.550596
uuid-a988da9226f44c428ff129e8fcda09ea,monotherapy,0.505604
uuid-a988da9226f44c428ff129e8fcda09ea,treatment,0.400625
uuid-a988da9226f44c428ff129e8fcda09ea,using nivo,0.470041
uuid-a988da9226f44c428ff129e8fcda09ea,NSCLC patients,0.36934
uuid-a988da9226f44c428ff129e8fcda09ea,approved,0.456821
uuid-a988da9226f44c428ff129e8fcda09ea,tumor types,0.352435
uuid-a988da9226f44c428ff129e8fcda09ea,feels,0.375047
uuid-a988da9226f44c428ff129e8fcda09ea,option,0.59698
uuid-3fa991f1435c4839b552e0c6705786ac,Opdivo,0.321288
uuid-3fa991f1435c4839b552e0c6705786ac,lung,0.332277
uuid-3fa991f1435c4839b552e0c6705786ac,stated,0.342991
uuid-3fa991f1435c4839b552e0c6705786ac,atezo,0.303184
uuid-3fa991f1435c4839b552e0c6705786ac,data,0.409213
uuid-3fa991f1435c4839b552e0c6705786ac,expressed,0.3027
uuid-3fa991f1435c4839b552e0c6705786ac,indication,0.464112
uuid-3fa991f1435c4839b552e0c6705786ac,AI,0.472463
uuid-3fa991f1435c4839b552e0c6705786ac,impressed,0.371014
uuid-3fa991f1435c4839b552e0c6705786ac,label,0.30887
uuid-3fa991f1435c4839b552e0c6705786ac,Keytruda,0.462435
uuid-3fa991f1435c4839b552e0c6705786ac,NCCN,0.486712
uuid-3fa991f1435c4839b552e0c6705786ac,flat dosing,0.365529
uuid-5e4b575a5ca045349bdcaed9e57715e6,patients,0.80261
uuid-5e4b575a5ca045349bdcaed9e57715e6,Opdivo,0.495836
uuid-5e4b575a5ca045349bdcaed9e57715e6,therapy,0.316274
uuid-5e4b575a5ca045349bdcaed9e57715e6,nivolumab,0.408558
uuid-5e4b575a5ca045349bdcaed9e57715e6,toxicity,0.522095
uuid-5e4b575a5ca045349bdcaed9e57715e6,regimen,0.551621
uuid-5e4b575a5ca045349bdcaed9e57715e6,treated,0.564468
uuid-5e4b575a5ca045349bdcaed9e57715e6,pts,0.420999
uuid-5e4b575a5ca045349bdcaed9e57715e6,treatment,0.58738
uuid-5e4b575a5ca045349bdcaed9e57715e6,progression,0.448501
uuid-5e4b575a5ca045349bdcaed9e57715e6,respond,0.410415
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,Nivo,0.338667
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,RTL,0.441483
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,BMS,0.378479
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,trial,0.594964
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,efficacy,0.49205
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,commented,0.383244
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,Ipi,0.30685
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,OS,0.567439
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,data,0.757433
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,expressed,0.350942
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,clinical trials,0.307432
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,PFS,0.53585
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,ORR,0.618483
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,nivo and pembro,0.351658
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,ASCO,0.387676
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,impressed,0.692297
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,LTL,0.327775
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,SCLC,0.316705
uuid-756eb5f94b44468d8ba8fb085dbe7eb1,feels,0.452781
uuid-f1311a502fa64a71b6b9ff9502698aa1,patients,0.346967
uuid-f1311a502fa64a71b6b9ff9502698aa1,tumor,0.309485
uuid-f1311a502fa64a71b6b9ff9502698aa1,bladder,0.338732
uuid-4a58aa8a5e4d4804b217be070c7fe523,TL,0.359666
uuid-4a58aa8a5e4d4804b217be070c7fe523,RTL,0.34503
uuid-4a58aa8a5e4d4804b217be070c7fe523,lung,0.638815
uuid-4a58aa8a5e4d4804b217be070c7fe523,1L,0.4253
uuid-4a58aa8a5e4d4804b217be070c7fe523,melanoma,0.485154
uuid-4a58aa8a5e4d4804b217be070c7fe523,shared,0.405673
uuid-4a58aa8a5e4d4804b217be070c7fe523,commented,0.365538
uuid-4a58aa8a5e4d4804b217be070c7fe523,RCC,0.82829
uuid-4a58aa8a5e4d4804b217be070c7fe523,TL stated,0.738146
uuid-4a58aa8a5e4d4804b217be070c7fe523,2L,0.483257
uuid-4a58aa8a5e4d4804b217be070c7fe523,stated,0.447637
uuid-4a58aa8a5e4d4804b217be070c7fe523,approval,0.373406
uuid-4a58aa8a5e4d4804b217be070c7fe523,preferred,0.382715
uuid-4a58aa8a5e4d4804b217be070c7fe523,PD-L1 testing,0.338835
uuid-4a58aa8a5e4d4804b217be070c7fe523,using nivo,0.438611
uuid-4a58aa8a5e4d4804b217be070c7fe523,clinical trials,0.301112
uuid-4a58aa8a5e4d4804b217be070c7fe523,PDL1 testing,0.583195
uuid-4a58aa8a5e4d4804b217be070c7fe523,NSCLC patients,0.340014
uuid-4a58aa8a5e4d4804b217be070c7fe523,approved,0.346612
uuid-4a58aa8a5e4d4804b217be070c7fe523,SCCHN,0.670911
uuid-4a58aa8a5e4d4804b217be070c7fe523,tumor types,0.479952
uuid-4a58aa8a5e4d4804b217be070c7fe523,oncologist,0.351664
uuid-4a58aa8a5e4d4804b217be070c7fe523,LTL,0.335529
uuid-4a58aa8a5e4d4804b217be070c7fe523,TLs,0.559061
uuid-4a58aa8a5e4d4804b217be070c7fe523,academic,0.321848
uuid-4a58aa8a5e4d4804b217be070c7fe523,Regional TL,0.571307
uuid-4a58aa8a5e4d4804b217be070c7fe523,RTL stated,0.590433
uuid-4a58aa8a5e4d4804b217be070c7fe523,TL shared,0.599158
uuid-4a58aa8a5e4d4804b217be070c7fe523,bladder,0.579662
uuid-56ba2106105c470ca71a9f62fd2018fe,1L,0.46375
uuid-56ba2106105c470ca71a9f62fd2018fe,PDL1,0.365413
uuid-56ba2106105c470ca71a9f62fd2018fe,RCC,0.407545
uuid-56ba2106105c470ca71a9f62fd2018fe,TL stated,0.476367
uuid-56ba2106105c470ca71a9f62fd2018fe,2L,0.379331
uuid-56ba2106105c470ca71a9f62fd2018fe,stated,0.447334
uuid-56ba2106105c470ca71a9f62fd2018fe,PD-L1,0.438312
uuid-56ba2106105c470ca71a9f62fd2018fe,approval,0.436584
uuid-56ba2106105c470ca71a9f62fd2018fe,PD-L1 testing,0.410565
uuid-56ba2106105c470ca71a9f62fd2018fe,testing,0.411376
uuid-56ba2106105c470ca71a9f62fd2018fe,using nivo,0.343362
uuid-56ba2106105c470ca71a9f62fd2018fe,data,0.35466
uuid-56ba2106105c470ca71a9f62fd2018fe,PDL1 testing,0.500342
uuid-56ba2106105c470ca71a9f62fd2018fe,NSCLC patients,0.416934
uuid-56ba2106105c470ca71a9f62fd2018fe,approved,0.433469
uuid-56ba2106105c470ca71a9f62fd2018fe,SCCHN,0.425523
uuid-56ba2106105c470ca71a9f62fd2018fe,impressed,0.354052
uuid-56ba2106105c470ca71a9f62fd2018fe,tumor types,0.3603
uuid-56ba2106105c470ca71a9f62fd2018fe,TLs,0.321791
uuid-56ba2106105c470ca71a9f62fd2018fe,Regional TL,0.385886
uuid-56ba2106105c470ca71a9f62fd2018fe,RTL stated,0.363768
uuid-56ba2106105c470ca71a9f62fd2018fe,bladder,0.328244
uuid-96fa8c6780ee41849b5dc774c898ead4,patients,0.443898
uuid-96fa8c6780ee41849b5dc774c898ead4,Opdivo,0.45976
uuid-96fa8c6780ee41849b5dc774c898ead4,regimen,0.348955
uuid-96fa8c6780ee41849b5dc774c898ead4,pts,0.329718
uuid-96fa8c6780ee41849b5dc774c898ead4,preferred,0.354047
uuid-96fa8c6780ee41849b5dc774c898ead4,monotherapy,0.353609
uuid-96fa8c6780ee41849b5dc774c898ead4,Keytruda,0.372954
uuid-96fa8c6780ee41849b5dc774c898ead4,feels,0.344005
uuid-96fa8c6780ee41849b5dc774c898ead4,option,0.419584
uuid-40dbdbcb249642c9a049dc340bf693f7,pembro,0.302493
uuid-40dbdbcb249642c9a049dc340bf693f7,PDL1,0.302069
uuid-40dbdbcb249642c9a049dc340bf693f7,efficacy,0.498018
uuid-40dbdbcb249642c9a049dc340bf693f7,OS,0.308053
uuid-40dbdbcb249642c9a049dc340bf693f7,atezo,0.415743
uuid-40dbdbcb249642c9a049dc340bf693f7,regards,0.351938
uuid-40dbdbcb249642c9a049dc340bf693f7,data,0.305357
uuid-40dbdbcb249642c9a049dc340bf693f7,PFS,0.3156
uuid-40dbdbcb249642c9a049dc340bf693f7,ORR,0.319744
uuid-40dbdbcb249642c9a049dc340bf693f7,nivo and pembro,0.453215
uuid-40dbdbcb249642c9a049dc340bf693f7,believes,0.377741
uuid-40dbdbcb249642c9a049dc340bf693f7,vs,0.319632
uuid-40dbdbcb249642c9a049dc340bf693f7,TLs,0.485344
uuid-40dbdbcb249642c9a049dc340bf693f7,PDL1 expression,0.30175
uuid-19b7d00dd2104e0e863a41557369a39d,TL,0.515807
uuid-19b7d00dd2104e0e863a41557369a39d,1L,0.313265
uuid-19b7d00dd2104e0e863a41557369a39d,TL stated,0.540259
uuid-19b7d00dd2104e0e863a41557369a39d,Merck,0.363017
uuid-19b7d00dd2104e0e863a41557369a39d,institution,0.318516
uuid-19b7d00dd2104e0e863a41557369a39d,PD-L1,0.556881
uuid-19b7d00dd2104e0e863a41557369a39d,approval,0.497453
uuid-19b7d00dd2104e0e863a41557369a39d,PD-L1 testing,0.738111
uuid-19b7d00dd2104e0e863a41557369a39d,testing,0.742989
uuid-19b7d00dd2104e0e863a41557369a39d,PDL1 testing,0.710334
uuid-19b7d00dd2104e0e863a41557369a39d,NSCLC patients,0.674452
uuid-19b7d00dd2104e0e863a41557369a39d,approved,0.319136
uuid-19b7d00dd2104e0e863a41557369a39d,SCCHN,0.368158
uuid-19b7d00dd2104e0e863a41557369a39d,assay,0.504776
uuid-19b7d00dd2104e0e863a41557369a39d,RTL stated,0.328177
uuid-cd951ad9b325405ba639f056e197cee5,trial,0.301487
uuid-cd951ad9b325405ba639f056e197cee5,Merck,0.311579
uuid-cd951ad9b325405ba639f056e197cee5,drug,0.539633
uuid-196f97a11c464b9ca866c5917fc61adf,patients,0.861436
uuid-196f97a11c464b9ca866c5917fc61adf,Opdivo,0.527748
uuid-196f97a11c464b9ca866c5917fc61adf,therapy,0.529528
uuid-196f97a11c464b9ca866c5917fc61adf,nivolumab,0.435525
uuid-196f97a11c464b9ca866c5917fc61adf,toxicity,0.328532
uuid-196f97a11c464b9ca866c5917fc61adf,regimen,0.557121
uuid-196f97a11c464b9ca866c5917fc61adf,treated,0.621752
uuid-196f97a11c464b9ca866c5917fc61adf,pts,0.568765
uuid-196f97a11c464b9ca866c5917fc61adf,treatment,0.775295
uuid-196f97a11c464b9ca866c5917fc61adf,response,0.454941
uuid-196f97a11c464b9ca866c5917fc61adf,progression,0.745575
uuid-196f97a11c464b9ca866c5917fc61adf,chemotherapy,0.302423
uuid-196f97a11c464b9ca866c5917fc61adf,respond,0.613333
uuid-274a4e5ae6c246389d16f627bfc2f9c1,patients,0.725982
uuid-274a4e5ae6c246389d16f627bfc2f9c1,Opdivo,0.319155
uuid-274a4e5ae6c246389d16f627bfc2f9c1,therapy,0.687978
uuid-274a4e5ae6c246389d16f627bfc2f9c1,nivolumab,0.350921
uuid-274a4e5ae6c246389d16f627bfc2f9c1,regimen,0.464956
uuid-274a4e5ae6c246389d16f627bfc2f9c1,treated,0.469766
uuid-274a4e5ae6c246389d16f627bfc2f9c1,chemo,0.385207
uuid-274a4e5ae6c246389d16f627bfc2f9c1,pts,0.505589
uuid-274a4e5ae6c246389d16f627bfc2f9c1,monotherapy,0.330549
uuid-274a4e5ae6c246389d16f627bfc2f9c1,treatment,0.824118
uuid-274a4e5ae6c246389d16f627bfc2f9c1,response,0.480163
uuid-274a4e5ae6c246389d16f627bfc2f9c1,PD1,0.359611
uuid-274a4e5ae6c246389d16f627bfc2f9c1,progression,0.721915
uuid-274a4e5ae6c246389d16f627bfc2f9c1,chemotherapy,0.466605
uuid-274a4e5ae6c246389d16f627bfc2f9c1,respond,0.567434
uuid-274a4e5ae6c246389d16f627bfc2f9c1,option,0.403917
uuid-c7f2f149a9ab465bb0aa77061e8615f6,expressed,0.341043
uuid-c7f2f149a9ab465bb0aa77061e8615f6,bladder,0.303582
uuid-61e20e418b7344da8e4f90db126202b5,patients,0.300017
uuid-61e20e418b7344da8e4f90db126202b5,Opdivo,0.50746
uuid-61e20e418b7344da8e4f90db126202b5,dose,0.723114
uuid-61e20e418b7344da8e4f90db126202b5,toxicity,0.356317
uuid-61e20e418b7344da8e4f90db126202b5,Ipi,0.431342
uuid-61e20e418b7344da8e4f90db126202b5,mentioned,0.420629
uuid-61e20e418b7344da8e4f90db126202b5,HCP,0.498594
uuid-61e20e418b7344da8e4f90db126202b5,vs,0.430091
uuid-61e20e418b7344da8e4f90db126202b5,drug,0.326339
uuid-61e20e418b7344da8e4f90db126202b5,Keytruda,0.371319
uuid-61e20e418b7344da8e4f90db126202b5,flat dosing,0.679296
uuid-7f61da2752b740c08eeed658dbf5dbcb,patients,0.582439
uuid-7f61da2752b740c08eeed658dbf5dbcb,regimen,0.376604
uuid-7f61da2752b740c08eeed658dbf5dbcb,treated,0.389773
uuid-7f61da2752b740c08eeed658dbf5dbcb,TL stated,0.368835
uuid-7f61da2752b740c08eeed658dbf5dbcb,pts,0.454211
uuid-7f61da2752b740c08eeed658dbf5dbcb,testing,0.306499
uuid-7f61da2752b740c08eeed658dbf5dbcb,PDL1 testing,0.30512
uuid-7f61da2752b740c08eeed658dbf5dbcb,NSCLC patients,0.572137
uuid-7f61da2752b740c08eeed658dbf5dbcb,progression,0.39812
uuid-7f61da2752b740c08eeed658dbf5dbcb,tumor types,0.309364
uuid-7f61da2752b740c08eeed658dbf5dbcb,respond,0.314079
uuid-7f61da2752b740c08eeed658dbf5dbcb,RTL stated,0.323377
uuid-705119b66a4e4dbca3abbd76e1935956,patients,0.684634
uuid-705119b66a4e4dbca3abbd76e1935956,Opdivo,0.365274
uuid-705119b66a4e4dbca3abbd76e1935956,therapy,0.493418
uuid-705119b66a4e4dbca3abbd76e1935956,nivolumab,0.493172
uuid-705119b66a4e4dbca3abbd76e1935956,toxicity,0.397908
uuid-705119b66a4e4dbca3abbd76e1935956,regimen,0.559848
uuid-705119b66a4e4dbca3abbd76e1935956,treated,0.635315
uuid-705119b66a4e4dbca3abbd76e1935956,pts,0.432251
uuid-705119b66a4e4dbca3abbd76e1935956,treatment,0.601121
uuid-705119b66a4e4dbca3abbd76e1935956,response,0.343536
uuid-705119b66a4e4dbca3abbd76e1935956,PD1,0.35507
uuid-705119b66a4e4dbca3abbd76e1935956,cHL,0.350885
uuid-705119b66a4e4dbca3abbd76e1935956,progression,0.626623
uuid-705119b66a4e4dbca3abbd76e1935956,chemotherapy,0.382657
uuid-705119b66a4e4dbca3abbd76e1935956,respond,0.410846
uuid-38b892c57ae54b0b8c52e7978231ee3a,nivolumab,0.318068
uuid-38b892c57ae54b0b8c52e7978231ee3a,treated,0.320592
uuid-382d63f96b224ca3bf60729c8d0b11dc,Nivo,0.356816
uuid-382d63f96b224ca3bf60729c8d0b11dc,patients,0.451516
uuid-382d63f96b224ca3bf60729c8d0b11dc,Opdivo,0.542063
uuid-382d63f96b224ca3bf60729c8d0b11dc,pembro,0.336691
uuid-382d63f96b224ca3bf60729c8d0b11dc,dose,0.866471
uuid-382d63f96b224ca3bf60729c8d0b11dc,nivolumab,0.303202
uuid-382d63f96b224ca3bf60729c8d0b11dc,toxicity,0.316142
uuid-382d63f96b224ca3bf60729c8d0b11dc,regimen,0.326898
uuid-382d63f96b224ca3bf60729c8d0b11dc,Ipi,0.467537
uuid-382d63f96b224ca3bf60729c8d0b11dc,vs,0.45254
uuid-382d63f96b224ca3bf60729c8d0b11dc,Keytruda,0.408563
uuid-382d63f96b224ca3bf60729c8d0b11dc,flat dosing,0.747731
uuid-4199d635d9b1423c8e5bfe86317e2812,TL,0.597564
uuid-4199d635d9b1423c8e5bfe86317e2812,PD-L1,0.331867
uuid-4199d635d9b1423c8e5bfe86317e2812,PD-L1 testing,0.596247
uuid-4199d635d9b1423c8e5bfe86317e2812,testing,0.491833
uuid-4199d635d9b1423c8e5bfe86317e2812,PDL1 testing,0.341626
uuid-4199d635d9b1423c8e5bfe86317e2812,NSCLC patients,0.30379
uuid-4199d635d9b1423c8e5bfe86317e2812,assay,0.415291
uuid-4a5f154d332c403592cca8a72dae7cb7,Nivo,0.340797
uuid-4a5f154d332c403592cca8a72dae7cb7,patients,0.718906
uuid-4a5f154d332c403592cca8a72dae7cb7,Opdivo,0.499143
uuid-4a5f154d332c403592cca8a72dae7cb7,therapy,0.640932
uuid-4a5f154d332c403592cca8a72dae7cb7,nivolumab,0.442122
uuid-4a5f154d332c403592cca8a72dae7cb7,toxicity,0.426969
uuid-4a5f154d332c403592cca8a72dae7cb7,regimen,0.614198
uuid-4a5f154d332c403592cca8a72dae7cb7,treated,0.429481
uuid-4a5f154d332c403592cca8a72dae7cb7,combination,0.371446
uuid-4a5f154d332c403592cca8a72dae7cb7,chemo,0.515679
uuid-4a5f154d332c403592cca8a72dae7cb7,pts,0.426841
uuid-4a5f154d332c403592cca8a72dae7cb7,monotherapy,0.467938
uuid-4a5f154d332c403592cca8a72dae7cb7,treatment,0.769958
uuid-4a5f154d332c403592cca8a72dae7cb7,response,0.402145
uuid-4a5f154d332c403592cca8a72dae7cb7,combo,0.310326
uuid-4a5f154d332c403592cca8a72dae7cb7,PD1,0.415401
uuid-4a5f154d332c403592cca8a72dae7cb7,progression,0.619722
uuid-4a5f154d332c403592cca8a72dae7cb7,chemotherapy,0.510937
uuid-4a5f154d332c403592cca8a72dae7cb7,respond,0.54047
uuid-4a5f154d332c403592cca8a72dae7cb7,option,0.459606
uuid-2abeb74291c54fbe8d5dc28880938eac,lung,0.369073
uuid-2abeb74291c54fbe8d5dc28880938eac,commented,0.361141
uuid-2abeb74291c54fbe8d5dc28880938eac,regards,0.413251
uuid-2abeb74291c54fbe8d5dc28880938eac,indication,0.366286
uuid-2abeb74291c54fbe8d5dc28880938eac,AI,0.349616
uuid-2abeb74291c54fbe8d5dc28880938eac,oncology,0.473662
uuid-2abeb74291c54fbe8d5dc28880938eac,TLs,0.409283
uuid-2abeb74291c54fbe8d5dc28880938eac,NCCN,0.363438
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,patients,0.529772
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,Opdivo,0.459064
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,dose,0.503426
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,nivolumab,0.362413
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,toxicity,0.550997
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,regimen,0.720748
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,treated,0.36947
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,combination,0.334585
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,pts,0.372471
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,Ipi,0.43802
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,monotherapy,0.358949
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,treatment,0.433979
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,combo,0.352319
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,progression,0.449406
uuid-a32964a277e84fbfa5d3afa0cbe6aae7,respond,0.370292
uuid-0a03768796e1410eb29cae2890958a71,discussed,0.583564
uuid-0a03768796e1410eb29cae2890958a71,regards,0.495235
uuid-0a03768796e1410eb29cae2890958a71,AI,0.358316
uuid-0a03768796e1410eb29cae2890958a71,oncology,0.311371
uuid-0a03768796e1410eb29cae2890958a71,clinical,0.307451
uuid-0a03768796e1410eb29cae2890958a71,academic,0.31609
uuid-0a03768796e1410eb29cae2890958a71,NCCN,0.369847
uuid-e329b50cd22a411b9e8d0a339e48978e,BMS,0.474526
uuid-e329b50cd22a411b9e8d0a339e48978e,trial,0.410092
uuid-e329b50cd22a411b9e8d0a339e48978e,commented,0.482103
uuid-e329b50cd22a411b9e8d0a339e48978e,Merck,0.325838
uuid-e329b50cd22a411b9e8d0a339e48978e,regards,0.37061
uuid-e329b50cd22a411b9e8d0a339e48978e,data,0.327255
uuid-e329b50cd22a411b9e8d0a339e48978e,expressed,0.313767
uuid-e329b50cd22a411b9e8d0a339e48978e,clinical trials,0.311456
uuid-e329b50cd22a411b9e8d0a339e48978e,lung cancer,0.336476
uuid-e329b50cd22a411b9e8d0a339e48978e,impressed,0.334054
uuid-e329b50cd22a411b9e8d0a339e48978e,feels,0.502738
uuid-4ac1a4c1ed284c258ef85a3badd07282,TL,0.545683
uuid-4ac1a4c1ed284c258ef85a3badd07282,PDL1,0.383429
uuid-4ac1a4c1ed284c258ef85a3badd07282,TL stated,0.390793
uuid-4ac1a4c1ed284c258ef85a3badd07282,Merck,0.347247
uuid-4ac1a4c1ed284c258ef85a3badd07282,institution,0.379048
uuid-4ac1a4c1ed284c258ef85a3badd07282,PD-L1,0.721867
uuid-4ac1a4c1ed284c258ef85a3badd07282,PD-L1 testing,0.779559
uuid-4ac1a4c1ed284c258ef85a3badd07282,testing,0.819418
uuid-4ac1a4c1ed284c258ef85a3badd07282,PDL1 testing,0.677071
uuid-4ac1a4c1ed284c258ef85a3badd07282,NSCLC patients,0.511667
uuid-4ac1a4c1ed284c258ef85a3badd07282,assay,0.713493
uuid-4ac1a4c1ed284c258ef85a3badd07282,biomarker,0.503733
uuid-491ba2594b1144aba43251f37759d612,toxicity,0.325723
uuid-491ba2594b1144aba43251f37759d612,regimen,0.315179
uuid-491ba2594b1144aba43251f37759d612,treated,0.34617
uuid-491ba2594b1144aba43251f37759d612,melanoma,0.334681
uuid-e36fa33cb10e4502868a2cd5f0861490,patients,0.506732
uuid-e36fa33cb10e4502868a2cd5f0861490,Opdivo,0.458935
uuid-e36fa33cb10e4502868a2cd5f0861490,therapy,0.45053
uuid-e36fa33cb10e4502868a2cd5f0861490,nivolumab,0.369293
uuid-e36fa33cb10e4502868a2cd5f0861490,regimen,0.344465
uuid-e36fa33cb10e4502868a2cd5f0861490,treated,0.368402
uuid-e36fa33cb10e4502868a2cd5f0861490,pts,0.358372
uuid-e36fa33cb10e4502868a2cd5f0861490,treatment,0.456186
uuid-e36fa33cb10e4502868a2cd5f0861490,progression,0.474908
uuid-e36fa33cb10e4502868a2cd5f0861490,respond,0.341682
uuid-e36fa33cb10e4502868a2cd5f0861490,feels,0.322167
uuid-1edf6d0735f548a994bf3a9850d35a77,discussed,0.349624
uuid-1edf6d0735f548a994bf3a9850d35a77,shared,0.413518
uuid-1edf6d0735f548a994bf3a9850d35a77,atezo,0.305414
uuid-1edf6d0735f548a994bf3a9850d35a77,preferred,0.34676
uuid-1edf6d0735f548a994bf3a9850d35a77,indication,0.360059
uuid-1edf6d0735f548a994bf3a9850d35a77,Keytruda,0.303997
uuid-1edf6d0735f548a994bf3a9850d35a77,TLs,0.366093
uuid-1edf6d0735f548a994bf3a9850d35a77,academic,0.361908
uuid-1edf6d0735f548a994bf3a9850d35a77,flat dosing,0.349418
uuid-646e7ee999814fc09161e3dc0e095f52,patients,0.460245
uuid-646e7ee999814fc09161e3dc0e095f52,tumor,0.588088
uuid-646e7ee999814fc09161e3dc0e095f52,pts,0.331809
uuid-646e7ee999814fc09161e3dc0e095f52,response,0.356931
uuid-646e7ee999814fc09161e3dc0e095f52,NSCLC patients,0.353287
uuid-646e7ee999814fc09161e3dc0e095f52,progression,0.364992
uuid-646e7ee999814fc09161e3dc0e095f52,respond,0.304775
uuid-3be5286a5994403996a23749d166f4df,BMS,0.35255
uuid-3be5286a5994403996a23749d166f4df,commented,0.368259
uuid-3be5286a5994403996a23749d166f4df,regards,0.31994
uuid-3be5286a5994403996a23749d166f4df,data,0.457566
uuid-3be5286a5994403996a23749d166f4df,nivo and pembro,0.344314
uuid-3be5286a5994403996a23749d166f4df,believes,0.355906
uuid-3be5286a5994403996a23749d166f4df,feels,0.488735
uuid-ff6ba01e982647999b670d54e58cd25d,TL,0.477109
uuid-ff6ba01e982647999b670d54e58cd25d,Merck,0.555716
uuid-eccd694dc1c14026b624eb6a3da714b9,physicians,0.446176
uuid-c580b921891b49c4bfaf21cbf50c4296,TL,0.524812
uuid-c580b921891b49c4bfaf21cbf50c4296,pembro,0.440493
uuid-c580b921891b49c4bfaf21cbf50c4296,RTL,0.310745
uuid-c580b921891b49c4bfaf21cbf50c4296,PDL1,0.310033
uuid-c580b921891b49c4bfaf21cbf50c4296,commented,0.406831
uuid-c580b921891b49c4bfaf21cbf50c4296,TL stated,0.469424
uuid-c580b921891b49c4bfaf21cbf50c4296,Merck,0.481807
uuid-c580b921891b49c4bfaf21cbf50c4296,stated,0.339323
uuid-c580b921891b49c4bfaf21cbf50c4296,PD-L1,0.484995
uuid-c580b921891b49c4bfaf21cbf50c4296,approval,0.412125
uuid-c580b921891b49c4bfaf21cbf50c4296,atezo,0.454617
uuid-c580b921891b49c4bfaf21cbf50c4296,PD-L1 testing,0.541061
uuid-c580b921891b49c4bfaf21cbf50c4296,testing,0.543794
uuid-c580b921891b49c4bfaf21cbf50c4296,data,0.33001
uuid-c580b921891b49c4bfaf21cbf50c4296,expressed,0.308224
uuid-c580b921891b49c4bfaf21cbf50c4296,mentioned,0.358568
uuid-c580b921891b49c4bfaf21cbf50c4296,PDL1 testing,0.595112
uuid-c580b921891b49c4bfaf21cbf50c4296,indication,0.32361
uuid-c580b921891b49c4bfaf21cbf50c4296,NSCLC patients,0.381361
uuid-c580b921891b49c4bfaf21cbf50c4296,SCCHN,0.365732
uuid-c580b921891b49c4bfaf21cbf50c4296,LTL,0.365541
uuid-c580b921891b49c4bfaf21cbf50c4296,TLs,0.361336
uuid-c580b921891b49c4bfaf21cbf50c4296,assay,0.437127
uuid-c580b921891b49c4bfaf21cbf50c4296,Regional TL,0.343004
uuid-c580b921891b49c4bfaf21cbf50c4296,bladder,0.330649
uuid-c62a1bdd86d946b8ab39463a13805985,RTL,0.33631
uuid-c62a1bdd86d946b8ab39463a13805985,nivolumab,0.376553
uuid-c62a1bdd86d946b8ab39463a13805985,NTL,0.5273
uuid-c62a1bdd86d946b8ab39463a13805985,mentioned,0.469824
uuid-c62a1bdd86d946b8ab39463a13805985,cHL,0.635027
uuid-c62a1bdd86d946b8ab39463a13805985,ASCO,0.436062
uuid-2a5654a906eb4cba9e66f7473ae75209,patients,0.332806
uuid-2a5654a906eb4cba9e66f7473ae75209,treated,0.332392
uuid-2a5654a906eb4cba9e66f7473ae75209,treatment,0.353021
uuid-2a5654a906eb4cba9e66f7473ae75209,progression,0.362476
uuid-2a5654a906eb4cba9e66f7473ae75209,immunotherapy,0.513435
uuid-e4b5a4a111db4aa19c0316cf810589d0,patients,0.416018
uuid-e4b5a4a111db4aa19c0316cf810589d0,treated,0.433006
uuid-e4b5a4a111db4aa19c0316cf810589d0,RCC,0.38877
uuid-e4b5a4a111db4aa19c0316cf810589d0,TL stated,0.311302
uuid-e4b5a4a111db4aa19c0316cf810589d0,preferred,0.491367
uuid-e4b5a4a111db4aa19c0316cf810589d0,using nivo,0.391086
uuid-e4b5a4a111db4aa19c0316cf810589d0,SCCHN,0.50662
uuid-e4b5a4a111db4aa19c0316cf810589d0,Regional TL,0.430224
uuid-e4b5a4a111db4aa19c0316cf810589d0,RTL stated,0.550696
uuid-e4b5a4a111db4aa19c0316cf810589d0,TL shared,0.375492
uuid-e4b5a4a111db4aa19c0316cf810589d0,option,0.335688
uuid-e4b5a4a111db4aa19c0316cf810589d0,bladder,0.312012
uuid-61da89349fc94c379eee9fb0258a0da3,patients,0.735834
uuid-61da89349fc94c379eee9fb0258a0da3,Opdivo,0.452756
uuid-61da89349fc94c379eee9fb0258a0da3,therapy,0.451677
uuid-61da89349fc94c379eee9fb0258a0da3,nivolumab,0.56203
uuid-61da89349fc94c379eee9fb0258a0da3,regimen,0.400591
uuid-61da89349fc94c379eee9fb0258a0da3,treated,0.7073
uuid-61da89349fc94c379eee9fb0258a0da3,pts,0.470897
uuid-61da89349fc94c379eee9fb0258a0da3,physicians,0.312441
uuid-61da89349fc94c379eee9fb0258a0da3,treatment,0.56096
uuid-61da89349fc94c379eee9fb0258a0da3,using nivo,0.417637
uuid-61da89349fc94c379eee9fb0258a0da3,cHL,0.402081
uuid-61da89349fc94c379eee9fb0258a0da3,progression,0.520058
uuid-61da89349fc94c379eee9fb0258a0da3,respond,0.337751
uuid-61da89349fc94c379eee9fb0258a0da3,RTL stated,0.374395
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,patients,0.363228
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,therapy,0.522457
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,nivolumab,0.360649
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,regimen,0.335205
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,treated,0.366491
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,RCC,0.431634
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,pts,0.38348
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,monotherapy,0.308403
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,treatment,0.509072
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,response,0.539933
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,PD1,0.374379
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,progression,0.555805
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,respond,0.310817
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,immunotherapy,0.310243
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,PD-1,0.328317
uuid-8a17bf6f02c84b9988c8151b6a45bc3e,TL shared,0.344472
uuid-26976cfa2ad442b2aa6ce05ecbef1a13,Opdivo,0.370546
uuid-26976cfa2ad442b2aa6ce05ecbef1a13,dose,0.707173
uuid-26976cfa2ad442b2aa6ce05ecbef1a13,toxicity,0.319895
uuid-26976cfa2ad442b2aa6ce05ecbef1a13,vs,0.321355
uuid-26976cfa2ad442b2aa6ce05ecbef1a13,drug,0.324391
uuid-26976cfa2ad442b2aa6ce05ecbef1a13,Keytruda,0.395067
uuid-26976cfa2ad442b2aa6ce05ecbef1a13,TLs,0.300681
uuid-26976cfa2ad442b2aa6ce05ecbef1a13,flat dosing,0.838999
uuid-6bd3d85db1544635b3806f36ab075a3b,Nivo,0.45676
uuid-6bd3d85db1544635b3806f36ab075a3b,nivolumab,0.334104
uuid-6bd3d85db1544635b3806f36ab075a3b,trial,0.557198
uuid-6bd3d85db1544635b3806f36ab075a3b,mentioned,0.300532
uuid-6bd3d85db1544635b3806f36ab075a3b,cHL,0.492782
uuid-e4904e4233eb47f2804030b45f4ee20c,Nivo,0.390754
uuid-e4904e4233eb47f2804030b45f4ee20c,pembro,0.440463
uuid-e4904e4233eb47f2804030b45f4ee20c,1L,0.385494
uuid-e4904e4233eb47f2804030b45f4ee20c,RCC,0.321786
uuid-e4904e4233eb47f2804030b45f4ee20c,2L,0.474436
uuid-e4904e4233eb47f2804030b45f4ee20c,stated,0.411238
uuid-e4904e4233eb47f2804030b45f4ee20c,approval,0.494101
uuid-e4904e4233eb47f2804030b45f4ee20c,atezo,0.440733
uuid-e4904e4233eb47f2804030b45f4ee20c,preferred,0.475835
uuid-e4904e4233eb47f2804030b45f4ee20c,using nivo,0.524631
uuid-e4904e4233eb47f2804030b45f4ee20c,clinical trials,0.366059
uuid-e4904e4233eb47f2804030b45f4ee20c,indication,0.330677
uuid-e4904e4233eb47f2804030b45f4ee20c,approved,0.500637
uuid-e4904e4233eb47f2804030b45f4ee20c,SCCHN,0.428461
uuid-e4904e4233eb47f2804030b45f4ee20c,tumor types,0.348283
uuid-e4904e4233eb47f2804030b45f4ee20c,LTL,0.32591
uuid-e4904e4233eb47f2804030b45f4ee20c,Regional TL,0.309833
uuid-e4904e4233eb47f2804030b45f4ee20c,RTL stated,0.550147
uuid-e4904e4233eb47f2804030b45f4ee20c,option,0.331941
uuid-e4904e4233eb47f2804030b45f4ee20c,bladder,0.579743
uuid-511067635dfc484e97c2db55f59383e2,TL,0.345202
uuid-511067635dfc484e97c2db55f59383e2,pembro,0.567435
uuid-511067635dfc484e97c2db55f59383e2,1L,0.670339
uuid-511067635dfc484e97c2db55f59383e2,RCC,0.412081
uuid-511067635dfc484e97c2db55f59383e2,TL stated,0.373513
uuid-511067635dfc484e97c2db55f59383e2,2L,0.649815
uuid-511067635dfc484e97c2db55f59383e2,agents,0.381885
uuid-511067635dfc484e97c2db55f59383e2,PD-L1,0.326946
uuid-511067635dfc484e97c2db55f59383e2,approval,0.500781
uuid-511067635dfc484e97c2db55f59383e2,atezo,0.554342
uuid-511067635dfc484e97c2db55f59383e2,preferred,0.537708
uuid-511067635dfc484e97c2db55f59383e2,testing,0.322222
uuid-511067635dfc484e97c2db55f59383e2,monotherapy,0.458616
uuid-511067635dfc484e97c2db55f59383e2,using nivo,0.52107
uuid-511067635dfc484e97c2db55f59383e2,combo,0.330514
uuid-511067635dfc484e97c2db55f59383e2,PDL1 testing,0.403303
uuid-511067635dfc484e97c2db55f59383e2,indication,0.311245
uuid-511067635dfc484e97c2db55f59383e2,NSCLC patients,0.370566
uuid-511067635dfc484e97c2db55f59383e2,approved,0.472505
uuid-511067635dfc484e97c2db55f59383e2,SCCHN,0.400831
uuid-511067635dfc484e97c2db55f59383e2,nivo and pembro,0.301105
uuid-511067635dfc484e97c2db55f59383e2,believes,0.328521
uuid-511067635dfc484e97c2db55f59383e2,TLs,0.322991
uuid-511067635dfc484e97c2db55f59383e2,feels,0.311878
uuid-511067635dfc484e97c2db55f59383e2,RTL stated,0.512249
uuid-511067635dfc484e97c2db55f59383e2,option,0.428686
uuid-511067635dfc484e97c2db55f59383e2,bladder,0.329247
uuid-012953546044464da3376705c3d87e8b,Nivo,0.43379
uuid-012953546044464da3376705c3d87e8b,pembro,0.436279
uuid-012953546044464da3376705c3d87e8b,nivolumab,0.380788
uuid-012953546044464da3376705c3d87e8b,1L,0.54481
uuid-012953546044464da3376705c3d87e8b,regimen,0.487793
uuid-012953546044464da3376705c3d87e8b,RCC,0.45328
uuid-012953546044464da3376705c3d87e8b,combination,0.44568
uuid-012953546044464da3376705c3d87e8b,chemo,0.35328
uuid-012953546044464da3376705c3d87e8b,2L,0.592215
uuid-012953546044464da3376705c3d87e8b,pts,0.377292
uuid-012953546044464da3376705c3d87e8b,agents,0.341596
uuid-012953546044464da3376705c3d87e8b,Ipi,0.358065
uuid-012953546044464da3376705c3d87e8b,stated,0.309348
uuid-012953546044464da3376705c3d87e8b,approval,0.312752
uuid-012953546044464da3376705c3d87e8b,atezo,0.423809
uuid-012953546044464da3376705c3d87e8b,preferred,0.521839
uuid-012953546044464da3376705c3d87e8b,monotherapy,0.61476
uuid-012953546044464da3376705c3d87e8b,using nivo,0.501552
uuid-012953546044464da3376705c3d87e8b,combo,0.525338
uuid-012953546044464da3376705c3d87e8b,PD1,0.352238
uuid-012953546044464da3376705c3d87e8b,approved,0.458898
uuid-012953546044464da3376705c3d87e8b,SCCHN,0.36248
uuid-012953546044464da3376705c3d87e8b,impressed,0.404842
uuid-012953546044464da3376705c3d87e8b,TLs,0.323842
uuid-012953546044464da3376705c3d87e8b,SCLC,0.316883
uuid-012953546044464da3376705c3d87e8b,feels,0.470344
uuid-012953546044464da3376705c3d87e8b,RTL stated,0.504195
uuid-012953546044464da3376705c3d87e8b,option,0.488272
uuid-012953546044464da3376705c3d87e8b,bladder,0.335482
uuid-456d2888aa6b464cb2e6b1c82b621f2f,patients,0.521433
uuid-456d2888aa6b464cb2e6b1c82b621f2f,toxicity,0.709591
uuid-456d2888aa6b464cb2e6b1c82b621f2f,regimen,0.621583
uuid-456d2888aa6b464cb2e6b1c82b621f2f,treated,0.518168
uuid-456d2888aa6b464cb2e6b1c82b621f2f,pts,0.368718
uuid-456d2888aa6b464cb2e6b1c82b621f2f,treatment,0.50988
uuid-456d2888aa6b464cb2e6b1c82b621f2f,response,0.353374
uuid-456d2888aa6b464cb2e6b1c82b621f2f,progression,0.461998
uuid-456d2888aa6b464cb2e6b1c82b621f2f,respond,0.469104
uuid-cad24df4c8084c15a8b4713c436377e8,patients,0.305296
uuid-cad24df4c8084c15a8b4713c436377e8,Opdivo,0.626481
uuid-cad24df4c8084c15a8b4713c436377e8,dose,0.673978
uuid-cad24df4c8084c15a8b4713c436377e8,toxicity,0.35494
uuid-cad24df4c8084c15a8b4713c436377e8,Ipi,0.301365
uuid-cad24df4c8084c15a8b4713c436377e8,mentioned,0.350429
uuid-cad24df4c8084c15a8b4713c436377e8,HCP,0.380113
uuid-cad24df4c8084c15a8b4713c436377e8,drug,0.362746
uuid-cad24df4c8084c15a8b4713c436377e8,Keytruda,0.611487
uuid-cad24df4c8084c15a8b4713c436377e8,flat dosing,0.665997
uuid-ddaf47686700446fae488693209b65d4,patients,0.877033
uuid-ddaf47686700446fae488693209b65d4,Opdivo,0.426264
uuid-ddaf47686700446fae488693209b65d4,therapy,0.609176
uuid-ddaf47686700446fae488693209b65d4,nivolumab,0.483179
uuid-ddaf47686700446fae488693209b65d4,toxicity,0.414284
uuid-ddaf47686700446fae488693209b65d4,regimen,0.621713
uuid-ddaf47686700446fae488693209b65d4,treated,0.587391
uuid-ddaf47686700446fae488693209b65d4,combination,0.304201
uuid-ddaf47686700446fae488693209b65d4,chemo,0.45602
uuid-ddaf47686700446fae488693209b65d4,pts,0.637858
uuid-ddaf47686700446fae488693209b65d4,monotherapy,0.444744
uuid-ddaf47686700446fae488693209b65d4,treatment,0.696522
uuid-ddaf47686700446fae488693209b65d4,response,0.479976
uuid-ddaf47686700446fae488693209b65d4,PD1,0.391875
uuid-ddaf47686700446fae488693209b65d4,cHL,0.30471
uuid-ddaf47686700446fae488693209b65d4,progression,0.685866
uuid-ddaf47686700446fae488693209b65d4,chemotherapy,0.487219
uuid-ddaf47686700446fae488693209b65d4,respond,0.513877
uuid-ddaf47686700446fae488693209b65d4,option,0.392539
uuid-c1a79bccb6a04110a5c1ba0c98fef463,PDL1,0.491413
uuid-c1a79bccb6a04110a5c1ba0c98fef463,efficacy,0.428668
uuid-c1a79bccb6a04110a5c1ba0c98fef463,discussed,0.357087
uuid-c1a79bccb6a04110a5c1ba0c98fef463,chemo,0.308152
uuid-c1a79bccb6a04110a5c1ba0c98fef463,OS,0.413768
uuid-c1a79bccb6a04110a5c1ba0c98fef463,data,0.328721
uuid-c1a79bccb6a04110a5c1ba0c98fef463,PFS,0.447608
uuid-c1a79bccb6a04110a5c1ba0c98fef463,ORR,0.402039
uuid-c1a79bccb6a04110a5c1ba0c98fef463,nivo and pembro,0.322598
uuid-c1a79bccb6a04110a5c1ba0c98fef463,believes,0.345065
uuid-c1a79bccb6a04110a5c1ba0c98fef463,feels,0.500774
uuid-c1a79bccb6a04110a5c1ba0c98fef463,PDL1 expression,0.502882
uuid-c1a79bccb6a04110a5c1ba0c98fef463,option,0.336299
uuid-c1a79bccb6a04110a5c1ba0c98fef463,biomarker,0.368519
uuid-5d33c2add3e74a3d9c3ad94a48399964,pembro,0.431789
uuid-5d33c2add3e74a3d9c3ad94a48399964,lung,0.449524
uuid-5d33c2add3e74a3d9c3ad94a48399964,NSCLC,0.379141
uuid-5d33c2add3e74a3d9c3ad94a48399964,trial,0.384043
uuid-5d33c2add3e74a3d9c3ad94a48399964,melanoma,0.301236
uuid-5d33c2add3e74a3d9c3ad94a48399964,RCC,0.379024
uuid-5d33c2add3e74a3d9c3ad94a48399964,TL stated,0.311717
uuid-5d33c2add3e74a3d9c3ad94a48399964,Merck,0.36326
uuid-5d33c2add3e74a3d9c3ad94a48399964,stated,0.330418
uuid-5d33c2add3e74a3d9c3ad94a48399964,atezo,0.42
uuid-5d33c2add3e74a3d9c3ad94a48399964,preferred,0.321763
uuid-5d33c2add3e74a3d9c3ad94a48399964,data,0.308149
uuid-5d33c2add3e74a3d9c3ad94a48399964,clinical trials,0.312354
uuid-5d33c2add3e74a3d9c3ad94a48399964,indication,0.395349
uuid-5d33c2add3e74a3d9c3ad94a48399964,SCCHN,0.488833
uuid-5d33c2add3e74a3d9c3ad94a48399964,TLs,0.381013
uuid-5d33c2add3e74a3d9c3ad94a48399964,Regional TL,0.347132
uuid-5d33c2add3e74a3d9c3ad94a48399964,RTL stated,0.359151
uuid-5d33c2add3e74a3d9c3ad94a48399964,TL shared,0.336389
uuid-5d33c2add3e74a3d9c3ad94a48399964,bladder,0.447542
uuid-50dadd4caaef43c8898a1e2a2f2ac736,patients,0.441247
uuid-50dadd4caaef43c8898a1e2a2f2ac736,Opdivo,0.519589
uuid-50dadd4caaef43c8898a1e2a2f2ac736,dose,0.322454
uuid-50dadd4caaef43c8898a1e2a2f2ac736,regimen,0.306681
uuid-50dadd4caaef43c8898a1e2a2f2ac736,pts,0.323742
uuid-50dadd4caaef43c8898a1e2a2f2ac736,progression,0.305011
uuid-50dadd4caaef43c8898a1e2a2f2ac736,feels,0.303764
uuid-50dadd4caaef43c8898a1e2a2f2ac736,flat dosing,0.316859
uuid-509f881d1b9a4d608d08aee85ea39e45,tumor,0.492822
uuid-509f881d1b9a4d608d08aee85ea39e45,response,0.389533
uuid-509f881d1b9a4d608d08aee85ea39e45,progression,0.342723
uuid-509f881d1b9a4d608d08aee85ea39e45,respond,0.39738
uuid-509f881d1b9a4d608d08aee85ea39e45,immunotherapy,0.31895
uuid-26f476e71ba74bad9c9672eafaa6981f,lung,0.413635
uuid-26f476e71ba74bad9c9672eafaa6981f,regimen,0.425226
uuid-26f476e71ba74bad9c9672eafaa6981f,melanoma,0.386801
uuid-26f476e71ba74bad9c9672eafaa6981f,RCC,0.373649
uuid-26f476e71ba74bad9c9672eafaa6981f,TL stated,0.428241
uuid-26f476e71ba74bad9c9672eafaa6981f,combo,0.309752
uuid-26f476e71ba74bad9c9672eafaa6981f,TL shared,0.394681
uuid-9e13be8106d64274a7e70627828b0935,RTL,0.328183
uuid-9e13be8106d64274a7e70627828b0935,NTL,0.315374
uuid-9e13be8106d64274a7e70627828b0935,melanoma,0.354727
uuid-9e13be8106d64274a7e70627828b0935,combination,0.318575
uuid-9e13be8106d64274a7e70627828b0935,stated,0.349092
uuid-9e13be8106d64274a7e70627828b0935,data,0.420692
uuid-9e13be8106d64274a7e70627828b0935,combo,0.307191
uuid-9e13be8106d64274a7e70627828b0935,PD1,0.304971
uuid-9e13be8106d64274a7e70627828b0935,impressed,0.352534
uuid-40f77e3a569542e0999629d85dedf8d1,therapy,0.457716
uuid-40f77e3a569542e0999629d85dedf8d1,regimen,0.410929
uuid-40f77e3a569542e0999629d85dedf8d1,treated,0.327466
uuid-40f77e3a569542e0999629d85dedf8d1,combination,0.447999
uuid-40f77e3a569542e0999629d85dedf8d1,chemo,0.444821
uuid-40f77e3a569542e0999629d85dedf8d1,IO,0.60204
uuid-40f77e3a569542e0999629d85dedf8d1,agents,0.382568
uuid-40f77e3a569542e0999629d85dedf8d1,physicians,0.343848
uuid-40f77e3a569542e0999629d85dedf8d1,preferred,0.329769
uuid-40f77e3a569542e0999629d85dedf8d1,monotherapy,0.463718
uuid-40f77e3a569542e0999629d85dedf8d1,treatment,0.573993
uuid-40f77e3a569542e0999629d85dedf8d1,response,0.336354
uuid-40f77e3a569542e0999629d85dedf8d1,combo,0.390684
uuid-40f77e3a569542e0999629d85dedf8d1,PD1,0.357961
uuid-40f77e3a569542e0999629d85dedf8d1,progression,0.4158
uuid-40f77e3a569542e0999629d85dedf8d1,chemotherapy,0.440699
uuid-40f77e3a569542e0999629d85dedf8d1,oncologist,0.368999
uuid-40f77e3a569542e0999629d85dedf8d1,respond,0.315659
uuid-40f77e3a569542e0999629d85dedf8d1,immunotherapy,0.309376
uuid-40f77e3a569542e0999629d85dedf8d1,option,0.459201
uuid-8eab451803b642a599bb04fd7e78b0d9,Nivo,0.380512
uuid-8eab451803b642a599bb04fd7e78b0d9,patients,0.577129
uuid-8eab451803b642a599bb04fd7e78b0d9,therapy,0.392239
uuid-8eab451803b642a599bb04fd7e78b0d9,nivolumab,0.344298
uuid-8eab451803b642a599bb04fd7e78b0d9,1L,0.533398
uuid-8eab451803b642a599bb04fd7e78b0d9,regimen,0.47702
uuid-8eab451803b642a599bb04fd7e78b0d9,combination,0.390228
uuid-8eab451803b642a599bb04fd7e78b0d9,chemo,0.490793
uuid-8eab451803b642a599bb04fd7e78b0d9,2L,0.540947
uuid-8eab451803b642a599bb04fd7e78b0d9,pts,0.516392
uuid-8eab451803b642a599bb04fd7e78b0d9,agents,0.322114
uuid-8eab451803b642a599bb04fd7e78b0d9,preferred,0.538867
uuid-8eab451803b642a599bb04fd7e78b0d9,monotherapy,0.662327
uuid-8eab451803b642a599bb04fd7e78b0d9,treatment,0.418664
uuid-8eab451803b642a599bb04fd7e78b0d9,using nivo,0.465592
uuid-8eab451803b642a599bb04fd7e78b0d9,combo,0.49446
uuid-8eab451803b642a599bb04fd7e78b0d9,PD1,0.368204
uuid-8eab451803b642a599bb04fd7e78b0d9,approved,0.418796
uuid-8eab451803b642a599bb04fd7e78b0d9,progression,0.434079
uuid-8eab451803b642a599bb04fd7e78b0d9,chemotherapy,0.39087
uuid-8eab451803b642a599bb04fd7e78b0d9,respond,0.356083
uuid-8eab451803b642a599bb04fd7e78b0d9,feels,0.48056
uuid-8eab451803b642a599bb04fd7e78b0d9,RTL stated,0.347596
uuid-8eab451803b642a599bb04fd7e78b0d9,option,0.765329
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,patients,0.417361
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,therapy,0.313351
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,1L,0.553738
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,PDL1,0.340852
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,TL stated,0.31804
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,2L,0.484508
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,PD-L1,0.583101
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,approval,0.311618
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,preferred,0.383952
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,PD-L1 testing,0.550545
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,testing,0.691163
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,monotherapy,0.321175
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,using nivo,0.330165
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,PDL1 testing,0.619531
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,NSCLC patients,0.683539
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,tumor types,0.304304
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,assay,0.329359
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,PD-1,0.307276
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,RTL stated,0.329846
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,option,0.435375
uuid-c019bd2c7a6f4b7c9f7ed60ff493def5,biomarker,0.312151
uuid-d771e2fc18254218bdec1cfa22af132f,Nivo,0.311488
uuid-d771e2fc18254218bdec1cfa22af132f,patients,0.470056
uuid-d771e2fc18254218bdec1cfa22af132f,therapy,0.4089
uuid-d771e2fc18254218bdec1cfa22af132f,1L,0.350404
uuid-d771e2fc18254218bdec1cfa22af132f,toxicity,0.349313
uuid-d771e2fc18254218bdec1cfa22af132f,regimen,0.585412
uuid-d771e2fc18254218bdec1cfa22af132f,chemo,0.6718
uuid-d771e2fc18254218bdec1cfa22af132f,pts,0.482852
uuid-d771e2fc18254218bdec1cfa22af132f,IO,0.377148
uuid-d771e2fc18254218bdec1cfa22af132f,OS,0.389041
uuid-d771e2fc18254218bdec1cfa22af132f,monotherapy,0.534772
uuid-d771e2fc18254218bdec1cfa22af132f,treatment,0.516063
uuid-d771e2fc18254218bdec1cfa22af132f,response,0.513197
uuid-d771e2fc18254218bdec1cfa22af132f,combo,0.423419
uuid-d771e2fc18254218bdec1cfa22af132f,PFS,0.341551
uuid-d771e2fc18254218bdec1cfa22af132f,PD1,0.433443
uuid-d771e2fc18254218bdec1cfa22af132f,progression,0.642502
uuid-d771e2fc18254218bdec1cfa22af132f,believes,0.383015
uuid-d771e2fc18254218bdec1cfa22af132f,chemotherapy,0.555513
uuid-d771e2fc18254218bdec1cfa22af132f,respond,0.495719
uuid-d771e2fc18254218bdec1cfa22af132f,feels,0.315855
uuid-d771e2fc18254218bdec1cfa22af132f,option,0.443636
uuid-346e4126a0cf485d9182ad32179ba1bc,BMS,0.426082
uuid-346e4126a0cf485d9182ad32179ba1bc,efficacy,0.361986
uuid-346e4126a0cf485d9182ad32179ba1bc,combination,0.633461
uuid-346e4126a0cf485d9182ad32179ba1bc,chemo,0.358839
uuid-346e4126a0cf485d9182ad32179ba1bc,IO,0.502169
uuid-346e4126a0cf485d9182ad32179ba1bc,agents,0.516094
uuid-346e4126a0cf485d9182ad32179ba1bc,monotherapy,0.39335
uuid-346e4126a0cf485d9182ad32179ba1bc,combo,0.572534
uuid-346e4126a0cf485d9182ad32179ba1bc,PD1,0.365019
uuid-346e4126a0cf485d9182ad32179ba1bc,believes,0.438574
uuid-346e4126a0cf485d9182ad32179ba1bc,feels,0.45333
uuid-346e4126a0cf485d9182ad32179ba1bc,option,0.302427
uuid-26da3706f7244c758619f530b379ba55,Nivo,0.304803
uuid-26da3706f7244c758619f530b379ba55,pembro,0.518949
uuid-26da3706f7244c758619f530b379ba55,dose,0.595947
uuid-26da3706f7244c758619f530b379ba55,BMS,0.35119
uuid-26da3706f7244c758619f530b379ba55,trial,0.560094
uuid-26da3706f7244c758619f530b379ba55,Merck,0.348204
uuid-26da3706f7244c758619f530b379ba55,Ipi,0.564877
uuid-26da3706f7244c758619f530b379ba55,atezo,0.410553
uuid-26da3706f7244c758619f530b379ba55,clinical trials,0.338518
uuid-26da3706f7244c758619f530b379ba55,vs,0.557756
uuid-26da3706f7244c758619f530b379ba55,flat dosing,0.502289
uuid-db14badbc800485ba7d02e5089de1a45,patients,0.678873
uuid-db14badbc800485ba7d02e5089de1a45,therapy,0.379211
uuid-db14badbc800485ba7d02e5089de1a45,nivolumab,0.345409
uuid-db14badbc800485ba7d02e5089de1a45,toxicity,0.37706
uuid-db14badbc800485ba7d02e5089de1a45,regimen,0.617407
uuid-db14badbc800485ba7d02e5089de1a45,treated,0.454522
uuid-db14badbc800485ba7d02e5089de1a45,combination,0.319497
uuid-db14badbc800485ba7d02e5089de1a45,chemo,0.395848
uuid-db14badbc800485ba7d02e5089de1a45,pts,0.504922
uuid-db14badbc800485ba7d02e5089de1a45,monotherapy,0.44703
uuid-db14badbc800485ba7d02e5089de1a45,treatment,0.49055
uuid-db14badbc800485ba7d02e5089de1a45,response,0.424934
uuid-db14badbc800485ba7d02e5089de1a45,combo,0.334337
uuid-db14badbc800485ba7d02e5089de1a45,progression,0.581347
uuid-db14badbc800485ba7d02e5089de1a45,chemotherapy,0.352937
uuid-db14badbc800485ba7d02e5089de1a45,respond,0.471883
uuid-db14badbc800485ba7d02e5089de1a45,option,0.353553
uuid-353c095d57494977a887739094becd1d,1L,0.482433
uuid-353c095d57494977a887739094becd1d,PDL1,0.34636
uuid-353c095d57494977a887739094becd1d,2L,0.451044
uuid-353c095d57494977a887739094becd1d,agents,0.325919
uuid-353c095d57494977a887739094becd1d,PD-L1,0.384839
uuid-353c095d57494977a887739094becd1d,preferred,0.475439
uuid-353c095d57494977a887739094becd1d,testing,0.374207
uuid-353c095d57494977a887739094becd1d,monotherapy,0.32724
uuid-353c095d57494977a887739094becd1d,PDL1 testing,0.473788
uuid-353c095d57494977a887739094becd1d,NSCLC patients,0.462543
uuid-353c095d57494977a887739094becd1d,tumor types,0.33316
uuid-353c095d57494977a887739094becd1d,PD-1,0.394107
uuid-353c095d57494977a887739094becd1d,RTL stated,0.363542
uuid-353c095d57494977a887739094becd1d,option,0.394485
uuid-9c230c4e671b43df92c45f4f4600ac27,dose,0.366371
uuid-9c230c4e671b43df92c45f4f4600ac27,toxicity,0.664186
uuid-9c230c4e671b43df92c45f4f4600ac27,regimen,0.623924
uuid-9c230c4e671b43df92c45f4f4600ac27,treated,0.315116
uuid-9c230c4e671b43df92c45f4f4600ac27,combination,0.352466
uuid-9c230c4e671b43df92c45f4f4600ac27,Ipi,0.335121
uuid-9c230c4e671b43df92c45f4f4600ac27,physicians,0.306746
uuid-9c230c4e671b43df92c45f4f4600ac27,monotherapy,0.34488
uuid-9c230c4e671b43df92c45f4f4600ac27,treatment,0.324158
uuid-9c230c4e671b43df92c45f4f4600ac27,combo,0.399187
uuid-9c230c4e671b43df92c45f4f4600ac27,feels,0.379386
uuid-fda97e7fcae44427b316b99abe6851f8,Nivo,0.555471
uuid-fda97e7fcae44427b316b99abe6851f8,pembro,0.54059
uuid-fda97e7fcae44427b316b99abe6851f8,1L,0.35291
uuid-fda97e7fcae44427b316b99abe6851f8,trial,0.51322
uuid-fda97e7fcae44427b316b99abe6851f8,efficacy,0.327067
uuid-fda97e7fcae44427b316b99abe6851f8,chemo,0.383755
uuid-fda97e7fcae44427b316b99abe6851f8,OS,0.359795
uuid-fda97e7fcae44427b316b99abe6851f8,atezo,0.375005
uuid-fda97e7fcae44427b316b99abe6851f8,data,0.30186
uuid-fda97e7fcae44427b316b99abe6851f8,PFS,0.36539
uuid-fda97e7fcae44427b316b99abe6851f8,ORR,0.330797
uuid-fda97e7fcae44427b316b99abe6851f8,approved,0.314091
uuid-fda97e7fcae44427b316b99abe6851f8,nivo and pembro,0.31247
uuid-fda97e7fcae44427b316b99abe6851f8,vs,0.369534
uuid-fda97e7fcae44427b316b99abe6851f8,feels,0.385576
uuid-fda97e7fcae44427b316b99abe6851f8,option,0.302677
uuid-a74236bd320d49b69e795a24cc0d1691,Nivo,0.374351
uuid-a74236bd320d49b69e795a24cc0d1691,therapy,0.469792
uuid-a74236bd320d49b69e795a24cc0d1691,1L,0.422978
uuid-a74236bd320d49b69e795a24cc0d1691,PDL1,0.358387
uuid-a74236bd320d49b69e795a24cc0d1691,efficacy,0.347875
uuid-a74236bd320d49b69e795a24cc0d1691,regimen,0.339049
uuid-a74236bd320d49b69e795a24cc0d1691,combination,0.43593
uuid-a74236bd320d49b69e795a24cc0d1691,chemo,0.775234
uuid-a74236bd320d49b69e795a24cc0d1691,pts,0.42953
uuid-a74236bd320d49b69e795a24cc0d1691,IO,0.353812
uuid-a74236bd320d49b69e795a24cc0d1691,agents,0.473607
uuid-a74236bd320d49b69e795a24cc0d1691,monotherapy,0.539347
uuid-a74236bd320d49b69e795a24cc0d1691,treatment,0.332816
uuid-a74236bd320d49b69e795a24cc0d1691,response,0.504215
uuid-a74236bd320d49b69e795a24cc0d1691,combo,0.454756
uuid-a74236bd320d49b69e795a24cc0d1691,PD1,0.56688
uuid-a74236bd320d49b69e795a24cc0d1691,nivo and pembro,0.378206
uuid-a74236bd320d49b69e795a24cc0d1691,progression,0.457059
uuid-a74236bd320d49b69e795a24cc0d1691,believes,0.551183
uuid-a74236bd320d49b69e795a24cc0d1691,chemotherapy,0.635686
uuid-a74236bd320d49b69e795a24cc0d1691,respond,0.496857
uuid-a74236bd320d49b69e795a24cc0d1691,feels,0.443998
uuid-a74236bd320d49b69e795a24cc0d1691,PD-1,0.35579
uuid-a74236bd320d49b69e795a24cc0d1691,option,0.505416
uuid-8464cf2fc26f4a448565b4e3723a8f00,pembro,0.359468
uuid-8464cf2fc26f4a448565b4e3723a8f00,trial,0.844475
uuid-8464cf2fc26f4a448565b4e3723a8f00,combination,0.332218
uuid-8464cf2fc26f4a448565b4e3723a8f00,clinical trials,0.420626
uuid-293275fbbcf048beac32ca06b3903e9f,Nivo,0.439063
uuid-293275fbbcf048beac32ca06b3903e9f,nivolumab,0.363579
uuid-293275fbbcf048beac32ca06b3903e9f,trial,0.487248
uuid-293275fbbcf048beac32ca06b3903e9f,efficacy,0.357066
uuid-293275fbbcf048beac32ca06b3903e9f,chemo,0.307307
uuid-293275fbbcf048beac32ca06b3903e9f,OS,0.408059
uuid-293275fbbcf048beac32ca06b3903e9f,data,0.510698
uuid-293275fbbcf048beac32ca06b3903e9f,PFS,0.420476
uuid-293275fbbcf048beac32ca06b3903e9f,ORR,0.432568
uuid-293275fbbcf048beac32ca06b3903e9f,chemotherapy,0.385225
uuid-293275fbbcf048beac32ca06b3903e9f,impressed,0.452879
uuid-293275fbbcf048beac32ca06b3903e9f,feels,0.439601
uuid-5c92491e755a451191d0e4812fc5f360,efficacy,0.524873
uuid-5c92491e755a451191d0e4812fc5f360,commented,0.418703
uuid-5c92491e755a451191d0e4812fc5f360,OS,0.36774
uuid-5c92491e755a451191d0e4812fc5f360,regards,0.393461
uuid-5c92491e755a451191d0e4812fc5f360,data,0.63049
uuid-5c92491e755a451191d0e4812fc5f360,expressed,0.362927
uuid-5c92491e755a451191d0e4812fc5f360,PFS,0.30247
uuid-5c92491e755a451191d0e4812fc5f360,ORR,0.387753
uuid-5c92491e755a451191d0e4812fc5f360,nivo and pembro,0.349795
uuid-5c92491e755a451191d0e4812fc5f360,ASCO,0.468124
uuid-5c92491e755a451191d0e4812fc5f360,impressed,0.502533
uuid-5c92491e755a451191d0e4812fc5f360,TLs,0.372814
uuid-ce43a56730df42aaab6751f93265b961,lung,0.389881
uuid-ce43a56730df42aaab6751f93265b961,regards,0.366257
uuid-ce43a56730df42aaab6751f93265b961,AI,0.668663
uuid-ce43a56730df42aaab6751f93265b961,oncology,0.316868
uuid-ce43a56730df42aaab6751f93265b961,NCCN,0.385907
uuid-ce43a56730df42aaab6751f93265b961,flat dosing,0.311075
uuid-4b2813a3395541589fcea5a19055a9e6,Nivo,0.305303
uuid-4b2813a3395541589fcea5a19055a9e6,pembro,0.448527
uuid-4b2813a3395541589fcea5a19055a9e6,1L,0.429311
uuid-4b2813a3395541589fcea5a19055a9e6,trial,0.304793
uuid-4b2813a3395541589fcea5a19055a9e6,RCC,0.31125
uuid-4b2813a3395541589fcea5a19055a9e6,TL stated,0.305453
uuid-4b2813a3395541589fcea5a19055a9e6,2L,0.363289
uuid-4b2813a3395541589fcea5a19055a9e6,Merck,0.301985
uuid-4b2813a3395541589fcea5a19055a9e6,stated,0.303625
uuid-4b2813a3395541589fcea5a19055a9e6,approval,0.449214
uuid-4b2813a3395541589fcea5a19055a9e6,OS,0.427351
uuid-4b2813a3395541589fcea5a19055a9e6,atezo,0.362701
uuid-4b2813a3395541589fcea5a19055a9e6,using nivo,0.372343
uuid-4b2813a3395541589fcea5a19055a9e6,data,0.331928
uuid-4b2813a3395541589fcea5a19055a9e6,PFS,0.367414
uuid-4b2813a3395541589fcea5a19055a9e6,ORR,0.327419
uuid-4b2813a3395541589fcea5a19055a9e6,approved,0.318861
uuid-4b2813a3395541589fcea5a19055a9e6,SCCHN,0.452606
uuid-4b2813a3395541589fcea5a19055a9e6,nivo and pembro,0.318248
uuid-4b2813a3395541589fcea5a19055a9e6,impressed,0.424389
uuid-4b2813a3395541589fcea5a19055a9e6,RTL stated,0.319837
uuid-4b2813a3395541589fcea5a19055a9e6,bladder,0.390445
uuid-65d5bffcf06c43399275bcb7001ab34e,patients,0.412514
uuid-65d5bffcf06c43399275bcb7001ab34e,Opdivo,0.345288
uuid-65d5bffcf06c43399275bcb7001ab34e,dose,0.353147
uuid-65d5bffcf06c43399275bcb7001ab34e,toxicity,0.715566
uuid-65d5bffcf06c43399275bcb7001ab34e,regimen,0.518582
uuid-65d5bffcf06c43399275bcb7001ab34e,treated,0.390283
uuid-65d5bffcf06c43399275bcb7001ab34e,treatment,0.503225
uuid-65d5bffcf06c43399275bcb7001ab34e,progression,0.322822
uuid-65d5bffcf06c43399275bcb7001ab34e,respond,0.395085
uuid-b119e55b7a104745a1f3b5faa8ae2da0,RTL,0.433625
uuid-b119e55b7a104745a1f3b5faa8ae2da0,trial,0.523619
uuid-b119e55b7a104745a1f3b5faa8ae2da0,NTL,0.569463
uuid-b119e55b7a104745a1f3b5faa8ae2da0,Merck,0.398618
uuid-b119e55b7a104745a1f3b5faa8ae2da0,data,0.333378
uuid-b119e55b7a104745a1f3b5faa8ae2da0,expressed,0.302561
uuid-b119e55b7a104745a1f3b5faa8ae2da0,ASCO,0.420434
uuid-b119e55b7a104745a1f3b5faa8ae2da0,impressed,0.306565
uuid-b119e55b7a104745a1f3b5faa8ae2da0,Regional TL,0.35788
uuid-991062fc3a0a434f922a61eb250027f1,RTL,0.521195
uuid-991062fc3a0a434f922a61eb250027f1,nivolumab,0.389471
uuid-991062fc3a0a434f922a61eb250027f1,NTL,0.538901
uuid-991062fc3a0a434f922a61eb250027f1,stated,0.514676
uuid-991062fc3a0a434f922a61eb250027f1,approval,0.32665
uuid-991062fc3a0a434f922a61eb250027f1,using nivo,0.373898
uuid-991062fc3a0a434f922a61eb250027f1,mentioned,0.518834
uuid-991062fc3a0a434f922a61eb250027f1,SCCHN,0.36017
uuid-991062fc3a0a434f922a61eb250027f1,cHL,0.569545
uuid-991062fc3a0a434f922a61eb250027f1,LTL,0.431016
uuid-991062fc3a0a434f922a61eb250027f1,Regional TL,0.477543
uuid-991062fc3a0a434f922a61eb250027f1,RTL stated,0.300544
uuid-f53fcf5e45dc460d9243f30f5e338b30,Nivo,0.376226
uuid-f53fcf5e45dc460d9243f30f5e338b30,patients,0.77881
uuid-f53fcf5e45dc460d9243f30f5e338b30,Opdivo,0.380514
uuid-f53fcf5e45dc460d9243f30f5e338b30,therapy,0.669308
uuid-f53fcf5e45dc460d9243f30f5e338b30,nivolumab,0.570026
uuid-f53fcf5e45dc460d9243f30f5e338b30,regimen,0.376328
uuid-f53fcf5e45dc460d9243f30f5e338b30,treated,0.551515
uuid-f53fcf5e45dc460d9243f30f5e338b30,chemo,0.327918
uuid-f53fcf5e45dc460d9243f30f5e338b30,pts,0.453231
uuid-f53fcf5e45dc460d9243f30f5e338b30,approval,0.325801
uuid-f53fcf5e45dc460d9243f30f5e338b30,monotherapy,0.338872
uuid-f53fcf5e45dc460d9243f30f5e338b30,treatment,0.648442
uuid-f53fcf5e45dc460d9243f30f5e338b30,using nivo,0.45119
uuid-f53fcf5e45dc460d9243f30f5e338b30,cHL,0.510828
uuid-f53fcf5e45dc460d9243f30f5e338b30,progression,0.512225
uuid-f53fcf5e45dc460d9243f30f5e338b30,chemotherapy,0.466132
uuid-f53fcf5e45dc460d9243f30f5e338b30,respond,0.309893
uuid-f53fcf5e45dc460d9243f30f5e338b30,RTL stated,0.388889
uuid-f53fcf5e45dc460d9243f30f5e338b30,option,0.397238
uuid-b8a64ff934da44a1a39a142f485e2015,TL,0.336261
uuid-b8a64ff934da44a1a39a142f485e2015,lung,0.322955
uuid-b8a64ff934da44a1a39a142f485e2015,1L,0.301123
uuid-b8a64ff934da44a1a39a142f485e2015,shared,0.38258
uuid-b8a64ff934da44a1a39a142f485e2015,commented,0.383509
uuid-b8a64ff934da44a1a39a142f485e2015,RCC,0.533149
uuid-b8a64ff934da44a1a39a142f485e2015,TL stated,0.519877
uuid-b8a64ff934da44a1a39a142f485e2015,2L,0.33855
uuid-b8a64ff934da44a1a39a142f485e2015,stated,0.337099
uuid-b8a64ff934da44a1a39a142f485e2015,approval,0.399684
uuid-b8a64ff934da44a1a39a142f485e2015,preferred,0.325791
uuid-b8a64ff934da44a1a39a142f485e2015,PD-L1 testing,0.371959
uuid-b8a64ff934da44a1a39a142f485e2015,testing,0.322418
uuid-b8a64ff934da44a1a39a142f485e2015,using nivo,0.325138
uuid-b8a64ff934da44a1a39a142f485e2015,PDL1 testing,0.49032
uuid-b8a64ff934da44a1a39a142f485e2015,approved,0.366452
uuid-b8a64ff934da44a1a39a142f485e2015,SCCHN,0.459524
uuid-b8a64ff934da44a1a39a142f485e2015,TLs,0.335218
uuid-b8a64ff934da44a1a39a142f485e2015,Regional TL,0.463643
uuid-b8a64ff934da44a1a39a142f485e2015,RTL stated,0.384113
uuid-b8a64ff934da44a1a39a142f485e2015,TL shared,0.357269
uuid-b8a64ff934da44a1a39a142f485e2015,bladder,0.336691
uuid-4ea9ff61255c46a984560f9b95f40183,pembro,0.312731
uuid-4ea9ff61255c46a984560f9b95f40183,BMS,0.566036
uuid-4ea9ff61255c46a984560f9b95f40183,commented,0.34797
uuid-4ea9ff61255c46a984560f9b95f40183,Merck,0.488344
uuid-4ea9ff61255c46a984560f9b95f40183,stated,0.338643
uuid-4ea9ff61255c46a984560f9b95f40183,approval,0.402523
uuid-4ea9ff61255c46a984560f9b95f40183,atezo,0.323208
uuid-4ea9ff61255c46a984560f9b95f40183,preferred,0.324457
uuid-4ea9ff61255c46a984560f9b95f40183,clinical trials,0.439755
uuid-4ea9ff61255c46a984560f9b95f40183,indication,0.428085
uuid-4ea9ff61255c46a984560f9b95f40183,approved,0.439973
uuid-4ea9ff61255c46a984560f9b95f40183,SCCHN,0.311138
uuid-4ea9ff61255c46a984560f9b95f40183,label,0.314405
uuid-4ea9ff61255c46a984560f9b95f40183,feels,0.316195
uuid-2376cef88ec248218540fe2cab35d43c,Nivo,0.309646
uuid-2376cef88ec248218540fe2cab35d43c,pembro,0.357672
uuid-2376cef88ec248218540fe2cab35d43c,trial,0.568304
uuid-2376cef88ec248218540fe2cab35d43c,combination,0.318477
uuid-2376cef88ec248218540fe2cab35d43c,chemotherapy,0.326283
uuid-e6563061d8e24d2f986954ab0f0ed303,pembro,0.348016
uuid-e6563061d8e24d2f986954ab0f0ed303,BMS,0.571639
uuid-e6563061d8e24d2f986954ab0f0ed303,1L,0.379322
uuid-e6563061d8e24d2f986954ab0f0ed303,PDL1,0.352774
uuid-e6563061d8e24d2f986954ab0f0ed303,trial,0.361493
uuid-e6563061d8e24d2f986954ab0f0ed303,agents,0.300198
uuid-e6563061d8e24d2f986954ab0f0ed303,Merck,0.506772
uuid-e6563061d8e24d2f986954ab0f0ed303,atezo,0.322929
uuid-e6563061d8e24d2f986954ab0f0ed303,data,0.327373
uuid-e6563061d8e24d2f986954ab0f0ed303,clinical trials,0.348763
uuid-e6563061d8e24d2f986954ab0f0ed303,indication,0.305463
uuid-e6563061d8e24d2f986954ab0f0ed303,approved,0.353704
uuid-e6563061d8e24d2f986954ab0f0ed303,nivo and pembro,0.431135
uuid-e6563061d8e24d2f986954ab0f0ed303,believes,0.383752
uuid-e6563061d8e24d2f986954ab0f0ed303,feels,0.450315
uuid-00f05c8ef63c4c3c94035f7be58d87de,Nivo,0.406609
uuid-00f05c8ef63c4c3c94035f7be58d87de,efficacy,0.362944
uuid-00f05c8ef63c4c3c94035f7be58d87de,OS,0.47627
uuid-00f05c8ef63c4c3c94035f7be58d87de,data,0.578016
uuid-00f05c8ef63c4c3c94035f7be58d87de,PFS,0.448609
uuid-00f05c8ef63c4c3c94035f7be58d87de,ORR,0.468893
uuid-00f05c8ef63c4c3c94035f7be58d87de,impressed,0.594616
uuid-00f05c8ef63c4c3c94035f7be58d87de,feels,0.3348
uuid-1c461fe6d47a4b04893086e1053d9136,patients,0.365772
uuid-1c461fe6d47a4b04893086e1053d9136,Opdivo,0.348043
uuid-1c461fe6d47a4b04893086e1053d9136,dose,0.301966
uuid-1c461fe6d47a4b04893086e1053d9136,toxicity,0.453108
uuid-1c461fe6d47a4b04893086e1053d9136,regimen,0.458625
uuid-1c461fe6d47a4b04893086e1053d9136,treated,0.319403
uuid-1c461fe6d47a4b04893086e1053d9136,physicians,0.311813
uuid-1c461fe6d47a4b04893086e1053d9136,treatment,0.439135
uuid-1c461fe6d47a4b04893086e1053d9136,respond,0.38115
uuid-c2ef6e214dca46809b0faf37abac6327,pembro,0.354439
uuid-c2ef6e214dca46809b0faf37abac6327,BMS,0.501425
uuid-c2ef6e214dca46809b0faf37abac6327,1L,0.365502
uuid-c2ef6e214dca46809b0faf37abac6327,PDL1,0.750144
uuid-c2ef6e214dca46809b0faf37abac6327,trial,0.474943
uuid-c2ef6e214dca46809b0faf37abac6327,efficacy,0.486816
uuid-c2ef6e214dca46809b0faf37abac6327,Merck,0.476025
uuid-c2ef6e214dca46809b0faf37abac6327,PD-L1,0.353272
uuid-c2ef6e214dca46809b0faf37abac6327,OS,0.557119
uuid-c2ef6e214dca46809b0faf37abac6327,atezo,0.32917
uuid-c2ef6e214dca46809b0faf37abac6327,data,0.727642
uuid-c2ef6e214dca46809b0faf37abac6327,PFS,0.554629
uuid-c2ef6e214dca46809b0faf37abac6327,ORR,0.576235
uuid-c2ef6e214dca46809b0faf37abac6327,nivo and pembro,0.583655
uuid-c2ef6e214dca46809b0faf37abac6327,believes,0.43856
uuid-c2ef6e214dca46809b0faf37abac6327,impressed,0.436127
uuid-c2ef6e214dca46809b0faf37abac6327,feels,0.410718
uuid-c2ef6e214dca46809b0faf37abac6327,PDL1 expression,0.646684
uuid-c2ef6e214dca46809b0faf37abac6327,biomarker,0.561893
uuid-0dd639f2f632495f964a810817ae3410,Nivo,0.62118
uuid-0dd639f2f632495f964a810817ae3410,patients,0.343291
uuid-0dd639f2f632495f964a810817ae3410,pembro,0.641372
uuid-0dd639f2f632495f964a810817ae3410,dose,0.520425
uuid-0dd639f2f632495f964a810817ae3410,1L,0.342015
uuid-0dd639f2f632495f964a810817ae3410,toxicity,0.320298
uuid-0dd639f2f632495f964a810817ae3410,efficacy,0.430249
uuid-0dd639f2f632495f964a810817ae3410,regimen,0.318185
uuid-0dd639f2f632495f964a810817ae3410,chemo,0.457107
uuid-0dd639f2f632495f964a810817ae3410,2L,0.445965
uuid-0dd639f2f632495f964a810817ae3410,agents,0.407953
uuid-0dd639f2f632495f964a810817ae3410,Ipi,0.420569
uuid-0dd639f2f632495f964a810817ae3410,atezo,0.57847
uuid-0dd639f2f632495f964a810817ae3410,preferred,0.494176
uuid-0dd639f2f632495f964a810817ae3410,monotherapy,0.473104
uuid-0dd639f2f632495f964a810817ae3410,using nivo,0.343071
uuid-0dd639f2f632495f964a810817ae3410,nivo and pembro,0.472552
uuid-0dd639f2f632495f964a810817ae3410,believes,0.343832
uuid-0dd639f2f632495f964a810817ae3410,chemotherapy,0.310342
uuid-0dd639f2f632495f964a810817ae3410,vs,0.642234
uuid-0dd639f2f632495f964a810817ae3410,feels,0.468913
uuid-0dd639f2f632495f964a810817ae3410,option,0.452255
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,RTL,0.637087
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,nivolumab,0.547343
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,treated,0.31591
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,NTL,0.478296
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,melanoma,0.373029
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,shared,0.436655
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,commented,0.345536
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,RCC,0.516104
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,stated,0.581213
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,approval,0.565311
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,using nivo,0.554684
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,expressed,0.318193
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,mentioned,0.443073
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,clinical trials,0.462823
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,approved,0.509981
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,SCCHN,0.700101
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,HCP,0.427536
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,tumor types,0.32976
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,label,0.424765
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,LTL,0.536833
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,SCLC,0.554662
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,Regional TL,0.645757
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,RTL stated,0.567151
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,TL shared,0.39891
uuid-7c43a3cf3ae6413ebb3f604eb0acb731,bladder,0.515627
uuid-f551f2fa1cc1482db658f161838b288b,Opdivo,0.367019
uuid-f551f2fa1cc1482db658f161838b288b,pembro,0.411681
uuid-f551f2fa1cc1482db658f161838b288b,dose,0.780682
uuid-f551f2fa1cc1482db658f161838b288b,Ipi,0.448734
uuid-f551f2fa1cc1482db658f161838b288b,approval,0.319318
uuid-f551f2fa1cc1482db658f161838b288b,atezo,0.410957
uuid-f551f2fa1cc1482db658f161838b288b,preferred,0.31792
uuid-f551f2fa1cc1482db658f161838b288b,indication,0.4061
uuid-f551f2fa1cc1482db658f161838b288b,vs,0.420105
uuid-f551f2fa1cc1482db658f161838b288b,Keytruda,0.375615
uuid-f551f2fa1cc1482db658f161838b288b,flat dosing,0.730298
uuid-580e37a023d245d1b965b570fd35b082,Nivo,0.390829
uuid-580e37a023d245d1b965b570fd35b082,patients,0.582081
uuid-580e37a023d245d1b965b570fd35b082,Opdivo,0.509588
uuid-580e37a023d245d1b965b570fd35b082,therapy,0.351794
uuid-580e37a023d245d1b965b570fd35b082,dose,0.619799
uuid-580e37a023d245d1b965b570fd35b082,nivolumab,0.351292
uuid-580e37a023d245d1b965b570fd35b082,toxicity,0.437175
uuid-580e37a023d245d1b965b570fd35b082,regimen,0.43066
uuid-580e37a023d245d1b965b570fd35b082,chemo,0.311441
uuid-580e37a023d245d1b965b570fd35b082,pts,0.39861
uuid-580e37a023d245d1b965b570fd35b082,Ipi,0.361556
uuid-580e37a023d245d1b965b570fd35b082,monotherapy,0.308728
uuid-580e37a023d245d1b965b570fd35b082,treatment,0.36427
uuid-580e37a023d245d1b965b570fd35b082,progression,0.384062
uuid-580e37a023d245d1b965b570fd35b082,chemotherapy,0.308466
uuid-580e37a023d245d1b965b570fd35b082,vs,0.368214
uuid-580e37a023d245d1b965b570fd35b082,option,0.30792
uuid-580e37a023d245d1b965b570fd35b082,flat dosing,0.520263
uuid-8b28836cdc384ce6a27fe5e969c1debb,PDL1,0.309565
uuid-8b28836cdc384ce6a27fe5e969c1debb,efficacy,0.430949
uuid-8b28836cdc384ce6a27fe5e969c1debb,regimen,0.344694
uuid-8b28836cdc384ce6a27fe5e969c1debb,combination,0.413968
uuid-8b28836cdc384ce6a27fe5e969c1debb,chemo,0.57599
uuid-8b28836cdc384ce6a27fe5e969c1debb,pts,0.461939
uuid-8b28836cdc384ce6a27fe5e969c1debb,IO,0.40888
uuid-8b28836cdc384ce6a27fe5e969c1debb,OS,0.534403
uuid-8b28836cdc384ce6a27fe5e969c1debb,monotherapy,0.362312
uuid-8b28836cdc384ce6a27fe5e969c1debb,response,0.708908
uuid-8b28836cdc384ce6a27fe5e969c1debb,combo,0.388137
uuid-8b28836cdc384ce6a27fe5e969c1debb,PFS,0.510628
uuid-8b28836cdc384ce6a27fe5e969c1debb,PD1,0.497412
uuid-8b28836cdc384ce6a27fe5e969c1debb,ORR,0.498403
uuid-8b28836cdc384ce6a27fe5e969c1debb,progression,0.454789
uuid-8b28836cdc384ce6a27fe5e969c1debb,believes,0.532692
uuid-8b28836cdc384ce6a27fe5e969c1debb,chemotherapy,0.428011
uuid-8b28836cdc384ce6a27fe5e969c1debb,respond,0.447406
uuid-8b28836cdc384ce6a27fe5e969c1debb,feels,0.380839
uuid-9e1bae7a9a584c95a4376919afd5c686,Nivo,0.326924
uuid-9e1bae7a9a584c95a4376919afd5c686,patients,0.343004
uuid-9e1bae7a9a584c95a4376919afd5c686,Opdivo,0.468952
uuid-9e1bae7a9a584c95a4376919afd5c686,pembro,0.373239
uuid-9e1bae7a9a584c95a4376919afd5c686,dose,0.880012
uuid-9e1bae7a9a584c95a4376919afd5c686,Ipi,0.510391
uuid-9e1bae7a9a584c95a4376919afd5c686,atezo,0.308323
uuid-9e1bae7a9a584c95a4376919afd5c686,vs,0.566183
uuid-9e1bae7a9a584c95a4376919afd5c686,drug,0.300003
uuid-9e1bae7a9a584c95a4376919afd5c686,Keytruda,0.411052
uuid-9e1bae7a9a584c95a4376919afd5c686,flat dosing,0.789626
uuid-5555983cf89e46c989e631f59a33bf99,pembro,0.538549
uuid-5555983cf89e46c989e631f59a33bf99,RTL,0.417066
uuid-5555983cf89e46c989e631f59a33bf99,1L,0.306417
uuid-5555983cf89e46c989e631f59a33bf99,trial,0.771216
uuid-5555983cf89e46c989e631f59a33bf99,NTL,0.330797
uuid-5555983cf89e46c989e631f59a33bf99,Merck,0.336554
uuid-5555983cf89e46c989e631f59a33bf99,approval,0.38447
uuid-5555983cf89e46c989e631f59a33bf99,atezo,0.383484
uuid-5555983cf89e46c989e631f59a33bf99,combo,0.315576
uuid-5555983cf89e46c989e631f59a33bf99,clinical trials,0.560804
uuid-5555983cf89e46c989e631f59a33bf99,approved,0.350745
uuid-5555983cf89e46c989e631f59a33bf99,SCCHN,0.374279
uuid-5555983cf89e46c989e631f59a33bf99,Regional TL,0.336161
uuid-5555983cf89e46c989e631f59a33bf99,RTL stated,0.305388
uuid-5555983cf89e46c989e631f59a33bf99,bladder,0.445573
uuid-1449dbaaecd349499dd4cad00ccc5b54,Nivo,0.63937
uuid-1449dbaaecd349499dd4cad00ccc5b54,patients,0.51376
uuid-1449dbaaecd349499dd4cad00ccc5b54,therapy,0.596574
uuid-1449dbaaecd349499dd4cad00ccc5b54,nivolumab,0.470286
uuid-1449dbaaecd349499dd4cad00ccc5b54,1L,0.436067
uuid-1449dbaaecd349499dd4cad00ccc5b54,toxicity,0.362839
uuid-1449dbaaecd349499dd4cad00ccc5b54,regimen,0.548583
uuid-1449dbaaecd349499dd4cad00ccc5b54,combination,0.552036
uuid-1449dbaaecd349499dd4cad00ccc5b54,chemo,0.66122
uuid-1449dbaaecd349499dd4cad00ccc5b54,2L,0.436824
uuid-1449dbaaecd349499dd4cad00ccc5b54,pts,0.489246
uuid-1449dbaaecd349499dd4cad00ccc5b54,IO,0.316584
uuid-1449dbaaecd349499dd4cad00ccc5b54,agents,0.396266
uuid-1449dbaaecd349499dd4cad00ccc5b54,Ipi,0.342483
uuid-1449dbaaecd349499dd4cad00ccc5b54,preferred,0.408197
uuid-1449dbaaecd349499dd4cad00ccc5b54,monotherapy,0.723702
uuid-1449dbaaecd349499dd4cad00ccc5b54,treatment,0.488629
uuid-1449dbaaecd349499dd4cad00ccc5b54,using nivo,0.445883
uuid-1449dbaaecd349499dd4cad00ccc5b54,response,0.503909
uuid-1449dbaaecd349499dd4cad00ccc5b54,combo,0.477167
uuid-1449dbaaecd349499dd4cad00ccc5b54,PD1,0.600913
uuid-1449dbaaecd349499dd4cad00ccc5b54,progression,0.55489
uuid-1449dbaaecd349499dd4cad00ccc5b54,believes,0.418729
uuid-1449dbaaecd349499dd4cad00ccc5b54,chemotherapy,0.581884
uuid-1449dbaaecd349499dd4cad00ccc5b54,respond,0.47864
uuid-1449dbaaecd349499dd4cad00ccc5b54,feels,0.412587
uuid-1449dbaaecd349499dd4cad00ccc5b54,RTL stated,0.323
uuid-1449dbaaecd349499dd4cad00ccc5b54,option,0.643837
uuid-8fdd30bdc43d491995afb1e7b0f88b91,Nivo,0.384212
uuid-8fdd30bdc43d491995afb1e7b0f88b91,patients,0.670774
uuid-8fdd30bdc43d491995afb1e7b0f88b91,Opdivo,0.365099
uuid-8fdd30bdc43d491995afb1e7b0f88b91,therapy,0.652312
uuid-8fdd30bdc43d491995afb1e7b0f88b91,nivolumab,0.607145
uuid-8fdd30bdc43d491995afb1e7b0f88b91,1L,0.317187
uuid-8fdd30bdc43d491995afb1e7b0f88b91,toxicity,0.346633
uuid-8fdd30bdc43d491995afb1e7b0f88b91,regimen,0.618184
uuid-8fdd30bdc43d491995afb1e7b0f88b91,treated,0.519942
uuid-8fdd30bdc43d491995afb1e7b0f88b91,RCC,0.355149
uuid-8fdd30bdc43d491995afb1e7b0f88b91,combination,0.535354
uuid-8fdd30bdc43d491995afb1e7b0f88b91,chemo,0.483922
uuid-8fdd30bdc43d491995afb1e7b0f88b91,2L,0.382027
uuid-8fdd30bdc43d491995afb1e7b0f88b91,pts,0.6048
uuid-8fdd30bdc43d491995afb1e7b0f88b91,preferred,0.388126
uuid-8fdd30bdc43d491995afb1e7b0f88b91,monotherapy,0.618458
uuid-8fdd30bdc43d491995afb1e7b0f88b91,treatment,0.640664
uuid-8fdd30bdc43d491995afb1e7b0f88b91,using nivo,0.461347
uuid-8fdd30bdc43d491995afb1e7b0f88b91,response,0.422636
uuid-8fdd30bdc43d491995afb1e7b0f88b91,combo,0.436954
uuid-8fdd30bdc43d491995afb1e7b0f88b91,PD1,0.522258
uuid-8fdd30bdc43d491995afb1e7b0f88b91,progression,0.655024
uuid-8fdd30bdc43d491995afb1e7b0f88b91,chemotherapy,0.49707
uuid-8fdd30bdc43d491995afb1e7b0f88b91,respond,0.499039
uuid-8fdd30bdc43d491995afb1e7b0f88b91,RTL stated,0.435381
uuid-8fdd30bdc43d491995afb1e7b0f88b91,option,0.526493
uuid-f7a582380e904538be3eaacd65f34def,RTL,0.469235
uuid-f7a582380e904538be3eaacd65f34def,BMS,0.302605
uuid-f7a582380e904538be3eaacd65f34def,trial,0.660023
uuid-f7a582380e904538be3eaacd65f34def,NTL,0.416776
uuid-f7a582380e904538be3eaacd65f34def,commented,0.320797
uuid-f7a582380e904538be3eaacd65f34def,OS,0.362758
uuid-f7a582380e904538be3eaacd65f34def,data,0.59551
uuid-f7a582380e904538be3eaacd65f34def,clinical trials,0.305307
uuid-f7a582380e904538be3eaacd65f34def,PFS,0.38663
uuid-f7a582380e904538be3eaacd65f34def,ORR,0.454563
uuid-f7a582380e904538be3eaacd65f34def,ASCO,0.344331
uuid-f7a582380e904538be3eaacd65f34def,impressed,0.571555
uuid-f7a582380e904538be3eaacd65f34def,LTL,0.310918
uuid-bd6feac5e018454ab8bc7e14a76c18fe,BMS,0.769646
uuid-bd6feac5e018454ab8bc7e14a76c18fe,Merck,0.545125
uuid-bd6feac5e018454ab8bc7e14a76c18fe,stated,0.337638
uuid-bd6feac5e018454ab8bc7e14a76c18fe,clinical trials,0.310273
uuid-bd6feac5e018454ab8bc7e14a76c18fe,approved,0.439403
uuid-bd6feac5e018454ab8bc7e14a76c18fe,label,0.340638
uuid-bd6feac5e018454ab8bc7e14a76c18fe,feels,0.342311
uuid-b467078c795d4692ab5e5018f9bc5380,Nivo,0.598529
uuid-b467078c795d4692ab5e5018f9bc5380,1L,0.316984
uuid-b467078c795d4692ab5e5018f9bc5380,efficacy,0.405332
uuid-b467078c795d4692ab5e5018f9bc5380,chemo,0.441538
uuid-b467078c795d4692ab5e5018f9bc5380,OS,0.480522
uuid-b467078c795d4692ab5e5018f9bc5380,monotherapy,0.30298
uuid-b467078c795d4692ab5e5018f9bc5380,PFS,0.417049
uuid-b467078c795d4692ab5e5018f9bc5380,ORR,0.377371
uuid-b467078c795d4692ab5e5018f9bc5380,nivo and pembro,0.331113
uuid-b467078c795d4692ab5e5018f9bc5380,chemotherapy,0.357721
uuid-b467078c795d4692ab5e5018f9bc5380,feels,0.30568
uuid-b467078c795d4692ab5e5018f9bc5380,option,0.370564
uuid-42b9b647ce6445e88068f91a5d23569c,trial,0.330098
uuid-42b9b647ce6445e88068f91a5d23569c,combination,0.44443
uuid-42b9b647ce6445e88068f91a5d23569c,combo,0.311368
uuid-42b9b647ce6445e88068f91a5d23569c,PD1,0.339579
uuid-42b9b647ce6445e88068f91a5d23569c,nivo and pembro,0.304179
uuid-42b9b647ce6445e88068f91a5d23569c,believes,0.301068
uuid-daf6d18cbe454a43bbff8e1855294ee5,patients,0.337201
uuid-6e02b91993c8446491c7ca771ba7e50f,Nivo,0.363782
uuid-6e02b91993c8446491c7ca771ba7e50f,patients,0.682947
uuid-6e02b91993c8446491c7ca771ba7e50f,Opdivo,0.32613
uuid-6e02b91993c8446491c7ca771ba7e50f,therapy,0.430403
uuid-6e02b91993c8446491c7ca771ba7e50f,dose,0.412476
uuid-6e02b91993c8446491c7ca771ba7e50f,nivolumab,0.551239
uuid-6e02b91993c8446491c7ca771ba7e50f,toxicity,0.368205
uuid-6e02b91993c8446491c7ca771ba7e50f,regimen,0.571281
uuid-6e02b91993c8446491c7ca771ba7e50f,treated,0.5272
uuid-6e02b91993c8446491c7ca771ba7e50f,melanoma,0.309671
uuid-6e02b91993c8446491c7ca771ba7e50f,RCC,0.330149
uuid-6e02b91993c8446491c7ca771ba7e50f,combination,0.402873
uuid-6e02b91993c8446491c7ca771ba7e50f,2L,0.341978
uuid-6e02b91993c8446491c7ca771ba7e50f,pts,0.502755
uuid-6e02b91993c8446491c7ca771ba7e50f,Ipi,0.454569
uuid-6e02b91993c8446491c7ca771ba7e50f,preferred,0.373133
uuid-6e02b91993c8446491c7ca771ba7e50f,monotherapy,0.499406
uuid-6e02b91993c8446491c7ca771ba7e50f,treatment,0.523902
uuid-6e02b91993c8446491c7ca771ba7e50f,using nivo,0.464481
uuid-6e02b91993c8446491c7ca771ba7e50f,combo,0.366307
uuid-6e02b91993c8446491c7ca771ba7e50f,PD1,0.315037
uuid-6e02b91993c8446491c7ca771ba7e50f,progression,0.435882
uuid-6e02b91993c8446491c7ca771ba7e50f,chemotherapy,0.314418
uuid-6e02b91993c8446491c7ca771ba7e50f,RTL stated,0.451461
uuid-6e02b91993c8446491c7ca771ba7e50f,TL shared,0.326942
uuid-6e02b91993c8446491c7ca771ba7e50f,option,0.418709
uuid-ee304975139c415da7f609e6d5222d8c,patients,0.371189
uuid-ee304975139c415da7f609e6d5222d8c,1L,0.308624
uuid-ee304975139c415da7f609e6d5222d8c,PDL1 testing,0.341988
uuid-ee304975139c415da7f609e6d5222d8c,NSCLC patients,0.573558
uuid-ee304975139c415da7f609e6d5222d8c,tumor types,0.340512
uuid-1a1a33602021484faaa5e52cf22bd934,toxicity,0.537917
uuid-1a1a33602021484faaa5e52cf22bd934,physicians,0.342318
uuid-5bc863e2fc8a4afca96d219979869873,RTL,0.491524
uuid-5bc863e2fc8a4afca96d219979869873,nivolumab,0.328354
uuid-5bc863e2fc8a4afca96d219979869873,lung,0.452567
uuid-5bc863e2fc8a4afca96d219979869873,treated,0.368569
uuid-5bc863e2fc8a4afca96d219979869873,NTL,0.642914
uuid-5bc863e2fc8a4afca96d219979869873,melanoma,0.462785
uuid-5bc863e2fc8a4afca96d219979869873,commented,0.35578
uuid-5bc863e2fc8a4afca96d219979869873,RCC,0.331919
uuid-5bc863e2fc8a4afca96d219979869873,mentioned,0.469832
uuid-5bc863e2fc8a4afca96d219979869873,SCCHN,0.413846
uuid-5bc863e2fc8a4afca96d219979869873,HCP,0.322919
uuid-5bc863e2fc8a4afca96d219979869873,LTL,0.344301
uuid-5bc863e2fc8a4afca96d219979869873,Regional TL,0.438845
uuid-5bc863e2fc8a4afca96d219979869873,RTL stated,0.382784
uuid-5bc863e2fc8a4afca96d219979869873,TL shared,0.537957
uuid-5bc863e2fc8a4afca96d219979869873,bladder,0.361698
uuid-6198af0752bd4ee38ed0979d9d04393a,Nivo,0.366578
uuid-6198af0752bd4ee38ed0979d9d04393a,patients,0.4384
uuid-6198af0752bd4ee38ed0979d9d04393a,therapy,0.689704
uuid-6198af0752bd4ee38ed0979d9d04393a,nivolumab,0.498203
uuid-6198af0752bd4ee38ed0979d9d04393a,regimen,0.40289
uuid-6198af0752bd4ee38ed0979d9d04393a,treated,0.433775
uuid-6198af0752bd4ee38ed0979d9d04393a,combination,0.562172
uuid-6198af0752bd4ee38ed0979d9d04393a,chemo,0.528036
uuid-6198af0752bd4ee38ed0979d9d04393a,pts,0.374477
uuid-6198af0752bd4ee38ed0979d9d04393a,monotherapy,0.437347
uuid-6198af0752bd4ee38ed0979d9d04393a,treatment,0.515426
uuid-6198af0752bd4ee38ed0979d9d04393a,response,0.477671
uuid-6198af0752bd4ee38ed0979d9d04393a,combo,0.35026
uuid-6198af0752bd4ee38ed0979d9d04393a,PD1,0.566438
uuid-6198af0752bd4ee38ed0979d9d04393a,cHL,0.412137
uuid-6198af0752bd4ee38ed0979d9d04393a,progression,0.528018
uuid-6198af0752bd4ee38ed0979d9d04393a,chemotherapy,0.670747
uuid-6198af0752bd4ee38ed0979d9d04393a,respond,0.315896
uuid-6198af0752bd4ee38ed0979d9d04393a,feels,0.303719
uuid-6198af0752bd4ee38ed0979d9d04393a,option,0.362519
uuid-9c42b463539442efb30365f8fe2fd609,data,0.30108
uuid-ea8b67cae7154dee87ff9daa09a23331,Nivo,0.436316
uuid-ea8b67cae7154dee87ff9daa09a23331,patients,0.480634
uuid-ea8b67cae7154dee87ff9daa09a23331,therapy,0.698462
uuid-ea8b67cae7154dee87ff9daa09a23331,nivolumab,0.663864
uuid-ea8b67cae7154dee87ff9daa09a23331,treated,0.426394
uuid-ea8b67cae7154dee87ff9daa09a23331,approval,0.308586
uuid-ea8b67cae7154dee87ff9daa09a23331,treatment,0.377656
uuid-ea8b67cae7154dee87ff9daa09a23331,using nivo,0.406577
uuid-ea8b67cae7154dee87ff9daa09a23331,mentioned,0.30881
uuid-ea8b67cae7154dee87ff9daa09a23331,PD1,0.367925
uuid-ea8b67cae7154dee87ff9daa09a23331,cHL,0.773193
uuid-ea8b67cae7154dee87ff9daa09a23331,progression,0.314964
uuid-ea8b67cae7154dee87ff9daa09a23331,chemotherapy,0.3734
uuid-663114752d994b45bf90c1625858bd3c,Nivo,0.554895
uuid-663114752d994b45bf90c1625858bd3c,pembro,0.522252
uuid-663114752d994b45bf90c1625858bd3c,1L,0.596726
uuid-663114752d994b45bf90c1625858bd3c,efficacy,0.325479
uuid-663114752d994b45bf90c1625858bd3c,RCC,0.431167
uuid-663114752d994b45bf90c1625858bd3c,chemo,0.357219
uuid-663114752d994b45bf90c1625858bd3c,2L,0.630769
uuid-663114752d994b45bf90c1625858bd3c,agents,0.471962
uuid-663114752d994b45bf90c1625858bd3c,atezo,0.502198
uuid-663114752d994b45bf90c1625858bd3c,preferred,0.583129
uuid-663114752d994b45bf90c1625858bd3c,monotherapy,0.505287
uuid-663114752d994b45bf90c1625858bd3c,using nivo,0.506752
uuid-663114752d994b45bf90c1625858bd3c,data,0.405518
uuid-663114752d994b45bf90c1625858bd3c,combo,0.376989
uuid-663114752d994b45bf90c1625858bd3c,indication,0.393482
uuid-663114752d994b45bf90c1625858bd3c,approved,0.457045
uuid-663114752d994b45bf90c1625858bd3c,SCCHN,0.330682
uuid-663114752d994b45bf90c1625858bd3c,nivo and pembro,0.465631
uuid-663114752d994b45bf90c1625858bd3c,believes,0.412886
uuid-663114752d994b45bf90c1625858bd3c,impressed,0.368294
uuid-663114752d994b45bf90c1625858bd3c,SCLC,0.300386
uuid-663114752d994b45bf90c1625858bd3c,feels,0.54752
uuid-663114752d994b45bf90c1625858bd3c,RTL stated,0.423495
uuid-663114752d994b45bf90c1625858bd3c,option,0.606277
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,Nivo,0.582162
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,patients,0.688025
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,therapy,0.592568
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,nivolumab,0.538966
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,1L,0.317987
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,regimen,0.51413
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,treated,0.420249
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,combination,0.424711
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,chemo,0.54223
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,2L,0.320588
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,pts,0.635416
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,monotherapy,0.58466
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,treatment,0.537538
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,using nivo,0.455163
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,response,0.557156
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,combo,0.355164
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,PD1,0.522442
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,cHL,0.315067
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,progression,0.684589
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,chemotherapy,0.4962
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,respond,0.495256
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,RTL stated,0.37165
uuid-23d7cbb9d5c741a18ef8d60c0ab15756,option,0.502208
uuid-4e34499ae3df4cf998af7934d09b7381,lung,0.335021
uuid-4e34499ae3df4cf998af7934d09b7381,regimen,0.338118
uuid-4e34499ae3df4cf998af7934d09b7381,melanoma,0.345593
uuid-4e34499ae3df4cf998af7934d09b7381,AI,0.687876
uuid-fd98eee949d044da8ef2627df699b20d,dose,0.3535
uuid-fd98eee949d044da8ef2627df699b20d,nivolumab,0.358521
uuid-fd98eee949d044da8ef2627df699b20d,trial,0.322901
uuid-fd98eee949d044da8ef2627df699b20d,combination,0.343091
uuid-fd98eee949d044da8ef2627df699b20d,vs,0.371101
uuid-fd98eee949d044da8ef2627df699b20d,flat dosing,0.331788
uuid-5aef45ceeca341ae8c9c03d2b96a7c69,commented,0.488785
uuid-5aef45ceeca341ae8c9c03d2b96a7c69,stated,0.319233
uuid-5aef45ceeca341ae8c9c03d2b96a7c69,regards,0.42241
uuid-5aef45ceeca341ae8c9c03d2b96a7c69,data,0.442432
uuid-5aef45ceeca341ae8c9c03d2b96a7c69,AI,0.314222
uuid-5aef45ceeca341ae8c9c03d2b96a7c69,SCCHN,0.303079
uuid-5aef45ceeca341ae8c9c03d2b96a7c69,ASCO,0.369495
uuid-5aef45ceeca341ae8c9c03d2b96a7c69,impressed,0.32224
uuid-5aef45ceeca341ae8c9c03d2b96a7c69,NCCN,0.732492
uuid-13214820ead741128fc45a77ab68cbdf,RTL,0.411213
uuid-13214820ead741128fc45a77ab68cbdf,nivolumab,0.463842
uuid-13214820ead741128fc45a77ab68cbdf,treated,0.334089
uuid-13214820ead741128fc45a77ab68cbdf,NTL,0.534385
uuid-13214820ead741128fc45a77ab68cbdf,cHL,0.35842
uuid-13214820ead741128fc45a77ab68cbdf,Regional TL,0.355906
uuid-28d44ae33b194a41a51cff1ac4406202,Nivo,0.548954
uuid-28d44ae33b194a41a51cff1ac4406202,patients,0.758521
uuid-28d44ae33b194a41a51cff1ac4406202,Opdivo,0.301867
uuid-28d44ae33b194a41a51cff1ac4406202,therapy,0.554854
uuid-28d44ae33b194a41a51cff1ac4406202,nivolumab,0.429466
uuid-28d44ae33b194a41a51cff1ac4406202,toxicity,0.302379
uuid-28d44ae33b194a41a51cff1ac4406202,regimen,0.550949
uuid-28d44ae33b194a41a51cff1ac4406202,treated,0.389332
uuid-28d44ae33b194a41a51cff1ac4406202,chemo,0.512241
uuid-28d44ae33b194a41a51cff1ac4406202,pts,0.587972
uuid-28d44ae33b194a41a51cff1ac4406202,Ipi,0.357332
uuid-28d44ae33b194a41a51cff1ac4406202,monotherapy,0.463602
uuid-28d44ae33b194a41a51cff1ac4406202,treatment,0.559774
uuid-28d44ae33b194a41a51cff1ac4406202,using nivo,0.31014
uuid-28d44ae33b194a41a51cff1ac4406202,response,0.462889
uuid-28d44ae33b194a41a51cff1ac4406202,PD1,0.40974
uuid-28d44ae33b194a41a51cff1ac4406202,progression,0.641286
uuid-28d44ae33b194a41a51cff1ac4406202,chemotherapy,0.512509
uuid-28d44ae33b194a41a51cff1ac4406202,respond,0.551238
uuid-28d44ae33b194a41a51cff1ac4406202,option,0.397955
uuid-d5d627191fcd499a9db07074312c3079,patients,0.333161
uuid-d211f7d9e58942278d78c67b79478b80,patients,0.333161
uuid-c253cefa62464b21b3697189ed4ed205,Nivo,0.674055
uuid-c253cefa62464b21b3697189ed4ed205,patients,0.477209
uuid-c253cefa62464b21b3697189ed4ed205,pembro,0.50894
uuid-c253cefa62464b21b3697189ed4ed205,therapy,0.32084
uuid-c253cefa62464b21b3697189ed4ed205,dose,0.568108
uuid-c253cefa62464b21b3697189ed4ed205,nivolumab,0.349209
uuid-c253cefa62464b21b3697189ed4ed205,1L,0.403818
uuid-c253cefa62464b21b3697189ed4ed205,toxicity,0.444668
uuid-c253cefa62464b21b3697189ed4ed205,efficacy,0.404051
uuid-c253cefa62464b21b3697189ed4ed205,regimen,0.61006
uuid-c253cefa62464b21b3697189ed4ed205,combination,0.498675
uuid-c253cefa62464b21b3697189ed4ed205,chemo,0.549917
uuid-c253cefa62464b21b3697189ed4ed205,2L,0.473231
uuid-c253cefa62464b21b3697189ed4ed205,pts,0.404671
uuid-c253cefa62464b21b3697189ed4ed205,agents,0.338146
uuid-c253cefa62464b21b3697189ed4ed205,Ipi,0.655585
uuid-c253cefa62464b21b3697189ed4ed205,atezo,0.437418
uuid-c253cefa62464b21b3697189ed4ed205,preferred,0.458615
uuid-c253cefa62464b21b3697189ed4ed205,monotherapy,0.6441
uuid-c253cefa62464b21b3697189ed4ed205,treatment,0.336992
uuid-c253cefa62464b21b3697189ed4ed205,using nivo,0.405261
uuid-c253cefa62464b21b3697189ed4ed205,combo,0.550055
uuid-c253cefa62464b21b3697189ed4ed205,PD1,0.394306
uuid-c253cefa62464b21b3697189ed4ed205,approved,0.329104
uuid-c253cefa62464b21b3697189ed4ed205,progression,0.356447
uuid-c253cefa62464b21b3697189ed4ed205,chemotherapy,0.47532
uuid-c253cefa62464b21b3697189ed4ed205,vs,0.500155
uuid-c253cefa62464b21b3697189ed4ed205,respond,0.305293
uuid-c253cefa62464b21b3697189ed4ed205,feels,0.371457
uuid-c253cefa62464b21b3697189ed4ed205,option,0.5315
uuid-0c6b0ab7d4ea443bb17dbc46bdcd95ba,2L,0.3727
uuid-0c6b0ab7d4ea443bb17dbc46bdcd95ba,agents,0.308683
uuid-0c6b0ab7d4ea443bb17dbc46bdcd95ba,preferred,0.443741
uuid-0c6b0ab7d4ea443bb17dbc46bdcd95ba,monotherapy,0.317885
uuid-0c6b0ab7d4ea443bb17dbc46bdcd95ba,using nivo,0.359786
uuid-0c6b0ab7d4ea443bb17dbc46bdcd95ba,SCCHN,0.308797
uuid-0c6b0ab7d4ea443bb17dbc46bdcd95ba,academic,0.393465
uuid-0c6b0ab7d4ea443bb17dbc46bdcd95ba,feels,0.548796
uuid-0c6b0ab7d4ea443bb17dbc46bdcd95ba,RTL stated,0.487919
uuid-0c6b0ab7d4ea443bb17dbc46bdcd95ba,option,0.404502
uuid-a5f68b42cd85466a9f04c7741f575741,patients,0.466648
uuid-a5f68b42cd85466a9f04c7741f575741,Opdivo,0.510207
uuid-a5f68b42cd85466a9f04c7741f575741,nivolumab,0.379048
uuid-a5f68b42cd85466a9f04c7741f575741,treated,0.375208
uuid-a5f68b42cd85466a9f04c7741f575741,approval,0.396711
uuid-a5f68b42cd85466a9f04c7741f575741,treatment,0.379065
uuid-a5f68b42cd85466a9f04c7741f575741,approved,0.303303
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,Nivo,0.470566
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,1L,0.362185
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,toxicity,0.327271
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,efficacy,0.621728
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,regimen,0.367319
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,combination,0.470409
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,chemo,0.584155
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,pts,0.345751
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,IO,0.344292
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,agents,0.348869
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,Ipi,0.43688
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,OS,0.511965
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,monotherapy,0.565514
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,response,0.442887
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,combo,0.570911
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,PFS,0.486499
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,PD1,0.569436
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,ORR,0.529513
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,nivo and pembro,0.49482
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,progression,0.349476
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,believes,0.614179
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,chemotherapy,0.437611
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,vs,0.362149
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,feels,0.338929
uuid-bd26a5c4f50b4670bdd1c7eb0433c774,option,0.339146
uuid-7acd0221734a4d67b8479de6b0111806,patients,0.515725
uuid-7acd0221734a4d67b8479de6b0111806,RTL,0.323553
uuid-7acd0221734a4d67b8479de6b0111806,nivolumab,0.47085
uuid-7acd0221734a4d67b8479de6b0111806,toxicity,0.33372
uuid-7acd0221734a4d67b8479de6b0111806,trial,0.329283
uuid-7acd0221734a4d67b8479de6b0111806,regimen,0.540227
uuid-7acd0221734a4d67b8479de6b0111806,treated,0.483258
uuid-7acd0221734a4d67b8479de6b0111806,combination,0.499733
uuid-7acd0221734a4d67b8479de6b0111806,pts,0.389338
uuid-7acd0221734a4d67b8479de6b0111806,Ipi,0.3289
uuid-7acd0221734a4d67b8479de6b0111806,monotherapy,0.432499
uuid-7acd0221734a4d67b8479de6b0111806,treatment,0.362974
uuid-7acd0221734a4d67b8479de6b0111806,using nivo,0.33005
uuid-7acd0221734a4d67b8479de6b0111806,combo,0.439218
uuid-7acd0221734a4d67b8479de6b0111806,clinical trials,0.403486
uuid-7acd0221734a4d67b8479de6b0111806,chemotherapy,0.34914
uuid-7acd0221734a4d67b8479de6b0111806,feels,0.304699
uuid-7acd0221734a4d67b8479de6b0111806,RTL stated,0.350506
uuid-7acd0221734a4d67b8479de6b0111806,TL shared,0.323907
uuid-7acd0221734a4d67b8479de6b0111806,bladder,0.328546
uuid-6331bd5aa8ee4bc384052049fa1c636a,patients,0.67818
uuid-6331bd5aa8ee4bc384052049fa1c636a,Opdivo,0.498052
uuid-6331bd5aa8ee4bc384052049fa1c636a,therapy,0.489662
uuid-6331bd5aa8ee4bc384052049fa1c636a,nivolumab,0.356292
uuid-6331bd5aa8ee4bc384052049fa1c636a,regimen,0.720078
uuid-6331bd5aa8ee4bc384052049fa1c636a,treated,0.394094
uuid-6331bd5aa8ee4bc384052049fa1c636a,chemo,0.411785
uuid-6331bd5aa8ee4bc384052049fa1c636a,pts,0.492707
uuid-6331bd5aa8ee4bc384052049fa1c636a,monotherapy,0.522353
uuid-6331bd5aa8ee4bc384052049fa1c636a,treatment,0.617707
uuid-6331bd5aa8ee4bc384052049fa1c636a,response,0.329897
uuid-6331bd5aa8ee4bc384052049fa1c636a,combo,0.316488
uuid-6331bd5aa8ee4bc384052049fa1c636a,PD1,0.308877
uuid-6331bd5aa8ee4bc384052049fa1c636a,progression,0.610498
uuid-6331bd5aa8ee4bc384052049fa1c636a,chemotherapy,0.480381
uuid-6331bd5aa8ee4bc384052049fa1c636a,respond,0.448148
uuid-6331bd5aa8ee4bc384052049fa1c636a,option,0.478861
uuid-a587f7e300864635b294a7544ef8eb0a,Nivo,0.503165
uuid-a587f7e300864635b294a7544ef8eb0a,patients,0.372905
uuid-a587f7e300864635b294a7544ef8eb0a,dose,0.421547
uuid-a587f7e300864635b294a7544ef8eb0a,toxicity,0.591004
uuid-a587f7e300864635b294a7544ef8eb0a,efficacy,0.363221
uuid-a587f7e300864635b294a7544ef8eb0a,regimen,0.479672
uuid-a587f7e300864635b294a7544ef8eb0a,combination,0.446223
uuid-a587f7e300864635b294a7544ef8eb0a,chemo,0.454091
uuid-a587f7e300864635b294a7544ef8eb0a,pts,0.38081
uuid-a587f7e300864635b294a7544ef8eb0a,Ipi,0.514713
uuid-a587f7e300864635b294a7544ef8eb0a,monotherapy,0.432219
uuid-a587f7e300864635b294a7544ef8eb0a,response,0.358001
uuid-a587f7e300864635b294a7544ef8eb0a,combo,0.386864
uuid-a587f7e300864635b294a7544ef8eb0a,progression,0.306514
uuid-a587f7e300864635b294a7544ef8eb0a,chemotherapy,0.397089
uuid-a587f7e300864635b294a7544ef8eb0a,vs,0.347593
uuid-a587f7e300864635b294a7544ef8eb0a,option,0.347138
uuid-8bed8e7ac3e74d6380f3c044594d1741,nivolumab,0.445932
uuid-2c92a652563f45e2a16fe4d53504346b,Nivo,0.338633
uuid-2c92a652563f45e2a16fe4d53504346b,nivolumab,0.457814
uuid-2c92a652563f45e2a16fe4d53504346b,trial,0.46876
uuid-2c92a652563f45e2a16fe4d53504346b,combination,0.564322
uuid-2c92a652563f45e2a16fe4d53504346b,chemo,0.424521
uuid-2c92a652563f45e2a16fe4d53504346b,agents,0.305834
uuid-2c92a652563f45e2a16fe4d53504346b,Ipi,0.330256
uuid-2c92a652563f45e2a16fe4d53504346b,combo,0.419893
uuid-2c92a652563f45e2a16fe4d53504346b,chemotherapy,0.424222
uuid-a1ede512f8a644a7a17b47fe315c8b8b,lung,0.562491
uuid-a1ede512f8a644a7a17b47fe315c8b8b,NTL,0.430767
uuid-a1ede512f8a644a7a17b47fe315c8b8b,melanoma,0.359073
uuid-a1ede512f8a644a7a17b47fe315c8b8b,shared,0.347864
uuid-a1ede512f8a644a7a17b47fe315c8b8b,commented,0.462083
uuid-a1ede512f8a644a7a17b47fe315c8b8b,RCC,0.493915
uuid-a1ede512f8a644a7a17b47fe315c8b8b,TL stated,0.517945
uuid-a1ede512f8a644a7a17b47fe315c8b8b,stated,0.351418
uuid-a1ede512f8a644a7a17b47fe315c8b8b,physicians,0.447196
uuid-a1ede512f8a644a7a17b47fe315c8b8b,oncology,0.30006
uuid-a1ede512f8a644a7a17b47fe315c8b8b,SCCHN,0.37613
uuid-a1ede512f8a644a7a17b47fe315c8b8b,ASCO,0.349925
uuid-a1ede512f8a644a7a17b47fe315c8b8b,oncologist,0.335865
uuid-a1ede512f8a644a7a17b47fe315c8b8b,TLs,0.42275
uuid-a1ede512f8a644a7a17b47fe315c8b8b,Regional TL,0.524819
uuid-a1ede512f8a644a7a17b47fe315c8b8b,RTL stated,0.313068
uuid-a1ede512f8a644a7a17b47fe315c8b8b,TL shared,0.429159
uuid-11c4270611cc4e5f86411abf5ab3ccec,patients,0.73157
uuid-11c4270611cc4e5f86411abf5ab3ccec,therapy,0.426336
uuid-11c4270611cc4e5f86411abf5ab3ccec,nivolumab,0.332516
uuid-11c4270611cc4e5f86411abf5ab3ccec,1L,0.384298
uuid-11c4270611cc4e5f86411abf5ab3ccec,regimen,0.42731
uuid-11c4270611cc4e5f86411abf5ab3ccec,treated,0.446752
uuid-11c4270611cc4e5f86411abf5ab3ccec,chemo,0.327862
uuid-11c4270611cc4e5f86411abf5ab3ccec,2L,0.34129
uuid-11c4270611cc4e5f86411abf5ab3ccec,pts,0.529928
uuid-11c4270611cc4e5f86411abf5ab3ccec,preferred,0.364611
uuid-11c4270611cc4e5f86411abf5ab3ccec,monotherapy,0.420233
uuid-11c4270611cc4e5f86411abf5ab3ccec,treatment,0.549347
uuid-11c4270611cc4e5f86411abf5ab3ccec,using nivo,0.351069
uuid-11c4270611cc4e5f86411abf5ab3ccec,NSCLC patients,0.541981
uuid-11c4270611cc4e5f86411abf5ab3ccec,PD1,0.306345
uuid-11c4270611cc4e5f86411abf5ab3ccec,progression,0.557949
uuid-11c4270611cc4e5f86411abf5ab3ccec,tumor types,0.348819
uuid-11c4270611cc4e5f86411abf5ab3ccec,respond,0.447037
uuid-11c4270611cc4e5f86411abf5ab3ccec,RTL stated,0.350542
uuid-11c4270611cc4e5f86411abf5ab3ccec,option,0.492612
uuid-a1fd43c72434441587ab65d1d9437849,Nivo,0.587431
uuid-a1fd43c72434441587ab65d1d9437849,pembro,0.419831
uuid-a1fd43c72434441587ab65d1d9437849,therapy,0.322576
uuid-a1fd43c72434441587ab65d1d9437849,1L,0.407283
uuid-a1fd43c72434441587ab65d1d9437849,PDL1,0.313876
uuid-a1fd43c72434441587ab65d1d9437849,efficacy,0.44724
uuid-a1fd43c72434441587ab65d1d9437849,combination,0.492484
uuid-a1fd43c72434441587ab65d1d9437849,chemo,0.483285
uuid-a1fd43c72434441587ab65d1d9437849,2L,0.398582
uuid-a1fd43c72434441587ab65d1d9437849,agents,0.573603
uuid-a1fd43c72434441587ab65d1d9437849,atezo,0.362615
uuid-a1fd43c72434441587ab65d1d9437849,preferred,0.317985
uuid-a1fd43c72434441587ab65d1d9437849,monotherapy,0.539597
uuid-a1fd43c72434441587ab65d1d9437849,data,0.340377
uuid-a1fd43c72434441587ab65d1d9437849,combo,0.472607
uuid-a1fd43c72434441587ab65d1d9437849,PD1,0.482819
uuid-a1fd43c72434441587ab65d1d9437849,approved,0.313454
uuid-a1fd43c72434441587ab65d1d9437849,nivo and pembro,0.428791
uuid-a1fd43c72434441587ab65d1d9437849,believes,0.458942
uuid-a1fd43c72434441587ab65d1d9437849,chemotherapy,0.436665
uuid-a1fd43c72434441587ab65d1d9437849,feels,0.495351
uuid-a1fd43c72434441587ab65d1d9437849,PD-1,0.308887
uuid-a1fd43c72434441587ab65d1d9437849,option,0.487334
uuid-9a86c6adc4c14622899890527236de5c,pembro,0.338563
uuid-9a86c6adc4c14622899890527236de5c,RTL,0.356143
uuid-9a86c6adc4c14622899890527236de5c,BMS,0.449559
uuid-9a86c6adc4c14622899890527236de5c,PDL1,0.369106
uuid-9a86c6adc4c14622899890527236de5c,trial,0.672465
uuid-9a86c6adc4c14622899890527236de5c,efficacy,0.440836
uuid-9a86c6adc4c14622899890527236de5c,commented,0.419264
uuid-9a86c6adc4c14622899890527236de5c,Merck,0.40819
uuid-9a86c6adc4c14622899890527236de5c,stated,0.323958
uuid-9a86c6adc4c14622899890527236de5c,OS,0.533141
uuid-9a86c6adc4c14622899890527236de5c,data,0.697098
uuid-9a86c6adc4c14622899890527236de5c,expressed,0.373529
uuid-9a86c6adc4c14622899890527236de5c,clinical trials,0.341902
uuid-9a86c6adc4c14622899890527236de5c,PFS,0.535793
uuid-9a86c6adc4c14622899890527236de5c,ORR,0.544616
uuid-9a86c6adc4c14622899890527236de5c,nivo and pembro,0.367006
uuid-9a86c6adc4c14622899890527236de5c,impressed,0.574654
uuid-9a86c6adc4c14622899890527236de5c,TLs,0.317121
uuid-9a86c6adc4c14622899890527236de5c,feels,0.463883
uuid-9a86c6adc4c14622899890527236de5c,PDL1 expression,0.326993
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,RTL,0.387651
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,BMS,0.450048
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,PDL1,0.365696
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,trial,0.622021
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,efficacy,0.380113
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,NTL,0.331334
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,commented,0.51314
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,Merck,0.376754
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,stated,0.342707
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,OS,0.510577
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,data,0.841343
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,expressed,0.360895
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,clinical trials,0.301357
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,PFS,0.491599
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,ORR,0.560341
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,nivo and pembro,0.383448
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,ASCO,0.341542
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,impressed,0.619368
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,feels,0.388926
uuid-7e406838dc9b4bbe8c53c12b8ac13fc2,PDL1 expression,0.372922
uuid-e2cbba3ca29a4ca3ad5dd90ebbec7136,treated,0.345676
uuid-e2cbba3ca29a4ca3ad5dd90ebbec7136,shared,0.412473
uuid-e2cbba3ca29a4ca3ad5dd90ebbec7136,physicians,0.319486
uuid-e2cbba3ca29a4ca3ad5dd90ebbec7136,feels,0.438011
uuid-517589214f00441d94bdf6d5b3212c49,Nivo,0.37262
uuid-517589214f00441d94bdf6d5b3212c49,patients,0.429477
uuid-517589214f00441d94bdf6d5b3212c49,therapy,0.444339
uuid-517589214f00441d94bdf6d5b3212c49,nivolumab,0.450572
uuid-517589214f00441d94bdf6d5b3212c49,1L,0.724982
uuid-517589214f00441d94bdf6d5b3212c49,regimen,0.483419
uuid-517589214f00441d94bdf6d5b3212c49,treated,0.326213
uuid-517589214f00441d94bdf6d5b3212c49,RCC,0.574781
uuid-517589214f00441d94bdf6d5b3212c49,TL stated,0.357596
uuid-517589214f00441d94bdf6d5b3212c49,combination,0.483688
uuid-517589214f00441d94bdf6d5b3212c49,chemo,0.515548
uuid-517589214f00441d94bdf6d5b3212c49,2L,0.748691
uuid-517589214f00441d94bdf6d5b3212c49,pts,0.516878
uuid-517589214f00441d94bdf6d5b3212c49,IO,0.3755
uuid-517589214f00441d94bdf6d5b3212c49,agents,0.48965
uuid-517589214f00441d94bdf6d5b3212c49,preferred,0.65694
uuid-517589214f00441d94bdf6d5b3212c49,monotherapy,0.765778
uuid-517589214f00441d94bdf6d5b3212c49,treatment,0.439505
uuid-517589214f00441d94bdf6d5b3212c49,using nivo,0.533003
uuid-517589214f00441d94bdf6d5b3212c49,response,0.322425
uuid-517589214f00441d94bdf6d5b3212c49,combo,0.536153
uuid-517589214f00441d94bdf6d5b3212c49,NSCLC patients,0.334438
uuid-517589214f00441d94bdf6d5b3212c49,PD1,0.558644
uuid-517589214f00441d94bdf6d5b3212c49,approved,0.42173
uuid-517589214f00441d94bdf6d5b3212c49,progression,0.484725
uuid-517589214f00441d94bdf6d5b3212c49,believes,0.352756
uuid-517589214f00441d94bdf6d5b3212c49,chemotherapy,0.394363
uuid-517589214f00441d94bdf6d5b3212c49,respond,0.325735
uuid-517589214f00441d94bdf6d5b3212c49,PD-1,0.407226
uuid-517589214f00441d94bdf6d5b3212c49,RTL stated,0.504169
uuid-517589214f00441d94bdf6d5b3212c49,TL shared,0.357767
uuid-517589214f00441d94bdf6d5b3212c49,option,0.675431
uuid-1e3aae5aaff34fa29795c52a916f0df6,lung,0.417676
uuid-1e3aae5aaff34fa29795c52a916f0df6,shared,0.362045
uuid-1e3aae5aaff34fa29795c52a916f0df6,institution,0.72573
uuid-1e3aae5aaff34fa29795c52a916f0df6,AI,0.567177
uuid-1e3aae5aaff34fa29795c52a916f0df6,oncology,0.610211
uuid-1e3aae5aaff34fa29795c52a916f0df6,clinical,0.371684
uuid-1e3aae5aaff34fa29795c52a916f0df6,NCCN,0.414684
uuid-58d7c14be44d4261a3e6f3289f532bed,Nivo,0.385519
uuid-58d7c14be44d4261a3e6f3289f532bed,patients,0.608722
uuid-58d7c14be44d4261a3e6f3289f532bed,therapy,0.433086
uuid-58d7c14be44d4261a3e6f3289f532bed,nivolumab,0.392169
uuid-58d7c14be44d4261a3e6f3289f532bed,1L,0.465443
uuid-58d7c14be44d4261a3e6f3289f532bed,toxicity,0.338091
uuid-58d7c14be44d4261a3e6f3289f532bed,regimen,0.550106
uuid-58d7c14be44d4261a3e6f3289f532bed,treated,0.332444
uuid-58d7c14be44d4261a3e6f3289f532bed,combination,0.48349
uuid-58d7c14be44d4261a3e6f3289f532bed,chemo,0.536706
uuid-58d7c14be44d4261a3e6f3289f532bed,2L,0.478605
uuid-58d7c14be44d4261a3e6f3289f532bed,pts,0.502676
uuid-58d7c14be44d4261a3e6f3289f532bed,IO,0.313674
uuid-58d7c14be44d4261a3e6f3289f532bed,agents,0.462407
uuid-58d7c14be44d4261a3e6f3289f532bed,preferred,0.5462
uuid-58d7c14be44d4261a3e6f3289f532bed,monotherapy,0.712366
uuid-58d7c14be44d4261a3e6f3289f532bed,treatment,0.453417
uuid-58d7c14be44d4261a3e6f3289f532bed,using nivo,0.386726
uuid-58d7c14be44d4261a3e6f3289f532bed,combo,0.483484
uuid-58d7c14be44d4261a3e6f3289f532bed,PD1,0.454746
uuid-58d7c14be44d4261a3e6f3289f532bed,progression,0.438954
uuid-58d7c14be44d4261a3e6f3289f532bed,chemotherapy,0.472148
uuid-58d7c14be44d4261a3e6f3289f532bed,respond,0.416389
uuid-58d7c14be44d4261a3e6f3289f532bed,feels,0.417622
uuid-58d7c14be44d4261a3e6f3289f532bed,RTL stated,0.38551
uuid-58d7c14be44d4261a3e6f3289f532bed,option,0.692066
uuid-e84edaa66f2b4d26a6ab4653cb924f3d,RTL,0.384736
uuid-e84edaa66f2b4d26a6ab4653cb924f3d,trial,0.385229
uuid-e84edaa66f2b4d26a6ab4653cb924f3d,NTL,0.513378
uuid-e84edaa66f2b4d26a6ab4653cb924f3d,Regional TL,0.333721
uuid-821e46b94c844dbcbfea5df00f6101f3,dose,0.348313
uuid-821e46b94c844dbcbfea5df00f6101f3,oncologist,0.306576
uuid-821e46b94c844dbcbfea5df00f6101f3,indicated,0.559819
uuid-821e46b94c844dbcbfea5df00f6101f3,flat dosing,0.438491
uuid-f5791a588910480fbc08ec655490075d,Nivo,0.472216
uuid-f5791a588910480fbc08ec655490075d,dose,0.563066
uuid-f5791a588910480fbc08ec655490075d,toxicity,0.525
uuid-f5791a588910480fbc08ec655490075d,trial,0.304692
uuid-f5791a588910480fbc08ec655490075d,efficacy,0.545748
uuid-f5791a588910480fbc08ec655490075d,regimen,0.521984
uuid-f5791a588910480fbc08ec655490075d,combination,0.447353
uuid-f5791a588910480fbc08ec655490075d,chemo,0.311638
uuid-f5791a588910480fbc08ec655490075d,Ipi,0.68815
uuid-f5791a588910480fbc08ec655490075d,monotherapy,0.351913
uuid-f5791a588910480fbc08ec655490075d,combo,0.499673
uuid-f5791a588910480fbc08ec655490075d,impressed,0.314703
uuid-f5791a588910480fbc08ec655490075d,vs,0.424081
uuid-f5791a588910480fbc08ec655490075d,feels,0.314737
uuid-f5791a588910480fbc08ec655490075d,flat dosing,0.355386
uuid-1361a91d5ef6412789b87f3c5d5cb012,patients,0.515102
uuid-1361a91d5ef6412789b87f3c5d5cb012,Opdivo,0.475083
uuid-1361a91d5ef6412789b87f3c5d5cb012,toxicity,0.331739
uuid-1361a91d5ef6412789b87f3c5d5cb012,regimen,0.377029
uuid-1361a91d5ef6412789b87f3c5d5cb012,treated,0.466714
uuid-1361a91d5ef6412789b87f3c5d5cb012,shared,0.310176
uuid-1361a91d5ef6412789b87f3c5d5cb012,physicians,0.354839
uuid-1361a91d5ef6412789b87f3c5d5cb012,treatment,0.40576
uuid-1361a91d5ef6412789b87f3c5d5cb012,progression,0.369816
uuid-1361a91d5ef6412789b87f3c5d5cb012,respond,0.349511
uuid-e17d0d824a924cb0be490c41242e4d8e,regimen,0.313506
uuid-e17d0d824a924cb0be490c41242e4d8e,combination,0.321229
uuid-e17d0d824a924cb0be490c41242e4d8e,NCCN,0.320254
uuid-449ac69b055f4a01b80575b9d7cd02bb,BMS,0.343683
uuid-449ac69b055f4a01b80575b9d7cd02bb,AI,0.45259
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,Nivo,0.573638
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,patients,0.37373
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,Opdivo,0.632136
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,pembro,0.460317
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,dose,0.563975
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,nivolumab,0.456557
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,Ipi,0.342088
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,approval,0.414369
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,atezo,0.342869
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,preferred,0.324234
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,using nivo,0.464591
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,indication,0.302977
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,approved,0.338398
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,cHL,0.488879
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,vs,0.422819
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,label,0.351435
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,Keytruda,0.44825
uuid-dc99b3dcac8c4225ac0db24ef3f81d2a,flat dosing,0.507576
uuid-427ea13394864f49a8f3f4319666e7e0,Nivo,0.536377
uuid-427ea13394864f49a8f3f4319666e7e0,patients,0.837155
uuid-427ea13394864f49a8f3f4319666e7e0,Opdivo,0.465625
uuid-427ea13394864f49a8f3f4319666e7e0,therapy,0.705721
uuid-427ea13394864f49a8f3f4319666e7e0,nivolumab,0.560172
uuid-427ea13394864f49a8f3f4319666e7e0,regimen,0.357722
uuid-427ea13394864f49a8f3f4319666e7e0,treated,0.456358
uuid-427ea13394864f49a8f3f4319666e7e0,chemo,0.34396
uuid-427ea13394864f49a8f3f4319666e7e0,pts,0.441706
uuid-427ea13394864f49a8f3f4319666e7e0,monotherapy,0.31496
uuid-427ea13394864f49a8f3f4319666e7e0,treatment,0.606919
uuid-427ea13394864f49a8f3f4319666e7e0,using nivo,0.365067
uuid-427ea13394864f49a8f3f4319666e7e0,response,0.338881
uuid-427ea13394864f49a8f3f4319666e7e0,PD1,0.338136
uuid-427ea13394864f49a8f3f4319666e7e0,cHL,0.625722
uuid-427ea13394864f49a8f3f4319666e7e0,progression,0.544878
uuid-427ea13394864f49a8f3f4319666e7e0,chemotherapy,0.426532
uuid-427ea13394864f49a8f3f4319666e7e0,respond,0.409896
uuid-427ea13394864f49a8f3f4319666e7e0,option,0.305328
uuid-4a4a1046545c45d88fa3ccb38bbacc1a,patients,0.448065
uuid-4a4a1046545c45d88fa3ccb38bbacc1a,treated,0.305306
uuid-4a4a1046545c45d88fa3ccb38bbacc1a,chemo,0.378676
uuid-4a4a1046545c45d88fa3ccb38bbacc1a,pts,0.420119
uuid-4a4a1046545c45d88fa3ccb38bbacc1a,NSCLC patients,0.321861
uuid-4a4a1046545c45d88fa3ccb38bbacc1a,progression,0.369736
uuid-4a4a1046545c45d88fa3ccb38bbacc1a,respond,0.382764
uuid-0f214d0d43cd42cb8584ae04f2aa598a,therapy,0.440226
uuid-0f214d0d43cd42cb8584ae04f2aa598a,mentioned,0.386253
uuid-0f214d0d43cd42cb8584ae04f2aa598a,cHL,0.690367
uuid-0faae4af10f141ecb60eb910d17cbf1b,patients,0.445075
uuid-0faae4af10f141ecb60eb910d17cbf1b,Opdivo,0.527948
uuid-0faae4af10f141ecb60eb910d17cbf1b,nivolumab,0.398487
uuid-0faae4af10f141ecb60eb910d17cbf1b,treated,0.391293
uuid-0faae4af10f141ecb60eb910d17cbf1b,approval,0.374233
uuid-0faae4af10f141ecb60eb910d17cbf1b,treatment,0.353154
uuid-edd0c28b93b645d3a6e9f526e57b7619,Nivo,0.412075
uuid-edd0c28b93b645d3a6e9f526e57b7619,pembro,0.546529
uuid-edd0c28b93b645d3a6e9f526e57b7619,lung,0.4747
uuid-edd0c28b93b645d3a6e9f526e57b7619,1L,0.658322
uuid-edd0c28b93b645d3a6e9f526e57b7619,melanoma,0.500173
uuid-edd0c28b93b645d3a6e9f526e57b7619,RCC,0.624092
uuid-edd0c28b93b645d3a6e9f526e57b7619,TL stated,0.426772
uuid-edd0c28b93b645d3a6e9f526e57b7619,2L,0.756389
uuid-edd0c28b93b645d3a6e9f526e57b7619,agents,0.343534
uuid-edd0c28b93b645d3a6e9f526e57b7619,approval,0.355084
uuid-edd0c28b93b645d3a6e9f526e57b7619,atezo,0.549372
uuid-edd0c28b93b645d3a6e9f526e57b7619,preferred,0.664703
uuid-edd0c28b93b645d3a6e9f526e57b7619,monotherapy,0.512121
uuid-edd0c28b93b645d3a6e9f526e57b7619,using nivo,0.665037
uuid-edd0c28b93b645d3a6e9f526e57b7619,combo,0.399529
uuid-edd0c28b93b645d3a6e9f526e57b7619,PDL1 testing,0.343533
uuid-edd0c28b93b645d3a6e9f526e57b7619,indication,0.301491
uuid-edd0c28b93b645d3a6e9f526e57b7619,NSCLC patients,0.306833
uuid-edd0c28b93b645d3a6e9f526e57b7619,approved,0.453397
uuid-edd0c28b93b645d3a6e9f526e57b7619,SCCHN,0.490367
uuid-edd0c28b93b645d3a6e9f526e57b7619,tumor types,0.333373
uuid-edd0c28b93b645d3a6e9f526e57b7619,RTL stated,0.617366
uuid-edd0c28b93b645d3a6e9f526e57b7619,TL shared,0.483048
uuid-edd0c28b93b645d3a6e9f526e57b7619,option,0.506497
uuid-edd0c28b93b645d3a6e9f526e57b7619,bladder,0.451968
uuid-587899b8e6884b0ba192bbfef4c454d9,patients,0.440429
uuid-587899b8e6884b0ba192bbfef4c454d9,RTL,0.356327
uuid-587899b8e6884b0ba192bbfef4c454d9,treated,0.527615
uuid-587899b8e6884b0ba192bbfef4c454d9,melanoma,0.413848
uuid-587899b8e6884b0ba192bbfef4c454d9,RCC,0.46738
uuid-587899b8e6884b0ba192bbfef4c454d9,TL stated,0.425495
uuid-587899b8e6884b0ba192bbfef4c454d9,tumor,0.34352
uuid-587899b8e6884b0ba192bbfef4c454d9,pts,0.423959
uuid-587899b8e6884b0ba192bbfef4c454d9,treatment,0.371544
uuid-587899b8e6884b0ba192bbfef4c454d9,SCCHN,0.360167
uuid-587899b8e6884b0ba192bbfef4c454d9,progression,0.478854
uuid-587899b8e6884b0ba192bbfef4c454d9,Regional TL,0.340632
uuid-587899b8e6884b0ba192bbfef4c454d9,RTL stated,0.359055
uuid-587899b8e6884b0ba192bbfef4c454d9,TL shared,0.469318
uuid-f70a215a20c644de9f6f693c51e2f2cc,Nivo,0.647906
uuid-f70a215a20c644de9f6f693c51e2f2cc,pembro,0.522596
uuid-f70a215a20c644de9f6f693c51e2f2cc,1L,0.41087
uuid-f70a215a20c644de9f6f693c51e2f2cc,efficacy,0.408
uuid-f70a215a20c644de9f6f693c51e2f2cc,chemo,0.578528
uuid-f70a215a20c644de9f6f693c51e2f2cc,2L,0.432985
uuid-f70a215a20c644de9f6f693c51e2f2cc,agents,0.427525
uuid-f70a215a20c644de9f6f693c51e2f2cc,Ipi,0.367055
uuid-f70a215a20c644de9f6f693c51e2f2cc,atezo,0.442304
uuid-f70a215a20c644de9f6f693c51e2f2cc,preferred,0.368354
uuid-f70a215a20c644de9f6f693c51e2f2cc,monotherapy,0.487843
uuid-f70a215a20c644de9f6f693c51e2f2cc,using nivo,0.306173
uuid-f70a215a20c644de9f6f693c51e2f2cc,combo,0.351232
uuid-f70a215a20c644de9f6f693c51e2f2cc,PD1,0.349877
uuid-f70a215a20c644de9f6f693c51e2f2cc,nivo and pembro,0.571667
uuid-f70a215a20c644de9f6f693c51e2f2cc,believes,0.534658
uuid-f70a215a20c644de9f6f693c51e2f2cc,chemotherapy,0.396898
uuid-f70a215a20c644de9f6f693c51e2f2cc,vs,0.452123
uuid-f70a215a20c644de9f6f693c51e2f2cc,respond,0.315246
uuid-f70a215a20c644de9f6f693c51e2f2cc,feels,0.472259
uuid-f70a215a20c644de9f6f693c51e2f2cc,option,0.457133
uuid-6a3fe182a67f427eb4cb03a76bebbd1f,Opdivo,0.468244
uuid-6a3fe182a67f427eb4cb03a76bebbd1f,dose,0.468949
uuid-6a3fe182a67f427eb4cb03a76bebbd1f,drug,0.458388
uuid-6a3fe182a67f427eb4cb03a76bebbd1f,Keytruda,0.714504
uuid-6a3fe182a67f427eb4cb03a76bebbd1f,flat dosing,0.583838
uuid-b40dfc47b3784f3d9bbd0c8504a74354,patients,0.677124
uuid-b40dfc47b3784f3d9bbd0c8504a74354,Opdivo,0.348243
uuid-b40dfc47b3784f3d9bbd0c8504a74354,therapy,0.498058
uuid-b40dfc47b3784f3d9bbd0c8504a74354,nivolumab,0.323093
uuid-b40dfc47b3784f3d9bbd0c8504a74354,toxicity,0.640373
uuid-b40dfc47b3784f3d9bbd0c8504a74354,regimen,0.649729
uuid-b40dfc47b3784f3d9bbd0c8504a74354,treated,0.431668
uuid-b40dfc47b3784f3d9bbd0c8504a74354,combination,0.325436
uuid-b40dfc47b3784f3d9bbd0c8504a74354,chemo,0.41314
uuid-b40dfc47b3784f3d9bbd0c8504a74354,pts,0.416258
uuid-b40dfc47b3784f3d9bbd0c8504a74354,monotherapy,0.46738
uuid-b40dfc47b3784f3d9bbd0c8504a74354,treatment,0.69044
uuid-b40dfc47b3784f3d9bbd0c8504a74354,response,0.401896
uuid-b40dfc47b3784f3d9bbd0c8504a74354,PD1,0.366281
uuid-b40dfc47b3784f3d9bbd0c8504a74354,progression,0.573555
uuid-b40dfc47b3784f3d9bbd0c8504a74354,chemotherapy,0.460674
uuid-b40dfc47b3784f3d9bbd0c8504a74354,respond,0.527171
uuid-b40dfc47b3784f3d9bbd0c8504a74354,option,0.41266
uuid-56ea5763e0d446ab8ee78fd97cfa7121,patients,0.516256
uuid-56ea5763e0d446ab8ee78fd97cfa7121,RTL,0.446383
uuid-56ea5763e0d446ab8ee78fd97cfa7121,therapy,0.346187
uuid-56ea5763e0d446ab8ee78fd97cfa7121,nivolumab,0.592915
uuid-56ea5763e0d446ab8ee78fd97cfa7121,regimen,0.381008
uuid-56ea5763e0d446ab8ee78fd97cfa7121,treated,0.573338
uuid-56ea5763e0d446ab8ee78fd97cfa7121,melanoma,0.431881
uuid-56ea5763e0d446ab8ee78fd97cfa7121,RCC,0.647426
uuid-56ea5763e0d446ab8ee78fd97cfa7121,TL stated,0.311132
uuid-56ea5763e0d446ab8ee78fd97cfa7121,pts,0.454075
uuid-56ea5763e0d446ab8ee78fd97cfa7121,stated,0.321958
uuid-56ea5763e0d446ab8ee78fd97cfa7121,approval,0.347133
uuid-56ea5763e0d446ab8ee78fd97cfa7121,monotherapy,0.360972
uuid-56ea5763e0d446ab8ee78fd97cfa7121,treatment,0.438062
uuid-56ea5763e0d446ab8ee78fd97cfa7121,using nivo,0.507919
uuid-56ea5763e0d446ab8ee78fd97cfa7121,PD1,0.327264
uuid-56ea5763e0d446ab8ee78fd97cfa7121,SCCHN,0.516196
uuid-56ea5763e0d446ab8ee78fd97cfa7121,progression,0.437136
uuid-56ea5763e0d446ab8ee78fd97cfa7121,oncologist,0.303974
uuid-56ea5763e0d446ab8ee78fd97cfa7121,LTL,0.304867
uuid-56ea5763e0d446ab8ee78fd97cfa7121,SCLC,0.328008
uuid-56ea5763e0d446ab8ee78fd97cfa7121,Regional TL,0.424665
uuid-56ea5763e0d446ab8ee78fd97cfa7121,RTL stated,0.601903
uuid-56ea5763e0d446ab8ee78fd97cfa7121,TL shared,0.508649
uuid-56ea5763e0d446ab8ee78fd97cfa7121,bladder,0.386173
uuid-0f5884cc430c41da88d945de5a0854c6,BMS,0.363389
uuid-0f5884cc430c41da88d945de5a0854c6,PDL1,0.354946
uuid-0f5884cc430c41da88d945de5a0854c6,trial,0.534648
uuid-0f5884cc430c41da88d945de5a0854c6,efficacy,0.500684
uuid-0f5884cc430c41da88d945de5a0854c6,commented,0.334643
uuid-0f5884cc430c41da88d945de5a0854c6,stated,0.331332
uuid-0f5884cc430c41da88d945de5a0854c6,OS,0.751875
uuid-0f5884cc430c41da88d945de5a0854c6,data,0.79177
uuid-0f5884cc430c41da88d945de5a0854c6,PFS,0.720384
uuid-0f5884cc430c41da88d945de5a0854c6,ORR,0.722119
uuid-0f5884cc430c41da88d945de5a0854c6,nivo and pembro,0.437284
uuid-0f5884cc430c41da88d945de5a0854c6,ASCO,0.316537
uuid-0f5884cc430c41da88d945de5a0854c6,believes,0.312112
uuid-0f5884cc430c41da88d945de5a0854c6,impressed,0.664368
uuid-0f5884cc430c41da88d945de5a0854c6,feels,0.45195
uuid-0f5884cc430c41da88d945de5a0854c6,PDL1 expression,0.301257
uuid-0fde4631048a414890b51c1ddce64b81,PDL1,0.43858
uuid-0fde4631048a414890b51c1ddce64b81,efficacy,0.493616
uuid-0fde4631048a414890b51c1ddce64b81,OS,0.602023
uuid-0fde4631048a414890b51c1ddce64b81,regards,0.347837
uuid-0fde4631048a414890b51c1ddce64b81,data,0.581559
uuid-0fde4631048a414890b51c1ddce64b81,PFS,0.61463
uuid-0fde4631048a414890b51c1ddce64b81,ORR,0.57071
uuid-0fde4631048a414890b51c1ddce64b81,nivo and pembro,0.580395
uuid-0fde4631048a414890b51c1ddce64b81,believes,0.471467
uuid-0fde4631048a414890b51c1ddce64b81,impressed,0.328077
uuid-0fde4631048a414890b51c1ddce64b81,indicated,0.368587
uuid-0fde4631048a414890b51c1ddce64b81,feels,0.35688
uuid-0fde4631048a414890b51c1ddce64b81,PDL1 expression,0.354551
uuid-2665405e11a6412b9610cdf1348b58d4,patients,0.772437
uuid-2665405e11a6412b9610cdf1348b58d4,Opdivo,0.37919
uuid-2665405e11a6412b9610cdf1348b58d4,therapy,0.520066
uuid-2665405e11a6412b9610cdf1348b58d4,nivolumab,0.497795
uuid-2665405e11a6412b9610cdf1348b58d4,regimen,0.574225
uuid-2665405e11a6412b9610cdf1348b58d4,treated,0.538516
uuid-2665405e11a6412b9610cdf1348b58d4,chemo,0.362624
uuid-2665405e11a6412b9610cdf1348b58d4,pts,0.490162
uuid-2665405e11a6412b9610cdf1348b58d4,physicians,0.300556
uuid-2665405e11a6412b9610cdf1348b58d4,monotherapy,0.389088
uuid-2665405e11a6412b9610cdf1348b58d4,treatment,0.591787
uuid-2665405e11a6412b9610cdf1348b58d4,using nivo,0.386594
uuid-2665405e11a6412b9610cdf1348b58d4,response,0.335869
uuid-2665405e11a6412b9610cdf1348b58d4,progression,0.546889
uuid-2665405e11a6412b9610cdf1348b58d4,chemotherapy,0.37204
uuid-2665405e11a6412b9610cdf1348b58d4,respond,0.426218
uuid-2665405e11a6412b9610cdf1348b58d4,option,0.317505
uuid-d4f22c30becd4ec3be74164f81d2a3a5,lung,0.600675
uuid-d4f22c30becd4ec3be74164f81d2a3a5,melanoma,0.460195
uuid-d4f22c30becd4ec3be74164f81d2a3a5,institution,0.377396
uuid-d4f22c30becd4ec3be74164f81d2a3a5,regards,0.434801
uuid-d4f22c30becd4ec3be74164f81d2a3a5,AI,0.89945
uuid-d4f22c30becd4ec3be74164f81d2a3a5,oncology,0.363763
uuid-d4f22c30becd4ec3be74164f81d2a3a5,NCCN,0.770682
uuid-e49d0f8096df4c18938938ab5f0c2881,physicians,0.353751
uuid-e49d0f8096df4c18938938ab5f0c2881,response,0.311648
uuid-e49d0f8096df4c18938938ab5f0c2881,progression,0.349623
uuid-e49d0f8096df4c18938938ab5f0c2881,indicated,0.383286
uuid-e49d0f8096df4c18938938ab5f0c2881,respond,0.451939
uuid-42689a003df84ea8b1928ac3bec6b2c9,pts,0.43979
uuid-42689a003df84ea8b1928ac3bec6b2c9,immunotherapy,0.448238
uuid-5336386afec742bbad05078cc5f38d18,patients,0.48633
uuid-5336386afec742bbad05078cc5f38d18,Opdivo,0.306287
uuid-5336386afec742bbad05078cc5f38d18,toxicity,0.558756
uuid-5336386afec742bbad05078cc5f38d18,regimen,0.615412
uuid-5336386afec742bbad05078cc5f38d18,treated,0.328961
uuid-5336386afec742bbad05078cc5f38d18,melanoma,0.359928
uuid-5336386afec742bbad05078cc5f38d18,pts,0.462762
uuid-5336386afec742bbad05078cc5f38d18,monotherapy,0.314052
uuid-5336386afec742bbad05078cc5f38d18,treatment,0.446735
uuid-5336386afec742bbad05078cc5f38d18,response,0.349953
uuid-5336386afec742bbad05078cc5f38d18,combo,0.368212
uuid-5336386afec742bbad05078cc5f38d18,progression,0.53086
uuid-5336386afec742bbad05078cc5f38d18,respond,0.454565
uuid-5336386afec742bbad05078cc5f38d18,TL shared,0.332486
uuid-6849344fe1f046ef8e0f73cc66d47def,Opdivo,0.462629
uuid-6849344fe1f046ef8e0f73cc66d47def,physicians,0.406556
uuid-6849344fe1f046ef8e0f73cc66d47def,drug,0.474305
uuid-b884b4873d0a4e29a21a330348aa15e2,patients,0.301165
uuid-b884b4873d0a4e29a21a330348aa15e2,tumor,0.583014
uuid-d03951e99d8545de8a51ee07222cd114,patients,0.639401
uuid-d03951e99d8545de8a51ee07222cd114,therapy,0.413469
uuid-d03951e99d8545de8a51ee07222cd114,nivolumab,0.306325
uuid-d03951e99d8545de8a51ee07222cd114,regimen,0.532904
uuid-d03951e99d8545de8a51ee07222cd114,treated,0.515764
uuid-d03951e99d8545de8a51ee07222cd114,chemo,0.318549
uuid-d03951e99d8545de8a51ee07222cd114,pts,0.533358
uuid-d03951e99d8545de8a51ee07222cd114,IO,0.312114
uuid-d03951e99d8545de8a51ee07222cd114,monotherapy,0.383781
uuid-d03951e99d8545de8a51ee07222cd114,treatment,0.58878
uuid-d03951e99d8545de8a51ee07222cd114,response,0.455747
uuid-d03951e99d8545de8a51ee07222cd114,PD1,0.3595
uuid-d03951e99d8545de8a51ee07222cd114,progression,0.648774
uuid-d03951e99d8545de8a51ee07222cd114,chemotherapy,0.321715
uuid-d03951e99d8545de8a51ee07222cd114,respond,0.475848
uuid-d03951e99d8545de8a51ee07222cd114,PD-1,0.314674
uuid-d03951e99d8545de8a51ee07222cd114,TL shared,0.321795
uuid-d03951e99d8545de8a51ee07222cd114,option,0.317244
uuid-c07eaa0fe9564947b94bc5ff3e8d3a91,patients,0.550755
uuid-c07eaa0fe9564947b94bc5ff3e8d3a91,Opdivo,0.413446
uuid-c07eaa0fe9564947b94bc5ff3e8d3a91,treated,0.319776
uuid-c07eaa0fe9564947b94bc5ff3e8d3a91,pts,0.363404
uuid-c07eaa0fe9564947b94bc5ff3e8d3a91,PD-L1,0.318539
uuid-c07eaa0fe9564947b94bc5ff3e8d3a91,approval,0.335936
uuid-c07eaa0fe9564947b94bc5ff3e8d3a91,PD-L1 testing,0.406019
uuid-c07eaa0fe9564947b94bc5ff3e8d3a91,testing,0.477162
uuid-c07eaa0fe9564947b94bc5ff3e8d3a91,PDL1 testing,0.387929
uuid-c07eaa0fe9564947b94bc5ff3e8d3a91,NSCLC patients,0.484619
uuid-c07eaa0fe9564947b94bc5ff3e8d3a91,tumor types,0.378476
uuid-51fefc795a5341069ff5167292d245bf,RTL,0.354213
uuid-51fefc795a5341069ff5167292d245bf,BMS,0.336798
uuid-51fefc795a5341069ff5167292d245bf,shared,0.468662
uuid-51fefc795a5341069ff5167292d245bf,Merck,0.436677
uuid-51fefc795a5341069ff5167292d245bf,stated,0.35983
uuid-51fefc795a5341069ff5167292d245bf,approval,0.390685
uuid-51fefc795a5341069ff5167292d245bf,physicians,0.324971
uuid-51fefc795a5341069ff5167292d245bf,clinical trials,0.630093
uuid-51fefc795a5341069ff5167292d245bf,approved,0.308983
uuid-51fefc795a5341069ff5167292d245bf,SCCHN,0.36922
uuid-51fefc795a5341069ff5167292d245bf,academic,0.308322
uuid-51fefc795a5341069ff5167292d245bf,Regional TL,0.376567
uuid-56bf5dc836f14458a03309b0b0297b0f,indicated,0.306644
uuid-4f806cfa70a4442cb52cf496f5ebc60a,patients,0.362431
uuid-4f806cfa70a4442cb52cf496f5ebc60a,therapy,0.307913
uuid-4f806cfa70a4442cb52cf496f5ebc60a,NSCLC,0.316946
uuid-4f806cfa70a4442cb52cf496f5ebc60a,1L,0.385348
uuid-4f806cfa70a4442cb52cf496f5ebc60a,pts,0.310926
uuid-4f806cfa70a4442cb52cf496f5ebc60a,IO,0.494481
uuid-4f806cfa70a4442cb52cf496f5ebc60a,PD-L1,0.36603
uuid-4f806cfa70a4442cb52cf496f5ebc60a,PD-L1 testing,0.376005
uuid-4f806cfa70a4442cb52cf496f5ebc60a,testing,0.452782
uuid-4f806cfa70a4442cb52cf496f5ebc60a,monotherapy,0.38325
uuid-4f806cfa70a4442cb52cf496f5ebc60a,treatment,0.336535
uuid-4f806cfa70a4442cb52cf496f5ebc60a,PDL1 testing,0.373428
uuid-4f806cfa70a4442cb52cf496f5ebc60a,NSCLC patients,0.431219
uuid-4f806cfa70a4442cb52cf496f5ebc60a,progression,0.30006
uuid-4f806cfa70a4442cb52cf496f5ebc60a,chemotherapy,0.329508
uuid-4f806cfa70a4442cb52cf496f5ebc60a,option,0.388314
uuid-c2cf2854e8d3470599861b4f8ce91a7d,pembro,0.3027
uuid-c2cf2854e8d3470599861b4f8ce91a7d,BMS,0.303604
uuid-c2cf2854e8d3470599861b4f8ce91a7d,lung,0.605483
uuid-c2cf2854e8d3470599861b4f8ce91a7d,1L,0.371389
uuid-c2cf2854e8d3470599861b4f8ce91a7d,melanoma,0.368315
uuid-c2cf2854e8d3470599861b4f8ce91a7d,RCC,0.388431
uuid-c2cf2854e8d3470599861b4f8ce91a7d,2L,0.356215
uuid-c2cf2854e8d3470599861b4f8ce91a7d,atezo,0.347593
uuid-c2cf2854e8d3470599861b4f8ce91a7d,regards,0.376109
uuid-c2cf2854e8d3470599861b4f8ce91a7d,expressed,0.33123
uuid-c2cf2854e8d3470599861b4f8ce91a7d,PDL1 testing,0.332516
uuid-c2cf2854e8d3470599861b4f8ce91a7d,indication,0.361603
uuid-c2cf2854e8d3470599861b4f8ce91a7d,AI,0.655394
uuid-c2cf2854e8d3470599861b4f8ce91a7d,nivo and pembro,0.432783
uuid-c2cf2854e8d3470599861b4f8ce91a7d,tumor types,0.352378
uuid-c2cf2854e8d3470599861b4f8ce91a7d,TL shared,0.315647
uuid-c2cf2854e8d3470599861b4f8ce91a7d,NCCN,0.356494
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,patients,0.782401
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,Opdivo,0.479
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,therapy,0.514407
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,nivolumab,0.619469
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,regimen,0.337846
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,treated,0.562841
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,pts,0.395234
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,approval,0.403197
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,preferred,0.328663
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,monotherapy,0.32128
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,treatment,0.590206
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,using nivo,0.486955
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,approved,0.342321
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,SCCHN,0.31744
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,cHL,0.381538
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,progression,0.388663
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,chemotherapy,0.315607
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,RTL stated,0.424173
uuid-3bb14e9b2ef445cebd6f218f1bd3f1b3,option,0.390202
uuid-e7a432f4b370485f9df0ce5ae7385d52,patients,0.459891
uuid-e7a432f4b370485f9df0ce5ae7385d52,Opdivo,0.338693
uuid-e7a432f4b370485f9df0ce5ae7385d52,dose,0.490021
uuid-e7a432f4b370485f9df0ce5ae7385d52,toxicity,0.578173
uuid-e7a432f4b370485f9df0ce5ae7385d52,regimen,0.529063
uuid-e7a432f4b370485f9df0ce5ae7385d52,treated,0.466029
uuid-e7a432f4b370485f9df0ce5ae7385d52,physicians,0.388143
uuid-e7a432f4b370485f9df0ce5ae7385d52,treatment,0.560285
uuid-e7a432f4b370485f9df0ce5ae7385d52,progression,0.325096
uuid-e7a432f4b370485f9df0ce5ae7385d52,respond,0.447339
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,patients,0.856668
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,Opdivo,0.339295
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,therapy,0.561521
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,nivolumab,0.45094
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,toxicity,0.447181
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,regimen,0.752201
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,treated,0.569356
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,combination,0.354459
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,chemo,0.505768
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,pts,0.621119
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,monotherapy,0.580625
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,treatment,0.700765
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,response,0.489995
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,combo,0.319141
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,PD1,0.401451
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,progression,0.699102
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,chemotherapy,0.484338
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,respond,0.572649
uuid-55c82bf35b8a4ec8a33f5400105e6e2a,option,0.473129
uuid-b627dddbb8ee49f79c5c01a831eecc8d,lung,0.380273
uuid-b627dddbb8ee49f79c5c01a831eecc8d,1L,0.475343
uuid-b627dddbb8ee49f79c5c01a831eecc8d,PDL1,0.466381
uuid-b627dddbb8ee49f79c5c01a831eecc8d,RCC,0.315657
uuid-b627dddbb8ee49f79c5c01a831eecc8d,TL stated,0.519483
uuid-b627dddbb8ee49f79c5c01a831eecc8d,2L,0.425371
uuid-b627dddbb8ee49f79c5c01a831eecc8d,institution,0.363091
uuid-b627dddbb8ee49f79c5c01a831eecc8d,PD-L1,0.599854
uuid-b627dddbb8ee49f79c5c01a831eecc8d,atezo,0.354012
uuid-b627dddbb8ee49f79c5c01a831eecc8d,preferred,0.381017
uuid-b627dddbb8ee49f79c5c01a831eecc8d,PD-L1 testing,0.500781
uuid-b627dddbb8ee49f79c5c01a831eecc8d,testing,0.679259
uuid-b627dddbb8ee49f79c5c01a831eecc8d,PDL1 testing,0.809247
uuid-b627dddbb8ee49f79c5c01a831eecc8d,indication,0.310556
uuid-b627dddbb8ee49f79c5c01a831eecc8d,NSCLC patients,0.613894
uuid-b627dddbb8ee49f79c5c01a831eecc8d,tumor types,0.487345
uuid-b627dddbb8ee49f79c5c01a831eecc8d,assay,0.37725
uuid-b627dddbb8ee49f79c5c01a831eecc8d,PDL1 expression,0.343653
uuid-b627dddbb8ee49f79c5c01a831eecc8d,biomarker,0.397838
uuid-f63083153f2e4c938a48a91ea0856784,patients,0.688777
uuid-f63083153f2e4c938a48a91ea0856784,Opdivo,0.396276
uuid-f63083153f2e4c938a48a91ea0856784,therapy,0.61051
uuid-f63083153f2e4c938a48a91ea0856784,nivolumab,0.557458
uuid-f63083153f2e4c938a48a91ea0856784,toxicity,0.433138
uuid-f63083153f2e4c938a48a91ea0856784,regimen,0.417603
uuid-f63083153f2e4c938a48a91ea0856784,treated,0.495966
uuid-f63083153f2e4c938a48a91ea0856784,pts,0.309948
uuid-f63083153f2e4c938a48a91ea0856784,treatment,0.548734
uuid-f63083153f2e4c938a48a91ea0856784,PD1,0.324353
uuid-f63083153f2e4c938a48a91ea0856784,cHL,0.556616
uuid-f63083153f2e4c938a48a91ea0856784,progression,0.4549
uuid-f63083153f2e4c938a48a91ea0856784,chemotherapy,0.333297
uuid-f63083153f2e4c938a48a91ea0856784,respond,0.388073
uuid-d5bd62cacb8548f082a6203979006cd2,pembro,0.319821
uuid-d5bd62cacb8548f082a6203979006cd2,PDL1,0.439379
uuid-d5bd62cacb8548f082a6203979006cd2,trial,0.365144
uuid-d5bd62cacb8548f082a6203979006cd2,efficacy,0.397439
uuid-d5bd62cacb8548f082a6203979006cd2,commented,0.350244
uuid-d5bd62cacb8548f082a6203979006cd2,OS,0.570069
uuid-d5bd62cacb8548f082a6203979006cd2,data,0.714461
uuid-d5bd62cacb8548f082a6203979006cd2,PFS,0.561528
uuid-d5bd62cacb8548f082a6203979006cd2,ORR,0.560614
uuid-d5bd62cacb8548f082a6203979006cd2,nivo and pembro,0.549282
uuid-d5bd62cacb8548f082a6203979006cd2,impressed,0.48354
uuid-d5bd62cacb8548f082a6203979006cd2,feels,0.317198
uuid-d5bd62cacb8548f082a6203979006cd2,PDL1 expression,0.395003
uuid-b73f104a478b436aaede9998ce9f9eb4,indication,0.32803
uuid-b73f104a478b436aaede9998ce9f9eb4,option,0.318739
uuid-b6423420df5e41bc8b5bb6e8125f6b1e,lung,0.55278
uuid-b6423420df5e41bc8b5bb6e8125f6b1e,melanoma,0.413483
uuid-b6423420df5e41bc8b5bb6e8125f6b1e,regards,0.446953
uuid-b6423420df5e41bc8b5bb6e8125f6b1e,expressed,0.314789
uuid-b6423420df5e41bc8b5bb6e8125f6b1e,AI,0.892713
uuid-b6423420df5e41bc8b5bb6e8125f6b1e,oncology,0.473417
uuid-b6423420df5e41bc8b5bb6e8125f6b1e,NCCN,0.493873
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,Nivo,0.310816
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,patients,0.826612
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,Opdivo,0.385895
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,therapy,0.60084
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,nivolumab,0.523252
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,toxicity,0.303998
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,regimen,0.416115
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,treated,0.627774
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,chemo,0.321622
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,pts,0.46238
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,preferred,0.340087
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,monotherapy,0.426541
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,treatment,0.623527
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,using nivo,0.436646
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,PD1,0.327121
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,cHL,0.393235
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,progression,0.471986
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,chemotherapy,0.436079
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,respond,0.375022
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,RTL stated,0.354447
uuid-e457afaa3e0740cc8bbb3b8d7ec31399,option,0.434257
uuid-0e4aded678b74b6b95a90de3bd294d5b,patients,0.650234
uuid-0e4aded678b74b6b95a90de3bd294d5b,Opdivo,0.48405
uuid-0e4aded678b74b6b95a90de3bd294d5b,therapy,0.395463
uuid-0e4aded678b74b6b95a90de3bd294d5b,nivolumab,0.389393
uuid-0e4aded678b74b6b95a90de3bd294d5b,regimen,0.573332
uuid-0e4aded678b74b6b95a90de3bd294d5b,treated,0.40531
uuid-0e4aded678b74b6b95a90de3bd294d5b,pts,0.328799
uuid-0e4aded678b74b6b95a90de3bd294d5b,IO,0.487423
uuid-0e4aded678b74b6b95a90de3bd294d5b,physicians,0.344462
uuid-0e4aded678b74b6b95a90de3bd294d5b,preferred,0.314389
uuid-0e4aded678b74b6b95a90de3bd294d5b,monotherapy,0.480057
uuid-0e4aded678b74b6b95a90de3bd294d5b,treatment,0.509993
uuid-0e4aded678b74b6b95a90de3bd294d5b,progression,0.473442
uuid-0e4aded678b74b6b95a90de3bd294d5b,option,0.385917
uuid-b61e4e9332c14c7f9302e106a9507e1b,patients,0.648612
uuid-b61e4e9332c14c7f9302e106a9507e1b,therapy,0.499128
uuid-b61e4e9332c14c7f9302e106a9507e1b,nivolumab,0.441507
uuid-b61e4e9332c14c7f9302e106a9507e1b,regimen,0.419339
uuid-b61e4e9332c14c7f9302e106a9507e1b,treated,0.519433
uuid-b61e4e9332c14c7f9302e106a9507e1b,chemo,0.404418
uuid-b61e4e9332c14c7f9302e106a9507e1b,pts,0.552448
uuid-b61e4e9332c14c7f9302e106a9507e1b,monotherapy,0.307819
uuid-b61e4e9332c14c7f9302e106a9507e1b,treatment,0.506193
uuid-b61e4e9332c14c7f9302e106a9507e1b,response,0.614019
uuid-b61e4e9332c14c7f9302e106a9507e1b,PD1,0.417576
uuid-b61e4e9332c14c7f9302e106a9507e1b,progression,0.618419
uuid-b61e4e9332c14c7f9302e106a9507e1b,chemotherapy,0.379404
uuid-b61e4e9332c14c7f9302e106a9507e1b,respond,0.562397
uuid-1c441265d8254acdb3ed0fefa3e7230b,Opdivo,0.361231
uuid-1c441265d8254acdb3ed0fefa3e7230b,RTL,0.365792
uuid-1c441265d8254acdb3ed0fefa3e7230b,NTL,0.336915
uuid-1c441265d8254acdb3ed0fefa3e7230b,shared,0.599113
uuid-1c441265d8254acdb3ed0fefa3e7230b,commented,0.44124
uuid-1c441265d8254acdb3ed0fefa3e7230b,stated,0.329219
uuid-1c441265d8254acdb3ed0fefa3e7230b,physicians,0.373178
uuid-1c441265d8254acdb3ed0fefa3e7230b,mentioned,0.471171
uuid-1c441265d8254acdb3ed0fefa3e7230b,ASCO,0.330187
uuid-1c441265d8254acdb3ed0fefa3e7230b,LTL,0.43028
uuid-1c441265d8254acdb3ed0fefa3e7230b,Regional TL,0.357092
uuid-1c441265d8254acdb3ed0fefa3e7230b,flat dosing,0.433019
uuid-aacc738e0b314adf937c1327061a50f2,shared,0.393138
uuid-aacc738e0b314adf937c1327061a50f2,commented,0.366552
uuid-aacc738e0b314adf937c1327061a50f2,RCC,0.319302
uuid-aacc738e0b314adf937c1327061a50f2,stated,0.460734
uuid-aacc738e0b314adf937c1327061a50f2,approval,0.317122
uuid-aacc738e0b314adf937c1327061a50f2,using nivo,0.418109
uuid-aacc738e0b314adf937c1327061a50f2,data,0.30306
uuid-aacc738e0b314adf937c1327061a50f2,SCCHN,0.481991
uuid-aacc738e0b314adf937c1327061a50f2,impressed,0.3784
uuid-aacc738e0b314adf937c1327061a50f2,LTL,0.411922
uuid-aacc738e0b314adf937c1327061a50f2,SCLC,0.355586
uuid-aacc738e0b314adf937c1327061a50f2,feels,0.459317
uuid-aacc738e0b314adf937c1327061a50f2,Regional TL,0.387661
uuid-aacc738e0b314adf937c1327061a50f2,RTL stated,0.447493
uuid-458ec3f299bc4bbc911b401dce100ef0,PDL1,0.457053
uuid-458ec3f299bc4bbc911b401dce100ef0,efficacy,0.585582
uuid-458ec3f299bc4bbc911b401dce100ef0,OS,0.587105
uuid-458ec3f299bc4bbc911b401dce100ef0,atezo,0.313256
uuid-458ec3f299bc4bbc911b401dce100ef0,regards,0.35706
uuid-458ec3f299bc4bbc911b401dce100ef0,data,0.671572
uuid-458ec3f299bc4bbc911b401dce100ef0,PFS,0.609044
uuid-458ec3f299bc4bbc911b401dce100ef0,ORR,0.614406
uuid-458ec3f299bc4bbc911b401dce100ef0,nivo and pembro,0.497422
uuid-458ec3f299bc4bbc911b401dce100ef0,impressed,0.439518
uuid-458ec3f299bc4bbc911b401dce100ef0,indicated,0.327718
uuid-458ec3f299bc4bbc911b401dce100ef0,TLs,0.305533
uuid-458ec3f299bc4bbc911b401dce100ef0,PDL1 expression,0.488182
uuid-2964cd0321f34e93ac7e509cfaaa2451,patients,0.333955
uuid-2964cd0321f34e93ac7e509cfaaa2451,Opdivo,0.44866
uuid-2964cd0321f34e93ac7e509cfaaa2451,shared,0.420653
uuid-2964cd0321f34e93ac7e509cfaaa2451,2L,0.305563
uuid-2964cd0321f34e93ac7e509cfaaa2451,institution,0.316557
uuid-2964cd0321f34e93ac7e509cfaaa2451,approval,0.361236
uuid-2964cd0321f34e93ac7e509cfaaa2451,preferred,0.420449
uuid-2964cd0321f34e93ac7e509cfaaa2451,using nivo,0.342211
uuid-2964cd0321f34e93ac7e509cfaaa2451,indication,0.34326
uuid-2964cd0321f34e93ac7e509cfaaa2451,approved,0.427997
uuid-2964cd0321f34e93ac7e509cfaaa2451,drug,0.44355
uuid-2964cd0321f34e93ac7e509cfaaa2451,option,0.318249
uuid-230f3b372bbe471084f935e984658134,patients,0.320145
uuid-230f3b372bbe471084f935e984658134,regimen,0.306789
uuid-230f3b372bbe471084f935e984658134,treatment,0.325885
uuid-230f3b372bbe471084f935e984658134,progression,0.323361
uuid-19173b42017f4c9a98de17676dc117a0,therapy,0.320165
uuid-19173b42017f4c9a98de17676dc117a0,regimen,0.314448
uuid-19173b42017f4c9a98de17676dc117a0,treated,0.322953
uuid-19173b42017f4c9a98de17676dc117a0,chemo,0.38436
uuid-19173b42017f4c9a98de17676dc117a0,pts,0.33293
uuid-19173b42017f4c9a98de17676dc117a0,treatment,0.336846
uuid-19173b42017f4c9a98de17676dc117a0,response,0.439445
uuid-19173b42017f4c9a98de17676dc117a0,progression,0.466444
uuid-19173b42017f4c9a98de17676dc117a0,respond,0.374331
uuid-337046c7b3bf4e1a8a8464be0ee86419,preferred,0.451358
uuid-337046c7b3bf4e1a8a8464be0ee86419,SCCHN,0.355812
uuid-337046c7b3bf4e1a8a8464be0ee86419,option,0.36456
uuid-c5da5891e516465c8b366cb827511a4b,Nivo,0.387006
uuid-c5da5891e516465c8b366cb827511a4b,lung,0.47623
uuid-c5da5891e516465c8b366cb827511a4b,trial,0.352058
uuid-c5da5891e516465c8b366cb827511a4b,melanoma,0.430699
uuid-c5da5891e516465c8b366cb827511a4b,RCC,0.344551
uuid-c5da5891e516465c8b366cb827511a4b,AI,0.545403
uuid-c5da5891e516465c8b366cb827511a4b,SCLC,0.332518
uuid-c5da5891e516465c8b366cb827511a4b,RTL stated,0.32212
uuid-c5da5891e516465c8b366cb827511a4b,bladder,0.305865
uuid-7c75846772f84aea90332951aa99806a,toxicity,0.586342
uuid-7c75846772f84aea90332951aa99806a,efficacy,0.448415
uuid-7c75846772f84aea90332951aa99806a,ORR,0.322148
uuid-177b65d51cf44393b8700cff883a2a84,patients,0.806825
uuid-177b65d51cf44393b8700cff883a2a84,Opdivo,0.528868
uuid-177b65d51cf44393b8700cff883a2a84,therapy,0.419256
uuid-177b65d51cf44393b8700cff883a2a84,dose,0.406715
uuid-177b65d51cf44393b8700cff883a2a84,nivolumab,0.372322
uuid-177b65d51cf44393b8700cff883a2a84,toxicity,0.350749
uuid-177b65d51cf44393b8700cff883a2a84,regimen,0.484219
uuid-177b65d51cf44393b8700cff883a2a84,treated,0.470128
uuid-177b65d51cf44393b8700cff883a2a84,pts,0.451044
uuid-177b65d51cf44393b8700cff883a2a84,treatment,0.643425
uuid-177b65d51cf44393b8700cff883a2a84,progression,0.596209
uuid-177b65d51cf44393b8700cff883a2a84,respond,0.454886
uuid-ac666116d2034a31807c124e517e4bdc,patients,0.476876
uuid-ac666116d2034a31807c124e517e4bdc,Opdivo,0.325328
uuid-ac666116d2034a31807c124e517e4bdc,TL,0.327362
uuid-ac666116d2034a31807c124e517e4bdc,PD-L1,0.35344
uuid-ac666116d2034a31807c124e517e4bdc,physicians,0.305528
uuid-ac666116d2034a31807c124e517e4bdc,PD-L1 testing,0.535809
uuid-ac666116d2034a31807c124e517e4bdc,testing,0.544532
uuid-ac666116d2034a31807c124e517e4bdc,treatment,0.322721
uuid-ac666116d2034a31807c124e517e4bdc,PDL1 testing,0.442307
uuid-ac666116d2034a31807c124e517e4bdc,NSCLC patients,0.50055
uuid-b67883c7e5134852886d681d04030d2d,patients,0.326025
uuid-b67883c7e5134852886d681d04030d2d,dose,0.40473
uuid-b67883c7e5134852886d681d04030d2d,regimen,0.375405
uuid-375f1a7529ec4657845c9cc6908e3bc1,patients,0.542725
uuid-375f1a7529ec4657845c9cc6908e3bc1,Opdivo,0.388407
uuid-375f1a7529ec4657845c9cc6908e3bc1,dose,0.393049
uuid-375f1a7529ec4657845c9cc6908e3bc1,toxicity,0.479327
uuid-375f1a7529ec4657845c9cc6908e3bc1,regimen,0.466019
uuid-375f1a7529ec4657845c9cc6908e3bc1,treated,0.631377
uuid-375f1a7529ec4657845c9cc6908e3bc1,physicians,0.588529
uuid-375f1a7529ec4657845c9cc6908e3bc1,treatment,0.586932
uuid-375f1a7529ec4657845c9cc6908e3bc1,respond,0.333703
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,pembro,0.411572
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,1L,0.586939
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,PDL1,0.389796
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,chemo,0.328893
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,2L,0.523962
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,agents,0.390211
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,PD-L1,0.322148
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,atezo,0.438556
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,preferred,0.442128
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,testing,0.310532
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,monotherapy,0.440276
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,using nivo,0.305786
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,combo,0.421809
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,PDL1 testing,0.365772
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,NSCLC patients,0.300051
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,approved,0.405619
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,nivo and pembro,0.34901
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,believes,0.517356
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,tumor types,0.338295
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,feels,0.329258
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,option,0.530582
uuid-f6ef1c5fe4bd4dd58d759d31ceca9f8e,biomarker,0.311212
uuid-1c9c590952c14dfdab05bf87d088b7d6,dose,0.412221
uuid-1c9c590952c14dfdab05bf87d088b7d6,regimen,0.312086
uuid-1c9c590952c14dfdab05bf87d088b7d6,Ipi,0.527817
uuid-1c9c590952c14dfdab05bf87d088b7d6,combo,0.324878
uuid-4f513079277b4271947a4beaf24ea4f1,regimen,0.304044
uuid-a4054ceac0cb4fa096239d578ff61faf,Nivo,0.5748
uuid-a4054ceac0cb4fa096239d578ff61faf,Opdivo,0.392737
uuid-a4054ceac0cb4fa096239d578ff61faf,pembro,0.413553
uuid-a4054ceac0cb4fa096239d578ff61faf,RTL,0.303049
uuid-a4054ceac0cb4fa096239d578ff61faf,nivolumab,0.560771
uuid-a4054ceac0cb4fa096239d578ff61faf,2L,0.403264
uuid-a4054ceac0cb4fa096239d578ff61faf,stated,0.455107
uuid-a4054ceac0cb4fa096239d578ff61faf,approval,0.743517
uuid-a4054ceac0cb4fa096239d578ff61faf,preferred,0.352619
uuid-a4054ceac0cb4fa096239d578ff61faf,using nivo,0.683043
uuid-a4054ceac0cb4fa096239d578ff61faf,mentioned,0.303237
uuid-a4054ceac0cb4fa096239d578ff61faf,indication,0.412738
uuid-a4054ceac0cb4fa096239d578ff61faf,approved,0.649005
uuid-a4054ceac0cb4fa096239d578ff61faf,SCCHN,0.433446
uuid-a4054ceac0cb4fa096239d578ff61faf,cHL,0.602154
uuid-a4054ceac0cb4fa096239d578ff61faf,label,0.584768
uuid-a4054ceac0cb4fa096239d578ff61faf,LTL,0.34424
uuid-a4054ceac0cb4fa096239d578ff61faf,SCLC,0.3171
uuid-a4054ceac0cb4fa096239d578ff61faf,Regional TL,0.300252
uuid-a4054ceac0cb4fa096239d578ff61faf,RTL stated,0.489876
uuid-a4054ceac0cb4fa096239d578ff61faf,bladder,0.320354
uuid-c625c48f278f49b69e4b5aeedf65fe3f,Nivo,0.355942
uuid-c625c48f278f49b69e4b5aeedf65fe3f,patients,0.462723
uuid-c625c48f278f49b69e4b5aeedf65fe3f,efficacy,0.356853
uuid-c625c48f278f49b69e4b5aeedf65fe3f,regimen,0.367425
uuid-c625c48f278f49b69e4b5aeedf65fe3f,chemo,0.449286
uuid-c625c48f278f49b69e4b5aeedf65fe3f,pts,0.429503
uuid-c625c48f278f49b69e4b5aeedf65fe3f,OS,0.411945
uuid-c625c48f278f49b69e4b5aeedf65fe3f,monotherapy,0.411693
uuid-c625c48f278f49b69e4b5aeedf65fe3f,response,0.330833
uuid-c625c48f278f49b69e4b5aeedf65fe3f,PFS,0.385247
uuid-c625c48f278f49b69e4b5aeedf65fe3f,ORR,0.348092
uuid-c625c48f278f49b69e4b5aeedf65fe3f,progression,0.391072
uuid-c625c48f278f49b69e4b5aeedf65fe3f,chemotherapy,0.429347
uuid-c625c48f278f49b69e4b5aeedf65fe3f,respond,0.359105
uuid-c625c48f278f49b69e4b5aeedf65fe3f,feels,0.381962
uuid-c625c48f278f49b69e4b5aeedf65fe3f,option,0.444092
uuid-3ca89c71ea514da197a5f7f32393f76e,Opdivo,0.473967
uuid-3ca89c71ea514da197a5f7f32393f76e,physicians,0.416039
uuid-3ca89c71ea514da197a5f7f32393f76e,treatment,0.421705
uuid-3ca89c71ea514da197a5f7f32393f76e,drug,0.339928
uuid-f89700915d4d4290bb20ed09230a9e54,regimen,0.385455
uuid-f89700915d4d4290bb20ed09230a9e54,treated,0.436315
uuid-f89700915d4d4290bb20ed09230a9e54,combination,0.37209
uuid-f89700915d4d4290bb20ed09230a9e54,physicians,0.376101
uuid-f89700915d4d4290bb20ed09230a9e54,treatment,0.405068
uuid-f89700915d4d4290bb20ed09230a9e54,response,0.312363
uuid-f89700915d4d4290bb20ed09230a9e54,progression,0.321063
uuid-f89700915d4d4290bb20ed09230a9e54,chemotherapy,0.316633
uuid-7ef3f2ae2a504b3099ac19fe595908d8,BMS,0.570928
uuid-7ef3f2ae2a504b3099ac19fe595908d8,PDL1,0.341045
uuid-7ef3f2ae2a504b3099ac19fe595908d8,trial,0.321839
uuid-7ef3f2ae2a504b3099ac19fe595908d8,Merck,0.581359
uuid-7ef3f2ae2a504b3099ac19fe595908d8,data,0.451417
uuid-7ef3f2ae2a504b3099ac19fe595908d8,expressed,0.329627
uuid-21db71ad14f74fc3a07baf94cf57ccf0,patients,0.324434
uuid-21db71ad14f74fc3a07baf94cf57ccf0,therapy,0.379085
uuid-21db71ad14f74fc3a07baf94cf57ccf0,dose,0.30961
uuid-21db71ad14f74fc3a07baf94cf57ccf0,nivolumab,0.434462
uuid-21db71ad14f74fc3a07baf94cf57ccf0,regimen,0.348243
uuid-21db71ad14f74fc3a07baf94cf57ccf0,combination,0.320399
uuid-21db71ad14f74fc3a07baf94cf57ccf0,chemo,0.319612
uuid-21db71ad14f74fc3a07baf94cf57ccf0,pts,0.37307
uuid-21db71ad14f74fc3a07baf94cf57ccf0,monotherapy,0.310637
uuid-21db71ad14f74fc3a07baf94cf57ccf0,treatment,0.385003
uuid-21db71ad14f74fc3a07baf94cf57ccf0,response,0.375305
uuid-21db71ad14f74fc3a07baf94cf57ccf0,PD1,0.550099
uuid-21db71ad14f74fc3a07baf94cf57ccf0,progression,0.422383
uuid-21db71ad14f74fc3a07baf94cf57ccf0,respond,0.35164
uuid-21db71ad14f74fc3a07baf94cf57ccf0,PD-1,0.390829
uuid-072474baf51048f59cebcb1676297631,indication,0.309317
uuid-072474baf51048f59cebcb1676297631,AI,0.322606
uuid-072474baf51048f59cebcb1676297631,oncology,0.426907
uuid-072474baf51048f59cebcb1676297631,approved,0.319501
uuid-072474baf51048f59cebcb1676297631,tumor types,0.465224
uuid-072474baf51048f59cebcb1676297631,clinical,0.337155
uuid-8f55c23a08924364a76a901917286851,patients,0.681065
uuid-8f55c23a08924364a76a901917286851,therapy,0.498959
uuid-8f55c23a08924364a76a901917286851,nivolumab,0.367138
uuid-8f55c23a08924364a76a901917286851,1L,0.325309
uuid-8f55c23a08924364a76a901917286851,regimen,0.509084
uuid-8f55c23a08924364a76a901917286851,treated,0.330952
uuid-8f55c23a08924364a76a901917286851,combination,0.352859
uuid-8f55c23a08924364a76a901917286851,chemo,0.522236
uuid-8f55c23a08924364a76a901917286851,pts,0.557414
uuid-8f55c23a08924364a76a901917286851,IO,0.364606
uuid-8f55c23a08924364a76a901917286851,monotherapy,0.523082
uuid-8f55c23a08924364a76a901917286851,treatment,0.518673
uuid-8f55c23a08924364a76a901917286851,response,0.443422
uuid-8f55c23a08924364a76a901917286851,combo,0.404437
uuid-8f55c23a08924364a76a901917286851,PD1,0.422319
uuid-8f55c23a08924364a76a901917286851,progression,0.648807
uuid-8f55c23a08924364a76a901917286851,chemotherapy,0.512784
uuid-8f55c23a08924364a76a901917286851,respond,0.448818
uuid-8f55c23a08924364a76a901917286851,option,0.481003
uuid-45b0e6d816da4fb3852ec24d59cc24d1,dose,0.36424
uuid-45b0e6d816da4fb3852ec24d59cc24d1,toxicity,0.475324
uuid-45b0e6d816da4fb3852ec24d59cc24d1,treated,0.354766
uuid-45b0e6d816da4fb3852ec24d59cc24d1,physicians,0.34537
uuid-45b0e6d816da4fb3852ec24d59cc24d1,treatment,0.409938
uuid-1389535a2b14482a84de92ec239d3c4e,patients,0.802107
uuid-1389535a2b14482a84de92ec239d3c4e,Opdivo,0.536665
uuid-1389535a2b14482a84de92ec239d3c4e,therapy,0.4381
uuid-1389535a2b14482a84de92ec239d3c4e,nivolumab,0.410219
uuid-1389535a2b14482a84de92ec239d3c4e,regimen,0.337281
uuid-1389535a2b14482a84de92ec239d3c4e,treated,0.52839
uuid-1389535a2b14482a84de92ec239d3c4e,pts,0.46646
uuid-1389535a2b14482a84de92ec239d3c4e,treatment,0.621634
uuid-1389535a2b14482a84de92ec239d3c4e,response,0.338713
uuid-1389535a2b14482a84de92ec239d3c4e,cHL,0.324325
uuid-1389535a2b14482a84de92ec239d3c4e,progression,0.608525
uuid-1389535a2b14482a84de92ec239d3c4e,respond,0.447204
uuid-883cc8568370498392938a7c56471659,patients,0.33187
uuid-883cc8568370498392938a7c56471659,TL,0.315904
uuid-883cc8568370498392938a7c56471659,treated,0.648861
uuid-883cc8568370498392938a7c56471659,RCC,0.303375
uuid-883cc8568370498392938a7c56471659,TL stated,0.31622
uuid-883cc8568370498392938a7c56471659,physicians,0.531322
uuid-883cc8568370498392938a7c56471659,treatment,0.41624
uuid-883cc8568370498392938a7c56471659,SCCHN,0.364791
uuid-883cc8568370498392938a7c56471659,oncologist,0.535449
uuid-883cc8568370498392938a7c56471659,Regional TL,0.382115
uuid-883cc8568370498392938a7c56471659,TL shared,0.354332
uuid-9bc586d8b9a74994af11e4bb2bf4c263,treated,0.384095
uuid-9bc586d8b9a74994af11e4bb2bf4c263,treatment,0.314025
uuid-9bc586d8b9a74994af11e4bb2bf4c263,clinical trials,0.361348
uuid-9bc586d8b9a74994af11e4bb2bf4c263,SCCHN,0.338026
uuid-9bc586d8b9a74994af11e4bb2bf4c263,tumor types,0.312647
uuid-9bc586d8b9a74994af11e4bb2bf4c263,Regional TL,0.319235
uuid-9bc586d8b9a74994af11e4bb2bf4c263,RTL stated,0.323604
uuid-9bc586d8b9a74994af11e4bb2bf4c263,TL shared,0.325779
uuid-9bc586d8b9a74994af11e4bb2bf4c263,bladder,0.340259
uuid-3b003afd668940478ba2db6d672474b4,patients,0.608727
uuid-3b003afd668940478ba2db6d672474b4,Opdivo,0.516291
uuid-3b003afd668940478ba2db6d672474b4,dose,0.361209
uuid-3b003afd668940478ba2db6d672474b4,nivolumab,0.322943
uuid-3b003afd668940478ba2db6d672474b4,toxicity,0.435069
uuid-3b003afd668940478ba2db6d672474b4,regimen,0.470861
uuid-3b003afd668940478ba2db6d672474b4,treated,0.505227
uuid-3b003afd668940478ba2db6d672474b4,pts,0.343963
uuid-3b003afd668940478ba2db6d672474b4,treatment,0.504585
uuid-3b003afd668940478ba2db6d672474b4,progression,0.419766
uuid-3b003afd668940478ba2db6d672474b4,respond,0.455316
uuid-7628c80a43904428a0e9e52c70c82400,Nivo,0.479318
uuid-7628c80a43904428a0e9e52c70c82400,pembro,0.478424
uuid-7628c80a43904428a0e9e52c70c82400,dose,0.396304
uuid-7628c80a43904428a0e9e52c70c82400,efficacy,0.364678
uuid-7628c80a43904428a0e9e52c70c82400,2L,0.33394
uuid-7628c80a43904428a0e9e52c70c82400,agents,0.321851
uuid-7628c80a43904428a0e9e52c70c82400,atezo,0.486383
uuid-7628c80a43904428a0e9e52c70c82400,preferred,0.40541
uuid-7628c80a43904428a0e9e52c70c82400,monotherapy,0.311117
uuid-7628c80a43904428a0e9e52c70c82400,using nivo,0.306402
uuid-7628c80a43904428a0e9e52c70c82400,indication,0.350343
uuid-7628c80a43904428a0e9e52c70c82400,approved,0.351117
uuid-7628c80a43904428a0e9e52c70c82400,vs,0.483176
uuid-7628c80a43904428a0e9e52c70c82400,feels,0.463593
uuid-7628c80a43904428a0e9e52c70c82400,option,0.360209
uuid-7628c80a43904428a0e9e52c70c82400,flat dosing,0.304104
uuid-60900bc96ac04895b6703c8d7ca96d71,Nivo,0.479292
uuid-60900bc96ac04895b6703c8d7ca96d71,patients,0.710884
uuid-60900bc96ac04895b6703c8d7ca96d71,therapy,0.596934
uuid-60900bc96ac04895b6703c8d7ca96d71,nivolumab,0.492756
uuid-60900bc96ac04895b6703c8d7ca96d71,1L,0.36628
uuid-60900bc96ac04895b6703c8d7ca96d71,regimen,0.467386
uuid-60900bc96ac04895b6703c8d7ca96d71,treated,0.375583
uuid-60900bc96ac04895b6703c8d7ca96d71,combination,0.358871
uuid-60900bc96ac04895b6703c8d7ca96d71,chemo,0.587337
uuid-60900bc96ac04895b6703c8d7ca96d71,2L,0.341852
uuid-60900bc96ac04895b6703c8d7ca96d71,pts,0.519076
uuid-60900bc96ac04895b6703c8d7ca96d71,preferred,0.373797
uuid-60900bc96ac04895b6703c8d7ca96d71,monotherapy,0.583013
uuid-60900bc96ac04895b6703c8d7ca96d71,treatment,0.54541
uuid-60900bc96ac04895b6703c8d7ca96d71,using nivo,0.382522
uuid-60900bc96ac04895b6703c8d7ca96d71,response,0.359875
uuid-60900bc96ac04895b6703c8d7ca96d71,PD1,0.422215
uuid-60900bc96ac04895b6703c8d7ca96d71,progression,0.531847
uuid-60900bc96ac04895b6703c8d7ca96d71,chemotherapy,0.614158
uuid-60900bc96ac04895b6703c8d7ca96d71,respond,0.382037
uuid-60900bc96ac04895b6703c8d7ca96d71,feels,0.398655
uuid-60900bc96ac04895b6703c8d7ca96d71,RTL stated,0.310144
uuid-60900bc96ac04895b6703c8d7ca96d71,option,0.603614
uuid-e32049be96f6462f8e05e589eb390486,Nivo,0.302561
uuid-e32049be96f6462f8e05e589eb390486,patients,0.530238
uuid-e32049be96f6462f8e05e589eb390486,therapy,0.519418
uuid-e32049be96f6462f8e05e589eb390486,nivolumab,0.383629
uuid-e32049be96f6462f8e05e589eb390486,regimen,0.337854
uuid-e32049be96f6462f8e05e589eb390486,chemo,0.355832
uuid-e32049be96f6462f8e05e589eb390486,pts,0.322265
uuid-e32049be96f6462f8e05e589eb390486,treatment,0.499404
uuid-e32049be96f6462f8e05e589eb390486,progression,0.44844
uuid-e32049be96f6462f8e05e589eb390486,chemotherapy,0.461251
uuid-c05dbe14a50b4b208a9eab1e7be78cf3,TL,0.659343
uuid-c05dbe14a50b4b208a9eab1e7be78cf3,PDL1,0.447142
uuid-c05dbe14a50b4b208a9eab1e7be78cf3,TL stated,0.352692
uuid-c05dbe14a50b4b208a9eab1e7be78cf3,institution,0.312502
uuid-c05dbe14a50b4b208a9eab1e7be78cf3,PD-L1,0.837586
uuid-c05dbe14a50b4b208a9eab1e7be78cf3,PD-L1 testing,0.886418
uuid-c05dbe14a50b4b208a9eab1e7be78cf3,testing,0.864262
uuid-c05dbe14a50b4b208a9eab1e7be78cf3,PDL1 testing,0.608117
uuid-c05dbe14a50b4b208a9eab1e7be78cf3,NSCLC patients,0.585561
uuid-c05dbe14a50b4b208a9eab1e7be78cf3,assay,0.803352
uuid-c05dbe14a50b4b208a9eab1e7be78cf3,PDL1 expression,0.323329
uuid-c05dbe14a50b4b208a9eab1e7be78cf3,biomarker,0.43678
uuid-dc87b147eb8f4293a118e51283ed87b3,Nivo,0.41256
uuid-dc87b147eb8f4293a118e51283ed87b3,patients,0.538236
uuid-dc87b147eb8f4293a118e51283ed87b3,pembro,0.555012
uuid-dc87b147eb8f4293a118e51283ed87b3,1L,0.596752
uuid-dc87b147eb8f4293a118e51283ed87b3,PDL1,0.305061
uuid-dc87b147eb8f4293a118e51283ed87b3,chemo,0.541626
uuid-dc87b147eb8f4293a118e51283ed87b3,2L,0.562032
uuid-dc87b147eb8f4293a118e51283ed87b3,pts,0.458168
uuid-dc87b147eb8f4293a118e51283ed87b3,agents,0.32909
uuid-dc87b147eb8f4293a118e51283ed87b3,PD-L1,0.343821
uuid-dc87b147eb8f4293a118e51283ed87b3,approval,0.305168
uuid-dc87b147eb8f4293a118e51283ed87b3,atezo,0.463648
uuid-dc87b147eb8f4293a118e51283ed87b3,preferred,0.50905
uuid-dc87b147eb8f4293a118e51283ed87b3,testing,0.350013
uuid-dc87b147eb8f4293a118e51283ed87b3,monotherapy,0.546729
uuid-dc87b147eb8f4293a118e51283ed87b3,using nivo,0.456711
uuid-dc87b147eb8f4293a118e51283ed87b3,NSCLC patients,0.531394
uuid-dc87b147eb8f4293a118e51283ed87b3,PD1,0.318257
uuid-dc87b147eb8f4293a118e51283ed87b3,approved,0.3694
uuid-dc87b147eb8f4293a118e51283ed87b3,believes,0.313755
uuid-dc87b147eb8f4293a118e51283ed87b3,chemotherapy,0.390544
uuid-dc87b147eb8f4293a118e51283ed87b3,respond,0.30509
uuid-dc87b147eb8f4293a118e51283ed87b3,option,0.543647
uuid-9a9e9fb36a1d41c6813eb7c218135bd2,patients,0.463201
uuid-9a9e9fb36a1d41c6813eb7c218135bd2,therapy,0.409319
uuid-9a9e9fb36a1d41c6813eb7c218135bd2,nivolumab,0.396509
uuid-9a9e9fb36a1d41c6813eb7c218135bd2,treated,0.431748
uuid-9a9e9fb36a1d41c6813eb7c218135bd2,treatment,0.408399
uuid-9a9e9fb36a1d41c6813eb7c218135bd2,progression,0.310321
uuid-9a9e9fb36a1d41c6813eb7c218135bd2,chemotherapy,0.391242
uuid-9a9e9fb36a1d41c6813eb7c218135bd2,option,0.314808
uuid-1b9c9faae2204663b2b1180798fa6859,Nivo,0.46543
uuid-1b9c9faae2204663b2b1180798fa6859,pembro,0.684177
uuid-1b9c9faae2204663b2b1180798fa6859,dose,0.344112
uuid-1b9c9faae2204663b2b1180798fa6859,1L,0.379565
uuid-1b9c9faae2204663b2b1180798fa6859,PDL1,0.360024
uuid-1b9c9faae2204663b2b1180798fa6859,efficacy,0.696082
uuid-1b9c9faae2204663b2b1180798fa6859,2L,0.467504
uuid-1b9c9faae2204663b2b1180798fa6859,agents,0.603923
uuid-1b9c9faae2204663b2b1180798fa6859,Ipi,0.353932
uuid-1b9c9faae2204663b2b1180798fa6859,atezo,0.74398
uuid-1b9c9faae2204663b2b1180798fa6859,preferred,0.406103
uuid-1b9c9faae2204663b2b1180798fa6859,monotherapy,0.331222
uuid-1b9c9faae2204663b2b1180798fa6859,data,0.436918
uuid-1b9c9faae2204663b2b1180798fa6859,combo,0.325559
uuid-1b9c9faae2204663b2b1180798fa6859,indication,0.350551
uuid-1b9c9faae2204663b2b1180798fa6859,nivo and pembro,0.643847
uuid-1b9c9faae2204663b2b1180798fa6859,believes,0.412102
uuid-1b9c9faae2204663b2b1180798fa6859,vs,0.679838
uuid-1b9c9faae2204663b2b1180798fa6859,TLs,0.314801
uuid-1b9c9faae2204663b2b1180798fa6859,feels,0.41952
uuid-1b9c9faae2204663b2b1180798fa6859,PDL1 expression,0.336335
uuid-e8a76dc6469845c5960e2c7254f045f4,Nivo,0.591688
uuid-e8a76dc6469845c5960e2c7254f045f4,patients,0.583803
uuid-e8a76dc6469845c5960e2c7254f045f4,pembro,0.544458
uuid-e8a76dc6469845c5960e2c7254f045f4,therapy,0.329873
uuid-e8a76dc6469845c5960e2c7254f045f4,nivolumab,0.404673
uuid-e8a76dc6469845c5960e2c7254f045f4,1L,0.332949
uuid-e8a76dc6469845c5960e2c7254f045f4,trial,0.421355
uuid-e8a76dc6469845c5960e2c7254f045f4,treated,0.357492
uuid-e8a76dc6469845c5960e2c7254f045f4,chemo,0.339205
uuid-e8a76dc6469845c5960e2c7254f045f4,2L,0.371365
uuid-e8a76dc6469845c5960e2c7254f045f4,pts,0.451688
uuid-e8a76dc6469845c5960e2c7254f045f4,Ipi,0.337454
uuid-e8a76dc6469845c5960e2c7254f045f4,approval,0.46046
uuid-e8a76dc6469845c5960e2c7254f045f4,atezo,0.351269
uuid-e8a76dc6469845c5960e2c7254f045f4,preferred,0.358364
uuid-e8a76dc6469845c5960e2c7254f045f4,monotherapy,0.343975
uuid-e8a76dc6469845c5960e2c7254f045f4,using nivo,0.485711
uuid-e8a76dc6469845c5960e2c7254f045f4,clinical trials,0.315229
uuid-e8a76dc6469845c5960e2c7254f045f4,approved,0.385088
uuid-e8a76dc6469845c5960e2c7254f045f4,chemotherapy,0.353297
uuid-e8a76dc6469845c5960e2c7254f045f4,vs,0.341044
uuid-e8a76dc6469845c5960e2c7254f045f4,RTL stated,0.358549
uuid-e8a76dc6469845c5960e2c7254f045f4,option,0.368277
uuid-e8a76dc6469845c5960e2c7254f045f4,bladder,0.341732
uuid-fd0566e20dca4285a10b915dbb18d58c,pembro,0.394626
uuid-fd0566e20dca4285a10b915dbb18d58c,BMS,0.525637
uuid-fd0566e20dca4285a10b915dbb18d58c,trial,0.738375
uuid-fd0566e20dca4285a10b915dbb18d58c,efficacy,0.626795
uuid-fd0566e20dca4285a10b915dbb18d58c,Merck,0.430592
uuid-fd0566e20dca4285a10b915dbb18d58c,OS,0.57095
uuid-fd0566e20dca4285a10b915dbb18d58c,atezo,0.329787
uuid-fd0566e20dca4285a10b915dbb18d58c,regards,0.37312
uuid-fd0566e20dca4285a10b915dbb18d58c,data,0.657636
uuid-fd0566e20dca4285a10b915dbb18d58c,indication,0.373089
uuid-fd0566e20dca4285a10b915dbb18d58c,PFS,0.564956
uuid-fd0566e20dca4285a10b915dbb18d58c,ORR,0.58975
uuid-fd0566e20dca4285a10b915dbb18d58c,nivo and pembro,0.484184
uuid-fd0566e20dca4285a10b915dbb18d58c,believes,0.304363
uuid-fd0566e20dca4285a10b915dbb18d58c,impressed,0.454739
uuid-fd0566e20dca4285a10b915dbb18d58c,vs,0.395123
uuid-fd0566e20dca4285a10b915dbb18d58c,PDL1 expression,0.330085
uuid-9dd614bee3e64f989000cf0982f1fd2a,data,0.475885
uuid-9dd614bee3e64f989000cf0982f1fd2a,NCCN,0.696388
uuid-2d50ce369dbc4da2a880c5f7b08fcf87,institution,0.306023
uuid-2d50ce369dbc4da2a880c5f7b08fcf87,AI,0.343228
uuid-2d50ce369dbc4da2a880c5f7b08fcf87,NCCN,0.779571
uuid-a818190932914c8dadd11cd3f4cdbc43,TL,0.303584
uuid-a818190932914c8dadd11cd3f4cdbc43,PDL1,0.308855
uuid-a818190932914c8dadd11cd3f4cdbc43,tumor,0.599146
uuid-a818190932914c8dadd11cd3f4cdbc43,PD-L1,0.40571
uuid-a818190932914c8dadd11cd3f4cdbc43,PD-L1 testing,0.363258
uuid-a818190932914c8dadd11cd3f4cdbc43,testing,0.341232
uuid-a818190932914c8dadd11cd3f4cdbc43,assay,0.442359
uuid-a818190932914c8dadd11cd3f4cdbc43,PDL1 expression,0.314764
uuid-2e3b043e4c584970a64842142d952c8e,patients,0.813226
uuid-2e3b043e4c584970a64842142d952c8e,Opdivo,0.496707
uuid-2e3b043e4c584970a64842142d952c8e,therapy,0.710501
uuid-2e3b043e4c584970a64842142d952c8e,nivolumab,0.612319
uuid-2e3b043e4c584970a64842142d952c8e,regimen,0.441335
uuid-2e3b043e4c584970a64842142d952c8e,treated,0.615548
uuid-2e3b043e4c584970a64842142d952c8e,pts,0.495067
uuid-2e3b043e4c584970a64842142d952c8e,monotherapy,0.331911
uuid-2e3b043e4c584970a64842142d952c8e,treatment,0.664203
uuid-2e3b043e4c584970a64842142d952c8e,using nivo,0.394097
uuid-2e3b043e4c584970a64842142d952c8e,response,0.354035
uuid-2e3b043e4c584970a64842142d952c8e,PD1,0.33495
uuid-2e3b043e4c584970a64842142d952c8e,cHL,0.584238
uuid-2e3b043e4c584970a64842142d952c8e,progression,0.623407
uuid-2e3b043e4c584970a64842142d952c8e,chemotherapy,0.420317
uuid-2e3b043e4c584970a64842142d952c8e,respond,0.384658
uuid-2e3b043e4c584970a64842142d952c8e,RTL stated,0.303356
uuid-2e3b043e4c584970a64842142d952c8e,option,0.329613
uuid-77d20cd0a27845c4b046a81ba7b397da,Opdivo,0.311102
uuid-77d20cd0a27845c4b046a81ba7b397da,toxicity,0.441676
uuid-77d20cd0a27845c4b046a81ba7b397da,regimen,0.328313
uuid-77d20cd0a27845c4b046a81ba7b397da,treated,0.337507
uuid-77d20cd0a27845c4b046a81ba7b397da,physicians,0.566939
uuid-77d20cd0a27845c4b046a81ba7b397da,treatment,0.501602
uuid-77d20cd0a27845c4b046a81ba7b397da,drug,0.338767
uuid-b675af0bd27b427995fb1b9bba08438c,Nivo,0.397045
uuid-b675af0bd27b427995fb1b9bba08438c,therapy,0.470293
uuid-b675af0bd27b427995fb1b9bba08438c,nivolumab,0.335341
uuid-b675af0bd27b427995fb1b9bba08438c,mentioned,0.378184
uuid-b675af0bd27b427995fb1b9bba08438c,cHL,0.660274
uuid-d7f689f11e734ea7a27712f7d08bb8b1,patients,0.465206
uuid-d7f689f11e734ea7a27712f7d08bb8b1,therapy,0.359977
uuid-d7f689f11e734ea7a27712f7d08bb8b1,chemo,0.423898
uuid-d7f689f11e734ea7a27712f7d08bb8b1,pts,0.307772
uuid-d7f689f11e734ea7a27712f7d08bb8b1,treatment,0.30615
uuid-d7f689f11e734ea7a27712f7d08bb8b1,response,0.323624
uuid-d7f689f11e734ea7a27712f7d08bb8b1,NSCLC patients,0.384076
uuid-d7f689f11e734ea7a27712f7d08bb8b1,progression,0.354692
uuid-d7f689f11e734ea7a27712f7d08bb8b1,tumor types,0.412734
uuid-d7f689f11e734ea7a27712f7d08bb8b1,respond,0.482722
uuid-d7f689f11e734ea7a27712f7d08bb8b1,PD-1,0.307401
uuid-d7f689f11e734ea7a27712f7d08bb8b1,option,0.3168
uuid-33e1ac50ee1441c680de20170ce8d26f,patients,0.405059
uuid-33e1ac50ee1441c680de20170ce8d26f,Opdivo,0.471175
uuid-33e1ac50ee1441c680de20170ce8d26f,nivolumab,0.306847
uuid-33e1ac50ee1441c680de20170ce8d26f,regimen,0.437403
uuid-33e1ac50ee1441c680de20170ce8d26f,treated,0.387189
uuid-33e1ac50ee1441c680de20170ce8d26f,shared,0.326052
uuid-33e1ac50ee1441c680de20170ce8d26f,physicians,0.61442
uuid-33e1ac50ee1441c680de20170ce8d26f,treatment,0.457442
uuid-24d61a2ffc3b403194d8646579641f56,patients,0.551768
uuid-24d61a2ffc3b403194d8646579641f56,Opdivo,0.32001
uuid-24d61a2ffc3b403194d8646579641f56,therapy,0.400162
uuid-24d61a2ffc3b403194d8646579641f56,nivolumab,0.350994
uuid-24d61a2ffc3b403194d8646579641f56,treated,0.409366
uuid-24d61a2ffc3b403194d8646579641f56,treatment,0.513148
uuid-24d61a2ffc3b403194d8646579641f56,cHL,0.321155
uuid-24d61a2ffc3b403194d8646579641f56,progression,0.381748
uuid-bdc6732cf5834e119ba87a2c66d523e6,therapy,0.326887
uuid-bdc6732cf5834e119ba87a2c66d523e6,combination,0.396561
uuid-bdc6732cf5834e119ba87a2c66d523e6,chemo,0.360628
uuid-bdc6732cf5834e119ba87a2c66d523e6,agents,0.369018
uuid-bdc6732cf5834e119ba87a2c66d523e6,PD1,0.32231
uuid-bdc6732cf5834e119ba87a2c66d523e6,chemotherapy,0.479735
uuid-bdc6732cf5834e119ba87a2c66d523e6,clinical,0.37134
uuid-bdc6732cf5834e119ba87a2c66d523e6,immunotherapy,0.534551
uuid-71f16f54ba82455bb4d59b2f8a51f457,tumor,0.47756
uuid-71f16f54ba82455bb4d59b2f8a51f457,PD-L1,0.378734
uuid-71f16f54ba82455bb4d59b2f8a51f457,PD-L1 testing,0.372268
uuid-71f16f54ba82455bb4d59b2f8a51f457,testing,0.477536
uuid-71f16f54ba82455bb4d59b2f8a51f457,PDL1 testing,0.314318
uuid-71f16f54ba82455bb4d59b2f8a51f457,assay,0.33762
uuid-71f16f54ba82455bb4d59b2f8a51f457,biomarker,0.373462
uuid-15971460ab584ab1826cc1e1d6ae1ff7,nivolumab,0.395296
uuid-15971460ab584ab1826cc1e1d6ae1ff7,combination,0.52163
uuid-15971460ab584ab1826cc1e1d6ae1ff7,clinical trials,0.380079
uuid-15971460ab584ab1826cc1e1d6ae1ff7,immunotherapy,0.377341
uuid-15971460ab584ab1826cc1e1d6ae1ff7,Regional TL,0.327497
uuid-15971460ab584ab1826cc1e1d6ae1ff7,bladder,0.309069
uuid-1a7699b7fa664eba8399561f545d8e6f,BMS,0.364338
uuid-1a7699b7fa664eba8399561f545d8e6f,efficacy,0.432667
uuid-1a7699b7fa664eba8399561f545d8e6f,discussed,0.347435
uuid-1a7699b7fa664eba8399561f545d8e6f,commented,0.527514
uuid-1a7699b7fa664eba8399561f545d8e6f,stated,0.375733
uuid-1a7699b7fa664eba8399561f545d8e6f,OS,0.501757
uuid-1a7699b7fa664eba8399561f545d8e6f,regards,0.452099
uuid-1a7699b7fa664eba8399561f545d8e6f,data,0.646131
uuid-1a7699b7fa664eba8399561f545d8e6f,expressed,0.360339
uuid-1a7699b7fa664eba8399561f545d8e6f,indication,0.308997
uuid-1a7699b7fa664eba8399561f545d8e6f,PFS,0.445987
uuid-1a7699b7fa664eba8399561f545d8e6f,ORR,0.450565
uuid-1a7699b7fa664eba8399561f545d8e6f,ASCO,0.491939
uuid-1a7699b7fa664eba8399561f545d8e6f,impressed,0.631187
uuid-1a7699b7fa664eba8399561f545d8e6f,TLs,0.346412
uuid-1a7699b7fa664eba8399561f545d8e6f,feels,0.342967
uuid-f65bd5e2ea294832b4dd06a0d300403c,Nivo,0.415113
uuid-f65bd5e2ea294832b4dd06a0d300403c,pembro,0.506481
uuid-f65bd5e2ea294832b4dd06a0d300403c,BMS,0.517431
uuid-f65bd5e2ea294832b4dd06a0d300403c,trial,0.633938
uuid-f65bd5e2ea294832b4dd06a0d300403c,efficacy,0.487131
uuid-f65bd5e2ea294832b4dd06a0d300403c,commented,0.368171
uuid-f65bd5e2ea294832b4dd06a0d300403c,Merck,0.38584
uuid-f65bd5e2ea294832b4dd06a0d300403c,Ipi,0.309152
uuid-f65bd5e2ea294832b4dd06a0d300403c,stated,0.382513
uuid-f65bd5e2ea294832b4dd06a0d300403c,approval,0.397843
uuid-f65bd5e2ea294832b4dd06a0d300403c,OS,0.371819
uuid-f65bd5e2ea294832b4dd06a0d300403c,atezo,0.39454
uuid-f65bd5e2ea294832b4dd06a0d300403c,regards,0.301082
uuid-f65bd5e2ea294832b4dd06a0d300403c,data,0.737678
uuid-f65bd5e2ea294832b4dd06a0d300403c,expressed,0.351737
uuid-f65bd5e2ea294832b4dd06a0d300403c,clinical trials,0.371067
uuid-f65bd5e2ea294832b4dd06a0d300403c,indication,0.460325
uuid-f65bd5e2ea294832b4dd06a0d300403c,PFS,0.361113
uuid-f65bd5e2ea294832b4dd06a0d300403c,ORR,0.432086
uuid-f65bd5e2ea294832b4dd06a0d300403c,approved,0.390967
uuid-f65bd5e2ea294832b4dd06a0d300403c,nivo and pembro,0.332261
uuid-f65bd5e2ea294832b4dd06a0d300403c,impressed,0.617246
uuid-f65bd5e2ea294832b4dd06a0d300403c,vs,0.345598
uuid-f65bd5e2ea294832b4dd06a0d300403c,label,0.336832
uuid-f65bd5e2ea294832b4dd06a0d300403c,LTL,0.312846
uuid-f65bd5e2ea294832b4dd06a0d300403c,feels,0.374672
uuid-f65bd5e2ea294832b4dd06a0d300403c,flat dosing,0.364327
uuid-5f56e2a6a1c749f490b247f276e8b8f9,pembro,0.467695
uuid-5f56e2a6a1c749f490b247f276e8b8f9,1L,0.496279
uuid-5f56e2a6a1c749f490b247f276e8b8f9,PDL1,0.470025
uuid-5f56e2a6a1c749f490b247f276e8b8f9,2L,0.353748
uuid-5f56e2a6a1c749f490b247f276e8b8f9,PD-L1,0.310173
uuid-5f56e2a6a1c749f490b247f276e8b8f9,approval,0.421534
uuid-5f56e2a6a1c749f490b247f276e8b8f9,OS,0.49033
uuid-5f56e2a6a1c749f490b247f276e8b8f9,atezo,0.352798
uuid-5f56e2a6a1c749f490b247f276e8b8f9,using nivo,0.303385
uuid-5f56e2a6a1c749f490b247f276e8b8f9,data,0.499182
uuid-5f56e2a6a1c749f490b247f276e8b8f9,PFS,0.394484
uuid-5f56e2a6a1c749f490b247f276e8b8f9,NSCLC patients,0.425889
uuid-5f56e2a6a1c749f490b247f276e8b8f9,ORR,0.39238
uuid-5f56e2a6a1c749f490b247f276e8b8f9,approved,0.364318
uuid-5f56e2a6a1c749f490b247f276e8b8f9,SCCHN,0.356385
uuid-5f56e2a6a1c749f490b247f276e8b8f9,nivo and pembro,0.336681
uuid-5f56e2a6a1c749f490b247f276e8b8f9,impressed,0.478525
uuid-5f56e2a6a1c749f490b247f276e8b8f9,PDL1 expression,0.393223
uuid-5f56e2a6a1c749f490b247f276e8b8f9,bladder,0.30093
uuid-d9485e3c6bca44aebd22ee8721b83558,TL,0.484561
uuid-d9485e3c6bca44aebd22ee8721b83558,PDL1,0.325355
uuid-d9485e3c6bca44aebd22ee8721b83558,TL stated,0.460163
uuid-d9485e3c6bca44aebd22ee8721b83558,institution,0.374748
uuid-d9485e3c6bca44aebd22ee8721b83558,PD-L1,0.768139
uuid-d9485e3c6bca44aebd22ee8721b83558,PD-L1 testing,0.83314
uuid-d9485e3c6bca44aebd22ee8721b83558,testing,0.903215
uuid-d9485e3c6bca44aebd22ee8721b83558,PDL1 testing,0.797006
uuid-d9485e3c6bca44aebd22ee8721b83558,NSCLC patients,0.717569
uuid-d9485e3c6bca44aebd22ee8721b83558,assay,0.634542
uuid-d9485e3c6bca44aebd22ee8721b83558,biomarker,0.399022
uuid-e76bdd8dc3994480bf00c5e642f242fe,Nivo,0.503622
uuid-e76bdd8dc3994480bf00c5e642f242fe,patients,0.317646
uuid-e76bdd8dc3994480bf00c5e642f242fe,therapy,0.673167
uuid-e76bdd8dc3994480bf00c5e642f242fe,nivolumab,0.348736
uuid-e76bdd8dc3994480bf00c5e642f242fe,combination,0.301936
uuid-e76bdd8dc3994480bf00c5e642f242fe,chemo,0.420238
uuid-e76bdd8dc3994480bf00c5e642f242fe,agents,0.401446
uuid-e76bdd8dc3994480bf00c5e642f242fe,preferred,0.303359
uuid-e76bdd8dc3994480bf00c5e642f242fe,monotherapy,0.457612
uuid-e76bdd8dc3994480bf00c5e642f242fe,treatment,0.333189
uuid-e76bdd8dc3994480bf00c5e642f242fe,using nivo,0.333254
uuid-e76bdd8dc3994480bf00c5e642f242fe,PD1,0.463947
uuid-e76bdd8dc3994480bf00c5e642f242fe,cHL,0.450821
uuid-e76bdd8dc3994480bf00c5e642f242fe,chemotherapy,0.492214
uuid-e76bdd8dc3994480bf00c5e642f242fe,PD-1,0.307794
uuid-e76bdd8dc3994480bf00c5e642f242fe,option,0.490344
uuid-cb760ff2602e485987b51cd0f57c7f00,Nivo,0.391841
uuid-cb760ff2602e485987b51cd0f57c7f00,patients,0.598781
uuid-cb760ff2602e485987b51cd0f57c7f00,Opdivo,0.385331
uuid-cb760ff2602e485987b51cd0f57c7f00,therapy,0.751019
uuid-cb760ff2602e485987b51cd0f57c7f00,nivolumab,0.493723
uuid-cb760ff2602e485987b51cd0f57c7f00,treated,0.321018
uuid-cb760ff2602e485987b51cd0f57c7f00,chemo,0.333111
uuid-cb760ff2602e485987b51cd0f57c7f00,treatment,0.520884
uuid-cb760ff2602e485987b51cd0f57c7f00,response,0.372045
uuid-cb760ff2602e485987b51cd0f57c7f00,PD1,0.386914
uuid-cb760ff2602e485987b51cd0f57c7f00,cHL,0.564804
uuid-cb760ff2602e485987b51cd0f57c7f00,progression,0.505165
uuid-cb760ff2602e485987b51cd0f57c7f00,chemotherapy,0.45853
uuid-cb760ff2602e485987b51cd0f57c7f00,respond,0.321147
uuid-cb760ff2602e485987b51cd0f57c7f00,option,0.350852
uuid-b8e81dc5fd5940fead30a28b1212fbfe,patients,0.755823
uuid-b8e81dc5fd5940fead30a28b1212fbfe,Opdivo,0.688184
uuid-b8e81dc5fd5940fead30a28b1212fbfe,therapy,0.48451
uuid-b8e81dc5fd5940fead30a28b1212fbfe,nivolumab,0.455501
uuid-b8e81dc5fd5940fead30a28b1212fbfe,regimen,0.357053
uuid-b8e81dc5fd5940fead30a28b1212fbfe,treated,0.4535
uuid-b8e81dc5fd5940fead30a28b1212fbfe,physicians,0.315229
uuid-b8e81dc5fd5940fead30a28b1212fbfe,treatment,0.595767
uuid-b8e81dc5fd5940fead30a28b1212fbfe,using nivo,0.316644
uuid-b8e81dc5fd5940fead30a28b1212fbfe,cHL,0.447078
uuid-b8e81dc5fd5940fead30a28b1212fbfe,progression,0.421396
uuid-135163b4284c4a4dabc6c66db6552833,Nivo,0.476939
uuid-135163b4284c4a4dabc6c66db6552833,patients,0.67638
uuid-135163b4284c4a4dabc6c66db6552833,Opdivo,0.537896
uuid-135163b4284c4a4dabc6c66db6552833,pembro,0.320842
uuid-135163b4284c4a4dabc6c66db6552833,therapy,0.308894
uuid-135163b4284c4a4dabc6c66db6552833,dose,0.785934
uuid-135163b4284c4a4dabc6c66db6552833,nivolumab,0.411646
uuid-135163b4284c4a4dabc6c66db6552833,toxicity,0.378139
uuid-135163b4284c4a4dabc6c66db6552833,regimen,0.505646
uuid-135163b4284c4a4dabc6c66db6552833,treated,0.332118
uuid-135163b4284c4a4dabc6c66db6552833,pts,0.3983
uuid-135163b4284c4a4dabc6c66db6552833,Ipi,0.493818
uuid-135163b4284c4a4dabc6c66db6552833,preferred,0.305701
uuid-135163b4284c4a4dabc6c66db6552833,treatment,0.453394
uuid-135163b4284c4a4dabc6c66db6552833,using nivo,0.304685
uuid-135163b4284c4a4dabc6c66db6552833,progression,0.347491
uuid-135163b4284c4a4dabc6c66db6552833,vs,0.433939
uuid-135163b4284c4a4dabc6c66db6552833,respond,0.316583
uuid-135163b4284c4a4dabc6c66db6552833,flat dosing,0.511357
uuid-bb188483fe54482ea10ce37160fa671a,Nivo,0.521344
uuid-bb188483fe54482ea10ce37160fa671a,pembro,0.569264
uuid-bb188483fe54482ea10ce37160fa671a,1L,0.301075
uuid-bb188483fe54482ea10ce37160fa671a,PDL1,0.363753
uuid-bb188483fe54482ea10ce37160fa671a,trial,0.548108
uuid-bb188483fe54482ea10ce37160fa671a,efficacy,0.595222
uuid-bb188483fe54482ea10ce37160fa671a,chemo,0.338883
uuid-bb188483fe54482ea10ce37160fa671a,OS,0.564039
uuid-bb188483fe54482ea10ce37160fa671a,atezo,0.415656
uuid-bb188483fe54482ea10ce37160fa671a,data,0.546369
uuid-bb188483fe54482ea10ce37160fa671a,PFS,0.586164
uuid-bb188483fe54482ea10ce37160fa671a,ORR,0.56741
uuid-bb188483fe54482ea10ce37160fa671a,nivo and pembro,0.532282
uuid-bb188483fe54482ea10ce37160fa671a,believes,0.37324
uuid-bb188483fe54482ea10ce37160fa671a,impressed,0.44361
uuid-bb188483fe54482ea10ce37160fa671a,vs,0.488417
uuid-bb188483fe54482ea10ce37160fa671a,feels,0.549694
uuid-bb188483fe54482ea10ce37160fa671a,PDL1 expression,0.358864
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,pembro,0.432656
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,BMS,0.382753
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,1L,0.362283
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,PDL1,0.526337
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,trial,0.664301
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,efficacy,0.401809
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,Merck,0.404161
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,OS,0.519594
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,atezo,0.366796
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,data,0.607816
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,PFS,0.514742
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,ORR,0.560255
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,nivo and pembro,0.522278
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,believes,0.351198
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,impressed,0.466669
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,TLs,0.354842
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,PDL1 expression,0.490028
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,biomarker,0.343461
uuid-9fe7cfb0bd0c41a6a30bdfebd8c99b70,bladder,0.319472
uuid-0516d624dc114104889b7f532711488e,patients,0.641537
uuid-0516d624dc114104889b7f532711488e,Opdivo,0.304096
uuid-0516d624dc114104889b7f532711488e,dose,0.353344
uuid-0516d624dc114104889b7f532711488e,nivolumab,0.30794
uuid-0516d624dc114104889b7f532711488e,toxicity,0.372753
uuid-0516d624dc114104889b7f532711488e,regimen,0.411877
uuid-0516d624dc114104889b7f532711488e,treated,0.498461
uuid-0516d624dc114104889b7f532711488e,melanoma,0.304826
uuid-0516d624dc114104889b7f532711488e,tumor,0.468123
uuid-0516d624dc114104889b7f532711488e,pts,0.490356
uuid-0516d624dc114104889b7f532711488e,treatment,0.515522
uuid-0516d624dc114104889b7f532711488e,response,0.329835
uuid-0516d624dc114104889b7f532711488e,progression,0.515222
uuid-0516d624dc114104889b7f532711488e,respond,0.364923
uuid-0516d624dc114104889b7f532711488e,TL shared,0.344399
uuid-c44e8225b3a94f58bbfc758125a272b1,patients,0.686969
uuid-c44e8225b3a94f58bbfc758125a272b1,Opdivo,0.360155
uuid-c44e8225b3a94f58bbfc758125a272b1,therapy,0.400178
uuid-c44e8225b3a94f58bbfc758125a272b1,nivolumab,0.340879
uuid-c44e8225b3a94f58bbfc758125a272b1,regimen,0.50555
uuid-c44e8225b3a94f58bbfc758125a272b1,treated,0.384797
uuid-c44e8225b3a94f58bbfc758125a272b1,chemo,0.462271
uuid-c44e8225b3a94f58bbfc758125a272b1,pts,0.60838
uuid-c44e8225b3a94f58bbfc758125a272b1,monotherapy,0.399531
uuid-c44e8225b3a94f58bbfc758125a272b1,treatment,0.54664
uuid-c44e8225b3a94f58bbfc758125a272b1,response,0.478183
uuid-c44e8225b3a94f58bbfc758125a272b1,PD1,0.350871
uuid-c44e8225b3a94f58bbfc758125a272b1,progression,0.662416
uuid-c44e8225b3a94f58bbfc758125a272b1,chemotherapy,0.347835
uuid-c44e8225b3a94f58bbfc758125a272b1,respond,0.532839
uuid-c44e8225b3a94f58bbfc758125a272b1,feels,0.326568
uuid-c44e8225b3a94f58bbfc758125a272b1,option,0.389086
uuid-2887d4e10ded4ee9b8e97b22df23357f,patients,0.625837
uuid-2887d4e10ded4ee9b8e97b22df23357f,therapy,0.639455
uuid-2887d4e10ded4ee9b8e97b22df23357f,nivolumab,0.351505
uuid-2887d4e10ded4ee9b8e97b22df23357f,toxicity,0.320264
uuid-2887d4e10ded4ee9b8e97b22df23357f,regimen,0.600355
uuid-2887d4e10ded4ee9b8e97b22df23357f,treated,0.458188
uuid-2887d4e10ded4ee9b8e97b22df23357f,melanoma,0.388288
uuid-2887d4e10ded4ee9b8e97b22df23357f,chemo,0.480434
uuid-2887d4e10ded4ee9b8e97b22df23357f,pts,0.543073
uuid-2887d4e10ded4ee9b8e97b22df23357f,monotherapy,0.462814
uuid-2887d4e10ded4ee9b8e97b22df23357f,treatment,0.641257
uuid-2887d4e10ded4ee9b8e97b22df23357f,response,0.610103
uuid-2887d4e10ded4ee9b8e97b22df23357f,AI,0.302451
uuid-2887d4e10ded4ee9b8e97b22df23357f,PD1,0.480456
uuid-2887d4e10ded4ee9b8e97b22df23357f,progression,0.718054
uuid-2887d4e10ded4ee9b8e97b22df23357f,chemotherapy,0.464566
uuid-2887d4e10ded4ee9b8e97b22df23357f,respond,0.57183
uuid-2887d4e10ded4ee9b8e97b22df23357f,TL shared,0.308012
uuid-2887d4e10ded4ee9b8e97b22df23357f,option,0.350467
uuid-df9c7a960a384392900257a18b6a323f,Nivo,0.555688
uuid-df9c7a960a384392900257a18b6a323f,patients,0.43225
uuid-df9c7a960a384392900257a18b6a323f,pembro,0.623098
uuid-df9c7a960a384392900257a18b6a323f,dose,0.364489
uuid-df9c7a960a384392900257a18b6a323f,nivolumab,0.433176
uuid-df9c7a960a384392900257a18b6a323f,1L,0.458933
uuid-df9c7a960a384392900257a18b6a323f,regimen,0.311021
uuid-df9c7a960a384392900257a18b6a323f,RCC,0.346706
uuid-df9c7a960a384392900257a18b6a323f,combination,0.33386
uuid-df9c7a960a384392900257a18b6a323f,2L,0.544817
uuid-df9c7a960a384392900257a18b6a323f,pts,0.319867
uuid-df9c7a960a384392900257a18b6a323f,Ipi,0.510816
uuid-df9c7a960a384392900257a18b6a323f,approval,0.568781
uuid-df9c7a960a384392900257a18b6a323f,atezo,0.45973
uuid-df9c7a960a384392900257a18b6a323f,preferred,0.530658
uuid-df9c7a960a384392900257a18b6a323f,monotherapy,0.444595
uuid-df9c7a960a384392900257a18b6a323f,using nivo,0.66216
uuid-df9c7a960a384392900257a18b6a323f,combo,0.396218
uuid-df9c7a960a384392900257a18b6a323f,clinical trials,0.303886
uuid-df9c7a960a384392900257a18b6a323f,indication,0.331604
uuid-df9c7a960a384392900257a18b6a323f,approved,0.588353
uuid-df9c7a960a384392900257a18b6a323f,SCCHN,0.355758
uuid-df9c7a960a384392900257a18b6a323f,vs,0.339701
uuid-df9c7a960a384392900257a18b6a323f,label,0.343998
uuid-df9c7a960a384392900257a18b6a323f,SCLC,0.322284
uuid-df9c7a960a384392900257a18b6a323f,RTL stated,0.455037
uuid-df9c7a960a384392900257a18b6a323f,option,0.449513
uuid-df9c7a960a384392900257a18b6a323f,bladder,0.345976
uuid-5b056ca5c2df44dda2f264367c712d5f,pembro,0.31745
uuid-5b056ca5c2df44dda2f264367c712d5f,RTL,0.442342
uuid-5b056ca5c2df44dda2f264367c712d5f,BMS,0.400425
uuid-5b056ca5c2df44dda2f264367c712d5f,PDL1,0.446215
uuid-5b056ca5c2df44dda2f264367c712d5f,trial,0.426151
uuid-5b056ca5c2df44dda2f264367c712d5f,efficacy,0.322616
uuid-5b056ca5c2df44dda2f264367c712d5f,commented,0.506428
uuid-5b056ca5c2df44dda2f264367c712d5f,Merck,0.425011
uuid-5b056ca5c2df44dda2f264367c712d5f,stated,0.392085
uuid-5b056ca5c2df44dda2f264367c712d5f,OS,0.536311
uuid-5b056ca5c2df44dda2f264367c712d5f,data,0.743152
uuid-5b056ca5c2df44dda2f264367c712d5f,expressed,0.449196
uuid-5b056ca5c2df44dda2f264367c712d5f,PFS,0.463212
uuid-5b056ca5c2df44dda2f264367c712d5f,ORR,0.501081
uuid-5b056ca5c2df44dda2f264367c712d5f,SCCHN,0.372091
uuid-5b056ca5c2df44dda2f264367c712d5f,HCP,0.324915
uuid-5b056ca5c2df44dda2f264367c712d5f,nivo and pembro,0.338725
uuid-5b056ca5c2df44dda2f264367c712d5f,ASCO,0.382633
uuid-5b056ca5c2df44dda2f264367c712d5f,impressed,0.669888
uuid-5b056ca5c2df44dda2f264367c712d5f,LTL,0.368303
uuid-5b056ca5c2df44dda2f264367c712d5f,TLs,0.384231
uuid-5b056ca5c2df44dda2f264367c712d5f,feels,0.343086
uuid-5b056ca5c2df44dda2f264367c712d5f,Regional TL,0.389882
uuid-5b056ca5c2df44dda2f264367c712d5f,PDL1 expression,0.388173
uuid-5b056ca5c2df44dda2f264367c712d5f,bladder,0.351166
uuid-c19c19ddcb244f0590c3d25273cfb466,efficacy,0.360685
uuid-c19c19ddcb244f0590c3d25273cfb466,tumor,0.331605
uuid-c19c19ddcb244f0590c3d25273cfb466,OS,0.372082
uuid-c19c19ddcb244f0590c3d25273cfb466,response,0.330249
uuid-c19c19ddcb244f0590c3d25273cfb466,data,0.335559
uuid-c19c19ddcb244f0590c3d25273cfb466,PFS,0.325591
uuid-c19c19ddcb244f0590c3d25273cfb466,ORR,0.363411
uuid-ce8199325a1949a7a5a333adb884bc68,patients,0.575524
uuid-ce8199325a1949a7a5a333adb884bc68,therapy,0.418204
uuid-ce8199325a1949a7a5a333adb884bc68,treated,0.322942
uuid-ce8199325a1949a7a5a333adb884bc68,pts,0.418365
uuid-ce8199325a1949a7a5a333adb884bc68,PD-L1,0.369409
uuid-ce8199325a1949a7a5a333adb884bc68,approval,0.371787
uuid-ce8199325a1949a7a5a333adb884bc68,PD-L1 testing,0.36821
uuid-ce8199325a1949a7a5a333adb884bc68,testing,0.497599
uuid-ce8199325a1949a7a5a333adb884bc68,treatment,0.403966
uuid-ce8199325a1949a7a5a333adb884bc68,PDL1 testing,0.333828
uuid-ce8199325a1949a7a5a333adb884bc68,NSCLC patients,0.501675
uuid-ce8199325a1949a7a5a333adb884bc68,progression,0.353778
uuid-ce8199325a1949a7a5a333adb884bc68,option,0.382382
uuid-af0b5158f21649b7a57c967a536596eb,agents,0.328069
uuid-af0b5158f21649b7a57c967a536596eb,clinical,0.308822
uuid-af0b5158f21649b7a57c967a536596eb,immunotherapy,0.533936
uuid-20721b0982f448d98d5652ead71f29ec,Nivo,0.413722
uuid-20721b0982f448d98d5652ead71f29ec,combination,0.305818
uuid-20721b0982f448d98d5652ead71f29ec,chemo,0.344561
uuid-20721b0982f448d98d5652ead71f29ec,agents,0.430995
uuid-20721b0982f448d98d5652ead71f29ec,believes,0.413059
uuid-1deddde39e24445fb5911370221feb9a,patients,0.331257
uuid-1deddde39e24445fb5911370221feb9a,tumor,0.677336
uuid-1deddde39e24445fb5911370221feb9a,pts,0.309467
uuid-1deddde39e24445fb5911370221feb9a,PD-L1,0.370172
uuid-1deddde39e24445fb5911370221feb9a,testing,0.467369
uuid-1deddde39e24445fb5911370221feb9a,PDL1 testing,0.327898
uuid-1deddde39e24445fb5911370221feb9a,NSCLC patients,0.412048
uuid-1deddde39e24445fb5911370221feb9a,progression,0.309133
uuid-1deddde39e24445fb5911370221feb9a,biomarker,0.379826
uuid-4c38d6959266408aa3a83f5c5f541ce5,patients,0.500862
uuid-4c38d6959266408aa3a83f5c5f541ce5,toxicity,0.407548
uuid-4c38d6959266408aa3a83f5c5f541ce5,regimen,0.339944
uuid-4c38d6959266408aa3a83f5c5f541ce5,treated,0.467425
uuid-4c38d6959266408aa3a83f5c5f541ce5,melanoma,0.329748
uuid-4c38d6959266408aa3a83f5c5f541ce5,pts,0.39083
uuid-4c38d6959266408aa3a83f5c5f541ce5,treatment,0.434346
uuid-4c38d6959266408aa3a83f5c5f541ce5,progression,0.438286
uuid-4c38d6959266408aa3a83f5c5f541ce5,respond,0.424532
uuid-4c38d6959266408aa3a83f5c5f541ce5,TL shared,0.465256
uuid-c7a12853e5bb400fa4ebc95b51a6c794,TL,0.376065
uuid-c7a12853e5bb400fa4ebc95b51a6c794,pembro,0.502563
uuid-c7a12853e5bb400fa4ebc95b51a6c794,1L,0.423519
uuid-c7a12853e5bb400fa4ebc95b51a6c794,PDL1,0.578766
uuid-c7a12853e5bb400fa4ebc95b51a6c794,trial,0.405159
uuid-c7a12853e5bb400fa4ebc95b51a6c794,TL stated,0.328893
uuid-c7a12853e5bb400fa4ebc95b51a6c794,Merck,0.475878
uuid-c7a12853e5bb400fa4ebc95b51a6c794,PD-L1,0.649278
uuid-c7a12853e5bb400fa4ebc95b51a6c794,approval,0.341253
uuid-c7a12853e5bb400fa4ebc95b51a6c794,atezo,0.470471
uuid-c7a12853e5bb400fa4ebc95b51a6c794,PD-L1 testing,0.526776
uuid-c7a12853e5bb400fa4ebc95b51a6c794,testing,0.654165
uuid-c7a12853e5bb400fa4ebc95b51a6c794,PDL1 testing,0.556795
uuid-c7a12853e5bb400fa4ebc95b51a6c794,NSCLC patients,0.498329
uuid-c7a12853e5bb400fa4ebc95b51a6c794,nivo and pembro,0.364656
uuid-c7a12853e5bb400fa4ebc95b51a6c794,assay,0.601803
uuid-c7a12853e5bb400fa4ebc95b51a6c794,PDL1 expression,0.462042
uuid-c7a12853e5bb400fa4ebc95b51a6c794,biomarker,0.416438
uuid-c7a12853e5bb400fa4ebc95b51a6c794,bladder,0.3439
uuid-62f83ff1366745399717b9f479157787,institution,0.395684
uuid-62f83ff1366745399717b9f479157787,oncology,0.354397
uuid-f7f16479c2614038ac3bcbb2d0e62527,commented,0.331432
uuid-f7f16479c2614038ac3bcbb2d0e62527,physicians,0.374204
uuid-f7f16479c2614038ac3bcbb2d0e62527,regards,0.361789
uuid-f7f16479c2614038ac3bcbb2d0e62527,AI,0.455032
uuid-f7f16479c2614038ac3bcbb2d0e62527,oncology,0.728754
uuid-f7f16479c2614038ac3bcbb2d0e62527,ASCO,0.370695
uuid-f7f16479c2614038ac3bcbb2d0e62527,clinical,0.472334
uuid-1735319676184385b03cdb48811690c4,NSCLC patients,0.302735
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,Nivo,0.337587
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,pembro,0.35592
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,therapy,0.411758
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,nivolumab,0.531317
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,1L,0.669744
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,regimen,0.349974
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,RCC,0.608889
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,combination,0.544332
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,chemo,0.345598
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,2L,0.746711
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,agents,0.57812
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,approval,0.365297
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,atezo,0.366028
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,preferred,0.768211
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,monotherapy,0.723016
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,using nivo,0.663456
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,combo,0.516704
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,indication,0.315583
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,PD1,0.458185
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,approved,0.539641
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,SCCHN,0.422384
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,chemotherapy,0.385302
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,tumor types,0.336697
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,PD-1,0.411525
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,RTL stated,0.67314
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,TL shared,0.376039
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,option,0.708845
uuid-8294f1b5604c4767a7c8a1f5ac2143ea,bladder,0.372737
uuid-36db2deb39444293b7bbfa0eb4372cec,patients,0.770014
uuid-36db2deb39444293b7bbfa0eb4372cec,Opdivo,0.420567
uuid-36db2deb39444293b7bbfa0eb4372cec,therapy,0.457288
uuid-36db2deb39444293b7bbfa0eb4372cec,nivolumab,0.52556
uuid-36db2deb39444293b7bbfa0eb4372cec,toxicity,0.315047
uuid-36db2deb39444293b7bbfa0eb4372cec,regimen,0.608529
uuid-36db2deb39444293b7bbfa0eb4372cec,treated,0.533722
uuid-36db2deb39444293b7bbfa0eb4372cec,combination,0.344086
uuid-36db2deb39444293b7bbfa0eb4372cec,chemo,0.383859
uuid-36db2deb39444293b7bbfa0eb4372cec,pts,0.639069
uuid-36db2deb39444293b7bbfa0eb4372cec,preferred,0.306102
uuid-36db2deb39444293b7bbfa0eb4372cec,monotherapy,0.478477
uuid-36db2deb39444293b7bbfa0eb4372cec,treatment,0.58417
uuid-36db2deb39444293b7bbfa0eb4372cec,using nivo,0.343444
uuid-36db2deb39444293b7bbfa0eb4372cec,response,0.379285
uuid-36db2deb39444293b7bbfa0eb4372cec,combo,0.356818
uuid-36db2deb39444293b7bbfa0eb4372cec,PD1,0.397175
uuid-36db2deb39444293b7bbfa0eb4372cec,progression,0.661962
uuid-36db2deb39444293b7bbfa0eb4372cec,chemotherapy,0.339286
uuid-36db2deb39444293b7bbfa0eb4372cec,respond,0.50832
uuid-36db2deb39444293b7bbfa0eb4372cec,RTL stated,0.332932
uuid-36db2deb39444293b7bbfa0eb4372cec,option,0.386351
uuid-f8fa2edfc0af476e9ace1b566a17d99e,trial,0.45249
uuid-f8fa2edfc0af476e9ace1b566a17d99e,efficacy,0.428611
uuid-f8fa2edfc0af476e9ace1b566a17d99e,chemo,0.314548
uuid-f8fa2edfc0af476e9ace1b566a17d99e,OS,0.628099
uuid-f8fa2edfc0af476e9ace1b566a17d99e,response,0.405619
uuid-f8fa2edfc0af476e9ace1b566a17d99e,data,0.385757
uuid-f8fa2edfc0af476e9ace1b566a17d99e,PFS,0.673329
uuid-f8fa2edfc0af476e9ace1b566a17d99e,ORR,0.619529
uuid-f8fa2edfc0af476e9ace1b566a17d99e,progression,0.30415
uuid-f8fa2edfc0af476e9ace1b566a17d99e,believes,0.322902
uuid-f8fa2edfc0af476e9ace1b566a17d99e,chemotherapy,0.337186
uuid-f8fa2edfc0af476e9ace1b566a17d99e,impressed,0.397775
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,trial,0.339943
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,efficacy,0.356572
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,combination,0.347052
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,chemo,0.323337
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,IO,0.532276
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,OS,0.464982
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,response,0.322468
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,data,0.413544
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,combo,0.378297
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,PFS,0.471337
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,PD1,0.316188
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,ORR,0.470295
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,believes,0.388484
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,chemotherapy,0.343747
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,impressed,0.372097
uuid-4eb67b8bb7cb41518aaf197e1ccbe464,feels,0.510446
uuid-7b299849c18f4e47baa548ef67ddca9d,1L,0.490322
uuid-7b299849c18f4e47baa548ef67ddca9d,RCC,0.300769
uuid-7b299849c18f4e47baa548ef67ddca9d,2L,0.425189
uuid-7b299849c18f4e47baa548ef67ddca9d,stated,0.413747
uuid-7b299849c18f4e47baa548ef67ddca9d,approval,0.462709
uuid-7b299849c18f4e47baa548ef67ddca9d,preferred,0.370649
uuid-7b299849c18f4e47baa548ef67ddca9d,using nivo,0.37065
uuid-7b299849c18f4e47baa548ef67ddca9d,clinical trials,0.344264
uuid-7b299849c18f4e47baa548ef67ddca9d,PDL1 testing,0.302695
uuid-7b299849c18f4e47baa548ef67ddca9d,indication,0.356502
uuid-7b299849c18f4e47baa548ef67ddca9d,approved,0.588526
uuid-7b299849c18f4e47baa548ef67ddca9d,SCCHN,0.405295
uuid-7b299849c18f4e47baa548ef67ddca9d,tumor types,0.414199
uuid-7b299849c18f4e47baa548ef67ddca9d,label,0.361676
uuid-7b299849c18f4e47baa548ef67ddca9d,feels,0.360957
uuid-7b299849c18f4e47baa548ef67ddca9d,RTL stated,0.344083
uuid-7b299849c18f4e47baa548ef67ddca9d,option,0.434301
uuid-70fd18116ba149358f5340ef72e03253,Nivo,0.418049
uuid-70fd18116ba149358f5340ef72e03253,patients,0.642814
uuid-70fd18116ba149358f5340ef72e03253,pembro,0.370354
uuid-70fd18116ba149358f5340ef72e03253,therapy,0.509535
uuid-70fd18116ba149358f5340ef72e03253,nivolumab,0.314777
uuid-70fd18116ba149358f5340ef72e03253,1L,0.696264
uuid-70fd18116ba149358f5340ef72e03253,regimen,0.446401
uuid-70fd18116ba149358f5340ef72e03253,combination,0.317895
uuid-70fd18116ba149358f5340ef72e03253,chemo,0.622405
uuid-70fd18116ba149358f5340ef72e03253,2L,0.655643
uuid-70fd18116ba149358f5340ef72e03253,pts,0.501038
uuid-70fd18116ba149358f5340ef72e03253,agents,0.438554
uuid-70fd18116ba149358f5340ef72e03253,atezo,0.321033
uuid-70fd18116ba149358f5340ef72e03253,preferred,0.671265
uuid-70fd18116ba149358f5340ef72e03253,monotherapy,0.715872
uuid-70fd18116ba149358f5340ef72e03253,treatment,0.468171
uuid-70fd18116ba149358f5340ef72e03253,using nivo,0.490202
uuid-70fd18116ba149358f5340ef72e03253,combo,0.379982
uuid-70fd18116ba149358f5340ef72e03253,NSCLC patients,0.419043
uuid-70fd18116ba149358f5340ef72e03253,PD1,0.417404
uuid-70fd18116ba149358f5340ef72e03253,approved,0.37311
uuid-70fd18116ba149358f5340ef72e03253,progression,0.429367
uuid-70fd18116ba149358f5340ef72e03253,chemotherapy,0.509312
uuid-70fd18116ba149358f5340ef72e03253,respond,0.351448
uuid-70fd18116ba149358f5340ef72e03253,feels,0.321395
uuid-70fd18116ba149358f5340ef72e03253,PD-1,0.320892
uuid-70fd18116ba149358f5340ef72e03253,RTL stated,0.393895
uuid-70fd18116ba149358f5340ef72e03253,option,0.763822
uuid-ba50122cda1f45a682c7922cde4129ff,Nivo,0.483414
uuid-ba50122cda1f45a682c7922cde4129ff,patients,0.302658
uuid-ba50122cda1f45a682c7922cde4129ff,dose,0.614455
uuid-ba50122cda1f45a682c7922cde4129ff,toxicity,0.586872
uuid-ba50122cda1f45a682c7922cde4129ff,efficacy,0.412825
uuid-ba50122cda1f45a682c7922cde4129ff,regimen,0.624921
uuid-ba50122cda1f45a682c7922cde4129ff,combination,0.515657
uuid-ba50122cda1f45a682c7922cde4129ff,chemo,0.469981
uuid-ba50122cda1f45a682c7922cde4129ff,pts,0.316735
uuid-ba50122cda1f45a682c7922cde4129ff,agents,0.311969
uuid-ba50122cda1f45a682c7922cde4129ff,Ipi,0.669625
uuid-ba50122cda1f45a682c7922cde4129ff,preferred,0.348141
uuid-ba50122cda1f45a682c7922cde4129ff,monotherapy,0.545773
uuid-ba50122cda1f45a682c7922cde4129ff,treatment,0.322168
uuid-ba50122cda1f45a682c7922cde4129ff,combo,0.514196
uuid-ba50122cda1f45a682c7922cde4129ff,PD1,0.312773
uuid-ba50122cda1f45a682c7922cde4129ff,believes,0.301228
uuid-ba50122cda1f45a682c7922cde4129ff,chemotherapy,0.39062
uuid-ba50122cda1f45a682c7922cde4129ff,vs,0.37565
uuid-ba50122cda1f45a682c7922cde4129ff,feels,0.339751
uuid-ba50122cda1f45a682c7922cde4129ff,option,0.408091
uuid-04cf6e94958b4f80980bbf28cf806bb7,TL,0.552509
uuid-04cf6e94958b4f80980bbf28cf806bb7,PDL1,0.52621
uuid-04cf6e94958b4f80980bbf28cf806bb7,Merck,0.413819
uuid-04cf6e94958b4f80980bbf28cf806bb7,PD-L1,0.670705
uuid-04cf6e94958b4f80980bbf28cf806bb7,PD-L1 testing,0.614498
uuid-04cf6e94958b4f80980bbf28cf806bb7,testing,0.588383
uuid-04cf6e94958b4f80980bbf28cf806bb7,data,0.319503
uuid-04cf6e94958b4f80980bbf28cf806bb7,PDL1 testing,0.361036
uuid-04cf6e94958b4f80980bbf28cf806bb7,NSCLC patients,0.325359
uuid-04cf6e94958b4f80980bbf28cf806bb7,assay,0.746923
uuid-04cf6e94958b4f80980bbf28cf806bb7,PDL1 expression,0.378426
uuid-04cf6e94958b4f80980bbf28cf806bb7,biomarker,0.420419
uuid-21ee59c201664cc0b1418aa6228106bc,TL,0.530153
uuid-21ee59c201664cc0b1418aa6228106bc,PDL1,0.335768
uuid-21ee59c201664cc0b1418aa6228106bc,TL stated,0.44587
uuid-21ee59c201664cc0b1418aa6228106bc,PD-L1,0.650072
uuid-21ee59c201664cc0b1418aa6228106bc,PD-L1 testing,0.685576
uuid-21ee59c201664cc0b1418aa6228106bc,testing,0.777819
uuid-21ee59c201664cc0b1418aa6228106bc,PDL1 testing,0.62848
uuid-21ee59c201664cc0b1418aa6228106bc,NSCLC patients,0.565446
uuid-21ee59c201664cc0b1418aa6228106bc,assay,0.603588
uuid-21ee59c201664cc0b1418aa6228106bc,biomarker,0.41875
uuid-5b7fc6e16d094387872facb731905cdc,Nivo,0.337185
uuid-5b7fc6e16d094387872facb731905cdc,trial,0.343608
uuid-5b7fc6e16d094387872facb731905cdc,efficacy,0.485152
uuid-5b7fc6e16d094387872facb731905cdc,OS,0.621871
uuid-5b7fc6e16d094387872facb731905cdc,data,0.499357
uuid-5b7fc6e16d094387872facb731905cdc,PFS,0.600653
uuid-5b7fc6e16d094387872facb731905cdc,ORR,0.59938
uuid-5b7fc6e16d094387872facb731905cdc,ASCO,0.306929
uuid-5b7fc6e16d094387872facb731905cdc,impressed,0.601699
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,patients,0.624234
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,therapy,0.595518
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,regimen,0.458697
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,treated,0.305708
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,chemo,0.487723
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,pts,0.421259
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,IO,0.315715
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,monotherapy,0.398518
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,treatment,0.684045
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,response,0.530141
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,PD1,0.398091
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,progression,0.695214
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,believes,0.325082
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,chemotherapy,0.485635
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,respond,0.595577
uuid-b21e54f6605d45a8ac4984b1cc15fa1f,option,0.47239
uuid-d372c05ef8b8490e95e77f60a8a5afad,Nivo,0.430787
uuid-d372c05ef8b8490e95e77f60a8a5afad,pembro,0.686058
uuid-d372c05ef8b8490e95e77f60a8a5afad,RTL,0.368498
uuid-d372c05ef8b8490e95e77f60a8a5afad,BMS,0.440092
uuid-d372c05ef8b8490e95e77f60a8a5afad,1L,0.349044
uuid-d372c05ef8b8490e95e77f60a8a5afad,trial,0.732604
uuid-d372c05ef8b8490e95e77f60a8a5afad,efficacy,0.333985
uuid-d372c05ef8b8490e95e77f60a8a5afad,commented,0.300123
uuid-d372c05ef8b8490e95e77f60a8a5afad,2L,0.353069
uuid-d372c05ef8b8490e95e77f60a8a5afad,Merck,0.445823
uuid-d372c05ef8b8490e95e77f60a8a5afad,stated,0.430285
uuid-d372c05ef8b8490e95e77f60a8a5afad,approval,0.499718
uuid-d372c05ef8b8490e95e77f60a8a5afad,atezo,0.560449
uuid-d372c05ef8b8490e95e77f60a8a5afad,using nivo,0.374092
uuid-d372c05ef8b8490e95e77f60a8a5afad,data,0.62813
uuid-d372c05ef8b8490e95e77f60a8a5afad,expressed,0.30175
uuid-d372c05ef8b8490e95e77f60a8a5afad,clinical trials,0.456289
uuid-d372c05ef8b8490e95e77f60a8a5afad,indication,0.424521
uuid-d372c05ef8b8490e95e77f60a8a5afad,ORR,0.342511
uuid-d372c05ef8b8490e95e77f60a8a5afad,approved,0.501058
uuid-d372c05ef8b8490e95e77f60a8a5afad,SCCHN,0.377872
uuid-d372c05ef8b8490e95e77f60a8a5afad,nivo and pembro,0.446704
uuid-d372c05ef8b8490e95e77f60a8a5afad,impressed,0.513045
uuid-d372c05ef8b8490e95e77f60a8a5afad,vs,0.322047
uuid-d372c05ef8b8490e95e77f60a8a5afad,label,0.302504
uuid-d372c05ef8b8490e95e77f60a8a5afad,LTL,0.33595
uuid-d372c05ef8b8490e95e77f60a8a5afad,TLs,0.304401
uuid-d372c05ef8b8490e95e77f60a8a5afad,SCLC,0.343698
uuid-d372c05ef8b8490e95e77f60a8a5afad,feels,0.349917
uuid-d372c05ef8b8490e95e77f60a8a5afad,Regional TL,0.356419
uuid-d372c05ef8b8490e95e77f60a8a5afad,bladder,0.43445
uuid-87181716891a4e168cad7210ba4c2396,physicians,0.535004
uuid-bbe759d53a4c498e827f3b182cc2cde7,Opdivo,0.415231
uuid-bbe759d53a4c498e827f3b182cc2cde7,dose,0.765796
uuid-bbe759d53a4c498e827f3b182cc2cde7,toxicity,0.309262
uuid-bbe759d53a4c498e827f3b182cc2cde7,vs,0.442968
uuid-bbe759d53a4c498e827f3b182cc2cde7,Keytruda,0.337759
uuid-bbe759d53a4c498e827f3b182cc2cde7,flat dosing,0.775888
uuid-c245da569dfa44bbaef01e617d680ae0,Nivo,0.305469
uuid-c245da569dfa44bbaef01e617d680ae0,patients,0.669447
uuid-c245da569dfa44bbaef01e617d680ae0,Opdivo,0.324722
uuid-c245da569dfa44bbaef01e617d680ae0,therapy,0.435851
uuid-c245da569dfa44bbaef01e617d680ae0,nivolumab,0.525054
uuid-c245da569dfa44bbaef01e617d680ae0,1L,0.591991
uuid-c245da569dfa44bbaef01e617d680ae0,regimen,0.478304
uuid-c245da569dfa44bbaef01e617d680ae0,treated,0.470602
uuid-c245da569dfa44bbaef01e617d680ae0,RCC,0.526924
uuid-c245da569dfa44bbaef01e617d680ae0,TL stated,0.305718
uuid-c245da569dfa44bbaef01e617d680ae0,combination,0.340103
uuid-c245da569dfa44bbaef01e617d680ae0,chemo,0.363732
uuid-c245da569dfa44bbaef01e617d680ae0,2L,0.651312
uuid-c245da569dfa44bbaef01e617d680ae0,pts,0.555399
uuid-c245da569dfa44bbaef01e617d680ae0,approval,0.331148
uuid-c245da569dfa44bbaef01e617d680ae0,preferred,0.633061
uuid-c245da569dfa44bbaef01e617d680ae0,monotherapy,0.651134
uuid-c245da569dfa44bbaef01e617d680ae0,treatment,0.518374
uuid-c245da569dfa44bbaef01e617d680ae0,using nivo,0.627649
uuid-c245da569dfa44bbaef01e617d680ae0,combo,0.360372
uuid-c245da569dfa44bbaef01e617d680ae0,NSCLC patients,0.331747
uuid-c245da569dfa44bbaef01e617d680ae0,PD1,0.370018
uuid-c245da569dfa44bbaef01e617d680ae0,approved,0.431969
uuid-c245da569dfa44bbaef01e617d680ae0,SCCHN,0.397922
uuid-c245da569dfa44bbaef01e617d680ae0,progression,0.473842
uuid-c245da569dfa44bbaef01e617d680ae0,chemotherapy,0.325064
uuid-c245da569dfa44bbaef01e617d680ae0,tumor types,0.307674
uuid-c245da569dfa44bbaef01e617d680ae0,RTL stated,0.615315
uuid-c245da569dfa44bbaef01e617d680ae0,TL shared,0.376737
uuid-c245da569dfa44bbaef01e617d680ae0,option,0.637801
uuid-b6d13f9a3c8c484e88376cb9305112ef,patients,0.542637
uuid-b6d13f9a3c8c484e88376cb9305112ef,toxicity,0.592816
uuid-b6d13f9a3c8c484e88376cb9305112ef,regimen,0.622375
uuid-b6d13f9a3c8c484e88376cb9305112ef,treated,0.378852
uuid-b6d13f9a3c8c484e88376cb9305112ef,pts,0.377568
uuid-b6d13f9a3c8c484e88376cb9305112ef,monotherapy,0.32601
uuid-b6d13f9a3c8c484e88376cb9305112ef,treatment,0.44656
uuid-b6d13f9a3c8c484e88376cb9305112ef,progression,0.437872
uuid-b6d13f9a3c8c484e88376cb9305112ef,respond,0.442039
uuid-fabbecfc72104f5fa0577de5b5bd3110,Nivo,0.736585
uuid-fabbecfc72104f5fa0577de5b5bd3110,pembro,0.648689
uuid-fabbecfc72104f5fa0577de5b5bd3110,1L,0.549669
uuid-fabbecfc72104f5fa0577de5b5bd3110,trial,0.336672
uuid-fabbecfc72104f5fa0577de5b5bd3110,efficacy,0.450803
uuid-fabbecfc72104f5fa0577de5b5bd3110,regimen,0.30526
uuid-fabbecfc72104f5fa0577de5b5bd3110,combination,0.657638
uuid-fabbecfc72104f5fa0577de5b5bd3110,chemo,0.639287
uuid-fabbecfc72104f5fa0577de5b5bd3110,2L,0.563772
uuid-fabbecfc72104f5fa0577de5b5bd3110,IO,0.312828
uuid-fabbecfc72104f5fa0577de5b5bd3110,agents,0.570175
uuid-fabbecfc72104f5fa0577de5b5bd3110,Ipi,0.618861
uuid-fabbecfc72104f5fa0577de5b5bd3110,atezo,0.557241
uuid-fabbecfc72104f5fa0577de5b5bd3110,preferred,0.526252
uuid-fabbecfc72104f5fa0577de5b5bd3110,monotherapy,0.668381
uuid-fabbecfc72104f5fa0577de5b5bd3110,using nivo,0.438874
uuid-fabbecfc72104f5fa0577de5b5bd3110,combo,0.644566
uuid-fabbecfc72104f5fa0577de5b5bd3110,PD1,0.449314
uuid-fabbecfc72104f5fa0577de5b5bd3110,approved,0.373834
uuid-fabbecfc72104f5fa0577de5b5bd3110,nivo and pembro,0.458165
uuid-fabbecfc72104f5fa0577de5b5bd3110,believes,0.497253
uuid-fabbecfc72104f5fa0577de5b5bd3110,chemotherapy,0.512386
uuid-fabbecfc72104f5fa0577de5b5bd3110,vs,0.468222
uuid-fabbecfc72104f5fa0577de5b5bd3110,feels,0.421503
uuid-fabbecfc72104f5fa0577de5b5bd3110,option,0.57622
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,TL,0.301458
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,1L,0.467102
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,PDL1,0.636085
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,2L,0.301108
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,PD-L1,0.821961
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,PD-L1 testing,0.635604
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,testing,0.829864
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,PDL1 testing,0.644782
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,NSCLC patients,0.686688
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,tumor types,0.300703
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,assay,0.602138
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,PD-1,0.378832
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,PDL1 expression,0.518548
uuid-4a1d0f20706b4fdab1a32db59e3ce2f8,biomarker,0.655708
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,pembro,0.390327
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,BMS,0.405389
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,PDL1,0.506793
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,trial,0.478966
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,efficacy,0.595232
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,agents,0.36396
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,Merck,0.334821
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,OS,0.48047
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,atezo,0.396252
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,regards,0.338675
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,data,0.685179
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,expressed,0.312392
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,PFS,0.5096
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,ORR,0.528255
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,nivo and pembro,0.630782
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,believes,0.458136
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,impressed,0.4645
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,TLs,0.361056
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,feels,0.537262
uuid-b1b9a4ba5c6347cd9d5f53250dd01d24,PDL1 expression,0.508743
uuid-9c01261836904bb39f23f8f08fcdcafb,patients,0.332864
uuid-9c01261836904bb39f23f8f08fcdcafb,dose,0.499663
uuid-9c01261836904bb39f23f8f08fcdcafb,toxicity,0.730652
uuid-9c01261836904bb39f23f8f08fcdcafb,regimen,0.477395
uuid-9c01261836904bb39f23f8f08fcdcafb,treatment,0.369723
uuid-9c01261836904bb39f23f8f08fcdcafb,respond,0.42818
uuid-4c741f820e494a06896af98b9b326287,Nivo,0.337677
uuid-4c741f820e494a06896af98b9b326287,patients,0.675726
uuid-4c741f820e494a06896af98b9b326287,Opdivo,0.316821
uuid-4c741f820e494a06896af98b9b326287,therapy,0.563715
uuid-4c741f820e494a06896af98b9b326287,nivolumab,0.384547
uuid-4c741f820e494a06896af98b9b326287,1L,0.403296
uuid-4c741f820e494a06896af98b9b326287,regimen,0.523911
uuid-4c741f820e494a06896af98b9b326287,treated,0.317643
uuid-4c741f820e494a06896af98b9b326287,combination,0.356827
uuid-4c741f820e494a06896af98b9b326287,chemo,0.521084
uuid-4c741f820e494a06896af98b9b326287,2L,0.383118
uuid-4c741f820e494a06896af98b9b326287,pts,0.607942
uuid-4c741f820e494a06896af98b9b326287,IO,0.362497
uuid-4c741f820e494a06896af98b9b326287,preferred,0.349465
uuid-4c741f820e494a06896af98b9b326287,monotherapy,0.578877
uuid-4c741f820e494a06896af98b9b326287,treatment,0.572701
uuid-4c741f820e494a06896af98b9b326287,using nivo,0.308687
uuid-4c741f820e494a06896af98b9b326287,response,0.513713
uuid-4c741f820e494a06896af98b9b326287,combo,0.373844
uuid-4c741f820e494a06896af98b9b326287,PD1,0.473058
uuid-4c741f820e494a06896af98b9b326287,progression,0.736859
uuid-4c741f820e494a06896af98b9b326287,chemotherapy,0.425399
uuid-4c741f820e494a06896af98b9b326287,respond,0.558576
uuid-4c741f820e494a06896af98b9b326287,option,0.542895
uuid-633a45cb8ad44c77ae9d34556d610ceb,Opdivo,0.469256
uuid-633a45cb8ad44c77ae9d34556d610ceb,dose,0.747635
uuid-633a45cb8ad44c77ae9d34556d610ceb,efficacy,0.320644
uuid-633a45cb8ad44c77ae9d34556d610ceb,Ipi,0.386282
uuid-633a45cb8ad44c77ae9d34556d610ceb,physicians,0.35425
uuid-633a45cb8ad44c77ae9d34556d610ceb,indication,0.308402
uuid-633a45cb8ad44c77ae9d34556d610ceb,vs,0.471448
uuid-633a45cb8ad44c77ae9d34556d610ceb,Keytruda,0.425289
uuid-633a45cb8ad44c77ae9d34556d610ceb,flat dosing,0.7731
uuid-96fd671c5f964c9b88aa5e9f48de7204,TL,0.436445
uuid-96fd671c5f964c9b88aa5e9f48de7204,RTL,0.384952
uuid-96fd671c5f964c9b88aa5e9f48de7204,lung,0.455601
uuid-96fd671c5f964c9b88aa5e9f48de7204,melanoma,0.377807
uuid-96fd671c5f964c9b88aa5e9f48de7204,RCC,0.539837
uuid-96fd671c5f964c9b88aa5e9f48de7204,TL stated,0.591499
uuid-96fd671c5f964c9b88aa5e9f48de7204,tumor,0.305937
uuid-96fd671c5f964c9b88aa5e9f48de7204,PD-L1,0.422316
uuid-96fd671c5f964c9b88aa5e9f48de7204,PD-L1 testing,0.510694
uuid-96fd671c5f964c9b88aa5e9f48de7204,testing,0.517719
uuid-96fd671c5f964c9b88aa5e9f48de7204,PDL1 testing,0.58063
uuid-96fd671c5f964c9b88aa5e9f48de7204,NSCLC patients,0.577947
uuid-96fd671c5f964c9b88aa5e9f48de7204,SCCHN,0.524341
uuid-96fd671c5f964c9b88aa5e9f48de7204,tumor types,0.383288
uuid-96fd671c5f964c9b88aa5e9f48de7204,oncologist,0.38309
uuid-96fd671c5f964c9b88aa5e9f48de7204,indicated,0.329461
uuid-96fd671c5f964c9b88aa5e9f48de7204,TLs,0.419177
uuid-96fd671c5f964c9b88aa5e9f48de7204,academic,0.470401
uuid-96fd671c5f964c9b88aa5e9f48de7204,Regional TL,0.454747
uuid-96fd671c5f964c9b88aa5e9f48de7204,RTL stated,0.408467
uuid-96fd671c5f964c9b88aa5e9f48de7204,TL shared,0.443122
uuid-96fd671c5f964c9b88aa5e9f48de7204,bladder,0.424302
uuid-381f25c0287f46368574aa99af965d98,RTL,0.418493
uuid-381f25c0287f46368574aa99af965d98,trial,0.460038
uuid-381f25c0287f46368574aa99af965d98,NTL,0.587336
uuid-381f25c0287f46368574aa99af965d98,Regional TL,0.309639
uuid-a9f55bdfbac84457ac3d6589089619b9,RTL,0.602287
uuid-a9f55bdfbac84457ac3d6589089619b9,BMS,0.540373
uuid-a9f55bdfbac84457ac3d6589089619b9,trial,0.42943
uuid-a9f55bdfbac84457ac3d6589089619b9,NTL,0.444869
uuid-a9f55bdfbac84457ac3d6589089619b9,discussed,0.327618
uuid-a9f55bdfbac84457ac3d6589089619b9,shared,0.384919
uuid-a9f55bdfbac84457ac3d6589089619b9,commented,0.551341
uuid-a9f55bdfbac84457ac3d6589089619b9,Merck,0.387108
uuid-a9f55bdfbac84457ac3d6589089619b9,stated,0.55276
uuid-a9f55bdfbac84457ac3d6589089619b9,regards,0.315686
uuid-a9f55bdfbac84457ac3d6589089619b9,data,0.59926
uuid-a9f55bdfbac84457ac3d6589089619b9,expressed,0.42298
uuid-a9f55bdfbac84457ac3d6589089619b9,mentioned,0.406946
uuid-a9f55bdfbac84457ac3d6589089619b9,clinical trials,0.362231
uuid-a9f55bdfbac84457ac3d6589089619b9,indication,0.307518
uuid-a9f55bdfbac84457ac3d6589089619b9,SCCHN,0.356171
uuid-a9f55bdfbac84457ac3d6589089619b9,HCP,0.312563
uuid-a9f55bdfbac84457ac3d6589089619b9,ASCO,0.379524
uuid-a9f55bdfbac84457ac3d6589089619b9,impressed,0.588887
uuid-a9f55bdfbac84457ac3d6589089619b9,LTL,0.499098
uuid-a9f55bdfbac84457ac3d6589089619b9,TLs,0.352319
uuid-a9f55bdfbac84457ac3d6589089619b9,Regional TL,0.548789
uuid-ab13893f2b184b5b9ff793287fc7988a,Nivo,0.547876
uuid-ab13893f2b184b5b9ff793287fc7988a,1L,0.406783
uuid-ab13893f2b184b5b9ff793287fc7988a,efficacy,0.369571
uuid-ab13893f2b184b5b9ff793287fc7988a,regimen,0.329689
uuid-ab13893f2b184b5b9ff793287fc7988a,RCC,0.376766
uuid-ab13893f2b184b5b9ff793287fc7988a,combination,0.358065
uuid-ab13893f2b184b5b9ff793287fc7988a,chemo,0.334595
uuid-ab13893f2b184b5b9ff793287fc7988a,2L,0.479866
uuid-ab13893f2b184b5b9ff793287fc7988a,agents,0.408081
uuid-ab13893f2b184b5b9ff793287fc7988a,atezo,0.316877
uuid-ab13893f2b184b5b9ff793287fc7988a,preferred,0.385061
uuid-ab13893f2b184b5b9ff793287fc7988a,monotherapy,0.472037
uuid-ab13893f2b184b5b9ff793287fc7988a,using nivo,0.385647
uuid-ab13893f2b184b5b9ff793287fc7988a,combo,0.396539
uuid-ab13893f2b184b5b9ff793287fc7988a,indication,0.403618
uuid-ab13893f2b184b5b9ff793287fc7988a,PD1,0.31694
uuid-ab13893f2b184b5b9ff793287fc7988a,approved,0.455183
uuid-ab13893f2b184b5b9ff793287fc7988a,nivo and pembro,0.310516
uuid-ab13893f2b184b5b9ff793287fc7988a,believes,0.348923
uuid-ab13893f2b184b5b9ff793287fc7988a,chemotherapy,0.300988
uuid-ab13893f2b184b5b9ff793287fc7988a,impressed,0.316595
uuid-ab13893f2b184b5b9ff793287fc7988a,SCLC,0.348244
uuid-ab13893f2b184b5b9ff793287fc7988a,feels,0.353823
uuid-ab13893f2b184b5b9ff793287fc7988a,option,0.491723
uuid-53edf253b59b4369a82f2cace6900d0c,oncology,0.384314
uuid-53edf253b59b4369a82f2cace6900d0c,drug,0.602775
uuid-caf1b696daf3497b8c4f6c0dae8a5cd9,TL,0.6075
uuid-caf1b696daf3497b8c4f6c0dae8a5cd9,TL stated,0.40973
uuid-caf1b696daf3497b8c4f6c0dae8a5cd9,institution,0.366352
uuid-caf1b696daf3497b8c4f6c0dae8a5cd9,PD-L1,0.601056
uuid-caf1b696daf3497b8c4f6c0dae8a5cd9,PD-L1 testing,0.808023
uuid-caf1b696daf3497b8c4f6c0dae8a5cd9,testing,0.790837
uuid-caf1b696daf3497b8c4f6c0dae8a5cd9,PDL1 testing,0.635778
uuid-caf1b696daf3497b8c4f6c0dae8a5cd9,NSCLC patients,0.639857
uuid-caf1b696daf3497b8c4f6c0dae8a5cd9,assay,0.535738
uuid-9625492968c64e20abcb7d52d8d1f405,RTL,0.376892
uuid-9625492968c64e20abcb7d52d8d1f405,NTL,0.373255
uuid-9625492968c64e20abcb7d52d8d1f405,shared,0.433548
uuid-9625492968c64e20abcb7d52d8d1f405,commented,0.506569
uuid-9625492968c64e20abcb7d52d8d1f405,stated,0.378156
uuid-9625492968c64e20abcb7d52d8d1f405,physicians,0.363418
uuid-9625492968c64e20abcb7d52d8d1f405,mentioned,0.34354
uuid-9625492968c64e20abcb7d52d8d1f405,clinical trials,0.353759
uuid-9625492968c64e20abcb7d52d8d1f405,oncology,0.544256
uuid-9625492968c64e20abcb7d52d8d1f405,SCCHN,0.430044
uuid-9625492968c64e20abcb7d52d8d1f405,ASCO,0.303741
uuid-9625492968c64e20abcb7d52d8d1f405,tumor types,0.36672
uuid-9625492968c64e20abcb7d52d8d1f405,LTL,0.373503
uuid-9625492968c64e20abcb7d52d8d1f405,Regional TL,0.646402
uuid-7fba15caa16c4857946bf90f52cf0f48,patients,0.310505
uuid-7fba15caa16c4857946bf90f52cf0f48,1L,0.60504
uuid-7fba15caa16c4857946bf90f52cf0f48,PDL1,0.304788
uuid-7fba15caa16c4857946bf90f52cf0f48,RCC,0.344195
uuid-7fba15caa16c4857946bf90f52cf0f48,TL stated,0.320711
uuid-7fba15caa16c4857946bf90f52cf0f48,2L,0.495084
uuid-7fba15caa16c4857946bf90f52cf0f48,pts,0.357032
uuid-7fba15caa16c4857946bf90f52cf0f48,PD-L1,0.519173
uuid-7fba15caa16c4857946bf90f52cf0f48,approval,0.365155
uuid-7fba15caa16c4857946bf90f52cf0f48,preferred,0.515522
uuid-7fba15caa16c4857946bf90f52cf0f48,PD-L1 testing,0.426433
uuid-7fba15caa16c4857946bf90f52cf0f48,testing,0.522587
uuid-7fba15caa16c4857946bf90f52cf0f48,monotherapy,0.4241
uuid-7fba15caa16c4857946bf90f52cf0f48,using nivo,0.418736
uuid-7fba15caa16c4857946bf90f52cf0f48,PDL1 testing,0.532308
uuid-7fba15caa16c4857946bf90f52cf0f48,NSCLC patients,0.622578
uuid-7fba15caa16c4857946bf90f52cf0f48,approved,0.39359
uuid-7fba15caa16c4857946bf90f52cf0f48,SCCHN,0.347771
uuid-7fba15caa16c4857946bf90f52cf0f48,tumor types,0.483217
uuid-7fba15caa16c4857946bf90f52cf0f48,RTL stated,0.440697
uuid-7fba15caa16c4857946bf90f52cf0f48,option,0.585602
uuid-3e5c19d53f634ca0a7eb21132938aed6,TL stated,0.339663
uuid-3e5c19d53f634ca0a7eb21132938aed6,PD-L1,0.541812
uuid-3e5c19d53f634ca0a7eb21132938aed6,PD-L1 testing,0.504758
uuid-3e5c19d53f634ca0a7eb21132938aed6,testing,0.730847
uuid-3e5c19d53f634ca0a7eb21132938aed6,PDL1 testing,0.67099
uuid-3e5c19d53f634ca0a7eb21132938aed6,NSCLC patients,0.717338
uuid-3e5c19d53f634ca0a7eb21132938aed6,tumor types,0.35803
uuid-3e5c19d53f634ca0a7eb21132938aed6,biomarker,0.356513
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,Nivo,0.37473
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,therapy,0.464195
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,nivolumab,0.327994
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,1L,0.320674
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,combination,0.433703
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,chemo,0.404575
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,2L,0.313008
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,agents,0.436818
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,preferred,0.311284
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,monotherapy,0.43411
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,using nivo,0.418937
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,combo,0.350762
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,PD1,0.457949
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,chemotherapy,0.493076
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,oncologist,0.35857
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,indicated,0.394529
uuid-6bce6d85a9e44f34a8c5cbe536c02dd1,option,0.46955
uuid-f6e68733da72481280169bd7d5d16bc1,pembro,0.515354
uuid-f6e68733da72481280169bd7d5d16bc1,BMS,0.376184
uuid-f6e68733da72481280169bd7d5d16bc1,1L,0.407878
uuid-f6e68733da72481280169bd7d5d16bc1,PDL1,0.346091
uuid-f6e68733da72481280169bd7d5d16bc1,2L,0.388538
uuid-f6e68733da72481280169bd7d5d16bc1,Merck,0.481669
uuid-f6e68733da72481280169bd7d5d16bc1,approval,0.49134
uuid-f6e68733da72481280169bd7d5d16bc1,atezo,0.44517
uuid-f6e68733da72481280169bd7d5d16bc1,preferred,0.331734
uuid-f6e68733da72481280169bd7d5d16bc1,data,0.424572
uuid-f6e68733da72481280169bd7d5d16bc1,indication,0.568224
uuid-f6e68733da72481280169bd7d5d16bc1,approved,0.563369
uuid-f6e68733da72481280169bd7d5d16bc1,SCCHN,0.317023
uuid-f6e68733da72481280169bd7d5d16bc1,nivo and pembro,0.335808
uuid-f6e68733da72481280169bd7d5d16bc1,tumor types,0.317843
uuid-f6e68733da72481280169bd7d5d16bc1,label,0.462087
uuid-f6e68733da72481280169bd7d5d16bc1,Keytruda,0.345315
uuid-f6e68733da72481280169bd7d5d16bc1,PDL1 expression,0.341531
uuid-f6e68733da72481280169bd7d5d16bc1,option,0.334398
uuid-fd10676b35f64f78b7a0921023b19297,Opdivo,0.384132
uuid-fd10676b35f64f78b7a0921023b19297,treated,0.37017
uuid-fd10676b35f64f78b7a0921023b19297,physicians,0.569883
uuid-c53619aadb1744168588e3acc55281fb,toxicity,0.319793
uuid-c53619aadb1744168588e3acc55281fb,regimen,0.38276
uuid-c53619aadb1744168588e3acc55281fb,physicians,0.422687
uuid-d47ebeab08ab458b9e9b47169ea4e780,Opdivo,0.307094
uuid-d47ebeab08ab458b9e9b47169ea4e780,dose,0.426387
uuid-d47ebeab08ab458b9e9b47169ea4e780,physicians,0.456888
uuid-d47ebeab08ab458b9e9b47169ea4e780,regards,0.31775
uuid-d47ebeab08ab458b9e9b47169ea4e780,indication,0.318273
uuid-d47ebeab08ab458b9e9b47169ea4e780,drug,0.427016
uuid-d47ebeab08ab458b9e9b47169ea4e780,flat dosing,0.49545
uuid-52290bbc11e8429786ec70ac99bdcce5,combination,0.314919
uuid-52290bbc11e8429786ec70ac99bdcce5,chemo,0.349944
uuid-52290bbc11e8429786ec70ac99bdcce5,tumor,0.569317
uuid-52290bbc11e8429786ec70ac99bdcce5,response,0.495339
uuid-52290bbc11e8429786ec70ac99bdcce5,immunotherapy,0.645788
uuid-3914ed0165be441281fa555cabfaa3eb,treated,0.301013
uuid-d56be81cac8c47acb762ccbdc7ba3680,Nivo,0.354938
uuid-d56be81cac8c47acb762ccbdc7ba3680,trial,0.445484
uuid-d56be81cac8c47acb762ccbdc7ba3680,combination,0.421871
uuid-d56be81cac8c47acb762ccbdc7ba3680,chemo,0.324364
uuid-d56be81cac8c47acb762ccbdc7ba3680,tumor,0.34322
uuid-d56be81cac8c47acb762ccbdc7ba3680,pts,0.538928
uuid-d56be81cac8c47acb762ccbdc7ba3680,Ipi,0.374521
uuid-d56be81cac8c47acb762ccbdc7ba3680,response,0.342971
uuid-d56be81cac8c47acb762ccbdc7ba3680,combo,0.316134
uuid-c877dff489ca4db0b203fe77d4619879,patients,0.314394
uuid-c877dff489ca4db0b203fe77d4619879,lung,0.394512
uuid-c877dff489ca4db0b203fe77d4619879,regimen,0.385291
uuid-c877dff489ca4db0b203fe77d4619879,treated,0.372631
uuid-c877dff489ca4db0b203fe77d4619879,melanoma,0.546663
uuid-c877dff489ca4db0b203fe77d4619879,RCC,0.44125
uuid-c877dff489ca4db0b203fe77d4619879,pts,0.401146
uuid-c877dff489ca4db0b203fe77d4619879,combo,0.322494
uuid-c877dff489ca4db0b203fe77d4619879,progression,0.360003
uuid-c877dff489ca4db0b203fe77d4619879,impressed,0.328713
uuid-c877dff489ca4db0b203fe77d4619879,respond,0.312135
uuid-c877dff489ca4db0b203fe77d4619879,SCLC,0.363952
uuid-c877dff489ca4db0b203fe77d4619879,TL shared,0.458072
uuid-67d4b54eeb3843f4899f6d825f8f9f25,Opdivo,0.605814
uuid-67d4b54eeb3843f4899f6d825f8f9f25,dose,0.582467
uuid-67d4b54eeb3843f4899f6d825f8f9f25,shared,0.303829
uuid-67d4b54eeb3843f4899f6d825f8f9f25,drug,0.423038
uuid-67d4b54eeb3843f4899f6d825f8f9f25,Keytruda,0.563399
uuid-67d4b54eeb3843f4899f6d825f8f9f25,flat dosing,0.756039
uuid-1566b64353ab453680e5c73f66e0946b,nivolumab,0.362325
uuid-1566b64353ab453680e5c73f66e0946b,lung,0.450396
uuid-1566b64353ab453680e5c73f66e0946b,regimen,0.534091
uuid-1566b64353ab453680e5c73f66e0946b,treated,0.458852
uuid-1566b64353ab453680e5c73f66e0946b,melanoma,0.759664
uuid-1566b64353ab453680e5c73f66e0946b,shared,0.410143
uuid-1566b64353ab453680e5c73f66e0946b,RCC,0.589982
uuid-1566b64353ab453680e5c73f66e0946b,TL stated,0.31698
uuid-1566b64353ab453680e5c73f66e0946b,combination,0.468384
uuid-1566b64353ab453680e5c73f66e0946b,pts,0.473713
uuid-1566b64353ab453680e5c73f66e0946b,monotherapy,0.435725
uuid-1566b64353ab453680e5c73f66e0946b,treatment,0.37256
uuid-1566b64353ab453680e5c73f66e0946b,combo,0.515018
uuid-1566b64353ab453680e5c73f66e0946b,PD1,0.362573
uuid-1566b64353ab453680e5c73f66e0946b,SCCHN,0.338684
uuid-1566b64353ab453680e5c73f66e0946b,progression,0.421306
uuid-1566b64353ab453680e5c73f66e0946b,SCLC,0.350439
uuid-1566b64353ab453680e5c73f66e0946b,RTL stated,0.462291
uuid-1566b64353ab453680e5c73f66e0946b,TL shared,0.590639
uuid-b3efb2802a5541928912b881974b5c0d,Nivo,0.338452
uuid-b3efb2802a5541928912b881974b5c0d,patients,0.53552
uuid-b3efb2802a5541928912b881974b5c0d,Opdivo,0.653057
uuid-b3efb2802a5541928912b881974b5c0d,therapy,0.393739
uuid-b3efb2802a5541928912b881974b5c0d,dose,0.356235
uuid-b3efb2802a5541928912b881974b5c0d,nivolumab,0.512624
uuid-b3efb2802a5541928912b881974b5c0d,toxicity,0.456698
uuid-b3efb2802a5541928912b881974b5c0d,regimen,0.578636
uuid-b3efb2802a5541928912b881974b5c0d,treated,0.427122
uuid-b3efb2802a5541928912b881974b5c0d,combination,0.361394
uuid-b3efb2802a5541928912b881974b5c0d,pts,0.316063
uuid-b3efb2802a5541928912b881974b5c0d,agents,0.303278
uuid-b3efb2802a5541928912b881974b5c0d,physicians,0.344302
uuid-b3efb2802a5541928912b881974b5c0d,preferred,0.427798
uuid-b3efb2802a5541928912b881974b5c0d,monotherapy,0.477126
uuid-b3efb2802a5541928912b881974b5c0d,treatment,0.509152
uuid-b3efb2802a5541928912b881974b5c0d,using nivo,0.36103
uuid-b3efb2802a5541928912b881974b5c0d,combo,0.300527
uuid-b3efb2802a5541928912b881974b5c0d,approved,0.332272
uuid-b3efb2802a5541928912b881974b5c0d,progression,0.389629
uuid-b3efb2802a5541928912b881974b5c0d,chemotherapy,0.331074
uuid-b3efb2802a5541928912b881974b5c0d,respond,0.333281
uuid-b3efb2802a5541928912b881974b5c0d,option,0.392645
uuid-8a6438623e554b7b808510ac5c00df63,patients,0.784829
uuid-8a6438623e554b7b808510ac5c00df63,Opdivo,0.409156
uuid-8a6438623e554b7b808510ac5c00df63,therapy,0.548239
uuid-8a6438623e554b7b808510ac5c00df63,nivolumab,0.496897
uuid-8a6438623e554b7b808510ac5c00df63,regimen,0.508362
uuid-8a6438623e554b7b808510ac5c00df63,treated,0.694938
uuid-8a6438623e554b7b808510ac5c00df63,chemo,0.318073
uuid-8a6438623e554b7b808510ac5c00df63,pts,0.615119
uuid-8a6438623e554b7b808510ac5c00df63,treatment,0.677156
uuid-8a6438623e554b7b808510ac5c00df63,response,0.552749
uuid-8a6438623e554b7b808510ac5c00df63,PD1,0.314563
uuid-8a6438623e554b7b808510ac5c00df63,progression,0.722743
uuid-8a6438623e554b7b808510ac5c00df63,chemotherapy,0.382222
uuid-8a6438623e554b7b808510ac5c00df63,respond,0.532392
uuid-2947130cad884423ad050a0ea1ba19af,Opdivo,0.454179
uuid-2947130cad884423ad050a0ea1ba19af,physicians,0.334389
uuid-2947130cad884423ad050a0ea1ba19af,treatment,0.326577
uuid-2947130cad884423ad050a0ea1ba19af,option,0.362303
uuid-c4650a83939b4729a67cc5e25500354c,Nivo,0.424949
uuid-c4650a83939b4729a67cc5e25500354c,patients,0.476773
uuid-c4650a83939b4729a67cc5e25500354c,Opdivo,0.494041
uuid-c4650a83939b4729a67cc5e25500354c,pembro,0.374288
uuid-c4650a83939b4729a67cc5e25500354c,dose,0.719678
uuid-c4650a83939b4729a67cc5e25500354c,toxicity,0.357835
uuid-c4650a83939b4729a67cc5e25500354c,regimen,0.420537
uuid-c4650a83939b4729a67cc5e25500354c,Ipi,0.443842
uuid-c4650a83939b4729a67cc5e25500354c,atezo,0.37366
uuid-c4650a83939b4729a67cc5e25500354c,preferred,0.312112
uuid-c4650a83939b4729a67cc5e25500354c,vs,0.469863
uuid-c4650a83939b4729a67cc5e25500354c,Keytruda,0.308909
uuid-c4650a83939b4729a67cc5e25500354c,flat dosing,0.521525
uuid-ab79faae0a2c4b7398ccf5572259779b,patients,0.360032
uuid-ab79faae0a2c4b7398ccf5572259779b,therapy,0.353326
uuid-ab79faae0a2c4b7398ccf5572259779b,1L,0.347295
uuid-ab79faae0a2c4b7398ccf5572259779b,regimen,0.318414
uuid-ab79faae0a2c4b7398ccf5572259779b,chemo,0.314689
uuid-ab79faae0a2c4b7398ccf5572259779b,2L,0.353246
uuid-ab79faae0a2c4b7398ccf5572259779b,agents,0.313165
uuid-ab79faae0a2c4b7398ccf5572259779b,preferred,0.373444
uuid-ab79faae0a2c4b7398ccf5572259779b,testing,0.300013
uuid-ab79faae0a2c4b7398ccf5572259779b,monotherapy,0.372867
uuid-ab79faae0a2c4b7398ccf5572259779b,treatment,0.482372
uuid-ab79faae0a2c4b7398ccf5572259779b,NSCLC patients,0.310445
uuid-ab79faae0a2c4b7398ccf5572259779b,respond,0.363124
uuid-ab79faae0a2c4b7398ccf5572259779b,option,0.486388
uuid-c6fa477bd47e4006979e0736333cfa0c,pembro,0.391944
uuid-c6fa477bd47e4006979e0736333cfa0c,1L,0.347636
uuid-c6fa477bd47e4006979e0736333cfa0c,PDL1,0.673336
uuid-c6fa477bd47e4006979e0736333cfa0c,trial,0.348828
uuid-c6fa477bd47e4006979e0736333cfa0c,efficacy,0.477289
uuid-c6fa477bd47e4006979e0736333cfa0c,PD-L1,0.318424
uuid-c6fa477bd47e4006979e0736333cfa0c,OS,0.531019
uuid-c6fa477bd47e4006979e0736333cfa0c,atezo,0.329074
uuid-c6fa477bd47e4006979e0736333cfa0c,data,0.615248
uuid-c6fa477bd47e4006979e0736333cfa0c,PFS,0.5336
uuid-c6fa477bd47e4006979e0736333cfa0c,ORR,0.520512
uuid-c6fa477bd47e4006979e0736333cfa0c,nivo and pembro,0.564843
uuid-c6fa477bd47e4006979e0736333cfa0c,believes,0.503282
uuid-c6fa477bd47e4006979e0736333cfa0c,impressed,0.405683
uuid-c6fa477bd47e4006979e0736333cfa0c,feels,0.511826
uuid-c6fa477bd47e4006979e0736333cfa0c,PDL1 expression,0.559464
uuid-c6fa477bd47e4006979e0736333cfa0c,biomarker,0.335084
uuid-239b6744292a4180b8c509a9adab6007,physicians,0.716295
uuid-239b6744292a4180b8c509a9adab6007,treatment,0.348353
uuid-2eb0c5307f374301946c444c5fc7b548,patients,0.381248
uuid-2eb0c5307f374301946c444c5fc7b548,therapy,0.34836
uuid-2eb0c5307f374301946c444c5fc7b548,toxicity,0.325893
uuid-2eb0c5307f374301946c444c5fc7b548,treatment,0.33687
uuid-2eb0c5307f374301946c444c5fc7b548,progression,0.36172
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,Nivo,0.432316
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,pembro,0.454436
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,RTL,0.396045
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,dose,0.394019
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,trial,0.465662
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,efficacy,0.437008
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,combination,0.451205
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,Ipi,0.657441
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,atezo,0.366628
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,data,0.448204
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,combo,0.468962
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,ORR,0.301133
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,impressed,0.550129
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,vs,0.433895
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,LTL,0.347024
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,TLs,0.377145
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,SCLC,0.37346
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,feels,0.419225
uuid-ea637e6bdfe44a0c9d89709a9ebc8e03,flat dosing,0.320021
uuid-46ac276b3a524fdeae60fe4d035c2106,patients,0.501381
uuid-46ac276b3a524fdeae60fe4d035c2106,Opdivo,0.527066
uuid-46ac276b3a524fdeae60fe4d035c2106,regimen,0.372529
uuid-46ac276b3a524fdeae60fe4d035c2106,treated,0.418969
uuid-46ac276b3a524fdeae60fe4d035c2106,stated,0.37294
uuid-46ac276b3a524fdeae60fe4d035c2106,physicians,0.509191
uuid-46ac276b3a524fdeae60fe4d035c2106,treatment,0.413029
uuid-46ac276b3a524fdeae60fe4d035c2106,HCP,0.305413
uuid-46ac276b3a524fdeae60fe4d035c2106,progression,0.436189
uuid-46ac276b3a524fdeae60fe4d035c2106,respond,0.326898
uuid-c7ae508b43694c6497a7a0338f54f1a3,physicians,0.52716
uuid-c7ae508b43694c6497a7a0338f54f1a3,oncology,0.368305
uuid-c7ae508b43694c6497a7a0338f54f1a3,drug,0.395951
uuid-c7ae508b43694c6497a7a0338f54f1a3,clinical,0.415349
uuid-4ced079bc2b94ae4abd608044db7e427,toxicity,0.337673
uuid-4ced079bc2b94ae4abd608044db7e427,physicians,0.338188
uuid-4ced079bc2b94ae4abd608044db7e427,treatment,0.367651
uuid-4ced079bc2b94ae4abd608044db7e427,lung cancer,0.377426
uuid-4ced079bc2b94ae4abd608044db7e427,respond,0.35428
uuid-53d557c255bb45849bb95c4edd150902,Opdivo,0.364405
uuid-53d557c255bb45849bb95c4edd150902,toxicity,0.365865
uuid-53d557c255bb45849bb95c4edd150902,physicians,0.590972
uuid-53d557c255bb45849bb95c4edd150902,treatment,0.317959
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,Nivo,0.480502
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,pembro,0.790313
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,1L,0.586378
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,PDL1,0.36169
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,efficacy,0.310375
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,2L,0.652586
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,agents,0.460526
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,Merck,0.328214
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,approval,0.493069
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,atezo,0.798021
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,preferred,0.593837
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,monotherapy,0.341181
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,using nivo,0.518145
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,data,0.424843
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,indication,0.528974
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,approved,0.588966
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,SCCHN,0.369917
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,nivo and pembro,0.55099
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,vs,0.315871
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,label,0.352877
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,feels,0.463146
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,RTL stated,0.373354
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,option,0.456596
uuid-444a53a79abd4e83a1d8c6acc21c7d1f,bladder,0.422399
uuid-44c86d61e34a4aeeb4fa250f00be0992,Nivo,0.430651
uuid-44c86d61e34a4aeeb4fa250f00be0992,pembro,0.477461
uuid-44c86d61e34a4aeeb4fa250f00be0992,dose,0.476153
uuid-44c86d61e34a4aeeb4fa250f00be0992,efficacy,0.732424
uuid-44c86d61e34a4aeeb4fa250f00be0992,Ipi,0.454646
uuid-44c86d61e34a4aeeb4fa250f00be0992,OS,0.508225
uuid-44c86d61e34a4aeeb4fa250f00be0992,atezo,0.488561
uuid-44c86d61e34a4aeeb4fa250f00be0992,data,0.440044
uuid-44c86d61e34a4aeeb4fa250f00be0992,PFS,0.443029
uuid-44c86d61e34a4aeeb4fa250f00be0992,ORR,0.556849
uuid-44c86d61e34a4aeeb4fa250f00be0992,nivo and pembro,0.405976
uuid-44c86d61e34a4aeeb4fa250f00be0992,impressed,0.41999
uuid-44c86d61e34a4aeeb4fa250f00be0992,vs,0.6214
uuid-44c86d61e34a4aeeb4fa250f00be0992,TLs,0.347774
uuid-44c86d61e34a4aeeb4fa250f00be0992,flat dosing,0.369941
uuid-1aa902e13ae94786b0328183b87dda2b,patients,0.754683
uuid-1aa902e13ae94786b0328183b87dda2b,Opdivo,0.391817
uuid-1aa902e13ae94786b0328183b87dda2b,therapy,0.743276
uuid-1aa902e13ae94786b0328183b87dda2b,nivolumab,0.447305
uuid-1aa902e13ae94786b0328183b87dda2b,regimen,0.534046
uuid-1aa902e13ae94786b0328183b87dda2b,treated,0.483287
uuid-1aa902e13ae94786b0328183b87dda2b,chemo,0.455626
uuid-1aa902e13ae94786b0328183b87dda2b,pts,0.662071
uuid-1aa902e13ae94786b0328183b87dda2b,monotherapy,0.444118
uuid-1aa902e13ae94786b0328183b87dda2b,treatment,0.729847
uuid-1aa902e13ae94786b0328183b87dda2b,response,0.78627
uuid-1aa902e13ae94786b0328183b87dda2b,PD1,0.502196
uuid-1aa902e13ae94786b0328183b87dda2b,cHL,0.333843
uuid-1aa902e13ae94786b0328183b87dda2b,progression,0.827387
uuid-1aa902e13ae94786b0328183b87dda2b,chemotherapy,0.486038
uuid-1aa902e13ae94786b0328183b87dda2b,respond,0.647357
uuid-1aa902e13ae94786b0328183b87dda2b,option,0.365161
uuid-9eba84065e37406a8c76db4ac6df9160,Nivo,0.445043
uuid-9eba84065e37406a8c76db4ac6df9160,pembro,0.667009
uuid-9eba84065e37406a8c76db4ac6df9160,dose,0.733052
uuid-9eba84065e37406a8c76db4ac6df9160,1L,0.351077
uuid-9eba84065e37406a8c76db4ac6df9160,2L,0.551908
uuid-9eba84065e37406a8c76db4ac6df9160,agents,0.38923
uuid-9eba84065e37406a8c76db4ac6df9160,Ipi,0.41333
uuid-9eba84065e37406a8c76db4ac6df9160,atezo,0.735848
uuid-9eba84065e37406a8c76db4ac6df9160,preferred,0.681725
uuid-9eba84065e37406a8c76db4ac6df9160,monotherapy,0.364309
uuid-9eba84065e37406a8c76db4ac6df9160,using nivo,0.418523
uuid-9eba84065e37406a8c76db4ac6df9160,indication,0.41135
uuid-9eba84065e37406a8c76db4ac6df9160,approved,0.409574
uuid-9eba84065e37406a8c76db4ac6df9160,vs,0.579574
uuid-9eba84065e37406a8c76db4ac6df9160,Keytruda,0.466836
uuid-9eba84065e37406a8c76db4ac6df9160,option,0.403393
uuid-9eba84065e37406a8c76db4ac6df9160,flat dosing,0.562652
uuid-3d8014a80d9742978c1e00a83ade781f,patients,0.341267
uuid-3d8014a80d9742978c1e00a83ade781f,toxicity,0.388836
uuid-3d8014a80d9742978c1e00a83ade781f,regimen,0.37324
uuid-3d8014a80d9742978c1e00a83ade781f,treated,0.329116
uuid-3d8014a80d9742978c1e00a83ade781f,melanoma,0.369659
uuid-3d8014a80d9742978c1e00a83ade781f,treatment,0.336033
uuid-3d8014a80d9742978c1e00a83ade781f,respond,0.34623
uuid-3d8014a80d9742978c1e00a83ade781f,SCLC,0.315288
uuid-3d8014a80d9742978c1e00a83ade781f,NCCN,0.485449
uuid-dc999a89b09a4ea69d488ea91e32d05d,patients,0.341267
uuid-dc999a89b09a4ea69d488ea91e32d05d,toxicity,0.388836
uuid-dc999a89b09a4ea69d488ea91e32d05d,regimen,0.37324
uuid-dc999a89b09a4ea69d488ea91e32d05d,treated,0.329116
uuid-dc999a89b09a4ea69d488ea91e32d05d,melanoma,0.369659
uuid-dc999a89b09a4ea69d488ea91e32d05d,treatment,0.336033
uuid-dc999a89b09a4ea69d488ea91e32d05d,respond,0.34623
uuid-dc999a89b09a4ea69d488ea91e32d05d,SCLC,0.315288
uuid-dc999a89b09a4ea69d488ea91e32d05d,NCCN,0.485449
uuid-f1370da2d7e940e29c2eb837f7ef5845,NCCN,0.611832
uuid-27e0462925784857bcb30347fd90ba27,patients,0.681688
uuid-27e0462925784857bcb30347fd90ba27,Opdivo,0.305201
uuid-27e0462925784857bcb30347fd90ba27,therapy,0.370438
uuid-27e0462925784857bcb30347fd90ba27,toxicity,0.43926
uuid-27e0462925784857bcb30347fd90ba27,regimen,0.488618
uuid-27e0462925784857bcb30347fd90ba27,treated,0.499935
uuid-27e0462925784857bcb30347fd90ba27,pts,0.343346
uuid-27e0462925784857bcb30347fd90ba27,physicians,0.41209
uuid-27e0462925784857bcb30347fd90ba27,treatment,0.718306
uuid-27e0462925784857bcb30347fd90ba27,response,0.365549
uuid-27e0462925784857bcb30347fd90ba27,progression,0.59565
uuid-27e0462925784857bcb30347fd90ba27,respond,0.536058
uuid-ec96455c7dc94909919a6b44b27c706c,treated,0.342716
uuid-ec96455c7dc94909919a6b44b27c706c,physicians,0.355306
uuid-ec96455c7dc94909919a6b44b27c706c,oncology,0.449795
uuid-ec96455c7dc94909919a6b44b27c706c,ASCO,0.316236
uuid-ec96455c7dc94909919a6b44b27c706c,oncologist,0.383624
uuid-ec96455c7dc94909919a6b44b27c706c,immunotherapy,0.433725
uuid-3bdea66daeb84124b7b382cf178e6bbf,tumor,0.484174
uuid-3bdea66daeb84124b7b382cf178e6bbf,response,0.472989
uuid-3bdea66daeb84124b7b382cf178e6bbf,progression,0.438249
uuid-3bdea66daeb84124b7b382cf178e6bbf,respond,0.336562
uuid-41d21fd407a241ae89df68e315fcef80,AI,0.362586
uuid-41d21fd407a241ae89df68e315fcef80,oncology,0.492967
uuid-41d21fd407a241ae89df68e315fcef80,oncologist,0.338241
uuid-41d21fd407a241ae89df68e315fcef80,clinical,0.55566
uuid-41d21fd407a241ae89df68e315fcef80,immunotherapy,0.358647
uuid-9c22833f77884cc5952b21fa5983ba2a,BMS,0.520987
uuid-9c22833f77884cc5952b21fa5983ba2a,trial,0.382568
uuid-9c22833f77884cc5952b21fa5983ba2a,efficacy,0.477846
uuid-9c22833f77884cc5952b21fa5983ba2a,commented,0.477881
uuid-9c22833f77884cc5952b21fa5983ba2a,Merck,0.308121
uuid-9c22833f77884cc5952b21fa5983ba2a,stated,0.383963
uuid-9c22833f77884cc5952b21fa5983ba2a,OS,0.517212
uuid-9c22833f77884cc5952b21fa5983ba2a,regards,0.312863
uuid-9c22833f77884cc5952b21fa5983ba2a,data,0.76828
uuid-9c22833f77884cc5952b21fa5983ba2a,expressed,0.400174
uuid-9c22833f77884cc5952b21fa5983ba2a,PFS,0.442427
uuid-9c22833f77884cc5952b21fa5983ba2a,ORR,0.500298
uuid-9c22833f77884cc5952b21fa5983ba2a,ASCO,0.360621
uuid-9c22833f77884cc5952b21fa5983ba2a,impressed,0.717795
uuid-9c22833f77884cc5952b21fa5983ba2a,feels,0.485164
uuid-053d3b7c722445bf979229613511bbec,RTL,0.382407
uuid-053d3b7c722445bf979229613511bbec,lung,0.390923
uuid-053d3b7c722445bf979229613511bbec,melanoma,0.33728
uuid-053d3b7c722445bf979229613511bbec,RCC,0.389952
uuid-053d3b7c722445bf979229613511bbec,stated,0.308325
uuid-053d3b7c722445bf979229613511bbec,approval,0.415018
uuid-053d3b7c722445bf979229613511bbec,clinical trials,0.347598
uuid-053d3b7c722445bf979229613511bbec,indication,0.396825
uuid-053d3b7c722445bf979229613511bbec,SCCHN,0.500956
uuid-053d3b7c722445bf979229613511bbec,label,0.351779
uuid-053d3b7c722445bf979229613511bbec,RTL stated,0.338428
uuid-053d3b7c722445bf979229613511bbec,TL shared,0.385266
uuid-053d3b7c722445bf979229613511bbec,bladder,0.462246
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,Nivo,0.528362
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,pembro,0.425828
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,1L,0.389849
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,toxicity,0.400749
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,efficacy,0.37355
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,regimen,0.400909
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,combination,0.403273
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,chemo,0.376323
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,2L,0.438159
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,agents,0.348672
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,Ipi,0.360707
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,atezo,0.399407
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,preferred,0.482212
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,monotherapy,0.560512
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,using nivo,0.432195
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,combo,0.389458
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,PD1,0.308129
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,impressed,0.305352
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,feels,0.523762
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,RTL stated,0.416176
uuid-8856ffad0495471f8a9f38e8c3cc4fa6,option,0.430597
uuid-42ed8efe02844855a3396e48bb067561,patients,0.514689
uuid-42ed8efe02844855a3396e48bb067561,Opdivo,0.503546
uuid-42ed8efe02844855a3396e48bb067561,treated,0.32183
uuid-42ed8efe02844855a3396e48bb067561,physicians,0.411423
uuid-42ed8efe02844855a3396e48bb067561,treatment,0.416824
uuid-e97ac7d2fbe0442694a55dc02af31b4f,Nivo,0.588221
uuid-e97ac7d2fbe0442694a55dc02af31b4f,patients,0.434356
uuid-e97ac7d2fbe0442694a55dc02af31b4f,pembro,0.390284
uuid-e97ac7d2fbe0442694a55dc02af31b4f,therapy,0.306907
uuid-e97ac7d2fbe0442694a55dc02af31b4f,nivolumab,0.352026
uuid-e97ac7d2fbe0442694a55dc02af31b4f,1L,0.523397
uuid-e97ac7d2fbe0442694a55dc02af31b4f,regimen,0.387878
uuid-e97ac7d2fbe0442694a55dc02af31b4f,RCC,0.330564
uuid-e97ac7d2fbe0442694a55dc02af31b4f,combination,0.342691
uuid-e97ac7d2fbe0442694a55dc02af31b4f,chemo,0.496422
uuid-e97ac7d2fbe0442694a55dc02af31b4f,2L,0.458653
uuid-e97ac7d2fbe0442694a55dc02af31b4f,pts,0.4416
uuid-e97ac7d2fbe0442694a55dc02af31b4f,OS,0.339658
uuid-e97ac7d2fbe0442694a55dc02af31b4f,preferred,0.361491
uuid-e97ac7d2fbe0442694a55dc02af31b4f,monotherapy,0.566894
uuid-e97ac7d2fbe0442694a55dc02af31b4f,using nivo,0.513022
uuid-e97ac7d2fbe0442694a55dc02af31b4f,combo,0.398439
uuid-e97ac7d2fbe0442694a55dc02af31b4f,PD1,0.393909
uuid-e97ac7d2fbe0442694a55dc02af31b4f,ORR,0.328432
uuid-e97ac7d2fbe0442694a55dc02af31b4f,approved,0.31557
uuid-e97ac7d2fbe0442694a55dc02af31b4f,SCCHN,0.347629
uuid-e97ac7d2fbe0442694a55dc02af31b4f,progression,0.332012
uuid-e97ac7d2fbe0442694a55dc02af31b4f,chemotherapy,0.469638
uuid-e97ac7d2fbe0442694a55dc02af31b4f,impressed,0.37065
uuid-e97ac7d2fbe0442694a55dc02af31b4f,SCLC,0.3611
uuid-e97ac7d2fbe0442694a55dc02af31b4f,feels,0.40311
uuid-e97ac7d2fbe0442694a55dc02af31b4f,RTL stated,0.387042
uuid-e97ac7d2fbe0442694a55dc02af31b4f,option,0.516111
uuid-e97ac7d2fbe0442694a55dc02af31b4f,bladder,0.33868
uuid-16d3f30e1b3e4cd0b1391c04cdf74d40,patients,0.310434
uuid-16d3f30e1b3e4cd0b1391c04cdf74d40,Opdivo,0.623541
uuid-16d3f30e1b3e4cd0b1391c04cdf74d40,physicians,0.427976
uuid-28506baa73be4199941c2fb08880cb6a,pembro,0.33124
uuid-28506baa73be4199941c2fb08880cb6a,1L,0.324964
uuid-28506baa73be4199941c2fb08880cb6a,PDL1,0.530268
uuid-28506baa73be4199941c2fb08880cb6a,efficacy,0.522577
uuid-28506baa73be4199941c2fb08880cb6a,chemo,0.361957
uuid-28506baa73be4199941c2fb08880cb6a,agents,0.359107
uuid-28506baa73be4199941c2fb08880cb6a,OS,0.305857
uuid-28506baa73be4199941c2fb08880cb6a,atezo,0.415152
uuid-28506baa73be4199941c2fb08880cb6a,PFS,0.31468
uuid-28506baa73be4199941c2fb08880cb6a,nivo and pembro,0.581077
uuid-28506baa73be4199941c2fb08880cb6a,believes,0.594973
uuid-28506baa73be4199941c2fb08880cb6a,vs,0.306104
uuid-28506baa73be4199941c2fb08880cb6a,PDL1 expression,0.445748
uuid-28506baa73be4199941c2fb08880cb6a,option,0.308801
uuid-28506baa73be4199941c2fb08880cb6a,biomarker,0.356167
uuid-1878d152f63a45c18d075ab3ac45d035,patients,0.80374
uuid-1878d152f63a45c18d075ab3ac45d035,Opdivo,0.543486
uuid-1878d152f63a45c18d075ab3ac45d035,therapy,0.610083
uuid-1878d152f63a45c18d075ab3ac45d035,nivolumab,0.549923
uuid-1878d152f63a45c18d075ab3ac45d035,regimen,0.457496
uuid-1878d152f63a45c18d075ab3ac45d035,treated,0.572531
uuid-1878d152f63a45c18d075ab3ac45d035,RCC,0.316625
uuid-1878d152f63a45c18d075ab3ac45d035,pts,0.537058
uuid-1878d152f63a45c18d075ab3ac45d035,treatment,0.694597
uuid-1878d152f63a45c18d075ab3ac45d035,using nivo,0.317601
uuid-1878d152f63a45c18d075ab3ac45d035,response,0.420689
uuid-1878d152f63a45c18d075ab3ac45d035,cHL,0.362661
uuid-1878d152f63a45c18d075ab3ac45d035,progression,0.688866
uuid-1878d152f63a45c18d075ab3ac45d035,chemotherapy,0.32683
uuid-1878d152f63a45c18d075ab3ac45d035,respond,0.427938
uuid-1878d152f63a45c18d075ab3ac45d035,TL shared,0.35759
uuid-70012ff3061645398c33b84a8f8073c1,pembro,0.416729
uuid-70012ff3061645398c33b84a8f8073c1,BMS,0.418654
uuid-70012ff3061645398c33b84a8f8073c1,1L,0.366514
uuid-70012ff3061645398c33b84a8f8073c1,PDL1,0.606747
uuid-70012ff3061645398c33b84a8f8073c1,trial,0.579765
uuid-70012ff3061645398c33b84a8f8073c1,efficacy,0.504428
uuid-70012ff3061645398c33b84a8f8073c1,Merck,0.345013
uuid-70012ff3061645398c33b84a8f8073c1,stated,0.305074
uuid-70012ff3061645398c33b84a8f8073c1,OS,0.58874
uuid-70012ff3061645398c33b84a8f8073c1,atezo,0.329186
uuid-70012ff3061645398c33b84a8f8073c1,data,0.739194
uuid-70012ff3061645398c33b84a8f8073c1,expressed,0.312588
uuid-70012ff3061645398c33b84a8f8073c1,PFS,0.58163
uuid-70012ff3061645398c33b84a8f8073c1,ORR,0.625462
uuid-70012ff3061645398c33b84a8f8073c1,nivo and pembro,0.644875
uuid-70012ff3061645398c33b84a8f8073c1,believes,0.477106
uuid-70012ff3061645398c33b84a8f8073c1,impressed,0.526665
uuid-70012ff3061645398c33b84a8f8073c1,feels,0.484927
uuid-70012ff3061645398c33b84a8f8073c1,PDL1 expression,0.531437
uuid-70012ff3061645398c33b84a8f8073c1,biomarker,0.30806
uuid-85af220997bd4ea9a052c144a0ea8f35,BMS,0.412231
uuid-85af220997bd4ea9a052c144a0ea8f35,PDL1,0.488839
uuid-85af220997bd4ea9a052c144a0ea8f35,trial,0.338901
uuid-85af220997bd4ea9a052c144a0ea8f35,efficacy,0.536434
uuid-85af220997bd4ea9a052c144a0ea8f35,Merck,0.349955
uuid-85af220997bd4ea9a052c144a0ea8f35,PD-L1,0.300748
uuid-85af220997bd4ea9a052c144a0ea8f35,regards,0.321368
uuid-85af220997bd4ea9a052c144a0ea8f35,nivo and pembro,0.409274
uuid-85af220997bd4ea9a052c144a0ea8f35,believes,0.35753
uuid-85af220997bd4ea9a052c144a0ea8f35,PDL1 expression,0.469737
uuid-85af220997bd4ea9a052c144a0ea8f35,biomarker,0.508898
uuid-01d9d1c7666a458fa49a2d28ce67e5ef,AI,0.362875
uuid-01d9d1c7666a458fa49a2d28ce67e5ef,oncology,0.37864
uuid-01d9d1c7666a458fa49a2d28ce67e5ef,indicated,0.362744
uuid-01d9d1c7666a458fa49a2d28ce67e5ef,drug,0.475343
uuid-01d9d1c7666a458fa49a2d28ce67e5ef,Keytruda,0.333638
uuid-01d9d1c7666a458fa49a2d28ce67e5ef,clinical,0.333618
uuid-01d9d1c7666a458fa49a2d28ce67e5ef,NCCN,0.308344
uuid-01d9d1c7666a458fa49a2d28ce67e5ef,flat dosing,0.366329
uuid-73c48dc13dbc46adb5e6f11538654ea4,patients,0.475961
uuid-73c48dc13dbc46adb5e6f11538654ea4,chemo,0.335616
uuid-73c48dc13dbc46adb5e6f11538654ea4,tumor,0.673781
uuid-73c48dc13dbc46adb5e6f11538654ea4,pts,0.473889
uuid-73c48dc13dbc46adb5e6f11538654ea4,treatment,0.305009
uuid-73c48dc13dbc46adb5e6f11538654ea4,response,0.325467
uuid-73c48dc13dbc46adb5e6f11538654ea4,progression,0.383822
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,RTL,0.465073
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,commented,0.497776
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,stated,0.364746
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,OS,0.354583
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,data,0.684082
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,expressed,0.330789
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,ORR,0.392575
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,SCCHN,0.395209
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,HCP,0.348261
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,ASCO,0.46938
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,impressed,0.710706
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,LTL,0.381535
uuid-0cd461eb6d6e4ce886b5c8b8e3ae89fe,Regional TL,0.411673
